PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ware, RE; Davis, BR; Schultz, WH; Brown, RC; Aygun, B; Sarnaik, S; Odame, I; Fuh, B; George, A; Owen, W; Luchtman-Jones, L; Rogers, ZR; Hilliard, L; Gauger, C; Piccone, C; Lee, MT; Kwiatkowski, JL; Jackson, S; Miller, ST; Roberts, C; Heeney, MM; Kalfa, TA; Nelson, S; Imran, H; Nottage, K; Alvarez, O; Rhodes, M; Thompson, AA; Rothman, JA; Helton, KJ; Roberts, D; Coleman, J; Bonner, MJ; Kutlar, A; Patel, N; Wood, J; Piller, L; Wei, P; Luden, J; Mortier, NA; Stuber, SE; Luban, NLC; Cohen, AR; Pressel, S; Adams, RJ				Ware, Russell E.; Davis, Barry R.; Schultz, William H.; Brown, R. Clark; Aygun, Banu; Sarnaik, Sharada; Odame, Isaac; Fuh, Beng; George, Alex; Owen, William; Luchtman-Jones, Lori; Rogers, Zora R.; Hilliard, Lee; Gauger, Cynthia; Piccone, Connie; Lee, Margaret T.; Kwiatkowski, Janet L.; Jackson, Sherron; Miller, Scott T.; Roberts, Carla; Heeney, Matthew M.; Kalfa, Theodosia A.; Nelson, Stephen; Imran, Hamayun; Nottage, Kerri; Alvarez, Ofelia; Rhodes, Melissa; Thompson, Alexis A.; Rothman, Jennifer A.; Helton, Kathleen J.; Roberts, Donna; Coleman, Jamie; Bonner, Melanie J.; Kutlar, Abdullah; Patel, Niren; Wood, John; Piller, Linda; Wei, Peng; Luden, Judy; Mortier, Nicole A.; Stuber, Susan E.; Luban, Naomi L. C.; Cohen, Alan R.; Pressel, Sara; Adams, Robert J.			Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial	LANCET			English	Article							SILENT CEREBRAL INFARCTS; IRON OVERLOAD; DISEASE; STROKE; PREVENTION; ULTRASONOGRAPHY; PHLEBOTOMY; THERAPY; SWITCH; RATES	Background For children with sickle cell anaemia and high transcranial doppler (TCD) flow velocities, regular blood transfusions can effectively prevent primary stroke, but must be continued indefinitely. The efficacy of hydroxycarbamide (hydroxyurea) in this setting is unknown; we performed the TWiTCH trial to compare hydroxyurea with standard transfusions. Methods TWiTCH was a multicentre, phase 3, randomised, open-label, non-inferiority trial done at 26 paediatric hospitals and health centres in the USA and Canada. We enrolled children with sickle cell anaemia who were aged 4-16 years and had abnormal TCD fl ow velocities (>= 200 cm/s) but no severe vasculopathy. After screening, eligible participants were randomly assigned 1: 1 to continue standard transfusions (standard group) or hydroxycarbamide (alternative group). Randomisation was done at a central site, stratified by site with a block size of four, and an adaptive randomisation scheme was used to balance the covariates of baseline age and TCD velocity. The study was open-label, but TCD examinations were read centrally by observers masked to treatment assignment and previous TCD results. Participants assigned to standard treatment continued to receive monthly transfusions to maintain 30% sickle haemoglobin or lower, while those assigned to the alternative treatment started oral hydroxycarbamide at 20 mg/kg per day, which was escalated to each participant's maximum tolerated dose. The treatment period lasted 24 months from randomisation. The primary study endpoint was the 24 month TCD velocity calculated from a general linear mixed model, with the non-inferiority margin set at 15 cm/s. The primary analysis was done in the intention-totreat population and safety was assessed in all patients who received at least one dose of assigned treatment. This study is registered with ClinicalTrials.gov, number NCT01425307. Findings Between Sept 20, 2011, and April 17, 2013, 159 patients consented and enrolled in TWiTCH. 121 participants passed screening and were then randomly assigned to treatment (61 to transfusions and 60 to hydroxycarbamide). At the first scheduled interim analysis, non-inferiority was shown and the sponsor terminated the study. Final model-based TCD velocities were 143 cm/s (95% CI 140-146) in children who received standard transfusions and 138 cm/s (135-142) in those who received hydroxycarbamide, with a difference of 4.54 (0.10-8.98). Non-inferiority (p= 8.82 x 10(-16)) and post-hoc superiority (p= 0.023) were met. Of 29 new neurological events adjudicated centrally by masked reviewers, no strokes were identified, but three transient ischaemic attacks occurred in each group. Magnetic resonance brain imaging and angiography (MRI and MRA) at exit showed no new cerebral infarcts in either treatment group, but worsened vasculopathy in one participant who received standard transfusions. 23 severe adverse events in nine (15%) patients were reported for hydroxycarbamide and ten serious adverse events in six (10%) patients were reported for standard transfusions. The most common serious adverse event in both groups was vaso-occlusive pain (11 events in five [8%] patients with hydroxycarbamide and three events in one [2%] patient for transfusions). Interpretation For high-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocities and help to prevent primary stroke.	[Ware, Russell E.; Schultz, William H.; Kalfa, Theodosia A.; Mortier, Nicole A.; Stuber, Susan E.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Davis, Barry R.; Piller, Linda; Wei, Peng; Pressel, Sara] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA; [Brown, R. Clark] Emory Univ, Atlanta, GA 30322 USA; [Aygun, Banu] Cohen Childrens Med Ctr, New Hyde Pk, NY USA; [Sarnaik, Sharada] Wayne State Univ, Detroit, MI USA; [Odame, Isaac] Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Fuh, Beng] E Carolina Univ, Greenville, NC 27858 USA; [George, Alex] Baylor Coll Med, Houston, TX 77030 USA; [Owen, William] Childrens Hosp Kings Daughters, Norfolk, VA USA; [Luchtman-Jones, Lori; Luban, Naomi L. C.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Rogers, Zora R.] UT Southwestern, Dallas, TX USA; [Hilliard, Lee] Univ Alabama Birmingham, Birmingham, AL USA; [Gauger, Cynthia] Nemours Childrens Clin, Jacksonville, FL USA; [Piccone, Connie] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Lee, Margaret T.] Columbia Univ, New York, NY USA; [Kwiatkowski, Janet L.; Cohen, Alan R.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Jackson, Sherron; Roberts, Donna; Luden, Judy] Med Univ S Carolina, Columbia, SC USA; [Miller, Scott T.] State Univ New York Downstate, Brooklyn, NY USA; [Roberts, Carla] Univ S Carolina, Columbia, SC 29208 USA; [Heeney, Matthew M.] Boston Childrens Hosp, Boston, MA USA; [Nelson, Stephen] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA; [Imran, Hamayun] Univ S Alabama, Mobile, AL 36688 USA; [Nottage, Kerri; Helton, Kathleen J.; Coleman, Jamie] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA; [Alvarez, Ofelia] Univ Miami, Miami, FL USA; [Rhodes, Melissa] Univ Mississippi, Jackson, MS 39216 USA; [Thompson, Alexis A.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Rothman, Jennifer A.; Bonner, Melanie J.] Duke Univ, Med Ctr, Durham, NC USA; [Kutlar, Abdullah; Patel, Niren] Georgia Regents Univ, Augusta, GA USA; [Wood, John] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA	Cincinnati Children's Hospital Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Emory University; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Wayne State University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of North Carolina; East Carolina University; Baylor College of Medicine; Children's National Health System; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Alabama System; University of Alabama Birmingham; Case Western Reserve University; Columbia University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Medical University of South Carolina; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Harvard University; Boston Children's Hospital; Children's Hospitals & Clinics of Minnesota; University of South Alabama; St Jude Children's Research Hospital; University of Miami; University of Mississippi; Ann & Robert H. Lurie Children's Hospital of Chicago; Duke University; University System of Georgia; Augusta University; Children's Hospital Los Angeles	Ware, RE (corresponding author), Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.	russell.ware@cchmc.org	Wei, Peng/X-2306-2019; Adams, Robert/GPW-8528-2022	Wei, Peng/0000-0001-7758-6116; Kalfa, Theodosia/0000-0002-0426-9686; Rothman, Jennifer/0000-0003-1582-2886	National Heart, Lung, and Blood Institute, National Institutes of Health; National Heart, Lung, and Blood Institute [R01 HL-095647, R01 HL-095511]; Data Coordinating Centre at the University of Texas School of Public Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095511, R01HL095647] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Data Coordinating Centre at the University of Texas School of Public Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	National Heart, Lung, and Blood Institute, National Institutes of Health.; This clinical trial was supported by the National Heart, Lung, and Blood Institute through grants R01 HL-095647 (REW) and R01 HL-095511 (BRD). Hydroxyurea is not approved by the US FDA for use in children with sickle cell anaemia, and the TWiTCH trial was performed under FDA IND #67289 with cross-reference to FDA IND #111926. We thank all staff at the Medical Coordinating Centre at Cincinnati Children's Hospital and the Data Coordinating Centre at the University of Texas School of Public Health for their support throughout the study. We acknowledge the assistance of Ronald Helms and Nancy Yovetich in the design of the study. FerriScan R2-MRI was provided at discount by Resonance Health (Claremont, WA, Australia). We also appreciate the efforts of all health-care providers, and especially the nursing staff, at each participating institution. We especially recognise the eager participation and time commitments made by the children and families who enrolled in this study.	ADAMS R, 1992, NEW ENGL J MED, V326, P605, DOI 10.1056/NEJM199202273260905; Adams RJ, 2005, NEW ENGL J MED, V353, P2769; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Almeida CB, 2015, BLOOD, V126, P711, DOI 10.1182/blood-2014-12-616250; Armstrong FD, 2013, PEDIATRICS, V131, pE406, DOI 10.1542/peds.2012-0283; Aygun B, 2015, BRIT J HAEMATOL, V169, P262, DOI 10.1111/bjh.13280; Aygun B, 2012, AM J HEMATOL, V87, P428, DOI 10.1002/ajh.23105; Bernaudin F, 2011, BLOOD, V117, P1130, DOI 10.1182/blood-2010-06-293514; Brambilla DJ, 2007, PEDIATR BLOOD CANCER, V49, P318, DOI 10.1002/pbc.21142; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; DeBaun MR, 2014, NEW ENGL J MED, V371, P699, DOI 10.1056/NEJMoa1401731; Flanagan JM, 2013, BLOOD, V121, P3237, DOI 10.1182/blood-2012-10-464156; Flanagan JM, 2011, BLOOD, V117, P6681, DOI 10.1182/blood-2011-01-332205; Greenway A, 2011, AM J HEMATOL, V86, P357, DOI 10.1002/ajh.21986; Gulbis B, 2005, BLOOD, V105, P2685, DOI 10.1182/blood-2004-07-2704; Heeney MM, 2008, PEDIATR CLIN N AM, V55, P483, DOI 10.1016/j.pcl.2008.02.003; Helton KJ, 2014, BLOOD, V124, P891, DOI 10.1182/blood-2013-12-545186; Hulbert ML, 2011, BLOOD, V117, P772, DOI 10.1182/blood-2010-01-261123; Kwiatkowski JL, 2011, PEDIATR BLOOD CANCER, V56, P777, DOI 10.1002/pbc.22951; Ohene-Frempong K, 1998, BLOOD, V91, P288; Raphael JL, 2008, PEDIATR BLOOD CANCER, V51, P647, DOI 10.1002/pbc.21677; Reboussin DM, 2000, CONTROL CLIN TRIALS, V21, P190, DOI 10.1016/S0197-2456(00)00057-X; Reeves SL, 2015, CLIN PEDIATR, V54, P336, DOI 10.1177/0009922814553429; Wang WC, 2011, LANCET, V377, P1663, DOI 10.1016/S0140-6736(11)60355-3; Ware RE, 2004, J PEDIATR-US, V145, P346, DOI 10.1016/j.jpeds.2004.04.058; Ware RE, HEMATOLOGY IN PRESS; Ware RE, 2011, PEDIATR BLOOD CANCER, V57, P1011, DOI 10.1002/pbc.23145; Ware RE, 2010, BLOOD, V115, P5300, DOI 10.1182/blood-2009-04-146852; Yawn BP, 2014, JAMA-J AM MED ASSOC, V312, P1033, DOI 10.1001/jama.2014.10517; Zimmerman SA, 2007, BLOOD, V110, P1043, DOI 10.1182/blood-2006-11-057893	30	270	273	1	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	2016	387	10019					661	670		10.1016/S0140-6736(15)01041-7	http://dx.doi.org/10.1016/S0140-6736(15)01041-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD3QH	26670617	Green Accepted, Green Submitted			2023-01-03	WOS:000369837100025
J	Wang, Z; Jin, Y; Shen, CY; Li, TT; Huang, YF; Li, BG				Wang, Zhan; Jin, Yan; Shen, Chongyang; Li, Tiantian; Huang, Yuanfang; Li, Baoguo			Spontaneous Detachment of Colloids from Primary Energy Minima by Brownian Diffusion	PLOS ONE			English	Article							MICROMETER-SCALE PARTICLES; POROUS-MEDIA; SURFACE-ROUGHNESS; SOLUTION CHEMISTRY; DLVO INTERACTION; CARBON NANOTUBES; IONIC-STRENGTH; RELEASE; DEPOSITION; TRANSPORT	The Derjaguin-Landau-Verwey-Overbeek (DLVO) interaction energy profile has been frequently used to interpret the mechanisms controlling colloid attachment/detachment and aggregation/disaggregation behavior. This study highlighted a type of energy profile that is characterized by a shallow primary energy well (i.e., comparable to the average kinetic energy of a colloid) at a small separation distance and a monotonic decrease of interaction energy with separation distance beyond the primary energy well. This energy profile is present due to variations of height, curvature, and density of discrete physical heterogeneities on collector surfaces. The energy profile indicates that colloids can be spontaneously detached from the shallow primary energy well by Brownian diffusion. The spontaneous detachment from primary minima was unambiguously confirmed by conducting laboratory column transport experiments involving flow interruptions for two model colloids (polystyrene latex microspheres) and engineered nanoparticles (fullerene C-60 aggregates). Whereas the spontaneous detachment has been frequently attributed to attachment in secondary minima in the literature, our study indicates that the detached colloids could be initially attached at primary minima. Our study further suggests that the spontaneous disaggregation from primary minima is more significant than spontaneous detachment because the primary minimum depth between colloid themselves is lower than that between a colloid and a collector surface.	[Wang, Zhan; Shen, Chongyang; Li, Tiantian; Huang, Yuanfang; Li, Baoguo] China Agr Univ, Dept Soil & Water Sci, Beijing 100193, Peoples R China; [Wang, Zhan] Shenyang Agr Univ, Coll Land & Environm, Shenyang 110866, Liaoning, Peoples R China; [Jin, Yan] Univ Delaware, Dept Plant & Soil Sci, Newark, DE 19716 USA	China Agricultural University; Shenyang Agricultural University; University of Delaware	Shen, CY; Li, BG (corresponding author), China Agr Univ, Dept Soil & Water Sci, Beijing 100193, Peoples R China.	chongyang.shen@gmail.com; libg@cau.edu.cn	Shen, Chongyang/W-8463-2019		Chinese Universities Scientific Fund [2015QC061]; National Natural Science Foundation of China [41271009]; Program for New Century Excellent Talents in University [NCET-13-0560]; National Key Technology RD Program [2012BAD05B02]	Chinese Universities Scientific Fund; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); National Key Technology RD Program(National Key Technology R&D Program)	The authors acknowledge the financial support provided by the Chinese Universities Scientific Fund (2015QC061, http://www.moe.edu.cn) (CS), National Natural Science Foundation of China (no. 41271009, http://www.nsfc.gov.cn) (CS), Program for New Century Excellent Talents in University (NCET-13-0560, http://www.moe.edu.cn) (CS), and National Key Technology R&D Program (no. 2012BAD05B02, http://www.most.gov.cn) (BL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acuna SM, 2008, LANGMUIR, V24, P4881, DOI 10.1021/la703866g; Assemi S, 2006, COLLOID SURFACE A, V286, P70, DOI 10.1016/j.colsurfa.2006.03.024; BALES RC, 1991, ENVIRON SCI TECHNOL, V25, P2088, DOI 10.1021/es00024a016; BALES RC, 1993, WATER RESOUR RES, V29, P957, DOI 10.1029/92WR02986; Batra A, 2001, AICHE J, V47, P2557, DOI 10.1002/aic.690471118; Bergendahl J, 2000, CHEM ENG SCI, V55, P1523, DOI 10.1016/S0009-2509(99)00422-4; Bergendahl JA, 2003, ENVIRON SCI TECHNOL, V37, P2317, DOI 10.1021/es0209316; Bhattacharjee S, 1997, J COLLOID INTERF SCI, V193, P273, DOI 10.1006/jcis.1997.5076; Bhattacharjee S, 1998, LANGMUIR, V14, P3365, DOI 10.1021/la971360b; Bhattacharjee S, 1998, CROAT CHEM ACTA, V71, P883; Bradford SA, 2015, J CONTAM HYDROL, V181, P141, DOI 10.1016/j.jconhyd.2015.04.003; Bradford SA, 2013, LANGMUIR, V29, P6944, DOI 10.1021/la4011357; Brant JA, 2002, ENVIRON ENG SCI, V19, P413, DOI 10.1089/109287502320963409; Burdick GM, 2005, THIN SOLID FILMS, V488, P116, DOI 10.1016/j.tsf.2005.04.112; Camesano TA, 2000, ENVIRON SCI TECHNOL, V34, P3354, DOI 10.1021/es9913176; CHAN DYC, 1984, J COLLOID INTERF SCI, V102, P400, DOI 10.1016/0021-9797(84)90242-X; Chen KL, 2006, LANGMUIR, V22, P10994, DOI 10.1021/la062072v; Clar JG, 2013, J AM CHEM SOC, V135, P17758, DOI 10.1021/ja4052526; CLAYFIELD EJ, 1970, ENVIRON SCI TECHNOL, V4, P413, DOI 10.1021/es60040a005; Considine RF, 2001, LANGMUIR, V17, P7777, DOI 10.1021/la0017227; DAHNEKE B, 1975, J COLLOID INTERF SCI, V50, P89, DOI 10.1016/0021-9797(75)90257-X; Desset S, 2000, LANGMUIR, V16, P10495, DOI 10.1021/la000734p; DUCKER WA, 1991, NATURE, V353, P239, DOI 10.1038/353239a0; Duffadar RD, 2008, J COLLOID INTERF SCI, V326, P18, DOI 10.1016/j.jcis.2008.07.004; Duffadar RD, 2007, J COLLOID INTERF SCI, V308, P20, DOI 10.1016/j.jcis.2006.12.068; ELIMELECH M, 1990, LANGMUIR, V6, P1153, DOI 10.1021/la00096a023; ELIMELECH M, 1990, ENVIRON SCI TECHNOL, V24, P1528, DOI 10.1021/es00080a012; Fuerstenau DW, 2005, ADV COLLOID INTERFAC, V114, P9, DOI 10.1016/j.cis.2004.08.006; Grolimund D, 2001, WATER RESOUR RES, V37, P559, DOI 10.1029/2000WR900285; Grolimund D, 2001, WATER RESOUR RES, V37, P571, DOI 10.1029/2000WR900286; Hahn MW, 2004, ENVIRON SCI TECHNOL, V38, P5915, DOI 10.1021/es049746d; Hahn MW, 2004, ENVIRON SCI TECHNOL, V38, P210, DOI 10.1021/es030416n; Hamaker HC, 1937, PHYSICA, V4, P1058, DOI 10.1016/S0031-8914(37)80203-7; HAPPEL J, 1958, AICHE J, V4, P197, DOI 10.1002/aic.690040214; Hoek EMV, 2006, J COLLOID INTERF SCI, V298, P50, DOI 10.1016/j.jcis.2005.12.031; Hoek EMV, 2003, LANGMUIR, V19, P4836, DOI 10.1021/la027083c; HOGG R, 1966, T FARADAY SOC, V62, P1638, DOI 10.1039/tf9666201638; Hotze EM, 2010, J ENVIRON QUAL, V39, P1909, DOI 10.2134/jeq2009.0462; Huang XF, 2010, LANGMUIR, V26, P2528, DOI 10.1021/la9028113; Hunter R.J., 1981, ZETA POTENTIAL COLLO, DOI 10.1016/B978-0-12-361961-7.50001-8; KALLAY N, 1987, ADV COLLOID INTERFAC, V27, P1, DOI 10.1016/0001-8686(87)85008-X; Kim JU, 2008, MACROMOLECULES, V41, P246, DOI 10.1021/ma071906t; Kovalchuk NM, 2012, ADV COLLOID INTERFAC, V179, P99, DOI 10.1016/j.cis.2011.05.009; Ninham BW, 1999, ADV COLLOID INTERFAC, V83, P1, DOI 10.1016/S0001-8686(99)00008-1; Oliveira R, 1997, EXP THERM FLUID SCI, V14, P316, DOI 10.1016/S0894-1777(96)00134-3; Pazmino E, 2014, ENVIRON SCI TECHNOL, V48, P9227, DOI 10.1021/es502503y; Redman JA, 2004, ENVIRON SCI TECHNOL, V38, P1777, DOI 10.1021/es034887l; Roy SB, 1996, COLLOID SURFACE A, V119, P133, DOI 10.1016/S0927-7757(96)03764-8; RYAN JN, 1994, ENVIRON SCI TECHNOL, V28, P1717, DOI 10.1021/es00058a025; RYAN JN, 1994, J COLLOID INTERF SCI, V164, P21, DOI 10.1006/jcis.1994.1139; Ryan JN, 1996, COLLOID SURFACE A, V107, P1, DOI 10.1016/0927-7757(95)03384-X; Ryde NP, 2000, COLLOID SURFACE A, V165, P59, DOI 10.1016/S0927-7757(99)00447-1; Schijven JF, 2000, CRIT REV ENV SCI TEC, V30, P49, DOI 10.1080/10643380091184174; Schowalter WR, 2001, P NATL ACAD SCI USA, V98, P3644, DOI 10.1073/pnas.061028498; Shay JS, 2001, J RHEOL, V45, P913, DOI 10.1122/1.1378030; Shen C, 2012, COLLOID SURF A, V107, P1; Shen CY, 2007, ENVIRON SCI TECHNOL, V41, P6976, DOI 10.1021/es070210c; Shen CY, 2015, J CONTAM HYDROL, V177, P18, DOI 10.1016/j.jconhyd.2015.03.003; Shen CY, 2015, J HAZARD MATER, V290, P60, DOI 10.1016/j.jhazmat.2015.02.067; Shen CY, 2014, J COLLOID INTERF SCI, V421, P103, DOI 10.1016/j.jcis.2014.01.033; Shen CY, 2013, COLLOID SURFACE A, V433, P14, DOI 10.1016/j.colsurfa.2013.04.048; Shen CY, 2012, LANGMUIR, V28, P14681, DOI 10.1021/la303163c; Shen CY, 2012, VADOSE ZONE J, V11, DOI 10.2136/vzj2011.0057; Shen CY, 2011, VADOSE ZONE J, V10, P1071, DOI 10.2136/vzj2011.0011; Shen CY, 2010, WATER RESOUR RES, V46, DOI 10.1029/2010WR009218; Suresh L, 1996, J COLLOID INTERF SCI, V183, P199, DOI 10.1006/jcis.1996.0535; Suresh L, 1997, J COLLOID INTERF SCI, V196, P177, DOI 10.1006/jcis.1997.5216; Tian Y, 2012, J HAZARD MATER, V231, P79, DOI 10.1016/j.jhazmat.2012.06.039; Torkzaban S, 2007, LANGMUIR, V23, P9652, DOI 10.1021/la700995e; Torkzaban S, 2016, WATER RES, V88, P274, DOI 10.1016/j.watres.2015.10.022; Torkzaban S, 2013, ENVIRON SCI TECHNOL, V47, P11528, DOI 10.1021/es402075f; Tosco T, 2009, ENVIRON SCI TECHNOL, V43, P4425, DOI 10.1021/es900245d; Tufenkji N, 2005, LANGMUIR, V21, P841, DOI 10.1021/la048102g; Verwey E.J.W, 1948, THEORY STABILITY LYO; Walz JY, 1998, ADV COLLOID INTERFAC, V74, P119, DOI 10.1016/S0001-8686(97)00042-0; Wu KL, 2005, LANGMUIR, V21, P3238, DOI 10.1021/la0476682; Wu L, 2012, ENVIRON SCI TECHNOL, V46, P8878, DOI 10.1021/es301365f; Yi P, 2013, ENVIRON SCI TECHNOL, V47, P12211, DOI 10.1021/es403133r; Zhuang J, 2005, ENVIRON SCI TECHNOL, V39, P7853, DOI 10.1021/es050265j	79	10	11	0	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2016	11	1							e0147368	10.1371/journal.pone.0147368	http://dx.doi.org/10.1371/journal.pone.0147368			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB5BP	26784446	gold, Green Published, Green Submitted			2023-01-03	WOS:000368528400144
J	Frauenknecht, K; Diederich, K; Leukel, P; Bauer, H; Schabitz, WR; Sommer, CJ; Minnerup, J				Frauenknecht, Katrin; Diederich, Kai; Leukel, Petra; Bauer, Henrike; Schaebitz, Wolf-Ruediger; Sommer, Clemens J.; Minnerup, Jens			Functional Improvement after Photothrombotic Stroke in Rats Is Associated with Different Patterns of Dendritic Plasticity after G-CSF Treatment and G-CSF Treatment Combined with Concomitant or Sequential Constraint-Induced Movement Therapy	PLOS ONE			English	Article							COLONY-STIMULATING FACTOR; ISCHEMIC-STROKE; PYRAMIDAL NEURONS; ANIMAL-MODELS; ADULT RATS; BRAIN; RECOVERY; CORTEX; CELLS; EFFICACY	We have previously shown that granulocyte-colony stimulating factor (G-CSF) treatment alone, or in combination with constraint movement therapy (CIMT) either sequentially or concomitantly, results in significantly improved sensorimotor recovery after photothrombotic stroke in rats in comparison to untreated control animals. CIMT alone did not result in any significant differences compared to the control group (Diederich et al., Stroke, 2012;43:185-192). Using a subset of rat brains from this former experiment the present study was designed to evaluate whether dendritic plasticity would parallel improved functional outcomes. Five treatment groups were analyzed (n = 6 each) (i) ischemic control (saline); (ii) CIMT (CIMT between post-stroke days 2 and 11); (iii) G-CSF (10 mu g/kg G-CSF daily between post-stroke days 2 and 11); (iv) combined concurrent group (CIMT plus G-CSF) and (v) combined sequential group (CIMT between post-stroke days 2 and 11; 10 mu g/kg G-CSF daily between post-stroke days 12 and 21, respectively). After impregnation of rat brains with a modified Golgi-Cox protocol layer V pyramidal neurons in the peri-infarct cortex as well as the corresponding contralateral cortex were analyzed. Surprisingly, animals with a similar degree of behavioral recovery exhibited quite different patterns of dendritic plasticity in both peri-lesional and contralesional areas. The cause for these patterns is not easily to explain but puts the simple assumption that increased dendritic complexity after stroke necessarily results in increased functional outcome into perspective.	[Frauenknecht, Katrin; Leukel, Petra; Bauer, Henrike; Sommer, Clemens J.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Neuropathol, D-55122 Mainz, Germany; [Diederich, Kai; Schaebitz, Wolf-Ruediger; Minnerup, Jens] Univ Munster, Dept Neurol, D-48149 Munster, Germany; [Schaebitz, Wolf-Ruediger] EVKB, Bethel, Neurol, Bielefeld, Germany	Johannes Gutenberg University of Mainz; University of Munster; Evangelical Hospital Bethel (EvKB) - House Gilead I	Sommer, CJ (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Neuropathol, D-55122 Mainz, Germany.	clemens.sommer@unimedizin-mainz.de	Frauenknecht, Katrin/AAF-1638-2020	Frauenknecht, Katrin/0000-0002-1372-3297; Diederich, Kai/0000-0002-6550-9460	German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) [SO 908/3-1, SCH 787/5-1]	German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)(German Research Foundation (DFG))	CS and WRS were supported from a grant by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; SO 908/3-1, SCH 787/5-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allred RP, 2010, BEHAV NEUROSCI, V124, P124, DOI 10.1037/a0018457; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Brown CE, 2007, J NEUROSCI, V27, P4101, DOI 10.1523/JNEUROSCI.4295-06.2007; Cui LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064684; Diederich K, 2012, STROKE, V43, P185, DOI 10.1161/STROKEAHA.111.622159; Diederich K, 2009, J NEUROSCI, V29, P11572, DOI 10.1523/JNEUROSCI.0453-09.2009; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Eadie BD, 2005, J COMP NEUROL, V486, P39, DOI 10.1002/cne.20493; Frauenknecht K, 2015, NEUROPATH APPL NEURO, V41, P657, DOI 10.1111/nan.12180; Gibb R, 1998, J NEUROSCI METH, V79, P1, DOI 10.1016/S0165-0270(97)00163-5; Gonzalez CLR, 2006, NEUROPHARMACOLOGY, V50, P777, DOI 10.1016/j.neuropharm.2005.11.018; Gonzalez CLR, 2003, EUR J NEUROSCI, V18, P1950, DOI 10.1046/j.1460-9568.2003.02928.x; Grotta JC, 2015, STROKE; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hermann DM, 2012, LANCET NEUROL, V11, P369, DOI 10.1016/S1474-4422(12)70039-X; JONES TA, 1994, J NEUROSCI, V14, P2140; Kolb B, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00015; Krakauer JW, 2012, NEUROREHAB NEURAL RE, V26, P923, DOI 10.1177/1545968312440745; Kwakkel G, 2015, LANCET NEUROL, V14, P224, DOI 10.1016/S1474-4422(14)70160-7; Liu ZW, 2010, J CEREBR BLOOD F MET, V30, P1288, DOI 10.1038/jcbfm.2010.8; Minnerup Jens, 2009, Exp Transl Stroke Med, V1, P2, DOI 10.1186/2040-7378-1-2; Mostany R, 2011, J NEUROSCI, V31, P1734, DOI 10.1523/JNEUROSCI.4386-10.2011; Papadopoulos CM, 2006, CEREB CORTEX, V16, P529, DOI 10.1093/cercor/bhi132; Rowntree S, 1997, EUR J NEUROSCI, V9, P2432, DOI 10.1111/j.1460-9568.1997.tb01660.x; Schmidt A, 2014, STROKE, V45, P239, DOI 10.1161/STROKEAHA.113.002048; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Shanina EV, 2006, NEUROSCIENCE, V139, P1495, DOI 10.1016/j.neuroscience.2006.01.016; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Silasi G, 2008, BEHAV BRAIN RES, V188, P219, DOI 10.1016/j.bbr.2007.10.030; Spratling M W, 2002, Behav Cogn Neurosci Rev, V1, P219, DOI 10.1177/1534582302001003003; Sprigg N, 2006, STROKE, V37, P2979, DOI 10.1161/01.STR.0000248763.49831.c3; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; Ueno Y, 2012, STROKE, V43, P2221, DOI 10.1161/STROKEAHA.111.646224; Zeiler SR, 2013, CURR OPIN NEUROL, V26, P609, DOI 10.1097/WCO.0000000000000025	34	7	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0146679	10.1371/journal.pone.0146679	http://dx.doi.org/10.1371/journal.pone.0146679			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6CA	26752421	Green Submitted, gold, Green Published			2023-01-03	WOS:000367888100127
J	Hodkinson, P; Argent, A; Wallis, L; Reid, S; Perera, R; Harrison, S; Thompson, M; English, M; Maconochie, I; Ward, A				Hodkinson, Peter; Argent, Andrew; Wallis, Lee; Reid, Steve; Perera, Rafael; Harrison, Sian; Thompson, Matthew; English, Mike; Maconochie, Ian; Ward, Alison			Pathways to Care for Critically Ill or Injured Children: A Cohort Study from First Presentation to Healthcare Services through to Admission to Intensive Care or Death	PLOS ONE			English	Article							CONFIDENTIAL INQUIRY; DISTRICT HOSPITALS; MORTALITY; DELIVERY	Purpose Critically ill or injured children require prompt identification, rapid referral and quality emergency management. We undertook a study to evaluate the care pathway of critically ill or injured children to identify preventable failures in the care provided. Methods A year-long cohort study of critically ill and injured children was performed in Cape Town, South Africa, from first presentation to healthcare services until paediatric intensive care unit (PICU) admission or emergency department death, using expert panel review of medical records and caregiver interview. Main outcomes were expert assessment of overall quality of care; avoidability of severity of illness and PICU admission or death and the identification of modifiable factors. Results The study enrolled 282 children, 252 emergency PICU admissions, and 30 deaths. Global quality of care was graded good in 10% of cases, with half having at least one major impact modifiable factor. Key modifiable factors related to access to care and identification of the critically ill, assessment of severity, inadequate resuscitation, and delays in decision making and referral. Children were transferred with median time from first presentation to PICU admission of 12.3 hours. There was potentially avoidable severity of illness in 185 (74%) of children, and death prior to PICU admission was avoidable in 17/30 (56.7%) of children. Conclusions The study presents a novel methodology, examining quality of care across an entire system, and highlighting the complexity of the pathway and the modifiable events amenable to interventions, that could reduce mortality and morbidity, and optimize utilization of scarce critical care resources; as well as demonstrating the importance of continuity and quality of care.	[Hodkinson, Peter; Wallis, Lee] Univ Cape Town, Div Emergency Med, ZA-7925 Cape Town, South Africa; [Argent, Andrew] Univ Cape Town, Dept Paediat, ZA-7925 Cape Town, South Africa; [Reid, Steve] Univ Cape Town, Directorate Primary Hlth Care, ZA-7925 Cape Town, South Africa; [Perera, Rafael; Harrison, Sian; Ward, Alison] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [Thompson, Matthew] Univ Washington, Dept Family Med, Seattle, WA 98195 USA; [English, Mike] Univ Oxford, Nuffield Dept Med, Oxford, England; [English, Mike] KEMRI Wellcome Trust Res Programme, Nairobi, Kenya; [Maconochie, Ian] Univ London Imperial Coll Sci Technol & Med, Paediat Emergency Med, London, England; [Maconochie, Ian] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	University of Cape Town; University of Cape Town; University of Cape Town; University of Oxford; University of Washington; University of Washington Seattle; University of Oxford; Imperial College London; Imperial College London	Hodkinson, P (corresponding author), Univ Cape Town, Div Emergency Med, ZA-7925 Cape Town, South Africa.	pwhodkinson@gmail.com	Reid, Stephen/AAY-6101-2020; Argent, Andrew/J-1605-2019; Hodkinson, PW W/N-3122-2018	Argent, Andrew/0000-0001-9333-2036; Hodkinson, PW W/0000-0002-0376-7982; Perera, Rafael/0000-0003-2418-2091; Wallis, Lee/0000-0003-2711-3139; Reid, Steve/0000-0003-2826-2304; Maconochie, Ian/0000-0001-6319-8550	Wellcome Trust [WT091107MA]; Nuffield Department of Primary Care Health Sciences, Oxford University	Wellcome Trust(Wellcome TrustEuropean Commission); Nuffield Department of Primary Care Health Sciences, Oxford University	The study was funded by the Wellcome Trust (WT091107MA) and the Nuffield Department of Primary Care Health Sciences, Oxford University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barasa EW, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001238; Berry L., 2013, SOUTH AFRICAN CHILD; Bhutta ZA, 2013, LANCET, V381, P1417, DOI 10.1016/S0140-6736(13)60648-0; Brent AJ, 2011, ARCH DIS CHILD, V96, P361, DOI 10.1136/adc.2010.183111; Campbell H, 2008, PEDIATRICS, V121, pE984, DOI 10.1542/peds.2007-1395; Christian CW, 2010, PEDIATRICS, V126, P592, DOI 10.1542/peds.2010-2006; DEVLIN HB, 1985, J ROY SOC MED, V78, P698; Drife J, 2008, BEST PRACT RES CL OB, V22, P501, DOI 10.1016/j.bpobgyn.2007.10.005; Drife J, 2012, SAJOG-S AFR J OBSTET, V18, P32; Egdell P, 2008, EMERG MED J, V25, P745, DOI 10.1136/emj.2007.054965; English M, 2005, ARCH DIS CHILD, V90, P974, DOI 10.1136/adc.2005.074468; English M, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-42; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; Harnden A, 2009, BRIT J GEN PRACT, V59, P819, DOI 10.3399/bjgp09X472520; IBM, 2012, SPSS STAT WIND VERS; Institute of Medicine Committee on Data Standards for Patient Safety, 2004, ACH NEW STAND CAR; Kissoon N, 2011, PEDIATR CRIT CARE ME, V12, P494, DOI 10.1097/PCC.0b013e318207096c; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Launay E, 2010, PEDIATR CRIT CARE ME, V11, P469, DOI 10.1097/PCC.0b013e3181ce752e; Lewis G., 2007, THE SEVENTH REPORT O; Mathews B, 2008, CHILD MALTREATMENT, V13, P50, DOI 10.1177/1077559507310613; Modig N., 2012, RHEOLOGICA; Mohan G, 1996, BRIT J GEN PRACT, V46, P529; Molyneux E, 2006, B WORLD HEALTH ORGAN, V84, P314, DOI 10.2471/BLT.04.019505; Mooney H, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e5138; Nadel S, 1998, J ACCID EMERG MED, V15, P298; Ninis N, 2005, BRIT MED J, V330, P1475, DOI 10.1136/bmj.330.7506.1475; Papworth S, 2005, SEMIN FETAL NEONAT M, V10, P39, DOI 10.1016/j.siny.2004.09.013; Paul R, 2012, PEDIATRICS, V130, pE273, DOI 10.1542/peds.2012-0094; Pearson GA, 2011, ARCH DIS CHILD, V96, P927, DOI 10.1136/adc.2009.177071; Rimsza ME, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e11; Seiger N, 2013, PEDIATRICS, V132, pE841, DOI 10.1542/peds.2012-3594; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Statistics South Africa, 2012, CENS 2011 MUN REP W; Tucker KM, 2009, J SPEC PEDIATR NURS, V14, P79, DOI 10.1111/j.1744-6155.2008.00178.x; Van den Bruel A, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6144; Weindling AM, 2003, ARCH DIS CHILD, V88, P1034, DOI 10.1136/adc.88.12.1034	37	33	33	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2016	11	1							e0145473	10.1371/journal.pone.0145473	http://dx.doi.org/10.1371/journal.pone.0145473			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA4VZ	26731245	gold, Green Published			2023-01-03	WOS:000367801400036
J	Kim, Y; Koo, YS; Lee, HY; Lee, SY				Kim, Yeshin; Koo, Yong Seo; Lee, Hee Young; Lee, Seo-Young			Can Continuous Positive Airway Pressure Reduce the Risk of Stroke in Obstructive Sleep Apnea Patients? A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							TRANSIENT ISCHEMIC ATTACK; CORONARY-HEART-DISEASE; CARDIOVASCULAR EVENTS; BLOOD-PRESSURE; MORTALITY; THERAPY; ASSOCIATION	Background and Purpose Obstructive sleep apnea (OSA) has been shown to increase the risk of stroke. Although continuous positive airway pressure (CPAP) is considered the treatment of choice for OSA, whether treating OSA with CPAP reduces the risk of stroke remains unclear. We aimed to evaluate the effects of CPAP on incidence of stroke in patients with OSA. Materials and Methods We conducted a systematic review and meta-analysis of all published studies that provided the number of incident strokes in OSA patients in light of their treatment status with CPAP. Results We identified 8 relevant studies: one randomized controlled study (RCT), 5 cohort studies, and 2 studies using administrative health data. The two overlapping cohort studies in women and the elderly and the 2 studies using administrative health data had analyzed the impact of CPAP on stroke apart from cardiac events, whereas the others had focused on the overall cardiovascular events. Based on a meta-analysis of the cohort studies, treatment with CPAP was associated with a lower incidence of stroke and cardiac events with relative risks of 0.27 [0.14-0.53], and 0.54 [0.38-0.75], respectively, although this could not be reproduced in the RCT and the studies using administrative data. Conclusions Treating with CPAP in patients with OSA might decrease the risk of stroke, although there is some conflicting evidence. Such effect was more pronounced in stroke than in cardiac events. Future studies analyzing stroke apart from cardiac disease would be of interest.	[Kim, Yeshin; Lee, Seo-Young] Kangwon Natl Univ, Coll Med, Dept Neurol, Chuncheon Si, Gangwon Do, South Korea; [Koo, Yong Seo] Korea Univ, Coll Med, Dept Neurol, Seoul 136705, South Korea; [Lee, Hee Young] Seoul Natl Univ, Bundang Hosp, Ctr Prevent Med & Publ Hlth, Songnam, Gyeonggi Do, South Korea	Kangwon National University; Korea University; Korea University Medicine (KU Medicine); Seoul National University (SNU)	Lee, HY (corresponding author), Seoul Natl Univ, Bundang Hosp, Ctr Prevent Med & Publ Hlth, Songnam, Gyeonggi Do, South Korea.	lhy0313@gmail.com; leeseoyoung@kangwon.ac.kr	lee, hy/GRS-0797-2022		Kangwon National University (KR)	Kangwon National University (KR)	This work was funded by Kangwon National University (KR) (www.kangwon.ac.kr) and the grant recipient was SYL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by Kangwon National University.	Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366; Bassetti CL, 2006, STROKE, V37, P967, DOI 10.1161/01.STR.0000208215.49243.c3; Bazzano LA, 2007, HYPERTENSION, V50, P417, DOI 10.1161/HYPERTENSIONAHA.106.085175; Benjamin JA, 2008, POSTGRAD MED J, V84, P15, DOI 10.1136/pgmj.2007.062836; Birkbak J, 2014, J CLIN SLEEP MED, V10, P103, DOI 10.5664/jcsm.3376; Buchner NJ, 2007, AM J RESP CRIT CARE, V176, P1274, DOI 10.1164/rccm.200611-1588OC; Campos-Rodriguez F, 2014, AM J RESP CRIT CARE, V189, P1544, DOI 10.1164/rccm.201311-2012OC; Campos-Rodriguez F, 2012, ANN INTERN MED, V156, P115, DOI 10.7326/0003-4819-156-2-201201170-00006; Doherty LS, 2005, CHEST, V127, P2076, DOI 10.1378/chest.127.6.2076; Elwood P, 2006, J EPIDEMIOL COMMUN H, V60, P69, DOI 10.1136/jech.2005.039057; Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043; Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238; Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Kasai T, 2012, CIRCULATION, V126, P1495, DOI 10.1161/CIRCULATIONAHA.111.070813; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Kim SY, 2013, J CLIN EPIDEMIOL, V66, P408, DOI 10.1016/j.jclinepi.2012.09.016; Lamberts M, 2014, J INTERN MED, V276, P659, DOI 10.1111/joim.12302; Lavie P, 2007, EUR RESPIR REV, V16, P203, DOI 10.1183/09059180.00010610; Lee SA, 2008, SLEEP, V31, P1207; Loke YK, 2012, CIRC-CARDIOVASC QUAL, V5, P720, DOI 10.1161/CIRCOUTCOMES.111.964783; Martinez-Garcia MA, 2012, EUR RESPIR J, V39, P906, DOI 10.1183/09031936.00011311; Martinez-Garcia MA, 2012, AM J RESP CRIT CARE, V186, P909, DOI 10.1164/rccm.201203-0448OC; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Molnar MZ, 2015, THORAX; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; Mooe T, 2001, AM J RESP CRIT CARE, V164, P1910, DOI 10.1164/ajrccm.164.10.2101072; Parra O, 2011, EUR RESPIR J, V37, P1128, DOI 10.1183/09031936.00034410; Peter B, 2011, PRINCIPLES PRACTICE, P1233; Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC; Somers VK, 2008, J AM COLL CARDIOL, V52, P686, DOI 10.1016/j.jacc.2008.05.002; Yaggi H, 2003, CLIN CHEST MED, V24, P223, DOI 10.1016/S0272-5231(03)00027-3; Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104	34	37	39	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2016	11	1							e0146317	10.1371/journal.pone.0146317	http://dx.doi.org/10.1371/journal.pone.0146317			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA4VZ	26731604	Green Published, Green Submitted, gold			2023-01-03	WOS:000367801400147
J	Yeji, F; Shibanuma, A; Oduro, A; Debpuur, C; Kikuchi, K; Owusu-Agei, S; Gyapong, M; Okawa, S; Ansah, E; Asare, GQ; Nanishi, K; Williams, J; Addei, S; Tawiah, C; Yasuoka, J; Enuameh, Y; Sakeah, E; Wontuo, P; Jimba, M; Hodgson, A				Yeji, Francis; Shibanuma, Akira; Oduro, Abraham; Debpuur, Cornelius; Kikuchi, Kimiyo; Owusu-Agei, Seth; Gyapong, Margaret; Okawa, Sumiyo; Ansah, Evelyn; Asare, Gloria Quansah; Nanishi, Keiko; Williams, John; Addei, Sheila; Tawiah, Charlotte; Yasuoka, Junko; Enuameh, Yeetey; Sakeah, Evelyn; Wontuo, Peter; Jimba, Masamine; Hodgson, Abraham		Ghana EMBRACE Implementation Res	Continuum of Care in a Maternal, Newborn and Child Health Program in Ghana: Low Completion Rate and Multiple Obstacle Factors	PLOS ONE			English	Article							FACILITY-BASED DELIVERY; SOCIOECONOMIC DETERMINANTS; NEONATAL-MORTALITY; SERVICES; BARRIERS; KENYA; BIRTH; DISTRICT; SURVIVAL; PROVINCE	Background Slow progress has been made in achieving the Millennium Development Goals 4 and 5 in Ghana. Ensuring continuum of care (at least four antenatal visits; skilled birth attendance; postnatal care within 48 hours, at two weeks, and six weeks) for mother and newborn is crucial in helping Ghana achieve these goals and beyond. This study examined the levels and factors associated with continuum of care (CoC) completion among Ghanaian women aged 15-49. Methods A retrospective cross-sectional survey was conducted among women who experienced live births between January 2011 and April 2013 in three regions of Ghana. In a two-stage random sampling method, 1,500 women with infants were selected and interviewed about maternal and newborn service usage in line with CoC. Multiple logistic regression models were used to assess factors associated with CoC completion. Results Only 8.0% had CoC completion; the greatest gap and contributor to the low CoC was detected between delivery and postnatal care within 48 hours postpartum. About 95% of women had a minimum of four antenatal visits and postnatal care at six weeks postpartum. A total of 75% had skilled assisted delivery and 25% received postnatal care within 48 hours. Factors associated with CoC completion at 95% CI were geographical location (OR = 0.35, CI 0.13-0.39), marital status (OR = 0.45; CI 0.22-0.95), education (OR = 2.71; CI 1.11-6.57), transportation (OR = 1.97; CI 1.07-3.62), and beliefs about childhood illnesses (OR = 0.34; CI0.21-0.61). Conclusion The continuum of care completion rate is low in the study site. Efforts should focus on increasing postnatal care within 48 hours and overcoming the known obstacles to increasing the continuum of care completion rate.	[Yeji, Francis; Oduro, Abraham; Debpuur, Cornelius; Williams, John; Sakeah, Evelyn; Wontuo, Peter] Navrongo Hlth Res Ctr, Navrongo, Upper East, Ghana; [Shibanuma, Akira; Kikuchi, Kimiyo; Okawa, Sumiyo; Nanishi, Keiko; Yasuoka, Junko; Jimba, Masamine] Univ Tokyo, Grad Sch Med, Dept Community & Global Hlth, Bunkyo Ku, Tokyo 1130033, Japan; [Owusu-Agei, Seth; Tawiah, Charlotte; Enuameh, Yeetey] Kintampo Hlth Res Ctr, Kintampo, Brong Ahafo, Ghana; [Gyapong, Margaret; Addei, Sheila] Dodowa Hlth Res Ctr, Dodowa, Greater Accra, Ghana; [Ansah, Evelyn; Hodgson, Abraham] Ghana Hlth Serv, Div Res & Dev, Accra, Ghana; [Asare, Gloria Quansah] Ghana Hlth Serv Headquarters, Accra, Ghana	Navrongo Health Research Center; University of Tokyo; Kintampo Health Research Centre; Ghana Health Service	Yeji, F (corresponding author), Navrongo Hlth Res Ctr, POB 114, Navrongo, Upper East, Ghana.	francis.yeji@gmail.com	Enuameh, Yeetey/AAO-7304-2020; Shibanuma, Akira/C-7652-2016; Jimba, Masamine/AAF-5630-2020; Yasuoka, Junko/GVT-8950-2022	Enuameh, Yeetey/0000-0003-3772-7425; Shibanuma, Akira/0000-0003-2058-1722; Debpuur, Cornelius/0000-0003-0968-5280; Gyapong, Margaret/0000-0002-4818-3497; ODURO, ABRAHAM/0000-0002-4191-7419; Ansah, Evelyn/0000-0003-0401-8606; Narh, Clement/0000-0002-4025-5433; Nanishi, Keiko/0000-0001-7067-8413	Japan International Cooperation Agency (JICA) Human Development Department; JICA Research Institute; District Health Management Teams of Kassena Nankana East; Kassena Nankana West; Kintampo North; Kintampo South; Shai-Osudoku; Ningo-Prampram; Dr. Joseph Green of the University of Tokyo	Japan International Cooperation Agency (JICA) Human Development Department; JICA Research Institute; District Health Management Teams of Kassena Nankana East; Kassena Nankana West; Kintampo North; Kintampo South; Shai-Osudoku; Ningo-Prampram; Dr. Joseph Green of the University of Tokyo	This paper was funded by the Japan International Cooperation Agency (JICA) Human Development Department, and JICA Research Institute (http://www.jica.go.jp/english/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors are grateful to the Ministry of Foreign Affairs in Japan, the Ministry of Health in Ghana, and the Ghana Health Service (GHS). We are particularly thankful to the study participants, and the District Health Management Teams of Kassena Nankana East, Kassena Nankana West, Kintampo North, Kintampo South, Shai-Osudoku, and Ningo-Prampram, for their support for this study. We also want to thank Dr. Joseph Green of the University of Tokyo for his support. The Ghana EMBRACE Implementation Research Project is conducted by the Government of Ghana, Japan International Cooperation Agency (JICA) Human Development Department, and JICA Research Institute. The views expressed in this study are solely that of the authors and do not necessarily represent the official views of the JICA Human Development Department, the JICA Research Institute, and the GHS	Abor PA, 2011, INT J SOC ECON, V38, P628, DOI 10.1108/03068291111139258; Adjuik M, 2010, GLOBAL HEALTH ACTION, V3, P15, DOI 10.3402/gha.v3i0.5233; Afulani PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117996; Ahmed S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011190; [Anonymous], 2015, GHANA MULTIPLE INDIC; [Anonymous], 2015, ASSESSMENT ANTENATAL; Awoonor-Williams JK, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-S2-S3; Barnighausen T, 2007, AIDS, V21, pS29, DOI 10.1097/01.aids.0000300533.59483.95; Bashour HN, 2008, PUBLIC HEALTH NURS, V25, P115, DOI 10.1111/j.1525-1446.2008.00688.x; Bazzano AN, 2008, TROP MED INT HEALTH, V13, P123, DOI 10.1111/j.1365-3156.2007.01981.x; Bazzano AN, 2008, INT J GYNECOL OBSTET, V102, P91, DOI 10.1016/j.ijgo.2008.02.004; Bhutta ZA, 2012, INT J GYNECOL OBSTET, V119, pS13, DOI 10.1016/j.ijgo.2012.04.001; Bohren MA, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-71; Denham AR, 2010, SOC SCI MED, V71, P608, DOI 10.1016/j.socscimed.2010.04.022; Doku D, 2012, BMC INT HEALTH HUM R, V12, DOI 10.1186/1472-698X-12-29; Eliason S, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-261; Esena RK, 2013, INTERNATINAL J SCI T, V5, P184; Exavery A, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-35; Fotso JC, 2008, J URBAN HEALTH, V85, P428, DOI 10.1007/s11524-008-9263-1; Gao Y, 2010, REPROD HEALTH MATTER, V18, P35, DOI 10.1016/S0968-8080(10)36523-2; Ghana Health Service, 2008, NAT SAF MOTH SERV PR; Ghana Statistical Service, 2012, MULT IND CLUST SURV; Ghana Statistical Service. Ghana Health Service, 2009, GHAN DEM HLTH SURV 2; Gitimu A, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0442-2; Gyapong M, 2013, INT J EPIDEMIOL, V42, P1686, DOI 10.1093/ije/dyt197; Johnson Joseph de Graft, OPPORTUNUTUES AFRICA; Karch LB., 2012, THINKING CHILDREN UN; Kayode GA, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-165; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Khanal V, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-19; Kikuchi K, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0539-3; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Lassi ZS, 2013, J MATERN-FETAL NEO M, V26, P3, DOI 10.3109/14767058.2013.784737; Lawn JE, 2009, BJOG-INT J OBSTET GY, V116, P49, DOI 10.1111/j.1471-0528.2009.02328.x; LIEBOWITZ B, 1970, GERONTOLOGIST, V10, P11, DOI 10.1093/geront/10.1_Part_1.11; Lincetto O, 2006, OPPOR AFR NEWBORNS P; Lincetto O, 2006, ANTENATAL CARE; Martines J, 2005, LANCET, V365, P1189, DOI 10.1016/S0140-6736(05)71882-1; Mills S, 2008, MATERN CHILD HLTH J, V12, P577, DOI 10.1007/s10995-007-0289-x; Morris SS, 2000, J EPIDEMIOL COMMUN H, V54, P381, DOI 10.1136/jech.54.5.381; Moyer CA, 2014, MATERN CHILD HLTH J, V18, P109, DOI 10.1007/s10995-013-1240-y; Mrisho M, 2007, TROP MED INT HEALTH, V12, P862, DOI 10.1111/j.1365-3156.2007.01855.x; Mwangome FK, 2012, RURAL REMOTE HEALTH, V12; Naariyong S, 2012, MATERN CHILD HLTH J, V16, P1709, DOI 10.1007/s10995-011-0880-z; Nair M, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004749; Nesbitt RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081089; Nettey OEA, 2010, GLOBAL HEALTH ACTION, V3, P8, DOI 10.3402/gha.v3i0.5258; Nyonator FK, 2005, HEALTH POLICY PLANN, V20, P25, DOI 10.1093/heapol/czi003; Oduro AR, 2012, INT J EPIDEMIOL, V41, P968, DOI 10.1093/ije/dys111; Oestergaard MZ, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001080; Okyere E, 2010, ANN TROP PAEDIATR, V30, P321, DOI 10.1179/146532810X12858955921311; Owusu-Agyei S, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.19033; Partnership for Maternal Newborn and Child Health, 2011, GLOB REV KEY INT REL; Pell C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053747; Phillips JF, 2006, B WORLD HEALTH ORGAN, V84, P949, DOI 10.2471/BLT.06.030064; Project Fives Alive, 2010, BREAKTHR RES POSTN C; Rishworth AC., 2014, WOMENS NAVIGATION MA; Sines E., 2007, POSTNATAL CARE CRITI; Speizer IS, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0398-7; Story WT, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-28; Tabatabaie MG, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-5; Takahashi Kenzo, 2013, Trop Med Health, V41, P135, DOI 10.2149/tmh.2013-14; The Partnership for Maternal Newborn & Child Health, 2011, STRAT FRAM 2012 2015; Tinker A, 2005, LANCET, V365, P822, DOI 10.1016/S0140-6736(05)71016-3; Titaley CR, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-232; Towns AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105972; UNICEF, 2015, STAT WORLDS CHILDR R; UNICEF, 2012, COMM CHILD SURV PROG; UNICEF, 2013, UNICEF 2013 IGME CHI; Warren C, 2006, POSTNATAL CARE OPPOR, P79; Welaga P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058924; WHO UNICEF, 2010, COUNTD 2015 DEC REP; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; World health organization, 2013, WORLD HLTH STAT 2013	74	58	58	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2015	10	12							e0142849	10.1371/journal.pone.0142849	http://dx.doi.org/10.1371/journal.pone.0142849			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CZ1YX	26650388	Green Published, gold, Green Submitted			2023-01-03	WOS:000366903300008
J	Pandey, S; Patel, MK; Mishra, A; Jha, B				Pandey, Sonika; Patel, Manish Kumar; Mishra, Avinash; Jha, Bhavanath			Physio-Biochemical Composition and Untargeted Metabolomics of Cumin (Cuminum cyminum L.) Make It Promising Functional Food and Help in Mitigating Salinity Stress	PLOS ONE			English	Article							ESSENTIAL OIL COMPOSITION; ANTIOXIDANT ACTIVITIES; FATTY-ACID; EXTINCTION COEFFICIENTS; SCAVENGING ACTIVITY; LIPID-PEROXIDATION; CHLOROPHYLL-A; SALT STRESS; TOLERANCE; WATER	Cumin is an annual, aromatic, herbaceous, medicinal, spice plant, most widely used as a food additive and flavoring agent in different cuisines. The study is intended to comprehensively analyse physiological parameters, biochemical composition and metabolites under salinity stress. Seed germination index, rate of seed emergence, rate of seed germination, mean germination time, plant biomass, total chlorophyll and carotenoid contents decreased concomitantly with salinity. In contrast, total antioxidant activity, H2O2, proline and MDA contents increased concurrently with stress treatments. Total phenolic and flavonoid contents were decreased initially about 1.4-fold at 50 mM, and thereafter increased about 1.2-fold at 100 mM NaCl stress. Relative water content remained unchanged up to 50 mM NaCl stress, and thereafter decreased significantly. About 2.8-fold electrolyte leakage was found in 50 mM, which increases further 4-fold at 100 mM NaCl stress. Saturated fatty acids (FAs) increased gradually with salinity, whereas unsaturation index and degree of unsaturation change arbitrarily along with the percent quantity of unsaturated FAs. Total lipid and fatty acid composition were significantly influenced by salinity stress. A total of 45 differentially expressed metabolites were identified, including luteolin, salvianolic acid, kaempferol and quercetin, which are phenolic, flavonoid or alkaloids in nature and contain antioxidant activities. Additionally, metabolites with bioactivity such as anticancerous ( docetaxel) and antimicrobial ( megalomicin) properties were also identified. The study evidenced that plant shoots are a rich source of metabolites, essential amino acids, phenolic compounds and fatty acids, which unveil the medicinal potential of this plant, and also provide useful insight about metabolic responses under salinity stress.	[Pandey, Sonika; Patel, Manish Kumar; Mishra, Avinash; Jha, Bhavanath] CSIR Cent Salt & Marine Chem Res Inst, Div Marine Biotechnol & Ecol, Bhavnagar, Gujarat, India; [Pandey, Sonika; Mishra, Avinash; Jha, Bhavanath] CSIR, Acad Sci & Innovat Res, New Delhi 110001, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Salt & Marine Chemical Research Institute (CSMCRI); Academy of Scientific & Innovative Research (AcSIR); Council of Scientific & Industrial Research (CSIR) - India	Mishra, A (corresponding author), CSIR Cent Salt & Marine Chem Res Inst, Div Marine Biotechnol & Ecol, G B Marg, Bhavnagar, Gujarat, India.	avinash@csmcri.org; bjha@csmcri.org	Patel, Manish Kumar/I-6335-2017; Mishra, Avinash/C-3210-2009; Mishra, Avinash/AAG-2961-2019	Patel, Manish Kumar/0000-0001-5250-1008; Mishra, Avinash/0000-0003-0342-010X; Mishra, Avinash/0000-0003-0342-010X	Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi [BSC0107-PlaGen]	Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi(Council of Scientific & Industrial Research (CSIR) - India)	This study was supported by the Council of Scientific and Industrial Research (CSIR; www.csir.res.in), Government of India, New Delhi [BSC0107-PlaGen]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1993, ANALYST, V118, P1089; ARUNA K, 1992, FOOD CHEM TOXICOL, V30, P953, DOI 10.1016/0278-6915(92)90180-S; Ashraf M, 2004, PLANT SCI, V166, P3, DOI 10.1016/j.plantsci.2003.10.024; Bajji M, 2002, PLANT GROWTH REGUL, V36, P61, DOI 10.1023/A:1014732714549; BARRS HD, 1962, AUST J BIOL SCI, V15, P413, DOI 10.1071/BI9620413; Bartels D, 2005, CRIT REV PLANT SCI, V24, P23, DOI 10.1080/07352680590910410; BATES LS, 1973, PLANT SOIL, V39, P205, DOI 10.1007/BF00018060; Bettaieb I, 2011, J AGR FOOD CHEM, V59, P328, DOI 10.1021/jf1037618; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaturvedi AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111379; CHEN GX, 1990, J BIOL CHEM, V265, P2775; D'Souza MR, 2010, ACTA PHYSIOL PLANT, V32, P341, DOI 10.1007/s11738-009-0412-2; De Lorenzo A, 2001, DIABETES NUTR METAB, V14, P181; De Vos RCH, 2007, NAT PROTOC, V2, P778, DOI 10.1038/nprot.2007.95; Deepak, 2013, INDIAN J TRADIT KNOW, V12, P300; Dhanalakshmi GS, 2003, NUTR CANCER, V47, P171, DOI 10.1207/s15327914nc4702_10; Ellis R. H., 1980, Seed production., P605; Epstein E, 2005, MINERAL NUTR PLANTS, P342; FAO, 2008, 91 FAO; FERGUSON IB, 1983, PLANT PHYSIOL, V71, P182, DOI 10.1104/pp.71.1.182; Gachkar L, 2007, FOOD CHEM, V102, P898, DOI 10.1016/j.foodchem.2006.06.035; Hajlaoui H, 2010, FOOD CHEM TOXICOL, V48, P2186, DOI 10.1016/j.fct.2010.05.044; Hare PD, 1997, PLANT GROWTH REGUL, V21, P79, DOI 10.1023/A:1005703923347; Hassanzadehdelouei M., 2013, Cercetari Agronomice in Moldova, V46, P89; Hazra B, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-63; Hodges DM, 1999, PLANTA, V207, P604, DOI 10.1007/s004250050524; Huang XS, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-230; Iacobellis NS, 2005, J AGR FOOD CHEM, V53, P57, DOI 10.1021/jf0487351; INSKEEP WP, 1985, PLANT PHYSIOL, V77, P483, DOI 10.1104/pp.77.2.483; Isaacson T, 2006, NAT PROTOC, V1, P769, DOI 10.1038/nprot.2006.102; Jha B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071136; Jha B, 2011, MOL BIOL REP, V38, P4823, DOI 10.1007/s11033-010-0625-x; Johri R K, 2011, Pharmacogn Rev, V5, P63, DOI 10.4103/0973-7847.79101; Kaewseejan N, 2015, J FUNCT FOODS, V12, P120, DOI 10.1016/j.jff.2014.11.001; Katembe WJ, 1998, ANN BOT-LONDON, V82, P167, DOI 10.1006/anbo.1998.0663; Khan MSA, 1997, J AGRON CROP SCI, V179, P163, DOI 10.1111/j.1439-037X.1997.tb00512.x; Kholova J, 2009, BIOL PLANTARUM, V53, P249, DOI 10.1007/s10535-009-0047-6; Kitajima J, 2003, PHYTOCHEMISTRY, V62, P115, DOI 10.1016/S0031-9422(02)00438-7; Kwanyuen P, 2010, J AM OIL CHEM SOC, V87, P127, DOI 10.1007/s11746-009-1484-2; Li XM, 2012, PLANT SOIL, V352, P377, DOI 10.1007/s11104-011-1003-8; Lopez-Cobo A, 2015, J FUNCT FOODS, V18, P1167, DOI 10.1016/j.jff.2014.10.023; Lu YR, 2001, TETRAHEDRON LETT, V42, P8223, DOI 10.1016/S0040-4039(01)01738-5; Lutts S, 1996, ANN BOT-LONDON, V78, P389, DOI 10.1006/anbo.1996.0134; MAGUIRE JAMES D., 1962, CROP SCI, V2, P176, DOI 10.2135/cropsci1962.0011183X000200020033x; Matthews S, 2011, SEED SCI TECHNOL, V39, P501, DOI 10.15258/sst.2011.39.2.21; Mishra A, 2015, J FUNCT FOODS, V13, P21, DOI 10.1016/j.jff.2014.12.027; Mishra A, 2009, BIORESOURCE TECHNOL, V100, P3382, DOI 10.1016/j.biortech.2009.02.006; Mittler R, 2004, TRENDS PLANT SCI, V9, P490, DOI 10.1016/j.tplants.2004.08.009; Mnif S, 2015, CHEM BIODIVERS, V12, P733, DOI 10.1002/cbdv.201400305; Moller IM, 2007, ANNU REV PLANT BIOL, V58, P459, DOI 10.1146/annurev.arplant.58.032806.103946; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Murillo-Amador B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094870; Navarro JM, 2006, FOOD CHEM, V96, P66, DOI 10.1016/j.foodchem.2005.01.057; Neffati M, 2011, FOOD CHEM, V124, P221, DOI 10.1016/j.foodchem.2010.06.022; NIU XM, 1995, PLANT PHYSIOL, V109, P735, DOI 10.1104/pp.109.3.735; Pandey S, 2013, APPL BIOCHEM BIOTECH, V171, P1, DOI 10.1007/s12010-013-0349-1; Panuccio MR, 2014, AOB PLANTS, V6, DOI 10.1093/aobpla/plu047; Patel MK, 2015, PLANT CELL TISS ORG, V122, P477, DOI 10.1007/s11240-015-0785-4; Poerschmann J, 2004, MICROB ECOL, V48, P78, DOI 10.1007/s00248-003-0144-6; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; POWELL AA, 1978, J EXP BOT, V29, P1215, DOI 10.1093/jxb/29.5.1215; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Rebey IB, 2012, IND CROP PROD, V36, P238, DOI 10.1016/j.indcrop.2011.09.013; Saeed N, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-221; Sangwan NS, 2001, PLANT GROWTH REGUL, V34, P3, DOI 10.1023/A:1013386921596; Shahidi F, 2015, J FUNCT FOODS, V18, P820, DOI 10.1016/j.jff.2015.06.018; Shahidi F, 2015, J FUNCT FOODS, V18, P757, DOI 10.1016/j.jff.2015.01.047; Shi J, 2010, TREE PHYSIOL, V30, P914, DOI 10.1093/treephys/tpq030; Shobbar MS, 2012, J PLANT NUTR, V35, P1037, DOI 10.1080/01904167.2012.671407; Shoor M, 2014, RES J AGR ENV MANAGE, V3, P340; Singh N, 2014, GENE, V547, P119, DOI 10.1016/j.gene.2014.06.037; Singh N, 2010, PLANT CELL TISS ORG, V103, P1, DOI 10.1007/s11240-010-9746-0; SMITH IK, 1988, ANAL BIOCHEM, V175, P408, DOI 10.1016/0003-2697(88)90564-7; Sowbhagya HB, 2013, CRIT REV FOOD SCI, V53, P1, DOI 10.1080/10408398.2010.500223; Takayanagi T, 2003, PHYTOCHEMISTRY, V63, P479, DOI 10.1016/S0031-9422(03)00103-1; Tiwari V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131567; Vallverdu-Queralt A, 2014, FOOD CHEM, V154, P299, DOI 10.1016/j.foodchem.2013.12.106; Vasconsuelo A, 2007, PLANT SCI, V172, P861, DOI 10.1016/j.plantsci.2007.01.006; Verpoorte R., 2002, Phytochemistry Reviews, V1, P13, DOI 10.1023/A:1015871916833; Xie ZX, 2008, J PLANT PHYSIOL, V165, P375, DOI 10.1016/j.jplph.2007.06.001; Xu XQ, 1997, PHYTOCHEMISTRY, V45, P655, DOI 10.1016/S0031-9422(96)00868-0; Xue TT, 2009, J EXP BOT, V60, P339, DOI 10.1093/jxb/ern291; Yu XY, 2012, BIORESOURCE TECHNOL, V121, P256, DOI 10.1016/j.biortech.2012.07.002; Zhang W, 2014, J FUNCT FOODS, V10, P427, DOI 10.1016/j.jff.2014.07.015; Zhu ZJ, 2013, NAT PROTOC, V8, P451, DOI 10.1038/nprot.2013.004	86	49	51	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2015	10	12							e0144469	10.1371/journal.pone.0144469	http://dx.doi.org/10.1371/journal.pone.0144469			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1YS	26641494	Green Submitted, gold, Green Published			2023-01-03	WOS:000366902700131
J	Sweeney, LA; Molloy, GJ; Byrne, M; Murphy, AW; Morgan, K; Hughes, CM; Ingham, R				Sweeney, Leigh-Ann; Molloy, Gerard J.; Byrne, Molly; Murphy, Andrew W.; Morgan, Karen; Hughes, Carmel M.; Ingham, Roger			A Qualitative Study of Prescription Contraception Use: The Perspectives of Users, General Practitioners and Pharmacists	PLOS ONE			English	Article							ACTING REVERSIBLE CONTRACEPTION; EMERGENCY CONTRACEPTION; UNINTENDED PREGNANCY; ATTITUDES; ADHERENCE; HEALTH; WOMEN	Background The oral contraceptive pill (OCP) remains the most popular form of prescription contraception in many countries, despite adherence difficulties for many. Uptake of long acting reversible contraceptives (LARCs), which are less reliant on user adherence, remains low. The aim of this study was to explore the experiences of, and attitudes towards, prescription contraception amongst samples of contraception users, general practitioners (GPs) and pharmacists. Methodology and Findings We conducted a qualitative study using semi-structured interviews with 18 contraception users, 18 GPs and 9 pharmacists. The study took place in Galway, Republic of Ireland between June and September 2014. Thematic analysis was used to analyse the data. Overall, contraception users were more familiar with the OCP, and all the women interviewed began their prescription contraception journey using this method. All participants identified episodes of poor adherence throughout the reproductive life course. The identified barriers for use of LARCs were lack of information, misconceptions, lack of access and high cost. In contrast, GPs believed that adherence to the OCP was good and stated they were more likely to prescribe the OCP than other methods, as they were most familiar with this option. Barriers to prescribing LARCSs were time, cost to practice, training and deskilling. Pharmacists also believed that adherence to the OCP was generally good and that their role was limited to dispensing medication and providing information when asked. Discussion and Conclusion There are contrasting perspectives between contraception service providers and contraceptive users. Training for healthcare providers is required to support informed contraceptive choice and adherence. It is necessary to address the practice barriers of cost and lack of time, to promote better communication around adherence issues and prescription contraception options. There is a need for more easily-accessible public health information to promote awareness on all methods of prescription contraception.	[Sweeney, Leigh-Ann; Molloy, Gerard J.; Byrne, Molly] Natl Univ Ireland, Sch Psychol, Galway, Ireland; [Sweeney, Leigh-Ann; Molloy, Gerard J.; Byrne, Molly] Natl Univ Ireland, Whitaker Inst Innovat & Societal Change, Galway, Ireland; [Murphy, Andrew W.] Natl Univ Ireland, Sch Med, Discipline Gen Practice, Galway, Ireland; [Morgan, Karen] Royal Coll Surgeons Ireland, Dept Psychol, Dublin 2, Ireland; [Morgan, Karen] Perdana Univ, Royal Coll Surg Ireland, Sch Med, Kuala Lumpur, Malaysia; [Hughes, Carmel M.] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland; [Ingham, Roger] Univ Southampton, Ctr Sexual Hlth Res, Southampton, Hants, England	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Royal College of Surgeons - Ireland; University College Dublin; Perdana University; Royal College of Surgeons - Ireland; Queens University Belfast; University of Southampton	Molloy, GJ (corresponding author), Natl Univ Ireland, Sch Psychol, Galway, Ireland.	gerry.molloy@nuigalway.ie	morgan, karen/C-3846-2012; Molloy, Gerard J/AAV-2634-2021; Molloy, Gerard J/C-5721-2008	morgan, karen/0000-0001-6193-1747; Molloy, Gerard J/0000-0002-7718-9898; Molloy, Gerard J/0000-0002-7718-9898; Murphy, Andrew/0000-0001-5549-8246; Byrne, Molly/0000-0001-8900-4320	Health Service Executive Crisis Pregnancy Programme [RPG2013-5]	Health Service Executive Crisis Pregnancy Programme	This study was funded by a project grant (Reference: RPG2013-5) awarded by the Health Service Executive Crisis Pregnancy Programme and administered by the Irish Research Council in December 2013 to Dr Gerry Molloy (Principal Investigator), Dr Karen Morgan, Dr Molly Byrne and Dr Andrew Murphy (Co-Investigators). Professor Carmel Hughes, Professor Roger Ingham and Professor Richard Layte were members of the steering committee for this study. Funder website: http://www.crisispregnancy.ie. Funding administered by: http://research.ie/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, WORLD CONTR PATT 201; Arrowsmith ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092205; Bazeley P., 2013, QUALITATIVE DATA ANA; Biggs MA, 2014, OBSTET GYNECOL, V123, P593, DOI 10.1097/AOG.0000000000000137; Bracken J, 2014, EUR J CONTRACEP REPR, V19, P276, DOI 10.3109/13625187.2014.917623; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Buhling KJ, 2014, CONTRACEPTION, V89, P162, DOI 10.1016/j.contraception.2013.11.011; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; Castano PM, 2013, CONTRACEPTION, V88, P475, DOI 10.1016/j.contraception.2013.08.002; Corden A., 2006, USING VERBATIM QUOTA; Dombrowski SU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039852; El-Ibiary SY, 2007, EUR J CONTRACEP REPR, V12, P58, DOI 10.1080/13625180601092537; Gipson JD, 2008, STUD FAMILY PLANN, V39, P18, DOI 10.1111/j.1728-4465.2008.00148.x; Glasier A, 2008, J FAM PLAN REPROD H, V34, P213, DOI 10.1783/147118908786000497; Halpern V, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004317.pub4; Hennink MM, 2007, INTERNATIONAL FOCUS GROUP RESEARCH: A HANDBOOK FOR THE HEALTH AND SOCIAL SCIENCES, P1, DOI 10.1017/CBO9780511619458; McBride O, 2012, IRISH CONTRACEPTION; Michie L, 2014, CONTRACEPTION, V90, P447, DOI 10.1016/j.contraception.2014.05.004; Michie L, 2013, Minerva Ginecol, V65, P241; Molloy GJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007794; Molloy GJ, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-838; Moos MK, 2003, CONTRACEPTION, V67, P115, DOI 10.1016/S0010-7824(02)00472-9; O'Donoghue C, 2011, CAMB J ECON, V35, P59, DOI 10.1093/cje/beq010; Okpo E, 2014, PUBLIC HEALTH, V128, P934, DOI 10.1016/j.puhe.2014.08.012; Potter L, 1996, FAM PLANN PERSPECT, V28, P154, DOI 10.2307/2136191; Secura GM, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.04.017; Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021; Weedle PB, 2011, PHARM MED LAW IRELAN; Wellings K, 2007, CONTRACEPTION, V76, P208, DOI 10.1016/j.contraception.2007.05.085; Wellings K, 2013, LANCET, V382, P1807, DOI 10.1016/S0140-6736(13)62071-1; WHO-World Health Organisation, 2008, CSDH FIN REP CLOS GA	31	8	8	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2015	10	12							e0144074	10.1371/journal.pone.0144074	http://dx.doi.org/10.1371/journal.pone.0144074			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX9QI	26633191	Green Accepted, gold, Green Published			2023-01-03	WOS:000366040000051
J	Iavicoli, I; Fontana, L; Corbi, M; Leso, V; Marinaccio, A; Leopold, K; Schindl, R; Sgambato, A				Iavicoli, Ivo; Fontana, Luca; Corbi, Maddalena; Leso, Veruscka; Marinaccio, Alessandro; Leopold, Kerstin; Schindl, Roland; Sgambato, Alessandro			Exposure to Palladium Nanoparticles Affects Serum Levels of Cytokines in Female Wistar Rats	PLOS ONE			English	Article							PLATINUM-GROUP ELEMENTS; BLOOD MONONUCLEAR-CELLS; AIRBORNE PLATINUM; RHODIUM CONCENTRATIONS; ORAL-EXPOSURE; TRAM DRIVERS; RELEASE; NANOMATERIALS; EMISSIONS; CITY	Background Information currently available on the impact of palladium on the immune system mainly derives from studies assessing the biological effects of palladium salts. However, in the last years, there has been a notable increase in occupational and environmental levels of fine and ultrafine palladium particles released from automobile catalytic converters, which may play a role in palladium sensitization. In this context, the evaluation of the possible effects exerted by palladium nanoparticles (Pd-NPs) on the immune system is essential to comprehensively assess palladium immunotoxic potential. Aim Therefore, the aim of this study was to investigate the effects of Pd-NPs on the immune system of female Wistar rats exposed to this xenobiotic for 14 days, by assessing possible quantitative changes in a number of cytokines: IL-1 alpha, IL-2, IL-4, IL-6, IL-10, IL-12, GM-CSF, INF-gamma and TNF-alpha. Methods Twenty rats were randomly divided into four exposure groups and one of control. Animals were given a single tail vein injection of vehicle (control group) and different concentrations of Pd-NPs (0.012, 0.12, 1.2 and 12 mu g/kg). A multiplex biometric enzyme linked immunosorbent assay was used to evaluate cytokine serum levels. Results The mean serum concentrations of all cytokines decreased after the administration of 0.012 mu g/kg of Pd-NPs, whereas exceeded the control levels at higher exposure doses.The highest concentration of Pd-NPs (12 mu g/kg) induced a significant increase of IL-1 alpha, IL-4, IL-6, IL-10, IL-12, GM-CSF and INF-gamma compared to controls. Discussion and Conclusions These results demonstrated that Pd-NP exposure can affect the immune response of rats inducing a stimulatory action that becomes significant at the highest administered dose. Our findings did not show an imbalance between cytokines produced by CD4(+) T helper (Th) cells 1 and 2, thus suggesting a generalized stimulation of the immune system with a simultaneous activation and polarization of the naive T cells towards Th1 and Th2 phenotype.	[Iavicoli, Ivo; Fontana, Luca; Leso, Veruscka] Univ Cattolica Sacro Cuore, Sect Occupat Med, Inst Publ Hlth, I-00168 Rome, Italy; [Corbi, Maddalena; Sgambato, Alessandro] Univ Cattolica Sacro Cuore, Inst Gen Pathol, I-00168 Rome, Italy; [Marinaccio, Alessandro] Italian Workers Compensat Author INAIL, Div Res, Dept Occupat Med, Epidemiol Unit, I-00198 Rome, Italy; [Leopold, Kerstin; Schindl, Roland] Univ Ulm, Inst Analyt & Bioanalyt Chem, D-89081 Ulm, Germany	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Ulm University	Iavicoli, I (corresponding author), Univ Cattolica Sacro Cuore, Sect Occupat Med, Inst Publ Hlth, Largo Francesco Vito 1, I-00168 Rome, Italy.	iavicoli.ivo@rm.unicatt.it	Leopold, Kerstin/GON-5246-2022; Iavicoli, Ivo/K-9062-2016; Leopold, Kerstin/AAU-1996-2021; Leso, Veruscka/J-8946-2018; Sgambato, Alessandro/K-7266-2016	Leopold, Kerstin/0000-0003-0586-7239; Iavicoli, Ivo/0000-0003-0444-3792; Leso, Veruscka/0000-0002-3039-2856; fontana, Luca/0000-0002-4621-7374; Sgambato, Alessandro/0000-0002-9487-4563				Acker H, 2005, PHILOS T R SOC B, V360, P2201, DOI 10.1098/rstb.2005.1760; Artelt S, 1999, ATMOS ENVIRON, V33, P3559, DOI 10.1016/S1352-2310(99)00109-0; Bencs L, 2003, SPECTROCHIM ACTA B, V58, P1723, DOI 10.1016/S0584-8547(03)00162-9; Berger A, 2000, BRIT MED J, V321, P424, DOI 10.1136/bmj.321.7258.424; Borm PJA, 2006, PART FIBRE TOXICOL, V3, DOI 10.1186/1743-8977-3-11; Boscolo P, 2004, ANN CLIN LAB SCI, V34, P299; Boscolo P, 2010, J BIOL REG HOMEOS AG, V24, P207; Brasch J, 1997, CONTACT DERMATITIS, V37, P286, DOI 10.1111/j.1600-0536.1997.tb02466.x; Calabrese EJ, 2010, HUM EXP TOXICOL, V29, P249, DOI 10.1177/0960327109363973; Calabrese EJ, 2009, ARCH TOXICOL, V83, P227, DOI 10.1007/s00204-009-0411-5; Chang C, 2010, J AUTOIMMUN, V34, pJ234, DOI 10.1016/j.jaut.2009.11.009; Chen BA, 2010, INT J NANOMED, V5, P593; Choi B, 2005, JSME INT J B-FLUID T, V48, P874, DOI 10.1299/jsmeb.48.874; CLAUSE BT, 1993, J HIST BIOL, V26, P329, DOI 10.1007/BF01061973; Cosmi L, 2014, CYTOM PART A, V85A, P36, DOI 10.1002/cyto.a.22348; Cristaudo A, 2007, ANAL LETT, V40, P3343, DOI 10.1080/00032710701689099; Descotes J, 2003, AN INTRODUCTION TO I; Dongarra G, 2003, APPL GEOCHEM, V18, P109, DOI 10.1016/S0883-2927(02)00051-3; Dubiella-Jackowska A, 2009, REV ENVIRON CONTAM T, V199, P111, DOI 10.1007/978-0-387-09808-1_3; Durosaro O, 2009, DERMATITIS, V20, P208, DOI 10.2310/6620.2009.08108; Faurschou A, 2011, CONTACT DERMATITIS, V64, P185, DOI 10.1111/j.1600-0536.2011.01878.x; Fontana L, 2015, NANOTOXICOLOGY, V9, P843, DOI 10.3109/17435390.2014.980759; Franco R, 2009, MUTAT RES-GEN TOX EN, V674, P3, DOI 10.1016/j.mrgentox.2008.11.012; Gaillet S, 2015, FOOD CHEM TOXICOL, V77, P58, DOI 10.1016/j.fct.2014.12.019; Gerberick GF, 2005, DERMATITIS, V16, P157, DOI 10.2310/6620.2005.05040; Iavicoli I, 2006, Int J Immunopathol Pharmacol, V19, P21; Iavicoli I, 2008, HUM EXP TOXICOL, V27, P493, DOI 10.1177/0960327108090489; Iavicoli I, 2009, J TOXICOL ENV HEAL A, V72, P88, DOI 10.1080/15287390802477387; Iavicoli I, 2008, J OCCUP ENVIRON MED, V50, P1158, DOI 10.1097/JOM.0b013e31818226a1; Iavicoli I, 2007, INT ARCH OCC ENV HEA, V81, P109, DOI 10.1007/s00420-007-0195-y; Iavicoli I, 2014, SCI TOTAL ENVIRON, V487, P361, DOI 10.1016/j.scitotenv.2014.04.023; Iavicoli I, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2302-9; Iavicoli I, 2013, INT J MOL SCI, V14, P16732, DOI 10.3390/ijms140816732; Iavicoli I, 2010, TOXICOL IND HEALTH, V26, P183, DOI 10.1177/0748233710362383; Kacew S, 1999, CELOEM, V5, P201; Kalavrouziotis IK, 2009, WATER AIR SOIL POLL, V196, P393, DOI 10.1007/s11270-008-9786-9; Kamala CT, 2015, ARCH ENVIRON CON TOX, V68, P421, DOI 10.1007/s00244-014-0114-7; Larese Filon Francesca, 2003, Am J Contact Dermat, V14, P78; Mathur R, 2011, ENVIRON EARTH SCI, V62, P1085, DOI 10.1007/s12665-010-0597-0; Medina-Reyes EI, 2015, ENVIRON RES, V136, P424, DOI 10.1016/j.envres.2014.10.016; Merget R, 2001, SCI TOTAL ENVIRON, V270, P165, DOI 10.1016/S0048-9697(00)00788-9; Mitzukami F, 1991, CATALYSIS AUTOMOTIVE, P557; Morawska L, 2008, ATMOS ENVIRON, V42, P8113, DOI 10.1016/j.atmosenv.2008.07.050; Muris J, 2015, CONTACT DERMATITIS, V72, P11, DOI 10.1111/cod.12295; Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397; Palacios M, 2000, SCI TOTAL ENVIRON, V257, P1, DOI 10.1016/S0048-9697(00)00464-2; Park EJ, 2010, TOXICOLOGY, V275, P65, DOI 10.1016/j.tox.2010.06.002; Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011; Rauch S, 2002, SCI TOTAL ENVIRON, V286, P243, DOI 10.1016/S0048-9697(01)00988-3; Ravindra K, 2004, SCI TOTAL ENVIRON, V318, P1, DOI 10.1016/S0048-9697(03)00372-3; Reale M, 2011, J OCCUP ENVIRON MED, V53, P1054, DOI 10.1097/JOM.0b013e318228115e; RICHTERREICHHELM HB, 1995, REGUL TOXICOL PHARM, V22, P54, DOI 10.1006/rtph.1995.1068; Schmalz G, 2000, EUR J ORAL SCI, V108, P442, DOI 10.1034/j.1600-0722.2000.108005442.x; Schmalz G, 1998, BIOMATERIALS, V19, P1689, DOI 10.1016/S0142-9612(98)00075-1; Schmitt N, 2015, CURR OPIN IMMUNOL, V34, P130, DOI 10.1016/j.coi.2015.03.007; Shi JP, 1999, SCI TOTAL ENVIRON, V235, P51, DOI 10.1016/S0048-9697(99)00189-8; Sobrova P, 2012, CENT EUR J CHEM, V10, P1369, DOI 10.2478/s11532-012-0073-7; Tsuji JS, 2006, TOXICOL SCI, V89, P42, DOI 10.1093/toxsci/kfi339; Walkey CD, 2012, CHEM SOC REV, V41, P2780, DOI 10.1039/c1cs15233e; *WHO, 2002, ENV HLTH; Wilkinson KE, 2011, ACS NANO, V5, P5312, DOI 10.1021/nn1032664; Wohrl S, 2003, PEDIATR DERMATOL, V20, P119, DOI 10.1046/j.1525-1470.2003.20204.x; Zereini F, 2007, ENVIRON SCI TECHNOL, V41, P451, DOI 10.1021/es061453s	63	19	19	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2015	10	11							e0143801	10.1371/journal.pone.0143801	http://dx.doi.org/10.1371/journal.pone.0143801			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7NW	26618704	Green Published, Green Submitted, gold			2023-01-03	WOS:000365889800073
J	Pogatzki-Zahn, E; Kutschar, P; Nestler, N; Osterbrink, J				Pogatzki-Zahn, Esther; Kutschar, Patrick; Nestler, Nadja; Osterbrink, Juergen			A Prospective Multicentre Study to Improve Postoperative Pain: Identification of Potentialities and Problems	PLOS ONE			English	Article							PERSISTENT POSTSURGICAL PAIN; RANDOMIZED-CONTROLLED-TRIALS; NATIONAL-SURVEY; MANAGEMENT; SURGERY; SATISFACTION; PREVALENCE; QUALITY; OPIOIDS	Many studies still indicate insufficient pain management after surgery, e.g., in patients after small-or medium-size operations. Yet it is still uncertain if postoperative pain based on patient-related outcomes can be improved by implementing guideline-related programmes in a multicentre approach. Adult patients in six hospitals in one German city were included in this prospective study. Data collection took place twice in each hospital, once before and once after implementation of concepts and in-house training. Pain and pain-related aspects were assessed one day after surgery and compared between the pre- and post-test group including subgroup analysis of certain surgical procedures by using Student's t-tests, Mann-Whitney U tests and chi-square tests (alpha(two-tailed) = 0.05). Overall, pain at rest and during movement was slightly lower after the intervention. Significant changes were observed after thoracic surgery, small joint surgery and other minor surgical procedures. The rather moderate decrease in pain likely relates to a reasonable pre-existing pain management and to detached improvements in certain patient subgroups. Interestingly, specific analyses revealed significantly lower post-test pain as compared to pre-test pain only in patients without pre-existing chronic pain. Side effects related to pain medication were significantly lower after intervention. Our data show, for the first time, benefits of a perioperative teaching programme in a multicentre approach. Pain ratings improved mainly in specific subgroups of patients, e.g., small surgical procedures and patients without preoperative pain. Thus, general improvement is possible but special attention should be paid to the group of patients with preoperative pain.	[Pogatzki-Zahn, Esther] Univ Hosp Muenster, Dept Anaesthesiol Intens Care & Pain Med, Munster, Germany; [Kutschar, Patrick; Nestler, Nadja; Osterbrink, Juergen] Paracelsus Med Univ, Inst Nursing Sci & Practice, Salzburg, Austria	University of Munster; Paracelsus Private Medical University	Pogatzki-Zahn, E (corresponding author), Univ Hosp Muenster, Dept Anaesthesiol Intens Care & Pain Med, Munster, Germany.	pogatzki@anit.uni-muenster.de	Kutschar, Patrick/AAR-7539-2020	Kutschar, Patrick/0000-0002-2029-2552	Province of Salzburg, Austria; City of Muenster, Germany; Mundipharma GmbH	Province of Salzburg, Austria; City of Muenster, Germany; Mundipharma GmbH	The project 'Action Alliance Pain-free City Muenster' was partly funded by the Province of Salzburg, Austria, the City of Muenster, Germany and Mundipharma GmbH. None of the funding parties were involved in planning the study, developing questionnaires or research plans, analysing data, discussion of data or writing of the present manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdalrahim Maysoon S, 2011, Nurse Educ Pract, V11, P250, DOI 10.1016/j.nepr.2010.11.016; Andreae MH, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007105.pub2; [Anonymous], ACUTE PAIN MANAGEMEN; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Benhamou D, 2008, PAIN, V136, P134, DOI 10.1016/j.pain.2007.06.028; Brill Silviu, 2013, J Pain Palliat Care Pharmacother, V27, P185, DOI 10.3109/15360288.2013.788605; Carroll IR, 2004, REGION ANESTH PAIN M, V29, P576, DOI 10.1016/j.rapm.2004.06.009; Chaparro LE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008307.pub2; Coulling Sarah, 2005, Nurs Stand, V19, P41; Erlenwein J, 2014, SCHMERZ, V28, P147, DOI 10.1007/s00482-014-1398-2; Fletcher D, 2008, PAIN, V137, P441, DOI 10.1016/j.pain.2008.02.026; Gan TJ, 2014, CURR MED RES OPIN, V30, P149, DOI 10.1185/03007995.2013.860019; Gerbershagen HJ, 2014, ANESTHESIOLOGY, V120, P1237, DOI 10.1097/ALN.0000000000000108; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Haroutiunian S, 2013, PAIN, V154, P95, DOI 10.1016/j.pain.2012.09.010; Johansen A, 2012, PAIN, V153, P1390, DOI 10.1016/j.pain.2012.02.018; Kinstner C, 2011, ANAESTHESIST, V60, P827, DOI 10.1007/s00101-011-1911-2; Liu WR, 2013, PATIENT PREFER ADHER, V7, P1157, DOI 10.2147/PPA.S53235; Loftus RW, 2010, ANESTHESIOLOGY, V113, P639, DOI 10.1097/ALN.0b013e3181e90914; Macintyre PE, 2009, ACUTE PAIN MANAGEMENT, P204, DOI 10.1017/CBO9780511576706.016; Maier C, 2010, DTSCH ARZTEBL INT, V107, P607, DOI 10.3238/arztebl.2010.0607; Minkowitz HS, 2014, AM J HEALTH-SYST PH, V71, P1556, DOI 10.2146/ajhp130031; Osterbrink J, 2010, SCHMERZ, V24, P613, DOI 10.1007/s00482-010-0983-2; Popping DM, 2014, ANN SURG, V259, P1056, DOI 10.1097/SLA.0000000000000237; Pogatzki-Zahn EM, 2012, EXPERT REV NEUROTHER, V12, P587, DOI [10.1586/ERN.12.30, 10.1586/ern.12.30]; Popping DM, 2008, BRIT J ANAESTH, V101, P832, DOI 10.1093/bja/aen300; Registed Nurses' Association of Ontario, 2013, ASS MAN PAIN CLIN BE; Schnabel A, 2013, PAIN, V154, P1140, DOI 10.1016/j.pain.2013.03.029; Schwenkglenks M, 2014, PAIN, V155, P1401, DOI 10.1016/j.pain.2014.04.021; Sommer M, 2008, EUR J ANAESTH, V25, P267, DOI 10.1017/S0265021507003031; Usichenko TI, 2013, BRIT J ANAESTH, V110, P87, DOI 10.1093/bja/aes352; White PF, 2010, ANESTHESIOLOGY, V112, P220, DOI 10.1097/ALN.0b013e3181c6316e	32	21	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2015	10	11							e0143508	10.1371/journal.pone.0143508	http://dx.doi.org/10.1371/journal.pone.0143508			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7DU	26600464	Green Published, gold, Green Submitted			2023-01-03	WOS:000365862600075
J	van Zuijdewijn, CLMD; Grooteman, MPC; Bots, ML; Blankestijn, PJ; Steppan, S; Buechel, J; Groenwold, RHH; Brandenburg, V; van den Dorpel, MA; ter Wee, PM; Nube, MJ; Vervloet, MG				van Zuijdewijn, Camiel L. M. de Roij; Grooteman, Muriel P. C.; Bots, Michiel L.; Blankestijn, Peter J.; Steppan, Sonja; Buechel, Janine; Groenwold, Rolf H. H.; Brandenburg, Vincent; van den Dorpel, Marinus A.; ter Wee, Piet M.; Nube, Menso J.; Vervloet, Marc G.			Serum Magnesium and Sudden Death in European Hemodialysis Patients	PLOS ONE			English	Article							CALCIUM ACETATE/MAGNESIUM CARBONATE; SMOOTH-MUSCLE-CELLS; ALL-CAUSE; ONLINE HEMODIAFILTRATION; CARDIOVASCULAR MORTALITY; SEVELAMER-HYDROCHLORIDE; VASCULAR CALCIFICATION; SIGNIFICANT PREDICTOR; ATHEROSCLEROSIS RISK; DISEASE	Despite suggestions that higher serum magnesium (Mg) levels are associated with improved outcome, the association with mortality in European hemodialysis (HD) patients has only scarcely been investigated. Furthermore, data on the association between serum Mg and sudden death in this patient group is limited. Therefore, we evaluated Mg in a post-hoc analysis using pooled data from the CONvective TRAnsport STudy (CONTRAST, NCT00205556), a randomized controlled trial (RCT) evaluating the survival risk in dialysis patients on hemodiafiltration (HDF) compared to HD with a mean follow-up of 3.1 years. Serum Mg was measured at baseline and 6, 12, 24 and 36 months thereafter. Cox proportional hazards models, adjusted for confounders using inverse probability weighting, were used to estimate hazard ratios (HRs) of baseline serum Mg on all-cause mortality, cardiovascular mortality, non-cardiovascular mortality and sudden death. A generalized linear mixed model was used to investigate Mg levels over time. Out of 714 randomized patients, a representative subset of 365 (51%) were analyzed in the present study. For every increase in baseline serum Mg of 0.1 mmol/L, the HR for all-cause mortality was 0.85 (95% CI 0.77-94), the HR for cardiovascular mortality 0.73 (95% CI 0.62-0.85) and for sudden death 0.76 (95% CI 0.62-0.93). These findings did not alter after extensive correction for potential confounders, including treatment modality. Importantly, no interaction was found between serum phosphate and serum Mg. Baseline serum Mg was not related to non-cardiovascular mortality. Mg decreased slightly but statistically significant over time (Delta -0.011 mmol/L/year, 95% CI -0.017 to -0.009, p = 0.03). In short, serum Mg has a strong, independent association with all-cause mortality, cardiovascular mortality and sudden death in European HD patients. Serum Mg levels decrease slightly over time.	[van Zuijdewijn, Camiel L. M. de Roij; Grooteman, Muriel P. C.; ter Wee, Piet M.; Nube, Menso J.; Vervloet, Marc G.] Vrije Univ Amsterdam Med Ctr, Dept Nephrol, Amsterdam, Netherlands; [van Zuijdewijn, Camiel L. M. de Roij; Grooteman, Muriel P. C.; ter Wee, Piet M.; Nube, Menso J.; Vervloet, Marc G.] Vrije Univ Amsterdam Med Ctr, VU Univ Med Ctr ICaR VU, Inst Cardiovasc Res, Amsterdam, Netherlands; [Bots, Michiel L.; Groenwold, Rolf H. H.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Blankestijn, Peter J.] Univ Med Ctr Utrecht, Dept Nephrol, Utrecht, Netherlands; [Steppan, Sonja; Buechel, Janine] Fresenius Med Care, Bad Homburg, Germany; [Brandenburg, Vincent] Univ Hosp Aachen, Dept Cardiol & Vasc Med, Aachen, Germany; [van den Dorpel, Marinus A.] Maasstad Hosp, Dept Internal Med, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; RWTH Aachen University; RWTH Aachen University Hospital; Maasstad Hospital	van Zuijdewijn, CLMD (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Nephrol, Amsterdam, Netherlands.	c.deroijvanzuijdewijn@vumc.nl	de Roij van Zuijdewijn, Camiel/AAE-7568-2020; Grooteman, Muriel/AAA-2602-2019	Grooteman, Muriel/0000-0001-5447-2546; Groenwold, Rolf/0000-0001-9238-6999; Vervloet, Marc/0000-0003-4607-9415; de Roij van Zuijdewijn, Camiel/0000-0002-6369-8341	Dutch Kidney Foundation (Nierstichting Nederland) [C02.2019]; Fresenius Medical Care (The Netherlands); Gambro Lundia AB (Sweden); Dr E.E. Twiss Fund; International Society of Nephrology/Baxter Extramural Grant Program; Dutch Organization for Health Research and Development (ZonMW) [17088.2802]; Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany; Fresenius Medical Care Deutschland GmbH; Roche Netherlands	Dutch Kidney Foundation (Nierstichting Nederland); Fresenius Medical Care (The Netherlands)(Netherlands Government); Gambro Lundia AB (Sweden); Dr E.E. Twiss Fund; International Society of Nephrology/Baxter Extramural Grant Program; Dutch Organization for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development); Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany; Fresenius Medical Care Deutschland GmbH; Roche Netherlands	CONTRAST was financially supported by a grant from the Dutch Kidney Foundation (Nierstichting Nederland, grant C02.2019) and unrestricted grants from Fresenius Medical Care (The Netherlands) and Gambro Lundia AB (Sweden). Additional support was received from the Dr E.E. Twiss Fund, Roche Netherlands, the International Society of Nephrology/Baxter Extramural Grant Program, and the Dutch Organization for Health Research and Development (ZonMW, grant 17088.2802). The funders had no role in study design, data collection, analysis, or the decision to publish. The present project was additionally funded by a grant from Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany. Fresenius Medical Care Deutschland GmbH did not have any additional role in the study design, data collection, and analysis of the manuscript, but provided support in the form of salaries for authors (SS, JB) and intellectual content, and consented to publish the manuscript. The specific roles of the authors related to Fresenius Medical Care are articulated in the 'author contributions' section.	Adragao T, 2004, NEPHROL DIAL TRANSPL, V19, P1480, DOI 10.1093/ndt/gfh217; Covic A, 2013, NEPHROL DIAL TRANSPL, V28, P2383, DOI 10.1093/ndt/gft203; de Francisco ALM, 2010, NEPHROL DIAL TRANSPL, V25, P3707, DOI 10.1093/ndt/gfq292; Del Gobbo LC, 2013, AM J CLIN NUTR, V98, P160, DOI 10.3945/ajcn.112.053132; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; Grooteman MPC, 2012, J AM SOC NEPHROL, V23, P1087, DOI 10.1681/ASN.2011121140; Hruby A, 2014, JACC-CARDIOVASC IMAG, V7, P59, DOI 10.1016/j.jcmg.2013.10.006; Ishimura E, 2007, MAGNESIUM RES, V20, P237, DOI 10.1684/mrh.2007.0116; Kanbay M, 2012, AM J NEPHROL, V36, P228, DOI 10.1159/000341868; Kircelli F, 2012, NEPHROL DIAL TRANSPL, V27, P514, DOI 10.1093/ndt/gfr321; Lacson E, 2015, AM J KIDNEY DIS, V66, P1056, DOI 10.1053/j.ajkd.2015.06.014; Li L, 2015, AM J KIDNEY DIS, V66, P1047, DOI 10.1053/j.ajkd.2015.05.024; Liao FZ, 1998, AM HEART J, V136, P480, DOI 10.1016/S0002-8703(98)70224-8; London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414; Lopes AA, 2010, J RENAL NUTR, V20, P224, DOI 10.1053/j.jrn.2009.10.002; Louvet L, 2013, NEPHROL DIAL TRANSPL, V28, P869, DOI 10.1093/ndt/gfs520; Maier Jeanette A. M., 2003, Molecular Aspects of Medicine, V24, P137; Matias PJ, 2014, BLOOD PURIFICAT, V38, P244, DOI 10.1159/000366124; MEEMA HE, 1987, KIDNEY INT, V32, P388, DOI 10.1038/ki.1987.222; de Oca AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089525; Mubagwa K, 2007, ARCH BIOCHEM BIOPHYS, V458, P73, DOI 10.1016/j.abb.2006.10.014; Naimi AI, 2014, EPIDEMIOLOGY, V25, P292, DOI 10.1097/EDE.0000000000000053; Parfrey PS, 1999, J AM SOC NEPHROL, V10, P1606; Peacock JM, 2010, AM HEART J, V160, P464, DOI 10.1016/j.ahj.2010.06.012; Pearson PJ, 1998, ANN THORAC SURG, V65, P967, DOI 10.1016/S0003-4975(98)00020-4; Penne EL, 2005, CURR CONTR TRIALS C, V6, DOI 10.1186/1468-6708-6-8; Sakaguchi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116273; Sakaguchi Y, 2014, KIDNEY INT, V85, P174, DOI 10.1038/ki.2013.327; Salem S, 2012, AM J NEPHROL, V35, P31, DOI 10.1159/000334742; Satayathum S, 2005, KIDNEY INT, V68, P330, DOI 10.1111/j.1523-1755.2005.00412.x; Shechter M, 2000, CIRCULATION, V102, P2353, DOI 10.1161/01.CIR.102.19.2353; Sigrist MK, 2007, CLIN J AM SOC NEPHRO, V2, P1241, DOI 10.2215/CJN.02190507; Yoshino M, 2006, J AM SOC NEPHROL, V17, P3510, DOI 10.1681/ASN.2006020156; Zhou BF, 2003, J HUM HYPERTENS, V17, P623, DOI 10.1038/sj.jhh.1001605	34	53	53	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2015	10	11							e0143104	10.1371/journal.pone.0143104	http://dx.doi.org/10.1371/journal.pone.0143104			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7AW	26600017	Green Published, Green Submitted, gold			2023-01-03	WOS:000365853900065
J	Sahin, M; Sur, M				Sahin, Mustafa; Sur, Mriganka			Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders	SCIENCE			English	Review							DOMAIN CRITERIA RDOC; WILD-TYPE MICROGLIA; FRAGILE-X-SYNDROME; MOUSE MODEL; RETT-SYNDROME; SPECTRUM DISORDERS; PROTEIN-SYNTHESIS; MUTANT MICE; SYNAPTIC PLASTICITY; CEREBELLAR INJURY	Research in the genetics of neurodevelopmental disorders such as autism suggests that several hundred genes are likely risk factors for these disorders. This heterogeneity presents a challenge and an opportunity at the same time. Although the exact identity of many of the genes remains to be discovered, genes identified to date encode proteins that play roles in certain conserved pathways: protein synthesis, transcriptional and epigenetic regulation, and synaptic signaling. The next generation of research in neurodevelopmental disorders must address the neural circuitry underlying the behavioral symptoms and comorbidities, the cell types playing critical roles in these circuits, and common intercellular signaling pathways that link diverse genes. Results from clinical trials have been mixed so far. Only when we can leverage the heterogeneity of neurodevelopmental disorders into precision medicine will the mechanism-based therapeutics for these disorders start to unlock success.	[Sahin, Mustafa] Boston Childrens Hosp, Dept Neurol, Translat Neurosci Ctr, FM Kirby Ctr Neurobiol, Boston, MA 02115 USA; [Sur, Mriganka] MIT, Dept Brain & Cognit Sci, Simons Ctr Social Brain, Picower Inst Learning & Memory, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT); Northwell Health	Sahin, M (corresponding author), Boston Childrens Hosp, Dept Neurol, Translat Neurosci Ctr, FM Kirby Ctr Neurobiol, Boston, MA 02115 USA.	mustafa.sahin@childrens.harvard.edu; msur@mit.edu	Sala, Carlo/A-2493-2009; SAHIN, MUSTAFA/I-8653-2019	Sala, Carlo/0000-0003-0662-9523; SAHIN, MUSTAFA/0000-0001-7044-2953	NIH [MH085802, NS090473, EY007023, U01 NS082320, P20 NS080199, P30 HD018655]; NSF [EF1451125]; Simons Foundation Autism Research Initiative; Department of Defense [W81XWH-13-1-0040]; Tuberous Sclerosis Alliance; Autism Speaks; Nancy Lurie Marks Family Foundation; Simons Foundation; Boston Children's Hospital Translational Research Program; Novartis; Shire; NCATS; NIMH; National Institute of Neurological Disorders and Stroke; Eunice Kennedy Shriver National Institute of Child Health and Human Development; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007023, F32EY007023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH085802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS092090, P20NS080199, U01NS082320, U01NS090473] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Simons Foundation Autism Research Initiative; Department of Defense(United States Department of Defense); Tuberous Sclerosis Alliance; Autism Speaks; Nancy Lurie Marks Family Foundation; Simons Foundation; Boston Children's Hospital Translational Research Program; Novartis(Novartis); Shire; NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank R. Kleiman, A. Poduri, and K. Dies for critically reviewing the manuscript. Due to limited space, we have not quoted all literature in the field, and we apologize to those whose articles are not referenced. Research in M. Sur's laboratory is supported by NIH grants MH085802, NS090473, and EY007023; NSF grant EF1451125; and the Simons Foundation Autism Research Initiative. Research in M. Sahin's laboratory is supported by the NIH (U01 NS082320, P20 NS080199, and P30 HD018655), Department of Defense (W81XWH-13-1-0040), Tuberous Sclerosis Alliance, Autism Speaks, Nancy Lurie Marks Family Foundation, Simons Foundation, Boston Children's Hospital Translational Research Program, and Novartis and Shire. The Developmental Synaptopathies Consortium (U54NS092090) is a part of the National Center for Advancing Translational Sciences (NCATS) Rare Diseases Clinical Research Network (RDCRN). RDCRN is an initiative of the Office of Rare Diseases Research (ORDR), NCATS, funded through collaboration between NCATS, NIMH, the National Institute of Neurological Disorders and Stroke, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.	Akshoomoff N, 2004, J AM ACAD CHILD PSY, V43, P349, DOI 10.1097/00004583-200403000-00018; Allen G, 2003, AM J PSYCHIAT, V160, P262, DOI 10.1176/appi.ajp.160.2.262; Amaral DG, 2008, TRENDS NEUROSCI, V31, P137, DOI 10.1016/j.tins.2007.12.005; Asano E, 2001, NEUROLOGY, V57, P1269, DOI 10.1212/WNL.57.7.1269; Auerbach BD, 2011, NATURE, V480, P63, DOI 10.1038/nature10658; Baudouin SJ, 2012, SCIENCE, V338, P128, DOI 10.1126/science.1224159; Bauman ML, 2005, INT J DEV NEUROSCI, V23, P183, DOI 10.1016/j.ijdevneu.2004.09.006; Ben-Ari Y, 2007, PHYSIOL REV, V87, P1215, DOI 10.1152/physrev.00017.2006; Ben-Shachar S, 2009, HUM MOL GENET, V18, P2431, DOI 10.1093/hmg/ddp181; Bernier R, 2014, CELL, V158, P263, DOI 10.1016/j.cell.2014.06.017; Bhattacharya A, 2012, NEURON, V76, P325, DOI 10.1016/j.neuron.2012.07.022; Blundell J, 2010, J NEUROSCI, V30, P2115, DOI 10.1523/JNEUROSCI.4517-09.2010; Bozdagi O, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-9; Calfa G, 2015, HIPPOCAMPUS, V25, P159, DOI 10.1002/hipo.22360; Casanova MF, 2007, BRAIN PATHOL, V17, P422, DOI 10.1111/j.1750-3639.2007.00100.x; Casey BJ, 2014, BIOL PSYCHIAT, V76, P350, DOI 10.1016/j.biopsych.2014.01.006; Castro J, 2014, P NATL ACAD SCI USA, V111, P9941, DOI 10.1073/pnas.1311685111; Castro J, 2013, CURR OPIN NEUROL, V26, P154, DOI 10.1097/WCO.0b013e32835f19a7; Chahrour M, 2008, SCIENCE, V320, P1224, DOI 10.1126/science.1153252; Chang QA, 2006, NEURON, V49, P341, DOI 10.1016/j.neuron.2005.12.027; Chao HT, 2007, NEURON, V56, P58, DOI 10.1016/j.neuron.2007.08.018; Chao HT, 2010, NATURE, V468, P263, DOI 10.1038/nature09582; Chen NY, 2012, P NATL ACAD SCI USA, V109, pE2832, DOI 10.1073/pnas.1206557109; COURCHESNE E, 1988, NEW ENGL J MED, V318, P1349, DOI 10.1056/NEJM198805263182102; Dani VS, 2005, P NATL ACAD SCI USA, V102, P12560, DOI 10.1073/pnas.0506071102; Darnell JC, 2011, CELL, V146, P247, DOI 10.1016/j.cell.2011.06.013; Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907; Durand S, 2012, NEURON, V76, P1078, DOI 10.1016/j.neuron.2012.12.004; Ebrahimi-Fakhari D, 2015, CURR OPIN NEUROL, V28, P91, DOI 10.1097/WCO.0000000000000186; Ehninger D, 2012, MOL PSYCHIATR, V17, P469, DOI 10.1038/mp.2011.39; Ehninger D, 2008, NAT MED, V14, P843, DOI 10.1038/nm1788; Eroglu C, 2010, NATURE, V468, P223, DOI 10.1038/nature09612; Fatemi SH, 2012, CEREBELLUM, V11, P777, DOI 10.1007/s12311-012-0355-9; Fyffe SL, 2008, NEURON, V59, P947, DOI 10.1016/j.neuron.2008.07.030; Gandal MJ, 2010, BIOL PSYCHIAT, V68, P1100, DOI 10.1016/j.biopsych.2010.09.031; Ganz M., 2006, UNDERSTANDING AUTISM, P475, DOI [10.1201/9781420004205.ch20, DOI 10.1201/1745691610383516]; Garay PA, 2013, BRAIN BEHAV IMMUN, V31, P54, DOI 10.1016/j.bbi.2012.07.008; Garay Paula A, 2010, Front Synaptic Neurosci, V2, P136, DOI 10.3389/fnsyn.2010.00136; Garbett K, 2008, NEUROBIOL DIS, V30, P303, DOI 10.1016/j.nbd.2008.01.012; Geschwind DH, 2015, LANCET NEUROL, V14, P1109, DOI 10.1016/S1474-4422(15)00044-7; Gillberg C, 2014, J AUTISM DEV DISORD, V44, P3274, DOI 10.1007/s10803-014-2163-1; Goffin D, 2014, NAT NEUROSCI, V17, P804, DOI 10.1038/nn.3710; Gogolla N, 2009, J NEURODEV DISORD, V1, P172, DOI 10.1007/s11689-009-9023-x; Gross C, 2015, CELL REP, V11, P727, DOI 10.1016/j.celrep.2015.03.060; Gross C, 2015, CELL REP, V11, P681, DOI 10.1016/j.celrep.2015.03.065; Guy J, 2007, SCIENCE, V315, P1143, DOI 10.1126/science.1138389; Haydon PG, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020438; Higashimori H, 2013, HUM MOL GENET, V22, P2041, DOI 10.1093/hmg/ddt055; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Huber KM, 2002, P NATL ACAD SCI USA, V99, P7746, DOI 10.1073/pnas.122205699; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; Iossifov I, 2012, NEURON, V74, P285, DOI 10.1016/j.neuron.2012.04.009; Jin P, 2004, NAT NEUROSCI, V7, P113, DOI 10.1038/nn1174; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kang DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068322; Kanner L, 1943, NERV CHILD, V2, P217; Kates WR, 2004, AM J PSYCHIAT, V161, P539, DOI 10.1176/appi.ajp.161.3.539; Kelleher RJ, 2008, CELL, V135, P401, DOI 10.1016/j.cell.2008.10.017; Khwaja OS, 2014, P NATL ACAD SCI USA, V111, P4596, DOI 10.1073/pnas.1311141111; Kondo M, 2008, EUR J NEUROSCI, V27, P3342, DOI 10.1111/j.1460-9568.2008.06305.x; Krueger DD, 2011, ANNU REV MED, V62, P411, DOI 10.1146/annurev-med-061109-134644; Lawrence YA, 2010, ACTA NEUROL SCAND, V121, P99, DOI 10.1111/j.1600-0404.2009.01234.x; Li Y, 2013, CELL STEM CELL, V13, P446, DOI 10.1016/j.stem.2013.09.001; Limperopoulos C, 2007, PEDIATRICS, V120, P584, DOI 10.1542/peds.2007-1041; Limperopoulos C, 2010, PEDIATR RES, V68, P145, DOI 10.1203/00006450-201011001-00282; Lioy DT, 2011, NATURE, V475, P497, DOI 10.1038/nature10214; Lipton JO, 2014, NEURON, V84, P275, DOI 10.1016/j.neuron.2014.09.034; Lord C., 2006, UNDERSTANDING AUTISM, P1, DOI DOI 10.1201/9781420004205.CH1; Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Mellios N, 2014, P NATL ACAD SCI USA, V111, P9947, DOI 10.1073/pnas.1309426111; Michalon A, 2012, NEURON, V74, P49, DOI 10.1016/j.neuron.2012.03.009; Molofsky AV, 2012, GENE DEV, V26, P891, DOI 10.1101/gad.188326.112; Morrow EM, 2008, SCIENCE, V321, P218, DOI 10.1126/science.1157657; Mulle JG, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-012-0337-0; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Parikshak NN, 2013, CELL, V155, P1008, DOI 10.1016/j.cell.2013.10.031; Patterson PH, 2009, BEHAV BRAIN RES, V204, P313, DOI 10.1016/j.bbr.2008.12.016; Peca J, 2011, NATURE, V472, P437, DOI 10.1038/nature09965; Peters JM, 2012, ACAD RADIOL, V19, P17, DOI 10.1016/j.acra.2011.08.016; Poduri A, 2013, SCIENCE, V341, P43, DOI 10.1126/science.1237758; Qin M, 2013, J CEREBR BLOOD F MET, V33, P499, DOI 10.1038/jcbfm.2012.205; Reeb-Sutherland BC, 2015, J AUTISM DEV DISORD, V45, P376, DOI 10.1007/s10803-013-1905-9; Reith RM, 2013, NEUROBIOL DIS, V51, P93, DOI 10.1016/j.nbd.2012.10.014; Restivo L, 2005, P NATL ACAD SCI USA, V102, P11557, DOI 10.1073/pnas.0504984102; Ricciardi S, 2011, HUM MOL GENET, V20, P1182, DOI 10.1093/hmg/ddq563; Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Rothwell PE, 2014, CELL, V158, P198, DOI 10.1016/j.cell.2014.04.045; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389; Scharf SH, 2015, CURR OPIN PHARMACOL, V20, P124, DOI 10.1016/j.coph.2014.11.004; Schummers J, 2008, SCIENCE, V320, P1638, DOI 10.1126/science.1156120; Scott-Van Zeeland AA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001344; Shcheglovitov A, 2013, NATURE, V503, P267, DOI 10.1038/nature12618; Shi LM, 2003, J NEUROSCI, V23, P297, DOI 10.1523/jneurosci.23-01-00297.2003; Silverman JL, 2010, NAT REV NEUROSCI, V11, P490, DOI 10.1038/nrn2851; Sudhof TC, 2008, NATURE, V455, P903, DOI 10.1038/nature07456; Tian D, 2015, NAT NEUROSCI, V18, P182, DOI 10.1038/nn.3911; Tropea D, 2009, P NATL ACAD SCI USA, V106, P2029, DOI 10.1073/pnas.0812394106; Tsai PT, 2012, NATURE, V488, P647, DOI 10.1038/nature11310; Turner TN, 2015, NATURE, V520, P51, DOI 10.1038/nature14186; Udagawa T, 2013, NAT MED, V19, P1473, DOI 10.1038/nm.3353; Urdinguio RG, 2010, EPIGENETICS-US, V5, P656, DOI 10.4161/epi.5.7.13055; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Vivanti G, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00354; Vogt D, 2015, CELL REP, V11, P944, DOI 10.1016/j.celrep.2015.04.019; Wang JQ, 2015, NATURE, V521, pE1, DOI 10.1038/nature14444; Weir RK, 2015, BRAIN BEHAV IMMUN, V48, P139, DOI 10.1016/j.bbi.2015.03.009; Whitney ER, 2008, CEREBELLUM, V7, P406, DOI 10.1007/s12311-008-0043-y; Willsey AJ, 2013, CELL, V155, P997, DOI 10.1016/j.cell.2013.10.020; Wohr M, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.19; Wood L, 2009, J NEUROSCI, V29, P12440, DOI 10.1523/JNEUROSCI.3321-09.2009; Wu H, 2010, P NATL ACAD SCI USA, V107, P18161, DOI 10.1073/pnas.1005595107; Xavier AL, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0593; Yasui DH, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-3; Yu TW, 2013, NEURON, V77, P259, DOI 10.1016/j.neuron.2012.11.002; Zoghbi HY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a009886	118	162	164	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	2015	350	6263					890	+	aab3897	10.1126/science.aab3897	http://dx.doi.org/10.1126/science.aab3897			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW4IP	26472761	Green Submitted, Green Accepted			2023-01-03	WOS:000364955200035
J	Lee, JH; Park, KM; Han, DJ; Bang, NY; Kim, DH; Na, H; Lim, S; Kim, TB; Kim, DG; Kim, HJ; Chung, Y; Sung, SH; Surh, YJ; Kim, S; Han, BW				Lee, Ji-Hyun; Park, Kyoung Mii; Han, Dong-Jin; Bang, Nam Young; Kim, Do-Hee; Na, Hyeongjin; Lim, Semi; Kim, Tae Bum; Kim, Dae Gyu; Kim, Hyun-Jung; Chung, Yeonseok; Sung, Sang Hyun; Surh, Young-Joon; Kim, Sunghoon; Han, Byung Woo			PharmDB-K: Integrated Bio-Pharmacological Network Database for Traditional Korean Medicine	PLOS ONE			English	Article							NF-KAPPA-B; COX-2 EXPRESSION; CHINESE MEDICINE; INFORMATION; UPDATE; SCHIZANDRIN; MECHANISM; RESOURCE; CANCER; CELLS	Despite the growing attention given to Traditional Medicine (TM) worldwide, there is no wellknown, publicly available, integrated bio-pharmacological Traditional Korean Medicine (TKM) database for researchers in drug discovery. In this study, we have constructed PharmDB-K, which offers comprehensive information relating to TKM-associated drugs (compound), disease indication, and protein relationships. To explore the underlying molecular interaction of TKM, we integrated fourteen different databases, six Pharmacopoeias, and literature, and established a massive bio-pharmacological network for TKM and experimentally validated some cases predicted from the PharmDB-K analyses. Currently, PharmDB-K contains information about 262 TKMs, 7,815 drugs, 3,721 diseases, 32,373 proteins, and 1,887 side effects. One of the unique sets of information in PharmDB-K includes 400 indicator compounds used for standardization of herbal medicine. Furthermore, we are operating PharmDB-K via phExplorer (a network visualization software) and BioMart (a data federation framework) for convenient search and analysis of the TKM network. Database URL: http://pharmdb-k.org, http://biomart.i-pharm.org.	[Lee, Ji-Hyun; Han, Dong-Jin; Bang, Nam Young; Lim, Semi; Kim, Dae Gyu; Kim, Sunghoon] Seoul Natl Univ, Med Bioconvergence Res Ctr, Seoul 152742, South Korea; [Lee, Ji-Hyun; Park, Kyoung Mii; Kim, Do-Hee; Na, Hyeongjin; Kim, Tae Bum; Chung, Yeonseok; Sung, Sang Hyun; Surh, Young-Joon; Han, Byung Woo] Seoul Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, Seoul 151742, South Korea; [Lee, Ji-Hyun; Park, Kyoung Mii; Han, Byung Woo] Seoul Natl Univ, Informat Ctr Biopharmacol Network, Suwon 443270, South Korea; [Han, Dong-Jin; Bang, Nam Young; Kim, Sunghoon] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Seoul 151742, South Korea; [Kim, Hyun-Jung] Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Chung Ang University	Han, BW (corresponding author), Seoul Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, Seoul 151742, South Korea.	bwhan@snu.ac.kr	Kim, Sunghoon/AAE-8314-2020	kim, sunghoon/0000-0002-1570-3230	Basic Science Research Program - Ministry of Education; Ministry of Science, ICT and Future Planning through the National Research Foundation of Korea [NRF-2013R1A1A2058353, NRF-2013M3A6A4043695]	Basic Science Research Program - Ministry of Education; Ministry of Science, ICT and Future Planning through the National Research Foundation of Korea	This research was supported by the Basic Science Research Program funded by the Ministry of Education [JL] and Global Frontier Project funded by the Ministry of Science, ICT and Future Planning through the National Research Foundation of Korea [BH] (NRF-2013R1A1A2058353 and NRF-2013M3A6A4043695). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Administration KFaD, 2012, KOR PHARM; Administration KFaD, 2012, KOR HERB PHARM; [Anonymous], 2014, DEF DICT MED HERBS; [Anonymous], 2014, KOR TRAD KNOWL PORT; Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504-431; Bolton E., 2008, PUBCHEM INTEGRATED P; Brown GR, 2015, NUCLEIC ACIDS RES, V43, pD36, DOI 10.1093/nar/gku1055; Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939; Chen X, 2006, BRIT J PHARMACOL, V149, P1092, DOI 10.1038/sj.bjp.0706945; Chung MH, 2014, MUTAT RES-FUND MOL M, V768, P74, DOI [10.1016/j.mrfmmm.2014.04.003, 1]; Commission CP, 2011, PHARMACOPOEIA PEOPLE; Commission DPsRoKP, 2011, PHARM DEM PEOPL REP; Davis AP, 2015, NUCLEIC ACIDS RES, V43, pD914, DOI 10.1093/nar/gku935; Fang XL, 2005, J MED CHEM, V48, P1481, DOI 10.1021/jm049838d; Fang YC, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-58; Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777; Gunther S, 2008, NUCLEIC ACIDS RES, V36, pD919, DOI 10.1093/nar/gkm862; Jang ES, 2007, KOREAN J OREINTAL ME, V13, P143; Kanphaet TKW, 2009, HERBAL PHARMACOPOEIA; Kasprzyk A, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar049; Khan AQ, 2012, FOOD CHEM TOXICOL, V50, P175, DOI 10.1016/j.fct.2011.10.043; Kim HY, 2011, TOXICOLOGY, V282, P104, DOI 10.1016/j.tox.2011.01.017; Kim SJ, 2010, PHYTOTHER RES, V24, P193, DOI 10.1002/ptr.2907; Kuhn M, 2014, NUCLEIC ACIDS RES, V42, pD401, DOI 10.1093/nar/gkt1207; Kuhn M, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2009.98; Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068; Lee B, 2007, BIOL PHARM BULL, V30, P1153, DOI 10.1248/bpb.30.1153; Lee HS, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-80; Lim E, 2010, NUCLEIC ACIDS RES, V38, pD781, DOI 10.1093/nar/gkp934; Liu YB, 2010, BIOINFORMATICS, V26, P587, DOI 10.1093/bioinformatics/btp697; Maglott D, 2011, NUCLEIC ACIDS RES, V39, pD52, DOI 10.1093/nar/gkq1237; Medicine M-NIoG, 2014, ONLINE MENDELIAN INH; Pharmaceutical Japan mdrsso, 2012, JAP PHARM ENGL VERS; Rahman S, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep076; ROGERS FB, 1963, B MED LIBR ASSOC, V51, P114; Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13; Salwinski L, 2004, NUCLEIC ACIDS RES, V32, pD449, DOI 10.1093/nar/gkh086; Shen JH, 2003, CURR MED CHEM, V10, P2327, DOI 10.2174/0929867033456729; Sohn SH, 2009, NEUROTOXICOLOGY, V30, P368, DOI 10.1016/j.neuro.2009.02.006; Xue RC, 2013, NUCLEIC ACIDS RES, V41, pD1089, DOI 10.1093/nar/gks1100; Yu R, 2006, J INT MED RES, V34, P231, DOI 10.1177/147323000603400301; Zanzoni A, 2002, FEBS LETT, V513, P135, DOI 10.1016/S0014-5793(01)03293-8; Zhu F, 2012, NUCLEIC ACIDS RES, V40, pD1128, DOI 10.1093/nar/gkr797	43	10	10	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2015	10	11							e0142624	10.1371/journal.pone.0142624	http://dx.doi.org/10.1371/journal.pone.0142624			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV7CT	26555441	gold, Green Published, Green Submitted			2023-01-03	WOS:000364430700143
J	Zhang, CS; Tan, HY; Zhang, GS; Zhang, AL; Xue, CC; Xie, YM				Zhang, Claire Shuiqing; Tan, Hsiewe Ying; Zhang, George Shengxi; Zhang, Anthony Lin; Xue, Charlie Changli; Xie, Yi Min			Placebo Devices as Effective Control Methods in Acupuncture Clinical Trials: A Systematic Review	PLOS ONE			English	Article							SHAM ACUPUNCTURE; SINGLE-BLIND; COMPARING ACUPUNCTURE; MANUAL ACUPUNCTURE; NEEDLE; PAIN; VALIDATION; REAL; PROPHYLAXIS; EFFICACY	While the use of acupuncture has been recognised by the World Health Organisation, its efficacy for many of the common clinical conditions is still undergoing validation through randomised controlled trials (RCTs). A credible placebo control for such RCTs to enable meaningful evaluation of its efficacy is to be established. While several non-penetrating acupuncture placebo devices, namely the Streitberger, the Park and the Takakura Devices, have been developed and used in RCTs, their suitability as inert placebo controls needs to be rigorously determined. This article systematically reviews these devices as placebo interventions. Electronic searches were conducted on four English and two Chinese data-bases from their inceptions to July 2014; hand searches of relevant references were also conducted. RCTs, in English or Chinese language, comparing acupuncture with one of the aforementioned devices as the control intervention on human participants with any clinical condition and evaluating clinically related outcomes were included. Thirty-six studies were included for qualitative analysis while 14 were in the meta-analysis. The meta-analysis does not support the notion of either the Streitberger or the Park Device being inert control interventions while none of the studies involving the Takakura Device was included in the meta-analysis. Sixteen studies reported the occurrence of adverse events, with no significant difference between verum and placebo acupuncture. Author-reported blinding credibility showed that participant blinding was successful in most cases; however, when blinding index was calculated, only one study, which utilised the Park Device, seemed to have an ideal blinding scenario. Although the blinding index could not be calculated for the Takakura Device, it was the only device reported to enable practitioner blinding. There are limitations with each of the placebo devices and more rigorous studies are needed to further evaluate their effects and blinding credibility.	[Zhang, Claire Shuiqing; Tan, Hsiewe Ying; Zhang, George Shengxi; Zhang, Anthony Lin; Xue, Charlie Changli] RMIT Univ, RMIT Hlth Innovat Res Inst, Sch Hlth Sci, Tradit & Complementary Med Res Program, Bundoora, Vic, Australia; [Xie, Yi Min] RMIT Univ, Sch Civil Environm & Chem Engn, Ctr Innovat Struct & Mat, Melbourne, Vic, Australia	Royal Melbourne Institute of Technology (RMIT); Royal Melbourne Institute of Technology (RMIT)	Xie, YM (corresponding author), RMIT Univ, Sch Civil Environm & Chem Engn, Ctr Innovat Struct & Mat, Melbourne, Vic, Australia.	mike.xie@rmit.edu.au	Tan, Hsiewe Ying/AAD-6255-2019; Xie, Yi M/A-3615-2012; Zhang, Anthony Lin/AAR-6673-2021; Xue, Charlie C/F-1244-2014	Tan, Hsiewe Ying/0000-0003-1289-3646; Xie, Yi M/0000-0001-5720-6649; Zhang, Anthony Lin/0000-0002-0968-9380; Zhang, Claire Shuiqing/0000-0003-3866-602X; Xue, Charlie/0000-0001-6937-9088				Andersen D, 2010, REPROD BIOMED ONLINE, V21, P366, DOI 10.1016/j.rbmo.2010.03.029; Anna E, 2008, COMPLEMENT THER MED, V16, P288, DOI 10.1016/j.ctim.2008.02.012; BANG H, 2010, CLIN RES REGUL AFF, V27, P42, DOI DOI 10.3109/10601331003777444; Bang HJ, 2004, CONTROL CLIN TRIALS, V25, P143, DOI 10.1016/j.cct.2003.10.016; Birch S., 2003, CLIN ACUPUNCT ORIENT, V3, P207, DOI [DOI 10.1016/S1461-1449(02)00044-0, 10.1016/S1461-1449(02)00044-0]; Bishop FL, 2008, J ACUPUNCT MERIDIAN, V1, P1, DOI 10.1016/S2005-2901(09)60001-7; Chae Y, 2009, MOVEMENT DISORD, V24, P1794, DOI 10.1002/mds.22673; Chen LX, 2013, JCR-J CLIN RHEUMATOL, V19, P308, DOI 10.1097/RHU.0b013e3182a21848; Chou LW, 2009, ARCH PHYS MED REHAB, V90, P905, DOI 10.1016/j.apmr.2008.12.020; Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9; Dorsher PT, 2010, ARCH PHYS MED REHAB, V91, P1306, DOI 10.1016/j.apmr.2010.04.025; Downs NM, 2005, ARCH PHYS MED REHAB, V86, P1252, DOI 10.1016/j.apmr.2004.10.037; Elden H, 2008, BJOG-INT J OBSTET GY, V115, P1655, DOI 10.1111/j.1471-0528.2008.01904.x; Enblom A, 2011, EVIDENCE BASED COMPL; Freed B, 2014, PSYCHIAT RES, V219, P241, DOI 10.1016/j.psychres.2014.05.023; Goddard G, 2005, J PAIN, V6, P237, DOI 10.1016/j.jpain.2004.12.009; Goldman RH, 2008, CLIN J PAIN, V24, P211, DOI 10.1097/AJP.0b013e31815ec20f; Gong X, 2014, J ACUPUNCT TUINA SCI, V12, P8, DOI [10.1007/s11726-014-0738-1, DOI 10.1007/S11726-014-0738-1]; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Kaptchuk TJ, 1998, LANCET, V352, P992, DOI 10.1016/S0140-6736(05)61551-6; Karst M, 2000, PAIN, V88, P199, DOI 10.1016/S0304-3959(00)00315-8; Kennedy S, 2008, COMPLEMENT THER MED, V16, P139, DOI 10.1016/j.ctim.2007.03.001; Kim S, 2008, J ACUPUNCT MERIDIAN, V1, P36, DOI 10.1016/S2005-2901(09)60005-4; Kleinhenz J, 1999, PAIN, V83, P235, DOI 10.1016/S0304-3959(99)00107-4; Kreiner M, 2010, ACUPUNCT MED, V28, P33, DOI 10.1136/aim.2009.001735; Lao L, 1996, J Altern Complement Med, V2, P23, DOI 10.1089/acm.1996.2.23; Lathia AT, 2009, J ALTERN COMPLEM MED, V15, P613, DOI 10.1089/acm.2008.0272; Linde M, 2005, CEPHALALGIA, V25, P41, DOI 10.1111/j.1468-2982.2004.00803.x; Lundeberg T, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep049; MacPherson H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093739; Manni L, 2010, AUTON NEUROSCI-BASIC, V157, P9, DOI 10.1016/j.autneu.2010.03.020; Modlock J, 2010, BJOG-INT J OBSTET GY, V117, P1255, DOI 10.1111/j.1471-0528.2010.02647.x; Moffet HH, 2008, J CLIN EPIDEMIOL, V61, P741, DOI 10.1016/j.jclinepi.2008.02.013; Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356; Moroz A, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/708251; Organization WH., 2003, PARKINSONISM RELAT D, pS163, DOI [10.1016/S1353-8020(11)70706-4, DOI 10.1016/S1353-8020(11)70706-4]; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Park J, 2005, ARCH INTERN MED, V165, P2026, DOI 10.1001/archinte.165.17.2026; Park J, 2004, PAIN, V109, P195, DOI 10.1016/j.pain.2004.02.010; Park J, 1999, ACUPUNCTURE MED; Rebhorn C, 2012, PAIN, V153, P1852, DOI 10.1016/j.pain.2012.05.026; Rogha M, 2011, J RES MED SCI, V16, P1217; Schliessbach J, 2012, EVID BASED COMPLEMEN, V785613; Schliessbach J, 2011, PAIN MED, V12, P268, DOI 10.1111/j.1526-4637.2010.01051.x; Smith MJ, 2005, ARCH PHYS MED REHAB, V86, P1741, DOI 10.1016/j.apmr.2004.11.044; Smith P, 2007, J DENT, V35, P259, DOI 10.1016/j.jdent.2006.09.004; So EWS, 2009, DTSCH Z AKUPUNKT, V52, P49, DOI 10.1016/j.dza.2009.02.008; So EWS, 2010, REPROD BIOMED ONLINE, V20, P814, DOI 10.1016/j.rbmo.2010.02.024; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Streitberger K, 2003, CLIN CANCER RES, V9, P2538; Sunay D, 2011, ACUPUNCT MED, V29, P27, DOI 10.1136/aim.2010.003285; Sunay D, 2011, EUR UROL, V59, P765, DOI 10.1016/j.eururo.2011.01.019; Suzuki M, 2012, ARCH INTERN MED, V172, P878, DOI 10.1001/archinternmed.2012.1233; Takakura N, 2009, OPEN MED, V3, P54; Takakura N, 2011, ACUPUNCT MED, V29, P203, DOI 10.1136/aim.2010.002857; Takakura N, 2010, ACUPUNCT MED, V28, P144, DOI 10.1136/aim.2009.001230; Takakura N, 2008, ACUPUNCT MED, V26, P224, DOI 10.1136/aim.26.4.224; Takakura Nobuari, 2007, BMC Complement Altern Med, V7, P31, DOI 10.1186/1472-6882-7-31; Tong J, 2010, GUANGZHOU ZHONGYIYAO, V27, P579; [童娟 TONG Juan], 2006, [针刺研究, Acupuncture Research], V31, P176; Tough EA, 2009, ACUPUNCT MED, V27, P118, DOI 10.1136/aim.2009.000737; Vase L, 2013, PAIN, V154, P1659, DOI 10.1016/j.pain.2013.05.008; Vickers AJ, 2002, EVAL HEALTH PROF, V25, P421, DOI 10.1177/0163278702238055; [张明敏 Zhang Mingmin], 2003, [中国针灸, Chinese Acupuncture and Moxibustion], V23, P3; White P, 2003, PAIN, V106, P401, DOI 10.1016/j.pain.2003.08.013; White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007; Xie YM, 2014, ACUPUNCT MED, V32, P146, DOI 10.1136/acupmed-2013-010472; Yao E, 2012, PM&R, V4, P367, DOI 10.1016/j.pmrj.2012.01.008; Zhang CS, 2014, ACUPUNCT MED, V32, P520, DOI 10.1136/acupmed-2014-010671; Zhang CS, 2014, ACUPUNCT MED, V32, P400, DOI 10.1136/acupmed-2014-010586; [张维 ZHANG Wei], 2010, [中医杂志, Journal of Traditional Chinese Medicine], V51, P139; Zheng S, 2011, GUIDING J TRADITIONA, V17, P66; Zhu D, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/628907	74	60	63	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2015	10	11							e0140825	10.1371/journal.pone.0140825	http://dx.doi.org/10.1371/journal.pone.0140825			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV5GZ	26536619	gold, Green Submitted, Green Published			2023-01-03	WOS:000364298400039
J	Schussler, S; Lohrmann, C				Schuessler, Sandra; Lohrmann, Christa			Change in Care Dependency and Nursing Care Problems in Nursing Home Residents with and without Dementia: A 2-Year Panel Study	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; INCONTINENCE; PREVALENCE; PREDICTORS; URINARY; RISK	Over time, chronic conditions like dementia can lead to care dependency and nursing care problems, often necessitating nursing home admission. This panel study (2012-2014) aims to explore changes in care dependency and nursing care problems (incontinence, malnutrition, decubitus, falls and restraints) in residents with and without dementia over time. In total, nine Austrian nursing homes participated, including 258 residents (178 with, 80 without dementia) who completed all five measurements. Data were collected with the International Prevalence Measurement of Care Problems questionnaire, the Care Dependency Scale and the Mini-Mental State Examination-2. Repeated measures ANOVA and crosstabs were used to analyse changes. The results showed that care dependency in dementia residents increased significantly for all 15 items of the Care Dependency Scale, with the highest increase being residents' day-/night pattern, contact with others, sense of rules/values and communication. In contrast, care dependency in residents without dementia increased for four of the 15 items, with the highest increase being for continence, followed by getting (un) dressed. With respect to the assessed nursing care problems, residents with dementia and those without only differed significantly in terms of an increase in urinary(12.3% vs. 14.2%), fecal-(17.4% vs. 10%), and double incontinence (16.7% vs. 11.9%). The results indicated that residents with dementia experienced increased care dependency in different areas than residents without dementia. Furthermore, residents with dementia experienced a lower increase in urinary incontinence but a higher increase in fecal-and double incontinence. These results help professionals to identify areas for improvement in dementia care.	[Schuessler, Sandra; Lohrmann, Christa] Med Univ Graz, Inst Nursing Sci, Graz, Austria	Medical University of Graz	Schussler, S (corresponding author), Med Univ Graz, Inst Nursing Sci, Graz, Austria.	sandra.schuessler@medunigraz.at	Lohrmann, Christa/AHA-0202-2022	Lohrmann, Christa/0000-0002-0778-5854				ADI (Alzheimer's Disease International), 2013, WORLD ALZH REP JOUM; Aslan E, 2009, J CLIN NURS, V18, P3290, DOI 10.1111/j.1365-2702.2009.02936.x; Banaszak-Holl J, 2011, J AGING HEALTH, V23, P862, DOI 10.1177/0898264311399759; Berger S, 2012, WISSENSCHAFTLICHE HI; BMASK (Bundesministerium fur Arbeit Soziales und Konsumentenschutz), 2014, INF ALT U PFLEG; Boyd M, 2012, AUSTRALAS J AGEING, V31, P233, DOI 10.1111/j.1741-6612.2011.00584.x; Braunseis F, 2012, ARCH GERONTOL GERIAT, V54, pE63, DOI 10.1016/j.archger.2011.06.023; Caljouw MAA, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-67; Carpenter G Iain, 2006, BMC Geriatr, V6, P7, DOI 10.1186/1471-2318-6-7; DEGAM (Deutsche Gesellschaft fur Allgemeinmedizin und Familienmedizin), 2008, DEM LEITL 12; Dijkstra A, 1998, Aust N Z J Ment Health Nurs, V7, P142; Dijkstra A, 1999, INT J NURS STUD, V36, P487, DOI 10.1016/S0020-7489(99)00044-9; Dijkstra A, 2012, NCG SERIES MEASUREME, V10, P40; DuBeau CE, 2010, NEUROUROL URODYNAM, V29, P165, DOI 10.1002/nau.20842; Folstein MF, 2010, MMSE 2 MANUAL DURCHF; Gustavsson A, 2011, ALZHEIMERS DEMENT, V7, P318, DOI 10.1016/j.jalz.2010.09.001; Helvik AS, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-45; Hjaltadottir I, 2012, INT J NURS STUD, V49, P1342, DOI 10.1016/j.ijnurstu.2012.06.004; Kow JK, 2013, BCMJ, V55, P96; Lohrmann C, 2003, SCAND J CARING SCI, V17, P51, DOI 10.1046/j.1471-6712.2003.00117.x; Lohrmann C, 2013, PFLEGEQUALITATSERHEB; McConnell ES, 2003, NURS RES, V52, P119, DOI 10.1097/00006199-200303000-00008; Nakrem S, 2009, INT J NURS STUD, V46, P848, DOI 10.1016/j.ijnurstu.2008.11.005; OECD, 2013, GOOD LIFE OLD AGE MO; Offermans MPW, 2009, NEUROUROL URODYNAM, V28, P288, DOI 10.1002/nau.20668; Reid C, 2008, CAN STUD POPUL, V35, P49; Saga S, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-87; Schussler S, 2015, EUR GERIATR MED, V6, P46, DOI 10.1016/j.eurger.2014.04.015; van Nie-Visser NC, 2013, J ADV NURS, V69, pE18, DOI 10.1111/jan.12190; World Health Organisation, 2001, ICF INT CLASFUNCT	30	11	11	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2015	10	10							e0141653	10.1371/journal.pone.0141653	http://dx.doi.org/10.1371/journal.pone.0141653			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV0ED	26513358	gold, Green Submitted, Green Published			2023-01-03	WOS:000363920300062
J	Szeto, CC; Kwan, BCH; Chow, KM; Cheng, PMS; Kwong, VWK; Choy, ASM; Law, MC; Leung, CB; Li, PKT				Szeto, Cheuk-Chun; Kwan, Bonnie C. H.; Chow, Kai-Ming; Cheng, Phyllis M. S.; Kwong, Vickie W. K.; Choy, Agnes S. M.; Law, Man-Ching; Leung, Chi-Bon; Li, Philip K. T.			The Effect of Neutral Peritoneal Dialysis Solution with Low Glucose-Degradation Product on the Fluid Status and Body Composition - A Randomized Control Trial	PLOS ONE			English	Article							RESIDUAL RENAL-FUNCTION; ARTERIAL STIFFNESS; IN-VITRO; PH; BIOCOMPATIBILITY; MEMBRANE; BIOIMPEDANCE; INFLAMMATION; KINETICS; BENEFITS	Background Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients treated with low glucose degradation product (GDP) solution. The effects of low GDP solution on body fluid status and arterial pulse wave velocity (PWV) have not been studied. Methods We randomly assigned 68 incident PD patients to low GDP (Intervention Group) or conventional solutions (Control Group); 4 dropped off before they received the assigned treatment. Patients were followed for 52 weeks for changes in ultrafiltration, residual renal function, body fluid status and arterial PWV. Result After 52 weeks, Intervention Group had higher overhydration (3.1 +/- 2.6 vs 1.9 +/- 2.2 L, p = 0.045) and extracellular water volume (17.7 +/- 3.9 vs 15.8 +/- 3.1 L, p = 0.034) than Control Group. There was no significant difference in PWV between groups. There was no significant difference in residual renal function between the Groups. Intervention Group had lower ultrafiltration volume than Control Group at 4 weeks (0.45 +/-.0.61 vs 0.90 +/- 0.79 L/day, p = 0.013), but the difference became insignificant at later time points. Intervention Group had lower serum CRP levels than Control Group (4.17 +/- 0.77 vs 4.91 +/- 0.95 mg/dL, p < 0.0001). Conclusion Incident PD patients treated with low GDP solution have less severe systemic inflammation but trends of less ultrafiltration, and more fluid accumulation. However, the effects on ultrafiltration and fluid accumulation disappear with time. The long term effect of low GDP solution requires further study.	[Szeto, Cheuk-Chun; Kwan, Bonnie C. H.; Chow, Kai-Ming; Cheng, Phyllis M. S.; Kwong, Vickie W. K.; Choy, Agnes S. M.; Law, Man-Ching; Leung, Chi-Bon; Li, Philip K. T.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Carol & Richard Yu Peritoneal Dialysis Res Ctr, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Szeto, CC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Carol & Richard Yu Peritoneal Dialysis Res Ctr, Shatin, Hong Kong, Peoples R China.	ccszeto@cuhk.edu.hk	Li, Philip K. T./D-4051-2017; Szeto, Cheuk Chun/N-4954-2015; Ming, Chow Kai/Y-5568-2019; Kwan, Bonnie/N-3463-2015	Szeto, Cheuk Chun/0000-0002-8898-8505; Ming, Chow Kai/0000-0001-5310-5197; Kwan, Bonnie/0000-0001-6742-8480	Fresenius Medical Care; CUHK research account [6901031]; Baxter Healthcare	Fresenius Medical Care; CUHK research account(Chinese University of Hong Kong); Baxter Healthcare	This study was supported in part by the Fresenius Medical Care, CUHK research account 6901031, and a research grant and consultancy from Baxter Healthcare (CCS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alscher DM, 2000, NEPHRON, V86, P62, DOI 10.1159/000045714; Bergstrom J, 1998, PERITON DIALYSIS INT, V18, P467; Breborowicz A, 1996, AM J KIDNEY DIS, V27, P738, DOI 10.1016/S0272-6386(96)90114-6; Cappelli G, 1999, ADV PERIT D, V15, P238; Cho Y, 2013, KIDNEY INT, V84, P969, DOI 10.1038/ki.2013.190; Choi HY, 2008, PERITON DIALYSIS INT, V28, P174; Contreras-Velazquez JC, 2008, KIDNEY INT S, V108, pS34; Davies SJ, 2014, KIDNEY INT, V86, P489, DOI 10.1038/ki.2014.207; Davies SJ, 1996, NEPHROL DIAL TRANSPL, V11, P498; ENIA G, 1993, NEPHROL DIAL TRANSPL, V8, P1094; Fan SLS, 2008, KIDNEY INT, V73, P200, DOI 10.1038/sj.ki.5002574; FORBES GB, 1976, AM J CLIN NUTR, V29, P1359, DOI 10.1093/ajcn/29.12.1359; Haag-Weber M, 2010, NEPHROL DIAL TRANSPL, V25, P2288, DOI 10.1093/ndt/gfq087; Johnson DW, 2012, NEPHROL DIAL TRANSPL, V27, P4445, DOI 10.1093/ndt/gfs314; Johnson DW, 2012, J AM SOC NEPHROL, V23, P1097, DOI 10.1681/ASN.2011121201; Johnson DW, 2004, PERITON DIALYSIS INT, V24, P460; Kalantar-Zadeh K, 2001, AM J KIDNEY DIS, V38, P1251, DOI 10.1053/ajkd.2001.29222; Kim S, 2009, NEPHROL DIAL TRANSPL, V24, P2899, DOI 10.1093/ndt/gfp054; Kocyigit I, 2014, PERITON DIALYSIS INT, V34, P781, DOI 10.3747/pdi.2013.00057; KREDIET R T, 1986, Blood Purification, V4, P194, DOI 10.1159/000169445; Kwan BCH, 2014, PERITON DIALYSIS INT, V34, P409, DOI 10.3747/pdi.2013.00066; Lage C, 2000, PERITON DIALYSIS INT, V20, pS28; Li PKT, 2010, CLIN J AM SOC NEPHRO, V5, P652, DOI 10.2215/CJN.05620809; LIBEREK T, 1993, NEPHRON, V65, P260, DOI 10.1159/000187485; Mak TWL, 1997, NEPHROL DIAL TRANSPL, V12, P184, DOI 10.1093/ndt/12.1.184; Montenegro J, 2006, PERITON DIALYSIS INT, V26, P89; Passlick-Deetjen J, 2001, PERITON DIALYSIS INT, V21, pS96; Schmitt CP, 2002, KIDNEY INT, V61, P1527, DOI 10.1046/j.1523-1755.2002.00255.x; Szeto CC, 2007, NEPHROL DIAL TRANSPL, V22, P552, DOI 10.1093/ndt/gfl559; Szeto CC, 2012, AM J NEPHROL, V35, P127, DOI 10.1159/000335580; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS INT, V7, P138; Van Biesen W., 1999, PERIT DIAL INT, V19, pS43; vanOlden RW, 1996, J AM SOC NEPHROL, V7, P745; *WHO COLL CTR DRUG, 1995, GUID ATC CLASS DDD A, P22; Williams JD, 2004, KIDNEY INT, V66, P408, DOI 10.1111/j.1523-1755.2004.00747.x	35	11	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2015	10	10							e0141425	10.1371/journal.pone.0141425	http://dx.doi.org/10.1371/journal.pone.0141425			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV0DL	26510186	Green Published, Green Submitted, gold			2023-01-03	WOS:000363918100079
J	Hidalgo, M; Carvajal, LP; Rincon, S; Faccini-Martinez, AA; Palacios, AAT; Mercado, M; Paloma, SL; Rayo, LX; Acevedo, JA; Reyes, J; Panesso, D; Garcia-Padilla, P; Alvarez, C; Arias, CA				Hidalgo, Marylin; Carvajal, Lina P.; Rincon, Sandra; Faccini-Martinez, Alvaro A.; Tres Palacios, Alba A.; Mercado, Marcela; Paloma, Sandra L.; Rayo, Leidy X.; Acevedo, Jessica A.; Reyes, Jinnethe; Panesso, Diana; Garcia-Padilla, Paola; Alvarez, Carlos; Arias, Cesar A.			Methicillin-Resistant Staphylococcus aureus USA300 Latin American Variant in Patients Undergoing Hemodialysis and HIV Infected in a Hospital in Bogota, Colombia	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; SOFT-TISSUE INFECTIONS; NASAL COLONIZATION; RISK-FACTORS; CARRIAGE; EVOLUTION; SKIN; IDENTIFICATION; PREVALENCE; PERSISTENT	We aimed to determine the prevalence of MRSA colonization and examine the molecular characteristics of colonizing isolates in patients receiving hemodialysis and HIV-infected in a Colombian hospital. Patients on hemodialysis and HIV-infected were prospectively followed between July 2011 and June 2012 in Bogota, Colombia. Nasal and axillary swabs were obtained and cultured. Colonizing S. aureus isolates were identified by standard and molecular techniques. Molecular typing was performed by using pulse-field gel electrophoresis and evaluating the presence of lukF-PV/lukS-PV by PCR. A total of 29% (n = 82) of HIV-infected and 45.5% (n = 15) of patients on hemodialysis exhibited S. aureus colonization. MSSA/MRSA colonization was observed in 28% and 3.6% of the HIV patients, respectively and in 42.4% and 13.3% of the hemodialysis patients, respectively. Staphylococcal cassette chromosome mec typing showed that four MRSA isolates harbored the type IV cassette, and one type I. In the hemodialysis group, two MRSA isolates were classified as belonging to the USA300-LV genetic lineage. Conversely, in the HIV infected group, no colonizing isolates belonging to the USA300-Latin American Variant (UDA300-LV) lineage were identified. Colonizing isolates recovered from the HIV-infected group belonged to the prevalent hospital-associated clones circulating in Latin America (Chilean [n = 1] and Pediatric [n = 2]). The prevalence of MRSA colonization in the study groups was 3.6% (HIV) and 13.3% (hemodialysis). Surveillance programs should be implemented in this group of patients in order to understand the dynamics of colonization and infection in high-risk patients.	[Hidalgo, Marylin; Faccini-Martinez, Alvaro A.; Tres Palacios, Alba A.; Paloma, Sandra L.; Rayo, Leidy X.; Acevedo, Jessica A.] Pontificia Univ Javeriana, Dept Microbiol, Bogota, Colombia; [Carvajal, Lina P.; Rincon, Sandra; Reyes, Jinnethe; Panesso, Diana; Arias, Cesar A.] Univ El Bosque, Mol Genet & Antimicrobial Resistance Unit, Bogota, Colombia; [Mercado, Marcela] Inst Nacl Salud, Direcc Vigilancia & Anal Riesgo Salud Publ, Bogota, Colombia; [Panesso, Diana; Arias, Cesar A.] Univ Texas Med Sch Houston, Div Infect Dis, Dept Internal Med, Houston, TX USA; [Garcia-Padilla, Paola; Alvarez, Carlos] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Bogota, Colombia	Pontificia Universidad Javeriana; Universidad El Bosque; Instituto Nacional de Salud (Colombia); University of Texas System; University of Texas Health Science Center Houston; Hospital Universitario San Ignacio; Pontificia Universidad Javeriana	Hidalgo, M (corresponding author), Pontificia Univ Javeriana, Dept Microbiol, Bogota, Colombia.	hidalgo.m@javeriana.edu.co	GARCIA, PAOLA/GXM-8600-2022; Moreno, carlos Arturo alvarez/P-6678-2016; Hidalgo, Marylin/AAF-5736-2019	Moreno, carlos Arturo alvarez/0000-0001-5419-4494; Faccini-Martinez, Alvaro A./0000-0002-1127-0132; Hidalgo, Marylin/0000-0001-8960-0616; TRESPALACIOS RANGEL, ALBA ALICIA/0000-0002-7540-5868; Garcia Padilla, Paola Karina/0000-0001-9852-749X; Rincon, Sandra/0000-0002-8482-4554	Pontificia Universidad Javeriana [4553]; NIH [R01 AI093749]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI093749] Funding Source: NIH RePORTER	Pontificia Universidad Javeriana; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Pontificia Universidad Javeriana provided financial support for the project "Colonizacion por Staphylococcus aureus en una cohorte de pacientes con riesgo de adquirir una infeccion (VIH y hemodialisis)", code 4553. CAA is supported by NIH grant R01 AI093749.	Aktas E, 2011, AM J INFECT CONTROL, V39, P421, DOI 10.1016/j.ajic.2010.06.012; Alexander EL, 2011, DIAGN MICR INFEC DIS, V70, P37, DOI 10.1016/j.diagmicrobio.2010.12.005; Alvarez CA, 2006, EMERG INFECT DIS, V12, P2000; Arias CA, 2008, NEW ENGL J MED, V359, P2177, DOI 10.1056/NEJMc0804021; Bettin A, 2012, BRAZ J INFECT DIS, V16, P329, DOI 10.1016/j.bjid.2012.06.017; Bogut A, 2007, NEW MICROBIOL, V30, P149; Carrillo RG, 2011, CLIN NEPHROL, V75, P174, DOI 10.5414/CN106479; Cenizal MJ, 2008, JAIDS-J ACQ IMM DEF, V48, P567, DOI 10.1097/QAI.0b013e31817e9b79; Cole J, 2013, CURR HIV-AIDS REP, V10, P244, DOI 10.1007/s11904-013-0161-0; Creech CB, 2010, ARCH PEDIAT ADOL MED, V164, P615, DOI 10.1001/archpediatrics.2010.93; Deleo FR, 2009, J CLIN INVEST, V119, P2464, DOI 10.1172/JCI38226; Deurenberg RH, 2009, CURR MOL MED, V9, P100, DOI 10.2174/156652409787581637; Deurenberg RH, 2008, INFECT GENET EVOL, V8, P747, DOI 10.1016/j.meegid.2008.07.007; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; FitzGerald F, 2011, J HOSP INFECT, V79, P218, DOI 10.1016/j.jhin.2011.06.015; Foster TJ, 2004, NAT MED, V10, P447, DOI 10.1038/nm0504-447a; Friedel David, 2007, Curr Infect Dis Rep, V9, P201, DOI 10.1007/s11908-007-0032-1; Ghazvini Kiarash, 2007, Iran J Kidney Dis, V1, P21; Giarola LB, 2012, BRAZ J MICROBIOL, V43, P923, DOI [10.1590/S1517-83822012000300011, 10.1590/S1517-838220120003000011]; Hidron Alicia I, 2010, Infect Drug Resist, V3, P73; Imaz A, 2013, J INFECTION, V66, P199, DOI 10.1016/j.jinf.2012.10.013; Imaz A, 2010, AIDS REV, V12, P153; Institute CaLS, 2013, PERF STAND ANT SUSC; Kang YC, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-284; Lai CF, 2013, J FORMOS MED ASSOC, V112, P365, DOI 10.1016/j.jfma.2012.07.009; Melles DC, 2008, MICROBES INFECT, V10, P151, DOI 10.1016/j.micinf.2007.10.017; Oliveira DC, 2002, ANTIMICROB AGENTS CH, V46, P2155, DOI 10.1128/AAC.46.7.2155-2161.2002; Padoveze MC, 2008, AM J INFECT CONTROL, V36, P187, DOI 10.1016/j.ajic.2007.05.012; Planet PJ, 2015, J INFECT DIS; Popovich KJ, 2013, CLIN INFECT DIS, V56, P1067, DOI 10.1093/cid/cit010; Popovich KJ, 2012, CLIN INFECT DIS, V54, P1296, DOI 10.1093/cid/cis030; Popovich KJ, 2010, CLIN INFECT DIS, V50, P979, DOI 10.1086/651076; Reyes J, 2014, 54 INT C ANT AG CHEM; Reyes J, 2009, CLIN INFECT DIS, V49, P1861, DOI 10.1086/648426; Rodriguez-Noriega E, 2010, INT J INFECT DIS, V14, pE560, DOI 10.1016/j.ijid.2009.08.018; Song YH, 2012, VACCINE, V30, P3675, DOI 10.1016/j.vaccine.2012.03.031; Sowash MG, 2013, METHODS MOL BIOL, V185, P25, DOI 10.1007/978-1-62703-664-1_2; Stevens DL, 2014, CLIN INFECT DIS, V59, pE10, DOI [10.1093/cid/ciu296, 10.1093/cid/ciu444]; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Uehara Y, 2013, J HOSP INFECT, V84, P81, DOI 10.1016/j.jhin.2013.01.004; Uhlemann AC, 2012, GENOME BIOL EVOL, V4, P1275, DOI 10.1093/gbe/evs094; Verhoeven PO, 2014, EXPERT REV ANTI-INFE, V12, P75, DOI 10.1586/14787210.2014.859985; Wang CY, 2012, J FORMOS MED ASSOC, V111, P14, DOI 10.1016/j.jfma.2012.01.001; Wang SH, 2015, J CLIN MICROBIOL, V53, P1599, DOI 10.1128/JCM.03147-14; Weidenmaier C, 2012, TRENDS MICROBIOL, V20, P243, DOI 10.1016/j.tim.2012.03.004	45	8	9	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2015	10	10							e0140748	10.1371/journal.pone.0140748	http://dx.doi.org/10.1371/journal.pone.0140748			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0DF	26474075	Green Submitted, Green Published, gold			2023-01-03	WOS:000363185500099
J	Sammarco, MC; Simkin, J; Cammack, AJ; Fassler, D; Gossmann, A; Marrero, L; Lacey, M; Van Meter, K; Muneoka, K				Sammarco, Mimi C.; Simkin, Jennifer; Cammack, Alexander J.; Fassler, Danielle; Gossmann, Alexej; Marrero, Luis; Lacey, Michelle; Van Meter, Keith; Muneoka, Ken			Hyperbaric Oxygen Promotes Proximal Bone Regeneration and Organized Collagen Composition during Digit Regeneration	PLOS ONE			English	Article							LIMB REGENERATION; TIP REGENERATION; FINGER; ANGIOGENESIS; MOBILIZATION; REPLACEMENT; OSTEOCLASTS; EXPRESSION; EPITHELIUM; AMPUTATION	Oxygen is critical for optimal bone regeneration. While axolotls and salamanders have retained the ability to regenerate whole limbs, mammalian regeneration is restricted to the distal tip of the digit (P3) in mice, primates, and humans. Our previous study revealed the oxygen microenvironment during regeneration is dynamic and temporally influential in building and degrading bone. Given that regeneration is dependent on a dynamic and changing oxygen environment, a better understanding of the effects of oxygen during wounding, scarring, and regeneration, and better ways to artificially generate both hypoxic and oxygen replete microenvironments are essential to promote regeneration beyond wounding or scarring. To explore the influence of increased oxygen on digit regeneration in vivo daily treatments of hyperbaric oxygen were administered to mice during all phases of the entire regenerative process. Micro-Computed Tomography (mu CT) and histological analysis showed that the daily application of hyperbaric oxygen elicited the same enhanced bone degradation response as two individual pulses of oxygen applied during the blastema phase. We expand past these findings to show histologically that the continuous application of hyperbaric oxygen during digit regeneration results in delayed blastema formation at a much more proximal location after amputation, and the deposition of better organized collagen fibers during bone formation. The application of sustained hyperbaric oxygen also delays wound closure and enhances bone degradation after digit amputation. Thus, hyperbaric oxygen shows the potential for positive influential control on the various phases of an epimorphic regenerative response.	[Sammarco, Mimi C.; Simkin, Jennifer; Cammack, Alexander J.; Fassler, Danielle] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA; [Gossmann, Alexej; Lacey, Michelle] Tulane Univ, Dept Math, New Orleans, LA 70118 USA; [Marrero, Luis; Van Meter, Keith] Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA USA; [Muneoka, Ken] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA	Tulane University; Tulane University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Texas A&M University System; Texas A&M University College Station	Sammarco, MC (corresponding author), Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.	msammarc@tulane.edu		Simkin, Jennifer/0000-0002-6122-4222; Sammarco, Mimi/0000-0001-9491-5735; Gossmann, Alexej/0000-0001-9068-3877	Eunice Kennedy Shriver National Institute of Child Health and Human Development [NIH-F32HD071763-02]; Defense Advanced Research Projects Agency (DARPA) [DARPA-W911NF-06-1-0161]; US Army Research Center [ARO-W911NF0910305]; John L. and Mary Wright Ebaugh Endowment Fund at Tulane University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [F32HD071763] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Defense Advanced Research Projects Agency (DARPA)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); US Army Research Center; John L. and Mary Wright Ebaugh Endowment Fund at Tulane University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Funding was provided by a research grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development NIH-F32HD071763-02 (MS), Defense Advanced Research Projects Agency (DARPA) DARPA-W911NF-06-1-0161 (KM), US Army Research Center ARO-W911NF0910305 (KM), and John L. and Mary Wright Ebaugh Endowment Fund at Tulane University (KM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of manuscript.	Agrawal V, 2011, TISSUE ENG PT A, V17, P3033, DOI [10.1089/ten.tea.2011.0257, 10.1089/ten.TEA.2011.0257]; Agrawal V, 2010, P NATL ACAD SCI USA, V107, P3351, DOI 10.1073/pnas.0905851106; BORGENS RB, 1982, SCIENCE, V217, P747, DOI 10.1126/science.7100922; Brockes JP, 2005, SCIENCE, V310, P1919, DOI 10.1126/science.1115200; Bryant SV, 2002, INT J DEV BIOL, V46, P887; Chadwick RB, 2007, WOUND REPAIR REGEN, V15, P275, DOI 10.1111/j.1524-475X.2007.00216.x; Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023; DOUGLAS BS, 1972, AUST PAEDIATR J, V8, P86; Fernando WA, 2011, DEV BIOL, V350, P301, DOI 10.1016/j.ydbio.2010.11.035; Ferris DR, 2010, DEV GROWTH DIFFER, V52, P715, DOI 10.1111/j.1440-169X.2010.01208.x; GOSS RJ, 1992, J EXP ZOOL, V264, P429, DOI 10.1002/jez.1402640408; Han M, 2008, DEV BIOL, V315, P125, DOI 10.1016/j.ydbio.2007.12.025; ILLINGWORTH CM, 1974, J PEDIATR SURG, V9, P853, DOI 10.1016/S0022-3468(74)80220-4; JAIN KK, 2004, TXB HYPERBARIC MED; JOHNELL O, 1977, CALC TISS RES, V23, P241, DOI 10.1007/BF02012792; Ke C, 2002, ASSIST SUITE S PLUS; Khanna S, 2006, FREE RADICAL BIO MED, V40, P2147, DOI 10.1016/j.freeradbiomed.2006.02.010; Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665; Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417; Lee JW, 2013, DEV BIOL, V382, P98, DOI 10.1016/j.ydbio.2013.07.020; Lehoczky JA, 2011, P NATL ACAD SCI USA, V108, P20609, DOI 10.1073/pnas.1118017108; Lowe J. S., 2015, STEVENS LOWES HUMAN; MONTES GS, 1991, MEM I OSWALDO CRUZ, V86, P1; Mu XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059105; NEUFELD DA, 1993, PROG CLIN BIOL RES, V383, P243; Neufeld Daniel A., 1995, Wound Repair and Regeneration, V3, P461, DOI 10.1046/j.1524-475X.1995.30410.x; Rich Lillian, 2005, Brazilian Journal of Morphological Sciences, V22, P97; Richmond KN, 1997, AM J PHYSIOL-CELL PH, V273, pC1613, DOI 10.1152/ajpcell.1997.273.5.C1613; Rinkevich Y, 2011, NATURE, V476, P409, DOI 10.1038/nature10346; Rollins MD, 2006, UNDERSEA HYPERBAR M, V33, P17; Said S, 2004, ANAT REC PART A, V278A, P443, DOI 10.1002/ar.a.20034; Sammarco MC, 2014, J BONE MINER RES, V29, P2336, DOI 10.1002/jbmr.2261; Sander AL, 2009, WOUND REPAIR REGEN, V17, P179, DOI 10.1111/j.1524-475X.2009.00455.x; Santosh N, 2011, DEV DYNAM, V240, P1127, DOI 10.1002/dvdy.22503; Siddiqui A, 1997, PLAST RECONSTR SURG, V99, P148, DOI 10.1097/00006534-199701000-00023; Simkin J, 2015, REGENERATION, V2, P93, DOI 10.1002/reg2.36; Simkin J, 2015, REGENERATION, V2, P106, DOI 10.1002/reg2.34; Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215; SINGER M, 1987, ANAT EMBRYOL, V177, P29, DOI 10.1007/BF00325287; Stevenson TJ, 2006, DEV DYNAM, V235, P606, DOI 10.1002/dvdy.20654; Takeo M, 2013, NATURE, V499, P228, DOI 10.1038/nature12214; Velazquez OC, 2007, J VASC SURG, V45, p39A, DOI 10.1016/j.jvs.2007.02.068; Wang Y, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/621414; Wang YD, 1998, J ROY STAT SOC B, V60, P159, DOI 10.1111/1467-9868.00115; Yang EV, 1999, DEV DYNAM, V216, P2, DOI 10.1002/(SICI)1097-0177(199909)216:1<2::AID-DVDY2>3.3.CO;2-G; Yu L, 2010, DEVELOPMENT, V137, P551, DOI 10.1242/dev.042424; ZHAO WG, 1995, J EXP ZOOL, V271, P155, DOI 10.1002/jez.1402710212	47	36	36	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2015	10	10							e0140156	10.1371/journal.pone.0140156	http://dx.doi.org/10.1371/journal.pone.0140156			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TY	26452224	Green Submitted, gold, Green Published			2023-01-03	WOS:000362511200044
J	George, AS; Branchini, C; Portela, A				George, Asha S.; Branchini, Casey; Portela, Anayda			Do Interventions that Promote Awareness of Rights Increase Use of Maternity Care Services? A Systematic Review	PLOS ONE			English	Review							HEALTH	Twenty years after the rights of women to go through pregnancy and childbirth safely were recognized by governments, we assessed the effects of interventions that promote awareness of these rights to increase use of maternity care services. Using inclusion and exclusion criteria defined in a peer-reviewed protocol, we searched published and grey literature from one database of studies on maternal health, two search engines, an internet search and contact with experts. From the 707 unique documents found, 219 made reference to rights, with 22 detailing interventions promoting awareness of rights for maternal and newborn health. Only four of these evaluated effects on health outcomes. While all four interventions promoted awareness of rights, they did so in different ways. Interventions included highly-scripted dissemination meetings with educational materials and other visual aids, participatory approaches that combined raising awareness of rights with improving accountability of services, and broader multi-stakeholder efforts to improve maternal health. Study quality ranged from weak to strong. Measured health outcomes included increased antenatal care and facility birth. Improvements in human rights outcomes such as availability, acceptability, accessibility, quality of care, as well as the capacity of rights holders and duty bearers were also reported to varying extents. Very little information on costs and almost no information on harms or risks were described. Despite searching multiple sources of information, while some studies did report on activities to raise awareness of rights, few detailed how they did so and very few measured effects on health outcomes. Promoting awareness of rights is one element of increasing demand for and use of quality maternity care services for women during pregnancy, birth and after birth. To date efforts have not been well documented in the literature and the program theories, processes and costs, let alone health effects have not been well evaluated.	[George, Asha S.; Branchini, Casey] Johns Hopkins Sch Publ Hlth, Dept Int Hlth, Hlth Syst Program, Baltimore, MD 21205 USA; [Portela, Anayda] WHO, Maternal Newborn Child & Adolescent Hlth, CH-1211 Geneva, Switzerland	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; World Health Organization	George, AS (corresponding author), Johns Hopkins Sch Publ Hlth, Dept Int Hlth, Hlth Syst Program, Baltimore, MD 21205 USA.	ageorg22@jhu.edu		Portela, Anayda/0000-0001-6368-1585; George, Asha/0000-0002-5968-1424	Norwegian Agency for Development; Department for International Development (DFID) [201888] Funding Source: researchfish	Norwegian Agency for Development; Department for International Development (DFID)	WHO Department of Maternal, Newborn, Child and Adolescent Health supported the systematic review with funds from the Norwegian Agency for Development. Asha George's time is also covered by the Future Health Systems research consortium. Anayda Portela is a staff member of the World Health Organization. The author alone is responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the World Health Organization.	Bjorkman M., 2007, POWER PEOPLE EVIDENC; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Bustreo F, 2013, WOMENS CHILDRENS HLT; EPHPP, 1998, QUAL ASS TOOL QUANT; Ferguson L, 2013, WOMENS CHILDRENS HLT, P140; Ganju K, 2014, PROMOTING ACCOUNTABI; George A, 2010, LANCET, V375, P1764, DOI 10.1016/S0140-6736(09)62102-4; Gruskin S, 2008, B WORLD HEALTH ORGAN, V86, P589, DOI 10.2471/BLT.07.050500; Mpinga EK, 2011, HEALTH HUM RIGHTS, V13, P102; OHCHR W, HUMAN RIGHTS BASED A, P4; Ooms G, 2014, BMC INT HEALTH HUM R, V14, DOI 10.1186/s12914-014-0036-5; Pandey P, 2007, JAMA-J AM MED ASSOC, V298, P1867, DOI 10.1001/jama.298.16.1867; Sinha D., 2008, EMPOWERING COMMUNITI; Starrs's Ann, 1997, SAFE MOTHERHOOD ACTI; United Nations, 1994, INT C POP DEV PROGR, P296; United Nations Economic and Social Council, 2000, GEN COMM 14 RIGHT HI; United Nations General Assembly, 1966, INT COV EC SOC CULT; United Nations Human Rights Council, 2009, PREV MAT MORT MORB H, P3; United Nations Human Rights Council, 2012, TECHN GUID APPL HUM, P20; United Nations Secretary General, 2010, GLOB STRAT WOM CHILD, P20; World Health Organization, 2014, WHORHR1423; Yamin AE, 2010, SUR, V12, P95; Yamin AE, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001546	23	17	18	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2015	10	10							e0138116	10.1371/journal.pone.0138116	http://dx.doi.org/10.1371/journal.pone.0138116			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TS	26444291	Green Published, Green Submitted, gold			2023-01-03	WOS:000362510600020
J	Kim, SB; Bozeman, RG; Kaisani, A; Kim, W; Zhang, L; Richardson, JA; Wright, WE; Shay, JW				Kim, S. B.; Bozeman, R. G.; Kaisani, A.; Kim, W.; Zhang, L.; Richardson, J. A.; Wright, W. E.; Shay, J. W.			Radiation promotes colorectal cancer initiation and progression by inducing senescence-associated inflammatory responses	ONCOGENE			English	Article							SOLAR PARTICLE EVENT; PROTON-BEAM THERAPY; CDDO-METHYL ESTER; EPITHELIAL-CELLS; MOUSE MODEL; DNA-DAMAGE; SPACE RADIATION; LUNG-CANCER; AUGUST 1972; TRITERPENOIDS	Proton radiotherapy is becoming more common as protons induce more precise DNA damage at the tumor site with reduced side effects to adjacent normal tissues. However, the long-term biological effects of proton irradiation in cancer initiation compared with conventional photon irradiation are poorly characterized. In this study, using a human familial adenomatous polyposis syndrome susceptible mouse model, we show that whole-body irradiation with protons are more effective in inducing senescence-associated inflammatory responses (SIRs), which are involved in colon cancer initiation and progression. After proton irradiation, a subset of SIR genes (Troy, Sox17, Opg, Faim2, Lpo, Tlr2 and Ptges) and a gene known to be involved in invasiveness (Plat), along with the senescence-associated gene (P19Arf), are markedly increased. Following these changes, loss of Casein kinase I alpha and induction of chronic DNA damage and TP53 mutations are increased compared with X-ray irradiation. Proton irradiation also increases the number of colonic polyps, carcinomas and invasive adenocarcinomas. Pretreatment with the non-steroidal anti-inflammatory drug, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid-ethyl amide (CDDO-EA), reduces proton irradiation-associated SIR and tumorigenesis. Thus exposure to proton irradiation elicits significant changes in colorectal cancer initiation and progression that can be mitigated using CDDO-EA.	[Kim, S. B.; Bozeman, R. G.; Kaisani, A.; Kim, W.; Zhang, L.; Wright, W. E.; Shay, J. W.] Univ Texas Southwestern Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd,MC9039, Dallas, TX 75390 USA; [Richardson, J. A.] Univ Texas Southwestern Med Ctr, Dept Pathol, Dallas, TX USA; [Richardson, J. A.] Univ Texas Southwestern Med Ctr, Dept Mol Biol, Dallas, TX USA; [Richardson, J. A.] Univ Texas Southwestern Med Ctr, Dept Plast Surg, Dallas, TX USA; [Shay, J. W.] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah, Saudi Arabia	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; King Abdulaziz University	Shay, JW (corresponding author), Univ Texas Southwestern Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd,MC9039, Dallas, TX 75390 USA.	jerry.shay@utsouthwestern.edu		Kim, Sang Bum/0000-0001-5965-3354	NIH grant [C06 RR30414]; NASA Grant [NNX15AI21G, NNX11AC15G, NNJ05HD36G, NNX09AU95G]; NATIONAL CANCER INSTITUTE [P50CA070907, T32CA124334] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR030414] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NASA Grant(National Aeronautics & Space Administration (NASA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank the support team at Brookhaven National Laboratory (BNL) and NASA Space Radiation Laboratory (NSRL) (Upton, NY, USA) for helping with the Proton and HZE particles delivery to animals. We thank Dr Michael Sporn (Hanover, NH, USA) and Reata Pharmaceuticals (Irving, TX, USA) for providing CDDO-EA reagent, Summer Barron (UT Southwestern, Dallas, TX, USA) for mouse colony maintenance and Gail Fasciani (UT Southwestern, Dallas, TX, USA) for histological processing. This work was performed in laboratories constructed with support from NIH grant C06 RR30414. This work was supported by NASA Grant nos. NNX15AI21G, NNX11AC15G, NNJ05HD36G and NNX09AU95G to JWS.	Ahn PH, 2014, CANCER J, V20, P421, DOI 10.1097/PPO.0000000000000077; Arnold CN, 2005, CANCER-AM CANCER SOC, V104, P2035, DOI 10.1002/cncr.21462; Bahnassy AA, 2004, BMC GASTROENTEROL, V4, DOI 10.1186/1471-230X-4-22; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Breuer H, 2013, PROTON THERAPY RADIO; Collis SJ, 2004, J BIOL CHEM, V279, P49624, DOI 10.1074/jbc.M409600200; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; DANGIO GJ, 1963, NUCLEONICS, V21, P56; Delgado O, 2014, CLIN CANCER RES, V20, P1610, DOI 10.1158/1078-0432.CCR-13-2589; Dicello JF, 2002, J RADIAT RES, V43, pS1; Eaton BR, 2014, CANCER J, V20, P403, DOI 10.1097/PPO.0000000000000079; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Eskiocak U, 2010, RADIAT RES, V174, P27, DOI 10.1667/RR2155.1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; George K, 2003, RADIAT RES, V160, P425, DOI 10.1667/RR3064; Hall EJ, RADIOBIOLOGY RADIOLO, V7th; Hellweg CE, 2007, NATURWISSENSCHAFTEN, V94, P517, DOI 10.1007/s00114-006-0204-0; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Keole S, 2014, CANCER J, V20, P409, DOI 10.1097/PPO.0000000000000084; Kim SB, 2014, LIFE SCI SPACE RES, V1, P67, DOI 10.1016/j.lssr.2014.02.001; Kim SB, 2013, RADIAT RES, V180, P259, DOI 10.1667/RR3371.1; Kim SB, 2012, P NATL ACAD SCI USA, V109, pE2949, DOI 10.1073/pnas.1207718109; Kim SB, 2014, GRAVIT SPACE RES, V2, P32; KUDO S, 1993, ENDOSCOPY, V25, P455, DOI 10.1055/s-2007-1010367; Lawrence J H, 1964, Trans Am Clin Climatol Assoc, V75, P111; Liby K, 2007, CANCER RES, V67, P2414, DOI 10.1158/0008-5472.CAN-06-4534; Ludlow AT, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku439; Miyaoka Y, 2014, NAT METHODS, V11, P291, DOI 10.1038/nmeth.2840; Moravek Z, 2009, Z MED PHYS, V19, P174, DOI 10.1016/j.zemedi.2009.04.006; Neymotin A, 2011, FREE RADICAL BIO MED, V51, P88, DOI 10.1016/j.freeradbiomed.2011.03.027; Parsons JL, 2000, RADIAT RES, V153, P729, DOI 10.1667/0033-7587(2000)153[0729:ICDRFT]2.0.CO;2; Petronelli A, 2009, ANTI-CANCER DRUG, V20, P880, DOI 10.1097/CAD.0b013e328330fd90; Pribluda A, 2013, CANCER CELL, V24, P242, DOI 10.1016/j.ccr.2013.06.005; Pugh TJ, 2014, CANCER J, V20, P415, DOI 10.1097/PPO.0000000000000083; Reisman SA, 2014, RADIAT RES, V181, P512, DOI 10.1667/RR13578.1; Rithidech KN, 2013, MUTAT RES-GEN TOX EN, V756, P127, DOI 10.1016/j.mrgentox.2013.06.001; Rutter MD, 2010, FRONTLINE GASTROENTE, V1, P126, DOI 10.1136/fg.2010.001438; Simone CB, 2014, CANCER J, V20, P427, DOI 10.1097/PPO.0000000000000080; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUIT HD, 1975, CANCER-AM CANCER SOC, V35, P1646, DOI 10.1002/1097-0142(197506)35:6<1646::AID-CNCR2820350626>3.0.CO;2-1; Thimmulappa RK, 2007, ANTIOXID REDOX SIGN, V9, P1963, DOI 10.1089/ars.2007.1745; TOWNSEND LW, 1991, RADIAT RES, V126, P108, DOI 10.2307/3578178; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; Vannini N, 2007, MOL CANCER THER, V6, P3139, DOI 10.1158/1535-7163.MCT-07-0451; VERHEY LJ, 1982, ANNU REV BIOPHYS BIO, V11, P331, DOI 10.1146/annurev.bb.11.060182.001555; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Williams JR, 1999, MUTAT RES-FUND MOL M, V430, P255, DOI 10.1016/S0027-5107(99)00137-2; Wilson JW, 1999, RADIAT MEAS, V30, P361, DOI 10.1016/S1350-4487(99)00063-3	50	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3365	3375		10.1038/onc.2015.395	http://dx.doi.org/10.1038/onc.2015.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26477319	Green Accepted			2023-01-03	WOS:000379270100002
J	Bitto, D; Halldorsson, S; Caputo, A; Huiskonen, JT				Bitto, David; Halldorsson, Steinar; Caputo, Alessandro; Huiskonen, Juha T.			Low pH and Anionic Lipid-dependent Fusion of Uukuniemi Phlebovirus to Liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						electron tomography; membrane; membrane fusion; virus entry; virus structure; bis(monoacylglycero)phosphate; bunyavirus; phlebovirus	SEMLIKI-FOREST-VIRUS; BORNE ENCEPHALITIS-VIRUS; MEMBRANE-FUSION; ELECTRON CRYOTOMOGRAPHY; SPONTANEOUS CURVATURE; SINDBIS VIRUS; FEVER; CHOLESTEROL; GLYCOPROTEIN; PROTEIN	Many phleboviruses (family Bunyaviridae) are emerging as medically important viruses. These viruses enter target cells by endocytosis and low pH-dependent membrane fusion in late endosomes. However, the necessary and sufficient factors for fusion have not been fully characterized. We have studied the minimal fusion requirements of a prototypic phlebovirus, Uukuniemi virus, in an in vitro virus-liposome assay. We show that efficient lipid mixing between viral and liposome membranes requires close to physiological temperatures and phospholipids with negatively charged headgroups, such as the late endosomal phospholipid bis(monoacylglycero)phosphate. We further demonstrate that bis(monoacylglycero)phosphate increases Uukuniemi virus fusion beyond the lipid mixing stage. By using electron cryotomography of viral particles in the presence or absence of liposomes, we observed that the conformation of phlebovirus glycoprotein capsomers changes from the native conformation toward a more elongated conformation at a fusion permissive pH. Our results suggest a rationale for phlebovirus entry in late endosomes.	[Bitto, David; Halldorsson, Steinar; Caputo, Alessandro; Huiskonen, Juha T.] Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Roosevelt Dr, Oxford OX3 7BN, England; [Caputo, Alessandro] Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Huiskonen, JT (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Roosevelt Dr, Oxford OX3 7BN, England.	juha@strubi.ox.ac.uk	Caputo, Alessandro/AFM-4954-2022; Huiskonen, Juha T/C-3043-2008	Caputo, Alessandro/0000-0001-5007-6896; Huiskonen, Juha T/0000-0002-0348-7323; Halldorsson, Steinar/0000-0003-1810-6607; Bitto, David/0000-0003-3530-4947	Wellcome Trust JIF [060208/Z/00/Z]	Wellcome Trust JIF	We thank A. Siebert for electron microscopy support, K. Grunewald for helpful suggestions, and T. Bowden for critically reading the manuscript. Oxford Particle Imaging Centre electron microscopy facility was founded by a Wellcome Trust JIF award 060208/Z/00/Z.	Alley SH, 2008, CHEM PHYS LIPIDS, V154, P64, DOI 10.1016/j.chemphyslip.2008.03.007; Amini-Bavil-Olyaee S, 2013, CELL HOST MICROBE, V13, P452, DOI 10.1016/j.chom.2013.03.006; Bowden TA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003374; BRATT MA, 1969, P NATL ACAD SCI USA, V64, P536, DOI 10.1073/pnas.64.2.536; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; Cao S, 2013, P NATL ACAD SCI USA, V110, P13362, DOI 10.1073/pnas.1301911110; Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; CORVER J, 1995, J VIROL, V69, P3220, DOI 10.1128/JVI.69.5.3220-3223.1995; Corver J, 2000, VIROLOGY, V269, P37, DOI 10.1006/viro.1999.0172; CYRKLAFF M, 1994, J MICROSC-OXFORD, V175, P135, DOI 10.1111/j.1365-2818.1994.tb03476.x; de Boer SM, 2012, J VIROL, V86, P13642, DOI 10.1128/JVI.01973-12; Dessau M, 2013, P NATL ACAD SCI USA, V110, P1696, DOI 10.1073/pnas.1217780110; ELLIOTT RM, 1990, J GEN VIROL, V71, P501, DOI 10.1099/0022-1317-71-3-501; Ergonul O, 2006, LANCET INFECT DIS, V6, P203, DOI 10.1016/S1473-3099(06)70435-2; Floyd DL, 2008, P NATL ACAD SCI USA, V105, P15382, DOI 10.1073/pnas.0807771105; Freiberg AN, 2008, J VIROL, V82, P10341, DOI 10.1128/JVI.01191-08; Fuller N, 2003, BIOPHYS J, V85, P1667, DOI 10.1016/S0006-3495(03)74596-2; Gallala HD, 2011, NEUROCHEM RES, V36, P1594, DOI 10.1007/s11064-010-0337-6; Garigliany MM, 2012, ANTIVIR RES, V95, P82, DOI 10.1016/j.antiviral.2012.05.014; Harmon B, 2012, J VIROL, V86, P12954, DOI 10.1128/JVI.02242-12; Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; Huiskonen JT, 2014, JOVE-J VIS EXP, DOI 10.3791/51714; Huiskonen JT, 2010, J VIROL, V84, P4889, DOI 10.1128/JVI.00057-10; Huiskonen JT, 2009, J VIROL, V83, P3762, DOI 10.1128/JVI.02483-08; Ikegami T, 2011, VIRUSES-BASEL, V3, P493, DOI 10.3390/v3050493; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; Kolter T, 2010, FEBS LETT, V584, P1700, DOI 10.1016/j.febslet.2009.10.021; Kooijman EE, 2005, BIOCHEMISTRY-US, V44, P2097, DOI 10.1021/bi0478502; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; KUISMANEN E, 1982, MOL CELL BIOL, V2, P1444, DOI 10.1128/MCB.2.11.1444; Kyoung M, 2011, P NATL ACAD SCI USA, V108, pE304, DOI 10.1073/pnas.1107900108; Lee KK, 2010, EMBO J, V29, P1299, DOI 10.1038/emboj.2010.13; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; Lozach PY, 2011, CELL HOST MICROBE, V10, P75, DOI 10.1016/j.chom.2011.06.007; Lozach PY, 2010, CELL HOST MICROBE, V7, P488, DOI 10.1016/j.chom.2010.05.007; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007; Mobius W, 2003, TRAFFIC, V4, P222; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; Overby AK, 2008, P NATL ACAD SCI USA, V105, P2375, DOI 10.1073/pnas.0708738105; PAL R, 1988, BIOCHEMISTRY-US, V27, P30, DOI 10.1021/bi00401a006; Prins M, 1998, TRENDS MICROBIOL, V6, P31, DOI 10.1016/S0966-842X(97)01173-6; RENKONEN O, 1972, VIROLOGY, V50, P899, DOI 10.1016/0042-6822(72)90443-6; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Sherman MB, 2009, VIROLOGY, V387, P11, DOI 10.1016/j.virol.2009.02.038; Smit JM, 1999, J VIROL, V73, P8476, DOI 10.1128/JVI.73.10.8476-8484.1999; Umashankar M, 2008, J VIROL, V82, P9245, DOI 10.1128/JVI.00975-08; van der Schaar HM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000244; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Waarts BL, 2005, J VIROL, V79, P7942, DOI 10.1128/JVI.79.12.7942-7948.2005; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; Walter CT, 2011, J GEN VIROL, V92, P2467, DOI 10.1099/vir.0.035105-0; Xu BL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002369; Yu XJ, 2011, NEW ENGL J MED, V364, P1523, DOI 10.1056/NEJMoa1010095; Zaitseva E, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001131	60	24	24	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2016	291	12					6412	6422		10.1074/jbc.M115.691113	http://dx.doi.org/10.1074/jbc.M115.691113			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DH6IM	26811337	hybrid, Green Published			2023-01-03	WOS:000372894200029
J	Baumgart, DC; le Claire, M				Baumgart, Daniel C.; le Claire, Marie			The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds	PLOS ONE			English	Article							COSTS; CLASSIFICATION; SYSTEM	Background Crohn's disease (CD) and ulcerative colitis (UC) challenge economies worldwide. Detailed health economic data of DRG based academic inpatient care for inflammatory bowel disease (IBD) patients in Europe is unavailable. Methods IBD was identified through ICD-10 K50 and K51 code groups. We took an actual costing approach, compared expenditures to G-DRG and non-DRG proceeds and performed detailed cost center and type accounting to identify coverage determinants. Results Of all 3093 hospitalized cases at our department, 164 were CD and 157 UC inpatients in 2012. On average, they were 44.1 (CD 44.9 UC 43.3 all 58) years old, stayed 10.1 (CD 11.8 UC 8.4 vs. all 8) days, carried 5.8 (CD 6.4 UC 5.2 vs. all 6.8) secondary diagnoses, received 7.4 (CD 7.7 UC 7 vs. all 6.2) procedures, had a higher cost weight (CD 2.8 UC 2.4 vs. all 1.6) and required more intense nursing. Their care was more costly (means: total cost IBD 8477(sic)CD 9051(sic)UC 7903(sic) vs. all 5078(sic)). However, expenditures were not fully recovered by DRG proceeds (means: IBD 7413(sic), CD 8441(sic), UC 6384(sic) vs all 4758(sic)). We discovered substantial disease specific mismatches in cost centers and types and identified the medical ward personnel and materials budgets to be most imbalanced. Non-DRG proceeds were almost double (IBD 16.1% vs. all 8.2%), but did not balance deficits at total coverage analysis, that found medications (antimicrobials, biologics and blood products), medical materials (mostly endoscopy items) to contribute most to the deficit. Conclusions DRGs challenge sophisticated IBD care.	[Baumgart, Daniel C.] Humboldt Univ, Ctr Inflammatory Bowel Dis, Dept Gastroenterol & Hepatol, Charite Med Sch, D-10099 Berlin, Germany; [le Claire, Marie] Humboldt Univ, Enterprise Controlling, Charite Med Sch, D-10099 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Baumgart, DC (corresponding author), Humboldt Univ, Ctr Inflammatory Bowel Dis, Dept Gastroenterol & Hepatol, Charite Med Sch, D-10099 Berlin, Germany.	daniel.baumgart@charite.de	Baumgart, Daniel C./AAU-2930-2021	Baumgart, Daniel C./0000-0003-2146-507X				[Anonymous], 2016, INT STAT CLASS DIS R, DOI DOI 10/2016/EN; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; Bernstein CN, 2012, INFLAMM BOWEL DIS, V18, P1498, DOI 10.1002/ibd.21878; Bernstein CN, 2000, AM J GASTROENTEROL, V95, P677; Busse R, 2011, DIAGNOSIS RELATED GR; Busse R, 2013, BMJ BRIT MED J, V346, DOI 10.1136/bmj.f3197; Cohen RD, 2010, ALIMENT PHARM THER, V31, P693, DOI 10.1111/j.1365-2036.2010.04234.x; Danese S, 2011, NEW ENGL J MED, V365, P1713, DOI 10.1056/NEJMra1102942; Farrokhyar F, 2002, CAN J GASTROENTEROL, V16, P519, DOI 10.1155/2002/619574; FETTER RB, 1976, YALE J BIOL MED, V49, P123; Ott C, 2008, EUR J GASTROEN HEPAT, V20, P917, DOI 10.1097/MEG.0b013e3282f97b33; Porter ME, 2015, REDEFINING GERMAN HL; Preyra C, 2004, HEALTH SERV RES, V39, P1027, DOI 10.1111/j.1475-6773.2004.00270.x; Quentin W, 2013, HEALTH AFFAIR, V32, P713, DOI 10.1377/hlthaff.2012.0876; Rogowski J R, 1990, Health Care Financ Rev, V12, P87; Scheller-Kreinsen D, 2011, VALUE HEALTH, V14, P1166, DOI 10.1016/j.jval.2011.07.001; Schreyogg Jonas, 2006, Health Care Manag Sci, V9, P215, DOI 10.1007/s10729-006-9040-1; Shiralkar AP, 2012, SAP NETWEAVER BW 7 3; Silverberg MS, 2005, CAN J GASTROENTEROL, V19, p5A, DOI 10.1155/2005/269076; Sutherland JM, 2015, HOSP PAYMENT MECH OV; Union E, 2006, OFFICIAL J EUROPEA C, VC323, P1; van der Valk ME, 2014, GUT, V63, P72, DOI 10.1136/gutjnl-2012-303376; Vavricka SR, 2011, AM J GASTROENTEROL, V106, P110, DOI 10.1038/ajg.2010.343; VULGAROPULOS SP, 1990, DIGEST DIS SCI, V35, P577, DOI 10.1007/BF01540404; World Health Organization, 2015, INT STAT CLASS DIS R; Yu AP, 2008, CURR MED RES OPIN, V24, P319, DOI 10.1185/03007990SX260790	26	10	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2016	11	1							e0147364	10.1371/journal.pone.0147364	http://dx.doi.org/10.1371/journal.pone.0147364			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB5BP	26784027	gold, Green Published, Green Submitted			2023-01-03	WOS:000368528400142
J	Lytle, KA; Jump, DB				Lytle, Kelli A.; Jump, Donald B.			Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr(-/-) Mice Reversible?	PLOS ONE			English	Article							FATTY LIVER-DISEASE; HEPATIC GENE-EXPRESSION; TOLL-LIKE RECEPTORS; STELLATE CELLS; MOUSE MODEL; FIBROSIS; INFLAMMATION; RESOLUTION; EPIDEMIOLOGY; FIBROGENESIS	Background Nonalcoholic fatty liver disease (NAFLD) is a major public health burden in western societies. The progressive form of NAFLD, nonalcoholic steatohepatitis (NASH), is characterized by hepatosteatosis, inflammation, oxidative stress, and hepatic damage that can progress to fibrosis and cirrhosis; risk factors for hepatocellular carcinoma. Given the scope of NASH, validating treatment protocols (i.e., low fat diets and weight loss) is imperative. Methods We evaluated the efficacy of two diets, a non-purified chow (NP) and purified (low-fat low-cholesterol, LFLC) diet to reverse western diet (WD)-induced NASH and fibrosis in Ldlr(-/-) mice. Results Mice fed WD for 22-24 weeks developed robust hepatosteatosis with mild fibrosis, while mice maintained on the WD an additional 7-8 weeks developed NASH with moderate fibrosis. Returning WD-fed mice to the NP or LFLC diets significantly reduced body weight and plasma markers of metabolic syndrome (dyslipidemia, hyperglycemia) and hepatic gene expression markers of inflammation (Mcp1), oxidative stress (Nox2), fibrosis (Col1A, LoxL2, Timp1) and collagen crosslinking (hydroxyproline). Time course analyses established that plasma triglycerides and hepatic Col1A1 mRNA were rapidly reduced following the switch from the WD to the LFLC diet. However, hepatic triglyceride content and fibrosis did not return to normal levels 8 weeks after the change to the LFLC diet. Time course studies further revealed a strong association (r(2) >= 0.52) between plasma markers of inflammation (TLR2 activators) and hepatic fibrosis markers (Col1A, Timp1, LoxL2). Inflammation and fibrosis markers were inversely associated (r(2) >= 0.32) with diet-induced changes in hepatic omega 3 and omega 6 polyunsaturated fatty acids (PUFA) content. Conclusion These studies establish a temporal link between plasma markers of inflammation and hepatic PUFA and fibrosis. Low-fat low-cholesterol diets promote reversal of many, but not all, features associated with WD-induced NASH and fibrosis in Ldlr(-/-) mice.	[Lytle, Kelli A.; Jump, Donald B.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Nutr Program, Corvallis, OR 97331 USA; [Lytle, Kelli A.; Jump, Donald B.] Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Jump, DB (corresponding author), Oregon State Univ, Sch Biol & Populat Hlth Sci, Nutr Program, Corvallis, OR 97331 USA.	Donald.Jump@oregonstate.edu			NIH [DK094600]; USDA National Institute of Food and Agriculture Grant [2009-65200-05846]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK094600] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USDA National Institute of Food and Agriculture Grant; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH DK094600 and USDA National Institute of Food and Agriculture Grant (2009-65200-05846).	Arendt BM, 2015, HEPATOLOGY, V61, P1565, DOI 10.1002/hep.27695; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bieghs V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030668; Moreira APB, 2012, BRIT J NUTR, V108, P801, DOI 10.1017/S0007114512001213; Cengiz M, 2015, J GASTROEN HEPATOL, V30, P1190, DOI 10.1111/jgh.12924; Clapper JR, 2013, AM J PHYSIOL-GASTR L, V305, pG483, DOI 10.1152/ajpgi.00079.2013; Cohen JC, 2011, SCIENCE, V332, P1519, DOI 10.1126/science.1204265; Depner CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083756; Depner CM, 2013, J NUTR, V143, P315, DOI 10.3945/jn.112.171322; Depner CM, 2012, J NUTR, V142, P1495, DOI 10.3945/jn.112.158865; Dixon JB, 2004, HEPATOLOGY, V39, P1647, DOI 10.1002/hep.20251; Ekstedt M, 2015, HEPATOLOGY, V61, P1547, DOI 10.1002/hep.27368; Fallowfield JA, 2007, J IMMUNOL, V178, P5288, DOI 10.4049/jimmunol.178.8.5288; Ghoshal S, 2009, J LIPID RES, V50, P90, DOI 10.1194/jlr.M800156-JLR200; Harte AL, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-15; Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Jump DB, 2011, BIOCHEM PHARMACOL, V81, P649, DOI 10.1016/j.bcp.2010.12.014; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; Lassailly G, 2015, GASTROENTEROLOGY, V149, P379, DOI 10.1053/j.gastro.2015.04.014; Lim JS, 2010, NAT REV GASTRO HEPAT, V7, P251, DOI 10.1038/nrgastro.2010.41; Liu Y, 2012, DIGEST DIS SCI, V57, P390, DOI 10.1007/s10620-011-1902-9; Lytle KA, 2015, J LIPID RES, V56, P1936, DOI 10.1194/jlr.M061275; Magkos F, 2015, PATHOGENESIS HEPATIC, P89; Mallat A, 2013, AM J PHYSIOL-CELL PH, V305, pC789, DOI 10.1152/ajpcell.00230.2013; Marcellin P, 2013, J GASTROEN HEPATOL, V28, P912, DOI 10.1111/jgh.12213; Mattar SG, 2005, ANN SURG, V242, P610, DOI 10.1097/01.sla.0000179652.07502.3f; McCullough AJ, 2011, J DIGEST DIS, V12, P333, DOI 10.1111/j.1751-2980.2010.00469.x; Michelsen KS, 2004, J IMMUNOL, V173, P5901, DOI 10.4049/jimmunol.173.10.5901; Min HK, 2012, CELL METAB, V15, P665, DOI 10.1016/j.cmet.2012.04.004; Moylan CA, 2014, HEPATOLOGY, V59, P471, DOI 10.1002/hep.26661; Pagliassotti MJ, 1996, AM J PHYSIOL-REG I, V271, pR1319, DOI 10.1152/ajpregu.1996.271.5.R1319; Park HG, 2015, BIOCH BIOPHYS ACTA M, V186, P91; Perepelyuk M, 2013, AM J PHYSIOL-GASTR L, V304, pG605, DOI 10.1152/ajpgi.00222.2012; Pickens MK, 2009, J LIPID RES, V50, P2072, DOI 10.1194/jlr.M900022-JLR200; Popov Y, 2010, AM J PHYSIOL-GASTR L, V298, pG323, DOI 10.1152/ajpgi.00394.2009; Puri P, 2007, HEPATOLOGY, V46, P1081, DOI 10.1002/hep.21763; Ramachandran P, 2012, QJM-INT J MED, V105, P813, DOI 10.1093/qjmed/hcs069; RicardBlum S, 1996, GASTROENTEROLOGY, V111, P172, DOI 10.1053/gast.1996.v111.pm8698196; Rivera CA, 2007, J HEPATOL, V47, P571, DOI 10.1016/j.jhep.2007.04.019; Roh YS, 2013, J GASTROEN HEPATOL, V28, P38, DOI 10.1111/jgh.12019; Schuppan D, 2013, J CLIN INVEST, V123, P1887, DOI 10.1172/JCI66028; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Suter M, 2006, OBES SURG, V16, P829, DOI 10.1381/096089206777822359; Taylor KR, 2004, J BIOL CHEM, V279, P17079, DOI 10.1074/jbc.M310859200; Thuy S, 2008, J NUTR, V138, P1452, DOI 10.1093/jn/138.8.1452; Tilg H, 2010, HEPATOLOGY, V52, P1836, DOI 10.1002/hep.24001; Tripathy S, 2013, J LIPID RES, V54, P71, DOI 10.1194/jlr.M028787; Tripathy S, 2010, J LIPID RES, V51, P2642, DOI 10.1194/jlr.M006080; Troeger JS, 2012, GASTROENTEROLOGY, V143, P1073, DOI 10.1053/j.gastro.2012.06.036; Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x; Welsh JA, 2012, J PEDIAT, V162, P496, DOI DOI 10.1016/J; Wouters K, 2008, HEPATOLOGY, V48, P474, DOI 10.1002/hep.22363; Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zois CD, 2008, ALIMENT PHARM THER, V28, P1175, DOI 10.1111/j.1365-2036.2008.03840.x	58	27	28	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2016	11	1							e0146942	10.1371/journal.pone.0146942	http://dx.doi.org/10.1371/journal.pone.0146942			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA8CX	26761430	gold, Green Published, Green Submitted			2023-01-03	WOS:000368033100056
J	Calanzani, N; Higginson, IJ; Koffman, J; Gomes, B				Calanzani, Natalia; Higginson, Irene J.; Koffman, Jonathan; Gomes, Barbara			Factors Associated with Participation, Active Refusals and Reasons for Not Taking Part in a Mortality Followback Survey Evaluating End-of-Life Care	PLOS ONE			English	Article							AFTER-DEATH INTERVIEWS; BEREAVEMENT RESEARCH; POSTAL QUESTIONNAIRES; PALLIATIVE CARE; CANCER-PATIENTS; RESPONSE RATES; SAMPLE CHARACTERISTICS; METHODOLOGICAL ISSUES; NONRESPONSE BIAS; PREFERRED PLACE	Background Examination of factors independently associated with participation in mortality followback surveys is rare, even though these surveys are frequently used to evaluate end-of-life care. We aimed to identify factors associated with 1) participation versus non-participation and 2) provision of an active refusal versus a silent refusal; and systematically examine reasons for refusal in a population-based mortality followback survey. Methods Postal survey about the end-of-life care received by 1516 people who died from cancer (aged >= 18), identified through death registrations in London, England (response rate 39.3%). The informant of death (a relative in 95.3% of cases) was contacted 4-10 months after the patient died. We used multivariate logistic regression to identify factors associated with participation/active refusals and content analysis to examine refusal reasons provided by 205 nonparticipants. Findings The odds of partaking were higher for patients aged 90+ (AOR 3.48, 95% CI: 1.52-8.00, ref: 20-49yrs) and female informants (AOR 1.70, 95% CI: 1.33-2.16). Odds were lower for hospital deaths (AOR 0.62, 95% CI: 0.46-0.84, ref: home) and proxies other than spouses/partners (AORs 0.28 to 0.57). Proxies of patients born overseas were less likely to provide an active refusal (AOR 0.49; 95% CI: 0.32-0.77). Refusal reasons were often multidimensional, most commonly study-related (36.0%), proxy-related and grief-related (25.1% each). One limitation of this analysis is the large number of nonparticipants who did not provide reasons for refusal (715/920). Conclusions Our survey better reached proxies of older patients while those dying in hospitals were underrepresented. Proxy characteristics played a role, with higher participation from women and spouses/partners. More information is needed about the care received by underrepresented groups. Study design improvements may guide future questionnaire development and help develop strategies to increase response rates.	[Calanzani, Natalia; Higginson, Irene J.; Koffman, Jonathan; Gomes, Barbara] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England; [Calanzani, Natalia] Univ Edinburgh, Sch Med, Usher Inst Populat Hlth Sci & Informat, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland	University of London; King's College London; University of Edinburgh	Calanzani, N (corresponding author), Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England.	natalia.calanzani@ed.ac.uk	Calanzani, Natalia/AAK-2007-2020; Higginson, Irene Julie/C-7309-2012	Calanzani, Natalia/0000-0002-5068-2543; Koffman, Jonathan/0000-0001-8513-5681; Higginson, Irene Julie/0000-0002-3687-1313; Gomes, Barbara/0000-0001-8149-1806	charity Cicely Saunders International; MRC [G0802654] Funding Source: UKRI; Medical Research Council [G0802654] Funding Source: researchfish	charity Cicely Saunders International; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was funded by the charity Cicely Saunders International (cicelysaundersinternational.org) as part of Dr Barbara Gomes' PhD studies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Addington-Hall J, 1998, J EPIDEMIOL COMMUN H, V52, P802, DOI 10.1136/jech.52.12.802; Addington-Hall J, 2002, EUR J CANCER CARE, V11, P220, DOI 10.1046/j.1365-2354.2002.00343.x; Addington- Hall J, 1999, POLICY; ADDINGTONHALL J, 1995, PALLIATIVE MED, V9, P27, DOI 10.1177/026921639500900105; Altman DG, 1991, PRACTICAL STAT MED R; [Anonymous], 2012, NAT STAT; [Anonymous], 2013, NAT STAT; [Anonymous], 2010, PUBLIC HLTH REPORT; [Anonymous], 2009, INFORMATION; [Anonymous], BEREAVEMENT; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Barriball KL, 1999, J ADV NURS, V30, P677, DOI 10.1046/j.1365-2648.1999.01117.x; Beccaro M, 2006, J EPIDEMIOL COMMUN H, V60, P412, DOI 10.1136/jech.2005.043646; Beck AM, 2007, DEATH STUD, V31, P783, DOI 10.1080/07481180701537220; Burt J, 2010, AGE AGEING, V39, P86, DOI 10.1093/ageing/afp212; Calanzani N, 2013, ATTACHMENT; CARTWRIGHT A, 1986, J EPIDEMIOL COMMUN H, V40, P267, DOI 10.1136/jech.40.3.267; Casarett D, 2010, J AM GERIATR SOC, V58, P2381, DOI 10.1111/j.1532-5415.2010.03175.x; Caserta M, 2010, HEALTH; COOK AS, 1995, DEATH STUD, V19, P157, DOI 10.1080/07481189508252722; Costantini M, 2005, PALLIATIVE MED, V19, P628, DOI 10.1191/0269216305pm1086oa; Curtis JR, 2002, J PAIN SYMPTOM MANAG, V24, P17, DOI 10.1016/S0885-3924(02)00419-0; Department for Communities and Local Government, 2009, IMPACT ASSESSMENT; Edwards P, 2004, CONTROL CLIN TRIALS, V25, P31, DOI 10.1016/j.cct.2003.08.013; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Edwards PJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000008.pub4; Emanuel EJ, 2004, ARCH INTERN MED, V164, P1999, DOI 10.1001/archinte.164.18.1999; Escobar Pinzon LC, 2010, BMC PALLIAT CARE, V9, P16, DOI [10.1186/1472-684X-9-16, DOI 10.1186/1472-684X-9-16]; Eurostat, 2014, HEALTH; Evans C, 2015, BMJ SUPPORT PALLIAT, V5, P116; Gill TM, 2010, NEW ENGL J MED, V362, P1173, DOI 10.1056/NEJMoa0909087; Gomes B, 2011, LIVING AGEING DYING, P3; Gomes B, 2013, SUPPORT CARE CANCER, P1; Gomes B, 2008, PALLIATIVE MED, V22, P33, DOI 10.1177/0269216307084606; Gomes B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0466-5; Gomes B, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-400; Grande G, 2008, PALLIATIVE MED, V22, P971, DOI 10.1177/0269216308098805; Grande GE, 2009, PALLIATIVE MED, V23, P248, DOI 10.1177/0269216309102620; Groves RM, 2008, PUBLIC OPIN QUART, V72, P167, DOI 10.1093/poq/nfn011; Hanratty B, 2000, BRIT J GEN PRACT, V50, P653; Higginson IJ, 2010, PALLIATIVE MED, V24, P352, DOI 10.1177/0269216309360489; Hunt KJ, 2011, VOICES REDESIGN TEST; Ingleton C, 2004, HEALTH SOC CARE COMM, V12, P43, DOI 10.1111/j.1365-2524.2004.00467.x; Jacoby A, 1999, PALLIATIVE MED, V13, P285, DOI 10.1191/026921699674259562; Kendall M, 2007, BMJ-BRIT MED J, V334, P521, DOI 10.1136/bmj.39097.582639.55; Koffman J, 2012, PALLIATIVE MED, V26, P379, DOI 10.1177/0269216311405091; Koopman L, 2013, J CLIN EPIDEMIOL, V66, P340, DOI 10.1016/j.jclinepi.2012.09.012; Kross EK, 2009, CHEST, V136, P1496, DOI 10.1378/chest.09-0589; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lund D, 1993, PRESS, P240; MacDonald SE, 2009, PUBLIC HEALTH NURS, V26, P95, DOI 10.1111/j.1525-1446.2008.00758.x; McLennan D, 2011, SOC POLICY; Menaca A, EUROPE, V82, P387; Miyashita M, 2008, J CLIN ONCOL, V26, P3845, DOI 10.1200/JCO.2007.15.8287; Neal MB, 1996, RES AGING, V18, P219, DOI 10.1177/0164027596182004; Office for National Statistics, 2010, NAT STAT; Office for National Statistics, 2011, NAT STAT; Office for National Statistics, 2014, NAT STAT; PARKES CM, 1995, DEATH STUD, V19, P171, DOI 10.1080/07481189508252723; Parkes CM, 2010, BEREAVEMENT STUDIES, P137; Perneger TV, 2005, MED CARE, V43, P374, DOI 10.1097/01.mlr.0000156856.36901.40; Phipps Etienne J, 2002, Gerontologist, V42 Spec No 3, P104; Pring A, 2012, NETWORK; Scott P, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-111; SEEMAN I, 1989, PUBLIC HEALTH REP, V104, P183; Skulason Bragi, 2010, BMC Palliat Care, V9, P7, DOI 10.1186/1472-684X-9-7; Stroebe M, 2003, PALLIATIVE MED, V17, P235, DOI 10.1191/0269216303pm768rr; STROEBE MS, 1989, OMEGA-J DEATH DYING, V20, P1, DOI 10.2190/C3JE-C9L1-5R91-DWDU; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno Joan M, 2005, J Palliat Med, V8 Suppl 1, pS42; Williams BR, 2008, DEATH STUD, V32, P197, DOI 10.1080/07481180701881297; World Health Organisation, 1992, ORGANISATION	73	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2016	11	1							e0146134	10.1371/journal.pone.0146134	http://dx.doi.org/10.1371/journal.pone.0146134			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DA5AX	26745379	Green Published, gold, Green Submitted			2023-01-03	WOS:000367815600027
J	Middleton, K				Middleton, Karen			Give patients direct access to physiotherapy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Middleton, Karen] Leeds Metropolitan Univ, Leeds LS1 3HE, W Yorkshire, England; [Middleton, Karen] Chartered Soc Physiotherapy, London, England	Leeds Beckett University	Middleton, K (corresponding author), Leeds Metropolitan Univ, Leeds LS1 3HE, W Yorkshire, England.	middletonk@csp.org.uk						Briggs T, 2015, GETTING IT RIGHT 1 T, P7; Bury TJ, 2013, PHYS THER, V93, P449, DOI 10.2522/ptj.20120060; Chartered Society of Physiotherapy, 2012, MUSC PHYS PAT SELF R; Chartered Society of Physiotherapy, 2015, PHYS WORKS SELF REF; Chartered Society of Physiotherapy, 2014, FREED INF AUD; Department of Health, 2006, JOINT DOCTRINE INTER; Department of Health, 2008, SELF REF PIL MUSC PH; Holdsworth LK, 2007, PHYSIOTHERAPY, V93, P3, DOI 10.1016/j.physio.2006.05.005; nfpSynergy, 2014, PRIM HEALTHC MON; NHS London, 2012, ALL HLTH PROF MSK TO, P28; Nordeman L, 2006, CLIN J PAIN, V22, P505, DOI 10.1097/01.ajp.0000210696.46250.0d; Royal College of General Practitioners, 2013, 2022 GP VIS GEN PRAC	12	9	9	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 5	2016	352								h6844	10.1136/bmj.h6844	http://dx.doi.org/10.1136/bmj.h6844			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA8MA	26732983				2023-01-03	WOS:000368057800005
J	Szollosi, D; Erdei, A; Gyimesi, G; Magyar, C; Hegedus, T				Szoellosi, Daniel; Erdei, Aron; Gyimesi, Gergely; Magyar, Csaba; Hegedus, Tamas			Access Path to the Ligand Binding Pocket May Play a Role in Xenobiotics Selection by AhR	PLOS ONE			English	Article							ARYL-HYDROCARBON RECEPTOR; DISCRETE MOLECULAR-DYNAMICS; PAS-B DOMAIN; MULTIDRUG-RESISTANCE; STRUCTURAL BASIS; FUNCTIONAL DOMAINS; DOCKING; IDENTIFICATION; EFFICIENT; PROTEINS	Understanding of multidrug binding at the atomic level would facilitate drug design and strategies to modulate drug metabolism, including drug transport, oxidation, and conjugation. Therefore we explored the mechanism of promiscuous binding of small molecules by studying the ligand binding domain, the PAS-B domain of the aryl hydrocarbon receptor (AhR). Because of the low sequence identities of PAS domains to be used for homology modeling, structural features of the widely employed HIF-2 alpha and a more recent suitable template, CLOCK were compared. These structures were used to build AhR PAS-B homology models. We performed molecular dynamics simulations to characterize dynamic properties of the PAS-B domain and the generated conformational ensembles were employed in in silico docking. In order to understand structural and ligand binding features we compared the stability and dynamics of the promiscuous AhR PAS-B to other PAS domains exhibiting specific interactions or no ligand binding function. Our exhaustive in silico binding studies, in which we dock a wide spectrum of ligand molecules to the conformational ensembles, suggest that ligand specificity and selection may be determined not only by the PAS-B domain itself, but also by other parts of AhR and its protein interacting partners. We propose that ligand binding pocket and access channels leading to the pocket play equally important roles in discrimination of endogenous molecules and xenobiotics.	[Szoellosi, Daniel; Erdei, Aron; Hegedus, Tamas] Hungarian Acad Sci, MTA SE Mol Biophys Res Grp, H-1094 Budapest, Hungary; [Szoellosi, Daniel; Hegedus, Tamas] Semmelweis Univ, Dept Biophys & Radiat Biol, H-1094 Budapest, Hungary; [Erdei, Aron] Pazmany Peter Catholic Univ, Fac Informat Technol & Bion, H-1083 Budapest, Hungary; [Gyimesi, Gergely] Univ Bern, Inst Biochem & Mol Med, CH-3012 Bern, Switzerland; [Magyar, Csaba] Hungarian Acad Sci, Inst Enzymol, Res Ctr Nat Sci, H-1117 Budapest, Hungary	Hungarian Academy of Sciences; Semmelweis University; University of Bern; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences	Hegedus, T (corresponding author), Hungarian Acad Sci, MTA SE Mol Biophys Res Grp, H-1094 Budapest, Hungary.	hegedus@hegelab.org	Magyar, Csaba/P-8288-2019; Gyimesi, Gergely/AAL-7340-2021; Szöllösi, Dániel/ABH-9228-2020	Magyar, Csaba/0000-0002-5023-6180; Gyimesi, Gergely/0000-0002-2054-4633; Szöllösi, Dániel/0000-0003-4641-3065	Bolyai Fellowship of the Hungarian Academy of Sciences; NKFIH [K 111678]; OTKA [NK 100482]; Marie Curie Actions International Fellowship Program (IFP) TransCure	Bolyai Fellowship of the Hungarian Academy of Sciences(Hungarian Academy of Sciences); NKFIH(National Research, Development & Innovation Office (NRDIO) - Hungary); OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Marie Curie Actions International Fellowship Program (IFP) TransCure	This work was supported by a Bolyai Fellowship of the Hungarian Academy of Sciences (TH), NKFIH K 111678 (TH), and OTKA NK 100482 (CM). Gergely Gyimesi was funded by the Marie Curie Actions International Fellowship Program (IFP) TransCure (www.nccr-transcure.ch).	Adaixo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059265; Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.20; Bisson WH, 2009, J MED CHEM, V52, P5635, DOI 10.1021/jm900199u; Blacklock K, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003679; Cao F, 2013, ENVIRON TOXICOL PHAR, V36, P626, DOI 10.1016/j.etap.2013.06.004; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; Chen YK, 2012, BIOCHEM PHARMACOL, V83, P1112, DOI 10.1016/j.bcp.2012.01.030; Chodera JD, 2007, J CHEM THEORY COMPUT, V3, P26, DOI 10.1021/ct0502864; Csermely P, 2010, TRENDS BIOCHEM SCI, V35, P539, DOI 10.1016/j.tibs.2010.04.009; Dagliyan O, 2013, P NATL ACAD SCI USA, V110, P6800, DOI 10.1073/pnas.1218319110; Dagliyan O, 2011, STRUCTURE, V19, P1837, DOI 10.1016/j.str.2011.09.014; de Waal PW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108607; Ding F, 2008, STRUCTURE, V16, P1010, DOI 10.1016/j.str.2008.03.013; Ding F, 2006, PLOS COMPUT BIOL, V2, P725, DOI 10.1371/journal.pcbi.0020085; Ding F, 2013, J CHEM INF MODEL, V53, P1871, DOI 10.1021/ci300478y; Ding F, 2010, J CHEM INF MODEL, V50, P1623, DOI 10.1021/ci100218t; Duda K, 2004, J BIOL CHEM, V279, P23311, DOI 10.1074/jbc.M400864200; Ekins S, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000594; Erbel PJA, 2003, P NATL ACAD SCI USA, V100, P15504, DOI 10.1073/pnas.2533374100; Esser C, 2015, PHARMACOL REV, V67, P259, DOI 10.1124/pr.114.009001; Eswar N., 2006, CURR PROT BIOINF, V15, P1, DOI [10.1002/0471250953.bi0506s15, DOI 10.1002/0471250953.BI0506S15]; Fraccalvieri D, 2013, BIOCHEMISTRY-US, V52, P714, DOI 10.1021/bi301457f; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Getzoff ED, 2003, NAT STRUCT BIOL, V10, P663, DOI 10.1038/nsb958; Gyimesi G, 2011, BBA-BIOMEMBRANES, V1808, P2954, DOI 10.1016/j.bbamem.2011.07.038; Handschin C, 2003, PHARMACOL REV, V55, P649, DOI 10.1124/pr.55.4.2; Hennig S, 2009, PLOS BIOL, V7, P836, DOI 10.1371/journal.pbio.1000094; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Huang NA, 2012, SCIENCE, V337, P189, DOI 10.1126/science.1222804; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Jones PM, 2013, CRIT REV BIOCHEM MOL, V48, P39, DOI 10.3109/10409238.2012.735644; Karagoz GE, 2011, P NATL ACAD SCI USA, V108, P580, DOI 10.1073/pnas.1011867108; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Kerr ID, 2010, FEBS J, V277, P550, DOI 10.1111/j.1742-4658.2009.07486.x; Key J, 2009, J AM CHEM SOC, V131, P17647, DOI 10.1021/ja9073062; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Guilloux V, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-168; Masetti M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094986; Melo F, 2007, PROTEIN SCI, V16, P2412, DOI 10.1110/ps.072895107; Moglich A, 2009, STRUCTURE, V17, P1282, DOI 10.1016/j.str.2009.08.011; Motto I, 2011, J CHEM INF MODEL, V51, P2868, DOI 10.1021/ci2001617; Nash AI, 2011, P NATL ACAD SCI USA, V108, P9449, DOI 10.1073/pnas.1100262108; Nuti R, 2014, J CHEM INF MODEL, V54, P3373, DOI 10.1021/ci5005459; O'Donnell EF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013128; Odio C, 2013, BIOCHEMISTRY-US, V52, P1746, DOI 10.1021/bi301722k; Ohkura K, 2009, ANTICANCER RES, V29, P935; Pandini A, 2007, BIOCHEMISTRY-US, V46, P696, DOI 10.1021/bi061460t; Pandini A, 2009, BIOCHEMISTRY-US, V48, P5972, DOI 10.1021/bi900259z; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Proctor EA, 2012, BIOPHYS J, V102, P144, DOI 10.1016/j.bpj.2011.11.4008; Proctor EA, 2011, WIRES COMPUT MOL SCI, V1, P80, DOI 10.1002/wcms.4; Punj S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088726; Ramachandran S, 2011, PROTEINS, V79, P261, DOI 10.1002/prot.22879; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; Riggs DL, 2004, CRIT REV BIOCHEM MOL, V39, P279, DOI 10.1080/10409230490892513; Rogers JL, 2013, J MED CHEM, V56, P1739, DOI 10.1021/jm301847z; Sarkadi B, 2006, PHYSIOL REV, V86, P1179, DOI 10.1152/physrev.00037.2005; Scheuermann TH, 2009, P NATL ACAD SCI USA, V106, P450, DOI 10.1073/pnas.0808092106; Schmidtke P, 2011, BIOINFORMATICS; Schrodinger L.L.C., 2015, SMALL MOL DRUG DISCO; Seifert C, 2012, BIOPHYS J, V103, P2195, DOI 10.1016/j.bpj.2012.09.008; Shirvanyants D, 2012, J PHYS CHEM B, V116, P8375, DOI 10.1021/jp2114576; Soshilov AA, 2014, MOL CELL BIOL, V34, P1707, DOI 10.1128/MCB.01183-13; Straub FB., 1964, MOL BIOL PROBLEMS PE, P182; Szollosi D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095795; Team RC, 2014, R LANG ENV STAT COMP; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Tsai CJ, 1999, PROTEIN SCI, V8, P1181, DOI 10.1110/ps.8.6.1181; Turk D, 2009, IDRUGS, V12, P246; Vohra S, 2013, PROTEIN SCI, V22, P1218, DOI 10.1002/pro.2309; Vreede J, 2003, J BIOL CHEM, V278, P18434, DOI 10.1074/jbc.M301701200; Watkins RE, 2003, J MOL BIOL, V331, P815, DOI 10.1016/S0022-2836(03)00795-2; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Wong CF, 2015, EXPERT OPIN DRUG DIS, V10, P1189, DOI 10.1517/17460441.2015.1078308; Xie W, 2004, DRUG DISCOV TODAY, V9, P442, DOI 10.1016/S1359-6446(04)03061-2; Xing YN, 2012, TOXICOL SCI, V129, P86, DOI 10.1093/toxsci/kfs194; Yuan JT, 2013, ENVIRON TOXICOL CHEM, V32, P1453, DOI 10.1002/etc.2191; ZAVODSZKY P., 1966, ACTA BIOCHIM BIOPHYS ACAD SCI HUNG, V1, P389	79	10	11	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2016	11	1							e0146066	10.1371/journal.pone.0146066	http://dx.doi.org/10.1371/journal.pone.0146066			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA3FF	26727491	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000367681500050
J	Periyakoil, VS				Periyakoil, Vyjeyanthi S.			A Never-Ending Battle	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Periyakoil, Vyjeyanthi S.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Periyakoil, Vyjeyanthi S.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Periyakoil, VS (corresponding author), Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.								0	2	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	2015	373	25					2399	2401		10.1056/NEJMp1505976	http://dx.doi.org/10.1056/NEJMp1505976			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CY5QD	26536398				2023-01-03	WOS:000366461400006
J	Chen, CC; Chen, CW; Ho, CK; Liu, IC; Lin, BC; Chan, TC				Chen, Chien-Chou; Chen, Chao-Wen; Ho, Chi-Kung; Liu, I-Chuan; Lin, Bo-Cheng; Chan, Ta-Chien			Spatial Variation and Resuscitation Process Affecting Survival after Out-of-Hospital Cardiac Arrests (OHCA)	PLOS ONE			English	Article							AUTOMATED EXTERNAL DEFIBRILLATORS; CARDIOPULMONARY-RESUSCITATION; POPULATION-DENSITY; PREDICTORS; OUTCOMES; REGISTRY; IMPACT; EPIDEMIOLOGY; MANAGEMENT; DEPLOYMENT	Background Ambulance response times and resuscitation efforts are critical predictors of the survival rate after out-of-hospital cardiac arrests (OHCA). On the other hand, rural-urban differences in the OHCA survival rates are an important public health issue. Methods We retrospectively reviewed the January 2011-December 2013 OHCA registry data of Kaohsiung City, Taiwan. With particular focus on geospatial variables, we aimed to unveil risk factors predicting the overall OHCA survival until hospital admission. Spatial analysis, network analysis, and the Kriging method by using geographic information systems were applied to analyze spatial variations and calculate the transport distance. Logistic regression was used to identify the risk factors for OHCA survival. Results Among the 4,957 patients, the overall OHCA survival to hospital admission was 16.5%. In the multivariate analysis, female sex (adjusted odds ratio:, AOR, 1.24 [1.06-1.45]), events in public areas (AOR: 1.30 [1.05-1.61]), exposure to automated external defibrillator (AED) shock (AOR: 1.70 [1.30-2.23]), use of laryngeal mask airway (LMA) (AOR: 1.35 [1.16-1.58]), non-trauma patients (AOR: 1.41 [1.04-1.90]), ambulance bypassed the closest hospital (AOR: 1.28 [1.07-1.53]), and OHCA within the high population density areas (AOR: 1.89 [1.55-2.32]) were positively associated with improved OHCA survival. By contrast, a prolonged total emergency medical services (EMS) time interval was negatively associated with OHCA survival (AOR: 0.98 [0.96-0.99]). Conclusions Resuscitative efforts, such as AED or LMA use, and a short total EMS time interval improved OHCA outcomes in emergency departments. The spatial heterogeneity of emergency medical resources between rural and urban areas might affect survival rate.	[Chen, Chien-Chou; Lin, Bo-Cheng; Chan, Ta-Chien] Acad Sinica, Ctr Geog Informat Sci, Res Ctr Humanities & Social Sci, Taipei 115, Taiwan; [Chen, Chao-Wen] Kaohsiung Med Univ Hosp, Dept Surg, Div Trauma, Kaohsiung, Taiwan; [Chen, Chao-Wen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Emergency Med, Kaohsiung, Taiwan; [Ho, Chi-Kung] Kaohsiung City Govt, Dept Hlth, Kaohsiung, Taiwan; [Liu, I-Chuan] Kaohsiung City Govt, Fire Bur, Kaohsiung, Taiwan	Academia Sinica - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Chen, CW (corresponding author), Kaohsiung Med Univ Hosp, Dept Surg, Div Trauma, Kaohsiung, Taiwan.	kmutrauma@gmail.com; dachianpig@gmail.com	Chen, Chien-Chou/AAD-7070-2019	Chen, Chao Wen/0000-0002-8405-342X; Lin, Bo-Cheng/0000-0003-3502-6203	Academia Sinica; Ministry of Science and Technology [MOST-103-2627-M-001-006]	Academia Sinica(Academia Sinica - Taiwan); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This research was mainly supported by the internal research project named "Multidisciplinary Health Cloud Research Program: Technology Development and Application of Big Health Data" funded by Academia Sinica and also partially supported by a research grant from the Ministry of Science and Technology (grants no. MOST-103-2627-M-001-006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Berdowski J, 2011, CIRCULATION, V124, P2225, DOI 10.1161/CIRCULATIONAHA.110.015545; Bertrand C, 2004, RESUSCITATION, V63, P175, DOI 10.1016/j.resuscitation.2004.05.011; Blom MT, 2013, RESUSCITATION, V84, P569, DOI 10.1016/j.resuscitation.2012.10.009; Boyce LW, 2015, NETH HEART J, V23, P20, DOI 10.1007/s12471-014-0617-x; Chen CY, 2013, PEDIATR SURG INT, V29, P471, DOI 10.1007/s00383-013-3302-z; Cudnik MT, 2010, RESUSCITATION, V81, P518, DOI 10.1016/j.resuscitation.2009.12.030; De Maio VJ, 2012, PREHOSP EMERG CARE, V16, P230, DOI 10.3109/10903127.2011.640419; Dyson K, 2014, RESUSCITATION, V85, P1134, DOI 10.1016/j.resuscitation.2014.05.020; Earnest A, 2012, PREHOSP EMERG CARE, V16, P256, DOI 10.3109/10903127.2011.615974; Fake AL, 2013, NEW ZEAL MED J, V126, P28; Goh ES, 2013, ANN ACAD MED SINGAP, V42, P437; Goldberg SA, 2013, CRIT CARE, V17, DOI 10.1186/cc13128; Guimaraes RJPS, 2009, ACTA TROP, V109, P181, DOI 10.1016/j.actatropica.2008.10.012; Hasegawa K, 2013, RESUSCITATION, V84, P1099, DOI 10.1016/j.resuscitation.2013.03.007; Hiltunen P, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-80; Iqbal MB, 2015, AM J CARDIOL, V115, P730, DOI 10.1016/j.amjcard.2014.12.033; Kitamura T, 2010, EUR HEART J, V31, P1365, DOI 10.1093/eurheartj/ehq059; Ko PCI, 2004, RESUSCITATION, V63, P167, DOI 10.1016/j.resuscitation.2004.04.002; Lee CC, 2011, EMERG MED J, V28, P432, DOI 10.1136/emj.2009.087593; Lin CH, 2013, RESUSCITATION, V84, P586, DOI 10.1016/j.resuscitation.2012.09.028; Lin YR, 2007, RESUSCITATION, V74, P83, DOI 10.1016/j.resuscitation.2006.11.022; Mahapatra S, 2005, RESUSCITATION, V65, P197, DOI 10.1016/j.resuscitation.2004.10.017; McNally Bryan, 2011, Morbidity and Mortality Weekly Report, V60, P1; Nielsen AM, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-34; Nordberg P, 2015, RESUSCITATION, V90, P143, DOI 10.1016/j.resuscitation.2015.02.036; Pollice A, 2010, ENVIRON MONIT ASSESS, V162, P177, DOI 10.1007/s10661-009-0786-z; Sasson C, 2011, RESUSCITATION, V82, P674, DOI 10.1016/j.resuscitation.2011.02.002; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Sladjana A, 2011, EUR J INTERN MED, V22, P386, DOI 10.1016/j.ejim.2011.04.003; Stromsoe A, 2011, RESUSCITATION, V82, P1307, DOI 10.1016/j.resuscitation.2011.04.025; Ta-Chien Chan, 2013, GEOMASKER 1 0; Tetsushi Tachikawa, 2011, NASA LAND PROCESSES; Tritsch L, 2014, RESUSCITATION, V85, P320, DOI 10.1016/j.resuscitation.2013.11.006; van de Glind EMM, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-68; Weisfeldt ML, 2011, NEW ENGL J MED, V364, P313, DOI 10.1056/NEJMoa1010663; Wibrandt I, 2015, BMC EMERG MED, V15, DOI 10.1186/s12873-015-0028-3; Wissenberg M, 2014, RESUSCITATION, V85, P1212, DOI 10.1016/j.resuscitation.2014.06.008; Writer H, 2010, BMJ CLIN EVID, V2010, P307; Yeung J, 2014, RESUSCITATION, V85, P898, DOI 10.1016/j.resuscitation.2014.02.018	40	19	19	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2015	10	12							e0144882	10.1371/journal.pone.0144882	http://dx.doi.org/10.1371/journal.pone.0144882			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9GR	26659851	Green Published, gold, Green Submitted			2023-01-03	WOS:000366715900133
J	Byrnes, J; Carrington, M; Chan, YK; Pollicino, C; Dubrowin, N; Stewart, S; Scuffham, PA				Byrnes, Joshua; Carrington, Melinda; Chan, Yih-Kai; Pollicino, Christine; Dubrowin, Natalie; Stewart, Simon; Scuffham, Paul A.			Cost-Effectiveness of a Home Based Intervention for Secondary Prevention of Readmission with Chronic Heart Disease	PLOS ONE			English	Article							RANDOMIZED-TRIAL; HEALTH-CARE; MULTICENTER; MANAGEMENT; RISK; IMPACT; YOUNG	The aim of this study is to consider the cost-effectiveness of a nurse-led, home-based intervention (HBI) in cardiac patients with private health insurance compared to usual post-discharge care. A within trial analysis of the Young @ Heart multicentre, randomized controlled trial along with a micro-simulation decision analytical model was conducted to estimate the incremental costs and quality adjusted life years associated with the home based intervention compared to usual care. For the micro-simulation model, future costs, from the perspective of the funder, and effects are estimated over a twenty-year time horizon. An Incremental Cost-Effectiveness Ratio, along with Incremental Net Monetary Benefit, is evaluated using a willingness to pay threshold of $50,000 per quality adjusted life year. Sub-group analyses are conducted for men and women across three age groups separately. Costs and benefits that arise in the future are discounted at five percent per annum. Overall, home based intervention for secondary prevention in patients with chronic heart disease identified in the Australian private health care sector is not cost-effective. The estimated within trial incremental net monetary benefit is -$3,116 [95% CI: -11,145, $4,914]; indicating that the costs outweigh the benefits. However, for males and in particular males aged 75 years and above, home based intervention indicated a potential to reduce health care costs when compared to usual care (within trial: -$10,416 [95% CI: -$26,745, $5,913]; modelled analysis: -$1,980 [95% CI: -$22,843, $14,863]). This work provides a crucial impetus for future research to understand for whom disease management programs are likely to benefit most.	[Byrnes, Joshua; Scuffham, Paul A.] Griffith Univ, Ctr Appl Hlth Econ, Meadowbrook, Qld 4131, Australia; [Carrington, Melinda; Chan, Yih-Kai; Stewart, Simon] Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, Australia; [Pollicino, Christine; Dubrowin, Natalie] Bupa Australia, Melbourne, Vic, Australia	Griffith University; Australian Catholic University	Byrnes, J (corresponding author), Griffith Univ, Ctr Appl Hlth Econ, Meadowbrook, Qld 4131, Australia.	j.byrnes@griffith.edu.au	Stewart, Simon/M-3316-2016; Scuffham, Paul/AAS-8084-2021; Byrnes, Josh/AAA-4387-2021; Scuffham, Paul/B-3066-2014	Stewart, Simon/0000-0001-9032-8998; Scuffham, Paul/0000-0001-5931-642X; Scuffham, Paul/0000-0001-5931-642X; Byrnes, Joshua/0000-0001-6562-711X; Chan, Yih-Kai/0000-0003-3836-8145	Bupa Australia	Bupa Australia	The Young@Heart trial was funded by Bupa Australia. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antes G, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1432; Armstrong BK, 2007, MED J AUSTRALIA, V187, P485, DOI 10.5694/j.1326-5377.2007.tb01383.x; Australian Institute of Health and Welfare, 2011, CARD DIS AUSTR FACTS; Australian Institute of Health and Welfare, 2014, HLTH EXP AUSTR 2012; Buchmueller TC, 2013, J HEALTH ECON, V32, P757, DOI 10.1016/j.jhealeco.2013.05.001; Byrnes JM, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-114; Carrington MJ, 2013, EUR J CARDIOVASC NUR, V12, P337, DOI 10.1177/1474515112451702; Carrington MJ, 2013, CIRC-CARDIOVASC QUAL, V6, P379, DOI 10.1161/CIRCOUTCOMES.111.000006; Chan YK, 2012, INT J CARDIOL, V154, P52, DOI 10.1016/j.ijcard.2010.08.071; Clark AM, 2010, EUR J CARDIOV PREV R, V17, P261, DOI 10.1097/HJR.0b013e32833090ef; Clark RA, 2012, CIRCULATION, V125, P2006, DOI 10.1161/CIRCULATIONAHA.111.083394; Kotseva K, 2009, EUR J CARDIOV PREV R, V16, P121, DOI 10.1097/HJR.0b013e3283294b1d; Maru S, 2015, EUR J CARDIOVASC NUR, V14, P26, DOI 10.1177/1474515114536093; National Heart Foundation of Australia The Cardiac Society of Australia and New Zealand, 2011, GUID PREV DET MAN CH; Private Health Insurance Administration Council, 2013, PRIV INS PEOPL HOSP; Smith SC, 2011, CIRCULATION, V124, P2458, DOI 10.1161/CIR.0b013e318235eb4d; StataCorp, 2013, STAT STAT SOFTW REL; Stewart S, 2015, EUR J HEART FAIL, V17, P620, DOI 10.1002/ejhf.272; Stewart S, 2015, LANCET, V385, P775, DOI 10.1016/S0140-6736(14)61992-9; Stewart S, 2014, INT J CARDIOL, V174, P600, DOI 10.1016/j.ijcard.2014.04.164; TreeAge Software, 2014, TREEAGE PRO 2014 R2; Viney R, 2011, VALUE HEALTH, V14, P928, DOI 10.1016/j.jval.2011.04.009; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Williams JR, 2008, B WORLD HEALTH ORGAN, V86, P650, DOI 10.2471/BLT.08.050955	24	5	5	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2015	10	12							e0144545	10.1371/journal.pone.0144545	http://dx.doi.org/10.1371/journal.pone.0144545			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1YZ	26657844	gold, Green Published, Green Submitted			2023-01-03	WOS:000366903500038
J	Neilson, J; O'Neill, F; Dawoud, D; Crean, P				Neilson, Julie; O'Neill, Frank; Dawoud, Dalia; Crean, Peter		Guideline Dev Grp	GUIDELINES Intravenous fluids in children and young people: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Neilson, Julie; O'Neill, Frank; Dawoud, Dalia] Natl Clin Guideline Ctr, London, England; [Dawoud, Dalia] Cairo Univ, Fac Pharm, Cairo, Egypt; [Crean, Peter] Royal Belfast Hosp Sick Children, Belfast, Antrim, North Ireland	Egyptian Knowledge Bank (EKB); Cairo University	Neilson, J (corresponding author), Natl Clin Guideline Ctr, London, England.	Julie.neilson@rcplondon.ac.uk	Dawoud, Dalia M/N-9741-2019	Dawoud, Dalia M/0000-0002-2105-1937				[Anonymous], 2009, DIARRHOEA VOMITING C; Joint Formulary Committee, 2015, BRIT NAT FORM CHILDR; Moritz ML, 2010, PEDIATR NEPHROL, V25, P1225, DOI 10.1007/s00467-009-1323-6; National Institute for Health and Care Excellence, 2013, INTR FLUID THER 16S; National Institute for Health and Care Excellence, 2015, INTR FLUIDS THER CHI; National Patient Safety Agency, 2007, RED RISK HYP ADM INT; National Patient Safety Agency, 2014, TEMPL PRESCR INTR IN	7	12	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 9	2015	351								h6388	10.1136/bmj.h6388	http://dx.doi.org/10.1136/bmj.h6388			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CY5SX	26662119				2023-01-03	WOS:000366468800002
J	Heroux, ME; Taylor, JL; Gandevia, SC				Heroux, Martin E.; Taylor, Janet L.; Gandevia, Simon C.			The Use and Abuse of Transcranial Magnetic Stimulation to Modulate Corticospinal Excitability in Humans	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; THETA-BURST STIMULATION; PUBLICATION BIAS; MOTOR CORTEX; PLASTICITY; INDUCTION; PREVALENCE; SCIENCE; SIZE	The magnitude and direction of reported physiological effects induced using transcranial magnetic stimulation (TMS) to modulate human motor cortical excitability have proven difficult to replicate routinely. We conducted an online survey on the prevalence and possible causes of these reproducibility issues. A total of 153 researchers were identified via their publications and invited to complete an anonymous internet-based survey that asked about their experience trying to reproduce published findings for various TMS protocols. The prevalence of questionable research practices known to contribute to low reproducibility was also determined. We received 47 completed surveys from researchers with an average of 16.4 published papers (95% CI 10.8-22.0) that used TMS to modulate motor cortical excitability. Respondents also had a mean of 4.0 (2.5-5.7) relevant completed studies that would never be published. Across a range of TMS protocols, 45-60% of respondents found similar results to those in the original publications; the other respondents were able to reproduce the original effects only sometimes or not at all. Only 20% of respondents used formal power calculations to determine study sample sizes. Others relied on previously published studies (25%), personal experience (24%) or flexible post-hoc criteria (41%). Approximately 44% of respondents knew researchers who engaged in questionable research practices (range 32-70%), yet only 18% admitted to engaging in them (range 6-38%). These practices included screening subjects to find those that respond in a desired way to a TMS protocol, selectively reporting results and rejecting data based on a gut feeling. In a sample of 56 published papers that were inspected, not a single questionable research practice was reported. Our survey revealed that approximately 50% of researchers are unable to reproduce published TMS effects. Researchers need to start increasing study sample size and eliminating-or at least reporting-questionable research practices in order to make the outcomes of TMS research reproducible.	[Heroux, Martin E.; Taylor, Janet L.; Gandevia, Simon C.] Neurosci Res Australia, Randwick, NSW, Australia; [Heroux, Martin E.; Taylor, Janet L.; Gandevia, Simon C.] Univ New S Wales, Randwick, NSW, Australia	Neuroscience Research Australia; University of New South Wales Sydney	Gandevia, SC (corresponding author), Neurosci Res Australia, Randwick, NSW, Australia.	s.gandevia@neura.edu.au	Taylor, Janet L/C-9667-2011; Heroux, Martin/AAD-7694-2021; Gandevia, Simon/D-5009-2011	Taylor, Janet L/0000-0001-8976-5162; Heroux, Martin/0000-0002-3354-7104; Gandevia, Simon/0000-0002-1345-3821	Australian Government, National Health and Medical Research Council [APP1055084]	Australian Government, National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by Australian Government, National Health and Medical Research Council, Program Grant (APP1055084) (https://www.nhmrc.gov.au/).	Alberts B, 2015, SCIENCE, V348, P1420, DOI 10.1126/science.aab3847; Anderson WP, 2015, NATURE, V519, P158, DOI 10.1038/519158a; Bakker M, 2012, PERSPECT PSYCHOL SCI, V7, P543, DOI 10.1177/1745691612459060; BARKER AT, 1985, LANCET, V1, P1106; Begley CG, 2015, NATURE, V525, P25, DOI 10.1038/525025a; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Cumming G, 2014, PSYCHOL SCI, V25, P7, DOI 10.1177/0956797613504966; Cunningham CT, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0016-z; DAY BL, 1989, BRAIN, V112, P649, DOI 10.1093/brain/112.3.649; Di Lazzaro V, 2014, J PHYSIOL-LONDON, V592, P4115, DOI 10.1113/jphysiol.2014.274316; Dwan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066844; Ferguson CJ, 2012, PSYCHOL METHODS, V17, P120, DOI 10.1037/a0024445; Franco A, 2014, SCIENCE, V345, P1502, DOI 10.1126/science.1255484; Halsey LG, 2015, NAT METHODS, V12, P179, DOI 10.1038/nmeth.3288; Hamada M, 2013, CEREB CORTEX, V23, P1593, DOI 10.1093/cercor/bhs147; Hayslett MM, 2004, LIBR INFORM SCI RES, V26, P73, DOI 10.1016/j.lisr.2003.11.005; Head ML, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002106; Holman L, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002190; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Ioannidis JPA, 2008, EPIDEMIOLOGY, V19, P640, DOI 10.1097/EDE.0b013e31818131e7; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; John LK, 2012, PSYCHOL SCI, V23, P524, DOI 10.1177/0956797611430953; Kaplan RM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132382; Kline R.B., 2013, SIGNIFICANCE TESTING; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Lopez-Alonso V, 2014, BRAIN STIMUL, V7, P372, DOI 10.1016/j.brs.2014.02.004; Martin PG, 2006, CLIN NEUROPHYSIOL, V117, P2684, DOI 10.1016/j.clinph.2006.08.008; Martinson BC, 2005, NATURE, V435, P737, DOI 10.1038/435737a; McGauran N, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-37; Mervis J, 2014, SCIENCE, V345, P992, DOI 10.1126/science.345.6200.992; Nakagawa S, 2007, BIOL REV, V82, P591, DOI 10.1111/j.1469-185X.2007.00027.x; Nieuwenhuis S, 2011, NAT NEUROSCI, V14, P1105, DOI 10.1038/nn.2886; Nosek BA, 2015, SCIENCE, V348, P1422, DOI 10.1126/science.aab2374; Nuzzo R, 2014, NATURE, V506, P150, DOI 10.1038/506150a; Oberman L, 2011, J CLIN NEUROPHYSIOL, V28, P67, DOI 10.1097/WNP.0b013e318205135f; Ridding MC, 2010, J PHYSIOL-LONDON, V588, P2291, DOI 10.1113/jphysiol.2010.190314; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Sale MV, 2007, EXP BRAIN RES, V181, P615, DOI 10.1007/s00221-007-0960-x; Schooler J, 2011, NATURE, V470, P437, DOI 10.1038/470437a; Simmons JP, 2011, PSYCHOL SCI, V22, P1359, DOI 10.1177/0956797611417632; Simonsohn U, 2014, J EXP PSYCHOL GEN, V143, P534, DOI 10.1037/a0033242; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; STERLING TD, 1959, J AM STAT ASSOC, V54, P30, DOI 10.2307/2282137; Vallence AM, 2015, NEUROSCIENCE, V304, P266, DOI 10.1016/j.neuroscience.2015.07.043; Vallence AM, 2014, CORTEX, V58, P261, DOI 10.1016/j.cortex.2013.12.006; Ziemann U, 2008, BRAIN STIMUL, V1, P164, DOI 10.1016/j.brs.2008.06.006	46	34	34	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2015	10	12							e0144151	10.1371/journal.pone.0144151	http://dx.doi.org/10.1371/journal.pone.0144151			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX8BI	26629998	Green Submitted, Green Published, gold			2023-01-03	WOS:000365926300165
J	Krewer, C; Luther, M; Koenig, E; Muller, F				Krewer, Carmen; Luther, Marianne; Koenig, Eberhard; Mueller, Friedemann			Tilt Table Therapies for Patients with Severe Disorders of Consciousness: A Randomized, Controlled Trial	PLOS ONE			English	Article							MODIFIED ASHWORTH SCALE; BRAIN-INJURY; VEGETATIVE STATE; DEFAULT MODE; RECOVERY; AROUSAL; NEUROREHABILITATION; REHABILITATION; RELIABILITY; AWARENESS	One major aim of the neurological rehabilitation of patients with severe disorders of consciousness (DOC) is to enhance patients' arousal and ability to communicate. Mobilization into a standing position by means of a tilt table has been shown to improve their arousal and awareness. However, due to the frequent occurrence of syncopes on a tilt table, it is easier to accomplish verticalization using a tilt table with an integrated stepping device. The objective of this randomized controlled clinical trial was to evaluate the effectiveness of a tilt table therapy with or without an integrated stepping device on the level of consciousness. A total of 50 participants in vegetative or minimally conscious states 4 weeks to 6 month after injury were treated with verticalization during this randomized controlled trial. Interventions involved ten 1-hour sessions of the specific treatment over a 3-week period. Blinded assessors made measurements before and after the intervention period, as well as after a 3-week follow-up period. The coma recovery scale-revised (CRS-R) showed an improvement by a median of 2 points for the group receiving tilt table with integrated stepping (Erigo). The rate of recovery of the group receiving the conventional tilt table therapy significantly increased by 5 points during treatment and by an additional 2 points during the 3-week follow-up period. Changes in spasticity did not significantly differ between the two intervention groups. Compared to the conventional tilt table, the tilt table with integrated stepping device failed to have any additional benefit for DOC patients. Verticalization itself seems to be beneficial though and should be administered to patients in DOC in early rehabilitation.	[Krewer, Carmen; Luther, Marianne; Koenig, Eberhard; Mueller, Friedemann] Schoen Klin Bad Aibling, Motor Res Dept, Bad Aibling, Germany		Krewer, C (corresponding author), Schoen Klin Bad Aibling, Motor Res Dept, Bad Aibling, Germany.	CKrewer@schoen-kliniken.de	Krewer, Carmen/H-2845-2019	Krewer, Carmen/0000-0002-4153-0791; Muller, Friedemann/0000-0002-2461-3536				BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Cruse D, 2010, CURR OPIN NEUROL, V23, P656, DOI 10.1097/WCO.0b013e32833fd4e7; Elliott L, 2005, NEUROPSYCHOL REHABIL, V15, P480, DOI 10.1080/09602010443000506; Elliott L, 2005, J NEUROL NEUROSUR PS, V76, P298, DOI 10.1136/jnnp.2004.047357; Fernandez-Espejo D, 2012, ANN NEUROL, V72, P335, DOI 10.1002/ana.23635; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Georgiopoulos M, 2010, STEREOT FUNCT NEUROS, V88, P199, DOI 10.1159/000314354; Giacino JT, 2013, SEMIN NEUROL, V33, P142, DOI 10.1055/s-0033-1348960; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Grill E, 2013, ARCH PHYS MED REHAB, V94, P1870, DOI 10.1016/j.apmr.2012.10.040; Guldenmund P, 2012, ARCH ITAL BIOL, V150, P107, DOI 10.4449/aib.v150i2.1373; JENNETT B, 1972, LANCET, V1, P734; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Kotchoubey B, 2013, J NEUROL, V260, P975, DOI 10.1007/s00415-012-6734-9; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lehembre R, 2012, FUNCT NEUROL, V27, P41; Lombardi FF, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001427; Luther MS, 2007, BRAIN INJURY, V21, P763, DOI 10.1080/02699050701481639; Luther MS, 2008, CLIN REHABIL, V22, P1034, DOI 10.1177/0269215508092821; Mantini D, 2013, NEUROSCIENTIST, V19, P76, DOI 10.1177/1073858412446202; Mehrholz J, 2005, CLIN REHABIL, V19, P751, DOI 10.1191/0269215505cr889oa; Oh H, 2003, J CLIN NURS, V12, P394, DOI 10.1046/j.1365-2702.2003.00750.x; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Riberholt CG, 2013, DAN MED J, V60; Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141; Thibaut A, 2015, EUR J PHYS REHAB MED, V51, P389; Thibaut A, 2014, NEUROLOGY, V82, P1112, DOI 10.1212/WNL.0000000000000260; Urbenjaphol P., 2009, J NEUROSCI NURS, V41, pE10, DOI [DOI 10.1097/JNN.0B013E3181A23E94, 10.1097/jnn.0b013e3181a23e94]; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Wilson BA, 2013, BRAIN IMPAIR, V14, P475, DOI 10.1017/BrImp.2013.34; Wood R L, 1992, Brain Inj, V6, P411, DOI 10.3109/02699059209008137	34	30	32	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2015	10	12							e0143180	10.1371/journal.pone.0143180	http://dx.doi.org/10.1371/journal.pone.0143180			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7OL	26623651	Green Submitted, gold, Green Published			2023-01-03	WOS:000365891600018
J	Er, F; Yuksel, D; Hellmich, M; Gassanov, N				Er, Fikret; Yueksel, Dilek; Hellmich, Martin; Gassanov, Natig			Comparison of Conventional versus Steerable-Catheter Guided Coronary Sinus Lead Positioning in Patients Undergoing Cardiac Resynchronization Device Implantation	PLOS ONE			English	Article							CHRONIC HEART-FAILURE; THERAPY; DEFIBRILLATOR; PREVENTION	Objectives The aim of this study was to compare conventional versus steerable catheter guided coronary sinus (CS) cannulation in patients with advanced heart failure undergoing cardiac resynchronization therapy (CRT). Background Steerable catheter guided coronary sinus cannulation could reduce fluoroscopy time and contrast medium use during CRT implantation. Methods 176 consecutive patients with ischemic and non-ischemic heart failure undergoing CRT implantation from January 2008 to December 2012 at the University Hospital of Cologne were identified. During the study period two concurrent CS cannulation techniques were used: standard CS cannulation technique (standard-group, n = 113) and CS cannulation using a steerable electrophysiology (EP) catheter (EPCath-group, n = 63). Propensity-score matched pairs of conventional and EP-catheter guided CS cannulation made up the study population (n = 59 pairs). Primary endpoints were total fluoroscopy time and contrast medium amount used during procedure. Results The total fluoroscopy time was 30.9 min (interquartile range (IQR), 19.9-44.0 min) in the standard-group and 23.4 min (IQR, 14.2-34-2 min) in the EPCath-group (p = 0.011). More contrast medium was used in the standard-group (60.0 ml, IQR, 30.0-100 ml) compared to 25.0 ml (IQR, 20.0-50.0 ml) in the EPCath-group (P<0.001). Conclusions Use of steerable EP catheter was associated with significant reduction of fluoroscopy time and contrast medium use in patients undergoing CRT implantation.	[Er, Fikret; Yueksel, Dilek; Gassanov, Natig] Univ Hosp Munster, Klinikum Gutersloh, Dept Internal Med 1, Gutersloh, Germany; [Hellmich, Martin] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50931 Cologne, Germany	University of Cologne	Er, F (corresponding author), Univ Hosp Munster, Klinikum Gutersloh, Dept Internal Med 1, Gutersloh, Germany.	Fikret.Er@klinikum-guetersloh.de		Hellmich, Martin/0000-0001-5174-928X				Ando G, 2013, CATHETER CARDIO INTE, V82, P878, DOI 10.1002/ccd.25023; Bax JJ, 2005, J AM COLL CARDIOL, V46, P2168, DOI 10.1016/j.jacc.2005.09.020; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Capodanno D, 2016, J CARDIOVASC MED, V17, P524, DOI 10.2459/JCM.0000000000000215; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Er F, 2012, CIRCULATION, V126, P296, DOI 10.1161/CIRCULATIONAHA.112.096370; Gregoratos G, 2005, AM FAM PHYSICIAN, V71, P1563; Kennergren C, 1996, AM J CARDIOL, V78, P15, DOI 10.1016/S0002-9149(96)00497-3; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Moss AJ, 2009, NEW ENGL J MED, V361, P1329, DOI 10.1056/NEJMoa0906431; Niazi I, 2014, J INTERV CARD ELECTR, V41, P147, DOI 10.1007/s10840-014-9932-9; Tang ASL, 2010, NEW ENGL J MED, V363, P2385, DOI 10.1056/NEJMoa1009540; Thibault B, 2015, PACE, V38, P63, DOI 10.1111/pace.12522; Wang LW, 2014, SCAND CARDIOVASC J, V48, P41, DOI 10.3109/14017431.2013.875623	14	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2015	10	11							e0143292	10.1371/journal.pone.0143292	http://dx.doi.org/10.1371/journal.pone.0143292			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7AW	26599637	gold, Green Published, Green Submitted			2023-01-03	WOS:000365853900088
J	Schlenstedt, C; Paschen, S; Kruse, A; Raethjen, J; Weisser, B; Deuschl, G				Schlenstedt, Christian; Paschen, Steffen; Kruse, Annika; Raethjen, Jan; Weisser, Burkhard; Deuschl, Guenther			Resistance versus Balance Training to Improve Postural Control in Parkinson's Disease: A Randomized Rater Blinded Controlled Study	PLOS ONE			English	Article							MUSCLE STRENGTH; RISK-FACTORS; EXERCISE; PEOPLE; FALLS; GAIT; PROGRAM; SCALE; STIMULATION; INSTABILITY	Background Reduced muscle strength is an independent risk factor for falls and related to postural instability in individuals with Parkinson's disease. The ability of resistance training to improve postural control still remains unclear. Objective To compare resistance training with balance training to improve postural control in people with Parkinson's disease. Methods 40 patients with idiopathic Parkinson's disease (Hoehn&Yahr: 2.5-3.0) were randomly assigned into resistance or balance training (2x/week for 7 weeks). Assessments were performed at baseline, 8- and 12-weeks follow-up: primary outcome: Fullerton Advanced Balance (FAB) scale; secondary outcomes: center of mass analysis during surface perturbations, Timed-up-and-go-test, Unified Parkinson's Disease Rating Scale, Clinical Global Impression, gait analysis, maximal isometric leg strength, PDQ-39, Beck Depression Inventory. Clinical tests were videotaped and analysed by a second rater, blind to group allocation and assessment time. Results 32 participants (resistance training: n = 17, balance training: n = 15; 8 drop-outs) were analyzed at 8-weeks follow-up. No significant difference was found in the FAB scale when comparing the effects of the two training types (p = 0.14; effect size (Cohen's d) = -0.59). Participants from the resistance training group, but not from the balance training group significantly improved on the FAB scale (resistance training: +2.4 points, Cohen's d = -0.46; balance training: +0.3 points, Cohen's d = -0.08). Within the resistance training group, improvements of the FAB scale were significantly correlated with improvements of rate of force development and stride time variability. No significant differences were found in the secondary outcome measures when comparing the training effects of both training types. Conclusions The difference between resistance and balance training to improve postural control in people with Parkinson's disease was small and not significant with this sample size. There was weak evidence that freely coordinated resistance training might be more effective than balance training. Our results indicate a relationship between the enhancement of rate of force development and the improvement of postural control.	[Schlenstedt, Christian; Paschen, Steffen; Raethjen, Jan; Deuschl, Guenther] Univ Kiel, Dept Neurol, Kiel, Germany; [Schlenstedt, Christian; Kruse, Annika; Weisser, Burkhard] Univ Kiel, Dept Sport Sci, Kiel, Germany	University of Kiel; University of Kiel	Deuschl, G (corresponding author), Univ Kiel, Dept Neurol, Kiel, Germany.	g.deuschl@neurologie.uni-kiel.de	Schlenstedt, Christian/I-3443-2019; Deuschl, Gunther/A-7986-2010	Schlenstedt, Christian/0000-0002-3838-6848; Deuschl, Gunther/0000-0002-4176-9196; Kruse, Annika/0000-0002-6754-1253	Coppenrath-Stiftung, Geeste/Gross-Hesepe, Niedersachsen, Germany; Krumme-Stiftung, Eckernforde, Schleswig-Holstein, Germany	Coppenrath-Stiftung, Geeste/Gross-Hesepe, Niedersachsen, Germany; Krumme-Stiftung, Eckernforde, Schleswig-Holstein, Germany	The project was funded by the Coppenrath-Stiftung, Geeste/Gross-Hesepe, Niedersachsen, Germany and Krumme-Stiftung, Eckernforde, Schleswig-Holstein, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen NE, 2010, MOVEMENT DISORD, V25, P1217, DOI 10.1002/mds.23082; Allen NE, 2012, PARKINSONS DIS, V2012, P854; Ashburn A, 2001, GERONTOLOGY, V47, P277, DOI 10.1159/000052812; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Brienesse LA, 2013, J AM MED DIR ASSOC, V14, P236, DOI 10.1016/j.jamda.2012.11.012; Canning CG, 2015, NEUROLOGY, V84, P304, DOI 10.1212/WNL.0000000000001155; Chung CL, 2015, CLIN REHABILITATION; Conradsson D, 2015, NEUROREHABILITATION; Corcos DM, 2013, MOVEMENT DISORD, V28, P1230, DOI 10.1002/mds.25380; Dibble LE, 2009, J NEUROL PHYS THER, V33, P14, DOI 10.1097/NPT.0b013e3181990fcc; Fahn S, 1987, RECENT DEV PARKINSON, P153; Fasano A, 2015, NAT REV NEUROL, V11, P98, DOI 10.1038/nrneurol.2014.252; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Geurts ACH, 2011, GAIT POSTURE, V33, P143, DOI 10.1016/j.gaitpost.2010.09.018; Gobbi LTB, 2009, PARKINSONISM RELAT D, V15, pS49; Goodwin VA, 2008, MOVEMENT DISORD, V23, P631, DOI 10.1002/mds.21922; Guy W., 1976, ASSESSMENT MANUAL PS, P217; Haley SM, 2006, PHYS THER, V86, P735, DOI 10.1093/ptj/86.5.735; Hass CJ, 2012, GAIT POSTURE, V35, P669, DOI 10.1016/j.gaitpost.2011.12.022; Hirsch MA, 2003, ARCH PHYS MED REHAB, V84, P1109, DOI 10.1016/S0003-9993(03)00046-7; Jenkinson C, 1997, AGE AGEING, V26, P353, DOI 10.1093/ageing/26.5.353; Joshua AM, 2014, J CLIN DIAGN RES, V8, P98, DOI 10.7860/JCDR/2014/8217.4119; Kerr GK, 2010, NEUROLOGY, V75, P116, DOI 10.1212/WNL.0b013e3181e7b688; Latt MD, 2009, MOVEMENT DISORD, V24, P1280, DOI 10.1002/mds.22561; Lima LO, 2013, J PHYSIOTHER, V59, P7, DOI 10.1016/S1836-9553(13)70141-3; Martins WR, 2013, ARCH GERONTOL GERIAT, V57, P8, DOI 10.1016/j.archger.2013.03.002; Nallegowda M, 2004, AM J PHYS MED REHAB, V83, P898, DOI 10.1097/01.PHM.0000146505.18244.43; Nantel J, 2012, PARKINSONISM RELAT D, V18, P285, DOI 10.1016/j.parkreldis.2011.11.005; Nocera JR, 2010, ARCH PHYS MED REHAB, V91, P589, DOI 10.1016/j.apmr.2009.11.026; Plotnik M, 2008, MOVEMENT DISORD, V23, pS444, DOI 10.1002/mds.21984; Plotnik M, 2007, EXP BRAIN RES, V181, P561, DOI 10.1007/s00221-007-0955-7; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Ricciardi L, 2015, NEUROLOGICAL SCI OFF; Robinson K, 2005, NEUROREHABILITATION, V20, P169; Rose DJ, 2006, ARCH PHYS MED REHAB, V87, P1478, DOI 10.1016/j.apmr.2006.07.263; Schilling BK, 2010, PARKINSONS DIS-US, V2010, DOI 10.4061/2010/824734; Schlenstedt C, 2015, ARCH PHYS MED REHAB, V96, P218, DOI 10.1016/j.apmr.2014.09.002; SLINKER BK, 1985, AM J PHYSIOL, V249, pR1, DOI 10.1152/ajpregu.1985.249.1.R1; Smania N, 2010, NEUROREHAB NEURAL RE, V24, P826, DOI 10.1177/1545968310376057; Tillman A, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00040; Tomlinson CL, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002815.pub2; Toole T, 2000, NEUROREHABILITATION, V14, P165; Visser JE, 2008, J NEUROL, V255, P205, DOI 10.1007/s00415-008-0636-x; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; Winter DA, 2003, J ELECTROMYOGR KINES, V13, P49, DOI 10.1016/S1050-6411(02)00085-8; Wood BH, 2002, J NEUROL NEUROSUR PS, V72, P721, DOI 10.1136/jnnp.72.6.721	47	38	38	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2015	10	10							e0140584	10.1371/journal.pone.0140584	http://dx.doi.org/10.1371/journal.pone.0140584			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU8NN	26501562	gold, Green Submitted, Green Published			2023-01-03	WOS:000363799900009
J	Zheng, HR; Wen, SS; Zhang, Y; Sun, ZL				Zheng, Hengrui; Wen, Songsong; Zhang, Yang; Sun, Zhenliang			Organosilane and Polyethylene Glycol Functionalized Magnetic Mesoporous Silica Nanoparticles as Carriers for CpG Immunotherapy In Vitro and In Vivo	PLOS ONE			English	Article							DRUG-DELIVERY; DEGRADATION BEHAVIOR; BACTERIAL-DNA; GENE; BIODISTRIBUTION; DISSOLUTION; ADSORPTION; ADJUVANT; CPG-7909; SEQUENCE	Cytosine-guanine (CpG) containing oligodeoxynucleotides (ODN) have significant clinical potential as immunotherapeutics. However, limitations exist due to their transient biological stability in vivo, lack of specificity for target cells, and poor cellular uptake. To address these issues, we prepared amine magnetic mesoporous silica nanoparticles (M-MSN-A) then further modified with polyethylene glycol (PEG) for use as CpG delivery vectors. The PEG modified M-MSN-A (M-MSN-P) had notable CpG ODN loading capacity, negligible cytotoxicity, and were easily internalized into cells where they released the loaded CpG into the cytoplasm. As a result, such complexes were effective in activating macrophages and inhibiting tumor cells when combined with chemotherapeutics in vitro. Furthermore, these complexes had excellent immuno-stimulating activity in vivo, compared to the free CpG therapeutics. We report here a highly effective MSNs-based delivery system with great potential as a therapeutic CpG formulation in cancer immunotherapy.	[Zheng, Hengrui] Qingdao Univ, Affiliated Hosp, Med Res Ctr, Qingdao 266003, Peoples R China; [Sun, Zhenliang] So Med Univ, Fengxian Hosp, Shanghai 201499, Peoples R China; [Wen, Songsong] Qilu Pharmaceut Co Ltd, Jinan 250101, Peoples R China; [Zhang, Yang] Shanghai Jiao Tong Univ, Tong Ren Hosp, Sch Med, Shanghai 200336, Peoples R China	Qingdao University; Southern Medical University - China; Shanghai Jiao Tong University	Sun, ZL (corresponding author), So Med Univ, Fengxian Hosp, 6600 NanFeng Rd, Shanghai 201499, Peoples R China.	hope1126@hotmail.com			Qilu Pharmaceutical Co. Ltd.	Qilu Pharmaceutical Co. Ltd.	The authors received no specific funding for this work. Qilu Pharmaceutical Co. Ltd. provided support in the form of salary for author S. Wen, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Chen KH, 2012, J MATER CHEM, V22, P22005, DOI 10.1039/c2jm34364a; Cooper CL, 2005, AIDS, V19, P1473, DOI 10.1097/01.aids.0000183514.37513.d2; Cooper CL, 2004, J CLIN IMMUNOL, V24, P693, DOI 10.1007/s10875-004-6244-3; Faneca H, 2002, BBA-BIOMEMBRANES, V1567, P23, DOI 10.1016/S0005-2736(02)00545-X; Hafeli UO, 2004, INT J PHARMACEUT, V277, P19, DOI 10.1016/S0378-5173(04)00127-9; Hartono SB, 2012, ACS NANO, V6, P2104, DOI 10.1021/nn2039643; He QJ, 2010, MICROPOR MESOPOR MAT, V131, P314, DOI 10.1016/j.micromeso.2010.01.009; Hwang SJ, 2001, CURR OPIN MOL THER, V3, P183; Kim J, 2008, ANGEW CHEM INT EDIT, V47, P8438, DOI 10.1002/anie.200802469; Kim N, 2012, INT J PHARMACEUT, V427, P123, DOI 10.1016/j.ijpharm.2011.08.014; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Kunzmann A, 2011, BBA-GEN SUBJECTS, V1810, P361, DOI 10.1016/j.bbagen.2010.04.007; Lang N, 2004, CHEM MATER, V16, P1961, DOI 10.1021/cm030633n; Li X, 2013, BIOMATERIALS, V34, P1391, DOI 10.1016/j.biomaterials.2012.10.072; Li X, 2012, LANGMUIR, V28, P2827, DOI 10.1021/la204443j; Li X, 2011, BIOMATERIALS, V32, P9546, DOI 10.1016/j.biomaterials.2011.08.068; Li X, 2011, LANGMUIR, V27, P6099, DOI 10.1021/la104653s; Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t; Liu J, 2012, BIOMATERIALS, V33, P970, DOI 10.1016/j.biomaterials.2011.10.001; Lu J, 2010, SMALL, V6, P1794, DOI 10.1002/smll.201000538; Lubbe AS, 2001, J SURG RES, V95, P200, DOI 10.1006/jsre.2000.6030; Mahato RI, 1998, HUM GENE THER, V9, P2083, DOI 10.1089/hum.1998.9.14-2083; Meyer O, 1998, J BIOL CHEM, V273, P15621, DOI 10.1074/jbc.273.25.15621; Mizuno Y, 2010, J CONTROL RELEASE, V141, P252, DOI 10.1016/j.jconrel.2009.09.014; Mutwiri GK, 2004, J CONTROL RELEASE, V97, P1, DOI 10.1016/j.jcornel.2004.02.022; Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010; Pontarollo RA, 2002, VET IMMUNOL IMMUNOP, V84, P43, DOI 10.1016/S0165-2427(01)00379-8; Rankin R, 2001, ANTISENSE NUCLEIC A, V11, P333, DOI 10.1089/108729001753231713; Ravikovitch PI, 1997, J PHYS CHEM B, V101, P3671, DOI 10.1021/jp9625321; Rosenholm JM, 2010, NANOSCALE, V2, P1870, DOI 10.1039/c0nr00156b; Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140; Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012; Slowing II, 2007, ADV FUNCT MATER, V17, P1225, DOI 10.1002/adfm.200601191; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Tanaka T, 2010, CANCER RES, V70, P3687, DOI 10.1158/0008-5472.CAN-09-3931; Tu J, 2012, BIOMATERIALS, V33, P7903, DOI 10.1016/j.biomaterials.2012.07.025; Vallet-Regi M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488; Verthelyi D, 2003, J IMMUNOL, V170, P4717, DOI 10.4049/jimmunol.170.9.4717; Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006-1211; Wilson KD, 2009, ADV DRUG DELIVER REV, V61, P233, DOI 10.1016/j.addr.2008.12.014; Xia T, 2008, ACS NANO, V2, P85, DOI 10.1021/nn700256c; Xu H, 2006, J AM CHEM SOC, V128, P15582, DOI 10.1021/ja066165a; YAMAMOTO T, 1994, MICROBIOL IMMUNOL, V38, P831, DOI 10.1111/j.1348-0421.1994.tb01867.x; Zhang JX, 2011, J COLLOID INTERF SCI, V361, P16, DOI 10.1016/j.jcis.2011.05.038; Zhu YF, 2011, J PHYS CHEM C, V115, P13630, DOI 10.1021/jp203454g; Zhu YF, 2011, J PHYS CHEM C, V115, P447, DOI 10.1021/jp109535d; Zhu YF, 2011, MICROPOR MESOPOR MAT, V141, P199, DOI 10.1016/j.micromeso.2010.11.013	49	15	17	1	65	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2015	10	10							e0140265	10.1371/journal.pone.0140265	http://dx.doi.org/10.1371/journal.pone.0140265			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TY	26451735	Green Submitted, Green Published, gold			2023-01-03	WOS:000362511200055
J	Staudacher, DL; Kaiser, M; Hehrlein, C; Bode, C; Ahrens, I				Staudacher, Dawid L.; Kaiser, Michael; Hehrlein, Christoph; Bode, Christoph; Ahrens, Ingo			Triple Antithrombotic Therapy after Percutaneous Coronary Intervention (PCI) in Patients with Indication for Oral Anticoagulation: Data from a Single Center Registry	PLOS ONE			English	Article							ELEVATION MYOCARDIAL-INFARCTION; ATRIAL-FIBRILLATION; RISK STRATIFICATION; CONTROLLED-TRIAL; BLEEDING RISK; CLOPIDOGREL; ASPIRIN; SCORE; GUIDELINES; MANAGEMENT	Antithrombotic therapy consisting of a dual anti-platelet therapy (DAPT) and oral anti-coagulation (OAC) with a vitamin k antagonist is often referred to as triple therapy. This combined anticoagulation is applied in patients undergoing coronary artery stent implantation while also having an indication for OAC. Triple therapy increases the risk for bleeding events compared to either DAPT or OAC alone and thereby might be associated with adverse outcomes. Clinical data on the frequency of bleeding events in patients on triple therapy from clinical trials derives from pre-selected patients and may differ from the real world patients. We report data on patient characteristics and bleeding incidence of patients dismissed on triple therapy from a single university hospital. Within the time span from January 2000 to December 2012, we identified a total of 213 patients undergoing PCI who were prescribed a triple therapy for at least 4 weeks (representing 0.86% of all patients treated). The usage of triple therapy significantly increased over the observed time period. The average CHA(2)DS(2)-VASc Score was 3.1 +/- 1.1 with an average HAS-BLED score of 2.5 +/- 0.86 representing a high-risk group for thromboembolic events as well as considerable risk for bleeding events. An on-treatment bleeding incidence of 9.4% was detected, with gastrointestinal and airway bleeding being the most frequent (5.1% and 1.4%, respectively). This is consistent with data from clinical trials and confirms the high risk of bleeding in patients on DAPT plus OAC. 29.0% of all patients receiving triple therapy had an indication for OAC other than non-valvular atrial fibrillation. This substantial patient group is underrepresented by clinical trials and needs further attention.	[Staudacher, Dawid L.; Kaiser, Michael; Hehrlein, Christoph; Bode, Christoph; Ahrens, Ingo] Univ Freiburg, Ctr Heart, Dept Cardiol & Angiol 1, D-79106 Freiburg, Germany	University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Staudacher, DL (corresponding author), Univ Freiburg, Ctr Heart, Dept Cardiol & Angiol 1, Hugstetter Str 55, D-79106 Freiburg, Germany.	dawid.staudacher@universitaets-herzzentrum.de	Staudacher, Dawid L./AAF-5263-2021	Staudacher, Dawid L./0000-0002-9423-9682	German Research Foundation (DFG); Albert Ludwigs University Freiburg	German Research Foundation (DFG)(German Research Foundation (DFG)); Albert Ludwigs University Freiburg	The article processing charge was funded by the German Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding programme Open Access Publishing.	Abraham NS, 2013, CIRCULATION, V128, P1869, DOI 10.1161/CIRCULATIONAHA.113.004747; Apostolakis S, 2012, J AM COLL CARDIOL, V60, P861, DOI 10.1016/j.jacc.2012.06.019; Connolly S, 2006, LANCET, V367, P1903, DOI 10.1016/s0140-6736(06)68845-4; Dewilde WJM, 2013, LANCET, V381, P1107, DOI 10.1016/S0140-6736(12)62177-1; Hamm CW, 2011, EUR HEART J, V32, P2999, DOI 10.1093/eurheartj/ehr236; Hansen ML, 2010, ARCH INTERN MED, V170, P1433, DOI 10.1001/archinternmed.2010.271; Lip GYH, 2011, J AM COLL CARDIOL, V57, P173, DOI 10.1016/j.jacc.2010.09.024; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; O'Gara PT, 2013, CIRCULATION, V127, P529, DOI 10.1161/CIR.0b013e3182742c84; Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134; Rossini R, 2008, AM J CARDIOL, V102, P1618, DOI 10.1016/j.amjcard.2008.08.021; Rubboli A, 2009, J CARDIOVASC MED, V10, P200, DOI 10.2459/JCM.0b013e3283212f07; Sorensen R, 2009, LANCET, V374, P1967, DOI 10.1016/S0140-6736(09)61751-7; Subherwal S, 2009, CIRCULATION, V119, P1873, DOI 10.1161/CIRCULATIONAHA.108.828541	14	9	9	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2015	10	10							e0140101	10.1371/journal.pone.0140101	http://dx.doi.org/10.1371/journal.pone.0140101			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TP	26439131	Green Published, Green Submitted, gold			2023-01-03	WOS:000362510300097
J	Wang, H; Li, B; Feng, YM; Cui, B; Wu, HM; Shi, HB; Yin, SK				Wang, Hui; Li, Bei; Feng, Yanmei; Cui, Biao; Wu, Hongmin; Shi, Haibo; Yin, Shankai			A Pilot Study of EEG Source Analysis Based Repetitive Transcranial Magnetic Stimulation for the Treatment of Tinnitus	PLOS ONE			English	Article							AUDITORY-CORTEX	Objective Repetitive Transcranial Magnetic Stimulation (rTMS) is a novel therapeutic tool to induce a suppression of tinnitus. However, the optimal target sites are unknown. We aimed to determine whether low-frequency rTMS induced lasting suppression of tinnitus by decreasing neural activity in the cortex, navigated by high-density electroencephalogram (EEG) source analysis, and the utility of EEG for targeting treatment. Methods In this controlled three-armed trial, seven normal hearing patients with tonal tinnitus received a 10-day course of 1-Hz rTMS to the cortex, navigated by high-density EEG source analysis, to the left temporoparietal cortex region, and to the left temporoparietal with sham stimulation. The Tinnitus handicap inventory (THI) and a visual analog scale (VAS) were used to assess tinnitus severity and loudness. Measurements were taken before, and immediately, 2 weeks, and 4 weeks after the end of the interventions. Results Low-frequency rTMS decreased tinnitus significantly after active, but not sham, treatment. Responders in the EEG source analysis-based rTMS group, 71.4%(5/7) patients, experienced a significant reduction in tinnitus loudness, as evidenced by VAS scores. The target site of neuronal generators most consistently associated with a positive response was the frontal lobe in the right hemisphere, sourced using high-density EEG equipment, in the tinnitus patients. After left temporoparietal rTMS stimulation, 42.8%(3/7) patients experienced a decrease in tinnitus loudness. Conclusions Active EEG source analysis based rTMS resulted in significant suppression in tinnitus loudness, showing the superiority of neuronavigation-guided coil positioning in dealing with tinnitus. Non-auditory areas should be considered in the pathophysiology of tinnitus. This knowledge in turn can contribute to investigate the pathophysiology of tinnitus.	[Wang, Hui; Li, Bei; Feng, Yanmei; Cui, Biao; Wu, Hongmin; Shi, Haibo; Yin, Shankai] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Otolaryngol Head & Neck Surg, Shanghai 200233, Peoples R China	Shanghai Jiao Tong University	Wu, HM (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Otolaryngol Head & Neck Surg, Shanghai 200233, Peoples R China.	wuhongmin88@126.com; haibo99@hotmail.com	Feng, Yanmei/GQB-1685-2022	Shi, Haibo/0000-0002-2920-0183				Baguley D, 2013, LANCET, V382, P1600, DOI 10.1016/S0140-6736(13)60142-7; De Ridder D, 2013, BRAIN STIMUL, V6, P355, DOI 10.1016/j.brs.2012.07.002; Henry JA, 2014, J AM ACAD AUDIOL, V25, P5, DOI 10.3766/jaaa.25.1.2; Houdayer E, 2015, CLIN NEUROPHYSIOLOGY; Husain FT, 2014, HEARING RES, V307, P153, DOI 10.1016/j.heares.2013.07.010; Kaltenbach JA, 2005, HEARING RES, V206, P200, DOI 10.1016/j.heares.2005.02.013; Khedr EM, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.127712; Landgrebe M, 2009, NEUROIMAGE, V46, P213, DOI 10.1016/j.neuroimage.2009.01.069; Lanting CP, 2009, HEARING RES, V255, P1, DOI 10.1016/j.heares.2009.06.009; Lanting CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110704; Lefaucheur JP, 2012, NEUROPHYSIOL CLIN, V42, P95, DOI 10.1016/j.neucli.2011.12.001; Melcher JR, 2000, J NEUROPHYSIOL, V83, P1058, DOI 10.1152/jn.2000.83.2.1058; Mennemeier M, 2011, LARYNGOSCOPE, V121, P815, DOI 10.1002/lary.21425; Muhlnickel W, 1998, P NATL ACAD SCI USA, V95, P10340, DOI 10.1073/pnas.95.17.10340; Nicolas-Puel Cecile, 2006, Int Tinnitus J, V12, P64; Norena AJ, 2003, HEARING RES, V183, P137, DOI 10.1016/S0378-5955(03)00225-9; Peng Z, 2012, OTOLARYNG HEAD NECK, V147, P817, DOI 10.1177/0194599812458771; Seki S, 2003, HEARING RES, V180, P28, DOI 10.1016/S0378-5955(03)00074-1; Takano B, 2004, NEUROIMAGE, V23, P849, DOI 10.1016/j.neuroimage.2004.06.032; Tunkel DE, 2014, OTOLARYNGOLOGY HEA S, V151, pS1, DOI [10.1177/0194599814545325, DOI 10.1177/0194599814545325]; Vanneste S, 2015, BRAIN CONNECTIVITY; Vanneste S, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00031; Yang HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070831; Yu Lisheng, 2014, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V28, P219	24	6	7	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2015	10	10							e0139622	10.1371/journal.pone.0139622	http://dx.doi.org/10.1371/journal.pone.0139622			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6HH	26430749	Green Published, Green Submitted, gold			2023-01-03	WOS:000362178700087
J	Andrich, S; Haastert, B; Neuhaus, E; Neidert, K; Arend, W; Ohmann, C; Grebe, J; Vogt, A; Jungbluth, P; Rosler, G; Windolf, J; Icks, A				Andrich, Silke; Haastert, Burkhard; Neuhaus, Elke; Neidert, Kathrin; Arend, Werner; Ohmann, Christian; Grebe, Juergen; Vogt, Andreas; Jungbluth, Pascal; Roesler, Grit; Windolf, Joachim; Icks, Andrea			Epidemiology of Pelvic Fractures in Germany: Considerably High Incidence Rates among Older People	PLOS ONE			English	Article							HIP FRACTURE; RING FRACTURES; BURDEN; OSTEOPOROSIS; MORTALITY; FINLAND; OUTCOMES; TRENDS; COSTS; WALES	Epidemiological data about pelvic fractures are limited. Until today, most studies only analyzed inpatient data. The purpose of this study was to estimate incidence rates of pelvic fractures in the German population aged 60 years or older, based on outpatient and inpatient data. We conducted a retrospective population-based observational study based on routine data from a large health insurance company in Germany. Age and sex-specific incidence rates of first fractures between 2008 and 2011 were calculated. We also standardized incidence rates with respect to age and sex in the German population. Multiple Poisson regression models were used to evaluate the association between the risk of first pelvic fracture as outcome and sex, age, calendar year and region as independent variables. The total number of patients with a first pelvic fracture corresponded to 8,041 and during the study period 5,978 insured persons needed inpatient treatment. Overall, the standardized incidence rate of all first pelvic fractures was 22.4 [95% CI 22.0-22.9] per 10,000 person-years, and the standardized incidence rate of inpatient treated fractures 16.5 [16.1-16.9]. Our adjusted regression analysis confirmed a significant sex (RR 2.38 [2.23-2.55], p < 0.001, men as reference) and age effect (higher risk with increasing age, p < 0.001) on first fracture risk. We found a slight association between calendar year (higher risk in later years compared to 2008, p = 0.0162) and first fracture risk and a further significant association with region (RR 0.92 [0.87-0.98], p = 0.006, Westfalen-Lippe as reference). The observed incidences are considerably higher than incidences described in the international literature, even if only inpatient treated pelvic fractures are regarded. Besides which, non-inclusion of outpatient data means that a relevant proportion of pelvic fractures are not taken into account. Prevention of low energy trauma among older people remains an important issue.	[Andrich, Silke; Haastert, Burkhard; Arend, Werner; Roesler, Grit; Icks, Andrea] Univ Dusseldorf, Fac Med, Dept Publ Hlth, Dusseldorf, Germany; [Haastert, Burkhard] MediStatistica, Neuenrade, Germany; [Neuhaus, Elke; Neidert, Kathrin] AOK NORDWEST, Dortmund, Germany; [Ohmann, Christian; Grebe, Juergen; Vogt, Andreas] Univ Dusseldorf, Fac Med, Coordinat Ctr Clin Trials, Dusseldorf, Germany; [Jungbluth, Pascal; Windolf, Joachim] Univ Hosp, Dept Trauma & Hand Surg, Dusseldorf, Germany; [Roesler, Grit] Joint Practice Diagnost Radiol & Nucl Med, Cologne, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Andrich, S (corresponding author), Univ Dusseldorf, Fac Med, Dept Publ Hlth, Dusseldorf, Germany.	silke.andrich@ddz.uni-duesseldorf.de	Ohmann, Christian/AAV-8608-2020; Jungbluth, Pascal/L-6703-2017		German Federal Ministry of Education and Research [01GY1136]	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	The project was supported by a grant of the German Federal Ministry of Education and Research (http://www.bmbf.de/; 01GY1136; coordinating investigator: AI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The AOK NORDWEST was responsible for the salary for Elke Neuhaus and Kathrin Neidert, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. mediStatistica was responsible for the salary for Burkhard Haastert, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Balogh Z, 2007, J TRAUMA, V63, P1066, DOI 10.1097/TA.0b013e3181589fa4; Benzinger P, 2013, J AM MED DIR ASSOC, V14, P673, DOI 10.1016/j.jamda.2013.03.012; Bleibler F, 2013, OSTEOPOROSIS INT, V24, P835, DOI 10.1007/s00198-012-2020-z; Bohme J, 2012, Z ORTHOP UNFALLCHIR, V150, P477, DOI 10.1055/s-0032-1315270; Boufous S, 2005, INJURY, V36, P1323, DOI 10.1016/j.injury.2005.02.008; Boufous S, 2007, INJURY PREV, V13, P211, DOI 10.1136/ip.2006.014654; Brauer CA, 2009, JAMA-J AM MED ASSOC, V302, P1573, DOI 10.1001/jama.2009.1462; Breuil V, 2008, JOINT BONE SPINE, V75, P585, DOI 10.1016/j.jbspin.2008.01.024; Cooper C, 2011, OSTEOPOROSIS INT, V22, P1277, DOI 10.1007/s00198-011-1601-6; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; Deakin DE, 2007, INJURY, V38, P312, DOI 10.1016/j.injury.2006.09.024; Grobe TG, 2011, SCHRIFTENREIHE GESUN; Henes FO, 2012, EUR J RADIOL, V81, P2337, DOI 10.1016/j.ejrad.2011.07.012; Hoffmann F, 2012, GESUNDHEITSWESEN, V74, P291, DOI 10.1055/s-0031-1275711; Hoffmann F, 2011, EXP CLIN ENDOCR DIAB, V119, P569, DOI 10.1055/s-0031-1275277; Icks A, 2008, OSTEOPOROSIS INT, V19, P1139, DOI 10.1007/s00198-007-0534-6; Icks A, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657-013-0140-5; Islam S, 2009, MENOPAUSE, V16, P77, DOI 10.1097/gme.0b013e31817b816e; Kannus P, 2000, OSTEOPOROSIS INT, V11, P443, DOI 10.1007/s001980070112; Kelsey JL, 2005, AM J EPIDEMIOL, V162, P879, DOI 10.1093/aje/kwi295; King AB, 2009, J BONE MINER RES, V24, P681, DOI 10.1359/JBMR.081226; Korhonen N, 2013, OSTEOPOROSIS INT, V24, P1599, DOI 10.1007/s00198-012-2190-8; Krappinger D, 2010, ARCH ORTHOP TRAUM SU, V130, P1167, DOI 10.1007/s00402-010-1108-1; Le CT, 2003, INTRO BIOSTATISTICS, DOI 10.1002/0471308889; Mann E, 2010, WIEN KLIN WOCHENSCHR, V122, P126, DOI 10.1007/s00508-010-1321-5; Morris RO, 2000, POSTGRAD MED J, V76, P646, DOI 10.1136/pmj.76.900.646; Nanninga GL, 2014, AGE AGEING, V43, P648, DOI 10.1093/ageing/aft212; Parkkari J, 1996, CALCIFIED TISSUE INT, V59, P79, DOI 10.1007/s002239900090; Pike C, 2010, PHARMACOECONOMICS, V28, P395, DOI 10.2165/11531040-000000000-00000; Prieto-Alhambra D, 2012, OSTEOPOROSIS INT, V23, P2797, DOI 10.1007/s00198-012-1907-z; RAGNARSSON B, 1992, ACTA ORTHOP SCAND, V63, P297, DOI 10.3109/17453679209154786; Soles GLS, 2012, CURR REV MUSCULOSKE, V5, P222, DOI 10.1007/s12178-012-9128-9; Sullivan MP, 2014, ORTHOPEDICS, V37, P151, DOI 10.3928/01477447-20140225-50; Swart E, 2015, GOOD PRACTICE SECOND; Van Staa TP, 2001, BONE, V29, P517, DOI 10.1016/S8756-3282(01)00614-7; WHO, 2011, GLOBAL HLTH AGING	36	62	64	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2015	10	9							e0139078	10.1371/journal.pone.0139078	http://dx.doi.org/10.1371/journal.pone.0139078			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6EV	26418971	Green Published, gold, Green Submitted			2023-01-03	WOS:000362171400038
J	Lancaster, KE; Powers, KA; Lungu, T; Mmodzi, P; Hosseinipour, MC; Chadwick, K; Go, VF; Pence, BW; Hoffman, IF; Miller, WC				Lancaster, Kathryn Elizabeth; Powers, Kimberly A.; Lungu, Thandie; Mmodzi, Pearson; Hosseinipour, Mina C.; Chadwick, Katy; Go, Vivian F.; Pence, Brian W.; Hoffman, Irving F.; Miller, William C.			The HIV Care Continuum among Female Sex Workers: A Key Population in Lilongwe, Malawi	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; DRIED BLOOD SPOTS; ANTIRETROVIRAL TREATMENT; RISK BEHAVIORS; RESPONDENT-DRIVEN; PREVENTION; TRANSMISSION; PREVALENCE; INFECTION; MEN	Objective The HIV care continuum among female sex workers (FSW), a key population, has not been well characterized, especially within the generalized epidemics of sub-Saharan Africa. This was the first study to characterize the HIV care continuum among FSW in Lilongwe, Malawi. Methods From July through September 2014, we used venue-based sampling to enroll 200 adult FSW in Lilongwe, Malawi into a cross-sectional evaluation assessing HIV care continuum outcomes. Seropositive FSW, identified using HIV rapid testing, received rapid CD4 counts in addition to viral loads using dried blood spots. We calculated proportions of HIV-infected FSW who had history of care, were on ART, and had suppressed viral load and we used Poisson regression to estimate the associations of demographic characteristics and transmission risk behaviors with each outcome. Results HIV seroprevalence was 69% (n = 138). Among all FSW the median age was 24 years (IQR: 22-28). Among the 20% who were newly diagnosed and reported previously testing negative, the median time since last HIV test was 11 months (interquartile range: 3-17). The majority (69%) of HIV-infected FSW had a history of HIV care, 52% reported current ART use, and 45% were virally suppressed. Of the FSW who reported current ART use, 86% were virally suppressed. Transmission risk behaviors were not associated with continuum outcomes. Conclusions FSW in Lilongwe were predominately young and have a high HIV prevalence. Only half of HIV-infected FSW reported current ART use, but the majority of those on ART were virally suppressed. To reduce ongoing transmission and improve health outcomes, increased HIV testing, care engagement, and ART coverage is urgently needed among FSW. Universal testing and treatment strategies for all FSWin Malawi must be strongly considered.	[Lancaster, Kathryn Elizabeth; Powers, Kimberly A.; Pence, Brian W.; Miller, William C.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Lungu, Thandie; Mmodzi, Pearson; Hosseinipour, Mina C.; Hoffman, Irving F.] Univ N Carolina, UNC Project Malawi, Lilongwe, Malawi; [Lancaster, Kathryn Elizabeth; Hosseinipour, Mina C.; Hoffman, Irving F.; Miller, William C.] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA; [Chadwick, Katy] Theatre Change, Lilongwe, Malawi; [Go, Vivian F.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Lancaster, KE (corresponding author), Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.; Lancaster, KE (corresponding author), Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA.	klancaster@unc.edu	Miller, William C/H-4800-2014	Miller, William C/0000-0002-1934-7827; Lancaster, Kathryn/0000-0003-2389-6973	NIH - Fogarty International Center [R25 TW009340]; NIH Office of the Director Office of AIDS Research; ORWH; NCI; NHLBI; NIAID [T32 AI0700]; University of North Carolina Center for AIDS Research; NIH [P30 AI50410]; National Institutes of Health [KL2 TR001109]; FOGARTY INTERNATIONAL CENTER [R25TW009340] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000700, P30AI050410, T32AI007001] Funding Source: NIH RePORTER	NIH - Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIH Office of the Director Office of AIDS Research; ORWH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Office of Research on Women's Health (ORWH)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); University of North Carolina Center for AIDS Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the NIH Research Training Grant [http://www.fic.nih.gov/] (grant number: R25 TW009340) funded by the Fogarty International Center, the NIH Office of the Director Office of AIDS Research, ORWH, NCI, and NHLBI, the NIAID T32 training grant (grant number: T32 AI0700 [KEL]), the University of North Carolina Center for AIDS Research, an NIH funded program [www.unccfar.org](grant number: P30 AI50410 [KEL]), and the National Institutes of Health (grant number: KL2 TR001109 [KAP]). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alary M, 2004, AIDS, V18, P945, DOI 10.1097/00002030-200404090-00013; Arredondo M, 2012, J CLIN MICROBIOL, V50, P569, DOI 10.1128/JCM.00418-11; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Baral S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115465; Baral S, 2012, LANCET INFECT DIS, V12, P538, DOI 10.1016/S1473-3099(12)70066-X; Batona G, 2015, JAIDS-J ACQ IMM DEF, V68, pS206, DOI 10.1097/QAI.0000000000000452; Bekker LG, 2015, LANCET, V385, P72, DOI 10.1016/S0140-6736(14)60974-0; Braunstein SL, 2011, JAIDS-J ACQ IMM DEF, V57, pE70, DOI 10.1097/QAI.0b013e3182170fd3; Bunnell R, 2006, AIDS, V20, P85, DOI 10.1097/01.aids.0000196566.40702.28; Chersich MF, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.17980; Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849; Chimbwandira F, 2013, MMWR-MORBID MORTAL W, V62, P148; Chimbwandria F, 2013, MMWR-MORBID MORTAL W, V62, P148; Chohan V, 2009, SEX TRANSM INFECT, V85, P489, DOI 10.1136/sti.2009.036103; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cowan FM, 2014, 20 INT AIDS C MELB A; Cowan FM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077080; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Delva W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001258; Dhana A, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/1744-8603-10-46; Donastorg Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088157; Family Planning Association of Malawi, 2011, COUNT UNC REP SIT AN; Fidler S, 2013, NEW ENGL J MED, V368, P207, DOI 10.1056/NEJMoa1110039; Fiscus SA, 2006, PLOS MED, V3, P1743, DOI 10.1371/journal.pmed.0030417; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Genberg BL, 2015, LANCET HIV, V2, pE20, DOI 10.1016/S2352-3018(14)00034-4; Goldenberg SM, 2016, AIDS BEHAV, V20, P977, DOI 10.1007/s10461-015-1102-2; Greenberg AE, 2009, HEALTH AFFAIR, V28, P1677, DOI 10.1377/hlthaff.28.6.1677; Herce ME, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1065-y; Holland CE, 2015, JAIDS-J ACQ IMM DEF, V68, pS232, DOI 10.1097/QAI.0000000000000443; Hollingsworth TD, 2008, J INFECT DIS, V198, P687, DOI 10.1086/590501; Johannessen A, 2009, CLIN INFECT DIS, V49, P976, DOI 10.1086/605502; Johnston LG, 2006, J URBAN HEALTH, V83, pI16, DOI 10.1007/s11524-006-9099-5; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Manabe YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034319; Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79; Matovu JKB, 2012, INT J STD AIDS, V23, P267, DOI 10.1258/ijsa.2011.011313; McGrath N, 2013, AIDS, V27, P2461, DOI 10.1097/01.aids.0000432473.69250.19; Metsch LR, 2008, CLIN INFECT DIS, V47, P577, DOI 10.1086/590153; Mountain E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105645; National Statistical Office, 2011, MAL DEM HLTH SURV 20; Organization. WH, 2012, PREV TREATM HIV OTH; Peitzmeier S, 2014, INT J STD AIDS, V25, P244, DOI 10.1177/0956462413498858; Powers KA, 2007, AIDS, V21, P2237, DOI 10.1097/QAD.0b013e3282f08b4d; Risher K, 2015, CURR OPIN HIV AIDS, V10, P420, DOI 10.1097/COH.0000000000000200; Rottinghaus E, ANTIVIR THER, P15; Rutstein SE, 2014, J CLIN VIROL, V60, P392, DOI 10.1016/j.jcv.2014.05.005; Schwartz S, 2015, 8 IAS C HIV PATH TRE; Schwartz S, 2014, 20 INT AIDS C MELB A; Scorgie F, 2012, AIDS BEHAV, V16, P920, DOI 10.1007/s10461-011-9985-z; Skov T, 1998, INT J EPIDEMIOL, V27, P91, DOI 10.1093/ije/27.1.91; Stueve A, 2001, AM J PUBLIC HEALTH, V91, P922, DOI 10.2105/AJPH.91.6.922; Sukapirom K, 2011, JAIDS-J ACQ IMM DEF, V58, P141, DOI 10.1097/QAI.0b013e31822866a2; Van Beckhoven D, 2014, J INT AIDS SOC, V17, P30, DOI 10.7448/IAS.17.4.19534; Vuylsteke B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032627; Weir SS, 2012, SEX TRANSM INFECT, V88, pI95, DOI 10.1136/sextrans-2012-050638; WHO, 2012, CONS GUID US ANT DRU; Wirtz AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088047; World Health Organization, 2021, ANT DRUGS TREAT PREG; Zachariah R, 2003, INT J STD AIDS, V14, P185, DOI 10.1258/095646203762869197; Zulliger R, 2015, JAIDS-J ACQ IMM DEF, V69, P216, DOI 10.1097/QAI.0000000000000590; Zulliger R, 2015, AIDS BEHAV, V19, P715, DOI 10.1007/s10461-014-0979-5	62	37	37	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147662	10.1371/journal.pone.0147662	http://dx.doi.org/10.1371/journal.pone.0147662			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DC9FZ	26808043	Green Published, gold, Green Submitted			2023-01-03	WOS:000369527800172
J	Sweet, DE; Altice, FL; Cohen, CJ; Vandewalle, B				Sweet, Donna E.; Altice, Frederick L.; Cohen, Calvin J.; Vandewalle, Bjoern			Cost-Effectiveness of Single-Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States	PLOS ONE			English	Article							EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE; ANTIRETROVIRAL THERAPY; DOUBLE-BLIND; INITIAL TREATMENT; EXPERIENCED PATIENTS; DRUG-RESISTANCE; TENOFOVIR DF; EFFICACY; SAFETY; COMBINATION	Background The possibility of incorporating generics into combination antiretroviral therapy and breaking apart once-daily single-tablet regimens (STRs), may result in less efficacious medications and/or more complex regimens with the expectation of marked monetary savings. A modeling approach that assesses the merits of such policies in terms of lifelong costs and health outcomes using adherence and effectiveness data from real-world U.S. settings. Methods A comprehensive computer-based microsimulation model was developed to assess the lifetime health (life expectancy and quality adjusted life-years-QALYs) and economic outcomes in HIV-1 infected patients initiating STRs compared with multiple-table regimens including generic medications where possible (gMTRs). The STRs considered included tenofovir disoproxil fumarate/emtricitabine and efavirenz or rilpivirine or elvitegravir/cobicistat. gMTRs substitutions included each counterpart to STRs, including generic lamivudine for emtricitabine and generic versus branded efavirenz. Results Life expectancy is estimated to be 1.301 years higher (discounted 0.619 QALY gain) in HIV-1 patients initiating a single-tablet regimen in comparison to a generic-based multiple-table regimen. STRs were associated with an average increment of $26,547.43 per patient in medication and $1,824.09 in other medical costs due to longer survival which were partially offset by higher inpatients costs ($12,035.61) with gMTRs treatment. Overall, STRs presented incremental lifetime costs of $16,335.91 compared with gMTRs, resulting in an incremental cost-effectiveness ratio of $26,383.82 per QALY gained. Conclusions STRs continue to represent good value for money under contemporary cost-effectiveness thresholds despite substantial price reductions of generic medications in the U.S.	[Sweet, Donna E.] Univ Kansas, Sch Med, Internal Med, Wichita, KS 67214 USA; [Altice, Frederick L.] Yale Univ, Sch Med, Infect Dis Sect, New Haven, CT USA; [Cohen, Calvin J.] CRI New England, Boston, MA USA; [Vandewalle, Bjoern] Exigo Consultores, Lisbon, Portugal; [Cohen, Calvin J.] Gilead Sci, Foster City, CA USA	University of Kansas; University of Kansas Medical Center; Yale University; Gilead Sciences	Vandewalle, B (corresponding author), Exigo Consultores, Lisbon, Portugal.	bjorn.vandewalle@exigoconsultores.com		Altice, Frederick/0000-0002-7860-693X	Gilead Sciences, Foster City, CA	Gilead Sciences, Foster City, CA(Gilead Sciences)	This work was supported by Gilead Sciences, Foster City, CA. DES, FLA, CJC and BV (prior to January 2015) are employees of independent academic institutions, research organizations or consulting firms and maintained independent scientific control over the study, including data analysis and interpretation of final results. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funder provided support in the form of salaries (after January 2015) for CJC. Gilead contracted with Exigo Consultores for the development of the model. Exigo Consultores provided support in the form of salaries for BV, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Arasteh K, 2009, ANTIVIR THER, V14, P859, DOI 10.3851/IMP1301; Barnett PG, 2011, MED CARE, V49, P848, DOI 10.1097/MLR.0b013e31821b34c0; Cahn P, 2013, LANCET, V382, P700, DOI 10.1016/S0140-6736(13)61221-0; Cassetti I, 2007, HIV CLIN TRIALS, V8, P164, DOI 10.1310/hct0803-164; Castagna A, 2014, J INFECT DIS, V210, P354, DOI 10.1093/infdis/jiu051; CDC, 2014, NATL VITAL STAT REPO, V63; Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8; Cohen C, 2014, AIDS, V28, P989, DOI 10.1097/QAD.0000000000000169; Cohen CJ, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003028; Colombo GL, 2014, THER CLIN RISK MANAG, V10, P9, DOI 10.2147/TCRM.S49428; Colombo GL, 2013, CLINICOECONOMIC OUTC, V5, P59, DOI 10.2147/CEOR.S38977; Colombo GL, 2011, CLINICOECONOMIC OUTC, V3, P197, DOI 10.2147/CEOR.S24130; Cook J, 1999, AIDS RES HUM RETROV, V15, P499, DOI 10.1089/088922299311024; DHHS, 2015, GUIDELINES USE ANTIR; FDA, 2011, EMTR RILP TEN DIS FU; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gardner EM, 2010, AIDS, V24, P395, DOI 10.1097/QAD.0b013e328335cd8a; Gazzard B, 2012, CLINICOECONOMIC OUTC, V4, P193, DOI 10.2147/CEOR.S12496; Gebo KA, 2010, AIDS, V24, P2705, DOI 10.1097/QAD.0b013e32833f3c14; Gilead, 2013, MARKET SHARE DATA Q; Guria J, 2005, ENVIRON RESOUR ECON, V32, P113, DOI 10.1007/s10640-005-6030-6; Haubrich R, 2007, AIDS, V21, pF11, DOI 10.1097/QAD.0b013e3280b07b47; Hill AM, 2011, AIDS REV, V13, P41; Hosseinipour MC, 2013, J INFECT DIS, V207, pS49, DOI 10.1093/infdis/jit107; Janssen, 2015, POWER 1 2 96 WEEK PO; Johnson M, 2006, AIDS, V20, P711, DOI 10.1097/01.aids.0000216371.76689.63; Johnson M, 2005, AIDS, V19, P153, DOI 10.1097/00002030-200501280-00007; Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7; Kauf TL, 2008, VALUE HEALTH, V11, P1144, DOI 10.1111/j.1524-4733.2008.00326.x; Lee FJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097482; Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003; Maggiolo F, 2015, PATIENT-RELAT OUTCOM, V6, P53, DOI 10.2147/PROM.S63586; Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007; Nachega JB, 2014, CLIN INFECT DIS, V58, P1297, DOI 10.1093/cid/ciu046; Nelson M, 2005, JAIDS-J ACQ IMM DEF, V40, P404, DOI 10.1097/01.qai.0000185314.56556.c3; Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158; O'Hagan A, 2006, RELIAB ENG SYST SAFE, V91, P1290, DOI 10.1016/j.ress.2005.11.025; Porter DP, 2014, JAIDS-J ACQ IMM DEF, V65, P318, DOI 10.1097/QAI.0000000000000017; Pozniak A, 2013, 20 C RETR OPP INF; Ramiro MA, 2014, ENFERM INFEC MICR CL, V32, P598, DOI 10.1016/j.eimc.2013.06.008; Rao G, 2013, IMPACT HAART REGIMEN; Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498; Rousseau FS, 2003, J INFECT DIS, V188, P1652, DOI 10.1086/379667; Sabin CA, 2000, J ACQ IMMUN DEF SYND, V23, P172; Samji H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081355; Sax PE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113031; Sax PE, 2012, LANCET, V379, P2439, DOI 10.1016/S0140-6736(12)60917-9; Sax PE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031591; Schackman BR, 2006, MED CARE, V44, P990, DOI 10.1097/01.mlr.0000228021.89490.2a; Schackman BR, 2015, MED CARE, V53, P293, DOI 10.1097/MLR.0000000000000308; Sloan CE, 2012, AIDS, V26, P45, DOI 10.1097/QAD.0b013e32834dce6e; Solem CT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098152; Sweet D, 2014, 20 INT AIDS C MELB A; Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961; Trottier B, 2005, JAIDS-J ACQ IMM DEF, V40, P413, DOI 10.1097/01.qai.0000185313.48933.2c; Walensky RP, 2013, ANN INTERN MED, V158, P84, DOI 10.7326/0003-4819-158-2-201301150-00002; WHO, 2012, PHARM EQ CLIN INT GE; Wohl DA, 2014, JAIDS-J ACQ IMM DEF, V65, pE118, DOI 10.1097/QAI.0000000000000057; Zolopa A, 2013, JAIDS-J ACQ IMM DEF, V63, P96, DOI 10.1097/QAI.0b013e318289545c	59	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147821	10.1371/journal.pone.0147821	http://dx.doi.org/10.1371/journal.pone.0147821			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26808503	Green Published, Green Submitted, gold			2023-01-03	WOS:000369527800217
J	Roberson, S; Dutton, M; Macdonald, M; Odoi, A				Roberson, Shamarial; Dutton, Matthew; Macdonald, Megan; Odoi, Agricola			Does Place of Residence or Time of Year Affect the Risk of Stroke Hospitalization and Death? A Descriptive Spatial and Temporal Epidemiologic Study	PLOS ONE			English	Article							HEART-DISEASE; GEOGRAPHIC DISPARITIES; UNITED-STATES; CARE; MORTALITY; BURDEN; ATTACK	Background Identifying geographic areas with significantly high risks of stroke is important for informing public health prevention and control efforts. The objective of this study was to investigate geographic and temporal patterns of stroke hospitalization and mortality risks so as to identify areas and seasons with significantly high burden of the disease in Florida. The information obtained will be useful for resource allocation for disease prevention and control. Methods Stroke hospitalization and mortality data from 1992 to 2012 were obtained from the Florida Agency for Health Care Administration. Age-adjusted stroke hospitalization and mortality risks for time periods 1992-94, 1995-97, 1998-2000, 2001-03, 2004-06, 2007-09 and 2010-12 were computed at the county spatial scale. Global Moran's I statistics were computed for each of the time periods to test for evidence of global spatial clustering. Local Moran indicators of spatial association (LISA) were also computed to identify local areas with significantly high risks. Results There were approximately 1.5 million stroke hospitalizations and over 196,000 stroke deaths during the study period. Based on global Moran's I tests, there was evidence of significant (p<0.05) global spatial clustering of stroke mortality risks but no evidence (p>0.05) of significant global clustering of stroke hospitalization risks. However, LISA showed evidence of local spatial clusters of both hospitalization and mortality risks with significantly high risks being observed in the north while the south had significantly low risks of stroke deaths. There were decreasing temporal trends and seasonal patterns of both hospitalization and mortality risks with peaks in the winter. Conclusions Although stroke hospitalization and mortality risks have declined in the past two decades, disparities continue to exist across Florida and it is evident from the results of this study that north Florida may, in fact, be part of the stroke belt despite not being in any of the traditional stroke belt states. These findings are useful for guiding public health efforts to reduce/eliminate inequities in stroke outcomes and inform policy decisions. There is need to continually identify populations with significantly high risks of stroke to better guide the targeting of limited resources to the highest risk populations.	[Roberson, Shamarial; Macdonald, Megan] Bur Chron Dis Prevent, Florida Dept Hlth, Tallahassee, FL USA; [Dutton, Matthew] Florida A&M Univ, Tallahassee, FL USA; [Odoi, Agricola] Univ Tennessee, Knoxville, TN USA	Florida Department of Health; State University System of Florida; Florida A&M University; University of Tennessee System; University of Tennessee Knoxville	Odoi, A (corresponding author), Univ Tennessee, Knoxville, TN USA.	aodoi@utk.edu	Odoi, Agricola/I-9532-2019	Odoi, Agricola/0000-0001-5050-6737	CDC through NACDD [5U58DP0002759-04]; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [U58DP002759] Funding Source: NIH RePORTER	CDC through NACDD(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The authors wish to state that CDC, through partnership with NACDD, only funded mentoring support through CDC Cooperative Agreement Number 5U58DP0002759-04 for the study and was not involved in any way in the conception, design, interpretation of study results, writing of the manuscript, or in the decision to submit the manuscript for publication.	Anselin L, 2003, GEO DA VERSION 0 95I; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Busingye D, 2011, SPAT SPATIO-TEMPORAL, V2, P247, DOI 10.1016/j.sste.2011.07.010; Douglas AS, 1995, J EPIDEMIOL COMMUN H, V49, P575, DOI 10.1136/jech.49.6.575; ESRI, 2010, ARCGIS VERS 10 1; Ferri CP, 2011, J NEUROL NEUROSUR PS, V82, P1074, DOI 10.1136/jnnp.2010.234153; Gillum RF, 1996, AM J EPIDEMIOL, V144, P665, DOI 10.1093/oxfordjournals.aje.a008979; Glymour MM, 2007, STROKE, V38, P2415, DOI 10.1161/STROKEAHA.107.482059; Go AS, 2014, CIRCULATION, V129, P399, DOI 10.1161/01.cir.0000442015.53336.12; Halverson J.A., 2002, ETHNIC DIS, V12, P82; Harris T, 2013, TIBETAN TRADE GLOBAL; Howard G, 2009, PREV MED, V49, P129, DOI 10.1016/j.ypmed.2009.03.004; Khan JA, 2011, PREV CHRONIC DIS, V8; Laditka JN, 2014, DISABIL HEALTH J, V7, P472, DOI 10.1016/j.dhjo.2014.06.005; Leira EC, 2008, ARCH NEUROL-CHICAGO, V65, P887, DOI 10.1001/archneur.65.7.887; Liao YL, 2009, STROKE, V40, P3336, DOI 10.1161/STROKEAHA.109.561688; Lichtman JH, 2009, STROKE, V40, P3574, DOI 10.1161/STROKEAHA.109.561472; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Microsoft, 2010, EXCEL; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Odoi A, 2014, SPAT SPATIO-TEMPORAL, V11, P109, DOI 10.1016/j.sste.2014.10.001; Pandian JD, 2013, J STROKE, V15, P128, DOI 10.5853/jos.2013.15.3.128; Pedigo A, 2011, BMC PUBLIC HEALTH, V11, P1471; Pedigo A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-644; Raj K, 2015, J STROKE CEREBROVASC, V24, P10, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.051; Rich DQ, 2007, STROKE, V38, P2221, DOI 10.1161/STROKEAHA.107.483719; Schieb LJ, 2013, STROKE, V44, P146, DOI 10.1161/STROKEAHA.112.669705; SIEGEL PZ, 1992, PUBLIC HEALTH REP, V107, P540; Tassone EC, 2009, EPIDEMIOLOGY, V20, P234, DOI 10.1097/EDE.0b013e3181935aee; The SAS Institute, 2013, SAS VERS 9 4; Towfighi A, 2011, STROKE, V42, P2740, DOI 10.1161/STROKEAHA.110.612648; United States Census Bureau, 2014, CART BOUND SHAP 2014	32	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2016	11	1							e0145224	10.1371/journal.pone.0145224	http://dx.doi.org/10.1371/journal.pone.0145224			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB6WB	26799559	gold, Green Published, Green Submitted			2023-01-03	WOS:000368655300004
J	Riley, C; Dellicour, S; Ouma, P; Kioko, U; ter Kuile, FO; Omar, A; Kariuki, S; Buff, AM; Desai, M; Gutman, J				Riley, Christina; Dellicour, Stephanie; Ouma, Peter; Kioko, Urbanus; ter Kuile, Feiko O.; Omar, Ahmeddin; Kariuki, Simon; Buff, Ann M.; Desai, Meghna; Gutman, Julie			Knowledge and Adherence to the National Guidelines for Malaria Case Management in Pregnancy among Healthcare Providers and Drug Outlet Dispensers in Rural, Western Kenya	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; CLUSTER RANDOMIZED-TRIAL; TEXT-MESSAGE REMINDERS; ANTIMALARIAL-DRUGS; WOMEN; SURVEILLANCE; UGANDA; LUMEFANTRINE; PREVALENCE; ARTEMETHER	Background Although prompt, effective treatment is a cornerstone of malaria control, information on provider adherence to malaria in pregnancy (MIP) treatment guidelines is limited. Incorrect or sub-optimal treatment can adversely affect the mother and fetus. This study assessed provider knowledge of and adherence to national case management guidelines for uncomplicated MIP. Methods We conducted a cross-sectional study from September to November 2013, in 51 health facilities (HF) and a randomly-selected sample of 39 drug outlets (DO) in the KEMRI/CDC Health and Demographic Surveillance System area in western Kenya. Provider knowledge of national treatment guidelines was assessed with standardized questionnaires. Correct practice required adequate diagnosis, pregnancy assessment, and treatment with correct drug and dosage. In HF, we conducted exit interviews in all women of childbearing age assessed for fever. In DO, simulated clients posing as first trimester pregnant women or as relatives of third trimester pregnant women collected standardized information. Results Correct MIP case management knowledge and practice were observed in 45% and 31% of HF and 0% and 3% of DO encounters, respectively. The correct drug and dosage for pregnancy trimester was prescribed in 62% of HF and 42% of DO encounters; correct prescription occurred less often in first than in second/third trimesters (HF: 24% vs. 65%, p<0.01; DO: 0% vs. 40%, p<0.01). Sulfadoxine-pyrimethamine, which is not recommended for malaria treatment, was prescribed in 3% of HF and 18% of DO encounters. Exposure to artemether-lumefantrine in first trimester, which is contraindicated, occurred in 29% and 49% of HF and DO encounters, respectively. Conclusion This study highlights knowledge inadequacies and incorrect prescribing practices in the treatment of MIP. Particularly concerning is the prescription of contraindicated medications in the first trimester. These issues should be addressed through comprehensive trainings and increased supportive supervision. Additional innovative means to improve care should be explored.	[Riley, Christina] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Dellicour, Stephanie; ter Kuile, Feiko O.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Ouma, Peter; Kariuki, Simon] Ctr Global Hlth Res, KEMRI, Kisumu, Kenya; [Kioko, Urbanus; Omar, Ahmeddin] Minist Hlth, Malaria Control Unit, Nairobi, Kenya; [Buff, Ann M.; Desai, Meghna; Gutman, Julie] US Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA; [Buff, Ann M.] US Presidents Malaria Initiat, Nairobi, Kenya; [Desai, Meghna] Ctr Dis Control & Prevent, Kisumu, Kenya	Emory University; Rollins School Public Health; Liverpool School of Tropical Medicine; University of Liverpool; Centers for Disease Control & Prevention - USA	Riley, C (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.; Gutman, J (corresponding author), US Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA.	riley.christinam@gmail.com; jgutman@cdc.gov	Kariuki, Simon/AFT-6596-2022; Kuile, Feiko ter/ABD-6681-2020	Kuile, Feiko ter/0000-0003-3663-5617	United States President's Malaria Initiative; U.S. Agency for International Development; U.S. Centers for Disease Control and Prevention (CDC)	United States President's Malaria Initiative(United States Agency for International Development (USAID)President's Malaria Initiative (PMI)); U.S. Agency for International Development(United States Agency for International Development (USAID)); U.S. Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This publication was made possible through support provided by the United States President's Malaria Initiative, U.S. Agency for International Development and U.S. Centers for Disease Control and Prevention (CDC), under the terms of an Interagency Agreement with CDC and through a Cooperative Agreement between the CDC and the Kenya Medical Research Institute (KEMRI). The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit for publication.	[Anonymous], 2007, ASS SAF ART COMP PRE; AVIV RI, 1993, S AFR MED J, V83, P657; Bigogo G, 2010, INT J INFECT DIS, V14, pE967, DOI 10.1016/j.ijid.2010.05.016; Brantuo MNA, 2014, TROP MED INT HEALTH, V19, P417, DOI 10.1111/tmi.12270; Bruxvoort K, 2014, AM J TROP MED HYG, V91, P844, DOI 10.4269/ajtmh.14-0126; Cheruiyot J, 2014, ANTIMICROB AGENTS CH, V58, P3737, DOI 10.1128/AAC.02472-14; Dellicour S, 2015, TREATMENT PRAC UNPUB; Dellicour S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000221; Desai M, 2015, CLIN INFECT DIS; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; DOMC, 2010, DIV MAL CONTR NAT GU; Fall B, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-310; Hanson C, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-41; Hill J, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001688; HUNTINGTON D, 1993, STUD FAMILY PLANN, V24, P187, DOI 10.2307/2939233; Iriemenam NC, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-134; Kamuhabwa A, 2011, INDIAN J PHARMACOL, V43, P345, DOI 10.4103/0253-7613.81503; Kebede B, 2009, PHARMACOEPIDEM DR S, V18, P462, DOI 10.1002/pds.1732; Kenya National Bureau of Statistics (KNBS) and ICF Macro, 2011, KEN DEM HLTH SURV 20; Kioko U, 2015, AVAILABILITY C UNPUB; Littrell M, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-327; Madden JM, 1997, SOC SCI MED, V45, P1465, DOI 10.1016/S0277-9536(97)00076-2; McCollum AM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-77; Nyandigisi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024781; Odhiambo FO, 2012, INT J EPIDEMIOL, V41, P977, DOI 10.1093/ije/dys108; Ouma P, 2007, TROP MED INT HEALTH, V12, P1515, DOI 10.1111/j.1365-3156.2007.01960.x; Perlman SE, 2001, J REPROD MED, V46, P163; Perrault SD, 2009, AM J TROP MED HYG, V80, P119, DOI 10.4269/ajtmh.2009.80.119; Pettinelli FO, 2004, AM J TROP MED HYG, V70, P635, DOI 10.4269/ajtmh.2004.70.635; Riley C, 2015, HLTH FACILITY UNPUB; Rohra DK, 2008, BMC PREGNANCY CHILDB, V8, P24, DOI DOI 10.1186/1471-2393-8-24; Sangare LR, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-152; Tarning J, 2013, ANTIMICROB AGENTS CH, V57, P5096, DOI 10.1128/AAC.00683-13; Ward SA, 2007, LANCET INFECT DIS, V7, P136, DOI 10.1016/S1473-3099(07)70025-7; WHO, 2010, GUID TREATM MAL, V2nd; World Health Organization (WHO), 2003, ASS SAF ART COMP PRE; Zurovac D, 2008, TROP MED INT HEALTH, V13, P784, DOI 10.1111/j.1365-3156.2008.02072.x; Zurovac D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092782; Zurovac D, 2011, LANCET, V378, P795, DOI 10.1016/S0140-6736(11)60783-6	39	18	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2016	11	1							e0145616	10.1371/journal.pone.0145616	http://dx.doi.org/10.1371/journal.pone.0145616			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB5BW	26789638	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000368529100012
J	Bauchner, H; Fontanarosa, PB				Bauchner, Howard; Fontanarosa, Phil B.			Death, Dying, and End of Life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Bauchner, Howard; Fontanarosa, Phil B.] JAMA, Chicago, IL 60611 USA		Bauchner, H (corresponding author), JAMA, 330 N Wabash Ave, Chicago, IL 60611 USA.	howard.bauchner@jamanetwork.org						[Anonymous], 2010, ECONOMIST; [Anonymous], DEATHS AND MORT; [Anonymous], WORLD BIRTH DEATH RA; Chochinov HM, 2016, JAMA-J AM MED ASSOC, V315, P253, DOI 10.1001/jama.2015.17435; Clodfelter RP, 2016, JAMA-J AM MED ASSOC, V315, P251, DOI 10.1001/jama.2015.16242; Dierickx S, 2015, JAMA INTERN MED, V175, P1703, DOI 10.1001/jamainternmed.2015.3982; Gawande A, 2016, JAMA-J AM MED ASSOC, V315, P267, DOI 10.1001/jama.2015.19206; Gostin LO, 2016, JAMA-J AM MED ASSOC, V315, P249, DOI 10.1001/jama.2015.16586; Krumholz HM, 2015, JAMA-J AM MED ASSOC, V314, P355, DOI 10.1001/jama.2015.8035; Lerner BH, 2015, JAMA INTERN MED, V175, P1640, DOI 10.1001/jamainternmed.2015.4086; Orentlicher D, 2014, JAMA-J AM MED ASSOC, V311, P1961, DOI 10.1001/jama.2014.4117; Quill TE, 2016, JAMA-J AM MED ASSOC, V315, P245, DOI 10.1001/jama.2015.16210; Snijdewind MC, 2015, JAMA INTERN MED, V175, P1633, DOI 10.1001/jamainternmed.2015.3978; Yang YT, 2016, JAMA-J AM MED ASSOC, V315, P247, DOI 10.1001/jama.2015.16194	14	9	9	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					270	271		10.1001/jama.2015.19102	http://dx.doi.org/10.1001/jama.2015.19102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784774				2023-01-03	WOS:000368371400023
J	Warner, DO; Flick, RP				Warner, David O.; Flick, Randall P.			Anaesthetics, infants, and neurodevelopment: case closed?	LANCET			English	Editorial Material							NEUROTOXICITY; BRAIN; EXPOSURE; SURGERY		[Warner, David O.; Flick, Randall P.] Mayo Clin, Dept Anesthesiol, Rochester, MN 55905 USA; [Flick, Randall P.] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Warner, DO (corresponding author), Mayo Clin, Dept Anesthesiol, Rochester, MN 55905 USA.	warner.david@mayo.edu						Backeljauw B, 2015, PEDIATRICS, V136, pE1, DOI 10.1542/peds.2014-3526; Davidson AJ, 2015, LANCET; Flick RP, 2012, ANESTHESIOLOGY, V117, P459, DOI 10.1097/ALN.0b013e31826446a5; Hansen TG, 2015, PEDIATR ANESTH, V25, P65, DOI 10.1111/pan.12548; Ing C, 2012, PEDIATRICS, V130, pE476, DOI 10.1542/peds.2011-3822; Ing CH, 2014, ANESTHESIOLOGY, V120, P1319, DOI 10.1097/ALN.0000000000000248; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Lee BH, 2014, INT J DEV NEUROSCI, V37, P87, DOI 10.1016/j.ijdevneu.2014.06.016; Lei SY, 2014, J NEUROSURG ANESTH, V26, P349, DOI 10.1097/ANA.0000000000000117; Paule MG, 2011, NEUROTOXICOL TERATOL, V33, P220, DOI 10.1016/j.ntt.2011.01.001; Rappaport BA, 2015, NEW ENGL J MED, V372, P796, DOI 10.1056/NEJMp1414786; Sanders RD, 2013, BRIT J ANAESTH, V110, P53, DOI 10.1093/bja/aet054; Stratmann G, 2014, NEUROPSYCHOPHARMACOL, V39, P2275, DOI 10.1038/npp.2014.134; Wang X, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085760, 10.1371/journal.pone.0096299]	14	13	13	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	2016	387	10015					202	204		10.1016/S0140-6736(15)00669-8	http://dx.doi.org/10.1016/S0140-6736(15)00669-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA9LQ	26507181				2023-01-03	WOS:000368130700005
J	De Rose, F; Marotta, R; Poddighe, S; Talani, G; Catelani, T; Setzu, MD; Solla, P; Marrosu, F; Sanna, E; Kasture, S; Acquas, E; Liscia, A				De Rose, Francescaelena; Marotta, Roberto; Poddighe, Simone; Talani, Giuseppe; Catelani, Tiziano; Setzu, Maria Dolores; Solla, Paolo; Marrosu, Francesco; Sanna, Enrico; Kasture, Sanjay; Acquas, Elio; Liscia, Anna			Functional and Morphological Correlates in the Drosophila LRRK2 loss-of-function Model of Parkinson's Disease: Drug Effects of Withania somnifera (Dunal) Administration	PLOS ONE			English	Article							EARLY-ONSET PARKINSONISM; MUTATIONS; GENE; NEURONS; PINK1; BRAIN; LOCALIZATION; DEGENERATION; MITOCHONDRIA; DYSFUNCTION	The common fruit fly Drosophila melanogaster (Dm) is a simple animal species that contributed significantly to the development of neurobiology whose leucine-rich repeat kinase 2 mutants (LRRK2) loss-of-function in the WD40 domain represent a very interesting tool to look into physiopathology of Parkinson's disease (PD). Accordingly, LRRK2 Dm have also the potential to contribute to reveal innovative therapeutic approaches to its treatment. Withania somnifera Dunal, a plant that grows spontaneously also in Mediterranean regions, is known in folk medicine for its anti-inflammatory and protective properties against neurodegeneration. The aim of this study was to evaluate the neuroprotective effects of its standardized root methanolic extract (Wse) on the LRRK2 loss-of-function Dm model of PD. To this end mutant and wild type (WT) flies were administered Wse, through diet, at different concentrations as larvae and adults (L+/A(+)) or as adults (L-/A(+)) only. LRRK2 mutants have a significantly reduced lifespan and compromised motor function and mitochondrial morphology compared to WT flies 1% Wse-enriched diet, administered to Dm LRRK2 as L-/A(+) and improved a) locomotor activity b) muscle electrophysiological response to stimuli and also c) protected against mitochondria degeneration. In contrast, the administration of Wse to Dm LRRK2 as L+/A(+), no matter at which concentration, worsened lifespan and determined the appearance of increased endosomal activity in the thoracic ganglia. These results, while confirming that the LRRK2 loss-of-function in the WD40 domain represents a valid model of PD, reveal that under appropriate concentrations Wse can be usefully employed to counteract some deficits associated with the disease. However, a careful assessment of the risks, likely related to the impaired endosomal activity, is required.	[De Rose, Francescaelena; Sanna, Enrico; Acquas, Elio; Liscia, Anna] Univ Cagliari, Dept Life & Environm Sci, Cagliari, Italy; [Marotta, Roberto; Catelani, Tiziano] Fdn Ist Italiano Tecnol, Nanochem Dept, Genoa, Italy; [Poddighe, Simone; Setzu, Maria Dolores] Univ Cagliari, Dept Biomed Sci, Cagliari, Italy; [Talani, Giuseppe] CNR, Inst Neurosci, Cagliari, Italy; [Solla, Paolo; Marrosu, Francesco] Univ Cagliari, Dept Publ Hlth Clin & Mol Med, Cagliari, Italy; [Kasture, Sanjay] Pinnacle Biomed Res Inst, Bhopal, India	University of Cagliari; Istituto Italiano di Tecnologia - IIT; University of Cagliari; Consiglio Nazionale delle Ricerche (CNR); University of Cagliari	Liscia, A (corresponding author), Univ Cagliari, Dept Life & Environm Sci, Cagliari, Italy.	liscia@unica.it	Solla, Paolo/GQZ-7556-2022; Solla, Paolo/R-5366-2016; Acquas, Elio/G-1705-2010; sanna, enrico/HHY-8509-2022; Marotta, Roberto/HGV-1599-2022; Marotta, Roberto/B-5382-2014; Solla, Paolo/AAL-9671-2020	Solla, Paolo/0000-0002-2982-0665; Marotta, Roberto/0000-0003-0634-5483; Poddighe, Simone/0000-0002-7244-9240; Liscia, Anna/0000-0002-1629-2090; Acquas, Elio/0000-0002-4783-9319	Fondazione Banco di Sardegna (ITA) [0172/2014]	Fondazione Banco di Sardegna (ITA)	This work was supported by Fondazione Banco di Sardegna (ITA) no. 0172/2014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad M, 2005, HUM EXP TOXICOL, V24, P137, DOI 10.1191/0906327105ht209oa; Allen Marcus J, 2010, Cold Spring Harb Protoc, V2010, DOI 10.1101/pdb.prot5453; Alviano DS, 2009, CURR PHARM BIOTECHNO, V10, P106, DOI 10.2174/138920109787048607; Augustin H, 2011, JOVE-J VIS EXP, DOI 10.3791/2412; Berg D, 2005, BRAIN, V128, P3000, DOI 10.1093/brain/awh666; Biskup S, 2006, ANN NEUROL, V60, P557, DOI 10.1002/ana.21019; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bonifati V, 2006, EUR J HUM GENET, V14, P1061, DOI 10.1038/sj.ejhg.5201695; Celotto AM, 2005, MOL INTERV, V5, P292, DOI 10.1124/mi.5.5.9; Cherra SJ, 2013, AM J PATHOL, V182, P474, DOI 10.1016/j.ajpath.2012.10.027; Dagenais M L-CSS BB, 2000, SCI BASIS THERAPEUTI, V5, P334; Dermaut B, 2005, J CELL BIOL, V170, P127, DOI 10.1083/jcb.200412001; Di Fonzo A, 2009, NEUROLOGY, V72, P240, DOI 10.1212/01.wnl.0000338144.10967.2b; Galter D, 2006, ANN NEUROL, V59, P714, DOI 10.1002/ana.20808; Gasser T, 2005, CURR OPIN NEUROL, V18, P363, DOI 10.1097/01.wco.0000170951.08924.3d; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Greggio E, 2008, J BIOL CHEM, V283, P16906, DOI 10.1074/jbc.M708718200; Higashi S, 2007, BRAIN RES, V1155, P208, DOI 10.1016/j.brainres.2007.04.034; Humphrey DM, 2012, HUM MOL GENET, V21, P2698, DOI 10.1093/hmg/dds096; Iaccarino C, 2007, HUM MOL GENET, V16, P1319, DOI 10.1093/hmg/ddm080; Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045; Jansen RLM, 2014, EFFECTS 5 AYURVEDIC; Jay Prakash, 2013, Advances in Bioscience and Biotechnology, V4, P1; Kasture S, 2013, ORIENTAL PHARM EXP M, V13, P165, DOI 10.1007/s13596-013-0126-2; Kawasaki F, 1999, J NEUROPHYSIOL, V82, P123, DOI 10.1152/jn.1999.82.1.123; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kuboyama T, 2014, BIOL PHARM BULL, V37, P892, DOI 10.1248/bpb.b14-00022; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lautier C, 2008, AM J HUM GENET, V82, P822, DOI 10.1016/j.ajhg.2008.01.015; Lee S, 2012, BIOCHEM SOC T, V40, P1047, DOI 10.1042/BST20120113; Lee SB, 2007, BIOCHEM BIOPH RES CO, V358, P534, DOI 10.1016/j.bbrc.2007.04.156; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Li TX, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/942412; Lieu CA, 2010, PARKINSONISM RELAT D, V16, P458, DOI 10.1016/j.parkreldis.2010.04.015; Lima SQ, 2005, CELL, V121, P141, DOI 10.1016/j.cell.2005.02.004; Liu Z, 2008, P NATL ACAD SCI USA, V105, P2693, DOI 10.1073/pnas.0708452105; Martinez VG, 2007, DEV NEUROBIOL, V67, P778, DOI 10.1002/dneu.20388; Mata IF, 2005, NEUROGENETICS, V6, P171, DOI 10.1007/s10048-005-0005-1; Matta S, 2012, NEURON, V75, P1008, DOI 10.1016/j.neuron.2012.08.022; Mattson MP, 2008, AGEING RES REV, V7, P1, DOI 10.1016/j.arr.2007.08.007; Ng CH, 2012, J NEUROSCI, V32, P14311, DOI 10.1523/JNEUROSCI.0499-12.2012; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Paisan-Ruiz C, 2009, ANN NEUROL, V65, P19, DOI 10.1002/ana.21415; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Piccoli G, 2011, J NEUROSCI, V31, P2225, DOI 10.1523/JNEUROSCI.3730-10.2011; Poddighe S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110802; Poddighe S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073156; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ramirez A, 2006, NAT GENET, V38, P1184, DOI 10.1038/ng1884; Reiter LT, 2001, GENOME RES, V11, P1114, DOI 10.1101/gr.169101; Schrag A, 2006, LANCET NEUROL, V5, P355, DOI 10.1016/S1474-4422(06)70411-2; Sheng DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000914; Taymans JM, 2006, J NEUROCHEM, V98, P951, DOI 10.1111/j.1471-4159.2006.03919.x; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Wang J, 2011, AM J NEURORADIOL, V32, P677, DOI 10.3174/ajnr.A2350; Xiao L, 2012, GLIA, V60, P1037, DOI 10.1002/glia.22333; Xie CL, 2014, NEUROL SCI, V35, P1495, DOI 10.1007/s10072-014-1878-2; Yang YF, 2006, P NATL ACAD SCI USA, V103, P10793, DOI 10.1073/pnas.0602493103; Yellman C, 1997, P NATL ACAD SCI USA, V94, P4131, DOI 10.1073/pnas.94.8.4131; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	61	17	18	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2016	11	1							e0146140	10.1371/journal.pone.0146140	http://dx.doi.org/10.1371/journal.pone.0146140			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA3FF	26727265	Green Published, gold, Green Submitted			2023-01-03	WOS:000367681500057
J	Neumann, PJ; Cohen, JT				Neumann, Peter J.; Cohen, Joshua T.			Measuring the Value of Prescription Drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Neumann, Peter J.; Cohen, Joshua T.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA 02111 USA	Tufts Medical Center	Neumann, PJ (corresponding author), Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA 02111 USA.							Abboud C, 2013, BLOOD, V121, P4439, DOI 10.1182/blood-2013-03-490003; [Anonymous], 2015, NY TIMES; DiJulio B, 2015, KAISER HLTH TRACKING	3	106	107	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	2015	373	27					2595	2597		10.1056/NEJMp1512009	http://dx.doi.org/10.1056/NEJMp1512009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CZ8UH	26580666				2023-01-03	WOS:000367374100003
J	Karlsson, H; Svensson, E; Gigg, C; Jarvius, M; Olsson-Stromberg, U; Savoldo, B; Dotti, G; Loskog, A				Karlsson, Hannah; Svensson, Emma; Gigg, Camilla; Jarvius, Malin; Olsson-Stromberg, Ulla; Savoldo, Barbara; Dotti, Gianpietro; Loskog, Angelica			Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors	PLOS ONE			English	Article							MODIFIED T-CELLS; ADOPTIVE IMMUNOTHERAPY; IN-VIVO; ANTITUMOR-ACTIVITY; CD28; LYMPHOMA; MEMORY; COSTIMULATION; ACTIVATION; SURVIVAL	CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although mainly second generation (2G) CARs carrying CD28 or 4-1BB have been investigated in patients, preclinical studies suggest that third generation (3G) CARs with both CD28 and 4-1BB have enhanced capacity. However, little is known about the intracellular signaling pathways downstream of CARs. In the present work, we have analyzed the signaling capacity post antigen stimulation in both 2G and 3G CARs. 3G CAR T cells expanded better than 2G CAR T cells upon repeated stimulation with IL-2 and autologous B cells. An antigen-driven accumulation of CAR+ cells was evident post antigen stimulation. The cytotoxicity of both 2G and 3G CAR T cells was maintained by repeated stimulation. The phosphorylation status of intracellular signaling proteins post antigen stimulation showed that 3G CAR T cells had a higher activation status than 2G. Several proteins involved in signaling downstream the TCR were activated, as were proteins involved in the cell cycle, cell adhesion and exocytosis. In conclusion, 3G CAR T cells had a higher degree of intracellular signaling activity than 2G CARs which may explain the increased proliferative capacity seen in 3G CAR T cells. The study also indicates that there may be other signaling pathways to consider when designing or evaluating new generations of CARs.	[Karlsson, Hannah; Svensson, Emma; Gigg, Camilla; Loskog, Angelica] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden; [Jarvius, Malin; Olsson-Stromberg, Ulla] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Olsson-Stromberg, Ulla] Univ Uppsala Hosp, Sect Hematol, Uppsala, Sweden; [Savoldo, Barbara; Dotti, Gianpietro] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA	Uppsala University; Uppsala University; Uppsala University; Uppsala University Hospital; Baylor College of Medicine	Loskog, A (corresponding author), Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden.	angelica.loskog@igp.uu.se		Jarvius, Malin/0000-0002-1565-6155	Swedish Society for Childhood Cancer [PROJ08/028]; Swedish Cancer Society [CAN 2008/936]; Swedish Research Council [K2008-64P-20744-01-4]; AFA Insurance; Ake Wibergs Stiftelse; Magn. Bervalls Stiftelse; Erik; Karin o Gosta Selanders Stiftelse; Goransson-Sandvikens Stiftelse; Ellen Bachrachts stiftelse; foundation of GC Claeson; Medical Faculty at Uppsala University; foundation of A Karlsson; foundation of L Eriksson; NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER	Swedish Society for Childhood Cancer; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); AFA Insurance; Ake Wibergs Stiftelse; Magn. Bervalls Stiftelse; Erik; Karin o Gosta Selanders Stiftelse; Goransson-Sandvikens Stiftelse; Ellen Bachrachts stiftelse; foundation of GC Claeson; Medical Faculty at Uppsala University; foundation of A Karlsson; foundation of L Eriksson; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The study was supported by grants from the Swedish Society for Childhood Cancer (PROJ08/028), The Swedish Cancer Society (CAN 2008/936), The Swedish Research Council (K2008-64P-20744-01-4), AFA Insurance, Ake Wibergs Stiftelse, Magn. Bervalls Stiftelse, Erik, Karin o Gosta Selanders Stiftelse, Goransson-Sandvikens Stiftelse, Ellen Bachrachts stiftelse, foundation of GC Claeson, A Karlsson and L Eriksson and the Medical Faculty at Uppsala University.	Abate-Daga D, 2014, HUM GENE THER, V25, P1003, DOI 10.1089/hum.2013.209; Austgen K, 2012, NAT CELL BIOL, V14, P87, DOI 10.1038/ncb2395; Barrett DM, 2014, CYTOTHERAPY, V16, P619, DOI 10.1016/j.jcyt.2013.10.013; Berger C, 2008, J CLIN INVEST, V118, P294, DOI 10.1172/JCI32103; Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Carpenito C, 2009, P NATL ACAD SCI USA, V106, P3360, DOI 10.1073/pnas.0813101106; Chapman NM, 2013, J IMMUNOL, V191, P6208, DOI 10.4049/jimmunol.1301587; Chunder N, 2012, J IMMUNOL, V189, P5659, DOI 10.4049/jimmunol.1202313; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; DUBOIS T, 1995, BIOCHEM J, V310, P243, DOI 10.1042/bj3100243; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Essand M, 2013, J INTERN MED, V273, P166, DOI 10.1111/joim.12020; Finney HM, 2004, J IMMUNOL, V172, P104, DOI 10.4049/jimmunol.172.1.104; Gao HP, 2014, CLIN CANCER RES, V20, P6418, DOI 10.1158/1078-0432.CCR-14-1170; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Grebe C, 2011, CARDIOVASC RES, V90, P521, DOI 10.1093/cvr/cvr023; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Gu HJ, 2014, CELL IMMUNOL, V290, P138, DOI 10.1016/j.cellimm.2014.05.004; Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631; Hillerdal V, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-30; Hinrichs CS, 2009, P NATL ACAD SCI USA, V106, P17469, DOI 10.1073/pnas.0907448106; Hombach AA, 2013, HUM GENE THER, V24, P259, DOI 10.1089/hum.2012.247; Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127; Imai C, 2004, LEUKEMIA, V18, P676, DOI 10.1038/sj.leu.2403302; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kang QZ, 2009, BLOOD, V113, P6128, DOI 10.1182/blood-2008-10-182329; Kershaw MH, 2006, CLIN CANCER RES, V12, P6106, DOI 10.1158/1078-0432.CCR-06-1183; KLEIN E, 1968, CANCER RES, V28, P1300; Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025; Kowolik CM, 2006, CANCER RES, V66, P10995, DOI 10.1158/0008-5472.CAN-06-0160; Lamers C., 2006, J CLIN ONCOL, V24, P20, DOI DOI 10.1200/JCO.2006.05.9964; Lapinski PE, 2011, J IMMUNOL, V187, P151, DOI 10.4049/jimmunol.1100178; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Liu JO, 2009, IMMUNOL REV, V228, P184, DOI 10.1111/j.1600-065X.2008.00756.x; Loskog A, 2006, LEUKEMIA, V20, P1819, DOI 10.1038/sj.leu.2404366; Maher J, 2002, NAT BIOTECHNOL, V20, P70, DOI 10.1038/nbt0102-70; Maude SL, 2015, BLOOD, V125, P4017, DOI 10.1182/blood-2014-12-580068; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Miao TZ, 2013, J IMMUNOL, V190, P58, DOI 10.4049/jimmunol.1200868; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Morawski PA, 2013, J BIOL CHEM, V288, P24494, DOI 10.1074/jbc.M113.467704; Nicholson IC, 1997, MOL IMMUNOL, V34, P1157, DOI 10.1016/S0161-5890(97)00144-2; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Proust R, 2014, MOL IMMUNOL, V58, P206, DOI 10.1016/j.molimm.2013.12.002; Pule MA, 2005, MOL THER, V12, P933, DOI 10.1016/j.ymthe.2005.04.016; Pule MA, 2008, NAT MED, V14, P1264, DOI 10.1038/nm.1882; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Robertson LK, 2011, J IMMUNOL, V187, P5824, DOI 10.4049/jimmunol.1003690; Sampson JH, 2014, CLIN CANCER RES, V20, P972, DOI 10.1158/1078-0432.CCR-13-0709; Santoro SP, 2015, CANCER IMMUNOL RES, V3, P68, DOI 10.1158/2326-6066.CIR-14-0192; Savoldo B, 2011, J CLIN INVEST, V121, P1822, DOI 10.1172/JCI46110; Singh H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064138; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Song DG, 2012, BLOOD, V119, P696, DOI 10.1182/blood-2011-03-344275; Tammana S, 2010, HUM GENE THER, V21, P75, DOI 10.1089/hum.2009.122; Till BG, 2008, BLOOD, V112, P2261, DOI 10.1182/blood-2007-12-128843; Till BG, 2012, BLOOD, V119, P3940, DOI 10.1182/blood-2011-10-387969; van Genderen HO, 2008, BBA-MOL CELL RES, V1783, P953, DOI 10.1016/j.bbamcr.2008.01.030; Vera J, 2006, BLOOD, V108, P3890, DOI 10.1182/blood-2006-04-017061; Wang J, 2007, HUM GENE THER, V18, P712, DOI 10.1089/hum.2007.028; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; Weyd H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062449; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Zaiss DMW, 2013, IMMUNITY, V38, P275, DOI 10.1016/j.immuni.2012.09.023; Zhong XS, 2010, MOL THER, V18, P413, DOI 10.1038/mt.2009.210	67	71	76	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0144787	10.1371/journal.pone.0144787	http://dx.doi.org/10.1371/journal.pone.0144787			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SI	26700307	Green Submitted, Green Published, gold			2023-01-03	WOS:000367092600032
J	Andrews, PJD; Sinclair, HL; Rodriguez, A; Harris, BA; Battison, CG; Rhodes, JKJ; Murray, GD				Andrews, Peter J. D.; Sinclair, H. Louise; Rodriguez, Aryelly; Harris, Bridget A.; Battison, Claire G.; Rhodes, Jonathan K. J.; Murray, Gordon D.		Eurotherm3235 Trial Collaborators	Hypothermia for Intracranial Hypertension after Traumatic Brain Injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE HEAD-INJURY; THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; PRESSURE REDUCTION; CLINICAL-TRIALS; FEVER CONTROL; MANAGEMENT; DISORDERS; DESIGN; PHASE	BACKGROUND In patients with traumatic brain injury, hypothermia can reduce intracranial hypertension. The benefit of hypothermia on functional outcome is unclear. METHODS We randomly assigned adults with an intracranial pressure of more than 20 mm Hg despite stage 1 treatments (including mechanical ventilation and sedation management) to standard care (control group) or hypothermia (32 to 35 degrees C) plus standard care. In the control group, stage 2 treatments (e.g., osmotherapy) were added as needed to control intracranial pressure. In the hypothermia group, stage 2 treatments were added only if hypothermia failed to control intracranial pressure. In both groups, stage 3 treatments (barbiturates and decompressive craniectomy) were used if all stage 2 treatments failed to control intracranial pressure. The primary outcome was the score on the Extended Glasgow Outcome Scale (GOS-E; range, 1 to 8, with lower scores indicating a worse functional outcome) at 6 months. The treatment effect was estimated with ordinal logistic regression adjusted for prespecified prognostic factors and expressed as a common odds ratio (with an odds ratio <1.0 favoring hypothermia). RESULTS We enrolled 387 patients at 47 centers in 18 countries from November 2009 through October 2014, at which time recruitment was suspended owing to safety concerns. Stage 3 treatments were required to control intracranial pressure in 54% of the patients in the control group and in 44% of the patients in the hypothermia group. The adjusted common odds ratio for the GOS-E score was 1.53 (95% confidence interval, 1.02 to 2.30; P = 0.04), indicating a worse outcome in the hypothermia group than in the control group. A favorable outcome (GOS-E score of 5 to 8, indicating moderate disability or good recovery) occurred in 26% of the patients in the hypothermia group and in 37% of the patients in the control group (P = 0.03). CONCLUSIONS In patients with an intracranial pressure of more than 20 mm Hg after traumatic brain injury, therapeutic hypothermia plus standard care to reduce intracranial pressure did not result in outcomes better than those with standard care alone.	[Andrews, Peter J. D.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Sinclair, H. Louise; Harris, Bridget A.; Battison, Claire G.; Rhodes, Jonathan K. J.] Univ Edinburgh, Dept Anaesthesia Crit Care & Pain Med, Edinburgh, Midlothian, Scotland; [Rodriguez, Aryelly; Battison, Claire G.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Harris, Bridget A.; Rhodes, Jonathan K. J.] Western Gen Hosp, Crit Care, NHS Lothian, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh	Andrews, PJD (corresponding author), Western Gen Hosp, Intens Care Unit, Ward 20,Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	p.andrews@ed.ac.uk	Mellinghoff, Johannes/V-4844-2019	Mellinghoff, Johannes/0000-0002-5455-8953; Deeb, Ahmad/0000-0002-3680-7338; Battison, Claire/0000-0001-9549-4522; Aragao, Irene/0000-0001-5750-2739; Vincent, Jean-Louis/0000-0001-6011-6951; Dimopoulos, Stavros/0000-0003-2199-3788; Verma, Vishwajit/0000-0003-2428-2391; Solodov, Aleksandr/0000-0002-8263-1433; Spapen, Herbert/0000-0002-7724-886X	National Institute for Health Research Health Technology Assessment program; Medical Research Council [G0800803] Funding Source: researchfish; National Institute for Health Research [11/01/30] Funding Source: researchfish; MRC [G0800803] Funding Source: UKRI	National Institute for Health Research Health Technology Assessment program; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funded by the National Institute for Health Research Health Technology Assessment program; Current Controlled Trials number, ISRCTN34555414.	Andrews PJD, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-277; Andrews PJD, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-8; [Anonymous], 2013, LANCET NEUROL, V12, P1127, DOI 10.1016/S1474-4422(13)70266-7; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Crossley S, 2014, CRIT CARE, V18, DOI 10.1186/cc13835; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Ker K, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a865; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Maekawa T, 2015, J NEUROTRAUM, V32, P422, DOI 10.1089/neu.2013.3197; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; NORDBY HK, 1984, ACTA NEUROCHIR, V72, P157, DOI 10.1007/BF01406868; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Sydenham E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub3; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Tokutomi T, 2009, J TRAUMA, V66, P166, DOI 10.1097/TA.0b013e318157dbec; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	35	275	288	1	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	2015	373	25					2403	2412		10.1056/NEJMoa1507581	http://dx.doi.org/10.1056/NEJMoa1507581			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CY5QD	26444221	Green Published, Bronze			2023-01-03	WOS:000366461400007
J	Strojny, B; Kurantowicz, N; Sawosz, E; Grodzik, M; Jaworski, S; Kutwin, M; Wierzbicki, M; Hotowy, A; Lipinska, L; Chwalibog, A				Strojny, Barbara; Kurantowicz, Natalia; Sawosz, Ewa; Grodzik, Marta; Jaworski, Slawomir; Kutwin, Marta; Wierzbicki, Mateusz; Hotowy, Anna; Lipinska, Ludwika; Chwalibog, Andre			Long Term Influence of Carbon Nanoparticles on Health and Liver Status in Rats	PLOS ONE			English	Article							NANOSCALE GRAPHENE OXIDE; C-REACTIVE PROTEIN; GRAPHITE NANOPLATELETS; OXIDATIVE STRESS; VIVO; TOXICITY; NANODIAMONDS; MICE; BIODISTRIBUTION; GLUTATHIONE	Due to their excellent biocompatibility, carbon nanoparticles have been widely investigated for prospective biomedical applications. However, their impact on an organism with prolonged exposure is still not well understood. Here, we performed an experiment investigating diamond, graphene oxide and graphite nanoparticles, which were repeatedly administrated intraperitoneally into Wistar rats for four weeks. Some of the animals was sacrificed after the last injection, whereas the rest were sacrificed twelve weeks after the last exposure. We evaluated blood morphology and biochemistry, as well as the redox and inflammatory state of the liver. The results show the retention of nanoparticles within the peritoneal cavity in the form of prominent aggregates in proximity to the injection site, as well as the presence of some nanoparticles in the mesentery. Small aggregates were also visible in the liver serosa, suggesting possible transportation to the liver. However, none of the tested nanoparticles affected the health of animals. This lack of toxic effect may suggest the potential applicability of nanoparticles as drug carriers for local therapies, ensuring accumulation and slow release of drugs into a targeted tissue without harmful systemic side effects.	[Strojny, Barbara; Kurantowicz, Natalia; Sawosz, Ewa; Grodzik, Marta; Jaworski, Slawomir; Kutwin, Marta; Wierzbicki, Mateusz; Hotowy, Anna] Warsaw Univ Life Sci, Div Nanobiotechnol, Warsaw, Poland; [Lipinska, Ludwika] Inst Elect Mat Technol, Dept Chem Technol, Warsaw, Poland; [Chwalibog, Andre] Univ Copenhagen, Dept Vet Clin & Anim Sci, Copenhagen, Denmark	Warsaw University of Life Sciences; Institute of Electronic Materials Technology; University of Copenhagen	Chwalibog, A (corresponding author), Univ Copenhagen, Dept Vet Clin & Anim Sci, Copenhagen, Denmark.	ach@sund.ku.dk	Jaworski, Sławomir/AAI-2313-2020; Grodzik, Marta/J-9404-2015; Wierzbicki, Mateusz/ABF-5482-2020; Grodzik, Marta/AAO-4319-2021	Jaworski, Sławomir/0000-0002-4619-941X; Grodzik, Marta/0000-0001-5359-1885; Wierzbicki, Mateusz/0000-0003-3623-8929; Grodzik, Marta/0000-0001-5359-1885; Kurantowicz, Natalia/0000-0002-7036-1325; Hotowy, Anna/0000-0002-0596-1201; Kutwin, Marta/0000-0001-7059-7875; Chwalibog, Andre/0000-0001-8150-2392; Sawosz Chwalibog, Ewa/0000-0002-0016-4721; Strojny, Barbara/0000-0002-2642-5491	National Science Centre (Poland) [2011/03/B/NZ9/03387, NN311 540840]; grant NCN from the National Science Centre (Poland) [2011/03/B/NZ9/03387, NN311 540840]	National Science Centre (Poland); grant NCN from the National Science Centre (Poland)	This work was supported by the National Science Centre (Poland) grant: 2011/03/B/NZ9/03387 and NN311 540840. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This report is a part of Barbara Strojny's PhD thesis. This work was supported by grant NCN 2011/03/B/NZ9/03387 and NN311 540840 from the National Science Centre (Poland). The authors thank Dr. Michal Mikula from The Maria Sklodowska-Curie Institute of Oncology for help with the cytokine membranes.	Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438; Bolliger AP., 2010, SCHALMS VET HEMATOLO, V6th; Buzea C, 2007, BIOINTERPHASES, V2, pMR17, DOI 10.1116/1.2815690; Chen GH, 2004, CARBON, V42, P753, DOI 10.1016/j.carbon.2003.12.074; Chowdhury SM, 2013, SCI REP-UK, V3, DOI 10.1038/srep02584; Cichoz-Lach H, 2014, WORLD J GASTROENTERO, V20, P8082, DOI 10.3748/wjg.v20.i25.8082; Deng XY, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/7/075101; Forman HJ, 2009, MOL ASPECTS MED, V30, P1, DOI 10.1016/j.mam.2008.08.006; Franco R., 2007, Archives of Physiology and Biochemistry, V113, P234, DOI 10.1080/13813450701661198; Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752; Grodzik M, 2011, INT J NANOMED, V6, P3041, DOI 10.2147/IJN.S25528; Hong H, 2012, ACS NANO, V6, P2361, DOI 10.1021/nn204625e; HURLIMANN J, 1966, J EXP MED, V123, P365, DOI 10.1084/jem.123.2.365; Jaworski S, 2013, INT J NANOMED, V8, P413, DOI 10.2147/IJN.S39456; Kanakia S, 2014, BIOMATERIALS, V35, P7022, DOI 10.1016/j.biomaterials.2014.04.066; Kanakia S, 2013, INT J NANOMED, V8, P2821, DOI 10.2147/IJN.S47062; Kovacic Peter, 2006, Birth Defects Research, V78, P333, DOI 10.1002/bdrc.20083; Kulakova II, 2004, PHYS SOLID STATE+, V46, P636, DOI 10.1134/1.1711440; Kurantowicz N, 2015, NANOSCALE RES LETT, V10, DOI 10.1186/s11671-015-1107-9; Kurantowicz N, 2015, NANOSCALE RES LETT, V10, DOI 10.1186/s11671-015-0749-y; Lalwani G, 2013, BIOMACROMOLECULES, V14, P900, DOI 10.1021/bm301995s; Leung L, 2012, DRUG METAB REV, V44, P18, DOI 10.3109/03602532.2011.605791; Li B, 2014, INT J NANOMED, V9, P4697, DOI 10.2147/IJN.S66591; Li J, 2010, BIOMATERIALS, V31, P8410, DOI 10.1016/j.biomaterials.2010.07.058; Li Z, 2011, J NANOMATER, V2011, DOI 10.1155/2011/842613; Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008; Ma-Hock L, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-23; Niemiec T, 2011, J NANOSCI NANOTECHNO, V11, P9072, DOI 10.1166/jnn.2011.3511; Parameters CS, CLIN LAB PARAMETERS; Patlolla AK, 2011, MOL CELL BIOCHEM, V358, P189, DOI 10.1007/s11010-011-0934-y; Pessayre D, 2012, DRUG METAB REV, V44, P34, DOI 10.3109/03602532.2011.604086; Puzyr AP, 2007, DIAM RELAT MATER, V16, P2124, DOI 10.1016/j.diamond.2007.07.025; Qu GB, 2013, J ENVIRON SCI, V25, P873, DOI 10.1016/S1001-0742(12)60252-6; Ribas V, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00151; Sanchez VC, 2012, CHEM RES TOXICOL, V25, P15, DOI 10.1021/tx200339h; Sawosz E, 2015, INT J MOL SCI, V16, P25214, DOI 10.3390/ijms161025214; Schrand AM, 2009, CRIT REV SOLID STATE, V34, P18, DOI 10.1080/10408430902831987; Talukdar Y, 2014, BIOMATERIALS, V35, P4863, DOI 10.1016/j.biomaterials.2014.02.054; Vaijayanthimala V, 2012, BIOMATERIALS, V33, P7794, DOI 10.1016/j.biomaterials.2012.06.084; Wierzbicki M, 2013, INT J NANOMED, V8, P3427, DOI 10.2147/IJN.S49745; Wierzbicki M, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-195; Xiao JS, 2013, BIOMATERIALS, V34, P9648, DOI 10.1016/j.biomaterials.2013.08.056; Yang K, 2013, BIOMATERIALS, V34, P2787, DOI 10.1016/j.biomaterials.2013.01.001; Yang K, 2013, CHEM SOC REV, V42, P530, DOI 10.1039/c2cs35342c; Yang K, 2012, BIOMATERIALS, V33, P2206, DOI 10.1016/j.biomaterials.2011.11.064; Zakrzewska KE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122579; Zanni E, 2012, NANO LETT, V12, P2740, DOI 10.1021/nl204388p; Zhang XY, 2010, TOXICOL LETT, V198, P237, DOI 10.1016/j.toxlet.2010.07.001; Zheng ZY, 2013, INT J MED SCI, V10, P653, DOI 10.7150/ijms.6050	49	38	39	3	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2015	10	12							e0144821	10.1371/journal.pone.0144821	http://dx.doi.org/10.1371/journal.pone.0144821			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9GR	26657282	Green Published, gold			2023-01-03	WOS:000366715900110
J	Inic-Kanada, A; Stojanovic, M; Schlacher, S; Stein, E; Belij-Rammerstorfer, S; Marinkovic, E; Lukic, I; Montanaro, J; Schuerer, N; Bintner, N; Kovacevic-Jovanovic, V; Krnjaja, O; Mayr, UB; Lubitz, W; Barisani-Asenbauer, T				Inic-Kanada, Aleksandra; Stojanovic, Marijana; Schlacher, Simone; Stein, Elisabeth; Belij-Rammerstorfer, Sandra; Marinkovic, Emilija; Lukic, Ivana; Montanaro, Jacqueline; Schuerer, Nadine; Bintner, Nora; Kovacevic-Jovanovic, Vesna; Krnjaja, Ognjen; Mayr, Ulrike Beate; Lubitz, Werner; Barisani-Asenbauer, Talin			Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers	PLOS ONE			English	Article							GENETICALLY INACTIVATED GHOSTS; HOMOLOGOUS AEROSOL CHALLENGE; FEMALE GUINEA-PIGS; BACTERIAL GHOSTS; GENITAL-INFECTION; OUTER-MEMBRANE; ACTINOBACILLUS-PLEUROPNEUMONIAE; CANDIDATE VACCINES; UNSAFE INJECTIONS; PROTECTIVE IMMUNITY	Trachoma, caused by the intracellular bacterium Chlamydia trachomatis (Ct), remains the world's leading preventable infectious cause of blindness. Recent attempts to develop effective vaccines rely on modified chlamydial antigen delivery platforms. As the mechanisms engaged in the pathology of the disease are not fully understood, designing a subunit vaccine specific to chlamydial antigens could improve safety for human use. We propose the delivery of chlamydia-specific antigens to the ocular mucosa using particulate carriers, bacterial ghosts (BGs). We therefore characterized humoral and cellular immune responses after conjunctival and subcutaneous immunization with a N-terminal portion (amino acid 1-893) of the chlamydial polymorphic membrane protein C (PmpC) of Ct serovar B, expressed in probiotic Escherichia coli Nissle 1917 bacterial ghosts (EcN BGs) in BALB/cmice. Three immunizations were performed at two-week intervals, and the immune responses were evaluated two weeks after the final immunization in mice. In a guinea pig model of ocular infection animals were immunized in the same manner as the mice, and protection against challenge was assessed two weeks after the last immunization. N-PmpC was successfully expressed within BGs and delivery to the ocularmucosa was well tolerated without signs of inflammation. N-PmpC- specific mucosal IgA levels in tears yielded significantly increased levels in the group immunized via the conjunctiva compared with the subcutaneously immunized mice. Immunization with N-PmpC EcN BGs via both immunization routes prompted the establishment of an N-PmpC-specific IFN gamma immune response. Immunization via the conjunctiva resulted in a decrease in intensity of the transitional inflammatory reaction in conjunctiva of challenged guinea pigs compared with subcutaneously and non-immunized animals. The delivery of the chlamydial subunit vaccine to the ocular mucosa using a particulate carrier, such as BGs, induced both humoral and cellular immune responses. Further investigations are needed to improve the immunization scheme and dosage.	[Inic-Kanada, Aleksandra; Schlacher, Simone; Stein, Elisabeth; Belij-Rammerstorfer, Sandra; Montanaro, Jacqueline; Schuerer, Nadine; Bintner, Nora; Barisani-Asenbauer, Talin] Med Univ Vienna, OCUVAC Ctr Ocular Inflammat & Infect, Laura Bassi Ctr Expertise, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Stojanovic, Marijana; Marinkovic, Emilija; Lukic, Ivana; Kovacevic-Jovanovic, Vesna; Krnjaja, Ognjen; Lubitz, Werner] Inst Virol Vaccines & Sera TORLAK, Dept Res & Dev, Belgrade, Serbia; [Mayr, Ulrike Beate] BIRD C GmbH&CoKG, Vienna, Austria	Medical University of Vienna	Barisani-Asenbauer, T (corresponding author), Med Univ Vienna, OCUVAC Ctr Ocular Inflammat & Infect, Laura Bassi Ctr Expertise, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.	talin.barisani@meduniwien.ac.at	Belij-Rammerstorfer, Sandra/B-8243-2018	Inic-Kanada, Aleksandra/0000-0001-7854-3812; Barisani-Asenbauer, Talin/0000-0002-8661-9183; Schuerer, Nadine/0000-0002-5894-2784; Belij-Rammerstorfer, Sandra/0000-0002-8637-3785; Stojanovic, Marijana/0000-0002-8204-4183; Lukic, Ivana/0000-0002-6330-471X; Stein, Elisabeth/0000-0002-1240-506X	"Laura Bassi Centers of Expertise" Program of the Austrian Federal Ministry of Economy through the Austrian Research Promotion Agency (FFG Project) [822768]; Ministry of Education, Science, and Technological Development of the Republic of Serbia [172049]; BIRD-C	"Laura Bassi Centers of Expertise" Program of the Austrian Federal Ministry of Economy through the Austrian Research Promotion Agency (FFG Project); Ministry of Education, Science, and Technological Development of the Republic of Serbia; BIRD-C	This research was funded by the "Laura Bassi Centers of Expertise" Program of the Austrian Federal Ministry of Economy through the Austrian Research Promotion Agency (FFG Project Number: 822768) and was partly supported by the Ministry of Education, Science, and Technological Development of the Republic of Serbia (Grant Number 172049). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. BIRD-C provided support in the form of salaries for authors BM and WL, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Barisani-Asenbauer T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060682; Becker E, 2014, MICROBIOLOGYOPEN, V3, P544, DOI 10.1002/mbo3.186; Boje S, 2016, IMMUNOL CELL BIOL, V94, P185, DOI 10.1038/icb.2015.79; CAMPOS M, 1995, INVEST OPHTH VIS SCI, V36, P1477; Clements CJ, 2004, VACCINE, V22, P2054, DOI 10.1016/j.vaccine.2004.01.008; Dicko M, 2000, B WORLD HEALTH ORGAN, V78, P163; DWYER RS, 1983, BRIT J OPHTHALMOL, V67, P737, DOI 10.1136/bjo.67.11.737; Eko FO, 2003, VACCINE, V21, P3663, DOI 10.1016/S0264-410X(03)00388-8; Eko FO, 2003, VACCINE, V21, P1694, DOI 10.1016/S0264-410X(02)00677-1; Fujkuyama Y, 2012, EXPERT REV VACCINES, V11, P367, DOI [10.1586/erv.11.196, 10.1586/ERV.11.196]; Gebril A, 2012, EXPERT REV VACCINES, V11, P1139, DOI [10.1586/ERV.12.81, 10.1586/erv.12.81]; Giudice EL, 2006, ADV DRUG DELIVER REV, V58, P68, DOI 10.1016/j.addr.2005.12.003; Gomes JP, 2005, MICROBES INFECT, V7, P410, DOI 10.1016/j.micinf.2004.11.014; Gomes JP, 2004, J BACTERIOL, V186, P4295, DOI 10.1128/JB.186.13.4295-4306.2004; GRAYSTON JT, 1962, J EXP MED, V115, P1009, DOI 10.1084/jem.115.5.1009; Hensel A, 1996, J BIOTECHNOL, V44, P171, DOI 10.1016/0168-1656(95)00150-6; Hensel A, 2000, VACCINE, V18, P2945, DOI 10.1016/S0264-410X(00)00107-9; Hutchings AB, 2004, J VIROL, V78, P947, DOI 10.1128/JVI.78.2.947-957.2004; Huter V, 2000, J BIOTECHNOL, V83, P161, DOI 10.1016/S0168-1656(00)00310-2; Jaffar Z, 2009, J IMMUNOL, V182, P4507, DOI 10.4049/jimmunol.0900237; Jechlinger W, 2005, VACCINE, V23, P3609, DOI 10.1016/j.vaccine.2004.11.078; Katinger A, 1999, J BIOTECHNOL, V73, P251, DOI 10.1016/S0168-1656(99)00143-1; Kelly KA, 1996, INFECT IMMUN, V64, P4976, DOI 10.1128/IAI.64.12.4976-4983.1996; Kermode M, 2004, HEALTH PROMOT INT, V19, P95, DOI 10.1093/heapro/dah110; Kersten G, 2007, EXPERT OPIN DRUG DEL, V4, P459, DOI 10.1517/17425247.4.5.459; Knop N, 2000, INVEST OPHTH VIS SCI, V41, P1270; Kudela P, 2011, J BIOTECHNOL, V153, P167, DOI 10.1016/j.jbiotec.2011.03.022; Lacy HM, 2011, INFECT IMMUN, V79, P1889, DOI 10.1128/IAI.01257-10; Langemann Timo, 2010, Bioeng Bugs, V1, P326, DOI 10.4161/bbug.1.5.12540; Levine MM, 2000, J PEDIATR GASTR NUTR, V31, P336, DOI 10.1097/00005176-200010000-00003; Liu XY, 2010, J BACTERIOL, V192, P2852, DOI 10.1128/JB.01628-09; Lu CX, 2012, INVEST OPHTH VIS SCI, V53, P2551, DOI 10.1167/iovs.11-9212; Mader HJ, 1997, VACCINE, V15, P195, DOI 10.1016/S0264-410X(96)00141-7; Marchart J, 2003, VACCINE, V21, P1415, DOI 10.1016/S0264-410X(02)00635-7; Miller MA, 1999, B WORLD HEALTH ORGAN, V77, P808; Mitragotri S, 2005, NAT REV IMMUNOL, V5, P905, DOI 10.1038/nri1728; MONNICKENDAM MA, 1983, BRIT MED BULL, V39, P187, DOI 10.1093/oxfordjournals.bmb.a071814; Montanaro J, 2015, DRUG DESIGN IN PRESS; MORRISON RP, 1989, J EXP MED, V169, P663, DOI 10.1084/jem.169.3.663; Muhammad A, 2012, EXPERT REV VACCINES, V11, P97, DOI [10.1586/erv.11.149, 10.1586/ERV.11.149]; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Nunes A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000878; Pasetti MF, 2011, IMMUNOL REV, V239, P125, DOI 10.1111/j.1600-065X.2010.00970.x; RAMSEY KH, 1988, INFECT IMMUN, V56, P1320, DOI 10.1128/IAI.56.5.1320-1325.1988; RANK RG, 1983, INFECT IMMUN, V39, P463, DOI 10.1128/IAI.39.1.463-465.1983; RANK RG, 1988, INFECT IMMUN, V56, P2243, DOI 10.1128/IAI.56.9.2243-2249.1988; RANK RG, 1995, INVEST OPHTH VIS SCI, V36, P1344; RANK RG, 1979, INFECT IMMUN, V26, P573, DOI 10.1128/IAI.26.2.573-579.1979; Rank RG, 2009, VACCINES FOR BIODEFENSE AND EMERGING AND NEGLECTED DISEASES, P845, DOI 10.1016/B978-0-12-369408-9.00044-5; Reinoso R, 2012, MUCOSAL IMMUNOL, V5, P455, DOI 10.1038/mi.2012.27; SCOTT JG, 1971, BRIT J OPHTHALMOL, V55, P189, DOI 10.1136/bjo.55.3.189; Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705; Simonsen L, 1999, B WORLD HEALTH ORGAN, V77, P789; SOMPOLINSKY D, 1992, ALLERGY, V47, P234, DOI 10.1111/j.1398-9995.1992.tb00656.x; Spiegelberg H L, 1974, Adv Immunol, V19, P259, DOI 10.1016/S0065-2776(08)60254-0; Stein E, 2013, INVEST OPHTH VIS SCI, V54, P6326, DOI 10.1167/iovs.13-12044; Tabrizi CA, 2004, CURR OPIN BIOTECH, V15, P530, DOI 10.1016/j.copbio.2004.10.004; Tifrea DF, 2013, INFECT IMMUN, V81, P1741, DOI 10.1128/IAI.00734-12; TREHARNE J D, 1991, Eye (London), V5, P299; Walcher Petra, 2004, Expert Rev Vaccines, V3, P681, DOI 10.1586/14760584.3.6.681; Walcher P, 2008, VACCINE, V26, P6832, DOI 10.1016/j.vaccine.2008.09.088; Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820; WILLIAMS DM, 1981, J INFECT DIS, V143, P238, DOI 10.1093/infdis/143.2.238; WILLIAMS DM, 1984, J INFECT DIS, V149, P630, DOI 10.1093/infdis/149.4.630; Wilson DP, 2009, J INFECT DIS, V199, P1780, DOI 10.1086/599093; Zhang YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039214	69	15	15	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2015	10	12							e0144380	10.1371/journal.pone.0144380	http://dx.doi.org/10.1371/journal.pone.0144380			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1ZA	26656797	gold, Green Published, Green Submitted			2023-01-03	WOS:000366903600041
J	Maruyama, Y; Yokoyama, K; Yokoo, T; Shigematsu, T; Iseki, K; Tsubakihara, Y				Maruyama, Yukio; Yokoyama, Keitaro; Yokoo, Takashi; Shigematsu, Takashi; Iseki, Kunitoshi; Tsubakihara, Yoshiharu			The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; ERYTHROPOIETIN REQUIREMENTS; RECEIVING HEMODIALYSIS; ANEMIA MANAGEMENT; PRACTICE PATTERNS; RISK-FACTORS; DOUBLE-BLIND; IRON; HEMOGLOBIN; METAANALYSIS	Background/Aims Monitoring of serum ferritin levels is widely recommended in the management of anemia among patients on dialysis. However, associations between serum ferritin and mortality are unclear and there have been no investigations among patients undergoing peritoneal dialysis (PD). Methods Baseline data of 191,902 patients on dialysis (age, 65 +/- 13 years; male, 61.1%; median dialysis duration, 62 months) were extracted from a nationwide dialysis registry in Japan at the end of 2007. Outcomes, such as one-year mortality, were then evaluated using the registry at the end of 2008. Results Within one year, a total of 15,284 (8.0%) patients had died, including 6,210 (3.2%) cardiovascular and 2,707 (1.4%) infection-related causes. Higher baseline serum ferritin levels were associated with higher mortality rates among patients undergoing hemodialysis (HD). In contrast, there were no clear associations between serum ferritin levels and mortality among PD patients. Multivariate Cox regression analysis of HD patients showed that those in the highest serum ferritin decile group had higher rates of all-cause and cardiovascular mortality than those in the lowest decile group (hazard ratio [HR], 1.54; 95% confidence interval [CI], 1.31-1.81 and HR, 1.44; 95% CI, 1.13-1.84, respectively), whereas associations with infection-related mortality became non-significant (HR, 1.14; 95% CI, 0.79-1.65). Conclusions Using Japanese nationwide dialysis registry, higher serum ferritin values were associated with mortality not in PD patients but in HD patients.	[Maruyama, Yukio; Yokoyama, Keitaro; Yokoo, Takashi] Jikei Univ, Sch Med, Div Nephrol & Hypertens, Tokyo, Japan; [Shigematsu, Takashi; Iseki, Kunitoshi; Tsubakihara, Yoshiharu] Japanese Soc Dialysis Therapy, Comm Renal Data Registry, Tokyo, Japan	Jikei University	Maruyama, Y (corresponding author), Jikei Univ, Sch Med, Div Nephrol & Hypertens, Tokyo, Japan.	maruyama@td5.so-net.ne.jp						Akizawa T, 2014, THER APHER DIAL, V18, P24, DOI 10.1111/1744-9987.12202; Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; [Anonymous], 2004, NEPHROL DIAL TRANSPL, V19, pii1; Bailie GR, 2013, NEPHROL DIAL TRANSPL, V28, P2570, DOI 10.1093/ndt/gft062; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Coronel F, 2003, J NEPHROL, V16, P697; Coyne DW, 2011, KIDNEY INT, V80, P240, DOI 10.1038/ki.2011.141; Cuevas X, 2012, BLOOD PURIFICAT, V33, P21, DOI 10.1159/000332395; Galic G, 2011, COLLEGIUM ANTROPOL, V35, P93; Hasuike Y, 2010, CLIN EXP NEPHROL, V14, P349, DOI 10.1007/s10157-010-0288-x; House AA, 1998, NEPHROL DIAL TRANSPL, V13, P1763, DOI 10.1093/ndt/13.7.1763; Ichii H, 2012, AM J NEPHROL, V36, P50, DOI 10.1159/000339285; Ishida JH, 2014, SEMIN DIALYSIS, V27, P26, DOI 10.1111/sdi.12168; Kalantar-Zadeh K, 2005, J AM SOC NEPHROL, V16, P3070, DOI 10.1681/ASN.2005040423; Kalantar-Zadeh K, 2006, CLIN J AM SOC NEPHRO, V1, pS9, DOI 10.2215/CJN.01390406; Kuragano T, 2014, KIDNEY INT, V86, P845, DOI 10.1038/ki.2014.114; Langston RD, 2003, KIDNEY INT, V64, P1398, DOI 10.1046/j.1523-1755.2003.00200.x; Levin A, 2006, AM J KIDNEY DIS, V47, pS9, DOI 10.1053/j.ajkd.2006.04.023; Li SL, 2004, KIDNEY INT, V65, P1864, DOI 10.1111/j.1523-1755.2004.00584.x; Litton E, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4822; Maruyama Y, 2012, CLIN NEPHROL, V78, P281, DOI 10.5414/CN107424; McFarlane PA, 2010, KIDNEY INT, V78, P215, DOI 10.1038/ki.2010.108; Molnar MZ, 2011, CLIN J AM SOC NEPHRO, V6, P1973, DOI 10.2215/CJN.01050211; Nakai S, 2009, THER APHER DIAL, V13, P457, DOI 10.1111/j.1744-9987.2009.00789.x; Palmer SC, 2010, ANN INTERN MED, V153, P23, DOI 10.7326/0003-4819-153-1-201007060-00252; Parfrey PS, 2005, J AM SOC NEPHROL, V16, P2180, DOI 10.1681/ASN.2004121039; Pisoni RL, 2004, AM J KIDNEY DIS, V44, P94, DOI 10.1053/j.ajkd.2004.03.023; Pollak VE, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-6; Tsubakihara Y, 2010, THER APHER DIAL, V14, P240, DOI 10.1111/j.1744-9987.2010.00836.x; Wetmore JB, 2015, AM J NEPHROL, V41, P354, DOI 10.1159/000431335	30	23	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2015	10	11							e0143430	10.1371/journal.pone.0143430	http://dx.doi.org/10.1371/journal.pone.0143430			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7AW	26599216	Green Submitted, gold, Green Published			2023-01-03	WOS:000365853900119
J	Nudo, RJ				Nudo, Randolph J.			REHABILITATION Boost for movement	NATURE			English	Editorial Material							STIMULATION; PLASTICITY; BEHAVIOR		[Nudo, Randolph J.] Univ Kansas, Med Ctr, Dept Rehabil Med, Landon Ctr Aging, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Nudo, RJ (corresponding author), Univ Kansas, Med Ctr, Dept Rehabil Med, Landon Ctr Aging, Kansas City, KS 66160 USA.	rnudo@kumc.edu						Angeli CA, 2014, BRAIN, V137, P1394, DOI 10.1093/brain/awu038; Guggenmos DJ, 2013, P NATL ACAD SCI USA, V110, P21177, DOI 10.1073/pnas.1316885110; Hebb D.O., 1949, ORG BEHAV; Jackson A, 2006, NATURE, V444, P56, DOI 10.1038/nature05226; Lucas TH, 2013, J NEUROSCI, V33, P5261, DOI 10.1523/JNEUROSCI.4683-12.2013; McPherson JG, 2015, P NATL ACAD SCI USA, V112, P12193, DOI 10.1073/pnas.1505383112; Mushahwar VK, 1998, ANN NY ACAD SCI, V860, P531, DOI 10.1111/j.1749-6632.1998.tb09096.x; Nishimura Y, 2013, NEURON, V80, P1301, DOI 10.1016/j.neuron.2013.08.028; Rebesco JM, 2011, PROG BRAIN RES, V192, P83, DOI 10.1016/B978-0-444-53355-5.00006-3; SHATZ CJ, 1992, SCI AM, V267, P61, DOI 10.1038/scientificamerican0992-60	10	6	6	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	2015	527	7578					314	315		10.1038/527314a	http://dx.doi.org/10.1038/527314a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW9ZN	26581287				2023-01-03	WOS:000365356800042
J	Avila, WM; Pordeus, IA; Paiva, SM; Martins, CC				Avila, Walesca M.; Pordeus, Isabela A.; Paiva, Saul M.; Martins, Carolina C.			Breast and Bottle Feeding as Risk Factors for Dental Caries: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							EARLY-CHILDHOOD CARIES; QUALITY-OF-LIFE; PRESCHOOL-CHILDREN; BIAS	Understanding the role that breastfeeding and bottle feeding play in the development of dental caries during childhood is essential in helping dentists and parents and care providers prevent the disease, and also for the development of effective public health policies. However, the issue is not yet fully understood. The aim of this systematic review and metaanalysis was to search for scientific evidence in response to the question: Do bottle fed children have more dental caries in primary dentition than breastfed children? Seven electronic databases and grey literature were used in the search. The protocol number of the study is PROSPERO CRD 42014006534. Two independent reviewers selected the studies, extracted data and evaluated risk of bias by quality assessment. A random effect model was used for meta-analysis, and the summary effect measure were calculated by odds ratio (OR) and 95% CI. Seven studies were included: five cross-sectional, one case-control and one cohort study. A meta-analysis of cross-sectional studies showed that breastfed children were less affected by dental caries than bottle fed children (OR: 0.43; 95% CI: 0.23-0.80). Four studies showed that bottle fed children had more dental caries (p<0.05), while three studies found no such association (p>0.05). The scientific evidence therefore indicated that breastfeeding can protect against dental caries in early childhood. The benefits of breastfeeding until age two is recommended by WHO/UNICEF guidelines. Further prospective observational cohort studies are needed to strengthen the evidence.	[Avila, Walesca M.; Pordeus, Isabela A.; Paiva, Saul M.; Martins, Carolina C.] Univ Fed Minas Gerais, Dept Pediat Dent & Orthodont, Fac Dent, Belo Horizonte, MG, Brazil	Universidade Federal de Minas Gerais	Martins, CC (corresponding author), Univ Fed Minas Gerais, Dept Pediat Dent & Orthodont, Fac Dent, Belo Horizonte, MG, Brazil.	carolcm10@hotmail.com	Martins, Carolina Castro/O-2514-2014; Martins, Carolina/AFD-8433-2022; Paiva, Saul Martins/H-5757-2012; PORDEUS, ISABELA A/B-1570-2013	Martins, Carolina Castro/0000-0001-9072-3226; Martins, Carolina/0000-0001-9072-3226; Paiva, Saul Martins/0000-0002-3968-1638; PORDEUS, ISABELA A/0000-0002-5902-7481	CAPES (Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior); Fapemig (Fundacao de Amparo a Pesquisa do estado de Minas Gerais); CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico); PRPq/UFMG (Pro-Reitoria de Pesquisa da UFMG)	CAPES (Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fapemig (Fundacao de Amparo a Pesquisa do estado de Minas Gerais)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); PRPq/UFMG (Pro-Reitoria de Pesquisa da UFMG)	The institutes which provided us funding were: CAPES (Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior), Fapemig (Fundacao de Amparo a Pesquisa do estado de Minas Gerais), CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) and PRPq/UFMG (Pro-Reitoria de Pesquisa da UFMG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	al-Dashti A A, 1995, Community Dent Health, V12, P42; Al-Jewair Thikriat S, 2010, J Contemp Dent Pract, V11, P001; American Academy of Pediatric Dentistry, 2014, OR HLTH POL REF MAN; [Anonymous], 2009, ORAL HLTH ATLAS MAPP; Biljana M, 1999, STUD HEALTH TECHNOL, V68, P323; Borenstein M., 2009, INTRO META ANAL; Chaffee BW, 2014, ANN EPIDEMIOL, V24, P448, DOI 10.1016/j.annepidem.2014.01.013; Correa-Faria P, 2013, BRAZ ORAL RES, V27, P356, DOI 10.1590/S1806-83242013005000021; Declerck D, 2008, COMMUNITY DENT ORAL, V36, P168, DOI 10.1111/j.1600-0528.2007.00385.x; Deeks JJ., 2012, COCHRANE HDB SYSTEMA, P243; Du M, 2000, INT DENT J, V50, P385, DOI 10.1111/j.1875-595X.2000.tb00573.x; Du MQ, 2007, QUINTESSENCE INT, V38, P143; Dye Bruce A, 2015, NCHS Data Brief, P1; Eklund S, 1993, CALIBRATION EXAMINER; Graue E., 2010, EDUC DIG, V75, P28; Harris Rebecca, 2004, Community Dent Health, V21, P71; [Health Care Office Surveillance Registry on Health Health Ministry], 2010, SB BRAZ PROJ OR HLTH; Hermont AP, 2015, INT J ENV RES PUB HE, V12, P3133, DOI 10.3390/ijerph120303133; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT., 2012, COCHRANE HDB SYSTEMA, P187; Hong L, 2014, PEDIATR DENT, V36, P342; Horta B.L., 2013, LONG TERM EFFECTS BR; Katikireddi SV, 2015, J EPIDEMIOL COMMUN H, V69, P189, DOI 10.1136/jech-2014-204711; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003517.pub2; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Majorana A, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-45; Martin-Bautista E, 2010, PUBLIC HEALTH NUTR, V13, P1653, DOI 10.1017/S1368980010001850; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Moynihan PJ, 2014, J DENT RES, V93, P8, DOI 10.1177/0022034513508954; Narvai P, 2006, PAN AM J PUBLIC HLTH, V19; O'Brien M, 2008, J ADV NURS, V63, P397, DOI 10.1111/j.1365-2648.2008.04722.x; Perera PJ, 2014, ASIA PAC J CLIN NUTR, V23, P272, DOI 10.6133/apjcn.2014.23.2.13; Pierce CA, 2008, ORGAN RES METHODS, V11, P188, DOI 10.1177/1094428106296641; Pitts AT, 1927, LANCET, V209, P502; Plonka KA, 2013, CARIES RES, V47, P117, DOI 10.1159/000345073; Public Health England, 2013, NAT DENT EP PROGR EN; Qadri G, 2012, QUINTESSENCE INT, V43, P503; Ramos-Jorge J, 2014, COMMUNITY DENT ORAL, V42, P311, DOI 10.1111/cdoe.12086; Roberts G J, 1993, Community Dent Health, V10, P405; Roberts G J, 1994, Community Dent Health, V11, P38; Schwendicke F, 2015, J DENT RES, V94, P10, DOI 10.1177/0022034514557546; Sheiham A, 2006, BRIT DENT J, V201, P625, DOI 10.1038/sj.bdj.4814259; Skelly Andrea C, 2012, Evid Based Spine Care J, V3, P9, DOI 10.1055/s-0031-1298595; Tham R, 2015, ACTA PAEDIATR, V104, P62, DOI 10.1111/apa.13118; Tyagi R, 2008, J Indian Soc Pedod Prev Dent, V26, P153; Valaitis R, 2000, CAN J PUBLIC HEALTH, V91, P411, DOI 10.1007/BF03404819; Wells GA, NEWCASTLE OTTAWA SCA; World Health Organization, 1997, WHO OR HLTH SURV BAS, V4th; World Health Organization, 2003, GLOB STRAT INF YOUNG; World Health Organization, 2013, ORAL HLTH SURVEYS BA, V5th; Wulaerhan J, 2014, BMC ORAL HEALTH, V14, DOI 10.1186/1472-6831-14-136	51	66	73	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2015	10	11							e0142922	10.1371/journal.pone.0142922	http://dx.doi.org/10.1371/journal.pone.0142922			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW7CD	26579710	Green Submitted, Green Published, gold			2023-01-03	WOS:000365154600068
J	Tran, BX; Nguyen, LH; Phan, HTT; Latkin, CA				Bach Xuan Tran; Long Hoang Nguyen; Huong Thu Thi Phan; Latkin, Carl A.			Patient Satisfaction with Methadone Maintenance Treatment in Vietnam: A Comparison of Different Integrative-Service Delivery Models	PLOS ONE			English	Article							QUALITY-OF-LIFE; INTRAVENOUS-DRUG-USERS; COST-EFFECTIVENESS; PRIMARY-CARE; CLIENT SATISFACTION; ABUSE TREATMENT; INJECT DRUGS; HEALTH-CARE; HIV; HIV/AIDS	Background Patient satisfaction is an important component of quality in healthcare delivery. To inform the expansion of Methadone Maintenance Treatment (MMT) services in Vietnam, we examined the satisfaction of patients with regards to different services delivery models and identified its associated factors. Methods We interviewed 1,016 MMT patients at 5 clinics in Hanoi and Nam Dinh province. The modified SATIS instrument, a 10-item scale, was used to measure three dimensions: "Services quality and convenience", "Health workers' capacity and responsiveness" and "Inter-professional care". Results The average score was high across three SATIS dimensions. However, only one third of patients completely satisfied with general health services and treatment outcomes. Older age, higher education, having any problem in self-care and anxiety/depression were negatively associated with patient's satisfaction. Meanwhile, patients receiving MMT at clinics, where more comprehensive HIV and general health care services were available, were more likely to report a complete satisfaction. Conclusion Patients were highly satisfied with MMT services in Vietnam. However, treatment for drug users should go beyond methadone maintenance to address complicated health demands of drug users. Integrating MMT with comprehensive HIV and general health services together with improving the capacity of health workers and efficiency of services organisation to provide interconnected health care for drug users are critical for improving the outcomes of the MMT program.	[Bach Xuan Tran; Long Hoang Nguyen] Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi 100803, Vietnam; [Bach Xuan Tran; Latkin, Carl A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Long Hoang Nguyen] Vietnam Natl Univ, Sch Med & Pharm, Hanoi, Vietnam; [Huong Thu Thi Phan] Minist Hlth, Author HIV AIDS Control, Hanoi, Vietnam	Hanoi Medical University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Vietnam National University Hanoi	Tran, BX (corresponding author), Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi 100803, Vietnam.	bach@hma.edu.vn	Nguyen, Long/E-6145-2015	Nguyen, Long/0000-0003-1658-2394	Vietnam Authority of HIV/AIDS Control World Bank supported HIV Project; International AIDS Society; US National Institute of Drug Abuse; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI094189] Funding Source: NIH RePORTER	Vietnam Authority of HIV/AIDS Control World Bank supported HIV Project; International AIDS Society; US National Institute of Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by the Vietnam Authority of HIV/AIDS Control World Bank supported HIV Project. Dr. Bach Tran received a fellowship from the International AIDS Society and US National Institute of Drug Abuse. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aziz Z, 2015, J SUBST ABUSE TREAT, V53, P47, DOI 10.1016/j.jsat.2014.12.008; Tran BX, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0063-0; Tran BX, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-014-0640-z; Tran BX, 2013, B WORLD HEALTH ORGAN, V91, P475, DOI 10.2471/BLT.12.115147; Tran BX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051569; Tran BX, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-132; Tran BX, 2012, GLOB PUBLIC HEALTH, V7, P1080, DOI 10.1080/17441692.2012.736259; Tran BX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046680; Tran BX, 2012, QUAL LIFE RES, V21, P613, DOI 10.1007/s11136-011-9963-y; Tran BX, 2012, AIDS CARE, V24, P283, DOI 10.1080/09540121.2011.608420; Tran BX, 2011, AIDS CARE, V23, P1236, DOI 10.1080/09540121.2011.555749; Chow MYK, 2012, ASIA-PAC J PUBLIC HE, V24, P406, DOI 10.1177/1010539510384843; Control VAoHA, 2015, ANN REV HIV AIDS CON; Crow R, 2002, Health Technol Assess, V6, P1; de los Cobos JP, 2005, DRUG ALCOHOL DEPEN, V79, P405, DOI 10.1016/j.drugalcdep.2005.03.021; de los Cobos JP, 2004, DRUG ALCOHOL DEPEN, V73, P307, DOI 10.1016/j.drugalcdep.2003.11.001; DONOGHOE MC, 1992, BRIT J ADDICT, V87, P405; EQOL G, 2011, EQ 5D 5L US GUID BAS; Herman M, 1997, J ADDICT DIS, V16, P91, DOI 10.1300/J069v16n01_06; Hogan Beth, 2007, Health Mark Q, V24, P93, DOI 10.1080/07359680802125923; Jardine M, 2012, HARM REDUCT J, V9, DOI 10.1186/1477-7517-9-26; Kelly SM, 2010, AM J DRUG ALCOHOL AB, V36, P150, DOI 10.3109/00952991003736371; Madden A, 2008, DRUG ALCOHOL REV, V27, P671, DOI 10.1080/09595230801935706; Marchand K, 2015, J ADDICT MED, V9, P391, DOI 10.1097/ADM.0000000000000145; Marchand KI, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-174; McLellan AT, 1996, MILBANK Q, V74, P51, DOI 10.2307/3350433; Mitike G, 2002, ETHIOPIAN MED J, V40, P387; Nguyen Tam T M, 2012, Adv Prev Med, V2012, P732484, DOI 10.1155/2012/732484; OCONNOR PG, 1992, AM J MED, V93, P382, DOI 10.1016/0002-9343(92)90166-9; Olowookere Samuel Anu, 2012, J Int Assoc Physicians AIDS Care (Chic), V11, P188, DOI 10.1177/1545109711402214; SAMET JH, 1995, SUBST ABUS, V16, P131, DOI DOI 10.1080/08897079509444716; SELWYN PA, 1993, PUBLIC HEALTH REP, V108, P492; Simpson DD, 1997, J SUBST ABUSE TREAT, V14, P565, DOI 10.1016/S0740-5472(97)00181-5; Smith P., 2008, EUROPEAN OBSERVATORY; Stein MD, 2002, ADDICT BEHAV, V27, P727, DOI 10.1016/S0306-4603(01)00205-2; Tran BX, 2012, DRUG ALCOHOL DEPEN, V125, P260, DOI 10.1016/j.drugalcdep.2012.02.021; Trujols J, 2012, DRUG ALCOHOL DEPEN, V123, P41, DOI 10.1016/j.drugalcdep.2011.10.014; Trujols J, 2010, J CLIN PSYCHOPHARM, V30, P95, DOI 10.1097/JCP.0b013e3181c8b439; UMBRICHTSCHNEITER A, 1994, AM J PUBLIC HEALTH, V84, P207, DOI 10.2105/AJPH.84.2.207; van Beek I, 2007, INT J DRUG POLICY, V18, P329, DOI 10.1016/j.drugpo.2006.11.005; Doubova SV, 2009, SALUD PUBLICA MEXICO, V51, P231, DOI 10.1590/S0036-36342009000300014; World Health Organization Department of Mental Health and Substance Abuse Management of Substance Abuse, 2006, TREATM INJ DRUG US H; Zhang L, 2015, EUR J GASTROEN HEPAT, V27, P550, DOI 10.1097/MEG.0000000000000321; Zhang ZW, 2008, J HEALTH PSYCHOL, V13, P388, DOI 10.1177/1359105307088142	44	20	21	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2015	10	11							e0142644	10.1371/journal.pone.0142644	http://dx.doi.org/10.1371/journal.pone.0142644			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV7CT	26556036	Green Submitted, Green Published, gold			2023-01-03	WOS:000364430700148
J	Gomez, CE; Perdiguero, B; Garcia-Arriaza, J; Cepeda, V; Sanchez-Sorzano, CO; Mothe, B; Jimenez, JL; Munoz-Fernandez, MA; Gatell, JM; de Quiros, JCLB; Brander, C; Garcia, F; Esteban, M				Elena Gomez, Carmen; Perdiguero, Beatriz; Garcia-Arriaza, Juan; Cepeda, Victoria; Oscar Sanchez-Sorzano, Carlos; Mothe, Beatriz; Luis Jimenez, Jose; Angeles Munoz-Fernandez, Maria; Gatell, Jose M.; Bernaldo de Quiros, Juan Carlos Lopez; Brander, Christian; Garcia, Felipe; Esteban, Mariano			A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART	PLOS ONE			English	Article							VIRAL LOAD; HIV-1; SAFETY; IMMUNOGENICITY; GAG; IMMUNIZATION; VACCINES; CD4(+); REPLICATION; EFFICACY	Trial Design Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2: 1) to receive either 3 intramuscular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens) or placebo, followed by interruption of HAART. Methods The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were assayed by intracellular cytokine staining (ICS) in 22 volunteers pre-and post-vaccination. Results MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude, broadly directed and showed an enhanced polyfunctionality with a T effector memory (TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1-specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8(+) T cell polyfunctional responses to the MVA vector antigens that increase in magnitude after two and three booster doses. Conclusion MVA-B vaccination represents a feasible strategy to improve T cell responses in individuals with pre-existing HIV-1-specific immunity.	[Elena Gomez, Carmen; Perdiguero, Beatriz; Garcia-Arriaza, Juan; Cepeda, Victoria; Oscar Sanchez-Sorzano, Carlos; Esteban, Mariano] CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid, Spain; [Mothe, Beatriz; Brander, Christian] Autonomous Univ Barcelona, Hosp Univ Germans Trias & Pujol, IrsiCaixa HIVACAT, Badalona, Spain; [Luis Jimenez, Jose; Angeles Munoz-Fernandez, Maria; Bernaldo de Quiros, Juan Carlos Lopez] Hosp Univ Gregorio Maranon, Madrid, Spain; [Gatell, Jose M.; Garcia, Felipe] IDIBAPS, Hosp Clin HIVACAT, Barcelona, Spain; [Brander, Christian] ICREA, Barcelona, Spain; [Brander, Christian] Univ Vic & Cent Catalonia, Vic, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; General University Gregorio Maranon Hospital; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; ICREA; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC)	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid, Spain.	mesteban@cnb.csic.es	GARCIA-ARRIAZA, JUAN/Q-6243-2017; Jiménez, José Luis/AAK-6193-2020; Gatell, Jose M/ABC-3607-2020; Sorzano, Carlos Oscar S S./F-2639-2016; , Felipe/F-4242-2014; S. Sorzano, Carlos Oscar/ABE-4884-2021; Gomez, Carmen Elena/K-1940-2014; Esteban, Mariano/ABG-5375-2020; Perdiguero, Beatriz/K-6587-2017	GARCIA-ARRIAZA, JUAN/0000-0002-5167-5724; Jiménez, José Luis/0000-0001-6187-6223; Sorzano, Carlos Oscar S S./0000-0002-9473-283X; , Felipe/0000-0001-7658-5832; S. Sorzano, Carlos Oscar/0000-0002-9473-283X; Gomez, Carmen Elena/0000-0002-5414-7935; Esteban, Mariano/0000-0003-0846-2827; Perdiguero, Beatriz/0000-0001-6276-7766; Munoz-Fernandez/0000-0002-0813-4500; Mothe, Beatriz/0000-0001-9975-407X	Spanish government [SAF2008-02036, FIPSE-360731/09, SAF2012-39075, EC10-153, TRA-094, FIS PS09/01297]; Red SIDA [RD12-0017-0037, RD12-0017-0038]; HIVACAT program; ICREA Funding Source: Custom	Spanish government(Spanish GovernmentEuropean Commission); Red SIDA; HIVACAT program; ICREA(ICREA)	This work was supported by the Spanish government (SAF2008-02036, FIPSE-360731/09, SAF2012-39075, EC10-153, TRA-094, FIS PS09/01297), Red SIDA (RD12-0017-0037 and RD12-0017-0038) and the HIVACAT program.	Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Carcelain G, 2013, IMMUNOL REV, V254, P355, DOI 10.1111/imr.12083; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Dahabieh MS, 2015, ANNU REV MED, V66, P407, DOI 10.1146/annurev-med-092112-152941; De Crignis E, 2014, VIRUSES-BASEL, V6, P4581, DOI 10.3390/v6114581; Dorrell L, 2007, VACCINE, V25, P3277, DOI 10.1016/j.vaccine.2007.01.005; Dorrell L, 2006, J VIROL, V80, P4705, DOI 10.1128/JVI.80.10.4705-4716.2006; Gomez CE, 2013, EXPERT REV VACCINES, V12, P1395, DOI 10.1586/14760584.2013.845531; Gomez CE, 2011, J VIROL, V85, P11468, DOI 10.1128/JVI.05165-11; Emery S, 2007, HUM VACCINES, V3, P260, DOI 10.4161/hv.4627; Emery S, 2005, HUM VACCINES, V1, P232, DOI 10.4161/hv.1.6.2342; Garcia F, 2012, HUM VACC IMMUNOTHER, V8, P569, DOI 10.4161/hv.19555; Garcia F, 2011, VACCINE, V29, P8309, DOI 10.1016/j.vaccine.2011.08.098; Garcia-Arriaza J, 2012, VIRUS RES, V167, P391, DOI 10.1016/j.virusres.2012.05.020; Garcia-Arriaza J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012395; Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27; Gomez CE, 2007, VACCINE, V25, P2863, DOI 10.1016/j.vaccine.2006.09.090; Greenough TC, 2008, VACCINE, V26, P6883, DOI 10.1016/j.vaccine.2008.09.084; Harari A, 2012, EUR J IMMUNOL, V42, P3038, DOI 10.1002/eji.201242696; Harrer E, 2005, ANTIVIR THER, V10, P285; Hashimoto C, 2011, EXPERT OPIN DRUG DIS, V6, P1067, DOI 10.1517/17460441.2011.611129; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Howles S, 2010, VACCINE, V28, P7306, DOI 10.1016/j.vaccine.2010.08.077; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Kilby JM, 2006, J INFECT DIS, V194, P1672, DOI 10.1086/509508; Kutscher S, 2010, GENE THER, V17, P1372, DOI 10.1038/gt.2010.90; Levy Y, 2005, AIDS, V19, P279; Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016; Najera JL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011406; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Mothe B, 2015, J ANTIMICROB CHEMOTH, V70, P1833, DOI 10.1093/jac/dkv046; Noe A, 2005, J ANTIMICROB CHEMOTH, V55, P410, DOI 10.1093/jac/dki038; Ondondo BO, 2006, EUR J IMMUNOL, V36, P2585, DOI 10.1002/eji.200636508; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pantaleo G, 2013, CURR OPIN HIV AIDS, V8, P236, DOI 10.1097/COH.0b013e32835fd5cd; Ramirez LA, 2013, EXPERT OPIN BIOL TH, V13, P563, DOI 10.1517/14712598.2013.758709; Rasmussen TA, 2013, HUM VACC IMMUNOTHER, V9, P790, DOI 10.4161/hv.23202; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Sahu GK, 2015, AIDS RES HUM RETROV, V31, P25, DOI [10.1089/aid.2014.0194, 10.1089/AID.2014.0194]; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Streeck H, 2013, NAT MED, V19, P143, DOI 10.1038/nm.3054; Vanham G, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-72; Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006	46	16	20	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2015	10	11							e0141456	10.1371/journal.pone.0141456	http://dx.doi.org/10.1371/journal.pone.0141456			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV6RT	26544853	Green Published, gold, Green Submitted			2023-01-03	WOS:000364398700025
J	Huang, Q; Zhou, CH; Chen, X; Dong, B; Chen, SQ; Zhang, N; Liu, YW; Li, AR; Yao, MC; Miao, J; Li, Q; Wang, Z				Huang, Qiang; Zhou, Changhua; Chen, Xiao; Dong, Bing; Chen, Siqi; Zhang, Ning; Liu, Yawei; Li, Anrong; Yao, Meicun; Miao, Ji; Li, Qing; Wang, Zhong			Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib	PLOS ONE			English	Article							SIGNALING PATHWAYS; IN-VIVO; ANGIOGENESIS; APOPTOSIS	Patients have responded well to the multi-targeted tyrosine kinase inhibitor (TKI) Sunitinib in the clinic. But the severe toxic side effects associated with Sunitinib limit its therapeutic index. To improve the therapeutic index of Sunitinib, a prodrug strategy was employed to modify Sunitinib. The inactive prodrug AST-003 can be converted to Sunitinib in vitro and in vivo. Compared with Sunitinib, AST-003 has unique biochemical, cellular and pharmacokinetic properties with improved tolerability in mice and yield higher efficacy in tumor xenograft models. This prodrug strategy may constitute a novel paradigm to improve the therapeutic index of Sunitinib and other TKI or anti-angiogenesis drugs in general.	[Huang, Qiang; Zhou, Changhua; Chen, Xiao; Dong, Bing; Chen, Siqi; Yao, Meicun; Miao, Ji; Li, Qing; Wang, Zhong] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510275, Guangdong, Peoples R China; [Huang, Qiang; Zhou, Changhua; Dong, Bing; Chen, Siqi; Li, Qing; Wang, Zhong] Sun Yat Sen Univ, Ctr Cellular & Struct Biol, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, Ning] Peking Univ, Canc Hosp, Beijing Inst Canc Res, Beijing 100871, Peoples R China; [Liu, Yawei] Gen Staff Dept PLA, Hlth Div, Guard Bur, Beijing, Peoples R China; [Li, Anrong] Ascenta Pharmaceut, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Peking University	Li, Q (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510275, Guangdong, Peoples R China.	liqing66@mail.sysu.edu.cn; wangzh357@mail.sysue.edu.cn			Introduced Innovative R&D Team Leadership of Guangdong Province (P.R. China) [2011Y038]	Introduced Innovative R&D Team Leadership of Guangdong Province (P.R. China)	This work received financial support from the Introduced Innovative R&D Team Leadership of Guangdong Province (P.R. China) (2011Y038) to Qing Li and Zhong Wang. The funder provided support in the form of partial salaries for authors Miao J, Li Q, and Wang Z, and research materials. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Campbell MT, 2014, CLIN GENITOURIN CANC; Mena AC, 2010, ANTI-CANCER DRUG, V21, pS3, DOI 10.1097/01.cad.0000361534.44052.c5; Christensen JG, 2007, ANN ONCOL, V18, P3, DOI 10.1093/annonc/mdm408; Escudier B, 2012, ANN ONCOL, V23, P65, DOI 10.1093/annonc/mds227; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Faivre S, 2006, SEMIN ONCOL, V33, P407, DOI 10.1053/j.seminoncol.2006.04.005; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Haznedar JO, 2009, CANCER CHEMOTH PHARM, V64, P691, DOI 10.1007/s00280-008-0917-1; Huttunen KM, 2011, PHARMACOL REV, V63, P750, DOI 10.1124/pr.110.003459; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Jing S, 2012, PLOS ONE, V7, P1; Keith Ian Q, 2014, BMJ CASE REPORTS, V2014, P1; Kutach AK, 2010, CHEM BIOL DRUG DES, V76, P154, DOI 10.1111/j.1747-0285.2010.00993.x; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Massey PR, 2014, SUPPORT CARE CANC; Mendel DB, 2003, CLIN CANCER RES, V9, P327; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Schmid MC, 2007, CANCER LETT, V250, P1, DOI 10.1016/j.canlet.2006.09.002; Valle JW, 2014, CANCER TREAT REV, V40, P1230, DOI 10.1016/j.ctrv.2014.09.001; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Xin H, 2009, CANCER RES, V69, P2506, DOI 10.1158/0008-5472.CAN-08-4323	25	6	6	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2015	10	10							e0141395	10.1371/journal.pone.0141395	http://dx.doi.org/10.1371/journal.pone.0141395			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV0ED	26513662	gold, Green Published, Green Submitted			2023-01-03	WOS:000363920300035
J	Putman, SB; Brown, JL; Franklin, AD; Schneider, EC; Boisseau, NP; Asa, CS; Pukazhenthi, BS				Putman, Sarah B.; Brown, Janine L.; Franklin, Ashley D.; Schneider, Emily C.; Boisseau, Nicole P.; Asa, Cheryl S.; Pukazhenthi, Budhan S.			Characterization of Ovarian Steroid Patterns in Female African Lions (Panthera leo), and the Effects of Contraception on Reproductive Function	PLOS ONE			English	Article							GNRH ANALOG DESLORELIN; MELENGESTROL ACETATE; SEXUAL-BEHAVIOR; ESTROUS-CYCLE; ESTRUS; FELIDS; WILD; CAT; PROGESTERONE; SUPPRESSION	Because of poor reproduction after the lifting of an 8-year breeding moratorium, a biomedical survey of female lions in U.S. zoos was initiated in 2007. Fecal estrogen (FEM), progestagen (FPM) and glucocorticoid (FGM) metabolites were analyzed in samples collected 3-4 times per wk from 28 lions at 17 facilities (0.9-13.8 yr of age) for 4 mo-3.5 yr and body weights were obtained similar to monthly from 17 animals at eight facilities (0.0-3.0 yr of age). Based on FEM, estrous cycle length averaged 17.5 +/- 0.4 d in duration, with estrus lasting 4.4 +/- 0.2 d. All but one female exhibited waves of estrogenic activity indicative of follicular activity; however, not all females expressed estrous behaviors (73%), suggesting silent estrus was common. Female lions experienced puberty earlier than expected; waves of estrogenic activity were observed as young as 1.1 yr of age, which may be related to a faster growth rate of captive vs. wild lions. Mean gestation length was 109.5 +/- 1.0 d, whereas the non-pregnant luteal phase was less than half (46.0 +/- 1.2 d). Non-mating induced increases in FPM were observed in 33% of females housed without a male, consistent with spontaneous ovulation. A number of study animals had been contracepted, and the return to cyclicity after treatment withdrawal, while variable, was similar to 4.0 yr and longer than the 1-yr expected efficacy, especially for those implanted with Suprelorin. For FGM, there were no differences in overall, baseline or peak mean concentrations among the age groups or across seasons, nor were there any relationships between reproductive parameters and FGM concentrations. Overall, results suggest that poor reproduction in lions after the breeding moratorium was not related to altered adrenal or ovarian steroid activity, but for some females may have been a consequence of individual institutions' management decisions.	[Putman, Sarah B.; Brown, Janine L.; Franklin, Ashley D.; Schneider, Emily C.; Boisseau, Nicole P.; Pukazhenthi, Budhan S.] Smithsonian Conservat Biol Inst, Front Royal, VA 22630 USA; [Putman, Sarah B.] George Mason Univ, Fairfax, VA 22030 USA; [Franklin, Ashley D.] Point Defiance Zoo & Aquarium, Tacoma, WA USA; [Schneider, Emily C.] Shady Grove Fertil, Rockville, MD USA; [Asa, Cheryl S.] AZA Wildlife Contracept Ctr, St Louis, MO USA	Smithsonian Institution; Smithsonian National Zoological Park & Conservation Biology Institute; George Mason University	Pukazhenthi, BS (corresponding author), Smithsonian Conservat Biol Inst, Front Royal, VA 22630 USA.	pukazhenthib@si.edu	Franklin, Ashley D/J-3069-2015	Franklin, Ashley D/0000-0002-0818-5156; Pukazhenthi, Budhan/0000-0003-4657-2023	ASLAN Fund National Zoo; Ritz Carlton	ASLAN Fund National Zoo; Ritz Carlton	This work was supported by ASLAN Fund National Zoo and Ritz Carlton. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackermann CL, 2012, THERIOGENOLOGY, V78, P817, DOI 10.1016/j.theriogenology.2012.03.030; ANDERSON LH, 1994, J ANIM SCI, V72, P2955, DOI 10.2527/1994.72112955x; Asa C, 2012, REPROD DOMEST ANIM, V47, P377, DOI 10.1111/rda.12004; Asa C.S., 2005, WILDLIFE CONTRACEPTI; Asa Cheryl S., 2005, P29; Asa Cheryl S., 2005, P83; Awasthi MK, 2007, ANIM REPROD SCI, V99, P258, DOI 10.1016/j.anireprosci.2006.05.014; Axner E, 2008, THERIOGENOLOGY, V70, P186, DOI 10.1016/j.theriogenology.2008.03.003; AZA Lion Species Survival Plan, 2012, AZA LION SPEC SURV P; Bauer H, 2004, ORYX, V38, P26, DOI 10.1017/S0030605304000055; Bauer H, 2003, CR BIOL, V326, pS112, DOI 10.1016/S1631-0691(03)00047-7; Beijerink NJ, 2007, DOMEST ANIM ENDOCRIN, V32, P63, DOI 10.1016/j.domaniend.2005.12.008; BERTRAM BCR, 1975, J ZOOL, V177, P463; Bertschinger HJ, 2008, WILDLIFE RES, V35, P525, DOI 10.1071/WR07141; BONNEY RC, 1981, J REPROD FERTIL, V63, P523; BOULANOUAR B, 1995, ANIM REPROD SCI, V40, P229, DOI 10.1016/0378-4320(95)01420-5; Briggs MB, 1990, ENDOCRINE PROFILES E; Brown JL, 2011, ANIM REPROD SCI, V124, P155, DOI 10.1016/j.anireprosci.2010.08.024; Brown JL, 1996, J REPROD FERTIL, V106, P337, DOI 10.1530/jrf.0.1060337; BROWN JL, 1995, BIOL REPROD, V53, P93, DOI 10.1095/biolreprod53.1.93; BROWN JL, 1993, J REPROD FERTIL, V97, P107; BROWN JL, 1994, BIOL REPROD, V51, P776, DOI 10.1095/biolreprod51.4.776; Cetin Y, 2013, REPROD DOMEST ANIM, V48, P195, DOI 10.1111/j.1439-0531.2012.02128.x; Chardonnet P., 2002, CONSERVATION AFRICAN; CHASTAIN CB, 1981, AM J VET RES, V42, P2029; Connell EB, 1998, ENCY REPROD, V3, P574; Cooper J., 1942, COMPAR PSYCHO MONOG, V17, P1; Crosier AE, 2011, BIOL REPROD, V85, P243, DOI 10.1095/biolreprod.110.089417; Daigle C. L., 2015, International Zoo Yearbook, V49, P198, DOI 10.1111/izy.12073; DICZFALUSY E, 1968, AM J OBSTET GYNECOL, V100, P136, DOI 10.1016/S0002-9378(15)33651-6; Eaton R. L., 1971, INT ZOO YB, V11, P198; Fazio J., 2010, BEHAV ASSESSMENT CLO; GERALL AA, 1973, PHYSIOL BEHAV, V10, P225, DOI 10.1016/0031-9384(73)90302-8; Goericke-Pesch S, 2013, THERIOGENOLOGY, V79, P640, DOI 10.1016/j.theriogenology.2012.11.018; Graham LH, 2006, GEN COMP ENDOCR, V147, P362, DOI 10.1016/j.ygcen.2006.02.008; GRAHAM LH, 1995, ZOO BIOL, V14, P223, DOI 10.1002/zoo.1430140304; Graham LH, 1996, ZOO BIOL, V15, P71, DOI 10.1002/(SICI)1098-2361(1996)15:1<71::AID-ZOO7>3.0.CO;2-9; Hayward MW, 2007, BIOL CONSERV, V139, P219, DOI 10.1016/j.biocon.2007.06.018; Herne B., 1999, LLC; IUCN (International Union for the Conservation of Nature and Natural Resources), 2022, ZOOL, Patent No. [eT158085A760192, 158085760192]; Kinoshita K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019314; Klein TA, 1998, ENCY REPROD, V4, P127; Lagendijk DDG, 2008, ENVIRON MANAGE, V42, P971, DOI 10.1007/s00267-008-9204-5; Lehmann MB, 2008, AFR ZOOL, V43, P230, DOI 10.3377/1562-7020-43.2.230; Levasseur M., 1980, REPROD LIFE CYCLES, P130; Macdonald KA, 2005, J DAIRY SCI, V88, P3363, DOI 10.3168/jds.S0022-0302(05)73020-4; Magni P, 2003, ENCY HORMONES, V2, P572; Mann M, 1997, ARCH INTERN MED, V157, P1651, DOI 10.1001/archinte.157.15.1651; MARKERKRAUS L, 1993, ZOO BIOL, V12, P5, DOI 10.1002/zoo.1430120104; MCCLINTOCK MK, 1971, NATURE, V229, P244, DOI 10.1038/229244a0; MELLEN JD, 1991, ZOO BIOL, V10, P95, DOI 10.1002/zoo.1430100202; Monfort SL, 2003, REPROD SCI INTEGRATE; Moreira N, 2001, ZOO BIOL, V20, P103, DOI 10.1002/zoo.1010; Mostl E, 1993, J Reprod Fertil Suppl, V47, P540; MUELLER CC, 1979, BIOL REPROD, V21, P1099, DOI 10.1095/biolreprod21.5.1099; Munson L, 2002, VET PATHOL, V39, P419, DOI 10.1354/vp.39-4-419; Munson L, 2001, J REP FER S, P269; Munson L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002545; Naing KK, 1999, CANCER, V86, P1044, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1044::AID-CNCR21>3.0.CO;2-C; Norris DO., 2007, VERTEBRATE ENDOCRINO, V4; ORFORD HJL, 1988, J ZOOL, V216, P717, DOI 10.1111/j.1469-7998.1988.tb02467.x; Packer C, 1998, NATURE, V392, P807, DOI 10.1038/33910; PACKER C, 1983, ANIM BEHAV, V31, P334, DOI 10.1016/S0003-3472(83)80051-7; Palme R, 2005, ANN NY ACAD SCI, V1040, P162, DOI 10.1196/annals.1327.021; Panthera Inc., 2013, LIONS PANTHERA LEADE; Pavlik EJ, 2000, GYNECOL ONCOL, V77, P410, DOI 10.1006/gyno.2000.5783; Pfaff SE, 2014, N AM REGIONAL AFRICA; Pope CE, 2006, THERIOGENOLOGY, V66, P59, DOI 10.1016/j.theriogenology.2006.03.014; Pukazhenthi BS, 2004, REPROD FERT DEVELOP, V16, P33, DOI 10.1071/RD03076; Ricklefs RE, 2007, ECOL LETT, V10, P867, DOI 10.1111/j.1461-0248.2007.01085.x; Riggio J, 2013, BIODIVERS CONSERV, V22, P17, DOI 10.1007/s10531-012-0381-4; RoelkeParker ME, 1996, NATURE, V379, P441, DOI 10.1038/379441a0; Roelofs JB, 2005, THERIOGENOLOGY, V64, P1690, DOI 10.1016/j.theriogenology.2005.04.004; Rudnai J, 1973, E AFR WILDL J, V11, P214; SADLEIR RMF, 1966, J REPROD FERTIL, V12, P411; Saltzman W, 2006, GEN COMP ENDOCR, V149, P90, DOI 10.1016/j.ygcen.2006.05.007; Sankhala K. S., 1967, International Zoo Yearbook, V7, P133, DOI 10.1111/j.1748-1090.1967.tb00354.x; Santymire RM, 2011, ANIM REPROD SCI, V128, P60, DOI 10.1016/j.anireprosci.2011.09.001; Scarlata CD, 2011, GEN COMP ENDOCR, V171, P373, DOI 10.1016/j.ygcen.2011.03.002; Schaller G. B., 1972, SERENGETI LION; SCHMIDT AM, 1979, J REPROD FERTIL, V57, P267, DOI 10.1530/jrf.0.0570267; SCHMIDT PM, 1983, BIOL REPROD, V28, P657, DOI 10.1095/biolreprod28.3.657; Schook MW, 2013, BIOL REPROD, DOI [10.1095/biolreprod.113.110122, DOI 10.1095/BI0LREPR0D.113.110122]; SCHRAMM RD, 1994, ZOO BIOL, V13, P301, DOI 10.1002/zoo.1430130403; Schwarzenberger F, 1996, ANIM REPROD SCI, V42, P515, DOI 10.1016/0378-4320(96)01561-8; SEAL US, 1976, J ZOO ANIM MED, V7, P12, DOI 10.2307/20094382; SELMAN PJ, 1994, EUR J ENDOCRINOL, V131, P422, DOI 10.1530/eje.0.1310422; Shoemaker Alan H., 1997, International Zoo Yearbook, V35, P120, DOI 10.1111/j.1748-1090.1997.tb01200.x; Smuts G. L., 1982, LION; SMUTS GL, 1978, CARNIVORE, V1, P17; SMUTS GL, 1980, J ZOOL, V190, P365; Stabenfeldt G. H., 1991, Feline husbandry: diseases and management in the multiple-cat environment., P129; Staley AM, 2007, J COMP PHYSIOL B, V177, P609, DOI 10.1007/s00360-007-0159-2; Steinman KJ, 2012, GEN COMP ENDOCR, V175, P389, DOI 10.1016/j.ygcen.2011.11.008; Stewart RA, 2010, GEN COMP ENDOCR, V166, P409, DOI 10.1016/j.ygcen.2009.12.016; Steyn TJ, 1951, FAUNA FLORA, V2, P37; Toydemir TSF, 2012, THERIOGENOLOGY, V77, P662, DOI 10.1016/j.theriogenology.2011.07.046; Tummers B., 2006, DATA THIEF; van Dorsser FJD, 2007, REPROD FERT DEVELOP, V19, P822, DOI 10.1071/RD07053; VERHAGE HG, 1976, BIOL REPROD, V14, P579, DOI 10.1095/biolreprod14.5.579; Wielebnowski N, 1998, ZOO BIOL, V17, P193, DOI 10.1002/(SICI)1098-2361(1998)17:3<193::AID-ZOO4>3.0.CO;2-4; Wildt D., 2010, BIOL CONSERVATION WI, P217; Wildt David E., 1997, International Zoo Yearbook, V35, P164, DOI 10.1111/j.1748-1090.1997.tb01207.x; WILDT DE, 1981, BIOL REPROD, V24, P217, DOI 10.1095/biolreprod24.1.217; Young KM, 2004, GEN COMP ENDOCR, V137, P148, DOI 10.1016/j.ygcen.2004.02.016; ZIMBELMAN RG, 1966, J REPROD FERTIL, V11, P193, DOI 10.1530/jrf.0.0110193	106	20	20	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2015	10	10							e0140373	10.1371/journal.pone.0140373	http://dx.doi.org/10.1371/journal.pone.0140373			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT6ZJ	26460849	Green Published, Green Submitted, gold			2023-01-03	WOS:000362962300085
J	Homer, CSE; Malata, A; ten Hoope-Bender, P				Homer, Caroline S. E.; Malata, Address; ten Hoope-Bender, Petra			Supporting women, families, and care providers after stillbirths	LANCET			English	Editorial Material							MIDWIFERY; HEALTH		[Homer, Caroline S. E.] Univ Technol Sydney, Ctr Midwifery Child & Family Hlth, Sydney, NSW 2007, Australia; [Malata, Address] Univ Malawi, Kamuzu Coll Nursing, Lilongwe, Malawi; [Malata, Address] Int Confederat Midwives, The Hague, Netherlands	University of Technology Sydney; University of Malawi	Homer, CSE (corresponding author), Univ Technol Sydney, Ctr Midwifery Child & Family Hlth, Sydney, NSW 2007, Australia.	caroline.homer@uts.edu.au	Homer, Caroline/J-2101-2014	Homer, Caroline/0000-0002-7454-3011				Darmstadt GL, 2011, LANCET, V377, P1550, DOI 10.1016/S0140-6736(11)60099-8; Flenady V, 2014, BJOG-INT J OBSTET GY, V121, P137, DOI 10.1111/1471-0528.13009; Flenady V, 2016, LANCET, V387, P691, DOI 10.1016/S0140-6736(15)01020-X; Froen JF, 2016, LANCET; Heazell AEP, 2016, LANCET, V387, P604, DOI 10.1016/S0140-6736(15)00836-3; Hennegan JM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008616; Homer CSE, 2014, LANCET, V384, P1146, DOI 10.1016/S0140-6736(14)60790-X; Kinney MV, 2016, LANCET; Lawn JE, 2016, LANCET; Partnership for Maternal Newborn and Child Health, 2011, GLOB REV KEY INT REL; Peters MDJ, 2015, WOMEN BIRTH, V28, P272, DOI 10.1016/j.wombi.2015.07.003; Renfrew MJ, 2014, LANCET, V384, P1129, DOI 10.1016/S0140-6736(14)60789-3; Smith R, 2011, MIDIRS MIDWIFERY DIG, V21, P19; ten Hoope-Bender P, 2014, LANCET, V384, P1226, DOI 10.1016/S0140-6736(14)60930-2; Van Lerberghe W, 2014, LANCET, V384, P1215, DOI 10.1016/S0140-6736(14)60919-3	15	21	25	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	2016	387	10018					516	+		10.1016/S0140-6736(15)01278-7	http://dx.doi.org/10.1016/S0140-6736(15)01278-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DD3PV	26794072	Green Submitted			2023-01-03	WOS:000369835800012
J	Cooper, JE; McCann, CJ; Natarajan, D; Choudhury, S; Boesmans, W; Delalande, JM; Vanden Berghe, P; Burns, AJ; Thapar, N				Cooper, Julie E.; McCann, Conor J.; Natarajan, Dipa; Choudhury, Shanas; Boesmans, Werend; Delalande, Jean-Marie; Vanden Berghe, Pieter; Burns, Alan J.; Thapar, Nikhil			In Vivo Transplantation of Enteric Neural Crest Cells into Mouse Gut; Engraftment, Functional Integration and Long-Term Safety	PLOS ONE			English	Article							SLOW-TRANSIT CONSTIPATION; NERVOUS-SYSTEM; HIRSCHSPRUNG DISEASE; STEM-CELLS; GASTROINTESTINAL-TRACT; INTERSTITIAL-CELLS; PRECURSOR CELLS; IMAGE-ANALYSIS; GLIAL-CELLS; NEURONS	Objectives Enteric neuropathies are severe gastrointestinal disorders with unsatisfactory outcomes. We aimed to investigate the potential of enteric neural stem cell therapy approaches for such disorders by transplanting mouse enteric neural crest cells (ENCCs) into ganglionic and aganglionic mouse gut in vivo and analysing functional integration and long-term safety. Design Neurospheres generated from yellow fluorescent protein (YFP) expressing ENCCs selected from postnatal Wnt1-cre; R26R-YFP/YFP murine gut were transplanted into ganglionic hindgut of wild-type littermates or aganglionic hindgut of Ednrb(tm1Ywa) mice (lacking functional endothelin receptor type-B). Intestines were then assessed for ENCC integration and differentiation using immunohistochemistry, cell function using calcium imaging, and long-term safety using PCR to detect off-target YFP expression. Results YFP+ ENCCs engrafted, proliferated and differentiated into enteric neurons and glia within recipient ganglionic gut. Transplanted cells and their projections spread along the endogenous myenteric plexus to form branching networks. Electrical point stimulation of endogenous nerve fibres resulted in calcium transients (F/F0 = 1.16 +/- 0.01; 43 cells, n = 6) in YFP+ transplanted ENCCs (abolished with TTX). Long-term follow-up (24 months) showed transplanted ENCCs did not give rise to tumours or spread to other organs (PCR negative in extraintestinal sites). In aganglionic gut ENCCs similarly spread and differentiated to form neuronal and glial networks with projections closely associated with endogenous neural networks of the transition zone. Conclusions Transplanted ENCCs successfully engrafted into recipient ganglionic and aganglionic gut showing appropriate spread, localisation and, importantly, functional integration without any long-term safety issues. This study provides key support for the development and use of enteric neural stem cell therapies.	[Cooper, Julie E.; McCann, Conor J.; Natarajan, Dipa; Choudhury, Shanas; Delalande, Jean-Marie; Burns, Alan J.; Thapar, Nikhil] UCL Inst Child Hlth, Stem Cells & Regenerat Med, 30 Guilford St, London, England; [Boesmans, Werend; Vanden Berghe, Pieter] Univ Leuven, Dept Clin & Expt Med, Translat Res Ctr GastroIntestinal Disorders, Lab Enter NeuroSci, Leuven, Belgium; [Delalande, Jean-Marie] Univ London, Barts & London Sch Med & Dent, Ctr Digest Dis, Blizard Bldg, London, England; [Burns, Alan J.] Erasmus MC Univ, Med Ctr, Dept Clin Genet, Rotterdam, Netherlands; [Thapar, Nikhil] Great Ormond St Hosp NHS Fdn Trust, Dept Gastroenterol, Great Ormond St, London, England	University of London; University College London; KU Leuven; University of London; Queen Mary University London; Erasmus University Rotterdam; Erasmus MC; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Burns, AJ; Thapar, N (corresponding author), UCL Inst Child Hlth, Stem Cells & Regenerat Med, 30 Guilford St, London, England.; Burns, AJ (corresponding author), Erasmus MC Univ, Med Ctr, Dept Clin Genet, Rotterdam, Netherlands.; Thapar, N (corresponding author), Great Ormond St Hosp NHS Fdn Trust, Dept Gastroenterol, Great Ormond St, London, England.	n.thapar@ucl.ac.uk; alan.burns@ucl.ac.uk	Burns, Alan/AAC-1266-2022; Burns, Alan J/C-4988-2008	Burns, Alan/0000-0002-1725-1071; Boesmans, Werend/0000-0002-2426-0451; Vanden Berghe, Pieter/0000-0002-0009-2094; McCann, Conor/0000-0002-9324-5984	Great Ormond Street Children's Charity (GOSHCC); GOSHCC grant; Medical Research Council [G0800973]; Fonds Wetenschappelijk Onderzoek [G.0501.10]; Bijzonder Onderzoeksfonds [OT 10/046]; National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust; University College London; MRC [G0800973] Funding Source: UKRI; Great Ormond Street Hospital Childrens Charity [V1258] Funding Source: researchfish	Great Ormond Street Children's Charity (GOSHCC); GOSHCC grant; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Fonds Wetenschappelijk Onderzoek(FWO); Bijzonder Onderzoeksfonds; National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust; University College London(General Electric); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Great Ormond Street Hospital Childrens Charity	NT is supported by Great Ormond Street Children's Charity (GOSHCC). JC, DN, CM and JMD are funded through a GOSHCC grant. JC was part-funded by the Medical Research Council (G0800973). PVB is supported by Fonds Wetenschappelijk Onderzoek (G.0501.10) and Bijzonder Onderzoeksfonds (OT 10/046). WB is a post-doctoral fellow of the Fonds Wetenschappelijk Onderzoek. The work was supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Almond S, 2007, GUT, V56, P489, DOI 10.1136/gut.2006.094565; Amiel J, 2008, J MED GENET, V45, P1, DOI 10.1136/jmg.2007.053959; Belkind-Gerson J, 2013, NEUROGASTROENT MOTIL, V25, P61, DOI 10.1111/nmo.12015; Binder E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119467; Boesmans W, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00183; Bondurand N, 2006, DEVELOPMENT, V133, P2075, DOI 10.1242/dev.02375; Bondurand N, 2003, DEVELOPMENT, V130, P6387, DOI 10.1242/dev.00857; Burns AJ, 2006, NEUROGASTROENT MOTIL, V18, P876, DOI 10.1111/j.1365-2982.2006.00806.x; Burns AJ, 2005, INT J DEV BIOL, V49, P143, DOI 10.1387/ijdb.041935ab; Burns AJ, 2014, NAT REV GASTRO HEPAT, V11, P317, DOI 10.1038/nrgastro.2013.226; Chuenkova MV, 2011, ADV PARASIT, V76, P195, DOI 10.1016/B978-0-12-385895-5.00009-8; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; De Giorgio R, 2004, NEUROGASTROENT MOTIL, V16, P515, DOI 10.1111/j.1365-2982.2004.00538.x; Dettmann HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097792; Dickson EJ, 2010, AM J PHYSIOL-GASTR L, V298, pG222, DOI 10.1152/ajpgi.00399.2009; Druckenbrod NR, 2005, DEV BIOL, V287, P125, DOI 10.1016/j.ydbio.2005.08.040; Facer P, 2001, BRIT J SURG, V88, P545, DOI 10.1046/j.1365-2168.2001.01731.x; Findlay Q, 2014, AM J PHYSIOL-GASTR L, V307, pG741, DOI 10.1152/ajpgi.00225.2014; FOX DA, 1983, J PHARMACOL EXP THER, V227, P538; Furness JB, 2006, AUTON NEUROSCI-BASIC, V125, P81, DOI 10.1016/j.autneu.2006.01.007; Geramizadeh B, 2009, HEPATO-GASTROENTEROL, V56, P1670; Ghoshal UC, 2012, WORLD J GASTROENTERO, V18, P3050, DOI 10.3748/wjg.v18.i24.3050; Giorgio V, 2013, NEUROGASTROENT MOTIL, V25, P70, DOI 10.1111/nmo.12016; Goto K, 2016, J PHYSIOL SCI, V66, P67, DOI 10.1007/s12576-015-0396-1; Hagl C, 2013, NEUROGASTROENT MOTIL, V25, DOI 10.1111/nmo.12119; Hao MM, 2011, J NEUROSCI, V31, P15352, DOI 10.1523/JNEUROSCI.3053-11.2011; Hetz S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093605; Hotta R, 2010, NEUROGASTROENT MOTIL, V22, DOI 10.1111/j.1365-2982.2009.01411.x; Hotta R, 2013, J CLIN INVEST, V123, P1182, DOI 10.1172/JCI65963; Hotta Ryo, 2011, J Pediatr Gastroenterol Nutr, V53 Suppl 2, pS43; Hotta R, 2011, CURR OPIN PHARMACOL, V11, P617, DOI 10.1016/j.coph.2011.09.004; KAPUR RP, 1992, DEVELOPMENT, V116, P167; Kwok CKM, 2013, J PEDIATR SURG, V48, P619, DOI 10.1016/j.jpedsurg.2012.08.026; Laranjeira C, 2011, J CLIN INVEST, V121, P3412, DOI 10.1172/JCI58200; Le Douarin N., 1999, NEURAL CREST, V2nd ed.; Lindley RM, 2008, GASTROENTEROLOGY, V135, P205, DOI 10.1053/j.gastro.2008.03.035; Lindley RM, 2009, J PEDIATR SURG, V44, P1249, DOI 10.1016/j.jpedsurg.2009.02.048; McKeown SJ, 2013, WIRES DEV BIOL, V2, P113, DOI 10.1002/wdev.57; Metzger M, 2009, GASTROENTEROLOGY, V137, P2063, DOI 10.1053/j.gastro.2009.06.038; Metzger M, 2009, GASTROENTEROLOGY, V136, P2214, DOI 10.1053/j.gastro.2009.02.048; Nishikawa R, 2015, CYTOTECHNOLOGY, V67, P661, DOI 10.1007/s10616-014-9754-8; Rauch U, 2006, INT J COLORECTAL DIS, V21, P554, DOI 10.1007/s00384-005-0051-z; Sasselli V, 2012, DEV BIOL, V366, P64, DOI 10.1016/j.ydbio.2012.01.012; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Stamp LA, 2015, J NEUROGASTROENTEROL, V21, P552, DOI 10.5056/jnm15079; Takahashi T, 2003, J GASTROENTEROL, V38, P421, DOI 10.1007/s00535-003-1094-y; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; Wagner JP, 2014, J PEDIATR SURG, V49, P1809, DOI 10.1016/j.jpedsurg.2014.09.023; Wagner JP, 2014, J PEDIATR SURG, V49, P1319, DOI 10.1016/j.jpedsurg.2014.01.061; Wedel T, 2002, GASTROENTEROLOGY, V123, P1459, DOI 10.1053/gast.2002.36600	52	31	31	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2016	11	1							e0147989	10.1371/journal.pone.0147989	http://dx.doi.org/10.1371/journal.pone.0147989			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9GH	26824433	Green Published, gold			2023-01-03	WOS:000369528600084
J	Alford, DP				Alford, Daniel P.			Opioid Prescribing for Chronic Pain - Achieving the Right Balance through Education	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MANAGEMENT		[Alford, Daniel P.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Alford, Daniel P.] Boston Med Ctr, Boston, MA USA	Boston University; Boston Medical Center	Alford, DP (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.; Alford, DP (corresponding author), Boston Med Ctr, Boston, MA USA.							Alford DP, 2015, PAIN MED; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Fishman SM, 2013, PAIN MED, V14, P971, DOI 10.1111/pme.12107; Nicolaidis C, 2011, PAIN MED, V12, P890, DOI 10.1111/j.1526-4637.2011.01117.x	5	63	64	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 28	2016	374	4					301	303		10.1056/NEJMp1512932	http://dx.doi.org/10.1056/NEJMp1512932			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DB8IJ	26816007	Bronze			2023-01-03	WOS:000368760100001
J	Bucher, HC; Achermann, R; Stohler, N; Meier, CR				Bucher, Heiner C.; Achermann, Rita; Stohler, Nadja; Meier, Christoph R.			Surveillance of Physicians Causing Potential Drug-Drug Interactions in Ambulatory Care: A Pilot Study in Switzerland	PLOS ONE			English	Article							PATIENT SAFETY; HEALTH-CARE; PHARMACIES; SUPPORT; RATES	Objectives We analysed potential drug-drug interactions (DDI) in ambulatory care in Switzerland based on claims data from three large health insurers in 2010 to identify physicians with peculiar prescription behaviour differing from peers of the same specialty. Methods We analysed contraindicated or potentially contraindicated DDI from the national drug formulary and calculated for each physician the ratios of the number of patients with a potential DDI divided by the number of patients at risk and used a zero inflated binomial distribution to correct for the inflated number of observations with no DDI. We then calculated the probability that the number of caused potential DDI of physicians was unlikely (p-value < 0.05 and >= 0.01) and very unlikely (p-value <0.01) to be due to chance. Results Of 1'607'233 females and 1'525'307 males 1.3% and 1.2% were exposed to at least one potential DDI during 12 months. When analysing the 40 most common DDI, 598 and 416 of 18,297 physicians (3.3% and 2.3%) were causing potential DDI in a frequency unlikely (p<0.05 and p >= 0.01) and very unlikely (p<0.01) to be explained by chance. Patients cared by general practitioners and cardiologists had the lowest probability (0.20 and 0.26) for not being exposed to DDI. Conclusions Contraindicated or potentially contraindicated DDI are frequent in ambulatory care in Switzerland, with a small proportion of physicians causing potential DDI in a frequency that is very unlikely to be explained by chance when compared to peers of the same specialty.	[Bucher, Heiner C.; Achermann, Rita] Univ Basel Hosp, Dept Clin Res, Basel Inst Clin Epidemiol & Biostat, CH-4031 Basel, Switzerland; [Stohler, Nadja; Meier, Christoph R.] Univ Basel, Dept Pharmaceut Sci, Inst Clin Pharm & Epidemiol, Basel, Switzerland; [Stohler, Nadja; Meier, Christoph R.] Univ Basel Hosp, Hosp Pharm, CH-4031 Basel, Switzerland	University of Basel; University of Basel; University of Basel	Bucher, HC (corresponding author), Univ Basel Hosp, Dept Clin Res, Basel Inst Clin Epidemiol & Biostat, CH-4031 Basel, Switzerland.	heiner.bucher@usb.ch			Swiss Medical Association (FMH); Santesuisse; Gottfried and Julia Bangerter-Rhyner-Foundation	Swiss Medical Association (FMH); Santesuisse; Gottfried and Julia Bangerter-Rhyner-Foundation	This study was supported by a grant from the Swiss Medical Association (FMH) and Santesuisse. The Basel Institute for Clinical Epidemiology has been supported by unrestricted research grants by Santesuisse and the Gottfried and Julia Bangerter-Rhyner-Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by a grant from the Swiss Medical Association (FMH) and Santesuisse. The Basel Institute for Clinical Epidemiology has been supported by unrestricted research grants by Santesuisse and the Gottfried and Julia Bangerter-Rhyner-Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achermann R., 2006, ABRECHNUNGSEFFEKTE B; Becker ML, 2007, PHARMACOEPIDEM DR S, V16, P641, DOI 10.1002/pds.1351; Bjerrum L, 2003, SCAND J PRIM HEALTH, V21, P153, DOI 10.1080/02813430310001806; Hammerlein A, 2007, ANN PHARMACOTHER, V41, P1825, DOI 10.1345/aph.1K207; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Johnell K, 2008, SCAND J PRIM HEALTH, V26, P86, DOI 10.1080/02813430802022196; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Merlo J, 2001, BRIT MED J, V323, P427, DOI 10.1136/bmj.323.7310.427; Solberg LI, 2004, AM J MANAG CARE, V10, P753; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Steele AW, 2005, PLOS MED, V2, P864, DOI 10.1371/journal.pmed.0020255; Suzuki Y, 2015, BIOL PHARM BULL, V38, P680, DOI 10.1248/bpb.b14-00191; Tamblyn R, 2003, CAN MED ASSOC J, V169, P549; Tanskanen A, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0140-z; VGAM: Vector Generalized Linear and Additive Models, 2014, VGAM VECTOR GEN LINE; Vonbach P., 2007, THESIS U BASEL; Weingart SN, 2009, ARCH INTERN MED, V169, P1465, DOI 10.1001/archinternmed.2009.252; Wolfstadt JI, 2008, J GEN INTERN MED, V23, P451, DOI 10.1007/s11606-008-0504-5	18	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147606	10.1371/journal.pone.0147606	http://dx.doi.org/10.1371/journal.pone.0147606			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26808430	Green Submitted, Green Published, gold			2023-01-03	WOS:000369527800147
J	Rune, I; Rolin, B; Larsen, C; Nielsen, DS; Kanter, JE; Bornfeldt, KE; Lykkesfeldt, J; Buschard, K; Kirk, RK; Christoffersen, B; Fels, JJ; Josefsen, K; Kihl, P; Hansen, AK				Rune, Ida; Rolin, Bidda; Larsen, Christian; Nielsen, Dennis Sandris; Kanter, Jenny E.; Bornfeldt, Karin E.; Lykkesfeldt, Jens; Buschard, Karsten; Kirk, Rikke Kaae; Christoffersen, Berit; Fels, Johannes Josef; Josefsen, Knud; Kihl, Pernille; Hansen, Axel Kornerup			Modulating the Gut Microbiota Improves Glucose Tolerance, Lipoprotein Profile and Atherosclerotic Plaque Development in ApoE-Deficient Mice	PLOS ONE			English	Article							GLUTEN-FREE DIET; NOD MICE; METABOLISM; OBESITY; INFLAMMATION; ANTIBIOTICS; DISEASE; PROMOTES; NUMBER	The importance of the gut microbiota (GM) in disease development has recently received increased attention, and numerous approaches have been made to better understand this important interplay. For example, metabolites derived from the GM have been shown to promote atherosclerosis, the underlying cause of cardiovascular disease (CVD), and to increase CVD risk factors. Popular interest in the role of the intestine in a variety of disease states has now resulted in a significant proportion of individuals without coeliac disease switching to gluten-free diets. The effect of gluten-free diets on atherosclerosis and cardiovascular risk factors is largely unknown. We therefore investigated the effect of a gluten-free high-fat cholesterol-rich diet, as compared to the same diet in which the gluten peptide gliadin had been added back, on atherosclerosis and several cardiovascular risk factors in apolipoprotein E-deficient (Apoe(-/-)) mice. The gluten-free diet transiently altered GM composition in these mice, as compared to the gliadin-supplemented diet, but did not alter body weights, glucose tolerance, insulin levels, plasma lipids, or atherosclerosis. In parallel, other Apoe(-/-) mice fed the same diets were treated with ampicillin, a broad-spectrum antibiotic known to affect GM composition. Ampicillin-treatment had a marked and sustained effect on GM composition, as expected. Furthermore, although ampicillin-treated mice were slightly heavier than controls, ampicillin-treatment transiently improved glucose tolerance both in the absence or presence of gliadin, reduced plasma LDL and VLDL cholesterol levels, and reduced aortic atherosclerotic lesion area. These results demonstrate that a gluten-free diet does not seem to have beneficial effects on atherosclerosis or several CVD risk factors in this mouse model, but that sustained alteration of GM composition with a broad-spectrum antibiotic has beneficial effects on CVD risk factors and atherosclerosis. These findings support the concept that altering the microbiota might provide novel treatment strategies for CVD.	[Rune, Ida; Larsen, Christian; Lykkesfeldt, Jens; Kihl, Pernille; Hansen, Axel Kornerup] Univ Copenhagen, Fac Hlth & Med Sci, Sect Expt Anim Models, Dept Vet Dis Biol, Thorvaldsensvej 57, DK-1871 Frederiksberg C, Denmark; [Rolin, Bidda; Kirk, Rikke Kaae; Christoffersen, Berit; Fels, Johannes Josef] Novo Nordisk AS, Global Res, Novo Nordisk Pk 1, DK-2760 Malov, Denmark; [Nielsen, Dennis Sandris] Univ Copenhagen, Dept Food Sci, Fac Sci, Rolighedsvej 26, DK-1958 Frederiksberg C, Denmark; [Kanter, Jenny E.; Bornfeldt, Karin E.] Univ Washington, Dept Med, Diabet & Obes Ctr Excellence, Seattle, WA 98109 USA; [Buschard, Karsten; Josefsen, Knud] Bartholin Inst, Rigshosp Dept 3733, Copenhagen Bioctr, Ole Maaloes Vej 5, DK-2200 Copenhagen N, Denmark	University of Copenhagen; Novo Nordisk; University of Copenhagen; University of Washington; University of Washington Seattle; Rigshospitalet	Rune, I (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Sect Expt Anim Models, Dept Vet Dis Biol, Thorvaldsensvej 57, DK-1871 Frederiksberg C, Denmark.	idarune@hotmail.com	Bornfeldt, Karin/AAI-2241-2019; Nielsen, Dennis/A-9769-2015; Lykkesfeldt, Jens/A-1072-2011	Bornfeldt, Karin/0000-0001-9208-6523; Nielsen, Dennis/0000-0001-8121-1114; Lykkesfeldt, Jens/0000-0002-6514-8407; Kanter, Jenny/0000-0003-3212-772X; Buschard, Karsten/0000-0002-0126-7423	Danish Ministry of Science, Technology and Innovation; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [R01HL062887, P01HL092969, R01HL097365, R01HL126028, P30DK017047]; American Heart Association [14GRNT20410033]; National Institutes of Health [R01HL062887, P01HL092969, R01HL126028, P30DK017047]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097365, P01HL092969, R01HL126028, R01HL062887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047] Funding Source: NIH RePORTER	Danish Ministry of Science, Technology and Innovation; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was carried out as a part of the 3G research program (Guts, grains and greens; http://www.3g-center.dk/). The 3G program is supported by the Danish Ministry of Science, Technology and Innovation. Ida Rune is part of LIFEPHARM (www.lifepharm.dk). Research reported in this publication was also supported in part by the National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award numbers R01HL062887, P01HL092969, R01HL097365, R01HL126028 and P30DK017047; and by the American Heart Association, 14GRNT20410033, to KEB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Christian Larsen, Lene Winther Takla, Line Rasmussen, Nicolai Hansen, Jane Larsen, Bettina Brandrup, Trine Pagh Ludvigsen, Cecilie Loe Licht and Annie Bjergby Kristensen are kindly thanked for their technical assistance. Karin E. Bornfeldt's laboratory is supported by the National Institutes of Health grants R01HL062887, P01HL092969, R01HL126028, and P30DK017047 and The American Heart Association (14GRNT20410033).	Angelakis E, 2013, LANCET INFECT DIS, V13, P889, DOI 10.1016/S1473-3099(13)70179-8; Antvorskov JC, 2014, DIABETOLOGIA; Bech-Nielsen GV, 2012, RES VET SCI, V92, P501, DOI 10.1016/j.rvsc.2011.04.005; Brown JM, 2008, J BIOL CHEM, V283, P10522, DOI 10.1074/jbc.M707659200; Brugman S, 2006, DIABETOLOGIA, V49, P2105, DOI 10.1007/s00125-006-0334-0; Caesar R, 2010, J INTERN MED, V268, P320, DOI 10.1111/j.1365-2796.2010.02270.x; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Cani PD, 2009, CURR PHARM DESIGN, V15, P1546, DOI 10.2174/138161209788168164; Carvalho BM, 2012, DIABETOLOGIA, V55, P2823, DOI 10.1007/s00125-012-2648-4; Cho I, 2012, NATURE, V488, P621, DOI 10.1038/nature11400; de Kort S, 2011, OBES REV, V12, P449, DOI 10.1111/j.1467-789X.2010.00845.x; De Palma G, 2009, BRIT J NUTR, V102, P1154, DOI 10.1017/S0007114509371767; Ejsing-Duun M, 2008, SCAND J IMMUNOL, V67, P553, DOI 10.1111/j.1365-3083.2008.02104.x; Funda DP, 2008, DIABETES-METAB RES, V24, P59, DOI 10.1002/dmrr.748; Hansen AK, 2006, DIABETES-METAB RES, V22, P220, DOI 10.1002/dmrr.609; Hansen CHF, 2014, DIABETES, V63, P2821, DOI 10.2337/db13-1612; Hansen CHF, 2014, DIABETES; Helmerhorst EJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013264; Hennessy AA, 2014, CURR CARDIOL REP, V16, DOI 10.1007/s11886-014-0515-2; Hufeldt MR, 2010, COMPARATIVE MED, V60, P336; Kanter JE, 2012, P NATL ACAD SCI USA, V109, pE715, DOI 10.1073/pnas.1111600109; Karlsson FH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2266; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; Lee RG, 2004, CIRC RES, V95, P998, DOI 10.1161/01.RES.0000147558.15554.67; Lima LFO, 2008, APPL BIOCHEM BIOTECH, V151, P283, DOI 10.1007/s12010-008-8187-2; Lykkesfeldt J, 2001, CLIN CHEM, V47, P1725; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Meir KS, 2004, ARTERIOSCL THROM VAS, V24, P1006, DOI 10.1161/01.ATV.0000128849.12617.f4; Membrez M, 2008, FASEB J, V22, P2416, DOI 10.1096/fj.07-102723; Miyata M, 2009, J PHARMACOL EXP THER, V331, P1079, DOI 10.1124/jpet.109.160093; Nash David T, 2014, Proc (Bayl Univ Med Cent), V27, P377; Rune I, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/319321; Schuppan D, 2009, GASTROENTEROLOGY, V137, P1912, DOI 10.1053/j.gastro.2009.09.008; Sildorf SM, 2012, BMJ CASE REP; Temel RE, 2005, J LIPID RES, V46, P2423, DOI 10.1194/jlr.M500232-JLR200; Thomas KE, 2006, J IMMUNOL, V176, P2512, DOI 10.4049/jimmunol.176.4.2512; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Zanoni G, 2006, PLOS MED, V3, P1637, DOI 10.1371/journal.pmed.0030358; Zaragoza C, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/497841	41	32	33	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2016	11	1							e0146439	10.1371/journal.pone.0146439	http://dx.doi.org/10.1371/journal.pone.0146439			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB6WB	26799618	Green Published, gold, Green Submitted			2023-01-03	WOS:000368655300021
J	Sinha, P; Aarnisalo, P; Chubb, R; Poulton, IJ; Guo, J; Nachtrab, G; Kimura, T; Swami, S; Saeed, H; Chen, M; Weinstein, LS; Schipani, E; Sims, NA; Kronenberg, HM; Wu, JY				Sinha, Partha; Aarnisalo, Piia; Chubb, Rhiannon; Poulton, Ingrid J.; Guo, Jun; Nachtrab, Gregory; Kimura, Takaharu; Swami, Srilatha; Saeed, Hamid; Chen, Min; Weinstein, Lee S.; Schipani, Ernestina; Sims, Natalie A.; Kronenberg, Henry M.; Wu, Joy Y.			Loss of G(s)alpha in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC CELLS; MESENCHYMAL PROGENITORS; POSTMENOPAUSAL WOMEN; INTERMITTENT PTH; PHOSPHOLIPASE-C; MINERAL DENSITY; PROTEIN-KINASE; IN-VIVO; DIFFERENTIATION; RECEPTOR	Parathyroid hormone (PTH) is an important regulator of osteoblast function and is the only anabolic therapy currently approved for treatment of osteoporosis. The PTH receptor (PTH1R) is a G protein-coupled receptor that signals via multiple G proteins including G(s)alpha. Mice expressing a constitutively active mutant PTH1R exhibited a dramatic increase in trabecular bone that was dependent upon expression of G(s)alpha in the osteoblast lineage. Postnatal removal of G(s)alpha in the osteoblast lineage (P-G(s)alpha(OsxKO) mice) yielded markedly reduced trabecular and cortical bone mass. Treatment with anabolic PTH(1-34) (80 mu g/kg/day) for 4 weeks failed to increase trabecular bone volume or cortical thickness in male and female P-G(s)alpha(OsxKO) mice. Surprisingly, in both male and female mice, PTH administration significantly increased osteoblast numbers and bone formation rate in both control and P-G(s)alpha(OsxKO) mice. In mice that express a mutated PTH1R that activates adenylyl cyclase and protein kinase A (PKA) via G(s)alpha but not phospholipase C via G(q/11) (D/D mice), PTH significantly enhanced bone formation, indicating that phospholipase C activation is not required for increased bone turnover in response to PTH. Therefore, although the anabolic effect of intermittent PTH treatment on trabecular bone volume is blunted by deletion of G(s)alpha in osteoblasts, PTH can stimulate osteoblast differentiation and bone formation. Together these findings suggest that alternative signaling pathways beyond G(s)alpha and G(q/11) act downstream of PTH on osteoblast differentiation.	[Sinha, Partha; Aarnisalo, Piia; Chubb, Rhiannon; Guo, Jun; Nachtrab, Gregory; Kronenberg, Henry M.; Wu, Joy Y.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; [Aarnisalo, Piia] Univ Helsinki, Dept Clin Chem, Helsinki 00029, Finland; [Aarnisalo, Piia] Univ Helsinki, Cent Hosp, HUSLAB, Lab Serv, Helsinki 00029, Finland; [Poulton, Ingrid J.; Sims, Natalie A.] Univ Melbourne, St Vincents Inst, Fitzroy, Vic 3065, Australia; [Poulton, Ingrid J.; Sims, Natalie A.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; [Kimura, Takaharu; Swami, Srilatha; Saeed, Hamid; Wu, Joy Y.] Stanford Univ, Sch Med, Div Endocrinol, 300 Pasteur Dr,S-025, Stanford, CA 94305 USA; [Chen, Min; Weinstein, Lee S.] NIDDK, NIH, Metab Dis Branch, Bethesda, MD 20892 USA; [Schipani, Ernestina] Univ Michigan, Dept Orthoped Surg, Ann Arbor, MI 48109 USA; [Schipani, Ernestina] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	Harvard University; Massachusetts General Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Wu, JY (corresponding author), Stanford Univ, Sch Med, Div Endocrinol, 300 Pasteur Dr,S-025, Stanford, CA 94305 USA.	jywu1@stanford.edu	Sims, Natalie Ann/A-7192-2012	Sims, Natalie Ann/0000-0003-1421-8468; Weinstein, Lee/0000-0002-1899-5152	National Institutes of Health [AR054741, AR059942, AR061228, DK011794]; NIDDK Intramural Research Program; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR065403, R03AR059942, K08AR054741, F32AR061228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043313, P01DK011794] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health Grants AR054741 and AR059942 (to J. Y. W.), AR061228 (to P. S.), and DK011794 (to H. M. K.) and the NIDDK Intramural Research Program (to M. C. and L. S. W.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; Bastepe M, 2004, P NATL ACAD SCI USA, V101, P14794, DOI 10.1073/pnas.0405091101; Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200; Boguslawski G, 2000, J BIOL CHEM, V275, P999, DOI 10.1074/jbc.275.2.999; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Burge R, 2007, J BONE MINER RES, V22, P465, DOI 10.1359/JBMR.061113; Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]; Davey RA, 2012, TRANSGENIC RES, V21, P885, DOI 10.1007/s11248-011-9581-z; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004-1282; Gesty-Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071; Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534-5807(02)00218-6; Guo J, 2010, ENDOCRINOLOGY, V151, P3502, DOI 10.1210/en.2009-1494; Hsiao EC, 2008, P NATL ACAD SCI USA, V105, P1209, DOI 10.1073/pnas.0707457105; Hsiao EC, 2010, J BONE MINER RES, V25, P584, DOI 10.1002/jbmr.3; Iida-Klein A, 2002, J BONE MINER RES, V17, P808, DOI 10.1359/jbmr.2002.17.5.808; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017; Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037; Kedlaya R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006627; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109; McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; PARTRIDGE NC, 1982, ENDOCRINOLOGY, V111, P178, DOI 10.1210/endo-111-1-178; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Semenov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200; Sims NA, 2006, AM J PHYSIOL-ENDOC M, V290, pE456, DOI 10.1152/ajpendo.00311.2005; Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717; Singh ATK, 2005, ENDOCRINOLOGY, V146, P2171, DOI 10.1210/en.2004-1283; Sinha P, 2014, J BONE MINER RES, V29, P2414, DOI 10.1002/jbmr.2270; Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001; Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105; Wu JY, 2011, J CLIN INVEST, V121, P3492, DOI 10.1172/JCI46406; Yang DH, 2008, ENDOCRINOLOGY, V149, P1728, DOI 10.1210/en.2007-0826	50	27	29	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2016	291	4					1631	1642		10.1074/jbc.M115.679753	http://dx.doi.org/10.1074/jbc.M115.679753			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DB6JI	26598522	Green Published, hybrid			2023-01-03	WOS:000368620700008
J	Odejide, OO				Odejide, Oreofe O.			A Policy Prescription for Hospice Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Odejide, Oreofe O.] Dana Farber Canc Inst, Dept Med Oncol, Div Populat Sci, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute	Odejide, OO (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Div Populat Sci, 450 Brookline Ave, Boston, MA 02215 USA.	oreofe_odejide@dfci.harvard.edu						[Anonymous], MED CAR CHOIC MOD; Brooks GA, 2014, HEALTH AFFAIR, V33, P1793, DOI 10.1377/hlthaff.2014.0280; El-Jawahri AR, 2015, CANCER-AM CANCER SOC, V121, P2840, DOI 10.1002/cncr.29430; National Hospice and Palliative Care Organization, 2019, NHPCO FACTS FIG HOSP; Odejide OO, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv280; Odejide OO, 2016, JAMA INTERN MED, V176, P263, DOI 10.1001/jamainternmed.2015.6599; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Spettell CM, 2009, J PALLIAT MED, V12, P827, DOI 10.1089/jpm.2009.0089	8	22	22	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					257	258		10.1001/jama.2015.18424	http://dx.doi.org/10.1001/jama.2015.18424			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784768				2023-01-03	WOS:000368371400017
J	Santos, CAB; de Albuquerque, UP; Souto, WMS; Alves, RRN				Batista Santos, Carlos Alberto; de Albuquerque, Ulysses Paulino; Silva Souto, Wedson Medeiros; Nobrega Alves, Romulo Romeu			Assessing the Effects of Indigenous Migration on Zootherapeutic Practices in the Semiarid Region of Brazil	PLOS ONE			English	Article							ANIMAL-DERIVED REMEDIES; COMPLEMENTARY MEDICINE; FISHING COMMUNITIES; KNOWLEDGE; PHARMACOPEIA; MARKETS; MAMMALS; TRADE; CRATO; NE	Human migration implies adaptations to new environments, such as ways to benefit from the available biodiversity. This study focused on the use of animal-derived remedies, and we investigated the effects of migration on the traditional medical system of the indigenous Truka people. This ethnic group lives in Northeast Brazil and is currently distributed in four distinct villages. In these villages, the zootherapeutic knowledge of 54 indigenous people was determined through semi-structured questionnaires given from September 2013 to January 2014. The interviewees indicated 137 zootherapeutic uses involving 21 animal species. The variety of species and their uses have a higher similarity between villages that are closer to each other, which can be a reflection of geographic and environmental factors. However, even close villages showed a low similarity in the zootherapeutic uses recorded, which reflects a strong idiosyncrasy regarding the knowledge of each village. Hence, each village may be influenced by the physical environment and contact with other cultures, which may maintain or reduce the contact of younger villages with the original village.	[Batista Santos, Carlos Alberto; de Albuquerque, Ulysses Paulino; Nobrega Alves, Romulo Romeu] Univ Fed Rural Pernambuco, Dept Ciencias Biol, Programa Pos Grad Etnobiol & Conservacao Nat, BR-52171900 Recife, PE, Brazil; [Batista Santos, Carlos Alberto] Univ Estado Bahia, Dept Tecnol & Ciencias Sociais, BR-48905680 Juazeiro, BA, Brazil; [Silva Souto, Wedson Medeiros] Univ Fed Piaui, BR-64800000 Floriano, PI, Brazil; [Silva Souto, Wedson Medeiros; Nobrega Alves, Romulo Romeu] Univ Fed Paraiba UFPB, Programa Posgrad Ciencias Biol Zool, Dept Sistemat & Ecol, Ctr Ciencias Exatas & Nat, BR-58051900 Joao Pessoa, Paraiba, Brazil; [Nobrega Alves, Romulo Romeu] Univ Estadual Paraiba, Dept Biol, BR-58109753 Campina Grande, PB, Brazil	Universidade Federal Rural de Pernambuco (UFRPE); Universidade do Estado Bahia; Universidade Federal do Piaui; Universidade Estadual da Paraiba	Alves, RRN (corresponding author), Univ Fed Rural Pernambuco, Dept Ciencias Biol, Programa Pos Grad Etnobiol & Conservacao Nat, Rua Dom Manoel de Medeiros S-N, BR-52171900 Recife, PE, Brazil.	romulo_nobrega@yahoo.com.br	Alves, Rômulo Romeu Nóbrega/A-7026-2009; Albuquerque, Ulysses P/I-5037-2012	Alves, Rômulo Romeu Nóbrega/0000-0001-6824-0797; Albuquerque, Ulysses P/0000-0002-8131-8429	National Council for Scientific and Technological Development (CNPq) [476460/2012-3]	National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This study was supported by the National Council for Scientific and Technological Development (CNPq) (grant number 476460/2012-3).	Adeodato S, 2014, CAATINGA SELVAGEM LE; Albuquerque U.P., 2014, METHODS TECHNIQUES E; Albuquerque Ulysses Paulino De, 1998, Anales del Jardin Botanico de Madrid, V56, P107; Alves RRN, 2007, BIOSCIENCE, V57, P949, DOI 10.1641/B571107; Alves RRN, 2007, J ETHNOPHARMACOL, V113, P541, DOI 10.1016/j.jep.2007.07.015; Alves RRN, 2007, J ETHNOPHARMACOL, V111, P82, DOI 10.1016/j.jep.2006.10.033; Alves RRN, 2006, J ETHNOPHARMACOL, V107, P259, DOI 10.1016/j.jep.2006.03.007; Alves RRN, 2009, J ETHNOPHARMACOL, V124, P600, DOI 10.1016/j.jep.2009.04.049; Alves RRN, 2009, J ETHNOBIOL ETHNOMED, V5, DOI [10.1186/1746-4269-5-12, 10.1186/1746-4269-5-1]; Bailey K., 1994, METHODS SOCIAL RES, V4th ed; Batista MRR., 2005, THESIS; Belliard JC, 2005, HISPANIC J BEHAV SCI, V27, P267, DOI 10.1177/0739986305278130; Berg ME, 1991, B MUSEU PARAENSE E B, V7, P485; Campos E, 1967, MED POPULAR NORDESTE; Ceuterick M, 2008, J ETHNOPHARMACOL, V120, P342, DOI 10.1016/j.jep.2008.09.004; Costa-Neto EM, 1999, ACTUAL BIOL, V21, P69; de Medeiros PM, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/807452; Fernandes V.N., 2012, THESIS; Ferreira FS, 2013, BIODIVERS CONSERV, V22, P839, DOI 10.1007/s10531-013-0475-7; Ferreira FS, 2009, J ETHNOBIOL ETHNOMED, V5, DOI 10.1186/1746-4269-5-21; Ferreira FS, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-17; Ferreira FS, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/126938; Vieira HTG, 2013, SAUDE SOC-SAO PAULO, V22, P566, DOI 10.1590/S0104-12902013000200025; Huntington HP, 2000, ECOL APPL, V10, P1270, DOI 10.1890/1051-0761(2000)010[1270:UTEKIS]2.0.CO;2; KRUSKAL WH, 1953, J AM STAT ASSOC, V48, P907, DOI 10.2307/2281082; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; Lacuna-Richman C, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-36; Lima JRB, 2010, ETNOBIOLOGIA, V8, P39; Machado Antonio Thomaz da Mata, 2008, Estud. av., V22, P195, DOI 10.1590/S0103-40142008000200013; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MARES MA, 1985, J BIOGEOGR, V12, P57, DOI 10.2307/2845029; Marques JGW, 2006, ECOLOGIAS SAO FRANCI; Martine G, 2010, POPULACAO CIDADES SU, P11; Martinez GJ, 2013, ETHNOBIOL CONSERV, V2, DOI 10.15451/ec2013-8-2.2-1-43; Medeiros P.M., 2014, INTRO ETHNOBIOLOGIA, P157; Nesheim I, 2006, HUM ECOL, V34, P99, DOI 10.1007/s10745-005-9004-y; Alves RRN, 2010, HUM ECOL, V38, P691, DOI 10.1007/s10745-010-9352-0; Novick S, 2008, MIGRACIONES AM LATIN; de Souza RSO, 2008, BRAZ ARCH BIOL TECHN, V51, P937, DOI 10.1590/S1516-89132008000500010; Oksanen J., 2011, VEGAN COMMUNITY ECOL, DOI DOI 10.1126/science.1210173; Oliveira ES, 2010, J ETHNOPHARMACOL, V130, P54, DOI 10.1016/j.jep.2010.04.010; OLIVEIRA J. A., 2003, ECOLOGIA CONSERVACAO, P275; ONU ONU, 2013, INT MIGRATION; RIBEIRO Darcy, 1995, POVO BRASILEIRO FORM, V2; Rodrigues M. T., 2003, ECOLOGIA CONSERVACAO, P181; Rosa I., 2013, ANIMALS TRADITIONAL, P109, DOI DOI 10.1007/978-3-642-29026-8; Sa-Menezes J, 1957, MED INDIGENA; Santos SC, 1981, 44 IWGIA; Servico Geologico do Brasil SGB, 2005, PROJ CAD FONT AB AG; SGB, 2005, PROJ CAD FONT AB AG; Silva TFS, 2005, MAMIFEROS BAHIA ESPE; Sousa GS, 1971, TRATADO DESCRITIVO B, V1587; Souto WMS, 2011, J ETHNOPHARMACOL, V134, P753, DOI 10.1016/j.jep.2011.01.041; Vandebroek I, 2010, ECON BOT, V64, P303, DOI 10.1007/s12231-010-9135-y; Volpato G, 2009, HUM ECOL, V37, P43, DOI 10.1007/s10745-008-9211-4; Waldstein A, 2006, J ETHNOPHARMACOL, V108, P299, DOI 10.1016/j.jep.2006.07.011; WILLIG M R, 1989, Revista Brasileira de Biologia, V49, P361; [No title captured]	58	9	9	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2016	11	1							e0146657	10.1371/journal.pone.0146657	http://dx.doi.org/10.1371/journal.pone.0146657			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DA5AX	26745882	Green Submitted, Green Published, gold			2023-01-03	WOS:000367815600073
J	Han, KT; Jang, SY; Park, S; Cho, KH; Yoo, KB; Choi, Y; Park, EC				Han, Kyu-Tae; Jang, Suk Yong; Park, Sohee; Cho, Kyung Hee; Yoo, Ki-Bong; Choi, Young; Park, Eun-Cheol			Social Welfare Centers Protect Outpatients with Mood Disorders from Risk of Hospital Admission	PLOS ONE			English	Article							MENTAL-HEALTH; SUICIDE RISK; QUALITY; SUPPORT; STRESS; CARE	Background South Korea faces difficulties in the management of mental disorders, and those difficulties are expected to gradually worsen. Therefore, we analyzed the relationship between social welfare centers and hospital admission after outpatient treatment for mood disorders. Methods We used data from the National Health Insurance Service National Sample Cohort 2002-2013, which included all medical claims filed for the 50,160 patients who were newly diagnosed with a mood disorder among the 1,025,340 individuals in a nationally representative sample. We performed a logistic regression analysis using generalized estimating equation (GEE) models to examine the relationship between social welfare centers and hospital admission after outpatient treatment for mood disorders (ICD-10: F3). Results There was a 3.9% admission rate among a total of 99,533 person-years. Outpatients who lived in regions with more social welfare centers were less likely to be admitted to a hospital (per increase of five social welfare centers per 100,000 people; OR: 0.958; 95% CI: 0.919-0.999). Social welfare centers had an especially strong protective effect on patients with relatively mild mood disorders and those who were vulnerable to medical expenditures. Conclusions Considering the protective role of social welfare centers in managing patients with mood disorders, health-policy makers need to consider strategies for activating mental healthcare.	[Han, Kyu-Tae; Jang, Suk Yong; Cho, Kyung Hee; Choi, Young] Yonsei Univ, Grad Sch, Dept Publ Hlth, Seoul 120749, South Korea; [Han, Kyu-Tae; Jang, Suk Yong; Cho, Kyung Hee; Choi, Young; Park, Eun-Cheol] Yonsei Univ, Coll Med, Inst Hlth Serv Res, Seoul, South Korea; [Park, Sohee] Yonsei Univ, Dept Biostat, Grad Sch Publ Hlth, Seoul 120749, South Korea; [Yoo, Ki-Bong] Eulji Univ, Dept Hosp Management, Songnam, South Korea; [Jang, Suk Yong; Park, Eun-Cheol] Yonsei Univ, Coll Med, Dept Prevent Med, Seoul, South Korea	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Eulji University; Yonsei University; Yonsei University Health System	Park, EC (corresponding author), Yonsei Univ, Coll Med, Inst Hlth Serv Res, Seoul, South Korea.	ecpark@yuhs.ac	Park, Eun-Cheol/O-5644-2019	Park, Eun-Cheol/0000-0002-2306-5398; Park, Sohee/0000-0001-8513-5163; Han, Kyu-Tae/0000-0002-5817-1203; Jang, Suk-Yong/0000-0003-0558-1505				Amaddeo F, 2001, SOC PSYCH PSYCH EPID, V36, P500, DOI 10.1007/s001270170015; Baca-Garcia E, 2007, BRIT J PSYCHIAT, V190, P210, DOI 10.1192/bjp.bp.106.024026; Cho MJ, 2011, J KOREAN MED SCI, V26, P1, DOI 10.3346/jkms.2011.26.1.1; Curyto KJ, 2001, AM J GERIAT PSYCHIAT, V9, P141, DOI 10.1176/appi.ajgp.9.2.141; Dussault Gilles, 2003, Hum Resour Health, V1, P1, DOI 10.1186/1478-4491-1-1; GUNNELL DJ, 1995, BRIT MED J, V311, P226, DOI 10.1136/bmj.311.6999.226; Hamano T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013214; Han KT, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/s12955-014-0109-0; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Health Insurance Review & Assessment Service, 2009, STAT DIS 2009 13; Kim KM, 2012, ASIA PAC EDUC REV, V13, P273, DOI 10.1007/s12564-011-9192-7; Kim NH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139924; Kim SS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030501, 10.1371/journal.pone.0045068]; LEE CK, 1990, J NERV MENT DIS, V178, P242, DOI 10.1097/00005053-199004000-00004; Lee JS, 2004, INT J INTERCULT REL, V28, P399, DOI 10.1016/j.ijintrel.2004.08.005; Ministry of Health & Welfare, 2001, EP SURV MENT DIS KOR; NORDSTROM P, 1995, ACTA PSYCHIAT SCAND, V92, P345, DOI 10.1111/j.1600-0447.1995.tb09595.x; OECD, 2013, HLTH GLANC 2013 OECD, DOI [10.1787/health_glance-2013-49-en, DOI 10.1787/HEALTH_GLANCE-2013-49-EN]; PADGETT D, 1990, MED CARE, V28, P805, DOI 10.1097/00005650-199009000-00010; Powell J, 2000, BRIT J PSYCHIAT, V176, P266, DOI 10.1192/bjp.176.3.266; Rihmer Z, 2007, CURR OPIN PSYCHIATR, V20, P17, DOI 10.1097/YCO.0b013e3280106868; Rost K, 2002, MED CARE RES REV, V59, P231, DOI 10.1177/1077558702059003001; Ruth U., 2013, GER J PSYCHIAT, V16, P1; Sadock BJ, 2015, SYNOPSIS PSYCHIAT BE; Saxena S, 2007, LANCET, V370, P878, DOI 10.1016/S0140-6736(07)61239-2; Song YJ, 2009, JPN MED ASS J, V52, P206; Swigar M E, 1991, Int J Soc Psychiatry, V37, P259, DOI 10.1177/002076409103700405; Taylor SE, 2004, J PERS SOC PSYCHOL, V87, P354, DOI 10.1037/0022-3514.87.3.354; Tyssen R, 2000, MED EDUC, V34, P374, DOI 10.1046/j.1365-2923.2000.00540.x	29	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2016	11	1							e0146754	10.1371/journal.pone.0146754	http://dx.doi.org/10.1371/journal.pone.0146754			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DA5AX	26745728	gold, Green Submitted, Green Published			2023-01-03	WOS:000367815600080
J	Kuan, CS; Yew, SM; Toh, YF; Chan, CL; Lim, SK; Lee, KW; Na, SL; Hoh, CC; Yee, WY; Ng, KP				Kuan, Chee Sian; Yew, Su Mei; Toh, Yue Fen; Chan, Chai Ling; Lim, Soo Kun; Lee, Kok Wei; Na, Shiang Ling; Hoh, Chee-Choong; Yee, Wai-Yan; Ng, Kee Peng			Identification and Characterization of a Rare Fungus, Quambalana cyanescens, Isolated from the Peritoneal Fluid of a Patient after Nocturnal Intermittent Peritoneal Dialysis	PLOS ONE			English	Article							SPOROTHRIX-CYANESCENS; ECHINOCANDIN RESISTANCE; EMERGENCE	Peritonitis is the leading complication of peritoneal dialysis, which is primarily caused by bacteria rather than fungi. Peritonitis is responsible for approximately 18% of the infection-related mortality in peritoneal dialysis patients. In this paper, we report the isolation of a rare fungus, Quambalaria cyanescens, from the peritoneal fluid of a man after he switched from continuous ambulatory peritoneal dialysis to nocturnal intermittent peritoneal dialysis. Based on the morphological examination and multigene phylogeny, the clinical isolate was confirmed as Q. cyanescens. This pathogen exhibited low sensitivity to all tested echinocandins and 5-flucytosine. Interestingly, morphological characterization revealed that Q. cyanescens UM 1095 produced different pigments at low temperatures (25 degrees C and 30 degrees C) on various culture media. It is important to monitor the emergence of this rare fungus as a potential human pathogen in the tropics. This study provides insight into Q. cyanescens UM 1095 phenotype profiles using a Biolog phenotypic microarray (PM). Of the 760 nutrient sources tested, Q. cyanescens UM 1095 utilized 42 compounds, and the fungus can adapt to a broad range of osmotic and acidic environments. To our knowledge, this is the first report of the isolation of Q. cyanescens from peritoneal fluid, revealing this rare fungus as a potential human pathogen that may be misidentified using conventional methods. The detailed morphological, molecular and phenotypic characterization of Q. cyanescens UM 1095 provides the basis for future studies on its biology, lifestyle, and potential pathogenicity.	[Kuan, Chee Sian; Yew, Su Mei; Toh, Yue Fen; Chan, Chai Ling; Na, Shiang Ling; Ng, Kee Peng] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia; [Lim, Soo Kun] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia; [Lee, Kok Wei; Hoh, Chee-Choong; Yee, Wai-Yan] Codon Genom SB, Selangor Darul Ehsan, Malaysia	Universiti Malaya; Universiti Malaya	Ng, KP (corresponding author), Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia.	kpng@ummc.edu.my	Lim, Soo Kun/Q-2012-2019; LIM, SOO KUN/B-8868-2010	Lim, Soo Kun/0000-0001-7589-5150; LIM, SOO KUN/0000-0001-7589-5150	High Impact Research MoE Grant from Ministry of Education Malaysia [UM.C/625/1/HIR/MOHE/MED/31, H-20001-00-E000070]; Codon Genomics SB	High Impact Research MoE Grant from Ministry of Education Malaysia; Codon Genomics SB	This study was supported by High Impact Research MoE Grant UM.C/625/1/HIR/MOHE/MED/31 (Account no. H-20001-00-E000070) from the Ministry of Education Malaysia. Codon Genomics SB provided support in the form of salaries for authors KWL, CCH and WYY, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions section.	Amin R. M., 2010, Mycology - An International Journal on Fungal Biology, V1, P67; Antropova A B, 2014, Mikrobiologiia, V83, P605; Axner-Elings M, 2011, J CLIN MICROBIOL, V49, P2516, DOI 10.1128/JCM.00201-11; Baixench MT, 2007, J ANTIMICROB CHEMOTH, V59, P1076, DOI 10.1093/jac/dkm095; Cheewangkoon R, 2009, PERSOONIA, V23, P55, DOI 10.3767/003158509X474752; Dannaoui E, 2012, EMERG INFECT DIS, V18, P86, DOI 10.3201/eid1801.110556; de Beer ZW, 2006, STUD MYCOL, P289, DOI 10.3114/sim.55.1.289; DEHOOG GS, 1973, A VAN LEEUW J MICROB, V39, P515, DOI 10.1007/BF02578895; Fan X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106949; Fekkar A, 2013, ANTIMICROB AGENTS CH, V57, P2380, DOI 10.1128/AAC.02037-12; Goldie SJ, 1996, AM J KIDNEY DIS, V28, P86, DOI 10.1016/S0272-6386(96)90135-3; Gunde-Cimerman N, 2000, FEMS MICROBIOL ECOL, V32, P235; Hamai K, 1999, CLIN EXP NEPHROL, V3, P59, DOI [10.1007/s101570050011, DOI 10.1007/S101570050011]; HAU T, 1990, WORLD J SURG, V14, P167, DOI 10.1007/BF01664869; Islam Saleem, 2002, Surg Infect (Larchmt), V3, P35, DOI 10.1089/109629602753681140; JACKSON L, 1990, J MED VET MYCOL, V28, P455; KERR CM, 1983, ANN INTERN MED, V99, P334, DOI 10.7326/0003-4819-99-3-334; Kleinpeter Myra A, 2004, Adv Perit Dial, V20, P58; Kogej T, 2007, MICROBIOL-SGM, V153, P4261, DOI 10.1099/mic.0.2007/010751-0; Kolarik Miroslav, 2006, Czech Mycology, V58, P81; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; MOORE RT, 1987, STUD MYCOL, P203; Moretti S, 2007, NUCLEIC ACIDS RES, V35, pW645, DOI 10.1093/nar/gkm333; NAGAPPAN R, 1992, AM J KIDNEY DIS, V20, P492, DOI 10.1016/S0272-6386(12)70262-7; Paap T, 2008, MYCOL RES, V112, P57, DOI 10.1016/j.mycres.2007.10.005; Padhi S, 2013, ANN MICROBIOL, V63, P793, DOI 10.1007/s13213-012-0534-4; Pasquale T, 2008, J ANTIMICROB CHEMOTH, V61, P219, DOI 10.1093/jac/dkm453; Pfaller MA, 2008, J CLIN MICROBIOL, V46, P2620, DOI 10.1128/JCM.00566-08; Pfaller MA, 2011, DRUG RESIST UPDATE, V14, P164, DOI 10.1016/j.drup.2011.01.004; Prasad KN, 2004, J INFECTION, V48, P96, DOI 10.1016/S0163-4453(03)00119-1; SIGLER L, 1990, J CLIN MICROBIOL, V28, P1009, DOI 10.1128/JCM.28.5.1009-1015.1990; Simpson J. A., 2000, Australasian Mycologist, V19, P57; Stodulkova E, 2008, FOLIA MICROBIOL, V53, P15, DOI 10.1007/s12223-008-0002-5; Stodulkova E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118913; Tambini R, 1996, J MED VET MYCOL, V34, P195; Wang AYM, 2000, AM J KIDNEY DIS, V36, P1183, DOI 10.1053/ajkd.2000.19833; Yew SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104352	37	7	8	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2015	10	12							e0145932	10.1371/journal.pone.0145932	http://dx.doi.org/10.1371/journal.pone.0145932			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0TN	26716988	gold, Green Submitted, Green Published			2023-01-03	WOS:000367510500098
J	Collis, E; Mather, H				Collis, Emily; Mather, Harriet			Nausea and vomiting in palliative care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CHEMOTHERAPY-INDUCED NAUSEA; ADVANCED CANCER; DOUBLE-BLIND; RELEASE METOCLOPRAMIDE; INTRACTABLE NAUSEA; REFRACTORY NAUSEA; MANAGEMENT; OLANZAPINE; PLACEBO; ONDANSETRON		[Collis, Emily] Cent & North West London NHS Fdn, Islington ELiPSe, Palliat Med, London, England; [Collis, Emily] Cent & North West London NHS Fdn, UCLH & HCA Palliat Care Serv, Palliat Med, London, England; [Mather, Harriet] Mt Vernon Hosp, Dept Palliat Med, Palliat Med, Northwood HA6 2RN, Middx, England		Collis, E (corresponding author), Cent & North West London NHS Fdn, Islington ELiPSe, Palliat Med, London, England.	emily.collis@nhs.net						Andrews PLR, 2014, EUR J PHARMACOL, V722, P108, DOI 10.1016/j.ejphar.2013.09.072; Ang SK, 2010, AM J HOSP PALLIAT ME, V27, P219, DOI 10.1177/1049909110361228; Atkinson SR, 2014, J PALLIAT MED, V17, P503, DOI 10.1089/jpm.2014.0030; Bentley A, 2001, PALLIATIVE MED, V15, P247, DOI 10.1191/026921601678576239; Benze G, 2012, SCHMERZ, V26, P500, DOI 10.1007/s00482-012-1216-7; Brooksbank MA, 2002, PALLIATIVE MED, V16, P520, DOI 10.1191/0269216302pm590oa; Bruera E, 2000, J PAIN SYMPTOM MANAG, V19, P427, DOI 10.1016/S0885-3924(00)00138-X; BRUERA ED, 1994, CANCER, V74, P3204, DOI 10.1002/1097-0142(19941215)74:12<3204::AID-CNCR2820741220>3.0.CO;2-G; Bruera E, 2013, J CLIN ONCOL, V31, P111, DOI 10.1200/JCO.2012.44.6518; Buchanan D, 2007, PALLIATIVE MED, V21, P725, DOI 10.1177/0269216307083383; Critchley P, 2001, J PAIN SYMPTOM MANAG, V22, P631, DOI 10.1016/S0885-3924(01)00323-2; Currow DC, 2015, J PAIN SYMPTOM MANAG, V49, P814, DOI 10.1016/j.jpainsymman.2014.09.013; Currow DC, 1997, J PAIN SYMPTOM MANAG, V13, P302, DOI 10.1016/S0885-3924(97)00079-1; Darvill E, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009420.pub2; Davis MP, 2008, EXPERT OPIN INV DRUG, V17, P85, DOI 10.1517/13543784.17.1.85; Dietrich Jorg, 2011, Expert Rev Clin Pharmacol, V4, P233, DOI 10.1586/ecp.11.1; Dietz I, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-2; Eisenchlas JH, 2005, PALLIATIVE MED, V19, P71, DOI 10.1191/0269216305pm972oa; Feuer DJ., 2000, COCHRANE DB SYST REV, V2000; General Medical Council, 2010, TREATM CAR END LIF G; Glare P, 2011, CLIN INTERV AGING, V6, P243, DOI 10.2147/CIA.S13109; Gordon P, 2014, EUR J PHARMACOL, V722, P187, DOI 10.1016/j.ejphar.2013.10.010; Hardy J, 2002, SUPPORT CARE CANCER, V10, P231, DOI 10.1007/s00520-001-0332-1; Hardy JR, 2010, J PAIN SYMPTOM MANAG, V40, P111, DOI 10.1016/j.jpainsymman.2009.11.321; Harris DG, 2010, BRIT MED BULL, V96, P175, DOI 10.1093/bmb/ldq031; Jackson W Clay, 2003, J Palliat Med, V6, P251, DOI 10.1089/109662103764978506; Jordan K, 2014, EUR J PHARMACOL, V722, P197, DOI 10.1016/j.ejphar.2013.09.073; Kaneishi K, 2012, J PAIN SYMPTOM MANAG, V44, P604, DOI 10.1016/j.jpainsymman.2011.10.023; Kennett A, 2005, SUPPORT CARE CANCER, V13, P715, DOI 10.1007/s00520-004-0768-1; Laval G, 2006, J PAIN SYMPTOM MANAG, V31, P502, DOI 10.1016/j.jpainsymman.2005.10.009; Lowery L, 2014, PALLIATIVE MED, V28, P990, DOI 10.1177/0269216314530180; Macleod AD, 2000, J PAIN SYMPTOM MANAG, V20, P388, DOI 10.1016/S0885-3924(00)00205-0; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V28, P412, DOI 10.1016/j.jpainsymman.2004.01.007; Mystakidou, 1997, Oncologist, V2, P319; Mystakidou K, 1998, J PAIN SYMPTOM MANAG, V15, P176, DOI 10.1016/S0885-3924(97)00349-7; Passik SD, 2002, J PAIN SYMPTOM MANAG, V23, P526, DOI 10.1016/S0885-3924(02)00391-3; Perkins P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006271.pub2; Saito M, 2009, LANCET ONCOL, V10, P115, DOI 10.1016/S1470-2045(08)70313-9; Srivastava M, 2003, J PAIN SYMPTOM MANAG, V25, P578, DOI 10.1016/S0885-3924(03)00143-X; Stephenson J, 2006, SUPPORT CARE CANCER, V14, P348, DOI 10.1007/s00520-005-0897-1; Teriaky A, 2012, SAUDI J GASTROENTERO, V18, P95, DOI 10.4103/1319-3767.93808	41	14	14	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 3	2015	351								h6249	10.1136/bmj.h6249	http://dx.doi.org/10.1136/bmj.h6249			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX9EZ	26635303				2023-01-03	WOS:000366009100003
J	Maletzki, C; Huehns, M; Knapp, P; Waukosin, N; Klar, E; Prall, F; Linnebacher, M				Maletzki, Claudia; Huehns, Maja; Knapp, Patrick; Waukosin, Nancy; Klar, Ernst; Prall, Friedrich; Linnebacher, Michael			Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype	PLOS ONE			English	Article							COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; BRAF MUTATION; CELL-LINES; IDENTIFICATION; ASSOCIATIONS; TARGET; GENES	Patient-individual tumor models constitute a powerful platform for basic and translational analyses both in vitro and in vivo. However, due to the labor-intensive and highly time-consuming process, only few well-characterized patient-derived cell lines and/or corresponding xenografts exist. In this study, we describe successful generation and functional analysis of novel tumor models from patients with sporadic primary colorectal carcinomas (CRC) showing CpG island methylator phenotype (CIMP). Initial DNA fingerprint analysis confirmed identity with the patient in all four cases. These freshly established cells showed characteristic features associated with the CIMP-phenotype (HROC40: APC(wt), TP53(mut), KRAS(mut); 3/8 marker methylated; HROC43: APC(mut), TP53(mut), KRAS(mut); 4/8 marker methylated; HROC60: APC(wt), TP53(mut), KRAS(wt); 4/8 marker methylated; HROC183: APC(mut), TP53(mut), KRAS(mut); 6/8 marker methylated). Cell lines were of epithelial origin (EpCAM(+)) with distinct morphology and growth kinetics. Response to chemotherapeutics was quite individual between cells, with stage I-derived cell line HROC60 being most susceptible towards standard clinically approved chemotherapeutics (e.g. 5-FU, Irinotecan). Of note, most cell lines were sensitive towards "non-classical" CRC standard drugs (sensitivity: Gemcitabin > Rapamycin > Nilotinib). This comprehensive analysis of tumor biology, genetic alterations and assessment of chemosensitivity towards a broad range of (chemo-) therapeutics helps bringing forward the concept of personalized tumor therapy.	[Maletzki, Claudia; Knapp, Patrick; Waukosin, Nancy; Linnebacher, Michael] Univ Rostock, Mol Oncol & Immunotherapy, D-18055 Rostock, Germany; [Huehns, Maja; Prall, Friedrich] Univ Rostock, Inst Pathol, D-18055 Rostock, Germany; [Klar, Ernst] Univ Rostock, Dept Gen Surg, D-18055 Rostock, Germany	University of Rostock; University of Rostock; University of Rostock	Linnebacher, M (corresponding author), Univ Rostock, Mol Oncol & Immunotherapy, D-18055 Rostock, Germany.	michael.linnebacher@med.uni-rostock.de	Linnebacher, Michael/AAT-3763-2021	Linnebacher, Michael/0000-0001-8054-1402				Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Atreya CE, 2012, INVEST NEW DRUG, V30, P2219, DOI 10.1007/s10637-012-9793-y; Cai ZR, 2014, ANN SURG ONCOL, V21, P179, DOI 10.1245/s10434-013-3146-8; Curtin Karen, 2011, Patholog Res Int, V2011, P902674, DOI 10.4061/2011/902674; FIELDING LP, 1991, J GASTROEN HEPATOL, V6, P325, DOI 10.1111/j.1440-1746.1991.tb00867.x; Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Hua VY, 1997, P NATL ACAD SCI USA, V94, P9614, DOI 10.1073/pnas.94.18.9614; Imamura Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-135; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jabbour E, 2014, AM J HEMATOL, V89, P547, DOI 10.1002/ajh.23691; JEN J, 1994, CANCER RES, V54, P5523; Jover R, 2011, GASTROENTEROLOGY, V140, P1174, DOI 10.1053/j.gastro.2010.12.035; Juo YY, 2014, ANN ONCOL, V25, P2314, DOI 10.1093/annonc/mdu149; Kaneda A, 2011, CANCER SCI, V102, P18, DOI 10.1111/j.1349-7006.2010.01712.x; Leroy C, 2010, ABSTRACT EJC S, V8; Maletzki C, 2015, WORLD J GASTROENTERO, V21, P164, DOI 10.3748/wjg.v21.i1.164; Maletzki C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052485; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Moon JW, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-4; Ogino S, 2006, J MOL DIAGN, V8, P582, DOI 10.2353/jmoldx.2006.060082; Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473; Ostwald C, 2009, INT J ONCOL, V35, P321, DOI 10.3892/ijo_00000343; Palena C, 2012, FUTURE ONCOL, V8, P713, DOI [10.2217/FON.12.59, 10.2217/fon.12.59]; Pytel D, 2009, ANTI-CANCER AGENT ME, V9, P66, DOI 10.2174/187152009787047752; Rosfjord E, 2014, BIOCHEM PHARMACOL, V91, P135, DOI 10.1016/j.bcp.2014.06.008; Sun J, 2010, CANCER IMMUNOL IMMUN, V59, P1163, DOI 10.1007/s00262-010-0841-1; Tomasetti C, 2015, P NATL ACAD SCI USA, V112, P118, DOI 10.1073/pnas.1421839112; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; van Rijnsoever M, 2003, CLIN CANCER RES, V9, P2898; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wilding JL, 2014, CANCER RES, V74, P2377, DOI 10.1158/0008-5472.CAN-13-2971; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Yamamoto E, 2012, AM J PATHOL, V181, P1847, DOI 10.1016/j.ajpath.2012.08.007	35	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2015	10	11							e0143194	10.1371/journal.pone.0143194	http://dx.doi.org/10.1371/journal.pone.0143194			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7NW	26618628	gold, Green Published			2023-01-03	WOS:000365889800027
J	Zuckerman, DM; Jury, NJ; Silcox, CE				Zuckerman, Diana M.; Jury, Nicholas J.; Silcox, Christina E.			21st Century Cures Act and similar policy efforts: at what cost?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GAMMA-SECRETASE INHIBITOR; BAPINEUZUMAB; COGNITION; DIMEBON; TRIAL		[Zuckerman, Diana M.; Jury, Nicholas J.; Silcox, Christina E.] Natl Ctr Hlth Res, Washington, DC 20036 USA		Zuckerman, DM (corresponding author), Natl Ctr Hlth Res, 1001 Connecticut Ave NW, Washington, DC 20036 USA.	dz@center4research.org		Jury, Nicholas/0000-0002-4233-117X				Altucher J., 2009, WALL STREET J; Alzheimer's Association, LAT MED MEM LOSS; [Anonymous], 2012, REUTERS; [Anonymous], 2015, ALZHEIMERS DEME 0712; [Anonymous], 2003, FORTUNE; Bachurin S, 2001, ANN NY ACAD SCI, V939, P425; Bateman RJ, 2009, ANN NEUROL, V66, P48, DOI 10.1002/ana.21623; Bezprozvanny I, 2010, DRUG NEWS PERSPECT, V23, P518, DOI 10.1358/dnp.2010.23.8.1500435; Doody RS, 2008, LANCET, V372, P207, DOI 10.1016/S0140-6736(08)61074-0; Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951; Fleisher AS, 2008, ARCH NEUROL-CHICAGO, V65, P1031, DOI 10.1001/archneur.65.8.1031; Humpel C, 2011, TRENDS BIOTECHNOL, V29, P26, DOI 10.1016/j.tibtech.2010.09.007; IMS Health, 2014, MED US SHIFT COSTS H; Kim C, 2015, JAMA INT MED; Liu EC, 2015, NEUROLOGY, V85, P692, DOI 10.1212/WNL.0000000000001877; Makuch RW, 2014, THER INNOV REGUL SCI, V48, P362, DOI 10.1177/2168479013517103; Nussbaum A., 2011, BLOOMBERG; Pollack A., 2010, NY TIMES; Pollack A., 2007, NY TIMES; Pollack A, 2015, NY TIMES, pB2; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; Rinne JO, 2010, LANCET NEUROL, V9, P363, DOI 10.1016/S1474-4422(10)70043-0; Rocchi Angela, 2013, Cost Eff Resour Alloc, V11, P31, DOI 10.1186/1478-7547-11-31; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Siemers ER, 2006, NEUROLOGY, V66, P602, DOI 10.1212/01.WNL.0000198762.41312.E1	26	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	2015	351								h6122	10.1136/bmj.h6122	http://dx.doi.org/10.1136/bmj.h6122			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX4SR	26597099				2023-01-03	WOS:000365691100001
J	Aung, NM; Kaung, M; Kyi, TT; Kyaw, MP; Min, M; Htet, ZW; Anstey, NM; Kyi, MM; Hanson, J				Aung, Ne Myo; Kaung, Myat; Kyi, Tint Tint; Kyaw, Myat Phone; Min, Myo; Htet, Zaw Win; Anstey, Nicholas M.; Kyi, Mar Mar; Hanson, Josh			The Safety of a Conservative Fluid Replacement Strategy in Adults Hospitalised with Malaria	PLOS ONE			English	Article							SEVERE FALCIPARUM-MALARIA; RESUSCITATION; MORTALITY; DYSFUNCTION; MANAGEMENT; SEVERITY; CHLORIDE; THERAPY; BALANCE; BOLUS	Background A conservative approach to fluid resuscitation improves survival in children with severe malaria; however, this strategy has not been formally evaluated in adults with the disease. Methods Adults hospitalised with malaria at two tertiary referral hospitals in Myanmar received intravenous fluid replacement with isotonic saline, administered at a maintenance rate using a simple weight-based algorithm. Clinical and biochemical indices were followed sequentially. Results Of 61 adults enrolled, 34 (56%) had Plasmodium falciparum mono-infection, 17 (28%) Plasmodium vivax mono-infection and 10 (16%) mixed infection; 27 (44%) patients were at high risk of death (P. falciparum infection and RCAM score >= 2). In the first six hours of hospitalisation patients received a mean 1.7 ml/kg/hour (range: 1.3-2.2) of intravenous fluid and were able to drink a mean of 0.8 ml/kg/hour (range: 0-3). Intravenous fluid administration and oral intake were similar for the remainder of the first 48 hours of hospitalisation. All 61 patients survived to discharge. No patient developed Adult Respiratory Distress Syndrome, a requirement for renal replacement therapy or hypotension (mean arterial pressure < 60mmHg). Plasma lactate was elevated (> 2 mmol/L) on enrolment in 26 (43%) patients but had declined by 6 hours in 25 (96%) and was declining at 24 hours in the other patient. Plasma creatinine was elevated (> 120 mu mol/L) on enrolment in 17 (28%) patients, but was normal or falling in 16 (94%) at 48 hours and declining in the other patient by 72 hours. There was no clinically meaningful increase in plasma lactate or creatinine in any patient with a normal value on enrolment. Patients receiving fluid replacement with the conservative fluid replacement algorithm were more likely to survive than historical controls in the same hospitals who had received fluid replacement guided by clinical judgement in the year prior to the study (p = 0.03), despite having more severe disease (p < 0.001). Conclusions A conservative fluid resuscitation strategy appears safe in adults hospitalised with malaria.	[Aung, Ne Myo; Kyi, Tint Tint; Htet, Zaw Win; Kyi, Mar Mar] Insein Gen Hosp, Yangon, Myanmar; [Kaung, Myat] Hpa An Hosp, Hpa An, Kayin State, Myanmar; [Kyaw, Myat Phone] Dept Med Res Lower Myanmar, Yangon, Myanmar; [Min, Myo] Myanmar Med Assoc, Yangon, Myanmar; [Anstey, Nicholas M.; Hanson, Josh] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia	Charles Darwin University; Menzies School of Health Research	Hanson, J (corresponding author), Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia.	drjoshhanson@gmail.com	Hanson, Josh/ABD-9328-2020; , Myat-Phone-Kyaw/P-1750-2019	Htet, Zaw Win/0000-0001-6913-5198; Hanson, Josh/0000-0002-1423-3839	National Health and Medical Research Council of Australia [1037304, 1042072, 1054195]; National Health and Medical Research Council of Australia [1037304, 1042072, 1054195]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This study was funded by the National Health and Medical Research Council of Australia (Program Grant 1037304 and Fellowships to NA [1042072] and JH [1054195]). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1990, Trans R Soc Trop Med Hyg, V84 Suppl 2, P1; [Anonymous], 2011, GUID DIAGN MAN MAL M; Anstey NM, 2012, ADV PARASIT, V80, P151, DOI 10.1016/B978-0-12-397900-1.00003-7; Anstey NM, 2007, PLOS MED, V4, P1291, DOI 10.1371/journal.pmed.0040267; Bagshaw SM, 2007, CURR OPIN CRIT CARE, V13, P541, DOI 10.1097/MCC.0b013e3282e2a978; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Bellomo R, 2012, CRIT CARE MED, V40, P1753, DOI 10.1097/CCM.0b013e318246b9c6; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; DAVIS TME, 1990, J CLIN INVEST, V86, P793, DOI 10.1172/JCI114776; DAVIS TME, 1992, CLIN INFECT DIS, V15, P256, DOI 10.1093/clinids/15.2.256; Day NPJ, 1996, LANCET, V348, P219, DOI 10.1016/S0140-6736(96)09096-4; Day NPJ, 2000, CRIT CARE MED, V28, P1833, DOI 10.1097/00003246-200006000-00025; Dondorp AM, 2008, J INFECT DIS, V197, P79, DOI 10.1086/523762; Faiz MA, 2005, LANCET, V366, P717; Gachot B, 1998, Rev Prat, V48, P273; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; HALL A, 1985, LANCET, V1, P1453; Hanson J, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0365-9; Hanson J, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0642-6; Hanson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087020; Hanson J, 2012, J INFECT DIS, V206, P571, DOI 10.1093/infdis/jis400; Hanson J, 2010, CLIN INFECT DIS, V50, P679, DOI 10.1086/649928; Hanson JP, 2013, CRIT CARE MED, V41, P972, DOI 10.1097/CCM.0b013e31827466d2; Harris JB, 2012, LANCET, V379, P2466, DOI 10.1016/S0140-6736(12)60436-X; Hilton AK, 2012, CRIT CARE, V16, DOI 10.1186/cc11154; Kaung M, 2015, MALARIA J, V14; Kitabchi AE, 2009, DIABETES CARE, V32, P1335, DOI 10.2337/dc09-9032; Krajewski ML, 2015, BRIT J SURG, V102, P24, DOI 10.1002/bjs.9651; Krishnan A, 2003, CRIT CARE MED, V31, P2278, DOI 10.1097/01.CCM.0000079603.82822.69; Maitland K, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-68; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Newton PN, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-229; Nguansangiam S, 2007, TROP MED INT HEALTH, V12, P1037, DOI 10.1111/j.1365-3156.2007.01881.x; OH TH, 1980, ANESTHESIOLOGY, V53, P351, DOI 10.1097/00000542-198010000-00020; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Raghunathan K, 2014, CRIT CARE MED, V42, P1585, DOI 10.1097/CCM.0000000000000305; SPITZ S, 1946, Mil Surg, V99, P555; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; WARRELL DA, 1985, BRIT MED J, V291, P1573, DOI 10.1136/bmj.291.6508.1573; WHO, WHO GUID TREATM MAL; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Wills BA, 2005, NEW ENGL J MED, V353, P877, DOI 10.1056/NEJMoa044057; World Health Organization, 2009, INT MAN AD AD ILLN 2; Yeo TW, 2013, J INFECT DIS, V207, P528, DOI 10.1093/infdis/jis692; Yunos NM, 2010, CRIT CARE, V14, DOI 10.1186/cc9052	45	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2015	10	11							e0143062	10.1371/journal.pone.0143062	http://dx.doi.org/10.1371/journal.pone.0143062			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW7CD	26581060	Green Published, Green Submitted, gold			2023-01-03	WOS:000365154600075
J	Carpenter, CR				Carpenter, Christopher R.			The Richmond Agitation Sedation Scale was accurate for detecting delirium in older patients in the ED	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EMERGENCY-DEPARTMENT		[Carpenter, Christopher R.] Washington Univ, St Louis, MO 63130 USA	Washington University (WUSTL)	Carpenter, CR (corresponding author), Washington Univ, St Louis, MO 63130 USA.		Carpenter, Christopher R./E-3720-2013	Carpenter, Christopher R./0000-0002-2603-7157				American College of Emergency Physicians American Geriatrics Society Emergency Nurses Association, 2014, ANN EMERG MED, V63, pe7, DOI DOI 10.1016/J.ANNEMERGMED.2014.02.008; Han JH, 2015, J HOSP MED, V10, P694, DOI 10.1002/jhm.2478; Han JH, 2009, ACAD EMERG MED, V16, P193, DOI 10.1111/j.1553-2712.2008.00339.x; LaMantia MA, 2014, ANN EMERG MED, V63, P551, DOI 10.1016/j.annemergmed.2013.11.010; Siddiqi N, 2007, COCHRANE DB SYST REV, V2	5	0	1	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2015	163	10					JC10	JC10		10.7326/ACPJC-2015-163-10-010	http://dx.doi.org/10.7326/ACPJC-2015-163-10-010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX5MQ	26571252				2023-01-03	WOS:000365746400011
J	Tamosaityte, S; Galli, R; Uckermann, O; Sitoci-Ficici, KH; Later, R; Beiermeister, R; Doberenz, F; Gelinsky, M; Leipnitz, E; Schackert, G; Koch, E; Sablinskas, V; Steiner, G; Kirsch, M				Tamosaityte, Sandra; Galli, Roberta; Uckermann, Ortrud; Sitoci-Ficici, Kerim H.; Later, Robert; Beiermeister, Rudolf; Doberenz, Falko; Gelinsky, Michael; Leipnitz, Elke; Schackert, Gabriele; Koch, Edmund; Sablinskas, Valdas; Steiner, Gerald; Kirsch, Matthias			Biochemical Monitoring of Spinal Cord Injury by FT-IR Spectroscopy-Effects of Therapeutic Alginate Implant in Rat Models	PLOS ONE			English	Article							PROMOTES FUNCTIONAL RECOVERY; CENTRAL-NERVOUS-SYSTEM; OF-THE-ART; ENHANCES ELONGATION; REPAIR STRATEGIES; HUMAN TISSUES; STEM-CELLS; ADULT-RATS; HYDROGEL; GROWTH	Spinal cord injury (SCI) induces complex biochemical changes, which result in inhibition of nervous tissue regeneration abilities. In this study, Fourier-transform infrared (FT-IR) spectroscopy was applied to assess the outcomes of implants made of a novel type of non-functionalized soft calcium alginate hydrogel in a rat model of spinal cord hemisection (n = 28). Using FT-IR spectroscopic imaging, we evaluated the stability of the implants and the effects on morphology and biochemistry of the injured tissue one and six months after injury. A semi-quantitative evaluation of the distribution of lipids and collagen showed that alginate significantly reduced injury-induced demyelination of the contralateral white matter and fibrotic scarring in the chronic state after SCI. The spectral information enabled to detect and localize the alginate hydrogel at the lesion site and proved its long-term persistence in vivo. These findings demonstrate a positive impact of alginate hydrogel on recovery after SCI and prove FT-IR spectroscopic imaging as alternative method to evaluate and optimize future SCI repair strategies.	[Tamosaityte, Sandra; Galli, Roberta; Koch, Edmund; Steiner, Gerald] Tech Univ Dresden, Fac Med, Dept Anesthesiol & Intens Care Med, Clin Sensoring & Monitoring, Dresden, Germany; [Tamosaityte, Sandra; Sablinskas, Valdas; Steiner, Gerald] Vilnius State Univ, Fac Phys, Dept Gen Phys & Spect, Vilnius, Lithuania; [Uckermann, Ortrud; Sitoci-Ficici, Kerim H.; Later, Robert; Leipnitz, Elke; Schackert, Gabriele; Kirsch, Matthias] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Neurosurg, Dresden, Germany; [Beiermeister, Rudolf; Doberenz, Falko; Gelinsky, Michael] Tech Univ Dresden, Ctr Translat Bone Joint & Soft Tissue Res, Dresden, Germany; [Kirsch, Matthias] Tech Univ Dresden, Cluster Excellence, CRTD DFG Ctr Regenerat Therapies Dresden, Dresden, Germany	Technische Universitat Dresden; Vilnius University; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Technische Universitat Dresden	Galli, R (corresponding author), Tech Univ Dresden, Fac Med, Dept Anesthesiol & Intens Care Med, Clin Sensoring & Monitoring, Dresden, Germany.	roberta.galli@tu-dresden.de; matthias.kirsch@uniklinikum-dresden.de	Gelinsky, Michael/A-9680-2012	Gelinsky, Michael/0000-0001-9075-5121; Koch, Edmund/0000-0003-0554-2178	German Federal Ministry of Education and Research (MediCARS project) [A.Z. 13N10777]; Medical Faculty of the TU Dresden (Habilitationsforderung fur Frauen); Saxon Development Bank (SAB)	German Federal Ministry of Education and Research (MediCARS project); Medical Faculty of the TU Dresden (Habilitationsforderung fur Frauen); Saxon Development Bank (SAB)	This research was partly funded by the German Federal Ministry of Education and Research (MediCARS project, A.Z. 13N10777). Moreover OU is recipient of a fellowship from the Medical Faculty of the TU Dresden (Habilitationsforderung fur Frauen) and RB is recipient of a scholarship from the Saxon Development Bank (SAB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansorena E, 2013, INT J PHARMACEUT, V455, P148, DOI 10.1016/j.ijpharm.2013.07.045; Arvanian VL, 2009, EXP NEUROL, V216, P471, DOI 10.1016/j.expneurol.2009.01.004; Awad BI, 2015, WORLD NEUROSURG, V83, P120, DOI 10.1016/j.wneu.2013.01.042; Belbachir K, 2009, ANAL BIOANAL CHEM, V395, P829, DOI 10.1007/s00216-009-3019-y; Boyce Vanessa S, 2014, Handb Exp Pharmacol, V220, P443, DOI 10.1007/978-3-642-45106-5_16; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705; Chanimov M, 2006, MED SCI MONITOR, V12, pBR63; Cheheltani R, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.5.056014; Christie SD, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E5; Daemi H, 2012, SCI IRAN, V19, P2023, DOI 10.1016/j.scient.2012.10.005; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Dhoot NO, 2004, J BIOMED MATER RES A, V71A, P191, DOI 10.1002/jbm.a.30103; Diem M, 2013, J BIOPHOTONICS, V6, P855, DOI 10.1002/jbio.201300131; Estrada V, 2014, NEUROBIOL DIS, V67, P165, DOI 10.1016/j.nbd.2014.03.018; Fajardo AR, 2012, RSC ADV, V2, P11095, DOI 10.1039/c2ra20785k; Galli R, 2012, ANAL CHEM, V84, P8707, DOI 10.1021/ac301938m; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hunanyan AS, 2011, J NEUROPHYSIOL, V105, P1033, DOI 10.1152/jn.00810.2010; Hurlbert RJ, 2013, NEUROSURGERY, V72, P93, DOI 10.1227/NEU.0b013e31827765c6; Kataoka K, 2004, TISSUE ENG, V10, P493, DOI 10.1089/107632704323061852; Kataoka K, 2001, J BIOMED MATER RES, V54, P373, DOI 10.1002/1097-4636(20010305)54:3<373::AID-JBM90>3.3.CO;2-H; Klapka N, 2006, J NEUROTRAUM, V23, P422, DOI 10.1089/neu.2006.23.422; Kong HJ, 2004, BIOMACROMOLECULES, V5, P1720, DOI 10.1021/bm049879r; Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003; Levin IW, 2005, ANNU REV PHYS CHEM, V56, P429, DOI 10.1146/annurev.physchem.56.092503.141205; Liu KZ, 2002, CLIN CHEM, V48, P499; Madigan NN, 2009, RESP PHYSIOL NEUROBI, V169, P183, DOI 10.1016/j.resp.2009.08.015; Martinon S, 2008, MINI-REV MED CHEM, V8, P222; Matyash M, 2014, TISSUE ENG PART C-ME, V20, P401, DOI [10.1089/ten.tec.2013.0252, 10.1089/ten.TEC.2013.0252]; Matyash M, 2012, TISSUE ENG PT A, V18, P55, DOI [10.1089/ten.tea.2011.0097, 10.1089/ten.TEA.2011.0097]; McKay CA, 2014, ACS APPL MATER INTER, V6, P1424, DOI 10.1021/am4027423; Meier RJ, 2005, CHEM SOC REV, V34, P743, DOI 10.1039/b503880d; Muse ED, 2001, J NEUROCHEM, V76, P77, DOI 10.1046/j.1471-4159.2001.00015.x; Novikov LN, 2002, BIOMATERIALS, V23, P3369, DOI 10.1016/S0142-9612(02)00037-6; Novikova LN, 2003, CURR OPIN NEUROL, V16, P711, DOI 10.1097/00019052-200312000-00011; Olsztynska-Janus S, 2012, ACTA BIOENG BIOMECH, V14, P121, DOI 10.5277/abb120414; Olsztynska-Janus S, 2012, ACTA BIOENG BIOMECH, V14, P101, DOI 10.5277/abb120314; Pakulska MM, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/2/024101; Perale G, 2008, J APPL BIOMATER BIOM, V6, P1; Perale G, 2011, ACS CHEM NEUROSCI, V2, P336, DOI 10.1021/cn200030w; Prang P, 2006, BIOMATERIALS, V27, P3560, DOI 10.1016/j.biomaterials.2006.01.053; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; 최기환, 2006, [Tissue Engineering and Regenerative Medicine, 조직공학과 재생의학], V3, P472; Sarker B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107952; Saxena T, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3549700; Shearer MC, 2001, CELL TISSUE RES, V305, P267, DOI 10.1007/s004410100384; Shoichet MS, 1996, BIOTECHNOL BIOENG, V50, P374, DOI 10.1002/(SICI)1097-0290(19960520)50:4<374::AID-BIT4>3.0.CO;2-I; Smith GM, 2011, BRAIN RES BULL, V84, P300, DOI 10.1016/j.brainresbull.2010.05.013; Storer PD, 2003, J NEUROSCI RES, V74, P502, DOI 10.1002/jnr.10787; Straley KS, 2010, J NEUROTRAUM, V27, P1, DOI 10.1089/neu.2009.0948; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Tobias CA, 2005, J NEUROTRAUM, V22, P138, DOI 10.1089/neu.2005.22.138	55	15	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2015	10	11							e0142660	10.1371/journal.pone.0142660	http://dx.doi.org/10.1371/journal.pone.0142660			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV7DR	26559822	gold, Green Published			2023-01-03	WOS:000364433100107
J	Amant, F; Vandenbroucke, T; Verheecke, M; Fumagalli, M; Halaska, MJ; Boere, I; Han, S; Gziri, MM; Peccatori, F; Rob, L; Lok, C; Witteveen, P; Voigt, JU; Naulaers, G; Vallaeys, L; Van den Heuvel, F; Lagae, L; Mertens, L; Claes, L; Van Calsteren, K				Amant, F.; Vandenbroucke, T.; Verheecke, M.; Fumagalli, M.; Halaska, M. J.; Boere, I.; Han, S.; Gziri, M. M.; Peccatori, F.; Rob, L.; Lok, C.; Witteveen, P.; Voigt, J-U; Naulaers, G.; Vallaeys, L.; Van den Heuvel, F.; Lagae, L.; Mertens, L.; Claes, L.; Van Calsteren, K.		INCIP	Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSPLACENTAL TRANSFER; AMERICAN-SOCIETY; BREAST-CANCER; CHEMOTHERAPY; CHILDREN; ANTHRACYCLINES; ECHOCARDIOGRAM; PERFORMANCE; BIRTH; FETAL	BACKGROUND Data on the long-term outcome of children who are exposed to maternal cancer with or without treatment during pregnancy are lacking. METHODS In this multicenter case-control study, we compared children whose mothers received a diagnosis of cancer during the pregnancy with matched children of women without a cancer diagnosis. We used a health questionnaire and medical files to collect data regarding neonatal and general health. All children were prospectively assessed (by means of a neurologic examination and the Bayley Scales of Infant Development) at 18 months, 36 months, or both. A cardiac assessment was performed at 36 months. RESULTS A total of 129 children (median age, 22 months; range, 12 to 42) were included in the group whose mother had cancer (prenatal-exposure group) with a matching number in the control group. During pregnancy, 96 children (74.4%) were exposed to chemotherapy (alone or in combination with other treatments), 11 (8.5%) to radiotherapy (alone or in combination), 13 (10.1%) to surgery alone, 2 (1.6%) to other drug treatments, and 14 (10.9%) to no treatment. Birth weight was below the 10th percentile in 28 of 127 children (22.0%) in the prenatal-exposure group and in 19 of 125 children (15.2%) in the control group (P = 0.16). There was no significant between-group difference in cognitive development on the basis of the Bayley score (P = 0.08) or in subgroup analyses. The gestational age at birth was correlated with the cognitive outcome in the two study groups. Cardiologic evaluation among 47 children at 36 months of age showed normal cardiac findings. CONCLUSIONS Prenatal exposure to maternal cancer with or without treatment did not impair the cognitive, cardiac, or general development of children in early childhood. Prematurity was correlated with a worse cognitive outcome, but this effect was independent of cancer treatment.	[Amant, F.; Vandenbroucke, T.; Verheecke, M.; Han, S.] Univ Hosp Leuven, Dept Gynecol Oncol, B-3000 Louvain, Belgium; [Amant, F.; Vandenbroucke, T.; Verheecke, M.; Han, S.] Katholieke Univ Leuven, Dept Oncol, Leuven, Belgium; [Voigt, J-U] Univ Hosp Leuven, Dept Cardiol, B-3000 Louvain, Belgium; [Naulaers, G.; Vallaeys, L.; Lagae, L.] Univ Hosp Leuven, Dept Pediat, B-3000 Louvain, Belgium; [Van Calsteren, K.] Univ Hosp Leuven, Dept Obstet, B-3000 Louvain, Belgium; [Naulaers, G.; Lagae, L.; Van Calsteren, K.] Katholieke Univ Leuven, Dept Growth & Regenerat, Leuven, Belgium; [Claes, L.] Katholieke Univ Leuven, Fac Psychol & Educ Sci, Leuven, Belgium; [Gziri, M. M.] Clin Univ St Luc, Dept Obstet, B-1200 Brussels, Belgium; [Fumagalli, M.] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neonatal Intens Care Unit, Milan, Italy; [Peccatori, F.] European Inst Oncol, Fertil & Reprod Unit, Milan, Italy; [Halaska, M. J.; Rob, L.] Charles Univ Prague, Dept Obstet & Gynecol, Prague, Czech Republic; [Boere, I.] Erasmus MC, Inst Canc, Dept Med Oncol, Rotterdam, Netherlands; [Amant, F.; Lok, C.] Antoni van Leeuwenhoek Netherlands Canc Inst, Ctr Gynecol Oncol Amsterdam, Amsterdam, Netherlands; [Witteveen, P.] Univ Med Ctr Utrecht, Ctr Canc, Dept Med Oncol, Utrecht, Netherlands; [Van den Heuvel, F.] Univ Oxford, Dept Phys, Oxford, England; [Van den Heuvel, F.] Univ Oxford, Dept Nucl Phys, Oxford OX1 3RH, England; [Van den Heuvel, F.] Univ Oxford, Dept Med Phys, Oxford, England; [Mertens, L.] Univ Toronto, Hosp Sick Children, Dept Cardiol, Toronto, ON M5G 1X8, Canada	KU Leuven; University Hospital Leuven; KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; KU Leuven; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS European Institute of Oncology (IEO); Charles University Prague; Erasmus University Rotterdam; Erasmus MC; Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; University of Oxford; University of Oxford; University of Oxford; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Amant, F (corresponding author), Univ Hosp Leuven, Dept Gynecol Oncol, Herestr 49, B-3000 Louvain, Belgium.	frederic.amant@uzleuven.be	Van den Heuvel, Frank/GOK-2337-2022; Peccatori, Fedro Alessandro/AAP-7058-2020; Halaska, Michael/AFR-7383-2022; Van den Heuvel, Frank/CAE-9338-2022; Naulaers, Gunnar/AAC-5022-2019; Rob, Lukas/AFQ-9215-2022; Peccatori, Fedro/AAL-3450-2021; Amant, Frédéric/W-7436-2019; Fumagalli, Monica/K-6717-2016; Lok, Christianne/ABB-4416-2020	Van den Heuvel, Frank/0000-0001-9904-502X; Peccatori, Fedro Alessandro/0000-0001-8227-8740; Van den Heuvel, Frank/0000-0001-9904-502X; Rob, Lukas/0000-0003-3770-651X; Amant, Frédéric/0000-0002-5452-4905; Fumagalli, Monica/0000-0002-0186-0710; Naulaers, Gunnar/0000-0003-0735-4808; Voigt, Jens-Uwe/0000-0002-0575-1888; Claes, Laurence/0000-0002-2287-3158; Mertens, Luc/0000-0001-7308-1268; Han, Sileny/0000-0002-7476-3372	Research Foundation-Flanters	Research Foundation-Flanters	Funded by Research Foundation-Flanters and others	Amant F, 2012, LANCET ONCOL, V13, P256, DOI 10.1016/S1470-2045(11)70363-1; Aviles A, 2006, ANN ONCOL, V17, P286, DOI 10.1093/annonc/mdj053; Aviles A, 2001, CLIN LYMPHOMA, V2, P173, DOI 10.3816/CLM.2001.n.023; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Bayley N., 2005, BAYLEY SCALES INFANT; Berveiller P, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.10.007; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Cardonick EH, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.11.032; Cotechini T, 2015, PLACENTA, V36, P960, DOI 10.1016/j.placenta.2015.05.016; Cunningham F.G., 2010, WILLIAMS OBSTET STUD, P842; Gziri MM, 2012, ACTA OBSTET GYN SCAN, V91, P1465, DOI 10.1111/j.1600-0412.2012.01524.x; Hahn KME, 2006, CANCER, V107, P1219, DOI 10.1002/cncr.22081; Lai WW, 2006, J AM SOC ECHOCARDIOG, V19, P1413, DOI 10.1016/j.echo.2006.09.001; Loibl S, 2012, LANCET ONCOL, V13, P887, DOI 10.1016/S1470-2045(12)70261-9; Lopez L, 2010, J AM SOC ECHOCARDIOG, V23, P465, DOI 10.1016/j.echo.2010.03.019; Lowe JR, 2012, ACTA PAEDIATR, V101, pE55, DOI 10.1111/j.1651-2227.2011.02517.x; Luis SA, 2009, J MED IMAG RADIAT ON, V53, P559, DOI 10.1111/j.1754-9485.2009.02124.x; Mir O, 2008, CANCER, V113, P3069, DOI 10.1002/cncr.23935; Murthy RK, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0500-0; Newbern D, 2011, CURR OPIN ENDOCRINOL, V18, P409, DOI 10.1097/MED.0b013e32834c800d; Rakers F, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.07.020; Roelants M, 2009, ANN HUM BIOL, V36, P680, DOI 10.3109/03014460903049074; Sankaran S, 2009, BEST PRACT RES CL OB, V23, P765, DOI 10.1016/j.bpobgyn.2009.05.003; Van Calsteren K, 2010, GYNECOL ONCOL, V119, P594, DOI 10.1016/j.ygyno.2010.08.019; Van Calsteren K, 2010, INT J GYNECOL CANCER, V20, P1456, DOI 10.1111/IGC.0b013e3181fb18c8; Van Calsteren K, 2010, J CLIN ONCOL, V28, P683, DOI 10.1200/JCO.2009.23.2801; van der Giessen PH, 2001, RADIOTHER ONCOL, V58, P209, DOI 10.1016/S0167-8140(00)00326-1	27	196	209	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	2015	373	19					1824	1834		10.1056/NEJMoa1508913	http://dx.doi.org/10.1056/NEJMoa1508913			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV3FK	26415085	Green Accepted, Green Submitted, Green Published, Bronze			2023-01-03	WOS:000364144000006
J	Cho, KH; Kim, YS; Nam, CM; Kim, TH; Kim, SJ; Han, KT; Park, EC				Cho, Kyoung Hee; Kim, Young Sam; Nam, Chung Mo; Kim, Tae Hyun; Kim, Sun Jung; Han, Kyu-Tae; Park, Eun-Cheol			The Association between Continuity of Care and All-Cause Mortality in Patients with Newly Diagnosed Obstructive Pulmonary Disease: A Population-Based Retrospective Cohort Study, 2005-2012	PLOS ONE			English	Article							AMBULATORY-CARE; ADULT PATIENTS; PREDICTORS; SURVIVAL; OUTCOMES; KOREA; COSTS; COPD	Background The disease burden is increasing for chronic obstructive pulmonary disease (COPD) due to increasing of the growth rate of prevalence and mortality. But the empirical researches are a little for COPD that studied the association between continuity of care and death and about predictors effect on mortality. Objective To investigate the association between continuity of care (COC) and chronic obstructive pulmonary disease (COPD) mortality and to identify other mortality-related factors in COPD patients. Methods We conducted a longitudinal, population-based retrospective cohort study in adult patients with COPD from 2002 to 2012 using a nationwide health insurance claims database. The study sample included individuals aged 40 years and over who developed COPD in 2005 and survived until 2006. We performed a Cox proportional hazard regression analysis with COC analyzed as a time-dependent covariate. Results Of the 3,090 participants, 60.8% died before the end of study (N = 1,879). The median years of survival for individuals with high COC (COC index >= 0.75) was 3.92, and that for patients with low COC (COC index<0.75) was 2.58 in a Kaplan Meier analysis. In a multivariate, time-dependent analysis, low COC was associated with a 22% increased risk of all-cause mortality (HR, 1.22; 95% CI, 1.09-1.36). Not receiving oxygen therapy at home was associated with a 23% increased risk of all-cause mortality (HR, 1.23; 95% CI, 1.01-1.49). Moreover, the risk of all-cause mortality for individuals who admitted one time increased 38%(HR, 1.38; 95% CI, 1.21-1.59), two times was 63%(HR, 1.63; 95% CI, 1.34-1.99) and 3+times was 96%(HR, 1.96; 95% CI, 1.63-2.36) relative to the reference group (no admission). Conclusions High COC was associated with a decreased risk of all-cause mortality. In addition, home oxygen therapy and number of hospital admissions may predict mortality in patients with COPD.	[Cho, Kyoung Hee; Kim, Sun Jung; Han, Kyu-Tae] Yonsei Univ, Grad Sch, Dept Publ Hlth, Seoul 120749, South Korea; [Cho, Kyoung Hee; Kim, Tae Hyun; Kim, Sun Jung; Han, Kyu-Tae; Park, Eun-Cheol] Yonsei Univ, Coll Med, Inst Hlth Serv Res, Seoul, South Korea; [Kim, Young Sam] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Nam, Chung Mo] Yonsei Univ, Coll Med, Dept Biostat, Seoul, South Korea; [Kim, Tae Hyun] Yonsei Univ, Grad Sch Publ Hlth, Seoul 120749, South Korea; [Park, Eun-Cheol] Yonsei Univ, Coll Med, Dept Prevent Med, Seoul, South Korea	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Park, EC (corresponding author), Yonsei Univ, Coll Med, Inst Hlth Serv Res, Seoul, South Korea.	ECPARK@yuhs.ac	Kim, Sun Jung/AAM-7334-2020; Park, Eun-Cheol/O-5644-2019	Kim, Sun Jung/0000-0003-1756-1376; Park, Eun-Cheol/0000-0002-2306-5398; Han, Kyu-Tae/0000-0002-5817-1203; Kim, Tae Hyun/0000-0003-1053-8958; Nam, Chung Mo/0000-0003-0985-0928; Kim, Young Sam/0000-0001-9656-8482; Cho, Kyoung Hee/0000-0003-0753-1560				Atlas SJ, 2009, ANN INTERN MED, V150, P325, DOI 10.7326/0003-4819-150-5-200903030-00008; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; Cabana MD, 2004, J FAM PRACTICE, V53, P974; Celli BR, 2008, RESP MED, V102, pS27, DOI 10.1016/S0954-6111(08)70005-2; Chen CC, 2012, BMC HEALTH SERV RES, V12, P405; Dela Coleta K, 2008, RESP MED, V102, P512, DOI 10.1016/j.rmed.2007.12.003; Esteban C, 2008, J GEN INTERN MED, V23, P1829, DOI 10.1007/s11606-008-0783-x; Gill James M, 2003, Ann Fam Med, V1, P162, DOI 10.1370/afm.22; Gray DP, 2003, J ROY SOC MED, V96, P160, DOI 10.1258/jrsm.96.4.160; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Hjalmarsen A, 1999, INT J TUBERC LUNG D, V3, P1120; Hong JS, 2014, MED CARE, V52, P446, DOI 10.1097/MLR.0000000000000110; Hong JS, 2013, HEALTH POLICY, V109, P158, DOI 10.1016/j.healthpol.2012.09.009; Hussey PS, 2014, JAMA INTERN MED, V174, P742, DOI 10.1001/jamainternmed.2014.245; Hussey PS, 2014, JAMA INTER MED, P17; Kim RY, 2011, INTRO NATL PATIENTS; Knight JC, 2009, POPUL HEALTH MANAG, V12, P81, DOI 10.1089/pop.2008.0020; Korea National Statistical Office, 2013, STAT ALL CAUS MORT 2; Mainous AG, 1998, AM J PUBLIC HEALTH, V88, P1539, DOI 10.2105/AJPH.88.10.1539; Malcolm JC, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-303; Menec Verena H, 2006, J Health Serv Res Policy, V11, P196, DOI 10.1258/135581906778476562; 김재용, 2006, Diabetes and Metabolism Journal, V30, P377; Parchman ML, 2002, MED CARE, V40, P137, DOI 10.1097/00005650-200202000-00008; Saultz John W, 2003, Ann Fam Med, V1, P134, DOI 10.1370/afm.23; Sharma G, 2010, ARCH INTERN MED, V170, P1664, DOI 10.1001/archinternmed.2010.345; Uijen AA, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X649115; van Walraven C, 2004, J CLIN EPIDEMIOL, V57, P672, DOI 10.1016/j.jclinepi.2003.12.008; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; Weiss LJ, 1996, AM J PUBLIC HEALTH, V86, P1742, DOI 10.2105/AJPH.86.12.1742	30	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2015	10	11							e0141465	10.1371/journal.pone.0141465	http://dx.doi.org/10.1371/journal.pone.0141465			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV1QH	26529224	gold, Green Published			2023-01-03	WOS:000364032600030
J	Stocks, SJ; Kontopantelis, E; Akbarov, A; Rodgers, S; Avery, AJ; Ashcroft, DM				Stocks, S. Jill; Kontopantelis, Evangelos; Akbarov, Artur; Rodgers, Sarah; Avery, Anthony J.; Ashcroft, Darren M.			Examining variations in prescribing safety in UK general practice: cross sectional study using the Clinical Practice Research Datalink	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; INDICATORS; INTERVENTION; TRIAL	STUDY QUESTION What is the prevalence of different types of potentially hazardous prescribing in general practice in the United Kingdom, and what is the variation between practices? METHODS A cross sectional study included all adult patients potentially at risk of a prescribing or monitoring error defined by a combination of diagnoses and prescriptions in 526 general practices contributing to the Clinical Practice Research Datalink (CPRD) up to 1 April 2013. Primary outcomes were the prevalence of potentially hazardous prescriptions of anticoagulants, anti-platelets, NSAIDs, beta blockers, glitazones, metformin, digoxin, antipsychotics, combined hormonal contraceptives, and oestrogens and monitoring by blood test less frequently than recommended for patients with repeated prescriptions of angiotensin converting enzyme inhibitors and loop diuretics, amiodarone, methotrexate, lithium, or warfarin. STUDY ANSWER and limitations 49 927 of 949 552 patients at risk triggered at least one prescribing indicator (5.26%, 95% confidence interval 5.21% to 5.30%) and 21 501 of 182 721 (11.8%, 11.6% to 11.9%) triggered at least one monitoring indicator. The prevalence of different types of potentially hazardous prescribing ranged from almost zero to 10.2%, and for inadequate monitoring ranged from 10.4% to 41.9%. Older patients and those prescribed multiple repeat medications had significantly higher risks of triggering a prescribing indicator whereas younger patients with fewer repeat prescriptions had significantly higher risk of triggering a monitoring indicator. There was high variation between practices for some indicators. Though prescribing safety indicators describe prescribing patterns that can increase the risk of harm to the patient and should generally be avoided, there will always be exceptions where the indicator is clinically justified. Furthermore there is the possibility that some information is not captured by CPRD for some practices-for example, INR results in patients receiving warfarin. WHAT THIS STUDY ADDS The high prevalence for certain indicators emphasises existing prescribing risks and the need for their appropriate consideration within primary care, particularly for older patients and those taking multiple medications. The high variation between practices indicates potential for improvement through targeted practice level intervention.	[Stocks, S. Jill; Ashcroft, Darren M.] Univ Manchester, Inst Populat Hlth, Ctr Primary Care, NIHR Greater Manchester Primary Care Patient Safe, Manchester M13 9PL, Lancs, England; [Kontopantelis, Evangelos] Univ Manchester, Inst Populat Hlth, Ctr Primary Care, NIHR Sch Primary Care Res, Manchester M13 9PL, Lancs, England; [Kontopantelis, Evangelos; Akbarov, Artur] Univ Manchester, Inst Populat Hlth, Ctr Hlth Informat, Manchester M13 9PL, Lancs, England; [Rodgers, Sarah; Avery, Anthony J.] Univ Nottingham, Sch Med, Queens Med Ctr, Div Primary Care, Nottingham, England; [Ashcroft, Darren M.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester Pharm Sch, Ctr Pharmacoepidemiol & Drug Safety, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester; University of Manchester; University of Nottingham; University of Manchester	Stocks, SJ (corresponding author), Univ Manchester, Inst Populat Hlth, Ctr Primary Care, NIHR Greater Manchester Primary Care Patient Safe, Manchester M13 9PL, Lancs, England.	jill.stocks@manchester.ac.uk	Kontopantelis, Evangelos/H-2966-2019; Ashcroft, Darren/G-3244-2015	Kontopantelis, Evangelos/0000-0001-6450-5815; Rodgers, Sarah/0000-0003-1676-1982; Stocks, Susan Jill/0000-0001-6034-476X; Ashcroft, Darren/0000-0002-2958-915X; Avery, Anthony/0000-0001-7591-4438	National Institute for Health Research through the Greater Manchester Primary Care Patient Safety Translational Research Centre (NIHR GM PSTRC) [GMPSTRC-2012-1]; MRC [MR/K006665/1] Funding Source: UKRI; Medical Research Council [MC_PC_13042, MR/K006665/1] Funding Source: researchfish; National Institute for Health Research [SPCR-042] Funding Source: researchfish	National Institute for Health Research through the Greater Manchester Primary Care Patient Safety Translational Research Centre (NIHR GM PSTRC); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the National Institute for Health Research through the Greater Manchester Primary Care Patient Safety Translational Research Centre (NIHR GM PSTRC), grant No GMPSTRC-2012-1. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.	Akbarov A, 2015, DRUG SAFETY, V38, P671, DOI 10.1007/s40264-015-0304-x; [Anonymous], 2014, PRESCR DISP COMM 200; [Anonymous], 2013, RCGP GUID REV GEN PR; [Anonymous], IND DEPR UK 2014; Avery AJ, 1998, J CLIN PHARM THER, V23, P441, DOI 10.1046/j.1365-2710.1998.00187.x; Avery AJ, 2011, INVESTIGATING PREVAL; Avery AJ, 2012, LANCET, V379, P1310, DOI 10.1016/S0140-6736(11)61817-5; Avery AJ, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X588501; Campbell SM, 2000, BRIT MED J, V321, P425, DOI 10.1136/bmj.321.7258.425; Dreischulte T, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-24; Dreischulte Tobias, 2012, BMC Clin Pharmacol, V12, P5, DOI 10.1186/1472-6904-12-5; Guthrie Bruce, 2011, BMJ, V342, pd3514, DOI 10.1136/bmj.d3514; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Kontopantelis E, 2013, BMJ OPEN, V3; Kontopantelis E, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g330; Mathur R, 2014, J PUBLIC HEALTH-UK, V36, P684, DOI 10.1093/pubmed/fdt116; Morris CJ, 2004, QUAL SAF HEALTH CARE, V13, P181, DOI 10.1136/qshc.2003.008334; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; PRIMIS, PINC AUD TOOL; Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549; Spencer R, 2014, BRIT J GEN PRACT, V64, pE181, DOI 10.3399/bjgp14X677806; Springate DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099825; Winterstein AG, 2002, ANN PHARMACOTHER, V36, P1238, DOI 10.1345/aph.1A225	23	51	52	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 3	2015	351								h5501	10.1136/bmj.h5501	http://dx.doi.org/10.1136/bmj.h5501			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV6OC	26537416	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000364388500002
J	Diaz, RS; Inocencio, LA; Sucupira, MCA; Pereira, AA; Hunter, J; Ferreira, JE; Araujo, LV; Souza, DFC; Sabino, EC				Diaz, Ricardo Sobhie; Inocencio, Lilian A.; Sucupira, Maria Cecilia Araripe; Pereira, Anderson Alvarenga; Hunter, James; Ferreira, Joao Eduardo; Araujo, Luciano V.; Souza, Denise F. C.; Sabino, Ester Cerdeira			The Virological and Immunological Characteristics of the HIV-1-Infected Population in Brazil: From Initial Diagnosis to Impact of Antiretroviral Use	PLOS ONE			English	Article							HIV-INFECTION; SUBTYPE-B; THERAPY; INDIVIDUALS; EXPERIENCE; ADULTS; RISK	Background Immunological and virological status of HIV-infected individuals entering the Brazilian public system over time was analyzed. We evaluated the impact of ART on virological, immunological and antiretroviral resistance over time. Methods CD4+ T cell counts, viral loads and genotypes from patients over 13 years old from 2001-2011 were analyzed according to demographic data. We compared groups using parametric t-tests and linear regression analysis in the R statistical software language. Results Mean baseline CD4+ T cell counts varied from 348 (2003) to 389 (2009) and was higher among women (p = 1.1 x 10(-8)), lower in older patients (p < 1 x 10(-8)) and lower in less developed regions (p = 1.864 x 10(-5)). Percentage of treated patients with undetectable viral loads increased linearly from 46% (2001) to 77% (2011), was lower among women (p = 2.851 x 10(-6)), younger ages (p = 1 x 10(-3)), and in less developed regions (p = 1.782 x 10(-4)). NRTI acquired resistance was 86% in 2001-3 and decreased over time. NNRTI resistance increased from 2001-3(50%) to 2006-9 (60%), PI resistance decreased from 2001-3 (60%) to 2009 (40%), and 3-class resistance was stable over time around 25%. Subtype prevalence comprised B (75.3%), B/F recombinants (12.2%), C (5.7%), F (5.3%) and B/C recombinants (1.5%), with regional variations. Three-class resistance was 26.5% among Bs, 22.4% among Fs and 17.2% among Cs. Conclusions HIV diagnosis occurs late, especially among elderly Brazilians. Younger individuals need special attention due to poor virological response to treatment. Antiretroviral Resistance profile is subtype related.	[Diaz, Ricardo Sobhie; Inocencio, Lilian A.; Sucupira, Maria Cecilia Araripe; Hunter, James] Univ Fed Sao Paulo, Sao Paulo, Brazil; [Inocencio, Lilian A.; Pereira, Anderson Alvarenga; Souza, Denise F. C.] Brazilian STD AIDS, Brasilia, DF, Brazil; [Inocencio, Lilian A.; Pereira, Anderson Alvarenga; Souza, Denise F. C.] Minist Hlth, Viruses Hepatitis Dept, Brasilia, DF, Brazil; [Ferreira, Joao Eduardo; Araujo, Luciano V.; Sabino, Ester Cerdeira] Univ Sao Paulo, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo	Diaz, RS (corresponding author), Univ Fed Sao Paulo, Sao Paulo, Brazil.	rsdiaz@catg.com.br	Ferreira, João E/L-1287-2016; Sabino, Ester C/F-7750-2010; Ferreira, Joao Eduardo/C-6025-2012; Hunter, James/J-6106-2016; Araripe Sucupira, Maria Cecilia/K-1931-2012	Sabino, Ester C/0000-0003-2623-5126; Ferreira, Joao Eduardo/0000-0001-9607-2014; Hunter, James/0000-0001-9524-0629; Araripe Sucupira, Maria Cecilia/0000-0002-1114-5382	Brazilian Ministry of Health	Brazilian Ministry of Health	Funding was provided by the Brazilian Ministry of Health. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Althoff KN, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-45; Althoff KN, 2010, CLIN INFECT DIS, V50, P1512, DOI 10.1086/652650; Caseiro MM, 2008, BRAZ J INFECT DIS, V12, P162, DOI 10.1590/S1413-86702008000300001; Chin-Hong PV, 2005, JAIDS-J ACQ IMM DEF, V40, P463, DOI 10.1097/01.qai.0000162238.93988.0c; Daar ES, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00316; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Dickson NP, 2012, HIV MED, V13, P182, DOI 10.1111/j.1468-1293.2011.00959.x; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Iwuji CC, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-397; Johnson Victoria A, 2010, Top HIV Med, V18, P156; Leal E, 2008, VIROLOGY, V381, P222, DOI 10.1016/j.virol.2008.08.029; Medeiros Roseane, 2002, Braz J Infect Dis, V6, P298, DOI 10.1590/S1413-86702002000600005; Miranda Ana Claudia, 2014, J Int AIDS Soc, V17, P19688, DOI 10.7448/IAS.17.4.19688; Montlahuc C, 2013, JAIDS-J ACQ IMM DEF, V64, P197, DOI 10.1097/QAI.0b013e31829cfbfa; Munerato P, 2010, AIDS RES HUM RETROV, V26, P265, DOI 10.1089/aid.2009.0288; O'Shea D, 2013, IRISH J MED SCI, V182, P389, DOI 10.1007/s11845-012-0898-2; R Core Team, 2014, R FDN STAT COMP; Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609; Sabin CA, 2008, AIDS, V22, P1463; SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994; Soares C, 2011, 18 C RETR OPP INF BO; Souza DCF, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-45; Teixeira PR, 2004, AIDS, V18, pS5, DOI 10.1097/00002030-200406003-00002; Torres AJL, 2009, BRAZ J INFECT DIS, V13, P221, DOI 10.1590/S1413-86702009000300013; Wensing Annemarie M, 2014, Top Antivir Med, V22, P642	25	17	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2015	10	10							e0139677	10.1371/journal.pone.0139677	http://dx.doi.org/10.1371/journal.pone.0139677			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV0DL	26509441	Green Published, gold, Green Submitted			2023-01-03	WOS:000363918100011
J	[Anonymous]				[Anonymous]			Transfusion of Blood (Reprinted form JAMA, vol 65, pg 1368-1369, 1915)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		[Anonymous], 1914, BLOOD TRANSFUSION SY, P1542; [Anonymous], 1914, J A M A         0328, P993; Brewer GE, 1909, SURG GYNECOL OBSTET, V9, P293; Curtis AH, 1911, J AMER MED ASSOC, V56, P35; Kimpton A. R., 1913, J A M A         0712, P117; Lewinsohn Richard, 1915, SURG GYNECOL OBSTET, V21, P37; Lindeman E, 1913, AM J DIS CHILD, V6, P28; Ottenberg R., 1915, AM J MED SCI, P36; Rous Peyton, 1915, J AM MED ASS    0612, P1980; Satterlee H. S., 1914, J A M A          JUN, P1781; Simons Irving, 1915, J A M A         1016, P1339; UNGER LJ, 1915, JAMA-J AM MED ASSOC, V64, P582; Weil R, 1915, J AMER MED ASSOC, V64, P425; 1915, JAMA, V65, P1369	14	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2015	314	15					1649	1649		10.1001/jama.2014.12042	http://dx.doi.org/10.1001/jama.2014.12042			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT7XK	26501550				2023-01-03	WOS:000363028500033
J	Parsel, SM; Grandis, JR; Thomas, SM				Parsel, S. M.; Grandis, J. R.; Thomas, S. M.			Nucleic acid targeting: towards personalized therapy for head and neck cancer	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; HERPES-SIMPLEX-VIRUS; P53 GENE-TRANSFER; SMALL INTERFERING RNA; MULTICENTER PHASE-II; FACTOR-KAPPA-B; IN-VIVO; RECURRENT HEAD; GLUCOSYLATED POLYETHYLENIMINE	In light of a detailed characterization of genetic aberrations in cancer, nucleic acid targeting represents an attractive therapeutic approach with significant translational potential. Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer deaths worldwide with stagnant 5-year survival rates. Advances in conventional treatment have done little to improve survival and combined chemoradiation is associated with significant adverse effects. Recent reports have characterized the genetic alterations in HNSCC and demonstrated that mutations confer resistance to conventional and molecular targeted therapies. The ability to use specific nucleic acid sequences to inhibit cancer-associated genes including non-druggable targets facilitates personalized medicine approaches with less adverse effects. Additionally, advances in drug delivery mechanisms have increased the transfection efficiency aiding in greater therapeutic responses. Given these advances, the stage has been set to translate the information garnered from genomic studies into personalized treatment strategies. Genes involved in the tumor protein 53 and epidermal growth factor receptor pathways have been extensively investigated and many promising preclinical studies have shown tumor inhibition through genetic modulation. We, and others, have demonstrated that targeting oncogene expression with gene therapy approaches is feasible in patients. Other methods such as RNA interference have proven to be effective and are potential candidates for clinical studies. This review summarizes the major advances in sequence-specific gene modulation in the preclinical setting and in clinical trials in head and neck cancer patients.	[Parsel, S. M.; Thomas, S. M.] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA; [Grandis, J. R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Thomas, S. M.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA; [Thomas, S. M.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Thomas, SM (corresponding author), Univ Kansas, Med Ctr, 3901 Rainbow Blvd,3020A Wahl Hall East, Kansas City, KS 66160 USA.	sthomas7@kumc.edu	Thomas, Sufi/O-1487-2018; Thomas, Sufi Mary/AFR-1642-2022; Parsel, Sean Michael/G-1228-2013; Parsel, Sean Michael/AAZ-4251-2020	Thomas, Sufi/0000-0001-5370-0842; Thomas, Sufi Mary/0000-0001-5370-0842; Parsel, Sean Michael/0000-0003-0821-7784; Parsel, Sean Michael/0000-0003-0821-7784	Department of Otolaryngology, University of Kansas Medical Center; University of Kansas Cancer Center's CCSG [1-P30-CA168524-02]; Kansas Intellectual and Developmental Disabilities Center [NICHD HD00258]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002528] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA168524, P50CA097190] Funding Source: NIH RePORTER	Department of Otolaryngology, University of Kansas Medical Center; University of Kansas Cancer Center's CCSG; Kansas Intellectual and Developmental Disabilities Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hinrich Staecker, Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS and Dr Stefan Rothenberg, K-State University, Manhattan, KS for critical review of the manuscript. We also thank Mr Phil Shafer for the artwork. We apologize to authors whose work was not cited due to space constraints. Department of Otolaryngology, University of Kansas Medical Center and University of Kansas Cancer Center's CCSG (1-P30-CA168524-02), and the Kansas Intellectual and Developmental Disabilities Center (NICHD HD00258) were the funding sources.	Accardi R, 2008, WORLD CANC REPORT 20, P30; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blackwell JL, 1999, ARCH OTOLARYNGOL, V125, P856, DOI 10.1001/archotol.125.8.856; Boehm AL, 2008, MOL PHARMACOL, V73, P1632, DOI 10.1124/mol.107.044636; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Carson AR, 2012, CANCER RES, V72, P6191, DOI 10.1158/0008-5472.CAN-11-4079; Chahlavi Ali, 1999, Neoplasia (New York), V1, P162, DOI 10.1038/sj.neo.7900016; Chang EH, 1997, ARCH OTOLARYNGOL, V123, P507; Chen SM, 2008, CANCER BIOL THER, V7, P734, DOI 10.4161/cbt.7.5.5722; Chen WH, 2015, CANCER LETT, V359, P65, DOI 10.1016/j.canlet.2014.12.052; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; Cohen EEW, 2004, J CLIN ONCOL, V22, P1743, DOI 10.1200/JCO.2004.06.147; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; Deng Y, 2014, GENE, V538, P217, DOI 10.1016/j.gene.2013.12.019; Dobrossy L, 2005, CANCER METAST REV, V24, P9, DOI 10.1007/s10555-005-5044-4; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dolivet G, 2002, CANCER GENE THER, V9, P708, DOI 10.1038/sj.cgt.7700485; Duan JM, 2007, MOL CANCER THER, V6, P37, DOI 10.1158/1535-7163.MCT-05-0285; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Ferris RL, 2007, CLIN CANCER RES, V13, P5663, DOI 10.1158/1078-0432.CCR-07-1544; Fujimoto Y, 2006, ACTA OTO-LARYNGOL, V126, P1115, DOI 10.1080/00016480600702100; Ganly I, 2000, CLIN CANCER RES, V6, P798; Garber K, 2006, J NATL CANCER I, V98, P298, DOI 10.1093/jnci/djj111; Gleich LL, 1998, ARCH OTOLARYNGOL, V124, P1097, DOI 10.1001/archotol.124.10.1097; Gleich LL, 2001, ARCH OTOLARYNGOL, V127, P775; Graff JR, 2007, J CLIN INVEST, V117, P2638, DOI 10.1172/JCI32044; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Guttmann DM, 2013, INT J RADIAT ONCOL, V87, P168, DOI 10.1016/j.ijrobp.2013.05.028; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; Hazar-Rethinam M, 2015, CLIN CANCER RES, V21, P417, DOI 10.1158/1078-0432.CCR-14-1962; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; Heise CC, 1999, CANCER RES, V59, P2623; Hong DS, 2011, CLIN CANCER RES, V17, P6582, DOI 10.1158/1078-0432.CCR-11-0430; Hsin CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113129; Hu JCC, 2006, CLIN CANCER RES, V12, P6737, DOI 10.1158/1078-0432.CCR-06-0759; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jing NJ, 2006, MOL CANCER THER, V5, P279, DOI 10.1158/1535-7163.MCT-05-0302; Kanazawa T, 2003, GENE THER, V10, P51, DOI 10.1038/sj.gt.3301837; Kaufman HL, 2010, ANN SURG ONCOL, V17, P718, DOI 10.1245/s10434-009-0809-6; Kawakami K, 2001, CANCER RES, V61, P6194; Kedmi R, 2010, BIOMATERIALS, V31, P6867, DOI 10.1016/j.biomaterials.2010.05.027; Kindt N, 2014, J CANCER RES CLIN, V140, P937, DOI 10.1007/s00432-014-1648-9; Klein JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081819; Konopka K, 2006, CELL MOL BIOL LETT, V11, P171, DOI 10.2478/s11658-006-0015-5; Kothari V, 2012, ANTICANCER RES, V32, P121; Lai SY, 2009, J CLIN ONCOL, V27, P1235, DOI 10.1200/JCO.2008.17.8251; Lalonde ES, 2002, HEAD NECK-J SCI SPEC, V24, P1038, DOI 10.1002/hed.10148; Lamont JP, 2000, ANN SURG ONCOL, V7, P588, DOI 10.1007/BF02725338; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Li DQ, 1999, CLIN CANCER RES, V5, P1551; Li MF, 2002, CLIN CANCER RES, V8, P3570; Li Y, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-16; Liu Dan, 2006, Ai Zheng, V25, P11; LIU TJ, 1995, CANCER RES, V55, P3117; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Lun MY, 2005, ANN CLIN LAB SCI, V35, P251; Mace ATM, 2007, ACTA OTO-LARYNGOL, V127, P880, DOI 10.1080/00016480601075381; Mace ATM, 2008, HEAD NECK-J SCI SPEC, V30, P1045, DOI 10.1002/hed.20840; Mansoori B, 2014, ADV PHARM BULL, V4, P313, DOI 10.5681/apb.2014.046; Masuelli L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-122; Matsui M, 2009, CANCER RES, V69, P2523, DOI 10.1158/0008-5472.CAN-08-2793; Mazumdar A, 2009, HEAD NECK-J SCI SPEC, V31, P625, DOI 10.1002/hed.21007; Michaluart P, 2008, CANCER GENE THER, V15, P676, DOI 10.1038/cgt.2008.35; Morris JC, 2000, MOL THER, V1, P56, DOI 10.1006/mthe.1999.0014; Ndoye A, 2004, INT J ONCOL, V25, P1575; Nemunaitis J, 2009, CLIN CANCER RES, V15, P7719, DOI 10.1158/1078-0432.CCR-09-1044; Nozawa H, 2006, CANCER SCI, V97, P1115, DOI 10.1111/j.1349-7006.2006.00287.x; Okunaga S, 2015, CANCER GENE THER, V22, P163, DOI 10.1038/cgt.2015.3; OMALLEY BW, 1995, CANCER RES, V55, P1080; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Park IK, 2005, ARCH PHARM RES, V28, P1302, DOI 10.1007/BF02978216; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Rahman MA, 2012, J CONTROL RELEASE, V159, P384, DOI 10.1016/j.jconrel.2012.01.045; Rao DD, 2009, ADV DRUG DELIVER REV, V61, P746, DOI 10.1016/j.addr.2009.04.004; Ren H, 2015, MED ONCOL, V32, P1; Saba NF, 2015, ORAL ONCOL, V51, P112, DOI 10.1016/j.oraloncology.2014.11.002; Sahu B, 2009, J ORG CHEM, V74, P1509, DOI 10.1021/jo802211n; Seiwert TY, 2013, ANN ONCOL, V24, P769, DOI 10.1093/annonc/mds523; Sen M, 2012, CANCER DISCOV, V2, P694, DOI 10.1158/2159-8290.CD-12-0191; Senzer NN, 2009, J CLIN ONCOL, V27, P5763, DOI 10.1200/JCO.2009.24.3675; Shimizu S, 2008, INT J CANCER, V123, P1816, DOI 10.1002/ijc.23710; Shin EJ, 2007, LARYNGOSCOPE, V117, P210, DOI 10.1097/01.mlg.0000246194.66295.d8; Skinner HD, 2012, CLIN CANCER RES, V18, P290, DOI 10.1158/1078-0432.CCR-11-2260; Smith NB, 2003, ULTRASOUND MED BIOL, V29, P311, DOI 10.1016/S0301-5629(02)00706-8; Sobral LM, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-32; Sok JC, 2006, CLIN CANCER RES, V12, P5064, DOI 10.1158/1078-0432.CCR-06-0913; Sorace AG, 2014, ULTRASOUND MED BIOL, V40, P755, DOI 10.1016/j.ultrasmedbio.2013.11.002; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sugano M, 2012, INT J PHARMACEUT, V422, P332, DOI 10.1016/j.ijpharm.2011.11.001; Suzuki R, 2007, J CONTROL RELEASE, V117, P130, DOI 10.1016/j.jconrel.2006.09.008; Tassone P, 2013, ORAL ONCOL, V49, P733, DOI 10.1016/j.oraloncology.2013.03.447; Thomas SM, 2003, CANCER GENE THER, V10, P518, DOI 10.1038/sj.cgt.7700567; Thomas SM, 2013, ACS CHEM BIOL, V8, P345, DOI 10.1021/cb3003946; Thomas SM, 2008, MOL PHARMACOL, V73, P627, DOI 10.1124/mol.107.041160; Tousignant JD, 2000, HUM GENE THER, V11, P2493, DOI 10.1089/10430340050207984; van den Broek GB, 2007, CLIN CANCER RES, V13, P4386, DOI 10.1158/1078-0432.CCR-06-2817; Vannucci L, 2013, NEW MICROBIOL, V36, P1; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Villaret D, 2002, HEAD NECK-J SCI SPEC, V24, P661, DOI 10.1002/hed.10107; Wang Y, 2008, CANCER BIOL THER, V7, P896, DOI 10.4161/cbt.7.6.5910; Wang YD, 2013, TECHNOL CANCER RES T, V12, P525, DOI 10.7785/tcrt.2012.500343; Xu L, 2002, MOL CANCER THER, V1, P337; Xu L, 2001, MOL MED, V7, P723, DOI 10.1007/BF03401962; Xu LA, 1999, HUM GENE THER, V10, P2941, DOI 10.1089/10430349950016357; Yoo GH, 2009, ARCH OTOLARYNGOL, V135, P869, DOI 10.1001/archoto.2009.122; Yuen AR, 1999, CLIN CANCER RES, V5, P3357; Zaoui K, 2012, CANCER GENE THER, V19, P181, DOI 10.1038/cgt.2011.75; Zeng Qing, 2002, J Exp Ther Oncol, V2, P174, DOI 10.1046/j.1359-4117.2002.01033.x; Zhang QZ, 2004, INT J CANCER, V111, P849, DOI 10.1002/ijc.20334	114	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3217	3226		10.1038/onc.2015.424	http://dx.doi.org/10.1038/onc.2015.424			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26592450	Bronze, Green Accepted, Green Submitted			2023-01-03	WOS:000378306400001
J	DeBaun, MR; Kirkham, FJ				DeBaun, Michael R.; Kirkham, Fenella J.			New option for primary stroke prevention in sickle cell anaemia	LANCET			English	Editorial Material							NIGERIAN CHILDREN; DISEASE		[DeBaun, Michael R.] Vanderbilt Univ, Sch Med, Dept Pediat & Med, Div Hematol Oncol, Nashville, TN 37232 USA; [DeBaun, Michael R.] Vanderbilt Univ, Sch Med, Vanderbilt Meharry Sickle Cell Ctr Excellence, Nashville, TN 37232 USA; [Kirkham, Fenella J.] UCL Inst Child Hlth, Dev Neurosci, London, England	Vanderbilt University; Vanderbilt University; University of London; University College London	DeBaun, MR (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat & Med, Div Hematol Oncol, Nashville, TN 37232 USA.; DeBaun, MR (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Meharry Sickle Cell Ctr Excellence, Nashville, TN 37232 USA.	M.DeBaun@vanderbilt.edu	Kirkham, Fenella/C-2442-2009	Kirkham, Fenella/0000-0002-2443-7958				ADAMS RJ, 1998, NEW ENGL J MED, V339, P5, DOI [DOI 10.1056/NEJM199807023390102, 10.1056/NEJM199807023390102]; Adams RJ, 2007, ARCH NEUROL-CHICAGO, V64, P1567, DOI 10.1001/archneur.64.11.1567; Galadanci NA, 2015, PEDIATR BLOOD CANCER, V62, P395, DOI 10.1002/pbc.25289; Kwiatkowski JL, 2011, PEDIATR BLOOD CANCER, V56, P777, DOI 10.1002/pbc.22951; Lagunju IA, 2013, PEDIATR BLOOD CANCER, V60, P1940, DOI 10.1002/pbc.24698; Lee MT, 2006, BLOOD, V108, P847, DOI 10.1182/blood-2005-10-009506; Piel FB, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001484; Ware RE, 2015, LANCET; Wood JC, 2016, BRIT J HAEMATOL, V172, P122, DOI 10.1111/bjh.13791	9	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	2016	387	10019					626	627		10.1016/S0140-6736(15)01130-7	http://dx.doi.org/10.1016/S0140-6736(15)01130-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD3QH	26670618	Green Submitted, Green Accepted			2023-01-03	WOS:000369837100006
J	Nayar, M; Vanderstay, R; Siegert, RJ; Turner-Stokes, L				Nayar, Meenakshi; Vanderstay, Roxana; Siegert, Richard J.; Turner-Stokes, Lynne			The UK Functional Assessment Measure (UK FIM plus FAM): Psychometric Evaluation in Patients Undergoing Specialist Rehabilitation following a Stroke from the National UK Clinical Dataset	PLOS ONE			English	Article							CROSS-CULTURAL ADAPTATION; INJURY REHABILITATION; INDEPENDENCE MEASURE; BRAIN INJURY; DISABILITY; NEGLECT; FIM+FAM; VERSION; SCALE	The UK Functional Assessment Measure (UKFIM+FAM) is the principal outcome measure for the UK Rehabilitation Outcomes Collaborative (UKROC) national database for specialist rehabilitation. Previously validated in a mixed neurorehabilitation cohort, this study is the first to explore its psychometric properties in a stroke population, and compare left and right hemispheric strokes (LHS vs RHS). We analysed in-patient episode data from 62 specialist rehabilitation units collated through the UKROC database 2010-2013. Complete data were analysed for 1,539 stroke patients (LHS: 588, RHS: 566 with clear localisation). For factor analysis, admission and discharge data were pooled and randomised into two equivalent samples; the first for exploratory factor analysis (EFA) using principal components analysis, and the second for confirmatory factor analysis (CFA). Responsiveness for each subject (change from admission to discharge) was examined using paired t-tests and differences between LHS and RHS for the entire group were examined using non-paired t-tests. EFA showed a strong general factor accounting for >48% of the total variance. A three-factor solution comprising motor, communication and psychosocial subscales, accounting for >69% total variance, provided acceptable fit statistics on CFA (Root Mean Square Error of Approximation was 0.08 and Comparative Fit Index/Tucker Lewis Index 0.922/0.907). All three subscales showed significant improvement between admission and discharge (p<0.001) with moderate effect sizes (>0.5). Total scores between LHS and RHS were not significantly different. However, LHS showed significantly higher motor scores (Mean 5.7, 95%CI 2.7, 8.6 p<0.001), while LHS had significantly lower cognitive scores, primarily in the communication domain (-6.8 95%CI -7.7, -5.8 p<0.001). To conclude, the UK FIM+FAM has a three-factor structure in stroke, similar to the general neurorehabilitation population. It is responsive to change during in-patient rehabilitation, and distinguishes between LHS and RHS. This tool extends stroke outcome measurement beyond physical disability to include cognitive, communication and psychosocial function.	[Nayar, Meenakshi; Vanderstay, Roxana; Turner-Stokes, Lynne] Kings Coll London, Fac Life Sci & Med, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England; [Nayar, Meenakshi; Turner-Stokes, Lynne] Northwick Pk Hosp & Clin Res Ctr, Reg Hyper Acute Rehabil Unit RHRU, London, England; [Siegert, Richard J.] Auckland Univ Technol, Sch Publ Hlth & Psychosocial Studies, Auckland, New Zealand; [Siegert, Richard J.] Auckland Univ Technol, Sch Rehabil & Occupat Studies, Auckland, New Zealand	University of London; King's College London; Imperial College London; Auckland University of Technology; Auckland University of Technology	Turner-Stokes, L (corresponding author), Kings Coll London, Fac Life Sci & Med, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England.; Turner-Stokes, L (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Reg Hyper Acute Rehabil Unit RHRU, London, England.	lynne.turner-stokes@dial.pipex.com	Turner-Stokes, Lynne/F-4418-2012; Siegert, Richard J./K-2030-2019	Turner-Stokes, Lynne/0000-0002-3302-9462; Siegert, Richard/0000-0002-3074-0929	National Institute for Health Research (NIHR) [RP-PG-0407-10185]; Dunhill Medical Trust; National Institute for Health Research [ACF-2013-17-021, RP-PG-0407-10185] Funding Source: researchfish	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Dunhill Medical Trust(Dunhill Medical Trust); National Institute for Health Research(National Institute for Health Research (NIHR))	This manuscript presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research programme (RP-PG-0407-10185). The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Financial support for the preparation of this manuscript was also provided by the Dunhill Medical Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3167; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; British Society of Rehabilitation Medicine, 2015, SPEC NEUR SERV PROV; Byrne Barbara M., 2013, STRUCTURAL EQUATION; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; DEHAAN R, 1993, STROKE, V24, P1178, DOI 10.1161/01.STR.24.8.1178; Hadian MR, 2012, NEUROL NEUROCHIR POL, V46, P351, DOI 10.5114/ninp.2012.30268; Hall K.M., 1993, J HEAD TRAUMA REHAB, DOI [10.1097/00001199-199308020-00008, DOI 10.1097/00001199-199308020-00008]; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Hillis AE, 2003, STROKE, V34, P2392, DOI 10.1161/01.STR.0000089681.84041.69; Hobart JC, 2001, NEUROLOGY, V57, P639, DOI 10.1212/WNL.57.4.639; Hooper D., 2008, ELECT J BUSINESS RES, V6, P53, DOI 10.21427/D79B73; Hsueh IP, 2002, J NEUROL NEUROSUR PS, V73, P188, DOI 10.1136/jnnp.73.2.188; Intercollegiate Stroke Working Party, 2011, NAT SENT STROK CLIN; Jorge LL, 2011, INT J REHABIL RES, V34, P89, DOI 10.1097/MRR.0b013e32833ba55f; Knecht S, 2000, BRAIN, V123, P74, DOI 10.1093/brain/123.1.74; Law J, 2009, DISABIL REHABIL, V31, P825, DOI 10.1080/09638280802355049; Linn R T, 1999, J Outcome Meas, V3, P339; Miki E, 2015, SCAND J OCCUP THER, V13, P1; Nilsson AL, 2011, J REHABIL MED, V43, P884, DOI 10.2340/16501977-0871; Ringman JM, 2004, NEUROLOGY, V63, P468, DOI 10.1212/01.WNL.0000133011.10689.CE; Spector P., 1994, SUMMATED RATING SCAL; Tabachnick BG, 2001, USING MULTIVARIATE S, V4th; Thompson B, 2004, EXPLORATORY CONFIRMA; Turner-Stokes L, 2002, DISABIL REHABIL, V24, P383, DOI 10.1080/096382801101550; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Turner-Stokes L, 2013, DISABIL REHABIL, V35, P1885, DOI 10.3109/09638288.2013.766271; Turner-Stokes L, 2012, DISABIL REHABIL, V34, P1871, DOI 10.3109/09638288.2012.670033; Turner-Stokes L, 2009, J REHABIL MED, V41, P528, DOI 10.2340/16501977-0383; Ween JE, 1996, NEUROLOGY, V47, P388, DOI 10.1212/WNL.47.2.388	31	17	17	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2016	11	1							e0147288	10.1371/journal.pone.0147288	http://dx.doi.org/10.1371/journal.pone.0147288			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DC9GH	26824696	gold, Green Published, Green Submitted			2023-01-03	WOS:000369528600022
J	Eloot, S; Schneditz, D; Cornelis, T; Van Biesen, W; Glorieux, G; Dhondt, A; Kooman, J; Vanholder, R				Eloot, Sunny; Schneditz, Daniel; Cornelis, Tom; Van Biesen, Wim; Glorieux, Griet; Dhondt, Annemie; Kooman, Jeroen; Vanholder, Raymond			Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis	PLOS ONE			English	Article							INCREASING DIALYSATE FLOW; INDOXYL SULFATE; P-CRESOL; PHOSPHORUS MOBILIZATION; RETENTION SOLUTES; REMOVAL; UREA; CRESYLSULPHATE; CLEARANCE; KINETICS	Aim We studied various hemodialysis strategies for the removal of protein-bound solutes, which are associated with cardiovascular damage. Methods This study included 10 patients on standard (3x4h/week) high-flux hemodialysis. Blood was collected at the dialyzer inlet and outlet at several time points during a midweek session. Total and free concentration of several protein-bound solutes was determined as well as urea concentration. Per solute, a two-compartment kinetic model was fitted to the measured concentrations, estimating plasmatic volume (V-1), total distribution volume (V-tot) and inter-compartment clearance (K-21). This calibrated model was then used to calculate which hemodialysis strategy offers optimal removal. Our own in vivo data, with the strategy variables entered into the mathematical simulations, was then validated against independent data from two other clinical studies. Results Dialyzer clearance K, V-1 and V-tot correlated inversely with percentage of protein binding. All Ks were different from each other. Of all protein-bound solutes, K-21 was 2.7-5.3 times lower than that of urea. Longer and/or more frequent dialysis that processed the same amount of blood per week as standard 3x4h dialysis at 300mL/min blood flow showed no difference in removal of strongly bound solutes. However, longer and/or more frequent dialysis strategies that processed more blood per week than standard dialysis were markedly more adequate. These conclusions were successfully validated. Conclusion When blood and dialysate flow per unit of time and type of hemodialyzer are kept the same, increasing the amount of processed blood per week by increasing frequency and/or duration of the sessions distinctly increases removal.	[Eloot, Sunny; Van Biesen, Wim; Glorieux, Griet; Dhondt, Annemie; Vanholder, Raymond] Ghent Univ Hosp, Dept Internal Med, Nephrol Sect, Ghent, Belgium; [Schneditz, Daniel] Med Univ Graz, Inst Physiol, Graz, Austria; [Cornelis, Tom; Kooman, Jeroen] Maastricht Univ, Med Ctr, Dept Internal Med, Div Nephrol, NL-6200 MD Maastricht, Netherlands	Ghent University; Ghent University Hospital; Medical University of Graz; Maastricht University	Eloot, S (corresponding author), Ghent Univ Hosp, Dept Internal Med, Nephrol Sect, Ghent, Belgium.	Sunny.Eloot@UGent.be	Schneditz, Daniel/E-6580-2010	Schneditz, Daniel/0000-0002-0124-1012	FWO Vlaanderen [G0A4614N]	FWO Vlaanderen(FWO)	This study was supported by FWO Vlaanderen - G0A4614N. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adijiang A, 2008, NEPHROL DIAL TRANSPL, V23, P1892, DOI 10.1093/ndt/gfm861; Agar BU, 2011, CLIN J AM SOC NEPHRO, V6, P2854, DOI 10.2215/CJN.03860411; Agar BU, 2011, HEMODIAL INT, V15, pS9, DOI 10.1111/j.1542-4758.2011.00596.x; Bammens B, 2006, KIDNEY INT, V69, P1081, DOI 10.1038/sj.ki.5000115; Bammens B, 2005, CONTRIB NEPHROL, V149, P175, DOI 10.1159/000085487; Barreto FC, 2009, CLIN J AM SOC NEPHRO, V4, P1551, DOI 10.2215/CJN.03980609; Basile C, 2011, NEPHROL DIAL TRANSPL, V26, P1296, DOI 10.1093/ndt/gfq543; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Cornelis T, 2014, AM J KIDNEY DIS, V64, P247, DOI 10.1053/j.ajkd.2014.02.016; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Dou L, 2004, KIDNEY INT, V65, P442, DOI 10.1111/j.1523-1755.2004.00399.x; Eloot S, 2008, KIDNEY INT, V73, P765, DOI 10.1038/sj.ki.5002750; Eloot S, 2005, KIDNEY INT, V67, P1566, DOI 10.1111/j.1523-1755.2005.00238.x; Eloot S, 2007, AM J KIDNEY DIS, V50, P279, DOI 10.1053/j.ajkd.2007.05.009; Eloot S, 2012, NEPHROL DIAL TRANSPL, V27, P4021, DOI 10.1093/ndt/gfs367; Eloot S, 2009, NEPHROL DIAL TRANSPL, V24, P2225, DOI 10.1093/ndt/gfp059; Fagugli RM, 2002, AM J KIDNEY DIS, V40, P339, DOI 10.1053/ajkd.2002.34518; Jourde-Chiche N, 2011, SEMIN DIALYSIS, V24, P327, DOI 10.1111/j.1525-139X.2011.00925.x; Krieter DH, 2010, NEPHROL DIAL TRANSPL, V25, P212, DOI 10.1093/ndt/gfp437; Lesaffer G, 2000, NEPHROL DIAL TRANSPL, V15, P50, DOI 10.1093/ndt/15.1.50; Liabeuf S, 2010, NEPHROL DIAL TRANSPL, V25, P1183, DOI 10.1093/ndt/gfp592; MAASRANI M, 1995, INT J ARTIF ORGANS, V18, P122, DOI 10.1177/039139889501800303; Maduell F, 2012, NEPHROL DIAL TRANSPL, V27, P1619, DOI 10.1093/ndt/gfr491; Meert N, 2012, NEPHROL DIAL TRANSPL, V27, P2388, DOI 10.1093/ndt/gfr672; Meert N, 2011, NEPHROL DIAL TRANSPL, V26, P2624, DOI 10.1093/ndt/gfq803; Meert N, 2009, NEPHROL DIAL TRANSPL, V24, P562, DOI 10.1093/ndt/gfn522; Meijers BKI, 2008, KIDNEY INT, V73, P1174, DOI 10.1038/ki.2008.31; Meijers B, 2011, AM J NEPHROL, V34, P226, DOI 10.1159/000330176; Meijers BKI, 2009, AM J KIDNEY DIS, V54, P891, DOI 10.1053/j.ajkd.2009.04.022; Meyer TW, 2005, KIDNEY INT, V68, P867, DOI 10.1111/j.1523-1755.2005.00469.x; Meyer TW, 2004, J AM SOC NEPHROL, V15, P1927, DOI 10.1097/01.asn.0000131521.62256.f0; Mischak H, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001249; NIWA T, 1988, CLIN CHEM, V34, P2264; ODELL RA, 1991, KIDNEY INT, V39, P909, DOI 10.1038/ki.1991.114; Ouseph R, 2001, AM J KIDNEY DIS, V37, P316, DOI 10.1053/ajkd.2001.21296; Ouseph R, 2008, NEPHROL DIAL TRANSPL, V23, P1704, DOI 10.1093/ndt/gfm916; Rocco MV, 2011, KIDNEY INT, V80, P1080, DOI 10.1038/ki.2011.213; Schepers E, 2007, NEPHROL DIAL TRANSPL, V22, P592, DOI 10.1093/ndt/gfl584; Schneditz D, 2001, SEMIN DIALYSIS, V14, P271, DOI 10.1046/j.1525-139X.2001.00066.x; Schulman G, 2006, AM J KIDNEY DIS, V47, P565, DOI 10.1053/j.ajkd.2005.12.036; Scribner BH, 2015, DIALYSIS TRANSPLANT, V31, P13; Sirich TL, 2012, NEPHROL DIAL TRANSPL, V27, P1574, DOI 10.1093/ndt/gfr691; Spalding EM, 2002, KIDNEY INT, V61, P655, DOI 10.1046/j.1523-1755.2002.00146.x; Stiller S, 2002, INT J ARTIF ORGANS, V25, P411, DOI 10.1177/039139880202500511; VANHOLDER R, 1992, KIDNEY INT, V41, P1707, DOI 10.1038/ki.1992.244; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; Vanholder R, 1999, J AM SOC NEPHROL, V10, P1815; Vanholder R, 2008, J AM SOC NEPHROL, V19, P863, DOI 10.1681/ASN.2007121377; VANHOLDER RC, 1992, CLIN CHEM, V38, P1429; Ward RA, 2006, KIDNEY INT, V69, P1431, DOI 10.1038/sj.ki.5000048; Yamamoto H, 2006, KIDNEY INT, V69, P1780, DOI 10.1038/sj.ki.5000340; Yu MA, 2010, J HYPERTENS, V28, P1234, DOI 10.1097/HJH.0b013e328337da1d; Zoccali C, 2006, J AM SOC NEPHROL, V17, P1466, DOI 10.1681/ASN.2005090949	53	37	40	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2016	11	1							e0147159	10.1371/journal.pone.0147159	http://dx.doi.org/10.1371/journal.pone.0147159			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB6WB	26799394	Green Published, Green Submitted, gold			2023-01-03	WOS:000368655300066
J	Gierthmuehlen, M; Stieglitz, T; Zentner, J; Plachta, DTT				Gierthmuehlen, Mortimer; Stieglitz, Thomas; Zentner, Josef; Plachta, Dennis T. T.			Haemodynamic Responses to Selective Vagal Nerve Stimulation under Enalapril Medication in Rats	PLOS ONE			English	Article							CONVERTING-ENZYME-INHIBITORS; RESISTANT HYPERTENSION; BLOOD-PRESSURE; HEART-FAILURE; DIABETIC-RATS; BAROREFLEX; ACTIVATION; THERAPY; CAPTOPRIL; SYSTEM	Selective vagal nerve stimulation (sVNS) has been demonstrated to lower blood pressure (BP) in rats without causing major side effects. This method might be adapted for the treatment of therapy-resistant hypertension in patients. Converting enzyme inhibitors (CEIs) are among the first drugs that are administered for arterial hypertension and prominently reduce BP primarily by interacting with the renin-angiotensin system of the kidneys. Beyond the reduction of BP, CEI have a positive effect on the survival rate after myocardial infarction; they reduce the rates of stroke and improve the neurohormonal status in heart-failure patients. If sVNS might be introduced as a therapy against resistant hypertension, patients will at least partially stay on their CEI medication. It is therefore the aim of this study to investigate the influence of the CEI enalapril on the haemodynamic and respiratory effects of sVNS. In 10 male Wistar rats, a polyimide-based multichannel-cuff-electrode was placed around the vagal nerve bundle to selectively stimulate the aortic depressor nerve fibres. Stimulation parameters were adapted to the thresholds of the individual animals and included repetition frequencies between 30 and 50 Hz, amplitudes of 0.5 to 1.5 mA and pulse widths between 0.4 ms and 1.0 ms. BP responses were detected with a microtip transducer in the left carotid artery, and electrocardiography was recorded with subcutaneous electrodes. After intravenous administration of enalapril (2 mg/kg bodyweight), the animals' mean arterial blood pressures (MAPs) decreased significantly, while the heart rates (HRs) were not significantly influenced. The effects of sVNS on BP and HR were attenuated by enalapril but were still present. We conclude that sVNS can lower the MAP during enalapril treatment without relevant side effects.	[Gierthmuehlen, Mortimer; Zentner, Josef; Plachta, Dennis T. T.] Univ Med Ctr Freiburg, Dept Neurosurg, Freiburg, Germany; [Stieglitz, Thomas; Plachta, Dennis T. T.] Univ Freiburg, Dept Microsyst Engn IMTEK, Lab Biomed Microtechnol, D-79106 Freiburg, Germany	University of Freiburg; University of Freiburg	Gierthmuehlen, M (corresponding author), Univ Med Ctr Freiburg, Dept Neurosurg, Freiburg, Germany.	mortimer.gierthmuehlen@uniklinik-freiburg.de	Stieglitz, Thomas/C-7916-2013	Stieglitz, Thomas/0000-0002-7349-4254; Gierthmuehlen, Mortimer/0000-0001-8575-6445	B. Braun Melsungen Foundation; Deutsche Gesellschaft fuer Neurochirurgie - Stiftung Neurochirurgische Forschung	B. Braun Melsungen Foundation; Deutsche Gesellschaft fuer Neurochirurgie - Stiftung Neurochirurgische Forschung	This work was supported by the B. Braun Melsungen Foundation (http://www.bbraun-stiftung.de/, to MG, DP) and Deutsche Gesellschaft fuer Neurochirurgie - Stiftung Neurochirurgische Forschung (www.dgnc.de, to MG, DP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akselrod S., 1985, AM J PHYSIOL, V249, pH867; Augustyniak RA, 2007, AM J PHYSIOL-REG I, V293, pR2260, DOI 10.1152/ajpregu.00509.2007; BILGUTAY AM, 1965, J AMER MED ASSOC, V191, P649, DOI 10.1001/jama.1965.03080080039010; BILGUTAY AM, 1966, AM J CARDIOL, V17, P663, DOI 10.1016/0002-9149(66)90404-8; Birincioglu M, 1997, FREE RADICAL RES, V27, P389, DOI 10.3109/10715769709065778; Bisognano JD, 2011, J AM COLL CARDIOL, V58, P765, DOI 10.1016/j.jacc.2011.06.008; Bloch MJ, 2012, J CLIN HYPERTENS, V14, P184, DOI 10.1111/j.1751-7176.2011.00584.x; GRICHOIS ML, 1992, J CARDIOVASC PHARM, V19, P863, DOI 10.1097/00005344-199206000-00004; Heesch CM, 1996, AM J PHYSIOL-REG I, V270, pR728, DOI 10.1152/ajpregu.1996.270.4.R728; Kaplan NM, 2005, J HYPERTENS, V23, P1441, DOI 10.1097/01.hjh.0000174968.72212.ac; Maliszewska-Scislo M, 2003, AM J PHYSIOL-HEART C, V284, pH1601, DOI 10.1152/ajpheart.00578.2002; McMullan S, 2009, RESP PHYSIOL NEUROBI, V166, P80, DOI 10.1016/j.resp.2009.02.006; NEISTADT A, 1967, SURGERY, V61, P923; NELISSENVRANCKEN HJMG, 1992, J CARDIOVASC PHARM, V19, P163, DOI 10.1097/00005344-199202000-00002; Plachta DTT, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/3/036011; Plachta DTT, 2012, IEEE ENG MED BIO, P3416, DOI 10.1109/EMBC.2012.6346699; Ramani R, 2008, J NEUROSURG ANESTH, V20, P29, DOI 10.1097/ANA.0b013e31815b7df1; Shearer F, 2013, CLIN PHARMACOL THER, V94, P459, DOI 10.1038/clpt.2013.135; Stieglitz T, 2000, BIOMED MICRODEVICES, V2, P283, DOI 10.1023/A:1009955222114; TAKEDA K, 1987, CLIN EXP HYPERTENS A, V9, P329, DOI 10.3109/10641968709164192; TAKEDA K, 1986, JPN HEART J, V27, P511; Waynforth H., 1992, EXPT SURG TECHNIQUE; Zariffa J, 2009, IEEE T NEUR SYS REH, V17, P420, DOI 10.1109/TNSRE.2009.2023301; Zhang WG, 2001, LIFE SCI, V68, P2769, DOI 10.1016/S0024-3205(01)01078-5	24	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2016	11	1							e0147045	10.1371/journal.pone.0147045	http://dx.doi.org/10.1371/journal.pone.0147045			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB4CC	26766419	Green Published, gold, Green Submitted			2023-01-03	WOS:000368459300060
J	Dorenkamp, S; Mesters, I; de Bie, R; Teijink, J; van Breukelen, G				Dorenkamp, Sarah; Mesters, Ilse; de Bie, Rob; Teijink, Joep; van Breukelen, Gerard			Patient Characteristics and Comorbidities Influence Walking Distances in Symptomatic Peripheral Arterial Disease: A Large One-Year Physiotherapy Cohort Study	PLOS ONE			English	Article							HEMOGLOBIN OXYGEN-SATURATION; SUPERVISED EXERCISE THERAPY; INTERMITTENT CLAUDICATION; OLDER; CAPACITY	Objectives The aim of this study is to investigate the association between age, gender, body-mass index, smoking behavior, orthopedic comorbidity, neurologic comorbidity, cardiac comorbidity, vascular comorbidity, pulmonic comorbidity, internal comorbidity and Initial Claudication Distance during and after Supervised Exercise Therapy at 1, 3, 6 and 12 months in a large sample of patients with Intermittent Claudication. Methods Data was prospectively collected in standard physiotherapy care. Patients received Supervised Exercise Therapy according to the guideline Intermittent Claudication of the Royal Dutch Society for Physiotherapy. Three-level mixed linear regression analysis was carried out to analyze the association between patient characteristics, comorbidities and Initial Claudication Distance at 1, 3, 6 and 12 months. Results Data from 2995 patients was analyzed. Results showed that being female, advanced age and a high body-mass index were associated with lower Initial Claudication Distance at all-time points (p = 0.000). Besides, a negative association between cardiac comorbidity and Initial Claudication Distance was revealed (p = 0.011). The interaction time by age, time by body-mass index and time by vascular comorbidity were significantly associated with Initial Claudication Distance (p <= 0.05). Per year increase in age (range: 33-93 years), the reduction in Initial Claudication Distance was 8m after 12 months of Supervised Exercise Therapy. One unit increase in body-mass index (range: 16-44 kg/m(2)) led to 10m less improvement in Initial Claudication Distance after 12 months and for vascular comorbidity the reduction in improvement was 85m after 12 months. Conclusions This study reveals that females, patients at advanced age, patients with a high body-mass index and cardiac comorbidity are more likely to show less improvement in Initial Claudication Distances (ICD) after 1, 3, 6 and 12 months of Supervised Exercise Therapy. Further research should elucidate treatment adaptations that optimize treatment outcomes for these subgroups.	[Dorenkamp, Sarah; Mesters, Ilse; de Bie, Rob; Teijink, Joep] Maastricht Univ, Dept Epidemiol, Functioning & Rehabil Programme, CAPRHI Sch Publ Hlth & Primary Care, Maastricht, Netherlands; [Teijink, Joep] Catharina Hosp, Dept Vasc Surg, Eindhoven, Netherlands; [van Breukelen, Gerard] Maastricht Univ, CAPRHI Sch Publ Hlth & Primary Care, Dept Methodol & Stat, Maastricht, Netherlands	Maastricht University; Catharina Hospital; Maastricht University	Dorenkamp, S (corresponding author), Maastricht Univ, Dept Epidemiol, Functioning & Rehabil Programme, CAPRHI Sch Publ Hlth & Primary Care, Maastricht, Netherlands.	sarah.dorenkamp@maastrichtuniversity.nl	van+Breukelen, Gerard/ACJ-5895-2022; mesters, Ilse/AAN-2824-2021	van+Breukelen, Gerard/0000-0003-0949-0272; mesters, Ilse/0000-0003-0605-6286	Netherlands Organisation for Scientific Research (NWO) Graduate Programme grant [022.003.036]	Netherlands Organisation for Scientific Research (NWO) Graduate Programme grant(Netherlands Organization for Scientific Research (NWO))	This study was made possible by a Netherlands Organisation for Scientific Research (NWO) Graduate Programme grant (grant number 022.003.036); URL: http://www.nwo.nl/en/funding/our-funding-instruments/nwo/graduate-programme/graduate-programme.html; authors who received funding: RdB; PhD Candidate funded by this grant SD.	Afaq A, 2007, VASC MED, V12, P167, DOI 10.1177/1358863x07081317; Amighi J, 2004, EUR J VASC ENDOVASC, V27, P254, DOI 10.1016/j.ejvs.2003.12.005; Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283; Bendermacher BLW, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005263.pub2; Bendermacher BL, 2007, J VASC SURG, V45, P1192, DOI 10.1016/j.jvs.2007.01.059; Davison KK, 2002, J AM GERIATR SOC, V50, P1802, DOI 10.1046/j.1532-5415.2002.50508.x; Dolan NC, 2002, DIABETES CARE, V25, P113, DOI 10.2337/diacare.25.1.113; Farah BQ, 2014, ANN VASC SURG, V28, P279, DOI 10.1016/j.avsg.2013.01.020; Field A., 2013, DISCOVERING STAT USI, P543; Fox J, 1997, APPL REGRESSION ANAL, P117; Gardner AW, 2010, J VASC SURG, V51, P610, DOI 10.1016/j.jvs.2009.09.059; Gardner AW, 2009, J VASC SURG, V50, P77, DOI 10.1016/j.jvs.2008.12.065; GARDNER AW, 1991, MED SCI SPORT EXER, V23, P402; Jankowski CM, 2008, OBESITY, V16, P1039, DOI 10.1038/oby.2007.84; Jonkert M, 2003, NED TIJD FYSIOTHER S, V113, P3; Katzel LI, 2001, VASC MED, V6, P157, DOI 10.1177/1358836X0100600306; Kruidenier LM, 2009, EUR J VASC ENDOVASC, V38, P449, DOI 10.1016/j.ejvs.2009.04.020; Lane R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000990.pub3; LAUGHLIN MH, 1999, AM J PHYSIOL, V277, P244; Newman AB, 2003, J GERONTOL A-BIOL, V58, P715; Parmenter BJ, 2015, SPORTS MED, V45, P231, DOI 10.1007/s40279-014-0261-z; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Powell JT, 1997, ATHEROSCLEROSIS, V129, P41, DOI 10.1016/S0021-9150(96)06012-1; Robeer GG, 1998, EUR J VASC ENDOVASC, V15, P36, DOI 10.1016/S1078-5884(98)80070-1; Snijders T, 2014, INT ENCY STAT SCI, P879; Troosters T, 1999, EUR RESPIR J, V14, P270, DOI 10.1034/j.1399-3003.1999.14b06.x; Verbeke G, 2000, LINEAR MIXED MODELS, P19, DOI [10.1007/978-0-387-22775-7_3, DOI 10.1007/978-1-4419-0300-6]; Versluis B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031514; Willigendael EM, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-49	29	18	18	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0146828	10.1371/journal.pone.0146828	http://dx.doi.org/10.1371/journal.pone.0146828			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6CA	26751074	Green Published, gold, Green Submitted			2023-01-03	WOS:000367888100159
J	Lu, Y; Starkey, N; Lei, W; Li, JL; Cheng, JL; Folk, WR; Lubahn, DB				Lu, Yuan; Starkey, Nicholas; Lei, Wei; Li, Jilong; Cheng, Jianlin; Folk, William R.; Lubahn, Dennis B.			Inhibition of Hedgehog-Signaling Driven Genes in Prostate Cancer Cells by Sutherlandia frutescens Extract	PLOS ONE			English	Article							PATHWAY	Sutherlandia frutescens (L) R. Br. (Sutherlandia) is a South African botanical that is traditionally used to treat a variety of health conditions, infections and diseases, including cancer. We hypothesized Sutherlandia might act through Gli/Hedgehog (Hh)-signaling in prostate cancer cells and used RNA-Seq transcription profiling to profile gene expression in TRAMPC2 murine prostate cancer cells with or without Sutherlandia extracts. We found 50% of Hh-responsive genes can be repressed by Sutherlandia ethanol extract, including the canonical Hh-responsive genes Gli1 and Ptch1 as well as newly distinguished Hh-responsive genes Hsd11b1 and Penk.	[Lu, Yuan; Starkey, Nicholas; Folk, William R.; Lubahn, Dennis B.] Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; [Lu, Yuan; Starkey, Nicholas; Lei, Wei; Li, Jilong; Cheng, Jianlin; Folk, William R.; Lubahn, Dennis B.] Univ Missouri, MU Ctr Bot Interact Studies, Columbia, MO 65211 USA; [Lei, Wei] Univ Missouri, Div Anim Sci, Columbia, MO 65211 USA; [Li, Jilong; Cheng, Jianlin] Univ Missouri, Dept Comp Sci, Columbia, MO 65211 USA; [Li, Jilong; Cheng, Jianlin] Univ Missouri, Inst Informat, Columbia, MO 65211 USA; [Lu, Yuan] Texas State Univ, Xiphophorus Genet Stock Ctr, San Marcos, TX 78666 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Texas State University System; Texas State University San Marcos	Lubahn, DB (corresponding author), Univ Missouri, Dept Biochem, Columbia, MO 65211 USA.	lubahnd@missouri.edu	Cheng, Jianlin/N-8209-2013	Cheng, Jianlin/0000-0003-0305-2853; Folk, William/0000-0003-2216-3233; Lei, Wei/0000-0002-0374-8642	National Center for Complementary and Integrative Health (NCCIH) [P50AT006273]; Office of Dietary Supplements (ODS); National Cancer Institute (NCI); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [P50AT006273] Funding Source: NIH RePORTER	National Center for Complementary and Integrative Health (NCCIH); Office of Dietary Supplements (ODS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	This publication or project was made possible in part by Grant Number P50AT006273 from the National Center for Complementary and Integrative Health (NCCIH), the Office of Dietary Supplements (ODS), and the National Cancer Institute (NCI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This publication or project was made possible in part by Grant Number P50AT006273 from the National Center for Complementary and Integrative Health (NCCIH), the Office of Dietary Supplements (ODS), and the National Cancer Institute (NCI). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM, ODS, NCI, or the National Institutes of Health.	Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bisi-Johnson MA, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-14; Chadwick WA, 2007, J ETHNOPHARMACOL, V109, P121, DOI 10.1016/j.jep.2006.07.012; Chen M, 2011, EXPERT REV ENDOCRINO, V6, P453, DOI 10.1586/EEM.11.24; Chinkwo KA, 2005, J ETHNOPHARMACOL, V98, P163, DOI 10.1016/j.jep.2005.01.016; De Smaele E, 2010, CURR OPIN INVEST DR, V11, P707; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Dormoy V, 2012, CARCINOGENESIS, V33, P2084, DOI 10.1093/carcin/bgs255; Dovio A, 2009, J STEROID BIOCHEM, V116, P29, DOI 10.1016/j.jsbmb.2009.04.007; Goo Young Ah, 2005, BMC Urol, V5, P17, DOI 10.1186/1471-2490-5-17; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lei W, 2015, J ETHNOPHARMACOL; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lin H, 2015, CELL BIOL INT; Lu Y, 2015, BMC MOL BIOL, V16, DOI 10.1186/s12867-015-0049-1; Lu Y, 2015, BMC MOL BIOL, V16, DOI 10.1186/s12867-015-0047-3; Maity T, 2005, P NATL ACAD SCI USA, V102, P17026, DOI 10.1073/pnas.0507848102; Muller AC, 2012, J PHARM PHARM SCI, V15, P221; NATH N, 1993, PROSTATE, V23, P225, DOI 10.1002/pros.2990230305; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Prevoo D, 2004, ENDOCR RES, V30, P745, DOI 10.1081/ERC-200044020; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Slusarz A, 2010, CANCER RES, V70, P3382, DOI 10.1158/0008-5472.CAN-09-3012; Tai J, 2004, J ETHNOPHARMACOL, V93, P9, DOI 10.1016/j.jep.2004.02.028; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; van Wyk BE, 2008, J ETHNOPHARMACOL, V119, P620, DOI 10.1016/j.jep.2008.08.003; VANKAMPE.KR, 1972, J ENDOCRINOL, V52, P549, DOI 10.1677/joe.0.0520549; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Vorster C, 2012, J ETHNOPHARMACOL, V140, P123, DOI 10.1016/j.jep.2011.12.045; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Yu M, 2009, J BIOL CHEM, V284, P5620, DOI 10.1074/jbc.M809172200	37	5	6	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2015	10	12							e0145507	10.1371/journal.pone.0145507	http://dx.doi.org/10.1371/journal.pone.0145507			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ9XO	26710108	Green Published, Green Submitted, gold			2023-01-03	WOS:000367451400058
J	Margolick, JB; Apuzzo, L; Singer, J; Wong, H; Lee, T; Gallant, JE; El-Helou, P; Loutfy, MR; Rachlis, A; Fraser, C; Kasper, K; Tremblay, C; Tossonian, H; Conway, B				Margolick, Joseph B.; Apuzzo, Linda; Singer, Joel; Wong, Hubert; Lee, Terry; Gallant, Joel E.; El-Helou, Phillippe; Loutfy, Mona R.; Rachlis, Anita; Fraser, Christopher; Kasper, Kenneth; Tremblay, Cecile; Tossonian, Harout; Conway, Brian			A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RESPONSES	Background It has been proposed that initiation of antiretroviral treatment (ART) very soon after establishment of HIV infection may be beneficial by improving host control of HIV replication and delaying disease progression. Methods People with documented HIV infection of less than 12 months' duration in Baltimore MD and seven Canadian sites were randomized to either a) observation and deferred ART, or b) immediate treatment with ART for 12 months. All subjects not receiving ART were followed quarterly and permanent ART was initiated according to contemporaneous treatment guidelines. The endpoint of the trial was total ART-free time from study entry until initiation of permanent ART. Results One hundred thirteen people were randomized, 56 to the observation arm and 57 to the immediate treatment arm. Twenty-three had acute (<2 months) infection and 90 early (2-12 months) infection. Of those randomized to the immediate treatment arm, 37 completed 12 months of ART according to protocol, 9 declined to stop ART after 12 months, and 11 were nonadherent to the protocol or lost to follow-up. Comparing those in the observation arm to either those who completed 12 months of ART or all 56 who were randomized to immediate ART, there was no significant difference between the arms in treatment-free interval after study entry, which was about 18 months in both arms. Conclusions This study did not find a benefit from administration of a brief, time-limited (12-month) course of ART in acute or early HIV infection.	[Margolick, Joseph B.; Apuzzo, Linda] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; [Singer, Joel; Wong, Hubert; Lee, Terry] CIHR Canadian HIV Trials Network, Vancouver, BC, Canada; [Gallant, Joel E.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA; [El-Helou, Phillippe] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Loutfy, Mona R.] Maple Leaf Med Clin, Toronto, ON, Canada; [Rachlis, Anita] Sunnybrook Hlth Sci, Toronto, ON, Canada; [Fraser, Christopher] Cool Aid Community Hlth Ctr, Victoria, BC, Canada; [Kasper, Kenneth] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada; [Tremblay, Cecile] Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ, Canada; [Tossonian, Harout; Conway, Brian] Vancouver Infect Dis Ctr, Vancouver, BC, Canada	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; McMaster University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Universite de Montreal	Margolick, JB (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.	Jmargol1@jhu.edu		Wong, Hubert/0000-0001-8840-4509	National Institutes of Health [AI056990, UL1RR025005]; CIHR Canadian HIV Trials Network; Janssen Therapeutics; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056990] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CIHR Canadian HIV Trials Network(Canadian Institutes of Health Research (CIHR)); Janssen Therapeutics; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health grants AI056990 and UL1RR025005 (JBM) and by the CIHR Canadian HIV Trials Network; Clinical Trials registration #: NCT00106171. Gilead Sciences, GlaxoSmithKline, Bristol-MyersSquibb, and Abbott Laboratories provided antiretroviral medications for this study and additional financial support was provided by Janssen Therapeutics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altfeld M, 2001, J EXP MED, V193, P169, DOI 10.1084/jem.193.2.169; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756; Fidler S, 2013, NEW ENGL J MED, V368, P207, DOI 10.1056/NEJMoa1110039; Grijsen ML, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001196; Hecht FM, 2006, J INFECT DIS, V194, P725, DOI 10.1086/506616; Hocqueloux L, 2013, J ANTIMICROB CHEMOTH, V68, P1169, DOI 10.1093/jac/dks533; Hogan CM, 2012, J INFECT DIS, V205, P87, DOI 10.1093/infdis/jir699; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Kothe D, 2003, JAIDS-J ACQ IMM DEF, V33, P625, DOI 10.1097/00126334-200308150-00012; Kshatriya R, 2008, J CLIN MICROBIOL, V46, P3482, DOI 10.1128/JCM.00665-08; Lichterfeld M, 2013, ANN INTERN MED, V159, P425, DOI 10.7326/0003-4819-159-6-201309170-00010; Markowitz M, 1999, J INFECT DIS, V179, P527, DOI 10.1086/314628; O'Brien M, 2012, CURR HIV-AIDS REP, V9, P101, DOI 10.1007/s11904-012-0113-0; Persaud D, 2013, NEW ENGL J MED, V369, P1828, DOI 10.1056/NEJMoa1302976; Phair JP, 1997, J INFECT DIS, V175, P959, DOI 10.1086/514000; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Streeck H, 2006, J INFECT DIS, V194, P734, DOI 10.1086/503811; Tossonian H, 2012, J INFECT DIS, V205, P10, DOI 10.1093/infdis/jir702	21	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2015	10	11							e0143259	10.1371/journal.pone.0143259	http://dx.doi.org/10.1371/journal.pone.0143259			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7DU	26600459	Green Published, gold, Green Submitted			2023-01-03	WOS:000365862600042
J	Aringstrom-Brannstrom, C; Engvall, G; Mullaney, T; Nilsson, K; Wickart-Johansson, G; Svard, AM; Nyholm, T; Lindh, J; Lindh, V				Angstrom-Brannstrom, Charlotte; Engvall, Gunn; Mullaney, Tara; Nilsson, Kristina; Wickart-Johansson, Gun; Svard, Anna-Maja; Nyholm, Tufve; Lindh, Jack; Lindh, Viveca			Children Undergoing Radiotherapy: Swedish Parents' Experiences and Suggestions for Improvement	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PEDIATRIC RADIOTHERAPY; GENERAL-ANESTHESIA; CANCER; PERCEPTIONS; INTERVENTION; SYMPTOMS; TOOL	Approximately 300 children, from 0 to 18 years old, are diagnosed with cancer in Sweden every year. Of these children, 80-90 of them undergo radiotherapy treatment for their cancer. Although radiotherapy is an encounter with advanced technology, few studies have investigated the child's and the parent's view of the procedure. As part of an ongoing multi-center study aimed to improve patient preparation and the care environment in pediatric radiotherapy, this article reports the findings from interviews with parents at baseline. The aim of the present study was twofold: to describe parents' experience when their child undergoes radiotherapy treatment, and to report parents' suggestions for improvements during radiotherapy for their children. Sixteen mothers and sixteen fathers of children between 2-16 years old with various cancer diagnoses were interviewed. Data were analyzed using content analysis. The findings showed that cancer and treatment turns people's lives upside down, affecting the entire family. Further, the parents experience the child's suffering and must cope with intense feelings. Radiotherapy treatment includes preparation by skilled and empathetic staff. The parents gradually find that they can deal with the process; and lastly, parents have suggestions for improvements during the radiotherapy treatment. An overarching theme emerged: that despair gradually turns to a sense of security, with a sustained focus on and close interaction with the child. In conclusion, an extreme burden was experienced around the start of radiotherapy, though parents gradually coped with the process.	[Angstrom-Brannstrom, Charlotte; Lindh, Viveca] Umea Univ, Dept Nursing, Umea, Sweden; [Engvall, Gunn] Uppsala Univ, Dept Women s & Childrens Hlth, Uppsala, Sweden; [Engvall, Gunn] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden; [Mullaney, Tara] Umea Univ, Umea Inst Design, Umea, Sweden; [Nilsson, Kristina] Univ Uppsala Hosp, Dept Oncol Radiol & Clin Immunol, Sect Oncol, Uppsala, Sweden; [Wickart-Johansson, Gun] Karolinska Univ Hosp, Dept Oncol Radiumhemmet, Stockholm, Sweden; [Svard, Anna-Maja; Nyholm, Tufve; Lindh, Jack] Umea Univ, Dept Radiat Sci, Umea, Sweden	Umea University; Uppsala University; Uppsala University; Umea University; Uppsala University; Uppsala University Hospital; Karolinska Institutet; Karolinska University Hospital; Umea University	Aringstrom-Brannstrom, C (corresponding author), Umea Univ, Dept Nursing, Umea, Sweden.	charlotte.angstrom@umu.se	Nyholm, Tufve/I-1402-2019; Mullaney, Tara/N-5628-2015	Nyholm, Tufve/0000-0002-8971-9788; Mullaney, Tara/0000-0002-7097-7736; Engvall, Gunn/0000-0002-5225-9650	Swedish Childhood Cancer Foundation (Barncancerfonden) [PR 2013-0025]	Swedish Childhood Cancer Foundation (Barncancerfonden)	Funding provided by grant number PR 2013-0025, The Swedish Childhood Cancer Foundation (Barncancerfonden), URL: http://www.barncancerfonden.se. TN received the funding.	Angstrom-Brannstrom C, 2010, J PEDIATR ONCOL NURS, V27, P266, DOI 10.1177/1043454210364623; Bertoni F, 1999, RADIOTHER ONCOL, V52, P185, DOI 10.1016/S0167-8140(99)00082-1; Bjork Maria, 2009, J Pediatr Nurs, V24, P423, DOI 10.1016/j.pedn.2008.01.082; Bowlby J., 1973, ATTACHMENT LOSS, P1; Bucholtz J D, 1994, Oncol Nurs Forum, V21, P987; Delany C, 2012, PEDIATR RADIOL, V42, P139, DOI 10.1007/s00247-011-2271-4; Benedetti GMD, 2014, REV LAT-AM ENFERM, V22, P425, DOI 10.1590/0104-1169.3264.2433; Filin A, 2009, J PEDIATR ONCOL NURS, V26, P81, DOI 10.1177/1043454208328766; Flury M, 2011, J PEDIATR ONCOL NURS, V28, P143, DOI 10.1177/1043454210378015; Gibbins J, 2012, J PEDIATR ONCOL NURS, V29, P253, DOI 10.1177/1043454212452791; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Griffiths M, 2011, J PEDIATR ONCOL NURS, V28, P83, DOI 10.1177/1043454210377902; Gustafsson G, CHILDHOOD CANC INCID; Haeberli S, 2008, RADIAT ONCOL, V3, DOI 10.1186/1748-717X-3-17; Harrison TM, 2010, J PEDIATR NURS, V25, P335, DOI 10.1016/j.pedn.2009.01.006; Heden L, 2013, J PAIN SYMPTOM MANAG, V46, P366, DOI 10.1016/j.jpainsymman.2012.09.012; Hildenbrand AK, 2011, J PEDIATR ONCOL NURS, V28, P344, DOI 10.1177/1043454211430823; Jackson AC, 2007, J PEDIATR ONCOL NURS, V24, P95, DOI 10.1177/1043454206296030; Kazak AE, 2004, J PEDIATR PSYCHOL, V29, P211, DOI 10.1093/jpepsy/jsh022; Klosky JL, 2007, CHILD HEALTH CARE, V36, P323, DOI 10.1080/02739610701601312; Kristensen I, 2009, ACTA ONCOL, V48, P146, DOI 10.1080/02841860802409520; Mealer Meredith, 2014, Nurse Res, V21, P32, DOI 10.7748/nr2014.03.21.4.32.e1229; Mullaney T, 2012, INT J DES, V6, P27; Olsen PR, 2009, CANCER NURS, V32, P493, DOI 10.1097/NCC.0b013e3181b3857e; Patton M. Q, 2015, QUALITATIVE RES EVAL, V4th; Poder U, 2008, PSYCHO-ONCOLOGY, V17, P430, DOI 10.1002/pon.1263; Poder U, 2010, J PAIN SYMPTOM MANAG, V40, P661, DOI 10.1016/j.jpainsymman.2010.02.012; Scott Linda, 2002, Eur J Oncol Nurs, V6, P15, DOI 10.1054/ejon.2001.0162; Shrimpton BJM, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001666; Soanes L, 2009, EUR J ONCOL NURS, V13, P255, DOI 10.1016/j.ejon.2009.03.009; Tornqvist E, 2015, J CHILD HEALTH CARE, V19, P359, DOI 10.1177/1367493513518374; Trier-Bieniek A, 2012, QUAL RES, V12, P630, DOI 10.1177/1468794112439005; Willis D, 2010, J MED IMAG RADIAT ON, V54, P249, DOI 10.1111/j.1754-9485.2010.02165.x	33	14	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2015	10	10							e0141086	10.1371/journal.pone.0141086	http://dx.doi.org/10.1371/journal.pone.0141086			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV0DL	26509449	Green Published, gold, Green Submitted			2023-01-03	WOS:000363918100051
J	Benso, B; Rosalen, PL; Alencar, SM; Murata, RM				Benso, Bruna; Rosalen, Pedro Luiz; Alencar, Severino Matias; Murata, Ramiro Mendonca			Malva sylvestris Inhibits Inflammatory Response in Oral Human Cells. An In Vitro Infection Model	PLOS ONE			English	Article							PERIODONTAL-DISEASE; NATURAL-PRODUCTS; PORPHYROMONAS-GINGIVALIS; PLANT-EXTRACTS; ACTINOMYCETEMCOMITANS; GROWTH; L.	The aim of this study was to investigate the in vitro anti-inflammatory activity of Malva sylvestris extract (MSE) and fractions in a co-culture model of cells infected by Aggregatibacter actinomycetemcomitans. In addition, we evaluated the phytochemical content in the extract and fractions of M. sylvestris and demonstrated that polyphenols were the most frequent group in all samples studied. An in vitro dual-chamber model to mimic the periodontal structure was developed using a monolayer of epithelial keratinocytes (OBA-9) and a subepithelial layer of fibroblasts (HGF-1). The invasive periodontopathogen A. actinomycetemcomitans (D7S-1) was applied to migrate through the cell layers and induce the synthesis of immune factors and cytokines in the host cells. In an attempt to analyze the antimicrobial properties of MSE and fractions, a susceptibility test was carried out. The extract (MIC 175 mu g/mL, MBC 500 mu g/mL) and chloroform fraction (MIC 150 mu g/mL, MBC 250 mu g/mL) were found to have inhibitory activity. The extract and all fractions were assessed using a cytotoxicity test and results showed that concentrations under 100 mu g/mL did not significantly reduce cell viability compared to the control group (p > 0.05, viability > 90%). In order to analyze the inflammatory response, transcriptional factors and cytokines were quantified in the supernatant released from the cells. The chloroform fraction was the most effective in reducing the bacterial colonization (p < 0.05) and controlling inflammatory mediators, and promoted the down-regulation of genes including IL-1beta, IL-6, IL-10, CD14, PTGS, MMP-1 and FOS as well as the reduction of the IL-1beta, IL-6, IL-8 and GM-CSF protein levels (p < 0.05). Malva sylvestris and its chloroform fraction minimized the A. actinomycetemcomitans infection and inflammation processes in oral human cells by a putative pathway that involves important cytokines and receptors. Therefore, this natural product may be considered as a successful dual anti-inflammatory-antimicrobial candidate.	[Benso, Bruna; Rosalen, Pedro Luiz] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Physiol Sci, Sao Paulo, Brazil; [Alencar, Severino Matias] Univ Sao Paulo, Luiz de Queiroz Coll Agr, Dept Agrifood Ind Food & Nutr, Sao Paulo, Brazil; [Murata, Ramiro Mendonca] Univ So Calif, Herman Ostrow Sch Dent, Div Periodontol Diagnost Sci & Dent Hyg, Los Angeles, CA 90089 USA; [Murata, Ramiro Mendonca] Univ So Calif, Herman Ostrow Sch Dent, Div Biomed Sci, Los Angeles, CA USA	Universidade Estadual de Campinas; Universidade de Sao Paulo; University of Southern California; University of Southern California	Murata, RM (corresponding author), Univ So Calif, Herman Ostrow Sch Dent, Div Periodontol Diagnost Sci & Dent Hyg, Los Angeles, CA 90089 USA.	ramiro.murata@usc.edu	Alencar, Severino Matias/B-7743-2012; Rosalen, Pedro Luiz/I-3718-2012; Benso, Bruna/L-1010-2015; Murata, Ramiro M/P-9052-2014	Alencar, Severino Matias/0000-0002-6637-7973; Rosalen, Pedro Luiz/0000-0003-0812-4027; Benso, Bruna/0000-0002-4425-5174; Murata, Ramiro M/0000-0002-8478-6981	National Center for Complementary and Integrative Health of the National Institutes of Health [R00AT006507]; Sao Paulo Research Foundation [FAPESP - 2011/23980-5]; Brazilian Federal Agency for the Support and Evaluation of Graduate Education [CAPES - 2317/2014-01]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R00AT006507] Funding Source: NIH RePORTER	National Center for Complementary and Integrative Health of the National Institutes of Health; Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Brazilian Federal Agency for the Support and Evaluation of Graduate Education; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Research reported in this publication was supported by: National Center for Complementary and Integrative Health of the National Institutes of Health under award number R00AT006507, Sao Paulo Research Foundation (FAPESP - 2011/23980-5), and Brazilian Federal Agency for the Support and Evaluation of Graduate Education (CAPES - 2317/2014-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barros L, 2010, FOOD CHEM TOXICOL, V48, P1466, DOI 10.1016/j.fct.2010.03.012; Chen C, 2010, J BACTERIOL, V192, P2643, DOI 10.1128/JB.00157-10; *CLIN LAB STAND I, 2009, M100S19 CLIN LAB STA; Cogo LL, 2010, BRAZ J MICROBIOL, V41, P304, DOI 10.1590/S1517-83822010000200007; Cragg GM, 2014, J NAT PROD, V77, P703, DOI 10.1021/np5000796; Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008; Cutillo F, 2006, PHYTOCHEMISTRY, V67, P481, DOI 10.1016/j.phytochem.2005.11.023; da Cunha MG, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-23; Darveau RP, 1997, PERIODONTOL 2000, V14, P12, DOI 10.1111/j.1600-0757.1997.tb00190.x; DellaGreca M, 2009, NAT PROD COMMUN, V4, P893; El Ghaoui WBJ, 2008, PHYTOTHER RES, V22, P1599, DOI 10.1002/ptr.2530; Folin O, 1912, J BIOL CHEM, V12, P239; Freires IA, 2015, MOLECULES, V20, P7329, DOI 10.3390/molecules20047329; Freires ID, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099086; Gasparetto JC, 2012, J PHARM PHARMACOL, V64, P172, DOI 10.1111/j.2042-7158.2011.01383.x; Graves DT, 2011, J DENT RES, V90, P143, DOI 10.1177/0022034510385236; Irwin CR, 1998, J ORAL PATHOL MED, V27, P255; Jain S, 2010, PERIODONTOL 2000, V54, P53, DOI 10.1111/j.1600-0757.2009.00333.x; Jeon JG, 2011, CARIES RES, V45, P243, DOI 10.1159/000327250; Johansson A., 2011, TOXINS, V3, P2459; Kang JH, 2014, J DENT RES, V93, P1116, DOI 10.1177/0022034514552677; Koeberle A, 2014, DRUG DISCOV TODAY, V19, P1871, DOI 10.1016/j.drudis.2014.08.006; Kornman KS, 1997, J CLIN PERIODONTOL, V24, P72, DOI 10.1111/j.1600-051X.1997.tb01187.x; Kusumoto Y, 2004, J PERIODONTOL, V75, P370, DOI 10.1902/jop.2004.75.3.370; Magro Ana, 2006, Revista Iberoamericana de Micologia, V23, P176; Negrato CA, 2013, J APPL ORAL SCI, V21, P1, DOI 10.1590/1678-7757201302106; Offenbacher S, 2007, J PERIODONTOL, V78, P1911, DOI 10.1902/jop.2007.060465; Pasetto S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115323; Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8; Prudente AS, 2013, FOOD CHEM TOXICOL, V58, P324, DOI 10.1016/j.fct.2013.04.042; Quave CL, 2008, J ETHNOPHARMACOL, V118, P418, DOI 10.1016/j.jep.2008.05.005; Rautemaa R, 2007, CLIN MICROBIOL INFEC, V13, P1041, DOI 10.1111/j.1469-0691.2007.01802.x; Reynier F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024828; Scapoli Luca, 2012, Dent Res J (Isfahan), V9, pS197, DOI 10.4103/1735-3327.109754; SEIBERG M, 2006, Patent No. 1811955; SEIBERG M, 2006, Patent No. 2006047470; SIEBERG M, 2006, Patent No. 2006088616; SLOTS J, 1980, INFECT IMMUN, V29, P1013; SOCRANSKY SS, 1977, J PERIODONTOL, V48, P497, DOI 10.1902/jop.1977.48.9.497; Stathopoulou PG, 2010, J CLIN PERIODONTOL, V37, P24, DOI 10.1111/j.1600-051X.2009.01505.x; Susin C, 2014, PERIODONTOL 2000, V65, P27, DOI 10.1111/prd.12019; Van Dyke TE, 2003, J DENT RES, V82, P82, DOI 10.1177/154405910308200202; Wang PL, 2002, CRIT REV ORAL BIOL M, V13, P132, DOI 10.1177/154411130201300204; Zhao LX, 2013, J PERIODONTOL, V84, P1847, DOI 10.1902/jop.2013.120548	44	28	30	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2015	10	10							e0140331	10.1371/journal.pone.0140331	http://dx.doi.org/10.1371/journal.pone.0140331			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT7WW	26479870	gold, Green Submitted, Green Published			2023-01-03	WOS:000363026600005
J	Hsu, YH; Cheng, JS; Ouyang, WC; Lin, CL; Huang, CT; Hsu, CC				Hsu, Yueh-Han; Cheng, Jur-Shan; Ouyang, Wen-Chen; Lin, Chen-Li; Huang, Chi-Ting; Hsu, Chih-Cheng			Lower Incidence of End-Stage Renal Disease but Suboptimal Pre-Dialysis Renal Care in Schizophrenia: A 14-Year Nationwide Cohort Study	PLOS ONE			English	Article							TYPE-2 DIABETES-MELLITUS; MENTAL-ILLNESS; HEALTH-CARE; CARDIOVASCULAR RISK; POPULATION; DIALYSIS; METAANALYSIS; PREVALENCE; DISORDERS; MORTALITY	Schizophrenia is closely associated with cardiovascular risk factors which are consequently attributable to the development of chronic kidney disease and end-stage renal disease (ESRD). However, no study has been conducted to examine ESRD-related epidemiology and quality of care before starting dialysis for patients with schizophrenia. By using nationwide health insurance databases, we identified 54,361 ESRD-free patients with schizophrenia and their age-/gender-matched subjects without schizophrenia for this retrospective cohort study (the schizophrenia cohort). We also identified a cohort of 1,244 adult dialysis patients with and without schizophrenia (1: 3) to compare quality of renal care before dialysis and outcomes (the dialysis cohort). Cox proportional hazard models were used to estimate the hazard ratio (HR) for dialysis and death. Odds ratio (OR) derived from logistic regression models were used to delineate quality of pre-dialysis renal care. Compared to general population, patients with schizophrenia were less likely to develop ESRD (HR = 0.6; 95% CI 0.4-0.8), but had a higher risk for death (HR = 1.2; 95% CI, 1.1-1.3). Patients with schizophrenia at the pre-ESRD stage received suboptimal pre-dialysis renal care; for example, they were less likely to visit nephrologists (OR = 0.6; 95% CI, 0.4-0.8) and received fewer erythropoietin prescriptions (OR = 0.7; 95% CI, 0.6-0.9). But they had a higher risk of hospitalization in the first year after starting dialysis (OR = 1.4; 95% CI, 1.0-1.8, P<.05). Patients with schizophrenia undertaking dialysis had higher risk for mortality than the general ESRD patients. A closer collaboration between psychiatrists and nephrologists or internists to minimize the gaps in quality of general care is recommended.	[Hsu, Yueh-Han] China Med Univ, Dept Publ Hlth, Taichung, Taiwan; [Hsu, Yueh-Han; Hsu, Chih-Cheng] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan; [Hsu, Yueh-Han] Chia Yi Christian Hosp, Div Nephrol, Dept Internal Med, Ditmanson Med Fdn, Chiayi, Taiwan; [Hsu, Yueh-Han] Min Hwei Coll Hlth Care Management, Dept Nursing, Tainan, Taiwan; [Cheng, Jur-Shan] Chang Gung Univ, Coll Med, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan; [Ouyang, Wen-Chen] Changhua Christian Hosp, Dept Psychiat, Changhua, Taiwan; [Ouyang, Wen-Chen] Changhua Christian Healthcare Syst, Changhua, Taiwan; [Ouyang, Wen-Chen] Lutung Christian Hosp, Changhua, Taiwan; [Ouyang, Wen-Chen] Chung Hwa Univ Med Technol, Dept Nursing, Coll Med & Life Sci, Tainan, Taiwan; [Ouyang, Wen-Chen] Kaohsiung Med Univ, Dept Psychiat, Kaohsiung, Taiwan; [Lin, Chen-Li] Taipei City Hosp, Fuyou Branch, Taipei, Taiwan; [Huang, Chi-Ting; Hsu, Chih-Cheng] Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Miaoli County, Taiwan	China Medical University Taiwan; China Medical University Taiwan; Chang Gung University; Changhua Christian Hospital; Chung Hua University; Kaohsiung Medical University; Taipei City Hospital; National Health Research Institutes - Taiwan	Hsu, CC (corresponding author), Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Miaoli County, Taiwan.	cch@nhri.org.tw	Lin, Chen-Li/AAT-9605-2021					[Anonymous], 2012, UN HLTH COV TAIW; Auquier P, 2006, PHARMACOEPIDEM DR S, V15, P873, DOI 10.1002/pds.1325; Bell RC, 2009, PSYCHIAT SERV, V60, P1686, DOI 10.1176/ps.2009.60.12.1686; Chan MR, 2007, AM J MED, V120, P1063, DOI 10.1016/j.amjmed.2007.04.024; Collins AJ, 2003, NEPHROL DIAL TRANSPL, V18, P2, DOI 10.1093/ndt/gfg1058; de Leon J, 2005, SCHIZOPHR RES, V76, P135, DOI 10.1016/j.schres.2005.02.010; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Doherty AM, 2014, SOC PSYCH PSYCH EPID, V49, P673, DOI 10.1007/s00127-014-0847-7; Druss BG, 2010, JAMA-J AM MED ASSOC, V303, P1972, DOI 10.1001/jama.2010.615; Fan ZX, 2013, J PSYCHIATR RES, V47, P1549, DOI 10.1016/j.jpsychires.2013.07.011; Fleischhacker WW, 2008, J CLIN PSYCHIAT, V69, P514, DOI 10.4088/JCP.v69n0401; Gladigau EL, 2014, INTERN MED J, V44, P65, DOI 10.1111/imj.12319; Gutierrez-Rojas L, 2014, ACTAS ESP PSIQUIATRI, V42, P9; Hsu CC, 2012, DIABETES CARE, V35, P2286, DOI 10.2337/dc11-2052; Hsu YH, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-509; Iacovides A, 2008, CURR OPIN PSYCHIATR, V21, P417, DOI 10.1097/YCO.0b013e328303ba42; Khan SS, 2005, KIDNEY INT, V67, P1038, DOI 10.1111/j.1523-1755.2005.00168.x; Kisely S, 2007, CAN MED ASSOC J, V176, P779, DOI 10.1503/cmaj.060482; Kohn R, 2004, B WORLD HEALTH ORGAN, V82, P858; Kung PT, 2012, RES DEV DISABIL, V33, P205, DOI 10.1016/j.ridd.2011.09.006; Kurdyak P, 2012, SCHIZOPHR RES, V142, P52, DOI 10.1016/j.schres.2012.09.003; Liao CH, 2011, SCHIZOPHR RES, V126, P110, DOI 10.1016/j.schres.2010.12.007; Lin GM, 2013, SCHIZOPHRENIA BULL, V39, P407, DOI 10.1093/schbul/sbr162; Lin TT, 2015, KIDNEY INT, V88, P378, DOI 10.1038/ki.2015.96; McCreadie RG, 2003, BRIT J PSYCHIAT, V183, P534, DOI 10.1192/bjp.183.6.534; Mendelssohn DC, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-22; Nasrallah HA, 2006, SCHIZOPHR RES, V86, P15, DOI 10.1016/j.schres.2006.06.026; Pope WS, 2011, J PSYCHOSOC NURS MEN, V49, P27, DOI 10.3928/02793695-20110802-01; Protopopova D, 2012, PSYCHIAT DANUB, V24, P307; Schoepf D, 2012, EUR PSYCHIAT, V27, P33, DOI 10.1016/j.eurpsy.2011.02.009; Taiwan National Health Research Institutes, 2014, INTR NAT HLTH INS RE; Tay YH, 2013, SCHIZOPHR RES, V147, P187, DOI 10.1016/j.schres.2013.03.023; Teo BW, 2010, ANN ACAD MED SINGAP, V39, P79; Torres-Gonzalez F, 2014, NEUROPSYCH DIS TREAT, V10, P97, DOI 10.2147/NDT.S41063; Tzeng NS, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006777; Wu PH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061930; Zhang X, 2013, J CLIN PSYCHIAT, V74, pE287, DOI 10.4088/JCP.12m07846	37	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2015	10	10							e0140510	10.1371/journal.pone.0140510	http://dx.doi.org/10.1371/journal.pone.0140510			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CU0CX	26469976	gold, Green Published, Green Submitted			2023-01-03	WOS:000363184600070
J	Du, J; Emilio, D; Pang, Y; Ma, Y; Mi, FL; Liu, YH; Li, L				Du, Jian; Emilio, Dirlikov; Pang, Yu; Ma, Yan; Mi, Fengling; Liu, Yuhong; Li, Liang			Tuberculosis Hospitalization Fees and Bed Utilization in China from 1999 to 2009: The Results of a National Survey of Tuberculosis Specialized Hospitals	PLOS ONE			English	Article							SHANDONG PROVINCE; TB SERVICES; HEALTH	Background China is transitioning towards concentrating tuberculosis (TB) diagnostic and treatment services in hospitals, while the Centers of Disease Control and Prevention (CDC) system will retain important public health functions. Patient expenditure incurred through hospitalization may lead to barriers to TB care or interruption of treatment. Methodology/Principal Findings We conducted a national survey of TB specialized hospitals to determine hospitalization fees and hospital bed utilization in 1999, 2004, and 2009. Hospitalization of TB patients increased 185.3% from 1999 to 2009. While the average hospitalization fees also increased, the proportion of those fees in relation to GDP per capita decreased. Hospitalization fees differed across the three regions (eastern, central, and western). Using a least standard difference (LSD) paired analysis, in 2004, the difference in hospitalization fees was significant when comparing eastern and central provinces (p<0.001) as well as to western provinces (p<0.001). In 2009, the difference remained statistically significant when comparing eastern province hospitalization fees with central provinces (p<0.001) and western provinces (p = 0.008). In 2004 and 2009, the cost associated with hospitalization as a proportion of GDP per capita was highest in the western region. The average in-patient stay decreased from 33 days in 1999 to 26 and 27 days in 2004 and 2009 respectively. Finally, hospital bed utilization in all three regions increased over this period. Conclusions/Significance Our findings show that both the total number of in-patients and hospitalization fees increased from 1999 to 2009, though the proportion of hospitalization fees to GDP per capita decreased. As diagnostic services move to hospitals, regulatory and monitoring mechanisms should be established, and hospitals should make use of the experience garnered by the CDC system through continued strong collaborations. Infrastructure and social protection mechanisms in high burden areas, such as in the western region, should be strengthened.	[Du, Jian; Ma, Yan; Mi, Fengling; Liu, Yuhong; Li, Liang] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China; [Du, Jian; Ma, Yan; Mi, Fengling; Liu, Yuhong; Li, Liang] Beijing TB & Thorac Tumor Res Inst, Beijing, Peoples R China; [Du, Jian; Ma, Yan; Mi, Fengling; Liu, Yuhong; Li, Liang] China CDC, Clin Ctr TB Control, Adm Off, Beijing, Peoples R China; [Emilio, Dirlikov] McGill Univ, Dept Anthropol, Montreal, PQ, Canada; [Pang, Yu] Chinese Ctr Dis Control & Prevent, Natl Ctr TB Control & Prevent, Beijing, Peoples R China	Capital Medical University; Chinese Center for Disease Control & Prevention; McGill University; Chinese Center for Disease Control & Prevention	Liu, YH (corresponding author), Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China.	liuyuhong0516@126.com; liliang69@tb123.org		Dirlikov, Emilio/0000-0003-4631-2643	Ministry of Health of China	Ministry of Health of China	This study was supported by Ministry of Health of China. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, CEINET STAT DAT; Barber SL, 2011, INT J HEALTH PLAN M, V26, P339, DOI 10.1002/hpm.1109; Chai SJ, 2013, HEALTH POLICY PLANN, V28, P100, DOI 10.1093/heapol/czs029; Du J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111945; Fan CC, 1997, INT J URBAN REGIONAL, V21, P620, DOI 10.1111/1468-2427.00105; He GX, 2012, INT J TUBERC LUNG D, V16, P1485, DOI 10.5588/ijtld.12.0193; Hipgrave David, 2011, J Glob Health, V1, P224; Lienhardt C, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001135; Liu J, 2005, CHINESE J HOSP STAT, V12, P227; MOH of the PRC, 2011, CHIN NAT TUB CONTR P; MOH of the PRC, 2002, 4 NAT SURV EP TUB 20; MOH of the PRC, 2011, 5 NAT SURV EP TUB 20; Oxlade O, 2009, INT J TUBERC LUNG D, V13, P1238; Qiu SS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126770; Wang WB, 2014, INT J TUBERC LUNG D, V18, P939, DOI 10.5588/ijtld.13.0131; Wei X, 2011, BMC PUBLIC HEALTH, V11, P1; Wei XL, 2009, INT J TUBERC LUNG D, V13, P514; Wei XL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090596; Wei XL, 2011, TROP MED INT HEALTH, V16, P847, DOI 10.1111/j.1365-3156.2011.02769.x; World Bank, 2014, CHIN DAT; World Health Organization, 2014, WHOHTMTB201408; Xu L, 2010, INT J TUBERC LUNG D, V14, P440; Yip WCM, 2010, LANCET, V375, P1120, DOI 10.1016/S0140-6736(10)60063-3; Zhan SK, 2004, INT J HEALTH PLAN M, V19, pS63, DOI 10.1002/hpm.778; Zhang TH, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-19; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; Zhao YL, 2012, NEW ENGL J MED, V366, P2161, DOI 10.1056/NEJMoa1108789; Zou GY, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-21	28	9	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2015	10	10							e0139901	10.1371/journal.pone.0139901	http://dx.doi.org/10.1371/journal.pone.0139901			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT6YZ	26457980	Green Published, gold, Green Submitted			2023-01-03	WOS:000362961100016
J	Lebwohl, B; Ludvigsson, JF; Green, PHR				Lebwohl, Benjamin; Ludvigsson, Jonas F.; Green, Peter H. R.			Celiac disease and non-celiac gluten sensitivity	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SMALL-INTESTINAL HISTOPATHOLOGY; POPULATION-BASED COHORT; BODY-MASS INDEX; FREE DIET; VILLOUS ATROPHY; DOUBLE-BLIND; AT-RISK; LYMPHOPROLIFERATIVE MALIGNANCY; PEDIATRIC GASTROENTEROLOGY; GASTROINTESTINAL SYMPTOMS	Celiac disease is a multisystem immune based disorder that is triggered by the ingestion of gluten in genetically susceptible individuals. The prevalence of celiac disease has risen in recent decades and is currently about 1% in most Western populations. The reason for this rise is unknown, although environmental factors related to the hygiene hypothesis are suspected. The pathophysiology of celiac disease involves both the innate and adaptive immune response to dietary gluten. Clinical features are diverse and include gastrointestinal symptoms, metabolic bone disease, infertility, and many other manifestations. Although a gluten-free diet is effective in most patients, this diet can be burdensome and can limit quality of life; consequently, non-dietary therapies are at various stages of development. This review also covers non-celiac gluten sensitivity. The pathophysiology of this clinical phenotype is poorly understood, but it is a cause of increasing interest in gluten-free diets in the general population.	[Lebwohl, Benjamin; Green, Peter H. R.] Columbia Univ, Coll Phys & Surg, Celiac Dis Ctr, Dept Med, New York, NY 10032 USA; [Lebwohl, Benjamin; Ludvigsson, Jonas F.] Karolinska Univ Hosp, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Lebwohl, Benjamin; Ludvigsson, Jonas F.] Karolinska Inst, Stockholm, Sweden; [Ludvigsson, Jonas F.] Orebro Univ Hosp, Dept Pediat, Orebro, Sweden	Columbia University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Orebro University	Green, PHR (corresponding author), Columbia Univ, Coll Phys & Surg, Celiac Dis Ctr, Dept Med, New York, NY 10032 USA.	PG11@columbia.edu	Ludvigsson, Jonas F/A-8560-2012	Ludvigsson, Jonas F/0000-0003-1024-5602	National Center for Advancing Translational Sciences, National Institutes of Health [UL1 TR000040]; Orebro University Hospital, Karolinska Institutet; Swedish Society of Medicine; Swedish Research Council-Medicine [522-2A09-195]; Swedish Coeliac Society; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000040] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Orebro University Hospital, Karolinska Institutet; Swedish Society of Medicine; Swedish Research Council-Medicine(Swedish Research Council); Swedish Coeliac Society; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	BL: National Center for Advancing Translational Sciences, National Institutes of Health (UL1 TR000040). JFL: Orebro University Hospital, Karolinska Institutet, the Swedish Society of Medicine, the Swedish Research Council-Medicine (522-2A09-195), and the Swedish Coeliac Society.	Adriaanse MPM, 2013, ALIMENT PHARM THER, V37, P482, DOI 10.1111/apt.12194; Aggarwal S, 2012, THER ADV GASTROENTER, V5, P37, DOI 10.1177/1756283X11417038; Aronsson CA, 2015, PEDIATRICS, V135, P239, DOI 10.1542/peds.2014-1787; Austin AS, 2002, SCAND J GASTROENTERO, V37, P978, DOI 10.1080/003655202760230973; Aziz I, 2014, EUR J GASTROEN HEPAT, V26, P33, DOI 10.1097/01.meg.0000435546.87251.f7; Bai JC, 2013, J CLIN GASTROENTEROL, V47, P121, DOI 10.1097/MCG.0b013e31827a6f83; Biagi F, 2008, DIGEST LIVER DIS, V40, P97, DOI 10.1016/j.dld.2007.10.004; Biesiekierski JR, 2014, NUTR CLIN PRACT, V29, P504, DOI 10.1177/0884533614529163; Biesiekierski JR, 2013, GASTROENTEROLOGY, V145, P320, DOI 10.1053/j.gastro.2013.04.051; Biesiekierski JR, 2011, AM J GASTROENTEROL, V106, P508, DOI 10.1038/ajg.2010.487; Brottveit M, 2013, AM J GASTROENTEROL, V108, P842, DOI 10.1038/ajg.2013.91; Caio G, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-26; Carlsson AK, 2001, PEDIATRICS, V107, P42, DOI 10.1542/peds.107.1.42; Cascella NG, 2011, SCHIZOPHRENIA BULL, V37, P94, DOI 10.1093/schbul/sbp055; Cataldo F, 2002, J PEDIATR GASTR NUTR, V35, P233, DOI 10.1097/00005176-200208000-00029; Catassi C, 1999, LANCET, V354, P647, DOI 10.1016/S0140-6736(99)02609-4; Catassi C, 2007, AM J CLIN NUTR, V85, P160, DOI 10.1093/ajcn/85.1.160; Catassi C, 2007, AM J GASTROENTEROL, V102, P1454, DOI 10.1111/j.1572-0241.2007.01173.x; Catassi C, 2013, NUTRIENTS, V5, P3839, DOI 10.3390/nu5103839; Catassi C, 2010, ANN MED, V42, P530, DOI 10.3109/07853890.2010.514285; Cheng JF, 2010, J CLIN GASTROENTEROL, V44, P267, DOI 10.1097/MCG.0b013e3181b7ed58; Chin RL, 2003, NEUROLOGY, V60, P1581, DOI 10.1212/01.WNL.0000063307.84039.C7; Collin P, 2007, J CLIN GASTROENTEROL, V41, P152, DOI 10.1097/01.mcg.0000212618.12455.a8; Comino I, 2012, AM J CLIN NUTR, V95, P670, DOI 10.3945/ajcn.111.026708; COOPER BT, 1980, GASTROENTEROLOGY, V79, P801; Decker E, 2010, PEDIATRICS, V125, pE1433, DOI 10.1542/peds.2009-2260; Di Sabatino A, 2015, CLIN GASTROENTEROL H; Dickerson F, 2010, BIOL PSYCHIAT, V68, P100, DOI 10.1016/j.biopsych.2010.03.021; Digiacomo DV, 2013, SCAND J GASTROENTERO, V48, P921, DOI 10.3109/00365521.2013.809598; Dixit R, 2014, DIGEST DIS SCI, V59, P1509, DOI 10.1007/s10620-014-3025-6; Dube C, 2005, GASTROENTEROLOGY, V128, pS57, DOI 10.1053/j.gastro.2005.02.014; Eaton WW, 2006, AM J PSYCHIAT, V163, P521, DOI 10.1176/appi.ajp.163.3.521; Elfstrom P, 2008, J CLIN ENDOCR METAB, V93, P3915, DOI 10.1210/jc.2008-0798; Elfstrom P, 2012, CLIN GASTROENTEROL H, V10, P30, DOI 10.1016/j.cgh.2011.06.029; Elfstrom P, 2011, JNCI-J NATL CANCER I, V103, P436, DOI 10.1093/jnci/djq564; ELLIS A, 1978, LANCET, V1, P1358; Emilsson L, 2013, ALIMENT PHARM THER, V37, P905, DOI 10.1111/apt.12271; Evans KE, 2010, DIGEST DIS SCI, V55, P2999, DOI 10.1007/s10620-010-1261-y; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; Fuchs V, 2014, SCAND J GASTROENTERO, V49, P1304, DOI 10.3109/00365521.2014.923502; Golley S, 2015, PUBLIC HEALTH NUTR, V18, P490, DOI 10.1017/S1368980014000652; Grainge MJ, 2011, AM J GASTROENTEROL, V106, P933, DOI 10.1038/ajg.2010.506; Green PHR, 2007, NEW ENGL J MED, V357, P1731, DOI 10.1056/NEJMra071600; Green PHR, 2015, J ALLERGY CLIN IMMUN, V135, P1099, DOI 10.1016/j.jaci.2015.01.044; Gutierrez-Achury J, 2011, J INTERN MED, V269, P591, DOI 10.1111/j.1365-2796.2011.02375.x; Hadithi M, 2007, WORLD J GASTROENTERO, V13, P1715, DOI 10.3748/wjg.v13.i11.1715; Hadjivassiliou Marios, 2014, Handb Clin Neurol, V120, P607, DOI 10.1016/B978-0-7020-4087-0.00041-3; Harper JW, 2007, AM J HEMATOL, V82, P996, DOI 10.1002/ajh.20996; Hill ID, 2005, J PEDIATR GASTR NUTR, V40, P1, DOI 10.1097/00005176-200501000-00001; Hollon J, 2015, NUTRIENTS, V7, P1565, DOI 10.3390/nu7031565; Huebener S, 2015, J PROTEOME RES, V14, P503, DOI 10.1021/pr500809b; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; HYOTY H, 1995, DIABETES, V44, P652, DOI 10.2337/diabetes.44.6.652; Ilus T, 2014, AM J GASTROENTEROL, V109, P1471, DOI 10.1038/ajg.2014.194; Ivarsson A, 2000, ACTA PAEDIATR, V89, P165, DOI 10.1080/080352500750028771; Ivarsson A, 2002, AM J CLIN NUTR, V75, P914, DOI 10.1093/ajcn/75.5.914; Junker Y, 2012, J EXP MED, V209, P2395, DOI 10.1084/jem.20102660; Kabbani TA, 2012, ALIMENT PHARM THER, V35, P723, DOI 10.1111/j.1365-2036.2012.05001.x; KAGNOFF MF, 1987, GUT, V28, P995, DOI 10.1136/gut.28.8.995; Kang JY, 2013, ALIMENT PHARM THER, V38, P226, DOI 10.1111/apt.12373; Katz KD, 2011, AM J GASTROENTEROL, V106, P1333, DOI 10.1038/ajg.2011.21; Kaukinen K, 2002, GASTROENTEROLOGY, V122, P881, DOI 10.1053/gast.2002.32416; Kelly CP, 2013, ALIMENT PHARM THER, V37, P252, DOI 10.1111/apt.12147; Khashan AS, 2010, HUM REPROD, V25, P528, DOI 10.1093/humrep/dep409; Kiefte-de Jong JC, 2013, GASTROENTEROLOGY, V144, P726, DOI 10.1053/j.gastro.2013.01.003; Lahdeaho ML, 2014, GASTROENTEROLOGY, V146, P1649, DOI 10.1053/j.gastro.2014.02.031; Lau NM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066155; Lebwohl B, 2014, Aliment Pharmacol Ther, V39, P488, DOI 10.1111/apt.12621; Lebwohl B, 2013, ALIMENT PHARM THER, V37, P332, DOI 10.1111/apt.12164; Lebwohl B, 2015, CLIN GASTROENTEROL H, V13, P1111, DOI 10.1016/j.cgh.2014.11.018; Lebwohl B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117529; Lebwohl B, 2014, CLIN GASTROENTEROL H, V12, P632, DOI 10.1016/j.cgh.2013.10.031; Lebwohl B, 2014, J CLIN ENDOCR METAB, V99, P609, DOI 10.1210/jc.2013-3164; Lebwohl B, 2014, DIGEST LIVER DIS, V46, P36, DOI 10.1016/j.dld.2013.08.128; Lebwohl B, 2013, AM J EPIDEMIOL, V178, P1721, DOI 10.1093/aje/kwt234; Lebwohl B, 2013, ANN INTERN MED, V159, P169, DOI 10.7326/0003-4819-159-3-201308060-00006; Lebwohl B, 2013, DIGEST DIS SCI, V58, P1293, DOI 10.1007/s10620-012-2551-3; Lee AR, 2007, J HUM NUTR DIET, V20, P423, DOI 10.1111/j.1365-277X.2007.00763.x; Leffler DA, 2007, CLIN GASTROENTEROL H, V5, P445, DOI 10.1016/j.cgh.2006.12.006; Leffler DA, 2012, AM J GASTROENTEROL, V107, P1554, DOI 10.1038/ajg.2012.211; Lionetti E, 2014, NEW ENGL J MED, V371, P1295, DOI 10.1056/NEJMoa1400697; Lis DM, 2015, INT J SPORT NUTR EXE, V25, P37, DOI 10.1123/ijsnem.2013-0247; Lohi S, 2007, ALIMENT PHARM THERAP, V26, P1217, DOI 10.1111/j.1365-2036.2007.03502.x; Ludvigsson JF, 2012, BRIT J CANCER, V106, P217, DOI 10.1038/bjc.2011.536; Ludvigsson JF, 2005, CLIN GASTROENTEROL H, V3, P869, DOI 10.1016/S1542-3565(05)00414-3; Ludvigsson JF, 2005, GASTROENTEROLOGY, V129, P454, DOI 10.1053/j.gastro.2005.05.065; Ludvigsson JF, 2014, NEW ENGL J MED, V371, P1341, DOI 10.1056/NEJMe1408011; Ludvigsson JF, 2014, GUT, V63, P1210, DOI 10.1136/gutjnl-2013-306578; Ludvigsson JF, 2013, JAMA PSYCHIAT, V70, P1224, DOI 10.1001/jamapsychiatry.2013.2048; Ludvigsson JF, 2013, AM J GASTROENTEROL, V108, P818, DOI 10.1038/ajg.2013.60; Ludvigsson JF, 2013, GUT, V62, P43, DOI 10.1136/gutjnl-2011-301346; Ludvigsson JF, 2012, INT J CANCER, V131, pE244, DOI 10.1002/ijc.26454; Ludvigsson JF, 2011, CIRCULATION, V123, P483, DOI 10.1161/CIRCULATIONAHA.110.965624; Ludvigsson JF, 2009, JAMA-J AM MED ASSOC, V302, P1171, DOI 10.1001/jama.2009.1320; Ludvigsson JF, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-19; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; Mahadev S, 2011, J CLIN GASTROENTEROL, V45, P912, DOI 10.1097/MCG.0b013e31822d31f7; Makharia GK, 2011, J GASTROEN HEPATOL, V26, P894, DOI 10.1111/j.1440-1746.2010.06606.x; Mardini HE, 2015, DIGEST DIS SCI, V60, P1738, DOI 10.1007/s10620-014-3514-7; Marild K, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-109; Marild K, 2012, GASTROENTEROLOGY, V142, P39, DOI 10.1053/j.gastro.2011.09.047; Martinelli P, 2000, GUT, V46, P332, DOI 10.1136/gut.46.3.332; Master S, 2013, J PEDIATR GASTR NUTR, V57, P527, DOI 10.1097/MPG.0b013e3182a321cc; Matysiak-Budnik T, 2008, J EXP MED, V205, P143, DOI 10.1084/jem.20071204; Mention JJ, 2003, GASTROENTEROLOGY, V125, P730, DOI 10.1016/S0016-5085(03)01047-3; Mirzaagha F, 2010, DIGEST LIVER DIS, V42, P620, DOI 10.1016/j.dld.2010.02.006; Mohamed BM, 2006, DIGEST DIS SCI, V51, P1862, DOI 10.1007/s10620-005-9038-4; Mooney PD, 2015, CLIN GASTROENTEROL H, V13, P1278, DOI 10.1016/j.cgh.2015.01.010; Mukherjee Rupa, 2012, Gastrointest Endosc Clin N Am, V22, P811, DOI 10.1016/j.giec.2012.09.001; Murray JA, 2004, AM J CLIN NUTR, V79, P669; Murray JA, 2003, CLIN GASTROENTEROL H, V1, P19, DOI 10.1053/jcgh.2003.50004; Mustalahti K, 2010, ANN MED, V42, P587, DOI 10.3109/07853890.2010.505931; Myleus A, 2009, J PEDIATR GASTR NUTR, V49, P170, DOI 10.1097/MPG.0b013e31818c52cc; Nachman F, 2011, CLIN GASTROENTEROL H, V9, P214, DOI 10.1016/j.cgh.2010.06.017; Nadal I, 2007, J MED MICROBIOL, V56, P1669, DOI 10.1099/jmm.0.47410-0; Narotsky D, 2012, EUR J GASTROEN HEPAT, V24, P1071, DOI 10.1097/MEG.0b013e328355a4ab; Nilsen EM, 1998, GASTROENTEROLOGY, V115, P551, DOI 10.1016/S0016-5085(98)70134-9; Nistico L, 2006, GUT, V55, P803, DOI 10.1136/gut.2005.083964; Olivares M, 2015, GUT, V64, P406, DOI 10.1136/gutjnl-2014-306931; Peters U, 2003, ARCH INTERN MED, V163, P1566, DOI 10.1001/archinte.163.13.1566; Rampertab SD, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.08.044; Reilly NR, 2012, MINERVA PEDIATR, V64, P71; Reilly NR, 2011, J PEDIATR GASTR NUTR, V53, P528, DOI 10.1097/MPG.0b013e3182276d5e; Riddle MS, 2012, AM J GASTROENTEROL, V107, P1248, DOI 10.1038/ajg.2012.130; Roberts SE, 2009, ALIMENT PHARM THER, V29, P222, DOI 10.1111/j.1365-2036.2008.03871.x; Rubio-Tapia A, 2013, AM J GASTROENTEROL, V108, P656, DOI 10.1038/ajg.2013.79; Rubio-Tapia A, 2012, AM J GASTROENTEROL, V107, P1538, DOI 10.1038/ajg.2012.219; Rubio-Tapia A, 2010, AM J GASTROENTEROL, V105, P1412, DOI 10.1038/ajg.2010.10; Rubio-Tapia A, 2009, GASTROENTEROLOGY, V137, P88, DOI 10.1053/j.gastro.2009.03.059; Sadr-Azodi O, 2012, CLIN GASTROENTEROL H, V10, P1136, DOI 10.1016/j.cgh.2012.06.023; Samaroo D, 2010, SCHIZOPHR RES, V118, P248, DOI 10.1016/j.schres.2009.08.009; Sanders DS, 2005, ANN SURG, V242, P201, DOI 10.1097/01.sla.0000171301.35513.cf; Sapone A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-13; Sapone A, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-23; Shah S, 2014, AM J GASTROENTEROL, V109, P1304, DOI 10.1038/ajg.2014.29; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Sharkey LM, 2013, ALIMENT PHARM THER, V38, P1278, DOI 10.1111/apt.12510; Simell S, 2007, AM J GASTROENTEROL, V102, P2026, DOI 10.1111/j.1572-0241.2007.01360.x; Simpson SM, 2013, DIABETES EDUCATOR, V39, P532, DOI 10.1177/0145721713487998; Smukalla Scott, 2014, Clin Adv Hematol Oncol, V12, P100; Smyth DJ, 2008, NEW ENGL J MED, V359, P2767, DOI 10.1056/NEJMoa0807917; Snook JA, 1996, GUT, V39, P60, DOI 10.1136/gut.39.1.60; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; Sorensen HT, 1999, GUT, V44, P736, DOI 10.1136/gut.44.5.736; Stene LC, 2006, AM J GASTROENTEROL, V101, P2333, DOI 10.1111/j.1572-0241.2006.00741.x; Sultan AA, 2015, GUT, V64, P1220, DOI 10.1136/gutjnl-2014-308285; Tang FM, 2009, J EXP MED, V206, P707, DOI 10.1084/jem.20071887; Tavakkoli A, 2014, DIGEST DIS SCI, V59, P1255, DOI 10.1007/s10620-013-2981-6; Taylor TB, 2015, J INVEST DERMATOL, V135, P623, DOI 10.1038/jid.2014.368; Tennyson CA, 2013, THER ADV GASTROENTER, V6, P358, DOI 10.1177/1756283X13492580; Tio M, 2012, ALIMENT PHARM THER, V35, P540, DOI 10.1111/j.1365-2036.2011.04972.x; Tuire I, 2012, AM J GASTROENTEROL, V107, P1563, DOI 10.1038/ajg.2012.220; van Heel DA, 2007, NAT GENET, V39, P827, DOI 10.1038/ng2058; Vazquez H, 2001, AM J GASTROENTEROL, V96, P798, DOI 10.1111/j.1572-0241.2001.03625.x; Vazquez-Roque MI, 2013, GASTROENTEROLOGY, V144, P903, DOI 10.1053/j.gastro.2013.01.049; Vilppula A, 2008, DIGEST LIVER DIS, V40, P809, DOI 10.1016/j.dld.2008.03.013; Visser J, 2009, ANN NY ACAD SCI, V1165, P195, DOI 10.1111/j.1749-6632.2009.04037.x; Volta U, 1998, LANCET, V352, P26, DOI 10.1016/S0140-6736(97)11222-3; Volta U, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0194-x; Volta U, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-85; Vriezinga SL, 2014, NEW ENGL J MED, V371, P1304, DOI 10.1056/NEJMoa1404172; Welander A, 2010, PEDIATRICS, V125, pE530, DOI 10.1542/peds.2009-1200; West J, 2004, BRIT MED J, V329, P716, DOI 10.1136/bmj.38169.486701.7C; West J, 2004, ALIMENT PHARM THERAP, V20, P73, DOI 10.1111/j.1365-2036.2004.02008.x; West J, 2003, GUT, V52, P960, DOI 10.1136/gut.52.7.960; West J, 2014, AM J GASTROENTEROL, V109, P757, DOI 10.1038/ajg.2014.55; Yuan JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081151; Zugna D, 2014, CLIN GASTROENTEROL H, V12, P1108, DOI 10.1016/j.cgh.2013.10.012; Zugna D, 2010, GUT, V59, P1471, DOI 10.1136/gut.2010.219030	169	174	178	0	122	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2015	351								h4347	10.1136/bmj.h4347	http://dx.doi.org/10.1136/bmj.h4347			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT3SC	26438584	Green Published			2023-01-03	WOS:000362726200001
J	Kesimer, M; Cullen, J; Cao, R; Radicioni, G; Mathews, KG; Seiler, G; Gookin, JL				Kesimer, Mehmet; Cullen, John; Cao, Rui; Radicioni, Giorgia; Mathews, Kyle G.; Seiler, Gabriela; Gookin, Jody L.			Excess Secretion of Gel-Forming Mucins and Associated Innate Defense Proteins with Defective Mucin Un-Packaging Underpin Gallbladder Mucocele Formation in Dogs	PLOS ONE			English	Article							GALL-BLADDER MUCOCELES; RESPIRATORY MUCIN; OLIGOMERIC MUCINS; EPITHELIAL-CELLS; GENE-EXPRESSION; CYSTIC-FIBROSIS; TREFOIL FACTORS; MUCUS; DISEASE; GLYCOPROTEIN	Mucosal protection of the gallbladder is vital yet we know very little about the mechanisms involved. In domestic dogs, an emergent syndrome referred to as gallbladder mucocele formation is characterized by excessive secretion of abnormal mucus that results in obstruction and rupture of the gallbladder. The cause of gallbladder mucocele formation is unknown. In these first mechanistic studies of this disease, we investigated normal and mucocele-forming dog gallbladders to determine the source, identity, biophysical properties, and protein associates of the culprit mucins with aim to identify causes for abnormal mucus behavior. We established that mucocele formation involves an adoptive excess secretion of gel forming mucins with abnormal properties by the gallbladder epithelium. The mucus is characterized by a disproportionally significant increase in Muc5ac relative to Muc5b, defective mucin un-packaging, and mucin-interacting innate defense proteins that are capable of dramatically altering the physical and functional properties of mucus. These findings provide an explanation for abnormal mucus behavior and based on similarity to mucus observed in the airways of people with cystic fibrosis, suggest that abnormal mechanisms for maintenance of gallbladder epithelial hydration may be an instigating factor for mucocele formation in dogs.	[Kesimer, Mehmet; Cao, Rui; Radicioni, Giorgia] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Kesimer, Mehmet; Cao, Rui; Radicioni, Giorgia] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC USA; [Cullen, John] N Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC USA; [Mathews, Kyle G.; Gookin, Jody L.] N Carolina State Univ, Ctr Comparat Med & Translat Res, Coll Vet, Dept Clin Sci, Raleigh, NC 27695 USA; [Seiler, Gabriela] N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University	Gookin, JL (corresponding author), N Carolina State Univ, Ctr Comparat Med & Translat Res, Coll Vet, Dept Clin Sci, Raleigh, NC 27695 USA.	Jody_Gookin@ncsu.edu	, Mehmet Kesimer/AHB-9223-2022; Cullen, John M/I-2051-2019	Gookin, Jody/0000-0002-2911-0874	Morris Animal Foundation [D12CA-044]; National Institutes of Health National Heart Lung and Blood Institute [HL103940]; Cystic Fibrosis Foundation [KESIME14XX0]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL103940] Funding Source: NIH RePORTER	Morris Animal Foundation; National Institutes of Health National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	These studies were funded by grant D12CA-044 from the Morris Animal Foundation (JLG), and partially supported by grant HL103940 (MK) from the National Institutes of Health National Heart Lung and Blood Institute and grant KESIME14XX0 (MK) from the Cystic Fibrosis Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguirre AL, 2007, JAVMA-J AM VET MED A, V231, P79, DOI 10.2460/javma.231.1.79; Ambort D, 2012, P NATL ACAD SCI USA, V109, P5645, DOI 10.1073/pnas.1120269109; Barbhuiya MA, 2011, PROTEOMICS, V11, P4443, DOI 10.1002/pmic.201100197; BERNHOFT RA, 1983, GASTROENTEROLOGY, V85, P1166; Buisine MP, 2000, J HISTOCHEM CYTOCHEM, V48, P1667, DOI 10.1177/002215540004801210; Chen EYT, 2010, AM J PHYSIOL-LUNG C, V299, pL542, DOI 10.1152/ajplung.00180.2010; Cooper JL, 2013, AM J PHYSIOL-LUNG C, V304, pL184, DOI 10.1152/ajplung.00143.2012; Crews LJ, 2009, JAVMA-J AM VET MED A, V234, P359, DOI 10.2460/javma.234.3.359; CROWTHER RS, 1984, BIORHEOLOGY, V21, P253; Cullen JM, 2014, J VET DIAGN INVEST, V26, P434, DOI 10.1177/1040638714532099; Farid SG, 2011, PROTEOMICS, V11, P2134, DOI 10.1002/pmic.201000653; Farina A, 2011, J PROTEOME RES, V10, P2047, DOI 10.1021/pr200011b; Finzi L, 2006, AM J PATHOL, V169, P2031, DOI 10.2353/ajpath.2006.060146; GEIL RG, 1977, J TOXICOL ENV HEALTH, V3, P179, DOI 10.1080/15287397709529557; Henderson AG, 2014, J CLIN INVEST, V124, P3047, DOI 10.1172/JCI73469; Ho SB, 2000, DIGEST DIS SCI, V45, P1061, DOI 10.1023/A:1005573213100; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; Jackowiak H., 2006, Folia Morphologica, V65, P105; Kesimer M, 2013, MUCOSAL IMMUNOL, V6, P379, DOI 10.1038/mi.2012.81; Kesimer M, 2010, AM J PHYSIOL-LUNG C, V298, pL15, DOI 10.1152/ajplung.00194.2009; Kesimer M, 2009, AM J PHYSIOL-LUNG C, V296, pL92, DOI 10.1152/ajplung.90388.2008; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537; Kjellev S, 2006, BRIT J PHARMACOL, V149, P92, DOI 10.1038/sj.bjp.0706840; Kobayashi K, 2002, GUT, V51, P169, DOI 10.1136/gut.51.2.169; KOVATCH RM, 1965, PATHOL VET, V2, P574, DOI 10.1177/030098586500200605; Kutsunai M, 2014, VET J, V199, P76, DOI 10.1016/j.tvjl.2013.10.019; Kuver R, 2006, AM J PHYSIOL-GASTR L, V291, pG1148, DOI 10.1152/ajpgi.00547.2005; Malek S, 2013, VET SURG, V42, P418, DOI 10.1111/j.1532-950X.2012.01072.x; MAUDESLE.LE, 1967, VET REC, V80, P658, DOI 10.1136/vr.80.22.658; Mesich MLL, 2009, J SMALL ANIM PRACT, V50, P630, DOI 10.1111/j.1748-5827.2009.00811.x; Meyerholz DK, 2010, AM J PATHOL, V176, P1377, DOI 10.2353/ajpath.2010.090849; Mollenhauer J, 2000, CANCER RES, V60, P1704; NUNES DP, 1995, BIOCHEM J, V310, P41, DOI 10.1042/bj3100041; Palaniyar N, 2003, ANN NY ACAD SCI, V1010, P471, DOI 10.1196/annals.1299.085; Peery AF, 2012, GASTROENTEROLOGY, V143, P1179, DOI 10.1053/j.gastro.2012.08.002; Pike FS, 2004, JAVMA-J AM VET MED A, V224, P1615, DOI 10.2460/javma.2004.224.1615; Ridley C, 2014, J BIOL CHEM, V289, P16409, DOI 10.1074/jbc.M114.566679; RUNDEGREN J, 1987, INFECT IMMUN, V55, P288, DOI 10.1128/IAI.55.2.288-292.1987; Sasaki M, 2007, PROG HISTOCHEM CYTO, V42, P61, DOI 10.1016/j.proghi.2007.02.001; SCOTT AJ, 1978, GUT, V19, P558, DOI 10.1136/gut.19.6.558; SELMAN PJ, 1995, VET QUART, V17, P128, DOI 10.1080/01652176.1995.9694551; Shaffer Eldon A, 2005, Curr Gastroenterol Rep, V7, P132; Sun XS, 2014, AM J PATHOL, V184, P1309, DOI 10.1016/j.ajpath.2014.01.035; Thim L, 2002, EUR J CLIN INVEST, V32, P519, DOI 10.1046/j.1365-2362.2002.01014.x; Thornton DJ, 2001, GLYCOBIOLOGY, V11, P969, DOI 10.1093/glycob/11.11.969; Tsukagoshi T, 2012, VET RADIOL ULTRASOUN, V53, P84, DOI 10.1111/j.1740-8261.2011.01868.x; Vandenhaute B, 1997, J HEPATOL, V27, P1057, DOI 10.1016/S0168-8278(97)80150-X; Wiede A, 1999, AM J RESP CRIT CARE, V159, P1330, DOI 10.1164/ajrccm.159.4.9804149; Worley DR, 2004, JAVMA-J AM VET MED A, V225, P1418, DOI 10.2460/javma.2004.225.1418; Yu H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020334; Zhu Y, 2008, J PHYSIOL-LONDON, V586, P1977, DOI 10.1113/jphysiol.2007.149310	52	36	36	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2015	10	9							e0138988	10.1371/journal.pone.0138988	http://dx.doi.org/10.1371/journal.pone.0138988			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6EO	26414376	Green Submitted, Green Published, gold			2023-01-03	WOS:000362170700031
J	Boni, L; Ruhs, PA; Windhab, EJ; Fischer, P; Kuster, S				Boeni, Lukas; Ruehs, Patrick A.; Windhab, Erich J.; Fischer, Peter; Kuster, Simon			Gelation of Soy Milk with Hagfish Exudate Creates a Flocculated and Fibrous Emulsion- and Particle Gel	PLOS ONE			English	Article							SLIME GLAND; PROTEIN; FIBERS; BIOLOGY; SALIVA	Hagfish slime is an ultra dilute, elastic and cohesive hydrogel that deploys within milliseconds in cold seawater from a glandularly secreted exudate. The slime is made of long keratin-like fibers and mucin-like glycoproteins that span a network which entraps water and acts as a defense mechanism against predators. Unlike other hydrogels, the slime only confines water physically and is very susceptible to mechanical stress, which makes it unsuitable for many processing operations and potential applications. Despite its huge potential, little work has been done to improve and functionalize the properties of this hydrogel. To address this shortcoming, hagfish exudate was mixed with a soy protein isolate suspension (4% w/v) and with a soy emulsion (commercial soy milk) to form a more stable structure and combine the functionalities of a suspension and emulsion with those of the hydrogel. Hagfish exudate interacted strongly with the soy systems, showing a markedly increased visco-elasticity and water retention. Hagfish mucin was found to induce a depletion and bridging mechanism, which caused the emulsion and suspension to flocculate, making "soy slime", a cohesive and cold-set emulsion-and particle gel. The flocculation network increases viscoelasticity and substantially contributes to liquid retention by entrapping liquid in the additional confinements between aggregated particles and protein fibers. Because the mucin-induced flocculation resembles the salt- or acid-induced flocculation in tofu curd production, the soy slime was cooked for comparison. The cooked soy slime was similar to conventional cooked tofu, but possessed a long-range cohesiveness from the fibers. The fibrous, cold-set, and curd-like structure of the soy slime represents a novel way for a cold coagulation and fiber incorporation into a suspension or emulsion. This mechanism could be used to efficiently gel functionalized emulsions or produce novel tofu-like structured food products.	[Boeni, Lukas; Windhab, Erich J.; Fischer, Peter; Kuster, Simon] ETH, Inst Food Nutr & Hlth, Food Proc Engn Grp, CH-8092 Zurich, Switzerland; [Ruehs, Patrick A.] ETH, Dept Mat, Complex Mat Grp, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Boni, L (corresponding author), ETH, Inst Food Nutr & Hlth, Food Proc Engn Grp, CH-8092 Zurich, Switzerland.	lukas.boeni@hest.ethz.ch	Fischer, Peter/A-8740-2011; Kuster, Simon/B-6140-2014; Windhab, Erich J/C-3381-2016; Boni, Lukas/B-2690-2015	Fischer, Peter/0000-0002-2992-5037; Kuster, Simon/0000-0003-2771-9667; Boni, Lukas/0000-0003-4958-0037	Walter Hochstrasser Stiftung; ETH Research Grant [ETH-19 14-1]	Walter Hochstrasser Stiftung; ETH Research Grant	The study was funded by the ETH Research Grant ETH-19 14-1.; The authors thank the curator Rune Veiseth and the whole team of the Atlanterhavsparken Aquarium in angstrom lesund for kindly providing the hagfish. We also express our thanks to Moreforsking angstrom lesund for the opportunity to use their facilities and Snorre Bakke for supervising the sampling of the hagfish according to the ethical guidelines (FOTS ID 6912). We thank Stephane Isabettini for his help with the Zetasizer measurements and Ruben Zurfluh for his support with the mucin dry weight measurements. We also thank the Walter Hochstrasser Stiftung that kindly provided funding in the initial project phase. This work was supported by ETH Research Grant ETH-19 14-1.	[Anonymous], 2012, LECTINS PROPERTIES F; Bocker L, 2016, ACS BIOMATERIALS SCI; Dickinson E, 2013, ADV COLLOID INTERFAC, V199, P114, DOI 10.1016/j.cis.2013.07.002; Dickinson E, 2012, FOOD HYDROCOLLOID, V28, P224, DOI 10.1016/j.foodhyd.2011.12.017; DOWNING SW, 1981, SCIENCE, V214, P1143, DOI 10.1126/science.7302586; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Ellis JE, 2015, FISH RES, V161, P24, DOI 10.1016/j.fishres.2014.06.011; ETZLER ME, 1985, ANNU REV PLANT PHYS, V36, P209, DOI 10.1146/annurev.pp.36.060185.001233; Everett D. H., 1988, RSC PAPERBACKS; Ferry JD, 1941, J BIOL CHEM, V138, P263; Fu J, 2015, BIOMACROMOLECULES, V16, P2327, DOI 10.1021/acs.biomac.5b00552; Fudge DS, 2011, ENCYCLOPEDIA OF FISH PHYSIOLOGY: FROM GENOME TO ENVIRONMENT, VOLS 1-3, P504; Fudge DS, 2005, J EXP BIOL, V208, P4613, DOI 10.1242/jeb.01963; Fudge DS, 2003, BIOPHYS J, V85, P2015, DOI 10.1016/S0006-3495(03)74629-3; FUKUSHIMA D, 1981, J AM OIL CHEM SOC, V58, P346, DOI 10.1007/BF02582376; Gabor F, 2004, ADV DRUG DELIVER REV, V56, P459, DOI 10.1016/j.addr.2003.10.015; HEALY TW, 1964, J COLL SCI IMP U TOK, V19, P323, DOI 10.1016/0095-8522(64)90034-0; Herr JE, 2010, J EXP BIOL, V213, P1092, DOI 10.1242/jeb.038992; HISAYASU S, 1992, J NUTR, V122, P1190, DOI 10.1093/jn/122.5.1190; Hyun K, 2011, PROG POLYM SCI, V36, P1697, DOI 10.1016/j.progpolymsci.2011.02.002; KINSELLA JE, 1979, J AM OIL CHEM SOC, V56, P242, DOI 10.1007/BF02671468; Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012; Lim J, 2006, J EXP BIOL, V209, P702, DOI 10.1242/jeb.02067; LUSAS EW, 1995, J NUTR, V125, pS573, DOI 10.1093/jn/125.3_Suppl.573S; Malhotra A, 2004, FOOD HYDROCOLLOID, V18, P101, DOI 10.1016/S0268-005X(03)00047-X; Maltais A, 2008, FOOD HYDROCOLLOID, V22, P550, DOI 10.1016/j.foodhyd.2007.01.026; Maltais A, 2009, FOOD HYDROCOLLOID, V23, P1647, DOI 10.1016/j.foodhyd.2008.12.006; McGuckin MA, 2012, METHODS MOL BIOL, V842, P1, DOI 10.1007/978-1-61779-513-8; Miserez A, 2013, CHEM SOC REV, V42, P1973, DOI 10.1039/c2cs35294j; NAGANO T, 1994, BIOPOLYMERS, V34, P1303, DOI 10.1002/bip.360341003; Negishi A, 2012, BIOMACROMOLECULES, V13, P3475, DOI 10.1021/bm3011837; Nishinari K, 2014, FOOD HYDROCOLLOID, V39, P301, DOI 10.1016/j.foodhyd.2014.01.013; Pinto N, 2014, BIOMACROMOLECULES, V15, P574, DOI 10.1021/bm401600a; Radford SJ, 2004, COLLOID SURFACE A, V238, P71, DOI 10.1016/j.colsurfa.2004.02.020; Raynal BDE, 2003, J BIOL CHEM, V278, P28703, DOI 10.1074/jbc.M304632200; SALO WL, 1983, PREP BIOCHEM, V13, P103, DOI 10.1080/00327488308068743; Schaffeld M, 2006, EXP CELL RES, V312, P1447, DOI 10.1016/j.yexcr.2006.01.005; Shurtleff W, 2000, TOFU SOYMILK PRODUCT; Silletti E, 2007, FOOD HYDROCOLLOID, V21, P596, DOI 10.1016/j.foodhyd.2006.07.004; Vingerhoeds MH, 2005, FOOD HYDROCOLLOID, V19, P915, DOI 10.1016/j.foodhyd.2004.12.005; Winegard TM, 2010, J EXP BIOL, V213, P1235, DOI 10.1242/jeb.038075	41	13	13	8	53	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147022	10.1371/journal.pone.0147022	http://dx.doi.org/10.1371/journal.pone.0147022			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26808048	Green Published, Green Submitted, gold			2023-01-03	WOS:000369527800046
J	[Anonymous]				[Anonymous]			Euthanasia (Reprinted from JAMA, vol 218, pg 249, 1971)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint							LIFE											ABELSON PH, 1971, SCIENCE, V173, P285, DOI 10.1126/science.173.3994.285; BROWN NK, 1970, J AMER MED ASSOC, V211, P76, DOI 10.1001/jama.211.1.76; LAWS EH, 1971, J MED EDUC, V46, P540; ODONNELL TJ, 1956, MORALS MEDICINE, P55; WILLIAMS RH, 1969, ARCH INTERN MED, V124, P215, DOI 10.1001/archinte.124.2.215; 1971, JAMA, V218, P249	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					310	310		10.1001/jama.2015.17071	http://dx.doi.org/10.1001/jama.2015.17071			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784789				2023-01-03	WOS:000368371400036
J	Richter, J; Panayiotou, C; Tryfonos, C; Koptides, D; Koliou, M; Kalogirou, N; Georgiou, E; Christodoulou, C				Richter, Jan; Panayiotou, Christakis; Tryfonos, Christina; Koptides, Dana; Koliou, Maria; Kalogirou, Nikolas; Georgiou, Eleni; Christodoulou, Christina			Aetiology of Acute Respiratory Tract Infections in Hospitalised Children in Cyprus	PLOS ONE			English	Article							REAL-TIME PCR; INFLUENZA-LIKE ILLNESS; SYNCYTIAL-VIRUS; VIRAL ETIOLOGY; EPIDEMIOLOGY; DIAGNOSIS; COINFECTION; SEASONALITY; PNEUMONIA	In order to improve clinical management and prevention of viral infections in hospitalised children improved etiological insight is needed. The aim of the present study was to assess the spectrum of respiratory viral pathogens in children admitted to hospital with acute respiratory tract infections in Cyprus. For this purpose nasopharyngeal swab samples from 424 children less than 12 years of age with acute respiratory tract infections were collected over three epidemic seasons and were analysed for the presence of the most common 15 respiratory viruses. A viral pathogen was identified in 86% of the samples, with multiple infections being observed in almost 20% of the samples. The most frequently detected viruses were RSV (30.4%) and Rhinovirus (27.4%). RSV exhibited a clear seasonality with marked peaks in January/February, while rhinovirus infections did not exhibit a pronounced seasonality being detected almost throughout the year. While RSV and PIV3 incidence decreased significantly with age, the opposite was observed for influenza A and B as well as adenovirus infections. The data presented expand our understanding of the epidemiology of viral respiratory tract infections in Cypriot children and will be helpful to the clinicians and researchers interested in the treatment and control of viral respiratory tract infections.	[Richter, Jan; Panayiotou, Christakis; Tryfonos, Christina; Koptides, Dana; Christodoulou, Christina] Cyprus Inst Neurol & Genet, Dept Mol Virol, Nicosia, Cyprus; [Koliou, Maria; Kalogirou, Nikolas; Georgiou, Eleni] Archbishop Makarios III Hosp, Dept Pediat, Nicosia, Cyprus		Richter, J (corresponding author), Cyprus Inst Neurol & Genet, Dept Mol Virol, Nicosia, Cyprus.	richter@cing.ac.cy			European Regional Development Fund; Republic of Cyprus through the Research Promotion Foundation [YGammaEIA/DeltaYGammaEIA/0609(BIE/25)]; Republic of Cyprus	European Regional Development Fund(European Commission); Republic of Cyprus through the Research Promotion Foundation; Republic of Cyprus	The work was co-funded by the European Regional Development Fund and the Republic of Cyprus through the Research Promotion Foundation grant number Y Gamma EIA/Delta Y Gamma EIA/0609(BIE/25). ("Co-funded" refers to the fact that the money came from both the European Regional Development Fund AND the Republic of Cyprus). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baccala GP, 2008, J CLIN VIROL, V43, P407, DOI 10.1016/j.jcv.2008.08.010; Berry M, 2015, VIRUSES-BASEL, V7, P996, DOI 10.3390/v7030996; Bonzel L, 2008, PEDIATR INFECT DIS J, V27, P589, DOI 10.1097/INF.0b013e3181694fb9; Brittain-Long R, 2008, J CLIN VIROL, V41, P53, DOI 10.1016/j.jcv.2007.10.029; Cho HJ, 2013, PEDIATR INT, V55, P49, DOI 10.1111/j.1442-200X.2012.03727.x; Cui BL, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0863-6; Essa S, 2015, ADV VIROL, V2015, DOI 10.1155/2015/714062; Farley R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005189.pub4; Fry AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015098; Halasa N, 2015, VACCINE; Harada Y, 2013, PEDIATR INFECT DIS J, V32, P441, DOI 10.1097/INF.0b013e31828ba08c; Harper SA, 2009, CLIN INFECT DIS, V48, P1003, DOI 10.1086/598513; Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382; Hoare Z, 2006, BMJ-BRIT MED J, V332, P1077, DOI 10.1136/bmj.332.7549.1077; Hombrouck A, 2012, EUR J CLIN MICROBIOL, V31, P999, DOI 10.1007/s10096-011-1398-4; Jacobs SE, 2013, CLIN MICROBIOL REV, V26, P135, DOI 10.1128/CMR.00077-12; Kesson AM, 2007, PAEDIATR RESPIR REV, V8, P240, DOI 10.1016/j.prrv.2007.07.003; Khadadah M, 2010, J MED VIROL, V82, P1462, DOI 10.1002/jmv.21823; Kim H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068081; Kim JK, 2013, J MICROBIOL BIOTECHN, V23, P267, DOI 10.4014/jmb.1212.12050; Louie JK, 2009, PEDIATR INFECT DIS J, V28, P337, DOI 10.1097/INF.0b013e31818ffc1b; Low D, 2008, CLIN MICROBIOL INFEC, V14, P298, DOI 10.1111/j.1469-0691.2007.01910.x; Lu XY, 2008, J CLIN MICROBIOL, V46, P533, DOI 10.1128/JCM.01739-07; Lu YQ, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/210490; Panayiotou C, 2014, EPIDEMIOL INFECT, V142, P2406, DOI 10.1017/S0950268814000028; Pierangeli A, 2007, J MED VIROL, V79, P463, DOI 10.1002/jmv.20832; Puzelli S, 2009, J MED VIROL, V81, P2066, DOI 10.1002/jmv.21610; Regamey N, 2008, PEDIATR INFECT DIS J, V27, P100, DOI 10.1097/INF.0b013e31815922c8; Richard N, 2008, PEDIATR INFECT DIS J, V27, P213, DOI 10.1097/INF.0b013e31815b4935; Richards J. C., 2014, ENGLISH FOREIGN LANG, P1; Schlaudecker EP, 2012, PEDIATR INFECT DIS J, V31, P1113, DOI 10.1097/INF.0b013e31826052eb; Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004; Tivejung-Lindell A, 2009, J MED VIROL, V81, P167, DOI 10.1002/jmv.21368; Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09; Tryfonos C, 2011, J MED MICROBIOL, V60, P1433, DOI 10.1099/jmm.0.029892-0; Watzinger F, 2004, J CLIN MICROBIOL, V42, P5189, DOI 10.1128/JCM.42.11.5189-5198.2004; Wenzel RP, 2006, NEW ENGL J MED, V355, P2125, DOI 10.1056/NEJMcp061493; WHO CDC, 2009, CDC PROT REALT RTPCR; Wu XD, 2015, RESPIRATION, V89, P343, DOI 10.1159/000369561; Zaas AK, 2014, TRENDS MOL MED, V20, P579, DOI 10.1016/j.molmed.2014.08.001	41	29	29	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2016	11	1							e0147041	10.1371/journal.pone.0147041	http://dx.doi.org/10.1371/journal.pone.0147041			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA8CX	26761647	Green Published, gold, Green Submitted			2023-01-03	WOS:000368033100066
J	Zeng, XZ; Lu, ZF; Lv, XQ; Guo, YP; Cui, XG				Zeng, Xian-Zhang; Lu, Zhi-Fang; Lv, Xiang-Qi; Guo, Yue-Ping; Cui, Xiao-Guang			Epidural Co-Administration of Dexmedetomidine and Levobupivacaine Improves the Gastrointestinal Motility Function after Colonic Resection in Comparison to Co-Administration of Morphine and Levobupivacaine	PLOS ONE			English	Article							RAT SPINAL-CORD; BUPIVACAINE; CLONIDINE; SURGERY; ROPIVACAINE; ANESTHESIA; ANALGESIA; EFFICACY; TRANSIT	Gastrointestinal motility may be impaired after intestinal surgery. Epidural morphine is effective in controlling postoperative pain, but can further reduce gastrointestinal motility. Here, we aimed to investigate the effects of epidural dexmedetomidine on gastrointestinalmotility in patients undergoing colonic resection. Seventy-four patients undergoing colonic resection were enrolled in this clinical trial and allocated randomly to treatment with dexmedetomidine (D group) or morphine (M group). The D group received a loading dose epidural administration of 3 ml dexmedetomidine (0.5 mu g kg(-1)) and then a continuous epidural administration of 80 mu g dexmedetomidine in 150 ml levobupivacaine (0.125%) at 3 ml h(-1) for two days. The M group received a loading dose epidural administration of 3 ml morphine (0.03mg kg(-1)) and then a continuous epidural administration of 4.5 mg morphine in 150 ml levobupivacaine at 3ml h(-1) for two days. Verbal rating score (VRS), postoperative analgesic requirements, side effects related to analgesia, the time to postoperative first flatus (FFL) and first feces (FFE) were recorded. VRS and postoperative analgesic requirements were not significantly different between treatment groups. In contrast, the time to FFL and time to FFE were significant longer in M group in comparison to D group (P < 0.05). Moreover, patients in M group had a significantly higher incidence of nausea, vomiting, and pruritus (P < 0.05). No patients showed neurologic deficits in either group. In comparison to morphine, epidural dexmedetomidine is safe and beneficial for the recovery of gastrointestinalmotility after colonic resection when used as an adjunct with levobupivacaine for postoperative pain control.	[Zeng, Xian-Zhang; Lu, Zhi-Fang; Lv, Xiang-Qi; Guo, Yue-Ping; Cui, Xiao-Guang] Harbin Med Univ, Dept Anesthesiol, Hosp 2, Harbin 150001, Heilongjiang, Peoples R China	Harbin Medical University	Cui, XG (corresponding author), Harbin Med Univ, Dept Anesthesiol, Hosp 2, 246 Xuefu Rd, Harbin 150001, Heilongjiang, Peoples R China.	cuixiaoguang1018@126.com						Asai T, 1997, BRIT J ANAESTH, V78, P301, DOI 10.1093/bja/78.3.301; Asano T, 2000, ANESTH ANALG, V90, P400, DOI 10.1097/00000539-200002000-00030; Aydin C, 2009, WORLD J GASTROENTERO, V15, P1620, DOI 10.3748/wjg.15.1620; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; El-Hennawy AM, 2009, BRIT J ANAESTH, V103, P268, DOI 10.1093/bja/aep159; Fairbanks CA, 2002, J PHARMACOL EXP THER, V300, P282, DOI 10.1124/jpet.300.1.282; Fukuda H, 2005, NEUROGASTROENT MOTIL, V17, P245, DOI 10.1111/j.1365-2982.2004.00602.x; Gupta R, 2011, INDIAN J ANAESTH, V55, P347, DOI 10.4103/0019-5049.84841; Holte K, 2000, BRIT J SURG, V87, P1480, DOI 10.1046/j.1365-2168.2000.01595.x; Iirola T, 2011, BRIT J ANAESTH, V106, P522, DOI 10.1093/bja/aer004; Ishii H, 2008, EUR J NEUROSCI, V27, P3182, DOI 10.1111/j.1460-9568.2008.06260.x; Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x; Konakci S, 2008, EUR J ANAESTH, V25, P403, DOI 10.1017/S0265021507003079; Memis D, 2006, EUR J ANAESTH, V23, P700, DOI 10.1017/S0265021506000512; Mohamed AA, 2012, PAIN PHYSICIAN, V15, P339; Rancourt MPM, 2012, ANESTH ANALG, V115, P958, DOI 10.1213/ANE.0b013e318265bab7; RAVINDRAN RS, 1982, ANESTH ANALG, V61, P279; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; Salgado PFS, 2008, REV ASSOC MED BRAS, V54, P110, DOI 10.1590/S0104-42302008000200011; Solanki SL, 2013, ANAESTH INTENS CARE, V41, P51, DOI 10.1177/0310057X1304100110; Vieira Antônio Mauro, 2004, Rev. Bras. Anestesiol., V54, P473, DOI 10.1590/S0034-70942004000400003; Yoshitomi T, 2008, ANESTH ANALG, V107, P96, DOI 10.1213/ane.0b013e318176be73; Zeng XZ, 2014, ANAESTH INTENS CARE, V42, P185, DOI 10.1177/0310057X1404200204; Zhang HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055556	24	9	9	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0146215	10.1371/journal.pone.0146215	http://dx.doi.org/10.1371/journal.pone.0146215			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6CA	26751791	Green Published, gold, Green Submitted			2023-01-03	WOS:000367888100052
J	Lobo, MR; Kukino, A; Tran, H; Schabel, MC; Springer, CS; Gillespie, GY; Grafe, MR; Woltjer, RL; Pike, MM				Lobo, Merryl R.; Kukino, Ayaka; Tran, Huong; Schabel, Matthias C.; Springer, Charles S., Jr.; Gillespie, G. Yancey; Grafe, Marjorie R.; Woltjer, Randall L.; Pike, Martin M.			Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM-STRESS; CONTRAST-ENHANCED MRI; PROTEASOME INHIBITOR BORTEZOMIB; INPUT FUNCTION ESTIMATION; MONTE-CARLO METHOD; IN-VIVO; KAPPA-B; PROLONGS SURVIVAL; KINASE INHIBITOR; TUMOR-GROWTH	Prognosis remains extremely poor for malignant glioma. Targeted therapeutic approaches, including single agent anti-angiogenic and proteasome inhibition strategies, have not resulted in sustained anti-glioma clinical efficacy. We tested the anti-glioma efficacy of the anti-angiogenic receptor tyrosine kinase inhibitor cediranib and the novel proteasome inhibitor SC68896, in combination and as single agents. To assess anti-angiogenic effects and evaluate efficacy we employed 4C8 intracranial mouse glioma and a dual-bolus perfusion MRI approach to measure K-trans, relative cerebral blood flow and volume (rCBF, rCBV), and relative mean transit time (rMTT) in combination with anatomical MRI measurements of tumor growth. While single agent cediranib or SC68896 treatment did not alter tumor growth or survival, combined cediranib/SC68896 significantly delayed tumor growth and increased median survival by 2-fold, compared to untreated. This was accompanied by substantially increased tumor necrosis in the cediranib/SC68896 group (p<0.01), not observed with single agent treatments. Mean vessel density was significantly lower, and mean vessel lumen area was significantly higher, for the combined cediranib/SC68896 group versus untreated. Consistent with our previous findings, cediranib alone did not significantly alter mean tumor rCBF, rCBV, rMTT, or K-trans. In contrast, SC68896 reduced rCBF in comparison to untreated, but without concomitant reductions in rCBV, rMTT, or K-trans. Importantly, combined cediranib/SC68896 substantially reduced rCBF, rCBV. rMTT, and K-trans. A novel analysis of K-trans/rCBV suggests that changes in K-trans with time and/or treatment are related to altered total vascular surface area. The data suggest that combined cediranib/SC68896 induced potent anti-angiogenic effects, resulting in increased vascular efficiency and reduced extravasation, consistent with a process of vascular normalization. The study represents the first demonstration that the combination of cediranib with a proteasome inhibitor substantially increases the anti-angiogenic efficacy produced from either agent alone, and synergistically slows glioma tumor growth and extends survival, suggesting a promising treatment which warrants further investigation.	[Lobo, Merryl R.; Kukino, Ayaka; Schabel, Matthias C.; Springer, Charles S., Jr.; Pike, Martin M.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97201 USA; [Lobo, Merryl R.; Pike, Martin M.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA; [Tran, Huong; Grafe, Marjorie R.; Woltjer, Randall L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA; [Gillespie, G. Yancey] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Alabama System; University of Alabama Birmingham	Pike, MM (corresponding author), Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97201 USA.	pikema@ohsu.edu	Schabel, Matthias C./H-4647-2019	Gillespie, George/0000-0001-6436-9542	National Institutes of Health, National Cancer Institute [1R21 CA114279-01A2, 1R21 CA167302-01]; NATIONAL CANCER INSTITUTE [R21CA114279, R21CA167302] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health, National Cancer Institute grants 1R21 CA114279-01A2 (MMP) and 1R21 CA167302-01 (MMP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Befani CD, 2012, J MOL MED, V90, P45, DOI 10.1007/s00109-011-0805-8; Belloni D, 2010, EXP CELL RES, V316, P1010, DOI 10.1016/j.yexcr.2009.11.005; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Birle DC, 2007, CANCER RES, V67, P1735, DOI 10.1158/0008-5472.CAN-06-2722; Boccadoro M, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-18; Brignole C, 2006, J NATL CANCER I, V98, P1142, DOI 10.1093/jnci/djj309; Buac D, 2013, CURR PHARM DESIGN, V19, P4025, DOI 10.2174/1381612811319220012; Chen KF, 2008, CANCER RES, V68, P6698, DOI 10.1158/0008-5472.CAN-08-0257; Chen KF, 2009, J BIOL CHEM, V284, P11121, DOI 10.1074/jbc.M806268200; Daniel KG, 2005, CURR CANCER DRUG TAR, V5, P529, DOI 10.2174/156800905774574075; de Wilt LHAM, 2013, CRIT REV ONCOL HEMAT, V85, P363, DOI 10.1016/j.critrevonc.2012.08.001; Drexler HCA, 2000, FASEB J, V14, P65, DOI 10.1096/fasebj.14.1.65; Driscoll JJ, 2012, SEMIN HEMATOL, V49, P277, DOI 10.1053/j.seminhematol.2012.04.002; DYER CA, 1995, J NEUROPATH EXP NEUR, V54, P852, DOI 10.1097/00005072-199511000-00012; Fels DR, 2008, CANCER RES, V68, P9323, DOI 10.1158/0008-5472.CAN-08-2873; Gladson CL, 2010, ANNU REV PATHOL-MECH, V5, P33, DOI 10.1146/annurev-pathol-121808-102109; Goel S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006486; Gotink KJ, 2010, ANGIOGENESIS, V13, P1, DOI 10.1007/s10456-009-9160-6; Hardee ME, 2012, AM J PATHOL, V181, P1126, DOI 10.1016/j.ajpath.2012.06.030; Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064; Inoue T, 2006, ANTI-CANCER DRUG, V17, P261, DOI 10.1097/00001813-200603000-00004; Jiang LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055527; Kaluz S, 2008, J CELL BIOCHEM, V104, P536, DOI 10.1002/jcb.21644; Kamoun WS, 2009, J CLIN ONCOL, V27, P2542, DOI 10.1200/JCO.2008.19.9356; Kardosh A, 2008, CANCER RES, V68, P843, DOI 10.1158/0008-5472.CAN-07-5555; Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115; Khan T, 2006, J IMMUNOL, V176, P6302, DOI 10.4049/jimmunol.176.10.6302; Labussiere M, 2008, ONCOL REP, V20, P1283, DOI 10.3892/or_00000142; Leban J, 2008, BIOORGAN MED CHEM, V16, P4579, DOI 10.1016/j.bmc.2008.02.042; LeBlanc R, 2002, CANCER RES, V62, P4996; Li X, 2009, NMR BIOMED, V22, P148, DOI 10.1002/nbm.1293; Lobo MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114110; Lobo MR, 2013, NEURO-ONCOLOGY, V15, P1673, DOI 10.1093/neuonc/not119; Martinho O, 2013, TRANSL ONCOL, V6, P187, DOI 10.1593/tlo.12400; Matsuo Y, 2010, DIGEST DIS SCI, V55, P1167, DOI 10.1007/s10620-009-0814-4; McConkey DJ, 2008, DRUG RESIST UPDATE, V11, P164, DOI 10.1016/j.drup.2008.08.002; Milano A, 2009, ONCOTARGETS THER, V2, P171; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Nestler U, 2015, ACTA NEUROCHIR, V157, P179, DOI 10.1007/s00701-014-2271-x; Njus JM, 2008, P INT SOC MAGN RESON, V16; Noguchi M, 2014, BBA-REV CANCER, V1846, P342, DOI 10.1016/j.bbcan.2014.07.013; Norden AD, 2009, NAT REV NEUROL, V5, P610, DOI 10.1038/nrneurol.2009.159; O'Connor JPB, 2012, NAT REV CLIN ONCOL, V9, P167, DOI 10.1038/nrclinonc.2012.2; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Peng L, 2013, ONCOL REP, V29, P571, DOI 10.3892/or.2012.2165; Phillips H, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2001; Pike MM, 2009, MAGN RESON MED, V61, P615, DOI 10.1002/mrm.21931; Rahimi N, 2012, MOL CANCER THER, V11, P538, DOI 10.1158/1535-7163.MCT-11-0555; Rahman R, 2010, J ONCOL, V2010, DOI 10.1155/2010/251231; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Roth P, 2009, CLIN CANCER RES, V15, P6609, DOI 10.1158/1078-0432.CCR-09-0548; Schabel MC, 2010, PHYS MED BIOL, V55, P4783, DOI 10.1088/0031-9155/55/16/011; Schabel MC, 2010, PHYS MED BIOL, V55, P4807, DOI 10.1088/0031-9155/55/16/012; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shin DH, 2008, ONCOGENE, V27, P1939, DOI 10.1038/sj.onc.1210826; Shin DH, 2008, BLOOD, V111, P3131, DOI 10.1182/blood-2007-11-120576; Sorensen AG, 2012, CANCER RES, V72, P402, DOI 10.1158/0008-5472.CAN-11-2464; Sourbron SP, 2012, PHYS MED BIOL, V57, pR1, DOI 10.1088/0031-9155/57/2/R1; Sterz J, 2008, EXPERT OPIN INV DRUG, V17, P879, DOI 10.1517/13543784.17.6.879 ; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Tabatabai G, 2009, CURR OPIN NEUROL, V22, P639, DOI 10.1097/WCO.0b013e328332ba28; Thaker NG, 2009, EXPERT REV NEUROTHER, V9, P1815, DOI 10.1586/ERN.09.116; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Veschini L, 2007, BLOOD, V109, P2565, DOI 10.1182/blood-2006-06-032664; Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Xie TX, 2010, ONCOL REP, V23, P725, DOI 10.3892/or_00000690; Yeramian A, 2012, INT J CANCER, V130, P967, DOI 10.1002/ijc.26096; Yu CR, 2006, MOL CANCER THER, V5, P2378, DOI 10.1158/1535-7163.MCT-06-0235; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200	74	7	7	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2015	10	12							e0144488	10.1371/journal.pone.0144488	http://dx.doi.org/10.1371/journal.pone.0144488			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1YV	26645398	Green Published, gold, Green Submitted			2023-01-03	WOS:000366903100026
J	Jing, W; Zhu, H; Guo, HB; Zhang, Y; Shi, F; Han, AQ; Li, MH; Kong, L; Yu, JM				Jing, Wang; Zhu, Hui; Guo, Hongbo; Zhang, Yan; Shi, Fang; Han, Anqin; Li, Minghuan; Kong, Li; Yu, Jinming			Feasibility of Elective Nodal Irradiation (ENI) and Involved Field Irradiation (IFI) in Radiotherapy for the Elderly Patients (Aged >= 70 Years) with Esophageal Squamous Cell Cancer: A Retrospective Analysis from a Single Institute	PLOS ONE			English	Article							DEFINITIVE CHEMORADIOTHERAPY; RADIATION-THERAPY; CARCINOMA; PATTERNS; TRIAL	Purpose We conducted a retrospective analysis to assess the feasibility of involved field irradiation (IFI) in elderly patients with esophageal squamous cell cancer (ESCC). Materials and Methods We performed a retrospective review of the records of elderly patients (>= 70 years) with unresectable ESCC and no distant metastases who received treatment with radiotherapy between January 2009 and March 2013. According to the irradiation volume, patients were allocated into either the elective nodal irradiation (ENI) group or the IFI group. Overall survival (OS), progression-free survival (PFS) and treatment-related toxicities were compared between the two groups. Results A total of 137 patients were enrolled. Fifty-four patients (39.4%) were allocated to the ENI group and 83 patients (60.6%) to the IFI group, the median doses in the two groups were 60 Gy and 59.4 Gy, respectively. For the entire group, the median survival time (MST) and PFS were 16 months and 12 months, respectively. The median PFS and 3-year PFS rate in the ENI group were 13 months and 20.6%, compared to 11 months and 21.0% in the IFI groups (p = 0.61). The MST and 3-year OS rate in the ENI and IFI groups were 17 months and 26.4% and 15.5 months and 21.7%, respectively (p = 0.25). The rate of grade >= 3 acute irradiation esophagitis in the ENI group was significantly higher than that in the IFI group (18.5% vs. 6.0%; p = 0.027). Other grade >= 3 treatment-related toxicities did not significantly differ between the two groups. Conclusions IFI resulted in decreased irradiation toxicities without sacrificing OS in elderly patients with ESCC.	[Jing, Wang] Weifang Med Univ, Weifang, Shandong, Peoples R China; [Zhu, Hui; Zhang, Yan; Shi, Fang; Han, Anqin; Li, Minghuan; Kong, Li; Yu, Jinming] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China; [Guo, Hongbo] Shandong Canc Hosp & Inst, Dept Thorac Surg, Jinan, Shandong, Peoples R China	Weifang Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences	Kong, L (corresponding author), Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China.	kongli7@sina.com; sdyujinming@126.com			Natural Science Foundation of Shandong Province [ZR2011HL029]	Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This study was supported by Grant NO. ZR2011HL029 from the Natural Science Foundation of Shandong Province to Hongbo Guo.	Button MR, 2009, INT J RADIAT ONCOL, V73, P818, DOI 10.1016/j.ijrobp.2008.04.062; Cooper JS, 1999, JAMA-J AM MED ASSOC, V281, P1623, DOI 10.1001/jama.281.17.1623; Fernandes AT, 2010, RADIOTHER ONCOL, V95, P178, DOI 10.1016/j.radonc.2010.02.007; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kato K, 2013, JPN J CLIN ONCOL, V43, P608, DOI 10.1093/jjco/hyt048; Kawaguchi Y, 2011, JPN J CLIN ONCOL, V41, P1007, DOI 10.1093/jjco/hyr069; Li Xue, 2015, Asian Pac J Cancer Prev, V16, P1463; Liu MN, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0232-4; Ma JB, 2011, ONKOLOGIE, V34, P599, DOI 10.1159/000334194; Minsky BD, 2002, J CLIN ONCOL, V20, P1167, DOI 10.1200/JCO.20.5.1167; Onozawa M, 2009, RADIOTHER ONCOL, V92, P266, DOI 10.1016/j.radonc.2008.09.025; Rizk NP, 2007, J CLIN ONCOL, V25, P507, DOI 10.1200/JCO.2006.08.0101; Rochigneux P, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00100; Semrau R, 2012, STRAHLENTHER ONKOL, V188, P226, DOI 10.1007/s00066-011-0039-2; Servagi-Vernat S, 2009, DRUG AGING, V26, P255, DOI 10.2165/00002512-200926030-00006; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Smith BD, 2009, J CLIN ONCOL, V27, P2758, DOI 10.1200/JCO.2008.20.8983; Takeuchi S, 2007, AM J CLIN ONCOL-CANC, V30, P607, DOI 10.1097/COC.0b013e3180ca7c84; Tougeron D, 2008, BRIT J CANCER, V99, P1586, DOI 10.1038/sj.bjc.6604749; Uno T, 2004, ANTICANCER RES, V24, P2483; Yamashita H, 2014, RADIOTHER ONCOL, V113, P182, DOI 10.1016/j.radonc.2014.11.004; Yamashita H, 2011, RADIOTHER ONCOL, V98, P255, DOI 10.1016/j.radonc.2010.10.021; Zhang P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105270; Zhang XJ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085007, 10.1186/1748-717X-9-64]; Zhao KL, 2010, INT J RADIAT ONCOL, V76, P446, DOI 10.1016/j.ijrobp.2009.02.078	25	16	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2015	10	12							e0143007	10.1371/journal.pone.0143007	http://dx.doi.org/10.1371/journal.pone.0143007			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY1CH	26636574	Green Published, Green Submitted, gold			2023-01-03	WOS:000366143800004
J	Liu, GL; Pi, HC; Hao, L; Li, DD; Wu, YG; Dong, J				Liu, Gui-Ling; Pi, Hai-Chen; Hao, Li; Li, Dan-Dan; Wu, Yong-Gui; Dong, Jie			Vitamin D Status Is an Independent Risk Factor for Global Cognitive Impairment in Peritoneal Dialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS; 25-HYDROXYVITAMIN D; D INSUFFICIENCY; CHOLECALCIFEROL; ASSOCIATION; PERFORMANCE; DECLINE; ADULTS	Objective Vitamin D (VD) deficiency is an independent risk factor for cognitive impairment (CI) in the general population, but VD status in peritoneal dialysis (PD) patients has not been investigated. In this study, we aimed to investigate the relationship between serum VD levels and global and specific cognitive functions in PD patients. Design and Setting Cross-sectional study, simultaneously conducted at two PD centers. Patients Clinically stable patients (n = 273) undergoing PD for at least 3 months were enrolled over a period of one year. Main outcome Measures Demographic and comorbidity data were recorded, and routine biochemical parameters and serum 25-hydroxyvitamin D (25(OH) D) levels of overnight fasted patients were determined. Global cognitive function was assessed by the Modified Mini-Mental State Examination (3MS) score; executive function, by the trail making tests (Trails A and B); and immediate memory, delayed memory, and language ability by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) sub-tests. Results In the univariate analysis, serum 25(OH) D levels significantly correlated with 3MS scores (r = -0.139; P = 0.02), and Trail A (r = -0.188; P = 0.002) and B (r = -0.154; P = 0.01) completion times. In the multivariate analysis, 25(OH) D was found to be independently associated with global CI, but not with executive dysfunction. Serum 25(OH) D could not predict scores of immediate/delayed memory and language ability. Conclusions VD deficiency is highly prevalent in PD patients and is an independent risk factor for global CI in this patient cohort.	[Liu, Gui-Ling; Hao, Li; Li, Dan-Dan; Wu, Yong-Gui] Anhui Med Univ, Hosp 2, Div Renal, Hefei, Anhui, Peoples R China; [Pi, Hai-Chen; Dong, Jie] Peking Univ, Div Renal, Dept Med,Minist Educ, Hosp 1,Inst Nephrol,Key Lab Renal Dis,Minist Hlth, Beijing 100871, Peoples R China	Anhui Medical University; Peking University	Wu, YG (corresponding author), Anhui Med Univ, Hosp 2, Div Renal, Hefei, Anhui, Peoples R China.	guilingliu369@yeah.net	Dong, Jie/AFM-0048-2022					Afsar B, 2013, GEN HOSP PSYCHIAT, V35, P28, DOI 10.1016/j.genhosppsych.2012.08.007; Andreeva VA, 2014, ANN NUTR METAB, V65, P81, DOI 10.1159/000365154; Annweiler C, 2012, COGN BEHAV NEUROL, V25, P121, DOI 10.1097/WNN.0b013e31826df647; Armas LAG, 2012, CLIN J AM SOC NEPHRO, V7, P1428, DOI 10.2215/CJN.12761211; Bossola M, 2011, J PSYCHOSOM RES, V71, P50, DOI 10.1016/j.jpsychores.2011.01.001; Breitling LP, 2012, EXP GERONTOL, V47, P122, DOI 10.1016/j.exger.2011.11.004; Chei CL, 2014, J AM GERIATR SOC, V62, P2125, DOI 10.1111/jgs.13082; Dong J, 2014, PERITON DIALYSIS INT, V34, P447, DOI 10.3747/pdi.2013.00001; Elias MF, 2009, NEPHROL DIAL TRANSPL, V24, P2446, DOI 10.1093/ndt/gfp107; Erbas O, 2014, LIFE SCI, V103, P68, DOI 10.1016/j.lfs.2014.03.035; Griva K, 2010, AM J KIDNEY DIS, V56, P693, DOI 10.1053/j.ajkd.2010.07.003; Hanna K, 2015, J HUM NUTR DIET, V28, P209, DOI 10.1111/jhn.12234; Hooshmand B, 2014, J GERONTOL A-BIOL, V69, P1132, DOI 10.1093/gerona/glu022; Jean G, 2009, NEPHROL DIAL TRANSPL, V24, P3799, DOI 10.1093/ndt/gfp370; Kalirao P, 2011, AM J KIDNEY DIS, V57, P612, DOI 10.1053/j.ajkd.2010.11.026; Kurella M, 2005, J AM SOC NEPHROL, V16, P2127, DOI 10.1681/ASN.2005010005; Kurella M, 2006, NEPHROL DIAL TRANSPL, V21, P2543, DOI 10.1093/ndt/gfl275; Llewellyn DJ, 2011, J GERONTOL A-BIOL, V66, P59, DOI 10.1093/gerona/glq185; Llewellyn DJ, 2010, ARCH INTERN MED, V170, P1135, DOI 10.1001/archinternmed.2010.173; Mason DL, 2013, HEMODIAL INT, V17, P3, DOI 10.1111/j.1542-4758.2012.00727.x; Milman S, 2014, J AM GERIATR SOC, V62, P153, DOI 10.1111/jgs.12601; Minasyan A, 2007, J STEROID BIOCHEM, V104, P274, DOI 10.1016/j.jsbmb.2007.03.032; Murray AM, 2007, AM J KIDNEY DIS, V50, P270, DOI 10.1053/j.ajkd.2007.05.010; Peterson A, 2012, J NUTR HEALTH AGING, V16, P898, DOI 10.1007/s12603-012-0378-4; Pettersen JA, 2014, CAN J NEUROL SCI, V41, P459, DOI 10.1017/S0317167100018497; Post JB, 2010, NEPHRON CLIN PRACT, V116, pC247, DOI 10.1159/000317206; Przybelski RJ, 2007, ARCH BIOCHEM BIOPHYS, V460, P202, DOI 10.1016/j.abb.2006.12.018; Raphael KL, 2012, AM J NEPHROL, V35, P49, DOI 10.1159/000334872; Sarnak MJ, 2013, NEUROLOGY, V80, P471, DOI 10.1212/WNL.0b013e31827f0f7f; Shaffi K, 2013, CLIN J AM SOC NEPHRO, V8, P979, DOI 10.2215/CJN.10651012; Slinin Y, 2012, J GERONTOL A-BIOL, V67, P1092, DOI 10.1093/gerona/gls075; Smith SC, 2004, CIRCULATION, V109, P3112, DOI 10.1161/01.CIR.0000133427.35111.67; Stilley CS, 2010, HEALTH PSYCHOL, V29, P50, DOI 10.1037/a0016940; Tamura MK, 2011, AM J KIDNEY DIS, V58, P756, DOI 10.1053/j.ajkd.2011.05.027; Tamura MK, 2010, CLIN J AM SOC NEPHRO, V5, P1429, DOI 10.2215/CJN.01090210; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Tokmak F, 2008, NEPHROL DIAL TRANSPL, V23, P4016, DOI 10.1093/ndt/gfn367; Xu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050766; Yaffe K, 2013, AM J KIDNEY DIS, V61, P219, DOI 10.1053/j.ajkd.2012.10.006; [杨贵刚 Yang Guigang], 2010, [中国心理卫生杂志, Chinese Mental Health Journal], V24, P926; YEUDALL LT, 1987, J CLIN PSYCHOL, V43, P346, DOI 10.1002/1097-4679(198705)43:3<346::AID-JCLP2270430308>3.0.CO;2-Q	41	11	11	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2015	10	12							e0143782	10.1371/journal.pone.0143782	http://dx.doi.org/10.1371/journal.pone.0143782			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CX8BI	26630385	Green Published, gold, Green Submitted			2023-01-03	WOS:000365926300098
J	Hirsch, C				Hirsch, Calvin			A balance retraining exercise program reduced injurious falls in at-risk older community-dwelling women	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Hirsch, Calvin] Univ Calif Davis, Davis, CA 95616 USA	University of California System; University of California Davis	Hirsch, C (corresponding author), Univ Calif Davis, Davis, CA 95616 USA.							Butt DA, 2013, OSTEOPOROSIS INT, V24, P2649, DOI 10.1007/s00198-013-2369-7; Centers for Disease Control and Prevention, 2015, STEADL MATERIALS FOR; Gillespie L. D., 2012, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD007146; Greenwood-Hickman MA, 2015, PREV CHRONIC DIS, V12, DOI 10.5888/pcd12.140574; Orces CH, 2014, INJURY PREV, V20, P421, DOI 10.1136/injuryprev-2014-041268	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2015	163	10					JC2	JC2		10.7326/ACPJC-2015-163-10-002	http://dx.doi.org/10.7326/ACPJC-2015-163-10-002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX5MQ	26571256				2023-01-03	WOS:000365746400003
J	da Silva, CM; Leal, MP; Brochetti, RA; Braga, T; Vitoretti, LB; Camara, NOS; Damazo, AS; Ligeiro-De-Oliveira, AP; Chavantes, MC; Lino-dos-Santos-Franco, A				da Silva, Cristiane Miranda; Leal, Mayara Peres; Brochetti, Robson Alexandre; Braga, Tarcio; Vitoretti, Luana Beatriz; Saraiva Camara, Niels Olsen; Damazo, Amilcar Sabino; Ligeiro-de-Oliveira, Ana Paula; Chavantes, Maria Cristina; Lino-dos-Santos-Franco, Adriana			Low Level Laser Therapy Reduces the Development of Lung Inflammation Induced by Formaldehyde Exposure	PLOS ONE			English	Article							ALLERGIC-ASTHMA; MAST-CELLS; RAT MODEL; LLLT; GRANULOPOIESIS; NEUTROPHILS; PRODUCTS; RELEASE; MARROW; TISSUE	Lung diseases constitute an important public health problem and its growing level of concern has led to efforts for the development of new therapies, particularly for the control of lung inflammation. Low Level Laser Therapy (LLLT) has been highlighted as a non-invasive therapy with few side effects, but its mechanisms need to be better understood and explored. Considering that pollution causes several harmful effects on human health, including lung inflammation, in this study, we have used formaldehyde (FA), an environmental and occupational pollutant, for the induction of neutrophilic lung inflammation. Our objective was to investigate the local and systemic effects of LLLT after FA exposure. Male Wistar rats were exposed to FA (1%) or vehicle (distillated water) during 3 consecutive days and treated or not with LLLT (1 and 5 hours after each FA exposure). Non-manipulated rats were used as control. 24 h after the last FA exposure, we analyzed the local and systemic effects of LLLT. The treatment with LLLT reduced the development of neutrophilic lung inflammation induced by FA, as observed by the reduced number of leukocytes, mast cells degranulated, and a decreased myeloperoxidase activity in the lung. Moreover, LLLT also reduced the microvascular lung permeability in the parenchyma and the intrapulmonary bronchi. Alterations on the profile of inflammatory cytokines were evidenced by the reduced levels of IL-6 and TNF-alpha and the elevated levels of IL-10 in the lung. Together, our results showed that LLLT abolishes FA-induced neutrophilic lung inflammation by a reduction of the inflammatory cytokines and mast cell degranulation. This study may provide important information about the mechanisms of LLLT in lung inflammation induced by a pollutant.	[da Silva, Cristiane Miranda; Leal, Mayara Peres; Brochetti, Robson Alexandre; Vitoretti, Luana Beatriz; Ligeiro-de-Oliveira, Ana Paula; Lino-dos-Santos-Franco, Adriana] Univ Nove de Julho UNINOVE, Post Grad Program Biophoton Appl Hlth Sci, Sao Paulo, Brazil; [Braga, Tarcio; Saraiva Camara, Niels Olsen] Univ Sao Paulo, Dept Immunol, Sao Paulo, Brazil; [Damazo, Amilcar Sabino] Fed Univ Cuiaba, Dept Basic Sci Hlth, Fac Med Sci, Cuiaba, Brazil; [Chavantes, Maria Cristina] Univ Nove de Julho UNINOVE, Post Grad Program Med, Sao Paulo, Brazil	Universidade Nove de Julho; Universidade de Sao Paulo; Universidade Nove de Julho	Lino-dos-Santos-Franco, A (corresponding author), Univ Nove de Julho UNINOVE, Post Grad Program Biophoton Appl Hlth Sci, Sao Paulo, Brazil.	alsantosfranco@gmail.com	camara, niels olsen saraiva/AAX-3269-2020; Damazo, Amilcar S/B-6659-2014; Braga, Tarcio/AAG-4475-2020; Franco, Adriana Lino dos Santos/AAA-7081-2019; Lino-dos-Santos-Franco, Adriana/F-6336-2012; Camara, Niels OS/G-8336-2011; Braga, Tarcio T/E-4827-2014; Chavantes, Maria Cristina/AAC-2459-2019	camara, niels olsen saraiva/0000-0001-5436-1248; Damazo, Amilcar S/0000-0003-2323-008X; Franco, Adriana Lino dos Santos/0000-0002-7854-2833; Camara, Niels OS/0000-0001-5436-1248; Braga, Tarcio T/0000-0002-2989-1076; Chavantes, Maria Cristina/0000-0002-8625-5076; Ligeiro de Oliveira, Ana Paula/0000-0001-6089-5107	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/51711-9, 2012/16498-5, 2015/00830-9]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study was sponsored by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP: 2011/51711-9; 2012/16498-5; 2015/00830-9). Adriana Lino-dos-Santos-Franco is a research fellow from FAPESP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aimbire F, 2006, LASER MED SCI, V21, P238, DOI 10.1007/s10103-006-0405-y; Aimbire F, 2005, LASER MED SCI, V20, P11, DOI 10.1007/s10103-005-0339-9; Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41; Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011; Carlson Ryan M, 2004, Dermatitis, V15, P169, DOI 10.2310/6620.2004.04021; Chavantes M.C, 2005, PHOTOMED LASER SURG, V1, P113; de Lima FM, 2014, J LASERS MED SCI, V5, P63; de Lima FM, 2011, LASER MED SCI, V26, P389, DOI 10.1007/s10103-010-0874-x; Eash KJ, 2009, BLOOD, V113, P4711, DOI 10.1182/blood-2008-09-177287; Faradzheva N A, 2007, Probl Tuberk Bolezn Legk, P50; Fialkow L, 2007, FREE RADICAL BIO MED, V42, P153, DOI 10.1016/j.freeradbiomed.2006.09.030; Franco ALD, 2006, TOXICOL APPL PHARM, V214, P35, DOI 10.1016/j.taap.2005.11.014; FUJIMAKI H, 1992, INT ARCH ALLERGY IMM, V98, P324, DOI 10.1159/000236206; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Garrett M.H., 1996, P 7 INT C IND AIR QU, V1, P617; Gulec M, 2006, TOXICOL IND HEALTH, V22, P117, DOI 10.1191/0748233706th248oa; Joensen J, 2012, PHOTOMED LASER SURG, V30, P688, DOI 10.1089/pho.2012.3306; Kashanskaia E P, 2009, Vopr Kurortol Fizioter Lech Fiz Kult, P19; Landyshev Iu S, 2002, Ter Arkh, V74, P25; Lino-dos-Santos-Franco A, 2013, FOOD CHEM TOXICOL, V59, P731, DOI 10.1016/j.fct.2013.07.027; Lino-dos-Santos-Franco A, 2011, TOXICOL LETT, V207, P278, DOI 10.1016/j.toxlet.2011.09.026; Lino-dos-Santos-Franco A, 2010, TOXICOL LETT, V197, P211, DOI 10.1016/j.toxlet.2010.05.022; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388, DOI 10.1136/oem.52.6.388; Oliveira MC, 2014, J PHOTOCH PHOTOBIO B, V134, P57, DOI 10.1016/j.jphotobiol.2014.03.021; Sagai Masaru, 2015, Nihon Eiseigaku Zasshi, V70, P220, DOI 10.1265/jjh.70.220; Salthammer T, 2013, ANGEW CHEM INT EDIT, V52, P3320, DOI 10.1002/anie.201205984; Peron JPS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136942; Silva VR, 2014, RESP PHYSIOL NEUROBI, V194, P37, DOI 10.1016/j.resp.2014.01.008; Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011; Stronosova NS, 2006, TERAPEVT ARKH, V78, P41; Tillie-Leblond I, 2005, ALLERGY, V60, P23, DOI 10.1111/j.1398-9995.2005.00632.x; Tomimura S, 2014, ARQ BRAS CARDIOL, V103, P161, DOI 10.5935/abc.20140117; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wu J, 2013, NANOSCALE RES LETT, V8, P1, DOI 10.1186/1556-276X-8-5	34	40	40	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2015	10	11							e0142816	10.1371/journal.pone.0142816	http://dx.doi.org/10.1371/journal.pone.0142816			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW5XP	26569396	Green Submitted, Green Published, gold			2023-01-03	WOS:000365070700076
J	Hulland, KRS; Chase, RP; Caruso, BA; Swain, R; Biswal, B; Sahoo, KC; Panigrahi, P; Dreibelbis, R				Hulland, Kristyna R. S.; Chase, Rachel P.; Caruso, Bethany A.; Swain, Rojalin; Biswal, Bismita; Sahoo, Krushna Chandra; Panigrahi, Pinaki; Dreibelbis, Robert			Sanitation, Stress, and Life Stage: A Systematic Data Collection Study among Women in Odisha, India	PLoS One			English	Article							LOCAL PERCEPTIONS; WATER INSECURITY; QUALITATIVE DATA; ACCESS; HEALTH; MANAGEMENT; DISTRESS; RANKING; AFRICA; GENDER	Emerging evidence demonstrates how inadequate access to water and sanitation is linked to psychosocial stress, especially among women, forcing them to navigate social and physical barriers during their daily sanitation routines. We examine sanitation-related psychosocial stress (SRPS) across women's reproductive lives in three distinct geographic sites (urban slums, rural villages, and rural tribal villages) in Odisha, India. We explored daily sanitation practices of adolescent, newly married, pregnant, and established adult women (n = 60) and identified stressors encountered during sanitation. Responding to structured data collection methods, women ranked seven sanitation activities (defecation, urination, menstruation, bathing, post-defecation cleaning, carrying water, and changing clothes) based on stress (high to low) and level of freedom (associated with greatest freedom to having the most restrictions). Women then identified common stressors they encountered when practicing sanitation and sorted stressors in constrained piles based on frequency and severity of each issue. The constellation of factors influencing SRPS varies by life stage and location. Overall, sanitation behaviors that were most restricted (i.e., menstruation) were the most stressful. Women in different sites encountered different stressors, and the level of perceived severity varied based on site and life stage. Understanding the influence of place and life stage on SRPS provides a nuanced understanding of sanitation, and may help identify areas for intervention.	[Hulland, Kristyna R. S.] Univ Chicago, Ctr Global Hlth, Chicago, IL 60637 USA; [Chase, Rachel P.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Caruso, Bethany A.] Emory Univ, Rollins Sch Publ Hlth, Ctr Global Safe Water, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA; [Swain, Rojalin; Biswal, Bismita; Sahoo, Krushna Chandra] Asian Inst Publ Hlth, Bhubaneswar, Orissa, India; [Panigrahi, Pinaki] Univ Nebraska Med Ctr, Coll Publ Hlth, Epidemiol & Pediat, Omaha, NE USA; [Panigrahi, Pinaki] Univ Nebraska Med Ctr, Coll Publ Hlth, Ctr Global Hlth & Dev, Omaha, NE USA; [Dreibelbis, Robert] Univ Oklahoma, Ctr Appl Social Res, Norman, OK 73019 USA	University of Chicago; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Emory University; Rollins School Public Health; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Oklahoma System; University of Oklahoma - Norman	Dreibelbis, R (corresponding author), Univ Oklahoma, Ctr Appl Social Res, Norman, OK 73019 USA.	rdreibe@ou.edu	Sahoo, Krushna Chandra/AAF-2813-2020; Kuang, Jinyi/L-8488-2017	Kuang, Jinyi/0000-0003-4173-3246; Chase, Rachel/0000-0002-1503-4954; Dreibelbis, Robert/0000-0002-9716-0419	Department for International Development (DfID) as part of the SHARE research programme; Water Supply and Sanitation Council (WSSCC)	Department for International Development (DfID) as part of the SHARE research programme; Water Supply and Sanitation Council (WSSCC)	Funding: This work was made possible with UK aid from the Department for International Development (DfID), as part of the SHARE research programme, and support from the Water Supply and Sanitation Council (WSSCC). However, the views expressed do not necessarily reflect DfID's official policies or the policies of WSSCC. The funding agencies had no involvement in study design, data collection, data analysis, and data interpretation.	Abrahams N, 2006, TROP MED INT HEALTH, V11, P751, DOI 10.1111/j.1365-3156.2006.01600.x; [Anonymous], RES GUID MAINSTR GEN; Biswas Soutik, BBC NEWS; Bolton P, 2001, J NERV MENT DIS, V189, P243, DOI 10.1097/00005053-200104000-00006; Bourey C, 2012, GLOB PUBLIC HEALTH, V7, P995, DOI 10.1080/17441692.2012.709259; Bradley EH, 2007, HEALTH SERV RES, V42, P1758, DOI 10.1111/j.1475-6773.2006.00684.x; Census Organization of India, 2011, OR POP CENS DAT; Crow B, 2002, SOC NATUR RESOUR, V15, P709, DOI 10.1080/08941920290069308; DeJordy R, 2007, FIELD METHOD, V19, P239, DOI 10.1177/1525822X07302104; Dohn MN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101007; Fisher Julie, 2006, WATER SANITATION HYG; Garg S, 2001, REPROD HEALTH MATTER, V9, P16, DOI 10.1016/S0968-8080(01)90004-7; Gruebner O, 2011, INT J HEALTH GEOGR, V10, DOI 10.1186/1476-072X-10-36; Hamal M, 2014, INT J HLTH SCI RES I, V4, P28; Hargreaves JR, 2007, WORLD DEV, V35, P212, DOI 10.1016/j.worlddev.2005.10.021; Henley P, 2014, CAN J PHYSIOL PHARM, V92, P725, DOI 10.1139/cjpp-2014-0035; Hossain Anushay, 2014, HUFFINGTON POST; Hueso A, 2013, WATER POLICY, V15, P1001, DOI 10.2166/wp.2013.032; KOLENDA PM, 1964, J ASIAN STUD, V23, P71, DOI 10.2307/2050622; Lennon S., 2011, FEAR ANGER PERCEPTIO; Massey K., 2011, INSECURITY SHAME EXP; McMahon SA, 2011, BMC INT HEALTH HUM R, V11, DOI 10.1186/1472-698X-11-7; McPeak JG, 2009, J DEV STUD, V45, P1663, DOI 10.1080/00220380902890219; Nallari A., 2015, ENV URBANIZATION; Nord M., 2014, INTRO ITEM RESPONSE; Nyamongo IK, 1999, TROP MED INT HEALTH, V4, P736, DOI 10.1046/j.1365-3156.1999.00484.x; Panda SM, 2007, GEND TECHNOL DEV, V11, P321, DOI 10.1177/097185240701100302; ROMNEY AK, 1964, AM ANTHROPOL, V66, P146; Sahoo KC, 2015, SOC SCI MED, V139, P80, DOI 10.1016/j.socscimed.2015.06.031; Schmidt M., 2002, EARLY CHILD DEV CARE, V172, P451, DOI [DOI 10.1080/03004430214550, 10.1080/03004430214550]; Singh N, 2006, GEND TECHNOL DEV, V10, P61, DOI 10.1177/097185240501000104; Sommer M, 2013, COMPARE, V43, P323, DOI 10.1080/03057925.2012.693280; Sorenson SB, 2011, SOC SCI MED, V72, P1522, DOI 10.1016/j.socscimed.2011.03.010; Stevenson EGJ, 2012, SOC SCI MED, V75, P392, DOI 10.1016/j.socscimed.2012.03.022; Stopnitzky Y, 2012, SSRN ELECT J, DOI [10.2139/ssrn.2031273, DOI 10.2139/SSRN.2031273]; Sultana F, 2011, GEOFORUM, V42, P163, DOI 10.1016/j.geoforum.2010.12.002; Sumpter C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062004; Tewary A., 2013, BBC NEWS; VANCAMPENHOUT B, 2006, J AFRICAN EC, V16, P406, DOI DOI 10.1093/JAE/EJL041; Weller S.C, 1988, SYSTEMATIC DATA COLL; World Health Organization & UNICEF, 2015, PROGR SAN DRINK WAT; Wutich A, 2008, SOC SCI MED, V67, P2116, DOI 10.1016/j.socscimed.2008.09.042	42	57	57	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2015	10	11							e0141883	10.1371/journal.pone.0141883	http://dx.doi.org/10.1371/journal.pone.0141883			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV7AC	26551866	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000364422800010
J	Kantor, ED; Rehm, CD; Haas, JS; Chan, AT; Giovannucci, EL				Kantor, Elizabeth D.; Rehm, Colin D.; Haas, Jennifer S.; Chan, Andrew T.; Giovannucci, Edward L.			Trends in Prescription Drug Use Among Adults in the United States From 1999-2012	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN PLUS PROGESTIN; MEDICATION USE; HEALTH; POPULATION; PREVALENCE	IMPORTANCE It is important to document patterns of prescription drug use to inform both clinical practice and research. OBJECTIVE To evaluate trends in prescription drug use among adults living in the United States. DESIGN, SETTING, AND PARTICIPANTS Temporal trends in prescription drug use were evaluated using nationally representative data from the National Health and Nutrition Examination Survey (NHANES). Participants included 37 959 noninstitutionalized US adults, aged 20 years and older. Seven NHANES cycles were included (1999-2000 to 2011-2012), and the sample size per cycle ranged from 4861 to 6212. EXPOSURES Calendar year, as represented by continuous NHANES cycle. MAIN OUTCOMES AND MEASURES Within each NHANES cycle, use of prescription drugs in the prior 30 days was assessed overall and by drug class. Temporal trends across cycles were evaluated. Analyses were weighted to represent the US adult population. RESULTS Results indicate an increase in overall use of prescription drugs among US adults between 1999-2000 and 2011-2012 with an estimated 51% of US adults reporting use of any prescription drugs in 1999-2000 and an estimated 59% reporting use of any prescription drugs in 2011-2012 (difference, 8%[95% CI, 3.8%-12%]; P for trend <. 001). The prevalence of polypharmacy (use of >= 5 prescription drugs) increased from an estimated 8.2% in 1999-2000 to 15% in 2011-2012 (difference, 6.6%[95% CI, 4.4%-8.2%]; P for trend <. 001). These trends remained statistically significant with age adjustment. Among the 18 drug classes used by more than 2.5% of the population at any point over the study period, the prevalence of use increased in 11 drug classes including antihyperlipidemic agents, antidepressants, prescription proton-pump inhibitors, and muscle relaxants. CONCLUSIONS AND RELEVANCE In this nationally representative survey, significant increases in overall prescription drug use and polypharmacy were observed. These increases persisted after accounting for changes in the age distribution of the population. The prevalence of prescription drug use increased in the majority of, but not all, drug classes.	[Kantor, Elizabeth D.; Giovannucci, Edward L.] Harvard Univ, Dept Epidemiol, TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Kantor, Elizabeth D.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10017 USA; [Rehm, Colin D.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA; [Rehm, Colin D.] Montefiore Med Ctr, Off Community & Populat Hlth, Bronx, NY 10467 USA; [Haas, Jennifer S.] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA; [Haas, Jennifer S.] Harvard Univ, Dept Social & Behav Sci, TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Chan, Andrew T.; Giovannucci, Edward L.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA; [Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA; [Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA; [Giovannucci, Edward L.] Harvard Univ, Dept Nutr, TH Chan Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Memorial Sloan Kettering Cancer Center; Tufts University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Kantor, ED (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 485 Lexington Ave,Second Floor, New York, NY 10017 USA.	kantore@mskcc.org	REHM, COLIN D./J-1215-2019	REHM, COLIN D./0000-0002-7644-0040; HAAS, JENNIFER/0000-0001-7227-851X	National Cancer Institute [T32 CA 009001]; National Institute of Diabetes and Digestive and Kidney Diseases [K24 DK098311]; Harvard Catalyst-The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst-The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]; Harvard University; NATIONAL CANCER INSTITUTE [T32CA009001] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK098311] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Harvard Catalyst-The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst-The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health); Harvard University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was conducted with support from the National Cancer Institute (support for Kantor, T32 CA 009001) and the National Institute of Diabetes and Digestive and Kidney Diseases (support for Chan, K24 DK098311). Support for Haas: Harvard Catalyst-The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health care centers.	Bennett WL, 2011, AHRQ PUBLICATION, V11-EHC038-EF; Bertisch SM, 2014, SLEEP, V37, P343, DOI 10.5665/sleep.3410; Blumner KH, 2009, PSYCHIAT SERV, V60, P306, DOI 10.1176/appi.ps.60.3.306; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Chong Yinong, 2013, NCHS Data Brief, P1; Clegg LX, 2009, STAT MED, V28, P3670, DOI 10.1002/sim.3733; Daubresse M, 2015, AM J RESP CRIT CARE, V192, P40, DOI 10.1164/rccm.201409-1585OC; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; Ford ES, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095305; Goodnick PJ, 1998, J PSYCHOPHARMACOL, V12, pS5, DOI 10.1177/0269881198012003021; Gu Q, 2014, NCHS DATA BRIEF, V177, P1; Gu Qiuping, 2010, NCHS Data Brief, P1; Gu QP, 2006, CIRCULATION, V113, P213, DOI 10.1161/CIRCULATIONAHA.105.542290; Jacobson BC, 2006, NEW ENGL J MED, V354, P2340, DOI 10.1056/NEJMoa054391; JAMES PA, 2014, JAMA-J AM MED ASSOC, V311, P507, DOI DOI 10.1001/JAMA.2013.284427; Jewett PI, 2014, OBSTET GYNECOL, V124, P727, DOI 10.1097/AOG.0000000000000469; Johnson CL, 2013, VITAL HLTH STAT, V2, P1; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Klein Richard J, 2002, Healthy People 2010 Stat Notes, P1; Kornfield R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055504; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; National Center for Health Statistics, NHANES RESP RAT POP; National Center for Health Statistics. National Center for Health Statistics, NHANES 2003 2004 PUB; National Center for Health Statistics (U.S.), 2014, HLTH US 2013 SPEC FE; National Health and Nutrition Examination Survey, CONT NHANES; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Paulose-Ram R, 2004, J CLIN EPIDEMIOL, V57, P309, DOI 10.1016/j.jclinepi.2003.05.001; Perez AD, 2009, POPUL DEV REV, V35, P1, DOI 10.1111/j.1728-4457.2009.00260.x; Qato DM, 2008, JAMA-J AM MED ASSOC, V300, P2867, DOI 10.1001/jama.2008.892; Ross JS, 2009, ARCH INTERN MED, V169, P1976, DOI 10.1001/archinternmed.2009.394; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schumock GT, 2014, AM J HEALTH-SYST PH, V71, P482, DOI 10.2146/ajhp130767; Selvin E, 2014, ANN INTERN MED, V160, P517, DOI 10.7326/M13-2411; SORLIE PD, 1993, JAMA-J AM MED ASSOC, V270, P2464, DOI 10.1001/jama.270.20.2464; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, DAWN REP ED VIS INV; Thielke SM, 2010, PAIN MED, V11, P248, DOI 10.1111/j.1526-4637.2009.00740.x; Viktil KK, 2007, BRIT J CLIN PHARMACO, V63, P187, DOI 10.1111/j.1365-2125.2006.02744.x; Yoon SS, 2015, HYPERTENSION, V65, P54, DOI 10.1161/HYPERTENSIONAHA.114.04012	40	740	753	2	49	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2015	314	17					1818	1831		10.1001/jama.2015.13766	http://dx.doi.org/10.1001/jama.2015.13766			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV0RO	26529160	Green Accepted, Bronze			2023-01-03	WOS:000363960200014
J	Cheng, RH; Leung, RKK; Chen, Y; Pan, YD; Tong, Y; Li, ZF; Ning, LW; Ling, XFB; He, JK				Cheng, Ronghai; Leung, Ross Ka-Kit; Chen, Yao; Pan, Yidan; Tong, Yin; Li, Zhoufang; Ning, Luwen; Ling, Xuefeng B.; He, Jiankui			Virtual Pharmacist: A Platform for Pharmacogenomics	PLOS ONE			English	Article							GENOME	We present Virtual Pharmacist, a web-based platform that takes common types of high-throughput data, namely microarray SNP genotyping data, FASTQ and Variant Call Format (VCF) files as inputs, and reports potential drug responses in terms of efficacy, dosage and toxicity at one glance. Batch submission facilitates multivariate analysis or data mining of targeted groups. Individual analysis consists of a report that is readily comprehensible to patients and practioners who have basic knowledge in pharmacology, a table that summarizes variants and potential affected drug response according to the US Food and Drug Administration pharmacogenomic biomarker labeled drug list and PharmGKB, and visualization of a gene-drug-target network. Group analysis provides the distribution of the variants and potential affected drug response of a target group, a sample-gene variant count table, and a sample-drug count table. Our analysis of genomes from the 1000 Genome Project underlines the potentially differential drug responses among different human populations. Even within the same population, the findings from Watson's genome highlight the importance of personalized medicine. Virtual Pharmacist can be accessed freely at http://www.sustc-genome.org.cn/vp or installed as a local web server. The codes and documentation are available at the GitHub repository (https://github.com/VirtualPharmacist/vp). Administrators can download the source codes to customize access settings for further development.	[Cheng, Ronghai; Chen, Yao; Pan, Yidan; Tong, Yin; Li, Zhoufang; Ning, Luwen; He, Jiankui] South Univ Sci & Technol China, Dept Biol, Shenzhen, Peoples R China; [Leung, Ross Ka-Kit] Chinese Univ Hong Kong, Div Genom & Bioinformat, Hong Kong, Hong Kong, Peoples R China; [Ling, Xuefeng B.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA	Southern University of Science & Technology; Chinese University of Hong Kong; Stanford University	He, JK (corresponding author), South Univ Sci & Technol China, Dept Biol, Shenzhen, Peoples R China.	hejk@sustc.edu.cn	ZHOUFANG, LI/GWN-1360-2022; Chen, Yao/S-4358-2019	Chen, Yao/0000-0003-2708-8674; Ling, Bruce/0000-0002-5386-3884	National Natural Science Foundation of China [31200688, 81470136]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study is supported by National Natural Science Foundation of China (Grant No. 31200688 and 81470136).	Aleman A, 2014, NUCLEIC ACIDS RES; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Ashley EA, 2010, LANCET, V375, P1525, DOI 10.1016/S0140-6736(10)60452-7; Capriotti E, 2012, BRIEF BIOINFORM, V13, P495, DOI 10.1093/bib/bbr070; Dalton R, 2006, NATURE, V443, P258, DOI 10.1038/443258a; Dondorp WJ, 2013, EUR J HUM GENET, V21, pS6, DOI 10.1038/ejhg.2013.73; Ginsburg GS, 2009, TRANSL RES, V154, P277, DOI 10.1016/j.trsl.2009.09.005; Hunter DJ, 2008, NEW ENGL J MED, V358, P105, DOI 10.1056/NEJMp0708162; Juan LR, 2014, NUCLEIC ACIDS RES, V42, pW192, DOI 10.1093/nar/gku361; Kaplun A, 2015, PHARMACOGENOMICS J; Karczewski KJ, 2012, PAC S BIOCOMPUT; Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu CC, 2014, NUCLEIC ACIDS RES, V42, pW137, DOI 10.1093/nar/gku412; Mardis ER, 2010, GENOME MED, V2, DOI 10.1186/gm205; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Relling MV, 2011, CLIN PHARMACOL THER, V89, P464, DOI 10.1038/clpt.2010.279; Sana ME, 2011, BIOINFORMATICS, V27, P9, DOI 10.1093/bioinformatics/btq603; Sconce EA, 2005, BLOOD, V106, P2329, DOI 10.1182/blood-2005-03-1108; Service RF, 2006, SCIENCE, V311, P1544, DOI 10.1126/science.311.5767.1544; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Shetty AC, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-471; Sulakhe D, 2014, NUCLEIC ACIDS RES, V42, pW473, DOI 10.1093/nar/gku517; Wang K, 2012, J MED GENETICS; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang LW, 2011, NEW ENGL J MED, V364, P1144, DOI 10.1056/NEJMra1010600; Wheeler DA, 2008, NATURE, V452, P872, DOI 10.1038/nature06884; Whirl-Carrillo M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/clpt.2012.96	28	9	9	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2015	10	10							e0141105	10.1371/journal.pone.0141105	http://dx.doi.org/10.1371/journal.pone.0141105			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU1VG	26496198	Green Published, gold, Green Submitted			2023-01-03	WOS:000363309200061
J	Feng, SY; Wang, YY; Cai, KC; Wu, H; Xiong, G; Wang, HF; Zhang, ZL				Feng, Siyang; Wang, Yuanyuan; Cai, Kaican; Wu, Hua; Xiong, Gang; Wang, Haofei; Zhang, Ziliang			Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy	PLOS ONE			English	Article							UNIDIRECTIONALLY PROGRESSIVE RESECTION; VINORELBINE PLUS CISPLATIN; 1ST-LINE TREATMENT; OPEN-LABEL; NEVER-SMOKERS; GEFITINIB; MUTATIONS; ERLOTINIB; MULTICENTER; ADENOCARCINOMA	Background Epidermal growth factor receptor (EGFR) mutations occur in up to 50% of Asian patients with non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC patients with EGFR-tyrosine kinase inhibitor (EGFR-TKI) confers a significant survival benefit. This study assessed the efficacy and safety of chemotherapy with or without icotinib in patients undergoing resection of stage IB to. A EGFR-mutated NSCLC. Methods Patients with surgically resected stage IB (with high risk factors) to. A EGFR-mutated NSCLC were randomly assigned (1: 1) to one of two treatment plans. One group received four cycles of platinum-based doublet chemotherapy every three weeks, and the other group received platinum-based chemotherapy supplemented with consolidation therapy of orally administered icotinib (125 mg thrice daily) two weeks after chemotherapy. The icotinib treatment continued for four to eight months, or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity. The primary endpoint was disease-free survival (DFS). Results 41 patients were enrolled between Feb 9, 2011 and Dec 17, 2012. 21 patients were assigned to the combined chemotherapy plus icotinib treatment group, while 20 patients received chemotherapy only. DFS at 12 months was 100% for icotinib-treated patients and 88.9% for chemotherapy-only patients (p = 0. 122). At 18 months DFS for icotinib-treated vs. chemotherapy-only patients was 95.2% vs. 83.3%(p = 0. 225), respectively, and at 24 months DFS was 90.5% vs. 66.7% (p = 0. 066). The adverse chemotherapy effects predominantly presented as gastrointestinal reactions and marrow suppression, and there was no significant difference between the two treatment groups. Patients in the chemotherapy plus icotinib treatment group showed favorable tolerance to oral icotinib. Conclusions The results suggest that chemotherapy plus orally icotinib displayed better DFS compared with chemotherapy only, yet the difference in DFS was not significant. We would think the preliminary result here was promising, and further trials with larger sample sizes might confirm the efficiency of adjuvant TKI in selected patients.	[Feng, Siyang; Cai, Kaican; Wu, Hua; Xiong, Gang; Wang, Haofei; Zhang, Ziliang] Southern Med Univ, Nanfang Hosp, Dept Thorac Surg, Guangzhou, Guangdong, Peoples R China; [Wang, Yuanyuan] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China	Cai, KC (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Thorac Surg, Guangzhou, Guangdong, Peoples R China.	doc_cai@163.com			"Twelfth Five Year" major drug discovery projects of China [2012zx09101103]	"Twelfth Five Year" major drug discovery projects of China	This study was supported in part by a grant from "Twelfth Five Year" major drug discovery projects of China (#2012zx09101103) [http://www.nmp.gov.cn/] (granted author: KCC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arasada RR, 2014, CANCER RES, V74, P5572, DOI 10.1158/0008-5472.CAN-13-3724; Arriagada R, 2010, J CLIN ONCOL, V28, P35, DOI 10.1200/JCO.2009.23.2272; Brundage MD, 2002, CHEST, V122, P1037, DOI 10.1378/chest.122.3.1037; Cai KC, 2015, NEOPLASMA, V62, P302, DOI 10.4149/neo_2015_036; Cai KC, 2014, J THORAC DIS, V6, P1843, DOI 10.3978/j.issn.2072-1439.2014.12.26; Cai KC, 2013, J THORAC DIS, V5, pS310, DOI 10.3978/j.issn.2072-1439.2013.08.07; Cappuzzo F, 2010, LANCET ONCOL, V11, P521, DOI 10.1016/S1470-2045(10)70112-1; Douillard JY, 2006, LANCET ONCOL, V7, P719, DOI 10.1016/S1470-2045(06)70804-X; Ethier SP, 2002, SEMIN RADIAT ONCOL, V12, P3, DOI 10.1053/srao.2002.34863; Goss GD, 2013, J CLIN ONCOL, V31, P3320, DOI 10.1200/JCO.2013.51.1816; Han JY, 2012, J CLIN ONCOL, V30, P1122, DOI 10.1200/JCO.2011.36.8456; Herbst RS, 2002, SEMIN ONCOL, V29, P27, DOI [10.1053/sonc.2002.31525, 10.1053/sonc.2002.33079]; Hirsch FR, 2009, LANCET ONCOL, V10, P432, DOI 10.1016/S1470-2045(09)70110-X; Janjigian YY, 2011, J THORAC ONCOL, V6, P569, DOI 10.1097/JTO.0b013e318202bffe; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Liang WH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085245; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mok TSK, 2009, J CLIN ONCOL, V27, P5080, DOI 10.1200/JCO.2008.21.5541; National Comprehensive Cancer Network, 2015, NCCN CLIN PRACT GUID; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pennell NA, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.7514; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Riely GJ, 2006, CLIN CANCER RES, V12, P7232, DOI 10.1158/1078-0432.CCR-06-0658; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Shi YK, 2013, LANCET ONCOL, V14, P953, DOI 10.1016/S1470-2045(13)70355-3; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Strauss GM, 2008, J CLIN ONCOL, V26, P5043, DOI 10.1200/JCO.2008.16.4855; Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008-5472.CAN-10-0881; Takeda K, 2010, J CLIN ONCOL, V28, P753, DOI 10.1200/JCO.2009.23.3445; [UC Davis Comprehensive Cancer Center SC New Presbyterian Hospital Weill Cornell Medical College NYN Department of Medical Oncology RWGC The Royal Marsden Hospital SUK Sarah Cannon Research Institute NT Karen Kelly NKAW], 2014 ASCO ANN M; Vincent MD, 2009, J CLIN ONCOL, V27; Wang Siyu, 2006, Zhongguo Fei Ai Za Zhi, V9, P434, DOI 10.3779/j.issn.1009-3419.2006.05.09; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1; Wu YL, 2013, LANCET ONCOL, V14, P777, DOI 10.1016/S1470-2045(13)70254-7; Yang JC, 2012, J CLIN ONCOL, P30; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X	41	28	28	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2015	10	10							e0140794	10.1371/journal.pone.0140794	http://dx.doi.org/10.1371/journal.pone.0140794			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0DF	26474174	Green Published, Green Submitted, gold			2023-01-03	WOS:000363185500110
J	Al Harun, MAY; Johnson, J; Uddin, MN; Robinson, RW				Al Harun, Md Abdullah Yousuf; Johnson, Joshua; Uddin, Md Nazim; Robinson, Randall W.			Identification and Phytotoxicity Assessment of Phenolic Compounds in Chrysanthemoides monilifera subsp monilifera (Boneseed)	PLOS ONE			English	Article							EXOTIC PLANT INVASION; ALLELOPATHIC INTERACTIONS; SEEDLING GROWTH; SSP ROTUNDATA; WATER-CONTENT; SOIL; ACIDS; GERMINATION; EXTRACTS; STRESS	Chrysanthemoides monilifera subsp. monilifera (boneseed), a weed of national significance in Australia, threatens indigenous species and crop production through allelopathy. We aimed to identify phenolic compounds produced by boneseed and to assess their phytotoxicity on native species. Phenolic compounds in water and methanol extracts, and in decomposed litter-mediated soil leachate were identified using HPLC, and phytotoxicity of identified phenolics was assessed (repeatedly) through a standard germination bioassay on native Isotoma axillaris. The impact of boneseed litter on native Xerochrysum bracteatum was evaluated using field soil in a greenhouse. Collectively, we found the highest quantity of phenolic compounds in boneseed litter followed by leaf, root and stem. Quantity varied with extraction media. The rank of phenolics concentration in boneseed was in the order of ferulic acid > phloridzin > catechin > p-coumaric acid and they inhibited germination of I. axillaris with the rank of ferulic acid > catechin > phloridzin > p-coumaric acid. Synergistic effects were more severe compared to individual phenolics. The litter-mediated soil leachate (collected after 15 days) exhibited strong phytotoxicity to I. axillaris despite the level of phenolic compounds in the decomposed leachate being decreased significantly compared with their initial level. This suggests the presence of other unidentified allelochemicals that individually or synergistically contributed to the phytotoxicity. Further, the dose response phytotoxic impacts exhibited by the boneseed litter-mediated soil to native X. bracteatum in a more naturalistic greenhouse experiment might ensure the potential allelopathy of other chemical compounds in the boneseed invasion. The reduction of leaf relative water content and chlorophyll level in X. bracteatum suggest possible mechanisms underpinning plant growth inhibition caused by boneseed litter allelopathy. The presence of a substantial quantity of free proline in the target species also suggests that the plant was in a stressed condition due to litter allelopathy. These findings are important for better understanding the invasive potential of boneseed and in devising control strategies.	[Al Harun, Md Abdullah Yousuf; Johnson, Joshua; Uddin, Md Nazim; Robinson, Randall W.] Victoria Univ, Coll Engn & Sci, Inst Sustainabil & Innovat, Melbourne, Vic 8001, Australia	Victoria University	Al Harun, MAY (corresponding author), Victoria Univ, Coll Engn & Sci, Inst Sustainabil & Innovat, Melbourne, Vic 8001, Australia.	mdabdullah.harun@live.vu.edu.au	Uddin, Nazim/AAX-1718-2020	Robinson, Randall/0000-0001-8425-0709; Johnson, Joshua/0000-0003-0000-5226; Uddin, Md. Nazim/0000-0002-7904-4115	Victoria University	Victoria University	There is no external funding source for this research, however, it is supported by the Victoria University internal research funds for postgraduate research students. The authors have duly acknowledged Victoria University in Acknowledgments section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adkins Stephen W., 1996, Plant Protection Quarterly, V11, P20; Al Harun MAY, 2015, J ENVIRON SCI, V33, P1, DOI 10.1016/j.jes.2014.12.017; Al Harun MAY, 2014, S AFR J BOT, V93, P157, DOI 10.1016/j.sajb.2014.04.008; Aranda E, 2006, INT BIODETER BIODEGR, V58, P176, DOI 10.1016/j.ibiod.2006.06.006; Bais HP, 2003, SCIENCE, V301, P1377, DOI 10.1126/science.1083245; Balasundram N, 2006, FOOD CHEM, V99, P191, DOI 10.1016/j.foodchem.2005.07.042; BATES LS, 1973, PLANT SOIL, V39, P205, DOI 10.1007/BF00018060; Batish DR, 2006, PLANT PHYSIOL BIOCH, V44, P819, DOI 10.1016/j.plaphy.2006.10.014; Baziramakenga R, 1997, CAN J BOT, V75, P445, DOI 10.1139/b97-047; Bertin C, 2009, J CHEM ECOL, V35, P1288, DOI 10.1007/s10886-009-9707-4; Blum U, 1999, CRIT REV PLANT SCI, V18, P673, DOI 10.1016/S0735-2689(99)00396-2; BLUM U, 1988, SOIL BIOL BIOCHEM, V20, P793, DOI 10.1016/0038-0717(88)90084-3; Blum U, 2011, PLANT-PLANT ALLELOPATHI INTERACTIONS: PHENOLIC ACIDS, COVER CROPS AND WEED EMERGENCE, P1, DOI 10.1007/978-94-007-0683-5; Blum U., 2014, PLANT PLANT ALLELOPA, V1st; Blum U, 2006, J CHEM ECOL, V32, P1817, DOI 10.1007/s10886-006-9111-2; Brougham K.J., 2006, BONESEED MANAGEMENT; Callaway RM, 2004, FRONT ECOL ENVIRON, V2, P436, DOI 10.1890/1540-9295(2004)002[0436:NWISAT]2.0.CO;2; Delfine S, 2005, AGR ECOSYST ENVIRON, V106, P243, DOI 10.1016/j.agee.2004.10.012; Department of Environment Conservation, 2006, NSW THREAT AB PLAN I; DUKE SO, 1987, WEED TECHNOL, V1, P122, DOI 10.1017/S0890037X00029304; Ens EJ, 2009, BIOL INVASIONS, V11, P275, DOI 10.1007/s10530-008-9232-3; Fu YZ, 2002, ADV ENVIRON RES, V7, P239, DOI 10.1016/S1093-0191(01)00123-X; Gallardo-Williams MT, 2002, PHYTOCHEMISTRY, V59, P305, DOI 10.1016/S0031-9422(01)00449-6; Hierro JL, 2003, PLANT SOIL, V256, P29, DOI 10.1023/A:1026208327014; Hossain MB, 2010, J AGR FOOD CHEM, V58, P10576, DOI 10.1021/jf102042g; INDERJIT, 1995, BOT REV, V61, P28, DOI 10.1007/BF02897150; INDERJIT, 1994, AM J BOT, V81, P799, DOI 10.2307/2445760; Inderjit, 2003, PLANTA, V217, P529, DOI 10.1007/s00425-003-1054-z; Inderjit, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002536; INSKEEP WP, 1985, PLANT PHYSIOL, V77, P483, DOI 10.1104/pp.77.2.483; Janas KM, 2000, PLANT PHYSIOL BIOCH, V38, P587, DOI 10.1016/S0981-9428(00)00778-6; Jefferson LV, 2003, J ARID ENVIRON, V55, P275, DOI 10.1016/S0140-1963(03)00028-4; Jiang XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062315; Ju ZY, 2003, J AGR FOOD CHEM, V51, P5207, DOI 10.1021/jf0302106; Koitabashi R, 1997, J PLANT RES, V110, P1, DOI 10.1007/BF02506836; Lane D, 1978, P 1 C COUNC AUSTR WE; Li ZH, 2010, MOLECULES, V15, P8933, DOI 10.3390/molecules15128933; Lin YC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054466, 10.1371/journal.pone.0069722]; Lindsay EA, 2005, J APPL ECOL, V42, P556, DOI 10.1111/j.1365-2664.2005.01036.x; McAlpine KG, 2009, NEW ZEAL J ECOL, V33, P72; Melland R.L., 2009, THESIS U ADELAIDE; MICHELSEN A, 1995, OECOLOGIA, V103, P407, DOI 10.1007/BF00328678; Northup RR, 1998, BIOGEOCHEMISTRY, V42, P189, DOI 10.1023/A:1005991908504; Parsons W.T., 1973, NOXIOUS WEEDS VICTOR; Rashid MH, 2010, WEED SCI, V58, P47, DOI 10.1614/WS-09-106.1; RASMUSSEN JA, 1977, J CHEM ECOL, V3, P197, DOI 10.1007/BF00994146; Reigosa MJ, 1999, PLANT GROWTH REGUL, V28, P83, DOI 10.1023/A:1006269716762; Rice, 1984, ALLELOPATHY; Roberts David, 2008, Plant Protection Quarterly, V23, P51; Romeo JT, 1998, METHODS CHEM ECOLOGY, V2, P179; Sakai AK, 2001, ANNU REV ECOL SYST, V32, P305, DOI 10.1146/annurev.ecolsys.32.081501.114037; Saura-Mas S, 2007, ANN BOT-LONDON, V99, P545, DOI 10.1093/aob/mcl284; Sharif N., 2014, International Journal of Agricultural Technology, V10, P1231; Simoes K, 2008, J CHEM ECOL, V34, P681, DOI 10.1007/s10886-008-9443-1; Singh HP, 2002, ANN APPL BIOL, V141, P111, DOI 10.1111/j.1744-7348.2002.tb00202.x; Souto XC, 2000, J CHEM ECOL, V26, P2025, DOI 10.1023/A:1005504029243; Uddin MN, 2014, J PLANT INTERACT, V9, P338, DOI 10.1080/17429145.2013.835879; Uddin MN, 2012, MAR FRESHWATER RES, V63, P777, DOI 10.1071/MF12071; VERNENGHI A, 1986, CAN J BOT, V64, P973, DOI 10.1139/b86-131; Vranjic JA, 2000, AUSTRAL ECOL, V25, P445, DOI 10.1046/j.1442-9993.2000.01086.x; Wang CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085162; Weidenhamer J, 2005, J CHEM ECOL, V31, P221, DOI 10.1007/s10886-005-1337-x; Weidenhamer JD, 2014, J CHEM ECOL, V40, P940, DOI 10.1007/s10886-014-0483-4; Grass MAY, 2012, J PLANT INTERACT, V7, P175, DOI 10.1080/17429145.2011.591504; Yang CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094198; Yang WW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067339; Yuan Y., 2012, J PLANT ECOL; Zhang JiangHong, 2007, Scientia Agricultura Sinica, V40, P492; Zhang JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093189; Zhou XG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048288; Zhu XZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025393	71	10	10	2	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2015	10	10							e0139992	10.1371/journal.pone.0139992	http://dx.doi.org/10.1371/journal.pone.0139992			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0CK	26465595	Green Published, Green Accepted, gold			2023-01-03	WOS:000363183100069
J	Fritz, JM; Magel, JS; McFadden, M; Asche, C; Thackeray, A; Meier, W; Brennan, G				Fritz, Julie M.; Magel, John S.; McFadden, Molly; Asche, Carl; Thackeray, Anne; Meier, Whitney; Brennan, Gerard			Early Physical Therapy vs Usual Care in Patients With Recent-Onset Low Back Pain A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FEAR-AVOIDANCE BELIEFS; PRACTICE GUIDELINES; PREDICTION RULE; SPINAL MANIPULATION; EUROPEAN GUIDELINES; HEALTH-STATUS; MANAGEMENT; COSTS; DISABILITY; ADHERENCE	IMPORTANCE Low back pain (LBP) is common in primary care. Guidelines recommend delaying referrals for physical therapy. OBJECTIVE To evaluate whether early physical therapy (manipulation and exercise) is more effective than usual care in improving disability for patients with LBP fitting a decision rule. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial with 220 participants recruited between March 2011 and November 2013. Participants with no LBP treatment in the past 6 months, aged 18 through 60 years (mean age, 37.4 years [SD, 10.3]), an Oswestry Disability Index (ODI) score of 20 or higher, symptom duration less than 16 days, and no symptoms distal to the knee in the past 72 hours were enrolled following a primary care visit. INTERVENTIONS All participants received education. Early physical therapy (n = 108) consisted of 4 physical therapy sessions. Usual care (n = 112) involved no additional interventions during the first 4 weeks. MAIN OUTCOMES AND MEASURES Primary outcome was change in the ODI score (range: 0-100; higher scores indicate greater disability; minimum clinically important difference, 6 points) at 3 months. Secondary outcomes included changes in the ODI score at 4-week and 1-year follow-up, and change in pain intensity, Pain Catastrophizing Scale (PCS) score, fear-avoidance beliefs, quality of life, patient-reported success, and health care utilization at 4-week, 3-month, and 1-year follow-up. RESULTS One-year follow-up was completed by 207 participants (94.1%). Using analysis of covariance, early physical therapy showed improvement relative to usual care in disability after 3 months (mean ODI score: early physical therapy group, 41.3 [95% CI, 38.7 to 44.0] at baseline to 6.6 [95% CI, 4.7 to 8.5] at 3 months; usual care group, 40.9 [95% CI, 38.6 to 43.1] at baseline to 9.8 [95% CI, 7.9 to 11.7] at 3 months; between-group difference, -3.2 [95% CI, -5.9 to -0.47], P = .02). A significant difference was found between groups for the ODI score after 4 weeks (between-group difference, -3.5 [95% CI, -6.8 to -0.08], P = .045]), but not at 1-year follow-up (between-group difference, -2.0 [95% CI, -5.0 to 1.0], P = .19). There was no improvement in pain intensity at 4-week, 3-month, or 1-year follow-up (between-group difference, -0.42 [95% CI, -0.90 to 0.02] at 4-week follow-up; -0.38 [95% CI, -0.84 to 0.09] at 3-month follow-up; and -0.17 [95% CI, -0.62 to 0.27] at 1-year follow-up). The PCS scores improved at 4 weeks and 3 months but not at 1-year follow-up (between-group difference, -2.7 [95% CI, -4.6 to -0.85] at 4-week follow-up; -2.2 [95% CI, -3.9 to -0.49] at 3-month follow-up; and -0.92 [95% CI, -2.7 to 0.61] at 1-year follow-up). There were no differences in health care utilization at any point. CONCLUSIONS AND RELEVANCE Among adults with recent-onset LBP, early physical therapy resulted in statistically significant improvement in disability, but the improvement was modest and did not achieve the minimum clinically important difference compared with usual care.	[Fritz, Julie M.; Magel, John S.; McFadden, Molly; Thackeray, Anne; Meier, Whitney] Univ Utah, Dept Phys Therapy, Salt Lake City, UT 84108 USA; [Magel, John S.; Thackeray, Anne; Brennan, Gerard] Intermt Healthcare, Dept Phys Therapy, Salt Lake City, UT USA; [Asche, Carl] Univ Illinois, Coll Med Peoria, Dept Internal Med, Peoria, IL USA	Utah System of Higher Education; University of Utah; Intermountain Healthcare; Intermountain Medical Center; University of Illinois System; University of Illinois Peoria	Fritz, JM (corresponding author), Univ Utah, Dept Phys Therapy, 520 Wakara Way, Salt Lake City, UT 84108 USA.	julie.fritz@utah.edu	Fritz, Julie/AAC-5638-2021	Magel, John/0000-0001-9087-4753; Thackeray, Anne/0000-0002-5496-7730	Agency for Healthcare Research and Quality [1R18HS018672]; University of Utah Study Design and Biostatistics Center; National Center for Research Resources of the National Institutes of Health [5UL1TRO01067-02]; National Center for Advancing Translational Sciences of the National Institutes of Health; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS018672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000105, UL1TR001067] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025764] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); University of Utah Study Design and Biostatistics Center; National Center for Research Resources of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study was funded by grant 1R18HS018672 from the Agency for Healthcare Research and Quality. The study was supported by the University of Utah Study Design and Biostatistics Center, with funding in part through grant 5UL1TRO01067-02 (formerly 8UL1TR000105 and UL1RR025764) from the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health.	Brennan GP, 2006, SPINE, V31, P623, DOI 10.1097/01.brs.0000202807.72292.a8; Childs JD, 2005, SPINE, V30, P1331, DOI 10.1097/01.brs.0000164099.92112.29; Childs JD, 2004, ANN INTERN MED, V141, P920, DOI 10.7326/0003-4819-141-12-200412210-00008; Chou R, 2007, ANN INTERN MED, V147, P492, DOI 10.7326/0003-4819-147-7-200710020-00007; Cleland JA, 2009, SPINE, V34, P2720, DOI 10.1097/BRS.0b013e3181b48809; Dagenais S, 2010, SPINE J, V10, P514, DOI 10.1016/j.spinee.2010.03.032; Davis MA, 2012, SPINE, V37, P1693, DOI 10.1097/BRS.0b013e3182541f45; Deyo RA, 2006, SPINE, V31, P2724, DOI 10.1097/01.brs.0000244618.06877.cd; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Flynn T, 2002, SPINE, V27, P2835, DOI 10.1097/00007632-200212150-00021; Foster NE, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-108; Freburger JK, 2009, ARCH INTERN MED, V169, P251, DOI 10.1001/archinternmed.2008.543; Fritz JM, 2001, PHYS THER, V81, P776, DOI 10.1093/ptj/81.2.776; Fritz JM, 2003, SPINE, V28, P1363; Fritz JM, 2007, MED CARE, V45, P973, DOI 10.1097/MLR.0b013e318070c6cd; Fritz JM, 2013, ARCH PHYS MED REHAB, V94, P808, DOI 10.1016/j.apmr.2013.01.008; Fritz JM, 2012, SPINE, V37, P2114, DOI 10.1097/BRS.0b013e31825d32f5; Fullen BM, 2007, EUR J PAIN, V11, P614, DOI 10.1016/j.ejpain.2006.09.007; Gellhorn AC, 2012, SPINE, V37, P775, DOI 10.1097/BRS.0b013e3181d79a09; Goossens MEJB, 2000, J CLIN EPIDEMIOL, V53, P688, DOI 10.1016/S0895-4356(99)00177-8; Graves JM, 2014, HEALTH SERV RES, V49, P645, DOI 10.1111/1475-6773.12098; Hill JC, 2008, ARTHRIT RHEUM-ARTHR, V59, P632, DOI 10.1002/art.23563; Hill JC, 2011, LANCET, V378, P1560, DOI 10.1016/S0140-6736(11)60937-9; Hurwitz EL, 2005, SPINE, V30, P1477, DOI 10.1097/01.brs.0000167821.39373.c1; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Koes BW, 2010, EUR SPINE J, V19, P2075, DOI 10.1007/s00586-010-1502-y; Kosloff TM, 2013, POPUL HEALTH MANAG, V16, P390, DOI 10.1089/pop.2012.0096; Licciardone John C, 2008, Osteopath Med Prim Care, V2, P11, DOI 10.1186/1750-4732-2-11; Macedo LG, 2009, PHYS THER, V89, P9, DOI 10.2522/ptj.20080103; Mafi JN, 2013, JAMA INTERN MED, V173, P1573, DOI 10.1001/jamainternmed.2013.8992; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; Martin R, 1996, THE BACK BOOK; Newcomer KL, 2010, PM&R, V2, P514, DOI 10.1016/j.pmrj.2010.03.034; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; van Tulder M, 2006, EUR SPINE J, V15, pS169, DOI 10.1007/s00586-006-1071-2; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; Webster BS, 2014, SPINE, V39, P1433, DOI 10.1097/BRS.0000000000000408; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	40	94	95	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2015	314	14					1459	1467		10.1001/jama.2015.11648	http://dx.doi.org/10.1001/jama.2015.11648			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT2QI	26461996	Bronze			2023-01-03	WOS:000362647800013
J	Downing, LE; Heidker, RM; Caiozzi, GC; Wong, BS; Rodriguez, K; Del Rey, F; Ricketts, ML				Downing, Laura E.; Heidker, Rebecca M.; Caiozzi, Gianella C.; Wong, Brian S.; Rodriguez, Kelvin; Del Rey, Fernando; Ricketts, Marie-Louise			A Grape Seed Procyanidin Extract Ameliorates Fructose-Induced Hypertriglyceridemia in Rats via Enhanced Fecal Bile Acid and Cholesterol Excretion and Inhibition of Hepatic Lipogenesis	PLOS ONE			English	Article							NONALCOHOLIC FATTY LIVER; FARNESOID-X-RECEPTOR; LOWER TRIGLYCERIDE LEVELS; METABOLIC SYNDROME; PPAR-ALPHA; DIETARY PROANTHOCYANIDINS; TARGETED DISRUPTION; SWEETENED BEVERAGES; IN-VIVO; EXPRESSION	The objective of this study was to determine whether a grape seed procyanidin extract (GSPE) exerts a triglyceride-lowering effect in a hyperlipidemic state using the fructose-fed rat model and to elucidate the underlying molecular mechanisms. Rats were fed either a starch control diet or a diet containing 65% fructose for 8 weeks to induce hypertriglyceridemia. During the 9th week of the study, rats were maintained on their respective diet and administered vehicle or GSPE via oral gavage for 7 days. Fructose increased serum triglyceride levels by 171% after 9 weeks, compared to control, while GSPE administration attenuated this effect, resulting in a 41% decrease. GSPE inhibited hepatic lipogenesis via downregulation of sterol regulatory element binding protein 1c and stearoyl-CoA desaturase 1 in the fructose-fed animals. GSPE increased fecal bile acid and total lipid excretion, decreased serum bile acid levels and increased the expression of genes involved in cholesterol synthesis. However, bile acid biosynthetic gene expression was not increased in the presence of GSPE and fructose. Serum cholesterol levels remained constant, while hepatic cholesterol levels decreased. GSPE did not modulate expression of genes responsible for esterification or biliary export of the newly synthesized cholesterol, but did increase fecal cholesterol excretion, suggesting that in the presence of GSPE and fructose, the liver may secrete more free cholesterol into the plasma which may then be shunted to the proximal small intestine for direct basolateral to apical secretion and subsequent fecal excretion. Our results demonstrate that GSPE effectively lowers serum triglyceride levels in fructose-fed rats after one week administration. This study provides novel insight into the mechanistic actions of GSPE in treating hypertriglyceridemia and demonstrates that it targets hepatic de novo lipogenesis, bile acid homeostasis and non-biliary cholesterol excretion as important mechanisms for reducing hypertriglyceridemia and hepatic lipid accumulation in the presence of fructose.	[Downing, Laura E.; Heidker, Rebecca M.; Caiozzi, Gianella C.; Wong, Brian S.; Rodriguez, Kelvin; Del Rey, Fernando; Ricketts, Marie-Louise] Univ Nevada, Dept Agr Nutr & Vet Sci, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Ricketts, ML (corresponding author), Univ Nevada, Dept Agr Nutr & Vet Sci, Reno, NV 89557 USA.	mricketts@cabnr.unr.edu		Ricketts, Marie-Louise/0000-0002-8306-7563; Heidker, Rebecca/0000-0002-8323-988X	University of Nevada Reno; USDA Hatch/Multi-State project: Beneficial and Adverse Effects of Natural Chemicals on Human Health and Food Safety [NEV 0738, W-3122]; CONICYT Bicentennial Becas-Chile Scholarship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103554] Funding Source: NIH RePORTER	University of Nevada Reno; USDA Hatch/Multi-State project: Beneficial and Adverse Effects of Natural Chemicals on Human Health and Food Safety; CONICYT Bicentennial Becas-Chile Scholarship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by start-up funding from the University of Nevada Reno and USDA Hatch (NEV 0738)/Multi-State project W-3122: Beneficial and Adverse Effects of Natural Chemicals on Human Health and Food Safety (http://nimss.umd.edu/lgu_v2/homepages/home.cfm?trackID=14436) to MLR. GCC was the recipient of a CONICYT Bicentennial Becas-Chile Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguila M, 2003, LIVER INT, V23, P363, DOI 10.1034/j.1478-3231.2003.00858.x; Auger C, 2004, J AGR FOOD CHEM, V52, P5297, DOI 10.1021/jf040125d; Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Birjmohun RS, 2005, J AM COLL CARDIOL, V45, P185, DOI 10.1016/j.jacc.2004.10.031; Caimari A, 2013, INT J OBESITY, V37, P576, DOI 10.1038/ijo.2012.75; Chan TF, 2014, NUTRIENTS, V6, P2088, DOI 10.3390/nu6052088; Chong MFF, 2007, AM J CLIN NUTR, V85, P1511, DOI 10.1093/ajcn/85.6.1511; Clifton PM, 2004, J BIOMED BIOTECHNOL, P272, DOI 10.1155/S1110724304403088; Dekker MJ, 2010, AM J PHYSIOL-ENDOC M, V299, pE685, DOI 10.1152/ajpendo.00283.2010; Del Bas JM, 2005, FASEB J, V19, P479, DOI 10.1096/fj.04-3095fje; Del Bas JM, 2008, MOL NUTR FOOD RES, V52, P1172, DOI 10.1002/mnfr.200800054; Duran-Sandoval D, 2004, DIABETES, V53, P890, DOI 10.2337/diabetes.53.4.890; Enjoji M, 2010, WORLD J GASTROENTERO, V16, P800, DOI 10.3748/wjg.v16.i7.800; Fernandez A, 2008, J GASTROEN HEPATOL, V23, pS9, DOI 10.1111/j.1440-1746.2007.05280.x; FOLCH J, 1957, J BIOL CHEM, V226, P497; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Houten SM, 2007, MOL ENDOCRINOL, V21, P1312, DOI 10.1210/me.2007-0113; Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003; Kastorini CM, 2011, J AM COLL CARDIOL, V57, P1299, DOI 10.1016/j.jacc.2010.09.073; Kelley Glen L, 2005, Nutr Metab (Lond), V2, P18, DOI 10.1186/1743-7075-2-18; Kelm MA, 2006, J AGR FOOD CHEM, V54, P1571, DOI 10.1021/jf0525941; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1; Lundasen T, 2007, BIOCHEM BIOPH RES CO, V360, P437, DOI 10.1016/j.bbrc.2007.06.068; Ma K, 2006, J CLIN INVEST, V116, P1102, DOI 10.1172/JCI25604; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844; Del Bas JM, 2009, MOL NUTR FOOD RES, V53, P805, DOI 10.1002/mnfr.200800364; Marriott BP, 2009, J NUTR, V139, pS1228, DOI 10.3945/jn.108.098277; Masterjohn C, 2013, NUTRIENTS, V5, P3311, DOI 10.3390/nu5083311; Modica Salvatore, 2011, Curr Protoc Mouse Biol, V1, P289, DOI 10.1002/9780470942390.mo100226; Montonen J, 2007, J NUTR, V137, P1447, DOI 10.1093/jn/137.6.1447; Moutzouri E, 2010, VASC HEALTH RISK MAN, V6, P525; Nagai Y, 2009, CELL METAB, V9, P252, DOI 10.1016/j.cmet.2009.01.011; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Osakabe N, 2013, J CLIN BIOCHEM NUTR, V52, P186, DOI 10.3164/jcbn.12-130; Quesada H, 2009, INT J OBESITY, V33, P1007, DOI 10.1038/ijo.2009.136; Quesada H, 2012, BRIT J NUTR, V108, P208, DOI 10.1017/S0007114511005472; Rasmussen SE, 2005, MOL NUTR FOOD RES, V49, P159, DOI 10.1002/mnfr.200400082; REAVEN GM, 1991, AM J HYPERTENS, V4, P610, DOI 10.1093/ajh/4.7.610; Roglans N, 2002, J PHARMACOL EXP THER, V302, P232, DOI 10.1124/jpet.302.1.232; Rucker R, 2002, J NUTR, V132, P2999, DOI 10.1093/jn/131.10.2999; Samuel VT, 2011, TRENDS ENDOCRIN MET, V22, P60, DOI 10.1016/j.tem.2010.10.003; Shrestha S, 2009, J NUTR, V139, P640, DOI 10.3945/jn.108.103341; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Stanhope KL, 2013, CURR OPIN LIPIDOL, V24, P198, DOI 10.1097/MOL.0b013e3283613bca; Terra X, 2009, J NUTR BIOCHEM, V20, P210, DOI 10.1016/j.jnutbio.2008.02.005; Untergasser A, 2007, NUCLEIC ACIDS RES, V35, pW71, DOI 10.1093/nar/gkm306; van der Velde AE, 2008, AM J PHYSIOL-GASTR L, V295, pG203, DOI 10.1152/ajpgi.90231.2008; Van der Velde AE, 2007, GASTROENTEROLOGY, V133, P967, DOI 10.1053/j.gastro.2007.06.019; van der Velde AE, 2010, CURR OPIN LIPIDOL, V21, P167, DOI 10.1097/MOL.0b013e3283395e45; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Wouters K, 2008, HEPATOLOGY, V48, P474, DOI 10.1002/hep.22363; Yamakoshi J, 2002, FOOD CHEM TOXICOL, V40, P599, DOI 10.1016/S0278-6915(02)00006-6; Zern TL, 2005, J NUTR, V135, P1911, DOI 10.1093/jn/135.8.1911	58	28	28	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2015	10	10							e0140267	10.1371/journal.pone.0140267	http://dx.doi.org/10.1371/journal.pone.0140267			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT6YZ	26458107	Green Published, gold, Green Submitted			2023-01-03	WOS:000362961100027
J	El-Kashlan, AM; Nooh, MM; Hassan, WA; Rizk, SM				El-Kashlan, Akram M.; Nooh, Mohammed M.; Hassan, Wafaa A.; Rizk, Sherine M.			Therapeutic Potential of Date Palm Pollen for Testicular Dysfunction Induced by Thyroid Disorders in Male Rats	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; OXIDATIVE STRESS; ESTROGEN; GRAINS; TESTIS; MICE	Hyper- or hypothyroidism can impair testicular function leading to infertility. The present study was designed to examine the protective effect of date palm pollen (DPP) extract on thyroid disorder-induced testicular dysfunction. Rats were divided into six groups. Group I was normal control. Group II received oral DPP extract (150 mg kg(-1)), group III (hyperthyroid group) received intraperitoneal injection of L-thyroxine (L-T4, 300 mu g kg(-1); i.p.), group IV received L-T4 plus DPP extract, group V (hypothyroid group) received propylthiouracil (PTU, 10 mg kg(-1); i.p.) and group VI received PTU plus DPP extract. All treatments were given every day for 56 days. L-T4 or PTU lowered genital sex organs weight, sperm count and motility, serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH) and testosterone (T), testicular function markers and activities of testicular 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) and 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD). Moreover, L-T4 or PTU increased estradiol (E2) serum level, testicular oxidative stress, DNA damage and apoptotic markers. Morphometric and histopathologic studies backed these observations. Treatment with DPP extract prevented LT4- or PTU induced changes. In addition, supplementation of DPP extract to normal rats augmented sperm count and motility, serum levels of LH, T and E2 paralleled with increased activities of 3 beta-HSD and 17 beta-HSD as well as testicular antioxidant status. These results provide evidence that DPP extract may have potential protective effects on testicular dysfunction induced by altered thyroid hormones.	[El-Kashlan, Akram M.; Hassan, Wafaa A.] Natl Org Drug Control & Res, Hormone Evaluat Dept, Giza, Egypt; [Nooh, Mohammed M.; Rizk, Sherine M.] Cairo Univ, Fac Pharm, Dept Biochem, Cairo 11562, Egypt	National Organization for Drug Control & Research (NODCAR); Egyptian Knowledge Bank (EKB); Cairo University	Nooh, MM (corresponding author), Cairo Univ, Fac Pharm, Dept Biochem, Kasr Al Aini St, Cairo 11562, Egypt.	mohamed.nooh@pharma.cu.edu.eg		Nooh, Mohammed/0000-0001-9794-4099				Abbas F. A., 2011, Australian Journal of Basic and Applied Sciences, V5, P606; Abedi A, 2013, ADV SEX MED, V3, P28; Ali BH, 1999, FOOD CHEM, V66, P437, DOI 10.1016/S0308-8146(98)00060-0; AOAC, 2007, OFFICIAL METHODS ANA, V18th; Asker ME, 2015, ANDROLOGIA, V47, P644, DOI 10.1111/and.12312; Assinder S, 2007, REPRODUCTION, V133, P11, DOI 10.1530/rep.1.01211; Bahmanpour S, 2006, IRAN J MED SCI, V31, P208; Barrett K E, 2010, GANONGS REV MED PHYS, P301; Bauza E, 2002, INT J TISSUE REACT, V24, P131; Bharti S, 2014, MOL CELL ENDOCRINOL, V383, P10, DOI 10.1016/j.mce.2013.11.021; Bishr M., 2012, Journal of Pharmacy and Nutrition Sciences, V2, P50; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Chattopadhyay S, 2010, GEN COMP ENDOCR, V169, P39, DOI 10.1016/j.ygcen.2010.07.014; CHAUNCEY B, 1988, ENZYME, V39, P231, DOI 10.1159/000469124; Conde-Hernandez LA, 2014, FOOD CHEM, V142, P455, DOI 10.1016/j.foodchem.2013.07.078; Corpuz MJAT, 2012, INT FOOD RES J, V20, P291; El-Neweshy MS, 2013, ANDROLOGIA, V45, P369, DOI 10.1111/and.12025; Elberry AA, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-40; ELRIDI MS, 1960, Z NATURFORSCH PT B, V15, P45, DOI 10.1515/znb-1960-0109; Faraone-Mennella MR, 2009, MOL CELL BIOCHEM, V323, P119, DOI 10.1007/s11010-008-9970-7; Hassan H. M. M., 2011, Global Journal of Biotechnology & Biochemistry, V6, P1; Hess RA, 2001, MOL CELL ENDOCRINOL, V178, P29, DOI 10.1016/S0303-7207(01)00412-9; Ibrahim W, 2011, GEN COMP ENDOCR, V174, P143, DOI 10.1016/j.ygcen.2011.08.012; JARABAK J, 1962, J BIOL CHEM, V237, P345; Krassas GE, 2013, WERNER INGBARS THYRO, P582; Kumar Anand, 2014, Indian J Endocrinol Metab, V18, P23, DOI 10.4103/2230-8210.126523; Lee KH, 2009, J ANAT, V214, P916, DOI 10.1111/j.1469-7580.2009.01080.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Metwaly MS, 2014, BIOLOGIA, V69, P254, DOI 10.2478/s11756-013-0297-9; Miller CJ, 2003, EUR J CLIN NUTR, V57, P427, DOI 10.1038/sj.ejcn.1601565; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Nantia EA, 2009, ANDROLOGIA, V19, P148, DOI DOI 10.1007/S12610-009-0030-2; Parmar HS, 2009, CHEM-BIOL INTERACT, V177, P254, DOI 10.1016/j.cbi.2008.11.006; Robertson KM, 2002, ENDOCRINOLOGY, V143, P2913, DOI 10.1210/en.143.8.2913; Russell L. D., 1990, HISTOLOGICAL HISTOPA, P41; Saafi EB, 2011, EXP TOXICOL PATHOL, V63, P433, DOI 10.1016/j.etp.2010.03.002; Sahoo D.K., 2013, WEBMED CENTRAL ENDOC, V4, P1; Sahoo DK, 2008, CHEM-BIOL INTERACT, V176, P121, DOI 10.1016/j.cbi.2008.07.009; Saleh AAS, 2015, J BASIC APPL ZOOL, V72, P173, DOI [DOI 10.1016/J.JOBAZ.2015.01.001, 10.1016/j.jobaz.2015.01.001]; Shiva M, 2011, CLIN BIOCHEM, V44, P319, DOI 10.1016/j.clinbiochem.2010.11.009; TALALAY P, 1962, METHOD ENZYMOL, V5, P512, DOI 10.1016/S0076-6879(62)05269-6; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; Wagner MS, 2009, MICROSC RES TECHNIQ, V72, P796, DOI 10.1002/jemt.20759; Zargari A, 1999, MED PLANTS, V3, P33	44	27	30	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2015	10	10							e0139493	10.1371/journal.pone.0139493	http://dx.doi.org/10.1371/journal.pone.0139493			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6GT	26425844	Green Submitted, gold, Green Published			2023-01-03	WOS:000362177100069
J	Shalev, D				Shalev, Daniel			A Final Course	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Shalev, Daniel] New York Presbyterian Columbia Univ, Dept Psychiat, New York, NY USA; [Shalev, Daniel] New York State Psychiat Inst & Hosp, New York, NY 10032 USA	New York State Psychiatry Institute	Shalev, D (corresponding author), New York Presbyterian Columbia Univ, Dept Psychiat, New York, NY USA.	das2043@nyp.org	Shalev, Daniel/AAA-8397-2019	Shalev, Daniel/0000-0002-8168-2255					0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					263	264		10.1001/jama.2015.17057	http://dx.doi.org/10.1001/jama.2015.17057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784771				2023-01-03	WOS:000368371400020
J	Zafari, Z; Sadatsafavi, M; Marra, CA; Chen, WJ; FitzGerald, JM				Zafari, Zafar; Sadatsafavi, Mohsen; Marra, Carlo A.; Chen, Wenjia; FitzGerald, J. Mark			Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma	PLOS ONE			English	Article							ANTI-IGE ANTIBODY; ADD-ON THERAPY; SEVERE PERSISTENT; UNCONTROLLED ASTHMA; HEALTH; ADULTS; SAFETY; EFFICACY; CORTICOSTEROIDS; EXACERBATIONS	Background Bronchial thermoplasty (BT) is a recently developed treatment for patients with moderate-to-severe asthma. A few studies have suggested the clinical efficacy of this intervention. However, no study has evaluated the cost-effectiveness of BT compared to other alternative treatments for moderate-to-severe allergic asthma, which currently include omalizumab and standard therapy. Objective To evaluate the cost-effectiveness of standard therapy, BT, and omalizumab for moderate-to-severe allergic asthma in the USA. Methods A probabilistic Markov model with weekly cycles was developed to reflect the course of asthma progression over a 5-year time horizon. The study population was adults with moderate-to-severe allergic asthma whose asthma remained uncontrolled despite using high-dose inhaled corticosteroids (ICS, with or without long-acting beta-agonists [LABA]). A perspective of the health-care system was adopted with asthma-related costs as well as quality-adjusted life years (QALYs) and exacerbations as the outcomes. Results For standard therapy, BT, and omalizumab, the discounted 5-year costs and QALYs were $15,400 and 3.08, $28,100 and 3.24, and $117,000 and 3.26, respectively. The incremental cost-effectiveness ratio (ICER) of BT versus standard therapy and omalizumab versus BT was $78,700/QALY and $3.86 million/QALY, respectively. At the willingness-to-pay (WTP) of $50,000/QALY and $100,000/QALY, the probability of BT being cost-effective was 9%, and 67%, respectively. The corresponding expected value of perfect information (EVPI) was $155 and $1,530 per individual at these thresholds. In sensitivity analyses, increasing the costs of BT from $14,900 to $30,000 increased its ICER relative to standard therapy to $178,000/QALY, and decreased the ICER of omalizumab relative to BT to $3.06 million/QALY. Reducing the costs of omalizumab by 25% decreased its ICER relative to BT by 29%. Conclusions Based on the available evidence, our study suggests that there is more than 60% chance that BT becomes cost-effective relative to omalizumab and standard therapy at the WTP of $100,000/QALY in patients with moderate-to-severe allergic asthma. However, there is a substantial uncertainty in the underlying evidence, indicating the need for future research towards reducing such uncertainty.	[Zafari, Zafar; Sadatsafavi, Mohsen; FitzGerald, J. Mark] Univ British Columbia, Fac Med, IHLH, Vancouver, BC, Canada; [Zafari, Zafar; Sadatsafavi, Mohsen; FitzGerald, J. Mark] Univ British Columbia, Ctr Clin Epidemiol & Evaluat, Vancouver Coastal Hlth Inst, Vancouver, BC V5Z 1M9, Canada; [Sadatsafavi, Mohsen; FitzGerald, J. Mark] Univ British Columbia, Fac Med, Div Resp Med, Vancouver, BC, Canada; [Marra, Carlo A.] Mem Univ Newfoundland, Sch Pharm, St John, NF, Canada; [Chen, Wenjia] Univ British Columbia, Fac Pharmaceut Sci, Collaborat Outcomes Res & Evaluat, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; Memorial University Newfoundland; University of British Columbia	Zafari, Z (corresponding author), Univ British Columbia, Fac Med, IHLH, Vancouver, BC, Canada.	zafar.zafari@ubc.ca	Marra, Carlo/AAE-4904-2021; Sadatsafayi, Mohsen/AAZ-1593-2020	Marra, Carlo/0000-0002-2625-2121; Sadatsafayi, Mohsen/0000-0002-0419-7862; Chen, Wenjia/0000-0001-8201-7145	University of British Columbia, Vancouver; Canadian Respiratory Disease Network; National Sanitarium Association; Allergen	University of British Columbia, Vancouver; Canadian Respiratory Disease Network; National Sanitarium Association; Allergen	Z.Z. received a 4-year doctoral fellowship award for his PhD studies from the University of British Columbia, Vancouver. His PhD research is partly funded by Canadian Respiratory Disease Network. M.S. received salary support from National Sanitarium Association. J.M.F. received a grant from Allergen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Arias E., 2007, US LIFE TABLES; Ayres JG, 2004, ALLERGY, V59, P701, DOI 10.1111/j.1398-9995.2004.00533.x; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Brown R, 2007, ALLERGY, V62, P149, DOI 10.1111/j.1398-9995.2006.01310.x; Campbell JD, 2010, ALLERGY, V65, P1141, DOI 10.1111/j.1398-9995.2010.02336.x; Cangelosi MJ, 2014, COST EFFECTIVENESS B, P1; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Chan KKW, 2014, MED DECIS MAKING, V34, P863, DOI 10.1177/0272989X13517750; Chung KF, 1999, EUR RESPIR J, V13, P1198; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Dewilde S, 2006, CURR MED RES OPIN, V22, P1765, DOI 10.1185/030079906X132389; Eichler HG, 2004, VALUE HEALTH, V7, P518, DOI 10.1111/j.1524-4733.2004.75003.x; Gildea TR, 2011, CLEV CLIN J MED, V78, P477, DOI 10.3949/ccjm.78a.10185; Grosse Scott D, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P165, DOI 10.1586/14737167.8.2.165; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Morishima Toshitaka, 2013, Value Health Reg Issues, V2, P29, DOI 10.1016/j.vhri.2013.01.007; Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158; NICE, 2013, OM TREAT SEV PERS AL; Oba Y, 2004, J ALLERGY CLIN IMMUN, V114, P265, DOI 10.1016/j.jaci.2004.05.049; Paltiel AD, 2001, J ALLERGY CLIN IMMUN, V108, P39, DOI 10.1067/mai.2001.116289; Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC; Pavord ID, 2013, ANN ALLERG ASTHMA IM, V111, P402, DOI 10.1016/j.anai.2013.05.002; Price DBR, 2004, PRIM CARE RESP, V13, P113; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Rodrigo GJ, 2011, CHEST, V139, P28, DOI 10.1378/chest.10-1194; Sadatsafavi M, 2014, CHEST, V145, P787, DOI 10.1378/chest.13-1619; Severens JL, 2004, VALUE HEALTH, V7, P397, DOI 10.1111/j.1524-4733.2004.74002.x; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Sullivan SD, 2007, ALLERGY, V62, P126, DOI 10.1111/j.1398-9995.2006.01254.x; Sullivan S. D., 2009, RISK IOF MORTALITY A; Sullivan SD, 2003, J ALLERGY CLIN IMMUN, V112, P1229, DOI 10.1016/j.jaci.2003.09.025; Thomson NC, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-8; Torrego A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009910.pub2; Tsuchiya A, 2002, SHEFFIELD HLTH EC GR; van Nooten Floortje, 2013, J Med Econ, V16, P342, DOI 10.3111/13696998.2012.756398; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Wu AC, 2007, J ALLERGY CLIN IMMUN, V120, P1146, DOI 10.1016/j.jaci.2007.07.055; Zafari Z, 2014, J ALLERGY CLIN IMMUN, V134, P908, DOI 10.1016/j.jaci.2014.04.009	40	47	49	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0146003	10.1371/journal.pone.0146003	http://dx.doi.org/10.1371/journal.pone.0146003			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6CA	26751790	Green Published, Green Submitted, gold			2023-01-03	WOS:000367888100038
J	Thomas, RG; Moon, MJ; Kim, JH; Lee, JH; Jeong, YY				Thomas, Reju George; Moon, Myeong Ju; Kim, Jo Heon; Lee, Jae Hyuk; Jeong, Yong Yeon			Effectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H/HeN Mice Model	PLOS ONE			English	Article							RENIN-ANGIOTENSIN SYSTEM; STELLATE CELLS; RECEPTOR ANTAGONIST; TARGETED DELIVERY; LIVER FIBROSIS; CIRRHOSIS; RAT; NANOPARTICLES; PATHOGENESIS; SUPPRESSION	Advanced hepatic fibrosis therapy using drug-delivering nanoparticles is a relatively unexplored area. Angiotensin type 1 (AT1) receptor blockers such as losartan can be delivered to hepatic stellate cells (HSC), blocking their activation and thereby reducing fibrosis progression in the liver. In our study, we analyzed the possibility of utilizing drug-loaded vehicles such as hyaluronic acid (HA) micelles carrying losartan to attenuate HSC activation. Losartan, which exhibits inherent lipophilicity, was loaded into the hydrophobic core of HA micelles with a 19.5% drug loading efficiency. An advanced liver fibrosis model was developed using C3H/HeN mice subjected to 20 weeks of prolonged TAA/ethanol weight-adapted treatment. The cytocompatibility and cell uptake profile of losartan-HA micelles were studied in murine fibroblast cells (NIH3T3), human hepatic stellate cells (hHSC) and FL83B cells (hepatocyte cell line). The ability of these nanoparticles to attenuate HSC activation was studied in activated HSC cells based on alpha smooth muscle actin (alpha-sma) expression. Mice treated with oral losartan or losartan-HA micelles were analyzed for serum enzyme levels (ALT/AST, CK and LDH) and collagen deposition (hydroxyproline levels) in the liver. The accumulation of HA micelles was observed in fibrotic livers, which suggests increased delivery of losartan compared to normal livers and specific uptake by HSC. Active reduction of alpha-sma was observed in hHSC and the liver sections of losartan-HA micelle-treated mice. The serum enzyme levels and collagen deposition of losartan-HA micelle-treated mice was reduced significantly compared to the oral losartan group. Losartan-HA micelles demonstrated significant attenuation of hepatic fibrosis via an HSC-targeting mechanism in our in vitro and in vivo studies. These nanoparticles can be considered as an alternative therapy for liver fibrosis.	[Thomas, Reju George; Jeong, Yong Yeon] Chonnam Natl Univ, Sch Med, Hwasun Hosp, Dept Radiol, Gwangju, South Korea; [Moon, Myeong Ju] DKC Corp BioActs, Inchon, South Korea; [Kim, Jo Heon; Lee, Jae Hyuk] Chonnam Natl Univ, Sch Med, Hwasun Hosp, Dept Pathol, Gwangju, South Korea	Chonnam National University; Chonnam National University	Jeong, YY (corresponding author), Chonnam Natl Univ, Sch Med, Hwasun Hosp, Dept Radiol, Gwangju, South Korea.	yjeong@jnu.ac.kr	Thomas, Reju/R-9111-2019		Basic Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science and future Planning [2015R1A2A2A01007798]; DKC Corporation (BioActs)	Basic Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science and future Planning; DKC Corporation (BioActs)	This research was supported by Basic Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and future Planning (2015R1A2A2A01007798). The funder (DKC Corporation (BioActs)) provided support in the form of salaries for authors and/or research materials [MMJ], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Bahde R, 2011, LIVER INT, V31, P642, DOI 10.1111/j.1478-3231.2011.02493.x; Bakris G, 2008, KIDNEY INT, V74, P364, DOI 10.1038/ki.2008.204; Bataller R, 2005, ANTIOXID REDOX SIGN, V7, P1346, DOI 10.1089/ars.2005.7.1346; Bataller R, 2003, GASTROENTEROLOGY, V125, P117, DOI 10.1016/S0016-5085(03)00695-4; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Beljaars L, 2001, LIVER, V21, P320, DOI 10.1034/j.1600-0676.2001.210504.x; Bisht S, 2011, LAB INVEST, V91, P1383, DOI 10.1038/labinvest.2011.86; Bosetti C, 2007, J HEPATOL, V46, P827, DOI 10.1016/j.jhep.2007.01.025; Choi KY, 2009, J MATER CHEM, V19, P4102, DOI 10.1039/b900456d; Colmenero J, 2009, AM J PHYSIOL-GASTR L, V297, pG726, DOI 10.1152/ajpgi.00162.2009; Guerra R. R., 2010, Brazilian Journal of Veterinary Pathology, V3, P9; Hernandez-Gea V, 2011, ANNU REV PATHOL-MECH, V6, P425, DOI 10.1146/annurev-pathol-011110-130246; Jin Yu-Jin, 2010, Journal of Pharmaceutical Investigation, V40, P33, DOI 10.4333/KPS.2010.40.S.033; Kabir N, 2014, RSC ADV, V4, P9012, DOI 10.1039/c3ra46093b; Kikuchi S, 2005, J BIOL CHEM, V280, P15398, DOI 10.1074/jbc.M414048200; Kim KS, 2010, ACS NANO, V4, P3005, DOI 10.1021/nn100589y; Kim M, 2008, J GASTROENTEROL, V43, P889, DOI 10.1007/s00535-008-2239-9; Kornek M, 2006, J HEPATOL, V45, P370, DOI 10.1016/j.jhep.2006.03.017; Kurikawa N, 2003, BRIT J PHARMACOL, V139, P1085, DOI 10.1038/sj.bjp.0705339; Levy BI, 2008, CIRCULATION, V118, P968, DOI 10.1161/CIRCULATIONAHA.107.763730; Li XN, 2002, J HEPATOL, V36, P488, DOI 10.1016/S0168-8278(02)00011-9; Liu YH, 2011, INT J PHARMACEUT, V421, P160, DOI 10.1016/j.ijpharm.2011.09.006; Moreno M, 2010, HEPATOLOGY, V51, P942, DOI 10.1002/hep.23419; Munshi MK, 2011, EXP BIOL MED, V236, P557, DOI 10.1258/ebm.2011.010375; Pereira RM, 2009, WORLD J GASTROENTERO, V15, P2579, DOI 10.3748/wjg.15.2579; Rehm J, 2013, J HEPATOL, V59, P160, DOI 10.1016/j.jhep.2013.03.007; Satoh T, 2000, J GASTROEN HEPATOL, V15, P402, DOI 10.1046/j.1440-1746.2000.02164.x; Schneider AW, 1999, HEPATOLOGY, V29, P334, DOI 10.1002/hep.510290203; Takei Y, 2004, FASEB J, V10; Thomas RG, 2015, INT J BIOL MACROMOL, V72, P510, DOI 10.1016/j.ijbiomac.2014.08.054; Urashima S, 2000, ALCOHOL CLIN EXP RES, V24, p34S, DOI 10.1111/j.1530-0277.2000.tb00009.x	31	35	36	2	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2015	10	12							e0145512	10.1371/journal.pone.0145512	http://dx.doi.org/10.1371/journal.pone.0145512			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0IX	26714035	Green Published, gold, Green Submitted			2023-01-03	WOS:000367481900049
J	Magi, T; Kuehni, CE; Torchetti, L; Wengenroth, L; Luer, S; Frei-Erb, M				Magi, Tatjana; Kuehni, Claudia E.; Torchetti, Loredana; Wengenroth, Laura; Lueer, Sonja; Frei-Erb, Martin			Use of Complementary and Alternative Medicine in Children with Cancer: A Study at a Swiss University Hospital	PLOS ONE			English	Article							PEDIATRIC ONCOLOGY PATIENTS; HERB-DRUG INTERACTIONS; CHILDHOOD-CANCER; PREVALENCE; POPULATION; CHEMOTHERAPY; THERAPIES; GERMANY	Background Though complementary and alternative medicine (CAM) are frequently used by children and adolescents with cancer, there is little information on how and why they use it. This study examined prevalence and methods of CAM, the therapists who applied it, reasons for and against using CAM and its perceived effectiveness. Parent-perceived communication was also evaluated. Parents were asked if medical staff provided information on CAM to patients, if parents reported use of CAM to physicians, and what attitude they thought physicians had toward CAM. Study Design All childhood cancer patients treated at the University Children's Hospital Bern between 2002-2011 were retrospectively surveyed about their use of CAM. Results Data was collected from 133 patients (response rate: 52%). Of those, 53% had used CAM (mostly classical homeopathy) and 25% of patients received information about CAM from medical staff. Those diagnosed more recently were more likely to be informed about CAM options. The most frequent reason for choosing CAM was that parents thought it would improve the patient's general condition. The most frequent reason for not using CAM was lack of information. Of those who used CAM, 87% perceived positive effects. Conclusions Since many pediatric oncology patients use CAM, patients' needs should be addressed by open communication between families, treating oncologists and CAM therapists, which will allow parents to make informed and safe choices about using CAM.	[Magi, Tatjana; Kuehni, Claudia E.; Wengenroth, Laura] Univ Bern, Inst Social & Prevent Med, Swiss Childhood Canc Registry, Bern, Switzerland; [Magi, Tatjana; Torchetti, Loredana; Frei-Erb, Martin] Univ Bern, Inst Complementary Med, Bern, Switzerland; [Lueer, Sonja] Univ Bern, Inselspital, Univ Childrens Hosp Bern, Div Pediat Hematol Oncol, CH-3010 Bern, Switzerland	University of Bern; University of Bern; University of Bern; University Hospital of Bern	Frei-Erb, M (corresponding author), Univ Bern, Inst Complementary Med, Bern, Switzerland.	martin.frei@ikom.unibe.ch		Kuehni, Claudia E./0000-0001-8957-2002; Frei-Erb, Martin/0000-0002-7923-3741	Swiss Paediatric Oncology Group; Schweizerische Konferenz der kantonalen Gesundheitsdirektorinnen und -direktoren; Swiss Cancer Research; Kinderkrebshilfe Schweiz; Ernst-Gohner Stiftung; Stiftung Domarena; CSL Behring; National Institute of Cancer Epidemiology and Registration	Swiss Paediatric Oncology Group; Schweizerische Konferenz der kantonalen Gesundheitsdirektorinnen und -direktoren; Swiss Cancer Research; Kinderkrebshilfe Schweiz; Ernst-Gohner Stiftung; Stiftung Domarena; CSL Behring; National Institute of Cancer Epidemiology and Registration	The work of the Swiss Childhood Cancer Registry is supported by the Swiss Paediatric Oncology Group (www.spog.ch), Schweizerische Konferenz der kantonalen Gesundheitsdirektorinnen und -direktoren (www.gdk-cds.ch), Swiss Cancer Research (www.krebsforschung.ch), Kinderkrebshilfe Schweiz (www.kinderkrebshilfe.ch), Ernst-Gohner Stiftung (http://www.ernst-goehner-stiftung.ch), Stiftung Domarena, CSL Behring (www.cslbehring.ch) and National Institute of Cancer Epidemiology and Registration (www.nicer.ch). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ben Arush M, 2006, J PEDIAT HEMATOL ONC, V28, P141; Bishop FL, 2010, PEDIATRICS, V125, P768, DOI 10.1542/peds.2009-1775; Clerici CA, 2009, PEDIATR BLOOD CANCER, V53, P599, DOI 10.1002/pbc.22093; ErfahrungsMedizinisches Register (EMR), BAS SWITZ EMR REG QU; Falkenberg T, 2012, FORSCH KOMPLEMENTMED, V19, P6, DOI 10.1159/000343812; Fernandez CV, 1998, J CLIN ONCOL, V16, P1279, DOI 10.1200/JCO.1998.16.4.1279; Gozum S, 2007, CANCER NURS, V30, P38, DOI 10.1097/00002820-200701000-00007; Gomez-Martinez R, 2007, PEDIATR BLOOD CANCER, V49, P820, DOI 10.1002/pbc.21101; Hamidah A, 2009, PEDIATR BLOOD CANCER, V52, P70, DOI 10.1002/pbc.21798; Hu ZP, 2005, PHARM RES-DORDR, V22, P902, DOI 10.1007/s11095-005-4585-0; Izzo AA, 2005, FUND CLIN PHARMACOL, V19, P1, DOI 10.1111/j.1472-8206.2004.00301.x; Klein SD, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13666; Laengler A, 2008, EUR J CANCER, V44, P2233, DOI 10.1016/j.ejca.2008.07.020; Langler A, 2005, KLIN PADIATR, V217, P357, DOI 10.1055/s-2005-872522; Martel D, 2005, PEDIATR BLOOD CANCER, V44, P660, DOI 10.1002/pbc.20205; McCune JS, 2004, SUPPORT CARE CANCER, V12, P454, DOI 10.1007/s00520-004-0598-1; Meijerman I, 2006, ONCOLOGIST, V11, P742, DOI 10.1634/theoncologist.11-7-742; Michel G, 2007, SWISS MED WKLY, V137, P502; National Center for Complementary and Integrative Health (NCCIH). Bethesda (MD), 2014, NCCIH PUBL D, VD156; Roth M, 2009, J PEDIAT HEMATOL ONC, V31, P177, DOI 10.1097/MPH.0b013e3181984f5a; Seely D, 2007, J PEDIAT HEMATOL ONC, V29, P32, DOI 10.1097/MPH.0b013e3180310521; Singendonk M, 2013, EUR J PEDIATR, V172, P31, DOI 10.1007/s00431-012-1821-6; Steliarova-Foucher E, 2005, CANCER-AM CANCER SOC, V103, P1457, DOI 10.1002/cncr.20910; Zuzak TJ, 2009, EUR J PEDIATR, V168, P431, DOI 10.1007/s00431-008-0765-3	24	23	23	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2015	10	12							e0145787	10.1371/journal.pone.0145787	http://dx.doi.org/10.1371/journal.pone.0145787			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SH	26694320	Green Published, Green Submitted, gold			2023-01-03	WOS:000367092500076
J	Schoene, D; Valenzuela, T; Toson, B; Delbaere, K; Severino, C; Garcia, J; Davies, TA; Russell, F; Smith, ST; Lord, SR				Schoene, Daniel; Valenzuela, Trinidad; Toson, Barbara; Delbaere, Kim; Severino, Connie; Garcia, Jaime; Davies, Thomas A.; Russell, Frances; Smith, Stuart T.; Lord, Stephen R.			Interactive Cognitive-Motor Step Training Improves Cognitive Risk Factors of Falling in Older Adults - A Randomized Controlled Trial	PLOS ONE			English	Article							DUAL-TASK CONDITIONS; VIDEO-GAME; DEPRESSION SEVERITY; EXERCISE; PEOPLE; SINGLE; GAIT; INTERVENTION; METAANALYSIS; PERFORMANCE	Purpose Interactive cognitive-motor training (ICMT) requires individuals to perform both gross motor movements and complex information processing. This study investigated the effectiveness of ICMT on cognitive functions associated with falls in older adults. Methods A single-blinded randomized controlled trial was conducted in community-dwelling older adults (N = 90, mean age 81.5 +/- 7) without major cognitive impairment. Participants in the intervention group (IG) played four stepping games that required them to divide attention, inhibit irrelevant stimuli, switch between tasks, rotate objects and make rapid decisions. The recommended minimum dose was three 20-minute sessions per week over a period of 16 weeks unsupervised at home. Participants in the control group (CG) received an evidence- based brochure on fall prevention. Measures of processing speed, attention/executive function (EF), visuo-spatial ability, concerns about falling and depression were assessed before and after the intervention. Results Eighty-one participants (90%) attended re-assessment. There were no improvements with respect to the Stroop Stepping Test (primary outcome) in the intervention group. Compared to the CG, the IG improved significantly in measures of processing speed, visuo-spatial ability and concern about falling. Significant interactions were observed for measures of EF and divided attention, indicating group differences varied for different levels of the covariate with larger improvements in IG participants with poorer baseline performance. The interaction for depression showed no change for the IG but an increase in the CG for those with low depressive symptoms at baseline. Additionally, low and high-adherer groups differed in their baseline performance and responded differently to the intervention. Compared to high adherers, low adherers improved more in processing speed and visual scanning while high-adherers improved more in tasks related to EF. Conclusions This study shows that unsupervised stepping ICMT led to improvements in specific cognitive functions associated with falls in older people. Low adherers improved in less complex functions while high-adherers improved in EF.	[Schoene, Daniel; Valenzuela, Trinidad; Toson, Barbara; Delbaere, Kim; Severino, Connie; Davies, Thomas A.; Smith, Stuart T.; Lord, Stephen R.] Univ New S Wales, Neurosci Res Australia, Sydney, NSW, Australia; [Schoene, Daniel] Univ Erlangen Nurnberg, Inst Biomed Aging, Nurnberg, Germany; [Valenzuela, Trinidad] Univ Finis Terrae, Fac Med, Sch Kinesiol, Exercise Sci Lab, Santiago, Chile; [Garcia, Jaime] Univ Technol Sydney, iNEXT, mHlth Lab, Sydney, NSW 2007, Australia; [Russell, Frances] Australian Catholic Univ, RSL LifeCare Chair Ageing, Sydney, NSW, Australia; [Smith, Stuart T.] Univ Sunshine Coast, Fac Arts & Business, Sippy Downs, Qld 4556, Australia	Neuroscience Research Australia; University of New South Wales Sydney; University of Erlangen Nuremberg; Universidad Finis Terrae; University of Technology Sydney; Australian Catholic University; University of the Sunshine Coast	Lord, SR (corresponding author), Univ New S Wales, Neurosci Res Australia, Sydney, NSW, Australia.	s.lord@neura.edu.au	Valenzuela, Trinidad/AAE-7451-2022; Schoene, Daniel/H-8861-2019; Delbaere, Kim/D-6370-2011; Toson, Barbara/M-4534-2019	Schoene, Daniel/0000-0003-0717-5746; Delbaere, Kim/0000-0002-5655-0234; Toson, Barbara/0000-0001-6661-9971; Lord, Stephen R/0000-0002-7111-8802; Garcia, Jaime/0000-0001-5718-1605; Valenzuela, Trinidad/0000-0001-7764-0223; Smith, Stuart/0000-0002-4735-6026	National Health and Medical Research Council [568975]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by National Health and Medical Research Council Partnership Grant (568975)-SRL, STS, KD; International Postgraduate Research Scholarship-DS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson-Hanley C, 2012, AM J PREV MED, V42, P109, DOI 10.1016/j.amepre.2011.10.016; Anstey KJ, 2009, NEUROPSYCHOLOGY, V23, P500, DOI 10.1037/a0015389; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Berteau-Pavy D, 2011, PEBL TECHNICAL REPOR; Best JR, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00353; Borson S, 2000, INT J GERIATR PSYCH, V15, P1021, DOI 10.1002/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6; Brach JS, 2013, J AM GERIATR SOC, V61, P1879, DOI 10.1111/jgs.12506; Bridle C, 2012, BRIT J PSYCHIAT, V201, P180, DOI 10.1192/bjp.bp.111.095174; Bula CJ, 2011, GERONTOLOGY, V57, P276, DOI 10.1159/000322241; Chatfield MD, 2005, J CLIN EPIDEMIOL, V58, P13, DOI 10.1016/j.jclinepi.2004.05.006; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; DEBRUIN ED, 2011, J NOV PHYSIOTHER, V1, P104, DOI DOI 10.4172/2165-7025.1000104; Delbaere K, 2011, J GERONTOLOGY A; Fabre C, 2002, INT J SPORTS MED, V23, P415, DOI 10.1055/s-2002-33735; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fan J, 2009, BRAIN COGNITION, V70, P209, DOI 10.1016/j.bandc.2009.02.002; Foley L. S., 2008, MENTAL HLTH PHYS ACT, V1, P69, DOI DOI 10.1016/J.MHPA.2008.07.001; Fraser SA, 2014, GAMES HEALTH J, V3, P172, DOI 10.1089/g4h.2013.0095; Gillespie L.D., 2012, COCHRANE DATABASE SY; Green CS, 2008, PSYCHOL AGING, V23, P692, DOI 10.1037/a0014345; Gregory MA, 2013, CURR SPORT MED REP, V12, P256, DOI 10.1249/JSR.0b013e31829a74fd; Groll DL, 2005, J CLIN EPIDEMIOL, V58, P595, DOI 10.1016/j.jclinepi.2004.10.018; Hsu CL, 2012, OSTEOPOROSIS INT, V23, P2409, DOI 10.1007/s00198-012-1992-z; Kayama H, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.3108; Kelly ME, 2014, AGEING RES REV, V16, P12, DOI 10.1016/j.arr.2014.05.002; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kueider AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040588; Kvelde T, 2013, J AM GERIATR SOC, V61, P694, DOI 10.1111/jgs.12209; Laver K, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-64; Lezak M., 2012, NEUROPSYCHOLOGICAL A; Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237; Lord SR, 2001, J GERONTOL A-BIOL, V56, pM627, DOI 10.1093/gerona/56.10.M627; Maillot P, 2012, PSYCHOL AGING, V27, P589, DOI 10.1037/a0026268; Martin K, 2009, DEMENT GERIATR COGN, V27, P451, DOI 10.1159/000216840; Martin KL, 2013, J GERONTOL A-BIOL, V68, P1091, DOI 10.1093/gerona/glt010; Martin M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006220.pub2; Mueller ST, 2014, J NEUROSCI METH, V222, P250, DOI 10.1016/j.jneumeth.2013.10.024; Oei AC, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00054; Oswald Wolf D, 2006, Eur J Ageing, V3, P179, DOI 10.1007/s10433-006-0035-z; Peng W, 2011, CYBERPSYCH BEH SOC N, V14, P681, DOI 10.1089/cyber.2010.0578; Pichierri G, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-74; Pichierri G, 2012, CLIN INTERV AGING, V7, P175, DOI 10.2147/CIA.S32558; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Raz A, 2006, NAT REV NEUROSCI, V7, P367, DOI 10.1038/nrn1903; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Schoene D, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-107; Schoene D, 2014, AGE AGEING, V43, P285, DOI 10.1093/ageing/aft157; Schoene D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057734; Schoene D, 2011, ARCH PHYS MED REHAB, V92, P947, DOI 10.1016/j.apmr.2011.01.012; Silsupadol P, 2009, ARCH PHYS MED REHAB, V90, P381, DOI 10.1016/j.apmr.2008.09.559; Smith ST, 2013, IEEE ENG MED BIO, P7033, DOI 10.1109/EMBC.2013.6611177; Spreen O., 1998, COMPENDIUM NEUROPSYC, Vsecond; Studenski S, 2010, J NUTR HEALTH AGING, V14, P850, DOI 10.1007/s12603-010-0119-5; Theill N, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-103; Van Breukelen GJP, 2006, J CLIN EPIDEMIOL, V59, P920, DOI 10.1016/j.jclinepi.2006.02.007; Wolf SL, 2003, J AM GERIATR SOC, V51, P1693, DOI 10.1046/j.1532-5415.2003.51552.x; Zhou SS, 2011, BRAIN COGNITION, V75, P205, DOI 10.1016/j.bandc.2010.12.003	57	73	74	3	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2015	10	12							e0145161	10.1371/journal.pone.0145161	http://dx.doi.org/10.1371/journal.pone.0145161			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CY9JH	26673919	Green Submitted, Green Published, gold			2023-01-03	WOS:000366722700109
J	Hammer, N; Mobius, R; Gries, A; Hossfeld, B; Bechmann, I; Bernhard, M				Hammer, Niels; Moebius, Robert; Gries, Andre; Hossfeld, Bjoern; Bechmann, Ingo; Bernhard, Michael			Comparison of the Fluid Resuscitation Rate with and without External Pressure Using Two Intraosseous Infusion Systems for Adult Emergencies, the CITRIN (Comparison of InTRaosseous infusion systems in emergency medicINe)-Study	PLOS ONE			English	Article							VASCULAR ACCESS; DEVICE; ANATOMY; HUMERUS; FEMUR; BONE	Introduction Intraosseous infusion is recommended if peripheral venous access fails for cardiopulmonary resuscitation or other medical emergencies. The aim of this study, using body donors, was to compare a semi-automatic (EZ-IO (R)) device at two insertion sites and a sternal intraosseous infusion device (FASTR (TM)). Methods Twenty-seven medical students being inexperienced first-time users were randomized into three groups using EZ-IO and FASTR. The following data were evaluated: attempts required for successful placement, insertion time and flow rates with and without external pressure to the infusion. Results The first-pass insertion success of the EZ-IO tibia, EZ-IO humerus and FASTR was 91%, 77%, and 95%, respectively. Insertion times (MW +/- SD) did not show significant differences with 17 +/- 7 (EZ-IO tibia) vs. 29 +/- 42 (EZ-IO humerus) vs. 33 +/- 21 (FASTR), respectively. One-minute flow rates using external pressures between 0 mmHg and 300 mmHg ranged between 27 +/- 5 to 69 +/- 54 ml/min (EZ-IO tibia), 16 +/- 3 to 60 +/- 44 ml/min (EZ-IO humerus) and 53 +/- 2 to 112 +/- 47 ml/min (FASTR), respectively. Concerning pressure-related increases in flow rates, negligible correlations were found for the EZ-IO tibia in all time frames (c = 0.107-0.366; p <= 0.013), moderate positive correlations were found for the EZ-IO humerus after 5 minutes (c = 0.489; p = 0.021) and strong positive correlations were found for the FASTR in all time frames (c = 0.63-0.80; p <= 0.007). Post-hoc statistical power was 0.62 with the given sample size. Conclusions The experiments with first-time users applying EZ-IO and FASTR in body donors indicate that both devices may be effective intraosseous infusion devices, likely suitable for fluid resuscitation using a pressure bag. Variations in flow rate may limit their reliability. Larger sample sizes will prospectively be required to substantiate our findings.	[Hammer, Niels] Univ Otago, Dept Anat, Dunedin, New Zealand; [Hammer, Niels; Moebius, Robert; Bechmann, Ingo] Univ Leipzig, Fac Med, Inst Anat, D-04109 Leipzig, Germany; [Gries, Andre; Bernhard, Michael] Univ Hosp Leipzig, Emergency Dept, Leipzig, Germany; [Hossfeld, Bjoern] Fed Armed Forces Med Hosp, Sect Emergency Med, Dept Anaesthesiol & Intens Care Med, Ulm, Germany	University of Otago; Leipzig University; Leipzig University	Hammer, N (corresponding author), Univ Otago, Dept Anat, Dunedin, New Zealand.	nlshammer@googlemail.com		Hammer, Niels/0000-0001-8230-9383	CITRIN study; German Research Foundation (DFG); Universitat Leipzig within the program of Open Access Publishing	CITRIN study; German Research Foundation (DFG)(German Research Foundation (DFG)); Universitat Leipzig within the program of Open Access Publishing	Departmental resources supported the CITRIN study. The authors acknowledge support from the German Research Foundation (DFG) and Universitat Leipzig within the program of Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anson JA, 2014, ANESTHESIOLOGY, V120, P1015, DOI 10.1097/ALN.0000000000000140; ARNOLD M, 1972, J THORAC CARDIOV SUR, V64, P596; Babinski MA, 2015, SURG RADIOL ANAT, V37, P287, DOI 10.1007/s00276-014-1339-x; Barnard EBG, 2015, EMERG MED J, V32, P449, DOI 10.1136/emermed-2014-203740; Brenner T, 2008, RESUSCITATION, V78, P314, DOI 10.1016/j.resuscitation.2008.04.004; Deakin CD, 2010, RESUSCITATION, V81, P1305, DOI 10.1016/j.resuscitation.2010.08.017; DEJESUS RA, 1995, ANN THORAC SURG, V59, P163, DOI 10.1016/0003-4975(94)00722-J; Dubick MA, 2000, MIL MED, V165, P552; FASTRESPONDER STERNAL IO, 2015, CLIN EV IND STERN RO; Fokin AA, 2005, ANN THORAC SURG, V79, P1352, DOI 10.1016/j.athoracsur.2004.08.012; FRANCEL TJ, 1992, ARCH SURG-CHICAGO, V127, P1107; Hammer N, 2015, ANAT SCI EDUC, V8, P74, DOI 10.1002/ase.1450; Hammer N, 2012, ANAT SCI EDUC, V5, P225, DOI 10.1002/ase.1270; Helm M, 2015, RESUSCITATION, V88, P43, DOI 10.1016/j.resuscitation.2014.12.015; Kleinman ME, 2010, CIRCULATION, V122, P8466, DOI [10.1161/CIRCULATIONAHA.110.971093, 10.1542/peds.2010-2972A]; Kurowski A, 2014, AM J EMERG MED, V32, P1490, DOI 10.1016/j.ajem.2014.09.007; Lairet JR, 2010, ANN EMERG MED, V56, pS26, DOI 10.1016/j.annemergmed.2010.06.122; Lairet J, 2013, PREHOSP EMERG CARE, V17, P280, DOI 10.3109/10903127.2012.755582; Lanz T von, 2013, LANZ WACHSMUTH PRAKT; Levitan RM, 2009, ANN EMERG MED, V54, P692, DOI 10.1016/j.annemergmed.2009.06.012; Lewis P, 2015, EMERG MED J, V32, P463, DOI 10.1136/emermed-2014-203588; Luck RP, 2010, J EMERG MED, V39, P468, DOI 10.1016/j.jemermed.2009.04.054; Miller L, 2010, ANN EMERG MED, V56, pS151, DOI 10.1016/j.annemergmed.2010.06.510; Nishi H, 2011, EUR J CARDIO-THORAC, V40, P240, DOI 10.1016/j.ejcts.2010.10.027; Ong MEH, 2009, AM J EMERG MED, V27, P8, DOI 10.1016/j.ajem.2008.01.025; Pasley J, 2015, J TRAUMA ACUTE CARE, V78, P295, DOI 10.1097/TA.0000000000000516; Philbeck TE, 2010, JEMS, V35, P69, DOI 10.1016/S0197-2510(10)70232-1; Pietrasik K, 1999, CLIN ANAT, V12, P307, DOI 10.1002/(SICI)1098-2353(1999)12:5<307::AID-CA1>3.0.CO;2-6; RHINELANDER FW, 1974, J BIOMED MATER RES, V8, P87, DOI 10.1002/jbm.820080111; RHINELANDER FW, 1974, CLIN ORTHOP RELAT R, P34; Rhinelander FW, 2012, BIOCH PHYSL BONE, V2, P1; Sajja Lokeswara Rao, 2015, Asian Cardiovasc Thorac Ann, V23, P88, DOI 10.1177/0218492314523629; Schwartz D, 2008, J TRAUMA, V64, P650, DOI 10.1097/TA.0b013e31814db2a6; Singh J, 2013, FORENSIC SCI INT, V228, p181e1, DOI 10. 1016/ j. forsciint. 2013.02.002; Tan BKK, 2012, AM J EMERG MED, V30, P1602, DOI 10.1016/j.ajem.2011.10.025; Tarladacalisir T, 2013, EUR J CARDIO-THORAC, V44, P384, DOI 10.1093/ejcts/ezt091; TONDEVOLD E, 1979, ACTA ORTHOP SCAND, V50, P645, DOI 10.3109/17453677908991287; WARREN DW, 1993, ANN EMERG MED, V22, P183, DOI 10.1016/S0196-0644(05)80199-4	38	14	14	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2015	10	12							e0143726	10.1371/journal.pone.0143726	http://dx.doi.org/10.1371/journal.pone.0143726			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX8BI	26630579	Green Published, gold, Green Submitted			2023-01-03	WOS:000365926300090
J	Borys, C; Lutz, J; Strauss, B; Altmann, U				Borys, Constanze; Lutz, Johannes; Strauss, Bernhard; Altmann, Uwe			Effectiveness of a Multimodal Therapy for Patients with Chronic Low Back Pain Regarding Pre-Admission Healthcare Utilization	PLOS ONE			English	Article							MULTIDISCIPLINARY REHABILITATION; EUROPEAN GUIDELINES; GERMAN; MANAGEMENT; IMPACT; LIFE	Objective The aim of the study was to examine the effectiveness of an intensive inpatient three-week multimodal therapy. We focused especially on the impact on the multimodal therapy outcome of the pre-admission number of treatment types patients had received and of medical specialist groups patients had consulted. Methods 155 patients with chronic low back pain and indication for multimodal therapy were evaluated with respect to pain intensity, depression, anxiety, well-being, and pre-admission health care utilization. In our controlled clinical trial we compared N = 66 patients on the waiting list with N = 89 patients who received immediate treatment. The waiting list patients likewise attended multimodal therapy after the waiting period. Longitudinal post-treatment data for both were collected at three- and twelve-month follow-ups. The impact of pre-admission health care utilization on multimodal therapy outcome (post) was analysed by structural equation model. Results Compared to the control group, multimodal therapy patients' pain intensity and psychological variables were significantly reduced. Longitudinal effects with respect to pre-measures were significant at three-month follow-up for pain intensity (ES = -0.48), well-being (ES = 0.78), anxiety (ES = -0.33), and depression (ES = -0.30). Effect sizes at twelve-month follow- up were small for anxiety (ES = -0.22), and moderate for general well-being (ES = 0.61). Structural equation model revealed that a higher number of pre-admission treatment types was associated with poorer post-treatment outcomes in pain intensity, well-being, and depression. Conclusion Multimodal therapy proved to be effective with regard to improvements in pain intensity, depression, anxiety, and well-being. The association between treatment effect and number of pre-admission pain treatment types suggests that patients would benefit more from attending multimodal therapy in an earlier stage of health care.	[Borys, Constanze; Strauss, Bernhard; Altmann, Uwe] Univ Jena, Inst Psychosocial Med & Psychotherapy, Univ Hosp Jena, Jena, Germany; [Lutz, Johannes] Cent Hosp Bad Berka, Interdisciplinary Pain Ctr, Bad Berka, Germany	Friedrich Schiller University of Jena; Zentralklinik Bad Berka	Borys, C (corresponding author), Univ Jena, Inst Psychosocial Med & Psychotherapy, Univ Hosp Jena, Jena, Germany.	Constanze.Borys@med.uni-jena.de		Altmann, Uwe/0000-0002-3429-2895	Berufsgenossenschaft Nahrungsmittel und Gastgewerbe	Berufsgenossenschaft Nahrungsmittel und Gastgewerbe	CB received a general grant for doctoral thesis from Berufsgenossenschaft Nahrungsmittel und Gastgewerbe. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Altenstetter C, 2003, AM J PUBLIC HEALTH, V93, P38, DOI 10.2105/AJPH.93.1.38; Angst F, 2006, J PAIN, V7, P807, DOI 10.1016/j.jpain.2006.03.009; Bertelsmann-Stiftung, 2007, GES RUECK INN KONZ V; Borys C, 2013, SCHMERZ, V27, P588, DOI 10.1007/s00482-013-1370-6; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Chenot JF, 2008, EUR J PAIN, V12, P275, DOI 10.1016/j.ejpain.2007.06.004; Chrubasik S, 1998, EUR J ANAESTH, V15, P397, DOI 10.1097/00003643-199807000-00004; Gatchel RJ, 2007, PSYCHOL BULL, V133, P581, DOI 10.1037/0033-2909.133.4.581; Gross DP, 2005, SPINE, V30, P235, DOI 10.1097/01.brs.0000150485.51681.80; Guzman J, 2001, BMJ-BRIT MED J, V322, P1511, DOI 10.1136/bmj.322.7301.1511; HAUTZINGER M, 1995, PSYCHIAT PRAX, V39, P302; Herda C., 1998, MARBURGER FRAGEBOGEN; Hildebrandt J, 1997, SPINE, V22, P990, DOI 10.1097/00007632-199705010-00011; Hinz A, 2002, DIAGNOSTICA, V48, P112, DOI 10.1026//0012-1924.48.2.112; Kamper SJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000963.pub3; Koes BW, 2006, BMJ-BRIT MED J, V332, P1430, DOI 10.1136/bmj.332.7555.1430; Kuchler A, 2012, SCHMERZ, V26, P670, DOI 10.1007/s00482-012-1223-8; Michaelson P, 2004, CLIN J PAIN, V20, P447, DOI 10.1097/00002508-200411000-00010; Muthen Linda K., 1998, STAT ANAL LATENT VAR; Nagel B, 2002, SCHMERZ, V16, P263, DOI 10.1007/s00482-002-0162-1; Nationale Versorgungsleitlinie Kreuzschmerz, 2010, BUND; Robert-Koch-Institute, 2013, GESUNDHEITSBERICHTER; Rothman MG, 2013, CLIN J PAIN, V29, P195, DOI 10.1097/AJP.0b013e318250e544; Turk DC, 2008, PAIN, V137, P276, DOI 10.1016/j.pain.2007.09.002; van Middelkoop M, 2011, EUR SPINE J, V20, P19, DOI 10.1007/s00586-010-1518-3; van Tulder M, 2006, EUR SPINE J, V15, pS169, DOI 10.1007/s00586-006-1071-2; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	23	23	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2015	10	11							e0143139	10.1371/journal.pone.0143139	http://dx.doi.org/10.1371/journal.pone.0143139			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CX7AW	26599232	Green Published, gold, Green Submitted			2023-01-03	WOS:000365853900069
J	Daudigeos-Dubus, E; Le Dret, L; Lanvers-Kaminsky, C; Bawa, O; Opolon, P; Vievard, A; Villa, I; Pages, M; Bosq, J; Vassal, G; Zopf, D; Geoerger, B				Daudigeos-Dubus, Estelle; Le Dret, Ludivine; Lanvers-Kaminsky, Claudia; Bawa, Olivia; Opolon, Paule; Vievard, Albane; Villa, Irene; Pages, Melanie; Bosq, Jacques; Vassal, Gilles; Zopf, Dieter; Geoerger, Birgit			Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SIMIAN SARCOMA-VIRUS; HIGH-GRADE GLIOMAS; COLORECTAL-CANCER; PHASE-II; HUMAN NEUROBLASTOMA; METASTATIC-DISEASE; ANGIOGENIC FACTORS; INHIBITS GROWTH; SOLID TUMORS	The multikinase inhibitor regorafenib (BAY 73-4506) exerts both anti-angiogenic and anti-tumorigenic activity in adult solid malignancies mainly advanced colorectal cancer and gastrointestinal stromal tumors. We intended to explore preclinically the potential of regorafenib against solid pediatric malignancies alone and in combination with anticancer agents to guide the pediatric development plan. In vitro effects on cell proliferation were screened against 33 solid tumor cell lines of the Innovative Therapies for Children with Cancer (ITCC) panel covering five pediatric solid malignancies. Regorafenib inhibited cell proliferation with a mean half maximal growth inhibition of 12.5 mu mol/L (range 0.7 mu mol/L to 28 mu mol/L). In vivo, regorafenib was evaluated alone at 10 or 30 mg/kg/d or in combination with radiation, irinotecan or the mitogen-activated protein kinase kinase (MEK) inhibitor refametinib against various tumor types, including patient-derived brain tumor models with an amplified platelet-derived growth factor receptor A (PDGFRA) gene. Regorafenib alone significantly inhibited tumor growth in all xenografts derived from nervous system and connective tissue tumors. Enhanced effects were observed when regorafenib was combined with irradiation and irinotecan against PDGFRA amplified IGRG93 glioma and IGRM57 medulloblastoma respectively, resulting in 100% tumor regressions. Antitumor activity was associated with decreased tumor vascularization, inhibition of PDGFR signaling, and induction of apoptotic cell death. Our work demonstrates that regorafenib exhibits significant antitumor activity in a wide spectrum of preclinical pediatric models through inhibition of angiogenesis and induction of apoptosis. Furthermore, radio- and chemosensitizing effects were observed with DNA damaging agents in PDGFR amplified tumors.	[Daudigeos-Dubus, Estelle; Le Dret, Ludivine; Vassal, Gilles; Geoerger, Birgit] Univ Paris 11, UMR 8203, Vectorol & Anticanc Therapeut, Villejuif, France; [Daudigeos-Dubus, Estelle; Le Dret, Ludivine; Vassal, Gilles; Geoerger, Birgit] CNRS, UMR 8203, Vectorol & Anticanc Therapeut, F-91405 Orsay, France; [Daudigeos-Dubus, Estelle; Le Dret, Ludivine; Vassal, Gilles; Geoerger, Birgit] Gustave Roussy, UMR 8203, Vectorol & Anticanc Therapeut, Villejuif, France; [Lanvers-Kaminsky, Claudia] Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Munster, Germany; [Bawa, Olivia; Opolon, Paule] Gustave Roussy, PFEP Plateforme Evaluat Preclin, Villejuif, France; [Vievard, Albane] Tribvn, Chatillon, France; [Villa, Irene; Bosq, Jacques] Gustave Roussy, Pathol Lab, Villejuif, France; [Pages, Melanie] St Annes Hosp, Dept Neuropathol, Paris, France; [Pages, Melanie] Paris Descartes Univ, Paris, France; [Zopf, Dieter] Bayer Pharma Aktiengesell, Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Bayer AG; Bayer Healthcare Pharmaceuticals	Geoerger, B (corresponding author), Univ Paris 11, UMR 8203, Vectorol & Anticanc Therapeut, Villejuif, France.	birgit.geoerger@gustaveroussy.fr	Lanvers-Kaminsky, Claudia/AAY-2071-2021; Pages, Melanie/S-1875-2019		Bayer Pharma Aktiengesellschaft; Enfants et Sante; Societe Francaise des Cancers de l'Enfant; Tribvn	Bayer Pharma Aktiengesellschaft; Enfants et Sante; Societe Francaise des Cancers de l'Enfant; Tribvn	This preclinical evaluation was supported by: Bayer Pharma Aktiengesellschaft, (BG), 'Enfants et Sante' and the 'Societe Francaise des Cancers de l'Enfant'. Bayer Pharma Aktiengesellschaft provided support in the form of salaries for authors [DZ] and had a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Tribvn provided support in the form of salaries for authors [AV] and had a collaborative role in data analysis and preparation of the manuscript without financial support. The specific roles of these authors are articulated in the 'author contributions' section.	Abou-Elkacem L, 2013, MOL CANCER THER, V12, P1322, DOI 10.1158/1535-7163.MCT-12-1162; [Anonymous], 2013, ONCOL WILLISTON PARK, V27, P164; [Anonymous], 2012, ONCOL WILLISTON PARK, V26, P896; Aprile G, 2013, BIODRUGS, V27, P213, DOI 10.1007/s40259-013-0014-9; Bruix J, 2013, EUR J CANCER, V49, P3412, DOI 10.1016/j.ejca.2013.05.028; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Carr BI, 2013, J CELL PHYSIOL, V228, P1344, DOI 10.1002/jcp.24291; Cassinelli G, 2013, BIOCHEM PHARMACOL, V85, P1424, DOI 10.1016/j.bcp.2013.02.023; Chan ASY, 1998, AM J SURG PATHOL, V22, P816, DOI 10.1097/00000478-199807000-00004; Crose LES, 2012, CLIN CANCER RES, V18, P3780, DOI 10.1158/1078-0432.CCR-10-3063; D'Alessandro R, 2013, CANCER CHEMOTH PHARM, V72, P869, DOI 10.1007/s00280-013-2269-8; Daudigeos-Dubus E, 2014, IN VIVO, V28, P425; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Demoulin JB, 2014, CYTOKINE GROWTH F R, V25, P273, DOI 10.1016/j.cytogfr.2014.03.003; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Fakhari M, 2002, J PEDIATR SURG, V37, P582, DOI 10.1053/jpsu.2002.31614; Geoerger B, 2002, CANCER RES, V62, P764; George S, 2012, J CLIN ONCOL, V30, P2401, DOI 10.1200/JCO.2011.39.9394; Grill J, 2013, NEURO-ONCOLOGY, V15, P1236, DOI 10.1093/neuonc/not097; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Gururangan S, 2010, J CLIN ONCOL, V28, P3069, DOI 10.1200/JCO.2009.26.8789; Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97; Hinson ARP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00183; Jeong YK, 2013, TUMORI, V99, P176, DOI 10.1700/1283.14189; Keles GE, 1995, ONCOL RES, V7, P493; Komuro H, 2001, J CANCER RES CLIN, V127, P739; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Miyagami Mitsusuke, 2005, Medical Molecular Morphology, V38, P36, DOI 10.1007/s00795-004-0273-0; Mross K, 2012, CLIN CANCER RES, V18, P2658, DOI 10.1158/1078-0432.CCR-11-1900; Narayana A, 2010, NEURO-ONCOLOGY, V12, P985, DOI 10.1093/neuonc/noq033; Paugh BS, 2013, CANCER RES, V73, P6219, DOI 10.1158/0008-5472.CAN-13-1491; Paugh BS, 2010, J CLIN ONCOL, V28, P3061, DOI 10.1200/JCO.2009.26.7252; PETER M, 1995, BRIT J CANCER, V72, P96, DOI 10.1038/bjc.1995.283; Peter M, 2001, LAB INVEST, V81, P905, DOI 10.1038/labinvest.3780299; Phillips JJ, 2013, BRAIN PATHOL, V23, P565, DOI 10.1111/bpa.12043; Puget S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030313; Rechsteiner M, 2015, ANN ONCOL, V26, P246, DOI 10.1093/annonc/mdu471; Rossler J, 2011, INT J CANCER, V128, P2748, DOI 10.1002/ijc.25611; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Sajithlal GB, 2013, MOL PHARMACOL, V84, P562, DOI 10.1124/mol.113.088005; Sanceau J, 2002, ONCOGENE, V21, P7700, DOI 10.1038/sj.onc.1205881; Schiavetti A, 2012, PEDIATR BLOOD CANCER, V59, P627, DOI 10.1002/pbc.24072; Schmieder R, 2014, INT J CANCER, V135, P1487, DOI 10.1002/ijc.28669; Schultheis B, 2013, ANN ONCOL, V24, P1560, DOI 10.1093/annonc/mdt056; Serra M, 2001, MODERN PATHOL, V14, P710, DOI 10.1038/modpathol.3880377; Sherman JH, 2014, J CLIN NEUROSCI, V21, P131, DOI 10.1016/j.jocn.2013.04.010; Sie M, 2014, CRIT REV ONCOL HEMAT, V89, P418, DOI 10.1016/j.critrevonc.2013.09.005; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Spaniol K, 2011, ANTI-CANCER DRUG, V22, P531, DOI 10.1097/CAD.0b013e3283454526; Taylor M, 2009, CLIN CANCER RES, V15, P4561, DOI 10.1158/1078-0432.CCR-08-2363; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Vassal G, 1996, INT J CANCER, V69, P146, DOI 10.1002/(SICI)1097-0215(19960422)69:2<146::AID-IJC14>3.0.CO;2-7; Virag J, 2014, PATHOL ONCOL RES, V20, P417, DOI 10.1007/s12253-013-9711-4; Waha A, 2003, J NEUROPATH EXP NEUR, V62, P1192, DOI 10.1093/jnen/62.11.1192; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864; Wohrle S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077652; Zopf D, 2010, AACR 101 ANN M ONL P; Zwerner JP, 2002, ONCOGENE, V21, P3847, DOI 10.1038/sj.onc.1205486	60	32	33	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2015	10	11							e0142612	10.1371/journal.pone.0142612	http://dx.doi.org/10.1371/journal.pone.0142612			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7AW	26599335	gold, Green Published, Green Submitted			2023-01-03	WOS:000365853900031
J	Kang, H; Chung, YS; Kim, SW; Choi, GJ; Kim, BG; Park, SW; Seok, JW; Hong, J				Kang, Hyun; Chung, Yoon Sang; Kim, Sang Wook; Choi, Geun Joo; Kim, Beom Gyu; Park, Suk Won; Seok, Ju Won; Hong, Joonhwa			Effect of Temperature-Sensitive Poloxamer Solution/Gel Material on Pericardial Adhesion Prevention: Supine Rabbit Model Study Mimicking Cardiac Surgery	PLOS ONE			English	Article							HYALURONIC-ACID; MITOMYCIN-C; REDUCTION; MEMBRANE; BARRIER; COMBINATION; EFFICACY; CLOSURE; FILM; GEL	Objective We investigated the mobility of a temperature-sensitive poloxamer/Alginate/CaCl2 mixture (PACM) in relation to gravity and cardiac motion and the efficacy of PACM on the prevention of pericardial adhesion in a supine rabbit model. Methods A total of 50 rabbits were randomly divided into two groups according to materials applied after epicardial abrasion: PACM and dye mixture (group PD; n = 25) and saline as the control group (group CO; n = 25). In group PD, rabbits were maintained in a supine position with appropriate sedation, and location of mixture of PACM and dye was assessed by CT scan at the immediate postoperative period and 12 hours after surgery. The grade of adhesions was evaluated macroscopically and microscopically two weeks after surgery. Results In group PD, enhancement was localized in the anterior pericardial space, where PACM and dye mixture was applied, on immediate post-surgical CT scans. However, the volume of the enhancement was significantly decreased at the anterior pericardial space 12 hours later (P < .001). Two weeks after surgery, group PD had significantly lower macroscopic adhesion score (P = .002) and fibrosis score (P = .018) than did group CO. Inflammation score and expression of anti-macrophage antibody in group PD were lower than those in group CO, although the differences were not significant. Conclusions In a supine rabbit model study, the anti-adhesion effect was maintained at the area of PACM application, although PACM shifted with gravity and heart motion. For more potent pericardial adhesion prevention, further research and development on the maintenance of anti-adhesion material position are required.	[Kang, Hyun; Choi, Geun Joo] Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 156756, South Korea; [Chung, Yoon Sang; Kim, Sang Wook; Hong, Joonhwa] Chung Ang Univ, Coll Med, Heart Res Inst, Seoul 156756, South Korea; [Kim, Sang Wook] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul 156756, South Korea; [Kang, Hyun; Chung, Yoon Sang; Hong, Joonhwa] Chung Ang Univ, Coll Med, Dept Thorac & Cardiovasc Surg, Seoul 156756, South Korea; [Kim, Beom Gyu] Chung Ang Univ, Coll Med, Dept Surg, Seoul 156756, South Korea; [Park, Suk Won] Chung Ang Univ, Coll Med, Dept Radiat Oncol, Seoul 156756, South Korea; [Seok, Ju Won] Chung Ang Univ, Coll Med, Dept Nucl Med, Seoul 156756, South Korea	Chung Ang University; Chung Ang University Hospital; Chung Ang University; Chung Ang University Hospital; Chung Ang University; Chung Ang University Hospital; Chung Ang University; Chung Ang University Hospital; Chung Ang University; Chung Ang University Hospital; Chung Ang University; Chung Ang University Hospital; Chung Ang University; Chung Ang University Hospital	Hong, J (corresponding author), Chung Ang Univ, Coll Med, Heart Res Inst, Seoul 156756, South Korea.	jhong@cau.ac.kr	Kang, Hyun/AAE-7872-2020; Choi, Geun Joo/AAF-5102-2021	Kang, Hyun/0000-0003-2844-5880; Hong, Joonhwa/0000-0003-2212-2861	Basic Science Research Program through the National Research Foundation (NRF) of Korea - Ministry of Education, Science and Technology [NRF-2015R1A2A2A01005153]	Basic Science Research Program through the National Research Foundation (NRF) of Korea - Ministry of Education, Science and Technology	This research was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science and Technology (NRF-2015R1A2A2A01005153) (http://www.nrf.re.kr/nrftot_cms/index.jsp?pmi-sso-return2=none). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science and Technology (NRF-2015R1A2A2A01005153).	Alizzi AM, 2012, HEART LUNG CIRC, V21, P22, DOI 10.1016/j.hlc.2011.10.002; Colak N, 2013, CARDIOVASC PATHOL, V22, P368, DOI 10.1016/j.carpath.2013.02.001; Colak N, 2013, CAN J CARDIOL, V29, P712, DOI 10.1016/j.cjca.2012.05.005; Connors RC, 2007, J SURG RES, V140, P237, DOI 10.1016/j.jss.2007.03.014; DUNCAN DA, 1988, J SURG RES, V45, P44, DOI 10.1016/0022-4804(88)90019-4; Edwards GA, 1997, J BIOMED MATER RES, V34, P291; GALLO JI, 1978, ANN THORAC SURG, V26, P149, DOI 10.1016/S0003-4975(10)63658-2; Hong JH, 2011, J SURG RES, V166, P206, DOI 10.1016/j.jss.2010.09.034; Kaushal S, 2011, J THORAC CARDIOV SUR, V141, P789, DOI 10.1016/j.jtcvs.2010.11.043; Lassaletta AD, 2012, J THORAC CARDIOV SUR, V143, P953, DOI 10.1016/j.jtcvs.2011.12.016; LEACH RE, 1990, AM J OBSTET GYNECOL, V162, P1317, DOI 10.1016/0002-9378(90)90044-8; MEUS PJ, 1983, J THORAC CARDIOV SUR, V85, P54; MITCHELL JD, 1994, J THORAC CARDIOV SUR, V107, P1481, DOI 10.1016/S0022-5223(12)70149-6; Naito Y, 2008, J THORAC CARDIOV SUR, V135, P850, DOI 10.1016/j.jtcvs.2007.10.062; Oh SH, 2005, J BIOMED MATER RES A, V72A, P306, DOI 10.1002/jbm.a.30239; Orhan A, 2014, HEART LUNG CIRC, V23, P357, DOI 10.1016/j.hlc.2013.10.080; Park JS, 2011, J SURG RES, V168, P49, DOI 10.1016/j.jss.2009.09.025; Park SO, 2013, AESTHET PLAST SURG, V37, P543, DOI 10.1007/s00266-013-0087-3; REVUELTA JM, 1985, J THORAC CARDIOV SUR, V89, P451; Saeidi Mahmood, 2009, Interact Cardiovasc Thorac Surg, V9, P26, DOI 10.1510/icvts.2009.204669; SEIFER DB, 1990, J GYNECOL SURG, V6, P3, DOI 10.1089/gyn.1990.6.3; Shen J, 2014, ARTIF ORGANS, V38, P224, DOI 10.1111/aor.12140; Sohn EJ, 2013, OPHTHAL PLAST RECONS, V29, P458, DOI 10.1097/IOP.0b013e3182a22bae; Vlahos A, 2001, AM SURGEON, V67, P15	24	12	12	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2015	10	11							e0143359	10.1371/journal.pone.0143359	http://dx.doi.org/10.1371/journal.pone.0143359			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW7CD	26580394	Green Published, Green Submitted, gold			2023-01-03	WOS:000365154600116
J	Wang, R; Chen, L; Fan, L; Gao, DW; Liang, ZR; He, J; Gong, WQ; Gao, LG				Wang, Rong; Chen, Lei; Fan, Li; Gao, Dewei; Liang, Zhiru; He, Jing; Gong, Weiqin; Gao, Linggen			Incidence and Effects of Polypharmacy on Clinical Outcome among Patients Aged 80(+): A Five-Year Follow-Up Study	PLOS ONE			English	Article							ADVERSE DRUG EVENTS; OLDER-ADULTS; POTENTIALLY INAPPROPRIATE; ELDERLY-PATIENTS; MEDICATION USE; HIP FRACTURE; RISK-FACTOR; FALL-RISK; MORTALITY; FRAILTY	Objectives Polypharmacy is a problem of growing interest in geriatrics with the increase in drug consumption in recent years, is defined according to the WHO criteria as the, "concurrent use of five or more different prescription medication". We investigated the clinical characteristics of polypharmacy and identified the effects of polypharmacy on clinical outcome among patients aged 80+ admitted to Chinese PLA general hospital. Methods Older men aged >= 80 years (n = 1562) were included in this study. The included participants attended a structured clinical examination and an interview carried out by a geriatrician and trained nurses. A follow-up survey in 2014 was carried out on survivors in the same way as in 2009. The clinical outcome measured were adverse drug reactions, falls, frailty, disability, cognitive impairment, mortality. The association between polypharmacy and clinical outcome was assessed by logistic regression. Results The mean (range) age of the included participants was 85.2 (80-104) years. Medication exposure was reported by 100% of the population. Mean number of medications reported in this population was 9.56 +/- 5.68. The prevalence of polypharmacy (>= 6 medications) in the present study was 70%. At the time of the follow-up survey, an increase in the number of taken medicines had occurred among half of the survivors. The risk of different outcomes in relation to number of medications rises significantly, the odds ratios were 1.21 (95% confidence interval [CI] 1.17-1.28) for adverse drug reactions, 1.18 (95% CI 1.10-1.26) for falls, 1.16 (95% CI 1.09-1.24) for disability, and 1.19 (95% CI 1.12-1.23) for mortality. There was no association between increasing number of medications and cognitive impairment. Conclusions Our study demonstrates that polypharmacy is very common in the very old patients, and observed that number of medications was a factor associated with difference clinical outcome independently of the age, type of medications prescribed and accompanied comorbidities.	[Wang, Rong; Gao, Dewei; Liang, Zhiru; He, Jing; Gong, Weiqin; Gao, Linggen] Gen Hosp Chinese Peoples Liberat Army, Dept Comprehens Surg, Beijing, Peoples R China; [Chen, Lei] Gen Hosp Chinese Peoples Liberat Army, Dept Thorac Surg, Beijing, Peoples R China; [Fan, Li] Gen Hosp Chinese Peoples Liberat Army, Dept Geriatr Cardiol, Beijing, Peoples R China		Fan, L (corresponding author), Gen Hosp Chinese Peoples Liberat Army, Dept Geriatr Cardiol, Beijing, Peoples R China.	fanlighcpl@gmail.com; gaodeweigdw@163.com			China Postdoctoral Science Foundation [2012T50865]; Military Healthcare Fund [12BJZ39]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Military Healthcare Fund	This work was supported by a general financial grant from the China Postdoctoral Science Foundation (2012T50865, to L.Gao.) and a grant from the Military Healthcare Fund 12BJZ39 (to L. Fan).	Aparasu RR, 2000, ANN PHARMACOTHER, V34, P338, DOI 10.1345/aph.19006; Bergman H, 2007, J GERONTOL A-BIOL, V62, P731, DOI 10.1093/gerona/62.7.731; Bourgeois FT, 2010, PHARMACOEPIDEM DR S, V19, P901, DOI 10.1002/pds.1984; Caselli G., 2002, GENUS, V58, P9; Damian J, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-6; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Espino DV, 2006, J GERONTOL A-BIOL, V61, P170, DOI 10.1093/gerona/61.2.170; Fialova D, 2005, JAMA-J AM MED ASSOC, V293, P1348, DOI 10.1001/jama.293.11.1348; Field TS, 2004, J AM GERIATR SOC, V52, P1349, DOI 10.1111/j.1532-5415.2004.52367.x; Fletcher Paula C, 2009, J Patient Saf, V5, P61, DOI 10.1097/PTS.0b013e3181a551ed; Frazier Susan C, 2005, J Gerontol Nurs, V31, P4; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Fulton Maryann M, 2005, J Am Acad Nurse Pract, V17, P123, DOI 10.1111/j.1041-2972.2005.0020.x; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Haider SI, 2007, INT J CLIN PHARM TH, V45, P643; Haleem S, 2008, INJURY, V39, P1157, DOI 10.1016/j.injury.2008.03.022; Harper K, 2010, INT J ENV RES PUB HE, V7, P675, DOI 10.3390/ijerph7020675; Hilmer SN, 2009, CLIN PHARMACOL THER, V85, P86, DOI 10.1038/clpt.2008.224; Hilmer SN, 2012, J GERONTOL A-BIOL, V67, P181, DOI 10.1093/gerona/glr066; Jyrkka J, 2009, DRUG AGING, V26, P493, DOI 10.2165/00002512-200926060-00006; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; Kojima T, 2011, GERIATR GERONTOL INT, V11, P438, DOI 10.1111/j.1447-0594.2011.00703.x; Lai SW, 2010, MEDICINE, V89, P295, DOI 10.1097/MD.0b013e3181f15efc; Lau DT, 2005, ARCH INTERN MED, V165, P68, DOI 10.1001/archinte.165.1.68; Lee CY, 2011, NEUROUROL URODYNAM, V30, P1286, DOI 10.1002/nau.21044; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Mansur N, 2008, ANN PHARMACOTHER, V42, P783, DOI 10.1345/aph.1L070; Pozzi C, 2010, PHARMACOEPIDEM DR S, V19, P954, DOI 10.1002/pds.1997; Schafer I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015941; Tromp AM, 2001, J CLIN EPIDEMIOL, V54, P837, DOI 10.1016/S0895-4356(01)00349-3; United Nations, 2002, WORLD POP AG; US General Accounting Office, 1995, PUBL GAO HEHS; Ziere G, 2006, BRIT J CLIN PHARMACO, V61, P218, DOI 10.1111/j.1365-2125.2005.02543.x	34	46	46	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2015	10	11							e0142123	10.1371/journal.pone.0142123	http://dx.doi.org/10.1371/journal.pone.0142123			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV7CT	26554710	Green Published, gold, Green Submitted			2023-01-03	WOS:000364430700056
J	White, SR; Bird, SM; Merrall, ELC; Hutchinson, SJ				White, Simon R.; Bird, Sheila M.; Merrall, Elizabeth L. C.; Hutchinson, Sharon J.			Drugs-Related Death Soon after Hospital-Discharge among Drug Treatment Clients in Scotland: Record Linkage, Validation, and Investigation of Risk-Factors	PLOS ONE			English	Article							MORTALITY; SUICIDE; INFECTION; DIAGNOSIS; PRISONERS; OVERDOSE; NALOXONE; RELEASE	We validate that the 28 days after hospital-discharge are high-risk for drugs-related death (DRD) among drug users in Scotland and investigate key risk-factors for DRDs soon after hospital-discharge. Using data from an anonymous linkage of hospitalisation and death records to the Scottish Drugs Misuse Database (SDMD), including over 98,000 individuals registered for drug treatment during 1 April 1996 to 31 March 2010 with 705,538 person-years, 173,107 hospital-stays, and 2,523 DRDs. Time-at-risk of DRD was categorised as: during hospitalization, within 28 days, 29-90 days, 91 days-1 year, >1 year since most recent hospital discharge versus 'never admitted'. Factors of interest were: having ever injected, misuse of alcohol, length of hospital-stay (0-1 versus 2+ days), and main discharge-diagnosis. We confirm SDMD clients' high DRD-rate soon after hospital-discharge in 2006-2010. DRD-rate in the 28 days after hospital-discharge did not vary by length of hospital-stay but was significantly higher for clients who had ever-injected versus otherwise. Three leading discharge-diagnoses accounted for only 150/290 DRDs in the 28 days after hospital-discharge, but ever-injectors for 222/290. Hospital-discharge remains a period of increased DRD-vulnerability in 2006-2010, as in 1996-2006, especially for those with a history of injecting.	[White, Simon R.; Bird, Sheila M.] Cambridge Inst Publ Hlth, Med Res Council Biostat Unit, Cambridge, England; [Merrall, Elizabeth L. C.] Novartis Vaccines & Diagnost, Novartis Pharam BV, NL-1101 CL Amsterdam, Netherlands; [Hutchinson, Sharon J.] Hlth Protect Scotland, Glasgow G3 7LN, Lanark, Scotland	MRC Biostatistics Unit; University of Cambridge; Novartis	White, SR (corresponding author), Cambridge Inst Publ Hlth, Med Res Council Biostat Unit, Cambridge, England.	Simon.White@mrc-bsu.cam.ac.uk	Hutchinson, Sharon/Y-3949-2019	Hutchinson, Sharon/0000-0002-6891-6758; White, Simon/0000-0001-8642-7037	Medical Research Council [MC_US_A030_0007 / 01]; Chief Scientist Office of the Scottish Executive; MRC [MC_U105260794, MC_U105292687] Funding Source: UKRI; Medical Research Council [MC_U105292687, MC_U105260794] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Chief Scientist Office of the Scottish Executive; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was funded by the Medical Research Council (reference: MC_US_A030_0007 / 01). The data for this work were made available as a result of research funded by a grant from the Chief Scientist Office of the Scottish Executive. No sponsor had any role in the study design, data collection, data analysis, data interpretation, or writing of the report.; The authors are grateful to Information Services Division for provision of the linked data. The data for this work were made available as a result of research funded by a grant from the Chief Scientist Office of the Scottish Executive.	Amin J, 2006, LANCET, V368, P938, DOI 10.1016/S0140-6736(06)69374-4; Cornish R, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5475; COX DR, 1972, J R STAT SOC B, V34, P187; Davoli M, 2007, ADDICTION, V102, P1954, DOI 10.1111/j.1360-0443.2007.02025.x; Degenhardt L, 2009, DRUG ALCOHOL DEPEN, V105, P9, DOI 10.1016/j.drugalcdep.2009.05.021; Hall W, 2010, ADDICTION, V105, P1332, DOI 10.1111/j.1360-0443.2010.02919.x; Hunt IM, 2009, PSYCHOL MED, V39, P443, DOI 10.1017/S0033291708003644; Information Services Division, 2009, IMP CHANG WE PRES OU; Information Services Division, 2014, NAT NAL PROGR SCOTL; Jackson G. W. L., 2001, 5 GEN REG OFF SCOTL; Kariminia A, 2007, INT J EPIDEMIOL, V36, P310, DOI 10.1093/ije/dyl225; Kariminia A, 2007, MED J AUSTRALIA, V187, P387, DOI 10.5694/j.1326-5377.2007.tb01307.x; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; McAuley A, 2012, DRUG-EDUC PREV POLIC, V19, P309, DOI 10.3109/09687637.2012.682232; McDonald SA, 2010, EPIDEMIOL INFECT, V138, P393, DOI 10.1017/S0950268809990616; McDonald SA, 2009, STAT METHODS MED RES, V18, P271, DOI 10.1177/0962280208094690; Merrall E. L. C., 2012, THESIS U CAMBRIDGE; Merrall E, 2013, ADDICT RES THEORY, V21, P52, DOI 10.3109/16066359.2012.690052; Merrall ELC, 2012, INT J DRUG POLICY, V23, P24, DOI 10.1016/j.drugpo.2011.05.010; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Merralll ELC, 2013, ADDICTION, V108, P377, DOI 10.1111/j.1360-0443.2012.04066.x; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Rome A., 2008, REDUCING DRUG USERS; Strang J, 2013, J URBAN HEALTH, V90, P983, DOI 10.1007/s11524-013-9803-1; Workshop C, 2010, ADDICT RES THEORY, V18, P194, DOI 10.3109/16066350902825948	25	23	23	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2015	10	11							e0141073	10.1371/journal.pone.0141073	http://dx.doi.org/10.1371/journal.pone.0141073			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV5IS	26539701	gold, Green Published, Green Submitted			2023-01-03	WOS:000364303800009
J	Dorner, SC; Jacobs, DB; Sommers, BD				Dorner, Stephen C.; Jacobs, Douglas B.; Sommers, Benjamin D.			Adequacy of Outpatient Specialty Care Access in Marketplace Plans Under the Affordable Care Act	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Dorner, Stephen C.; Jacobs, Douglas B.; Sommers, Benjamin D.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Dorner, SC (corresponding author), Harvard Univ, TH Chan Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA.	stephen.dorner@post.harvard.edu						Centers for Disease Control and Prevention, NAT AMB MED CAR SURV; Haeder SF, 2015, HEALTH AFFAIR, V34, P741, DOI 10.1377/hlthaff.2014.1406; Jacobs DB, 2015, NEW ENGL J MED, V372, P399, DOI 10.1056/NEJMp1411376; Resneck JS, 2014, JAMA DERMATOL, V150, P1290, DOI 10.1001/jamadermatol.2014.3902; US Department of Health and Human Services, HLTH INS MARK 2015 O	5	45	45	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2015	314	16					1749	1750		10.1001/jama.2015.9375	http://dx.doi.org/10.1001/jama.2015.9375			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CU7HC	26505601	Green Published, Bronze			2023-01-03	WOS:000363706300026
J	Benson, EA; Skaar, TC; Liu, YL; Nephew, KP; Matei, D				Benson, Eric A.; Skaar, Todd C.; Liu, Yunlong; Nephew, Kenneth P.; Matei, Daniela			Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study	PLOS ONE			English	Article							MICRORNAS; EXPRESSION; BLOOD; PATHOGENESIS; CARCINOMA	Objective Plasma miRNAs represent potential minimally invasive biomarkers to monitor and predict outcomes from chemotherapy. The primary goal of the current study-consisting of patients with recurrent, platinum-resistant ovarian cancer-was to identify the changes in circulating miRNA concentrations associated with decitabine followed by carboplatin chemotherapy treatment. A secondary goal was to associate clinical response with changes in circulating miRNA concentration. Methods We measured miRNA concentrations in plasma samples from 14 patients with platinum-resistant, recurrent ovarian cancer enrolled in a phase II clinical trial that were treated with a low dose of the hypomethylating agent (HMA) decitabine for 5 days followed by carboplatin on day 8. The primary endpoint was to determine chemotherapy-associated changes in plasma miRNA concentrations. The secondary endpoint was to correlate miRNA changes with clinical response as measured by progression free survival (PFS). Results Seventy-eight miRNA plasma concentrations were measured at baseline (before treatment) and at the end of the first cycle of treatment (day 29). Of these, 10 miRNAs (miR-193a-5p, miR-375, miR-339-3p, miR-340-5p, miR-532-3p, miR-133a-3p, miR-25-3p, miR-10a-5p, miR-616-5p, and miR-148b-5p) displayed fold changes in concentration ranging from -2.9 to 4 (p < 0.05), in recurrent platinum resistant ovarian cancer patients, that were associated with response to decitabine followed by carboplatin chemotherapy. Furthermore, lower concentrations of miR-148b-5p after this chemotherapy regimen were associated (P < 0.05) with the PFS. Conclusions This is the first report demonstrating altered circulating miRNA concentrations following a combination platinum plus HMA chemotherapy regiment. In addition, circulating miR-148b-5p concentrations were associated with PFS and may represent a novel biomarker of therapeutic response, with this chemotherapy regimen, in women with recurrent, drug-resistant ovarian cancer.	[Benson, Eric A.; Skaar, Todd C.; Matei, Daniela] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Benson, Eric A.; Skaar, Todd C.] Indiana Univ Sch Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA; [Benson, Eric A.; Matei, Daniela] Indiana Univ Sch Med, VA Roudebush Hosp, Indianapolis, IN 46202 USA; [Liu, Yunlong] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Liu, Yunlong] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA; [Nephew, Kenneth P.] Indiana Univ Sch Med, Dept Cellular Physiol, Indianapolis, IN 46202 USA; [Nephew, Kenneth P.] Indiana Univ Sch Med, Dept Integrat Physiol, Indianapolis, IN 46202 USA; [Nephew, Kenneth P.; Matei, Daniela] Indiana Univ Sch Med, Dept Obstet & Gynecol, Med Sci Program, Indianapolis, IN 46202 USA; [Nephew, Kenneth P.; Matei, Daniela] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA; [Matei, Daniela] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington	Benson, EA (corresponding author), Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.	eabenson@iu.edu	Skaar, Todd/ABD-7827-2021	Benson, Eric/0000-0002-3111-9464; Matei, Daniela/0000-0003-2169-5035	National Cancer Institute [CA133877-01, NCI-CA182832]; National Institute of General Medical Sciences [5T32GM008425-19]; Indiana University Simon Cancer Center Cancer Center [P30 CA082709-15]; NATIONAL CANCER INSTITUTE [R21CA133877, P30CA082709, R01CA182832] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001108, UL1TR002529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008425, R01GM088076] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Indiana University Simon Cancer Center Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was partly funded by the National Cancer Institute Award CA133877-01 (DM), NCI-CA182832 (DM & KPN), National Institute of General Medical Sciences 5T32GM008425-19 (EAB), and the Indiana University Simon Cancer Center Cancer Center Support Grant P30 CA082709-15 supporting the Bioinformatics core. The authors thank Eisai Co., Ltd. (Tokyo, Japan) for providing decitabine, Mrs. Amber Allen, Carol Kulesavage, Nancy Menning, and Jessica Roy for coordination of clinical trial activities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Benson EA, 2013, DRUG METAB DISPOS, V41, P1778, DOI 10.1124/dmd.113.052357; Chang H, 2012, MOL MED REP, V5, P1277, DOI 10.3892/mmr.2012.794; Chen X, 2012, PROTEIN CELL, V3, P28, DOI 10.1007/s13238-012-2003-z; Creighton CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034546; Eitan R, 2009, GYNECOL ONCOL, V114, P253, DOI 10.1016/j.ygyno.2009.04.024; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Frederick PJ, 2013, BIOTECH HISTOCHEM, V88, P403, DOI 10.3109/10520295.2013.788736; Gezer U, 2014, ONCOL LETT, V8, P845, DOI 10.3892/ol.2014.2188; Gu YY, 2015, ONCOTARGET, V6, P2397, DOI 10.18632/oncotarget.2963; Karst AM, 2010, J ONCOL, V2010, DOI 10.1155/2010/932371; Kjersem JB, 2014, MOL ONCOL, V8, P59, DOI 10.1016/j.molonc.2013.09.001; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909; Mezzanzanica D, 2010, INT J BIOCHEM CELL B, V42, P1262, DOI 10.1016/j.biocel.2009.12.017; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Muller V, 2014, BREAST CANCER RES TR, V147, P61, DOI 10.1007/s10549-014-3079-3; Nakano H, 2013, INT J ONCOL, V42, P1875, DOI 10.3892/ijo.2013.1896; Plumb JA, 2000, CANCER RES, V60, P6039; Schorge JO, 2010, GYNECOL ONCOL, V119, P7, DOI 10.1016/j.ygyno.2010.06.003; Triozzi PL, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-241; Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa; Wen Z, 2015, MOL MED REPORTS; Xiang Y, 2014, ONCOGENE, V33, P378, DOI 10.1038/onc.2012.575; Zhao HM, 2015, TUMOUR BIOL; Zhao S, 2015, MOL MED REPORTS; Zhao YN, 2014, EXP HEMATOL ONCOL, V3, DOI 10.1186/2162-3619-3-14; Zheng H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077853; Zhou X, 2012, ONCOL REP, V27, P447, DOI 10.3892/or.2011.1482	29	45	48	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2015	10	10							e0141279	10.1371/journal.pone.0141279	http://dx.doi.org/10.1371/journal.pone.0141279			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT7XI	26485143	gold, Green Published			2023-01-03	WOS:000363028100129
J	Bahcall, O				Bahcall, Orli			Precision Medicine	NATURE			English	Editorial Material														Bahcall, Orli/0000-0002-2891-1637					0	35	36	5	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 15	2015	526	7573					335	335		10.1038/526335a	http://dx.doi.org/10.1038/526335a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT3TQ	26469043	Bronze			2023-01-03	WOS:000362730200035
J	Geller, AI; Shehab, N; Weidle, NJ; Lovegrove, MC; Wolpert, BJ; Timbo, BB; Mozersky, RP; Budnitz, DS				Geller, Andrew I.; Shehab, Nadine; Weidle, Nina J.; Lovegrove, Maribeth C.; Wolpert, Beverly J.; Timbo, Babgaleh B.; Mozersky, Robert P.; Budnitz, Daniel S.			Emergency Department Visits for Adverse Events Related to Dietary Supplements	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HERBAL MEDICINES; SURVEILLANCE; MEDICATIONS	BACKGROUND Dietary supplements, such as herbal or complementary nutritional products and micronutrients (vitamins and minerals), are commonly used in the United States, yet national data on adverse effects are limited. METHODS We used nationally representative surveillance data from 63 emergency departments obtained from 2004 through 2013 to describe visits to U.S. emergency departments because of adverse events related to dietary supplements. RESULTS On the basis of 3667 cases, we estimated that 23,005 (95% confidence interval [CI], 18,611 to 27,398) emergency department visits per year were attributed to adverse events related to dietary supplements. These visits resulted in an estimated 2154 hospitalizations (95% CI, 1342 to 2967) annually. Such visits frequently involved young adults between the ages of 20 and 34 years (28.0% of visits; 95% CI, 25.1 to 30.8) and unsupervised children (21.2% of visits; 95% CI, 18.4 to 24.0). After the exclusion of unsupervised ingestion of dietary supplements by children, 65.9% (95% CI, 63.2 to 68.5) of emergency department visits for single-supplement-related adverse events involved herbal or complementary nutritional products; 31.8% (95% CI, 29.2 to 34.3) involved micronutrients. Herbal or complementary nutritional products for weight loss (25.5%; 95% CI, 23.1 to 27.9) and increased energy (10.0%; 95% CI, 8.0 to 11.9) were commonly implicated. Weight-loss or energy products caused 71.8% (95% CI, 67.6 to 76.1) of supplement-related adverse events involving palpitations, chest pain, or tachycardia, and 58.0% (95% CI, 52.2 to 63.7) involved persons 20 to 34 years of age. Among adults 65 years of age or older, choking or pill-induced dysphagia or globus caused 37.6% (95% CI, 29.1 to 46.2) of all emergency department visits for supplement-related adverse events; micronutrients were implicated in 83.1% (95% CI, 73.3 to 92.9) of these visits. CONCLUSIONS An estimated 23,000 emergency department visits in the United States every year are attributed to adverse events related to dietary supplements. Such visits commonly involve cardiovascular manifestations from weight-loss or energy products among young adults and swallowing problems, often associated with micronutrients, among older adults.	[Geller, Andrew I.; Shehab, Nadine; Lovegrove, Maribeth C.; Budnitz, Daniel S.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA; [Weidle, Nina J.] Chenega Govt Consulting, Atlanta, GA USA; [Wolpert, Beverly J.; Timbo, Babgaleh B.] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA; [Wolpert, Beverly J.; Timbo, Babgaleh B.] US FDA, Div Publ Hlth Informat & Analyt, College Pk, MD USA; [Mozersky, Robert P.] US FDA, Div Dietary Supplement Programs, College Pk, MD USA	Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Geller, AI (corresponding author), CDC, Div Healthcare Qual Promot, 1825 Century Blvd NE,Mailstop D-26, Atlanta, GA 30345 USA.	ageller@cdc.gov		Budnitz, Daniel/0000-0002-0136-2623; Shehab, Nadine/0000-0001-8700-8539	Department of Health and Human Services	Department of Health and Human Services	Funded by the Department of Health and Human Services.	Ang-Lee MK, 2001, JAMA-J AM MED ASSOC, V286, P208, DOI 10.1001/jama.286.2.208; [Anonymous], 2008, SENT IN NAT STRAT MO; [Anonymous], 2001, ADV EV REP DIET SUPP; [Anonymous], 2015, SIZ SHAP OTH PHYS AT; Bailey RL, 2013, JAMA INTERN MED, V173, P355, DOI 10.1001/jamainternmed.2013.2299; Bailey RL, 2011, J NUTR, V141, P261, DOI 10.3945/jn.110.133025; Budnitz DS, 2006, JAMA-J AM MED ASSOC, V296, P1858, DOI 10.1001/jama.296.15.1858; Budnitz DS, 2011, PEDIATRICS, V127, pE1597, DOI 10.1542/peds.2011-0926; Centers for Disease Control and Prevention, 2010, DIST PUBL HLTH NONR; Cohen AL, 2006, NEW ENGL J MED, V354, P2294, DOI 10.1056/NEJMc060860; Cohen PA, 2014, JAMA-J AM MED ASSOC, V312, P1691, DOI 10.1001/jama.2014.10308; Cohen PA, 2014, NEW ENGL J MED, V370, P1277, DOI 10.1056/NEJMp1315559; Commission on Dietary Supplement Labels, 1997, REP COMM DIET SUPPL; Denham BE, 2011, JAMA-J AM MED ASSOC, V306, P428, DOI 10.1001/jama.2011.982; Dennehy CE, 2005, AM J HEALTH-SYST PH, V62, P1476, DOI 10.2146/ajhp040412; Department of Health and Human Services, 2014, NEW DIET INGR DIET S; Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics, 2012, 2011 2012 NAT HLTH N; Department of Health and Human Services Food and Drug Administration, 2008 HLTH DIET SURV; Gardiner P, 2008, PHARMACOEPIDEM DR S, V17, P962, DOI 10.1002/pds.1627; Gardiner P, 2015, PATIENT EDUC COUNS, V98, P512, DOI 10.1016/j.pec.2014.12.010; Gardiner Paula, 2013, Glob Adv Health Med, V2, P46, DOI 10.7453/gahmj.2012.071; Gardiner Paula, 2007, BMC Complement Altern Med, V7, P39, DOI 10.1186/1472-6882-7-39; Government Accountability Office, 2013, DIET SUPPL FDA MAY H; Haller CA, 2008, J MED TOXICOL, V4, P84, DOI 10.1007/BF03160960; Harel Z, 2013, JAMA INTERN MED, V173, P926, DOI 10.1001/jamainternmed.2013.379; Hensrud DD, 1999, MAYO CLIN PROC, V74, P443; Iovate Health Sciences International, HYDR WEIGHT LOSS PRO; Jhung MA, 2007, MED CARE, V45, pS96, DOI 10.1097/MLR.0b013e318041f737; Kaye AD, 2000, J CLIN ANESTH, V12, P468, DOI 10.1016/S0952-8180(00)00195-1; Nahin Richard L, 2009, Natl Health Stat Report, P1; Starr RR, 2015, AM J PUBLIC HEALTH, V105, P478, DOI 10.2105/AJPH.2014.302348; Timbo BB, 2006, J AM DIET ASSOC, V106, P1966, DOI 10.1016/j.jada.2006.09.002	32	249	251	3	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	2015	373	16					1531	1540		10.1056/NEJMsa1504267	http://dx.doi.org/10.1056/NEJMsa1504267			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT5VX	26465986	Green Accepted, Bronze			2023-01-03	WOS:000362880300009
J	Lanhers, C; Duclos, M; Guttmann, A; Coudeyre, E; Pereira, B; Ouchchane, L				Lanhers, Charlotte; Duclos, Martine; Guttmann, Aline; Coudeyre, Emmanuel; Pereira, Bruno; Ouchchane, Lemlih			General Practitioners' Barriers to Prescribe Physical Activity: The Dark Side of the Cluster Effects on the Physical Activity of Their Type 2 Diabetes Patients	PLOS ONE			English	Article							PRIMARY-CARE; EXERCISE; INTERVENTION; VALIDATION; QUALITY; GPS	Aims/hypothesis To describe barriers to physical activity (PA) in type 2 diabetes patients and their general practitioners (GPs), looking for practitioner's influence on PA practice of their patients. Methods We conducted a cross-sectional study on GPs (n = 48) and their type 2 diabetes patients (n = 369) measuring respectively barriers to prescribe and practice PA using a self-assessment questionnaire: barriers to physical activity in diabetes (BAPAD). Statistical analysis was performed accounting hierarchical data structure. Similar practitioner's patients were considered a cluster sharing common patterns. Results The higher the patient's BAPAD score, the higher the barriers to PA, the higher the risk to declare practicing no PA (p<0.001), low frequency and low duration of PA (p<0.001). A high patient's BAPAD score was also associated with a higher risk to have HbA(1c) >= 7% (53 mmol/mol) (p = 0.001). The intra-class correlation coefficient between type 2 diabetes patients and GPs was 34%, indicating a high cluster effect. A high GP's BAPAD score, regarding the PA prescription, is predictive of a high BAPAD score with their patients, regarding their practice (p = 0.03). Conclusion/interpretation Type 2 diabetes patients with lower BAPAD score, thus lower barriers to physical activity, have a higher PA level and a better glycemic control. An important and deleterious cluster effect between GPs and their patients is demonstrated: the higher the GP's BAPAD score, the higher the type 2 diabetes patients' BAPAD score. This important cluster effect might designate GPs as a relevant lever for future interventions regarding patient's education towards PA and type 2 diabetes management.	[Lanhers, Charlotte; Duclos, Martine] Clermont Ferrand Univ Hosp CHU, Dept Sport Med & Funct Explorat, F-63001 Clermont Ferrand 1, France; [Duclos, Martine] INRA, UMR 1019, Human Nutr Lab, Clermont Ferrand, France; [Guttmann, Aline; Ouchchane, Lemlih] Clermont Ferrand Univ Hosp, Dept Publ Hlth, Biostat Unit, Clermont Ferrand, France; [Guttmann, Aline; Pereira, Bruno; Ouchchane, Lemlih] Auvergne Univ, Lab Image Sci Intervent Tech, CNRS, UMR 6284,ISIT,UdA, F-63001 Clermont Ferrand, France; [Lanhers, Charlotte; Duclos, Martine; Coudeyre, Emmanuel] Univ Auvergne, Clermont Univ, Clermont Ferrand, France; [Coudeyre, Emmanuel] Clermont Ferrand Univ Hosp, Dept Phys Med & Rehabil, Clermont Ferrand, France; [Pereira, Bruno] Clermont Ferrand Univ Hosp, Innovat & Clin Res, Clermont Ferrand, France	CHU Clermont Ferrand; INRAE; CHU Clermont Ferrand; Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); Universite Clermont Auvergne (UCA); CHU Clermont Ferrand; CHU Clermont Ferrand	Lanhers, C (corresponding author), Clermont Ferrand Univ Hosp CHU, Dept Sport Med & Funct Explorat, BP 68, F-63001 Clermont Ferrand 1, France.	lanhers.charlotte@gmail.com	Duclos, Martine/AAI-5684-2020; Guttmann, Aline/G-1879-2014	Pereira, Bruno/0000-0003-3778-7161; Guttmann, Aline/0000-0003-0162-837X				Allison KR, 1999, PREV MED, V28, P608, DOI 10.1006/pmed.1999.0489; [Anonymous], 2015, DIABETES CARE, V38; Campbell Marion K, 2004, BMC Med Res Methodol, V4, P9, DOI 10.1186/1471-2288-4-9; Colberg SR, 2010, MED SCI SPORT EXER, V42, P2282, DOI 10.1249/MSS.0b013e3181eeb61c; Di Loreto C, 2003, DIABETES CARE, V26, P404, DOI 10.2337/diacare.26.2.404; Dube MC, 2006, DIABETES RES CLIN PR, V72, P20, DOI 10.1016/j.diabres.2005.08.008; Duclos Martine, 2011, Diabetes Care, V34, pe122, DOI 10.2337/dc11-0140; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Hays LM, 1999, DIABETES CARE, V22, P706, DOI 10.2337/diacare.22.5.706; Kim C, 2005, DIABETES CARE, V28, P1594, DOI 10.2337/diacare.28.7.1594; Kinmonth AL, 2008, LANCET, V371, P41, DOI 10.1016/S0140-6736(08)60070-7; Kraus WE, 2002, NEW ENGL J MED, V347, P1483, DOI [DOI 10.1056/NEJMOA020194, 10.1056/NEJMoa020194, DOI 10.1056/NEJMoa020194]; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; Pate RR, 2005, AM J PUBLIC HEALTH, V95, P1582, DOI 10.2105/AJPH.2004.045807; Roter DL, 2002, JAMA-J AM MED ASSOC, V288, P756, DOI 10.1001/jama.288.6.756; Shojaee-Moradie F, 2007, DIABETOLOGIA, V50, P404, DOI 10.1007/s00125-006-0498-7; Snowling NJ, 2006, DIABETES CARE, V29, P2518, DOI 10.2337/dc06-1317; Supper I, 2011, FAM PRACT, V28, P226, DOI 10.1093/fampra/cmq073; Tabenkin H, 2010, ANN FAM MED, V8, P25, DOI 10.1370/afm.1071; Tan MY, 2004, DIABETES RES CLIN PR, V66, P71, DOI 10.1016/j.diabres.2004.02.021; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Williamson MK, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-42	22	16	16	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2015	10	10							e0140429	10.1371/journal.pone.0140429	http://dx.doi.org/10.1371/journal.pone.0140429			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0CX	26468874	Green Published, Green Submitted, gold			2023-01-03	WOS:000363184600060
J	Marchant, J				Marchant, Jo			Consider all the evidence on alternative therapies	NATURE			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL					jomarchant26@yahoo.co.uk						Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55	2	2	2	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 15	2015	526	7573					295	295		10.1038/526295a	http://dx.doi.org/10.1038/526295a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CT3TQ	26469005	Bronze			2023-01-03	WOS:000362730200004
J	Choi, W; Kim, JC; Kim, WS; Oh, HJ; Yang, JM; Lee, JB; Yoon, KC				Choi, Won; Kim, Jae Chan; Kim, Won Soo; Oh, Han Jin; Yang, Jee Myung; Lee, Jee Bum; Yoon, Kyung Chul			Clinical Effect of Antioxidant Glasses Containing Extracts of Medicinal Plants in Patients with Dry Eye Disease: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial	PLOS ONE			English	Article							CORNEAL EPITHELIAL-CELLS; OXIDATIVE STRESS; GREEN	Purpose To investigate the clinical efficacy and safety of wearable antioxidant glasses containing extracts of medicinal plants in patients with mild dry eye disease (DED). Methods Fifty patients with mild DED were randomly assigned to wear either extracts of antioxidant medicinal plants containing (N = 25) or placebo glasses (N = 25). Patients wore the glasses for 15 min three times daily. The ocular surface disease index (OSDI) score, tear film break up time (BUT), and Schirmer's test were evaluated and compared within the group and between the groups at baseline, 4 weeks, and 8 weeks after treatment. Results OSDI score and tear film BUT were significantly improved in the treatment group at 4 and 8 weeks after wearing glasses (all P < 0.001). Compared to the placebo group, the OSDI scores were significantly lower in the treatment group at 8 weeks (P = 0.007). The results of the Schirmer's test showed significant improvement in the treatment group at 4 weeks (P = 0.035), however there were no significant differences between the other groups or within the groups. No adverse events were reported during the study. Conclusions Antioxidant glasses containing extracts of medicinal plants were effective in improving in DED both subjectively and objectively. Wearing antioxidants glasses might be a safe and adjunctive therapeutic option for DED.	[Choi, Won; Oh, Han Jin; Yang, Jee Myung; Yoon, Kyung Chul] Chonnam Natl Univ, Med Sch & Hosp, Dept Ophthalmol, Gwangju, South Korea; [Kim, Jae Chan; Kim, Won Soo] Chung Ang Univ, Coll Med, Chung Ang Univ Hosp, Dept Ophthalmol, Seoul 156756, South Korea; [Lee, Jee Bum] Chonnam Natl Univ, Med Sch & Hosp, Dept Dermatol, Gwangju, South Korea	Chonnam National University; Chung Ang University; Chung Ang University Hospital; Chonnam National University	Lee, JB (corresponding author), Chonnam Natl Univ, Med Sch & Hosp, Dept Dermatol, Gwangju, South Korea.	jbmlee@jnu.ac.kr; kcyoon@jnu.ac.kr		Yang, Jee Myung/0000-0001-5729-2233	Chonnam National University Hospital Biomedical Research Institute [CRI13906-22]	Chonnam National University Hospital Biomedical Research Institute	This study was supported by the Chonnam National University Hospital Biomedical Research Institute (CRI13906-22). BM Biotechnology (http://www.bmdoctor.com/?lang_type = en) provided the antioxidant glasses. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AUGUSTIN AJ, 1995, GRAEF ARCH CLIN EXP, V233, P694, DOI 10.1007/BF00164671; Blades KJ, 2001, EUR J CLIN NUTR, V55, P589, DOI 10.1038/sj.ejcn.1601186; Calonge M, 2001, SURV OPHTHALMOL, V45, pS227, DOI 10.1016/S0039-6257(00)00205-8; Cavet ME, 2011, MOL VIS, V17, P533; Dogru M, 2009, CORNEA, V28, pS70, DOI 10.1097/ICO.0b013e3181ae8689; Drouault-Holowacz S, 2009, EUR J OPHTHALMOL, V19, P337, DOI 10.1177/112067210901900302; Gayton JL, 2009, CLIN OPHTHALMOL, V3, P405; Higuchi A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009911; Jarvinen RL, 2011, CORNEA, V30, P1013, DOI 10.1097/ICO.0b013e3182035ad9; Jeon JH, 2010, J ALTERN COMPLEM MED, V16, P1291, DOI 10.1089/acm.2009.0537; Jeong IY, 2008, CHONNAM MED J, V44, P151; Kangari H, 2013, OPHTHALMOLOGY, V120, P2191, DOI 10.1016/j.ophtha.2013.04.006; Kim EC, 2009, AM J OPHTHALMOL, V147, P206, DOI 10.1016/j.ajo.2008.08.015; Lee JB, 2014, INVEST OPHTH VIS SCI, V55, P4119, DOI 10.1167/iovs.13-13441; Lee JE, 2014, BRIT J OPHTHALMOL, V98, P46, DOI 10.1136/bjophthalmol-2013-303742; Li ZR, 2014, CURR EYE RES, V39, P871, DOI 10.3109/02713683.2014.884595; Nakamura S, 2007, INVEST OPHTH VIS SCI, V48, P1552, DOI 10.1167/iovs.06-1027; Schiffman RM, 2000, ARCH OPHTHALMOL-CHIC, V118, P615, DOI 10.1001/archopht.118.5.615; Uchino Yuichi, 2012, Cornea, V31 Suppl 1, pS63, DOI 10.1097/ICO.0b013e31826a5de1; Wakamatsu TH, 2013, INVEST OPHTH VIS SCI, V54, P201, DOI 10.1167/iovs.12-10325; Yoon KC, 2006, CORNEA, V25, P268, DOI 10.1097/01.ico.0000183484.85636.b6; Yoon KC, 2011, CORNEA, V30, P972, DOI 10.1097/ICO.0b013e31820687dd	22	18	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2015	10	10							e0139761	10.1371/journal.pone.0139761	http://dx.doi.org/10.1371/journal.pone.0139761			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT6YZ	26457673	Green Submitted, Green Published, gold			2023-01-03	WOS:000362961100013
J	Choi, Y; Oh, DY; Kim, TY; Lee, KH; Han, SW; Im, SA; Kim, TY; Bang, YJ				Choi, Younak; Oh, Do-Youn; Kim, Tae-Yong; Lee, Kyung-Hun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue			Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index	PLOS ONE			English	Article							SARCOPENIC OBESITY; PREVALENCE; TOXICITY; CARE; TOMOGRAPHY; INFECTION; CACHEXIA; RECOVERY; SURVIVAL; MEN	Introduction Body composition has emerged as a prognostic factor in cancer patients. We investigated whether sarcopenia at diagnosis and loss of skeletal muscle during palliative chemotherapy were associated with survival in patients with pancreatic cancer. Methods We retrospectively reviewed the clinical outcomes of pancreatic cancer patients receiving palliative chemotherapy between 2003 and 2010. The cross-sectional area of skeletal muscle at L3 by computed tomography was analyzed with Rapidia 3D software. We defined sarcopenia as a skeletal muscle index (SMI)<42.2 cm(2)/m(2) (male) and <33.9 cm(2)/m(2) (female) using ROC curve. Results Among 484 patients, 103 (21.3%) patients were sarcopenic at diagnosis. Decrease in SMI during chemotherapy was observed in 156 (60.9%) male and 65 (40.6%) female patients. Decrease in body mass index (BMI) was observed in 149 patients (37.3%), with no gender difference. By multivariate analysis, sarcopenia (P<0.001), decreasedBMI and SMI during chemotherapy (P = 0.002, P = 0.004, respectively) were poor prognostic factors for overall survival (OS). While the OS of male patients was affected with sarcopenia (P<0.001) and decreased SMI (P = 0.001), the OS of female patients was influenced with overweight at diagnosis (P = 0.006), decreased BMI (P = 0.032) and decreased SMI (P = 0.014). Particularly, while the change of BMI during chemotherapy did not have impact on OS within the patients with maintained SMI (P = 0.750), decrease in SMI was associated with poor OS within the patients with maintained BMI (HR 1.502; P = 0.002). Conclusions Sarcopenia at diagnosis and depletion of skeletal muscle, independent of BMI change, during chemotherapy were poor prognostic factors in advanced pancreatic cancer.	[Choi, Younak; Oh, Do-Youn; Kim, Tae-Yong; Lee, Kyung-Hun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea; [Oh, Do-Youn; Kim, Tae-Yong; Lee, Kyung-Hun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Oh, DY (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.	ohdoyoun@snu.ac.kr	Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				Andreyev HJN, 1998, EUR J CANCER, V34, P503, DOI 10.1016/S0959-8049(97)10090-9; Antoun S, 2010, ANN ONCOL, V21, P1594, DOI 10.1093/annonc/mdp605; Aslani A, 2000, CANCER-AM CANCER SOC, V88, P796, DOI 10.1002/(SICI)1097-0142(20000215)88:4<796::AID-CNCR10>3.0.CO;2-P; Aversa Z, 2012, ANN SURG ONCOL, V19, P1350, DOI 10.1245/s10434-011-1720-5; Baumgartner RN, 1998, AM J EPIDEMIOL, V147, P755, DOI 10.1093/oxfordjournals.aje.a009520; Biolo G, 2005, INT J BIOCHEM CELL B, V37, P2169, DOI 10.1016/j.biocel.2005.05.001; Biolo G, 2014, CLIN NUTR, V33, P737, DOI 10.1016/j.clnu.2014.03.007; Choi Y, 2014, J PAIN SYMPTOM MANAG, V48, P13, DOI 10.1016/j.jpainsymman.2013.08.017; Cosqueric G, 2006, BRIT J NUTR, V96, P895, DOI 10.1017/BJN20061943; Demontis F, 2013, AGING CELL, V12, P943, DOI 10.1111/acel.12126; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Gallagher D, 1997, J APPL PHYSIOL, V83, P229, DOI 10.1152/jappl.1997.83.1.229; Huillard O, 2013, BRIT J CANCER, V108, P1034, DOI 10.1038/bjc.2013.58; Kim YS, 2012, J GERONTOL A-BIOL, V67, P1107, DOI 10.1093/gerona/gls071; Kyle UG, 2005, CLIN NUTR, V24, P133, DOI 10.1016/j.clnu.2004.08.012; Lau EMC, 2005, J GERONTOL A-BIOL, V60, P213, DOI 10.1093/gerona/60.2.213; Lieffers JR, 2012, BRIT J CANCER, V107, P931, DOI 10.1038/bjc.2012.350; Martin L, 2013, J CLIN ONCOL, V31, P1539, DOI 10.1200/JCO.2012.45.2722; Mitsiopoulos N, 1998, J APPL PHYSIOL, V85, P115, DOI 10.1152/jappl.1998.85.1.115; Mourtzakis M, 2008, APPL PHYSIOL NUTR ME, V33, P997, DOI 10.1139/H08-075; Muller MJ, 2013, CURR OPIN CLIN NUTR, V16, P501, DOI 10.1097/MCO.0b013e328363bdf9; Olsen RH, 2008, JAMA-J AM MED ASSOC, V299, P1261, DOI 10.1001/jama.299.11.1259; Prado CMM, 2008, LANCET ONCOL, V9, P629, DOI 10.1016/S1470-2045(08)70153-0; Prado CMM, 2009, CLIN CANCER RES, V15, P2920, DOI 10.1158/1078-0432.CCR-08-2242; Rodrigues HV, 2013, EUR J CANCER, V49, P3068, DOI 10.1016/j.ejca.2013.06.026; Tan BHL, 2009, CLIN CANCER RES, V15, P6973, DOI 10.1158/1078-0432.CCR-09-1525; Washington TA, 2011, ACTA PHYSIOL, V202, P657, DOI 10.1111/j.1748-1716.2011.02281.x	27	102	105	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2015	10	10							e0139749	10.1371/journal.pone.0139749	http://dx.doi.org/10.1371/journal.pone.0139749			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0PR	26437072	Green Published, gold, Green Submitted			2023-01-03	WOS:000362499200058
J	Gong, J; Chen, XG; Li, SJ				Gong, Jie; Chen, Xinguang; Li, Sijian			Efficacy of a Community-Based Physical Activity Program KM2H(2) for Stroke and Heart Attack Prevention among Senior Hypertensive Patients: A Cluster Randomized Controlled Phase-II Trial	PLOS ONE			English	Article							BLOOD-PRESSURE CONTROL; TRANSTHEORETICAL MODEL; SECONDARY PREVENTION; BEHAVIOR-CHANGE; RURAL ADULTS; PREVALENCE; EXERCISE; AWARENESS; DISEASE; HEALTH	Objective To evaluate the efficacy of the program Keep Moving toward Healthy Heart and Healthy Brain (KM2H(2)) in encouraging physical activities for the prevention of heart attack and stroke among hypertensive patients enrolled in the Community-Based Hypertension Control Program (CBHCP). Design Cluster randomized controlled trial with three waves of longitudinal assessments at baseline, 3 and 6 months post intervention. Setting Community-based and patient-centered self-care for behavioral intervention in urban settings of China. Participants A total of 450 participants diagnosed with hypertension from 12 community health centers in Wuhan, China were recruited, and were randomly assigned by center to receive either KM2H(2) plus standard CBHCP care (6 centers and 232 patients) or the standard care only (6 centers and 218 patients). Intervention KM2H(2) is a behavioral intervention guided by the Transtheoretical Model, the Model of Personalized Medicine and Social Capital Theory. It consists of six intervention sessions and two booster sessions engineered in a progressive manner. The purpose is to motivate and maintain physical activities for the prevention of heart attack and stroke. Outcome Measures Heart attack and stroke (clinically diagnosed, primary outcome), blood pressure (measured, secondary outcome), and physical activity (self-report, tertiary outcome) were assessed at the individual level during the baseline, 3- and 6-month post-intervention. Results Relative to the standard care, receiving KM2H(2) was associated with significant reductions in the incidence of heart attack (3.60% vs. 7.03%, p < .05) and stroke (5.11% vs. 9.90%, p < 0.05), andmoderate reduction in blood pressure (-3.72mmHg in DBP and -2.92mmHg in DBP) at 6-month post-intervention; and significant increases in physical activity at 3-(d = 0.53, 95% CI: 0.21, 0.85) and 6-month (d = 0.45, 95% CI: 0.04, 0.85) post-intervention, respectively. Conclusion The program KM2H(2) is efficacious to reduce the risk of heart attack and stroke among senior patients who are on anti-hypertensive medication. Findings of this study provide solid data supporting a formal phase-III trial to establish the effectiveness of KM2H(2) for use in community settings for prevention.	[Gong, Jie; Chen, Xinguang] Wuhan Ctr Dis Prevent & Control, Dept Chron Dis, Wuhan, Peoples R China; [Chen, Xinguang] Univ Florida, Dept Epidemiol, Gainesville, FL USA; [Li, Sijian] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R China	State University System of Florida; University of Florida; Hong Kong Polytechnic University	Gong, J (corresponding author), Wuhan Ctr Dis Prevent & Control, Dept Chron Dis, Wuhan, Peoples R China.	gongjie@whcdc.org; jimax.chen@ufl.edu			Wuhan Center for Disease Prevention and Control; School of Nursing, the Hong Kong Polytechnic University; University of Florida	Wuhan Center for Disease Prevention and Control; School of Nursing, the Hong Kong Polytechnic University(Hong Kong Polytechnic University); University of Florida(University of Florida)	This project was funded in part by Wuhan Center for Disease Prevention and Control, School of Nursing, the Hong Kong Polytechnic University, and University of Florida. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahams E, 2005, AM J PHARMACOGENOMIC, V5, P345, DOI 10.2165/00129785-200505060-00002; Abrahams E, 2008, CTS-CLIN TRANSL SCI, V1, P11, DOI 10.1111/j.1752-8062.2008.00003.x; Barengo NC, 2005, J HYPERTENS, V23, P293, DOI 10.1097/00004872-200502000-00011; Brown RE, 2013, AM J HYPERTENS, V26, P1005, DOI 10.1093/ajh/hpt063; BuHamra SS, 2010, STAT PAP, V51, P775, DOI 10.1007/s00362-008-0165-9; Chang L, 2003, HEALTH PROMOT INT, V18, P219, DOI 10.1093/heapro/dag017; Chen X, 2009, HEALTH EDUC RES, V24, P306, DOI 10.1093/her/cyn020; Chen XG, 2015, SOC INDIC RES, V120, P669, DOI 10.1007/s11205-014-0611-0; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Chogahara M, 2004, J AGING PHYS ACTIV, V12, P400; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Darden D, 2013, CURR CARDIOVASC RISK, V7, P411, DOI 10.1007/s12170-013-0354-5; Diaz KM, 2013, CURR HYPERTENS REP, V15, P659, DOI 10.1007/s11906-013-0386-8; Eden KB, 2002, ANN INTERN MED, V137, P208, DOI 10.7326/0003-4819-137-3-200208060-00015; Gao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065938; Halpern D., 2004, SOCIAL CAPITAL; Heo M, 2014, J BIOPHARM STAT, V24, P507, DOI 10.1080/10543406.2014.888442; Hu S, 2003, CHINESE HLTH EC, V22, P32; Huai PC, 2013, HYPERTENSION, V62, P1021, DOI 10.1161/HYPERTENSIONAHA.113.01965; Huang JS, 1960, NAT S HEART VASC DIS; Hutchison AJ, 2009, HEALTH EDUC BEHAV, V36, P829, DOI 10.1177/1090198108318491; James PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427; Karmisholt K, 2005, DAN MED BULL, V52, P90; Lewsey JD, 2004, STAT MED, V23, P897, DOI 10.1002/sim.1665; Lin GS, 2007, REPORT CHRONIC NONIN; Lindstrom M, 2011, PUBLIC HEALTH, V125, P442, DOI 10.1016/j.puhe.2011.01.015; Liu L, 2012, 2010 CHINESE GUIDELI; Liu M, 2007, LANCET NEUROL, V6, P456, DOI 10.1016/S1474-4422(07)70004-2; Marcus B., 2009, MOTIVATING PEOPLE BE; Murray D.M., 1998, DESIGN ANAL GROUP RA; Mutrie, 2008, PSYCHOL PHYS ACTIVIT; Nissen SE, 2004, JAMA-J AM MED ASSOC, V292, P2217, DOI 10.1001/jama.292.18.2217; O'Donovan C, 2014, J PHYS ACT HEALTH, V11, P272, DOI 10.1123/jpah.2012-0075; Ogden LG, 2000, HYPERTENSION, V35, P539, DOI 10.1161/01.HYP.35.2.539; Pang WY, 2010, MED PRIN PRACT, V19, P22, DOI 10.1159/000252830; Prochaska JO, 2008, APPL PSYCHOL-INT REV, V57, P561, DOI 10.1111/j.1464-0597.2008.00345.x; Roberts CK, 2013, AM J PHYSIOL-REG I, V305, pR552, DOI 10.1152/ajpregu.00131.2013; Seals JG, 2007, J AM ACAD NURSE PRAC, V19, P63, DOI 10.1111/j.1745-7599.2006.00196.x; Semlitsch T, 2013, SPORTS MED, V43, P1009, DOI 10.1007/s40279-013-0065-6; Sun ZQ, 2013, INT J STROKE, V8, P701, DOI 10.1111/j.1747-4949.2012.00897.x; Swift DL, 2013, CIRC J, V77, P281, DOI 10.1253/circj.CJ-13-0007; Wang JW, 2014, AM J HYPERTENS, V27, P1355, DOI 10.1093/ajh/hpu053; WHELTON PK, 2004, CLIN TRIALS CARDIOVA, P282; Wu XG, 1995, INT J CARDIOL, V52, P39, DOI 10.1016/0167-5273(95)02443-Z; Xi B, 2012, INT J CARDIOL, V158, P326, DOI 10.1016/j.ijcard.2012.04.140; Yan Ya-qiong, 2012, Zhonghua Liu Xing Bing Xue Za Zhi, V33, P779; ZHAO YM, 2013, PLOS COMPUT BIOL, V9, DOI DOI 10.1371/JOURNAL.PONE.0061779; Zhu CY, 2012, CHINESE J PUBLIC H S, V28, P1	48	26	28	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2015	10	10							e0139442	10.1371/journal.pone.0139442	http://dx.doi.org/10.1371/journal.pone.0139442			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CS6GT	26426421	gold, Green Submitted, Green Published			2023-01-03	WOS:000362177100061
J	Baker, TB; Piper, ME; Stein, JH; Smith, SS; Bolt, DM; Fraser, DL; Fiore, MC				Baker, Timothy B.; Piper, Megan E.; Stein, James H.; Smith, Stevens S.; Bolt, Daniel M.; Fraser, David L.; Fiore, Michael C.			Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSTAINED-RELEASE BUPROPION; RECEPTOR PARTIAL AGONIST; UNITED-STATES; PLACEBO; ADHERENCE; CIGARETTE; PHARMACOTHERAPIES; OUTCOMES	IMPORTANCE Smoking cessation medications are routinely used in health care; it is vital to identify medications that most effectively treat this leading cause of preventable mortality. OBJECTIVE To compare the efficacies of varenicline, combination nicotine replacement therapy (C-NRT), and the nicotine patch for 26-week quit rates. DESIGN, SETTING, AND PARTICIPANTS Three-group randomized intention-to-treat clinical trial occurring from May 2012 to November 2015 among smokers recruited in the Madison, Wisconsin, and Milwaukee, Wisconsin, communities; 65.5% of smokers offered the study (2687/4102) refused participation prior to randomization. INTERVENTIONS Participants were randomized to one of three 12-week open-label smoking cessation pharmacotherapy groups: (1) nicotine patch only (n = 241); (2) varenicline only (including 1 prequit week; n = 424); and (3) C-NRT (nicotine patch + nicotine lozenge; n = 421). Six counseling sessions were offered. MAIN OUTCOMES AND MEASURES The primary outcome was carbon monoxide-confirmed self-reported 7-day point-prevalence abstinence at 26 weeks. Secondary outcomes were carbon monoxide-confirmed self-reported initial abstinence, prolonged abstinence at 26 weeks, and point-prevalence abstinence at weeks 4, 12, and 52. RESULTS Among 1086 smokers randomized (52% women; 67% white; mean age, 48 years; mean of 17 cigarettes smoked per day), 917 (84%) provided 12-month follow-up data. Treatments did not differ on any abstinence outcome measure at 26 or 52 weeks, including point-prevalence abstinence at 26 weeks (nicotine patch, 22.8%[55/241]; varenicline, 23.6% [100/424]; and C-NRT, 26.8%[113/421]) or at 52 weeks (nicotine patch, 20.8%[50/241]; varenicline, 19.1% [81/424]; and C-NRT, 20.2%[85/421]). At 26 weeks, the risk differences for abstinence were, for patch vs varenicline, -0.76%(95% CI, -7.4% to 5.9%); for patch vs C-NRT, -4.0%(95% CI, -10.8% to 2.8%); and for varenicline vs C-NRT, -3.3%(95% CI, -9.1% to 2.6%). All medications were well tolerated, but varenicline produced more frequent adverse events than did the nicotine patch for vivid dreams, insomnia, nausea, constipation, sleepiness, and indigestion. CONCLUSIONS AND RELEVANCE Among adults motivated to quit smoking, 12 weeks of open-label treatment with nicotine patch, varenicline, or C-NRT produced no significant differences in biochemically confirmed rates of smoking abstinence at 26 weeks. The results raise questions about the relative effectiveness of intense smoking pharmacotherapies.	[Baker, Timothy B.; Piper, Megan E.; Smith, Stevens S.; Fraser, David L.; Fiore, Michael C.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Ste 200, Madison, WI 53711 USA; [Baker, Timothy B.; Piper, Megan E.; Smith, Stevens S.; Fiore, Michael C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, 1930 Monroe St,Ste 200, Madison, WI 53711 USA; [Stein, James H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Cardiovasc Med, 1930 Monroe St,Ste 200, Madison, WI 53711 USA; [Bolt, Daniel M.] Univ Wisconsin, Dept Educ Psychol, 1930 Monroe St,Ste 200, Madison, WI 53711 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Baker, TB (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, 1930 Monroe St,Ste 200, Madison, WI 53711 USA.	tbb@ctri.wisc.edu		Smith, Stevens/0000-0002-6824-2829; Stein, James/0000-0002-2770-8223	National Heart, Lung, and Blood Institute [5R01HL109031]; National Cancer Institute [K05CA139871]; NATIONAL CANCER INSTITUTE [K05CA139871, P01CA180945, R35CA197573] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL109031] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was supported by grant 5R01HL109031 from the National Heart, Lung, and Blood Institute and grant K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention.	Adhikari B., 2008, Morbidity and Mortality Weekly Report, V57, P1226; Agaku Israel, 2012, Morbidity and Mortality Weekly Report, V61, P889; Ahmed AIA, 2013, J CLIN PSYCHOPHARM, V33, P55, DOI 10.1097/JCP.0b013e31827c0117; Asthana A, 2012, AM HEART J, V163, P81, DOI 10.1016/j.ahj.2011.06.023; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Catz SL, 2011, NICOTINE TOB RES, V13, P361, DOI 10.1093/ntr/ntr003; Cohen J., 2002, APPL MULTIPLE REGRES, V3rd, DOI 10.4324/9780203774441; Cooper TV, 2004, ADDICT BEHAV, V29, P1565, DOI 10.1016/j.addbeh.2004.02.033; Eisenberg MJ, 2008, CAN MED ASSOC J, V179, P135, DOI 10.1503/cmaj.070256; Fix BV, 2011, INT J ENV RES PUB HE, V8, P222, DOI 10.3390/ijerph8010222; Gonzales D, 2006, JAMA-J AM MED ASSOC, V296, P47, DOI 10.1001/jama.296.1.47; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hedeker D, 2007, ADDICTION, V102, P1564, DOI 10.1111/j.1360-0443.2007.01946.x; Hosmer D. J., 2013, APPL LOGISTIC REGRES, DOI DOI 10.1002/9781118548387; Hsueh KC, 2014, PSYCHOPHARMACOLOGY, V231, P2819, DOI 10.1007/s00213-014-3482-9; Jamal A, 2014, MMWR-MORBID MORTAL W, V63, P1108; Jorenby DE, 2006, JAMA-J AM MED ASSOC, V296, P56, DOI 10.1001/jama.296.1.56; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Liberman JN, 2013, J MANAGE CARE PHARM, V19, P125, DOI 10.18553/jmcp.2013.19.2.125; Marrone GF, 2011, ADDICTION, V106, P1325, DOI 10.1111/j.1360-0443.2011.03441.x; Mills Edward J, 2010, Tob Induc Dis, V8, P8, DOI 10.1186/1617-9625-8-8; Nides M, 2008, AM J HEALTH BEHAV, V32, P664, DOI 10.5555/ajhb.2008.32.6.664; Piper ME, 2009, ARCH GEN PSYCHIAT, V66, P1253, DOI 10.1001/archgenpsychiatry.2009.142; Smith SS, 2009, ARCH INTERN MED, V169, P2148, DOI 10.1001/archinternmed.2009.426; Stein JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098278; Swan GE, 2010, AM J PREV MED, V38, P482, DOI 10.1016/j.amepre.2010.01.024; Tonstad S, 2006, JAMA-J AM MED ASSOC, V296, P64, DOI 10.1001/jama.296.1.64; Transdisciplinary Tobacco Use Research Center (TTURC) Tobacco Dependence, 2007, Nicotine Tob Res, V9 Suppl 4, pS555, DOI 10.1080/14622200701673480; Zhu SH, 2016, TOB CONTROL, V25, P464, DOI 10.1136/tobaccocontrol-2015-052332	30	117	119	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2016	315	4					371	379		10.1001/jama.2015.19284	http://dx.doi.org/10.1001/jama.2015.19284			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB5YI	26813210	Green Accepted, hybrid			2023-01-03	WOS:000368589500015
J	Oliver, D				Oliver, David			David Oliver: Keeping care home residents out of hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						[Anonymous], GOOD PRACT; Badger B, 2007, EUR J PALLIAT CARE, V14, P238; British Geriatrics Society, 2013, COMM GUID HIGH QUAL; British Geriatrics Society, 2011, QUEST QUAL INQ QUAL; Connolly W, 2015, BRIT GER SOC SCI M M, P53; Dwyer R, 2014, AGE AGEING, V43, P759, DOI 10.1093/ageing/afu117; Gordon AL, 2015, J ROY COLL PHYS EDIN, V45, P148, DOI 10.4997/JRCPE.2015.213; Lisk R, 2015, BRIT GERIATRICS 0313; National Institute for Health and Care Excellence, 2015, OLD PEOPL SOC CAR NE; O'Keefe J, 2015, BRIT GER SOC SCI M M, P56; Oliver D, 2015, ENHANCING HEALTHCARE; Roberts S, 2015, BRIT GERIATRICS 0729; Smith P, 2015, QUALITYWATCH FOCUS A	13	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 26	2016	352								i458	10.1136/bmj.i458	http://dx.doi.org/10.1136/bmj.i458			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC6EQ	26813928	Bronze, Green Published			2023-01-03	WOS:000369313000009
J	Gawande, A				Gawande, Atul			Quantity and Quality of Life Duties of Care in Life-Limiting Illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gawande, Atul] Brigham & Womens Hosp, Ariadne Labs, Boston, MA 02115 USA; [Gawande, Atul] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Gawande, A (corresponding author), Ariadne Labs, 401 Pk Dr,Third Floor E, Boston, MA 02215 USA.	agawande@partners.org						Angus DC, 2016, JAMA-J AM MED ASSOC, V315, P255, DOI 10.1001/jama.2015.18681; Bekelman JE, 2016, JAMA-J AM MED ASSOC, V315, P272, DOI 10.1001/jama.2015.18603; Bernacki RE, 2014, JAMA INTERN MED, V174, P1994, DOI 10.1001/jamainternmed.2014.5271; Blecker S, 2016, JAMA-J AM MED ASSOC, V315, P301, DOI 10.1001/jama.2015.16976; CMS, MED CAR CHOIC MOD; Connor SR, 2007, J PAIN SYMPTOM MANAG, V33, P238, DOI 10.1016/j.jpainsymman.2006.10.010; Kellehear, 2014, INNER LIFE DYING PER; Klinger CA, 2014, PALLIATIVE MED, V28, P111, DOI 10.1177/0269216313493342; National Consensus Project for Quality Palliative Care, 2013, CLIN PRACT GUID QUAL; Odejide OO, 2016, JAMA-J AM MED ASSOC, V315, P257, DOI 10.1001/jama.2015.18424; Olson RA, 2014, INT J RADIAT ONCOL, V89, P1092, DOI 10.1016/j.ijrobp.2014.04.048; Prigerson HG, 2015, JAMA ONCOL, V1, P778, DOI 10.1001/jamaoncol.2015.2378; Quill TE, 2016, JAMA-J AM MED ASSOC, V315, P245, DOI 10.1001/jama.2015.16210; Singer AE, 2015, ANN INTERN MED, V162, P175, DOI 10.7326/M13-1609; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Weissman JS, 2016, JAMA-J AM MED ASSOC, V315, P303, DOI 10.1001/jama.2015.17408; Wright AA, 2016, JAMA-J AM MED ASSOC, V315, P284, DOI 10.1001/jama.2015.18604; Yang YT, 2016, JAMA-J AM MED ASSOC, V315, P247, DOI 10.1001/jama.2015.16194	18	38	38	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					267	269		10.1001/jama.2015.19206	http://dx.doi.org/10.1001/jama.2015.19206			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784773				2023-01-03	WOS:000368371400022
J	Gostin, LO; Roberts, AE				Gostin, Lawrence O.; Roberts, Anna E.			Physician-Assisted Dying A Turning Point?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EUTHANASIA; END		[Gostin, Lawrence O.; Roberts, Anna E.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				[Anonymous], ECONOMIST; Hirschhorn D., TERMINALLY WOMAN WHO; Onwuteaka-Philipsen BD, 2012, LANCET, V380, P908, DOI 10.1016/S0140-6736(12)61034-4; Oregon Public Health Division, 2014, DEATH DIGN ACT ANN R; Peretti-Watel P, 2003, BRIT MED J, V327, P595, DOI 10.1136/bmj.327.7415.595; Stone Kathlyn, 2009, Lancet Neurol, V8, P882, DOI 10.1016/S1474-4422(09)70249-2	6	27	27	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					249	250		10.1001/jama.2015.16586	http://dx.doi.org/10.1001/jama.2015.16586			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784764				2023-01-03	WOS:000368371400013
J	Byun, JI; Lee, ST; Jung, KH; Sunwoo, JS; Moon, J; Lim, JA; Lee, DY; Shin, YW; Kim, TJ; Lee, KJ; Lee, WJ; Lee, HS; Jun, J; Kim, DY; Kim, MY; Kim, H; Kim, HJ; Suh, HI; Lee, Y; Kim, DW; Jeong, JH; Choi, WC; Bae, DW; Shin, JW; Jeon, D; Park, KI; Jung, KY; Chu, K; Lee, SK				Byun, Jung-Ick; Lee, Soon-Tae; Jung, Keun-Hwa; Sunwoo, Jun-Sang; Moon, Jangsup; Lim, Jung-Ah; Lee, Doo Young; Shin, Yong-Won; Kim, Tae-Joon; Lee, Keon-Joo; Lee, Woo-Jin; Lee, Han-Sang; Jun, Jinsun; Kim, Dong-Yub; Kim, Man-Young; Kim, Hyunjin; Kim, Hyeon Jin; Suh, Hong Il; Lee, Yoojin; Kim, Dong Wook; Jeong, Jin Ho; Choi, Woo Chan; Bae, Dae Woong; Shin, Jung-Won; Jeon, Daejong; Park, Kyung-Il; Jung, Ki-Young; Chu, Kon; Lee, Sang Kun			Effect of Immunotherapy on Seizure Outcome in Patients with Autoimmune Encephalitis: A Prospective Observational Registry Study	PLOS ONE			English	Article							NMDA-RECEPTOR ENCEPHALITIS; FACIOBRACHIAL DYSTONIC SEIZURES; CLINICAL-MANIFESTATIONS; STATUS EPILEPTICUS; LIMBIC ENCEPHALITIS; ANTIBODIES; EPILEPSY; RITUXIMAB; UTILITY; SYSTEM	Objective To evaluate the seizure characteristics and outcome after immunotherapy in adult patients with autoimmune encephalitis (AE) and new-onset seizure. Methods Adult (age >= 18 years) patients with AE and new-onset seizure who underwent immunotherapy and were followed-up for at least 6 months were included. Seizure frequency was evaluated at 2-4 weeks and 6 months after the onset of the initial immunotherapy and was categorized as "seizure remission", "> 50% seizure reduction", or "no change" based on the degree of its decrease. Results Forty-one AE patients who presented with new-onset seizure were analysed. At 2-4 weeks after the initial immunotherapy, 51.2% of the patients were seizure free, and 24.4% had significant seizure reduction. At 6 months, seizure remission was observed in 73.2% of the patients, although four patients died during hospitalization. Rituximab was used as a second-line immunotherapy in 12 patients who continued to have seizures despite the initial immunotherapy, and additional seizure remission was achieved in 66.6% of them. In particular, those who exhibited partial response to the initial immunotherapy had a better seizure outcome after rituximab, with low adverse events. Conclusion AE frequently presented as seizure, but only 18.9% of the living patients suffered from seizure at 6 months after immunotherapy. Aggressive immunotherapy can improve seizure outcome in patients with AE.	[Byun, Jung-Ick; Lee, Soon-Tae; Jung, Keun-Hwa; Sunwoo, Jun-Sang; Lim, Jung-Ah; Lee, Doo Young; Shin, Yong-Won; Kim, Tae-Joon; Lee, Keon-Joo; Lee, Woo-Jin; Lee, Han-Sang; Jun, Jinsun; Jeon, Daejong; Park, Kyung-Il; Jung, Ki-Young; Chu, Kon; Lee, Sang Kun] Seoul Natl Univ Hosp, Dept Neurol, Seoul 110744, South Korea; [Byun, Jung-Ick; Lee, Soon-Tae; Jung, Keun-Hwa; Sunwoo, Jun-Sang; Lim, Jung-Ah; Shin, Yong-Won; Kim, Tae-Joon; Lee, Keon-Joo; Lee, Woo-Jin; Lee, Han-Sang; Jun, Jinsun; Park, Kyung-Il; Jung, Ki-Young; Chu, Kon; Lee, Sang Kun] Seoul Natl Univ, Coll Med, Program Neurosci, Seoul, South Korea; [Moon, Jangsup] Ewha Womans Univ, Sch Med, Dept Neurol, Seoul, South Korea; [Moon, Jangsup] Ewha Med Res Inst, Seoul, South Korea; [Kim, Dong-Yub] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul, South Korea; [Kim, Man-Young] Chosun Univ Hosp, Dept Neurol, Gwangju, South Korea; [Kim, Hyunjin; Lee, Yoojin] Asan Med Ctr, Dept Neurol, Seoul, South Korea; [Kim, Hyeon Jin] Ewha Womans Univ Hosp, Dept Neurol, Seoul, South Korea; [Suh, Hong Il] Ajou Univ, Med Ctr, Dept Neurol, Suwon 441749, South Korea; [Kim, Dong Wook] Konkuk Univ, Med Ctr, Dept Neurol, Seoul, South Korea; [Jeong, Jin Ho] Inje Univ, Busan Paik Hosp, Dept Neurol, Busan, South Korea; [Choi, Woo Chan] Kyungpook Natl Univ Hosp, Dept Neurol, Daegu, South Korea; [Bae, Dae Woong] St Marys Hosp, Dept Neurol, Seoul, South Korea; [Shin, Jung-Won] Cha Univ, CHA Bundang Med Ctr, Dept Neurol, Songnam, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Ewha Womans University; Ewha Womans University; Sungkyunkwan University (SKKU); Samsung Medical Center; Chosun University; University of Ulsan; Asan Medical Center; Ewha Womans University; Ajou University; Konkuk University; Konkuk University Medical Center; Inje University; Kyungpook National University; Kyungpook National University Hospital; Catholic University of Korea; Catholic University Korea Hospital; Seoul St. Mary's Hospital; Pochon Cha University	Chu, K; Lee, SK (corresponding author), Seoul Natl Univ Hosp, Dept Neurol, Seoul 110744, South Korea.; Chu, K; Lee, SK (corresponding author), Seoul Natl Univ, Coll Med, Program Neurosci, Seoul, South Korea.	stemcell.snu@gmail.com; sangkun2923@gmail.com	Kim, Hyeonjin/M-3761-2019	Jung, Keun-Hwa/0000-0003-1433-8005; Jeon, Daejong/0000-0002-6998-7603; Sunwoo, Jun-Sang/0000-0001-8834-0568; Chu, Kon/0000-0001-5863-0302; Kim, Hyeon Jin/0000-0003-1401-9258; Moon, Jangsup/0000-0003-1282-4528; Lee, Soon-Tae/0000-0003-4767-7564; Park, Kyung-Il/0000-0001-8064-6749	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI14C25020000]; Seoul National University Hospital Research Fund [2520140040]	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea; Seoul National University Hospital Research Fund	This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C25020000). Dr. Kon Chu was supported by the Seoul National University Hospital Research Fund (2520140040).	Bien CG, 2014, NEUROTHERAPEUTICS, V11, P311, DOI 10.1007/s13311-014-0264-3; Bien CG, 2012, BRAIN, V135, P1622, DOI 10.1093/brain/aws082; Dale RC, 2014, NEUROLOGY, V83, P142, DOI 10.1212/WNL.0000000000000570; Dalmau J, 2008, LANCET NEUROL, V7, P327, DOI 10.1016/S1474-4422(08)70060-7; Dalmau J, 2014, NEURO-ONCOLOGY, V16, P771, DOI 10.1093/neuonc/nou030; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Davies G, 2010, CRIT CARE MED, V38, P679, DOI 10.1097/CCM.0b013e3181cb0968; Davis R, 2013, EPILEPSIA, V54, P46, DOI 10.1111/epi.12276; Dericioglu N, 2013, EPILEPTIC DISORD, V15, P166, DOI 10.1684/epd.2013.0566; Diamond B, 2009, NAT REV IMMUNOL, V9, P449, DOI 10.1038/nri2529; Holzer FJ, 2012, EUR NEUROL, V68, P310, DOI 10.1159/000341143; Iorio R, 2015, EUR J NEUROL, V22, P70, DOI 10.1111/ene.12529; Irani SR, 2014, JAMA NEUROL, V71, P896, DOI 10.1001/jamaneurol.2014.463; Irani SR, 2013, BRAIN, V136, P3151, DOI 10.1093/brain/awt212; Irani SR, 2011, ANN NEUROL, V69, P892, DOI 10.1002/ana.22307; Lancaster E, 2011, NEUROLOGY, V77, P179, DOI 10.1212/WNL.0b013e318224afde; Lancaster E, 2010, LANCET NEUROL, V9, P67, DOI 10.1016/S1474-4422(09)70324-2; Lim JA, 2014, J CLIN NEUROL, V10, P157, DOI 10.3988/jcn.2014.10.2.157; Lowenstein DH, 1999, EPILEPSIA, V40, P120, DOI 10.1111/j.1528-1157.1999.tb02000.x; Melzer N, 2013, J NEUROL, V260, P1215, DOI 10.1007/s00415-012-6657-5; Moon J, 2014, J NEUROIMMUNOL, V274, P209, DOI 10.1016/j.jneuroim.2014.07.011; Quek AML, 2012, ARCH NEUROL-CHICAGO, V69, P582, DOI 10.1001/archneurol.2011.2985; Sarkis RA, 2014, EPILEPSY BEHAV, V39, P21, DOI 10.1016/j.yebeh.2014.07.018; Sen A, 2014, LANCET, V383, P2018, DOI 10.1016/S0140-6736(14)60684-X; Shin YW, 2013, J NEUROIMMUNOL, V265, P75, DOI 10.1016/j.jneuroim.2013.10.005; Spatola M, 2015, NEUROLOGY, V85, P464, DOI 10.1212/WNL.0000000000001717; Sunwoo JS, 2015, J NEUROIMMUNOL, V281, P17, DOI 10.1016/j.jneuroim.2015.03.005; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Toledano M, 2014, NEUROLOGY, V82, P1578, DOI 10.1212/WNL.0000000000000383; Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6; Walczak TS, 2001, NEUROLOGY, V56, P519, DOI 10.1212/WNL.56.4.519; Zuliani L, 2012, J NEUROL NEUROSUR PS, V83, P638, DOI 10.1136/jnnp-2011-301237	32	32	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2016	11	1							e0146455	10.1371/journal.pone.0146455	http://dx.doi.org/10.1371/journal.pone.0146455			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB6ME	26771547	Green Published, Green Submitted, gold			2023-01-03	WOS:000368628300021
J	Wu, B; Zheng, JX; Zhou, M; Xi, XH; Wang, Q; Hua, J; Hu, XF; Liu, JQ				Wu, Bin; Zheng, Jinxia; Zhou, Ming; Xi, Xiaohong; Wang, Qin; Hua, Jing; Hu, Xuefeng; Liu, Jiang-Qin			Improvement of Expressed Breast Milk in Mothers of Preterm Infants by Recording Breast Milk Pumping Diaries in a Neonatal Center in China	PLOS ONE			English	Article							BIRTH-WEIGHT INFANTS; TRIAL	Objectives Because inadequate expression of human milk (EBM) in mothers of hospitalized infants were noticed in a neonatal center of our hospital, family education program was carried out to increase the EBM. Methods A breast milk pumping diary was introduced to the mothers with preterm infant(s) admitted in the NICU. The ratios of EBM (days of EBM to NICU/hospitalized days), breast milk feeding (BMF) (days of infants fed with exclusive human milk/hospitalized days), mixed feeding (MF) (days of infants fed with partial breast milk and partial formula/hospitalized days), and formula feeding (FF) (days of infants fed with preterm formula/hospitalized days) were evaluated. Results During January to April, 2014, the ratios of EBM to the NICU, BMF, MF and FF were 28.11%, 6.6%, 32.8% and 60.6%, respectively. After the introduction of breast milk pumping diary to the mothers from May 2014, the ratio of EBM to the NICU increased significantly to 53.3% (p<0.01) within the following eight months. Both the ratios of BMF and MF also rose to 23.8% and MF 55.3%, respectively. Consequently, the ratio of FF was reduced to 20.9%. Exclusive breast milk feeding also significantly reduce the duration of nil per oral (NPO) of the very low birth weight infants during hospital stay as compared to those fed with mixed feeding and formula feeding. Conclusion The introduction of a breast milk pumping diary was associated with a significant increase in the intake of EBM of the hospitalized preterm newborns.	[Wu, Bin; Zheng, Jinxia; Zhou, Ming; Xi, Xiaohong; Wang, Qin; Hu, Xuefeng; Liu, Jiang-Qin] Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Dept Neonatol, Shanghai 200092, Peoples R China; [Hua, Jing] Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Dept Maternal & Child Hlth, Shanghai 200092, Peoples R China	Tongji University; Tongji University	Liu, JQ (corresponding author), Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Dept Neonatol, Shanghai 200092, Peoples R China.	jiangqinliu@yahoo.com						Acuna-Muga J, 2014, J HUM LACT, V30, P41, DOI 10.1177/0890334413509140; Arslanoglu S, 2013, J PERINAT MED, V41, P129, DOI 10.1515/jpm-2012-0196; Boucher CA, 2011, NEONATAL NETW, V30, P21, DOI 10.1891/0730-0832.30.1.21; Cristofalo EA, 2013, J PEDIATR-US, V163, P1592, DOI 10.1016/j.jpeds.2013.07.011; Dougherty D, 2008, NEONATAL NETW, V27, P371, DOI 10.1891/0730-0832.27.6.371; Flacking R, 2006, SOC SCI MED, V62, P70, DOI 10.1016/j.socscimed.2005.05.026; Flaherman VJ, 2013, PEDIATR CLIN N AM, V60, P227, DOI 10.1016/j.pcl.2012.10.003; Furman L, 2003, ARCH PEDIAT ADOL MED, V157, P66, DOI 10.1001/archpedi.157.1.66; Hill P D, 2001, J Hum Lact, V17, P9, DOI 10.1177/089033440101700103; Hill PD, 2005, J HUM LACT, V21, P22, DOI 10.1177/0890334404272407; Hylander M A, 2001, J Perinatol, V21, P356, DOI 10.1038/sj.jp.7210548; Jones E, 2001, ARCH DIS CHILD-FETAL, V85, pF91, DOI 10.1136/fn.85.2.F91; Jones E, 2007, ARCH DIS CHILD-FETAL, V92, P236, DOI 10.1136/adc.2006.100941; Josephson CD, 2014, JAMA PEDIATR, V168, P1054, DOI 10.1001/jamapediatrics.2014.1360; Kavanaugh K, 1997, J Hum Lact, V13, P15, DOI 10.1177/089033449701300111; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; Meier PP, 2007, NEOREVIEWS, V8, P467, DOI DOI 10.1542/NEO.8-11-E467; Patel AL, 2013, J PERINATOL, V33, P514, DOI 10.1038/jp.2013.2; Ronnestad A, 2005, PEDIATRICS, V115, pE269, DOI 10.1542/peds.2004-1833; Sullivan S, 2010, J PEDIATR-US, V156, P562, DOI 10.1016/j.jpeds.2009.10.040; Sweet L, 2008, INT BREASTFEED J, V3, DOI 10.1186/1746-4358-3-30; Vohr BR, 2006, PEDIATRICS, V118, pE115, DOI 10.1542/peds.2005-2382	22	6	6	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2015	10	12							e0144123	10.1371/journal.pone.0144123	http://dx.doi.org/10.1371/journal.pone.0144123			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY1CH	26637118	gold, Green Submitted, Green Published			2023-01-03	WOS:000366143800043
J	Eisenstein, M				Eisenstein, Michael			Medicine: Eyes on the target	NATURE			English	Editorial Material							METASTATIC BREAST-CANCER; PERTUZUMAB PLUS TRASTUZUMAB; CHEMOTHERAPY; DOCETAXEL; PHASE-2; SAFETY; TRIAL											Bachelot T, 2013, LANCET ONCOL, V14, P64, DOI 10.1016/S1470-2045(12)70432-1; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Giuliano M, 2015, CLIN CANCER RES, V21, P3995, DOI 10.1158/1078-0432.CCR-14-2728; Modi S, 2011, CLIN CANCER RES, V17, P5132, DOI 10.1158/1078-0432.CCR-11-0072; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Schneeweiss A, 2013, ANN ONCOL, V24, P2278, DOI 10.1093/annonc/mdt182; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Slamon DJ, 2015, J CLIN ONCOL, V33; Swain SM, 2014, ANN ONCOL, V25, P1116, DOI 10.1093/annonc/mdu133; Tefferi A, 2015, MAYO CLIN PROC, V90, P996, DOI 10.1016/j.mayocp.2015.06.001	11	7	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	2015	527	7578					S110	S112		10.1038/527S110a	http://dx.doi.org/10.1038/527S110a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW9ZN	26580159	Bronze			2023-01-03	WOS:000365356800004
J	Bedran, TBL; Morin, MP; Spolidorio, DP; Grenier, D				Lombardo Bedran, Telma Blanca; Morin, Marie-Pierre; Spolidorio, Denise Palomari; Grenier, Daniel			Black Tea Extract and Its Theaflavin Derivatives Inhibit the Growth of Periodontopathogens and Modulate Interleukin-8 and beta-Defensin Secretion in Oral Epithelial Cells	PLOS ONE			English	Article							GREEN TEA; PORPHYROMONAS-GINGIVALIS; PERIODONTAL-DISEASE; HEALTH; POLYPHENOLS; COMBINATION; CONSUMPTION; EXPRESSION; CHEMOKINES; THERAPY	Over the years, several studies have brought evidence suggesting that tea polyphenols, mostly from green tea, may have oral health benefits. Since few data are available concerning the beneficial properties of black tea and its theaflavin derivatives against periodontal disease, the objective of this study was to investigate their antibacterial activity as well as their ability to modulate interleukin-8 and human beta-defensin (hBD) secretion in oral epithelial cells. Among the periodontopathogenic bacteria tested, Porphyromonas gingivalis was found to be highly susceptible to the black tea extract and theaflavins. Moreover, our data indicated that the black tea extract, theaflavin and theaflavin-3,3'-digallate can potentiate the antibacterial effect of metronidazole and tetracycline against P. gingivalis. Using lipopolysaccharide-stimulated oral epithelial cells, the black tea extract (100 mu g/ml), as well as theaflavin and theaflavin-3,3'-digallate (50 mu g/ml) reduced interleukin-8 (IL-8) secretion by 85%, 79%, and 86%, respectively, thus suggesting an anti-inflammatory property. The ability of the black tea extract and its theaflavin derivatives to induce the secretion of the antimicrobial peptides hBD-1, hBD-2 and hBD-4 by oral epithelial cells was then evaluated. Our results showed that the black tea extract as well as theaflavin-3,3'-digallate were able to increase the secretion of the three hBDs. In conclusion, the ability of a black tea extract and theaflavins to exert antibacterial activity against major periodontopathogens, to attenuate the secretion of IL-8, and to induce hBD secretion in oral epithelial cells suggest that these components may have a beneficial effect against periodontal disease.	[Lombardo Bedran, Telma Blanca] UNINOVE Univ, Sao Paulo Dent Sch, Sao Paulo, Brazil; [Morin, Marie-Pierre; Grenier, Daniel] Univ Laval, Fac Dent, Oral Ecol Res Grp, Quebec City, PQ, Canada; [Spolidorio, Denise Palomari] State Univ Sao Paulo, Araraquara Dent Sch, Dept Oral Diag & Surg, Sao Paulo, Brazil	Universidade Nove de Julho; Laval University; Universidade Estadual Paulista	Grenier, D (corresponding author), Univ Laval, Fac Dent, Oral Ecol Res Grp, Quebec City, PQ, Canada.	Daniel.Grenier@greb.ulaval.ca	Spolidorio, Denise Madalena Palomari/P-3530-2016	Spolidorio, Denise Madalena Palomari/0000-0003-2376-1024	Laboratoire de Controle Microbiologique	Laboratoire de Controle Microbiologique	This work was supported by Laboratoire de Controle Microbiologique 2015 (DG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrian E, 2006, J DENT RES, V85, P392, DOI 10.1177/154405910608500502; Aneja R, 2004, CRIT CARE MED, V32, P2097, DOI 10.1097/01.CCM.0000142661.73633.15; Asahi Y, 2014, J APPL MICROBIOL, V116, P1164, DOI 10.1111/jam.12458; Berezow AB, 2011, PERIODONTOL 2000, V55, P36, DOI 10.1111/j.1600-0757.2010.00350.x; Betts JW, 2012, J MICROB BIOTEC FOOD, V2, P1068; Butt MS, 2014, CRIT REV FOOD SCI, V54, P1002, DOI 10.1080/10408398.2011.623198; Cabrera C, 2006, J AM COLL NUTR, V25, P79, DOI 10.1080/07315724.2006.10719518; Canas PG, 2015, J AM DENT ASSOC, V146, P150, DOI 10.1016/j.adaj.2014.12.015; Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002; Chung WO, 2007, CURR PHARM DESIGN, V13, P3073, DOI 10.2174/138161207782110435; Dale BA, 2002, PERIODONTOL 2000, V30, P70, DOI 10.1034/j.1600-0757.2002.03007.x; Ebersole JL, 2013, PERIODONTOL 2000, V62, P163, DOI 10.1111/prd.12005; Gamonal J, 2001, J PERIODONTAL RES, V36, P194, DOI 10.1034/j.1600-0765.2001.360309.x; Gardner EJ, 2007, EUR J CLIN NUTR, V61, P3, DOI 10.1038/sj.ejcn.1602489; Gursoy Ulvi Kahraman, 2012, J Oral Microbiol, V4, DOI 10.3402/jom.v4i0.15127; HALL MJ, 1983, J ANTIMICROB CHEMOTH, V11, P427, DOI 10.1093/jac/11.5.427; Hayat K, 2015, CRIT REV FOOD SCI, V55, P939, DOI 10.1080/10408398.2012.678949; Hirasawa M, 2002, J PERIODONTAL RES, V37, P433, DOI 10.1034/j.1600-0765.2002.01640.x; Hosokawa Y, 2010, MOL NUTR FOOD RES, V54, pS151, DOI 10.1002/mnfr.200900549; Jain A, 2013, TOXICOL LETT, V220, P82, DOI 10.1016/j.toxlet.2013.04.010; Jin LJ, 2002, J CLIN PERIODONTOL, V29, P604, DOI 10.1034/j.1600-051X.2002.290704.x; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Komatsuzawa H, 2007, CURR PHARM DESIGN, V13, P3084, DOI 10.2174/138161207782110426; Kong LX, 2015, ARCH ORAL BIOL, V60, P12, DOI 10.1016/j.archoralbio.2014.08.019; Koyama Y, 2010, PREV MED, V50, P173, DOI 10.1016/j.ypmed.2010.01.010; Kushiyama M, 2009, J PERIODONTOL, V80, P372, DOI 10.1902/jop.2009.080510 ; Liu YCG, 2010, PERIODONTOL 2000, V52, P163, DOI 10.1111/j.1600-0757.2009.00321.x; Loesche WJ, 2001, CLIN MICROBIOL REV, V14, P727, DOI 10.1128/CMR.14.4.727-752.2001; Lombardo Bedran TB, J PERIODONT RES, V201, P615; Milward MR, 2007, CLIN EXP IMMUNOL, V148, P307, DOI 10.1111/j.1365-2249.2007.03342.x; Morin MP, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0557-z; Narotzki B, 2012, ARCH ORAL BIOL, V57, P429, DOI 10.1016/j.archoralbio.2011.11.017; Otomo-Corgel Joan, 2012, J Evid Based Dent Pract, V12, P20, DOI 10.1016/S1532-3382(12)70006-4; Otte JM, 2008, J CELL BIOCHEM, V104, P2286, DOI 10.1002/jcb.21787; Palaska I, 2013, EUR J PHARMACOL, V720, P77, DOI 10.1016/j.ejphar.2013.10.047; PANYANGARM Y, 1988, CU DENT J, V11, P43; Pinto MD, 2013, FOOD RES INT, V53, P558, DOI 10.1016/j.foodres.2013.01.038; Ramos R, 2011, PEPTIDES, V32, P1469, DOI 10.1016/j.peptides.2011.06.005; Sharma V, 2009, CRIT REV FOOD SCI, V49, P379, DOI 10.1080/10408390802068066; Silva TA, 2007, J DENT RES, V86, P306, DOI 10.1177/154405910708600403; Sirk TW, 2011, J AGR FOOD CHEM, V59, P3780, DOI 10.1021/jf2006547; Slots J, 1999, PERIODONTOL 2000, V20, P82, DOI 10.1111/j.1600-0757.1999.tb00159.x; Socransky SS, 1998, J CLIN PERIODONTOL, V25, P134, DOI 10.1111/j.1600-051X.1998.tb02419.x; Varoni EM, 2012, CURR MED CHEM, V19, P1706; Vuong QV, 2014, CRIT REV FOOD SCI, V54, P523, DOI 10.1080/10408398.2011.594184; Xu X, 2011, ANTIMICROB AGENTS CH, V55, P1229, DOI 10.1128/AAC.01016-10; Zhang J, 1998, CARIES RES, V32, P233, DOI 10.1159/000016458	47	34	36	2	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2015	10	11							e0143158	10.1371/journal.pone.0143158	http://dx.doi.org/10.1371/journal.pone.0143158			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW7CD	26581041	Green Submitted, Green Published, gold			2023-01-03	WOS:000365154600093
J	Juthani-Mehta, M; Malani, PN; Mitchell, SL				Juthani-Mehta, Manisha; Malani, Preeti N.; Mitchell, Susan L.			Antimicrobials at the End of Life An Opportunity to Improve Palliative Care and Infection Management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NURSING-HOME RESIDENTS; ADVANCED DEMENTIA; HOSPICE CARE		[Juthani-Mehta, Manisha] Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06520 USA; [Malani, Preeti N.] Univ Michigan Hlth Syst, Div Infect Dis, Dept Internal Med, Ann Arbor, MI USA; [Mitchell, Susan L.] Beth Israel Deaconess Med Ctr, Dept Med, Hebrew SeniorLife Inst Aging Res, Boston, MA 02215 USA; [Mitchell, Susan L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Yale University; University of Michigan System; University of Michigan; Harvard University; Beth Israel Deaconess Medical Center; Hebrew SeniorLife; Harvard University; Harvard Medical School	Juthani-Mehta, M (corresponding author), Yale Univ, Sch Med, Dept Internal Med, POB 208022, New Haven, CT 06520 USA.	manisha.juthani@yale.edu			NIA NIH HHS [K24 AG033640, K24AG033640] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K24AG033640] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albrecht JS, 2013, J PAIN SYMPTOM MANAG, V46, P483, DOI 10.1016/j.jpainsymman.2012.09.010; D'Agata E, 2008, ARCH INTERN MED, V168, P357, DOI 10.1001/archinternmed.2007.104; Furuno JP, 2014, ANTIMICROB AGENTS CH, V58, P5473, DOI 10.1128/AAC.02873-14; Givens JL, 2010, ARCH INTERN MED, V170, P1102, DOI 10.1001/archinternmed.2010.181; Levin PD, 2010, CHEST, V138, P588, DOI 10.1378/chest.09-2757; Mitchell SL, 2014, JAMA INTERN MED, V174, P1660, DOI 10.1001/jamainternmed.2014.3918; Morrison RS, 1998, J PAIN SYMPTOM MANAG, V15, P91, DOI 10.1016/S0885-3924(97)00261-3; Rosenberg JH, 2013, J PALLIAT MED, V16, P1568, DOI 10.1089/jpm.2013.0276; Thompson AJ, 2012, AM J HOSP PALLIAT ME, V29, P599, DOI 10.1177/1049909111432625	9	49	50	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2015	314	19					2017	2018		10.1001/jama.2015.13080	http://dx.doi.org/10.1001/jama.2015.13080			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW1PR	26426830	Green Accepted			2023-01-03	WOS:000364764200010
J	James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB				James, Nicholas D.; Sydes, Matthew R.; Clarke, Noel W.; Mason, Malcolm D.; Dearnaley, David P.; Spears, Melissa R.; Ritchie, Alastair W. S.; Parker, Christopher C.; Russell, J. Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J.; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J.; Brock, Susannah; Cathomas, Richard; Chakraborti, Prabir; Chowdhury, Simon; Cook, Audrey; Elliott, Tony; Gale, Joanna; Gibbs, Stephanie; Graham, John D.; Hetherington, John; Hughes, Robert; Laing, Robert; McKinna, Fiona; McLaren, Duncan B.; O'Sullivan, Joe M.; Parikh, Omi; Peedell, Clive; Protheroe, Andrew; Robinson, Angus J.; Srihari, Narayanan; Srinivasan, Rajaguru; Staffurth, John; Sundar, Santhanam; Tolan, Shaun; Tsang, David; Wagstaff, John; Parmar, Mahesh K. B.		STAMPEDE Investigators	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial	LANCET			English	Article							ANDROGEN-DEPRIVATION THERAPY; OPEN-LABEL; CLINICAL-TRIALS; CHEMOTHERAPY; MITOXANTRONE; PREDNISONE; ENZALUTAMIDE; ESTRAMUSTINE; CABAZITAXEL; DESIGN	Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone. Methods Standard of care was hormone therapy for at least 2 years; radiotherapy was encouraged for men with N0M0 disease to November, 2011, then mandated; radiotherapy was optional for men with node-positive non-metastatic (N+M0) disease. Stratified randomisation (via minimisation) allocated men 2:1:1:1 to standard of care only (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc). Zoledronic acid (4 mg) was given for six 3-weekly cycles, then 4-weekly until 2 years, and docetaxel (75 mg/m(2)) for six 3-weekly cycles with prednisolone 10 mg daily. There was no blinding to treatment allocation. The primary outcome measure was overall survival. Pairwise comparisons of research versus control had 90% power at 2.5% one-sided a for hazard ratio (HR) 0.75, requiring roughly 400 control arm deaths. Statistical analyses were undertaken with standard log-rank-type methods for time-to-event data, with hazard ratios (HRs) and 95% CIs derived from adjusted Cox models. This trial is registered at ClinicalTrials.gov (NCT00268476) and ControlledTrials.com (ISRCTN78818544). Findings 2962 men were randomly assigned to four groups between Oct 5, 2005, and March 31, 2013. Median age was 65 years (IQR 60-71). 1817 (61%) men had M+ disease, 448 (15%) had N+/X M0, and 697 (24%) had N0M0. 165 (6%) men were previously treated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23-184). Median follow-up was 43 months (IQR 30-60). There were 415 deaths in the control group (347 [84%] prostate cancer). Median overall survival was 71 months (IQR 32 to not reached) for SOC-only, not reached (32 to not reached) for SOC + ZA (HR 0.94, 95% CI 0.79-1.11; p= 0.450), 81 months (41 to not reached) for SOC + Doc (0.78, 0.66-0.93; p= 0.006), and 76 months (39 to not reached) for SOC + ZA + Doc (0.82, 0.69-0.97; p= 0.022). There was no evidence of heterogeneity in treatment effect (for any of the treatments) across prespecified subsets. Grade 3-5 adverse events were reported for 399 (32%) patients receiving SOC, 197 (32%) receiving SOC + ZA, 288 (52%) receiving SOC + Doc, and 269 (52%) receiving SOC + ZA + Doc. Interpretation Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population. Docetaxel chemotherapy, given at the time of long-term hormone therapy initiation, showed evidence of improved survival accompanied by an increase in adverse events. Docetaxel treatment should become part of standard of care for adequately fit men commencing long-term hormone therapy.	[James, Nicholas D.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England; [James, Nicholas D.] Univ Birmingham, Sch Med, Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Sydes, Matthew R.; Spears, Melissa R.; Ritchie, Alastair W. S.; Amos, Claire; Matheson, David; Millman, Robin; Parmar, Mahesh K. B.] UCL, MRC Clin Trials Unit, London WC2B 6NH, England; [Clarke, Noel W.] Christie & Salford Royal NHS Fdn Trusts, Dept Urol, Manchester, Lancs, England; [Mason, Malcolm D.; Staffurth, John] Cardiff Univ, Sch Med, Velindre Hosp, Cardiff CF10 3AX, S Glam, Wales; [Dearnaley, David P.; Parker, Christopher C.; Attard, Gerhardt; de Bono, Johann] Inst Canc Res, London SW3 6JB, England; [Dearnaley, David P.; Parker, Christopher C.; Attard, Gerhardt; de Bono, Johann] Royal Marsden NHS Fdn Trust, London, England; [Russell, J. Martin; Jones, Rob J.] Univ Glasgow, Inst Canc Sci, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Cross, William] Leeds Teaching Hosp NHS Trust, Dept Urol, Leeds, W Yorkshire, England; [Thalmann, George] Univ Hosp Bern, Dept Urol, CH-3010 Bern, Switzerland; [Alzouebi, Mymoona] Weston Pk Hosp, Dept Oncol, Sheffield, S Yorkshire, England; [Alzouebi, Mymoona] Weston Pk Hosp, Dept Oncol, Doncaster, England; [Beesley, Sharon] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England; [Birtle, Alison J.] Royal Preston Hosp, Dept Oncol, Rosemere Canc Ctr, Preston, Lancs, England; [Brock, Susannah] Poole Hosp NHS Fdn Trust, Dept Oncol, Poole, Dorset, England; [Brock, Susannah] Royal Bournemouth Hosp NHS Fdn Trust, Bournemouth, Dorset, England; [Cathomas, Richard] Kantonsspital Graubunden, Chur, Switzerland; [Chakraborti, Prabir] Derby Hosp NHS Fdn Trust, Dept Oncol, Royal Derby Hosp, Derby, England; [Chowdhury, Simon] Guys Hosp, Dept Med Oncol, London SE1 9RT, England; [Cook, Audrey] Cheltenham Gen Hosp, Dept Oncol, Cheltenham, Glos, England; [Cook, Audrey] Hereford Cty Hosp, Hereford, England; [Elliott, Tony] Christie NHS Fdn Trust, Dept Clin Oncol, Manchester, Lancs, England; [Gale, Joanna] Queen Alexandra Hosp, Oncol & Haematol Clin Trials Unit, Portsmouth, Hants, England; [Gibbs, Stephanie] Queens Hosp, Dept Oncol, Romford, Essex, England; [Graham, John D.] Musgrove Pk Hosp, Beacon Ctr, Taunton, Somerset, England; [Hetherington, John] Hull & East Yorkshire Hosp NHS Trust, Dept Urol, Kingston Upon Hull, N Humberside, England; [Hughes, Robert] Mt Vernon Hosp, Mt Vernon Grp, Northwood, Middx, England; [Laing, Robert] Royal Surrey Cty Hosp, Dept Oncol, Guildford, Surrey, England; [McKinna, Fiona] East Sussex Hosp Trust, Dept Oncol, Crowborough, E Sussex, England; [McLaren, Duncan B.] Western Gen Hosp, Dept Oncol, Edinburgh EH4 2XU, Midlothian, Scotland; [O'Sullivan, Joe M.] Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [Parikh, Omi] East Lancashire Hosp NHS Trust, Dept Oncol, Burnley, East Lancashire, England; [Peedell, Clive] South Tees NHS Trust, Dept Radiotherapy & Oncol, Middlesbrough, Cleveland, England; [Protheroe, Andrew] Churchill Hosp, Dept Oncol, Oxford OX3 7LJ, England; [Robinson, Angus J.] Sussex Canc Ctr, Dept Oncol, Brighton, E Sussex, England; [Srihari, Narayanan] Shrewsbury & Telford Hosp NHS Trust, Dept Oncol, Shrewsbury, Salop, England; [Srinivasan, Rajaguru] Royal Devon & Exeter Hosp, Dept Oncol, Exeter EX2 5DW, Devon, England; [Srinivasan, Rajaguru] Torbay Hosp, Torquay, England; [Sundar, Santhanam] Nottingham Univ Hosp NHS Trust, Dept Oncol, Nottingham, England; [Tolan, Shaun] Clatterbridge Canc Ctr, Dept Radiotherapy & Oncol, Wirral, Merseyside, England; [Tsang, David] Southend Hosp, Dept Oncol, Westcliff On Sea, Essex, England; [Tsang, David] Basildon Hosp, Dept Oncol, Basildon, Essex, England; [Wagstaff, John] South West Wales Canc Inst, Swansea, W Glam, Wales; [Wagstaff, John] Swansea Univ, Coll Med, Swansea, W Glam, Wales	University of Warwick; University of Birmingham; Medical Research Council Clinical Trials Unit; University of London; University College London; Christie NHS Foundation Trust; Cardiff University; Velindre Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Beatson Oncology Centre; University of Glasgow; University of Leeds; University of Bern; University Hospital of Bern; Weston Park Hospital; Weston Park Hospital; Royal Preston Hospital; Kantonsspital Graubunden; University of Nottingham; Guy's & St Thomas' NHS Foundation Trust; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; Christie NHS Foundation Trust; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Musgrove Park Hospital; Royal Surrey County Hospital; University of Edinburgh; Belfast City Hospital; Queens University Belfast; University of Oxford; University of Exeter; Nottingham University Hospital NHS Trust; Clatterbridge Cancer Centre; Swansea University	Sydes, MR (corresponding author), UCL, MRC Clin Trials Unit, London WC2B 6NH, England.	m.sydes@ucl.ac.uk	Dearnaley, David P/J-2318-2014; McLaren, Duncan Bruce/M-3153-2019; Mason, Malcolm D/H-6979-2013; Sundar, Santhanam/AAF-3011-2021; James, Nick/AAL-6802-2020; Sydes, Matthew/C-3373-2008; Matheson, David/V-4076-2017	Dearnaley, David P/0000-0002-3954-2806; McLaren, Duncan Bruce/0000-0002-9862-4158; Sundar, Santhanam/0000-0003-0850-5161; Sydes, Matthew/0000-0002-9323-1371; de Bono, Johann S/0000-0002-2034-595X; Jain, Sunjay/0000-0002-6173-4863; Adeyoju, Adebanji/0000-0003-4010-5985; Wagstaff, John/0000-0002-1140-5981; James, Nicholas/0000-0002-7314-8204; Rogers, Paul/0000-0003-2593-2595; Camilleri, Philip/0000-0002-2677-5627; Graham, John/0000-0003-3381-9787; O'Sullivan, Joe/0000-0001-6999-2739; Attard, Gerhardt/0000-0002-4811-7983; Matheson, David/0000-0002-3695-3167; Herrera, Fernanda/0000-0001-7984-0472; Engeler, Daniel/0000-0003-1383-4701; Ansari, JAWAHER/0000-0001-5525-548X; Azzabi, Ashraf/0000-0003-4801-9109; Rentsch, Cyrill/0000-0002-8085-6006; Jones, Robert/0000-0002-2904-6980	National Institute for Health Research; Novartis Pharmaceuticals UK Limited; Sanofi-Aventis; Institute of Cancer Research Biomedical Research Centre; MRC [MC_UU_12023/28] Funding Source: UKRI; Cancer Research UK [13239, 12459, 19727, 3804] Funding Source: researchfish; Medical Research Council [MC_UU_12023/28, MC_UU_12023/20, MC_UU_12023/25] Funding Source: researchfish; National Institute for Health Research [CL-2008-22-001, NF-SI-0611-10106] Funding Source: researchfish; Prostate Cancer UK [PG12-49] Funding Source: researchfish; Public Health Agency [SPI/3315/06] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR)); Novartis Pharmaceuticals UK Limited; Sanofi-Aventis(Sanofi-Aventis); Institute of Cancer Research Biomedical Research Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Prostate Cancer UK; Public Health Agency	DPD, CCP, GA, and JdB acknowledge support from the National Institute for Health Research to the Royal Marsden NHS Trust and The Institute of Cancer Research Biomedical Research Centre. Support for the STAMPEDE trial has been provided by Novartis Pharmaceuticals UK Limited (educational grant, free drug, distribution costs) and Sanofi-Aventis (education grant, free and discounted drug). Affiliations and full details of contributions made by STAMPEDE investigators are provided in the appendix page 11.	Aapro MS, 2011, EUR J CANCER, V47, P8, DOI 10.1016/j.ejca.2010.10.013; Barthel FMS, 2009, STATA J, V9, P505, DOI 10.1177/1536867X0900900401; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Cook RJ, 1996, J ROY STAT SOC A STA, V159, P93, DOI 10.2307/2983471; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470-2045(09)70201-3; Denham JW, 2014, LANCET ONCOL, V15, P1076, DOI 10.1016/S1470-2045(14)70328-6; Fizazi K, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.5005; FOLLMANN DA, 1994, BIOMETRICS, V50, P325, DOI 10.2307/2533376; Franke RM, 2010, J CLIN ONCOL, V28, P4562, DOI 10.1200/JCO.2010.30.7025; Gravis G, 2015, P AM SOC CLIN ONCO S, VGU, P140; Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470-2045(12)70560-0; James ND, 2008, CLIN ONCOL-UK, V20, P577, DOI 10.1016/j.clon.2008.07.002; James ND, 2015, JAMA ONCOL, V25, P1; James ND, 2012, LANCET ONCOL, V13, P549, DOI 10.1016/S1470-2045(12)70088-8; James ND, 2015, EUR UROL, V67, P1028, DOI 10.1016/j.eururo.2014.09.032; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Omlin A, 2015, CLIN GENITOURIN CANC, V13, pE205, DOI 10.1016/j.clgc.2015.01.010; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Parmar MKB, 2008, JNCI-J NATL CANCER I, V100, P1204, DOI 10.1093/jnci/djn267; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141; Sandler HM, 2015, P AM SOC CLIN ONCO S, V33; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schweizer MT, 2013, CANCER-AM CANCER SOC, V119, P3610, DOI 10.1002/cncr.28270; Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003; Smith MR, 2014, J CLIN ONCOL, V13, P27; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Sydes MR, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-168; Sydes MR, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-39; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470-2045(15)00489-1; Wason JMS, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-364; Wirth M, 2015, EUR UROL, V67, P482, DOI 10.1016/j.eururo.2014.02.014	37	1236	1273	5	99	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 19	2016	387	10024					1163	1177		10.1016/S0140-6736(15)01037-5	http://dx.doi.org/10.1016/S0140-6736(15)01037-5			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DG9OB	26719232	Green Published, hybrid, Green Accepted, Green Submitted			2023-01-03	WOS:000372412000028
J	[Anonymous]				[Anonymous]			Acupuncture for Treatment of Menopausal Hot Flashes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																		Ee C, 2016, ANN INTERN MED, V164, P146, DOI 10.7326/M15-1380	1	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	2016	164	3					I24	I24		10.7326/P16-9004	http://dx.doi.org/10.7326/P16-9004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC4DD	26785248				2023-01-03	WOS:000369169400015
J	Russell, S; Martin, F; Zalwango, F; Namukwaya, S; Nalugya, R; Muhumuza, R; Katongole, J; Seeley, J				Russell, Steve; Martin, Faith; Zalwango, Flavia; Namukwaya, Stella; Nalugya, Ruth; Muhumuza, Richard; Katongole, Joseph; Seeley, Janet			Finding Meaning: HIV Self-Management and Wellbeing among People Taking Antiretroviral Therapy in Uganda	PLOS ONE			English	Article							QUALITY-OF-LIFE; SUB-SAHARAN AFRICA; POSTTRAUMATIC GROWTH; OLDER-PEOPLE; SOUTH-AFRICA; HEALTH; ADHERENCE; INTERVENTIONS; COUNTRIES; HIV/AIDS	The health of people living with HIV (PLWH) and the sustained success of antiretroviral therapy (ART) programmes depends on PLWH's motivation and ability to self-manage the condition over the long term, including adherence to drugs on a daily basis. PLWH's self-management of HIV and their wellbeing are likely to be interrelated. Successful self-management sustains wellbeing, and wellbeing is likely to motivate continued self-management. Detailed research is lacking on PLWH's self-management processes on ART in resource-limited settings. This paper presents findings from a study of PLWH's self-management and wellbeing in Wakiso District, Uganda. Thirty-eight PLWH (20 women, 18 men) were purposefully selected at ART facilities run by the government and by The AIDS Support Organisation in and around Entebbe. Two in-depth interviews were completed with each participant over three or four visits. Many were struggling economically, however the recovery of health and hope on ART had enhanced wellbeing and motivated self-management. The majority were managing their condition well across three broad domains of self-management. First, they had mobilised resources, notably through good relationships with health workers. Advice and counselling had helped them to reconceptualise their condition and situation more positively and see hope for the future, motivating their work to self-manage. Many had also developed a new network of support through contacts they had developed at the ART clinic. Second, they had acquired knowledge and skills to manage their health, a useful framework to manage their condition and to live their life. Third, participants were psychologically adjusting to their condition and their new 'self': they saw HIV as a normal disease, were coping with stigma and had regained self-esteem, and were finding meaning in life. Our study demonstrates the centrality of social relationships and other non-medical aspects of wellbeing for self-management which ART programmes might explore further and encourage.	[Russell, Steve] Univ E Anglia, Sch Int Dev, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England; [Zalwango, Flavia; Namukwaya, Stella; Nalugya, Ruth; Muhumuza, Richard; Katongole, Joseph; Seeley, Janet] Uganda Virus Res Inst, Med Res Council, Uganda Res Unit AIDS, Entebbe, Uganda; [Martin, Faith] Univ E Anglia, Sch Int Dev, External Res Associate, Norwich NR4 7TJ, Norfolk, England; [Seeley, Janet] London Sch Hyg & Trop Med, London WC1, England	University of East Anglia; Uganda Virus Research Institute; University of East Anglia; University of London; London School of Hygiene & Tropical Medicine	Russell, S (corresponding author), Univ E Anglia, Sch Int Dev, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England.	s.russell@uea.ac.uk		Martin, Faith/0000-0002-0141-1210; Seeley, Janet/0000-0002-0583-5272; Muhumuza, Richard/0000-0002-9931-7600	UK Economic and Social Research Council (ESRC) [RES-063-23-2663, ES/H043551/1]; Medical Research Council and Department for International Development; Economic and Social Research Council [ES/H043551/1] Funding Source: researchfish; Medical Research Council [MC_U950097150] Funding Source: researchfish; ESRC [ES/H043551/1] Funding Source: UKRI; MRC [MC_U950097150] Funding Source: UKRI	UK Economic and Social Research Council (ESRC)(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council and Department for International Development(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The research was funded by the UK Economic and Social Research Council (ESRC) (project number: RES-063-23-2663; Research Fish Award No: ES/H043551/1), and Medical Research Council and Department for International Development.	Aantjes CJ, 2014, PATIENT EDUC COUNS, V95, P185, DOI 10.1016/j.pec.2014.01.007; Barnighausen T, 2011, LANCET INFECT DIS, V11, P942, DOI 10.1016/S1473-3099(11)70181-5; Bajunirwe F, 2009, AIDS CARE, V21, P271, DOI 10.1080/09540120802241863; Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Barskova T, 2009, DISABIL REHABIL, V31, P1709, DOI 10.1080/09638280902738441; Beard J, 2009, AIDS CARE, V21, P1343, DOI 10.1080/09540120902889926; Hefferon K, 2009, BRIT J HEALTH PSYCH, V14, P343, DOI 10.1348/135910708X332936; Kuteesa MO, 2012, AJAR-AFR J AIDS RES, V11, P295, DOI 10.2989/16085906.2012.754829; Martin F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105154; Martin F, 2013, AIDS PATIENT CARE ST, V27, P697, DOI 10.1089/apc.2013.0254; Mbonye M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-804; McGrath JW, 2014, MED ANTHROPOL, V33, P303, DOI 10.1080/01459740.2014.892483; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Mills EJ, 2011, ANN INTERN MED, V155, P209, DOI 10.7326/0003-4819-155-4-201108160-00358; Mutabazi-Mwesigire D, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-343; Negin J, 2013, J CROSS-CULT GERONTO, V28, P491, DOI 10.1007/s10823-013-9215-4; Nguyen VK, 2007, AIDS, V21, pS31, DOI 10.1097/01.aids.0000298100.48990.58; Nyirenda M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-259; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Roura M, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-22; Russell S, 2015, QUALITATIVE IN PRESS; Russell S, 2010, SOC SCI MED, V70, P375, DOI 10.1016/j.socscimed.2009.10.039; RUTA D, 2007, J SOCIOECONOMICS, V0036; Schulman-Green D, 2012, J NURS SCHOLARSHIP, V44, P136, DOI 10.1111/j.1547-5069.2012.01444.x; Sharpe L, 2006, SOC SCI MED, V62, P1153, DOI 10.1016/j.socscimed.2005.07.010; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Stangl A, 2009, AIDS CARE, V19, P626; Swendeman D, 2009, AIDS CARE, V21, P1321, DOI 10.1080/09540120902803158; Trevino KM, 2010, AIDS BEHAV, V14, P379, DOI 10.1007/s10461-007-9332-6; TVERSKY A, 1993, MANAGE SCI, V39, P1179, DOI 10.1287/mnsc.39.10.1179; Ware NC, 2009, PLOS MED, V6, P39, DOI 10.1371/journal.pmed.1000011; Watkins-Hayes C, 2012, SOC SCI MED, V74, P2028, DOI 10.1016/j.socscimed.2012.02.001; White S, 2009, 0944 WED U BATH ESRC; Wouters E, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-103; Wright S, 2012, J CROSS-CULT GERONTO, V27, P319, DOI 10.1007/s10823-012-9178-x; Yalom ID, 2005, THEORY PRACTICE GROU	36	25	26	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147896	10.1371/journal.pone.0147896	http://dx.doi.org/10.1371/journal.pone.0147896			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DC9FZ	26807932	gold, Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000369527800241
J	Koronowicz, AA; Kopec, A; Master, A; Smolen, S; Piatkowska, E; Biezanowska-Kopec, R; Ledwozyw-Smolen, I; Skoczylas, L; Rakoczy, R; Leszczynska, T; Kapusta-Duch, J; Pysz, M				Koronowicz, Aneta A.; Kopec, Aneta; Master, Adam; Smolen, Sylwester; Piatkowska, Ewa; Biezanowska-Kopec, Renata; Ledwozyw-Smolen, Iwona; Skoczylas, Lukasz; Rakoczy, Roksana; Leszczynska, Teresa; Kapusta-Duch, Joanna; Pysz, Miroslaw			Transcriptome Profiling of Caco-2 Cancer Cell Line following Treatment with Extracts from Iodine-Biofortified Lettuce (Lactuca sativa L.)	PLOS ONE			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; THYROID-HORMONE; C-MYC; VAPOR GENERATION; DIFFERENTIATION; PROTEINS; APOPTOSIS; E2F1; 6-IODOLACTONE; EXPRESSION	Although iodization of salt is the most common method used to obtain iodine-enriched food, iodine deficiency disorders are still a global health problem and profoundly affect the quality of human life. Iodine is required for the synthesis of thyroid hormones, which are crucial regulators of human metabolism, cell growth, proliferation, apoptosis and have been reported to be involved in carcinogenesis. In this study, for the first time, we evaluated the effect of iodine-biofortified lettuce on transcriptomic profile of Caco-2 cancer cell line by applying the Whole Human Genome Microarray assay. We showed 1326 differentially expressed Caco2 transcripts after treatment with iodine-biofortified (BFL) and non-fortified (NFL) lettuce extracts. We analysed pathways, molecular functions, biological processes and protein classes based on comparison between BFL and NFL specific genes. Iodine, which was expected to act as a free ion (KI-NFL) or at least in part to be incorporated into lettuce macromolecules (BFL), differently regulated pathways of numerous transcription factors leading to different cellular effects. In this study we showed the inhibition of Caco-2 cells proliferation after treatment with BFL, but not potassium iodide (KI), and BFL-mediated induction of mitochondrial apoptosis and/or cell differentiation. Our results showed that iodine-biofortified plants can be effectively used by cells as an alternative source of this trace element. Moreover, the observed differences in action of both iodine sources may suggest a potential of BFL in cancer treatment.	[Koronowicz, Aneta A.; Kopec, Aneta; Piatkowska, Ewa; Biezanowska-Kopec, Renata; Leszczynska, Teresa; Kapusta-Duch, Joanna; Pysz, Miroslaw] Univ Agr, Fac Food Technol, Dept Human Nutr, Krakow, Poland; [Master, Adam] Med Ctr Postgrad Educ, Dept Biochem & Mol Biol, Warsaw, Poland; [Smolen, Sylwester; Rakoczy, Roksana] Univ Agr, Unit Plant Nutr, Inst Plant Biol & Biotechnol, Fac Hort, Krakow, Poland; [Ledwozyw-Smolen, Iwona] Univ Agr, Biochem Unit, Inst Plant Biol & Biotechnol, Fac Biotechnol & Hort, Krakow, Poland; [Skoczylas, Lukasz] Univ Agr, Fac Food Technol, Dept Fruit Vegetable & Mushroom Proc, Krakow, Poland	Agricultural University Krakow; Centre of Postgraduate Medical Education - Poland; Agricultural University Krakow; Agricultural University Krakow; Agricultural University Krakow	Koronowicz, AA (corresponding author), Univ Agr, Fac Food Technol, Dept Human Nutr, Krakow, Poland.	aneta.koronowicz@gmail.com	Smoleń, Sylwester/S-4081-2019; Kapusta-Duch, Joanna/AAF-9894-2019	Rakoczy-Lelek, Roksana/0000-0002-9782-3200; Kapusta-Duch, Joanna/0000-0003-3882-2483; Piatkowska, Ewa/0000-0003-3699-314X; Skoczylas, Lukasz/0000-0002-8349-4477; Smolen, Sylwester/0000-0001-8093-3801	Polish National Science Center [DEC-2011/03/D/NZ9/05560]	Polish National Science Center	This work was financed by the 2012-2015 Polish National Science Center, grant no. DEC-2011/03/D/NZ9/05560, "I and Se biofortification of selected vegetables, including the influence of these microelements on yield quality as well as evaluation of iodine absorption and selected biochemical parameters in rats fed with vegetables biofortified with iodine."	Aceves C, 2013, THYROID, V23, P938, DOI 10.1089/thy.2012.0579; Aceves C, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-33; [Anonymous], 2011, PHIE; Arroyo-Helguera O, 2006, ENDOCR-RELAT CANCER, V13, P1147, DOI 10.1677/erc.1.01250; Asadpour E, 2014, ACTA POL PHARM, V71, P409; Avram M, 2014, J MED AR, VXVII, P64; BELFIORE A, 1987, CANCER, V60, P3096, DOI 10.1002/1097-0142(19871215)60:12<3096::AID-CNCR2820601240>3.0.CO;2-V; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Dai JL, 2004, BIOL TRACE ELEM RES, V101, P265, DOI 10.1385/BTER:101:3:265; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Enechi O. C., 2014, African Journal of Biotechnology, V13, P4215, DOI 10.5897/AJB2013.13128; Eskin B A, 1977, Adv Exp Med Biol, V91, P293; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Haldimann M, 2005, J FOOD COMPOS ANAL, V18, P461, DOI 10.1016/j.jfca.2004.06.003; Henson DE, 2013, CANCER CAUSE CONTROL, V24, P609, DOI 10.1007/s10552-012-0135-3; Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001; Knudsen N, 2001, J CLIN ENDOCR METAB, V86, P3599, DOI 10.1210/jc.86.8.3599; Kopec A, 2015, J FUNCT FOODS, V14, P479, DOI 10.1016/j.jff.2015.02.027; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Master A., 2014, ATLAS GENET CYTOGENE, V18, P400, DOI 10.4267/2042/53769; Master A, 2010, BBA-MOL BASIS DIS, V1802, P995, DOI 10.1016/j.bbadis.2010.07.025; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; MILLARD MM, 1988, PLANT CELL PHYSIOL, V29, P901; Nava-Villalba M, 2014, PROSTAG OTH LIPID M, V112, P27, DOI 10.1016/j.prostaglandins.2014.07.001; Olvera-Caltzontzin P, 2013, MOL MED, V19, P409, DOI 10.2119/molmed.2013.00093; Perez-Juste G, 2000, J BIOL CHEM, V275, P1307, DOI 10.1074/jbc.275.2.1307; Romaris-Hortas V, 2014, TALANTA, V127, P175, DOI 10.1016/j.talanta.2014.04.003; Romaris-Hortas V, 2013, J CHROMATOGR A, V1309, P33, DOI 10.1016/j.chroma.2013.08.022; Rosati A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.24; Rusanescu G, 2014, J CELL MOL MED, V18, P2103, DOI 10.1111/jcmm.12362; Sainmont J., 2014, STRATEGIES SUCCESS C; Simile MM, 2004, CARCINOGENESIS, V25, P333, DOI 10.1093/carcin/bgh014; Smolen S, 2014, SCI HORTIC-AMSTERDAM, V166, P9, DOI 10.1016/j.scienta.2013.11.011; Soriguer F, 2011, NUTR ENDOCRINOLOGY, V105, P1783, DOI DOI 10.1017/S0007114510005568; Swanson CA, 2012, J NUTR, V142, p1175S, DOI 10.3945/jn.111.156448; Thomasz L, 2013, PROSTAG LEUKOTR ESS, V88, P273, DOI 10.1016/j.plefa.2013.01.002; Tonacchera M, 2013, J CLIN ENDOCR METAB, V98, pE694, DOI 10.1210/jc.2012-3509; Turowska O, 2007, THYROID, V17, P1039, DOI 10.1089/thy.2007.0075; Vejbjerg P, 2009, EUR J ENDOCRINOL, V161, P475, DOI 10.1530/EJE-09-0262; Venturi S, 2000, Adv Clin Path, V4, P11; Vtorushina EA, 2008, J ANAL CHEM+, V63, P643, DOI 10.1134/S1061934808070071; Vtorushina EA, 2009, J ANAL CHEM+, V64, P129, DOI 10.1134/S1061934809020063; Wang B, 2014, HEPATOLOGY, V59, P555, DOI 10.1002/hep.26712; Weng HX, 2008, BIOL TRACE ELEM RES, V125, P59, DOI 10.1007/s12011-008-8155-2; Weng HX, 2009, ENVIRON GEOCHEM HLTH, V31, P401, DOI 10.1007/s10653-008-9193-6; White PJ, 2009, NEW PHYTOL, V182, P49, DOI 10.1111/j.1469-8137.2008.02738.x; World Health Organization, 2008, 2008 2013 ACT PLAN G; Zanirato V, 2009, Patent No. [PCT/EP2009/ 050142, 2009050142, PCT/EP2009/050142]; Zhang WX, 2015, MOL MED REP, V11, P3148, DOI 10.3892/mmr.2014.3096; Zimmermann MB, 2009, ENDOCR REV, V30, P376, DOI 10.1210/er.2009-0011	50	12	12	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2016	11	1							e0147336	10.1371/journal.pone.0147336	http://dx.doi.org/10.1371/journal.pone.0147336			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB6WB	26799209	Green Published, gold, Green Submitted			2023-01-03	WOS:000368655300096
J	Curry, TA				Curry, Teddi Anderson			What Would Mom Want?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					261	262		10.1001/jama.2015.13326	http://dx.doi.org/10.1001/jama.2015.13326			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784770				2023-01-03	WOS:000368371400019
J	Liu, NN; Ma, XW; Zhou, SH; Wang, P; Sun, Y; Li, XC; Hou, YX				Liu, Nana; Ma, Xiaowen; Zhou, Sihong; Wang, Ping; Sun, Yun; Li, Xiancai; Hou, Yuxia			Molecular and Functional Characterization of a Polygalacturonase-Inhibiting Protein from Cynanchum komarovii That Confers Fungal Resistance in Arabidopsis	PLOS ONE			English	Article							LEUCINE-RICH REPEAT; SIGNAL-TRANSDUCTION PATHWAYS; BOTRYTIS-CINEREA; PHASEOLUS-VULGARIS; SALICYLIC-ACID; DEFENSE RESPONSES; TRANSGENIC PLANTS; ABIOTIC STRESS; CELL-WALLS; PEAR PGIP	Compliance with ethical standards: This study did not involve human participants and animals, and the plant of interest is not an endangered species. Polygalacturonase-inhibiting proteins (PGIPs) are leucine-rich repeat proteins that plants produce against polygalacturonase, a key virulence agent in pathogens. In this paper, we cloned and purified CkPGIP1, a gene product from Cynanchum komarovii that effectively inhibits polygalacturonases from Botrytis cinerea and Rhizoctonia solani. We found the expression of CkPGIP1 to be induced in response to salicylic acid, wounding, and infection with B. cinerea and R. solani. In addition, transgenic overexpression in Arabidopsis enhanced resistance against B. cinerea. Furthermore, CkPGIP1 obtained from transgenic Arabidopsis inhibited the activity of B. cinerea and R. solani polygalacturonases by 62.7-66.4% and 56.5-60.2%, respectively. Docking studies indicated that the protein interacts strongly with the B1-sheet at the N-terminus of the B. cinerea polygalacturonase, and with the C-terminus of the polygalacturonase from R. solani. This study highlights the significance of CkPGIP1 in plant disease resistance, and its possible application to manage fungal pathogens.	[Liu, Nana; Ma, Xiaowen; Zhou, Sihong; Wang, Ping; Sun, Yun; Li, Xiancai; Hou, Yuxia] China Agr Univ, Coll Sci, Beijing 100193, Peoples R China	China Agricultural University	Hou, YX (corresponding author), China Agr Univ, Coll Sci, Beijing 100193, Peoples R China.	houyuxia@cau.edu.cn		Liu, Nana/0000-0001-9745-8525	Program of National Nature Science Foundation of China [31071751]; Genetically Modified Organism Breeding Major Project [2015ZX08005-002]	Program of National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Genetically Modified Organism Breeding Major Project	This work was supported by the Program of National Nature Science Foundation of China (Grant no. 31071751) and the Genetically Modified Organism Breeding Major Project (Grant no. 2015ZX08005-002). And YXH received the funding.	Abramovitch RB, 2006, NAT REV MOL CELL BIO, V7, P601, DOI 10.1038/nrm1984; ABUGOUKH AA, 1983, PHYSIOL PLANT PATHOL, V23, P123, DOI 10.1016/0048-4059(83)90039-5; Afzal AJ, 2007, PROTEIN EXPRES PURIF, V53, P346, DOI 10.1016/j.pep.2006.12.017; Aguero CB, 2005, MOL PLANT PATHOL, V6, P43, DOI 10.1111/j.1364-3703.2004.00262.x; Ahsan N, 2005, PLANT SCI, V169, P1081, DOI 10.1016/j.plantsci.2005.07.006; Akagi A, 2010, EUR J PLANT PATHOL, V128, P423, DOI 10.1007/s10658-010-9684-z; Bennett A, 1996, U.S. Patent, Patent No. [5569830, No. 5,569,830]; Bezier A, 2002, EUR J PLANT PATHOL, V108, P111, DOI 10.1023/A:1015061108045; Centis S, 1997, MOL PLANT MICROBE IN, V10, P769, DOI 10.1094/MPMI.1997.10.6.769; Cheong YH, 2002, PLANT PHYSIOL, V129, P661, DOI 10.1104/pp.002857; D'Ovidio R, 2006, PLANTA, V224, P633, DOI 10.1007/s00425-006-0235-y; De Lorenzo G, 2001, ANNU REV PHYTOPATHOL, V39, P313, DOI 10.1146/annurev.phyto.39.1.313; Desiderio A, 1997, MOL PLANT MICROBE IN, V10, P852, DOI 10.1094/MPMI.1997.10.7.852; Di Matteo A, 2003, P NATL ACAD SCI USA, V100, P10124, DOI 10.1073/pnas.1733690100; FAVARON F, 1994, PLANTA, V195, P80, DOI 10.1007/BF00206295; Ferrari S, 2003, PLANT CELL, V15, P93, DOI 10.1105/tpc.005165; Ferrari S, 2006, MOL PLANT MICROBE IN, V19, P931, DOI 10.1094/MPMI-19-0931; FREDIANI M, 1993, THEOR APPL GENET, V87, P369, DOI 10.1007/BF01184925; Gruner R, 2003, EUR J BIOCHEM, V270, P4876, DOI 10.1046/j.1432-1033.2003.03888.x; Isshiki A, 2001, MOL PLANT MICROBE IN, V14, P749, DOI 10.1094/MPMI.2001.14.6.749; Johnson C, 2003, PLANT CELL, V15, P1846, DOI 10.1105/tpc.012211; JOHNSTON DJ, 1993, J EXP BOT, V44, P971, DOI 10.1093/jxb/44.5.971; Jones DA, 1997, ADV BOT RES, V24, P89; Joubert DA, 2006, TRANSGENIC RES, V15, P687, DOI 10.1007/s11248-006-9019-1; KARR AL, 1970, PLANT PHYSIOL, V46, P69, DOI 10.1104/pp.46.1.69; Kars I, 2005, PLANT J, V43, P213, DOI 10.1111/j.1365-313X.2005.02436.x; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Komjanc M, 1999, PLANT MOL BIOL, V40, P945, DOI 10.1023/A:1006275924882; Leckie F, 1999, EMBO J, V18, P2352, DOI 10.1093/emboj/18.9.2352; Li RG, 2003, PLANTA, V217, P299, DOI 10.1007/s00425-003-0988-5; Lim JM, 2009, J PROTEOME RES, V8, P673, DOI 10.1021/pr800855f; Lu LX, 2012, PLANT CELL REP, V31, P1173, DOI 10.1007/s00299-012-1239-7; Manfredini C, 2005, PHYSIOL MOL PLANT P, V67, P108, DOI 10.1016/j.pmpp.2005.10.002; Mariotti L, 2008, PHYLLOPHILUM MYCOL R; Matsushima N, 2012, BIOMOLECULES, V2, P288, DOI 10.3390/biom2020288; Mattei B, 2001, BIOCHEMISTRY-US, V40, P569, DOI 10.1021/bi0017632; Maulik A, 2013, PROTEINS, V81, P852, DOI 10.1002/prot.24243; Maulik A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S3-S19; Mengiste T, 2003, PLANT CELL, V15, P2551, DOI 10.1105/tpc.014167; Misas-Villamil JC, 2008, CURR OPIN PLANT BIOL, V11, P380, DOI 10.1016/j.pbi.2008.04.007; Oeser B, 2002, FUNGAL GENET BIOL, V36, P176, DOI 10.1016/S1087-1845(02)00020-8; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pietro AD, 1998, MOL PLANT MICROBE IN, V11, P91; Powell ALT, 2000, MOL PLANT MICROBE IN, V13, P942, DOI 10.1094/MPMI.2000.13.9.942; Prabhu SA, 2014, J EXP BOT, V65, P5033, DOI 10.1093/jxb/eru266; Ramanathan V, 1997, J EXP BOT, V48, P1185, DOI 10.1093/jxb/48.6.1185; Ramonell KM, 2002, CURR OPIN PLANT BIOL, V5, P291, DOI 10.1016/S1369-5266(02)00266-2; Sathiyaraj G, 2010, MOL BIOL REP, V37, P3445, DOI 10.1007/s11033-009-9936-1; SHARROCK KR, 1994, PHYSIOL MOL PLANT P, V45, P305, DOI 10.1016/S0885-5765(05)80061-X; Shieh MT, 1997, APPL ENVIRON MICROB, V63, P3548, DOI 10.1128/AEM.63.9.3548-3552.1997; Shirano Y, 2002, PLANT CELL, V14, P3149, DOI 10.1105/tpc.005348; Sicilia F, 2005, PLANT PHYSIOL, V139, P1380, DOI 10.1104/pp.105.067546; Sun WX, 2009, GENESIS, V47, P535, DOI 10.1002/dvg.20530; SZECSI A, 1990, J PHYTOPATHOL, V130, P188, DOI 10.1111/j.1439-0434.1990.tb01167.x; TAYLOR RJ, 1988, PHYTOPATHOLOGY, V78, P1101, DOI 10.1094/Phyto-78-1101; ten Have A, 1998, MOL PLANT MICROBE IN, V11, P1009, DOI 10.1094/MPMI.1998.11.10.1009; Veronese P, 2006, PLANT CELL, V18, P257, DOI 10.1105/tpc.105.035576; Wang QH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016930; Wang R, 2015, PLANT MOL BIOL, V87, P181, DOI 10.1007/s11103-014-0269-7; Wang XJ, 2013, PLANT MOL BIOL, V81, P379, DOI 10.1007/s11103-013-0007-6; Zhu YF, 2014, PLANT CELL, V26, P4149, DOI 10.1105/tpc.114.128611	61	17	19	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0146959	10.1371/journal.pone.0146959	http://dx.doi.org/10.1371/journal.pone.0146959			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6CA	26752638	Green Submitted, gold, Green Published			2023-01-03	WOS:000367888100185
J	Zhang, XM; Wu, WL; Zhu, YC; Jiang, Y; Du, J; Chen, RC				Zhang, Xianming; Wu, Weiliang; Zhu, Yongcheng; Jiang, Ying; Du, Juan; Chen, Rongchang			Abdominal Muscle Activity during Mechanical Ventilation Increases Lung Injury in Severe Acute Respiratory Distress Syndrome	PLOS ONE			English	Article							PRESSURE RELEASE VENTILATION; ANIMAL-MODELS; OXYGENATION	Objective It has proved that muscle paralysis was more protective for injured lung in severe acute respiratory distress syndrome (ARDS), but the precise mechanism is not clear. The purpose of this study was to test the hypothesis that abdominal muscle activity during mechanically ventilation increases lung injury in severe ARDS. Methods Eighteen male Beagles were studied under mechanical ventilation with anesthesia. Severe ARDS was induced by repetitive oleic acid infusion. After lung injury, Beagles were randomly assigned into spontaneous breathing group (BIPAPSB) and abdominal muscle paralysis group (BIPAP(AP)). All groups were ventilated with BIPAP model for 8h, and the high pressure titrated to reached a tidal volume of 6ml/kg, the low pressure was set at 10 cmH(2)O, with I:E ratio 1:1, and respiratory rate adjusted to a PaCO2 of 35-60mmHg. Six Beagles without ventilator support comprised the control group. Respiratory variables, end-expiratory volume (EELV) and gas exchange were assessed during mechanical ventilation. The levels of Interleukin (IL)-6, IL-8 in lung tissue and plasma were measured by qRT-PCR and ELISA respectively. Lung injury scores were determined at end of the experiment. Results For the comparable ventilator setting, as compared with BIPAPSB group, the BIPAPAP group presented higher EELV (427 +/- 47 vs. 366 +/- 38 ml) and oxygenation index (293 +/- 36 vs. 226 +/- 31 mmHg), lower levels of IL-6(216.6 +/- 48.0 vs. 297.5 +/- 71.2 pg/ml) and IL-8(246.8 +/- 78.2 vs. 357.5 +/- 69.3 pg/ml) in plasma, and lower express levels of IL-6 mRNA (15.0 +/- 3.8 vs. 21.2 +/- 3.7) and IL-8 mRNA (18.9 +/- 6.8 vs. 29.5 +/- 7.9) in lung tissues. In addition, less lung histopathology injury were revealed in the BIPAPAP group (22.5 +/- 2.0 vs. 25.2 +/- 2.1). Conclusion Abdominal muscle activity during mechanically ventilation is one of the injurious factors in severe ARDS, so abdominal muscle paralysis might be an effective strategy to minimize ventilator-induce lung injury.	[Zhang, Xianming; Du, Juan] Guangyang Med Univ, Affiliated Hosp 1, Guangyang, Guizhou, Peoples R China; [Wu, Weiliang; Zhu, Yongcheng; Jiang, Ying; Chen, Rongchang] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, Resp Mech Lab,State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China	Guangzhou Medical University; State Key Laboratory of Respiratory Disease	Chen, RC (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, Resp Mech Lab,State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.	chenrongchang8@163.com	Zhang, XZ/HJA-4189-2022; zhang, xian/GYA-0290-2022		National Project 973 [2009CB522108]	National Project 973(National Basic Research Program of China)	This work was supported by National Project 973, 2009CB522108 (Study on the system for the prevention and control of lung injury).	BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788; Caironi P, 2010, AM J RESP CRIT CARE, V181, P578, DOI 10.1164/rccm.200905-0787OC; Carvalho AR, 2009, ANESTH ANALG, V109, P856, DOI 10.1213/ane.0b013e3181aff245; Daoud EG, 2012, RESP CARE, V57, P282, DOI 10.4187/respcare.01238; de Abreu MG, 2012, CURR OPIN ANESTHESIO, V25, P148, DOI 10.1097/ACO.0b013e3283504bde; Dembinski R, 2007, CRIT CARE MED, V35, P2359, DOI 10.1097/01.CCM.0000281857.87354.A5; DOUGLAS WW, 1977, AM REV RESPIR DIS, V115, P559; DUGGAN JE, 1989, ANESTH ANALG, V69, P598; Esquer C, 2008, NEONATOLOGY, V94, P100, DOI 10.1159/000116634; Frawley P M, 2001, AACN Clin Issues, V12, P234, DOI 10.1097/00044067-200105000-00007; Hardman JG, 2003, ANESTH ANALG, V97, P1846, DOI 10.1213/01.ANE.0000090316.46604.89; Henzler D, 2010, INTENS CARE MED, V36, P1427, DOI 10.1007/s00134-010-1827-3; Malbrain MLNG, 2005, CURR OPIN CRIT CARE, V11, P156, DOI 10.1097/01.ccx.0000155355.86241.1b; Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Patroniti N, 2004, INTENS CARE MED, V30, P282, DOI 10.1007/s00134-003-2109-0; Putensen C, 2006, CURR OPIN CRIT CARE, V12, P13, DOI 10.1097/01.ccx.0000198994.37319.60; Putensen C, 1999, AM J RESP CRIT CARE, V159, P1241, DOI 10.1164/ajrccm.159.4.9806077; Roy S, 2013, SHOCK, V39, P28, DOI 10.1097/SHK.0b013e31827b47bb; Schweiger JW, 2003, CRIT CARE MED, V31, P2364, DOI 10.1097/01.CCM.0000085187.36136.9B; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; Suh GY, 1999, J KOREAN MED SCI, V14, P613, DOI 10.3346/jkms.1999.14.6.613; Wang HM, 2008, EUR SURG RES, V40, P305, DOI 10.1159/000121471; WARNER DO, 1991, J APPL PHYSIOL, V70, P539, DOI 10.1152/jappl.1991.70.2.539; Wrigge H, 2003, ANESTHESIOLOGY, V99, P376, DOI 10.1097/00000542-200308000-00019; Xia JG, 2014, ANESTHESIOLOGY, V120, P1441, DOI 10.1097/ALN.0000000000000259; Xia JG, 2011, CRIT CARE, V15, DOI 10.1186/cc10502; Yoshida T, 2013, CRIT CARE MED, V41, P536, DOI 10.1097/CCM.0b013e3182711972	28	3	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2016	11	1							e0145694	10.1371/journal.pone.0145694	http://dx.doi.org/10.1371/journal.pone.0145694			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA5AX	26745868	Green Submitted, Green Published, gold			2023-01-03	WOS:000367815600012
J	Larkin, J; Hatswell, AJ; Nathan, P; Lebmeier, M; Lee, D				Larkin, James; Hatswell, Anthony J.; Nathan, Paul; Lebmeier, Maximilian; Lee, Dawn			The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK	PLOS ONE			English	Article							OPEN-LABEL; FOLLOW-UP; VEMURAFENIB; BLOCKADE; MUTATION; PHASE-3	Background Evaluating long-term prognosis is important for physicians, patients and payers. This study reports the results of a model developed to predict long-term survival for UK patients receiving second-line ipilimumab. Methods MDX010-20 trial data were used to predict survival for ipilimumab versus UK best supportive care. Two aspects of this analysis required novel approaches: 1) The overall survival Kaplan-Meier data shape is unusual: an initial steep decline is observed before a 'plateau'. 2) The need to extrapolate beyond the trial end (4.6 years). Based upon UK clinician advice, a three-part curve fit was used: from 0-1.5 years, Kaplan-Meier data from the trial; from 1.5-5 years, standard parametric curve fits; after 5 years, long-term data from the American Joint Committee on Cancer registry. Results This approach provided good internal validity: low mean absolute error and good match to median and mean trial data. Lifetime predicted means were 2.77 years for ipilimumab and 1.07 for best supportive care, driven by increased long-term survival with ipilimumab. Conclusion To understand the full benefit of treatment and to meet reimbursement requirements, accurate estimation of treatment benefit is key. Models, such as the one presented, can be used to extrapolate beyond trials.	[Larkin, James] Royal Marsden Fdn NHS Trust, London SW3 6JJ, England; [Hatswell, Anthony J.; Lee, Dawn] BresMed, Sheffield S1 2DW, S Yorkshire, England; [Nathan, Paul] Mt Vernon Canc Ctr, Northwood HA6 2RN, Middx, England; [Lebmeier, Maximilian] Bristol Myers Squibb Pharmaceut Ltd, Uxbridge UB8 1DH, Middx, England	Royal Marsden NHS Foundation Trust; Mount Vernon Cancer Centre; Bristol-Myers Squibb	Lee, D (corresponding author), BresMed, 84 Queen St, Sheffield S1 2DW, S Yorkshire, England.	dlee@bresmed.co.uk	lee, dawn/GRJ-7459-2022	Nathan, Paul/0000-0002-2327-3250; Lebmeier, Maximilian/0000-0002-5343-0122; Larkin, James/0000-0001-5569-9523; Hatswell, Anthony/0000-0003-1129-326X	Bristol-Myers Squibb Pharmaceuticals Limited	Bristol-Myers Squibb Pharmaceuticals Limited	Financial support for this study was provided by Bristol-Myers Squibb Pharmaceuticals Limited. The author Maximillian Lebmeier, who was employed by the sponsor at the time, was responsible for data acquisition, coordination of the analysis and review of the manuscript for content.	Annemans L, 2012, ISPOR CONNECTIONS, V18, P5; Ascierto PA, 2014, CANCER-AM CANCER SOC, V120, P1617, DOI 10.1002/cncr.28622; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Bhatia S, 2014, LANCET, V384, P1078, DOI 10.1016/S0140-6736(14)61140-5; Buxton MJ, 1997, HEALTH ECON, V6, P217, DOI 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W; Cancer Research UK, 2014, SKIN CANC CANC STAT; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Collinson FJ, NAT CANC RES I C; Gogas HJ, 2007, CANCER-AM CANCER SOC, V109, P455, DOI 10.1002/cncr.22427; Hauschild A, 2013, 10 INT M SOC MEL RES; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Jang S, 2013, LANCET ONCOL, V14, pE60, DOI 10.1016/S1470-2045(12)70539-9; Johnson DB, 2013, CURR TREAT OPTION ON, V14, P280, DOI 10.1007/s11864-013-0226-8; Korn EL, 2008, J CLIN ONCOL, V26, P527, DOI 10.1200/JCO.2007.12.7837; Kotapati S, 2011, AM SOC CLIN ONC 47 A; Latimer N., 14 NICE DSU; Livingstone E, 2010, EXPERT OPIN INV DRUG, V19, P1439, DOI 10.1517/13543784.2010.527945; Lorigan P, 2014, BRIT J DERMATOL, V170, P87, DOI 10.1111/bjd.12503; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; National Institute for Health and Care Excellence (NICE), 2014, TA319 MEL STAG 3 4 I; National Institute for Health and Clinical Excellence (NICE), TA268 MEL STAG 3 4 I; National Institute for Health and Clinical Excellence (NICE), TA343 MEL STAG 3 4 D; National Institute for Health and Clinical Excellence (NICE), TA269 MEL STAG 3 4 V; Office for National Statistics, 2010, INT LIF TABL; Prieto PA, 2012, CLIN CANCER RES, V18, P2039, DOI 10.1158/1078-0432.CCR-11-1823; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Salama AKS, 2011, CLIN CANCER RES, V17, P4622, DOI 10.1158/1078-0432.CCR-10-2232; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736	30	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0145524	10.1371/journal.pone.0145524	http://dx.doi.org/10.1371/journal.pone.0145524			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SI	26700304	Green Published, gold, Green Submitted			2023-01-03	WOS:000367092600092
J	Trampe, D; Quoidbach, J; Taquet, M				Trampe, Debra; Quoidbach, Jordi; Taquet, Maxime			Emotions in Everyday Life	PLOS ONE			English	Article							CIRCUMPLEX MODEL; EXPERIENCE; SELF	Despite decades of research establishing the causes and consequences of emotions in the laboratory, we know surprisingly little about emotions in everyday life. We developed a smartphone application that monitored real-time emotions of an exceptionally large (N = 11,000+) and heterogeneous participants sample. People's everyday life seems profoundly emotional: participants experienced at least one emotion 90% of the time. The most frequent emotion was joy, followed by love and anxiety. People experienced positive emotions 2.5 times more often than negative emotions, but also experienced positive and negative emotions simultaneously relatively frequently. We also characterized the interconnections between people's emotions using network analysis. This novel approach to emotion research suggests that specific emotions can fall into the following categories 1) connector emotions (e.g., joy), which stimulate same valence emotions while inhibiting opposite valence emotions, 2) provincial emotions (e.g., gratitude), which stimulate same valence emotions only, or 3) distal emotions (e.g., embarrassment), which have little interaction with other emotions and are typically experienced in isolation. Providing both basic foundations and novel tools to the study of emotions in everyday life, these findings demonstrate that emotions are ubiquitous to life and can exist together and distinctly, which has important implications for both emotional interventions and theory.	[Trampe, Debra] Univ Groningen, Fac Econ & Business, Dept Mkt, Groningen, Netherlands; [Quoidbach, Jordi] Pompeu Fabra Univ, Dept Econ & Business, Barcelona, Spain; [Taquet, Maxime] Harvard Univ, Sch Med, Computat Radiol Lab, Boston Childrens Hosp, Boston, MA USA	University of Groningen; Pompeu Fabra University; Harvard University; Boston Children's Hospital; Harvard Medical School	Quoidbach, J (corresponding author), Pompeu Fabra Univ, Dept Econ & Business, Barcelona, Spain.	Jordi.quoidbach@upf.edu		Taquet, Maxime/0000-0002-8987-952X	Barcelona School of Management; Spanish Ministry of Science and Education [PSI2013-41909-P]; Helaers Foundation	Barcelona School of Management; Spanish Ministry of Science and Education(Spanish Government); Helaers Foundation	JQ was supported by the Barcelona School of Management and grant PSI2013-41909-P from the Spanish Ministry of Science and Education. MT was supported by the Helaers Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors are grateful to Jennifer Jordan, Yating Le, Hans Risselada, Yves-Alexandre de Monjoye, and Martin Desseilles for their help during various stages of the research. JQ was supported by the Barcelona School of Management and grant PSI2013-41909-P from the Spanish Ministry of Science and Education. MT was supported by the Helaers Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	aan het Rot M, 2012, CLIN PSYCHOL REV, V32, P510, DOI 10.1016/j.cpr.2012.05.007; Barrett LF, 2000, PERS SOC PSYCHOL B, V26, P1027, DOI 10.1177/01461672002611001; Barrett LF, 2001, COGNITION EMOTION, V15, P713, DOI 10.1080/02699930143000239; Barrett LF, 2006, PERSPECT PSYCHOL SCI, V1, P28, DOI 10.1111/j.1745-6916.2006.00003.x; BERKOWITZ L, 1990, AM PSYCHOL, V45, P494, DOI 10.1037/0003-066X.45.4.494; Bigot R., 2013, DIFFUSION TECHNOLOGI; Carstensen LL, 2000, J PERS SOC PSYCHOL, V79, P644, DOI 10.1037//0022-3514.79.4.644; CHAIKEN S, 1989, P212; Diener E, 2014, PERS SOC PSYCHOL REV, P1; Emmons RA, 2003, J PERS SOC PSYCHOL, V84, P377, DOI 10.1037/0022-3514.84.2.377; FORGAS JP, 1995, PSYCHOL BULL, V117, P39, DOI 10.1037/0033-2909.117.1.39; Fredrickson B., 2013, LOVE 2 0 CREATING HA; Fredrickson BL, 2003, J PERS SOC PSYCHOL, V84, P365, DOI 10.1037/0022-3514.84.2.365; Frijda N. H., 1986, EMOTIONS STUDIES EMO; Heiy JE, 2014, EMOTION, V14, P878, DOI 10.1037/a0037231; Hutcherson CA, 2008, EMOTION, V8, P720, DOI 10.1037/a0013237; Izard C.E., 2013, HUMAN EMOTIONS; Larsen JT, 2011, J PERS SOC PSYCHOL, V100, P1095, DOI 10.1037/a0021846; Lerner J. S., 2015, PSYCHOLOGY, P66; MARKUS HR, 1991, PSYCHOL REV, V98, P224, DOI 10.1037/0033-295X.98.2.224; PHILIPPOT P, 1993, COGNITION EMOTION, V7, P171, DOI 10.1080/02699939308409183; Philippot P, 2003, EMOTION, V3, P270, DOI 10.1037/1528-3542.3.3.270; Quoidbach J, 2014, J EXP PSYCHOL GEN, V143, P2057, DOI 10.1037/a0038025; Remington NA, 2000, J PERS SOC PSYCHOL, V79, P286, DOI 10.1037//0022-3514.79.2.286; Rudd M, 2012, PSYCHOL SCI, V23, P1130, DOI 10.1177/0956797612438731; Russell JA, 1999, J PERS SOC PSYCHOL, V76, P805, DOI 10.1037/0022-3514.76.5.805; RUSSELL JA, 1980, J PERS SOC PSYCHOL, V39, P1161, DOI 10.1037/h0077714; Schaefer A, 2010, COGNITION EMOTION, V24, P1153, DOI 10.1080/02699930903274322; SCHLOSBERG H, 1952, J EXP PSYCHOL, V44, P229, DOI 10.1037/h0055778; SMITH CA, 1993, COGNITION EMOTION, V7, P233, DOI 10.1080/02699939308409189; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Tichy N.M., 1979, ACAD MANAGE REV, V4, P507; Tugade MM, 2004, J PERS, V72, P1161, DOI 10.1111/j.1467-6494.2004.00294.x; van den Heuvel MP, 2013, J NEUROSCI, V33, P14489, DOI 10.1523/JNEUROSCI.2128-13.2013; Vansteelandt K, 2005, J RES PERS, V39, P325, DOI 10.1016/j.jrp.2004.05.006; Weis R, 2011, PSYCHOL WELL-BEING, V1, DOI 10.1186/2211-1522-1-5; Wood AM, 2010, CLIN PSYCHOL REV, V30, P890, DOI 10.1016/j.cpr.2010.03.005; Youngstrom EA, 2003, EDUC PSYCHOL MEAS, V63, P279, DOI 10.1177/0013164403253226; Zelenski JM, 2000, J RES PERS, V34, P178, DOI 10.1006/jrpe.1999.2275	39	73	74	10	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0145450	10.1371/journal.pone.0145450	http://dx.doi.org/10.1371/journal.pone.0145450			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CZ4SI	26698124	Green Published, gold, Green Submitted			2023-01-03	WOS:000367092600081
J	Wilson, MH; Habig, K; Wright, C; Hughes, A; Davies, G; Imray, CHE				Wilson, Mark H.; Habig, Karel; Wright, Christopher; Hughes, Amy; Davies, Gareth; Imray, Chirstopher H. E.			Pre-hospital emergency medicine	LANCET			English	Article							RAPID-SEQUENCE INTUBATION; TRAUMA PATIENTS; HEMORRHAGE CONTROL; HEAD-INJURY; STROKE; HELICOPTER; MANAGEMENT; SERVICES; CARE; DISPATCH	Pre-hospital care is emergency medical care given to patients before arrival in hospital after activation of emergency medical services. It traditionally incorporated a breadth of care from bystander resuscitation to statutory emergency medical services treatment and transfer. New concepts of care including community paramedicine, novel roles such as emergency care practitioners, and physician delivered pre-hospital emergency medicine are re-defining the scope of pre-hospital care. For severely ill or injured patients, acting quickly in the pre-hospital period is crucial with decisions and interventions greatly affecting outcomes. The transfer of skills and procedures from hospital care to pre-hospital medicine enables early advanced care across a range of disciplines. The variety of possible pathologies, challenges of environmental factors, and hazardous situations requires management that is tailored to the patient's clinical need and setting. Pre-hospital clinicians should be generalists with a broad understanding of medical, surgical, and trauma pathologies, who will often work from locally developed standard operating procedures, but who are able to revert to core principles. Pre-hospital emergency medicine consists of not only clinical care, but also logistics, rescue competencies, and scene management skills (especially in major incidents, which have their own set of management principles). Traditionally, research into the hyper-acute phase (the first hour) of disease has been difficult, largely because physicians are rarely present and issues of consent, transport expediency, and resourcing of research. However, the pre-hospital phase is acknowledged as a crucial period, when irreversible pathology and secondary injury to neuronal and cardiac tissue can be prevented. The development of pre-hospital emergency medicine into a sub-specialty in its own right should bring focus to this period of care.	[Wilson, Mark H.; Hughes, Amy; Davies, Gareth] Royal London Hosp, Londons Air Ambulance, Inst Prehosp Care, London E1 1BB, England; [Wilson, Mark H.; Wright, Christopher] Univ London Imperial Coll Sci Technol & Med, St Marys Major Trauma Ctr, London, England; [Habig, Karel] Greater Sydney HEMS Serv, Sydney, NSW, Australia; [Imray, Chirstopher H. E.] UHCW NHS Trust, Warwick Med Sch, Dept Surg, Warwick, England	Barts Health NHS Trust; Royal London Hospital; Imperial College London; University of Warwick	Wilson, MH (corresponding author), Royal London Hosp, Londons Air Ambulance, Inst Prehosp Care, Helipad, London E1 1BB, England.	mark@rcsed.ac.uk		Wilson, Mark/0000-0002-2346-4911				Aerden D, 2014, ACTA CHIR BELG, V114, P228, DOI 10.1080/00015458.2014.11681017; Aguilar SA, 2013, J EMERG MED, V45, P210, DOI 10.1016/j.jemermed.2013.01.044; Ahmed Syed Moied, 2008, J Emerg Trauma Shock, V1, P97, DOI 10.4103/0974-2700.43190; American College of Surgeons, 2012, ADV TRAUM LIF SUPP S; [Anonymous], 2005, JEMS, V30, P14; Aslami H, 2010, NETH J MED, V68, P190; Atkinson JLD, 1998, J TRAUMA, V45, P941, DOI 10.1097/00005373-199811000-00016; Audebert HJ, 2013, NEUROLOGY, V81, P501, DOI 10.1212/WNL.0b013e31829e0fdd; Aylwin CJ, 2008, ANN ROY COLL SURG, V90, P54, DOI 10.1308/003588408X242286; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bredmose PP, 2009, EMERG MED J, V26, P62, DOI 10.1136/emj.2007.052753; Brenner ML, 2013, J TRAUMA ACUTE CARE, V75, P506, DOI 10.1097/TA.0b013e31829e5416; Bukur M, 2011, J SURG RES, V170, pE117, DOI 10.1016/j.jss.2011.04.005; Chaudery M, 2015, J TRAUMA ACUTE CARE, V78, P153, DOI 10.1097/TA.0000000000000472; Chiara O, 2002, INJURY, V33, P553, DOI 10.1016/S0020-1383(02)00123-7; Cooper GE, 1979, P NASA IND WORKSH HE, P255; Davenport R, 2014, CRIT CARE, V18, DOI 10.1186/cc13923; Davies GE, 2011, J TRAUMA, V70, pE75, DOI 10.1097/TA.0b013e3181f6f72f; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Ebinger M, 2014, JAMA-J AM MED ASSOC, V311, P1622, DOI 10.1001/jama.2014.2850; Ebinger M, 2013, JOVE-J VIS EXP, DOI 10.3791/50534; Ellis D, 2010, CASES PREHOSPITAL RE; Fortin JL, 2006, CLIN TOXICOL, V44, P37, DOI 10.1080/15563650600811870; Galvagno SM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009228.pub2; Galvagno SM, 2012, JAMA-J AM MED ASSOC, V307, P1602, DOI 10.1001/jama.2012.467; Garner AA, 2015, EMERG MED J, V32, P869, DOI 10.1136/emermed-2014-204390; Giannakopoulos GF, 2013, EUR J EMERG MED, V20, P79, DOI 10.1097/MEJ.0b013e328352ac9b; Goldstein P, 2005, Minerva Anestesiol, V71, P297; Gunning M, 2013, SAMJ, S. Afr. med. j., V103, P632, DOI 10.7196/samj.6656; Hacke W, 2004, LANCET, V363, P768; Helmreich RL, 1999, INT J AVIAT PSYCHOL, V9, P19, DOI 10.1207/s15327108ijap0901_2; Hilker M, 2013, THORAC CARDIOVASC SU, V61, P45; Hodgetts TJ, 2006, EMERG MED J, V23, P745, DOI 10.1136/emj.2006.039610; Kleber C, 2013, WORLD J SURG, V37, P1154, DOI 10.1007/s00268-013-1964-2; Knudsen L, 2011, ACTA ANAESTH SCAND, V55, P377, DOI 10.1111/j.1399-6576.2011.02400.x; Kragh JF, 2008, J TRAUMA, V64, pS38, DOI 10.1097/TA.0b013e31816086b1; Lamhaut L, 2012, RESUSCITATION, V83, pE177, DOI 10.1016/j.resuscitation.2012.03.016; Lee C, 2005, EMERG MED J, V22, P660, DOI 10.1136/emj.2005.024489; Lee C, 2007, EMERG MED J, V24, P130, DOI 10.1136/emj.2006.041384; Leis C, 2010, RESUSCITATION, V81, pS50; Lendrum RA, 2013, EMERG MED J, V30, P247, DOI 10.1136/emermed-2012-202302; Lockey D, 2014, BRIT J ANAESTH, V113, P220, DOI 10.1093/bja/aeu227; Lockey DJ, 2013, BMC ANESTHESIOL, V13, DOI 10.1186/1471-2253-13-21; Lyon RM, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-73; Morrison JJ, 2014, SURG-J R COLL SURG E, V12, P119, DOI 10.1016/j.surge.2013.10.004; Morrison JJ, 2013, ANN SURG, V257, P330, DOI 10.1097/SLA.0b013e31827eefcf; Olaussen A, 2012, PREHOSP DISASTER MED, V27, P468, DOI 10.1017/S1049023X12001124; Omori K, 2013, RESUSCITATION, V84, P1045, DOI 10.1016/j.resuscitation.2013.01.014; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Qureshi A, 2005, EMERG MED J, V22, P885, DOI 10.1136/emj.2004.015891; Ringh M, 2015, NEW ENGL J MED, V372, P2316, DOI 10.1056/NEJMoa1406038; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Sherren PB, 2014, EMERG MED J, V31, P229, DOI 10.1136/emermed-2012-201879; Shields A, 2013, EMERG MED J, V30, P350, DOI 10.1136/emermed-2012-201422; Smith AH, 2013, EMERG MED J, V30, P784, DOI 10.1136/emermed-2012-201581; Taylor C, 2012, INJURY, V43, P1843, DOI 10.1016/j.injury.2012.07.184; van Schuppen H, 2015, EUR J EMERG MED, V22, P384, DOI 10.1097/MEJ.0000000000000204; WALL MJ, 1994, J TRAUMA, V36, P131, DOI 10.1097/00005373-199401000-00025; Watkins CL, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-318; Weaver AE., 2013, SCAND J TRAUMA RESUS, V21, pS27, DOI DOI 10.1186/1757-7241-21-S1-S27; Weber JE, 2013, NEUROLOGY, V80, P163, DOI 10.1212/WNL.0b013e31827b90e5; Weiser C, 2013, RESUSCITATION, V84, P883, DOI 10.1016/j.resuscitation.2012.12.017; Wild G, 2013, J ROY ARMY MED CORPS, V159, P24, DOI 10.1136/jramc-2013-000013; Wise D, 2005, EMERG MED J, V22, P22, DOI 10.1136/emj.2003.012963	65	44	44	5	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 19	2015	386	10012					2526	2534		10.1016/S0140-6736(15)00985-X	http://dx.doi.org/10.1016/S0140-6736(15)00985-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CZ1LD	26738719				2023-01-03	WOS:000366866400027
J	Bach, PB; Pearson, SD				Bach, Peter B.; Pearson, Steven D.			Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Bach, Peter B.] Mem Sloan Kettering Canc Ctr, Hlth Outcomes Res Grp, New York, NY 10021 USA; [Pearson, Steven D.] Inst Clin & Econ Review, Boston, MA USA	Memorial Sloan Kettering Cancer Center	Bach, PB (corresponding author), Mem Sloan Kettering Canc Ctr, Hlth Outcomes Res Grp, 1275 York Ave,POB 44, New York, NY 10021 USA.	bachp@mskcc.org						Anderson JL, 2014, J AM COLL CARDIOL, V63, P2304, DOI 10.1016/j.jacc.2014.03.016; [Anonymous], 2013 COMP PRIC REP V; Bach PB, 2009, NEW ENGL J MED, V360, P626, DOI 10.1056/NEJMhpr0807774; Cherny NI, 2015, ANN ONCOL, V26, P1547, DOI 10.1093/annonc/mdv249; Dusetzina SB, 2014, J CLIN ONCOL, V32, P306, DOI 10.1200/JCO.2013.52.9123; Keehan SP, 2015, HEALTH AFFAIR, V34, P1407, DOI 10.1377/hlthaff.2015.0600; Loftus P., 2015, WALL STREET J	7	62	63	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	2015	314	23					2503	2504		10.1001/jama.2015.16843	http://dx.doi.org/10.1001/jama.2015.16843			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CY4PV	26619354				2023-01-03	WOS:000366391500013
J	Pearce, G; Pinnock, H; Epiphaniou, E; Parke, HL; Heavey, E; Griffiths, CJ; Greenhalgh, T; Sheikh, A; Taylor, SJC				Pearce, Gemma; Pinnock, Hilary; Epiphaniou, Eleni; Parke, Hannah L.; Heavey, Emily; Griffiths, Christopher J.; Greenhalgh, Trish; Sheikh, Aziz; Taylor, Stephanie J. C.			Experiences of Self-Management Support Following a Stroke: A Meta-Review of Qualitative Systematic Reviews	PLOS ONE			English	Review							REHABILITATION; EFFICACY; CARE	Background Supporting self-management in stroke patients improves psychological and functional outcomes but evidence on how to achieve this is sparse. We aimed to synthesise evidence from systematic reviews of qualitative studies in an overarching meta-review to inform the delivery and development of self-management support interventions. Methods We systematically searched eight electronic databases including MEDLINE, EMBASE and CINAHL for qualitative systematic reviews (published January 1993 to June 2012). We included studies exploring patients', carers' or health care professionals' experiences relevant to self-management support following a stroke, including studies describing the lived experience of surviving a stroke. We meta-synthesised the included review findings using a meta-ethnographic framework. Results Seven reviews, reporting 130 unique studies, were included. Themes emerging from the reviews were pertinent, consistent and showed data saturation; though explicit mention of self-management support was rare. Our meta-review highlighted the devastating impact of stroke on patients' self-image; the varying needs for self-management support across the trajectory of recovery; the need for psychological and emotional support throughout recovery particularly when physical recovery plateaus; the considerable information needs of patients and carers which also vary across the trajectory of recovery; the importance of good patient-professional communication; the potential benefits of goal-setting and action-planning; and the need for social support which might be met by groups for stroke survivors. Conclusions The observed data saturation suggests that, currently, no further qualitative research simply describing the lived experience of stroke is needed; we propose that it would be more useful to focus on qualitative research informing self-management support interventions and their implementation. Our findings demonstrate both the on-going importance of self-management support and the evolving priorities throughout the stages of recovery following a stroke. The challenge now is to ensure these findings inform routine practice and the development of interventions to support self-management amongst stroke survivors.	[Pearce, Gemma] Coventry Univ, CTEHR, Coventry, W Midlands, England; [Pinnock, Hilary; Sheikh, Aziz] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Epiphaniou, Eleni; Parke, Hannah L.; Griffiths, Christopher J.; Taylor, Stephanie J. C.] Barts & London Queen Marys Sch Med & Dent, Ctr Primary Care & Publ Hlth, mEsh, Blizard Inst, London, England; [Heavey, Emily] Univ York, Social Policy Res Unit, York YO10 5DD, N Yorkshire, England; [Greenhalgh, Trish] Univ Oxford, Div Med Sci, Nuffield Dept Primary Care Hlth Sci, Oxford, England	Coventry University; University of Edinburgh; University of London; Queen Mary University London; University of York - UK; University of Oxford	Taylor, SJC (corresponding author), Barts & London Queen Marys Sch Med & Dent, Ctr Primary Care & Publ Hlth, mEsh, Blizard Inst, London, England.	s.j.c.taylor@qmul.ac.uk	TAYLOR, STEPHANIE/GYV-4768-2022; Greenhalgh, Trisha/B-1825-2015; Pearce, Gary/S-3830-2017	Greenhalgh, Trisha/0000-0003-2369-8088; Pearce, Gary/0000-0003-3959-2616; Sheikh, Aziz/0000-0001-7022-3056; Taylor, Stephanie/0000-0001-7454-6354; Pearce, Gemma/0000-0002-2928-0048; Heavey, Emily/0000-0003-0920-7705	National Institute for Health Research Health Services and Delivery Research Programme [11/1014/04]; Primary Care Research Career Award from the Chief Scientist's Office of the Scottish Government; National Institute for Health Research [NF-SI-0512-10031, 11/1014/04] Funding Source: researchfish	National Institute for Health Research Health Services and Delivery Research Programme; Primary Care Research Career Award from the Chief Scientist's Office of the Scottish Government; National Institute for Health Research(National Institute for Health Research (NIHR))	This project was funded by the National Institute for Health Research Health Services and Delivery Research Programme (project number 11/1014/04. http://www.nets.nihr.ac.uk/projects/hsdr/11101404). The funders wrote the brief, called for applications, arranged peer review, and approved the study design, but had no role in data collection and analysis, decision to publish, or preparation of the manuscript. HP was supported at the time of the study by a Primary Care Research Career Award from the Chief Scientist's Office of the Scottish Government.	Adams KM, 2004, SUMM 1 ANN CROSS QUA; [Anonymous], 2010, MULT CHRON COND STRA; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Barnett-Page E, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-59; Boger E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130990; Boger EJ, 2013, DISABIL REHABIL, V35, P1415, DOI 10.3109/09638288.2012.737080; BURY M, 1991, SOCIOL HEALTH ILL, V13, P451, DOI 10.1111/j.1467-9566.1991.tb00522.x; Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-9566.ep11339939; Carandang R, 2006, JAMA-J AM MED ASSOC, V296, P2939, DOI 10.1001/jama.296.24.2939; Corbin J.M., 1988, UNENDING WORK CARE M; Department of Health, 2004, IMPR CHRON DIS MAN; Department of Health, 2001, EXP PAT NEW APPR CHR; Dixon-Woods M, 2008, J EVAL CLIN PRACT, V7, P125; Dixon-Woods Mary, 2005, J Health Serv Res Policy, V10, P45, DOI 10.1258/1355819052801804; Eilertsen G, 2013, J ADV NURS, V69, P514, DOI 10.1111/jan.12002; Gallacher K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001473; Goffman E., 1963, STIGMA NOTES MANAGEM; Goffman Erving, 1959, PRESENTATION SELF EV; Greenhalgh T, 2005, BRIT MED J, V331, P1064, DOI 10.1136/bmj.38636.593461.68; Hole E, 2014, SCI WORLD J, DOI 10.1155/2014/349151; Jones E. E., 1964, INGRATIATION SOCIAL; Jones F, 2011, DISABIL REHABIL, V33, P797, DOI 10.3109/09638288.2010.511415; Kung Jason, 2010, Open Dent J, V4, P84, DOI 10.2174/1874210601004020084; Lamb M, 2008, INT J EVID-BASED HEA, V6, P173, DOI 10.1111/j.1479-6988.2008.00079.x; LEARY MR, 1995, SELF PRESENTATION IM; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; LORIG K, 1984, GERONTOLOGIST, V24, P455; Lorig K R, 2001, Eff Clin Pract, V4, P256; Lui MHL, 2005, STROKE, V36, P2514, DOI 10.1161/01.STR.0000185743.41231.85; McCorkle R, 2011, CA-CANCER J CLIN, V61, P50, DOI 10.3322/caac.20093; McKevitt C, 2004, STROKE, V35, P1499, DOI 10.1161/01.STR.0000127532.64840.36; Murray J, 2003, BRIT J GEN PRACT, V53, P137; Noblit G.W., 1988, METAETHNOGRAPHY SYNT, V11; Parke HL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131448; Peoples H, 2011, SCAND J OCCUP THER, V18, P163, DOI 10.3109/11038128.2010.509887; Pinnock H, 2014, HLTH SERV DELIV RES, P2, DOI DOI 10.3310/HSDR02530; Reed MC, 2012, DISABIL REHABIL, V34, P553, DOI 10.3109/09638288.2011.613511; Salter K, 2008, J REHABIL MED, V40, P595, DOI 10.2340/16501977-0238; Sarre S, 2014, DISABIL REHABIL, V36, P716, DOI 10.3109/09638288.2013.814724; Satink T, 2013, ARCH PHYS MED REHAB, V94, P1171, DOI 10.1016/j.apmr.2013.01.011; Secretary of State for Health, 2006, OUR HLTH OUR CAR OUR; Walsh ME, 2015, DISABIL REHABIL, V37, P1599, DOI 10.3109/09638288.2014.974834; Wanless D, 2001, SECURING OUR FUTURE; Williams S, 2013, BRIT J OCCUP THER, V76, P370, DOI 10.4276/030802213X13757040168351; World Health Organization, 2002, INNOVATIVE CARE CHRO	45	41	41	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2015	10	12							e0141803	10.1371/journal.pone.0141803	http://dx.doi.org/10.1371/journal.pone.0141803			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CY9GR	26657458	Green Published, gold, Green Submitted			2023-01-03	WOS:000366715900004
J	Trevisanuto, D; Bertuola, F; Lanzoni, P; Cavallin, F; Matediana, E; Manzungu, OW; Gomez, E; Da Dalt, L; Putoto, G				Trevisanuto, Daniele; Bertuola, Federica; Lanzoni, Paolo; Cavallin, Francesco; Matediana, Eduardo; Manzungu, Olivier Wingi; Gomez, Ermelinda; Da Dalt, Liviana; Putoto, Giovanni			Effect of a Neonatal Resuscitation Course on Healthcare Providers' Performances Assessed by Video Recording in a Low-Resource Setting	PLOS ONE			English	Article							MORTALITY; BIRTH	Background We assessed the effect of an adapted neonatal resuscitation program (NRP) course on healthcare providers' performances in a low-resource setting through the use of video recording. Methods A video recorder, mounted to the radiant warmers in the delivery rooms at Beira Central Hospital, Mozambique, was used to record all resuscitations. One-hundred resuscitations (50 before and 50 after participation in an adapted NRP course) were collected and assessed based on a previously published score. Results All 100 neonates received initial steps; from these, 77 and 32 needed bag-mask ventilation (BMV) and chest compressions (CC), respectively. There was a significant improvement in resuscitation scores in all levels of resuscitation from before to after the course: for "initial steps", the score increased from 33% (IQR 28-39) to 44% (IQR 39-56), p<0.0001; for BMV, from 20% (20-40) to 40% (40-60), p = 0.001; and for CC, from 0% (0-10) to 20% (0-50), p = 0.01. Times of resuscitative interventions after the course were improved in comparison to those obtained before the course, but remained non-compliant with the recommended algorithm. Conclusions Although resuscitations remained below the recommended standards in terms of quality and time of execution, clinical practice of healthcare providers improved after participation in an adapted NRP course. Video recording was well-accepted by the staff, useful for objective assessment of performance during resuscitation, and can be used as an educational tool in a low-resource setting.	[Trevisanuto, Daniele; Bertuola, Federica; Da Dalt, Liviana] Univ Padua, Sch Med, Dept Women & Children Hlth, Azienda Osped Padova, Padua, Italy; [Lanzoni, Paolo; Putoto, Giovanni] Doctors Africa CUAMM, Padua, Italy; [Matediana, Eduardo] Beira Cent Hosp, Dept Obstet & Gynecol, Beira, Mozambique; [Manzungu, Olivier Wingi; Gomez, Ermelinda] Beira Cent Hosp, Dept Pediat, Beira, Mozambique	University of Padua; Azienda Ospedaliera - Universita di Padova	Trevisanuto, D (corresponding author), Univ Padua, Sch Med, Dept Women & Children Hlth, Azienda Osped Padova, Padua, Italy.	trevo@pediatria.unipd.it	Putoto, Giovanni/ABG-2069-2020; van Griensven, Martijn/F-5808-2012	van Griensven, Martijn/0000-0001-5104-9881	Associazione Pulcino, Italy	Associazione Pulcino, Italy	Associazione Pulcino, Italy supported the study providing funds for video cameras. The funders had no role in the study design or conduct; the management, analysis, or interpretation of the data; the preparation, review, or approval of the report; or the decision to submit the manuscript for publication.	American Heart Association American Academy of Pediatrics, 2011, NEON RES TXB; Brugada M, 2011, NEONATOLOGY, V100, P99, DOI 10.1159/000322009; Carbine DN, 2000, PEDIATRICS, V106, P654, DOI 10.1542/peds.106.4.654; Carlo WA, 2010, NEW ENGL J MED, V362, P614, DOI 10.1056/NEJMsa0806033; Dickson KE, 2014, LANCET, V384, P438, DOI 10.1016/S0140-6736(14)60582-1; Ersdal HL, 2013, RESUSCITATION, V84, P1422, DOI 10.1016/j.resuscitation.2013.04.005; Ersdal HL, 2012, PEDIATRICS, V129, pE1238, DOI 10.1542/peds.2011-3134; Jabbour M, 1996, ANN EMERG MED, V28, P690, DOI 10.1016/S0196-0644(96)70095-1; Kattwinkel J, 2010, PEDIATRICS, V126, pE1400, DOI 10.1542/peds.2010-2972E; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Lee ACC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S12; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; McCarthy LK, 2013, J PEDIATR-US, V163, P1553, DOI 10.1016/j.jpeds.2013.06.007; O'Donnell CPF, 2008, ARCH DIS CHILD-FETAL, V93, pF82, DOI 10.1136/adc.2007.118505; Opiyo N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001599; Perlman JM, 2015, CIRCULATION, V132, pS204, DOI 10.1161/CIR.0000000000000276; Schilleman K, 2012, RESUSCITATION, V83, P1135, DOI 10.1016/j.resuscitation.2012.01.036; Singhal N, 2012, RESUSCITATION, V83, P90, DOI 10.1016/j.resuscitation.2011.07.010; Trevisanuto D, 2007, PEDIATR ANESTH, V17, P28, DOI 10.1111/j.1460-9592.2006.02001.x; UNICEF, 2017, LEVELS TRENDS CHILD; Wall SN, 2009, INT J GYNECOL OBSTET, V107, pS47, DOI 10.1016/j.ijgo.2009.07.013; WHO, 2014, HLTH REL MILL DEV GO; World Health Organization,, 2012, GUID BAS NEWB RES; Xu T, 2014, RESUSCITATION, V85, P253, DOI 10.1016/j.resuscitation.2013.10.020	24	26	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2015	10	12							e0144443	10.1371/journal.pone.0144443	http://dx.doi.org/10.1371/journal.pone.0144443			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1ZA	26659661	Green Published, gold, Green Submitted			2023-01-03	WOS:000366903600047
J	Slocum, C; Gerrard, P; Black-Schaffer, R; Goldstein, R; Singhal, A; DiVita, MA; Ryan, CM; Mix, J; Purohit, M; Niewczyk, P; Kazis, L; Zafonte, R; Schneider, JC				Slocum, Chloe; Gerrard, Paul; Black-Schaffer, Randie; Goldstein, Richard; Singhal, Aneesh; DiVita, Margaret A.; Ryan, Colleen M.; Mix, Jacqueline; Purohit, Maulik; Niewczyk, Paulette; Kazis, Lewis; Zafonte, Ross; Schneider, Jeffrey C.			Functional Status Predicts Acute Care Readmissions from Inpatient Rehabilitation in the Stroke Population	PLOS ONE			English	Article							HOSPITAL READMISSIONS; PERFORMANCE; COMPLICATIONS; VALIDATION; DISCHARGE; HEALTH	Objective Acute care readmission risk is an increasingly recognized problem that has garnered significant attention, yet the reasons for acute care readmission in the inpatient rehabilitation population are complex and likely multifactorial. Information on both medical comorbidities and functional status is routinely collected for stroke patients participating in inpatient rehabilitation. We sought to determine whether functional status is a more robust predictor of acute care readmissions in the inpatient rehabilitation stroke population compared with medical comorbidities using a large, administrative data set. Methods A retrospective analysis of data from the Uniform Data System for Medical Rehabilitation from the years 2002 to 2011 was performed examining stroke patients admitted to inpatient rehabilitation facilities. A Basic Model for predicting acute care readmission risk based on age and functional status was compared with models incorporating functional status and medical comorbidities (Basic-Plus) or models including age and medical comorbidities alone (Age-Comorbidity). C-statistics were compared to evaluate model performance. Findings There were a total of 803,124 patients: 88,187 (11%) patients were transferred back to an acute hospital: 22,247 (2.8%) within 3 days, 43,481 (5.4%) within 7 days, and 85,431 (10.6%) within 30 days. The C-statistics for the Basic Model were 0.701, 0.672, and 0.682 at days 3, 7, and 30 respectively. As compared to the Basic Model, the best-performing Basic-Plus model was the Basic+Elixhauser model with C-statistics differences of +0.011, +0.011, and +0.012, and the best-performing Age-Comorbidity model was the Age+Elixhauser model with C-statistic differences of -0.124, -0.098, and -0.098 at days 3, 7, and 30 respectively. Conclusions Readmission models for the inpatient rehabilitation stroke population based on functional status and age showed better predictive ability than models based on medical comorbidities.	[Slocum, Chloe; Gerrard, Paul; Black-Schaffer, Randie; Goldstein, Richard; Zafonte, Ross; Schneider, Jeffrey C.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02138 USA; [Slocum, Chloe; Gerrard, Paul; Black-Schaffer, Randie; Zafonte, Ross; Schneider, Jeffrey C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Singhal, Aneesh] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [DiVita, Margaret A.; Mix, Jacqueline; Niewczyk, Paulette] Uniform Data Syst Med Rehabil, Amherst, NY USA; [Niewczyk, Paulette] Daemen Coll, Hlth Care Studies Dept, Amherst, NY USA; [Ryan, Colleen M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Sumner Redstone Burn Ctr,Surg Serv, Boston, MA USA; [Ryan, Colleen M.] Shriners Hosp Children Boston, Boston, MA USA; [Purohit, Maulik] Ft Belvoir Community Hosp, Natl Intrepid Ctr Excellence, Intrepid Spirit 1, Neurorehabil & Traumat Brain Injury, Ft Belvoir, VA USA; [Kazis, Lewis] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA	Harvard University; Harvard Medical School; Spaulding Rehabilitation Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Boston University	Schneider, JC (corresponding author), Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02138 USA.	jcschneider@partners.org	Schneider, Jeffrey/AAO-2126-2020; Black-Schaffer, Randie/AAY-4671-2021	Ryan, Colleen/0000-0002-6455-936X; DiVita, Margaret/0000-0002-4878-2959				Bhattacharya P, 2011, J NEUROL SCI, V307, P50, DOI 10.1016/j.jns.2011.05.022; BREZINSKI D, 1991, AM HEART J, V121, P1374, DOI 10.1016/0002-8703(91)90141-4; Brosseau Lucie, 1996, Physiotherapy Theory and Practice, V12, P161, DOI 10.3109/09593989609036432; Burke RE, 2013, JAMA INTERN MED, V173, P695, DOI 10.1001/jamainternmed.2013.171; Cesari M, 2005, J AM GERIATR SOC, V53, P1675, DOI 10.1111/j.1532-5415.2005.53501.x; Cesari Matteo, 2008, BMC Geriatr, V8, P34, DOI 10.1186/1471-2318-8-34; Cesari M, 2009, J AM GERIATR SOC, V57, P251, DOI 10.1111/j.1532-5415.2008.02126.x; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Chung DM, 2012, AM J PHYS MED REHAB, V91, P387, DOI 10.1097/PHM.0b013e3182aac27; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DISLER PB, 1993, ARCH PHYS MED REHAB, V74, P139; Donze J, 2013, JAMA INTERN MED, V173, P632, DOI 10.1001/jamainternmed.2013.3023; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Faulk CE, 2013, PM&R, V5, P757, DOI 10.1016/j.pmrj.2013.06.002; Gerrard P, 2015, AM J MANAG CARE, V21, pE282; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; Hamilton BB, 1999, ARCH PHYS MED REHAB, V80, P385, DOI 10.1016/S0003-9993(99)90274-5; Hodgson CL, 2013, CRIT CARE, V17, DOI 10.1186/cc11820; Hoyer EH, 2014, J HOSP MED, V9, P277, DOI 10.1002/jhm.2152; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Lin MF, 2013, INFORM SYST RES, V24, P906, DOI 10.1287/isre.2013.0480; Lo A, 2012, INT J STROKE, V7, P118, DOI 10.1111/j.1747-4949.2011.00694.x; Marks E, 2013, JAMA INTERN MED, V173, P629, DOI 10.1001/jamainternmed.2013.4065; Ohman EM, 2000, JAMA-J AM MED ASSOC, V284, P876, DOI 10.1001/jama.284.7.876; Ottenbacher KJ, 2012, J GERONTOL A-BIOL, V67, P875, DOI 10.1093/gerona/glr247; Pepe MS, 2013, STAT MED, V32, P1467, DOI 10.1002/sim.5727; Roth EJ, 2001, STROKE, V32, P523, DOI 10.1161/01.STR.32.2.523; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Schneider JC, 2013, PM&R, V5, P114, DOI 10.1016/j.pmrj.2012.07.014; Schneider JC, 2012, J TRAUMA ACUTE CARE, V73, P1596, DOI 10.1097/TA.0b013e318270d73d; Stillman G, 2009, PM&R, V1, P234, DOI 10.1016/j.pmrj.2008.10.014; Stineman MG, 2003, ARCH PHYS MED REHAB, V84, P712, DOI 10.1016/S0003-9993(03)04850-5; UB Foundation Activities Inc., 2004, UN DAT SYST MED REH; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]	35	34	34	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2015	10	11							e0142180	10.1371/journal.pone.0142180	http://dx.doi.org/10.1371/journal.pone.0142180			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7AW	26599009	Green Published, Green Submitted, gold			2023-01-03	WOS:000365853900021
J	Chai, M; Zhu, XP; Cui, HX; Jiang, CD; Zhang, JZ; Shi, L				Chai, Min; Zhu, Xiaopei; Cui, Hongxia; Jiang, Chuangdao; Zhang, Jinzheng; Shi, Lei			Lily Cultivars Have Allelopathic Potential in Controlling Orobanche aegyptiaca Persoon	PLOS ONE			English	Article							CHINESE MEDICINAL HERBS; ROOT PARASITIC PLANTS; GERMINATION STIMULANTS; SEED-GERMINATION; STRIGA SPP.; STRIGOLACTONES; WEEDS; SOIL; INHIBITION; INDUCTION	As a devastating holoparasitic weed, Orobanche aegyptiaca Persoon. (Egyptian broom-rape) causes serious damage to agricultural production and threatens economic development, which has raised widespread concern. The present study was conducted to determine whether lilies have the potential to be used as 'trap crops' for controlling O. aegyptiaca Persoon. In the experiments, the ability of three popular lily cultivars (Lilium Oriental hybrids 'Sorbonne', Lilium LA (Longiflorum hybrids x Asiatic hybrids) hybrids 'Ceb Dazzle', and Lilium Longiflorum hybrids (L. formosanum x L. longiflorum) 'L. formolongo') to induce O. aegyptiaca Persoon. seed germination was assessed. Parts of the three lily cultivars, including the rhizosphere soil and underground and above-ground organs, all induced "suicidal germination" of parasitic O. aegyptiaca Persoon. seed at four growth stages. Specifically, Sorbonne and Ceb Dazzle behaved with similar allelopathy, and the bulb, scale leaf and aerial stem exhibited stronger allelopathic effects on O. aegyptiaca Pers. germination compared to other organs. Aqueous L. formolongo leaf extracts may contain more stable, effective stimulants given that they induced the highest germination rate at 76.7% even though the extracts were serially diluted. We speculate that these organs may be advantageous in further isolating and purifying economical active substances that can be substitutes for GR24. These results indicate that lilies have the potential to be used as a trap crops or can be processed into green herbicide formulations that can be applied in agriculture production to rapidly deplete the seed bank of O. aegyptiaca Persoon. parasitic weeds in soil.	[Chai, Min; Zhu, Xiaopei; Cui, Hongxia; Jiang, Chuangdao; Zhang, Jinzheng; Shi, Lei] Chinese Acad Sci, Inst Bot, Key Lab Plant Resources, Beijing 100093, Peoples R China; [Chai, Min; Zhu, Xiaopei; Cui, Hongxia; Jiang, Chuangdao; Zhang, Jinzheng; Shi, Lei] Chinese Acad Sci, Inst Bot, Beijing Bot Garden, Beijing 100093, Peoples R China; [Chai, Min; Zhu, Xiaopei] Univ Chinese Acad Sci, Beijing 100049, Peoples R China	Chinese Academy of Sciences; Institute of Botany, CAS; Chinese Academy of Sciences; Institute of Botany, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Shi, L (corresponding author), Chinese Acad Sci, Inst Bot, Key Lab Plant Resources, Beijing 100093, Peoples R China.	shilei@ibcas.ac.cn			National High-tech Research and Development Projects (863 Program) [2011AA10020805, 2012BAC01B05]	National High-tech Research and Development Projects (863 Program)	This work was supported by grants 2011AA10020805 [LS] and 2012BAC01B05 [HXC] from National High-tech Research and Development Projects (863 Program) (http://www.863.gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Awad AA, 2006, PLANT GROWTH REGUL, V48, P221, DOI 10.1007/s10725-006-0009-3; BABIKER AGT, 1987, WEED RES, V27, P173, DOI 10.1111/j.1365-3180.1987.tb00751.x; Beveridge CA, 2006, CURR OPIN PLANT BIOL, V9, P35, DOI 10.1016/j.pbi.2005.11.006; Botanga CJ, 2003, CROP SCI, V43, P483, DOI 10.2135/cropsci2003.0483; Bouwmeester HJ, 2007, TRENDS PLANT SCI, V12, P224, DOI 10.1016/j.tplants.2007.03.009; Bouwmeester HJ, 2003, CURR OPIN PLANT BIOL, V6, P358, DOI 10.1016/S1369-5266(03)00065-7; BROWN R, 1951, BIOCHEM J, V48, P559, DOI 10.1042/bj0480559; Cheng ZH, 2013, ACTA AGR SCAND B-S P, V63, P169, DOI 10.1080/09064710.2012.734323; Dong SQ, 2012, ALLELOPATHY J, V30, P247; EDWARDS WG, 1976, Z PFLANZENPHYSIOL, V80, P105, DOI 10.1016/S0044-328X(76)80147-X; FOY C L, 1989, Reviews of Weed Science, V4, P123; Goldwasser Y, 1997, WEED SCI, V45, P756, DOI 10.1017/S0043174500088937; Gomez-Roldan V, 2008, NATURE, V455, P189, DOI 10.1038/nature07271; Hooper AM, 2009, PEST MANAG SCI, V65, P546, DOI 10.1002/ps.1731; Joel D. M., 2007, Horticultural Reviews, V33, P267, DOI 10.1002/9780470168011.ch4; Joel DM, 2000, CROP PROT, V19, P753, DOI 10.1016/S0261-2194(00)00100-9; JOHNSON AW, 1976, WEED RES, V16, P223, DOI 10.1111/j.1365-3180.1976.tb00406.x; Kgosi RL, 2012, WEED RES, V52, P197, DOI 10.1111/j.1365-3180.2012.00912.x; Khanh TD, 2005, CROP PROT, V24, P421, DOI 10.1016/j.cropro.2004.09.020; Klee H, 2008, NATURE, V455, P176, DOI 10.1038/455176a; KOHKI A, 2005, NATURE, V435, P824; Lins RD, 2006, WEED RES, V46, P313, DOI 10.1111/j.1365-3180.2006.00515.x; Lopez-Raez JA, 2008, NEW PHYTOL, V178, P863, DOI 10.1111/j.1469-8137.2008.02406.x; Ma YQ, 2014, J PLANT INTERACT, V9, P722, DOI 10.1080/17429145.2014.912358; Ma YQ, 2013, CROP SCI, V53, P260, DOI 10.2135/cropsci2012.03.0197; Ma YQ, 2012, AGRON J, V104, P569, DOI 10.2134/agronj2011.0372; Ma YQ, 2012, SCI CHINA LIFE SCI, V55, P250, DOI 10.1007/s11427-012-4302-2; Ma YQ, 2004, AGRON J, V96, P1349, DOI 10.2134/agronj2004.1349; Manschadi AM, 2001, WEED RES, V41, P311, DOI 10.1046/j.1365-3180.2001.00240.x; Mediene S, 2011, AGRON SUSTAIN DEV, V31, P491, DOI 10.1007/s13593-011-0009-1; Mwakaboko AS, 2011, PLANT CELL PHYSIOL, V52, P699, DOI 10.1093/pcp/pcr031; Parker C., 1993, ARMED DANGEROUS AM A; Parker C, 2012, WEED SCI, V60, P269, DOI 10.1614/WS-D-11-00068.1; Ratnadass A, 2012, AGRON SUSTAIN DEV, V32, P273, DOI 10.1007/s13593-011-0022-4; RILEY D, 1969, SOIL SCI SOC AM PRO, V33, P905, DOI 10.2136/sssaj1969.03615995003300060031x; Romanova V., 2001, P 7 INT PAR WEED S N, P80; Rubiales D, 2009, WEED RES, V49, P23, DOI 10.1111/j.1365-3180.2009.00742.x; SHAY FJ, 1973, PLANT PHYSIOL, V51, P1061, DOI 10.1104/pp.51.6.1061; WEGMANN K, 2002, 2 JOINT M WORK GROUP, P29; Westerdahl B. B., 1998, Journal of Nematology, V30, P581; WHITNEY PJ, 1981, ANN BOT-LONDON, V48, P919, DOI 10.1093/oxfordjournals.aob.a086201; WHITNEY PJ, 1978, ANN APPL BIOL, V89, P475, DOI 10.1111/j.1744-7348.1978.tb05976.x; Xie X, 2007, J AGR FOOD CHEM, V55, P8067, DOI 10.1021/jf0715121; Xie XN, 2010, ANNU REV PHYTOPATHOL, V48, P93, DOI 10.1146/annurev-phyto-073009-114453; Xu Peng, 2011, Journal of Northwest A & F University - Natural Science Edition, V39, P167; Yoneyama K, 2010, PLANT CELL PHYSIOL, V51, P1095, DOI 10.1093/pcp/pcq055; Yu M, 2004, CHINESE J SOIL SCI, V35, P377; Zhang W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059715	48	9	9	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2015	10	11							e0142811	10.1371/journal.pone.0142811	http://dx.doi.org/10.1371/journal.pone.0142811			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA2MI	26565398	gold, Green Published, Green Submitted			2023-01-03	WOS:000367628500056
J	Falade-Nwulia, O; Seaberg, EC; Snider, AE; Rinaldo, CR; Phair, J; Witt, MD; Thio, CL				Falade-Nwulia, Oluwaseun; Seaberg, Eric C.; Snider, Anna E.; Rinaldo, Charles R.; Phair, John; Witt, Mallory D.; Thio, Chloe L.			Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART Periods A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							MULTICENTER AIDS COHORT; ANTIRETROVIRAL THERAPY; RISK BEHAVIOR; VIRAL LOAD; YOUNG MEN; IMMUNIZATION; RESPONSES; TRENDS	Background: Men who have sex with men (MSM) are at high risk for hepatitis B virus (HBV) infection. Data on the effect of highly active antiretroviral therapy (HAART) on incident HBV infection in HIV-infected and HIV-uninfected MSM are limited. Objective: To determine predictors of incident HBV infection in MSM during pre-HAART and HAART periods. Design: Observational cohort study. Setting: Cohort of MSM who have, or are at risk for, HIV infection. Patients: 2375 HBV-uninfected MSM in the Multicenter AIDS Cohort Study. Measurements: Poisson regression was used to compare incidence rates of HBV infection in the pre-HAART and HAART eras and to identify factors associated with incidence of HBV infection. Results: In 25 322 person-years of follow-up, 244 incident HBV infections occurred. The unadjusted incidence rate was higher in HIV-infected MSM than in HIV-uninfected MSM (incidence rate ratio [IRR], 1.9 [95% CI, 1.5 to 2.4]) and was significantly lower in the HAART era than in the pre-HAART era among HIV-infected (IRR, 0.2 [CI, 0.1 to 0.4]) and HIV-uninfected (IRR, 0.3 [CI, 0.2 to 0.4]) MSM. Age younger than 40 years (IRR, 2.3 [CI, 1.7 to 3.0]), more than 1 recent sexual partner (IRR, 3.1 [CI, 2.3 to 4.2]), and HIV infection (IRR, 2.4 [CI, 1.8 to 3.1]) were independently associated with higher incidence of HBV infection, whereas HBV vaccination was protective (IRR, 0.3 [CI, 0.2 to 0.4]). Highly active antiretroviral therapy with HIV RNA levels less than 400 copies/mL was associated with protection (IRR, 0.2 [CI, 0.1 to 0.5]), but HAART in those with HIV RNA levels of 400 copies/mL or greater was not. Limitation: The observational nature limits inferences about causality. Conclusion: Effective HAART is associated with lower incidence of HBV infection; however, even in the HAART era, incidence of HBV infection remains high among MSM.	[Falade-Nwulia, Oluwaseun] Johns Hopkins Univ, Baltimore, MD 21205 USA; [Snider, Anna E.; Thio, Chloe L.] Johns Hopkins Univ, Baltimore, MD 21231 USA; [Rinaldo, Charles R.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Witt, Mallory D.] Univ Calif Los Angeles, Los Angeles Biomed Res Inst Harbor, Med Ctr, Torrance, CA 90502 USA	Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; Feinberg School of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Falade-Nwulia, O (corresponding author), Johns Hopkins Univ, 725 North Wolfe St,Room 215, Baltimore, MD 21205 USA.	ofalade1@jhmi.edu; ecs@jhu.edu		Falade-Nwulia, Oluwaseun/0000-0003-2321-2295	National Institute of Allergy and Infectious Diseases; National Cancer Institute [UO1-AI-35042, UL1-RR025005, UO1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041, UL1TR000124, R03AI096918]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035043, U01AI035042, UM1AI035043, U01AI035040, U01AI035039, U01AI035041, R03AI096918] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	By the National Institute of Allergy and Infectious Diseases, with additional funding from the National Cancer Institute (UO1-AI-35042, UL1-RR025005, UO1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041, UL1TR000124, and R03AI096918).	[Anonymous], 1991, MMWR Recomm Rep, V40, P1; Centers for Disease Control and Prevention, 2015, VIR HEP STAT SURV SU; Centers for Disease Control and Prevention, 2015, VIR HEP CDC REC SPEC; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V52, P1252; Centers for Disease Control and Prevention (CDC), 1982, MMWR-MORBID MORTAL W, V31, P327; Centers for Disease Control (CDC), 1982, MMWR Morb Mortal Wkly Rep, V31, P317; Chen SY, 2002, AM J PUBLIC HEALTH, V92, P1387, DOI 10.2105/AJPH.92.9.1387-a; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; Chun HM, 2010, CLIN INFECT DIS, V50, P426, DOI 10.1086/649885; Detels R, 2012, PUBLIC HEALTH, V126, P196, DOI 10.1016/j.puhe.2011.11.013; Detels R, 2001, AIDS, V15, P347, DOI 10.1097/00002030-200102160-00008; Gatanaga H, 2013, CLIN INFECT DIS, V56, P1812, DOI 10.1093/cid/cit145; Heffelfinger JD, 2007, AM J PUBLIC HEALTH, V97, P1076, DOI 10.2105/AJPH.2005.070417; Heuft MM, 2014, AIDS, V28, P999, DOI 10.1097/QAD.0000000000000180; Hoover KW, 2012, SEX TRANSM DIS, V39, P349, DOI 10.1097/OLQ.0b013e318244a923; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; Kellerman SE, 2003, J INFECT DIS, V188, P571, DOI 10.1086/377135; Landrum ML, 2010, AIDS, V24, P545, DOI 10.1097/QAD.0b013e32832cd99e; Leichliter JS, 2013, JAIDS-J ACQ IMM DEF, V63, P254, DOI 10.1097/QAI.0b013e31828e0cfc; MacKellar DA, 2001, AM J PUBLIC HEALTH, V91, P965, DOI 10.2105/AJPH.91.6.965; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Menza TW, 2011, AIDS BEHAV, V15, P319, DOI 10.1007/s10461-009-9626-y; Miyazawa M, 2009, AIDS, V23, P161, DOI 10.1097/QAD.0b013e3283196a80; Mizukoshi E, 2008, J INFECT DIS, V198, P203, DOI 10.1086/589510; Purcell David W, 2012, Open AIDS J, V6, P98, DOI 10.2174/1874613601206010098; Resino S, 2003, J CLIN IMMUNOL, V23, P279, DOI 10.1023/A:1024536816684; Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8; Watanabe T, 2015, ANTIMICROB AGENTS CH, V59, P1292, DOI 10.1128/AAC.04459-14; Weinbaum CM, 2008, AM J PUBLIC HEALTH, V98, P839, DOI 10.2105/AJPH.2006.101915; Wiegand J, 2010, J VIRAL HEPATITIS, V17, P631, DOI 10.1111/j.1365-2893.2009.01220.x	30	17	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 3	2015	163	9					673	+		10.7326/M15-0547	http://dx.doi.org/10.7326/M15-0547			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CX3PF	26457744	Green Accepted			2023-01-03	WOS:000365610600004
J	Nakatsuji, M; Inoue, H; Kohno, M; Saito, M; Tsuge, S; Shimizu, S; Ishida, A; Ishibashi, O; Inui, T				Nakatsuji, Masatoshi; Inoue, Haruka; Kohno, Masaki; Saito, Mayu; Tsuge, Syogo; Shimizu, Shota; Ishida, Atsuko; Ishibashi, Osamu; Inui, Takashi			Human Lipocalin-Type Prostaglandin D Synthase-Based Drug Delivery System for Poorly Water-Soluble Anti-Cancer Drug SN-38	PLOS ONE			English	Article							LIPOPHILIC LIGANDS; POLYMERIC MICELLES; CANCER; CPT-11; SN38; MODEL; TUMOR; CAMPTOTHECIN; IRINOTECAN; BINDING	Lipocalin-type prostaglandin D synthase (L-PGDS) is a member of the lipocalin superfamily, which is composed of secretory transporter proteins, and binds a wide variety of small hydrophobic molecules. Using this function, we have reported the feasibility of using L-PGDS as a novel drug delivery vehicle for poorly water-soluble drugs. In this study, we show the development of a drug delivery system using L-PGDS, one that enables the direct clinical use of 7-ethyl-10-hydroxy-camptothecin (SN-38), a poorly water-soluble anti-cancer drug. In the presence of 2 mM L-PGDS, the concentration of SN-38 in PBS increased 1,130-fold as compared with that in PBS. Calorimetric experiments revealed that L-PGDS bound SN-38 at a molecular ratio of 1: 3 with a dissociation constant value of 60 mu M. The results of an in vitro growth inhibition assay revealed that the SN-38/L-PGDS complexes showed high anti-tumor activity against 3 human cancer cell lines, i.e., Colo201, MDA-MB-231, and PC-3 with a potency similar to that of SN-38 used alone. The intravenous administration of SN-38/L-PGDS complexes to mice bearing Colo201 tumors showed a pronounced anti-tumor effect. Intestinal mucositis, which is one of the side effects of this drug, was not observed in mice administered SN-38/L-PGDS complexes. Taken together, L-PGDS enables the direct usage of SN-38 with reduced side effects.	[Nakatsuji, Masatoshi; Inoue, Haruka; Kohno, Masaki; Saito, Mayu; Tsuge, Syogo; Shimizu, Shota; Ishida, Atsuko; Ishibashi, Osamu; Inui, Takashi] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Appl Life Sci, Naka Ku, Sakai, Osaka 5998531, Japan	Osaka Metropolitan University	Inui, T (corresponding author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Appl Life Sci, Naka Ku, 1-1 Gakuen Cho, Sakai, Osaka 5998531, Japan.	inuit@bioinfo.osakafu-u.ac.jp	Ishibashi, Osamu/J-8413-2019; Inui, Takashi/G-1069-2011	Ishibashi, Osamu/0000-0003-4698-460X; 	Japan Society for the Promotion of Science [25242046, 21200076]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Grants 25242046 (to TI), and 21200076 (to TI) from Japan Society for the Promotion of Science (http://www.jsps.go.jp/english/).	Abu Lila AS, 2013, J CONTROL RELEASE, V172, P38, DOI 10.1016/j.jconrel.2013.07.026; Al-Jamal WT, 2011, ACCOUNTS CHEM RES, V44, P1094, DOI 10.1021/ar200105p; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Bae YH, 2011, J CONTROL RELEASE, V153, P198, DOI 10.1016/j.jconrel.2011.06.001; Bala V, 2013, J CONTROL RELEASE, V172, P48, DOI 10.1016/j.jconrel.2013.07.022; Cavadas M, 2011, NANOMED-NANOTECHNOL, V7, P730, DOI 10.1016/j.nano.2011.04.006; Chadha R, 2008, J SCI IND RES INDIA, V67, P185; Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223; Ebrahimnejad P, 2011, INT J PHARMACEUT, V406, P122, DOI 10.1016/j.ijpharm.2010.12.022; Fukuhara A, 2012, J CONTROL RELEASE, V159, P143, DOI 10.1016/j.jconrel.2011.12.020; Fukuhara A, 2012, BIOCHEM J, V443, P75, DOI 10.1042/BJ20111889; FUKUOKA M, 1992, J CLIN ONCOL, V10, P16, DOI 10.1200/JCO.1992.10.1.16; Garcia-Carbonero R, 2002, CLIN CANCER RES, V8, P641; Gong J, 2012, J CONTROL RELEASE, V159, P312, DOI 10.1016/j.jconrel.2011.12.012; Guichard S, 1999, BRIT J CANCER, V80, P364, DOI 10.1038/sj.bjc.6690364; Guo Q, 2012, COLLOID SURFACE B, V100, P138, DOI 10.1016/j.colsurfb.2012.04.041; Inoue K, 2009, J BIOCHEM, V145, P169, DOI 10.1093/jb/mvn154; Inui T, 2003, J BIOL CHEM, V278, P2845, DOI 10.1074/jbc.M209934200; Inui T, 2014, J CEREBR BLOOD F MET, V34, P1558, DOI 10.1038/jcbfm.2014.127; Jiskoot W, 2009, PHARM RES-DORDR, V26, P1303, DOI 10.1007/s11095-009-9855-9; Koizumi F, 2006, CANCER RES, V66, P10048, DOI 10.1158/0008-5472.CAN-06-1605; Kume S, 2012, BIOCHEM J, V446, P279, DOI 10.1042/BJ20120324; Melo MLP, 2008, CANCER CHEMOTH PHARM, V61, P775, DOI 10.1007/s00280-007-0534-4; Meyer-Losic F, 2008, CLIN CANCER RES, V14, P2145, DOI 10.1158/1078-0432.CCR-07-4580; Miyamoto Y, 2010, J STRUCT BIOL, V169, P209, DOI 10.1016/j.jsb.2009.10.005; Mizoguchi M, 2015, EUR J PHARM SCI, V74, P77, DOI 10.1016/j.ejps.2015.04.012; Peng CL, 2009, BIOMATERIALS, V30, P3614, DOI 10.1016/j.biomaterials.2009.03.048; ROTHENBERG ML, 1993, J CLIN ONCOL, V11, P2194, DOI 10.1200/JCO.1993.11.11.2194; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; Sapra P, 2008, CLIN CANCER RES, V14, P1888, DOI 10.1158/1078-0432.CCR-07-4456; Sepehri N, 2014, INT J PHARMACEUT, V471, P485, DOI 10.1016/j.ijpharm.2014.05.046; Shimamoto S, 2007, J BIOL CHEM, V282, P31373, DOI 10.1074/jbc.M700123200; Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402; Slatter JG, 2000, DRUG METAB DISPOS, V28, P423; Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023; Takasuna K, 1996, CANCER RES, V56, P3752; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Urade Y, 2000, BBA-PROTEIN STRUCT M, V1482, P259, DOI 10.1016/S0167-4838(00)00161-8; Vangara KK, 2014, AAPS PHARMSCITECH, V15, P472, DOI 10.1208/s12249-013-0068-5; Verhoef JJF, 2013, DRUG DELIV TRANSL RE, V3, P499, DOI 10.1007/s13346-013-0176-5; Zhao H, 2008, BIOCONJUGATE CHEM, V19, P849, DOI 10.1021/bc700333s; Zhou YY, 2010, FASEB J, V24, P4668, DOI 10.1096/fj.10-164863	44	6	7	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2015	10	11							e0142206	10.1371/journal.pone.0142206	http://dx.doi.org/10.1371/journal.pone.0142206			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV1QH	26529243	Green Published, Green Submitted, gold			2023-01-03	WOS:000364032600110
J	Gray, AL; Wirtz, VJ; M'tHoen, EF; Reich, MR; Hogerzeil, HV				Gray, Andy L.; Wirtz, Veronika J.; M'tHoen, Ellen F.; Reich, Michael R.; Hogerzeil, Hans V.			Essential medicines are still essential	LANCET			English	Editorial Material									[Gray, Andy L.; Wirtz, Veronika J.; M'tHoen, Ellen F.; Reich, Michael R.; Hogerzeil, Hans V.] Lancet Commiss Essential Med Policies, Mexico City, DF, Mexico; [Gray, Andy L.] Univ KwaZulu Natal, Sch Hlth Sci, Durban, South Africa; [Wirtz, Veronika J.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Reich, Michael R.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [M'tHoen, Ellen F.; Hogerzeil, Hans V.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands	University of Kwazulu Natal; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; University of Groningen	Hogerzeil, HV (corresponding author), Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.	h.v.hogerzeil@umcg.nl	Wirtz, Veornika/AAG-9712-2019; Gray, Andrew/F-2104-2013	Gray, Andrew/0000-0001-7815-8180; 't Hoen, Ellen/0000-0003-4477-6866; Wirtz, Veronika J./0000-0002-0863-8768				[Anonymous], 2014, LANCET, V384, P1642, DOI 10.1016/S0140-6736(14)62017-1; [Anonymous], 2015, NY TIMES; [Anonymous], 2013, WHO TECHN REP SER, V985; Hogerzeil HV, 2004, BRIT MED J, V329, P1169, DOI 10.1136/bmj.329.7475.1169; Manikandan S, 2015, J PHARMACOL PHARMACO, V6, P123, DOI 10.4103/0976-500X.162008; Moucheraud C, 2015, B WORLD HEALTH ORGAN, V93, P693, DOI 10.2471/BLT.14.149914; van de Ven N, 2015, HEPATOLOGY, V61, P1174, DOI 10.1002/hep.27641; WHO, 2015, WHO TECH REP SER, V994, P1; WHO, 2002, WHO TECHN REP SER, V914, P14; WHO, 2005, WHO TECHN REP SER, V933; WHO, 2015, PAT SIT KEY PROD TRE; World Health Organization, 2015, 19 WHO MOD LIST ESS; World Health Organization, 2012, PROP INCL TRAST WHO; World Trade Organization, 2006, PHARM PAT TRIPS AGR	14	21	24	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	2015	386	10004					1601	1603		10.1016/S0140-6736(15)00514-0	http://dx.doi.org/10.1016/S0140-6736(15)00514-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CU0HS	26595616				2023-01-03	WOS:000363197500005
J	Okoshi, T; Yamaguchi, I; Ozawa, D; Hasegawa, K; Naiki, H				Okoshi, Tadakazu; Yamaguchi, Itaru; Ozawa, Daisaku; Hasegawa, Kazuhiro; Naiki, Hironobu			Endocytosed 2-Microglobulin Amyloid Fibrils Induce Necrosis and Apoptosis of Rabbit Synovial Fibroblasts by Disrupting Endosomal/Lysosomal Membranes: A Novel Mechanism on the Cytotoxicity of Amyloid Fibrils	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM; CELL-DEATH; PROTEIN; BETA(2)-MICROGLOBULIN; BETA-2-MICROGLOBULIN; OLIGOMERS; POLYMERIZATION; HEMODIALYSIS; AGGREGATION; DYSFUNCTION	Dialysis-related amyloidosis is a major complication in long-term hemodialysis patients. In dialysis-related amyloidosis, beta 2-microglobulin (beta 2-m) amyloid fibrils deposit in the osteoarticular tissue, leading to carpal tunnel syndrome and destructive arthropathy with cystic bone lesions, but the mechanism by which these amyloid fibrils destruct bone and joint tissue is not fully understood. In this study, we assessed the cytotoxic effect of beta 2-m amyloid fibrils on the cultured rabbit synovial fibroblasts. Under light microscopy, the cells treated with amyloid fibrils exhibited both necrotic and apoptotic changes, while the cells treated with beta 2-m monomers and vehicle buffer exhibited no morphological changes. As compared to beta 2-m monomers and vehicle buffer, beta 2-m amyloid fibrils significantly reduced cellular viability as measured by the lactate dehydrogenase release assay and the 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction assay and significantly increased the percentage of apoptotic cells as measured by the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling method. beta 2-m amyloid fibrils added to the medium adhered to cell surfaces, but did not disrupt artificial plasma membranes as measured by the liposome dye release assay. Interestingly, when the cells were incubated with amyloid fibrils for several hours, many endosomes/lysosomes filled with amyloid fibrils were observed under confocal laser microscopy and electron microscopy, Moreover, some endosomal/lysosomal membranes were disrupted by intravesicular fibrils, leading to the leakage of the fibrils into the cytosol and adjacent to mitochondria. Inhibition of actin-dependent endocytosis by cytochalasin D attenuated the toxicity of amyloid fibrils. These results suggest that endocytosed beta 2-m amyloid fibrils induce necrosis and apoptosis by disrupting endosomal/lysosomal membranes, and this novel mechanism on the cytotoxicity of amyloid fibrils is described.	[Okoshi, Tadakazu; Yamaguchi, Itaru; Ozawa, Daisaku; Hasegawa, Kazuhiro; Naiki, Hironobu] Univ Fukui, Fac Med Sci, Dept Pathol Sci, Div Mol Pathol, Fukui 910, Japan	University of Fukui	Naiki, H (corresponding author), Univ Fukui, Fac Med Sci, Dept Pathol Sci, Div Mol Pathol, Fukui 910, Japan.	naiki@u-fukui.ac.jp	Naiki, Hironobu/G-5599-2014		Ministry of Education, Culture, Sports, Science, and Technology, Japan [26860236, 25293094]; Ministry of Health, Labour and Welfare, Japan [H23-012]	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported in part by grants-in-aid for young scientists (B) 26860236 (TO) and scientific research (B) 25293094 (HN) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (http://www.mext.go.jp/), and for research on specific diseases "amyloidosis" H23-012 (HN) from the Ministry of Health, Labour and Welfare, Japan (http://www.mhlw.go.jp/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Argiles A, 2002, NEPHROL DIAL TRANSPL, V17, P1136, DOI 10.1093/ndt/17.6.1136; BARLAND P, 1962, J CELL BIOL, V14, P207, DOI 10.1083/jcb.14.2.207; Bellotti V, 2008, CURR OPIN STRUC BIOL, V18, P771, DOI 10.1016/j.sbi.2008.10.001; Bucciantini M, 2012, FASEB J, V26, P818, DOI 10.1096/fj.11-189381; Bullough PG, 2012, HISTOLOGY PATHOLOGIS, P107; CAMPISTOL JM, 1992, AM J PATHOL, V141, P241; Campistol JM, 1996, KIDNEY INT, V50, P1262, DOI 10.1038/ki.1996.436; Cecchi C, 2013, BIOPHYS CHEM, V182, P30, DOI 10.1016/j.bpc.2013.06.003; CHARRA B, 1985, P EUR DIAL TRANS, V21, P291; Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Davies P, 1978, Front Biol, V46, P143; Davison AM, 1995, NEPHROL DIAL TRANSPL, V10, P48; Demuro A, 2013, J NEUROSCI, V33, P3824, DOI 10.1523/JNEUROSCI.4367-12.2013; DESTRIHOU CV, 1991, KIDNEY INT, V39, P1012, DOI 10.1038/ki.1991.128; Ditaranto K, 2001, NEUROBIOL DIS, V8, P19, DOI 10.1006/nbdi.2000.0364; Eichner T, 2011, FEBS J, V278, P3868, DOI 10.1111/j.1742-4658.2011.08186.x; Eisenberg D, 2012, CELL, V148, P1188, DOI 10.1016/j.cell.2012.02.022; Engel MFM, 2008, P NATL ACAD SCI USA, V105, P6033, DOI 10.1073/pnas.0708354105; Fell H B, 1978, J Clin Pathol Suppl (R Coll Pathol), V12, P14; Floege J, 1996, NEPHRON, V72, P9, DOI 10.1159/000188801; Floege J, 2001, KIDNEY INT, V59, pS164, DOI 10.1046/j.1523-1755.2001.59780164.x; Garcia-Garcia M, 1999, KIDNEY INT, V55, P899, DOI 10.1046/j.1523-1755.1999.055003899.x; Gargar C, 1999, KIDNEY INT, V55, P1983, DOI 10.1046/j.1523-1755.1999.00430.x; Gejyo F, 1990, Contrib Nephrol, V78, P47; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GEJYO F, 1986, NEW ENGL J MED, V314, P585; GEORGESCU HI, 1988, IN VITRO CELL DEV B, V24, P1015; Gharibyan AL, 2007, J MOL BIOL, V365, P1337, DOI 10.1016/j.jmb.2006.10.101; GOREVIC PD, 1986, P NATL ACAD SCI USA, V83, P7908, DOI 10.1073/pnas.83.20.7908; Guan J, 2014, EMBO MOL MED, V6, P1493, DOI 10.15252/emmm.201404190; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Habib LK, 2010, J BIOL CHEM, V285, P38933, DOI 10.1074/jbc.M110.132860; Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217; Huang B, 2009, BIOCHEMISTRY-US, V48, P5794, DOI 10.1021/bi900219c; Jakhria T, 2014, J BIOL CHEM, V289, P35781, DOI 10.1074/jbc.M114.586222; Kihara M, 2005, J BIOL CHEM, V280, P12012, DOI 10.1074/jbc.M411949200; Kiichle C, 1996, AM J NEPHROL, V16, P484, DOI 10.1159/000169048; KOCH KM, 1992, KIDNEY INT, V41, P1416, DOI 10.1038/ki.1992.207; Kumar V., 2012, ROBBINS BASIC PATHOL, V9, P1; Leung E, 2011, NEUROBIOL AGING, V32, P387, DOI 10.1016/j.neurobiolaging.2009.02.025; Lonnemann G, 2002, J AM SOC NEPHROL, V13, pS72; Malchiodi-Albedi F, 2010, BBA-MOL BASIS DIS, V1802, P406, DOI 10.1016/j.bbadis.2010.01.007; Meratan AA, 2011, J MOL BIOL, V409, P826, DOI 10.1016/j.jmb.2011.04.045; Naiki H, 2009, J BIOCHEM, V146, P751, DOI 10.1093/jb/mvp119; OHASHI K, 1992, KIDNEY INT, V41, P1646, DOI 10.1038/ki.1992.237; Okada T, 2008, J MOL BIOL, V382, P1066, DOI 10.1016/j.jmb.2008.07.072; Okada T, 2007, J MOL BIOL, V371, P481, DOI 10.1016/j.jmb.2007.05.069; Ookoshi T, 2008, NEPHROL DIAL TRANSPL, V23, P3247, DOI 10.1093/ndt/gfn231; Porter MY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027353; Ritchlin C, 2000, ARTHRITIS RES, V2, P356, DOI 10.1186/ar112; Sheynis T, 2013, BIOPHYS J, V105, P745, DOI 10.1016/j.bpj.2013.06.015; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Umeda T, 2011, J NEUROSCI RES, V89, P1031, DOI 10.1002/jnr.22640; Wakabayashi M, 2007, J MOL BIOL, V371, P924, DOI 10.1016/j.jmb.2007.06.008; Walsh P, 2014, J BIOL CHEM, V289, P10419, DOI 10.1074/jbc.M113.515866; Xue WF, 2009, J BIOL CHEM, V284, P34272, DOI 10.1074/jbc.M109.049809	58	21	21	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2015	10	9							e0139330	10.1371/journal.pone.0139330	http://dx.doi.org/10.1371/journal.pone.0139330			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6GF	26421922	Green Published, gold, Green Submitted			2023-01-03	WOS:000362175700096
J	Herbst, RS; Baas, P; Kim, DW; Felip, E; Perez-Gracia, JL; Han, JY; Molina, J; Kim, JH; Arvis, CD; Ahn, MJ; Majem, M; Fidler, MJ; de Castro, G; Garrido, M; Lubiniecki, GM; Shentu, Y; Im, E; Dolled-Filhart, M; Garon, EB				Herbst, Roy S.; Baas, Paul; Kim, Dong-Wan; Felip, Enriqueta; Perez-Gracia, Jose L.; Han, Ji-Youn; Molina, Julian; Kim, Joo-Hang; Arvis, Catherine Dubos; Ahn, Myung-Ju; Majem, Margarita; Fidler, Mary J.; de Castro, Gilberto, Jr.; Garrido, Marcelo; Lubiniecki, Gregory M.; Shentu, Yue; Im, Ellie; Dolled-Filhart, Marisa; Garon, Edward B.			Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial	LANCET			English	Article							ANTI-PD-L1 ANTIBODY; BLOCKADE; THERAPY; CHEMOTHERAPY; NIVOLUMAB; PD-L1	Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. Methods We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m(2) every 3 weeks. The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumour cells. We used a threshold for significance of p<0.00825 (one-sided) for the analysis of overall survival and a threshold of p<0.001 for progression-free survival. This trial is registered at ClinicalTrials.gov, number NCT01905657. Findings Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients:345 allocated to pembrolizumab 2 mg/kg, 346 allocated to pembrolizumab 10 mg/kg, and 343 allocated to docetaxel. By Sept 30, 2015, 521 patients had died. In the total population, median overall survival was 10.4 months with pembrolizumab 2 mg/kg, 12.7 months with pembrolizumab 10 mg/kg, and 8.5 months with docetaxel. Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel (hazard ratio [HR] 0.71, 95% CI 0.58-0.88; p=0.0008) and for pembrolizumab 10 mg/kg versus docetaxel (0.61, 0.49-0.75; p<0.0001). Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg, 4.0 months with pembrolizumab 10 mg/kg, and 4.0 months with docetaxel, with no significant difference for pembrolizumab 2 mg/kg versus docetaxel (0.88, 0.74-1.05; p=0.07) or for pembrolizumab 10 mg/kg versus docetaxel (HR 0.79, 95% CI 0.66-0.94; p=0.004). Among patients with at least 50% of tumour cells expressing PD-L1, overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 14.9 months vs 8.2 months; HR 0.54, 95% CI 0.38-0.77; p=0.0002) and with pembrolizumab 10 mg/kg than with docetaxel (17.3 months vs 8.2 months; 0.50, 0.36-0.70; p<0.0001). Likewise, for this patient population, progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 5.0 months vs 4.1 months; HR 0.59, 95% CI 0.44-0.78; p=0.0001) and with pembrolizumab 10 mg/kg than with docetaxel (5.2 months vs 4.1 months; 0.59, 0.45-0.78; p<0.0001). Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel (43 [13%] of 339 patients given 2 mg/kg, 55 [16%] of 343 given 10 mg/kg, and 109 [35%] of 309 given docetaxel). Interpretation Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection.	[Herbst, Roy S.] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA; [Herbst, Roy S.] Smilow Canc Hosp, New Haven, CT USA; [Baas, Paul] Netherlands Canc Inst, Amsterdam, Netherlands; [Baas, Paul] Acad Med Hosp Amsterdam, Amsterdam, Netherlands; [Kim, Dong-Wan] Seoul Natl Univ Hosp, Seoul 110744, South Korea; [Felip, Enriqueta] Vall DHebron Univ Hosp, Barcelona, Spain; [Felip, Enriqueta] Vall dHebron Inst Oncol, Barcelona, Spain; [Perez-Gracia, Jose L.] Univ Navarra Clin, Pamplona, Spain; [Han, Ji-Youn] Natl Canc Ctr, Goyang, South Korea; [Molina, Julian] Mayo Clin, Rochester, MN USA; [Kim, Joo-Hang] CHA Univ, CHA Bundang Med Ctr, Gyeonggi Do, South Korea; [Arvis, Catherine Dubos] Ctr Francois Baclesse, Caen, France; [Ahn, Myung-Ju] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Majem, Margarita] Hosp Santa Creu & Sant Pau, Barcelona, Spain; [Fidler, Mary J.] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [de Castro, Gilberto, Jr.] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil; [Garrido, Marcelo] Pontificia Univ Catolica Chile, Alameda 340, Santiago, Chile; [Lubiniecki, Gregory M.; Shentu, Yue; Im, Ellie; Dolled-Filhart, Marisa] Merck & Co Inc, Kenilworth, NJ USA; [Garon, Edward B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	Yale University; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Seoul National University (SNU); Seoul National University Hospital; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); University of Navarra; National Cancer Center - Korea (NCC); Mayo Clinic; Pochon Cha University; UNICANCER; Centre Francois Baclesse; Sungkyunkwan University (SKKU); Samsung Medical Center; Hospital of Santa Creu i Sant Pau; Rush University; Pontificia Universidad Catolica de Chile; Merck & Company; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Herbst, RS (corresponding author), Yale Univ, Sch Med, Yale Comprehens Canc Ctr, Thorac Oncol Res Program,Smilow Canc Hosp, 333 Cedar St,WWW221, New Haven, CT 06520 USA.	roy.herbst@yale.edu	Kim, Dong-Wan/J-5391-2012; de Castro, Gilberto/C-1627-2013; Miquel, Josep Maria/AAG-3508-2019; FELIP, ENRIQUETA/AAG-6316-2019; Perez-Gracia, Jose Luis/I-8372-2017	de Castro, Gilberto/0000-0001-8765-3044; Perez-Gracia, Jose Luis/0000-0003-4941-9075; Balmana, Judith/0000-0002-0762-6415; FELIP, ENRIQUETA/0000-0002-7620-0098	Merck Co.	Merck Co.(Merck & Company)	Merck & Co.	Ascierto PA, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-54; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer JR, 2014, J CLIN ONCOL, V32, P8021, DOI DOI 10.1200/jco.2014.32.15_suppl.8021; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Camidge DR, 2014, NAT REV CLIN ONCOL, V11, P473, DOI 10.1038/nrclinonc.2014.104; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; EFRON B, 1977, J AM STAT ASSOC, V72, P557, DOI 10.2307/2286217; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Flotten O, 2015, J THORAC ONCOL S2, V10, P3024; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X; Gettinger S, 2014, CANCER J, V20, P281, DOI 10.1097/PPO.0000000000000063; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Messina JL, 2012, SCI REP-UK, V2, DOI 10.1038/srep00765; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Papadimitrakopoulou V, 2015, J CLIN ONCOL, V33; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patnaik A, 2015, ASCO M, V33, P8011, DOI DOI 10.1200/JC0.2015.33.15_; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Schalper KA, 2014, CLIN CANCER RES, V20, P2773, DOI 10.1158/1078-0432.CCR-13-2702; Sequist LV, 2015, NEW ENGL J MED, V372, P1700, DOI 10.1056/NEJMoa1413654; Shaw AT, 2014, NEW ENGL J MED, V370, P2537, DOI 10.1056/NEJMc1404894; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Spira AI, 2015, ASCO M, V33, P8010, DOI DOI 10.HTTPS://D0I.0RG/10.1200/JC0.2015.33.15_; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624	33	3206	3326	19	419	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2016	387	10027					1540	1550		10.1016/S0140-6736(15)01281-7	http://dx.doi.org/10.1016/S0140-6736(15)01281-7			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DI8HH	26712084				2023-01-03	WOS:000373741600030
J	Weissman, JS; Cooper, Z; Hyder, JA; Lipsitz, S; Jiang, W; Zinner, MJ; Prigerson, HG				Weissman, Joel S.; Cooper, Zara; Hyder, Joseph A.; Lipsitz, Stuart; Jiang, Wei; Zinner, Michael J.; Prigerson, Holly G.			End-of-Life Care Intensity for Physicians, Lawyers, and the General Population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DEATH		[Weissman, Joel S.; Cooper, Zara; Lipsitz, Stuart; Jiang, Wei; Zinner, Michael J.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA; [Hyder, Joseph A.] Mayo Clin, Dept Anesthesiol, Rochester, MN USA; [Prigerson, Holly G.] Weill Cornell Med, Ctr Res End Life Care, New York, NY USA	Harvard University; Brigham & Women's Hospital; Mayo Clinic; Cornell University	Weissman, JS (corresponding author), Harvard Univ, Brigham andWomens Hosp, Ctr Surg & Publ Hlth, Dept Surg,Med Sch, 1620 Tremont St,Ste 4-020X, Boston, MA 02120 USA.	jweissman@partners.org	Prigerson, Holly/L-3800-2019; Prigerson, Holly/GWV-3283-2022	Prigerson, Holly/0000-0002-7075-4268; 	NATIONAL CANCER INSTITUTE [R35CA197730] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		HILLIER TA, 1995, ARCH INTERN MED, V155, P1289, DOI 10.1001/archinte.155.12.1289; Huber P. J., 2011, ROBUST STAT; Kwok AC, 2011, LANCET, V378, P1408, DOI 10.1016/S0140-6736(11)61268-3; Nicholas LH, 2011, JAMA-J AM MED ASSOC, V306, P1447, DOI 10.1001/jama.2011.1410; STEENLAND K, 1984, J OCCUP ENVIRON MED, V26, P288; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624	6	18	18	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					303	305		10.1001/jama.2015.17408	http://dx.doi.org/10.1001/jama.2015.17408			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784782	Bronze			2023-01-03	WOS:000368371400030
J	Vilar, E; Boltiador, C; Wong, J; Viljoen, A; Machado, A; Uthayakumar, A; Farrington, K				Vilar, Enric; Boltiador, Capella; Wong, Jonathan; Viljoen, Adie; Machado, Ashwini; Uthayakumar, Arani; Farrington, Ken			Plasma Levels of Middle Molecules to Estimate Residual Kidney Function in Haemodialysis without Urine Collection	PLOS ONE			English	Article							GLOMERULAR-FILTRATION-RATE; HIGH-FLUX HEMODIALYSIS; SERUM CYSTATIN-C; PERITONEAL-DIALYSIS PATIENTS; RENAL-FUNCTION; ONLINE HEMODIAFILTRATION; BETA-2-MICROGLOBULIN LEVEL; CARDIOVASCULAR EVENTS; MORTALITY; CLEARANCE	Background Residual Kidney Function (RKF) is associated with survival benefits in haemodialysis (HD) but is difficult to measure without urine collection. Middle molecules such as Cystatin C and beta 2-microglobulin accumulate in renal disease and plasma levels have been used to estimate kidney function early in this condition. We investigated their use to estimate RKF in patients on HD. Design Cystatin C, beta 2-microglobulin, urea and creatinine levels were studied in patients on incremental high-flux HD or hemodiafiltration(HDF). Over sequential HD sessions, blood was sampled pre-and post-session 1 and pre-session 2, for estimation of these parameters. Urine was collected during the whole interdialytic interval, for estimation of residual GFR (GFR(Residual) = mean of urea and creatinine clearance). The relationships of plasma Cystatin C and beta 2-microglobulin levels to GFR(Residual) and urea clearance were determined. Results Of the 341 patients studied, 64% had urine output> 100ml/day, 32.6% were on high-flux HD and 67.4% on HDF. Parameters most closely correlated with GFR(Residual) were 1/beta 2-micoglobulin (r(2) 0.67) and 1/Cystatin C (r(2) 0.50). Both these relationships were weaker at low GFR(Residual). The best regression model for GFR(Residual), explaining 67% of the variation, was: GFR(Residual) = 160. 3 . (1/beta 2m)-4.2 Where beta 2m is the pre-dialysis beta 2 microglobulin concentration (mg/L). This model was validated in a separate cohort of 50 patients using Bland-Altman analysis. Areas under the curve in Receiver Operating Characteristic analysis aimed at identifying subjects with urea clearance >= 2ml/min/1.73m(2) was 0.91 for beta 2-microglobulin and 0.86 for Cystatin C. A plasma beta 2-microglobulin cut-off of <= 19.2mg/L allowed identification of patients with urea clearance >= 2ml/min/1.73m(2) with 90% specificity and 65% sensitivity. Conclusion Plasma pre-dialysis beta 2-microglobulin levels can provide estimates of RKF which may have clinical utility and appear superior to cystatin C. Use of cut-off levels to identify patients with RKF may provide a simple way to individualise dialysis dose based on RKF.	[Vilar, Enric; Wong, Jonathan; Machado, Ashwini; Uthayakumar, Arani; Farrington, Ken] Lister Hosp, Renal Unit, Stevenage, Herts, England; [Vilar, Enric; Wong, Jonathan; Farrington, Ken] Univ Hertfordshire, Dept Postgrad Med, Hatfield AL10 9AB, Herts, England; [Boltiador, Capella; Viljoen, Adie] Lister Hosp, Dept Pathol, Stevenage, Herts, England; [Boltiador, Capella] Univ W England, Bristol BS16 1QY, Avon, England	Lister Hospital; University of Hertfordshire; Lister Hospital; University of West England	Vilar, E (corresponding author), Lister Hosp, Renal Unit, Stevenage, Herts, England.	enric.vilar@nhs.net	Farrington, Ken/V-1531-2019		British Renal Society; Kidney Research UK [TF9/2010]; National Institute for Health Research through the Renal Research Network	British Renal Society; Kidney Research UK(Kidney Research UK (KRUK)); National Institute for Health Research through the Renal Research Network	This work was supported by the British Renal Society Grant, 9th Round Awards for EV. (http://www.britishrenal.org/getattachment/Research-for-Renal/Grants-Awarded/Summary-of-9th-Round-BRS-Grant-Awards-(2).doc.aspx) Funders reviewed the study design as part of the peer-review process for grant application but had no role in data collection, analysis, decision to publish or manuscript preparation. This work was also supported by the Kidney Research UK (www.kidneyresearchuk.org) funded EV (Fellowship TF9/2010). The funder had no role in the study design, data collection, analysis, decision to publish or preparation of the manuscript. Support was received through the National Institute for Health Research through the Renal Research Network. The funder had no role in the study design, data collection, analysis, decision to publish or preparation of the manuscript.	AMICI G, 1993, NEPHRON, V65, P469, DOI 10.1159/000187533; Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; Bokenkamp A, 1998, PEDIATRICS, V101, P875, DOI 10.1542/peds.101.5.875; Canaud B, 2006, KIDNEY INT, V69, P2087, DOI 10.1038/sj.ki.5000447; Carter JL, 2011, NEPHROL DIAL TRANSPL, V26, P3729, DOI 10.1093/ndt/gfr112; Coll E, 2000, AM J KIDNEY DIS, V36, P29, DOI 10.1053/ajkd.2000.8237; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Depner Thomas A, 2005, Hemodial Int, V9, P241, DOI 10.1111/j.1492-7535.2005.01138.x; Diaz-Buxo JA, 1999, AM J KIDNEY DIS, V33, P523, DOI 10.1016/S0272-6386(99)70190-3; Finney H, 1997, CLIN CHEM, V43, P1016; Fry AC, 2007, BLOOD PURIFICAT, V25, P295, DOI 10.1159/000104870; Gerhardt T, 2008, NEPHROL DIAL TRANSPL, V23, P309, DOI 10.1093/ndt/gfm510; GHISO J, 1990, P NATL ACAD SCI USA, V87, P1288, DOI 10.1073/pnas.87.4.1288; Gotch FA, 1995, CLIN DIALYSIS, P156; GREIPP PR, 1988, BLOOD, V72, P219; GRUBB A, 1992, CLIN NEPHROL, V38, pS20; Grubb AO, 2001, ADV CLIN CHEM, V35, P63, DOI 10.1016/S0065-2423(01)35015-1; Hemodialysis Adequacy 2006 Work Group, 2006, AM J KIDNEY DIS, V48, pS2, DOI [10.1053/j.ajkd.2006.03.051, DOI 10.1053/J.AJKD.2006.03.051]; Hoek FJ, 2007, NEPHROL DIAL TRANSPL, V22, P1633, DOI 10.1093/ndt/gfm027; HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005; Ix JH, 2007, CIRCULATION, V115, P173, DOI 10.1161/CIRCULATIONAHA.106.644286; Kjaergaard KD, 2013, CLIN PHYSIOL FUNCT I, V33, P224, DOI 10.1111/cpf.12018; LEYPOLDT JK, 1991, BLOOD PURIFICAT, V9, P74, DOI 10.1159/000170000; Lopez-Menchero R, 1999, NEPHRON, V83, P219, DOI 10.1159/000045514; Lornoy W, 2000, NEPHROL DIAL TRANSPL, V15, P49, DOI 10.1093/oxfordjournals.ndt.a027964; Maduell F, 2013, J AM SOC NEPHROL, V24, P487, DOI 10.1681/ASN.2012080875; Marsenic O, 2013, HEMODIAL INT, V17, pS11, DOI 10.1111/hdi.12083; Merz GS, 1997, J CELL PHYSIOL, V173, P423; Mulay A, 2008, AM J KIDNEY DIS, V52, P194, DOI 10.1053/j.ajkd.2008.04.022; ODELL RA, 1991, KIDNEY INT, V39, P909, DOI 10.1038/ki.1991.114; Ok E, 2013, NEPHROL DIAL TRANSPL, V28, P192, DOI 10.1093/ndt/gfs407; Shemin D, 2001, AM J KIDNEY DIS, V38, P85, DOI 10.1053/ajkd.2001.25198; Sjostrom P, 2005, SCAND J CLIN LAB INV, V65, P111, DOI 10.1080/00365510510013523; Stevens LA, 2008, AM J KIDNEY DIS, V51, P395, DOI 10.1053/j.ajkd.2007.11.018; Tattersall JE, 1996, KIDNEY INT, V50, P2094, DOI 10.1038/ki.1996.534; Vilar E, 2014, CLIN J AM SOC NEPHRO, V9, P1240, DOI 10.2215/CJN.07510713; Vilar E, 2009, CLIN J AM SOC NEPHRO, V4, P1944, DOI 10.2215/CJN.05560809; Vilar E, 2009, NEPHROL DIAL TRANSPL, V24, P2502, DOI 10.1093/ndt/gfp071; Vinge E, 1999, SCAND J CLIN LAB INV, V59, P587, DOI 10.1080/00365519950185076; Ward RA, 2000, J AM SOC NEPHROL, V11, P2344, DOI 10.1681/ASN.V11122344; Xu XQ, 2001, ASAIO J, V47, P623, DOI 10.1097/00002480-200111000-00011	41	22	23	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2015	10	12							e0143813	10.1371/journal.pone.0143813	http://dx.doi.org/10.1371/journal.pone.0143813			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX8BI	26629900	Green Published, Green Submitted, gold			2023-01-03	WOS:000365926300104
J	Zhang, L; Zou, X; Zhang, D; Li, XL; Zhao, PZ; Ling, L				Zhang, Lei; Zou, Xia; Zhang, Di; Li, Xiaoling; Zhao, Peizhen; Ling, Li			Investigation of Repeat Client Drop-Out and Re-Enrolment Cycles in Fourteen Methadone Maintenance Treatment Clinics in Guangdong, China	PLOS ONE			English	Article							INJECTING DRUG-USERS; YUNNAN PROVINCE; HEALTH-STATUS; HEROIN; HIV; MISCONCEPTIONS; EMPLOYMENT; BEHAVIORS; GUANGZHOU; PATTERNS	Objective Client adherence is vital for effective methadone maintenance treatment (MMT). This study explores the pattern and associated factors of client adherence, drop-out and re-enrolment in the Chinese MMT programme over the period of 2006-2013. Methods This retrospective study was conducted in 14 MMT clinics in Guangdong Province, China. We employed Kaplan-Meier survival analysis to estimate the rates of drop-out and re-enrolment of MMT clients and multivariate Cox regression to identify associated factors. Results Among 1,512 study participants, 79% have experienced 'drop-out' during the 7-year study period. However, 82% 'dropped-out' clients resumed treatment at a later time. Low education level (junior high or below versus otherwise, HR = 1.21, 1.05-1.40), low methadone dosage in the first treatment episode (<50 ml versus >= 50 ml, HR = 1.84, 1.64-2.06) and higher proportion of positive urine test (>= 50% versus <50%, HR = 3.72, 3.30-4.20) during the first treatment episode were strong predictors of subsequent drop-outs of the participants. Among the 'dropped-out' clients, being female (HR = 1.40, 1.23-1.60), being married (HR = 1.19, 1.09-1.30), and having a higher proportion of positive urine tests in the first treatment episode (>= 50% versus <50%, HR = 1.35, 1.20-1.51) had greater likelihood of subsequent re-enrolment in MMT. Clients receiving lower methadone dosage (first treatment episode <50 ml versus >= 50 ml, HR = 1.12, 1.03-1.23; the last intake before drop-out <50 ml versus >= 50 ml, HR = 1.16, 1.04-1.30) were also more likely to re-enrol. Conclusion Persistent cycling in-and-out of clients in MMT programmes is common. Insufficient dosage and higher proportion of positive urine samples in the first treatment episode are the key determinants for subsequent client drop-out and re-enrolment. Interventions should target clients in their early stage of treatment to improve retention in the long term.	[Zhang, Lei; Zou, Xia; Zhang, Di; Li, Xiaoling; Zhao, Peizhen; Ling, Li] Sun Yat Sen Univ, Sun Yat Sen Ctr Migrant Hlth Policy, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Lei] Univ New S Wales, Kirby Inst, Sydney, NSW, Australia; [Zou, Xia; Zhang, Di; Li, Xiaoling; Zhao, Peizhen; Ling, Li] Sun Yat Sen Univ, Sch Publ Hlth, Fac Med Stat & Epidemiol, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Di] Sun Yat Sen Univ, Off Med Sci, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; University of New South Wales Sydney; Kirby Institute; Sun Yat Sen University; Sun Yat Sen University	Ling, L (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Ctr Migrant Hlth Policy, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	lingli@mail.sysu.edu.cn	Zhang, Lei/D-4039-2011; Zou, Xia/U-2205-2019	Zhang, Lei/0000-0003-2343-084X; 	National Natural Science Foundation of China [30972552, 71173245, 81473065]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (grant 30972552, grant 71173245, grant 81473065). Grants received by LL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bell J, 2006, DRUG ALCOHOL DEPEN, V81, P55, DOI 10.1016/j.drugalcdep.2005.05.010; Beynon CM, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-205; Bohang W, 2013, INFORM TIMES; Che YH, 2011, AM J DRUG ALCOHOL AB, V37, P148, DOI 10.3109/00952990.2010.535578; Chou YC, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-190; Cohen JE, 2008, PLOS MED, V5, P1682, DOI 10.1371/journal.pmed.0050234; Deering DE, 2004, DRUG ALCOHOL REV, V23, P273, DOI 10.1080/09595230412331289428; Deren S, 2001, J SUBST ABUSE TREAT, V20, P185, DOI 10.1016/S0740-5472(00)00153-7; Dobler-Mikola A, 2005, J SUBST ABUSE TREAT, V29, P259, DOI 10.1016/j.jsat.2005.08.002; Ellul Rita Darmanin, 2009, Int J Adolesc Med Health, V21, P591; Fareed A, 2011, J ADDICT DIS, V30, P27, DOI 10.1080/10550887.2010.531672; Fareed A, 2010, AM J DRUG ALCOHOL AB, V36, P332, DOI 10.3109/00952990.2010.505991; GEARING FR, 1974, AM J EPIDEMIOL, V100, P101, DOI 10.1093/oxfordjournals.aje.a112012; Gu J, 2012, ADDICTION, V107, P1641, DOI 10.1111/j.1360-0443.2012.03859.x; Hosmer D. W., 2008, APPL SURVIVAL ANAL R; Kleinbaum DG, 2012, STAT BIOL HEALTH, P1, DOI 10.1007/978-1-4419-6646-9; Lau JTF, 2008, SEX TRANSM DIS, V35, P325, DOI 10.1097/OLQ.0b013e3181614364; Leavitt S. B., 2003, ATF FORUM; Lin CQ, 2011, SUBST USE MISUSE, V46, P1190, DOI 10.3109/10826084.2011.561905; Marsch LA, 1998, ADDICTION, V93, P515, DOI 10.1046/j.1360-0443.1998.9345157.x; Mathers BM, 2010, LANCET, V375, P1014, DOI 10.1016/S0140-6736(10)60232-2; Narcotics Control Bureau of the Ministry of Public Security, 2014, ANN REP DRUG CONTR C; National Health and Family Planning Commission of the People's Republic of China, 2013, BACKGR AIDS CONTR CH; Nava F, 2006, J ADDICT DIS, V25, P9, DOI 10.1300/J069v25n02_02; Noori R, 2012, SUBST USE MISUSE, V47, P767, DOI 10.3109/10826084.2010.517726; Office of Canada's Drug Strategy Health Canada, 2002, LIT REV METH MAINT T; Pang L, 2007, AIDS, V21, pS103, DOI 10.1097/01.aids.0000304704.71917.64; Philbin MM, 2010, AIDS CARE, V22, P623, DOI 10.1080/09540120903311490; Qadir F, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1150; Richardson L, 2012, J SUBST ABUSE TREAT, V43, P276, DOI 10.1016/j.jsat.2011.12.008; RUTHERFORD MJ, 1994, J SUBST ABUSE TREAT, V11, P415, DOI 10.1016/0740-5472(94)90094-9; Shi J, 2007, J ADDICT MED, V1, P186, DOI 10.1097/ADM.0b013e318156cc19; Sullivan SG, 2007, INT J DRUG POLICY, V18, P118, DOI 10.1016/j.drugpo.2006.11.014; Svensson B, 2012, NORD STUD ALCOHOL DR, V29, P173, DOI 10.2478/v10199-012-0012-0; Termorshuizen F, 2005, DRUG ALCOHOL DEPEN, V79, P231, DOI 10.1016/j.drugalcdep.2005.01.013; WANG P, 2009, CHIN J DRUGS ABUSE P, V15, P77; Wu F, 2012, J PUBLIC HLTH OXF; Wu ZY, 2007, AIDS, V21, pS115, DOI 10.1097/01.aids.0000304706.79541.ef; Xu HF, 2012, ADDICT BEHAV, V37, P657, DOI 10.1016/j.addbeh.2012.01.020; YANG M, 2012, PRACTICAL PREVENTIVE, V19, P1582; Yang M, 2012, PRACTICAL PREVENTIVE, V19, P1589; Yin WY, 2010, INT J EPIDEMIOL, V39, pII29, DOI 10.1093/ije/dyq210; Zhang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076931; Zhang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068906; Zhao Y, 2013, B WORLD HEALTH ORGAN, V91, P93, DOI 10.2471/BLT.12.108944; Zhu WX, 2009, DRUG ALCOHOL REV, V28, P641, DOI 10.1111/j.1465-3362.2009.00068.x	46	22	25	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2015	10	10							e0139942	10.1371/journal.pone.0139942	http://dx.doi.org/10.1371/journal.pone.0139942			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CT7XI	26484772	Green Submitted, Green Published, gold			2023-01-03	WOS:000363028100016
J	Oettle, H; Lehmann, T				Oettle, Helmut; Lehmann, Thorsten			Gemcitabine-resistant pancreatic cancer: a second-line option	LANCET			English	Editorial Material							IRINOTECAN; MONOTHERAPY; SURVIVAL		[Oettle, Helmut] Zentrum Tumormed, D-88045 Friedrichshafen, Germany; [Lehmann, Thorsten] Klinikum Friedrichshafen, Klin Allgemein & Viszeralchirurg, Friedrichshafen, Germany		Oettle, H (corresponding author), Zentrum Tumormed, D-88045 Friedrichshafen, Germany.	helmut.oettle@charite.de						Chen L-T, 2015, 2015 GASTR CANC S SA; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Kalra AV, 2014, CANCER RES, V74, P7003, DOI 10.1158/0008-5472.CAN-14-0572; Lee V, 2012, J PANCREAS, V13, P182; Lima CMR, 2004, J CLIN ONCOL, V22, P3776, DOI 10.1200/JCO.2004.12.082; Oettle H, 2014, CANCER TREAT REV, V40, P1039, DOI 10.1016/j.ctrv.2014.07.003; Oettle H, 2014, J CLIN ONCOL, V32, P2423, DOI 10.1200/JCO.2013.53.6995; Stathopoulos GP, 2006, BRIT J CANCER, V95, P587, DOI 10.1038/sj.bjc.6603301; Sun HH, 2014, SCI REP-UK, V4, DOI 10.1038/srep06747; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang-Gillam A, 2015, LANCET	11	10	16	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	2016	387	10018					507	508		10.1016/S0140-6736(15)01035-1	http://dx.doi.org/10.1016/S0140-6736(15)01035-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD3PV	26616909				2023-01-03	WOS:000369835800007
J	Du, Y; Yamaguchi, H; Wei, Y; Hsu, JL; Wang, HL; Hsu, YH; Lin, WC; Yu, WH; Leonard, PG; Lee, GR; Chen, MK; Nakai, K; Hsu, MC; Chen, CT; Sun, Y; Wu, Y; Chang, WC; Huang, WC; Liu, CL; Chang, YC; Chen, CH; Park, M; Jones, P; Hortobagyi, GN; Hung, MC				Du, Yi; Yamaguchi, Hirohito; Wei, Yongkun; Hsu, Jennifer L.; Wang, Hung-Ling; Hsu, Yi-Hsin; Lin, Wan-Chi; Yu, Wen-Hsuan; Leonard, Paul G.; Lee, Gilbert R.; Chen, Mei-Kuang; Nakai, Katsuya; Hsu, Ming-Chuan; Chen, Chun-Te; Sun, Ye; Wu, Yun; Chang, Wei-Chao; Huang, Wen-Chien; Liu, Chien-Liang; Chang, Yuan-Ching; Chen, Chung-Hsuan; Park, Morag; Jones, Philip; Hortobagyi, Gabriel N.; Hung, Mien-Chie			Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors	NATURE MEDICINE			English	Article							NEGATIVE BREAST-CANCER; OXIDATIVE DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE; CELLS; TRAFFICKING; GROWTH; REPAIR; INSTABILITY; CARCINOMA; FEATURES	Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in clinical trials'. One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently approved by the FDA to treat ovarian cancer with mutations in BRCA genes. BRCA1 and BRCA2 have essential roles in repairing DNA double-strand breaks, and a deficiency of BRCA proteins sensitizes cancer cells to PARP inhibition(2,3). Here we show that the receptor tyrosine kinase c-Met associates with and phosphorylates PARP1 at Tyr907 (PARP1 pTyr907 or pY907). PARP1 pY907 increases PARP1 enzymatic activity and reduces binding to a PARP inhibitor, thereby rendering cancer cells resistant to PARP inhibition. The combination of c-Met and PARP1 inhibitors synergized to suppress the growth of breast cancer cells in vitro and xenograft tumor models, and we observed similar synergistic effects in a lung cancer xenograft tumor model. These results suggest that the abundance of PARP1 pY907 may predict tumor resistance to PARP inhibitors, and that treatment with a combination of c-Met and PARP inhibitors may benefit patients whose tumors show high c-Met expression and who do not respond to PARP inhibition alone.	[Du, Yi; Yamaguchi, Hirohito; Wei, Yongkun; Hsu, Jennifer L.; Hsu, Yi-Hsin; Lin, Wan-Chi; Yu, Wen-Hsuan; Chen, Mei-Kuang; Nakai, Katsuya; Hsu, Ming-Chuan; Chen, Chun-Te; Sun, Ye; Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Wang, Hung-Ling; Chang, Wei-Chao; Hung, Mien-Chie] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Wang, Hung-Ling; Chang, Wei-Chao; Hung, Mien-Chie] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Yu, Wen-Hsuan; Chen, Mei-Kuang; Hung, Mien-Chie] Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX USA; [Leonard, Paul G.; Lee, Gilbert R.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Leonard, Paul G.; Lee, Gilbert R.; Jones, Philip] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA; [Wu, Yun] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Chang, Wei-Chao; Chen, Chung-Hsuan] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Huang, Wen-Chien; Liu, Chien-Liang; Chang, Yuan-Ching] Mackay Mem Hosp, Dept Surg, Taipei, Taiwan; [Park, Morag] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Hung, Mien-Chie] Asia Univ, Dept Biotechnol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Taiwan; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Academia Sinica - Taiwan; Mackay Memorial Hospital; McGill University; University of Texas System; UTMD Anderson Cancer Center; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.; Hung, MC (corresponding author), China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan.; Hung, MC (corresponding author), China Med Univ, Ctr Mol Med, Taichung, Taiwan.; Hung, MC (corresponding author), Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX USA.; Hung, MC (corresponding author), Asia Univ, Dept Biotechnol, Taichung, Taiwan.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; CHEN, MEI-KUANG/V-9284-2017; Hsu, MC/AAE-5310-2020; Sun, Ye/AAN-4214-2021	Hung, Mien-Chie/0000-0003-4317-4740; Sun, Ye/0000-0002-3464-4600; Yu, Wen-Hsuan/0000-0002-0816-7409; CHEN, MEI-KUANG/0000-0001-8027-8990; NAKAI, KATSUYA/0000-0003-4142-8508; Du, Yi/0000-0002-3969-2652	US National Institutes of Health [CA109311, CA099031]; Cancer Center Support Grant [CA16672]; Susan G. Komen Foundation [SAC100016]; Breast Cancer Research Foundation; Patel Memorial Breast Cancer Endowment Fund; University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; Ministry of Science and Technology, International Research-intensive Centers of Excellence in Taiwan (I-RiCE) [MOST 104-2911-1-002-302]; Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence [MOHW104-TDU-B-212-124-002]; Center for Biological Pathways at The University of Texas MD Anderson Cancer Center; Ting Tsung and Wei Fong Chao Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA109311, P01CA099031] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant; Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; Patel Memorial Breast Cancer Endowment Fund; University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; Ministry of Science and Technology, International Research-intensive Centers of Excellence in Taiwan (I-RiCE); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence; Center for Biological Pathways at The University of Texas MD Anderson Cancer Center; Ting Tsung and Wei Fong Chao Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded in part by the following: the US National Institutes of Health grants (nos. CA109311 (M.-C. Hung) and CA099031 (M.-C. Hung), and a Cancer Center Support Grant CA16672); the Susan G. Komen Foundation (SAC100016 (M.-C. Hung)); the Breast Cancer Research Foundation; the Patel Memorial Breast Cancer Endowment Fund; The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; the Ministry of Science and Technology, International Research-intensive Centers of Excellence in Taiwan (I-RiCE; MOST 104-2911-1-002-302 (M.-C. Hung)); the Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (MOHW104-TDU-B-212-124-002 (M.-C. Hung)); the Center for Biological Pathways at The University of Texas MD Anderson Cancer Center; and the Ting Tsung and Wei Fong Chao Research Fund. We also thank S. Patterson of the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for her editorial assistance.	Anders CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061359; Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Du Y, 2014, ONCOGENE, V33, P756, DOI 10.1038/onc.2013.1; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng FY, 2015, MOL CELL, V58, P925, DOI 10.1016/j.molcel.2015.04.016; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Gomes DA, 2008, J BIOL CHEM, V283, P4344, DOI 10.1074/jbc.M706550200; Ho-Yen CM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0547-6; Hsu YH, 2014, CANCER RES, V74, P4822, DOI 10.1158/0008-5472.CAN-14-0584; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jagadeeswaran R, 2007, AM J PHYSIOL-LUNG C, V292, pL1488, DOI 10.1152/ajplung.00147.2006; Javle M, 2011, BRIT J CANCER, V105, P1114, DOI 10.1038/bjc.2011.382; Knight JF, 2013, P NATL ACAD SCI USA, V110, pE1301, DOI 10.1073/pnas.1210353110; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Linding R, 2007, CELL, V129, P1415, DOI 10.1016/j.cell.2007.05.052; Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144; Matteucci E, 2009, CARCINOGENESIS, V30, P937, DOI 10.1093/carcin/bgp080; Maynard S, 2009, CARCINOGENESIS, V30, P2, DOI 10.1093/carcin/bgn250; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Nowsheen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046614; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Robaszkiewicz A, 2012, FREE RADICAL BIO MED, V53, P1552, DOI 10.1016/j.freeradbiomed.2012.08.567; Ruf A, 1996, P NATL ACAD SCI USA, V93, P7481, DOI 10.1073/pnas.93.15.7481; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Speers C, 2009, CLIN CANCER RES, V15, P6327, DOI 10.1158/1078-0432.CCR-09-1107; Swindall Amanda F, 2013, Cancers (Basel), V5, P943, DOI 10.3390/cancers5030943; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Wang YN, 2012, J BIOL CHEM, V287, P16869, DOI 10.1074/jbc.M111.314799; Wang YN, 2010, BIOCHEM BIOPH RES CO, V399, P498, DOI 10.1016/j.bbrc.2010.07.096; Zagouri F, 2013, BRIT J CANCER, V108, P1100, DOI 10.1038/bjc.2013.31	40	147	157	2	62	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2016	22	2					194	201		10.1038/nm.4032	http://dx.doi.org/10.1038/nm.4032			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	DC8JX	26779812	Green Accepted			2023-01-03	WOS:000369466800013
J	Tramacere, I; Del Giovane, C; Filippini, G				Tramacere, Irene; Del Giovane, Cinzia; Filippini, Graziella			Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Tramacere, Irene] Fdn IRCCS Ist Neurol Carlo Besta, Neuroepidemiol Unit, I-20133 Milan, Italy; [Del Giovane, Cinzia] Univ Modena & Reggio Emilia, Dept Diagnost Clin & Publ Hlth Med, Italian Cochrane Ctr, Modena, Italy; [Filippini, Graziella] Fdn IRCCS Ist Neurol Carlo Besta, Sci Direct, Via Mangiagalli 3, I-20133 Milan, Italy	IRCCS Istituto Neurologico Besta; Universita di Modena e Reggio Emilia; IRCCS Istituto Neurologico Besta	Filippini, G (corresponding author), Fdn IRCCS Ist Neurol Carlo Besta, Sci Direct, Via Mangiagalli 3, I-20133 Milan, Italy.	gfilippini@istituto-besta.it	tramacere, irene/B-2876-2013	tramacere, irene/0000-0001-5550-3412; Del Giovane, Cinzia/0000-0002-5028-932X				Ebers GC, 2008, NEUROLOGY, V71, P624, DOI 10.1212/01.wnl.0000313034.46883.16; Mills EJ, 2012, JAMA-J AM MED ASSOC, V308, P1246, DOI 10.1001/2012.jama.11228; Salanti G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099682; Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037; Scolding Neil, 2015, Pract Neurol, V15, P273, DOI 10.1136/practneurol-2015-001139; Tramacere I, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011381.pub2	6	4	4	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2016	315	4					409	410		10.1001/jama.2015.18984	http://dx.doi.org/10.1001/jama.2015.18984			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB5YI	26813214				2023-01-03	WOS:000368589500019
J	Chisolm, MS; Payne, JL				Chisolm, Margaret S.; Payne, Jennifer L.			Management of psychotropic drugs during pregnancy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SEROTONIN-REUPTAKE INHIBITORS; PERSISTENT PULMONARY-HYPERTENSION; IN-UTERO EXPOSURE; ANTIDEPRESSANT USE; MATERNAL USE; DEPRESSIVE SYMPTOMS; OPIOID DEPENDENCE; ATYPICAL ANTIPSYCHOTICS; CONGENITAL-MALFORMATIONS; 1ST-TRIMESTER EXPOSURE	Psychiatric conditions (including substance misuse disorders) are serious, potentially life threatening illnesses that can be successfully treated by psychotropic drugs, even during pregnancy. Because few rigorously designed prospective studies have examined the safety of these drugs during pregnancy, the default clinical recommendation has been to discontinue them, especially during the first trimester. However, in the past decade, as more evidence has accumulated, it seems that most psychotropic drugs are relatively safe to use in pregnancy and that not using them when indicated for serious psychiatric illness poses a greater risk to both mother and child, including tragic outcomes like suicide and infanticide. This review presents an up to date and careful examination of the most rigorous scientific studies on the effects of psychotropic drugs in pregnancy. The lack of evidence in several areas means that definite conclusions cannot be made about the risks and benefits of all psychotropic drug use in pregnancy.	[Chisolm, Margaret S.; Payne, Jennifer L.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA	Johns Hopkins University	Payne, JL (corresponding author), Womens Mood Disorders Ctr, Baltimore, MD 21205 USA.	Jpayne5@jhmi.edu			Astra Zeneca; Johnson and Johnson; Pfizer; Eli Lilly	Astra Zeneca(AstraZeneca); Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA); Pfizer(Pfizer); Eli Lilly(Eli Lilly)	We have read and understood BMJ policy on declaration of interests and declare the following: MSC: no support from any organization for the submitted work and no competing interests. JLP: No support from any organization for the submitted work. JLP has received legal consulting fees from Astra Zeneca, Johnson and Johnson, Pfizer, and Eli Lilly.	ACOG Committee on Health Care for Underserved Women, 2012, Obstet Gynecol, V119, P1070, DOI 10.1097/AOG.0b013e318256496e; ACOG Committee on Practice Bulletins--Obstetrics, 2008, Obstet Gynecol, V111, P1001, DOI 10.1097/AOG.0b013e31816fd910; Addis A, 2000, PSYCHOL MED, V30, P89, DOI 10.1017/S0033291799001270; Alto WA, 2011, AM J OBSTET GYNECOL, V205, P302, DOI 10.1016/j.ajog.2011.04.001; Altshuler LL, 1996, AM J PSYCHIAT, V153, P592; Alwan S, 2007, NEW ENGL J MED, V356, P2684, DOI 10.1056/NEJMoa066584; Alwan S, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.02.015; Alwan S, 2009, CNS DRUGS, V23, P493, DOI 10.2165/00023210-200923060-00004; Andersson L, 2003, AM J OBSTET GYNECOL, V189, P148, DOI 10.1067/mob.2003.336; Andrade SE, 2009, PHARMACOEPIDEM DR S, V18, P246, DOI 10.1002/pds.1710; Ashman SB, 2002, DEV PSYCHOPATHOL, V14, P333, DOI 10.1017/S0954579402002080; Barnes TRE, 2011, J PSYCHOPHARMACOL, V25, P567, DOI 10.1177/0269881110391123; Bearer C, 1997, ENVIRON HEALTH PERSP, V105, P202; Black RA, 2003, AM FAM PHYSICIAN, V67, P2517; Bolea-Alamanac BM, 2014, BRIT J CLIN PHARMACO, V77, P96, DOI 10.1111/bcp.12138; Brennan PA, 2008, J CHILD PSYCHOL PSYC, V49, P1099, DOI 10.1111/j.1469-7610.2008.01914.x; Bro SP, 2015, CLIN EPIDEMIOL, V7, P139, DOI 10.2147/CLEP.S72906; Bromley RL, 2013, J NEUROL NEUROSUR PS, V84, P637, DOI 10.1136/jnnp-2012-304270; Brunner E, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-38; Byatt N, 2013, ACTA PSYCHIAT SCAND, V127, P94, DOI 10.1111/acps.12042; Byatt N, 2014, GEN HOSP PSYCHIAT, V36, P644, DOI 10.1016/j.genhosppsych.2014.07.011; Chambers CD, 2006, NEW ENGL J MED, V354, P579, DOI 10.1056/NEJMoa052744; Christensen J, 2013, JAMA-J AM MED ASSOC, V309, P1696, DOI 10.1001/jama.2013.2270; Chun-Fai-Chan B, 2005, AM J OBSTET GYNECOL, V192, P932, DOI 10.1016/j.ajog.2004.09.027; Clark CT, 2013, AM J PSYCHIAT, V170, P1240, DOI 10.1176/appi.ajp.2013.13010006; Cohen LS, 2006, JAMA-J AM MED ASSOC, V295, P499, DOI 10.1001/jama.295.5.499; COHEN LS, 1994, JAMA-J AM MED ASSOC, V271, P146, DOI 10.1001/jama.271.2.146; Cole JA, 2007, PHARMACOEPIDEM DR S, V16, P474, DOI 10.1002/pds.1296; Coppola D, 2007, DRUG SAFETY, V30, P247, DOI 10.2165/00002018-200730030-00006; Croen LA, 2011, ARCH GEN PSYCHIAT, V68, P1104, DOI 10.1001/archgenpsychiatry.2011.73; Cunningham FG, 2010, WILLIAMS OBSTET, V23th; Cunnington M, 2005, NEUROLOGY, V64, P955, DOI 10.1212/01.WNL.0000154515.94346.89; Dadashova R, 2012, MENT ILLN, V4, P96, DOI 10.4081/mi.2012.e19; Davis EP, 2005, DEV NEUROSCI-BASEL, V27, P299, DOI 10.1159/000086709; Davis J, 1993, ANTIPSYCHOTIC DRUGS, P183; Davis RL, 2007, PHARMACOEPIDEM DR S, V16, P1086, DOI 10.1002/pds.1462; Debelak K, 2013, AM J ADDICTION, V22, P252, DOI 10.1111/j.1521-0391.2012.12005.x; DeVane C Lindsay, 2006, J Psychopharmacol, V20, P54, DOI 10.1177/1359786806066054; Diego MA, 2004, PSYCHIATRY, V67, P63, DOI 10.1521/psyc.67.1.63.31251; Dolk H, 2008, NEUROLOGY, V71, P714, DOI 10.1212/01.wnl.0000316194.98475.d8; Einarson TR, 2005, PHARMACOEPIDEM DR S, V14, P823, DOI 10.1002/pds.1084; Essex MJ, 2002, BIOL PSYCHIAT, V52, P776, DOI 10.1016/S0006-3223(02)01553-6; Fejzo MS, 2013, EUR J OBSTET GYN R B, V170, P71, DOI 10.1016/j.ejogrb.2013.04.017; Field T, 2006, INFANT BEHAV DEV, V29, P445, DOI 10.1016/j.infbeh.2006.03.003; Field T, 2010, INFANT BEHAV DEV, V33, P409, DOI 10.1016/j.infbeh.2010.04.005; Fischer G, 2006, ADDICTION, V101, P275, DOI 10.1111/j.1360-0443.2006.01321.x; Food and Drug Administration, DRUG SAF COMM ANT DR; Fujii H, 2013, NEUROLOGY, V80, P1565, DOI 10.1212/WNL.0b013e31828f18c1; Fullerton CA, 2014, PSYCHIAT SERV, V65, P146, DOI 10.1176/appi.ps.201300235; Gentile S, 2004, ANN PHARMACOTHER, V38, P1265, DOI 10.1345/aph.1D485; Gentile S, 2010, SCHIZOPHRENIA BULL, V36, P518, DOI 10.1093/schbul/sbn107; GILBERT PL, 1995, ARCH GEN PSYCHIAT, V52, P173; Gilboa SM, 2014, EXPERT OPIN DRUG SAF, V13, P1667, DOI 10.1517/14740338.2014.970164; Grace S L, 2003, Arch Womens Ment Health, V6, P263, DOI 10.1007/s00737-003-0024-6; Grof P, 2000, J AFFECT DISORDERS, V61, P31, DOI 10.1016/S0165-0327(99)00197-4; Habermann F, 2013, J CLIN PSYCHOPHARM, V33, P453, DOI 10.1097/JCP.0b013e318295fe12; Haervig KB, 2014, PHARMACOEPIDEM DR S, V23, P526, DOI 10.1002/pds.3600; HAGEMAN JR, 1984, AM J DIS CHILD, V138, P592, DOI 10.1001/archpedi.1984.02140440076021; Halligan SL, 2004, BIOL PSYCHIAT, V55, P376, DOI 10.1016/j.biopsych.2003.09.013; Hanley GE, 2014, BEST PRACT RES CL OB, V28, P37, DOI 10.1016/j.bpobgyn.2013.09.001; Hemels MEH, 2005, ANN PHARMACOTHER, V39, P803, DOI 10.1345/aph.1E547; Hernandez-Diaz S, 2007, PEDIATRICS, V120, pE272, DOI 10.1542/peds.2006-3037; Holmes LB, 2006, BIRTH DEFECTS RES A, V76, P318; Holmes LB, 2012, BIRTH DEFECTS RES A, V94, P599, DOI 10.1002/bdra.23028; Howard LM, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7394; Humphreys C, 2007, CAN FAM PHYSICIAN, V53, P1153; Huybrechts KF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092778; Huybrechts KF, 2015, JAMA-J AM MED ASSOC, V313, P2142, DOI 10.1001/jama.2015.5605; Hviid A, 2013, NEW ENGL J MED, V369, P2406, DOI 10.1056/NEJMoa1301449; Iqbal MM, 2002, PSYCHIAT SERV, V53, P39, DOI 10.1176/appi.ps.53.1.39; JACOBSON SJ, 1992, LANCET, V339, P530, DOI 10.1016/0140-6736(92)90346-5; Jimenez-Solem E, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001148; Johnson KC, 2012, ARCH GEN PSYCHIAT, V69, P787, DOI 10.1001/archgenpsychiatry.2012.160; Jones HE, 2005, DRUG ALCOHOL DEPEN, V79, P1, DOI 10.1016/j.drugalcdep.2004.11.013; Jones HE, 2008, J SUBST ABUSE TREAT, V35, P245, DOI 10.1016/j.jsat.2007.10.007; Jones HE, 2008, AM J ADDICTION, V17, P372, DOI 10.1080/10550490802266276; Jones HE, 2013, NEUROTOXICOL TERATOL, V39, P110, DOI 10.1016/j.ntt.2013.05.003; Jones HE, 2013, ADDICTION, V108, P233, DOI 10.1111/j.1360-0443.2012.03811.x; Jones HE, 2012, ADDICTION, V107, P28, DOI 10.1111/j.1360-0443.2012.04036.x; Jones HE, 2012, ADDICTION, V107, P5, DOI 10.1111/j.1360-0443.2012.04035.x; Jones HE, 2012, DRUGS, V72, P747, DOI 10.2165/11632820-000000000-00000; Jones HE, 2010, NEW ENGL J MED, V363, P2320, DOI 10.1056/NEJMoa1005359; Kallen B, 2006, REPROD TOXICOL, V21, P221, DOI 10.1016/j.reprotox.2005.11.006; Kallen B, 2008, PHARMACOEPIDEM DR S, V17, P801, DOI 10.1002/pds.1570; Kallen BAJ, 2007, BIRTH DEFECTS RES A, V79, P301, DOI 10.1002/bdra.20327; Kaltenbach K, 1998, OBSTET GYN CLIN N AM, V25, P139, DOI 10.1016/S0889-8545(05)70362-4; KALTENBACH K, 1984, NEUROBEH TOXICOL TER, V6, P271; Kandall SR, 1999, CLIN PERINATOL, V26, P173, DOI 10.1016/S0095-5108(18)30077-0; KENDELL RE, 1987, BRIT J PSYCHIAT, V151, P499, DOI 10.1192/bjp.151.4.499; Khalifeh H, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2260; Khazaie H, 2013, PSYCHIAT RES, V210, P901, DOI 10.1016/j.psychres.2013.08.017; Kieler H, 2012, BMJ-BRIT MED J, V344, pd8012, DOI DOI 10.1136/BMJ.D8012; Li D, 2009, HUM REPROD, V24, P146, DOI 10.1093/humrep/den342; Lin AE, 2004, BIRTH DEFECTS RES A, V70, P534, DOI 10.1002/bdra.20051; Louik C, 2007, NEW ENGL J MED, V356, P2675, DOI 10.1056/NEJMoa067407; Marcus SM, 2003, J WOMEN HEALTH GEN-B, V12, P373, DOI 10.1089/154099903765448880; Mattick RP, 2002, COCHRANE DB SYST REV, V4; Mattick RP, 2009, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD002209; MINOZZI S, 2013, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD006318.PUB3; Molgaard-Nielsen D, 2011, JAMA-J AM MED ASSOC, V305, P1996, DOI 10.1001/jama.2011.624; Moses-Kolko EL, 2005, JAMA-J AM MED ASSOC, V293, P2372, DOI 10.1001/jama.293.19.2372; Mosher WD, 1996, FAM PLANN PERSPECT, V28, P4, DOI 10.2307/2135956; Nakhai-Pour HR, 2010, CAN MED ASSOC J, V182, P1031, DOI 10.1503/cmaj.091208; Newham JJ, 2008, BRIT J PSYCHIAT, V192, P333, DOI 10.1192/bjp.bp.107.041541; Newport DJ, 2007, AM J PSYCHIAT, V164, P1214, DOI 10.1176/appi.ajp.2007.06111886; Nulman I, 1997, NEW ENGL J MED, V336, P258, DOI 10.1056/NEJM199701233360404; O'Brien L, 2008, J OBSTET GYNAECOL CA, V30, P696, DOI 10.1016/S1701-2163(16)32918-8; O'Connor TG, 2005, BIOL PSYCHIAT, V58, P211, DOI 10.1016/j.biopsych.2005.03.032; Oberlander TF, 2004, J CLIN PSYCHIAT, V65, P230; Oberlander TF, 2008, BIRTH DEFECTS RES B, V83, P68, DOI 10.1002/bdrb.20144; Okun ML, 2015, AM J OBSTET GYNECOL, V212, P428, DOI 10.1016/j.ajog.2014.10.1106; Orr ST, 2007, J WOMENS HEALTH, V16, P535, DOI 10.1089/jwh.2006.0116; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; Paton C, 2008, BRIT J PSYCHIAT, V192, P321, DOI 10.1192/bjp.bp.108.049585; Pavek P, 2009, CURR DRUG METAB, V10, P520, DOI 10.2174/138920009788897993; Payne JL, 2007, AM J PSYCHIAT, V164, P1329, DOI 10.1176/appi.ajp.2007.07030390; Payne JL, 2009, CLIN OBSTET GYNECOL, V52, P469, DOI 10.1097/GRF.0b013e3181b52e20; Pearlstein T, 2013, WOMENS HEALTH, V9, P605, DOI [10.2217/whe.13.54, 10.2217/WHE.13.54]; Peng M, 2013, PSYCHOPHARMACOLOGY, V228, P577, DOI 10.1007/s00213-013-3060-6; Pottegard A, 2014, J CLIN PSYCHIAT, V75, pE88, DOI 10.4088/JCP.13m08708; Rahimi R, 2006, REPROD TOXICOL, V22, P571, DOI 10.1016/j.reprotox.2006.03.019; Rai D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2059; Ramos E, 2008, BRIT J PSYCHIAT, V192, P344, DOI 10.1192/bjp.bp.107.042523; Reis M, 2010, PSYCHOL MED, V40, P1723, DOI 10.1017/S0033291709992194; Reis M, 2008, J CLIN PSYCHOPHARM, V28, P279, DOI 10.1097/JCP.0b013e318172b8d5; Reis M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002166; Robinson GE, 2012, J POPUL THER CLIN PH, V19, pE380; Ross LE, 2013, JAMA PSYCHIAT, V70, P436, DOI 10.1001/jamapsychiatry.2013.684; Seeman MV, 2013, ACTA PSYCHIAT SCAND, V127, P12, DOI 10.1111/j.1600-0447.2012.01897.x; Seeman MV, 2004, AM J PSYCHIAT, V161, P1324, DOI 10.1176/appi.ajp.161.8.1324; Shiu Jennifer R, 2012, Can J Hosp Pharm, V65, P380; Simon GE, 2002, AM J PSYCHIAT, V159, P2055, DOI 10.1176/appi.ajp.159.12.2055; Soyka M, 2013, CNS DRUGS, V27, P653, DOI 10.1007/s40263-013-0072-z; Stine SM, 2009, AM J DRUG ALCOHOL AB, V35, P429, DOI 10.3109/00952990903374080; THIELS C, 1987, PHARMACOPSYCHIATRY, V20, P133, DOI 10.1055/s-2007-1017092; Tracy TS, 2005, AM J OBSTET GYNECOL, V192, P633, DOI 10.1016/j.ajog.2004.08.030; Unger A, 2010, J ADDICT DIS, V29, P217, DOI 10.1080/10550881003684814; US National Library of Medicine, SEARCH STRAT US CREA; Vigod SN, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2298; Viguera AC, 1997, ARCH GEN PSYCHIAT, V54, P49; Viguera AC, 2000, AM J PSYCHIAT, V157, P179, DOI 10.1176/appi.ajp.157.2.179; Viguera AC, 2007, AM J PSYCHIAT, V164, P1817, DOI 10.1176/appi.ajp.2007.06101639; Walsh-Sukys MC, 2000, PEDIATRICS, V105, P14, DOI 10.1542/peds.105.1.14; Wang LH, 2010, CLIN PHARMACOL THER, V88, P369, DOI 10.1038/clpt.2010.97; Wang S, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001681; Ward RM, 2000, PEDIATRICS, V105, P880; Webb RT, 2004, COCHRANE DB SYST REV, V2; WEBSTER PAC, 1973, LANCET, V2, P318; Wichman CL, 2009, MAYO CLIN PROC, V84, P23, DOI 10.4065/84.1.23; Wilson KL, 2011, AM J PERINAT, V28, P19, DOI 10.1055/s-0030-1262507; Winklbaur B, 2008, ADDICTION, V103, P1429, DOI 10.1111/j.1360-0443.2008.02283.x; Wong S, 2011, J OBSTET GYNAECOL CA, V33, P367, DOI 10.1016/S1701-2163(16)34855-1; Yonkers KA, 2014, ANNU REV CLIN PSYCHO, V10, P369, DOI 10.1146/annurev-clinpsy-032813-153626; Yonkers KA, 2012, EPIDEMIOLOGY, V23, P677, DOI 10.1097/EDE.0b013e31825838e9; Yonkers KA, 2009, GEN HOSP PSYCHIAT, V31, P403, DOI [10.1097/AOG.0b013e3181ba0632, 10.1016/j.genhosppsych.2009.04.003]; ZUCKERMAN B, 1989, AM J OBSTET GYNECOL, V160, P1107, DOI 10.1016/0002-9378(89)90170-1	156	60	60	0	39	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 20	2016	352								h5918	10.1136/bmj.h5918	http://dx.doi.org/10.1136/bmj.h5918			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC4ZT	26791406				2023-01-03	WOS:000369230200001
J	Yang, YT; Curlin, FA				Yang, Y. Tony; Curlin, Farr A.			Why Physicians Should Oppose Assisted Suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Yang, Y. Tony] George Mason Univ, Dept Hlth Adm & Policy, Fairfax, VA 22030 USA; [Curlin, Farr A.] Duke Univ, Trent Ctr Bioeth Humanities & Hist Med, Durham, NC USA	George Mason University; Duke University	Yang, YT (corresponding author), George Mason Univ, Dept Hlth Adm & Policy, 4400 Univ Dr,MS 1J3, Fairfax, VA 22030 USA.	ytyang@gmu.edu						*AMA, H140952 AMA; [Anonymous], OR DEATH DIGN ACT 20; Botelho G., 2015, CNN             1006; Burt RA, 1996, HASTINGS CENT REP, V26, P30, DOI 10.2307/3528468; Edelstein L, 1943, HIPPOCRATIC OATH TEX; Maynard Brittany, 2014, CNN             1102; Snyder L, 2001, ANN INTERN MED, V135, P209, DOI 10.7326/0003-4819-135-3-200108070-00015	7	21	21	0	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					247	248		10.1001/jama.2015.16194	http://dx.doi.org/10.1001/jama.2015.16194			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784763				2023-01-03	WOS:000368371400012
J	Tabisz, L; Tukibayeva, A; Pankiewicz, R; Dobielska, M; Leska, B				Tabisz, Lukasz; Tukibayeva, Ainur; Pankiewicz, Radoslaw; Dobielska, Marta; Leska, Boguslawa			Disiloxanes and Functionalized Silica Gels: One Route, Two Complementary Outcomes-Guanidinium and Pyridinium Ion-Exchangers	PLOS ONE			English	Article							ANION; IMMOBILIZATION; EXTRACTION; RECEPTORS; COMPLEXES; SILOXANES; CATALYSTS; BINDING	Five novel disiloxane compounds comprising guanidinium and pyridinium moieties were obtained with high yields and purity. The verified synthetic pathways were then applied for modification of pre-functionalized silica gel, producing materials with the analogous organic side-chains. These halide-containing compounds and materials were then compared as to their ion-exchange properties: two disiloxanes proved to be effective in leaching different anions (nitrate, benzoate and ascorbate) from solid to organic phase, and pyridinium-functionalized silica gels showed selectivity towards perchlorate ion, removing it from methanolic solutions with preference to other singly charged anions. The results presented demonstrate that both compounds and materials containing silicon-carbon bonds can be produced using the same methodology, but offer strikingly different application opportunities. Comparison of their properties provides additional insight into the binding mode of different anions and hints at how the transition from a flexible siloxane bridge to immobilization on solid surface influences anion-binding selectivity. Additionally, one of the siloxane dipodands was found to form a crystalline and poorly soluble nitrate salt (1.316 g/L, water), although it was miscible with a wide range of solvents as a hydrochloride. A possible explanation is given with the help of semi-empirical calculations. A simple, time-and cost-efficient automated potentiometric titration methodology was used as a viable analytical tool for studying ion-exchange processes for both compounds and materials, in addition to standard NMR, FT-IR and ESI-MS methods.	[Tabisz, Lukasz; Pankiewicz, Radoslaw; Dobielska, Marta; Leska, Boguslawa] Adam Mickiewicz Univ, Fac Chem, PL-61614 Poznan, Poland; [Tukibayeva, Ainur] M Auezov South Kazakhstan State Univ, Dept Chem, Shymkent 160012, Kazakhstan	Adam Mickiewicz University; M. Auezov South Kazakhstan State University	Leska, B (corresponding author), Adam Mickiewicz Univ, Fac Chem, Umultowska 89b, PL-61614 Poznan, Poland.	bogunial@amu.edu.pl	Tabisz, Łukasz/AAW-3738-2020; Sabirov, Vakhobjan/K-4761-2015; Tukibayeva, Ainur S/N-8994-2017	Tabisz, Łukasz/0000-0002-5281-3826; Leska, Boguslawa/0000-0002-9504-5265; Pankiewicz, Radoslaw/0000-0002-0929-6018	Kazakh Committee of Science MES [68-35]	Kazakh Committee of Science MES(Government of the Republic of KazakhstanMinistry of Education and Science of the Republic of Kazakhstan)	Financial support was given under Grant No. 68-35, realized from 12.02.2015, by the Kazakh Committee of Science MES, http://control.edu.gov.kz/en, AT. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Belcher WJ, 2006, ORG BIOMOL CHEM, V4, P781, DOI 10.1039/b516027h; COLVIN EW, 1978, CHEM SOC REV, V7, P15, DOI 10.1039/cs9780700015; Cypryk M, 2002, ORGANOMETALLICS, V21, P2165, DOI 10.1021/om011055s; Houk RJT, 2005, TOP CURR CHEM, V255, P199, DOI 10.1007/b101167; Ibrahim I.A.M., 2010, J AM SCI, V6, P985, DOI 10.7537/marsjas061110.133; Ikem VO, 2008, ANGEW CHEM INT EDIT, V47, P8277, DOI 10.1002/anie.200802244; Jal PK, 2004, TALANTA, V62, P1005, DOI 10.1016/j.talanta.2003.10.028; Kittappa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130253; Kubota LT, 1996, ELECTROCHIM ACTA, V41, P1465, DOI 10.1016/0013-4686(95)00395-9; Maia A, 2003, TETRAHEDRON LETT, V44, P4149, DOI 10.1016/S0040-4039(03)00838-4; Maiga DT, 2014, PHYS CHEM EARTH, V72-75, P83, DOI 10.1016/j.pce.2014.09.012; Pankiewicz R, 2007, J MOL STRUCT, V829, P120, DOI 10.1016/j.molstruc.2006.06.013; Patai S, 2001, CHEM ORGANIC SILICON, V3; Pu QS, 1998, ANALYST, V123, P239, DOI 10.1039/a706135h; Rosciszewski P, 2004, WLASCIWOSCI ZASTOSOW; Seo Y, 2015, MICROPOR MESOPOR MAT, V207, P156, DOI 10.1016/j.micromeso.2015.01.021; Shu XZ, 2015, J AM CHEM SOC, V137, P7083, DOI 10.1021/jacs.5b04294; Soroceanu A, 2013, EUR J INORG CHEM, P1458, DOI 10.1002/ejic.201201080; Tabisz L, 2015, TETRAHEDRON, V71, P2267, DOI 10.1016/j.tet.2015.02.056; Tabisz L, 2014, TETRAHEDRON LETT, V55, P6416, DOI 10.1016/j.tetlet.2014.09.117; Van der Voort P, 2013, CHEM SOC REV, V42, P3913, DOI 10.1039/c2cs35222b; Vlad A, 2012, EUR J INORG CHEM, P5078, DOI 10.1002/ejic.201200612; Wang N, 2015, RSC ADV, V5, P15500, DOI 10.1039/c4ra13861a; Weinhold F, 2013, J AM CHEM SOC, V135, P5762, DOI 10.1021/ja312222k; Zaltariov MF, 2014, EUR J INORG CHEM, P4946, DOI 10.1002/ejic.201402578	25	3	3	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2015	10	12							e0145680	10.1371/journal.pone.0145680	http://dx.doi.org/10.1371/journal.pone.0145680			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0IX	26714187	Green Published, Green Submitted, gold			2023-01-03	WOS:000367481900066
J	Blinderman, CD; Billings, JA				Blinderman, Craig D.; Billings, J. Andrew			Comfort Care for Patients Dying in the Hospital	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; OPIOID-INDUCED CONSTIPATION; OF-LIFE DISCUSSIONS; PALLIATIVE CARE; DOUBLE-BLIND; ADVANCED CANCER; MANAGEMENT; PAIN; END; SYMPTOMS		[Blinderman, Craig D.] Columbia Univ, Med Ctr, Adult Palliat Care Serv, Dept Med, 601 W 168th St,Suite 38, New York, NY 10032 USA; [Billings, J. Andrew] Harvard Univ, Sch Med, Div Palliat Care, Massachusetts Gen Hosp,Dept Med, Boston, MA 02115 USA; [Billings, J. Andrew] Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA 02115 USA	Columbia University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Blinderman, CD (corresponding author), Columbia Univ, Med Ctr, Adult Palliat Care Serv, Dept Med, 601 W 168th St,Suite 38, New York, NY 10032 USA.	cdb21@columbis.edu						Acosta A, 2015, GASTROENTEROL CLIN N, V44, P97, DOI 10.1016/j.gtc.2014.11.008; Back AL, 2005, CA-CANCER J CLIN, V55, P164, DOI 10.3322/canjclin.55.3.164; Bausewein C, 2013, DTSCH ARZTEBL INT, V110, P563, DOI 10.3238/arztebl.2013.0563; Ben-Aharon I, 2008, J CLIN ONCOL, V26, P2396, DOI 10.1200/JCO.2007.15.5796; Bernacki RE, 2014, JAMA INTERN MED, V174, P1994, DOI 10.1001/jamainternmed.2014.5271; Billings JA, 2012, CRIT CARE MED, V40, P625, DOI 10.1097/CCM.0b013e318228235d; Blinderman CD, 2012, JAMA-J AM MED ASSOC, V307, P917, DOI 10.1001/jama.2012.236; Blinderman CD, 2010, J PAIN SYMPTOM MANAG, V39, P309, DOI 10.1016/j.jpainsymman.2009.11.242; Breitbart W, 2000, ONCOLOGY-NY, V14, P695; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; Bruera E, 2004, J PAIN SYMPTOM MANAG, V28, P381, DOI 10.1016/j.jpainsymman.2004.01.009; Bruera E, 2013, J CLIN ONCOL, V31, P111, DOI 10.1200/JCO.2012.44.6518; Bull J, 2015, J PALLIAT MED, V18, P593, DOI 10.1089/jpm.2014.0362; Bush SH, 2014, J PAIN SYMPTOM MANAG, V48, P215, DOI 10.1016/j.jpainsymman.2014.05.009; Candy B, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004770.pub2; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Cherny NI, 2009, PALLIATIVE MED, V23, P581, DOI 10.1177/0269216309107024; Chung KF, 2005, EXPERT OPIN INV DRUG, V14, P19, DOI 10.1517/13543784.14.1.19; Clayton JM, 2007, MED J AUSTRALIA, V186, pS83; Clayton JM, 2007, MED J AUST S, V186, pS79; Clayton JM, 2007, MED J AUSTRALIA, V186, pS77, DOI DOI 10.5694/J.1326-5377.2007.TB01100.X; Cranston JM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004769.pub2; Currow DC, 2015, J PAIN SYMPTOM MANAG, V49, P814, DOI 10.1016/j.jpainsymman.2014.09.013; Davis MP, 2010, J PAIN SYMPTOM MANAG, V39, P756, DOI 10.1016/j.jpainsymman.2009.08.010; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; Dy SM, 2010, CANCER J, V16, P507, DOI 10.1097/PPO.0b013e3181f45877; Ekstrom MP, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g445; Elkington H, 2005, PALLIATIVE MED, V19, P485, DOI 10.1191/0269216305pm1056oa; Galbraith S, 2010, J PAIN SYMPTOM MANAG, V39, P831, DOI 10.1016/j.jpainsymman.2009.09.024; Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580; Glare P, 2011, CLIN INTERV AGING, V6, P243, DOI 10.2147/CIA.S13109; Good P, 2008, COCHRANE DB SYST REV, V4; Goy ER, 2011, J PAIN SYMPTOM MANAG, V41, P394, DOI 10.1016/j.jpainsymman.2010.04.015; Grassi L, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0550-8; Hall Margaret Jean, 2013, NCHS Data Brief, P1; Haywood A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010756.pub2; Higginson IJ, 2010, CANCER J, V16, P423, DOI 10.1097/PPO.0b013e3181f684e5; Holbrook AM, 2000, CAN MED ASSOC J, V162, P225; Hui D, 2014, J PAIN SYMPTOM MANAG; Hui D, 2015, CANCER-AM CANCER SOC, V121, P960, DOI 10.1002/cncr.29048; Inouye SK, 2014, LANCET, V383, P911, DOI 10.1016/S0140-6736(13)60688-1; Jensen MP, 2003, J PAIN, V4, P2, DOI 10.1054/jpai.2003.1; Kellehear, 2014, INNER LIFE DYING PER; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Kutner JS, 2015, JAMA INTERN MED, V175, P691, DOI 10.1001/jamainternmed.2015.0289; Levenson JW, 2000, J AM GERIATR SOC, V48, pS101, DOI 10.1111/j.1532-5415.2000.tb03119.x; Lindqvist O, 2013, J PALLIAT MED, V16, P38, DOI 10.1089/jpm.2012.0205; Lokker ME, 2014, J PAIN SYMPTOM MANAG, V47, P105, DOI 10.1016/j.jpainsymman.2013.03.011; Lonergan E, 2009, COCHRANE DB SYST REV, V4; Longford E., 2015, BMJ SUPPORT PALLIAT, V5, P119, DOI [10.1136/bmjspcare-2014-000838.44, DOI 10.1136/BMJSPCARE-2014-000838.44]; Lupu D, 2010, J PAIN SYMPTOM MANAG, V40, P899, DOI 10.1016/j.jpainsymman.2010.07.004; Mack JW, 2010, J CLIN ONCOL, V28, P1203, DOI 10.1200/JCO.2009.25.4672; Mahler DA, 2015, CHEST, V147, P232, DOI 10.1378/chest.14-0800; Marciniuk DD, 2011, CAN RESPIR J, V18, P69, DOI 10.1155/2011/745047; McCarthy EP, 2000, J AM GERIATR SOC, V48, pS110, DOI 10.1111/j.1532-5415.2000.tb03120.x; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; McNicol ED, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006146.pub2; Morice AH, 2007, AM J RESP CRIT CARE, V175, P312, DOI 10.1164/rccm.200607-892OC; Morita T, 2001, J PAIN SYMPTOM MANAG, V21, P282, DOI 10.1016/S0885-3924(01)00258-5; Nakagawa S, 2010, J PALLIAT MED, V13, P535, DOI 10.1089/jpm.2009.0336; Parsons HA, 2008, J PALLIAT MED, V11, P1319, DOI 10.1089/jpm.2008.0155; PORTENOY RK, 1987, MED CLIN N AM, V71, P233, DOI 10.1016/S0025-7125(16)30867-7; Portenoy RK, 2014, J CLIN ONCOL, V32, P1662, DOI 10.1200/JCO.2013.52.5188; Puntillo K, 2004, AM J CRIT CARE, V13, P292, DOI 10.4037/ajcc2004.13.4.292; Puntillo KA, 2010, CRIT CARE MED, V38, P2155, DOI 10.1097/CCM.0b013e3181f267ee; Quigley C, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004847; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Quill TE, 2009, ANN INTERN MED, V151, P421, DOI 10.7326/0003-4819-151-6-200909150-00007; Ryan NM, 2015, EXPERT OPIN PHARMACO, V16, P135, DOI 10.1517/14656566.2015.981524; Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895; Schuckit MA, 2014, NEW ENGL J MED, V371, P2109, DOI 10.1056/NEJMra1407298; Simon ST, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007354.pub2; Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119; Tarumi Y, 2013, J PAIN SYMPTOM MANAG, V45, P2, DOI 10.1016/j.jpainsymman.2012.02.008; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Thomas J, 2008, NEW ENGL J MED, V358, P2332, DOI 10.1056/NEJMoa0707377; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Tulsky James A, 2005, J Palliat Med, V8 Suppl 1, pS95; Uronis H, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006429.pub2; Villa A, 2015, THER CLIN RISK MANAG, V11, P45, DOI 10.2147/TCRM.S76282; Wee B, 2008, COCHRANE DB SYST REV, V1; White C, 2007, J PALLIAT MED, V10, P345, DOI 10.1089/jpm.2006.0112; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Yuen JK, 2011, J GEN INTERN MED, V26, P791, DOI 10.1007/s11606-011-1632-x; Zhao I, 2008, PALLIATIVE MED, V22, P693, DOI 10.1177/0269216308095024	86	101	107	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	2015	373	26					2549	2561		10.1056/NEJMra1411746	http://dx.doi.org/10.1056/NEJMra1411746			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CZ7SG	26699170	Bronze			2023-01-03	WOS:000367299700010
J	Gothard, D; Smith, EL; Kanczler, JM; Black, CR; Wells, JA; Roberts, CA; White, LJ; Qutachi, O; Peto, H; Rashidi, H; Rojo, L; Stevens, MM; El Haj, AJ; Rose, FRAJ; Shakesheff, KM; Oreffo, ROC				Gothard, David; Smith, Emma L.; Kanczler, Janos M.; Black, Cameron R.; Wells, Julia A.; Roberts, Carol A.; White, Lisa J.; Qutachi, Omar; Peto, Heather; Rashidi, Hassan; Rojo, Luis; Stevens, Molly M.; El Haj, Alicia J.; Rose, Felicity R. A. J.; Shakesheff, Kevin M.; Oreffo, Richard O. C.			In Vivo Assessment of Bone Regeneration in Alginate/Bone ECM Hydrogels with Incorporated Skeletal Stem Cells and Single Growth Factors	PLOS ONE			English	Article							FACTOR-RELEASING HYDROGELS; EXTRACELLULAR-MATRIX; CHONDROGENIC DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; MORPHOGENETIC PROTEIN-2; MECHANICAL-PROPERTIES; GRAFT SUBSTITUTES; COLLAGEN HYDROGEL; FACTOR DELIVERY; TISSUE-REPAIR	The current study has investigated the use of decellularised, demineralised bone extracellular matrix (ECM) hydrogel constructs for in vivo tissue mineralisation and bone formation. Stro-1-enriched human bone marrow stromal cells were incorporated together with select growth factors including VEGF, TGF-beta 3, BMP-2, PTHrP and VitD3, to augment bone formation, and mixed with alginate for structural support. Growth factors were delivered through fast (non-osteogenic factors) and slow (osteogenic factors) release PLGA microparticles. Constructs of 5 mm length were implanted in vivo for 28 days within mice. Dense tissue assessed by micro-CT correlated with histologically assessed mineralised bone formation in all constructs. Exogenous growth factor addition did not enhance bone formation further compared to alginate/bone ECM (ALG/ECM) hydrogels alone. UV irradiation reduced bone formation through degradation of intrinsic growth factors within the bone ECM component and possibly also ECM cross-linking. BMP-2 and VitD3 rescued osteogenic induction. ALG/ECM hydrogels appeared highly osteoinductive and delivery of angiogenic or chondrogenic growth factors led to altered bone formation. All constructs demonstrated extensive host tissue invasion and vascularisation aiding integration and implant longevity. The proposed hydrogel system functioned without the need for growth factor incorporation or an exogenous inducible cell source. Optimal growth factor concentrations and spatiotemporal release profiles require further assessment, as the bone ECM component may suffer batch variability between donor materials. In summary, ALG/ECM hydrogels provide a versatile biomaterial scaffold for utilisation within regenerative medicine which may be tailored, ultimately, to form the tissue of choice through incorporation of select growth factors.	[Gothard, David; Smith, Emma L.; Kanczler, Janos M.; Black, Cameron R.; Wells, Julia A.; Roberts, Carol A.; Oreffo, Richard O. C.] Univ Southampton, Bone & Joint Res Grp, Ctr Human Dev Stem Cells & Regenerat, Inst Dev Sci, Southampton SO16 6YD, Hants, England; [White, Lisa J.; Qutachi, Omar; Peto, Heather; Rashidi, Hassan; Rose, Felicity R. A. J.; Shakesheff, Kevin M.] Univ Nottingham, Wolfson Ctr Stem Cells Tissue Engn & Modelling, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England; [Shakesheff, Kevin M.] Locate Therapeut Ltd, MediCity, Nottingham NG90 6BH, England; [Rojo, Luis; Stevens, Molly M.] Univ London Imperial Coll Sci Technol & Med, Royal Sch Mines, Dept Mat, London SW7 2AZ, England; [Rojo, Luis; Stevens, Molly M.] Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London SW7 2AZ, England; [Rojo, Luis; Stevens, Molly M.] Univ London Imperial Coll Sci Technol & Med, Inst Biomed Engn, London SW7 2AZ, England; [Rojo, Luis] Guys Hosp, Biomat Biomimet Biophoton Res Div, Kings Coll London, Inst Dent, London SE1 9RT, England; [El Haj, Alicia J.] Keele Univ, Inst Sci & Technol Med, Guy Hilton Res Ctr, Keele ST4 7BQ, Staffs, England	University of Southampton; University of Nottingham; Imperial College London; Imperial College London; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Keele University	Gothard, D (corresponding author), Univ Southampton, Bone & Joint Res Grp, Ctr Human Dev Stem Cells & Regenerat, Inst Dev Sci, Southampton SO16 6YD, Hants, England.	D.Gothard@soton.ac.uk; roco@soton.ac.uk	Rojo, Luis/B-3073-2009; Rashidi, Hassan/N-9313-2014; White, Lisa/AAM-9012-2021; Qutachi, Omar/AAD-7332-2019; Shakesheff, Kevin M/O-6371-2018; Shakesheff, Kevin/AAR-6603-2021; Oreffo, Richard/A-4615-2011	Rojo, Luis/0000-0001-6334-6736; Rashidi, Hassan/0000-0001-8078-6688; Qutachi, Omar/0000-0002-5026-7358; Shakesheff, Kevin M/0000-0003-3236-2439; Wells, Julia Anne/0000-0001-8272-0236; Stevens, Molly/0000-0002-7335-266X; Kanczler, Janos/0000-0001-7249-0414; Oreffo, Richard/0000-0001-5995-6726; White, Lisa/0000-0003-0571-999X; El Haj, Alicia/0000-0003-3544-5678; Rose, Felicity/0000-0001-6640-8840	BBSRC (sLOLA grant) [BB/G010579/1]; BBSRC [BB/G010579/1, BB/G010617/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/G010579/1, BB/G010617/1] Funding Source: researchfish	BBSRC (sLOLA grant); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the BBSRC (sLOLA grant BB/G010579/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank the Mr Douglas Dunlop and colleagues at the Southampton General Hospital for provision of adult human bone marrow samples. We would also like to thank Dr Jens Madsen for his help with statistical analysis. Research funding from the BBSRC (sLOLA BB/G010579/1) is gratefully acknowledged.	Alsberg E, 2001, J DENT RES, V80, P2025, DOI 10.1177/00220345010800111501; Ambikaipalan A, 2013, CURR STEM CELL RES T, V8, P210, DOI 10.2174/1574888X11308030005; Anseth KS, 1996, BIOMATERIALS, V17, P1647, DOI 10.1016/0142-9612(96)87644-7; Augst AD, 2006, MACROMOL BIOSCI, V6, P623, DOI 10.1002/mabi.200600069; Badylak SF, 2009, ACTA BIOMATER, V5, P1, DOI 10.1016/j.actbio.2008.09.013; Baroli B, 2007, J PHARM SCI-US, V96, P2197, DOI 10.1002/jps.20873; Basmanav FB, 2008, BIOMATERIALS, V29, P4195, DOI 10.1016/j.biomaterials.2008.07.017; Bhakta G, 2013, ACTA BIOMATER, V9, P9098, DOI 10.1016/j.actbio.2013.07.008; Bhakta G, 2012, BIOMATERIALS, V33, P6113, DOI 10.1016/j.biomaterials.2012.05.030; Bonfield W, 2006, PHILOS T R SOC A, V364, P227, DOI 10.1098/rsta.2005.1692; Bosnakovski D, 2006, BIOTECHNOL BIOENG, V93, P1152, DOI 10.1002/bit.20828; BRADLEY CM, 1992, AUST NZ J SURG, V62, P39, DOI 10.1111/j.1445-2197.1992.tb05352.x; Brown BN, 2009, BIOMATERIALS, V30, P1482, DOI 10.1016/j.biomaterials.2008.11.040; Burdick JA, 2009, TISSUE ENG PT A, V15, P205, DOI 10.1089/ten.tea.2008.0131; Buttermann GR, 2008, SPINE J, V8, P426, DOI 10.1016/j.spinee.2006.12.006; Chan G, 2008, TRENDS BIOTECHNOL, V26, P382, DOI 10.1016/j.tibtech.2008.03.011; Chiarello E, 2013, AGING CLIN EXP RES, V25, pS101, DOI 10.1007/s40520-013-0088-8; Coyac BR, 2013, J DENT RES, V92, P648, DOI 10.1177/0022034513488599; Dadsetan M, 2008, BIOMATERIALS, V29, P2193, DOI 10.1016/j.biomaterials.2008.01.006; Dawson JI, 2008, ARCH BIOCHEM BIOPHYS, V473, P124, DOI 10.1016/j.abb.2008.03.024; Fedorovich NE, 2007, TISSUE ENG, V13, P1905, DOI 10.1089/ten.2006.0175; Flausse A, 2013, J BIOMED MATER RES A, V101, P3211, DOI 10.1002/jbm.a.34629; Geckil H, 2010, NANOMEDICINE-UK, V5, P469, DOI [10.2217/nnm.10.12, 10.2217/NNM.10.12]; Ghosh K, 2007, ADV DRUG DELIVER REV, V59, P1306, DOI 10.1016/j.addr.2007.08.014; Gothard D, 2014, J TISSUE ENG, V5, DOI 10.1177/2041731414551763; Greenwald AS, 2001, J BONE JOINT SURG AM, V83A, P98, DOI 10.2106/00004623-200100022-00007; Gruskin E, 2012, ADV DRUG DELIVER REV, V64, P1063, DOI 10.1016/j.addr.2012.06.008; He XZ, 2008, LANGMUIR, V24, P12508, DOI 10.1021/la802447v; Howard D, 2008, J ANAT, V213, P66, DOI 10.1111/j.1469-7580.2008.00878.x; Jakob F, 2013, MATURITAS, V75, P118, DOI 10.1016/j.maturitas.2013.03.004; Johnson TD, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/49/494015; Kanczler JA, 2008, BIOMATERIALS, V29, P1892, DOI 10.1016/j.biomaterials.2007.12.031; Kim BS, 1998, TRENDS BIOTECHNOL, V16, P224, DOI 10.1016/S0167-7799(98)01191-3; Kim J, 2013, J KOREAN SOC ATMOS E, V29, P1, DOI 10.5572/KOSAE.2013.29.1.001; Kirby GTS, 2011, POLYMERS-BASEL, V3, P571, DOI 10.3390/polym3010571; Kisiel M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078551; Kolambkar YM, 2011, BIOMATERIALS, V32, P65, DOI 10.1016/j.biomaterials.2010.08.074; Kuhls Rainer, 2001, Cell and Tissue Banking, V2, P143, DOI 10.1023/A:1020173119669; Laschke MW, 2008, J BIOMED MATER RES A, V85A, P397, DOI 10.1002/jbm.a.31503; Lee CSD, 2010, BIOMATERIALS, V31, P4926, DOI 10.1016/j.biomaterials.2010.03.001; LEO WJ, 1990, BIOTECHNOL PROGR, V6, P51, DOI 10.1021/bp00001a008; Li ZS, 2005, BIOMATERIALS, V26, P3919, DOI 10.1016/j.biomaterials.2004.09.062; Ma K, 2012, ACTA BIOMATER, V8, P3754, DOI 10.1016/j.actbio.2012.06.028; Mano JF, 2007, J R SOC INTERFACE, V4, P999, DOI 10.1098/rsif.2007.0220; Markel DC, 2012, J INFLAMM RES, V5, P13, DOI 10.2147/JIR.S21411; Marsh D, 1998, CLIN ORTHOP RELAT R, pS22; Mladenov KV, 2010, EUR SPINE J, V19, pS135, DOI 10.1007/s00586-009-1179-2; Murphy WL, 1999, J PERIODONTAL RES, V34, P413, DOI 10.1111/j.1600-0765.1999.tb02275.x; Nakasone S, 2013, CLIN ORTHOP RELAT R, V471, P1926, DOI 10.1007/s11999-013-2833-x; Nukavarapu SP, 2013, BIOTECHNOL ADV, V31, P706, DOI 10.1016/j.biotechadv.2012.11.004; Parenteau-Bareil R, 2010, MATERIALS, V3, P1863, DOI 10.3390/ma3031863; Peterson B, 2004, J BONE JOINT SURG AM, V86A, P2243, DOI 10.2106/00004623-200410000-00016; Rabie A B, 1999, Aust Orthod J, V15, P269; Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071; Rose FRAJ, 2002, BIOCHEM BIOPH RES CO, V292, P1, DOI 10.1006/bbrc.2002.6519; Rutledge K, 2014, TISSUE ENG PART C-ME, V20, P865, DOI [10.1089/ten.tec.2013.0411, 10.1089/ten.TEC.2013.0411]; Sawkins MJ, 2013, ACTA BIOMATER, V9, P7865, DOI 10.1016/j.actbio.2013.04.029; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider GB, 2004, BIOMATERIALS, V25, P3023, DOI 10.1016/j.biomaterials.2003.09.084; Silva NA, 2013, BIOCHIMIE, V95, P2314, DOI 10.1016/j.biochi.2013.08.016; Singh M, 2008, TISSUE ENG PART B-RE, V14, P341, DOI 10.1089/ten.teb.2008.0304; Smith EL, 2014, ACTA BIOMATER, V10, P4186, DOI 10.1016/j.actbio.2014.06.011; Smith EL, 2014, ACTA BIOMATER, V10, P4197, DOI 10.1016/j.actbio.2014.05.025; Stoppel WL, 2014, J BIOMED MATER RES B, V102, P877, DOI 10.1002/jbm.b.33070; Suarez-Gonzalez D, 2013, TISSUE ENG A; Tabata Y, 2003, TISSUE ENG, V9, pS5, DOI 10.1089/10763270360696941; Taghavi CE, 2010, SPINE, V35, P1144, DOI 10.1097/BRS.0b013e3181bb5203; Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361; TULI SM, 1978, J BONE JOINT SURG BR, V60, P116, DOI 10.1302/0301-620X.60B1.342532; Wang JC, 2007, EUR SPINE J, V16, P1233, DOI 10.1007/s00586-006-0282-x; Wenger MPE, 2007, BIOPHYS J, V93, P1255, DOI 10.1529/biophysj.106.103192; White LJ, 2013, MAT SCI ENG C-MATER, V33, P2578, DOI 10.1016/j.msec.2013.02.020; Williams EL, 2013, METHODS MOL BIOL, V1035, P67, DOI 10.1007/978-1-62703-508-8_7; Yan TQ, 2013, J SURG RES; Zhang L, 2012, J BIOMED MATER RES A, V100A, P2717, DOI 10.1002/jbm.a.34194; Zheng L, 2010, J BIOMED MATER RES A, V93A, P783, DOI 10.1002/jbm.a.32588	76	51	53	2	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2015	10	12							e0145080	10.1371/journal.pone.0145080	http://dx.doi.org/10.1371/journal.pone.0145080			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9JH	26675008	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000366722700096
J	Stupp, R; Taillibert, S; Kanner, AA; Kesari, S; Steinberg, DM; Toms, SA; Taylor, LP; Lieberman, F; Silvani, A; Fink, KL; Barnett, GH; Zhu, JJ; Henson, JW; Engelhard, HH; Chen, TC; Tran, DD; Sroubek, J; Iran, ND; Hottinger, AF; Landolfi, J; Desai, R; Caroli, M; Kew, Y; Honnorat, J; Idbaih, A; Kirson, ED; Weinberg, U; Palti, Y; Hegi, ME; Ram, Z				Stupp, Roger; Taillibert, Sophie; Kanner, Andrew A.; Kesari, Santosh; Steinberg, David M.; Toms, Steven A.; Taylor, Lynne P.; Lieberman, Frank; Silvani, Antonio; Fink, Karen L.; Barnett, Gene H.; Zhu, Jay-Jiguang; Henson, John W.; Engelhard, Herbert H.; Chen, Thomas C.; Tran, David D.; Sroubek, Jan; Iran, Nam D.; Hottinger, Andreas F.; Landolfi, Joseph; Desai, Rajiv; Caroli, Manuela; Kew, Yvonne; Honnorat, Jerome; Idbaih, Ahmed; Kirson, Eilon D.; Weinberg, Uri; Palti, Yoram; Hegi, Monika E.; Ram, Zvi			Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEWLY-DIAGNOSED GLIOBLASTOMA; ALTERNATING ELECTRIC-FIELDS; QUALITY-OF-LIFE; PHASE-III TRIAL; RECURRENT GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; TREATMENT MODALITY; OPEN-LABEL; RADIOTHERAPY; NOVOTTF-100A	iMPORTANCE Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly. OBJECTIVE To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma. DESIGN, SETTING, AND PARTICIPANTS After completion of chemoradiotherapy, patients with glioblastoma were randomized (2:1) to receive maintenance treatment with either TTFields plus temozolomide (n = 466) or temozolomide alone (n = 229) (median time from diagnosis to randomization, 3.8 months in both groups). The study enrolled 695 of the planned 700 patients between July 2009 and November 2014 at 83 centers in the United States, Canada, Europe, Israel, and South Korea. The trial was terminated based on the results of this planned interim analysis. INTERVENTIONS Treatment with TTFields was delivered continuously (>18 hours/day) via 4 transducer arrays placed on the shaved scalp and connected to a portable medical device. Temozolomide (150-200 mg/m(2)/d) was given for 5 days of each 28-day cycle. MAIN OUTCOMES AND MEASURES The primary end point was progression-free survival in the intent-to-treat population (significance threshold of .01) with overall survival in the per-protocol population (n = 280) as a powered secondary end point (significance threshold of .006). This prespecified interim analysis was to be conducted on the first 315 patients after at least 18 months of follow-up. RESULTS The interim analysis included 210 patients randomized to TTFields plus temozolomide and 105 randomized to temozolomide alone, and was conducted at a median follow-up of 38 months (range, 18-60 months). Median progression-free survival in the intent-to-treat population was 7.1 months (95% Cl, 5.9-8.2 months) in the TTFields plus temozolomide group and 4.0 months (95% Cl, 3.3-5.2 months) in the temozolomide alone group (hazard ratio [HR], 0.62 [98.7% Cl, 0.43-0.89]; P =.001). Median overall survival in the per-protocol population was 20.5 months (95% Cl, 16.7-25.0 months) in the TTFields plus temozolomide group (n = 196) and 15.6 months (95% Cl, 13.3-19.1 months) in the temozolomide alone group (n = 84) (HR, 0.64 [99.4% Cl, 0.42-0.98]; P =.004). CONCLUSIONS AND RELEVANCE In this interim analysis of 315 patients with glioblastoma who had completed standard chemoradiation therapy, adding TTFields to maintenance temozolomide chemotherapy significantly prolonged progression-free and overall survival.	[Stupp, Roger] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Stupp, Roger] Univ Zurich, Zurich, Switzerland; [Stupp, Roger; Hottinger, Andreas F.; Hegi, Monika E.] Lausanne Univ Hosp CHUV, Lausanne, Switzerland; [Taillibert, Sophie; Idbaih, Ahmed] Univ Paris 06, La Pitie Salpetriere Univ Hosp, Assistance Publ Hop Paris, Paris, France; [Kanner, Andrew A.; Ram, Zvi] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; [Kesari, Santosh] Univ Calif San Diego, San Diego, CA 92103 USA; [Steinberg, David M.] Tel Aviv Univ, IL-69978 Tel Aviv, Israel; [Toms, Steven A.] Geisinger Hlth Syst, Danville, PA USA; [Taylor, Lynne P.] Tufts Med Ctr, Boston, MA USA; [Lieberman, Frank] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Silvani, Antonio] Ist Nazl Neurol Carlo Besta, Milan, Italy; [Fink, Karen L.; Zhu, Jay-Jiguang] Baylor Univ, Med Ctr, Dallas, TX USA; [Barnett, Gene H.] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Zhu, Jay-Jiguang] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA; [Henson, John W.] Swedish Neurosci Inst, Seattle, WA USA; [Engelhard, Herbert H.] Univ Illinois, Chicago, IL USA; [Chen, Thomas C.] Univ So Calif, Los Angeles, CA USA; [Tran, David D.] Washington Univ, Barnes Jewish Hosp, St Louis, MO USA; [Sroubek, Jan] Na Homolce Hosp, Prague, Czech Republic; [Iran, Nam D.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Landolfi, Joseph] New Jersey Neurosci Inst, Edison, NJ USA; [Desai, Rajiv] Maine Med Ctr, Portland, OR USA; [Caroli, Manuela] Fdn Osped Maggiore Policlin, Milan, Italy; [Kew, Yvonne] Houston Methodist Hosp, Houston, TX USA; [Honnorat, Jerome] Univ Claude Bernard Lyon 1, Hosp Civils Lyon, Lyon, France; [Kirson, Eilon D.; Weinberg, Uri; Palti, Yoram] Novocure, Haifa, Israel	University of Zurich; University Zurich Hospital; University of Zurich; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; University of California System; University of California San Diego; Tel Aviv University; Geisinger Health System; Tufts Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; IRCCS Istituto Neurologico Besta; Baylor University; Baylor University Medical Center; Cleveland Clinic Foundation; University of Texas System; University of Texas Health Science Center Houston; Swedish Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Southern California; Barnes-Jewish Hospital; Washington University (WUSTL); Na Homolce Hospital; H Lee Moffitt Cancer Center & Research Institute; IRCCS Ca Granda Ospedale Maggiore Policlinico; The Methodist Hospital System; The Methodist Hospital - Houston; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Novocure Limited	Stupp, R (corresponding author), Univ Zurich Hosp, Dept Oncol, CH-8091 Zurich, Switzerland.	roger.stupp@usz.ch	Kesari, Santosh/E-8461-2013; Taylor, Lynne P./S-8154-2019; Toms, Steven/HJA-7831-2022; Hegi, Monika/O-4796-2015; Stupp, Roger/L-3303-2019; Honnorat, jerome/G-6394-2017; Sroubek, Jan/AAO-6261-2021; Silvani, Antonio/AAA-4600-2019; Caroli, Manuela/AAB-9019-2019; Idbaih, Ahmed/N-8746-2017	Taylor, Lynne P./0000-0001-5946-3796; Hegi, Monika/0000-0003-0855-6495; Honnorat, jerome/0000-0002-4721-5952; Sroubek, Jan/0000-0003-0833-7444; Silvani, Antonio/0000-0002-4791-1042; Kanner, Andrew Ariye/0000-0002-0812-8573; Engelhard, Herbert/0000-0003-4993-9265; Idbaih, Ahmed/0000-0001-5290-1204	Novocure Ltd.	Novocure Ltd.	The study was funded by Novocure Ltd.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Chvetzoff G, 2003, J NATL CANCER I, V95, P19, DOI 10.1093/jnci/95.1.19; DeMets D L, 1995, Cancer Treat Res, V75, P1; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; Fonkem E, 2012, EXPERT REV NEUROTHER, V12, P895, DOI 10.1586/ERN.12.80; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Gilbert MR, 2013, J CLIN ONCOL, V31, P4085, DOI 10.1200/JCO.2013.49.6968; Gutin Philip H, 2012, Am Soc Clin Oncol Educ Book, P126, DOI 10.14694/EdBook_AM.2012.32.126; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Kirson ED, 2004, CANCER RES, V64, P3288, DOI 10.1158/0008-5472.CAN-04-0083; Kirson ED, 2007, P NATL ACAD SCI USA, V104, P10152, DOI 10.1073/pnas.0702916104; Kirson Eilon D, 2009, BMC Med Phys, V9, P1, DOI 10.1186/1756-6649-9-1; Lacouture Mario E, 2014, Semin Oncol, V41 Suppl 4, pS1, DOI 10.1053/j.seminoncol.2014.03.011; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; MACDONALD DR, 1990, J CLIN ONCOL, V8, P1277, DOI 10.1200/JCO.1990.8.7.1277; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2014, LANCET ONCOL, V15, P1100, DOI 10.1016/S1470-2045(14)70379-1; Stupp R, 2012, EUR J CANCER, V48, P2192, DOI 10.1016/j.ejca.2012.04.011; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Taphoorn MJB, 2010, EUR J CANCER, V46, P1033, DOI 10.1016/j.ejca.2010.01.012; Team R.C., 2021, R FOUN DATION STAT C; Vlassenbroeck I, 2008, J MOL DIAGN, V10, P332, DOI 10.2353/jmoldx.2008.070169; Westphal M, 2015, EUR J CANCER, V51, P522, DOI 10.1016/j.ejca.2014.12.019	25	717	734	5	117	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	2015	314	23					2535	2543		10.1001/jama.2015.16669	http://dx.doi.org/10.1001/jama.2015.16669			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CY4PV	26670971	Green Published, Bronze			2023-01-03	WOS:000366391500020
J	Cole, EA				Cole, Ellen Aronofsky			My Life as a (Fake) Patient	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2015	373	24					2302	2303		10.1056/NEJMp1508706	http://dx.doi.org/10.1056/NEJMp1508706			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CY0QW	26650151				2023-01-03	WOS:000366111600004
J	Wang, LG; Tao, T; Fan, CL; Gao, WB; Wei, CG				Wang, Ligang; Tao, Ting; Fan, Chunlei; Gao, Wenbin; Wei, Chuguang			The Influence of Chronic Ego Depletion on Goal Adherence: An Experience Sampling Study	PLOS ONE			English	Article							SELF-CONTROL; RESOURCE-DEPLETION; LIMITED RESOURCES; MOTIVATION; BEHAVIOR; FAILURE; MODEL; STRENGTH; FATIGUE; LIFE	Although ego depletion effects have been widely observed in experiments in which participants perform consecutive self-control tasks, the process of ego depletion remains poorly understood. Using the strength model of self-control, we hypothesized that chronic ego depletion adversely affects goal adherence and that mental effort and motivation are involved in the process of ego depletion. In this study, 203 students reported their daily performance, mental effort, and motivation with respect to goal directed behavior across a 3-week time period. People with high levels of chronic ego depletion were less successful in goal adherence than those with less chronic ego depletion. Although daily effort devoted to goal adherence increased with chronic ego depletion, motivation to adhere to goals was not affected. Participants with high levels of chronic ego depletion showed a stronger positive association between mental effort and performance, but chronic ego depletion did not play a regulatory role in the effect of motivation on performance. Chronic ego depletion increased the likelihood of behavior regulation failure, suggesting that it is difficult for people in an ego-depletion state to adhere to goals. We integrate our results with the findings of previous studies and discuss possible theoretical implications.	[Wang, Ligang; Tao, Ting; Fan, Chunlei; Gao, Wenbin] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China; [Wei, Chuguang] Chinese Acad Sci, Inst Psychol, Core Facilies, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Psychology, CAS; Chinese Academy of Sciences; Institute of Psychology, CAS	Gao, WB (corresponding author), Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China.	gaowb@psych.ac.cn			Natural Sciences Foundation of China [31400885]; Key Laboratory of Mental Health, Chinese Academy of Sciences [KLMH2014ZG12]	Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Key Laboratory of Mental Health, Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by the Natural Sciences Foundation of China (No. 31400885; URL: http://www.nsfc.gov.cn/publish/portal1/). This funder had a role in study design, data collection and analysis. The work was also supported by Key Laboratory of Mental Health, Chinese Academy of Sciences (No. KLMH2014ZG12; URL: http://www.psych.ac.cn/jkzdsys/). This funder had a role in the decision to publish and preparation of the manuscript.	Aiken JS, 1991, MULTIPLE REGRESSION; Baumeister RF, 1996, PSYCHOL INQ, V7, P1, DOI 10.1207/s15327965pli0701_1; Baumeister RF, 2009, SOCIAL PSYCHOL HDB B, P516; Bertrams A, 2010, J RES PERS, V44, P738, DOI 10.1016/j.jrp.2010.09.005; BREHM JW, 1989, ANNU REV PSYCHOL, V40, P109, DOI 10.1146/annurev.ps.40.020189.000545; Burkard C, 2014, NEUROPSYCHOL REHABIL, V24, P266, DOI 10.1080/09602011.2014.887023; Clarkson JJ, 2010, J PERS SOC PSYCHOL, V98, P29, DOI 10.1037/a0017539; Hagger MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076888; Hagger MS, 2010, PSYCHOL BULL, V136, P495, DOI 10.1037/a0019486; Heatherton TF, 1998, PSYCHOL INQ, V9, P212, DOI 10.1207/s15327965pli0903_4; Hofmann W, 2012, PSYCHOL SCI, V23, P582, DOI 10.1177/0956797612437426; Hofmann W, 2009, J EXP SOC PSYCHOL, V45, P431, DOI 10.1016/j.jesp.2008.09.013; Inzlicht M, 2012, PERSPECT PSYCHOL SCI, V7, P450, DOI 10.1177/1745691612454134; Liu X., 1997, CHIN J CLIN PSYCHOL, V5, P34, DOI DOI 10.16128/J.CNKI.1005-3611.1997.01.011; Masicampo EJ, 2014, SOC PERSONAL PSYCHOL, V8, P638, DOI 10.1111/spc3.12139; Muraven M, 2000, PSYCHOL BULL, V126, P247, DOI 10.1037/0033-2909.126.2.247; Muraven M, 2003, PERS SOC PSYCHOL B, V29, P894, DOI 10.1177/0146167203029007008; Muraven M, 2007, MOTIV EMOTION, V31, P322, DOI 10.1007/s11031-007-9073-x; Muraven M, 2006, J PERS SOC PSYCHOL, V91, P524, DOI 10.1037/0022-3514.91.3.524; Neal DT, 2013, J PERS SOC PSYCHOL, V104, P959, DOI 10.1037/a0032626; Nes LS, 2013, J PAIN RES, V6, P181, DOI 10.2147/JPR.S40014; Nes LS, 2010, PAIN, V151, P37, DOI 10.1016/j.pain.2010.05.009; Norris FH, 1996, J PERS SOC PSYCHOL, V71, P498, DOI 10.1037/0022-3514.71.3.498; OBRIST PA, 1976, PSYCHOPHYSIOLOGY, V13, P95, DOI 10.1111/j.1469-8986.1976.tb00081.x; Park CL, 1997, J PERS, V65, P421, DOI 10.1111/j.1467-6494.1997.tb00960.x; Salmon SJ, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00647; Schmeichel BJ, 2010, J PERS SOC PSYCHOL, V99, P162, DOI 10.1037/a0019797; Stewart CC, 2009, PSYCHOPHYSIOLOGY, V46, P1141, DOI 10.1111/j.1469-8986.2009.00862.x; Vohs KD, 2000, PSYCHOL SCI, V11, P249, DOI 10.1111/1467-9280.00250; [王利刚 Wang LiGang], 2015, [中国心理卫生杂志, Chinese Mental Health Journal], V29, P290; Wills TA, 2002, J CONSULT CLIN PSYCH, V70, P986, DOI 10.1037//0022-006X.70.4.986; Wood W, 2009, J CONSUM PSYCHOL, V19, P579, DOI 10.1016/j.jcps.2009.08.003; Wright RA, 2013, BIOL PSYCHOL, V93, P316, DOI 10.1016/j.biopsycho.2013.02.016	33	5	6	8	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2015	10	11							e0142220	10.1371/journal.pone.0142220	http://dx.doi.org/10.1371/journal.pone.0142220			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV7UL	26562839	gold, Green Submitted, Green Published			2023-01-03	WOS:000364480900021
J	Curado, MR; Cossio, EG; Broetz, D; Agostini, M; Cho, W; Brasil, FL; Yilmaz, O; Liberati, G; Lepski, G; Birbaumer, N; Ramos-Murguialday, A				Curado, Marco Rocha; Cossio, Eliana Garcia; Broetz, Doris; Agostini, Manuel; Cho, Woosang; Brasil, Fabricio Lima; Yilmaz, Oezge; Liberati, Giulia; Lepski, Guilherme; Birbaumer, Niels; Ramos-Murguialday, Ander			Residual Upper Arm Motor Function Primes Innervation of Paretic Forearm Muscles in Chronic Stroke after Brain-Machine Interface (BMI) Training	PLOS ONE			English	Article							UPPER-EXTREMITY; UPPER-LIMB; RECOVERY; SYNERGIES; BCI; EMG	Background Abnormal upper arm-forearm muscle synergies after stroke are poorly understood. We investigated whether upper arm function primes paralyzed forearm muscles in chronic stroke patients after Brain-Machine Interface (BMI)-based rehabilitation. Shaping upper arm-forearm muscle synergies may support individualized motor rehabilitation strategies. Methods Thirty-two chronic stroke patients with no active finger extensions were randomly assigned to experimental or sham groups and underwent daily BMI training followed by physiotherapy during four weeks. BMI sessions included desynchronization of ipsilesional brain activity and a robotic orthosis to move the paretic limb (experimental group, n = 16). In the sham group (n = 16) orthosis movements were random. Motor function was evaluated with electromyography (EMG) of forearm extensors, and upper arm and hand Fugl-Meyer assessment (FMA) scores. Patients performed distinct upper arm (e.g., shoulder flexion) and hand movements (finger extensions). Forearm EMG activity significantly higher during upper arm movements as compared to finger extensions was considered facilitation of forearm EMG activity. Intraclass correlation coefficient (ICC) was used to test inter-session reliability of facilitation of forearm EMG activity. Results Facilitation of forearm EMG activity ICC ranges from 0.52 to 0.83, indicating fair to high reliability before intervention in both limbs. Facilitation of forearm muscles is higher in the paretic as compared to the healthy limb (p<0.001). Upper arm FMA scores predict facilitation of forearm muscles after intervention in both groups (significant correlations ranged from R = 0.752, p = 0.002 to R = 0.779, p = 0.001), but only in the experimental group upper arm FMA scores predict changes in facilitation of forearm muscles after intervention (R = 0.709, p = 0.002; R = 0.827, p<0.001). Conclusions Residual upper arm motor function primes recruitment of paralyzed forearm muscles in chronic stroke patients and predicts changes in their recruitment after BMI training. This study suggests that changes in upper arm-forearm synergies contribute to stroke motor recovery, and provides candidacy guidelines for similar BMI-based clinical practice.	[Curado, Marco Rocha; Cossio, Eliana Garcia; Broetz, Doris; Agostini, Manuel; Cho, Woosang; Yilmaz, Oezge; Birbaumer, Niels; Ramos-Murguialday, Ander] Univ Tubingen, Inst Med Psychol & Behav Neurobiol, D-72076 Tubingen, Germany; [Curado, Marco Rocha; Cossio, Eliana Garcia; Yilmaz, Oezge] Int Max Planck Res Sch Neural & Behav Sci, Tubingen, Germany; [Brasil, Fabricio Lima] Inst Santos Dumond, Edmond & Lily Safra Int Inst Neurosci, Natal, RN, Brazil; [Lepski, Guilherme] Catholic Univ Louvain, Inst Neurosci, Louvain, Belgium; [Lepski, Guilherme] Univ Sao Paulo, Dept Neurol, Sao Paulo, Brazil; [Lepski, Guilherme] Univ Tubingen, Dept Neurosurg, D-72076 Tubingen, Germany; [Birbaumer, Niels] Univ Tubingen, Helmholtz Ctr Munich, Inst Diabet Res & Metab Dis, D-72076 Tubingen, Germany; [Ramos-Murguialday, Ander] TECNALIA Hlth Technol, San Sebastian, Spain	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Max Planck Society; Universite Catholique Louvain; Universidade de Sao Paulo; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Curado, MR (corresponding author), Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Silcherstr 5, D-72076 Tubingen, Germany.	marco.curado@gmail.com	Coish, Elizabeth/AAU-1245-2020; Lepski, Guilherme/E-1508-2012; yilmaz, ozge/B-3866-2014; Lepski, Guilherme/V-6905-2019; Lepski, Guilherme A/C-1951-2014; Brasil, Fabricio Lima/I-7529-2015	Lepski, Guilherme/0000-0002-9030-4192; Brasil, Fabricio Lima/0000-0002-9984-1007; Liberati, Giulia/0000-0002-5684-4443; Birbaumer, Niels/0000-0002-6786-5127; Ramos-Murguialday, Dr. Ander/0000-0002-1549-4029	German Federal Ministry of Education and Research (BMBF) [01GQ0831, 01GI0925]; Deutsche Forschungsgemeinschaft (DFG); European Research Council [ERC 227632]; European Union Information and Communication Technologies Framework Programme 7 (ICT-FP7) [HUMOUR 231724]; TECNALIA; Baden Wuerttemberg Stiftung [ROB-1]; Natural Science Foundation of China [NSFC 31450110072]; Volkswagen Stiftung; CAPES (Coordination for the Improvement of Higher Level -or Education-Personnel, Brazil); CNPq (Brazilian National Counsel of Technological and Scientific Development); DAAD (Deutscher Akademischer Austauschdienst); Interuniversity Center for the Research in Cognitive Processing of Natural and Artificial Systems (ECoNa); Sapienza University of Rome	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); European Research Council(European Research Council (ERC)European Commission); European Union Information and Communication Technologies Framework Programme 7 (ICT-FP7); TECNALIA; Baden Wuerttemberg Stiftung; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Volkswagen Stiftung(Volkswagen); CAPES (Coordination for the Improvement of Higher Level -or Education-Personnel, Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq (Brazilian National Counsel of Technological and Scientific Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); DAAD (Deutscher Akademischer Austauschdienst)(Deutscher Akademischer Austausch Dienst (DAAD)); Interuniversity Center for the Research in Cognitive Processing of Natural and Artificial Systems (ECoNa); Sapienza University of Rome	This work was supported by the German Federal Ministry of Education and Research (BMBF, Forderzeichen 01GQ0831, http://www.bmbf.de/, and DZD, 01GI0925); Deutsche Forschungsgemeinschaft (DFG, http://www.dfg.de/); European Research Council (ERC 227632, http://erc.europa.eu/) and European Union Information and Communication Technologies Framework Programme 7 (ICT-FP7, http://cordis.europa.eu/fp7/ict/) (HUMOUR 231724); TECNALIA (http://www.tecnalia.com/en/); Baden Wuerttemberg Stiftung (ROB-1, http://www.bwstiftung.de/); Natural Science Foundation of China (NSFC 31450110072) and Volkswagen Stiftung. MRC was funded by CAPES (Coordination for the Improvement of Higher Level -or Education-Personnel, Brazil, http://www.capes.gov.br/); FLB by CNPq (Brazilian National Counsel of Technological and Scientific Development, http://www.cnpq.br/); MRC, ECG, FLB, WC and OY were funded by DAAD (Deutscher Akademischer Austauschdienst, https://www.daad.org/) scholarship; and GLi was funded by the Interuniversity Center for the Research in Cognitive Processing of Natural and Artificial Systems (ECoNa, http://w3.uniroma1.it/econa/), Sapienza University of Rome. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ang K. K., 2014, CLIN EEG NE IN PRESS; Beaglehole R, 2003, WORLD HLTH REPORT 20, P1; Caria A, 2011, PSYCHOPHYSIOLOGY, V48, P578, DOI 10.1111/j.1469-8986.2010.01117.x; Chae J, 2002, NEUROREHAB NEURAL RE, V16, P241, DOI 10.1177/154596802401105180; Cheung VCK, 2012, P NATL ACAD SCI USA, V109, P14652, DOI 10.1073/pnas.1212056109; Cheung VCK, 2009, P NATL ACAD SCI USA, V106, P19563, DOI 10.1073/pnas.0910114106; Crow JL, 2008, PHYS THER, V88, P1554, DOI 10.2522/ptj.20070186; Daly JJ, 2009, J NEUROL PHYS THER, V33, P203, DOI 10.1097/NPT.0b013e3181c1fc0b; Garcia-Cossio E, 2013, I IEEE EMBS C NEUR E, P1545, DOI 10.1109/NER.2013.6696241; Grefkes C, 2014, NEUROSCIENTIST, V20, P56, DOI 10.1177/1073858413491147; Houwink A, 2013, ARCH PHYS MED REHAB, V94, P839, DOI 10.1016/j.apmr.2012.11.031; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Latash ML, 2006, PHYS THER, V86, P1151, DOI 10.1093/ptj/86.8.1151; Lee SW, 2011, IEEE T NEUR SYS REH, V19, P558, DOI 10.1109/TNSRE.2010.2079334; Li XY, 2014, CLIN NEUROPHYSIOL, V125, P988, DOI 10.1016/j.clinph.2013.09.044; Liu ZW, 2013, STROKE, V44, P1951, DOI 10.1161/STROKEAHA.113.001162; Manschot S, 1998, J NEUROL NEUROSUR PS, V64, P253, DOI 10.1136/jnnp.64.2.253; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.1.30; Miller LC, 2012, CLIN NEUROPHYSIOL, V123, P1216, DOI 10.1016/j.clinph.2012.01.009; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; Ono Takashi, 2014, Front Neuroeng, V7, P19, DOI 10.3389/fneng.2014.00019; Pandian S, 2012, TOP STROKE REHABIL, V19, P545, DOI 10.1310/tsr1906-545; Patten C, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-1; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Ramos-Murguialday A, 2013, ANN NEUROL, V74, P100, DOI 10.1002/ana.23879; Roh J, 2013, J NEUROPHYSIOL, V109, P768, DOI 10.1152/jn.00670.2012; Starkey ML, 2012, BRAIN, V135, P3265, DOI 10.1093/brain/aws270; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Taub E, 2006, STROKE, V37, P1045, DOI 10.1161/01.STR.0000206463.66461.97; Turk R, 2008, NEUROREHAB NEURAL RE, V22, P684, DOI 10.1177/1545968308315599; TWITCHELL TE, 1951, BRAIN, V74, P443, DOI 10.1093/brain/74.4.443; Whitall J, 2000, STROKE, V31, P2390, DOI 10.1161/01.STR.31.10.2390; Wright ZA, 2012, IEEE ENG MED BIO, P879, DOI 10.1109/EMBC.2012.6346072	34	15	17	5	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2015	10	10							e0140161	10.1371/journal.pone.0140161	http://dx.doi.org/10.1371/journal.pone.0140161			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU1VG	26495971	Green Submitted, Green Published, gold			2023-01-03	WOS:000363309200014
J	Luedike, P; Rammos, C; Pohl, J; Heisler, M; Totzeck, M; Kleophas, W; Hetzel, GR; Kelm, M; Hendgen-Cotta, U; Rassaf, T				Luedike, Peter; Rammos, Christos; Pohl, Julia; Heisler, Martin; Totzeck, Matthias; Kleophas, Werner; Hetzel, Gerd R.; Kelm, Malte; Hendgen-Cotta, Ulrike; Rassaf, Tienush			Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR OUTCOMES; OXIDATIVE STRESS; DYSFUNCTION; EXPRESSION; CHEMOKINE; INFLAMMATION; ACTIVATION; PLATELETS; SECRETION	Background End stage renal disease (ESRD) patients are characterized by increased morbidity and mortality due to highest prevalence of cardiovascular disease. Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine that controls cellular signaling in human physiology, pathophysiology, and diseases. Increased MIF plasma levels promote vascular inflammation and development of atherosclerosis. We have shown that MIF is associated with vascular dysfunction in ESRD patients. Whether hemodialysis (HD) affects circulating MIF plasma levels is unknown. We here aimed to investigate whether HD influences the circulating MIF pool in ESRD patients. Methods and Results An observational single-center study was conducted. MIF plasma levels in ESRD patients were assessed before, during, and after a HD session (n = 29). Healthy age-matched volunteers served as controls to compare correlations of MIF plasma levels with inflammatory plasma components (n = 20). MIF removed from the circulating blood pool could be detected in the dialysate and allowed for calculation of totally removed MIF (MIF content in dialysate 219 +/- 4 mu g/HD-session). MIF plasma levels were markedly decreased 2 hour after initiation of HD (MIF plasma level pre-HD 84.8 +/- 6 ng/ml to intra-HD 61.2 +/- 5 ng/ml p<0.001) and were replenished already 20 min after termination of HD to basal levels (intra-HD 61.2 +/- 5 ng/ml to post-HD 79.8 +/- 5 ng/ml, p<0.001). Conclusion MIF is a dialyzable plasma component that is effectively filtrated during HD from the patient blood pool in large amounts. After removal of remarkable amounts of MIF during a single HD session, MIF plasma pool is early reconstituted after termination of HD from unknown sources.	[Luedike, Peter; Rammos, Christos; Pohl, Julia; Heisler, Martin; Totzeck, Matthias; Kelm, Malte; Hendgen-Cotta, Ulrike; Rassaf, Tienush] Univ Hosp Dusseldorf, Fac Med, Div Cardiol Pulmonol & Vasc Med, D-40225 Dusseldorf, Germany; [Kleophas, Werner; Hetzel, Gerd R.] DaVita Renal Ctr, D-40210 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital	Rassaf, T (corresponding author), Univ Hosp Essen, Dept Cardiol, West German Heart & Vasc Ctr Essen, Hufelandstr 55, D-45122 Essen, Germany.	Tienush.Rassaf@uk-essen.de		Kelm, Malte/0000-0003-0060-1052	Research Committee of the medical faculty of the University of Duesseldorf [23/2013, 86/2012]; DFG [Ra969/7-2]	Research Committee of the medical faculty of the University of Duesseldorf; DFG(German Research Foundation (DFG))	PL and MT were funded by the Research Committee of the medical faculty of the University of Duesseldorf (23/2013 to PL, 86/2012 to MT). TR is a Heisenberg professor funded by the DFG (Ra969/7-2).	Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365; Bernhagen J, 1998, J MOL MED-JMM, V76, P151, DOI 10.1007/s001090050204; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Burger-Kentischer A, 2002, CIRCULATION, V105, P1561, DOI 10.1161/01.CIR.0000012942.49244.82; Chatterjee M, 2014, CIRC RES, V115, P939, DOI 10.1161/CIRCRESAHA.115.305171; Fassbinder W, 2003, KIDNEY BLOOD PRESS R, V26, P96, DOI 10.1159/000070990; Filiopoulos V, 2009, INT J ARTIF ORGANS, V32, P872, DOI 10.1177/039139880903201206; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Gremmel T, 2013, NEPHROL DIAL TRANSPL, V28, P2116, DOI 10.1093/ndt/gft103; Luedike P, 2012, CIRCULATION, V125, P1880, DOI 10.1161/CIRCULATIONAHA.111.069104; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; Meyer C, 2010, J AM COLL CARDIOL, V55, P454, DOI 10.1016/j.jacc.2009.07.068; Miyazaki H, 2000, CIRCULATION, V101, P1002, DOI 10.1161/01.CIR.101.9.1002; Petrovsky N, 2003, IMMUNOL CELL BIOL, V81, P137, DOI 10.1046/j.0818-9641.2002.01148.x; Rammos C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/582586; Rammos C, 2014, MECH AGEING DEV, V135, P15, DOI 10.1016/j.mad.2014.01.001; Rammos C, 2013, INT J CARDIOL, V168, P5249, DOI 10.1016/j.ijcard.2013.08.021; Rassaf T, 2014, CARDIOVASC RES, V102, P321, DOI 10.1093/cvr/cvu071; Rex S, 2014, MINI-REV MED CHEM, V14, P1116; Schober A, 2004, CIRCULATION, V109, P380, DOI 10.1161/01.CIR.0000109201.72441.09; Schober A, 2008, J MOL MED, V86, P761, DOI 10.1007/s00109-008-0334-2; Simons D, 2011, J CELL MOL MED, V15, P668, DOI 10.1111/j.1582-4934.2010.01041.x; Sobierajski J, 2013, FREE RADICAL BIO MED, V63, P236, DOI 10.1016/j.freeradbiomed.2013.05.018; Stenvinkel P, 2006, NEPHROLOGY, V11, P36, DOI 10.1111/j.1440-1797.2006.00541.x; Stoppe C, 2013, ANTIOXID REDOX SIGN, V19, P231, DOI 10.1089/ars.2012.5015; Stoppe C, 2012, MOL MED, V18, P843, DOI 10.2119/molmed.2012.00071; Stoppe C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033512; Strussmann T, 2013, THROMB HAEMOSTASIS, V110, P1004, DOI 10.1160/TH13-01-0049; Tillmann S, 2012, CYTOKINE, V59, P499, DOI 10.1016/j.cyto.2012.06.032; Wirtz TH, 2015, ATHEROSCLEROSIS, V239, P1, DOI 10.1016/j.atherosclerosis.2014.12.039; Zernecke A, 2008, CIRCULATION, V117, P1594, DOI 10.1161/CIRCULATIONAHA.107.729125	31	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2015	10	10							e0140215	10.1371/journal.pone.0140215	http://dx.doi.org/10.1371/journal.pone.0140215			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT7XI	26485680	Green Submitted, Green Published, gold			2023-01-03	WOS:000363028100023
J	Chen, CL; Chen, YP; Lin, MW; Huang, YB; Chang, FR; Duh, TH; Wu, DC; Wu, WC; Kao, YC; Yang, PH				Chen, Chun-Lin; Chen, Ying-Pin; Lin, Ming-Wei; Huang, Yaw-Bin; Chang, Fang-Rong; Duh, Tsai-Hui; Wu, Deng-Chyang; Wu, Wei-Chiang; Kao, Yu-Chen; Yang, Pei-Hua			Euphol from Euphorbia tirucalli Negatively Modulates TGF-beta Responsiveness via TGF-beta Receptor Segregation inside Membrane Rafts	PLOS ONE			English	Article							CANCER-CELLS; LIPID RAFTS; CHOLESTEROL DEPLETION; SIGNALING PATHWAY; CA2+ ENTRY; GROWTH; ACTIVATION; BINDING; INHIBITION; PROTEIN	Transforming growth factor-beta (TGF-beta) responsiveness in cultured cells can be modulated by TGF-beta partitioning between lipid raft/caveolae- and clathrin-mediated endocytosis pathways. Lipid rafts are plasma membrane microdomains with an important role in cell survival signaling, and cholesterol is necessary for the lipid rafts' structure and function. Euphol is a euphane-type triterpene alcohol that is structurally similar to cholesterol and has a wide range of pharmacological properties, including anti-inflammatory and anti-cancer effects. In the present study, euphol suppressed TGF-beta signaling by inducing TGF-beta receptor movement into lipid-raft microdomains and degrading TGF-beta receptors.	[Chen, Chun-Lin; Chen, Ying-Pin; Huang, Yaw-Bin; Kao, Yu-Chen; Yang, Pei-Hua] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan; [Chen, Chun-Lin] Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung 80424, Taiwan; [Chen, Chun-Lin] Acad Sinica, Kaohsiung, Taiwan; [Lin, Ming-Wei; Huang, Yaw-Bin] Kaohsiung Med Univ, Sch Pharm, Dept Pharm, Kaohsiung, Taiwan; [Chang, Fang-Rong] Kaohsiung Med Univ, Coll Pharm, Grad Inst Nat Prod, Kaohsiung, Taiwan; [Duh, Tsai-Hui] Kaohsiung Med Univ, Dept Med & Appl Chem, Kaohsiung, Taiwan; [Wu, Deng-Chyang] Kaohsiung Med Univ Hosp, Div Gastroenterol, Dept Internal Med, Kaohsiung, Taiwan; [Wu, Wei-Chiang] Kaohsiung Med Univ, Fac Pharm, Kaohsiung, Taiwan; [Chen, Chun-Lin; Lin, Ming-Wei; Huang, Yaw-Bin; Chang, Fang-Rong; Wu, Deng-Chyang] Kaohsiung Med Univ, Ctr Stem Cell Res, Kaohsiung, Taiwan	National Sun Yat Sen University; National Sun Yat Sen University; Academia Sinica - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University	Chen, CL (corresponding author), Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan.	chunlinchen@mail.nsysu.edu.tw	Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Huang, Yaw-Bin/0000-0002-6024-0108; Chang, Fang-Rong/0000-0003-2549-4193	National Science Council of Taiwan [101-2320-B-110-003, 102-2320-B-110-007, 103-2314-B-037-064, 103-2320-B-037-014]; KMU Center for Stem Cell Research [KMU-TP103G01, KMU-TP103G00, KMU-TP103G03, KMU-TP103G04, KMU-TP103G05]; NSYSU-KMU Joint Research Project [NSYSUKMU2013-I006]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); KMU Center for Stem Cell Research; NSYSU-KMU Joint Research Project	This work is supported by the National Science Council of Taiwan (101-2320-B-110-003, 102-2320-B-110-007, 103-2314-B-037-064, and 103-2320-B-037-014), KMU Center for Stem Cell Research (KMU-TP103G01, KMU-TP103G00, KMU-TP103G03, KMU-TP103G04 & KMU-TP103G05) and NSYSU-KMU Joint Research Project (NSYSUKMU2013-I006).	Akihisa T, 2001, LIPIDS, V36, P507, DOI 10.1007/s11745-001-0750-4; Alakurtti S, 2006, EUR J PHARM SCI, V29, P1, DOI 10.1016/j.ejps.2006.04.006; Baniadam S, 2014, IRAN J PHARM RES, V13, P135; Bauge C, 2012, BBA-MOL CELL RES, V1823, P983, DOI 10.1016/j.bbamcr.2012.02.017; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Chen CL, 2008, J CELL PHYSIOL, V215, P223, DOI 10.1002/jcp.21303; Chen CL, 2007, J CELL SCI, V120, P3509, DOI 10.1242/jcs.006916; Chen CL, 2011, J NUTR BIOCHEM, V22, P649, DOI 10.1016/j.jnutbio.2010.05.004; Chen CL, 2006, J BIOL CHEM, V281, P11506, DOI 10.1074/jbc.M512821200; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Critchley P, 2004, BIOCHEM BIOPH RES CO, V313, P559, DOI 10.1016/j.bbrc.2003.12.004; Danielsen EM, 2003, BBA-BIOMEMBRANES, V1617, P1, DOI 10.1016/j.bbamem.2003.09.005; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Duarte N, 2009, ANTICANCER RES, V29, P4467; Dutra RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027122; Dutra RC, 2012, BIOCHEM PHARMACOL, V83, P531, DOI 10.1016/j.bcp.2011.11.026; Hammond S M, 1977, Prog Med Chem, V14, P105, DOI 10.1016/S0079-6468(08)70148-6; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hinzey AH, 2012, INDIAN J BIOCHEM BIO, V49, P329; Hsieh WT, 2011, NUTR CANCER, V63, P1339, DOI 10.1080/01635581.2011.608481; Huang SS, 2005, J CELL BIOCHEM, V96, P447, DOI 10.1002/jcb.20558; Jilani K, 2013, TOXICOL IN VITRO, V27, P52, DOI 10.1016/j.tiv.2012.09.004; Jilani K, 2011, J NAT PROD, V74, P2181, DOI 10.1021/np2005133; Kasperczyk H, 2005, ONCOGENE, V24, P6945, DOI 10.1038/sj.onc.1208842; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lin MW, 2012, FOOD CHEM TOXICOL, V50, P4333, DOI 10.1016/j.fct.2012.05.029; Madureira AM, 2006, J NAT PROD, V69, P950, DOI 10.1021/np060046r; Mason RP, 2004, CIRCULATION, V109, P34, DOI 10.1161/01.CIR.0000129503.62747.03; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; Massey JB, 2006, CURR OPIN LIPIDOL, V17, P296, DOI 10.1097/01.mol.0000226123.17629.ab; Muriel O, 2011, J CELL SCI, V124, P2763, DOI 10.1242/jcs.080804; Nabi IR, 2009, NAT CELL BIOL, V11, P789, DOI 10.1038/ncb0709-789; Ostroukhova M, 2006, J CLIN INVEST, V116, P996, DOI 10.1172/JCI26490; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; Passos GF, 2013, EUR J PHARMACOL, V698, P413, DOI 10.1016/j.ejphar.2012.10.019; Pettit GR, 2002, J NAT PROD, V65, P1886, DOI 10.1021/np020216+; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; Ringerike T, 2002, J CELL SCI, V115, P1331; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Schraw W, 2002, J BIOL CHEM, V277, P34642, DOI 10.1074/jbc.M203466200; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sundivakkam PC, 2009, AM J PHYSIOL-CELL PH, V296, pC403, DOI 10.1152/ajpcell.00470.2008; Thafeni MA, 2012, MOL BIOL REP, V39, P10785, DOI 10.1007/s11033-012-1972-6; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trapani JA, 2005, CANCER CELL, V8, P349, DOI 10.1016/j.ccr.2005.10.018; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Verma SP, 2009, CURR DRUG TARGETS, V10, P51, DOI 10.2174/138945009787122851; Wang L, 2013, MOL MED REP, V8, P1279, DOI 10.3892/mmr.2013.1650; Wang ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041249; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Yang JL, 2013, MOL MED REP, V7, P1403, DOI 10.3892/mmr.2013.1380; Yawata A, 2009, EUR J PHARM SCI, V38, P355, DOI 10.1016/j.ejps.2009.08.011; Yi JS, 2009, BIOCHEM BIOPH RES CO, V385, P154, DOI 10.1016/j.bbrc.2009.05.028; Zheng YZ, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.007146	61	20	20	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2015	10	10							e0140249	10.1371/journal.pone.0140249	http://dx.doi.org/10.1371/journal.pone.0140249			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TW	26448474	gold, Green Published, Green Submitted			2023-01-03	WOS:000362511000112
J	Chen, S; Li, WJ; Zhang, ZL; Min, HY; Li, H; Wang, HQ; Zhuang, YG; Chen, YZ; Gao, CJ; Peng, H				Chen, Sheng; Li, Wenjie; Zhang, Zhonglin; Min, Hongye; Li, Hong; Wang, Huiqi; Zhuang, Yugang; Chen, Yuanzhuo; Gao, Chengjin; Peng, Hu			Evaluating the Quality of Cardiopulmonary Resuscitation in the Emergency Department by Real-Time Video Recording System	PLOS ONE			English	Article							MECHANICAL CHEST COMPRESSOR; HOSPITAL CARDIAC-ARREST; BASIC LIFE-SUPPORT; CPR; RETENTION; TRANSPORT; OUTCOMES; NURSES; SKILLS	Objectives To compare cardiopulmonary resuscitation (CPR) quality between manual CPR and miniaturized chest compressor (MCC) CPR. To improve CPR quality through evaluating the quality of our clinical work of resuscitation by real-time video recording system. Methods The study was a retrospective observational study of adult patients who experienced CPR at the emergency department of Shanghai Tenth People's Hospital from March 2013 to August 2014. All the performance of CPR were checked back by the record of "digital real-time video recording system". Average chest compression rate, actual chest compression rate, the percentage of hands-off period, time lag from patient arrival to chest compression, time lag from patient arrival to manual ventilation, time lag from patient arrival to first IV establish were compared. Causes of chest compression hands-off time were also studied. Results 112 cases of resuscitation attempts were obtained. Average chest compression rate was over 100 compression per minute (cpm) in the majority of cases. However, indicators such as percentage of hands-off periods, time lag from patient arrival to the first manual ventilation and time lag from patient arrival to the first IV establish seemed to be worse in the manual CPR group compared to MCC CPR group. The saving of operators change time seemed to counteract the time spent on MCC equipment. Indicators such as percentage of hands-off periods, time lag between patient arrival to the first chest compression, time lag between patient arrival to the first manual ventilation and time lag from patient arrival to the first IV establish may influence the survival. Conclusion Our CPR quality remained to be improved. MCC may have a potentially positive role in CPR.	[Chen, Sheng; Li, Wenjie; Zhang, Zhonglin; Wang, Huiqi; Zhuang, Yugang; Chen, Yuanzhuo; Gao, Chengjin; Peng, Hu] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Emergency Dept, Shanghai 200092, Peoples R China; [Min, Hongye; Li, Hong] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Nursing, Shanghai 200092, Peoples R China	Tongji University; Tongji University	Chen, YZ (corresponding author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Emergency Dept, Shanghai 200092, Peoples R China.	chenyuanzhuo021@hotmail.com; denkepeng@189.cn	Li, Wenjie/ABB-7358-2021	Li, Wenjie/0000-0003-3411-0868	National Natural Science Foundation of China [81000024]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was funded by the National Natural Science Foundation of China (No. 81000024).	[Anonymous], 2010, 2010 AM HEART ASS S; Aufderheide TP, 2005, RESUSCITATION, V64, P353, DOI 10.1016/j.resuscitation.2004.10.007; Berg RA, 2010, CIRCULATION, V122, pS685, DOI 10.1161/CIRCULATIONAHA.110.970939; Bonnemeier H, 2011, RESUSCITATION, V82, P155, DOI 10.1016/j.resuscitation.2010.10.019; Brooks SC, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007260.pub2; Broomfield R, 1996, J ADV NURS, V23, P1016; Chen W, 2012, CRIT CARE MED, V40, P3007, DOI 10.1097/CCM.0b013e31825d924d; Cunningham LM, 2012, AM J EMERG MED, V30, P1630, DOI 10.1016/j.ajem.2012.02.015; Jiang C, 2010, RESUSCITATION, V81, P1664, DOI 10.1016/j.resuscitation.2010.06.023; KAYE W, 1986, CRIT CARE MED, V14, P620, DOI 10.1097/00003246-198607000-00007; Kern K B., 2000, BAILLIERE CLIN ANAES, V14, P59; Li YQ, 2010, CRIT CARE MED, V38, P910, DOI 10.1097/CCM.0b013e3181cc4944; Odegaard S, 2009, RESUSCITATION, V80, P843, DOI 10.1016/j.resuscitation.2009.03.032; Ong MEH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-39; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Ristagno G, 2008, RESUSCITATION, V76, P191, DOI 10.1016/j.resuscitation.2007.07.004; Sutton RM, 2014, RESUSCITATION, V85, P70, DOI 10.1016/j.resuscitation.2013.08.014; Sutton RM, 2013, RESUSCITATION, V84, P1680, DOI 10.1016/j.resuscitation.2013.07.029; Tipton M, 2007, RESUSCITATION, V75, P332, DOI 10.1016/j.resuscitation.2007.04.027; Wang HC, 2007, RESUSCITATION, V74, P453, DOI 10.1016/j.resuscitation.2007.01.018; Westfall M, 2013, CRIT CARE MED, V41, P1782, DOI 10.1097/CCM.0b013e31828a24e3; Xu JF, 2014, RESUSCITATION, V85, P683, DOI 10.1016/j.resuscitation.2014.01.014; Yang ZF, 2014, AM J EMERG MED, V32, P50, DOI 10.1016/j.ajem.2013.09.043; Zevitz M E., 2003, VENTRICULAR FIBRILLA	26	5	5	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2015	10	10							e0139825	10.1371/journal.pone.0139825	http://dx.doi.org/10.1371/journal.pone.0139825			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6HH	26431420	Green Published, gold, Green Submitted			2023-01-03	WOS:000362178700120
J	Korner, A; Coroiu, A; Copeland, L; Gomez-Garibello, C; Albani, C; Zenger, M; Brahler, E				Koerner, Annett; Coroiu, Adina; Copeland, Laura; Gomez-Garibello, Carlos; Albani, Cornelia; Zenger, Markus; Braehler, Elmar			The Role of Self-Compassion in Buffering Symptoms of Depression in the General Population	PLOS ONE			English	Article							MENTAL-HEALTH; CHILDHOOD MALTREATMENT; VALIDITY; ACCESS; PHQ-9; MINDFULNESS; ASSOCIATION; VALIDATION; RUMINATION; CRITICISM	Self-compassion, typically operationalized as the total score of the Self-Compassion Scale (SCS; Neff, 2003b), has been shown to be related to increased psychological well-being and lower depression in students of the social sciences, users of psychology websites and psychotherapy patients. The current study builds on the existing literature by examining the link between self-compassion and depressive symptomatology in a sample representative of the German general population (n = 2,404). The SCS subscales of self-judgment, isolation, and over-identification, and the "self-coldness", composite score, which encompass these three negative subscales, consistently differed between subsamples of individuals without any depressive symptoms, with any depressive syndromes, and with major depressive disorder. The contribution of the positive SCS subscales of self-kindness, common humanity, and mindfulness to the variance in depressive symptomatology was almost negligible. However, when combined to a "self-compassion composite", the positive SCS subscales significantly moderated the relationship between "self-coldness" and depressive symptoms in the general population. This speaks for self-compassion having the potential to buffer self-coldness related to depression-providing an argument for interventions that foster self-caring, kind, and forgiving attitudes towards oneself.	[Koerner, Annett; Coroiu, Adina; Copeland, Laura; Gomez-Garibello, Carlos] McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada; [Koerner, Annett] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Koerner, Annett] McGill Univ, Jewish Gen Hosp, Louise Granofsky Psychosocial Oncol Program, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada; [Koerner, Annett] McGill Univ, Ctr Hlth, Psychosocial Oncol Program, Montreal, PQ, Canada; [Albani, Cornelia; Zenger, Markus; Braehler, Elmar] Univ Leipzig, Dept Med Psychol & Med Sociol, D-04109 Leipzig, Germany; [Zenger, Markus] Univ Appl Sci Magdeburg & Stendal, Fac Appl Human Studies, Stendal, Germany; [Braehler, Elmar] Univ Med Ctr Mainz, Dept Psychosomat Med & Psychotherapy, Mainz, Germany	McGill University; McGill University; McGill University; McGill University; Leipzig University; Johannes Gutenberg University of Mainz	Zenger, M (corresponding author), Univ Leipzig, Dept Med Psychol & Med Sociol, D-04109 Leipzig, Germany.	markus.zenger@hs-magdeburg.de	Braehler, Elmar/C-6535-2009	Braehler, Elmar/0000-0002-2648-2728	Open Access Publishing Program of the University of Leipzig, Germany; German Research Foundation (DFG)	Open Access Publishing Program of the University of Leipzig, Germany; German Research Foundation (DFG)(German Research Foundation (DFG))	This manuscript was supported by the Open Access Publishing Program of the University of Leipzig, Germany, and the German Research Foundation (DFG). The funders had no role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.	Akin A., 2010, INT ONLINE J ED SCI, V2, P702; Amireault S, 2015, J CANC SURVIV, P1; Barnard LK, 2011, REV GEN PSYCHOL, V15, P289, DOI 10.1037/a0025754; Barraca J, 2012, INT J CLIN HLTH PSYC, V12, P109; Beucke JC, 2013, JAMA PSYCHIAT, V70, P619, DOI 10.1001/jamapsychiatry.2013.173; Bradley S, 2014, CAN PSYCHOL, V55, P80, DOI 10.1037/a0036453; Cohen KR, 2014, CAN PSYCHOL, V55, P126, DOI 10.1037/a0036499; Cox DW, 2014, CAN PSYCHOL, V55, P68, DOI 10.1037/a0036296; Deci E.L., 1995, EFFICACY AGENCY SELF, P31, DOI [DOI 10.1007/978-1-4899-1280-0_3, 10.1007/978-1-4899-1280-0_3]; Edwards M, 2014, J SPEC GROUP WORK, V39, P145, DOI 10.1080/01933922.2014.891683; Ferguson LJ, 2014, J SPORT EXERCISE PSY, V36, P203, DOI 10.1123/jsep.2013-0096; Gaziano C., 2008, ENCY SURVEY RES METH; Gilbert P, 2006, CLIN PSYCHOL PSYCHOT, V13, P353, DOI 10.1002/cpp.507; Gilbert P, 2011, PSYCHOL PSYCHOTHER-T, V84, P239, DOI [10.1348/147608310X526511, 10.1111/j.2044-8341.2011.02046.x]; Hayes A. F., 2013, MEDIATION MODERATION; Hayes A. F., 2012, CISC VIS NETW IND GL; Hupfeld J, 2011, Z KL PSYCH PSYCHOTH, V40, P115, DOI 10.1026/1616-3443/a000088; Kelly AC, 2010, J SOC CLIN PSYCHOL, V29, P727, DOI 10.1521/jscp.2010.29.7.727; Kessler RC, 2012, PSYCHIAT CLIN N AM, V35, P1, DOI 10.1016/j.psc.2011.11.005; Kleine-Budde K, 2013, J AFFECT DISORDERS, V147, P137, DOI 10.1016/j.jad.2012.10.024; Kliem S, 2014, J AFFECT DISORDERS, V156, P236, DOI 10.1016/j.jad.2013.11.024; Kocalevent RD, 2013, GEN HOSP PSYCHIAT, V35, P551, DOI 10.1016/j.genhosppsych.2013.04.006; Koch A., 1994, GEWICHTUNG UMFRAGEPR, P99; Krieger T, 2013, BEHAV THER, V44, P501, DOI 10.1016/j.beth.2013.04.004; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Kutner M., 2004, APPL LINEAR STAT MOD; Kuyken W, 2010, BEHAV RES THER, V48, P1105, DOI 10.1016/j.brat.2010.08.003; Leary MR, 2007, J PERS SOC PSYCHOL, V92, P887, DOI 10.1037/0022-3514.92.5.887; Leary MR, 2010, SELF COMPASSIO UNPUB; MacBeth A, 2012, CLIN PSYCHOL REV, V32, P545, DOI 10.1016/j.cpr.2012.06.003; Martin A, 2006, GEN HOSP PSYCHIAT, V28, P71, DOI 10.1016/j.genhosppsych.2005.07.003; Mills A, 2007, CLIN PSYCHOL PSYCHOT, V14, P358, DOI 10.1002/cpp.537; Mosewich AD, 2011, J SPORT EXERCISE PSY, V33, P103, DOI 10.1123/jsep.33.1.103; Neff KD., 2009, HDB INDIVIDUAL DIFFE, P561; Neff K, 2003, SELF IDENTITY, V2, P85, DOI 10.1080/15298860390129863; Neff KD, 2008, J CROSS CULT PSYCHOL, V39, P267, DOI 10.1177/0022022108314544; Neff KD, 2007, J RES PERS, V41, P908, DOI 10.1016/j.jrp.2006.08.002; Neff KD, 2007, J RES PERS, V41, P139, DOI 10.1016/j.jrp.2006.03.004; Neff KD, 2005, SELF IDENTITY, V4, P263, DOI 10.1080/13576500444000317; Neff KD, 2003, SELF IDENTITY, V2, P223, DOI 10.1080/15298860390209035; Neff KD, 2013, J CLIN PSYCHOL, V69, P28, DOI 10.1002/jclp.21923; Ng JYY, 2012, PERSPECT PSYCHOL SCI, V7, P325, DOI 10.1177/1745691612447309; Noorbala Fatemeh, 2013, Iran J Psychiatry, V8, P113; Nunes M, 2014, CAN PSYCHOL, V55, P101, DOI 10.1037/a0036476; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Raes F, 2010, PERS INDIV DIFFER, V48, P757, DOI 10.1016/j.paid.2010.01.023; Shapira LB, 2010, J POSIT PSYCHOL, V5, P377, DOI 10.1080/17439760.2010.516763; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Statistisches Bundesamt, 2013, STAT JB DEUTSCHL INT; Talbot F, 2014, CAN PSYCHOL, V55, P75, DOI 10.1037/a0036449; Tanaka M, 2011, CHILD ABUSE NEGLECT, V35, P887, DOI 10.1016/j.chiabu.2011.07.003; Van Dam NT, 2011, J ANXIETY DISORD, V25, P123, DOI 10.1016/j.janxdis.2010.08.011; Vettese LC, 2011, INT J MENT HEALTH AD, V9, P480, DOI 10.1007/s11469-011-9340-7; Wong CCY, 2013, J COUNS PSYCHOL, V60, P162, DOI 10.1037/a0030451; World Health Organization, FACTS FIG PREV MENT; World Health Organization, DEPR 2012; Yarnell LM, 2013, SELF IDENTITY, V12, P146, DOI 10.1080/15298868.2011.649545; Ying YW, 2009, J SOC WORK EDUC, V45, P309, DOI 10.5175/JSWE.2009.200700072	59	67	67	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2015	10	10							e0136598	10.1371/journal.pone.0136598	http://dx.doi.org/10.1371/journal.pone.0136598			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CS6HH	26430893	Green Published, gold, Green Submitted			2023-01-03	WOS:000362178700004
J	Schenberg, EE; Alexandre, JFM; Filev, R; Cravo, AM; Sato, JR; Muthukumaraswamy, SD; Yonamine, M; Waguespack, M; Lomnicka, I; Barker, SA; da Silveira, DX				Schenberg, Eduardo Ekman; Morel Alexandre, Joao Felipe; Filev, Renato; Cravo, Andre Mascioli; Sato, Joao Ricardo; Muthukumaraswamy, Suresh D.; Yonamine, Mauricio; Waguespack, Marian; Lomnicka, Izabela; Barker, Steven A.; da Silveira, Dartiu Xavier			Acute Biphasic Effects of Ayahuasca	PLOS ONE			English	Article							PSYCHOACTIVE BEVERAGE AYAHUASCA; AMERICAN HALLUCINOGENIC PLANTS; MONOAMINE-OXIDASE INHIBITORS; BETA-CARBOLINES; BANISTERIOPSIS-CAAPI; HARMALA ALKALOIDS; SELF-LOCATION; EEG; N,N-DIMETHYLTRYPTAMINE; BINDING	Ritual use of ayahuasca, an amazonian Amerindian medicine turned sacrament in syncretic religions in Brazil, is rapidly growing around the world. Because of this internationalization, a comprehensive understanding of the pharmacological mechanisms of action of the brew and the neural correlates of the modified states of consciousness it induces is important. Employing a combination of electroencephalogram (EEG) recordings and quantification of ayahuasca's compounds and their metabolites in the systemic circulation we found ayahuasca to induce a biphasic effect in the brain. This effect was composed of reduced power in the alpha band (8-13 Hz) after 50 minutes from ingestion of the brew and increased slow- and fast-gamma power (30-50 and 50-100 Hz, respectively) between 75 and 125 minutes. Alpha power reductions were mostly located at left parieto-occipital cortex, slow-gamma power increase was observed at left centro-parieto-occipital, left fronto-temporal and right frontal cortices while fast-gamma increases were significant at left centro-parieto-occipital, left fronto-temporal, right frontal and right parieto-occipital cortices. These effects were significantly associated with circulating levels of ayahuasca's chemical compounds, mostly N, N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine and some of their metabolites. An interpretation based on a cognitive and emotional framework relevant to the ritual use of ayahuasca, as well as it's potential therapeutic effects is offered.	[Schenberg, Eduardo Ekman; Filev, Renato; da Silveira, Dartiu Xavier] Univ Fed Sao Paulo, Dept Psiquiatria, Sao Paulo, Brazil; [Morel Alexandre, Joao Felipe; Cravo, Andre Mascioli; Sato, Joao Ricardo] Univ Fed ABC, Ctr Matemat Comp & Cognicao, Santo Andre, Brazil; [Muthukumaraswamy, Suresh D.] Univ Auckland, Sch Pharm, Auckland 1, New Zealand; [Muthukumaraswamy, Suresh D.] Univ Auckland, Sch Psychol, Auckland 1, New Zealand; [Yonamine, Mauricio] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil; [Waguespack, Marian; Lomnicka, Izabela; Barker, Steven A.] Louisiana State Univ, Sch Vet Med, Dept Comparat Biomed Sci, Baton Rouge, LA 70803 USA	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal do ABC (UFABC); University of Auckland; University of Auckland; Universidade de Sao Paulo; Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University	Schenberg, EE (corresponding author), Inst Plantando Consciencia, Sao Paulo, Brazil.	eduardoschenberg@gmail.com	Cravo, Andre M/B-8874-2014; Cravo, Andre/C-7966-2013; Yonamine, Mauricio/C-6316-2012	Cravo, Andre M/0000-0002-8580-5697; Cravo, Andre/0000-0002-8580-5697; Yonamine, Mauricio/0000-0002-4615-1088; Schenberg, Eduardo/0000-0001-7111-9891; Muthukumaraswamy, Suresh/0000-0001-7042-3920; Sato, Joao Ricardo/0000-0002-7503-9781	Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/11341-8, 2012/07699-7, 2014/07540-3, 2015/13536-1]; Medical Research Council [MC_UU_12013/1] Funding Source: researchfish	Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP) grants 2011/11341-8 (EES), 2012/07699-7 (DXS), 2014/07540-3 (EES) and 2015/13536-1 (DXS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIRAKSINEN MM, 1981, MED BIOL, V59, P190; Berntson GG, 2003, EUR J NEUROSCI, V18, P2103, DOI 10.1046/j.1460-9568.2003.02967.x; Brierley DI, 2012, PROG NEURO-PSYCHOPH, V39, P263, DOI 10.1016/j.pnpbp.2012.06.001; Callaway JC, 2005, J PSYCHOACTIVE DRUGS, V37, P151, DOI 10.1080/02791072.2005.10399796; Callaway JC, 1999, J ETHNOPHARMACOL, V65, P243, DOI 10.1016/S0378-8741(98)00168-8; Callaway JC, 2005, J PSYCHOACTIVE DRUGS, V37, P145, DOI 10.1080/02791072.2005.10399795; Callaway JC, 2005, J PSYCHOACTIVE DRUGS, V37, P157, DOI 10.1080/02791072.2005.10399797; Callaway JC, 1996, J ANAL TOXICOL, V20, P492, DOI 10.1093/jat/20.6.492; Castellano M, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00064; Cozzi NV, 2009, J NEURAL TRANSM, V116, P1591, DOI 10.1007/s00702-009-0308-8; DAVIDSON RJ, 1988, INT J NEUROSCI, V39, P71, DOI 10.3109/00207458808985694; Davis W., 2014, ONE RIVER; de Araujo DB, 2012, HUM BRAIN MAPP, V33, P2550, DOI 10.1002/hbm.21381; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Don NS, 1998, PHYTOMEDICINE, V5, P87, DOI 10.1016/S0944-7113(98)80003-2; dos Santos RG, 2012, PSYCHOPHARMACOLOGY, V219, P1039, DOI 10.1007/s00213-011-2434-x; Erritzoe D, 2009, NEUROIMAGE, V46, P23, DOI 10.1016/j.neuroimage.2009.01.050; Fontanilla D, 2009, SCIENCE, V323, P934, DOI 10.1126/science.1166127; Frecska E, 2013, J NEURAL TRANSM, V120, P1295, DOI 10.1007/s00702-013-1024-y; Fries P, 2007, TRENDS NEUROSCI, V30, P309, DOI 10.1016/j.tins.2007.05.005; Gatch MB, 2009, PSYCHOPHARMACOLOGY, V204, P715, DOI 10.1007/s00213-009-1501-z; Ginovart N, 2006, J CEREBR BLOOD F MET, V26, P330, DOI 10.1038/sj.jcbfm.9600197; Glennon RA, 2000, DRUG ALCOHOL DEPEN, V60, P121, DOI 10.1016/S0376-8716(99)00148-9; Glennon RA, 2004, BIOORG MED CHEM LETT, V14, P999, DOI 10.1016/j.bmcl.2003.11.078; Grella B, 2003, BIOORG MED CHEM LETT, V13, P4421, DOI 10.1016/j.bmcl.2003.09.027; Grella B, 1998, DRUG ALCOHOL DEPEN, V50, P99, DOI 10.1016/S0376-8716(97)00163-4; Grob CS, 1996, J NERV MENT DIS, V184, P86, DOI 10.1097/00005053-199602000-00004; Gu XS, 2013, J COMP NEUROL, V521, P3371, DOI 10.1002/cne.23368; Herraiz T, 2010, FOOD CHEM TOXICOL, V48, P839, DOI 10.1016/j.fct.2009.12.019; Herraiz T, 2014, BIOCHEM BIOPH RES CO, V451, P42, DOI 10.1016/j.bbrc.2014.07.047; Hoffmann E, 2001, MAPS B, V11, P25; Holmstedt B, 1967, Psychopharmacol Bull, V4, P16; Ionta S, 2011, NEURON, V70, P363, DOI 10.1016/j.neuron.2011.03.009; Jensen O, 2007, TRENDS NEUROSCI, V30, P317, DOI 10.1016/j.tins.2007.05.001; Jensen O, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00186; Jiang XL, 2013, DRUG METAB DISPOS, V41, P975, DOI 10.1124/dmd.112.050724; Johnson MW, 2008, J PSYCHOPHARMACOL, V22, P603, DOI 10.1177/0269881108093587; Keeley PW, 2011, NAUSEA AND VOMITING; Kometer M, 2013, J NEUROSCI, V33, P10544, DOI 10.1523/JNEUROSCI.3007-12.2013; Labate BC, 2012, INT J DRUG POLICY, V23, P154, DOI 10.1016/j.drugpo.2011.06.006; Lutz A, 2004, P NATL ACAD SCI USA, V101, P16369, DOI 10.1073/pnas.0407401101; Maris E, 2007, J NEUROSCI METH, V164, P177, DOI 10.1016/j.jneumeth.2007.03.024; Mayer EA, 2011, NAT REV NEUROSCI, V12, P453, DOI 10.1038/nrn3071; McIlhenny EH, 2012, BIOMED CHROMATOGR, V26, P301, DOI 10.1002/bmc.1657; McIlhenny EH, 2009, J CHROMATOGR A, V1216, P8960, DOI 10.1016/j.chroma.2009.10.088; MCKENNA DJ, 1984, J ETHNOPHARMACOL, V10, P195, DOI 10.1016/0378-8741(84)90003-5; MCKENNA DJ, 1984, J ETHNOPHARMACOL, V12, P179, DOI 10.1016/0378-8741(84)90048-5; Metzner R, 1998, J PSYCHOACTIVE DRUGS, V30, P333; Mitra PP, 1999, BIOPHYS J, V76, P691, DOI 10.1016/S0006-3495(99)77236-X; Mizumoto S, 2011, REV PSIQ CLIN-BRAZIL, V38, P231; Morillas-Romero A, 2013, CLIN EEG NEUROSCI, V44, P188, DOI 10.1177/1550059412465871; Muthukumaraswamy SD, 2013, J NEUROSCI, V33, P15171, DOI 10.1523/JNEUROSCI.2063-13.2013; Muthukumaraswamy SD, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00138; Napadow V, 2013, CEREB CORTEX, V23, P806, DOI 10.1093/cercor/bhs073; Naranjo C, 1967, Psychopharmacol Bull, V4, P16; Naranjo C., 1967, ETHNOPHARMACOLOGIC S; Naranjo C., 1987, J MENTAL IMAGERY, V11, P131; Naranjo P., 1959, REV CONFEDERACION ME, V6, P1; Nelson SM, 2013, NEUROSCIENTIST, V19, P578, DOI 10.1177/1073858413492389; Nexus D., ENTHEOGENIC EFFECTS; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Ott J, 1999, J PSYCHOACTIVE DRUGS, V31, P171, DOI 10.1080/02791072.1999.10471741; PENNES HH, 1957, AM J PSYCHIAT, V113, P887, DOI 10.1176/ajp.113.10.887; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; Pharmahuasca Ott J., 1997, YB ETHNOMEDICINE, P1; Popov T, 2012, PSYCHOPHYSIOLOGY, V49, P1545, DOI 10.1111/j.1469-8986.2012.01484.x; Riba J, 2006, PSYCHOPHARMACOLOGY, V186, P93, DOI 10.1007/s00213-006-0358-7; Riba J, 2005, J PSYCHOACTIVE DRUGS, V37, P219, DOI 10.1080/02791072.2005.10399804; Riba J, 2004, NEUROPSYCHOBIOLOGY, V50, P89, DOI 10.1159/000077946; Riba J, 2002, BRIT J CLIN PHARMACO, V53, P613, DOI 10.1046/j.1365-2125.2002.01609.x; Riba J, 2012, DRUG TEST ANAL, V4, P610, DOI 10.1002/dta.1344; RIVIER L, 1972, ECON BOT, V26, P101, DOI 10.1007/BF02860772; Rodd R, 2008, J PSYCHOACTIVE DRUGS, V40, P301, DOI 10.1080/02791072.2008.10400645; Rodriguez E, 1999, NATURE, V397, P430, DOI 10.1038/17120; Sacher J, 2012, J CEREBR BLOOD F MET, V32, P443, DOI 10.1038/jcbfm.2011.184; Samoylenko V, 2010, J ETHNOPHARMACOL, V127, P357, DOI 10.1016/j.jep.2009.10.030; Sandkuhler S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001459; Schmid JT, 2014, HEALING AYAHUASCA NO, P77; Schultes R. E, 1973, BOT CHEM HALLUCINOGE; SCHULTES RE, 1969, SCIENCE, V163, P245, DOI 10.1126/science.163.3864.245; Serino A, 2013, CONSCIOUS COGN, V22, P1239, DOI 10.1016/j.concog.2013.08.013; Shanon B., 2013, THERAPEUTIC USE AYAH, P59; Shen HW, 2010, CURR DRUG METAB, V11, P659, DOI 10.2174/138920010794233495; Shepard GH, 1998, J PSYCHOACTIVE DRUGS, V30, P321; SHULGIN AT, 1977, J PSYCHEDEL DRUG, V9, P79, DOI 10.1080/02791072.1977.10472029; Singer T, 2009, TRENDS COGN SCI, V13, P334, DOI 10.1016/j.tics.2009.05.001; Smith RL, 1998, PHARMACOL BIOCHEM BE, V61, P323, DOI 10.1016/S0091-3057(98)00110-5; Stuckey DE, 2005, J PSYCHOACTIVE DRUGS, V37, P163, DOI 10.1080/02791072.2005.10399798; Szara Stephen, 2007, Neuropsychopharmacol Hung, V9, P201; Tupper KW, 2014, CURRENT DRUG ABUSE R, P1; Vitale AA, 2011, J NUCL MED, V52, P970, DOI 10.2967/jnumed.110.083246; Vollenweider FX, 1998, NEUROREPORT, V9, P3897, DOI 10.1097/00001756-199812010-00024; Voss U, 2014, NAT NEUROSCI, V17, P810, DOI 10.1038/nn.3719; Voss U, 2009, SLEEP, V32, P1191, DOI 10.1093/sleep/32.9.1191; Wallach JV, 2009, MED HYPOTHESES, V72, P91, DOI 10.1016/j.mehy.2008.07.052; Zhao T, 2012, FOOD CHEM, V134, P1096, DOI 10.1016/j.foodchem.2012.03.024	97	55	56	1	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2015	10	9							e0137202	10.1371/journal.pone.0137202	http://dx.doi.org/10.1371/journal.pone.0137202			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6GF	26421727	Green Published, gold, Green Submitted			2023-01-03	WOS:000362175700010
J	Palmer, AC				Palmer, Adam C.			The many genes of drug mechanism	NATURE CHEMICAL BIOLOGY			English	News Item							SENSITIVITY; IDENTIFICATION; CELLS	A small molecule's biological activity in a cell depends on the actions of many gene products. Correlations between basal gene expression and compound sensitivity across hundreds of human cell lines reveal a broad view of cellular mechanisms of action.	[Palmer, Adam C.] Harvard Univ, Sch Med, Lab Syst Pharmacol, Boston, MA USA; [Palmer, Adam C.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia	Harvard University; Harvard Medical School; University of New South Wales Sydney	Palmer, AC (corresponding author), Harvard Univ, Sch Med, Lab Syst Pharmacol, Boston, MA USA.; Palmer, AC (corresponding author), Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia.	adam_palmer@hms.harvard.edu	Palmer, Adam/N-5495-2019; Palmer, Adam C/J-3589-2012	Palmer, Adam/0000-0001-5028-7028; Palmer, Adam C/0000-0001-5028-7028				Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003; de Waal L, 2016, NAT CHEM BIOL, V12, P102, DOI [10.1038/NCHEMBIO.1984, 10.1038/nchembio.1984]; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104; NITISS JL, 1992, CANCER RES, V52, P4467; Palmer AC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5296; Rees MG, 2016, NAT CHEM BIOL, V12, P109, DOI [10.1038/NCHEMBIO.1986, 10.1038/nchembio.1986]; Schenone M, 2013, NAT CHEM BIOL, V9, P232, DOI [10.1038/nchembio.1199, 10.1038/NCHEMBIO.1199]; Seashore-Ludlow B, 2015, CANCER DISCOV, V5, P1210, DOI 10.1158/2159-8290.CD-15-0235; Yu C., 2013, US Patent, Patent No. [WO 2013138585 A1, 2013138585]	11	1	1	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2016	12	2					57	58		10.1038/nchembio.2010	http://dx.doi.org/10.1038/nchembio.2010			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DC6GG	26784844				2023-01-03	WOS:000369317300003
J	Arbillaga-Etxarri, A; Torrent-Pallicer, J; Gimeno-Santos, E; Barberan-Garcia, A; Delgado, A; Balcells, E; Rodriguez, DA; Vilaro, J; Vall-Casas, P; Irurtia, A; Rodriguez-Roisin, R; Garcia-Aymerich, J				Arbillaga-Etxarri, Ane; Torrent-Pallicer, Jaume; Gimeno-Santos, Elena; Barberan-Garcia, Anael; Delgado, Anna; Balcells, Eva; Rodriguez, Diego A.; Vilaro, Jordi; Vall-Casas, Pere; Irurtia, Alfredo; Rodriguez-Roisin, Robert; Garcia-Aymerich, Judith		Urban Training Study Grp	Validation of Walking Trails for the Urban Training (TM) of Chronic Obstructive Pulmonary Disease Patients	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; EXERCISE CAPACITY; COPD; ENVIRONMENT; PEOPLE; ADULTS; SOCIETY	Purpose Accessible interventions to train patients with chronic obstructive pulmonary disease (COPD) are needed. We designed urban trails of different intensities (low, moderate and high) in different types of public spaces (boulevard, beach and park). We aimed to validate the trails' design by assessing the physiological response to unsupervised walking trails of: (1) different intensities in COPD patients, and (2) same intensity from different public spaces in healthy adults. Methods On different days and under standardized conditions, 10 COPD patients walked the three intensity trails designed in a boulevard space, and 10 healthy subjects walked the three intensity trails in three different spaces. We measured physiological response and energy expenditure using a gas analyzer. We compared outcomes across trails intensity and/or spaces using mixed-effects linear regression. Results In COPD patients, physiological response and energy expenditure increased significantly according to the trails intensity: mean (SD) peak (V) over dotO(2) 15.9 (3.5), 17.4 (4.7), and 17.7 (4.4) mL/min/kg (p-trend = 0.02), and MET-min 60 (23), 64 (26), 72 (31) (p-trend<0.01) in low, moderate and high intensity trails, respectively. In healthy subjects there were no differences in physiological response to walking trails of the same intensity across different spaces. Conclusions We validated the trails design for the training of COPD patients by showing that the physiological response to and energy expenditure on unsupervised walking these trails increased according to the predefined trails' intensity and did not change across trails of the same intensity in different public space. Walkable public spaces allow the design of trails that could be used for the training of COPD patients in the community.	[Arbillaga-Etxarri, Ane; Torrent-Pallicer, Jaume; Gimeno-Santos, Elena; Delgado, Anna; Garcia-Aymerich, Judith] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Arbillaga-Etxarri, Ane; Torrent-Pallicer, Jaume; Gimeno-Santos, Elena; Delgado, Anna; Balcells, Eva; Garcia-Aymerich, Judith] UPF, Barcelona, Spain; [Arbillaga-Etxarri, Ane; Torrent-Pallicer, Jaume; Gimeno-Santos, Elena; Delgado, Anna; Garcia-Aymerich, Judith] CIBER Epidemiol & Publ Hlth CIBERESP, Barcelona, Spain; [Gimeno-Santos, Elena] Ramon Llull Univ, Res Grp Phys Act & Hlth SAFE, FCS Blanquerna, Barcelona, Spain; [Barberan-Garcia, Anael; Rodriguez-Roisin, Robert] Hosp Clin Barcelona, Dept Pneumol, Barcelona, Spain; [Barberan-Garcia, Anael; Rodriguez-Roisin, Robert] Univ Barcelona, August Pi & Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain; [Barberan-Garcia, Anael; Balcells, Eva; Rodriguez, Diego A.; Rodriguez-Roisin, Robert] CIBER Resp Dis CIBERES, Bunyola, Illes Balears, Spain; [Delgado, Anna; Balcells, Eva; Rodriguez, Diego A.] Hosp del Mar Med Res Inst IMIM, Barcelona, Spain; [Balcells, Eva; Rodriguez, Diego A.] Hosp del Mar, Dept Pneumol, Barcelona, Spain; [Vall-Casas, Pere] Univ Int Catalunya, Barcelona, Spain; [Irurtia, Alfredo] Catalan Natl Inst Phys Educ INEFC, Barcelona, Spain	Pompeu Fabra University; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Universitat Ramon Llull; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Universitat Internacional de Catalunya (UIC)	Garcia-Aymerich, J (corresponding author), Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.	jgarcia@creal.cat	J, Garcia-Aymerich/G-6867-2014; IRURTIA, ALFREDO/R-3360-2019; Martin Cantera, Carlos/D-2693-2011	J, Garcia-Aymerich/0000-0002-7097-4586; Martin Cantera, Carlos/0000-0003-0656-8126; Arbillaga-Etxarri, Ane/0000-0003-3565-0751; Benet Mora, Marta/0000-0001-9600-3510; Simonet, Pere J/0000-0002-4978-1747; Marin, Alicia/0000-0002-9358-2120; Barberan-Garcia, Anael/0000-0002-0378-4467; Irurtia, Alfredo/0000-0002-3463-6643; Rodriguez Chiaradia, Diego A./0000-0002-8566-4011	Fondo de Investigacion Sanitaria, Ministry of Health, Spain [FIS PI11/01283]; ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion; Fondo Europeo de Desarrollo Regional (FEDER); Spanish Society of Pneumology and Thoracic Surgery [SEPAR 147/2011, 201/2011]; Catalan Society of Pneumology (SOCAP Fisioterapia); Agaur, Catalan Government [2014-SGR-661]	Fondo de Investigacion Sanitaria, Ministry of Health, Spain(Spanish GovernmentInstituto de Salud Carlos III); ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion; Fondo Europeo de Desarrollo Regional (FEDER)(European Commission); Spanish Society of Pneumology and Thoracic Surgery; Catalan Society of Pneumology (SOCAP Fisioterapia); Agaur, Catalan Government(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR))	The study was funded by grants from Supported by Fondo de Investigacion Sanitaria, Ministry of Health, Spain (FIS PI11/01283), integrated into Plan Estatal I+D+I 2013-2016 and co-funded by ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion and Fondo Europeo de Desarrollo Regional (FEDER); Spanish Society of Pneumology and Thoracic Surgery (SEPAR 147/2011 and 201/2011), and Catalan Society of Pneumology (SOCAP Fisioterapia 2013). Anael Barberan-Garcia had personal funding from Agaur 2014-SGR-661, Catalan Government. There was no involvement of any funding source in study design, in the collection, analysis and interpretation of data, in the writing of the report, nor in the decision to submit the article for publication.	Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; Barberan-Garcia A, 2015, RESPIRATION, V89, P221, DOI 10.1159/000371356; Breyer MK, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-112; Castro AAM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079727; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Darter BJ, 2013, RES Q EXERCISE SPORT, V84, P223, DOI 10.1080/02701367.2013.784720; Edwards P., 2006, PROMOTING PHYS ACTIV, P9; Gimeno-Santos E, 2014, THORAX, V69, P731, DOI 10.1136/thoraxjnl-2013-204763; Inoue S, 2011, J EPIDEMIOL, V21, P481, DOI 10.2188/jea.JE20110044; Jeng C, 2003, HEART LUNG, V32, P121, DOI 10.1067/mhl.2003.20; Leung RWM, 2010, J PHYSIOTHER, V56, P105, DOI 10.1016/S1836-9553(10)70040-0; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Marrugat J, 1998, MED CLIN-BARCELONA, V111, P267; Moran M, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/1479-5868-11-79; Owen N, 2004, AM J PREV MED, V27, P67, DOI 10.1016/j.amepre.2004.03.006; Palacios-Cena D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-799; Pleguezuelos E, 2013, RESP MED, V107, P1948, DOI 10.1016/j.rmed.2013.07.008; Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Ries Andrew L, 2005, COPD, V2, P105; Roman-Vinas B, 2007, PUBLIC HLTH NUTR, V10; Simpson ME, 2003, AM J PREV MED, V25, P95, DOI 10.1016/S0749-3797(03)00112-0; Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST; Starnes HA, 2011, J PHYS ACT HEALTH, V8, P1160, DOI 10.1123/jpah.8.8.1160; Van Holle V, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-807; Wootton SL, 2014, EUR RESPIR J, V44, P885, DOI 10.1183/09031936.00078014; World Health Organization, 2009, INT DIET PHYS ACT WH; Zainuldin R, 2015, J CARDIOPULM REHABIL, V35, P65, DOI 10.1097/HCR.0000000000000074	28	15	15	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2016	11	1							e0146705	10.1371/journal.pone.0146705	http://dx.doi.org/10.1371/journal.pone.0146705			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB4CC	26766184	gold, Green Published, Green Submitted			2023-01-03	WOS:000368459300035
J	Choudhry, NK; Denberg, TD; Qaseem, A				Choudhry, Niteesh K.; Denberg, Thomas D.; Qaseem, Amir		Amer Coll Phys	Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							BRAND-NAME DRUGS; CARDIOVASCULAR MEDICATIONS; MEDICARE BENEFICIARIES; ECONOMIC CONSEQUENCES; ANTIEPILEPTIC DRUGS; DECISION-SUPPORT; PILL APPEARANCE; SUBSTITUTION; IMPACT; QUALITY	Description: The discrepancy between health care spending and achieved outcomes in the United States has fueled efforts to identify and address situations where unnecessarily expensive therapies are used when less costly, equally effective options are available. The underuse of generic medications is an important example. Methods: A literature review was conducted to answer 5 questions about generic medications: 1) How commonly are brand-name medications used when a generic version is available? 2) How does the use of generic medications influence adherence? 3) What is the evidence that brand-name and generic medications have similar clinical effects? 4) What are the barriers to increasing the use of generic medications? 5) What strategies can be used to promote cost savings through greater generic medication use? This article was reviewed and approved by the American College of Physicians Clinical Guidelines Committee. Best Practice Advice: Clinicians should prescribe generic medications, if possible, rather than more expensive brand-name medications.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Caril Clin, Roanoke, VA USA; [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; American College of Physicians	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.	aqaseem@acponline.org			ACP	ACP	Financial support for the development of this paper comes from the ACP operating budget.	Austvoll-Dahlgren A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007017; Banahan BF, 1997, ARCH INTERN MED, V157, P2080, DOI 10.1001/archinte.157.18.2080; Berkowitz SA, 2014, JAMA INTERN MED, V174, P1955, DOI 10.1001/jamainternmed.2014.5294; Bhargava V, 2010, J MANAGE CARE PHARM, V16, P384, DOI 10.18553/jmcp.2010.16.6.384; Brennan TA, 2004, ANN INTERN MED, V141, P126, DOI 10.7326/0003-4819-141-2-200407200-00011; Briesacher BA, 2009, AM J MANAG CARE, V15, P450; Brill A, 2011, OVERSPENDING MULTISO; Campbell EG, 2007, NEW ENGL J MED, V357, P1796, DOI 10.1056/NEJMp078141; Campbell EG, 2013, JAMA INTERN MED, V173, P237, DOI 10.1001/jamainternmed.2013.1539; Centers for Medicare & Medicaid Services, 2015, 5 STAR QU RAT SYST; Choudhry NK, 2008, AM HEART J, V155, P904, DOI 10.1016/j.ahj.2007.11.039; Choudhry NK, 2010, AM J PHARM BENEFIST, V2, P33; Choudhry NK, 2011, NEW ENGL J MED, V365, P2088, DOI 10.1056/NEJMsa1107913; Cox E, 2005, GENERIC DRUG USAGE R; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Dentali F, 2011, PHARMACOTHERAPY, V31, P386, DOI 10.1592/phco.31.4.386; Desai NR, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2011.07.033; Digiuni M, 2013, J GLAUCOMA, V22, P707, DOI 10.1097/IJG.0b013e318259b47c; Doran T, 2006, NEW ENGL J MED, V355, P375, DOI 10.1056/NEJMsa055505; Easthall C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002749; Eban K, 2013, DIRTY MED; Federman AD, 2007, MED CARE, V45, P109, DOI 10.1097/01.mlr.0000250293.24939.2e; Fein AJ, 2014, DRUG CHANNELS   0812; Fischer MA, 2004, JAMA-J AM MED ASSOC, V291, P1850, DOI 10.1001/jama.291.15.1850; Fischer MA, 2003, HEALTH SERV RES, V38, P1051, DOI 10.1111/1475-6773.00162; Fischer MA, 2008, ARCH INTERN MED, V168, P2433, DOI 10.1001/archinte.168.22.2433; Frisk P, 2011, J PHARM HEALTH SERV, V2, P9, DOI 10.1111/j.1759-8893.2011.00036.x; Gagne JJ, 2014, ANN INTERN MED, V161, P400, DOI 10.7326/M13-2942; Gartlehner G, 2006, DRUG CLASS REV 2 GEN; Gellad WF, 2013, ANN INTERN MED, V159, P105, DOI 10.7326/0003-4819-159-2-201307160-00664; Golan S, 2015, CLIN EXP PHARMACOL P, V42, P220, DOI 10.1111/1440-1681.12329; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Grant RW, 2011, DIABETES EDUCATOR, V37, P78, DOI 10.1177/0145721710388427; Haas JS, 2005, ANN INTERN MED, V142, P891, DOI 10.7326/0003-4819-142-11-200506070-00006; Hashemi M, 2012, IRAN J OPHTHALMOL, V24, P11; Helfand C, 2013, TOP 10 GENERICS MAKE; Holahan J, 2012, COST COVERAGE IMPLIC; Holmes DR, 2011, CIRCULATION, V124, P1290, DOI 10.1161/CIR.0b013e31822d97d5; Huang ES, 2007, DIABETES CARE, V30, P2478, DOI 10.2337/dc07-0499; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; IMS Institute for Healthcare Informatics, 2013, DECL MED US COST BET; Ip S, 2005, AHRQ PUBLICATION, V05-E020-2; Kelton CML, 2013, HEALTH AFFAIR, V32, P1204, DOI 10.1377/hlthaff.2013.0161; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Kesselheim AS, 2014, ANN INTERN MED, V161, P96, DOI 10.7326/M13-2381; Kesselheim AS, 2013, JAMA INTERN MED, V173, P202, DOI 10.1001/2013.jamainternmed.997; Kesselheim AS, 2010, DRUGS, V70, P605, DOI 10.2165/10898530-000000000-00000; Lindenauer PK, 2007, NEW ENGL J MED, V356, P486, DOI 10.1056/NEJMsa064964; Mott DA, 2002, MED CARE, V40, P662, DOI 10.1097/00005650-200208000-00006; Mottram P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003491.pub2; Narayanaswamy Arun, 2007, Indian Journal of Ophthalmology, V55, P127; O'Malley AJ, 2006, HEALTH SERV RES, V41, P1876, DOI 10.1111/j.1475-6773.2006.00579.x; Petersen LA, 2006, ANN INTERN MED, V145, P265, DOI 10.7326/0003-4819-145-4-200608150-00006; Qaseem A, 2008, ANN INTERN MED, V149, P725, DOI 10.7326/0003-4819-149-10-200811180-00007; Rathe J, 2013, EUR J CLIN PHARMACOL, V69, P1827, DOI 10.1007/s00228-013-1539-z; Rector TS, 2003, MED CARE, V41, P398, DOI 10.1097/00005650-200303000-00008; Roebuck MC, 2011, HEALTH AFFAIR, V30, P91, DOI 10.1377/hlthaff.2009.1087; Rogers T, 2014, JAMA-J AM MED ASSOC, V311, P2065, DOI 10.1001/jama.2014.3485; Rosenthal E, 2014, NY TIMES, pB9; Sanfelix-Gimeno G, 2014, MED CARE, V52, P669, DOI 10.1097/MLR.0000000000000148; Scott AB, 2007, J MANAGE CARE PHARM, V13, P412, DOI 10.18553/jmcp.2007.13.5.412; Sedjo RL, 2008, AM J MANAG CARE, V14, P813; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shrank WH, 2011, AM J MED, V124, P309, DOI 10.1016/j.amjmed.2010.11.020; Shrank WH, 2011, ANN PHARMACOTHER, V45, P31, DOI 10.1345/aph.1P389; Shrank WH, 2010, ANN INTERN MED, V153, P633, DOI 10.7326/0003-4819-153-10-201011160-00005; Shrank WH, 2010, HEALTH AFFAIR, V29, P1383, DOI 10.1377/hlthaff.2009.0424; Shrank WH, 2009, HEALTH AFFAIR, V28, P546, DOI 10.1377/hlthaff.28.2.546; Shrank WH, 2009, AM HEART J, V157, P613, DOI 10.1016/j.ahj.2008.12.006; Sokol MC, 2005, MED CARE, V43, P521, DOI 10.1097/01.mlr.0000163641.86870.af; Stacey D, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431.pub4, 10.1002/14651858.CD001431.pub2, 10.1002/14651858.CD001431.pub3]; Steinman MA, 2007, J GEN INTERN MED, V22, P645, DOI 10.1007/s11606-006-0074-3; Stenner SP, 2010, J AM MED INFORM ASSN, V17, P681, DOI 10.1136/jamia.2009.002568; Stewart WC, 2002, CURR EYE RES, V24, P387, DOI 10.1076/ceyr.24.5.387.8516; STROM BL, 1987, NEW ENGL J MED, V316, P1456, DOI 10.1056/NEJM198706043162306; Stuart BC, 2009, DIABETES CARE, V32, P647, DOI 10.2337/dc08-1311; Taira DA, 2006, AM J MANAG CARE, V12, P678; Thakurta S, 2009, DRUG CLASS REV PROTO; U.S. Department of Health and Human Services, 2010, EXP US GEN DRUG; U.S. Food and Drug Administration, 2014, UPD BUPR HYDR EXT RE; U.S. Food and Drug Administration, 2015, REV THER EQ GEN BUPR; U.S. Food and Drug Administration, 2008, THYR MED Q A MARY PR; U.S. Food and Drug Administration, 2014, OR BOOK APPR DRUG PR; Waber RL, 2008, JAMA-J AM MED ASSOC, V299, P1016, DOI 10.1001/jama.299.9.1016; Wang B, 2012, ARCH INTERN MED, V172, P1109, DOI 10.1001/archinternmed.2012.2013; Yong PL, 2010, HEALTHCARE IMPERATIV	86	55	56	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	2016	164	1					41	+		10.7326/M14-2427	http://dx.doi.org/10.7326/M14-2427			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DA4WC	26594818				2023-01-03	WOS:000367801700009
J	Park, MS; Patel, MM; Sarezky, D; Rojas, C; Choo, C; Choi, M; Liu, DC; Rademaker, AW; Tanna, AP				Park, Meghan S.; Patel, Marguerite M.; Sarezky, Daniel; Rojas, Carin; Choo, Clara; Choi, Michael; Liu, Dachao; Rademaker, Alfred W.; Tanna, Angelo P.			Inter-Rater Agreement in the Assessment of Video Recordings of Eye Drop Instillation by Glaucoma Patients	PLOS ONE			English	Article							MEDICATIONS; SEVERITY; EYEDROPS	Purpose To create a standardized method for evaluating the video recordings of patients self-instilling eye drops and to determine the level of agreement of eye drop instillation efficacy, safety and efficiency ratings by three masked graders. Design Prospective cross-sectional study. Participants 78 patients with open-angle glaucoma or ocular hypertension who had at least 6 months of experience with the use of eye drop medications. Methods Participants were video recorded while self-instilling artificial tears sequentially to both eyes. Three masked observers graded these video recordings on three criteria: efficacy (the determination of whether an eye drop was instilled on the ocular surface), safety (assessment of whether the tip of the medication bottle made contact with the ocular surface or eyelids), and efficiency (the number of eye drops expressed from the bottle). Main Outcome Measures After grading the video recordings based on efficacy, safety, and efficiency, kappa statistics were used to estimate inter-rater agreement. Results The mean kappa level of agreement for efficacy, safety, and efficiency was 0.64 (95% confidence interval (CI), 0.42-0.87), 0.73 (95% CI, 0.58-0.88), and 0.62 (95% CI, 0.42-0.81), respectively. Conclusions We demonstrated good inter-rater reproducibility of the masked analysis of video recordings of patients self-instilling eye drops based on three criteria: efficiency, safety, and efficacy.	[Park, Meghan S.; Patel, Marguerite M.; Rojas, Carin; Tanna, Angelo P.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA; [Sarezky, Daniel] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA; [Choo, Clara] Univ Arizona, Dept Ophthalmol, Tucson, AZ USA; [Choi, Michael] Mayo Clin, Dept Ophthalmol, Rochester, MN USA; [Liu, Dachao; Rademaker, Alfred W.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Arizona; Mayo Clinic; Northwestern University; Feinberg School of Medicine	Tanna, AP (corresponding author), Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.	atanna@northwestern.edu		Tanna, Angelo/0000-0003-3089-6664	Research to Prevent Blindness, New York, NY; Department of Ophthalmology; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001422] Funding Source: NIH RePORTER	Research to Prevent Blindness, New York, NY(Research to Prevent Blindness (RPB)); Department of Ophthalmology; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	APT is supported by an unrestricted grant to Northwestern University from Research to Prevent Blindness, New York, NY. The Northwestern University Biostatistics Consultation Service received funding from the Department of Ophthalmology to carry out the statistical analysis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alm A, 2008, SURV OPHTHALMOL, V53, pS93, DOI 10.1016/j.survophthal.2008.08.004; Aptel F, 2009, BRIT J OPHTHALMOL, V93, P700, DOI 10.1136/bjo.2008.139840; BROWN MM, 1984, CAN J OPHTHALMOL, V19, P2; BURNS E, 1992, AGE AGEING, V21, P168, DOI 10.1093/ageing/21.3.168; Dickinson C, 2007, INVEST OPHTH VIS SCI, V48, P4368, DOI 10.1167/iovs.07-0001; GEYER O, 1995, BRIT J OPHTHALMOL, V79, P376, DOI 10.1136/bjo.79.4.376; Hennessy AL, 2011, AM J OPHTHALMOL, V152, P982, DOI 10.1016/j.ajo.2011.05.015; Hennessy AL, 2010, OPHTHALMOLOGY, V117, P2345, DOI 10.1016/j.ophtha.2010.03.040; KASS MA, 1982, ANN OPHTHALMOL, V14, P889; Sleath B, 2006, OPHTHALMOLOGY, V113, P431, DOI 10.1016/j.ophtha.2005.10.034; Sleath B, 2011, OPHTHALMOLOGY, V118, P2398, DOI 10.1016/j.ophtha.2011.05.013; Stone JL, 2009, ARCH OPHTHALMOL-CHIC, V127, P732, DOI 10.1001/archophthalmol.2009.96; WINFIELD AJ, 1990, BRIT J OPHTHALMOL, V74, P477, DOI 10.1136/bjo.74.8.477	13	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2016	11	1							e0145764	10.1371/journal.pone.0145764	http://dx.doi.org/10.1371/journal.pone.0145764			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA4VZ	26730605	Green Published, Green Submitted, gold			2023-01-03	WOS:000367801400050
J	Jasien, JV; Jonas, JB; de Moraes, CG; Ritch, R				Jasien, Jessica V.; Jonas, Jost B.; de Moraes, C. Gustavo; Ritch, Robert			Intraocular Pressure Rise in Subjects with and without Glaucoma during Four Common Yoga Positions	PLOS ONE			English	Article							OPEN-ANGLE GLAUCOMA; BODY POSITION; APPLANATION TONOMETRY; GRAVITY INVERSION; TENSION GLAUCOMA; POSTURAL CHANGE; PROGRESSION	Purpose To measure changes in intraocular pressure (IOP) in association with yoga exercises with a head-down position. Methods The single Center, prospective, observational study included 10 subjects with primary open-angle glaucoma and 10 normal individuals, who performed the yoga exercises of Adho Mukha Svanasana, Uttanasana, Halasana and Viparita Karani for two minutes each. IOP was measured by pneumatonometry at baseline and during and after the exercises. Results All yoga poses were associated with a significant (P<0.01) rise in IOP within one minute after assuming the yoga position. The highest IOP increase (P<0.01) was measured in the Adho Mukha Svanasana position (IOP increase from 17 +/- 3.2 mmHg to 28 +/- 3.8 mmHg in glaucoma patients; from 17 +/- 2.8 mmHg to 29 +/- 3.9 mmHg in normal individuals), followed by the Uttanasana position (17 +/- 3.9 mmHg to 27 +/- 3.4 mmHg (glaucoma patients) and from 18 +/- 2.5 mmHg to 26 +/- 3.6 mmHg normal individuals)), the Halasana position (18 +/- 2.8 mmHg to 24 +/- 3.5 mmHg (glaucoma patients); 18 +/- 2.7 mmHg to 22 +/- 3.4 mmHg (normal individuals)), and finally the Viparita Kirani position (17 +/- 4 mmHg to 21 +/- 3.6 mmHg (glaucoma patients); 17 +/- 2.8 to 21 +/- 2.4 mmHg (normal individuals)). IOP dropped back to baseline values within two minutes after returning to a sitting position. Overall, IOP rise was not significantly different between glaucoma and normal subjects (P = 0.813), all though glaucoma eyes tended to have measurements 2 mm Hg higher on average. Conclusions Yoga exercises with head-down positions were associated with a rapid rise in IOP in glaucoma and healthy eyes. IOP returned to baseline values within 2 minutes. Future studies are warranted addressing whether yoga exercise associated IOP changes are associated with similar changes in cerebrospinal fluid pressure and whether they increase the risk of glaucoma progression.	[Jasien, Jessica V.; Ritch, Robert] New York Ear Eye & Ear Infirm Mt Sinai, Einhom Clin Res Ctr, New York, NY 10003 USA; [Jonas, Jost B.] Heidelberg Univ, Seegartenklin Heidelberg, Med Fac Mannheim, Dept Ophthalmol, D-69115 Heidelberg, Germany; [de Moraes, C. Gustavo] Columbia Univ, Dept Ophthalmol, Med Ctr, New York, NY 10027 USA	New York Eye & Ear Infirmary of Mount Sinai; Ruprecht Karls University Heidelberg; Columbia University	Jasien, JV (corresponding author), New York Ear Eye & Ear Infirm Mt Sinai, Einhom Clin Res Ctr, New York, NY 10003 USA.	jjasien.ganyresearch@gmail.com			New York Glaucoma Research Institute, New York, NY	New York Glaucoma Research Institute, New York, NY	Supported by donations from Joseph M. Cohen to the New York Glaucoma Research Institute, New York, NY and New York Glaucoma Research Institute, New York, NY.	Almubrad TM, 2010, CLIN EXP OPTOM, V93, P77, DOI 10.1111/j.1444-0938.2010.00453.x; ANDERSON DR, 1973, INVEST OPHTH VISUAL, V12, P204; Baskaran M, 2006, OPHTHALMOLOGY, V113, P1327, DOI 10.1016/j.ophtha.2006.02.063; Bertschinger DR, 2007, BRIT J OPHTHALMOL, V91, P1413, DOI 10.1136/bjo.2007.114546; BUCHANAN RA, 1985, AM J OPTOM PHYS OPT, V62, P59; CARLSON KH, 1987, INVEST OPHTH VIS SCI, V28, P1346; Cramer H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075515; de Barros DSM, 2008, OPHTHAL SURG LAS IM, V39, P339; FRIBERG TR, 1985, ARCH OPHTHALMOL-CHIC, V103, P1687; Gallardo MJ, 2006, ADV THER, V23, P921, DOI 10.1007/BF02850214; Gaton DD, 2010, CURR EYE RES, V35, P475, DOI 10.3109/02713681003678824; Hirooka K, 2003, J GLAUCOMA, V12, P379, DOI 10.1097/00061198-200308000-00015; JAIN MR, 1976, BRIT J OPHTHALMOL, V60, P687, DOI 10.1136/bjo.60.10.687; Johannesson G, 2014, ACTA OPHTHALMOL, V92, P111, DOI 10.1111/aos.12058; Kiuchi T, 2006, OPHTHALMOLOGY, V113, P2150, DOI 10.1016/j.ophtha.2006.06.014; KLATZ RM, 1983, J AM OSTEOPATH ASSOC, V82, P853; LEMARR JD, 1984, AM J OPTOM PHYS OPT, V61, P679; LINDER BJ, 1988, INVEST OPHTH VIS SCI, V29, P1492; Mosaed S, 2005, AM J OPHTHALMOL, V139, P320, DOI 10.1016/j.ajo.2004.09.062; Pettinato Y, 2002, SIMPLY YOGA, P22; Prata TS, 2010, SURV OPHTHALMOL, V55, P445, DOI 10.1016/j.survophthal.2009.12.002; Saper RB, 2004, ALTERN THER HEALTH M, V10, P44; Sit AJ, 2008, INVEST OPHTH VIS SCI, V49, P1473, DOI 10.1167/iovs.07-1139; TARKKANEN A, 1967, ACTA OPHTHALMOL, V45, P569; TSUKAHARA S, 1984, BRIT J OPHTHALMOL, V68, P389, DOI 10.1136/bjo.68.6.389; WEBER AK, 1981, ANN OPHTHALMOL, V13, P323; WEINREB RN, 1984, AM J OPHTHALMOL, V98, P784, DOI 10.1016/0002-9394(84)90698-6; Wilensky J T, 1991, Trans Am Ophthalmol Soc, V89, P757	28	39	45	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0144505	10.1371/journal.pone.0144505	http://dx.doi.org/10.1371/journal.pone.0144505			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SI	26698309	Green Published, Green Submitted, gold			2023-01-03	WOS:000367092600022
J	Hanass-Hancock, J; Myezwa, H; Carpenter, B				Hanass-Hancock, Jill; Myezwa, Hellen; Carpenter, Bradley			Disability and Living with HIV: Baseline from a Cohort of People on Long Term ART in South Africa	PLOS ONE			English	Article							QUALITY-OF-LIFE; HIV/AIDS; REHABILITATION; HEALTH; ADULTS; RISK; PREVALENCE; DEPRESSION; INFECTION; CONTEXT	Background Through access to life saving antiretroviral treatment (ART) in southern Africa, HIV has been reconceptualised as a chronic disease. This comes with new challenges of HIV-related co-morbidities and disabilities. We still lack an understanding of the types and scope of disabilities experienced by people on long term ART and how this impacts health, adherence, and livelihood. This paper describes the results of a cohort study examining the new health-and disability-related needs of the millions of people on ART in the region. Methods Data was collected from a cohort of people who had been on ART for six months or longer in a semi-urban public health care setting in South Africa. 1042 adults (18 and older) participated in the cross-sectional study which investigated disabilities/activity limitations, health, ART adherence, depression symptoms, and livelihood. We analysed the associations between these constructs using descriptive statistics, and bivariate and multivariate analyses. Results A large number of participants (35.5%) obtained a weighted score of two or more on the WHODAS 2.0 indicating possible activity limitations. A positive relationship was found between activity limitations and depression symptoms, adherence, and worse health outcomes, while none was found for BMI or CD4 count. These associations varied by type of activity limitations and, in some cases, by gender. Conclusion Activity limitations are potentially experienced by a large portion of people on ART in southern Africa which impacts health and ART adherence negatively. These results highlight the importance of better understanding the new health-related needs of people who are on long term ART, as well as the nuances of the disability they experience. This is urgently needed in order to enable HIV-endemic countries to better prepare for the new health-related needs of the millions of people on ART in southern Africa.	[Hanass-Hancock, Jill; Carpenter, Bradley] Univ KwaZulu Natal, Hlth Econ & HIV & AIDS Res Div HEARD, Durban, Kwazulu Natal, South Africa; [Myezwa, Hellen] Univ Witwatersrand, Fac Hlth Sci, Dept Physiotherapy, Johannesburg, Gauteng, South Africa	University of Kwazulu Natal; University of Witwatersrand	Hanass-Hancock, J (corresponding author), Univ KwaZulu Natal, Hlth Econ & HIV & AIDS Res Div HEARD, Durban, Kwazulu Natal, South Africa.	hanasshj@ukzn.ac.za	Myezwa, Hellen/AAH-1380-2021; Carpenter, Bradley/F-2554-2015; Hanass-Hancock, Jill/AAV-7141-2021	Myezwa, Hellen/0000-0003-4562-6413; Carpenter, Bradley/0000-0002-2968-1968; Hanass-Hancock, Jill/0000-0003-3662-8548	HEARD's internal SIDA funding; SIDA	HEARD's internal SIDA funding; SIDA	The authors JHH and BC are employed by HEARD which receives SIDA funding to conduct research on HIV and other health conditions in Eastern and Southern Africa (general SIDA support; no grant number). HM is permanently employed by Wits University and her time is funded through this post. The funding for the fieldwork of this study was provided by HEARD's internal SIDA funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almazan-Isla J, 2014, DISABIL HEALTH J, V7, P78, DOI 10.1016/j.dhjo.2013.08.004; [Anonymous], 2013, ACC ANT THER AFR 201; [Anonymous], 2011, NAT STRAT PLAN HIV S; Banks LM, 2014, TROPICAL MED INT HLT; Booysen FLR, 2007, SOC INDIC RES, V81, P283, DOI 10.1007/s11205-006-9011-4; Brandt R, 2009, AJAR-AFR J AIDS RES, V8, P123, DOI 10.2989/AJAR.2009.8.2.1.853; Canadian HIV/AIDS Legal Network, 2008, UN CONV RIGHTS PERS; Canadian Working Group on HIV and Rehabilitation, 2011, E MOD EV INF HIV REH; COBALT, 2015, COM AFF DIS AIDS HIV; Cobbing S, 2014, DISABIL REHABIL, V36, P1687, DOI 10.3109/09638288.2013.872199; Cummings P, 2009, STATA J, V9, P175, DOI 10.1177/1536867X0900900201; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Delva W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001258; Duran S, 2001, HIV Clin Trials, V2, P38; Groce NE, 2013, LANCET GLOB HEALTH, V1, pE180, DOI 10.1016/S2214-109X(13)70056-1; Hanass-Hancock J, 2015, DISABIL REHABIL; Hanass-Hancock J, 2014, ELEMENTS FINANCIAL E; Hanass-Hancock J, 2013, WORLD J AIDS, V3, P257, DOI DOI 10.4236/WJA.2013.33034; Hanass-Hancock J, 2010, HIV DISABILITY REHAB; Hanass-Hancock J, 2013, AJOD, V2, P1; Hanass-Hancock J, 2015, DISABIL REHABIL, V37, P2051, DOI 10.3109/09638288.2014.993432; Hanass-Hancock J, 2011, DISABIL REHABIL, V33, P2389, DOI 10.3109/09638288.2011.573055; Hanass-Hancock J, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-34; Hanass-Hancock Jill, 2009, J Int AIDS Soc, V12, P28, DOI 10.1186/1758-2652-12-28; Hughes K, 2012, LANCET, V379, P1621, DOI 10.1016/S0140-6736(11)61851-5; Jelsma J, 2006, SOUTH AFR J PHYSIOTH, V62, P7; Jones L, 2012, LANCET, V380, P899, DOI 10.1016/S0140-6736(12)60692-8; Kabore I, 2010, AIDS PATIENT CARE ST, V24, P581, DOI 10.1089/apc.2009.0307; Mannheimer S, 2008, AIDS CARE, V20, P161, DOI 10.1080/09540120701534699; Meintjes G, 2012, S AFR J HIV MED, DOI 10.7196/SAJHIVMED.862; Mitra S, 2013, WORLD DEV, V41, P1, DOI 10.1016/j.worlddev.2012.05.024; Mutimura E, 2008, QUALITY LIFE RES; Mutimura E, 2008, AIDS RES HUM RETROV, V24, P15, DOI 10.1089/aid.2007.0023; Myer L, 2008, AIDS PATIENT CARE ST, V22, P147, DOI 10.1089/apc.2007.0102; Myezwa H, 2011, PHYSIOTHERAPY, V97, P17, DOI 10.1016/j.physio.2010.08.015; Nakasujja N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044415; Nixon S, 2011, S AFR J HIV MED, P12; Nixon SA, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18806; Nixon SA, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-41; Nyirenda M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-259; O'Brien KK, 2009, J INT AIDS SOC, V12, DOI [10.1186/1758-2652-12-30, 10.1186/1758-2652-2-5]; Petersen I, 2014, J AFFECT DISORDERS, V158, P78, DOI 10.1016/j.jad.2014.02.013; Petersen I., 2013, Health, V5, P557; Pollard N, 2008, DISABIL REHABIL, V30, P62, DOI 10.1080/09638280701192980; PRIME, PROGR IMPR MENT HLTH; Roos R, 2015, AFR J PRIM HEALTH CA, V7, DOI 10.4102/phcfm.v7i1.772; Rule S, 2006, DISABILITY SOCIAL CH; Sherr L, 2011, PSYCHOL HEALTH MED, V16, P612, DOI 10.1080/13548506.2011.579991; Smart T, 2009, HIV AIDS TREATMENT P, V145, P1; Statistics South Africa, 2014, PROF PERS DIS CENS 2; UNAIDS, 2013, HIV AND AG S; UNAIDS, 2014, UND FAST TRACK ACC A; UNAIDS, 2014, THE GAP REP; Ustun T. B., 2010, Measuring health and disability: manual for WHO Disability Assessment Schedule (WHODAS 2.0); van Egeraat L, 2015, AJAR-AFR J AIDS RES, V14, P285, DOI 10.2989/16085906.2015.1084938; Walston J, 2006, J AM GERIATR SOC, V54, P991, DOI 10.1111/j.1532-5415.2006.00745.x; WHO, 2011, WORLD REPORT ON DISABILITY, P1; World Health Organization, 2010, COMM BAS REH CBR GUI; Yoshida K, 2014, DISABIL REHABIL, V36, P2161, DOI 10.3109/09638288.2014.894144; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zhang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040793	61	54	54	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2015	10	12							e0143936	10.1371/journal.pone.0143936	http://dx.doi.org/10.1371/journal.pone.0143936			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CX7OL	26625001	Green Published, Green Submitted, gold			2023-01-03	WOS:000365891600077
J	Halpern, SD				Halpern, Scott D.			Toward Evidence-Based End-of-Life Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVANCE DIRECTIVES		[Halpern, Scott D.] Univ Penn, Fostering Improvement End Life Decis Sci FIELD Pr, Leonard Davis Inst Hlth Econ,Dept Med Eth Hlth Po, Div Pulm Allergy & Crit Care Med,Dept Med, Philadelphia, PA 19104 USA; [Halpern, Scott D.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Halpern, SD (corresponding author), Univ Penn, Fostering Improvement End Life Decis Sci FIELD Pr, Leonard Davis Inst Hlth Econ,Dept Med Eth Hlth Po, Div Pulm Allergy & Crit Care Med,Dept Med, Philadelphia, PA 19104 USA.		Harding, Richard/G-9729-2012					Halpern SD, 2015, ANN INTERN MED, V162, P224, DOI 10.7326/M14-2476; Halpern SD, 2013, HEALTH AFFAIR, V32, P408, DOI 10.1377/hlthaff.2012.0895; Hickman SE, 2015, J AM GERIATR SOC, V63, P341, DOI 10.1111/jgs.13248; Nicholas LH, 2011, JAMA-J AM MED ASSOC, V306, P1447, DOI 10.1001/jama.2011.1410; Silveira MJ, 2010, NEW ENGL J MED, V362, P1211, DOI 10.1056/NEJMsa0907901	5	54	54	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 19	2015	373	21					2001	2003		10.1056/NEJMp1509664	http://dx.doi.org/10.1056/NEJMp1509664			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CW4JN	26465826				2023-01-03	WOS:000364957700005
J	Kigen, G; Busakhala, N; Ogaro, F; Chesire, E; Saat, N; Too, R; Nyandiko, W				Kigen, Gabriel; Busakhala, Naftali; Ogaro, Francis; Chesire, Emily; Saat, Nathan; Too, Robert; Nyandiko, Winstone			A Review of the Ingredients Contained in Over the Counter (OTC) Cough Syrup Formulations in Kenya. Are They Harmful to Infants?	PLOS ONE			English	Review							COLD MEDICATIONS; DIPHENHYDRAMINE MONOINTOXICATION; ADULT LITERATURE; PEDIATRIC COUGH; MEDICINE ABUSE; ADVERSE EVENTS; CHILDREN; ANTIHISTAMINES; PROMETHAZINE; WARNINGS	Background Cough syrups are widely used in the developing world, but safety of their use in infants and children less than two years has not been well documented. Some syrups contain multiple combinations of such drugs as promethazine, diphenhydramine and ephedrine; which are individually now contraindicated in children less than two years. Despite this, the syrups are available as over the counter drugs and may be dispensed to mothers who are unaware of the potentially hazardous effects to their infants. A descriptive cross-sectional study was used to investigate suitability of cough syrups sold within Eldoret municipality for use in children less than two years of age based on their formulations and available literature. Methods Two semi-structured questionnaires were administered to pharmacy attendants and mothers attending sick child clinic at a referral hospital to establish whether cough syrups containing more than one active ingredient of compounds, now contraindicated in children are administered to infants, and awareness of potential serious adverse effects. Data from labeled contents of cough syrups from retail pharmacies was recorded and corroborated with information from literature to determine those deemed to contain the ingredients. The second questionnaire was administered to mothers with children less than two years to ascertain whether they had used the identified syrups. A total of 260 mothers and 55 pharmacy attendants were interviewed. Results There was widespread use of the syrups in children, including infants, with 192 (74%) of the respondents having used identified syrups and over 90% of these on children less than 2 years including those less than three months. 146 (76%) mothers had administered the syrup at double the recommended dose. Conclusion The regulatory authorities should make concerted efforts to discourage use of cough syrups containing ingredients that pose adverse events to infants, including campaigns to educate pharmacy workers and mothers.	[Kigen, Gabriel; Busakhala, Naftali] Moi Univ, Dept Pharmacol & Toxicol, Sch Med, Eldoret, Kenya; [Ogaro, Francis; Chesire, Emily] Moi Teaching & Referral Hosp, Dept Paediat, Eldoret, Kenya; [Saat, Nathan] Moi Univ, Dept Pharm, Hlth Serv, Eldoret, Kenya; [Too, Robert] Moi Univ, Sch Publ Hlth, Dept Epidemiol & Nutr, Eldoret, Kenya; [Nyandiko, Winstone] Moi Univ, Sch Med, Dept Child Hlth & Pediat, Eldoret, Kenya	Moi University; Moi University; Moi University; Moi University	Kigen, G (corresponding author), Moi Univ, Dept Pharmacol & Toxicol, Sch Med, Eldoret, Kenya.	gkigen@mu.ac.ke	Kigen, Gabriel K/C-8494-2018	Kigen, Gabriel K/0000-0002-5047-4066				ACCP, 2006, PAT INF PAR CHILD CO; American Academy of Pediatrics, 2021, AAP AACAP CHA DECL N; [Anonymous], 1995, Pediatrics, V95, P598; Ashkin E, 2013, J FAM PRACTICE, V62, P145; Avois L, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2006.027557; Baker AM, 2003, J FORENSIC SCI, V48, P425; BENADRYL, 2013, BENADRYL DIPH HYDR I; Berg Ansgar, 2010, Tidsskr Nor Laegeforen, V130, P2474, DOI 10.4045/tidsskr.10.0503; Braude D, 2008, ACAD EMERG MED, V15, P209, DOI 10.1111/j.1553-2712.2008.00060.x; BRONCHODILATE, 2012, BRONCHO DILATE EPH H; BRONCHOLATE, 2007, BRONCHOLATE SYRUP PR; BRONKAID Bayer Corporation, BRONK EPH SULF 25 MG; Buck ML, 2010, MONTHLY NEWSLETTER H, V16; Chang CC, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006088.pub4; Church MK, 2010, ALLERGY, V65, P459, DOI 10.1111/j.1398-9995.2009.02325.x; Cooper R, 2013, HEALTH SOC CARE COMM, V21, P254, DOI 10.1111/hsc.12012; Cooper RJ, 2013, J SUBST USE, V18, P82, DOI 10.3109/14659891.2011.615002; Cote CJ, 2000, PEDIATRICS, V106, P633, DOI 10.1542/peds.106.4.633; Davila I, 2013, J INVEST ALLERG CLIN, V23, P1; del Cuvillo A, 2007, J INVEST ALLERG CLIN, V17, P28; Duggal HS, 2001, AUST NZ J PSYCHIAT, V35, P250; FDA, 2006, INF HEALTHC PROF PRO; Goldman RD, 2011, PAED CHILD HEALT-CAN, V16, P564, DOI 10.1093/pch/16.9.564; Isbister GK, 2012, J PAEDIATR CHILD H, V48, P91, DOI 10.1111/j.1440-1754.2010.01780.x; Knol K, 2000, ALLERGY, V55, P31, DOI 10.1034/j.1398-9995.2000.00005.x; Kuffner E, 2010, AM J FOREN MED PATH, V31, P106, DOI 10.1097/PAF.0b013e3181c2159c; Lazarus SG, 2013, CLIN PEDIATR, V52, P534, DOI 10.1177/0009922813482761; Lokker N, 2009, PEDIATRICS, V123, P1464, DOI 10.1542/peds.2008-0854; Maglione M, 2005, AM J PSYCHIAT, V162, P189, DOI 10.1176/appi.ajp.162.1.189; Morin CM, 2005, SLEEP, V28, P1465, DOI 10.1093/sleep/28.11.1465; Nine JS, 2006, AM J FOREN MED PATH, V27, P36, DOI 10.1097/01.paf.0000188093.45675.ee; Ostroff C, 2011, CHEST, V140, P295, DOI 10.1378/chest.11-0981; PHENERGAN, 2010, PHENERGAN PROM HYDR; PPB, 2014, CHILDR OV THE COUNT; Rimsza ME, 2008, PEDIATRICS, V122, pE318, DOI 10.1542/peds.2007-3813; Ryan Teresa, 2008, Pediatr Nurs, V34, P174; Salocks C, 2003, OFFICE ENV HLTH HAZA; Schaefer MK, 2008, PEDIATRICS, V121, P783, DOI 10.1542/peds.2007-3638; Sen EF, 2011, BRIT J CLIN PHARMACO, V71, P943, DOI 10.1111/j.1365-2125.2010.03860.x; Sharfstein JM, 2007, NEW ENGL J MED, V357, P2321, DOI 10.1056/NEJMp0707400; Shefrin AE, 2009, CAN FAM PHYSICIAN, V55, P1081; Simons FER, 2007, ARCH PEDIAT ADOL MED, V161, P105, DOI 10.1001/archpedi.161.1.105-a; Smith SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001831.pub4; Standardmedia, 2014, WHY HON NOT COUGH SY; Starke PR, 2005, NEW ENGL J MED, V352, P2653, DOI 10.1056/NEJM200506233522522; Vassilev ZP, 2010, EXPERT OPIN DRUG SAF, V9, P233, DOI 10.1517/14740330903496410; Vernacchio L, 2008, PEDIATRICS, V122, pE323, DOI 10.1542/peds.2008-0498; Waris A, 2014, E AFRICAN MED J, V91	48	7	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2015	10	11							e0142092	10.1371/journal.pone.0142092	http://dx.doi.org/10.1371/journal.pone.0142092			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV5IS	26540251	Green Published, Green Submitted, gold			2023-01-03	WOS:000364303800055
J	Sato, C; Sekiguchi, A; Kawai, M; Kotozaki, Y; Nouchi, R; Tada, H; Takeuchi, H; Ishida, T; Taki, Y; Kawashima, R; Ohuchi, N				Sato, Chiho; Sekiguchi, Atsushi; Kawai, Masaaki; Kotozaki, Yuka; Nouchi, Rui; Tada, Hiroshi; Takeuchi, Hikaru; Ishida, Takanori; Taki, Yasuyuki; Kawashima, Ryuta; Ohuchi, Noriaki			Postoperative Structural Brain Changes and Cognitive Dysfunction in Patients with Breast Cancer	PLOS ONE			English	Article							QUALITY-OF-LIFE; PREFRONTAL CORTEX; NEUROCOGNITIVE FUNCTION; GENERAL-ANESTHESIA; ATTENTION; SURGERY; SEVOFLURANE; NEUROINFLAMMATION; CHEMOTHERAPY; MECHANISMS	Objective The primary purpose of this study was to clarify the influence of the early response to surgery on brain structure and cognitive function in patients with breast cancer. It was hypothesized that the structure of the thalamus would change during the early response after surgery due to the effects of anesthesia and would represent one aspect of an intermediate phenotype of postoperative cognitive dysfunction (POCD). Methods We examined 32 postmenopausal females with breast cancer and 20 age-matched controls. We assessed their cognitive function (attention, memory, and executive function), and performed brain structural MRI 1.5 +/- 0.5 days before and 5.6 +/- 1.2 days after surgery. Results We found a significant interaction between regional grey matter volume (rGMV) in the thalamus (P < 0.05, familywise error (FWE), small volume correction (SVC)) and one attention domain subtest (P = 0.001, Bonferroni correction) after surgery in the patient group compared with the control group. Furthermore, the changes in attention were significantly associated with sevoflurane anesthetic dose (r(2) = 0.247, beta = -0.471, P = 0.032) and marginally associated with rGMV changes in the thalamus (P = 0.07, FWE, SVC) in the Pt group. Conclusion Our findings suggest that alterations in brain structure, particularly in the thalamus, may occur shortly after surgery and may be associated with attentional dysfunction. This early postoperative response to anesthesia may represent an intermediate phenotype of POCD. It was assumed that patients experiencing other risk factors of POCD, such as the severity of surgery, the occurrence of complications, and pre-existing cognitive impairments, would develop clinical POCD with broad and multiple types of cognitive dysfunction.	[Sato, Chiho; Sekiguchi, Atsushi; Kawashima, Ryuta] Tohoku Univ, IDAC, Dept Funct Brain Imaging, Sendai, Miyagi 980, Japan; [Sato, Chiho; Tada, Hiroshi; Ishida, Takanori; Ohuchi, Noriaki] Tohoku Univ, Grad Sch Med, Div Surg Oncol, Sendai, Miyagi 980, Japan; [Sekiguchi, Atsushi; Taki, Yasuyuki] Tohoku Univ, Tohoku Med Megabank Org, Dept Community Med Supports, Div Med Neuroimage Anal, Sendai, Miyagi 980, Japan; [Sekiguchi, Atsushi] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Dept Adult Mental Hlth, Tokyo, Japan; [Kawai, Masaaki] Miyagi Canc Ctr Hosp, Dept Breast Oncol, Natori, Miyagi, Japan; [Kotozaki, Yuka] Fukushima Med Univ, Sch Med, Med Ind Translat Res Ctr, Div Clin Res, Fukushima, Japan; [Nouchi, Rui] Tohoku Univ, Frontier Res Inst Interdisciplinary Sci, Creat Interdisciplinary Res Div, Sendai, Miyagi 980, Japan; [Nouchi, Rui; Kawashima, Ryuta] Tohoku Univ, Dept Adv Brain Sci, Smart Ageing Int Res Ctr, IDAC, Sendai, Miyagi 980, Japan; [Nouchi, Rui] Tohoku Univ, Int Res Inst Disaster Sci, Human & Social Response Res Div, Sendai, Miyagi 980, Japan; [Takeuchi, Hikaru; Taki, Yasuyuki; Kawashima, Ryuta] Tohoku Univ, Div Dev Cognit Neurosci, IDAC, Sendai, Miyagi 980, Japan; [Taki, Yasuyuki] Tohoku Univ, Inst Dev Aging & Canc, Dept Nucl Med & Radiol, Sendai, Miyagi 980, Japan	Tohoku University; Tohoku University; Tohoku University; National Center for Neurology & Psychiatry - Japan; Miyagi Cancer Center; Fukushima Medical University; Tohoku University; Tohoku University; Tohoku University; Tohoku University; Tohoku University	Sekiguchi, A (corresponding author), Tohoku Univ, IDAC, Dept Funct Brain Imaging, Sendai, Miyagi 980, Japan.	asekiguchi@ncnp.go.jp	Kotozaki, Yuka/ABA-2922-2020; Tada, Hiroshi/G-2551-2014; Nouchi, Rui/GQH-1608-2022; Kotozaki, Yuka/ABA-2267-2020; Takeuchi, Hikaru/D-1057-2011	Kotozaki, Yuka/0000-0002-4659-1200; Tada, Hiroshi/0000-0003-2670-8982; xing zhi, shi zhi/0000-0003-3289-5681; Takeuchi, Hikaru/0000-0002-8022-9694; Nouchi, Rui/0000-0002-2078-9518	International Research Institute of Disaster Science; Ministry of Education, Culture, Sports, Science and Technology in Japan [KAKENHI 24790653]	International Research Institute of Disaster Science; Ministry of Education, Culture, Sports, Science and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Funding: Financial support for this study was provided by a Grant for Special Project Research from the International Research Institute of Disaster Science, a Grant-in-Aid for Young Scientists (B) (KAKENHI 24790653) from the Ministry of Education, Culture, Sports, Science and Technology in Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler LJ, 1997, ANESTH ANALG, V84, P120, DOI 10.1097/00000539-199701000-00023; Ahles TA, 2005, J CLIN ONCOL, V23, P4399, DOI 10.1200/JCO.2005.03.343; Ahles TA, 2012, J CLIN ONCOL, V30, P3675, DOI 10.1200/JCO.2012.43.0116; Alkire MT, 2000, CONSCIOUS COGN, V9, P370, DOI 10.1006/ccog.1999.0423; Bercker S, 2009, NEUROTOX RES, V16, P140, DOI 10.1007/s12640-009-9063-8; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cao XZ, 2010, PROG NEURO-PSYCHOPH, V34, P1426, DOI 10.1016/j.pnpbp.2010.07.027; Carrasco M, 2001, P NATL ACAD SCI USA, V98, P5363, DOI 10.1073/pnas.081074098; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chen MH, 2013, J ANESTH, V27, P487, DOI 10.1007/s00540-012-1548-6; Chun MM, 2007, CURR OPIN NEUROBIOL, V17, P177, DOI 10.1016/j.conb.2007.03.005; Correa DD, 2008, CANCER J, V14, P396, DOI 10.1097/PPO.0b013e31818d8769; Coull JT, 1998, PROG NEUROBIOL, V55, P343, DOI 10.1016/S0301-0082(98)00011-2; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fidalgo AR, 2011, NEUROSCIENCE, V190, P194, DOI 10.1016/j.neuroscience.2011.05.073; Fiset P, 1999, J NEUROSCI, V19, P5506; Fougnie D, 2008, RELATIONSHIP ATTENTI; Franks NP, 2011, CAN J ANESTH, V58, P139, DOI 10.1007/s12630-010-9420-3; Gaster C, 2011, VBM TOOLBOX SPM8; Guay J, 2011, INDIAN J ANAESTH, V55, P358, DOI 10.4103/0019-5049.84850; Hakoda Y, 1990, KYOIKUSHINRIGAKUKENK, P389; Hatta T, 2004, APPL NEUROPSYCHOL, V11, P153, DOI 10.1207/s15324826an1103_3; Hedayati E, 2011, ACTA ONCOL, V50, P1027, DOI 10.3109/0284186X.2011.572911; Hermelink K, 2007, CANCER, V109, P1905, DOI 10.1002/cncr.22610; Hofacer RD, 2013, ANN NEUROL, V73, P695, DOI 10.1002/ana.23892; HOLE A, 1980, ACTA ANAESTH SCAND, V24, P279, DOI 10.1111/j.1399-6576.1980.tb01549.x; Hovens IB, 2012, BRAIN BEHAV IMMUN, V26, P1169, DOI 10.1016/j.bbi.2012.06.004; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Ketz NA, 2015, TRENDS NEUROSCI, V38, P3, DOI 10.1016/j.tins.2014.09.007; Klein A, 2009, NEUROIMAGE, V46, P786, DOI 10.1016/j.neuroimage.2008.12.037; Kline RP, 2012, ANESTHESIOLOGY, V116, P603, DOI 10.1097/ALN.0b013e318246ec0b; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Nakane Y, 1997, WHOQOL 26 INFORM; Newman MF, 2001, STROKE, V32, P2874, DOI 10.1161/hs1201.099803; Newman S, 2007, ANESTHESIOLOGY, V106, P572, DOI 10.1097/00000542-200703000-00023; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; Omura K, 2004, J CLIN EXP NEUROPSYC, V26, P645, DOI 10.1080/13803390490504272; Phillips-Bute B, 2006, PSYCHOSOM MED, V68, P369, DOI 10.1097/01.psy.0000221272.77984.e2; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Price CC, 2008, ANESTHESIOLOGY, V108, P8, DOI 10.1097/01.anes.0000296072.02527.18; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Rosczyk HA, 2008, EXP GERONTOL, V43, P840, DOI 10.1016/j.exger.2008.06.004; Rossi AF, 2009, EXP BRAIN RES, V192, P489, DOI 10.1007/s00221-008-1642-z; Schlunzen L, 2004, ACTA ANAESTH SCAND, V48, P1268, DOI 10.1111/j.1399-6576.2004.00505.x; Schlunzen L, 2010, ACTA ANAESTH SCAND, V54, P603, DOI 10.1111/j.1399-6576.2010.02208.x; Sherman S.M., 2009, EXPLORING THALAMUS I, V2nd Edn; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sugishita M, 2001, WECHSLER MEMORY SCAL; Tashiro M, 2005, BREAST CANC, V12; Taubert M, 2010, J NEUROSCI, V30, P11670, DOI 10.1523/JNEUROSCI.2567-10.2010; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Tuch DS, 2005, P NATL ACAD SCI USA, V102, P12212, DOI 10.1073/pnas.0407259102; Vardy J, 2008, ANN ONCOL, V19, P623, DOI 10.1093/annonc/mdm500; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th, DOI DOI 10.1037/T15169-000; Wechsler D., 1987, WECHSLER MEMORY SCAL; White NS, 2003, NEUROIMAGE, V19, P402, DOI 10.1016/S1053-8119(03)00103-4; Yon JH, 2005, NEUROSCIENCE, V135, P815, DOI 10.1016/j.neuroscience.2005.03.064; Yoshizaki K, 2006, D CAT MANUAL SCREENI; Zehnder Antoinette E, 2007, Am J Alzheimers Dis Other Demen, V22, P416, DOI 10.1177/1533317507302448	64	22	24	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2015	10	11							e0140655	10.1371/journal.pone.0140655	http://dx.doi.org/10.1371/journal.pone.0140655			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV5GZ	26536672	Green Submitted, Green Published, gold			2023-01-03	WOS:000364298400030
J	Ko, HC; Powers, AR; Sheu, RD; Kerns, SL; Rosenstein, BS; Krieger, SC; Mourad, WF; Hu, KS; Gupta, V; Bakst, RL				Ko, Huaising C.; Powers, Allison R.; Sheu, Ren-dih; Kerns, Sarah L.; Rosenstein, Barry S.; Krieger, Stephen C.; Mourad, Waleed F.; Hu, Kenneth S.; Gupta, Vishal; Bakst, Richard L.			Lhermitte's Sign following VMAT-Based Head and Neck Radiation-Insights into Mechanism	PLOS ONE			English	Article							CERVICAL-SPINAL-CORD; INDUCED APOPTOSIS; RAT; OLIGODENDROCYTES; IRRADIATION; MYELOPATHY; INJURY; OXALIPLATIN; TOLERANCE; DISEASE	Purpose/Objectives We observed a number of patients who developed Lhermitte's sign (LS) following radiation to the head and neck (H/N), since instituting volumetric modulated arc therapy (VMAT). We aimed to investigate the incidence of LS following VMAT-based RT without chemotherapy, and determine the dosimetric parameters that predict its development. We explored whether the role of inhomogeneous dose distribution across the spinal cord, causing a "bath-and-shower" effect, explains this finding. Methods and Materials From 1/20/2010-12/9/2013, we identified 33 consecutive patients receiving adjuvant RT using VMAT to the H/N without chemotherapy at our institution. Patients' treatment plans were analyzed for dosimetric parameters, including dose gradients along the anterior, posterior, right, and left quadrants at each cervical spine level. Institutional Review Board approval was obtained. Results 5 out of 33 (15.2%) patients developed LS in our patient group, all of whom had RT to the ipsilateral neck only. LS patients had a steeper dose gradient between left and right quadrants across all cervical spine levels (repeated-measures ANOVA, p = 0.030). Within the unilateral treatment group, LS patients received a higher mean dose across all seven cervical spinal levels (repeated-measures ANOVA, p = 0.046). Dose gradients in the anteriorposterior direction and mean doses to the cord were not significant between LS and non-LS patients. Conclusions Dose gradients along the axial plane of the spinal cord may contribute to LS development; however, a threshold dose within the high dose region of the cord may still be required. This is the first clinical study to suggest that inhomogeneous dose distributions in the cord may be relevant in humans. Further investigation is warranted to determine treatment-planning parameters associated with development of LS.	[Ko, Huaising C.; Powers, Allison R.; Sheu, Ren-dih; Kerns, Sarah L.; Rosenstein, Barry S.; Mourad, Waleed F.; Hu, Kenneth S.; Gupta, Vishal; Bakst, Richard L.] Mt Sinai Hosp, Icahn Sch Med, Dept Radiat Oncol, New York, NY 10029 USA; [Kerns, Sarah L.] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA; [Krieger, Stephen C.] Mt Sinai Hosp, Icahn Sch Med, Dept Neurol, New York, NY 10029 USA; [Mourad, Waleed F.; Hu, Kenneth S.] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Mt Sinai, New York, NY 10003 USA; [Mourad, Waleed F.] Montefiore Med Ctr, Dept Radiat Oncol, Albert Einstein Sch Med, New York, NY USA	Icahn School of Medicine at Mount Sinai; University of Rochester; Icahn School of Medicine at Mount Sinai; Harvard University; Beth Israel Deaconess Medical Center; Montefiore Medical Center; Yeshiva University	Bakst, RL (corresponding author), Mt Sinai Hosp, Icahn Sch Med, Dept Radiat Oncol, New York, NY 10029 USA.	Richard.Bakst@mountsinai.org						Atkinson S, 2003, INT J RADIAT ONCOL, V57, P1093, DOI 10.1016/S0360-3016(03)00735-1; Atkinson SL, 2005, INT J RADIAT ONCOL, V62, P535, DOI 10.1016/j.ijrobp.2005.01.061; Bauer S, 2007, NAT REV NEUROSCI, V8, P221, DOI 10.1038/nrn2054; Bijl HP, 2006, INT J RADIAT ONCOL, V64, P1204, DOI 10.1016/j.ijrobp.2005.06.046; Bijl HP, 2003, INT J RADIAT ONCOL, V57, P274, DOI [10.1016/S0360-3016(03)00529-7, 10.1016/s0360-3016(03)00529-7]; Bijl HP, 2002, INT J RADIAT ONCOL, V52, P205, DOI 10.1016/S0360-3016(01)02687-6; BODEN G, 1948, BRIT J RADIOL, V21, P464, DOI 10.1259/0007-1285-21-249-464; Chari DM, 2003, J NEUROSCI RES, V73, P787, DOI 10.1002/jnr.10700; Ciucci G, 2003, EUR J NEUROL, V10, P328, DOI 10.1046/j.1468-1331.2003.00579.x; DELATTRE JY, 1988, BRAIN, V111, P1319, DOI 10.1093/brain/111.6.1319; Esik O, 2003, PATHOL ONCOL RES, V9, P115, DOI 10.1007/BF03033755; FEIN DA, 1993, INT J RADIAT ONCOL, V27, P1029, DOI 10.1016/0360-3016(93)90519-2; Franklin RJM, 1997, J NEUROSCI RES, V50, P337, DOI 10.1002/(SICI)1097-4547(19971015)50:2<337::AID-JNR21>3.0.CO;2-3; Gemici C, 2010, CRIT REV ONCOL HEMAT, V74, P79, DOI 10.1016/j.critrevonc.2009.04.009; JONES A, 1964, BRIT J RADIOL, V37, P727, DOI 10.1259/0007-1285-37-442-727; Jurado JM, 2008, ANN ONCOL, V19, P2093, DOI 10.1093/annonc/mdn684; Kurita H, 2001, NEUROL RES, V23, P869, DOI 10.1179/016164101101199324; Leung WM, 2005, HEAD NECK-J SCI SPEC, V27, P187, DOI 10.1002/hed.20140; Li YQ, 1996, RADIOTHER ONCOL, V39, P35, DOI 10.1016/0167-8140(96)01705-7; Li YQ, 1996, CANCER RES, V56, P5417; Lu FG, 2004, INT J RADIAT BIOL, V80, P39, DOI 10.1080/09553000310001642876; Mul VEM, 2012, STRAHLENTHER ONKOL, V188, P71, DOI 10.1007/s00066-011-0010-2; Pak D, 2012, INT J RADIAT ONCOL, V83, P1528, DOI 10.1016/j.ijrobp.2011.10.052; Quan EZM, 2012, INT J RADIAT ONCOL, V83, P1169, DOI 10.1016/j.ijrobp.2011.09.015; Sano K, 2000, NEUROL MED-CHIR, V40, P495, DOI 10.2176/nmc.40.495; St Clair WH, 2003, SEMIN RADIAT ONCOL, V13, P322, DOI 10.1016/S1053-4296(03)00025-0; WORD JA, 1980, INT J RADIAT ONCOL, V6, P1731, DOI 10.1016/0360-3016(80)90261-8	27	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2015	10	10							e0139448	10.1371/journal.pone.0139448	http://dx.doi.org/10.1371/journal.pone.0139448			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TW	26448647	gold, Green Submitted, Green Published			2023-01-03	WOS:000362511000027
J	Kahn, JM; Barnato, AE; Lave, JR; Pike, F; Weissfeld, LA; Le, TQ; Angus, DC				Kahn, Jeremy M.; Barnato, Amber E.; Lave, Judith R.; Pike, Francis; Weissfeld, Lisa A.; Le, Tri Q.; Angus, Derek C.			A Comparison of Free-Standing versus Co-Located Long-Term Acute Care Hospitals	PLOS ONE			English	Article							MECHANICALLY VENTILATED PATIENTS; SURVIVAL; OUTCOMES	Background Long-term acute care hospitals (LTACs) provide specialized treatment for patients with chronic critical illness. Increasingly LTACs are co-located within traditional short-stay hospitals rather than operated as free-standing facilities, which may affect LTAC utilization patterns and outcomes. Methods We compared free-standing and co-located LTACs using 2005 data from the United States Centers for Medicare & Medicaid Services. We used bivariate analyses to examine patient characteristics and timing of LTAC transfer, and used propensity matching and multivariable regression to examine mortality, readmissions, and costs after transfer. Results Of 379 LTACs in our sample, 192 (50.7%) were free-standing and 187 (49.3%) were co-located in a short-stay hospital. Co-located LTACs were smaller (median bed size: 34 vs. 66, p < 0.001) and more likely to be for-profit (72.2% v. 68.8%, p = 0.001) than freestanding LTACs. Co-located LTACs admitted patients later in their hospital course (average time prior to transfer: 15.5 days vs. 14.0 days) and were more likely to admit patients for ventilator weaning (15.9% vs. 12.4%). In the multivariate propensity-matched analysis, patients in co-located LTACs experienced higher 180-day mortality (adjusted relative risk: 1.05, 95% CI: 1.00-1.11, p = 0.04) but lower readmission rates (adjusted relative risk: 0.86, 95% CI: 0.75-0.98, p = 0.02). Costs were similar between the two hospital types (mean difference in costs within 180 days of transfer: -$3,580, 95% CI: -$8,720 -$1,550, p = 0.17). Conclusions Compared to patients in free-standing LTACs, patients in co-located LTACs experience slightly higher mortality but lower readmission rates, with no change in overall resource use as measured by 180 day costs.	[Kahn, Jeremy M.; Barnato, Amber E.; Lave, Judith R.; Pike, Francis; Weissfeld, Lisa A.; Angus, Derek C.] Univ Pittsburgh, Sch Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Kahn, Jeremy M.; Barnato, Amber E.; Lave, Judith R.; Le, Tri Q.; Angus, Derek C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA; [Barnato, Amber E.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA; [Pike, Francis] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Weissfeld, Lisa A.] Stat Collaborat Inc, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kahn, JM (corresponding author), Univ Pittsburgh, Sch Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	kahnjm@upmc.edu	Angus, Derek C/E-9671-2012	Kahn, Jeremy/0000-0001-9688-5576	United States National Institutes of Health [R01HL096651, UL1RR024153, UL1TR000005]; Statistics Collaborative, Inc.; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096651] Funding Source: NIH RePORTER	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Statistics Collaborative, Inc.; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was funded by the United States National Institutes of Health (R01HL096651, UL1RR024153 and UL1TR000005) and Statistics Collaborative, Inc. The National Institutes of Health had no role in the collection, analysis or interpretation of data; in the writing of the manuscript, or in the decision to submit the manuscript for publication. Statistics Collaborative, Inc. provided support in the form of salary for author LAW but had no role in the collection, analysis or interpretation of data; in the writing of the manuscript, or in the decision to submit the manuscript for publication. The specific role of LAW is articulated in the "author contributions" section.	Carson SS, 2007, CHEST, V131, P2, DOI 10.1378/chest.06-2513; Carson SS, 2012, CRIT CARE MED, V40, P1171, DOI 10.1097/CCM.0b013e3182387d43; Coulam R F, 1991, Health Care Financ Rev Annu Suppl, P45; Dehejia RH, 2002, REV ECON STAT, V84, P151, DOI 10.1162/003465302317331982; Dobson A, 2004, THE CLINICAL AND ECO; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Kahn JM, 2015, CRIT CARE MED, V43, P282, DOI 10.1097/CCM.0000000000000710; Kahn JM, 2013, JAMA-J AM MED ASSOC, V309, P719, DOI 10.1001/jama.2013.848; Kahn JM, 2012, MED CARE RES REV, V69, P339, DOI 10.1177/1077558711432889; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; Kahn Jeremy M, 2010, BMC Res Notes, V3, P205, DOI 10.1186/1756-0500-3-205; Kahn JM, 2010, JAMA-J AM MED ASSOC, V303, P2253, DOI 10.1001/jama.2010.761; Kim MM, 2010, ARCH INTERN MED, V170, P369, DOI 10.1001/archinternmed.2009.521; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; Liu K, 2001, HEALTH CARE FINANC R, V23, P1; Long-term care hospital services, 2013, REP C MED PAYM POL; Nelson JE, 2010, AM J RESP CRIT CARE, V182, P446, DOI 10.1164/rccm.201002-0210CI; Pilcher DV, 2005, THORAX, V60, P187, DOI 10.1136/thx.2004.026500; Riley GF, 2009, MED CARE, V47, pS51, DOI 10.1097/MLR.0b013e31819c95aa; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Scheinhorn DJ, 2007, CHEST, V131, P85, DOI 10.1378/chest.06-1081; Schonhofer B, 2002, INTENS CARE MED, V28, P908, DOI 10.1007/s00134-002-1287-5; Thoemmes FJ, 2011, MULTIVAR BEHAV RES, V46, P514, DOI 10.1080/00273171.2011.569395; Wilcox ME, 2013, CRIT CARE MED, V41, P2253, DOI 10.1097/CCM.0b013e318292313a	25	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2015	10	10							e0139742	10.1371/journal.pone.0139742	http://dx.doi.org/10.1371/journal.pone.0139742			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CT0TP	26440102	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000362510300048
J	Wenger, N; Moraud, EM; Gandar, J; Musienko, P; Capogrosso, M; Baud, L; Le Goff, CG; Barraud, Q; Pavlova, N; Dominici, N; Minev, IR; Asboth, L; Hirsch, A; Duis, S; Kreider, J; Mortera, A; Haverbeck, O; Kraus, S; Schmitz, F; DiGiovanna, J; van den Brand, R; Bloch, J; Detemple, P; Lacour, SP; Bezard, E; Micera, S; Courtine, G				Wenger, Nikolaus; Moraud, Eduardo Martin; Gandar, Jerome; Musienko, Pavel; Capogrosso, Marco; Baud, Laetitia; Le Goff, Camille G.; Barraud, Quentin; Pavlova, Natalia; Dominici, Nadia; Minev, Ivan R.; Asboth, Leonie; Hirsch, Arthur; Duis, Simone; Kreider, Julie; Mortera, Andrea; Haverbeck, Oliver; Kraus, Silvio; Schmitz, Felix; DiGiovanna, Jack; van den Brand, Rubia; Bloch, Jocelyne; Detemple, Peter; Lacour, Stephanie P.; Bezard, Erwan; Micera, Silvestro; Courtine, Gregoire			Spatiotemporal neuromodulation therapies engaging muscle synergies improve motor control after spinal cord injury	NATURE MEDICINE			English	Article							EPIDURAL ELECTRICAL-STIMULATION; FUNCTIONAL WALKING; PRIMITIVES; CIRCUITS; LUMBAR; IDENTIFICATION; MODULATION; LOCOMOTION; COMPONENTS; MOVEMENTS	Electrical neuromodulation of lumbar segments improves motor control after spinal cord injury in animal models and humans. However, the physiological principles underlying the effect of this intervention remain poorly understood, which has limited the therapeutic approach to continuous stimulation applied to restricted spinal cord locations. Here we developed stimulation protocols that reproduce the natural dynamics of motoneuron activation during locomotion. For this, we computed the spatiotemporal activation pattern of muscle synergies during locomotion in healthy rats. Computer simulations identified optimal electrode locations to target each synergy through the recruitment of proprioceptive feedback circuits. This framework steered the design of spatially selective spinal implants and real-time control software that modulate extensor and flexor synergies with precise temporal resolution. Spatiotemporal neuromodulation therapies improved gait quality, weight-bearing capacity, endurance and skilled locomotion in several rodent models of spinal cord injury. These new concepts are directly translatable to strategies to improve motor control in humans.	[Wenger, Nikolaus; Gandar, Jerome; Musienko, Pavel; Baud, Laetitia; Le Goff, Camille G.; Barraud, Quentin; Pavlova, Natalia; Dominici, Nadia; Asboth, Leonie; Duis, Simone; Kreider, Julie; van den Brand, Rubia; Courtine, Gregoire] Swiss Fed Inst Technol EPFL, Ctr Neuroprosthet, Int Parapleg Fdn Chair Spinal Cord Repair, Lausanne, Switzerland; [Wenger, Nikolaus; Gandar, Jerome; Musienko, Pavel; Baud, Laetitia; Le Goff, Camille G.; Barraud, Quentin; Pavlova, Natalia; Dominici, Nadia; Asboth, Leonie; Duis, Simone; Kreider, Julie; van den Brand, Rubia; Courtine, Gregoire] Swiss Fed Inst Technol EPFL, Sch Life Sci, Brain Mind Inst, Lausanne, Switzerland; [Wenger, Nikolaus] Charite, Dept Neurol Expt Neurol, D-13353 Berlin, Germany; [Wenger, Nikolaus] Charite, Ctr Stroke Res Berlin, D-13353 Berlin, Germany; [Moraud, Eduardo Martin; Capogrosso, Marco; Mortera, Andrea; DiGiovanna, Jack; Micera, Silvestro] Ecole Polytech Fed Lausanne, Ctr Neuroprosthet, Bertarelli Fdn Chair Translat Neuroengn, CH-1015 Lausanne, Switzerland; [Moraud, Eduardo Martin; Capogrosso, Marco; Mortera, Andrea; DiGiovanna, Jack; Micera, Silvestro] Ecole Polytech Fed Lausanne, Sch Bioengn, Inst Bioengn, CH-1015 Lausanne, Switzerland; [Musienko, Pavel; Pavlova, Natalia] IP Pavlov Physiol Inst, Motor Physiol Lab, St Petersburg 199034, Russia; [Musienko, Pavel] St Petersburg State Univ, Inst Translat Biomed, Lab Neuroprosthet, St Petersburg 199034, Russia; [Musienko, Pavel] Inst Physiopulmonol, Dept Nonpulmonary TB, Childrens Surg & Orthoped Clin, Lab Neurophysiol & Expt Neurorehabil, St Petersburg, Russia; [Capogrosso, Marco; Micera, Silvestro] Scuola Super Sant Anna, BioRobot Inst, Pisa, Italy; [Dominici, Nadia] Vrije Univ Amsterdam, Fac Behav & Movement Sci, MOVE Res Inst Amsterdam, Amsterdam, Netherlands; [Minev, Ivan R.; Hirsch, Arthur; Lacour, Stephanie P.] Ecole Polytech Fed Lausanne, Ctr Neuroprosthet, Bertarelli Fdn Chair Neuroprosthet Technol, CH-1015 Lausanne, Switzerland; [Minev, Ivan R.; Hirsch, Arthur; Lacour, Stephanie P.] Ecole Polytech Fed Lausanne, Inst Bioengn, CH-1015 Lausanne, Switzerland; [Haverbeck, Oliver; Kraus, Silvio] Micromotive GmbH, Mainz, Germany; [Schmitz, Felix; Detemple, Peter] Fraunhofer Inst Chem Technol, Mainz Inst Microtechnol ICT IMM, Mainz, Germany; [Bloch, Jocelyne; Courtine, Gregoire] CHU Vaudois, Lausanne, Switzerland; [Bezard, Erwan] Motac Neurosci Inc, Beijing, Peoples R China; [Bezard, Erwan] Univ Bordeaux, Inst Malad Neurodegenerat, Bordeaux, France; [Bezard, Erwan] CNRS, Inst Malad Neurodegenerat, Bordeaux, France	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Pavlov Institute of Physiology Russian Academy of Sciences; Saint Petersburg State University; St. Petersburg State Research Institute of Phthisiopulmonology; Scuola Superiore Sant'Anna; Vrije Universiteit Amsterdam; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Fraunhofer Gesellschaft; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS)	Courtine, G (corresponding author), Swiss Fed Inst Technol EPFL, Ctr Neuroprosthet, Int Parapleg Fdn Chair Spinal Cord Repair, Lausanne, Switzerland.; Courtine, G (corresponding author), Swiss Fed Inst Technol EPFL, Sch Life Sci, Brain Mind Inst, Lausanne, Switzerland.; Courtine, G (corresponding author), CHU Vaudois, Lausanne, Switzerland.	gregoire.courtine@epfl.ch	Micera, Silvestro/AAD-6630-2021; Minev, Ivan/AAI-6072-2021; Lacour, Stephanie/AAR-2213-2020; Bezard, Erwan/ABD-5153-2021; courtine, gregoire/AAJ-1694-2020; Bloch, Jocelyne/A-9668-2017; Lacour, Stephanie P./E-6375-2010; Musienko, Pavel/L-6677-2015	Minev, Ivan/0000-0003-2055-7386; Lacour, Stephanie/0000-0001-9075-4022; courtine, gregoire/0000-0002-5744-4142; Bloch, Jocelyne/0000-0002-6405-1590; Martin Moraud, Eduardo/0000-0002-6148-7065; Barraud, Quentin/0000-0003-0894-1959; Bezard, Erwan/0000-0002-0410-4638; Dominici, Nadia/0000-0003-2312-915X; Musienko, Pavel/0000-0002-7324-9021; Asboth, Leonie/0000-0003-2414-9574; Capogrosso, Marco/0000-0002-0975-316X	Charite-Universitatsmedizin Berlin; Berlin Institute of Health; European Commission [CP-IP 258654]; European Research Council [ERC 261247]; Russian Science Foundation (RSF) [14-15-00788]; Swiss National Science Foundation Centre of Competence in Research (NCCR) in Robotics; Dynamo project; NanoTera.ch program (SpineRepair); Russian Science Foundation [14-15-00788] Funding Source: Russian Science Foundation	Charite-Universitatsmedizin Berlin; Berlin Institute of Health; European Commission(European CommissionEuropean Commission Joint Research Centre); European Research Council(European Research Council (ERC)European Commission); Russian Science Foundation (RSF)(Russian Science Foundation (RSF)); Swiss National Science Foundation Centre of Competence in Research (NCCR) in Robotics; Dynamo project; NanoTera.ch program (SpineRepair); Russian Science Foundation(Russian Science Foundation (RSF))	We thank people who have helped over the past 6 years to take care of injured animals and to test multiple iterations of neural implants. We also would like to thank D. Pioletti for providing access to the microcomputed tomography scanner. N.W. is a participant in the Charite Clinical Scientist Program funded by the Charite-Universitatsmedizin Berlin and the Berlin Institute of Health. Funding was provided by the European Commission's Seventh Framework Programme (CP-IP 258654, NeuWALK, G.C., S.M., E.B., J.B. and P.D.); a Starting Grant from the European Research Council (ERC 261247, Walk Again, G.C.); the Russian Science Foundation (RSF grant 14-15-00788, P.M.) and the Swiss National Science Foundation Centre of Competence in Research (NCCR) in Robotics (G.C., S.L., S.M.), Dynamo project (S.M.) and NanoTera.ch program (SpineRepair) (G.C., S.L. and S.M.).	Afshar P, 2013, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00117; Angeli CA, 2014, BRAIN, V137, P1394, DOI 10.1093/brain/awu038; Arber S, 2012, NEURON, V74, P975, DOI 10.1016/j.neuron.2012.05.011; Barthelemy D, 2007, J NEUROPHYSIOL, V97, P1986, DOI 10.1152/jn.00818.2006; Berniker M, 2009, P NATL ACAD SCI USA, V106, P7601, DOI 10.1073/pnas.0901512106; Bernstein N.A., 1967, COORDINATION REGULAT; Bizzi E, 2000, NAT REV NEUROSCI, V1, P101, DOI 10.1038/35039000; Borton D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005968; Bourane S, 2015, CELL, V160, P503, DOI 10.1016/j.cell.2015.01.011; Canbay S, 2014, CLIN ANAT, V27, P227, DOI 10.1002/ca.22253; Capaday C, 2002, TRENDS NEUROSCI, V25, P370, DOI 10.1016/S0166-2236(02)02173-2; Capogrosso M, 2013, J NEUROSCI, V33, P19326, DOI 10.1523/JNEUROSCI.1688-13.2013; Cappellini G, 2010, J NEUROPHYSIOL, V104, P3064, DOI 10.1152/jn.00318.2010; Carhart MR, 2004, IEEE T NEUR SYS REH, V12, P32, DOI 10.1109/TNSRE.2003.822763; Clarac F, 2000, TRENDS NEUROSCI, V23, P199, DOI 10.1016/S0166-2236(99)01535-0; Consortium for Addressing Paralysis through Spinal Stimulation Technologies, 2015, FRAM RES STUD EP SPI; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; Danner SM, 2015, BRAIN, V138, P577, DOI 10.1093/brain/awu372; Dominici N, 2011, SCIENCE, V334, P997, DOI 10.1126/science.1210617; Edgerton VR, 2008, BRAIN RES REV, V57, P241, DOI 10.1016/j.brainresrev.2007.09.002; Gad P, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-38; Gerasimenko YP, 2006, J NEUROSCI METH, V157, P253, DOI 10.1016/j.jneumeth.2006.05.004; Gerasimenko YP, 2015, J NEUROTRAUM, V32, P1968, DOI 10.1089/neu.2015.4008; Giszter SF, 2015, CURR OPIN NEUROBIOL, V33, P156, DOI 10.1016/j.conb.2015.04.004; Grillner S, 2009, CURR OPIN NEUROBIOL, V19, P572, DOI 10.1016/j.conb.2009.10.011; Hagglund M, 2013, P NATL ACAD SCI USA, V110, P11589, DOI 10.1073/pnas.1304365110; Hart CB, 2010, J NEUROSCI, V30, P1322, DOI 10.1523/JNEUROSCI.5894-08.2010; Herman R, 2002, SPINAL CORD, V40, P65, DOI 10.1038/sj.sc.3101263; Hofstoetter US, 2015, J NEUROPHYSIOL, V114, P400, DOI 10.1152/jn.00136.2015; Holinski BJ, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/5/056008; Ichiyama RM, 2008, J NEUROSCI, V28, P7370, DOI 10.1523/JNEUROSCI.1881-08.2008; Ivanenko YP, 2003, J NEUROPHYSIOL, V90, P3555, DOI 10.1152/jn.00223.2003; Kargo WJ, 2010, J NEUROPHYSIOL, V103, P573, DOI 10.1152/jn.01054.2007; Kiehn O, 2006, ANNU REV NEUROSCI, V29, P279, DOI 10.1146/annurev.neuro.29.051605.112910; La Scaleia V, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00305; Ladenbauer J, 2010, IEEE T NEUR SYS REH, V18, P637, DOI 10.1109/TNSRE.2010.2054112; Lavrov I, 2008, J NEUROSCI, V28, P6022, DOI 10.1523/JNEUROSCI.0080-08.2008; Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565; Levine AJ, 2014, NAT NEUROSCI, V17, P586, DOI 10.1038/nn.3675; Lozano AM, 2013, NEURON, V77, P406, DOI 10.1016/j.neuron.2013.01.020; Mariani B, 2013, IEEE T BIO-MED ENG, V60, P155, DOI 10.1109/TBME.2012.2227317; Minassian K, 2004, SPINAL CORD, V42, P401, DOI 10.1038/sj.sc.3101615; Rattay F, 2000, SPINAL CORD, V38, P473, DOI 10.1038/sj.sc.3101039; Rejc E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133998; Sayenko DG, 2014, J NEUROPHYSIOL, V111, P1088, DOI 10.1152/jn.00489.2013; Tripodi M, 2011, NATURE, V479, P61, DOI 10.1038/nature10538; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Wenger N, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008325; Yakovenko S, 2002, J NEUROPHYSIOL, V87, P1542, DOI 10.1152/jn.00479.2001; Zeng Fan-Gang, 2008, IEEE Rev Biomed Eng, V1, P115, DOI 10.1109/RBME.2008.2008250	50	181	196	1	79	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2016	22	2					138	145		10.1038/nm.4025	http://dx.doi.org/10.1038/nm.4025			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	DC8JX	26779815	Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000369466800007
J	Bao, W; Tobias, DK; Hu, FB; Chavarro, JE; Zhang, CL				Bao, Wei; Tobias, Deirdre K.; Hu, Frank B.; Chavarro, Jorge E.; Zhang, Cuilin			Pre-pregnancy potato consumption and risk of gestational diabetes mellitus: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; FOOD-CONSUMPTION; DIETARY PATTERNS; GLYCEMIC INDEX; LIFE-STYLE; GLUCOSE; REPRODUCIBILITY; QUESTIONNAIRE; REGRESSION; PREGNANCY	STUDY QUESTION What is the association between potato consumption before pregnancy and the risk of gestational diabetes mellitus (GDM)? METHODS This prospective cohort study included 15 632 women from the Nurses' Health Study II (1991-2001). They had no previous GDM or chronic diseases before pregnancy. Consumption of potatoes and other foods was assessed every four years. Incident first time GDM was ascertained from self reports of a physician diagnosis of GDM, which was previously validated by medical records. STUDY ANSWER AND LIMITATIONS Over the 10 year follow-up there were 854 incident cases of GDM among 21 693 singleton pregnancies. After adjustment for age, parity, and dietary and non-dietary factors, women who consumed more potatoes before pregnancy had higher rates of developing GDM. Substitution of two servings a week of total potatoes with other vegetables, legumes, and whole grain foods was significantly associated with a 9-12% lower risk of GDM. Consumption and diabetes were self reported, and severity of diabetes was unknown. More than 90% of women were white. A causal association cannot be assumed.	[Bao, Wei; Zhang, Cuilin] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Intramural Populat Hlth Res, NIH, Rockville, MD 20852 USA; [Tobias, Deirdre K.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; [Tobias, Deirdre K.; Hu, Frank B.; Chavarro, Jorge E.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Tobias, Deirdre K.; Hu, Frank B.; Chavarro, Jorge E.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Hu, Frank B.; Chavarro, Jorge E.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Hu, Frank B.; Chavarro, Jorge E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Zhang, CL (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Intramural Populat Hlth Res, NIH, Rockville, MD 20852 USA.	zhangcu@mail.nih.gov	Chavarro, Jorge E/AAE-5665-2021; Bao, Wei/AAG-2431-2019	Chavarro, Jorge E/0000-0002-4436-9630; Bao, Wei/0000-0002-7301-5786; Zhang, Cuilin/0000-0002-8014-2708	Intramural Research Program of Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health [HHSN275201000020C]; National Institutes of Health [DK58845, CA50385, P30 DK46200, UM1 CA176726]; American Diabetes Association [7-12-MN-34]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008889] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [UM1CA176726, R01CA050385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK103720, P30DK046200, R01DK058845] Funding Source: NIH RePORTER	Intramural Research Program of Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (contract No HHSN275201000020C). The Nurses' Health Study II was funded by research grants DK58845, CA50385, P30 DK46200, and UM1 CA176726 from the National Institutes of Health. DKT and FBH were supported by a mentored fellowship from the American Diabetes Association (No 7-12-MN-34).	American Diabetes Association, 2004, DIABETES CARE, V27, pS88, DOI [DOI 10.2337/DIACARE.27.2007.S88, 10.2337/diacare.27.2007.S88]; Bao W, 2014, AM J CLIN NUTR, V99, P1378, DOI 10.3945/ajcn.113.082966; Bao W, 2013, DIABETES CARE, V36, P2001, DOI 10.2337/dc12-2018; Cahill LE, 2014, AM J CLIN NUTR, V100, P667, DOI 10.3945/ajcn.114.084129; Cai WJ, 2012, P NATL ACAD SCI USA, V109, P15888, DOI 10.1073/pnas.1205847109; Camire ME, 2009, CRIT REV FOOD SCI, V49, P823, DOI 10.1080/10408390903041996; Center for Nutrition Policy and Promotion, 2010, DIET GUID AM; Ceriello A, 2008, DIABETES, V57, P1349, DOI 10.2337/db08-0063; Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222; Colditz GA, 2005, NAT REV CANCER, V5, P388, DOI 10.1038/nrc1608; Ferrara A, 2002, DIABETES CARE, V25, P1625, DOI 10.2337/diacare.25.9.1625; Forbes GB, 1999, AM J CLIN NUTR, V69, P572; Freedman MR., 2012, J NUTR THER, V1, P1, DOI [DOI 10.6000/1929-5634.2012.01.01.1, 10.6000/1929-5634.2012.01.01.1]; Goldberg T, 2004, J AM DIET ASSOC, V104, P1287, DOI 10.1016/j.jada.2004.05.214; Guallar-Castillon P, 2007, AM J CLIN NUTR, V86, P198, DOI 10.1093/ajcn/86.1.198; Guallar-Castillon P, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e363; Halton TL, 2006, AM J CLIN NUTR, V83, P284; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; HARRIS M, 1979, DIABETES, V28, P1039; Hodge AM, 2004, DIABETES CARE, V27, P2701, DOI 10.2337/diacare.27.11.2701; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; King JC, 2013, ADV NUTR, V4, p393S, DOI 10.3945/an.112.003525; Liu SM, 2004, DIABETES CARE, V27, P2993, DOI 10.2337/diacare.27.12.2993; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; McGill CR, 2013, ANN MED, V45, P467, DOI 10.3109/07853890.2013.813633; Metzger BE, 2008, NEW ENGL J MED, V358, P1991, DOI 10.1056/NEJMoa0707943; Montonen J, 2005, EUR J CLIN NUTR, V59, P441, DOI 10.1038/sj.ejcn.1602094; Mozaffarian D, 2011, NEW ENGL J MED, V364, P2392, DOI 10.1056/NEJMoa1014296; Pan A, 2012, ARCH INTERN MED, V172, P555, DOI 10.1001/archinternmed.2011.2287; Pokorn Jan, 2003, Forum Nutr, V56, P348; Qi QB, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1610; Reece EA, 2009, LANCET, V373, P1789, DOI 10.1016/S0140-6736(09)60515-8; Riccardi G, 2008, AM J CLIN NUTR, V87, p269S, DOI 10.1093/ajcn/87.1.269S; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; Schoenaker DAJM, 2015, DIABETOLOGIA, V58, P2726, DOI 10.1007/s00125-015-3742-1; Scholl TO, 2004, AM J EPIDEMIOL, V159, P467, DOI 10.1093/aje/kwh068; Solomon CG, 1997, JAMA-J AM MED ASSOC, V278, P1078, DOI 10.1001/jama.278.13.1078; Tieu J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006674.pub2; Tobias DK, 2012, AM J CLIN NUTR, V96, P289, DOI 10.3945/ajcn.111.028266; UK National Health Service, EATW PLAT; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; Willett W, 2002, AM J CLIN NUTR, V76, p274S, DOI 10.1093/ajcn/76.1.274S; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; Willett WC, 1998, AM J CLIN NUTR, V68, P218, DOI 10.1093/ajcn/68.2.218; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; Ylonen SK, 2007, DIABETIC MED, V24, P1049, DOI 10.1111/j.1464-5491.2007.02206.x; Zhang CL, 2006, DIABETES CARE, V29, P2223, DOI 10.2337/dc06-0266; Zhang CL, 2011, AM J CLIN NUTR, V94, p1975S, DOI 10.3945/ajcn.110.001032; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	51	36	41	1	40	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 12	2016	352								h6898	10.1136/bmj.h6898	http://dx.doi.org/10.1136/bmj.h6898			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2YB	26759275	hybrid, Green Published			2023-01-03	WOS:000368375500001
J	De Hert, M; Van Bos, L; Sweers, K; Wampers, M; De Lepeleire, J; Correll, CU				De Hert, Marc; Van Bos, Liesbet; Sweers, Kim; Wampers, Martien; De Lepeleire, Jan; Correll, Christophe U.			Attitudes of Psychiatric Nurses about the Request for Euthanasia on the Basis of Unbearable Mental Suffering(UMS)	PLOS ONE			English	Article							PHYSICIAN-ASSISTED SUICIDE; PALLIATIVE CARE; INVOLVEMENT	Introduction When psychiatric patients express a wish for euthanasia, this should first and foremost be interpreted as a cry for help. Due to their close day-to-day relationship, psychiatric nurses may play an important and central role in responding to such requests. However, little is known about nurses' attitudes towards euthanasia motivated by unbearable mental suffering. Objectives The aim of this study was to provide insight into the attitudes and actions taken by psychiatric nurses when confronted with a patient's euthanasia request based on unbearable mental suffering (UMS). Method A questionnaire was sent to 11 psychiatric hospitals in the Flemish part of Belgium. Results The overall response rate was 70% (N = 627). Psychiatric nurses were frequently confronted with a request for euthanasia, either directly (N = 329, 53%) or through a colleague (N = 427, 69%). A majority (N = 536, 84%) did not object to euthanasia in a psychiatrically ill population with UMS. Confounding factors were the psychiatric diagnosis and the type of ward where the nurses were working. Most participants acknowledged a lack of knowledge and skills to adequately address the euthanasia request (N = 434, 71%). Nearly unanimously (N = 618, 99%), study participants indicated that dealing with euthanasia requests and other end-of-life issues should be part of the formal training of nurses. Conclusion The results highlight the need for ethically sound and comprehensive provision of care. Psychiatric nurses play an important role in dealing with the complex issue of requests for euthanasia. There is also a need for education, training and clear guidelines on the level of health care organizations.	[De Hert, Marc; Van Bos, Liesbet; Sweers, Kim; Wampers, Martien; De Lepeleire, Jan] Katholieke Univ Leuven, Dept Neurosci, Univ Psychiat Ctr Z Org, Leuven, Belgium; [De Lepeleire, Jan] Acad Ctr Gen Practice, Leuven, Belgium; [De Lepeleire, Jan] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Kortenberg, Belgium; [Correll, Christophe U.] Zucker Hillside Hosp, Glen Oaks, NY USA	KU Leuven; KU Leuven; Northwell Health	Sweers, K (corresponding author), Katholieke Univ Leuven, Dept Neurosci, Univ Psychiat Ctr Z Org, Leuven, Belgium.	kim.sweers@upckuleuven.be	Correll, Christoph/D-3530-2011; Correll, Christoph U/AAY-3179-2021; De Lepeleire, Jan/AAE-5876-2019; De Hert, Marc/AAH-6090-2021	Correll, Christoph/0000-0002-7254-5646; De Lepeleire, Jan/0000-0001-6152-2134; De Hert, Marc/0000-0003-4255-5920				Berghmans R, 2013, INT J LAW PSYCHIAT, V36, P436, DOI 10.1016/j.ijlp.2013.06.020; Bernheim J, 2012, TIJDSCHR GENEESK, V68, P549; Brzostek T, 2008, NURS ETHICS, V15, P761, DOI 10.1177/0969733008095386; de Casterle BD, 2006, J MED ETHICS, V32, P187, DOI 10.1136/jme.2005.011783; De Hert M, 2012, NEURON, V17, P4; De Hert M, 2011, WORLD PSYCHIATRY, V10, P52, DOI 10.1002/j.2051-5545.2011.tb00014.x; De Lepeleire J, 2013, LEUVEN LEUVEN METAFO, P1; de Scheur GGV, 2008, J MED ETHICS, V34, P254, DOI 10.1136/jme.2006.018507; Denier Y, 2009, J PALLIAT CARE, V25, P264, DOI 10.1177/082585970902500404; Distelmans W, 2012, LEDEREEN HEEFT RECHT, P1; Finoulst M, 2013, INTERVIEW VANLOON TH, P32; Gielen J, 2009, INT J PALLIAT NURS, V15, P488, DOI 10.12968/ijpn.2009.15.10.44886; Goethals S, 2010, INT J NURS STUD, V47, P635, DOI 10.1016/j.ijnurstu.2009.12.010; Haarhuis JM, 2007, ONDERWIJS GEZONDHEID, V31, P236; Inghelbrecht E, 2010, CAN MED ASSOC J, V182, P905, DOI 10.1503/cmaj.091881; Inghelbrecht E, 2009, INT J NURS STUD, V46, P1209, DOI 10.1016/j.ijnurstu.2009.02.009; Janssen W, 2012, BUNNIK AGORA ONDERST, P1; Klimkiewicz A, 2015, PSYCHIATR POL, V49, P277, DOI 10.12740/PP/26071; Lynn J, 2003, RAND HLTH, P1; Macdonald E, 2009, EASEFUL DEATH IS THE, P1; Milders C F A, 2011, Tijdschr Psychiatr, V53, P415; Quaghebeur T, 2009, NURS ETHICS, V16, P466, DOI 10.1177/0969733009104610; Ruissen A, 2011, Tijdschr Psychiatr, V53, P405; Schotsmans P, 2009, CAMB Q HEALTHC ETHIC, V18, P420, DOI 10.1017/S0963180109090616; Sweers K, 2011, PSYCHIAT VERPLEGING, V87, P156; Sweers K, 2013, ARCH PSYCHIAT NURS, V27, P246, DOI 10.1016/j.apnu.2013.05.003; Thienpont L, 2011, UITGEGEVEN VZW VONKE, P1; Thienpont L, 2012, GOEDE DOOD 2002 2012, P191; Tholen AJ, 2009, RICHTLIJN OMGAAN MET, P1; Vandenberghe J, 2013, 11 KU LEUV MET, P1; Vandenberghe J, 2012, EUTHANASIE PSYCHIAT; Wasserman J, 2005, OMEGA-J DEATH DYING, V51, P229, DOI 10.2190/FGHE-YXHX-QJEA-MTM0	32	23	23	1	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0144749	10.1371/journal.pone.0144749	http://dx.doi.org/10.1371/journal.pone.0144749			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CZ4SI	26700007	Green Submitted, Green Published, gold			2023-01-03	WOS:000367092600030
J	Dobbins, GC; Ugai, H; Curiel, DT; Gillespie, GY				Dobbins, G. Clement; Ugai, Hideyo; Curiel, David T.; Gillespie, G. Yancey			A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents	PLOS ONE			English	Article							GENE-TRANSFER EFFICIENCY; MALIGNANT GLIOMA; OVARIAN-CANCER; IN-VIVO; CELLS; PROTEIN; VIROTHERAPY; GENERATION; INFECTION; RECEPTOR	Studies have demonstrated that oncolytic adenoviruses based on a 24 base pair deletion in the viral E1A gene (D24) may be promising therapeutics for treating a number of cancer types. In order to increase the therapeutic potential of these oncolytic viruses, a novel conditionally replicating adenovirus targeting multiple receptors upregulated on tumors was generated by incorporating an Ad5/3 fiber with a carboxyl terminus RGD ligand. The virus displayed full cytopathic effect in all tumor lines assayed at low titers with improved cytotoxicity over Ad5-RGD D24, Ad5/3 D24 and an HSV oncolytic virus. The virus was then engineered to deliver immunotherapeutic agents such as GM-CSF while maintaining enhanced heterogenic oncolysis.	[Dobbins, G. Clement] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA; [Dobbins, G. Clement; Gillespie, G. Yancey] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA; [Ugai, Hideyo] Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO USA; [Curiel, David T.] Washington Univ, Sch Med, Dept Radiat Oncol, Biol Therapeut Ctr, St Louis, MO USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); Washington University (WUSTL)	Dobbins, GC (corresponding author), Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA.	gclemd@uab.edu; yancey@uab.edu	Ugai, Hideyo/K-4920-2017	Ugai, Hideyo/0000-0002-9121-8480; Gillespie, George/0000-0001-6436-9542	National Institutes of Health [T32-NS048039]; American Cancer Society [PF-12-143-01-CCE]; Susan G. Komen for the Cure [KG100194]; UAB/UMN SPORE in Pancreatic Cancer [5P50 CA101955-07]; UAB Brain Tumor SPORE [5P20 CA151129-03, P01 CA071933]; NATIONAL CANCER INSTITUTE [P50CA101955, P01CA071933, P20CA151129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS048039] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Susan G. Komen for the Cure(Susan G. Komen Breast Cancer Foundation); UAB/UMN SPORE in Pancreatic Cancer; UAB Brain Tumor SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the following grants: T32-NS048039 from the National Institutes of Health and PF-12-143-01-CCE from the American Cancer Society (G.C.D); Susan G. Komen for the Cure KG100194 (D.T.C., H.U.); UAB/UMN SPORE in Pancreatic Cancer 5P50 CA101955-07 (D.T.C.); UAB Brain Tumor SPORE 5P20 CA151129-03 (G.Y.G.) and P01 CA071933 (G.Y.G.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arellano M, 2008, BIOL-TARGETS THER, V2, P13; Bauerschmitz GJ, 2002, INT J ONCOL, V21, P1161; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fukuda K, 2003, CANCER RES, V63, P4434; Gill BJ, 2014, P NATL ACAD SCI USA, V111, P12550, DOI 10.1073/pnas.1405839111; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Horwitz MS, 2004, J GENE MED, V6, pS172, DOI 10.1002/jgm.495; Jiang H, 2011, J VIROL, V85, P4720, DOI 10.1128/JVI.02032-10; Kanerva A, 2002, CLIN CANCER RES, V8, P275; Kim KH, 2011, HUM GENE THER, V22, P821, DOI 10.1089/hum.2010.180; Kimball KJ, 2010, CLIN CANCER RES, V16, P5277, DOI 10.1158/1078-0432.CCR-10-0791; Kimball KJ, 2009, MOL IMAGING, V8, P264, DOI 10.2310/7290.2009.00025; Koski A, 2015, MOL THER, V23, P1641, DOI 10.1038/mt.2015.125; Koski A, 2010, MOL THER, V18, P1874, DOI 10.1038/mt.2010.161; Krasnykh VN, 1996, J VIROL, V70, P6839, DOI 10.1128/JVI.70.10.6839-6846.1996; Lenaerts L, 2008, REV MED VIROL, V18, P357, DOI 10.1002/rmv.589; Li EG, 1998, J VIROL, V72, P2055, DOI 10.1128/JVI.72.3.2055-2061.1998; Liu YP, 2014, GYNECOL ONCOL, V132, P722, DOI 10.1016/j.ygyno.2014.01.009; Lu ZZ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003718; MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Megison ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086843; Meulenbroek RA, 2004, MOL THER, V9, P617, DOI 10.1016/j.ymthe.2004.01.012; Miller CR, 1998, CANCER RES, V58, P5738; Parker JN, 2000, P NATL ACAD SCI USA, V97, P2208, DOI 10.1073/pnas.040557897; Pesonen S, 2011, MOL PHARMACEUT, V8, P12, DOI 10.1021/mp100219n; Pol J, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28694; Rein Daniel T, 2006, Future Oncol, V2, P137, DOI 10.2217/14796694.2.1.137; Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287; Sauthoff H, 2004, MOL THER, V10, P749, DOI 10.1016/j.ymthe.2004.07.014; Senzer NN, 2009, J CLIN ONCOL, V27, P5763, DOI 10.1200/JCO.2009.24.3675; Soria C, 2010, NATURE, V466, P1076, DOI 10.1038/nature09307; Suzuki K, 2001, CLIN CANCER RES, V7, P120; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Tyler MA, 2006, MOL CANCER THER, V5, P2408, DOI 10.1158/1535-7163.MCT-06-0187; Ugai H, 2005, BIOCHEM BIOPH RES CO, V331, P1053, DOI 10.1016/j.bbrc.2005.03.227; Ugai H, 2007, J MOL BIOL, V366, P1142, DOI 10.1016/j.jmb.2006.11.090; Ugai H, 2010, J MOL BIOL, V395, P55, DOI 10.1016/j.jmb.2009.10.034; Ulasov IV, 2007, J NEUROSURG, V107, P617, DOI 10.3171/JNS-07/09/0617; Volk AL, 2003, CANCER BIOL THER, V2, P511, DOI 10.4161/cbt.2.5.440; Wang HJ, 2011, NAT MED, V17, P96, DOI 10.1038/nm.2270; Young AM, 2012, MOL THER, V20, P1676, DOI 10.1038/mt.2012.116; Zheng CY, 2000, NAT BIOTECHNOL, V18, P176, DOI 10.1038/72628; Zhu ZB, 2007, INT J ONCOL, V31, P1213	48	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2015	10	12							e0145272	10.1371/journal.pone.0145272	http://dx.doi.org/10.1371/journal.pone.0145272			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SF	26689910	Green Published, gold, Green Submitted			2023-01-03	WOS:000367092300052
J	Wang, DC; Shanina, I; Toyofuku, WM; Horwitz, MS; Scott, MD				Wang, Duncheng; Shanina, Iryna; Toyofuku, Wendy M.; Horwitz, Marc S.; Scott, Mark D.			Inhibition of Autoimmune Diabetes in NOD Mice by miRNA Therapy	PLOS ONE			English	Article							REGULATORY T-CELLS; METHOXYPOLY(ETHYLENE GLYCOL); ISLET TRANSPLANTATION; DENDRITIC CELLS; TH17 CELLS; IMMUNOCAMOUFLAGE; PREVENTION; INDUCTION; RECOGNITION; EFFICACY	Autoimmune destruction of the pancreatic islets in Type 1 diabetes is mediated by both increased proinflammatory (Teff) and decreased regulatory (Treg) T lymphocytes resulting in a significant decrease in the Treg: Teff ratio. The non-obese diabetic (NOD) mouse is an excellent in vivo model for testing potential therapeutics for attenuating the decrease in the Treg: Teff ratio and inhibiting disease pathogenesis. Here we show for the first time that a bioreactor manufactured therapeutic consisting of a complex of miRNA species (denoted as TA1) can effectively reset the NOD immune system from a proinflammatory to a tolerogenic state thus preventing or delaying autoimmune diabetes. Treatment of NOD mice with TA1 resulted in a systemic broad-spectrum upregulation of tolerogenic T cell subsets with a parallel downregulation of Teff subsets yielding a dramatic increase in the Treg: Teff ratio. Moreover, the murine-derived TA1 was highly effective in the inhibition of allorecognition of HLA-disparate human PBMC. TA1 demonstrated dose-responsiveness and exhibited equivalent or better inhibition of allorecognition driven proliferation than etanercept (a soluble TNF receptor). These findings demonstrate that miRNA-based therapeutics can effectively attenuate or arrest autoimmune disease processes and may be of significant utility in a broad range of autoimmune diseases including Type 1 diabetes.	[Wang, Duncheng; Toyofuku, Wendy M.; Scott, Mark D.] Canadian Blood Serv, Ctr Innovat, Ottawa, ON, Canada; [Wang, Duncheng; Toyofuku, Wendy M.; Scott, Mark D.] Univ British Columbia, Ctr Blood Res, Vancouver, BC V5Z 1M9, Canada; [Shanina, Iryna; Horwitz, Marc S.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V5Z 1M9, Canada; [Scott, Mark D.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	Canadian Blood Services; University of British Columbia; University of British Columbia; University of British Columbia	Scott, MD (corresponding author), Canadian Blood Serv, Ctr Innovat, Ottawa, ON, Canada.	mdscott@mail.ubc.ca		Wang, Duncheng/0000-0002-2085-9512	Canadian Institutes of Health Research [123317]; Canadian Blood Services; Health Canada; Canada Foundation for Innovation; Michael Smith Foundation for Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Blood Services; Health Canada; Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research)	This work was supported by grants from the Canadian Institutes of Health Research (Grant No. 123317; MDS), Canadian Blood Services (MDS) and Health Canada (MDS). The views expressed herein do not necessarily represent the view of the federal government of Canada. We thank the Canada Foundation for Innovation and the Michael Smith Foundation for Health Research for infrastructure funding at the University of British Columbia Centre for Blood Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146/annurev.immunol.23.021704.115643; Atkinson MA, 1999, NAT MED, V5, P601, DOI 10.1038/9442; Balasa B, 1997, J IMMUNOL, V159, P4620; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Bhardwaj Arun, 2010, Mol Cell Pharmacol, V2, P213; Braicu C, 2013, CURR MED CHEM; Chen AM, 2003, J BIOMED MATER RES A, V67A, P626, DOI 10.1002/jbm.a.10146; Chen AM, 2001, BIODRUGS, V15, P833, DOI 10.2165/00063030-200115120-00005; Chen AM, 2006, ARTIF CELL BLOOD SUB, V34, P305, DOI 10.1080/10731190600683845; Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990; Cortes JR, 2014, J AUTOIMMUN, V55, P51, DOI 10.1016/j.jaut.2014.05.007; Creusot RJ, 2010, MOL THER, V18, P2112, DOI 10.1038/mt.2010.146; D'Alise AM, 2008, P NATL ACAD SCI USA, V105, P19857, DOI 10.1073/pnas.0810713105; Feuerer M, 2009, IMMUNITY, V31, P654, DOI 10.1016/j.immuni.2009.08.023; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gaudreau S, 2007, J IMMUNOL, V179, P3638, DOI 10.4049/jimmunol.179.6.3638; Gregori S, 2003, J IMMUNOL, V171, P4040, DOI 10.4049/jimmunol.171.8.4040; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Guay C, 2011, TRANSL RES, V157, P253, DOI 10.1016/j.trsl.2011.01.009; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Korn T, 2007, SEMIN IMMUNOL, V19, P362, DOI 10.1016/j.smim.2007.10.007; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Korn T, 2008, P NATL ACAD SCI USA, V105, P18460, DOI 10.1073/pnas.0809850105; Kriegel MA, 2012, P NATL ACAD SCI USA, V109, P3457, DOI 10.1073/pnas.1115308109; Kyluik-Price DL, 2014, BIOMATERIALS, V35, P412, DOI 10.1016/j.biomaterials.2013.09.016; Le Y, 2010, ACTA BIOMATER, V6, P2631, DOI 10.1016/j.actbio.2010.01.031; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lin MS, 2011, IMMUNOL RES, V50, P213, DOI 10.1007/s12026-011-8215-0; Lindley S, 2005, DIABETES, V54, P92, DOI 10.2337/diabetes.54.1.92; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Luo XR, 2010, IMMUNITY, V32, P488, DOI 10.1016/j.immuni.2010.04.002; MONTANA E, 1993, J CLIN INVEST, V91, P780, DOI 10.1172/JCI116297; Murad KL, 1999, BLOOD, V94, P2135; Nielsen LB, 2012, EXP DIABETES RES, V2012, DOI DOI 10.1155/2012/896362; Nishio J, 2010, J EXP MED, V207, P1879, DOI 10.1084/jem.20100205; Noorchashm H, 1997, DIABETOLOGIA, V40, pB50, DOI 10.1007/BF03168187; Richer MJ, 2008, DIABETES, V57, P1302, DOI 10.2337/db07-1460; Richer MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031153; Ryan EA, 2001, DIABETES, V50, P710, DOI 10.2337/diabetes.50.4.710; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Shen EX, 2011, CELL BIOL INT, V35, P705, DOI 10.1042/CBI20100528; Tang XY, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/345347; Thayer TC, 2010, ENDOCRIN METAB CLIN, V39, P541, DOI 10.1016/j.ecl.2010.05.001; Thomas David, 2005, Rev Diabet Stud, V2, P9, DOI 10.1900/RDS.2005.2.9; Tritt M, 2008, DIABETES, V57, P113, DOI 10.2337/db06-1700; Wang DC, 2012, BIOMATERIALS, V33, P3002, DOI 10.1016/j.biomaterials.2011.12.041; Wang DC, 2011, BIOMATERIALS, V32, P9494, DOI 10.1016/j.biomaterials.2011.08.061; Wei B, 2010, CELL MOL IMMUNOL, V7, P175, DOI 10.1038/cmi.2010.19; Yang H, 2012, TRANSPLANTATION, V93, P580, DOI 10.1097/TP.0b013e318244dd67; You S, 2005, DIABETES, V54, P1415, DOI 10.2337/diabetes.54.5.1415	53	7	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2015	10	12							e0145179	10.1371/journal.pone.0145179	http://dx.doi.org/10.1371/journal.pone.0145179			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9JH	26674203	Green Published, gold, Green Submitted			2023-01-03	WOS:000366722700111
J	Zhang, Y; Zou, W; Zhang, YH; Ye, WM; Chen, XD; Liu, Q; Liu, HD; Si, CF; Jia, HY				Zhang, Yuan; Zou, Wen; Zhang, Yinghui; Ye, Weimin; Chen, Xingdong; Liu, Qian; Liu, Huandi; Si, Chunfeng; Jia, Hongying			Reducing Antibiotic Use for Young Children with Intussusception following Successful Air Enema Reduction	PLOS ONE			English	Article							MANAGEMENT; DIAGNOSIS	China introduced a new policy regarding the management of antibiotic use. We evaluated the reasonableness of antibiotic use among children suffering from intussusception before and after policy. A retrospective study was conducted involving 234 young children with intussusception who were treated between January 1, 2011 and December 30, 2013. Demographics and detailed antibiotics regimens were collected. chi(2) test was used to evaluate differences between the phase I (preintervention, n = 68) and phase II (postintervention, n = 166). We determined that the overall antibiotic use rate following successful air enema reduction was 41% (97/234), which decreased from 99% (67/68) in phase I to 18% (30/166) in phase II. In phase I, prophylactic antibiotic usage reached up to 84% (56/67). The quantity of aztreonam for injection accounted for 63% (45/71), and cefamandole nafate for injection accounted for 25% (18/71). In phases II, prophylactic antibiotic usage were reduced to 13% (4/30). The quantity of aztreonam for injection was decreased to 12% (4/33) and cefamandole nafate for injection was 3% (1/33). Antibiotics' options were more diverse. In conclusion, policy intervention was effective in addressing some aspects of antibacterial drug usage among young children with intussusception. However, excessive drug use remains a public health problem. The guidelines for the antibiotic management of intussusception for children must be established in China.	[Zhang, Yuan; Jia, Hongying] Shandong Univ, Hosp 2, Ctr Evidence Based Med, Jinan 250100, Shandong, Peoples R China; [Zou, Wen] Shandong Univ, Hosp 2, Dept Pharm, Jinan 250100, Shandong, Peoples R China; [Zhang, Yinghui] Shandong Univ, Hosp 2, Dept Med Records, Jinan 250100, Shandong, Peoples R China; [Ye, Weimin; Chen, Xingdong] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Liu, Qian] Shandong Univ, Hosp 2, Dept Pediat Surg, Jinan 250100, Shandong, Peoples R China; [Liu, Huandi; Si, Chunfeng] Shandong Univ, Hosp 2, Informat Ctr, Jinan 250100, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Karolinska Institutet; Shandong University; Shandong University	Jia, HY (corresponding author), Shandong Univ, Hosp 2, Ctr Evidence Based Med, Jinan 250100, Shandong, Peoples R China.	jiahongying@sdu.edu.cn	zhang, ying/HJB-1230-2022	ye, weimin/0000-0002-6859-4648	Youth Fund of the 2nd Hospital of Shandong University [Y2013010071]	Youth Fund of the 2nd Hospital of Shandong University	The study was supported by Youth Fund of the 2nd Hospital of Shandong University (Y2013010071). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Tokhais T, 2012, J PEDIATR SURG, V47, P928, DOI 10.1016/j.jpedsurg.2012.01.050; [Anonymous], 2011, NOTICE SPECIAL RECTI; Arnold G, 2012, PEDIAT SURG, P1069; del-Pozo G, 1999, RADIOGRAPHICS, V19, P299, DOI 10.1148/radiographics.19.2.g99mr14299; Guidos RJ, 2011, CLIN INFECT DIS, V52, pS397, DOI 10.1093/cid/cir153; Ito Y, 2012, PEDIATR INT, V54, P948, DOI 10.1111/j.1442-200X.2012.03622_1.x; LEBEL MH, 1988, PEDIATR INFECT DIS J, V7, P331, DOI 10.1097/00006454-198805000-00009; Lochhead A, 2013, CLIN PEDIATR, V52, P1029, DOI 10.1177/0009922813506255; Mandeville K, 2012, PEDIATR EMERG CARE, V28, P842, DOI 10.1097/PEC.0b013e318267a75e; Ministry of Health C, 2004, GUID CLIN US ANT; Pepper VK, 2012, SURG CLIN N AM, V92, P505, DOI 10.1016/j.suc.2012.03.011; Somekh E, 1996, RADIOLOGY, V200, P217, DOI 10.1148/radiology.200.1.8657914; Waseem M, 2008, PEDIATR EMERG CARE, V24, P793, DOI 10.1097/PEC.0b013e31818c2a3e; Weckx L, 2012, BRAZ J OTORHINOLAR, V78, P2, DOI 10.1590/S1808-86942012000200001	14	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2015	10	11							e0142999	10.1371/journal.pone.0142999	http://dx.doi.org/10.1371/journal.pone.0142999			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW5XP	26569111	gold, Green Submitted, Green Published			2023-01-03	WOS:000365070700113
J	Park, H; Imoto, S; Miyano, S				Park, Heewon; Imoto, Seiya; Miyano, Satoru			Recursive Random Lasso (RRLasso) for Identifying Anti-Cancer Drug Targets	PLOS ONE			English	Article							HUMAN BREAST-CANCER; LUNG-CANCER; GASTRIC-CANCER; EXPRESSION; GENE; PROLIFERATION; INVASION; MARKER; GROWTH; CELLS	Uncovering driver genes is crucial for understanding heterogeneity in cancer. L-1-type regularization approaches have been widely used for uncovering cancer driver genes based on genome-scale data. Although the existing methods have been widely applied in the field of bioinformatics, they possess several drawbacks: subset size limitations, erroneous estimation results, multicollinearity, and heavy time consumption. We introduce a novel statistical strategy, called a Recursive Random Lasso (RRLasso), for high dimensional genomic data analysis and investigation of driver genes. For time-effective analysis, we consider a recursive bootstrap procedure in line with the random lasso. Furthermore, we introduce a parametric statistical test for driver gene selection based on bootstrap regression modeling results. The proposed RRLasso is not only rapid but performs well for high dimensional genomic data analysis. Monte Carlo simulations and analysis of the "Sanger Genomics of Drug Sensitivity in Cancer dataset from the Cancer Genome Project" show that the proposed RRLasso is an effective tool for high dimensional genomic data analysis. The proposed methods provide reliable and biologically relevant results for cancer driver gene selection.	[Park, Heewon; Imoto, Seiya; Miyano, Satoru] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan	University of Tokyo	Park, H (corresponding author), Yamaguchi Univ, Fac Global & Sci Studies, Yamaguchi, Yamaguchi, Japan.	hwpark@yamaguchi-u.ac.jp		Miyano, Satoru/0000-0002-1753-6616	RIKEN Advanced Institute for Computational Science through the HPCI System Research project [hp140230]	RIKEN Advanced Institute for Computational Science through the HPCI System Research project	This research used computational resources of the K computer provided by the RIKEN Advanced Institute for Computational Science through the HPCI System Research project (Project ID:hp140230) and the Super Computer System, Human Genome Center, Institute of Medical Science, University of Tokyo. The authors would like to thank the associate editor and anonymous reviewers for the constructive and valuable comments that improved the quality of the paper.	Abou-Sharieha Samah, 2009, Chinese Journal of Clinical Oncology, V6, P1, DOI 10.1007/s11805-009-0001-6; Akino K, 2007, CANCER SCI, V98, P88, DOI 10.1111/j.1349-7006.2006.00351.x; Amaia G, 2007, DRUG DISCOVERY TECHN; Berlato C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2838; Bhushan L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022484; Bilecova-Rabajdova M, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/156034; Buess M, 2004, NEOPLASIA, V6, P813, DOI 10.1593/neo.04307; Chan CWM, 2009, P NATL ACAD SCI USA, V106, P1936, DOI 10.1073/pnas.0812904106; Chen QR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105393; Chen YL, 2013, BIOCHEM BIOPH RES CO, V442, P56, DOI 10.1016/j.bbrc.2013.10.165; Chen YZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091104; Chiang S. F., 2014, SURG SCI, V5, P418, DOI DOI 10.4236/SS.2014.510067; Cho H, 2014, ONCOTARGET, V5, P3482, DOI 10.18632/oncotarget.1947; Chorawala MR, 2012, INT J PHARM SCI DRUG, V4, P1, DOI DOI 10.7243/2050-120x-1-1; Chung FH, INTEGRATION NETWORK; Coghlin C, 2006, J PATHOL, V210, P351, DOI 10.1002/path.2056; Colombo J, 2013, BIOL PROCED ONLINE, V15, DOI 10.1186/1480-9222-15-10; Drayton RM, 2014, CLIN CANCER RES, V20, P1990, DOI 10.1158/1078-0432.CCR-13-2805; Dupouy S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004223; Edwards YJK, 2011, PLOS ONE, V8; Frezza C, 2014, GAUDE FREZZA CANC ME, V2; Gemma A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-174; HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634; Huang HC, 2010, TECHNOL CANCER RES T, V9, P219, DOI 10.1177/153303461000900301; Iwao-Koizumi K, 2005, J CLIN ONCOL, V23, P422, DOI 10.1200/JCO.2005.09.078; Jarzab M, 2005, BREAST CANCER RES, V7; Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568; Kashiwagi K, 2012, PATHOL INT, V62, P232, DOI 10.1111/j.1440-1827.2011.02781.x; Kato M, 2012, CANCER SCI, V103, P1363, DOI 10.1111/j.1349-7006.2012.02298.x; Katoh M, 2012, INT J ONCOL, V41, P1913, DOI 10.3892/ijo.2012.1669; Khin SS, 2009, INT J CANCER, V125, P328, DOI 10.1002/ijc.24318; Kim BY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/584604; Kohn KW, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0035716, DOI 10.1371/J0URNAL.P0NE.0035716]; Kohno T, 2011, J THORAC ONCOL, V6, P813, DOI 10.1097/JTO.0b013e3181ee80ef; Kong CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022666; Kostianets O, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-161; Kundu J, 2012, INT J ONCOL, V41, P839, DOI 10.3892/ijo.2012.1517; Larriba Maria Jesus, 2013, Cancers (Basel), V5, P1242, DOI 10.3390/cancers5041242; Lee HJ, 2010, GASTROENTEROLOGY, V139, P213, DOI 10.1053/j.gastro.2010.04.008; Li CD, 2012, MOL CELL BIOCHEM, V370, P127, DOI 10.1007/s11010-012-1404-x; Lin H, 2012, CANCER GENE THER, V19, P845, DOI 10.1038/cgt.2012.70; Liu XX, 2011, FEBS LETT, V585, P1363, DOI 10.1016/j.febslet.2011.04.018; Llarena AM, 2009, J CLIN ONCOL, V27; Loberg RD, 2006, NEOPLASIA, V8, P69, DOI 10.1593/neo.05679; Miao LY, 2013, BIOCHEM BIOPH RES CO, V440, P792, DOI 10.1016/j.bbrc.2013.10.024; OKOCHI T, 1979, CANCER RES, V39, P1829; Ooe A, 2007, BREAST CANCER RES TR, V101, P305, DOI 10.1007/s10549-006-9293-x; Papapetropoulos S, 2006, GENE EXPRESSION, V13, P205, DOI 10.3727/000000006783991827; Pils D, 2010, GYNECOL ONCOL, V117, P189, DOI 10.1016/j.ygyno.2009.12.034; Samah NA, 2011, IIUM ENG J, V12, P213; Schulte Janin, 2011, BMC Med, V9, P137, DOI 10.1186/1741-7015-9-137; Sengupta D, 2014, BRIT J CANCER, V110, P2144, DOI 10.1038/bjc.2014.53; Shinojima T, 2012, EPIGENETICS-US, V7, P1279, DOI 10.4161/epi.22333; Spraggs CF, 2011, J CLIN ONCOL, V29, P667, DOI 10.1200/JCO.2010.31.3197; Stefanska B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068439; Sugiura T, 2007, CANCER BIOL THER, V6, P957, DOI 10.4161/cbt.6.6.4192; Suh KS, 2005, J INVEST DERM SYMP P, V10, P105, DOI 10.1111/j.1087-0024.2005.200402.x; Sun LG, 2014, CANCER GENET-NY, V207, P291, DOI 10.1016/j.cancergen.2014.07.003; TATA DB, 1993, ULTRASONICS, V31, P447, DOI 10.1016/0041-624X(93)90054-4; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; Ummanni R, 2012, J PROTEOME RES, V11, P2452, DOI 10.1021/pr201172n; Velusamy T, 2013, P NATL ACAD SCI USA, V110, P3035, DOI 10.1073/pnas.1214326110; Wang SJ, 2011, ANN APPL STAT, V5, P468, DOI 10.1214/10-AOAS377; Wu GJ, 2006, CANCER RES, V66, P9829, DOI 10.1158/0008-5472.CAN-06-0506; Jiao Y, 2007, ACTA PHARMACOL SIN, V28, P1628, DOI 10.1111/j.1745-7254.2007.00647.x; Yao Q, 2009, ONCOL REP, V22, P541, DOI 10.3892/or_00000469; Yokomizo K, 2012, ANTICANCER RES, V32, P1319; Yun HM, 2014, FREE RADICAL BIO MED, V69, P367, DOI 10.1016/j.freeradbiomed.2014.02.001; Zhang J, 2011, MED ONCOL, V28, P494, DOI 10.1007/s12032-010-9489-0; Zhao Y, 2013, INT J MOL SCI, V14, P19670, DOI 10.3390/ijms141019670; Zhiying X, 2013, CENT EUR J IMMUNOL, V38, P416, DOI [10.5114/ceji.2013.39755, DOI 10.5114/CEJI.2013.39755]; Zhu R, 2013, ONCOL REP, V30, P2137, DOI 10.3892/or.2013.2697; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x; Zou H, 2009, ANN STAT, V37, P1733, DOI 10.1214/08-AOS625	74	9	9	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2015	10	11							e0141869	10.1371/journal.pone.0141869	http://dx.doi.org/10.1371/journal.pone.0141869			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV6RT	26544691	Green Published, gold, Green Submitted			2023-01-03	WOS:000364398700056
J	Lima, SIVC; Diniz, RS; Egito, EST; Azevedo, PRM; Oliveira, AG; Araujo, IB				Lima, Sara I. V. C.; Diniz, Rodrigo S.; Egito, Eryvaldo S. T.; Azevedo, Paulo R. M.; Oliveira, Antonio G.; Araujo, Ivonete B.			Rationality of Antimicrobial Prescriptions in Community Pharmacy Users	PLOS ONE			English	Article							ANTIBIOTICS; COMPLETENESS; HANDWRITTEN; LEGIBILITY; QUALITY; MISUSE; CITY	Background Although there is a conflict between the treatment benefits for a single individual and society, restrictions on antibiotic use are needed to reduce the prevalence of resistance to these drugs, which is the main result of irrational use. Brazil, cataloged as a pharmemerging market, has implemented restrictive measures for the consumption of antibiotics. The objective of this study was to investigate the quality of antimicrobial prescriptions and user knowledge of their treatment with these drugs. Methods and Findings A two-stage cross-sectional, combined and stratified survey of pharmacy users holding an antimicrobial prescription was conducted in the community between May and November 2014. A pharmacist analyzed each prescription for legibility and completeness, and applied a structured questionnaire to the users or their caregivers on their knowledge regarding treatment and user sociodemographic data. An estimated 29.3% of prescriptions had one or more illegible items, 91.3% had one or more missing items, and 29.0% had both illegible and missing items. Dosing schedule and patient identification were the most commonly unreadable items in prescriptions, 18.81% and 12.14%, respectively. The lack of complete patient identification occurred in 90.53% of the prescriptions. It is estimated that 40.3% of users have used antimicrobials without prescription and that 46.49% did not receive any guidance on the administration of the drug. Conclusions Despite the measures taken by health authorities to restrict the misuse of antimicrobials, it was observed that prescribers still do not follow the criteria of current legislation, particularly relating to items needed for completion of the prescription. Moreover, users receive little information about their antimicrobial treatment.	[Lima, Sara I. V. C.; Diniz, Rodrigo S.; Egito, Eryvaldo S. T.; Oliveira, Antonio G.; Araujo, Ivonete B.] Univ Fed Rio Grande do Norte, Ctr Ciencias Saude, Programa Posgrad Ciencias Saude, BR-59072970 Natal, RN, Brazil; [Diniz, Rodrigo S.] Univ Fed Campina Grande, Ctr Educ Saude, Dept Farmacia, Cuite, PB, Brazil; [Egito, Eryvaldo S. T.; Araujo, Ivonete B.] Univ Fed Rio Grande do Norte, Ctr Ciencias Saude, Dept Farmacia, BR-59072970 Natal, RN, Brazil; [Azevedo, Paulo R. M.] Univ Fed Rio Grande do Norte, Ctr Ciencias Exatas Terra, Dept Estat, BR-59072970 Natal, RN, Brazil	Universidade Federal do Rio Grande do Norte; Universidade Federal de Campina Grande; Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte	Lima, SIVC (corresponding author), Univ Fed Rio Grande do Norte, Ctr Ciencias Saude, Programa Posgrad Ciencias Saude, BR-59072970 Natal, RN, Brazil.	sivclima@gmail.com	ST Egito, Socrates/O-1813-2014	ST Egito, Socrates/0000-0002-2180-3991				Abrantes PD, 2008, CIENC SAUDE COLETIVA, V13, P711, DOI 10.1590/S1413-81232008000700021; Agencia Nacional de Vigilancia Sanitiria-ANVISA, 2010, RDC 44 OCTOBER 26 20; Agencia Nacional de Vigilancia Sanitiria-ANVISA, 2011, RDC 20 MAY 5 2011; Albarrak AI, 2014, SAUDI PHARM J, V22, P522, DOI 10.1016/j.jsps.2014.02.013; Barker KN, 2002, ARCH INTERN MED, V162, P1897, DOI 10.1001/archinte.162.16.1897; BRASIL, 2013, DEFINIDA NOVA DATA P; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; Calligaris Laura, 2009, BMC Clin Pharmacol, V9, P9, DOI 10.1186/1472-6904-9-9; Cisneros Jose Miguel, 2010, Enferm Infecc Microbiol Clin, V28 Suppl 4, P28, DOI 10.1016/S0213-005X(10)70039-2; de Vries TPGM, 1994, GUIDE GOOD PRESCRIBI; French GL, 2010, INT J ANTIMICROB AG, V36, pS3, DOI 10.1016/S0924-8579(10)70003-0; IBGE, 2010, DIRETORIA PESQISAS C; IMS Health, PHARMERGING MARKETS; Nicolini P, 2008, CIENC SAUDE COLETIVA, V13, P689, DOI 10.1590/S1413-81232008000700018; Porco TC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046505; Rosa Mário Borges, 2009, Rev. Saúde Pública, V43, P490, DOI 10.1590/S0034-89102009005000028; Santa-Ana-Tellez Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075550; Shehadeh M, 2012, SAUDI PHARM J, V20, P125, DOI 10.1016/j.jsps.2011.11.005; Silverio MS, 2010, REV ASSOC MED BRAS, V56, P675, DOI 10.1590/S0104-42302010000600016; Tripathi N, 2012, CLIN PERINATOL, V39, P61, DOI 10.1016/j.clp.2011.12.003; Waltham MA, 2015, CIPROFLOXACIN SYSTEM; WHO, 2001, WHO GLOB STRAT CONT; Wilf-Miron R, 2012, J MANAGE CARE PHARM, V18, P324, DOI 10.18553/jmcp.2012.18.4.324; Winslow EH, 1997, HEART LUNG, V26, P158, DOI 10.1016/S0147-9563(97)90076-5	25	6	6	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2015	10	10							e0141615	10.1371/journal.pone.0141615	http://dx.doi.org/10.1371/journal.pone.0141615			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV0EH	26517874	Green Published, gold, Green Submitted			2023-01-03	WOS:000363920800062
J	Straney, LD; Bray, JE; Beck, B; Finn, J; Bernard, S; Dyson, K; Lijovic, M; Smith, K				Straney, Lahn D.; Bray, Janet E.; Beck, Ben; Finn, Judith; Bernard, Stephen; Dyson, Kylie; Lijovic, Marijana; Smith, Karen			Regions of High Out-Of-Hospital Cardiac Arrest Incidence and Low Bystander CPR Rates in Victoria, Australia	PLOS ONE			English	Article							INITIATED CPR; CARDIOPULMONARY-RESUSCITATION; NEIGHBORHOOD CHARACTERISTICS; WESTERN-AUSTRALIA; SURVIVAL RATES; ASSOCIATION; CARE; INTERVENTION; OUTCOMES; VICTIMS	Background Out-of-hospital cardiac arrest (OHCA) remains a major public health issue and research has shown that large regional variation in outcomes exists. Of the interventions associated with survival, the provision of bystander CPR is one of the most important modifiable factors. The aim of this study is to identify census areas with high incidence of OHCA and low rates of bystander CPR in Victoria, Australia Methods We conducted an observational study using prospectively collected population-based OHCA data from the state of Victoria in Australia. Using ArcGIS (ArcMap 10.0), we linked the location of the arrest using the dispatch coordinates (longitude and latitude) to Victorian Local Government Areas (LGAs). We used Bayesian hierarchical models with random effects on each LGA to provide shrunken estimates of the rates of bystander CPR and the incidence rates. Results Over the study period there were 31,019 adult OHCA attended, of which 21,436 (69.1%) cases were of presumed cardiac etiology. Significant variation in the incidence of OHCA among LGAs was observed. There was a 3 fold difference in the incidence rate between the lowest and highest LGAs, ranging from 38.5 to 115.1 cases per 100,000 person-years. The overall rate of bystander CPR for bystander witnessed OHCAs was 62.4%, with the rate increasing from 56.4% in 2008-2010 to 68.6% in 2010-2013. There was a 25.1% absolute difference in bystander CPR rates between the highest and lowest LGAs. Conclusion Significant regional variation in OHCA incidence and bystander CPR rates exists throughout Victoria. Regions with high incidence and low bystander CPR participation can be identified and would make suitable targets for interventions to improve CPR participation rates.	[Straney, Lahn D.; Bray, Janet E.; Beck, Ben; Finn, Judith; Bernard, Stephen; Dyson, Kylie; Smith, Karen] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Bray, Janet E.; Finn, Judith] Curtin Univ, Fac Hlth Sci, Perth, WA 6845, Australia; [Finn, Judith] St John Ambulance Western Australia, Perth, WA, Australia; [Bernard, Stephen] Alfred Hosp Melbourne, Intens Care Unit, Melbourne, Vic, Australia; [Dyson, Kylie; Lijovic, Marijana; Smith, Karen] Ambulance Victoria, Melbourne, Vic, Australia	Monash University; Curtin University	Straney, LD (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.	lahn.straney@monash.edu	Finn, Judith C/B-2678-2010; Dyson, Kylie/AAA-5115-2019; Beck, Ben/ABD-5556-2020; Bray, Janet/H-7089-2014	Finn, Judith C/0000-0002-7307-7944; Dyson, Kylie/0000-0002-0037-3195; Beck, Ben/0000-0003-3262-5956; Smith, Karen/0000-0002-9057-0685; Bray, Janet/0000-0002-1559-5882	NHMRC Australian Resuscitation Outcomes Consortium (Aus-ROC) Centre of Research Excellence (CRE) [1029983]; National Health and Medical Research Council (NHMRC) Public Health Postgraduate Research Scholarship [1075456]; NHMRC Aus-ROC CRE; NHMRC; Heart Foundation; St John Ambulance Western Australia	NHMRC Australian Resuscitation Outcomes Consortium (Aus-ROC) Centre of Research Excellence (CRE)(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council (NHMRC) Public Health Postgraduate Research Scholarship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Aus-ROC CRE(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Heart Foundation; St John Ambulance Western Australia	LS, BB, JB and JF receive salary support from the NHMRC Australian Resuscitation Outcomes Consortium (Aus-ROC) Centre of Research Excellence (CRE) (ID: 1029983, https://www.ausroc.org.au). KD is supported by a National Health and Medical Research Council (NHMRC) Public Health Postgraduate Research Scholarship (ID: 1075456) and a scholarship funded through the NHMRC Aus-ROC CRE. JB receives an early career researcher fellowship from the NHMRC and the Heart Foundation. JF receives salary support from St John Ambulance Western Australia.	[Anonymous], 1998, INTRO MULTILEVEL MOD; Australian Bureau of Statistics, POP PEOPL POP PEOPL; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Bossaert L, 1989, RESUSCITATION S, V17, pS55; Bray JE, 2014, RESUSCITATION, V85, P757, DOI 10.1016/j.resuscitation.2014.02.017; Bray JE, 2011, RESUSCITATION, V82, P1393, DOI 10.1016/j.resuscitation.2011.06.018; Brooks SC, 2010, RESUSCITATION, V81, P175, DOI 10.1016/j.resuscitation.2009.10.021; Chiang WC, 2014, RESUSCITATION, V85, P53, DOI 10.1016/j.resuscitation.2013.07.033; COPLEY DP, 1977, CIRCULATION, V56, P901, DOI 10.1161/01.CIR.56.6.901; Department of Housing and Settlement Areas of Banyumas Regency, 2011, SPATIAL STRUCTURE MA; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; Finn JC, 2001, RESUSCITATION, V51, P247, DOI 10.1016/S0300-9572(01)00408-7; Fosbol EL, 2014, RESUSCITATION, V85, P1512, DOI 10.1016/j.resuscitation.2014.08.013; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; Heward A, 2004, EMERG MED J, V21, P115, DOI 10.1136/emj.2003.006940; Iwami T, 2009, CIRCULATION, V119, P728, DOI 10.1161/CIRCULATIONAHA.108.802058; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Jennings PA, 2006, MED J AUSTRALIA, V185, P135, DOI 10.5694/j.1326-5377.2006.tb00498.x; Lund-Kordahl I, 2010, RESUSCITATION, V81, P422, DOI 10.1016/j.resuscitation.2009.12.020; Nehme Z, 2014, MED J AUSTRALIA, P200; Nehme Z, 2015, CIRC-CARDIOVASC QUAL, V8, P56, DOI 10.1161/CIRCOUTCOMES.114.001185; Nolan J, 2006, RESUSCITATION, V71, P270, DOI 10.1016/j.resuscitation.2006.09.001; O'Keeffe C, 2011, EMERG MED J, V28, P703, DOI 10.1136/emj.2009.086363; Ornato JP, 2010, CIRCULATION, V122, P1876, DOI 10.1161/CIRCULATIONAHA.110.963991; Raun LH, 2013, AM J PREV MED, V45, P137, DOI 10.1016/j.amepre.2013.03.013; RITTER G, 1985, AM HEART J, V110, P932, DOI 10.1016/0002-8703(85)90187-5; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; Sasson C, 2012, NEW ENGL J MED, V367, P1607, DOI 10.1056/NEJMoa1110700; Sasson C, 2012, ACAD EMERG MED, V19, P139, DOI 10.1111/j.1553-2712.2011.01284.x; Sasson C, 2010, ANN INTERN MED, V153, P19, DOI 10.7326/0003-4819-153-1-201007060-00255; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Semple HM, 2013, J COMMUN HEALTH, V38, P277, DOI 10.1007/s10900-012-9611-7; Srebotnjak T, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-26; Vaillancourt C, 2008, RESUSCITATION, V79, P417, DOI 10.1016/j.resuscitation.2008.07.012; Vaillancourt C, 2008, CAN J EMERG MED, V10, P51, DOI 10.1017/S1481803500010010	35	17	17	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2015	10	10							e0139776	10.1371/journal.pone.0139776	http://dx.doi.org/10.1371/journal.pone.0139776			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TW	26447844	Green Published, gold			2023-01-03	WOS:000362511000053
J	Vonderheide, RH				Vonderheide, Robert H.			CD47 blockade as another immune checkpoint therapy for cancer	NATURE MEDICINE			English	Editorial Material							EAT-ME; CELL; PHAGOCYTOSIS; MACROPHAGES	The role of CD47-often expressed on tumor cells-as a 'don't eat me' signal that inhibits macrophage phagocytosis is well established. But new work reveals a major role for other immune cell types-T cells and dendritic cells-in the anti-tumor effects of therapeutic CD47 blockade.	Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Vonderheide, RH (corresponding author), Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.	rhv@exchange.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA169123] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA169123] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett DM, 2014, ANNU REV MED, V65, P333, DOI 10.1146/annurev-med-060512-150254; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Grimsley C, 2003, TRENDS CELL BIOL, V13, P648, DOI 10.1016/j.tcb.2003.10.004; Lesokhin AM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010274; Liu XJ, 2015, NAT MED, V21, P1209, DOI 10.1038/nm.3931; McCracken MN, 2015, CLIN CANCER RES, V21, P3597, DOI 10.1158/1078-0432.CCR-14-2520; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Soto-Pantoja DR, 2014, CANCER RES, V74, P6771, DOI 10.1158/0008-5472.CAN-14-0037-T; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; Vonderheide RH, 2013, CLIN CANCER RES, V19, P1035, DOI 10.1158/1078-0432.CCR-12-2064; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109	12	74	79	3	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2015	21	10					1122	1123		10.1038/nm.3965	http://dx.doi.org/10.1038/nm.3965			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	CS8RG	26444633				2023-01-03	WOS:000362355400009
J	Wood, FM; Phillips, M; Jovic, T; Cassidy, JT; Cameron, P; Edgar, DW				Wood, Fiona M.; Phillips, Michael; Jovic, Tom; Cassidy, John T.; Cameron, Peter; Edgar, Dale W.		Steering Comm Burn Registry Austra	Water First Aid Is Beneficial In Humans Post-Burn: Evidence from a Bi-National Cohort Study	PLOS ONE			English	Article							BURN VICTIMS; HYPOTHERMIA; KNOWLEDGE; MORTALITY; INTERNET; CARE	Introduction Reported first aid application, frequency and practices around the world vary greatly. Based primarily on animal and observational studies, first aid after a burn injury is considered to be integral in reducing scar and infection, and the need for surgery. The current recommendation for optimum first aid after burn is water cooling for 20 minutes within three hours. However, compliance with this guideline is reported as poor to moderate at best and evidence exists to suggest that overcooling can be detrimental. This prospective cohort study of a binational burn patient registry examined data collected between 2009 and 2012. The aim of the study was to quantify the magnitude of effects of water cooling first aid after burn on indicators of burn severity in a large human cohort. Method The data for the analysis was provided by the Burn Registry of Australia and New Zealand (BRANZ). The application of first aid cooling prior to admission to a dedicated burn service, was analysed for its influence on four outcomes related to injury severity. The patient related outcomes were whether graft surgery occurred, and death while the health system (cost) outcomes included total hospital length of stay and admission to ICU. Robust regression analysis using bootstrapped estimation adjusted using a propensity score was used to control for confounding and to estimate the strength of association with first aid. Dose-response relationships were examined to determine associations with duration of first aid. The influence of covariates on the impact of first aid was assessed. Results Cooling was provided before Burn Centre admission for 68% of patients, with at least twenty minutes duration for 46%. The results indicated a reduction in burn injury severity associated with first aid. Patients probability for graft surgery fell by 0.070 from 0.537 (13% reduction) (p = 0.014). The probability for ICU admission fell by 0.084 from 0.175 (48% reduction) (p < 0.001) and hospital length of stay (LOS) fell by 2.27 days from 12.9 days (18% reduction) (p = 0.001). All outcomes except death showed a dose-response relationship with the duration of first aid. The size of burn and age interacted with many of the relationships between first aid and outcome and these are described and discussed. Discussion & Conclusion This study suggests that there are significant patient and health system benefits from cooling water first aid, particularly if applied for up to 20 minutes. The results of this study estimate the effect size of post-burn first aid and confirm that efforts to promote first aid knowledge are not only warranted, but provide potential cost savings.	[Wood, Fiona M.; Edgar, Dale W.] Fiona Stanley Hosp, State Adult Burn Unit, Burn Serv Western Australia, Murdoch, WA, Australia; [Wood, Fiona M.] Univ Western Australia, Burn Injury Res Unit, Crawley, WA, Australia; [Wood, Fiona M.; Edgar, Dale W.] Fiona Wood Fdn, Murdoch, WA, Australia; [Phillips, Michael] Royal Perth Hosp, Perkins Inst Med Res, Perth, WA 6001, Australia; [Phillips, Michael] Univ Western Australia, Crawley, WA, Australia; [Jovic, Tom] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Jovic, Tom; Cassidy, John T.] Royal Perth Hosp, Burn Serv Western Australia, Burn Unit, Perth, WA 6001, Australia; [Cassidy, John T.] James Connolly Mem Hosp, Dublin, Ireland; [Cameron, Peter] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Edgar, Dale W.] Univ Notre Dame Australia, Burn Injury Res Node, Fremantle, WA, Australia	University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Edinburgh; Royal Perth Hospital; Monash University; University of Notre Dame Australia	Wood, FM (corresponding author), Fiona Stanley Hosp, State Adult Burn Unit, Burn Serv Western Australia, Murdoch, WA, Australia.; Wood, FM (corresponding author), Univ Western Australia, Burn Injury Res Unit, Crawley, WA, Australia.; Wood, FM (corresponding author), Fiona Wood Fdn, Murdoch, WA, Australia.	Fiona.wood@health.wa.gov.au	Jovic, Thomas H/N-7155-2019; Edgar, Dale W/AAV-9394-2021; fiona, wood/F-4703-2013	Jovic, Thomas H/0000-0002-8325-0931; Edgar, Dale W/0000-0001-7336-9317; Wood, Fiona Melanie/0000-0002-3284-6540; Phillips, Michael/0000-0002-0252-9085; Cameron, Peter/0000-0002-1443-557X; fiona, wood/0000-0001-5427-6588	Australian Commission on Safety and Quality in Health Care; Helen Macpherson Smith Trust; Thyne Reid Foundation; Fiona Wood Foundation	Australian Commission on Safety and Quality in Health Care; Helen Macpherson Smith Trust; Thyne Reid Foundation; Fiona Wood Foundation	The study is unfunded and completed with support of the Fiona Wood Foundation http://www.fionawoodfoundation.com/ research team in their routine capacity. The Burn Registry of Australia and New Zealand is co-funded by ANZBA http://anzba.org.au/ and the Julian Burton Burns Trust http://www.burnstrust.com.au/ with additional funding received from the Australian Commission on Safety and Quality in Health Care (2008-2009) http://www.safetyandquality.gov.au/, Helen Macpherson Smith Trust (2010) http://hmstrust.org.au/ and the Thyne Reid Foundation (2011-2012). The BRANZ did not contribute funds to this project.	Bartlett N, 2008, J BURN CARE RES, V29, P828, DOI 10.1097/BCR.0b013e3181855c9a; Cuttle L, 2009, J BURN CARE RES, V30, P1028, DOI 10.1097/BCR.0b013e3181bfb7d1; Cuttle L, 2009, BURNS, V35, P768, DOI 10.1016/j.burns.2008.10.011; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; JACKSON DM, 1979, ANN ROY COLL SURG, V61, P335; Lunceford JK, 2004, STAT MED, V23, P2937, DOI 10.1002/SIM.1903; Maitz PM, 2014, EMERGENCY MANAGEMENT; Mlcak R, 1998, PEDIATR EMERG CARE, V14, P51, DOI 10.1097/00006565-199802000-00013; MUNSTER AM, 1994, BURNS, V20, P61, DOI 10.1016/0305-4179(94)90109-0; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Rea S, 2005, BURNS, V31, P1029, DOI 10.1016/j.burns.2005.05.010; Singer AJ, 2010, ACAD EMERG MED, V17, P456, DOI 10.1111/j.1553-2712.2010.00702.x; Skinner A, 2002, NZ MED J, V115, P199; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Tiller G, 2006, BURNS, V32, P897, DOI 10.1016/j.burns.2006.02.020; Tung KY, 2005, BURNS, V31, pS12, DOI 10.1016/j.burns.2004.10.006; Wallace HJ, 2013, BURNS, V39, P1162, DOI 10.1016/j.burns.2013.02.007; Watterson D, 2011, BURNS, V37, P1296, DOI 10.1016/j.burns.2011.08.007	18	55	55	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147259	10.1371/journal.pone.0147259	http://dx.doi.org/10.1371/journal.pone.0147259			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26808839	gold, Green Published, Green Submitted			2023-01-03	WOS:000369527800068
J	Wood, R; Morrow, C; Barry, CE; Bryden, WA; Call, CJ; Hickey, AJ; Rodes, CE; Scriba, TJ; Blackburn, J; Issarow, C; Mulder, N; Woodward, J; Moosa, A; Singh, V; Mizrahi, V; Warner, DF				Wood, Robin; Morrow, Carl; Barry, Clifton E., III; Bryden, Wayne A.; Call, Charles J.; Hickey, Anthony J.; Rodes, Charles E.; Scriba, Thomas J.; Blackburn, Jonathan; Issarow, Chacha; Mulder, Nicola; Woodward, Jeremy; Moosa, Atica; Singh, Vinayak; Mizrahi, Valerie; Warner, Digby F.			Real-Time Investigation of Tuberculosis Transmission: Developing the Respiratory Aerosol Sampling Chamber (RASC)	PLOS ONE			English	Article							AIRBORNE MYCOBACTERIUM-TUBERCULOSIS; AIR; INFECTION; COMPLEX; CYCLE	Knowledge of the airborne nature of respiratory disease transmission owes much to the pioneering experiments of Wells and Riley over half a century ago. However, the mechanical, physiological, and immunopathological processes which drive the production of infectious aerosols by a diseased host remain poorly understood. Similarly, very little is known about the specific physiological, metabolic and morphological adaptations which enable pathogens such as Mycobacterium tuberculosis (Mtb) to exit the infected host, survive exposure to the external environment during airborne carriage, and adopt a form that is able to enter the respiratory tract of a new host, avoiding innate immune and physical defenses to establish a nascent infection. As a first step towards addressing these fundamental knowledge gaps which are central to any efforts to interrupt disease transmission, we developed and characterized a small personal clean room comprising an array of sampling devices which enable isolation and representative sampling of airborne particles and organic matter from tuberculosis (TB) patients. The complete unit, termed the Respiratory Aerosol Sampling Chamber (RASC), is instrumented to provide real-time information about the particulate output of a single patient, and to capture samples via a suite of particulate impingers, impactors and filters. Applying the RASC in a clinical setting, we demonstrate that a combination of molecular and microbiological assays, as well as imaging by fluorescence and scanning electron microscopy, can be applied to investigate the identity, viability, and morphology of isolated aerosolized particles. Importantly, from a preliminary panel of active TB patients, we observed the real-time production of large numbers of airborne particles including Mtb, as confirmed by microbiological culture and polymerase chain reaction (PCR) genotyping. Moreover, direct imaging of captured samples revealed the presence of multiple rod-like Mtb organisms whose physical dimensions suggested the capacity for travel deep into the alveolar spaces of the human lung.	[Wood, Robin; Morrow, Carl; Barry, Clifton E., III; Scriba, Thomas J.; Blackburn, Jonathan; Issarow, Chacha; Mulder, Nicola; Moosa, Atica; Singh, Vinayak; Mizrahi, Valerie; Warner, Digby F.] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med IDM, ZA-7925 Cape Town, South Africa; [Wood, Robin; Morrow, Carl] Univ Cape Town, IDM, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa; [Barry, Clifton E., III] NIAID, Lab Clin Infect Dis, US Natl Inst Hlth, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Bryden, Wayne A.; Call, Charles J.] Zeteo Tech LLC, Ellicott City, MD USA; [Hickey, Anthony J.] RTI Int, Res Triangle Pk, NC USA; [Rodes, Charles E.] Aerosol Exposure Dimens, Cary, NC USA; [Scriba, Thomas J.] Univ Cape Town, Dept Paediat & Child Hlth, South African TB Vaccine Initiat, Cape Town, South Africa; [Blackburn, Jonathan; Issarow, Chacha; Mulder, Nicola; Woodward, Jeremy] Univ Cape Town, Fac Hlth Sci, Dept Integrat Biomed Sci, Struct Biol Res Unit, ZA-7925 Cape Town, South Africa; [Moosa, Atica; Singh, Vinayak; Mizrahi, Valerie; Warner, Digby F.] Univ Cape Town, Fac Hlth Sci, MRC NHLS UCT Mol Mycobacteriol Res Unit, Cape Town, South Africa; [Moosa, Atica; Singh, Vinayak; Mizrahi, Valerie; Warner, Digby F.] Univ Cape Town, Fac Hlth Sci, DST NRF Ctr Excellence Biomed TB Res, Dept Pathol, Cape Town, South Africa	University of Cape Town; University of Cape Town; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Research Triangle Institute; University of Cape Town; University of Cape Town; University of Cape Town; National Research Foundation - South Africa; University of Cape Town	Morrow, C (corresponding author), Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med IDM, ZA-7925 Cape Town, South Africa.; Morrow, C (corresponding author), Univ Cape Town, IDM, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa.	Carl.Morrow@hiv-research.org.za	Scriba, Thomas/GPX-2573-2022; Warner, Digby F/K-4355-2012; Barry, III, Clifton/H-3839-2012; Barry, Clifton E/ABE-7992-2020; Singh, Vinayak/O-5099-2019; Scriba, Thomas/AAH-9413-2020; SINGH, VINAYAK/L-8442-2016	Scriba, Thomas/0000-0002-0641-1359; Warner, Digby F/0000-0002-4146-0930; Barry, III, Clifton/0000-0002-2927-270X; Barry, Clifton E/0000-0002-2927-270X; Singh, Vinayak/0000-0001-9002-2489; SINGH, VINAYAK/0000-0001-9002-2489; Mulder, Nicola J/0000-0003-4905-0941; Woodward, Jeremy/0000-0002-7350-8302; Moosa, Atica/0000-0001-9012-3634	Bill & Melinda Gates Foundation [OPP1116641, 26123]; National Treasury under Economic Competitiveness and Support Package [MRC-RFA-UFSP-01-2013/CCAMP]; Intramural Research Program of the NIAID, NIH; South African Medical Research Council (MRC); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001214] Funding Source: NIH RePORTER	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); National Treasury under Economic Competitiveness and Support Package; Intramural Research Program of the NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); South African Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work is funded by grants from the Bill & Melinda Gates Foundation (OPP1116641), and the South African Medical Research Council (MRC) with funds from National Treasury under the Economic Competitiveness and Support Package (MRC-RFA-UFSP-01-2013/CCAMP) (RW CM TJS JB CI NM JW AM VS VM DFW); the Intramural Research Program of the NIAID, NIH (CEB); and Bill & Melinda Gates Foundation Investment ID 26123 (WAB CJC AJH CER).; Academic and technical support was provided from The Tuberculosis Aerobiology Advisory Group (TAAG) funded by the Bill and Melinda Gates Foundation.	ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; Andrews JR, 2015, AM J RESP CRIT CARE, V191, P584, DOI 10.1164/rccm.201409-1704OC; Andrews JR, 2014, J INFECT DIS, V210, P597, DOI 10.1093/infdis/jiu138; Caceres N, 2013, TUBERCULOSIS, V93, P690, DOI 10.1016/j.tube.2013.08.003; Chan K, 2002, P NATL ACAD SCI USA, V99, P3920, DOI 10.1073/pnas.002024599; Chen PS, 2005, AEROSOL SCI TECH, V39, P371, DOI 10.1080/027868290945767; Crowder TM, 2002, PHARMACEUT RES, V19, P239, DOI 10.1023/A:1014426530935; Dharmadhikari AS, 2011, TUBERCULOSIS, V91, P329, DOI 10.1016/j.tube.2011.03.002; Ernst JD, 2012, NAT REV IMMUNOL, V12, P581, DOI 10.1038/nri3259; Escombe AR, 2008, PLOS MED, V5, P1387, DOI 10.1371/journal.pmed.0050188; Eum SY, 2010, CHEST, V137, P122, DOI 10.1378/chest.09-0903; Fennelly KP, 2012, AM J RESP CRIT CARE, V186, P450, DOI 10.1164/rccm.201203-0444OC; Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; GORDON RE, 1953, J BACTERIOL, V66, P41, DOI 10.1128/JB.66.1.41-48.1953; Issarow CM, 2015, J THEOR BIOL, V372, P100, DOI 10.1016/j.jtbi.2015.02.010; KOCH R, 1882, AETIOLOGY TUBERCULOS; Mastorides SM, 1999, CHEST, V115, P19, DOI 10.1378/chest.115.1.19; Matuka O, 2015, J HOSP INFECT, V89, P192, DOI 10.1016/j.jhin.2014.11.013; Middelkoop K, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-156; Richardson ET, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096334; RILEY RL, 1962, AM REV RESPIR DIS, V85, P511; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; Swift D, 2007, INHALATION AEROSOLS, P55; Thanky NR, 2007, TUBERCULOSIS, V87, P231, DOI 10.1016/j.tube.2006.10.004; van Belkum A, 2012, J CLIN MICROBIOL, V50, P1513, DOI 10.1128/JCM.00420-12; Wan GH, 2004, AM J INFECT CONTROL, V32, P17, DOI 10.1016/S0196-6553(03)00090-7; Warren RM, 2006, INT J TUBERC LUNG D, V10, P818; Wood R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106622	29	30	30	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0146658	10.1371/journal.pone.0146658	http://dx.doi.org/10.1371/journal.pone.0146658			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26807816	Green Published, gold			2023-01-03	WOS:000369527800030
J	Kajubi, P; Whyte, SR; Kyaddondo, D; Katahoire, AR				Kajubi, Phoebe; Whyte, Susan Reynolds; Kyaddondo, David; Katahoire, Anne Ruhweza			Tensions in Communication between Children on Antiretroviral Therapy and Their Caregivers: A Qualitative Study in Jinja District, Uganda	PLOS ONE			English	Article							HIV STATUS; DISCLOSURE MODEL; DIAGNOSIS; ADOLESCENTS; CHILDHOODS; HIV/AIDS; ANTHROPOLOGY; DISTRESS; HEALTH	Introduction HIV treatment and disclosure guidelines emphasize the importance of communicating diagnosis and treatment to infected children in ways that are appropriate to children's developmental stage and age. Minimal attention, however, has been given to communication challenges confronted by HIV-infected children and their caregivers. This study examined the tensions between children and their caregivers arising from differing perspectives regarding when and what to communicate about antiretroviral therapy (ART). Methods This qualitative study was conducted between November 2011 and December 2012 and involved 29 HIV-infected children aged 8-17 years on ART and their caregivers. Data were collected through observations and in-depth interviews, which took place in homes, treatment centres and post-test clubs. Children and caregivers were sampled from among the 394 HIV-infected children and (their) 393 caregivers who participated in the cross-sectional survey that preceded the qualitative study. ATLAS.ti. Version 7 was used in the management of the qualitative data and in the coding of the emerging themes. The data were then analyzed using content thematic analysis. Results While the children felt that they were mature enough to know what they were suffering and what the medications were for, the caregivers wanted to delay discussions relating to the children's HIV diagnosis and medication until they felt that the children were mature enough to deal with the information and keep it a secret and this caused a lot of tension. The children employed different tactics including refusing to take the medicines, to find out what they were suffering from and what the medications were for. Children also had their own ideas about when, where and with whom to discuss their HIV condition, ideas that did not necessarily coincide with those of their caregivers, resulting in tensions. Conclusions Guidelines should take into consideration differing perceptions of maturity when recommending ages at which caregivers should communicate with their children about diagnosis and ART. Health care providers should also encourage caregivers to recognize and respect children's efforts to learn about and manage their condition. Children's questions and expressions of feelings should be treated as openings for communication on these issues.	[Kajubi, Phoebe; Kyaddondo, David; Katahoire, Anne Ruhweza] Makerere Univ, Coll Hlth Sci, Child Hlth & Dev Ctr, Kampala, Uganda; [Whyte, Susan Reynolds] Univ Copenhagen, Dept Anthropol, Copenhagen, Denmark	Makerere University; University of Copenhagen	Kajubi, P (corresponding author), Makerere Univ, Coll Hlth Sci, Child Hlth & Dev Ctr, Kampala, Uganda.	phoebekajubi@yahoo.com		Whyte, Susan/0000-0001-7253-6478	Danish Ministry of Foreign Affairs, Uganda, through a project called "Quality Medicine Use for Children in Uganda (ChildMed)" [09-100KU]; ChildMed coordination team	Danish Ministry of Foreign Affairs, Uganda, through a project called "Quality Medicine Use for Children in Uganda (ChildMed)"; ChildMed coordination team	The study was funded by the Danish Ministry of Foreign Affairs, Uganda, through a project called "Quality Medicine Use for Children in Uganda (ChildMed)" project number: 09-100KU; website: http://childmed.ku.dk/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank the children and their caregivers who participated in the study and the health workers in all the study sites for their support. We acknowledge the support of the ChildMed coordination team.	Abadia-Barrero CE, 2006, AIDS PATIENT CARE ST, V20, P36, DOI 10.1089/apc.2006.20.36; Abebe W, 2012, AIDS CARE, V24, P1097, DOI 10.1080/09540121.2012.656565; [Anonymous], 2009, HIGH LOC GOV STAT AB; Aries Philippe, 1962, CENTURIES CHILDHOOD; Arun S, 2009, INDIAN J PEDIATR, V76, P805, DOI 10.1007/s12098-009-0177-z; Baaroy JO, 1999, THESIS U OSLO NORWAY; Bernard H.R, 2017, RES METHODS ANTHR QU, Vsixth; Biadgilign S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017572; Blasini I, 2004, J DEV BEHAV PEDIATR, V25, P181, DOI 10.1097/00004703-200406000-00007; Bluebond-Langner M, 2007, AM ANTHROPOL, V109, P241, DOI 10.1525/AA.2007.109.2.241; Boyden J., 2003, CHILDREN YOUTH ENV, V13, P1; Brannen J, 2004, CHILDHOOD, V11, P409, DOI 10.1177/0907568204047104; Buhler-Niederberger D, 2008, CHILDHOOD, V15, P147, DOI 10.1177/0907568207088419; Campbell C, 2015, HEALTH PLACE, V31, P54, DOI 10.1016/j.healthplace.2014.09.008; Gerson A C, 2001, J Pediatr Health Care, V15, P161, DOI 10.1067/mph.2001.114835; Goffman E., 1963, BEHAV PUBLIC PLACES; Hardman C, 2001, CHILDHOOD, V8, P501, DOI 10.1177/0907568201008004006; HARDY MS, 1994, J DEV BEHAV PEDIATR, V15, pS49; Heeren GA, 2011, INNOVATION-ABINGDON, V24, P199, DOI 10.1080/13511610.2011.553506; Instone S L, 2000, J Pediatr Health Care, V14, P235, DOI 10.1067/mph.2000.107338; Jenks C, 2004, CHILDHOOD, V11, P5, DOI 10.1177/0907568204040179; Kajubi P, 2014, CHILD YOUTH SERV REV, V45, P38, DOI 10.1016/j.childyouth.2014.03.036; Kajubi P, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19012; Kalibala S, 2010, SITUATION ANAL VULNE, P2; Kidia KK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087322; Kiwanuka J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093276; Kouyoumdjian FG, 2005, J TROP PEDIATRICS, V51, P285, DOI 10.1093/tropej/fmi014; Kyaddondo D, 2013, SAHARA J-J SOC ASP H, V10, pS37, DOI 10.1080/02664763.2012.755323; Lancy D. F., 2008, ANTHR CHILDHOOD CHER; Ledlie SW, 1999, NURS RES, V48, P141, DOI 10.1097/00006199-199905000-00004; Lee CL, 1999, AIDS PATIENT CARE ST, V13, P41, DOI 10.1089/apc.1999.13.41; LEE M, 1999, AIDS BEHAV, V3, P33, DOI DOI 10.1023/A:1025415418759; Lester P, 2002, JAIDS-J ACQ IMM DEF, V31, P309, DOI 10.1097/00126334-200211010-00006; LeVine RA, 2007, AM ANTHROPOL, V109, P247, DOI 10.1525/AA.2007.109.2.247; Mburu G, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18866; Meinert L., 2009, HOPES FRICTION SCH H; Ministry of Health (MOH) [Uganda] and ICF International, 2011, UG AIDS IND SURV 201; MOH, 2009, UG NAT ANT TREATM GU; MOH, 2005, UG NAT POL HIV COUNS; Moodley K, 2008, S AFR MED J, V96, P201; Mupambireyi Z, 2014, CHILDREN YOUTH SERVI; Murphy DA, 2000, J ADOLESCENT HEALTH, V27, P391, DOI 10.1016/S1054-139X(00)00158-0; Myer L, 2006, J TROP PEDIATRICS, V52, P293, DOI 10.1093/tropej/fml004; Oberdorfer P, 2006, J PAEDIATR CHILD H, V42, P283, DOI 10.1111/j.1440-1754.2006.00855.x; Onyango-Ouma W, 2001, CHILDREN HLTH COMMUN; Punch S, 2003, SOCIOLOGY, V37, P277, DOI 10.1177/0038038503037002004; Rushforth H, 1999, J CHILD PSYCHOL PSYC, V40, P683, DOI 10.1017/S0021963099003996; Rwemisisi J, 2008, HEALTH POLICY PLANN, V23, P36, DOI 10.1093/heapol/czm040; Siu GE, 2012, AIDS CARE, V24, P606, DOI 10.1080/09540121.2011.630346; Skovdal M, 2012, AJAR-AFR J AIDS RES, V11, P153, DOI 10.2989/16085906.2012.734975; Suris JC, 2004, ARCH DIS CHILD, V89, P938, DOI 10.1136/adc.2003.045369; The Government of the Republic of Uganda, 2010, NAT POL DIS PREP MAN; UAC, 2013, UG HIV AIDS COUNTR P; Vaz L, 2011, J DEV BEHAV PEDIAT J; Vaz LME, 2010, AIDS PATIENT CARE ST, V24, P247, DOI 10.1089/apc.2009.0217; Vreeman RC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086616; Vreeman RC, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18466; Vreeman RC, 2010, AIDS PATIENT CARE ST, V24, P639, DOI 10.1089/apc.2010.0079; WHO, 2013, GLOB UPD HIV TREATM; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E; Wiener L, 2007, J DEV BEHAV PEDIATR, V28, P155, DOI 10.1097/01.DBP.0000267570.87564.cd; Wilfert C, 1999, PEDIATRICS, V103, P164; World Health Organization, 2011, GUID HIV DISCL COUNS; World Health Organization, 2013, GUID HIV TEST COUNS	64	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2016	11	1							e0147119	10.1371/journal.pone.0147119	http://dx.doi.org/10.1371/journal.pone.0147119			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DB5BP	26784904	Green Published, Green Submitted, gold			2023-01-03	WOS:000368528400113
J	Davidson, AJ; Disma, N; de Graaff, JC; Withington, DE; Dorris, L; Bell, G; Stargatt, R; Bellinger, DC; Schuster, T; Arnup, SJ; Hardy, P; Hunt, RW; Takagi, MJ; Giribaldi, G; Hartmann, PL; Salvo, I; Morton, NS; Sternberg, BSV; Locatelli, BG; Wilton, N; Lynn, A; Thomas, JJ; Polaner, D; Bagshaw, O; Szmuk, P; Absalom, AR; Frawley, G; Berde, C; Ormond, GD; Marmor, J; McCann, ME				Davidson, Andrew J.; Disma, Nicola; de Graaff, Jurgen C.; Withington, Davinia E.; Dorris, Liam; Bell, Graham; Stargatt, Robyn; Bellinger, David C.; Schuster, Tibor; Arnup, Sarah J.; Hardy, Pollyanna; Hunt, Rodney W.; Takagi, Michael J.; Giribaldi, Gaia; Hartmann, Penelope L.; Salvo, Ida; Morton, Neil S.; Sternberg, Britta S. von Ungern; Locatelli, Bruno Guido; Wilton, Niall; Lynn, Anne; Thomas, Joss J.; Polaner, David; Bagshaw, Oliver; Szmuk, Peter; Absalom, Anthony R.; Frawley, Geoff; Berde, Charles; Ormond, Gillian D.; Marmor, Jacki; McCann, Mary Ellen		Gas Consortium	Neurodevelopmental outcome at 2 years of age after general anaesthesia and awake-regional anaesthesia in infancy (GAS): an international multicentre, randomised controlled trial	LANCET			English	Article							EARLY EXPOSURE; LEARNING-DISABILITIES; ACADEMIC-PERFORMANCE; CHILDHOOD EXPOSURE; CLINICAL-RESEARCH; DEVELOPING BRAIN; BIRTH COHORT; CELL-DEATH; NEUROTOXICITY; CHILDREN	Background Preclinical data suggest that general anaesthetics affect brain development. There is mixed evidence from cohort studies that young children exposed to anaesthesia can have an increased risk of poor neurodevelopmental outcome. We aimed to establish whether general anaesthesia in infancy has any effect on neurodevelopmental outcome. Here we report the secondary outcome of neurodevelopmental outcome at 2 years of age in the General Anaesthesia compared to Spinal anaesthesia (GAS) trial. Methods In this international assessor-masked randomised controlled equivalence trial, we recruited infants younger than 60 weeks postmenstrual age, born at greater than 26 weeks ' gestation, and who had inguinal herniorrhaphy, from 28 hospitals in Australia, Italy, the USA, the UK, Canada, the Netherlands, and New Zealand. Infants were randomly assigned (1:1) to receive either awake-regional anaesthesia or sevoflurane-based general anaesthesia. Web-based randomisation was done in blocks of two or four and stratified by site and gestational age at birth. Infants were excluded if they had existing risk factors for neurological injury. The primary outcome of the trial will be the Wechsler Preschool and Primary Scale of Intelligence Third Edition (WPPSI-III) Full Scale Intelligence Quotient score at age 5 years. The secondary outcome, reported here, is the composite cognitive score of the Bayley Scales of Infant and Toddler Development III, assessed at 2 years. The analysis was as per protocol adjusted for gestational age at birth. A difference in means of five points (1/3 SD) was predefined as the clinical equivalence margin. This trial is registered with ANZCTR, number ACTRN12606000441516 and ClinicalTrials.gov, number NCT00756600. Findings Between Feb 9, 2007, and Jan 31, 2013, 363 infants were randomly assigned to receive awake-regional anaesthesia and 359 to general anaesthesia. Outcome data were available for 238 children in the awake-regional group and 294 in the general anaesthesia group. In the as-per-protocol analysis, the cognitive composite score (mean [SD]) was 98.6 (14.2) in the awake-regional group and 98.2 (14.7) in the general anaesthesia group. There was equivalence in mean between groups (awake-regional minus general anaesthesia 0.169, 95% CI-2.30 to 2.64). The median duration of anaesthesia in the general anaesthesia group was 54 min. Interpretation For this secondary outcome, we found no evidence that just less than 1 h of sevoflurane anaesthesia in infancy increases the risk of adverse neurodevelopmental outcome at 2 years of age compared with awake-regional anaesthesia. Funding Australia National Health and Medical Research Council (NHMRC), Health Technologies Assessment-National Institute for Health Research UK, National Institutes of Health, Food and Drug Administration, Australian and New Zealand College of Anaesthetists, Murdoch Childrens Research Institute, Canadian Institute of Health Research, Canadian Anesthesiologists ' Society, Pfizer Canada, Italian Ministry of Heath, Fonds NutsOhra, and UK Clinical Research Network (UKCRN).	[Davidson, Andrew J.; Takagi, Michael J.; Hartmann, Penelope L.; Frawley, Geoff; Ormond, Gillian D.] Murdoch Childrens Res Inst, Anaesthesia & Pain Management Res Grp, Melbourne, Vic, Australia; [Davidson, Andrew J.] Murdoch Childrens Res Inst, Melbourne Childrens Trials Ctr, Melbourne, Vic, Australia; [Davidson, Andrew J.; Frawley, Geoff] Royal Childrens Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; [Davidson, Andrew J.; Hunt, Rodney W.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Disma, Nicola; Giribaldi, Gaia] Ist Giannina Gaslini, Dept Anesthesia, I-16148 Genoa, Italy; [de Graaff, Jurgen C.] Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Dept Anaesthesia, Utrecht, Netherlands; [Withington, Davinia E.] Montreal Childrens Hosp, Dept Anesthesia, Montreal, PQ H3H 1P3, Canada; [Withington, Davinia E.] McGill Univ, Dept Anesthesia, Montreal, PQ, Canada; [Dorris, Liam] Royal Hosp Children, Paediat Neurosci Res Grp, Fraser Allander Unit, Glasgow, Lanark, Scotland; [Bell, Graham; Morton, Neil S.] Royal Hosp Children, Dept Anaesthesia, Glasgow, Lanark, Scotland; [Dorris, Liam] Univ Glasgow, Mental Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Stargatt, Robyn] La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3086, Australia; [Stargatt, Robyn; Takagi, Michael J.] Murdoch Childrens Res Inst, Child Neuropsychol, Melbourne, Vic, Australia; [Bellinger, David C.; Marmor, Jacki] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Neurol, Boston, MA USA; [Bellinger, David C.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Psychiat, Boston, MA USA; [Bellinger, David C.] Harvard T H Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Schuster, Tibor] Murdoch Childrens Res Inst, Clin Epidemiol & Biostatist Unit, Melbourne, Vic, Australia; [Hunt, Rodney W.] Murdoch Childrens Res Inst, Neonatal Res Grp, Melbourne, Vic, Australia; [Hardy, Pollyanna] Univ Oxford, Clin Trials Unit, Natl Perinatal Epidemiol Unit, Oxford, England; [Hunt, Rodney W.] Royal Childrens Hosp, Dept Neonatal Med, Melbourne, Vic, Australia; [Salvo, Ida] Osped Pediat Vittore Buzzi, Dept Anesthesiol & Pediat Intens Care, Milan, Italy; [Morton, Neil S.] Univ Glasgow, Glasgow, Lanark, Scotland; [Sternberg, Britta S. von Ungern] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Sternberg, Britta S. von Ungern] Princess Margaret Hosp Children, Dept Anaesthesia & Pain Management, Perth, WA, Australia; [Locatelli, Bruno Guido] Osped Papa Giovanni XXIII, Dept Anesthesia, Bergamo, Italy; [Wilton, Niall] Starship Childrens Hosp, Auckland Dist Hlth Board, Dept Paediat Anaesthesia & Operating Rooms, Auckland, New Zealand; [Lynn, Anne] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Thomas, Joss J.] Univ Minnesota, Dept Anesthesia, Minneapolis, MN USA; [Polaner, David] Childrens Hosp Colorado, Dept Anesthesiol, Aurora, CO USA; [Polaner, David] Univ Colorado, Sch Med, Aurora, CO USA; [Bagshaw, Oliver] Birmingham Childrens Hosp, Dept Anaesthesia, Birmingham, W Midlands, England; [Szmuk, Peter] Childrens Med Ctr Dallas, Dept Anesthesiol, Dallas, TX USA; [Absalom, Anthony R.] Univ Groningen, Univ Med Ctr Groningen, Dept Anaesthesiol, Groningen, Netherlands; [Berde, Charles; McCann, Mary Ellen] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA	Murdoch Children's Research Institute; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; University of Genoa; IRCCS Istituto Giannina Gaslini; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; McGill University; McGill University; University of Glasgow; La Trobe University; Murdoch Children's Research Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Murdoch Children's Research Institute; Murdoch Children's Research Institute; University of Oxford; Royal Children's Hospital Melbourne; University of Glasgow; University of Western Australia; University of Western Australia; ASST Papa Giovanni XXIII; Auckland District Health Board; Starship Children's Hospital; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Birmingham; University of Groningen; Harvard University; Boston Children's Hospital; Harvard Medical School	Davidson, AJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Anaesthesia & Pain Management Res Grp, Flemington Rd, Parkville, Vic 3052, Australia.	andrew.davidson@rch.org.au	von Ungern-Sternberg, Britta/S-5532-2019; Absalom, Anthony/GPG-1582-2022; Dorris, Liam/AAK-2273-2021; von Ungern-Sternberg, Britta/CAG-9904-2022; De Graaff, Jurgen C/G-2298-2017; Disma, Nicola/AAA-8868-2020; Polaner, David M/AAX-2514-2021; Soriano, Sulpicio/K-3501-2019; Morton, Neil/AAE-6594-2020	Dorris, Liam/0000-0002-9502-3154; von Ungern-Sternberg, Britta/0000-0002-8043-8541; De Graaff, Jurgen C/0000-0002-2168-7900; Polaner, David M/0000-0001-8716-6289; Morton, Neil/0000-0001-8848-7914; Absalom, Anthony/0000-0001-7563-9157; Visser, Melissa/0000-0002-5313-3347; Hunt, Rodney/0000-0002-2446-1739; Titler, Sarah/0000-0001-8433-3379; Arnup, Sarah/0000-0002-9497-1902; Disma, Nicola/0000-0002-2960-9333; Hays, Stephen/0000-0003-2166-8811; Myles, Paul/0000-0002-3324-5456; Hartmann, Penelope/0000-0003-4706-4485; Takagi, Michael/0000-0003-2903-7598	Australia National Health and Medical Research Council (NHMRC); Health Technologies Assessment-National Institute for Health Research UK; National Institutes of Health; Food and Drug Administration; Australian and New Zealand College of Anaesthetists; Murdoch Childrens Research Institute; Canadian Institute of Health Research; Canadian Anesthesiologists' Society; Pfizer Canada; Italian Ministry of Heath; Fonds NutsOhra; UK Clinical Research Network (UKCRN); The Australian National Health & Medical Research Council [1002906, 491226]; Australian and New Zealand College of Anaesthetists [11/021, 07/012]; Victorian Government's Operational Infrastructure Support Program; National Institute of Health [NIH 1-R01 hD06 1136-01A1]; Food and Drug Administration [FDA-SOL-08-SAFEKIDS-Clin 002-Project 2]; Italian Ministry of Heath, Young Researchers Grant [167/GR-2009-1476067]; Fonds NutsOhra grant [1305-144]; Vrienden WKZ [16.13.038]; Canadian Institute of Health Research [MCT-98031]; Pfizer Canada Inc.; Health Technologies Assessment-National Institute for Health Research UK [07/01/05]; National Institute for Health Research [07/01/05] Funding Source: researchfish; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD061336, U54HD090255, R01HD084566] Funding Source: NIH RePORTER	Australia National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Health Technologies Assessment-National Institute for Health Research UK; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food and Drug Administration(United States Department of Health & Human Services); Australian and New Zealand College of Anaesthetists; Murdoch Childrens Research Institute; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Anesthesiologists' Society; Pfizer Canada(Pfizer); Italian Ministry of Heath; Fonds NutsOhra; UK Clinical Research Network (UKCRN); The Australian National Health & Medical Research Council; Australian and New Zealand College of Anaesthetists; Victorian Government's Operational Infrastructure Support Program; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food and Drug Administration(United States Department of Health & Human Services); Italian Ministry of Heath, Young Researchers Grant; Fonds NutsOhra grant; Vrienden WKZ; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Pfizer Canada Inc.; Health Technologies Assessment-National Institute for Health Research UK; National Institute for Health Research(National Institute for Health Research (NIHR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Australia National Health and Medical Research Council (NHMRC), Health Technologies Assessment-National Institute for Health Research UK, National Institutes of Health, Food and Drug Administration, Australian and New Zealand College of Anaesthetists, Murdoch Childrens Research Institute, Canadian Institute of Health Research, Canadian Anesthesiologists' Society, Pfizer Canada, Italian Ministry of Heath, Fonds NutsOhra, and UK Clinical Research Network (UKCRN).; All hospitals and centres were generously supported by departmental funding. In addition to this funding, specific grants received for this study are as follows: Australia: The Australian National Health & Medical Research Council (Project Grants #1002906 and 491226); Australian and New Zealand College of Anaesthetists (Project Grant #11/021 and 07/012); Murdoch Childrens Research Institute; Victorian Government's Operational Infrastructure Support Program. US: National Institute of Health (Project Grant # NIH 1-R01 hD06 1136-01A1); Food and Drug Administration (Project Grant #FDA-SOL-08-SAFEKIDS-Clin 002-Project 2). Italy: Italian Ministry of Heath, Young Researchers Grant (Project Grant #167/GR-2009-1476067). Netherlands: Fonds NutsOhra grant #1305-144 and Vrienden WKZ 16.13.038. Canada: Canadian Institute of Health Research (Project Grant #MCT-98031), Canadian Anesthesiologists' Society, Pfizer Canada Inc. UK: Health Technologies Assessment-National Institute for Health Research UK (Project Grant #07/01/05). We are also grateful to the following individuals who contributed to the running of the study: Mark Fagjman (Department of Anaesthesia, Monash Medical Centre, Melbourne, VIC, Australia); Daniela Tronconi (Department of Anesthesia, Istituto Giannina Gaslini, Genoa, Italy); David C van der Zee (Department of Pediatric Surgery, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Netherlands); Jan Hulscher (Department of Surgery, University Medical Center Groningen, Groningen University, Groningen, Netherlands); Michael Rivkin (Department of Neurology, Children's Hospital Boston, Boston, MA, USA); Michelle Sadler-Greever (University of Washington, Seattle Children's Hospital, Department of Anesthesia and Pain Medicine, Seattle, WA, USA); Debra Faulk (Children's Hospital Colorado and University of Colorado School of Medicine, Department of Anesthesiology, Colorado, CO, USA); Greta Wilkening (Neurosciences Institute, Children's Hospital Colorado, CO, USA); Edward Goldson (Department of Pediatrics, Division of Developmental-Behavioral Pediatrics, Children's Hospital Colorado, Colorado, USA). Danai Udomtecha and Sarah Titler (The University of Iowa Hospital, Department of Anesthesia, Iowa, IA, USA); Roxana Ploski and Alan Farrow-Gilespie (Children's Medical Centre Dallas, Department of Anesthesiology, University of Texas Southwestern Medical Center, Dallas and Children's Medical Center at Dallas and Outcome Research Consortium, Dallas, TX, USA); Timothy Cooper (Division of Developmental Medicine and the Center for Child Development, Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, TN, USA); Elizabeth Card (Perioperative Clinical Research Institute, Vanderbilt University Medical Center, Nashville, TN, USA); Wendy Boardman (Dartmouth-Hitchcock Medical Center, Department of Anesthesiology, NH, USA); Theodora K Goebel (Department of Anesthesiology and Critical Care Children's Hospital of Philadelphia, Philadelphia, PA, USA).	Bartels M, 2009, TWIN RES HUM GENET, V12, P246, DOI 10.1375/twin.12.3.246; Bayley N, 2006, BAYLEY SCALES INFANT; Block RI, 2012, ANESTHESIOLOGY, V117, P494, DOI 10.1097/ALN.0b013e3182644684; Bode MM, 2014, J DEV BEHAV PEDIATR, V35, P570, DOI 10.1097/DBP.0000000000000110; Bong CL, 2013, ANESTH ANALG, V117, P1419, DOI 10.1213/ANE.0b013e318299a7c2; Brambrink AM, 2012, ANN NEUROL, V72, P525, DOI 10.1002/ana.23652; Brambrink AM, 2010, ANESTHESIOLOGY, V112, P834, DOI 10.1097/ALN.0b013e3181d049cd; Briner A, 2011, ANESTHESIOLOGY, V115, P282, DOI 10.1097/ALN.0b013e318221fbbd; Crosby G, 2013, ANESTH ANALG, V117, P1270, DOI 10.1213/ANE.0b013e3182a9667f; Davidson AJ, 2015, ANESTHESIOLOGY, V123, P38, DOI 10.1097/ALN.0000000000000709; Davidson AJ, 2015, PEDIATR ANESTH, V25, P447, DOI 10.1111/pan.12652; Davidson AJ, 2011, PEDIATR ANESTH, V21, P716, DOI 10.1111/j.1460-9592.2010.03506.x; DiMaggio C, 2012, J NEUROSURG ANESTH, V24, P376, DOI 10.1097/ANA.0b013e31826a038d; DiMaggio C, 2011, ANESTH ANALG, V113, P1143, DOI 10.1213/ANE.0b013e3182147f42; DiMaggio C, 2009, J NEUROSURG ANESTH, V21, P286, DOI 10.1097/ANA.0b013e3181a71f11; Fenson L., 2006, MACARTHUR BATES COMM, V2; Flick RP, 2011, PEDIATRICS, V128, pE1053, DOI 10.1542/peds.2011-0351; Frawley G, 2015, ANESTHESIOLOGY, V123, P55, DOI 10.1097/ALN.0000000000000708; Hansen TG, 2015, PEDIATR ANESTH, V25, P65, DOI 10.1111/pan.12548; Hansen TG, 2013, PEDIATR ANESTH, V23, P883, DOI 10.1111/pan.12225; Hansen TG, 2011, ANESTHESIOLOGY, V114, P1076, DOI 10.1097/ALN.0b013e31820e77a0; Harris S R, 1994, J Perinatol, V14, P275; Ing C, 2012, PEDIATRICS, V130, pE476, DOI 10.1542/peds.2011-3822; Ing CH, 2014, ANESTHESIOLOGY, V120, P1319, DOI 10.1097/ALN.0000000000000248; Istaphanous GK, 2013, ANESTH ANALG, V116, P845, DOI 10.1213/ANE.0b013e318281e988; Jevtovic-Todorovic V, 2013, BRIT J ANAESTH, V111, P143, DOI 10.1093/bja/aet177; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Johnson SA, 2008, J NEUROSURG ANESTH, V20, P21, DOI 10.1097/ANA.0b013e3181271850; Lee BH, 2014, NEUROPHARMACOLOGY, V83, P9, DOI 10.1016/j.neuropharm.2014.03.011; Lei SY, 2014, J NEUROSURG ANESTH, V26, P349, DOI 10.1097/ANA.0000000000000117; Paule MG, 2011, NEUROTOXICOL TERATOL, V33, P220, DOI 10.1016/j.ntt.2011.01.001; Psaty BM, 2015, JAMA-J AM MED ASSOC, V313, P1515, DOI 10.1001/jama.2015.1149; Raper J, 2015, ANESTHESIOLOGY, V123, P1084, DOI 10.1097/ALN.0000000000000851; Rappaport BA, 2015, NEW ENGL J MED, V372, P796, DOI 10.1056/NEJMp1414786; Sanchez V, 2011, ANESTHESIOLOGY, V115, P992, DOI 10.1097/ALN.0b013e3182303a63; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Slikker W, 2007, TOXICOL SCI, V98, P145, DOI 10.1093/toxsci/kfm084; Sprung J, 2012, MAYO CLIN PROC, V87, P120, DOI 10.1016/j.mayocp.2011.11.008; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Wang X, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085760, 10.1371/journal.pone.0096299]; Wilder RT, 2009, ANESTHESIOLOGY, V110, P796, DOI 10.1097/01.anes.0000344728.34332.5d	41	530	545	7	120	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	2016	387	10015					239	250		10.1016/S0140-6736(15)00608-X	http://dx.doi.org/10.1016/S0140-6736(15)00608-X			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA9LQ	26507180	Green Accepted, Green Published, Bronze, Green Submitted			2023-01-03	WOS:000368130700031
J	Ryu, JA; Bang, OY; Suh, GY; Yang, JH; Lee, D; Park, J; Cho, J; Chung, CR; Park, CM; Jeon, K				Ryu, Jeong-Am; Bang, Oh Young; Suh, Gee Young; Yang, Jeong Hoon; Lee, Daesang; Park, Jinkyeong; Cho, Joongbum; Chung, Chi Ryang; Park, Chi-Min; Jeon, Kyeongman			Ischemic Stroke in Critically Ill Patients with Malignancy	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; CEREBRAL INFARCTION; CANCER-PATIENTS; CEREBROVASCULAR COMPLICATIONS; NEUROLOGIC COMPLICATIONS; RISK-FACTOR; CHEMOTHERAPY; ETIOLOGY; PATTERN	Background Cerebrovascular diseases are a frequent cause of neurological symptoms in patients with cancer. The clinical characteristics of ischemic stroke (IS) in patients with cancer have been reported in several studies; however, limited data are available regarding critically ill patients with cancer who develop IS during their stay in the intensive care unit (ICU). Methods All consecutive patients who underwent brain magnetic resonance imaging (MRI) for suspicion of IS with acute abnormal neurologic symptoms or who developed signs of IS while in the ICU were retrospectively evaluated. We compared the clinical characteristics and diffusion- weighted imaging (DWI) lesion patterns between patients finally diagnosed as having or not having IS. Results Over the study period, a total of 88 patients underwent brain MRI for suspicion of IS, with altered mental status in 55 (63%), hemiparesis in 28 (32%), and seizure in 20 (23%). A total of 43 (49%) patients were ultimately diagnosed with IS. Multiple DWI lesions (41%) were more common than single lesions (8%). The etiologies of IS were not determined in the majority of patients (n = 27, 63%). In the remaining 16 (37%) patients, the most common aetiology of IS was cardioembolism (n = 8), followed by large-vessel atherosclerosis (n = 3) and small-vessel occlusion (n = 2). However, brain metastases were newly diagnosed in only 7 (8%) patients. Univariate comparison of the baseline characteristics between patients with or without IS did not reveal any significant differences in sex, malignancy type, recent chemotherapy, vascular risk factors, or serum D-dimer levels at the time of suspicion of IS. Thrombotic events were more common in the IS group than in the non-IS group (P = 0.028). However, patients who were ultimately diagnosed with IS had more hemiparesis symptoms at the time of suspicion of IS (P = 0.001). This association was significant even after adjusting for potentially confounding factors (adjusted odds ratio 5.339; 95% confidence interval, 1.521-19.163). Conclusions IS developed during ICU stays in critically ill patients with cancer have particular features that may be associated with cancer-related mechanism.	[Ryu, Jeong-Am; Suh, Gee Young; Yang, Jeong Hoon; Lee, Daesang; Park, Jinkyeong; Cho, Joongbum; Chung, Chi Ryang; Park, Chi-Min; Jeon, Kyeongman] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Crit Care Med, Seoul, South Korea; [Bang, Oh Young] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul, South Korea; [Suh, Gee Young; Jeon, Kyeongman] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, Seoul, South Korea; [Yang, Jeong Hoon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Cardiol,Dept Med, Seoul, South Korea; [Park, Chi-Min] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Jeon, K (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Crit Care Med, Seoul, South Korea.	kjeon@skku.edu	Suh, Gee Young/O-3676-2019; Park, Jinkyeong/GLV-1649-2022; Park, Jinkyeong/AGB-3445-2022; Jeon, Kyeongman/F-5963-2019	Suh, Gee Young/0000-0001-5473-1712; Park, Jinkyeong/0000-0002-8833-9062; Jeon, Kyeongman/0000-0002-4822-1772	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI14C0743]; Samsung Medical Center	Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea; Samsung Medical Center(Samsung)	This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C0743). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. In addition, Samsung Medical Center provided support in the form of salaries for all of authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Adams Jr HP, 1993, ARTERIOSCLER THROMB, V24, P35, DOI DOI 10.1161/01.STR.24.1.35; Bang OY, 2011, J CLIN NEUROL, V7, P53, DOI 10.3988/jcn.2011.7.2.53; Barlas I, 2001, Curr Opin Crit Care, V7, P68, DOI 10.1097/00075198-200104000-00003; Benoit DD, 2006, INTENS CARE MED, V32, P93, DOI 10.1007/s00134-005-2836-5; BLECK TP, 1993, CRIT CARE MED, V21, P98, DOI 10.1097/00003246-199301000-00019; Cestari DM, 2004, NEUROLOGY, V62, P2025, DOI 10.1212/01.WNL.0000129912.56486.2B; CHATURVEDI S, 1994, STROKE, V25, P1215, DOI 10.1161/01.STR.25.6.1215; Chong JN, 1998, AM J NEURORADIOL, V19, P1733; Darmon M, 2005, CRIT CARE MED, V33, P2488, DOI 10.1097/01.CCM.0000181728.13354.0A; Doriath V, 2007, J NEURO-ONCOL, V83, P285, DOI 10.1007/s11060-006-9319-6; GRAUS F, 1985, MEDICINE, V64, P16, DOI 10.1097/00005792-198501000-00002; Isensee LM, J CRIT CARE, V4, P208; Kim SG, 2010, STROKE, V41, P798, DOI 10.1161/STROKEAHA.109.571356; Lee EJ, 2014, INT J STROKE, V9, P406, DOI 10.1111/ijs.12124; LEFKOVITZ NW, 1986, STROKE, V17, P555, DOI 10.1161/01.STR.17.3.555; Naik-Tolani S, 1999, CLIN CHEST MED, V20, P423, DOI 10.1016/S0272-5231(05)70150-7; ONEILL BP, 1987, CANCER, V60, P90, DOI 10.1002/1097-0142(19870701)60:1<90::AID-CNCR2820600116>3.0.CO;2-C; Osias J, 2014, CRIT CARE CLIN, V30, P785, DOI 10.1016/j.ccc.2014.06.008; Pilato F, 2009, MINERVA ANESTESIOL, V75, P245; Rogers LR, 2010, SEMIN NEUROL, V30, P311, DOI 10.1055/s-0030-1255224; Schwebel C, 2013, CRIT CARE MED, V41, P1919, DOI 10.1097/CCM.0b013e31828a3bbd; Song JU, 2012, INTENS CARE MED, V38, P1505, DOI 10.1007/s00134-012-2594-0; Stefan O, 2009, J NEURO-ONCOL, V94, P221, DOI 10.1007/s11060-009-9818-3; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327, DOI 10.1055/s-0037-1616068; Tuma R, 2000, ARCH NEUROL-CHICAGO, V57, P1727, DOI 10.1001/archneur.57.12.1727; Wilcox ME, 2013, CRIT CARE MED, V41, pS81, DOI 10.1097/CCM.0b013e3182a16946; Yoo H, 2013, CRIT CARE, V17, DOI 10.1186/cc12829; Zhang YY, 2006, ACTA NEUROL SCAND, V114, P378, DOI 10.1111/j.1600-0404.2006.00709.x; Zhang YY, 2007, CEREBROVASC DIS, V23, P181, DOI 10.1159/000097639	29	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0146836	10.1371/journal.pone.0146836	http://dx.doi.org/10.1371/journal.pone.0146836			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6CA	26751213	Green Submitted, gold, Green Published			2023-01-03	WOS:000367888100160
J	Mastropasqua, R; Toto, L; Borrelli, E; Di Antonio, L; De Nicola, C; Mastrocola, A; Di Nicola, M; Carpineto, P				Mastropasqua, Rodolfo; Toto, Lisa; Borrelli, Enrico; Di Antonio, Luca; De Nicola, Chiara; Mastrocola, Alessandra; Di Nicola, Marta; Carpineto, Paolo			Morphology and Function over a One-Year Follow Up Period after Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema	PLOS ONE			English	Article							VASCULAR LEAKAGE; CONTROLLED-TRIAL; RETINOPATHY; NEURODEGENERATION; LEUKOSTASIS; ASSOCIATION; RETINA	Background To investigate changes in macular morphology and function after an intravitreal dexamethasone implant for diabetic macular edema (DME). Methods Twenty-seven eyes in 27 treatment-naive patients affected by DME were treated with intravitreal Ozurdex (R) injections (IVOI) and followed up 12 months to evaluate morphological and functional changes by means of best-corrected visual acuity (BCVA), microperimetry (MP1), multifocal electroretinography (mfERG), pattern electroretinography (PERG) and spectral domain optical coherence tomography (SD-OCT). Results Both BCVA and retinal sensitivity improved significantly at one month after the IVOI (p = 0.031 and p<0.0001, respectively). After five months, the improvement of BCVA remained statistically significant compared with baseline values (p = 0.022); retinal sensitivity improvement was statistically significant for up to four months after the IVOI (p = 0.059). Moreover, central macular thickness significantly decreased for up to four months. Interestingly, PERG and mfERG values did not change significantly for up to four months post-IVOI, but then began to worsen. Conclusions In eyes with DME, intravitreal dexamethasone implant determined morphological and functional improvement as soon as one month and for up to four months after the treatment.	[Mastropasqua, Rodolfo] Univ Verona, Ophthalmol Clin, I-37100 Verona, Italy; [Toto, Lisa; Borrelli, Enrico; Di Antonio, Luca; De Nicola, Chiara; Mastrocola, Alessandra; Carpineto, Paolo] Univ G dAnnunzio, Dept Med & Sci Aging, Ophthalmol Clin, Chieti, Italy; [Di Nicola, Marta] Univ G DAnnunzio Chieti, Ctr Excellence Aging, Lab Biostat, Chieti, Italy; [Di Nicola, Marta] Univ G DAnnunzio Chieti, Dept Biomed Sci, Lab Biostat, Chieti, Italy	University of Verona; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Toto, L (corresponding author), Univ G dAnnunzio, Dept Med & Sci Aging, Ophthalmol Clin, Chieti, Italy.	l.toto@unich.it	Carpineto, Paolo/AAN-9688-2020; Borrelli, Enrico/AAR-3693-2020; Mastropasqua, Rodolfo/AAC-6453-2022; Toto, Lisa/K-3473-2018	Borrelli, Enrico/0000-0003-2815-5031; Toto, Lisa/0000-0001-5311-5184				Bach M, 2013, DOC OPHTHALMOL, V126, P1, DOI 10.1007/s10633-012-9353-y; Bandello F, 2010, OPHTHALMOLOGICA, V224, P41, DOI 10.1159/000315161; Bandello F., 2014, CLIN STRATEGIES MANA, V1st; Bearse MA, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-014-0526-9; Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001; Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024; Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034; De Benedetto U, 2014, RETINA-J RET VIT DIS, V34, P2171, DOI 10.1097/IAE.0000000000000205; Dong N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125329; Funatsu H, 2009, OPHTHALMOLOGY, V116, P73, DOI 10.1016/j.ophtha.2008.09.037; Haller JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P289, DOI 10.1001/archophthalmol.2010.21; Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8; Huang H, 2011, INVEST OPHTH VIS SCI, V52, P1336, DOI 10.1167/iovs.10-5768; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Pacella E, 2013, CLIN TER, V164, pE121, DOI 10.7417/CT.2013.1543; Pacella E, 2014, SENSES SCI, V1, P164; Pacella E, 2013, CLIN OPHTHALMOL, V7, P1423, DOI 10.2147/OPTH.S48364; Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039; Querques G, 2014, OPTOMETRY VISION SCI, V91, P760, DOI 10.1097/OPX.0000000000000308; Querques G, 2014, RETINA-J RET VIT DIS, V34, P330, DOI 10.1097/IAE.0b013e31829f7495; Scaramuzzi M, 2015, RETINA-J RET VIT DIS, V35, P1216, DOI 10.1097/IAE.0000000000000443; Simo R, 2014, TRENDS ENDOCRIN MET, V25, P23, DOI 10.1016/j.tem.2013.09.005; Stem MS, 2013, CURR MED CHEM, V20, P3241, DOI 10.2174/09298673113209990027; Tamura H, 2005, INVEST OPHTH VIS SCI, V46, P1440, DOI 10.1167/iovs.04-0905; Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141; Wang K, 2008, BIOL PHARM BULL, V31, P1541, DOI 10.1248/bpb.31.1541; Zitkus Bruce S, 2014, Nurse Pract, V39, P22, DOI 10.1097/01.NPR.0000451880.48790.50	27	28	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2015	10	12							e0145663	10.1371/journal.pone.0145663	http://dx.doi.org/10.1371/journal.pone.0145663			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0TR	26720268	Green Published, gold, Green Submitted			2023-01-03	WOS:000367510900019
J	Curtis, KJ; O'Brien, KA; Tanner, RJ; Polkey, JI; Minnion, M; Feelisch, M; Polkey, MI; Edwards, LM; Hopkinson, NS				Curtis, Katrina J.; O'Brien, Katie A.; Tanner, Rebecca J.; Polkey, Juliet I.; Minnion, Magdalena; Feelisch, Martin; Polkey, Michael I.; Edwards, Lindsay M.; Hopkinson, Nicholas S.			Acute Dietary Nitrate Supplementation and Exercise Performance in COPD: A Double-Blind, Placebo-Controlled, Randomised Controlled Pilot Study	PLOS ONE			English	Article							BLOOD-PRESSURE; INORGANIC NITRATE; O-2 COST; MUSCLE; STANDARDIZATION; VALIDATION; GENERATION; EFFICIENCY; INTENSITY; RESPONSES	Background Dietary nitrate supplementation can enhance exercise performance in healthy people, but it is not clear if it is beneficial in COPD. We investigated the hypotheses that acute nitrate dosing would improve exercise performance and reduce the oxygen cost of submaximal exercise in people with COPD. Methods We performed a double-blind, placebo-controlled, cross-over single dose study. Subjects were randomised to consume either nitrate-rich beetroot juice (containing 12.9mmoles nitrate) or placebo (nitrate-depleted beetroot juice) 3 hours prior to endurance cycle ergometry, performed at 70% of maximal workload assessed by a prior incremental exercise test. After a minimum washout period of 7 days the protocol was repeated with the crossover beverage. Results 21 subjects successfully completed the study (age 68 +/- 7years; BMI 25.2 +/- 5.5kg/m(2); FEV1 percentage predicted 50.1 +/- 21.6%; peak VO2 18.0 +/- 5.9ml/min/kg). Resting diastolic blood pressure fell significantly with nitrate supplementation compared to placebo (-7 +/- 8mmHg nitrate vs. -1 +/- 8mmHg placebo; p = 0.008). Median endurance time did not differ significantly; nitrate 5.65 (3.90-10.40) minutes vs. placebo 6.40 (4.01-9.67) minutes (p = 0.50). However, isotime oxygen consumption (VO2) was lower following nitrate supplementation (16.6 +/- 6.0ml/min/kg nitrate vs. 17.2 +/- 6.0ml/min/kg placebo; p = 0.043), and consequently nitrate supplementation caused a significant lowering of the amplitude of the VO2-percentage isotime curve. Conclusions Acute administration of oral nitrate did not enhance endurance exercise performance; however the observation that beetroot juice caused reduced oxygen consumption at isotime suggests that further investigation of this treatment approach is warranted, perhaps targeting a more hypoxic phenotype.	[Curtis, Katrina J.; Tanner, Rebecca J.; Polkey, Juliet I.; Polkey, Michael I.; Hopkinson, Nicholas S.] Royal Brompton & Harefield NHS Trust, NIHR Resp Biomed Res Unit, London, England; [Curtis, Katrina J.; Tanner, Rebecca J.; Polkey, Juliet I.; Polkey, Michael I.; Hopkinson, Nicholas S.] Univ London Imperial Coll Sci Technol & Med, London, England; [O'Brien, Katie A.; Edwards, Lindsay M.] Kings Coll London, Ctr Human & Aerosp Physiol Sci, London WC2R 2LS, England; [Minnion, Magdalena; Feelisch, Martin] Univ Southampton, Fac Med Clin & Expt Sci, Southampton, Hants, England; [Minnion, Magdalena; Feelisch, Martin] Southampton Gen Hosp, Southampton NIHR Resp Biomed Res Unit, Southampton SO9 4XY, Hants, England	Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Imperial College London; University of London; King's College London; University of Southampton; University of Southampton	Hopkinson, NS (corresponding author), Royal Brompton & Harefield NHS Trust, NIHR Resp Biomed Res Unit, London, England.	n.hopkinson@ic.ac.uk	Feelisch, Martin/C-3042-2008	Feelisch, Martin/0000-0003-2320-1158	National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; UK Medical Research Council [MR/J000620/1, G1001536]; Imperial College London; MRC [MR/J000620/1, G1001536] Funding Source: UKRI; Medical Research Council [G1001536, MR/J000620/1] Funding Source: researchfish	National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Imperial College London(General Electric); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This project was funded by the National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London who partly funded MIP's salary. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. KJC is funded by the UK Medical Research Council (www.mrc.ac.uk; grant reference MR/J000620/1) and MF acknowledges support from the UK Medical Research Council (G1001536). LME was initially an employee of King's College London, but subsequently moved to work for GSK. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ameer F, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000238.pub2; Ashmore T, 2015, FASEB J, V29, P1102, DOI 10.1096/fj.14-263004; Ashmore T, 2014, J PHYSIOL-LONDON, V592, P4715, DOI 10.1113/jphysiol.2014.275263; Bailey SJ, 2010, J APPL PHYSIOL, V109, P135, DOI 10.1152/japplphysiol.00046.2010; Bailey SJ, 2009, J APPL PHYSIOL, V107, P1144, DOI 10.1152/japplphysiol.00722.2009; Bentley R, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12089; Casaburi Richard, 2014, Ann Am Thorac Soc, V11, P1351, DOI 10.1513/AnnalsATS.201404-174OC; EDWARDS RHT, 1977, CLIN SCI MOL MED, V52, P283, DOI 10.1042/cs0520283; Evangelista AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011209; GIBSON GJ, 1993, THE EUROPEAN RESPIRA, V6, P155; Govoni M, 2008, NITRIC OXIDE-BIOL CH, V19, P333, DOI 10.1016/j.niox.2008.08.003; Hill K, 2010, THORAX, V65, P486, DOI 10.1136/thx.2009.128702; Ishii T, 1998, FEBS LETT, V440, P218, DOI 10.1016/S0014-5793(98)01460-4; Jones AM, 2014, SPORTS MED, V44, P35, DOI 10.1007/s40279-014-0149-y; Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509; Jungersten L, 1997, J APPL PHYSIOL, V82, P760, DOI 10.1152/jappl.1997.82.3.760; Kenjale AA, 2011, J APPL PHYSIOL, V110, P1582, DOI 10.1152/japplphysiol.00071.2011; Kerley CP, 2015, NITRIC OXIDE-BIOL CH, V44, P105, DOI 10.1016/j.niox.2014.12.010; Kessler R, 2011, EUR RESPIR J, V37, P264, DOI 10.1183/09031936.00051110; Lansley KE, 2011, J APPL PHYSIOL, V110, P591, DOI 10.1152/japplphysiol.01070.2010; Larsen FJ, 2007, ACTA PHYSIOL, V191, P59, DOI 10.1111/j.1748-1716.2007.01713.x; Larsen FJ, 2011, CELL METAB, V13, P149, DOI 10.1016/j.cmet.2011.01.004; Larsen FJ, 2006, NEW ENGL J MED, V355, P2792, DOI 10.1056/NEJMc062800; Leong P, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0057-4; Lundberg JO, 2004, FREE RADICAL BIO MED, V37, P395, DOI 10.1016/j.freeradbiomed.2004.04.027; Lundberg JO, 2010, BIOCHEM BIOPH RES CO, V396, P39, DOI 10.1016/j.bbrc.2010.02.136; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Maltais F, 2005, CHEST, V128, P1168, DOI 10.1378/chest.128.3.1168; Masschelein E, 2012, J APPL PHYSIOL, V113, P736, DOI 10.1152/japplphysiol.01253.2011; McConell GK, 2007, AM J PHYSIOL-REG I, V293, pR821, DOI 10.1152/ajpregu.00796.2006; Meguro M, 2007, CHEST, V132, P456, DOI 10.1378/chest.06-0702; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Murphy M, 2012, J ACAD NUTR DIET, V112, P548, DOI 10.1016/j.jand.2011.12.002; Nikolic SB, 2014, METABOLOMICS, V10, P105, DOI 10.1007/s11306-013-0557-2; O'Donnell DE, 2011, RESP MED, V105, P1030, DOI 10.1016/j.rmed.2011.03.014; Polkey MI, 2000, THORAX, V55, P547, DOI 10.1136/thorax.55.7.547; Porcelli S, 2015, J APPL PHYSIOL, V119, P762; Porcelli S, 2015, MED SCI SPORT EXER, V47, P1643, DOI 10.1249/MSS.0000000000000577; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; Seymour JM, 2009, THORAX, V64, P418, DOI 10.1136/thx.2008.103986; Shields GS, 2015, MUSCLE NERVE, V51, P214, DOI 10.1002/mus.24289; Steiner MC, 2002, EUR RESPIR J, V19, P626, DOI 10.1183/09031936.02.00279602; Vanhatalo A, 2010, AM J PHYSIOL-REG I, V299, pR1121, DOI 10.1152/ajpregu.00206.2010; Vogiatzis I, 2009, SCAND J MED SCI SPOR, V19, P364, DOI 10.1111/j.1600-0838.2008.00808.x; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; Webb AJ, 2008, HYPERTENSION, V51, P784, DOI 10.1161/HYPERTENSIONAHA.107.103523; Wylie LJ, 2013, J APPL PHYSIOL, V115, P325, DOI 10.1152/japplphysiol.00372.2013; Ysart G, 1999, FOOD ADDIT CONTAM A, V16, P521, DOI 10.1080/026520399283669	49	24	24	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0144504	10.1371/journal.pone.0144504	http://dx.doi.org/10.1371/journal.pone.0144504			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SI	26698120	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000367092600021
J	Azzoni, L; Barbour, R; Papasavvas, E; Glencross, DK; Stevens, WS; Cotton, MF; Violari, A; Montaner, LJ				Azzoni, Livio; Barbour, Russell; Papasavvas, Emmanouil; Glencross, Deborah K.; Stevens, Wendy S.; Cotton, Mark F.; Violari, Avy; Montaner, Luis J.			Early ART Results in Greater Immune Reconstitution Benefits in HIV-Infected Infants: Working with Data Missingness in a Longitudinal Dataset	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; T-CELL-ACTIVATION; MICROBIAL TRANSLOCATION; INTERLEUKIN-7 LEVELS; PLASMA-LEVELS; CHILDREN; RECOVERY; SUBSETS; RESPONSES; PREDICT	Background Early initiation of anti-retroviral treatment (ART) decreases mortality as compared to deferred treatment, but whether it preserves immune cells from early loss or promotes their recovery remains undefined. Determination of complex immunological endpoints in infants is often marred by missing data due to missed visits and/or inadequate sampling. Specialized methods are required to address missingness and facilitate data analysis. Methods We characterized the changes in cellular and humoral immune parameters over the first year of life in 66 HIV-infected infants (0-1 year of age) enrolled in the CHER study starting therapy within 12 weeks of birth (n = 42) or upon disease progression (n = 24). A convenience cohort of 23 uninfected infants aged 0-6 months born to mothers with HIV-1 infection was used as controls. Flow cytometry and ELISA were used to evaluate changes in natural killer (NK) cells, plasmacytoid dendritic cells (pDC), and CD4(+) or CD8(+) T-cell frequencies. Data missingness was assessed using Little's test. Complete datasets for analysis were created using Multiple Imputation (MI) or Bayesian modeling and multivariate analysis was conducted on the imputed datasets. Results HIV-1-infected infants had greater frequency of CD4(+) T cells with naive phenotype, as well as higher serum IL-7 levels than HIV exposed/uninfected infants. The elevated data missingness was completely at random, allowing the use of both MI and Bayesian modeling. Both methods indicate that early ART initiation results in higher CD4(+) T cell frequency, lower expression of CD95 in CD8(+) T cell, and preservation of naive T cell subsets. In contrast, innate immune effectors appeared to be similar independently of the timing of ART initiation. Conclusions Early ART initiation in infants with perinatal HIV infection reduces immune activation and preserves an early expansion of naive T-cells with undiminished innate cell numbers, giving greater immune reconstitution than achieved with deferred ART. Both statistical approaches concurred in this finding.	[Azzoni, Livio; Papasavvas, Emmanouil; Montaner, Luis J.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Barbour, Russell] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA; [Glencross, Deborah K.; Stevens, Wendy S.] Univ Witwatersrand, Dept Mol Med & Hematol, Johannesburg, South Africa; [Glencross, Deborah K.; Stevens, Wendy S.] Natl Hlth Lab Serv, Johannesburg, South Africa; [Cotton, Mark F.] Univ Stellenbosch, Dept Paediat & Child Hlth, Childrens Infect Dis Clin Res Unit, Cape Town, South Africa; [Violari, Avy] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa	The Wistar Institute; Yale University; University of Witwatersrand; National Health Laboratory Service; Stellenbosch University; University of Witwatersrand	Montaner, LJ (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	Montaner@wistar.org	Cotton, Mark/AAQ-9936-2020	Cotton, Mark/0000-0003-2559-6034; Glencross, Deborah/0000-0001-7106-769X	National Institute of Allergy and Infectious Disease (NIAID) [AI062512]; Philadelphia Foundation (Robert I. Jacobs Fund); Stengel-Miller family; Commonwealth of Pennsylvania; Commonwealth Universal Research Enhancement Program; Pennsylvania Department of Health; National Cancer Institute Wistar Cancer Center [P30 CA10815]; NIMH [5P30MH062294-12]; Center for Interdisciplinary Research on AIDS; National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes for Health (NIH), through the Comprehensive International Program of Research on AIDS (CIPRA) network [U19 AI53217]; Departments of Health of the Western Cape; Gauteng, South Africa; GlaxoSmithKline plc; Dean of Yale's School of Public Health; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI053217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062294] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Disease (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Philadelphia Foundation (Robert I. Jacobs Fund); Stengel-Miller family; Commonwealth of Pennsylvania; Commonwealth Universal Research Enhancement Program; Pennsylvania Department of Health; National Cancer Institute Wistar Cancer Center; NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Center for Interdisciplinary Research on AIDS; National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes for Health (NIH), through the Comprehensive International Program of Research on AIDS (CIPRA) network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Departments of Health of the Western Cape; Gauteng, South Africa; GlaxoSmithKline plc(GlaxoSmithKline); Dean of Yale's School of Public Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was primarily supported by a grant to L.J. Montaner by the National Institute of Allergy and Infectious Disease (NIAID AI062512, www.niaid.nih.gov). Additional support was provided by The Philadelphia Foundation (Robert I. Jacobs Fund), https://www.philafound.org; The Stengel-Miller family, AIDS funds from the Commonwealth of Pennsylvania and from the Commonwealth Universal Research Enhancement Program (www.portal.state.pa.us/portal/server.pt/community/health_research_program_cure/14189), Pennsylvania Department of Health (www.health.pa.gov), as well as by the National Cancer Institute Wistar Cancer Center Grant (P30 CA10815, www.cancer.gov/). Dr. Barbour's work was supported by NIMH grant 5P30MH062294-12 (https://www.nimh.nih.gov) to Paul Cleary, Dean of Yale's School of Public Health. This grant supports the Center for Interdisciplinary Research on AIDS. Support for the CIPRA-SA CHER study was provided by the National Institute of Allergy and Infectious Diseases (NIAID, www.niaid.nih.gov) of the US National Institutes for Health (NIH), through the Comprehensive International Program of Research on AIDS (CIPRA) network, grant number U19 AI53217. The Departments of Health of the Western Cape (https://www.westerncape.gov.za/dept/health) and Gauteng (www.health.gpg.gov.za), South Africa and GlaxoSmithKline plc (www.gsk.com) provided additional support. The CIPRA-SA CHER study was conducted under the supervision of the USA Food and Drug Administration (IND n. 71494). The content of this publication does not necessarily reflect the views or policies of NIAID, nor does mention of trade names, commercial projects, or organizations imply endorsement by the US Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alter G, 2005, BLOOD, V106, P3366, DOI 10.1182/blood-2005-03-1100; Anselmi A, 2007, CLIN EXP IMMUNOL, V150, P442, DOI 10.1111/j.1365-2249.2007.03526.x; Azzoni L, 2005, J INFECT DIS, V191, P1451, DOI 10.1086/429300; Azzoni L, 2002, J IMMUNOL, V168, P5764, DOI 10.4049/jimmunol.168.11.5764; Azzoni L, 2007, AIDS, V21, P293, DOI 10.1097/QAD.0b013e328012b85f; Blackwell M, 2017, SOCIOL METHOD RES, V46, P342, DOI 10.1177/0049124115589052; Blanco A, 2008, J IMMUNOL, V180, P530, DOI 10.4049/jimmunol.180.1.530; BONAGURA VR, 1992, J PEDIATR-US, V121, P195, DOI 10.1016/S0022-3476(05)81187-4; Boulassel MR, 2007, VIRAL IMMUNOL, V20, P649, DOI 10.1089/vim.2007.0047; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Cagigi A, 2014, PEDIATR INFECT DIS J, V33, pE126, DOI 10.1097/INF.0000000000000144; Chehimi J, 2002, J IMMUNOL, V168, P4796, DOI 10.4049/jimmunol.168.9.4796; Chiappini E, 2003, JAIDS-J ACQ IMM DEF, V33, P601, DOI 10.1097/00126334-200308150-00008; Coetzee LM, 2009, CYTOM PART B-CLIN CY, V76B, P375, DOI 10.1002/cyto.b.20478; Correa R, 2003, J CLIN IMMUNOL, V23, P401, DOI 10.1023/A:1025325718213; Cotton MF, 2013, LANCET, V382, P1555, DOI 10.1016/S0140-6736(13)61409-9; Crawly M., 2005, STAT INTRO USING R; DeSouza CM, 2009, J BIOPHARM STAT, V19, P1055, DOI 10.1080/10543400903242795; Gelman A., 2007, DATA ANAL USING REGR; Gorelick MH, 2006, J CLIN EPIDEMIOL, V59, P1115, DOI 10.1016/j.jclinepi.2004.11.029; Holmes TH, 2014, J IMMUNOL METHODS, V414, P32, DOI 10.1016/j.jim.2014.08.001; Honaker J, 2011, J STAT SOFTW, V45, P1; Honaker J, 2010, AM J POLIT SCI, V54, P561, DOI 10.1111/j.1540-5907.2010.00447.x; Imai K, 2008, J COMPUT GRAPH STAT, V17, P892, DOI 10.1198/106186008X384898; Jordan KA, 2006, VIROLOGY, V347, P117, DOI 10.1016/j.virol.2005.12.002; Kaambwa Billingsley, 2012, BMC Res Notes, V5, P330, DOI 10.1186/1756-0500-5-330; Kopka J, 2005, J CLIN VIROL, V33, P237, DOI 10.1016/j.jcv.2004.11.014; Le J, 2014, THER DRUG MONIT, V36, P510, DOI 10.1097/FTD.0000000000000039; Little R. J. A., 1987, STAT ANAL MISSING DA; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Little TD, 2014, J PEDIATR PSYCHOL, V39, P151, DOI 10.1093/jpepsy/jst048; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Madhi SA, 2010, J INFECT DIS, V202, P355, DOI 10.1086/653704; Mansoor N, 2009, CLIN IMMUNOL, V130, P280, DOI 10.1016/j.clim.2008.09.006; Mansourian M, 2014, J TROP PEDIATRICS, V60, P61, DOI 10.1093/tropej/fmt078; Mason A, 2012, BAYESIAN ANAL, V7, P109, DOI 10.1214/12-BA704; Newell M-L, 1994, PEDIATRICS, V94, P815; Owen MJ, 2013, EVERYONES STAT SOFTW; Papasavvas E, 2011, PEDIATR INFECT DIS J, V30, P877, DOI 10.1097/INF.0b013e31821d141e; Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106; PLAEGERMARSHALL S, 1994, CLIN IMMUNOL IMMUNOP, V71, P19, DOI 10.1006/clin.1994.1046; Rainwater-Lovett K, 2014, JAIDS-J ACQ IMM DEF, V67, P455, DOI 10.1097/QAI.0000000000000342; Resino S, 2006, J ANTIMICROB CHEMOTH, V57, P798, DOI 10.1093/jac/dkl032; Resino S, 2001, CLIN EXP IMMUNOL, V125, P266, DOI 10.1046/j.1365-2249.2001.01612.x; Roberts L, 2010, AIDS, V24, P819, DOI 10.1097/QAD.0b013e3283367836; Rosso R, 2010, SCAND J IMMUNOL, V71, P45, DOI 10.1111/j.1365-3083.2009.02345.x; Rubin D, 2008, MULTIPLE IMPUTATION; Rubin D. B., 1992, STAT SCI, V7, P457, DOI DOI 10.1111/j.1469-8137.2011.03796.x; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Ruel T, 2009, CLIN IMMUNOL, V131, P410, DOI 10.1016/j.clim.2009.01.016; Sharland M, 2002, HIV Med, V3, P215, DOI 10.1046/j.1468-1293.2002.00120.x; Simani OE, 2014, AIDS, V28, P531, DOI 10.1097/QAD.0000000000000127; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; Ssewanyana I, 2009, AIDS RES HUM RETROV, V25, P65, DOI 10.1089/aid.2008.0138; Steyerberg EW, 2007, J CLIN EPIDEMIOL, V60, P979, DOI 10.1016/j.jclinepi.2007.03.003; Tobin NH, 2014, CURR HIV-AIDS REP, V11, P1, DOI 10.1007/s11904-013-0189-1; VOICULESCU C, 1994, FEMS IMMUNOL MED MIC, V9, P217, DOI 10.1111/j.1574-695X.1994.tb00496.x; Wallet MA, 2010, AIDS, V24, P1281, DOI 10.1097/QAD.0b013e328339e228; White IR, 2010, STAT MED, V29, P2920, DOI 10.1002/sim.3944; Wiens JJ, 2008, J SYST EVOL, V46, P307, DOI 10.3724/SP.J.1002.2008.08040; Woodward P, 2005, J STAT SOFTW, V14; Woodward P, 2011, BAYESIAN ANAL MADE S; Xiao L, 2014, J AM STAT ASSOC, V109, P1, DOI 10.1080/01621459.2013.830070; Ye P, 2004, CURR HIV RES, V2, P177, DOI 10.2174/1570162043484898; Ziegner U, 1999, CLIN DIAGN LAB IMMUN, V6, P718, DOI 10.1128/CDLI.6.5.718-724.1999	65	8	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2015	10	12							e0145320	10.1371/journal.pone.0145320	http://dx.doi.org/10.1371/journal.pone.0145320			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9HZ	26671450	Green Published, gold			2023-01-03	WOS:000366719300058
J	Nijman, SMB				Nijman, Sebastian M. B.			Functional genomics to uncover drug mechanism of action	NATURE CHEMICAL BIOLOGY			English	Review							EMBRYONIC STEM-CELLS; MODE-OF-ACTION; SMALL MOLECULES; OVEREXPRESSION SCREEN; TARGET IDENTIFICATION; SYNTHETIC LETHALITY; BIOACTIVE COMPOUNDS; SYSTEMATIC ANALYSIS; RNA-INTERFERENCE; GENE-EXPRESSION	The upswing in US Food and Drug Administration and European Medicines Agency drug approvals in 2014 may have marked an end to the dry spell that has troubled the pharmaceutical industry over the past decade. Regardless, the attrition rate of drugs in late clinical phases remains high, and a lack of target validation has been highlighted as an explanation. This has led to a resurgence in appreciation of phenotypic drug screens, as these may be more likely to yield compounds with relevant modes of action. However, cell-based screening approaches do not directly reveal cellular targets, and hence target deconvolution and a detailed understanding of drug action are needed for efficient lead optimization and biomarker development. Here, recently developed functional genomics technologies that address this need are reviewed. The approaches pioneered in model organisms, particularly in yeast, and more recently adapted to mammalian systems are discussed. Finally, areas of particular interest and directions for future tool development are highlighted.	[Nijman, Sebastian M. B.] Ludwig Inst Canc Res Ltd, Oxford, England; [Nijman, Sebastian M. B.] Univ Oxford, Nuffield Dept Med, Target Discovery Inst, Oxford, England; [Nijman, Sebastian M. B.] Austrian Acad Sci CeMM, Res Ctr Mol Med, Vienna, Austria	Ludwig Institute for Cancer Research; University of Oxford; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences	Nijman, SMB (corresponding author), Ludwig Inst Canc Res Ltd, Oxford, England.	sebastian.nijman@ludwig.ox.ac.uk		Nijman, Sebastian/0000-0003-0464-6661				ANDERSSON BS, 1987, CANCER GENET CYTOGEN, V24, P335, DOI 10.1016/0165-4608(87)90116-6; Andrusiak K, 2012, BIOORGAN MED CHEM, V20, P1952, DOI 10.1016/j.bmc.2011.12.023; Arnoldo A, 2014, GENOME MED, V6, DOI 10.1186/gm549; Auerbach C, 1973, CHEM MUTAGENS, P1; Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140; Birsoy K, 2013, NAT GENET, V45, P104, DOI 10.1038/ng.2471; Blomen VA, 2015, SCIENCE, V350, P1092, DOI 10.1126/science.aac7557; Bolotin A, 2005, MICROBIOL-SGM, V151, P2551, DOI 10.1099/mic.0.28048-0; Brummelkamp TR, 2006, NAT CHEM BIOL, V2, P202, DOI 10.1038/nchembio774; Burckstummer T, 2013, NAT METHODS, V10, P965, DOI 10.1038/nmeth.2609; Bunnage ME, 2015, NAT CHEM BIOL, V11, P368, DOI 10.1038/nchembio.1813; Butcher RA, 2006, NAT CHEM BIOL, V2, P103, DOI 10.1038/nchembio762; Carette JE, 2011, NAT BIOTECHNOL, V29, P542, DOI 10.1038/nbt.1857; Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845; Carette JE, 2009, SCIENCE, V326, P1231, DOI 10.1126/science.1178955; Castoreno AB, 2010, NAT CHEM BIOL, V6, P457, DOI 10.1038/nchembio.363; Chong YT, 2015, CELL, V161, P1413, DOI 10.1016/j.cell.2015.04.051; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; de la Cruz FF, 2015, ANNU REV PHARMACOL, V55, P513, DOI 10.1146/annurev-pharmtox-010814-124511; Dejonghe W, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00352; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elling U, 2011, CELL STEM CELL, V9, P563, DOI 10.1016/j.stem.2011.10.012; Enserink JM, 2012, MOLECULES, V17, P9258, DOI 10.3390/molecules17089258; Ericson E, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000151; Essletzbichler P, 2014, GENOME RES, V24, P2059, DOI 10.1101/gr.177220.114; Gamier J.P, 2008, HARVARD BUS REV, V86, P66; Garnier JP, 2008, HARVARD BUS REV, V86, P128; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; Giaever G, 2004, P NATL ACAD SCI USA, V101, P793, DOI 10.1073/pnas.0307490100; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hillenmeyer ME, 2008, SCIENCE, V320, P362, DOI 10.1126/science.1150021; Hillenmeyer ME, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r30; Ho CH, 2011, CURR OPIN CHEM BIOL, V15, P66, DOI 10.1016/j.cbpa.2010.10.023; Ho CH, 2009, NAT BIOTECHNOL, V27, P369, DOI 10.1038/nbt.1534; Hoon S, 2008, NAT CHEM BIOL, V4, P498, DOI 10.1038/nchembio.100; Huang Z, 2013, CELL REP, V3, P577, DOI 10.1016/j.celrep.2013.01.019; Jae LT, 2014, SCIENCE, V344, P1506, DOI 10.1126/science.1252480; Jiang H, 2011, NAT CHEM BIOL, V7, P92, DOI 10.1038/NCHEMBIO.503; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Jones AK, 2005, NAT REV DRUG DISCOV, V4, P321, DOI 10.1038/nrd1692; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kaelin WG, 2012, SCIENCE, V337, P421, DOI 10.1126/science.1225787; Kasap C, 2014, NAT CHEM BIOL, V10, P626, DOI 10.1038/nchembio.1551; Kell DB, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00231; Kleinstiver BP, 2015, NATURE, V523, P481, DOI 10.1038/nature14592; Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136; Kotecki M, 1999, EXP CELL RES, V252, P273, DOI 10.1006/excr.1999.4656; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lee AY, 2014, SCIENCE, V344, P208, DOI 10.1126/science.1250217; Leeb M, 2011, NATURE, V479, P131, DOI 10.1038/nature10448; Li W, 2014, CELL STEM CELL, V14, P404, DOI 10.1016/j.stem.2013.11.016; Luesch H, 2005, CHEM BIOL, V12, P55, DOI 10.1016/j.chembiol.2004.10.015; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Makarova KS, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-7; Mali P, 2013, NAT METHODS, V10, P957, DOI [10.1038/NMETH.2649, 10.1038/nmeth.2649]; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Martins MM, 2015, CANCER DISCOV, V5, P154, DOI 10.1158/2159-8290.CD-14-0552; Matheny CJ, 2013, CHEM BIOL, V20, P1352, DOI 10.1016/j.chembiol.2013.09.014; Melnick JS, 2006, P NATL ACAD SCI USA, V103, P3153, DOI 10.1073/pnas.0511292103; Mojica FJM, 2005, J MOL EVOL, V60, P174, DOI 10.1007/s00239-004-0046-3; Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695; Nichols RJ, 2011, CELL, V144, P143, DOI 10.1016/j.cell.2010.11.052; Nihongaki Y, 2015, NAT BIOTECHNOL, V33, P755, DOI 10.1038/nbt.3245; Nihongaki Y, 2015, CHEM BIOL, V22, P169, DOI 10.1016/j.chembiol.2014.12.011; Nijman SMB, 2013, SCIENCE, V342, P809, DOI 10.1126/science.1244669; Nishimura S, 2010, NAT CHEM BIOL, V6, P519, DOI [10.1038/nchembio.387, 10.1038/NCHEMBIO.387]; Parnas O, 2015, CELL, V162, P675, DOI 10.1016/j.cell.2015.06.059; Parsons AB, 2006, CELL, V126, P611, DOI 10.1016/j.cell.2006.06.040; Pathania R, 2009, NAT CHEM BIOL, V5, P849, DOI 10.1038/nchembio.221; Perlstein EO, 2006, CHEM BIOL, V13, P319, DOI 10.1016/j.chembiol.2006.01.010; Perlstein EO, 2007, NAT GENET, V39, P496, DOI 10.1038/ng1991; Pettitt SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061520; Pourcel C, 2005, MICROBIOL-SGM, V151, P653, DOI 10.1099/mic.0.27437-0; Qi LS, 2013, CELL, V152, P1173, DOI 10.1016/j.cell.2013.02.022; Reiling JH, 2011, P NATL ACAD SCI USA, V108, P11756, DOI 10.1073/pnas.1018098108; Reinhold WC, 2015, HUM GENET, V134, P3, DOI 10.1007/s00439-014-1482-9; Rix U, 2009, NAT CHEM BIOL, V5, P616, DOI 10.1038/nchembio.216; Savitski MM, 2014, SCIENCE, V346, P55, DOI 10.1126/science.1255784; Schenone M, 2013, NAT CHEM BIOL, V9, P232, DOI [10.1038/nchembio.1199, 10.1038/NCHEMBIO.1199]; Segawa K, 2014, SCIENCE, V344, P1164, DOI 10.1126/science.1252809; Shalem O, 2015, NAT REV GENET, V16, P299, DOI 10.1038/nrg3899; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shoichet BK, 2012, TRENDS PHARMACOL SCI, V33, P268, DOI 10.1016/j.tips.2012.03.007; Smurnyy Y, 2014, NAT CHEM BIOL, V10, P623, DOI 10.1038/nchembio.1550; Swarts DC, 2014, NATURE, V507, P258, DOI 10.1038/nature12971; Wacker SA, 2012, NAT CHEM BIOL, V8, P235, DOI [10.1038/NCHEMBIO.779, 10.1038/nchembio.779]; Wallace IM, 2011, CHEM BIOL, V18, P1273, DOI 10.1016/j.chembiol.2011.07.018; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Winter GE, 2014, NAT CHEM BIOL, V10, P768, DOI [10.1038/NCHEMBIO.1590, 10.1038/nchembio.1590]; Xu DM, 2007, PLOS PATHOG, V3, P835, DOI 10.1371/journal.ppat.0030092; Yan Z, 2008, NAT METHODS, V5, P719, DOI 10.1038/nmeth.1231; Yang H, 2013, CELL RES, V23, P1187, DOI 10.1038/cr.2013.93; Yi MS, 2009, SCIENCE, V326, P430, DOI 10.1126/science.1175151	98	54	54	2	46	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	DEC	2015	11	12					942	948		10.1038/nchembio.1963	http://dx.doi.org/10.1038/nchembio.1963			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CX6TG	26575241				2023-01-03	WOS:000365834000011
J	Sarri, G; Davies, M; Lumsden, MA				Sarri, Grammati; Davies, Melanie; Lumsden, Mary Ann		Guideline Dev Grp	GUIDELINES Diagnosis and management of menopause: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DURATION		[Sarri, Grammati; Davies, Melanie] Royal Coll Gynaecologists & Obstetricians, Natl Collaborating Ctr Womens & Childrens Hlth, London NW1 4RG, England; [Davies, Melanie] Univ Coll London Hosp, London E1 1BB, England; [Lumsden, Mary Ann] Univ Glasgow, Reprod & Maternal Med, Glasgow, Lanark, Scotland; [Lumsden, Mary Ann] Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of Glasgow; University of Glasgow	Sarri, G (corresponding author), Royal Coll Gynaecologists & Obstetricians, Natl Collaborating Ctr Womens & Childrens Hlth, London NW1 4RG, England.	gsarri@rcog.org.uk		Davies, Melanie/0000-0001-6907-5527; Bowring, Claire/0000-0003-4219-4117				Avis NE, 2015, JAMA INTERN MED, V175, P531, DOI 10.1001/jamainternmed.2014.8063; Blumel JE, 2011, MENOPAUSE, V18, P778, DOI 10.1097/gme.0b013e318207851d; Chiechi L. M., 1999, Clinical and Experimental Obstetrics and Gynecology, V26, P88; Health and Social Care Information Centre, 2011, PRESCR COST AN ENGL; Krieger N, 2005, J EPIDEMIOL COMMUN H, V59, P740, DOI 10.1136/jech.2005.033316; Lumsden M, 2005, BJOG-INT J OBSTET GY, V112, P689, DOI 10.1111/j.1471-0528.2005.00613.x; National Institute for Health and Care Excellence, 2015, SUSP CANC REC REF; National Institute for Health and Care Excellence, 2009, EARL LOC ADV BREAST; National Institute for Health and Care Excellence, 2013, FAM BREAST CANC CLAS; National Institute for Health and Care Excellence, 2009, DEPR AD REC MAN; National Institute for Health and Care Excellence, 2015, MEN DIAGN MAN MEN NI	11	54	55	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2015	351								h5746	10.1136/bmj.h5746	http://dx.doi.org/10.1136/bmj.h5746			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW4GE	26563259				2023-01-03	WOS:000364948600002
J	Gilbody, S; Littlewood, E; Hewitt, C; Brierley, G; Tharmanathan, P; Araya, R; Barkham, M; Bower, P; Cooper, C; Gask, L; Kessler, D; Lester, H; Lovell, K; Parry, G; Richards, DA; Andersen, P; Brabyn, S; Knowles, S; Shepherd, C; Tallon, D; White, D				Gilbody, Simon; Littlewood, Elizabeth; Hewitt, Catherine; Brierley, Gwen; Tharmanathan, Puvan; Araya, Ricardo; Barkham, Michael; Bower, Peter; Cooper, Cindy; Gask, Linda; Kessler, David; Lester, Helen; Lovell, Karina; Parry, Glenys; Richards, David A.; Andersen, Phil; Brabyn, Sally; Knowles, Sarah; Shepherd, Charles; Tallon, Debbie; White, David		REEACT Team	Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary care (REEACT trial): large scale pragmatic randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADULT DEPRESSION; INTERNET; QUESTIONNAIRES; DISORDERS; ANXIETY; PHQ-9	STUDY QUESTION How effective is supported computerised cognitive behaviour therapy (cCBT) as an adjunct to usual primary care for adults with depression? METHODS This was a pragmatic, multicentre, three arm, parallel randomised controlled trial with simple randomisation. Treatment allocation was not blinded. Participants were adults with symptoms of depression (score >= 10 on nine item patient health questionnaire, PHQ-9) who were randomised to receive a commercially produced cCBT programme ("Beating the Blues") or a free to use cCBT programme (MoodGYM) in addition to usual GP care. Participants were supported and encouraged to complete the programme via weekly telephone calls. Control participants were offered usual GP care, with no constraints on the range of treatments that could be accessed. The primary outcome was severity of depression assessed with the PHQ-9 at four months. Secondary outcomes included health related quality of life (measured by SF-36) and psychological wellbeing (measured by CORE-OM) at four, 12, and 24 months and depression at 12 and 24 months. STUDY ANSWER AND LIMITATIONS Participants offered commercial or free to use cCBT experienced no additional improvement in depression compared with usual GP care at four months (odds ratio 1.19 (95% confidence interval 0.75 to 1.88) for Beating the Blues v usual GP care; 0.98 (0.62 to 1.56) for MoodGYM v usual GP care). There was no evidence of an overall difference between either programme compared with usual GP care (0.99 (0.57 to 1.70) and 0.68 (0.42 to 1.10), respectively) at any time point. Commercially provided cCBT conferred no additional benefit over free to use cCBT or usual GP care at any follow-up point. Uptake and use of cCBT was low, despite regular telephone support. Nearly a quarter of participants (24%) had dropped out by four months. The study did not have enough power to detect small differences so these cannot be ruled out. Findings cannot be generalised to cCBT offered with a much higher level of guidance and support. WHAT THIS STUDY ADDS Supported cCBT does not substantially improve depression outcomes compared with usual GP care alone. In this study, neither a commercially available nor free to use computerised CBT intervention was superior to usual GP care. FUNDING, COMPETING INTERESTS, DATA SHARING Commissioned and funded by the UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (project No 06/43/05). The authors have no competing interests. Requests for patient level data will be considered by the REEACT trial management group	[Gilbody, Simon; Littlewood, Elizabeth; Andersen, Phil; Brabyn, Sally] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Hewitt, Catherine; Tharmanathan, Puvan] Univ York, Dept Hlth Sci, York Trials Unit, York YO10 5DD, N Yorkshire, England; [Brierley, Gwen] Univ Cambridge, Sch Clin Med, MRC Epidemiol Unit, Cambridge CB2 0QQ, England; [Araya, Ricardo] London Sch Hyg & Trop Med, Dept Populat Hlth, London WC1E 7HT, England; [Barkham, Michael] Univ Sheffield, Dept Psychol, Ctr Psychol Serv Res, Sheffield S10 2TP, S Yorkshire, England; [Bower, Peter; Gask, Linda; Knowles, Sarah] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Sch Primary Care Res, Manchester M13 9NT, Lancs, England; [Cooper, Cindy; White, David] Univ Sheffield, Sch Hlth & Related Res, Clin Trials Res Unit, Sheffield S1 4DA, S Yorkshire, England; [Kessler, David; Tallon, Debbie] Univ Bristol, Sch Social & Community Med, Ctr Acad Primary Care, Bristol BS8 2BN, Avon, England; [Lester, Helen] Univ Birmingham, Birmingham B15 2TT, W Midlands, England; [Lovell, Karina] Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester M13 9PL, Lancs, England; [Parry, Glenys] Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England; [Richards, David A.] Univ Exeter, Sch Med, Exeter EX1 2LU, Devon, England; [Shepherd, Charles] Univ Hull, Fac Hlth & Social Care, Kingston Upon Hull HU6 7RX, N Humberside, England	University of York - UK; University of York - UK; University of Cambridge; University of London; London School of Hygiene & Tropical Medicine; University of Sheffield; University of Manchester; University of Sheffield; University of Bristol; University of Birmingham; University of Manchester; University of Sheffield; University of Exeter; University of Hull	Gilbody, S (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	simon.gilbody@york.ac.uk	Araya, Ricardo/S-3144-2019; Bower, Peter/A-1508-2011; Kessler, david/ABB-6489-2021; Gilbody, Simon/AAY-3720-2021; Lovell, Karina S E/E-6410-2012; Richards, David/B-4807-2009	Araya, Ricardo/0000-0002-0420-5148; Bower, Peter/0000-0001-9558-3349; Gilbody, Simon/0000-0002-8236-6983; Lovell, Karina S E/0000-0001-8821-895X; Knowles, Sarah/0000-0002-0863-5866; Barkham, Michael/0000-0003-1687-6376; Hewitt, Catherine Elizabeth/0000-0002-0415-3536; Richards, David/0000-0002-8821-5027; Andersen, Phil/0000-0002-6609-5925	NIHR Health Technology Assessment programme [06/43/05]; National Institute for Health Research [06/43/504, NF-SI-0514-10037, 06/43/05, NF-SI-0611-10203] Funding Source: researchfish	NIHR Health Technology Assessment programme(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	This project was funded by the NIHR Health Technology Assessment programme (project No 06/43/05). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS, or the Department of Health. The funder played no role in the study design, in the collection, analysis or interpretation of the data, in the writing of the paper or in the decision to submit the article for publication. All authors were independent from the funders.	Andersson G, 2014, WORLD PSYCHIATRY, V13, P288, DOI 10.1002/wps.20151; Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P196, DOI 10.1080/16506070903318960; Andrews G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013196; Barkham M, 2001, J CONSULT CLIN PSYCH, V69, P184, DOI 10.1037//0022-006X.69.2.184; Bower P, 2005, BRIT J PSYCHIAT, V186, P11, DOI 10.1192/bjp.186.1.11; Christensen H, 2004, BRIT MED J, V328, P265, DOI 10.1136/bmj.37945.566632.EE; Clark DM, 2011, INT REV PSYCHIATR, V23, P318, DOI 10.3109/09540261.2011.606803; Cuijpers P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021274; Cuijpers P, 2009, BRIT J GEN PRACT, V59, P120, DOI 10.3399/bjgp09X395139; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Kaltenthaler E, 2008, PSYCHOL MED, V38, P1521, DOI 10.1017/S0033291707002607; Kaltenthaler E, 2006, HEALTH TECHNOL ASSES, V10, P1, DOI 10.3310/hta10330; Kendrick T, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b750; Kessler D, 2009, LANCET, V374, P628, DOI 10.1016/S0140-6736(09)61257-5; King M, 2000, Health Technol Assess, V4, P1; Knowles SE, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008581; Kohn R, 2004, B WORLD HEALTH ORGAN, V82, P811; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Layard R, 2006, BRIT MED J, V332, P1030, DOI 10.1136/bmj.332.7548.1030; Lester H, 2008, POSTGRAD MED J, V84, P545, DOI 10.1136/pgmj.2008.068387; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; Littlewood E, 2015, HLTH TECHNO IN PRESS; Manea L, 2012, CAN MED ASSOC J, V184, pE191, DOI 10.1503/cmaj.110829; National Institute for Health and Care Excellence, 2009, DEPR AD TREATM MAN D, V90; Papanikolaou PN, 2004, AM J PSYCHIAT, V161, P1692, DOI 10.1176/appi.ajp.161.9.1692; Peveler R, 2005, Health Technol Assess, V9, P1; Proudfoot J, 2003, PSYCHOL MED, V33, P217, DOI 10.1017/S0033291702007225; Roth A., 2005, WHAT WORKS WHOM CRIT, V2nd; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; So M, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-113; Spek V, 2007, PSYCHOL MED, V37, P319, DOI 10.1017/S0033291706008944; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Ustun TB, 2004, BRIT J PSYCHIAT, V184, P386, DOI 10.1192/bjp.184.5.386; Waller R, 2009, PSYCHOL MED, V39, P705, DOI 10.1017/S0033291708004224; Ware J.E., 1993, SF 36 HLTH SURVEY MA, DOI 10.1097/00007632-200012150-00008; Ware Jr JE, 2001, SCORE VERSION 2 SF 3; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; World Health Organization, 1990, INT STAT CLASS DIS R	38	265	267	4	59	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	2015	351								h5627	10.1136/bmj.h5627	http://dx.doi.org/10.1136/bmj.h5627			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CW4FX	26559241	hybrid, Green Accepted, Green Published			2023-01-03	WOS:000364947900002
J	Ambrose, BK; Day, HR; Rostron, B; Conway, KP; Borek, N; Hyland, A; Villanti, AC				Ambrose, Bridget K.; Day, Hannah R.; Rostron, Brian; Conway, Kevin P.; Borek, Nicolette; Hyland, Andrew; Villanti, Andrea C.			Flavored Tobacco Product Use Among US Youth Aged 12-17 Years, 2013-2014	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Ambrose, Bridget K.; Day, Hannah R.; Rostron, Brian; Borek, Nicolette] US FDA, Ctr Tobacco Prod, Silver Spring, MD 20993 USA; [Conway, Kevin P.] NIDA, Div Epidemiol Serv & Prevent Res, Bethesda, MD 20892 USA; [Hyland, Andrew] Roswell Pk Canc Inst, Dept Hlth Behav, Buffalo, NY 14263 USA; [Villanti, Andrea C.] Truth Initiat, Schroeder Inst Tobacco Res & Policy Studies, Washington, DC USA	US Food & Drug Administration (FDA); FDA Center for Tobacco Products (CTP); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Roswell Park Cancer Institute	Ambrose, BK (corresponding author), US FDA, Off Sci, Ctr Tobacco Prod, 10903 New Hampshire Ave,Bldg 75,Room 4432, Silver Spring, MD 20993 USA.	bridget.ambrose@fda.hhs.gov	Villanti, Andrea/AAM-9433-2021; Hyland, Andrew/ABE-6249-2020; Villanti, Andrea/ABE-6283-2020	Villanti, Andrea/0000-0003-3104-966X; Villanti, Andrea/0000-0003-3104-966X; Conway, Kevin/0000-0002-7638-339X	NCI NIH HHS [P50 CA111236] Funding Source: Medline; NIDA NIH HHS [HHSN271201100027C] Funding Source: Medline; PHS HHS [HHSN271201100027C] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA111236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arrozola RA, 2015, MMWR-MORBID MORTAL W, V64, P381; Biglan M, 2004, NICOTINE TOB RES, V6, P427, DOI 10.1080/14622200410001696592; Corey CG, 2015, MMWR-MORBID MORTAL W, V64, P1066, DOI 10.15585/mmwr.mm6438a2; National Center for Chronic Disease Prevention and Health Promotion, 2012, PREV TOB UYOUTH YO; US Office of Management and Budget, PATH STUD INT REP	5	220	223	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2015	314	17					1871	1873		10.1001/jama.2015.13802	http://dx.doi.org/10.1001/jama.2015.13802			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV0RO	26502219	Bronze, Green Accepted			2023-01-03	WOS:000363960200022
J	Sanghavi, P; Jena, AB; Newhouse, JP; Zaslavsky, AM				Sanghavi, Prachi; Jena, Anupam B.; Newhouse, Joseph P.; Zaslavsky, Alan M.			Outcomes of Basic Versus Advanced Life Support for Out-of-Hospital Medical Emergencies	ANNALS OF INTERNAL MEDICINE			English	Article							ADVANCED AIRWAY MANAGEMENT; PREHOSPITAL TRAUMA CARE; CARDIAC-ARREST; ENDOTRACHEAL INTUBATION; INSTRUMENTAL VARIABLES; BRAIN-INJURY; MORTALITY; SURVIVAL; ASSOCIATION	Background: Most Medicare patients seeking emergency medical transport are treated by ambulance providers trained in advanced life support (ALS). Evidence supporting the superiority of ALS over basic life support (BLS) is limited, but some studies suggest ALS may harm patients. Objective: To compare outcomes after ALS and BLS in out-of-hospital medical emergencies. Design: Observational study with adjustment for propensity score weights and instrumental variable analyses based on county-level variations in ALS use. Setting: Traditional Medicare. Patients: 20% random sample of Medicare beneficiaries from nonrural counties between 2006 and 2011 with major trauma, stroke, acute myocardial infarction (AMI), or respiratory failure. Measurements: Neurologic functioning and survival to 30 days, 90 days, 1 year, and 2 years. Results: Except in cases of AMI, patients showed superior unadjusted outcomes with BLS despite being older and having more comorbidities. In propensity score analyses, survival to 90 days among patients with trauma, stroke, and respiratory failure was higher with BLS than ALS (6.1 percentage points [95% CI, 5.4 to 6.8 percentage points] for trauma; 7.0 percentage points [CI, 6.2 to 7.7 percentage points] for stroke; and 3.7 percentage points [CI, 2.5 to 4.8 percentage points] for respiratory failure). Patients with AMI did not exhibit differences in survival at 30 days but had better survival at 90 days with ALS (1.0 percentage point [CI, 0.1 to 1.9 percentage points]). Neurologic functioning favored BLS for all diagnoses. Results from instrumental variable analyses were broadly consistent with propensity score analyses for trauma and stroke, showed no survival differences between BLS and ALS for respiratory failure, and showed better survival at all time points with BLS than ALS for patients with AMI. Limitation: Only Medicare beneficiaries from nonrural counties were studied. Conclusion: Advanced life support is associated with substantially higher mortality for several acute medical emergencies than BLS.	[Sanghavi, Prachi] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA; [Jena, Anupam B.; Newhouse, Joseph P.; Zaslavsky, Alan M.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	University of Chicago; Harvard University; Harvard Medical School	Sanghavi, P (corresponding author), Univ Chicago, Dept Publ Hlth Sci, 5841 South Maryland Ave,MC2000, Chicago, IL 60637 USA.	psanghavi@health.bsd.uchicago.edu	Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022		National Science Foundation Graduate Research Fellowship; Agency for Healthcare Research and Quality [1R36HS022798-01]; National Institutes of Health Early Independence Award [1DP5OD017897-01]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R36HS022798] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD017897] Funding Source: NIH RePORTER	National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institutes of Health Early Independence Award; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	By a National Science Foundation Graduate Research Fellowship (Dr. Sanghavi), an Agency for Healthcare Research and Quality grant (1R36HS022798-01; Dr. Sanghavi), and the National Institutes of Health Early Independence Award (1DP5OD017897-01; Dr. Jena).	Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; [Anonymous], AR HLTH RES FIL AHRF; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Bur A, 2001, INTENS CARE MED, V27, P1474, DOI 10.1007/s001340101045; Gagne JJ, 2011, J CLIN EPIDEMIOL, V64, P749, DOI 10.1016/j.jclinepi.2010.10.004; Goodman DC, 2009, 2009 POPULATION ESTI; Grenvik ASP., 1981, BRAIN FAILURE RESUSC, P155; Haas B, 2008, CRIT CARE, V12, DOI 10.1186/cc6980; Hanif MA, 2010, ACAD EMERG MED, V17, P926, DOI 10.1111/j.1553-2712.2010.00829.x; Hasegawa K, 2013, JAMA-J AM MED ASSOC, V309, P257, DOI 10.1001/jama.2012.187612; Haut ER, 2011, ANN SURG, V253, P371, DOI 10.1097/SLA.0b013e318207c24f; Isenberg DL, 2005, PREHOSPITAL DISASTER, V20, P265, DOI 10.1017/S1049023X0000265X; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Jayaraman S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003109.pub2; Lecky F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001429.pub2; Liberman M, 2003, ANN SURG, V237, P153, DOI 10.1097/00000658-200302000-00001; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Ma MHM, 2007, RESUSCITATION, V74, P461, DOI 10.1016/j.resuscitation.2007.02.006; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; Medicare Payment Advisory Commission, 2012, PAYM BAS AMB SERV PA; Medicare Payment Advisory Commission, 2013, REP C MED HLTH CAR D; Meredith JW, 2002, J TRAUMA, V53, P621, DOI 10.1097/00005373-200210000-00001; Prasad V, 2013, JAMA-J AM MED ASSOC, V309, P241, DOI 10.1001/jama.2012.96867; Ryynanen OP, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-62; Sanghavi P, 2015, JAMA INTERN MED, V175, P196, DOI 10.1001/jamainternmed.2014.5420; Sasser S., 2005, PREHOSPITAL TRAUMA C; Sasser SM, 2006, B WORLD HEALTH ORGAN, V84, P507, DOI 10.2471/BLT.06.033605; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; Stiell IG, 2007, NEW ENGL J MED, V356, P2156, DOI 10.1056/NEJMoa060334; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Sukumaran S, 2005, EMERG MED J, V22, P60, DOI 10.1136/emj.2004.016873; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; Wang HE, 2005, CRIT CARE MED, V33, P1718, DOI 10.1097/01.CCM.0000171208.07895.2A; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2013, JAMA-J AM MED ASSOC, V309, P285, DOI 10.1001/jama.2012.216998	40	38	38	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 3	2015	163	9					681	+		10.7326/M15-0557	http://dx.doi.org/10.7326/M15-0557			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX3PF	26457627	Green Accepted			2023-01-03	WOS:000365610600005
J	McCartney, M				McCartney, Margaret			Margaret McCartney: Honesty, placebos, and pain care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; OSTEOARTHRITIS; PARACETAMOL; EFFICACY; SAFETY					margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9; Bhugra D, 2015, INT J SOC PSYCHIATR, V61, P615, DOI 10.1177/0020764015591492; deCraen AJM, 1996, BRIT MED J, V313, P321, DOI 10.1136/bmj.313.7053.321; European Medicines Agency, 2013, NEW SAF ADV DICL CMD; Fox C, 2011, J AM GERIATR SOC, V59, P1477, DOI 10.1111/j.1532-5415.2011.03491.x; Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591; Machado GC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1225; Makris UE, 2010, J RHEUMATOL, V37, P1236, DOI 10.3899/jrheum.090935; Moore R Andrew, 2014, Cochrane Database Syst Rev, pCD007938, DOI 10.1002/14651858.CD007938.pub3; Myint PK, 2015, AGE AGEING, V44, P219, DOI 10.1093/ageing/afu185; NHS England Public Health England, 2014, ADV PRESCR RISK MIS; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Roberts E, 2016, ANN RHEUM DIS, V75, P552, DOI 10.1136/annrheumdis-2014-206914; Snowden S, 2011, CARDIOL REV, V19, P184, DOI 10.1097/CRD.0b013e31821ddcf4	14	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2015	351								h5103	10.1136/bmj.h5103	http://dx.doi.org/10.1136/bmj.h5103			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT3SC	26438576	Bronze			2023-01-03	WOS:000362726200004
J	Zalcman, G; Mazieres, J; Margery, J; Greillier, L; Audigier-Valette, C; Moro-Sibilot, D; Molinier, O; Corre, R; Monnet, I; Gounant, V; Riviere, F; Janicot, H; Gervais, R; Locher, C; Milleron, B; Tran, Q; Lebitasy, MP; Morin, F; Creveuil, C; Parienti, JJ; Scherpereel, A				Zalcman, Gerard; Mazieres, Julien; Margery, Jacques; Greillier, Laurent; Audigier-Valette, Clarisse; Moro-Sibilot, Denis; Molinier, Olivier; Corre, Romain; Monnet, Isabelle; Gounant, Valerie; Riviere, Frederic; Janicot, Henri; Gervais, Radj; Locher, Chrystele; Milleron, Bernard; Quan Tran; Lebitasy, Marie-Paule; Morin, Franck; Creveuil, Christian; Parienti, Jean-Jacques; Scherpereel, Arnaud		Frech Cooperative Thoracic	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial	LANCET			English	Article							ENDOTHELIAL GROWTH-FACTOR; MALIGNANT MESOTHELIOMA; PLUS BEVACIZUMAB; PROGNOSTIC-FACTORS; 1ST-LINE THERAPY; MULTICENTER; CANCER; FLUOROURACIL; CARBOPLATIN; COMBINATION	Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis, linked to occupational asbestos exposure. Vascular endothelial growth factor is a key mitogen for malignant pleural mesothelioma cells, therefore targeting of vascular endothelial growth factor might prove effective. We aimed to assess the effect on survival of bevacizumab when added to the present standard of care, cisplatin plus pemetrexed, as first-line treatment of advanced malignant pleural mesothelioma. Methods In this randomised, controlled, open-label, phase 3 trial, we recruited patients aged 18-75 years with unresectable malignant pleural mesothelioma who had not received previous chemotherapy, had an Eastern Cooperative Oncology Group performance status of 0-2, had no substantial cardiovascular comorbidity, were not amenable to curative surgery, had at least one evaluable (pleural effusion) or measurable (pleural tumour solid thickening) lesion with CT, and a life expectancy of >12 weeks from 73 hospitals in France. Exclusion criteria were presence of central nervous system metastases, use of antiaggregant treatments (aspirin >= 325 mg per day, clopidogrel, ticlopidine, or dipyridamole), anti-vitamin K drugs at a curative dose, treatment with low-molecular-weight heparin at a curative dose, and treatment with non-steroidal anti-inflammatory drugs. We randomly allocated patients (1: 1; minimisation method used [random factor of 0.8]; patients stratified by histology [epithelioid vs sarcomatoid or mixed histology subtypes], performance status score [0-1 vs 2], study centre, or smoking status [never smokers vs smokers]) to receive intravenously 500 mg/m(2) pemetrexed plus 75 mg/m(2) cisplatin with (PCB) or without (PC) 15 mg/kg bevacizumab in 21 day cycles for up to six cycles, until progression or toxic effects. The primary outcome was overall survival (OS) in the intention-to treat population. Treatment was open label. This IFCT-GFPC-0701 trial is registered with ClinicalTrials.gov, number NCT00651456. Findings From Feb 13, 2008, to Jan 5, 2014, we randomly assigned 448 patients to treatment (223 [50%] to PCB and 225 [50%] to PC). OS was significantly longer with PCB (median 18.8 months [95% CI 15.9-22.6]) than with PC (16.1 months [14.0-17.9]; hazard ratio 0.77 [0.62-0.95]; p=0.0167). Overall, 158 (71%) of 222 patients given PCB and 139 (62%) of 224 patients given PC had grade 3-4 adverse events. We noted more grade 3 or higher hypertension (51 [23%] of 222 vs 0) and thrombotic events (13 [6%] of 222 vs 2 [1%] of 224) with PCB than with PC. Interpretation Addition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease.	[Zalcman, Gerard] Univ Caen, Dept Pulmonol & Thorac Oncol, Ctr Hosp Univ Cote Nacre, F-14032 Caen, France; [Zalcman, Gerard] Univ Paris 07, Dept Thorac Oncol, Hosp Bichat Claude Bernard, AP HP,Ctr Invest Clin,Inst Natl Sante & Rech Med, F-75877 Paris 18, France; [Mazieres, Julien] Larrey Hosp, Dept Pulmonol, Toulouse, France; [Margery, Jacques] Inst Gustave Roussy, Villejuif, France; [Greillier, Laurent] Assistance Publ Hop Marseille, Marseille, France; [Audigier-Valette, Clarisse] Ctr Hosp Intercommunal Toulon, Dept Pulmonol, Toulon, France; [Moro-Sibilot, Denis] CHU Grenoble, Pole Thorax & Vaisseaux, F-38043 Grenoble, France; [Molinier, Olivier] Ctr Hosp Le Mans, Dept Pulmonol, Le Mans, France; [Corre, Romain] Ponchaillou Univ Hosp, Dept Pulmonol, Rennes, France; [Monnet, Isabelle] Ctr Hosp Intercommunal Creteil, Dept Pulmonol, Creteil, France; [Gounant, Valerie] Hop Tenon, AP HP, F-75970 Paris, France; [Riviere, Frederic] Hop Instruct Armees Percy, Dept Pulmonol, Clamart, France; [Janicot, Henri] Gabriel Montpied Univ, Dept Pulmonol, Clermont Ferrand, France; [Gervais, Radj] Ctr Reg Lutte Canc Francois Baclesse, Caen, France; [Locher, Chrystele] Ctr Hosp Meaux, Dept Pulmonol, Meaux, France; [Milleron, Bernard; Quan Tran; Lebitasy, Marie-Paule; Morin, Franck] French Cooperat Thorac Grp, Paris, France; [Creveuil, Christian; Parienti, Jean-Jacques] Ctr Hosp Univ Cote Nacre, Dept Biostat & Clin Res, Caen, France; [Creveuil, Christian; Parienti, Jean-Jacques] Caen Normandy Univ, Equipe Accueil 4655, Caen, France; [Scherpereel, Arnaud] Univ Lille, Pulm & Thorac Oncol Dept, Ctr Hosp Univ Lille, INSERM,U10191,Ctr Infect & Immunite Lille, Lille, France	CHU de Caen NORMANDIE; Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de Toulouse; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Centre Hospitalier Le Mans; CHU Rennes; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Clermont Ferrand; UNICANCER; Centre Francois Baclesse; CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Caen Normandie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille	Zalcman, G (corresponding author), Univ Paris 07, Dept Thorac Oncol, Hosp Bichat Claude Bernard, AP HP,Ctr Invest Clin,Inst Natl Sante & Rech Med, F-75877 Paris 18, France.	gerard.zalcman@aphp.fr	CREVEUIL, Christian/L-7215-2015; ZALCMAN, Gerard/M-8113-2019; Parienti, Jean-Jacques/AAD-1701-2021; MAZIERES, JULIEN/M-3986-2014	CREVEUIL, Christian/0000-0002-5506-5296; Parienti, Jean-Jacques/0000-0002-4774-5590; MAZIERES, JULIEN/0000-0002-5921-7613; MORO-SIBILOT, Denis/0000-0001-6776-8610; Morin, Franck/0000-0002-7510-2787	Intergroupe Francophone de Cancerologie Thoracique (IFCT); French Ministry of Health (Programme Hospitalier de Recherche Clinique); French League against Cancer; Caen University Hospital; Canceropole North-West; Normandy League against Cancer	Intergroupe Francophone de Cancerologie Thoracique (IFCT); French Ministry of Health (Programme Hospitalier de Recherche Clinique); French League against Cancer; Caen University Hospital; Canceropole North-West; Normandy League against Cancer	Intergroupe Francophone de Cancerologie Thoracique (IFCT).; This study was funded by the Intergroupe Francophone de Cancerologie Thoracique (IFCT). This study was supported by funds from the French Ministry of Health (Programme Hospitalier de Recherche Clinique, 2007), the French League against Cancer funding for IFCT, research subventions for biomarker correlative studies from F Hoffmann-La Roche to IFCT, and funds from Caen University Hospital (Apricus Biosciences 2013), Canceropole North-West (2013), and the Normandy League against Cancer (2014) to GZ. On behalf of all Mesothelioma Avastin Cisplatin Pemetrexed Study investigators (appendix), we acknowledge the dedication of the nursing and medical staff of the participating centres, IFCT clinical research staff and statistician (Alexandra Langlais), and the study participants, without whom this study could not have been completed. We also acknowledge the independent data monitoring committee members (Dominique Valeyre, Aimery De Gramont, Ariane Dunant, and Thierry Berghmans) for their rigorous work, and pathologists from the participating centres and the French Panel MESOPATH. Medical writing assistance was provided by Gardiner-Caldwell Communications.	BAUER P, 1991, STAT MED, V10, P871, DOI 10.1002/sim.4780100609; BOUTIN C, 1995, CHEST, V108, P754, DOI 10.1378/chest.108.3.754; Buikhuisen WA, 2013, LANCET ONCOL, V14, P543, DOI 10.1016/S1470-2045(13)70125-6; Byrne MJ, 2004, ANN ONCOL, V15, P257, DOI 10.1093/annonc/mdh059; Ceresoli GL, 2013, BRIT J CANCER, V109, P552, DOI 10.1038/bjc.2013.368; Ceresoli GL, 2006, J CLIN ONCOL, V24, P1443, DOI 10.1200/JCO.2005.04.3190; Curran D, 1998, J CLIN ONCOL, V16, P145, DOI 10.1200/JCO.1998.16.1.145; Dowell JE, 2012, LUNG CANCER, V77, P567, DOI 10.1016/j.lungcan.2012.05.111; Dubey S, 2010, J THORAC ONCOL, V5, P1655, DOI 10.1097/JTO.0b013e3181ec18db; Garland LL, 2011, J THORAC ONCOL, V6, P1938, DOI 10.1097/JTO.0b013e318229586e; Gelvez-Zapata SM, 2013, INTERACT CARDIOV TH, V16, P533, DOI 10.1093/icvts/ivs542; Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305; Gray R, 2009, J CLIN ONCOL, V27, P4966, DOI 10.1200/JCO.2008.21.6630; Hollen PJ, 2004, CANCER-AM CANCER SOC, V101, P587, DOI 10.1002/cncr.20315; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jackman DM, 2008, CANCER-AM CANCER SOC, V113, P808, DOI 10.1002/cncr.23617; Kahan BC, 2012, STAT MED, V31, P328, DOI 10.1002/sim.4431; Kindler HL, 2012, J CLIN ONCOL, V30, P2509, DOI 10.1200/JCO.2011.41.5869; Labby ZE, 2012, J THORAC ONCOL, V7, P1728, DOI 10.1097/JTO.0b013e318269fe21; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; Nowak AK, 2012, J THORAC ONCOL, V7, P1449, DOI 10.1097/JTO.0b013e31825f22ee; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Reck M, 2009, J CLIN ONCOL, V27, P1227, DOI 10.1200/JCO.2007.14.5466; Scherpereel A, 2010, EUR RESPIR J, V35, P479, DOI [10.1183/09031936.00063109, 10.3779/j.issn.1009-3419.2010.10.14]; Steele JPC, 2005, HEMATOL ONCOL CLIN N, V19, P1041, DOI 10.1016/j.hoc.2005.09.009; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Treasure T, 2011, LANCET ONCOL, V12, P763, DOI 10.1016/S1470-2045(11)70149-8; Van Schil PE, 2010, EUR RESPIR J, V36, P1362, DOI 10.1183/09031936.00039510; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; WAGNER J C, 1960, Br J Ind Med, V17, P260; Zalcman G, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.7020; Zhu XL, 2007, AM J KIDNEY DIS, V49, P186, DOI 10.1053/j.ajkd.2006.11.039	34	544	557	4	65	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	2016	387	10026					1405	1414		10.1016/S0140-6736(15)01238-6	http://dx.doi.org/10.1016/S0140-6736(15)01238-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DI0WH	26719230				2023-01-03	WOS:000373217500033
J	Yee, A; Danaee, M; Loh, HS; Sulaiman, AH; Ng, CG				Yee, Anne; Danaee, Mahmoud; Loh, Huai Seng; Sulaiman, Ahmad Hatim; Ng, Chong Guan			Sexual Dysfunction in Heroin Dependents: A Comparison between Methadone and Buprenorphine Maintenance Treatment	PLOS ONE			English	Article							MEN RECEIVING METHADONE; NEUROPSYCHIATRIC INTERVIEW MINI; ERECTILE DYSFUNCTION; INTERNATIONAL INDEX; OPIOID DEPENDENCE; TESTOSTERONE; BEHAVIOR; USERS; METAANALYSIS; EJACULATION	Introduction Methadone has long been regarded as an effective treatment for opioid dependence. However, many patients discontinue maintenance therapy because of its side effects, with one of the most common being sexual dysfunction. Buprenorphine is a proven alternative to methadone. This study aimed to investigate sexual dysfunction in opioid-dependent men on buprenorphine maintenance treatment (BMT) and methadone maintenance treatment (MMT). The secondary aim was to investigate the correlation between sexual dysfunction and the quality of life in these patients. Methods Two hundred thirty-eight men participated in this cross-sectional study. Four questionnaires were used, the Mini International Neuropsychiatric Interview, Opiate Treatment Index, Malay version of the International Index of Erectile Function 15 (Mal-IIEF-15), and World Health Organization Quality of Life-BREF Scale. Multivariate analysis of covariance was used to examine the relationship between MMT and BMT and the Mal-IIEF 15 scores while controlling for all the possible confounders. Results The study population consisted of 171 patients (71.8%) on MMT and 67 (28.2%) on BMT. Patients in the MMT group who had a sexual partner scored significantly lower in the sexual desire domain (p < 0.012) and overall satisfaction (p = 0.043) domain compared with their counterparts in the BMT group. Similarly, patients in the MMT group without a sexual partner scored significantly lower in the orgasmic function domain (p = 0.008) compared with those in the BMT group without a partner. Intercourse satisfaction (p = 0.026) and overall satisfaction (p = 0.039) were significantly associated with the social relationships domain after adjusting for significantly correlated sociodemographic variables. Conclusions Sexual functioning is critical for improving the quality of life in patients in an opioid rehabilitation program. Our study showed that buprenorphine causes less sexual dysfunction than methadone. Thus, clinicians may consider the former when treating heroin dependents who have concerns about sexual function.	[Yee, Anne; Danaee, Mahmoud; Sulaiman, Ahmad Hatim; Ng, Chong Guan] Univ Malaya, Fac Med, Dept Psychol Med, Ctr Addict Sci, Kuala Lumpur, Malaysia; [Loh, Huai Seng] Newcastle Univ Med Malaysia, Clin Acad Unit Family Med, Nusajaya, Johor, Malaysia	Universiti Malaya	Yee, A (corresponding author), Univ Malaya, Fac Med, Dept Psychol Med, Ctr Addict Sci, Kuala Lumpur, Malaysia.	annyee17@um.edu.my	Danaee, Mahmoud/F-4147-2012; Hway Ann, Yee/D-7968-2012; Ng, Chong Guan/G-6170-2010; Loh, Huai Seng/G-9604-2013; Danaee, Mahmomoud/AAW-3097-2021; SULAIMAN, AHMAD HATIM/B-8156-2010	Danaee, Mahmoud/0000-0002-5014-5684; Hway Ann, Yee/0000-0002-9835-6798; Danaee, Mahmomoud/0000-0002-5014-5684; SULAIMAN, AHMAD HATIM/0000-0002-8364-4594				Argiolas A, 2013, PROG NEUROBIOL, V108, P80, DOI 10.1016/j.pneurobio.2013.06.006; Babakhanian M, 2012, ARCH IRAN MED, V15, P751, DOI 0121512/AIM.006; Balon R., 2005, HDB SEXUAL DYSFUNCTI; Bawor M, 2015, DRUG ALCOHOL DEPEN, V149, P1, DOI 10.1016/j.drugalcdep.2015.01.038; Bliesener N, 2005, J CLIN ENDOCR METAB, V90, P203, DOI 10.1210/jc.2004-0929; Bodie J, 2003, J UROLOGY, V169, P2262, DOI 10.1097/01.ju.0000063940.19080.58; Brown R, 2005, J ADDICT DIS, V24, P91, DOI 10.1300/J069v24n02_08; Chekuri V, 2012, ADDICT BEHAV, V37, P124, DOI 10.1016/j.addbeh.2011.08.005; Chen W, 2012, J ADDICT MED, V6, P212, DOI 10.1097/ADM.0b013e318259b2c4; CICERO TJ, 1975, NEW ENGL J MED, V292, P882, DOI 10.1056/NEJM197504242921703; Cioe PA, 2010, J ADDICT DIS, V29, P455, DOI 10.1080/10550887.2010.509279; Curcio F, 2011, EUR REV MED PHARMACO, V15, P871; DARKE S, 1991, 11 NDARC; Gill JS, 2007, ASEAN J PSYCHIATR, V8, P64; GLADUE BA, 1980, ENDOCRINOLOGY, V106, P1917, DOI 10.1210/endo-106-6-1917; Hallinan R, 2009, INT J ANDROL, V32, P131, DOI 10.1111/j.1365-2605.2007.00824.x; Hallinan R, 2008, J SEX MED, V5, P684, DOI 10.1111/j.1743-6109.2007.00702.x; HANBURY R, 1977, AM J DRUG ALCOHOL AB, V4, P13, DOI 10.3109/00952997709002743; Hariri AG, 2009, COMPR PSYCHIAT, V50, P353, DOI 10.1016/j.comppsych.2008.09.009; Hasanah C I, 2003, Med J Malaysia, V58, P79; Heidari Z, 2012, INT J HIGH RISK BEHA, V1, P12; Hospital Kuala Lumpur, 2009, METH MAINT THER PHAR; Huong AGW, 2009, ASEAN J PSYCHIATR, V10, P8; HYYPPA M, 1970, ACTA NEUROL SCAND, V46, P223; JOHNSON AR, 1992, J UROLOGY, V147, P1542, DOI 10.1016/S0022-5347(17)37620-6; Levine SB, 2003, ARCH SEX BEHAV, V32, P279, DOI 10.1023/A:1023421819465; Maremmani I., 2010, PRINCIPLE PRACTICE M; Matuszewich L, 1995, PSYCHOPHARMACOLOGY, V122, P330, DOI 10.1007/BF02246262; Meuleman EJ, 2015, CLIN UROANDROLOGY, P133; Nimroozi R, 2014, J DEV DRUGS, V3, P2, DOI DOI 10.4172/2329-6631.1000117; NOVICK DM, 1993, DRUG ALCOHOL DEPEN, V33, P235, DOI 10.1016/0376-8716(93)90110-C; Pfaus JG, 2009, J SEX MED, V6, P1506, DOI 10.1111/j.1743-6109.2009.01309.x; Quaglio G, 2008, DRUG ALCOHOL DEPEN, V94, P12, DOI 10.1016/j.drugalcdep.2007.09.025; Quek KF, 2002, INT J IMPOT RES, V14, P310, DOI 10.1038/sj.ijir.3900902; Ramdurg S, 2012, J SEX MED, V9, P3198, DOI 10.1111/j.1743-6109.2011.02219.x; Ramli M, 2009, Malays Fam Physician, V4, P77; Rosen RC, 2002, INT J IMPOT RES, V14, P226, DOI 10.1038/sj.ijir.3900857; Rowland D, 2010, J SEX MED, V7, P1668, DOI 10.1111/j.1743-6109.2010.01782.x; Sheehan DV, 1997, EUR PSYCHIAT, V12, P232, DOI 10.1016/S0924-9338(97)83297-X; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Tatari Faezeh, 2010, Iran J Psychiatry, V5, P164; Xia YH, 2013, PSYCHOL HEALTH MED, V18, P321, DOI 10.1080/13548506.2012.729845; Yee A, 2014, INT J IMPOT RES, V26, P161, DOI 10.1038/ijir.2014.18; Yee A, 2014, J SEX MED, V11, P22, DOI 10.1111/jsm.12352; Zhang Yao, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P739, DOI 10.3969/j.issn.1672-7347.2011.08.007	45	28	28	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2016	11	1							e0147852	10.1371/journal.pone.0147852	http://dx.doi.org/10.1371/journal.pone.0147852			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9GF	26820154	Green Published, gold, Green Submitted			2023-01-03	WOS:000369528400050
J	Cantin, D; Djeddi, D; Carriere, V; Samson, N; Nault, S; Jia, WL; Beck, J; Praud, JP				Cantin, Danny; Djeddi, Djamal; Carriere, Vincent; Samson, Nathalie; Nault, Stephanie; Jia, Wan Lu; Beck, Jennifer; Praud, Jean-Paul			Inhibitory Effect of Nasal Intermittent Positive Pressure Ventilation on Gastroesophageal Reflux	PLOS ONE			English	Article							LOWER ESOPHAGEAL SPHINCTER; NONSEDATED NEWBORN LAMBS; AIRWAY PRESSURE; MUSCLE-ACTIVITY; PRETERM LAMBS; INFANTS; APNEA	Non-invasive intermittent positive pressure ventilation can lead to esophageal insufflations and in turn to gastric distension. The fact that the latter induces transient relaxation of the lower esophageal sphincter implies that it may increase gastroesophageal refluxes. We previously reported that nasal Pressure Support Ventilation (nPSV), contrary to nasal Neurally-Adjusted Ventilatory Assist (nNAVA), triggers active inspiratory laryngeal closure. This suggests that esophageal insufflations are more frequent in nPSV than in nNAVA. The objectives of the present study were to test the hypotheses that: i) gastroesophageal refluxes are increased during nPSV compared to both control condition and nNAVA; ii) esophageal insufflations occur more frequently during nPSV than nNAVA. Polysomno-graphic recordings and esophageal multichannel intraluminal impedance pHmetry were performed in nine chronically instrumented newborn lambs to study gastroesophageal refluxes, esophageal insufflations, states of alertness, laryngeal closure and respiration. Recordings were repeated without sedation in control condition, nPSV (15/4 cmH(2)O) and nNAVA (similar to 15/4 cmH(2)O). The number of gastroesophageal refluxes recorded over six hours, expressed as median (interquartile range), decreased during both nPSV (1 (0, 3)) and nNAVA [1 (0, 3)] compared to control condition (5 (3, 10)), (p < 0.05). Meanwhile, the esophageal insufflation index did not differ between nPSV (40 (11, 61) h(-1)) and nNAVA (10 (9, 56) h(-1)) (p = 0.8). In conclusion, nPSV and nNAVA similarly inhibit gastroesophageal refluxes in healthy newborn lambs at pressures that do not lead to gastric distension. In addition, the occurrence of esophageal insufflations is not significantly different between nPSV and nNAVA. The strong inhibitory effect of nIPPV on gastroesophageal refluxes appears identical to that reported with nasal continuous positive airway pressure.	[Cantin, Danny; Djeddi, Djamal; Carriere, Vincent; Samson, Nathalie; Nault, Stephanie; Jia, Wan Lu; Praud, Jean-Paul] Univ Sherbrooke, Dept Pediat, Neonatal Resp Res Unit, Sherbrooke, PQ J1K 2R1, Canada; [Cantin, Danny; Carriere, Vincent; Samson, Nathalie; Nault, Stephanie; Jia, Wan Lu; Praud, Jean-Paul] Univ Sherbrooke, Dept Physiol, Sherbrooke, PQ J1K 2R1, Canada; [Djeddi, Djamal] Univ Picardie Jules Verne, Dept Pediat, Amiens, France; [Beck, Jennifer] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Beck, Jennifer] St Michaels Hosp, Keenan Res Ctr Biomed Sci, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Beck, Jennifer] Ryerson Univ, iBEST, Toronto, ON, Canada; [Beck, Jennifer] St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada	University of Sherbrooke; University of Sherbrooke; Picardie Universites; Universite de Picardie Jules Verne (UPJV); University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Toronto Metropolitan University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Praud, JP (corresponding author), Univ Sherbrooke, Dept Pediat, Neonatal Resp Res Unit, Sherbrooke, PQ J1K 2R1, Canada.; Praud, JP (corresponding author), Univ Sherbrooke, Dept Physiol, Sherbrooke, PQ J1K 2R1, Canada.	Jean-Paul.Praud@USherbrooke.ca			Faculte de Medecine et des Sciences de la Sante of the Universite de Sherbrooke; Canadian Institutes of Health Research [RS-286032]; Canada Research Chair in Neonatal Respiratory Physiology; Fonds de la recherche Quebec - Sante	Faculte de Medecine et des Sciences de la Sante of the Universite de Sherbrooke; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chair in Neonatal Respiratory Physiology; Fonds de la recherche Quebec - Sante(Fonds de la Recherche en Sante du Quebec)	DC was supported by a training scholarship from the Faculte de Medecine et des Sciences de la Sante of the Universite de Sherbrooke. JPP: The study was funded by an operating grant from the Canadian Institutes of Health Research (RS-286032) and the Canada Research Chair in Neonatal Respiratory Physiology. JPP is a member of the Sherbrooke University Hospital Research Center, which is funded by the Fonds de la recherche Quebec - Sante. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Babaei A, 2008, GASTROENTEROLOGY, V134, P1322, DOI 10.1053/j.gastro.2008.02.031; Barwing J, 2009, INTENS CARE MED, V35, P1809, DOI 10.1007/s00134-009-1587-0; Boudaa N, 2013, J APPL PHYSIOL, V114, P637, DOI 10.1152/japplphysiol.00599.2012; Campanozzi A, 2009, PEDIATRICS, V123, P779, DOI 10.1542/peds.2007-3569; Carriere V, 2015, CRIT CARE MED, V43, pE296, DOI 10.1097/CCM.0000000000001080; Carron M, 2013, BRIT J ANAESTH, V110, P896, DOI 10.1093/bja/aet070; Czinn SJ, 2013, PEDIATR DRUGS, V15, P19, DOI 10.1007/s40272-012-0004-2; DeMauro SB, 2014, CURR OPIN PEDIATR, V26, P157, DOI 10.1097/MOP.0000000000000066; DiBlasi RM, 2011, RESP CARE, V56, P1273, DOI 10.4187/respcare.01376; Djeddi D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107736; Djeddi D, 2012, J PEDIATR GASTR NUTR, V55, P745, DOI 10.1097/MPG.0b013e318263cae0; Hadj-Ahmed MA, 2015, NEONATOLOGY, V107, P199, DOI 10.1159/000369120; Hadj-Ahmed MA, 2012, J APPL PHYSIOL, V113, P63, DOI 10.1152/japplphysiol.01496.2011; Hershcovici T, 2011, NEUROGASTROENT MOTIL, V23, P819, DOI 10.1111/j.1365-2982.2011.01738.x; Hill NS, 1997, RESP CARE, V42, P432; Jadcherla SR, 2015, PEDIATR RES, V77, P99, DOI 10.1038/pr.2014.147; JOUNIEAUX V, 1995, J APPL PHYSIOL, V79, P186, DOI 10.1152/jappl.1995.79.1.186; KERR P, 1992, CHEST, V101, P1539, DOI 10.1378/chest.101.6.1539; KERR P, 1993, J CLIN GASTROENTEROL, V17, P276, DOI 10.1097/00004836-199312000-00002; Lagarde S, 2010, ANESTH ANALG, V110, P1676, DOI 10.1213/ANE.0b013e3181d8a14c; Lightdale JR, 2013, PEDIATRICS, V131, pE1684, DOI 10.1542/peds.2013-0421; Mathai Ss, 2012, Med J Armed Forces India, V68, P12, DOI 10.1016/S0377-1237(11)60123-8; Moreau-Bussiere F, 2007, J APPL PHYSIOL, V102, P2149, DOI 10.1152/japplphysiol.00891.2006; Pandolifino JE, 2006, GASTROENTEROLOGY, V131, P1725, DOI 10.1053/j.gastro.2006.09.009; Renolleau S, 1999, AM J RESP CRIT CARE, V159, P1396, DOI 10.1164/ajrccm.159.5.9807088; ROSEN CL, 1986, AM J DIS CHILD, V140, P547, DOI 10.1001/archpedi.1986.02140200057027; Samson N, 2005, J APPL PHYSIOL, V99, P1636, DOI 10.1152/japplphysiol.00464.2005; Samson N, 2011, RESP PHYSIOL NEUROBI, V179, P111, DOI 10.1016/j.resp.2011.09.008; Shepherd K, 2013, J CLIN SLEEP MED, V9, P13, DOI 10.5664/jcsm.2328; Shepherd KL, 2007, AM J PHYSIOL-GASTR L, V292, pG1200, DOI 10.1152/ajpgi.00476.2006; Tawk M, 2006, CHEST, V130, P1003, DOI 10.1378/chest.130.4.1003; Wenzl TG, 2012, J PEDIATR GASTR NUTR, V55, P230, DOI 10.1097/MPG.0b013e3182592b65	32	9	9	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2016	11	1							e0146742	10.1371/journal.pone.0146742	http://dx.doi.org/10.1371/journal.pone.0146742			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB5BP	26785264	Green Submitted, Green Published, gold			2023-01-03	WOS:000368528400062
J	Ishikawa, T; Abe, S; Hoshii, A; Yamada, Y; Iiduka, A; Nemoto, T; Takeda, K; Yoshida, T				Ishikawa, Toru; Abe, Satoshi; Hoshii, Asami; Yamada, Yumi; Iiduka, Akihiko; Nemoto, Takeo; Takeda, Keiko; Yoshida, Toshiaki			Cone-Beam Computed Tomography Correlates with Conventional Helical Computed Tomography in Evaluation of Lipiodol Accumulation in HCC after Chemoembolization	PLOS ONE			English	Article							TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION	Background & Aims The amount of drug-loaded lipiodol in an HCC tumor post-transarterial chemoembolization (TACE) correlates with the risk of local tumor recurrence. Lipiodol enhancement of a tumor on conventional CT, measured in Hounsfield units (HU), can predict tumor response. Here we investigate whether cone-beam CT (CBCT) can also be used to predict tumor response, providing the benefit of being able to optimize the patient's treatment plan intra-procedurally. Methods A total of 82 HCC nodules (82 patients), <= 5 cm in diameter, were treated with balloon-occluded TACE using miriplatin between December 2013 and November 2014. For each patient, both CBCT and conventional CT images were obtained post-TACE. The degree of correlation between CBCT and conventional CT was determined by comparing identical regions of interest for each imaging modality using pixel values. Results The pixel values from conventional CT and CBCT were highly correlated, with a Pearson correlation coefficient of 0.912 (p< 0.001). The location of the nodules within the liver did not affect the results; the correlation coefficient was 0.891 (p< 0.001) for the left lobe and 0.926 (p< 0.001) for the right lobe. The mean pixel value for conventional CT was 439 +/- 279 HU, and the mean pixel value for CBCT was 416 +/- 311 HU. Conclusions CBCT may be used as a substitute for conventional CT to quantitatively evaluate the amount of drug-loaded lipiodol within an HCC nodule and, hence, the efficacy of TACE treatment. The major benefit of using CBCT is the ability to predict the likelihood of local recurrence intra-procedurally, enabling subsequent treatment optimization.	[Ishikawa, Toru; Abe, Satoshi; Yoshida, Toshiaki] Saiseikai Niigata Daini Hosp, Dept Gastroenterol & Hepatol, Niigata, Japan; [Hoshii, Asami; Yamada, Yumi; Iiduka, Akihiko] Saiseikai Niigata Daini Hosp, Dept Med Radiol, Niigata, Japan; [Nemoto, Takeo; Takeda, Keiko] Saiseikai Niigata Daini Hosp, Dept Radiol, Niigata, Japan		Ishikawa, T (corresponding author), Saiseikai Niigata Daini Hosp, Dept Gastroenterol & Hepatol, Niigata, Japan.	toruishi@ngt.saiseikai.or.jp						Imai N, 2012, JPN J CLIN ONCOL, V42, P175, DOI 10.1093/jjco/hyr189; Irie T, 2016, HEPATOL RES, V46, P209, DOI 10.1111/hepr.12564; Irie T, 2013, CARDIOVASC INTER RAD, V36, P706, DOI 10.1007/s00270-012-0476-z; Ishikawa T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083786; Iwazawa Jin, 2012, Cancer Manag Res, V4, P113, DOI 10.2147/CMAR.S30431; Kaneko S, 2012, HEPATOL RES, V42, P523, DOI 10.1111/j.1872-034X.2012.00981.x; Miyayama S, 2012, JPN J RADIOL, V30, P263, DOI 10.1007/s11604-011-0043-6; Miyayama S, 2011, JPN J RADIOL, V29, P371, DOI 10.1007/s11604-011-0568-8; Ogawa M, 2016, HEPATOL RES, V46, pE60, DOI 10.1111/hepr.12527; UCHIDA H, 1990, CARDIOVASC INTER RAD, V13, P140, DOI 10.1007/BF02575465; Wang ZJ, 2014, ACAD RADIOL, V21, P393, DOI 10.1016/j.acra.2013.11.006	11	12	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0145546	10.1371/journal.pone.0145546	http://dx.doi.org/10.1371/journal.pone.0145546			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6CA	26752696	Green Published, gold, Green Submitted			2023-01-03	WOS:000367888100018
J	McAninch, EA; Bianco, AC				McAninch, Elizabeth A.; Bianco, Antonio C.			The History and Future of Treatment of Hypothyroidism	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							THYROXINE PLUS TRIIODOTHYRONINE; THYROID-DISEASE; DOUBLE-BLIND; THYROTROPIN; GUIDELINES; THERAPY; RADIOIMMUNOASSAY; T3; LEVOTHYROXINE; ASSOCIATION	Thyroid hormone replacement has been used for more than a century to treat hypothyroidism. Natural thyroid preparations (thyroid extract, desiccated thyroid, or thyroglobulin), which contain both thyroxine (T-4) and triiodothyronine (T-3), were the first pharmacologic treatments available and dominated the market for the better part of the 20th century. Dosages were adjusted to resolve symptoms and to normalize the basal metabolic rate and/or serum protein-bound iodine level, but thyrotoxic adverse effects were not uncommon. Two major developments in the 1970s led to a transition in clinical practice: 1) The development of the serum thyroid-stimulating hormone (TSH) radioimmunoassay led to the discovery that many patients were overtreated, resulting in a dramatic reduction in thyroid hormone replacement dosage, and 2) the identification of peripheral deiodinase-mediated T-4-to-T-3 conversion provided a physiologic means to justify L-thyroxine monotherapy, obviating concerns about inconsistencies with desiccated thyroid. Thereafter, L-thyroxine monotherapy at doses to normalize the serum TSH became the standard of care. Since then, a subgroup of thyroid hormone-treated patients with residual symptoms of hypothyroidism despite normalization of the serum TSH has been identified. This has brought into question the inability of L-thyroxine monotherapy to universally normalize serum T-3 levels. New research suggests mechanisms for the inadequacies of L-thyroxine monotherapy and highlights the possible role for personalized medicine based on deiodinase polymorphisms. Understanding the historical events that affected clinical practice trends provides invaluable insight into formulation of an approach to help all patients achieve clinical and biochemical euthyroidism.	[McAninch, Elizabeth A.; Bianco, Antonio C.] Rush Univ, Med Ctr, Chicago, IL 60612 USA	Rush University	McAninch, EA (corresponding author), Rush Univ, Med Ctr, Div Endocrinol & Metab, 1735 West Harrison St,Cohn Bldg,Room 312, Chicago, IL 60612 USA.	Elizabeth_A_McAninch@Rush.edu	McAninch, Elizabeth/AAF-6701-2020; Bianco, Antonio/AAK-6336-2020	Bianco, Antonio/0000-0001-7737-6813; McAninch, Elizabeth/0000-0003-3993-4663	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077148, R01DK065055, R01DK058538] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK058538, R01 DK065055, R01 DK077148] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdalla SM, 2014, CLIN ENDOCRINOL, V81, P633, DOI 10.1111/cen.12538; ASPER SP, 1953, B JOHNS HOPKINS HOSP, V93, P164; Bettencourt R., 1890, SEM M D, V10, P294; Bianco AC, 2012, EUR THYROID J, V1, P88, DOI 10.1159/000339447; BRAVERMAN LE, 1970, J CLIN INVEST, V49, P855, DOI 10.1172/JCI106304; BRAVERMAN LE, 1964, NEW ENGL J MED, V270, P439, DOI 10.1056/NEJM196402272700903; Bunevicius R, 1999, NEW ENGL J MED, V340, P424, DOI 10.1056/NEJM199902113400603; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; CARR D, 1988, CLIN ENDOCRINOL, V28, P325, DOI 10.1111/j.1365-2265.1988.tb01219.x; CHALMERS JR, 1949, J CHEM SOC, P3424, DOI 10.1039/jr9490003424; Chesky VE, 1929, HOSP MANAGEMENT GOIT, P209; COBB WE, 1978, AM J HOSP PHARM, V35, P51, DOI 10.1093/ajhp/35.1.51; Cooper DS, 2012, LANCET, V379, P1142, DOI 10.1016/S0140-6736(11)60276-6; COTTON GE, 1971, NEW ENGL J MED, V285, P529, DOI 10.1056/NEJM197109022851001; Dawson R., 1893, MONTREAL MED J, V22, P437; de Castro JPW, 2015, J CLIN INVEST, V125, P769, DOI 10.1172/JCI77588; DeGroot LJ, 1996, THYROID ITS DIS, P351; Duntas LH, 2002, THYROID, V12, P287, DOI 10.1089/10507250252949405; EscobarMorreale HF, 1996, ENDOCRINOLOGY, V137, P2490, DOI 10.1210/en.137.6.2490; EVERED D, 1973, BRIT MED J, V3, P131, DOI 10.1136/bmj.3.5872.131; FRAWLEY TF, 1956, JAMA-J AM MED ASSOC, V160, P646, DOI 10.1001/jama.1956.02960430036007; Garber JR, 2012, THYROID, V22, P1200, DOI 10.1089/thy.2012.0205; GORMAN CA, 1979, J CLIN ENDOCR METAB, V49, P1; GROSS J, 1952, LANCET, V262, P1044; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Gullo D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022552; HART FD, 1950, J ENDOCRINOL, V6, pR34, DOI 10.1677/joe.0.006XXXIV; HERSHMAN JM, 1971, ANN INTERN MED, V74, P481, DOI 10.7326/0003-4819-74-4-481; Hoang TD, 2013, J CLIN ENDOCR METAB, V98, P1982, DOI 10.1210/jc.2012-4107; Hoffenberg R., 1978, WERNERS THYROID FUND, P1255; Ingbar SH, 1968, TXB ENDOCRINOLOGY, P232; Ingbar SH, 1974, TXB ENDOCRINOLOGY, P191; JACKSON IMD, 1978, AM J MED, V64, P284, DOI 10.1016/0002-9343(78)90057-8; Jonklaas J, 2014, THYROID, V24, P1670, DOI 10.1089/thy.2014.0028; Kaufman S C, 1991, Thyroid, V1, P285, DOI 10.1089/thy.1991.1.285; Kazerouni F, 2012, CASP J INTERN MED, V3, P400; Kocher A, 1923, BRIT MED J, V1923, P560, DOI 10.1136/bmj.2.3274.560; LARSEN PR, 1973, J CLIN ENDOCR METAB, V37, P177, DOI 10.1210/jcem-37-2-177; LAVIETES PH, 1964, ANN INTERN MED, V60, P79, DOI 10.7326/0003-4819-60-1-79; Lindholm J, 2011, J THROID RES, V2011, DOI 10.4061/2011/809341; Lundie RA, 1893, EDINBURGH MED J, V38, P996; Ma RS, 2015, THYROID, V25, P455, DOI 10.1089/thy.2014.0537; Mackenzie H W, 1892, Br Med J, V2, P940; MAGNUS-LEVY A, 1947, J Hist Med Allied Sci, V2, P307; MANGIERI CN, 1970, J CLIN ENDOCR METAB, V30, P102, DOI 10.1210/jcem-30-1-102; McAninch EA, 2015, J CLIN ENDOCR METAB, V100, P920, DOI 10.1210/jc.2014-4092; MCGAVACK TH, 1956, AM J MED, V20, P774, DOI 10.1016/0002-9343(56)90159-0; Ord W M, 1893, Br Med J, V2, P217; PALMER W. W., 1934, Bulletin of the New York Academy of Medicine, V10, P52; Panicker V, 2009, J CLIN ENDOCR METAB, V94, P1623, DOI 10.1210/jc.2008-1301; Peeters RP, 2003, J CLIN ENDOCR METAB, V88, P2880, DOI 10.1210/jc.2002-021592; Roberts N, 1996, PSYCHOL PROBLEMS THY, P3; Saravanan P, 2002, CLIN ENDOCRINOL, V57, P577, DOI 10.1046/j.1365-2265.2002.01654.x; Saravanan P, 2006, J CLIN ENDOCR METAB, V91, P3389, DOI 10.1210/jc.2006-0414; SINGER PA, 1995, JAMA-J AM MED ASSOC, V273, P808, DOI 10.1001/jama.273.10.808; Skinner GRB, 1997, BRIT MED J, V314, P1764, DOI 10.1136/bmj.314.7096.1764; SMITH RN, 1970, BRIT MED J, V4, P145, DOI 10.1136/bmj.4.5728.145; Stanbury JB, 1991, A CONSTANT FERMENT; SURKS MI, 1972, J CLIN INVEST, V51, P3104, DOI 10.1172/JCI107137; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; SURKS MI, 1973, J CLIN INVEST, V52, P805, DOI 10.1172/JCI107244; Tanis BC, 1996, CLIN ENDOCRINOL, V44, P643, DOI 10.1046/j.1365-2265.1996.739560.x; Taylor PN, 2014, JAMA INTERN MED, V174, P32, DOI 10.1001/jamainternmed.2013.11312; Thompson WO, 1933, J CLIN INVEST, V12, P235, DOI 10.1172/JCI100492; UTIGER RD, 1971, ANN INTERN MED, V74, P627, DOI 10.7326/0003-4819-74-4-627; Walsh JP, 2006, J CLIN ENDOCR METAB, V91, P2624, DOI 10.1210/jc.2006-0099; Werner SC, 1978, THYROID, P965; Werner SC, 1962, THYROID           ED, P817; Werner SC, 1971, THYROID FUNDAMENTAL, P832; Wiersinga WM, 2012, EUR THYROID J, V1, P55, DOI [10.1159/000339444, 10.1159/000337020]; Wiersinga WM, 2014, NAT REV ENDOCRINOL, V10, P164, DOI 10.1038/nrendo.2013.258; WILLIAMS RH, 1948, J CLIN ENDOCRINOL, V8, P257, DOI 10.1210/jcem-8-3-257; Williams RH, 1955, TXB ENDOCRINOLOGY, P99; Woeber KA, 1979, CONT ENDOCRINOLOGY, P77	74	58	64	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	2016	164	1					50	+		10.7326/M15-1799	http://dx.doi.org/10.7326/M15-1799			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA4WC	26747302	Green Accepted			2023-01-03	WOS:000367801700010
J	Luo, WM; Kong, J; Gong, Y; Liu, XQ; Yang, RX; Zhao, YX				Luo, Wei-min; Kong, Jing; Gong, Yan; Liu, Xiao-qiong; Yang, Rui-xue; Zhao, Yu-xia			Tongxinluo Protects against Hypertensive Kidney Injury in Spontaneously-Hypertensive Rats by Inhibiting Oxidative Stress and Activating Forkhead Box O1 Signaling	PLOS ONE			English	Article							GINSENOSIDE RG1; MESENCHYMAL TRANSITION; RENAL STRUCTURE; BLOOD-PRESSURE; TRANSCRIPTION; PODOCYTES; DISEASE; INFLAMMATION; MARKERS; DAMAGE	Hypertension is an independent risk factor for the progression of chronic renal failure, and oxidative stress plays a critical role in hypertensive renal damage. Forkbox O1(FoxO1) signaling protects cells against oxidative stress and may be a useful target for treating oxidative stress-induced hypertension. Tongxinluo is a traditional Chinese medicine with cardioprotective and renoprotective functions. Therefore, this study aimed to determine the effects of Tongxinluo in hypertensive renal damage in spontaneously hypertensive rats (SHRs) and elucidate the possible involvement of oxidative stress and FoxO1 signaling in its molecular mechanisms. SHRs treated with Tongxinluo for 12 weeks showed a reduction in systolic blood pressure. In addition to increasing creatinine clearance, Tongxinluo decreased urinary albumin excretion, oxidative stress injury markers including malondialdehyde and protein carbonyls, and expression of nicotinamide adenine dinucleotide phosphate oxidase subunits and its activity in SHR kidneys. While decreasing phosphorylation of FoxO1, Tongxinluo also inhibited the phosphorylation of extracellular signal-regulated kinase1/2 and p38 and enhanced manganese superoxide dismutase and catalase activities in SHR kidneys. Furthermore, histology revealed attenuation of glomerulosclerosis and renal podocyte injury, while Tongxinluo decreased the expression of alpha-smooth muscle actin, extracellular matrixprotein, transforming growth factor beta 1 and small mothers against decapentaplegic homolog 3, and improved tubulointerstitial fibrosis in SHR kidneys. Finally, Tongxinluo inhibited inflammatory cell infiltration as well as expression of tumor necrosis factor-a and interleukin-6. In conclusion, Tongxinluo protected SHRs against hypertension-induced renal injury by exerting antioxidant, antifibrotic, and anti-inflammatory activities. Moreover, the underlying mechanisms of these effects may involve inhibition of oxidative stress and functional activation of FoxO1 signaling.	[Luo, Wei-min; Kong, Jing] Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Jinan, Shandong, Peoples R China; [Luo, Wei-min; Zhao, Yu-xia] Shandong Univ, Qilu Hosp, Dept Tradit Chinese Med, Jinan, Shandong, Peoples R China; [Gong, Yan] Jinan Hosp Infect Dis, Dept Magnet Resonance Imaging, Jinan, Shandong, Peoples R China; [Liu, Xiao-qiong; Yang, Rui-xue] Shandong Univ, Qilu Hosp, Dept Cardiol, Jinan, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University	Zhao, YX (corresponding author), Shandong Univ, Qilu Hosp, Dept Tradit Chinese Med, Jinan, Shandong, Peoples R China.	yxzhao@sdu.edu.cn		Luo, Weimin/0000-0002-3403-4183	National 973 Basic Research Program of China [2012CB518603]; National Natural Science Foundation of China [30873325, 81100103, 81173251, 81302939]; Shandong Province Medical Science and Technology Development Plan [2014WS0147]	National 973 Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Province Medical Science and Technology Development Plan	This work was supported by the National 973 Basic Research Program of China, www.973.gov.cn (no. 2012CB518603 to YXZ), the National Natural Science Foundation of China, www.nsfc.gov.cn (30873325, 81100103, 81173251, 81302939 to YXZ), and the Shandong Province Medical Science and Technology Development Plan, www.sdwsjs.gov.cn (2014WS0147 to RXY). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal D, 2012, ANTIOXID REDOX SIGN, V16, P139, DOI 10.1089/ars.2011.3967; Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009; Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Biswas SK, 2007, FREE RADICAL RES, V41, P216, DOI 10.1080/10715760601059672; Boccitto M, 2011, CURR DRUG TARGETS, V12, P1303, DOI 10.2174/138945011796150316; Cao HB, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-84; Chandran G, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/608512; Cifarelli V, 2012, MOL ENDOCRINOL, V26, P1213, DOI 10.1210/me.2011-1276; Crews DC, 2010, HYPERTENSION, V55, P1102, DOI 10.1161/HYPERTENSIONAHA.110.150722; Daehn I, 2014, J CLIN INVEST, V124, P1608, DOI 10.1172/JCI71195; Doggrell SA, 1998, CARDIOVASC RES, V39, P89, DOI 10.1016/S0008-6363(98)00076-5; Dounousi E, 2006, AM J KIDNEY DIS, V48, P752, DOI 10.1053/j.ajkd.2006.08.015; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; Erejuwa OO, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/374037; Guo F, 2016, J CELL BIOCHEM, V117, P74, DOI 10.1002/jcb.25249; HASSENKHODJA R, 1992, J CARDIOVASC SURG, V33, P199; Heijnen BFJ, 2014, HYPERTENS RES, V37, P100, DOI 10.1038/hr.2013.99; Joshi S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/462361; Jung YA, 2009, BIOCHEM BIOPH RES CO, V386, P757, DOI 10.1016/j.bbrc.2009.06.124; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; LEE LK, 1995, J CLIN INVEST, V96, P953, DOI 10.1172/JCI118143; Liu C, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0347-4; Ludikhuize J, 2007, ARTHRITIS RHEUM-US, V56, P2180, DOI 10.1002/art.22653; Ma LY, 2015, EUR HEART J SUPPL, V17, pB5, DOI 10.1093/eurheartj/suv020; Ma LJ, 2005, J AM SOC NEPHROL, V16, P966, DOI 10.1681/ASN.2004060492; Maiese K, 2009, CLIN SCI, V116, P191, DOI 10.1042/CS20080113; Mao N, 2014, ACTA PHARMACOL SIN, V35, P513, DOI 10.1038/aps.2013.187; Olzinski AR, 2005, CARDIOVASC RES, V66, P170, DOI 10.1016/j.cardiores.2004.12.021; Palm F, 2011, AM J PHYSIOL-REG I, V301, pR1229, DOI 10.1152/ajpregu.00720.2010; Palmer SC, 2015, LANCET, V385, P2047, DOI 10.1016/S0140-6736(14)62459-4; Paravicini TM, 2008, DIABETES CARE, V31, pS170, DOI 10.2337/dc08-s247; Ponugoti B, 2012, EXP DIABETES RES, DOI 10.1155/2012/939751; Reiser J, 2014, NAT REV NEPHROL, V10, P104, DOI 10.1038/nrneph.2013.274; Ruiz S, 2013, KIDNEY INT, V83, P1029, DOI 10.1038/ki.2012.439; Shao D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4315; Sun Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080859; Wang B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098047; Wang J, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/187979; Wang JY, 2014, AM J PHYSIOL-RENAL, V306, pF486, DOI 10.1152/ajprenal.00528.2013; Xie XS, 2010, PHYTOTHER RES, V24, P1581, DOI 10.1002/ptr.3190; Xie XS, 2009, CHIN J INTEGR MED, V15, P133, DOI 10.1007/s11655-009-0133-9; Xie XS, 2009, J ETHNOPHARMACOL, V122, P35, DOI 10.1016/j.jep.2008.11.020; Zhang L, 2009, AM J PHYSIOL-HEART C, V297, pH2004, DOI 10.1152/ajpheart.00208.2009; Zhang MH, 2013, PLANTA MED, V79, P1319, DOI 10.1055/s-0033-1350649; Zhang MH, 2011, J ETHNOPHARMACOL, V137, P99, DOI 10.1016/j.jep.2011.04.045; Zhang WR, 2012, HYPERTENSION, V59, P136, DOI 10.1161/HYPERTENSIONAHA.111.173328	46	22	24	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2015	10	12							e0145130	10.1371/journal.pone.0145130	http://dx.doi.org/10.1371/journal.pone.0145130			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9JH	26673167	Green Published, Green Submitted, gold			2023-01-03	WOS:000366722700104
J	Wang, M; Xie, TT; Chang, ZY; Wang, L; Xie, XY; Kou, YH; Xu, HX; Gao, XL				Wang, Mei; Xie, Tingting; Chang, Zhanying; Wang, Ling; Xie, Xiangyun; Kou, Yaohong; Xu, Hongxia; Gao, Xiaoli			A New Type of Liquid Silymarin Proliposome Containing Bile Salts: Its Preparation and Improved Hepatoprotective Effects	PLOS ONE			English	Article							IMPROVED ORAL DELIVERY; IN-VITRO EVALUATION; LIPOSOMES; BIOAVAILABILITY; SYSTEM; FORMULATION; LIPIDS; MODEL	Silymarin, a known extract, is used in the treatment of liver diseases with various origins, but its current administration form cannot target the liver because of its poor oral bioavailability. A new type of oral silymarin proliposome aimed at improving silymarin's poor bioavailability and hepatoprotective effects, is introduced in this work. Silymarin-loaded liquid proliposome were prepared using a simple dissolving process. The morphology, particle size, zeta potential, and entrapment efficiency of the silymarin liposomes were analysed. The everted gut sac transport model was used to measure the intestinal transport of liposomes. The liposomal hepatoprotective activity was evaluated in three types of experimental hepatitis animal models. After staining with haematoxylin and eosin, the livers were microscopically examined to analyse any pathological changes. The prepared silymarin proliposome formed silymarin liposomes with a multilayer liposome structure and improved intestinal transport. In an injured liver, the silymarin liposomes produced a stronger hepatoprotective effect through a significant decrease in both the aminotransferase and MDA levels and a significant increase in the SOD and GSH-PX levels compared to orally administered silymarin tablets. This effect was also confirmed histopathologically. In a word, incorporation of silymarin into a liposomal carrier system increased intestinal absorption and showed better hepatoprotective effects compared to silymarin tablets.	[Wang, Mei; Chang, Zhanying; Wang, Ling; Xie, Xiangyun; Kou, Yaohong; Xu, Hongxia; Gao, Xiaoli] Xinjiang Med Univ, Coll Pharm, Dept Pharmaceut, Urumqi, Peoples R China; [Xie, Tingting] Peoples Liberat Army Gen Hosp, Dept Pharmaceut Care, Beijing, Peoples R China	Xinjiang Medical University; Chinese People's Liberation Army General Hospital	Gao, XL (corresponding author), Xinjiang Med Univ, Coll Pharm, Dept Pharmaceut, Urumqi, Peoples R China.	Xli_g@sina.com						Alam MA, 2012, J PHARM PHARMACOL, V64, P326, DOI 10.1111/j.2042-7158.2011.01391.x; BARZAGHI N, 1990, EUR J DRUG METAB PH, V15, P333, DOI 10.1007/BF03190223; Cao X, 2012, ACTA BIOMATER, V8, P2104, DOI 10.1016/j.actbio.2012.02.011; Chen YP, 2009, INT J PHARMACEUT, V376, P153, DOI 10.1016/j.ijpharm.2009.04.022; Chu C, 2011, ACTA PHARMACOL SIN, V32, P973, DOI 10.1038/aps.2011.25; El-Samaligy MS, 2006, INT J PHARMACEUT, V319, P121, DOI 10.1016/j.ijpharm.2006.04.023; Elmowafy M, 2013, EUR J PHARM SCI, V50, P161, DOI 10.1016/j.ejps.2013.06.012; Gao Xiao-li, 2005, Yaoxue Xuebao, V40, P1139; Ghosh A, 2012, J PHARM SCI TECHNOL, V2, P348; Hildebrand A, 2003, COLLOID SURFACE B, V32, P335, DOI 10.1016/j.colsurfb.2003.08.001; Hiremath PS, 2009, INT J PHARMACEUT, V380, P96, DOI 10.1016/j.ijpharm.2009.07.008; Karn PR, 2013, NANOMEDICINE-UK, V8, P1529, DOI [10.2217/NNM.13.131, 10.2217/nnm.13.131]; Kossena GA, 2003, J PHARM SCI-US, V92, P634, DOI 10.1002/jps.10329; Kumar N, 2014, PHARMACOL REP, V66, P788, DOI 10.1016/j.pharep.2014.04.007; Li XR, 2010, AAPS PHARMSCITECH, V11, P672, DOI 10.1208/s12249-010-9432-x; Liu L., 2007, ASIAN J PHARM SCI, V2, P150; Maherani B, 2011, CURR NANOSCI, V7, P436, DOI 10.2174/157341311795542453; Niu M, 2011, EUR J PHARM BIOPHARM, V81, P265; Parveen R, 2011, INT J PHARMACEUT, V413, P245, DOI 10.1016/j.ijpharm.2011.04.041; Porter CJH, 2007, NAT REV DRUG DISCOV, V6, P231, DOI 10.1038/nrd2197; Potluri P, 2006, DRUG DELIV, V13, P227, DOI 10.1080/10717540500395007; Rao S, 2014, J CONTROL RELEASE, V193, P174, DOI 10.1016/j.jconrel.2014.05.013; Shaji J, 2013, INT J PHARM BIO SCI, V4, P150; Sonali D, 2010, ACTA PHARMACEUT, V60, P427, DOI 10.2478/v10007-010-0038-3; Sun CD, 2013, AAPS PHARMSCITECH, V14, P332, DOI 10.1208/s12249-013-9924-6; Theodosiou E, 2014, PHYTOCHEM REV, V13, P1, DOI 10.1007/s11101-013-9285-5; Wagner A, 2011, LIPOSOME TECHNOLOGY; Wang J, 2005, J CHIN MED IND, V36, P707; Wang M, 2011, CHIN J NEW DRUGS, V20, P75; Wu W, 2006, EUR J PHARM BIOPHARM, V63, P288, DOI 10.1016/j.ejpb.2005.12.005; Zhang Y, 2010, RESOURCES, V18, P239	31	11	11	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2015	10	12							e0143625	10.1371/journal.pone.0143625	http://dx.doi.org/10.1371/journal.pone.0143625			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9JH	26674103	Green Published, Green Submitted, gold			2023-01-03	WOS:000366722700013
J	Raiho, AM; Hooten, MB; Bates, S; Hobbs, NT				Raiho, Ann M.; Hooten, Mevin B.; Bates, Scott; Hobbs, N. Thompson			Forecasting the Effects of Fertility Control on Overabundant Ungulates: White-Tailed Deer in the National Capital Region	PLOS ONE			English	Article							CAUSE-SPECIFIC MORTALITY; SURVIVAL RATES; IMMUNOCONTRACEPTION; POPULATIONS; EFFICACY; PATTERNS	Overabundant populations of ungulates have caused environmental degradation and loss of biological diversity in ecosystems throughout the world. Culling or regulated harvest is often used to control overabundant species. These methods are difficult to implement in national parks, other types of conservation reserves, or in residential areas where public hunting may be forbidden by policy. As a result, fertility control has been recommended as a non-lethal alternative for regulating ungulate populations. We evaluate this alternative using white-tailed deer in national parks in the vicinity of Washington, D.C., USA as a model system. Managers seek to reduce densities of white-tailed deer from the current average (50 deer per km(2)) to decrease harm to native plant communities caused by deer. We present a Bayesian hierarchical model using 13 years of population estimates from 8 national parks in the National Capital Region Network. We offer a novel way to evaluate management actions relative to goals using short term forecasts. Our approach confirms past analyses that fertility control is incapable of rapidly reducing deer abundance. Fertility control can be combined with culling to maintain a population below carrying capacity with a high probability of success. This gives managers confronted with problematic overabundance a framework for implementing management actions with a realistic assessment of uncertainty.	[Raiho, Ann M.; Hobbs, N. Thompson] Colorado State Univ, Dept Ecosyst Sci & Sustainabil, Nat Resource Ecol Lab, Ft Collins, CO 80523 USA; [Raiho, Ann M.; Hobbs, N. Thompson] Colorado State Univ, Grad Degree Program Ecol, Ft Collins, CO 80523 USA; [Hooten, Mevin B.] Colorado State Univ, Colorado Cooperat Fish & Wildlife Res Unit, US Geol Survey, Ft Collins, CO 80523 USA; [Hooten, Mevin B.] Colorado State Univ, Dept Fish Wildlife & Conservat Biol, Ft Collins, CO 80523 USA; [Hooten, Mevin B.] Colorado State Univ, Dept Stat, Ft Collins, CO 80523 USA; [Bates, Scott] Natl Pk Serv, Urban Ecol Ctr, Natl Capital Reg, Washington, DC 20240 USA	Colorado State University; Colorado State University; Colorado State University; United States Department of the Interior; United States Geological Survey; Colorado State University; Colorado State University; United States Department of the Interior	Raiho, AM (corresponding author), St Marys Coll, Dept Biol, Notre Dame, IN 46556 USA.	araiho@nd.edu	Hobbs, Tom/C-5263-2016		Rocky Mountains Cooperative Ecosystem Studies Unit (RM-CESU), RM-CESU [H2370094000, J2340110031]; NTH; National Parks Service, Biological Resources Management Division	Rocky Mountains Cooperative Ecosystem Studies Unit (RM-CESU), RM-CESU; NTH; National Parks Service, Biological Resources Management Division	This work was supported by Rocky Mountains Cooperative Ecosystem Studies Unit (RM-CESU), RM-CESU Cooperative Agreement Number: H2370094000 (WASO), J2340110031. The PI for this grant is NTH. The task agreement follows: A primary mission of the Natural Resource Ecology Laboratory at Colorado State University is to understand and quantify ecosystems, and effectively communicate this information to decision-makers, managers, students, and the public. This project will meet these mission goals by 1) summarizing the issues, data protocols, approaches, and future needs for ungulate management throughout the NPS; and 2) quantifying population sizes, trajectories, and effects of different management strategies. Products will be summarized in a report to NPS managers and leadership. In addition, results will be presented to a wide variety of audiences, including: academics and managers via peer-reviewed publications and at science conferences; students and faculty of Colorado State University during lectures and seminars (Dr. Hobbs teaches a modeling course "Systems Ecology", which incorporates real-world results and models); and the general public through NPS press releases, newspaper articles, and the NPS website. This agreement will provide employment and education opportunities for a research assistant and graduate student at Colorado State University. The research assistant will gain hands on experience and direct knowledge about ungulate management science and real world management implementation in the NPS. Additionally, the research assistant will learn how to create searchable databases, facilitate a science/management workshop, gain a variety of perspectives from parks and managers during interviews for data and the workshop, and develop their writing abilities. These collective experiences will increase the capability of the research assistant to find future work in a state or federal wildlife agency or private sector (e.g., one of the many private consultants that works on ungulate management plans). The graduate student will learn state-of-the-art modeling procedures, greatly increase their quantitative, writing, and presentation capabilities, and develop materials that will be presented at university classes and seminars and national science conferences. The knowledge gained during the process will also facilitate interactions within the academic and agency setting and give the student a set of quantitative skills that are very marketable (e.g., developing hierarchical models in a Bayesian framework). The review (task 1) developed in this agreement will benefit the scientific community at large by informing them of current trends in NPS management and the scientific basis for those decisions. The models (task 2) will further the wildlife scientific and management communities on the limitations and requirements of using fertility control technology and culling to control ungulate populations. It will also increase the ability of the NPS to obtain correct targets during reduction operations, which will facilitate cooperative management efforts with state agencies outside of NPS units. The funders provided the data and helped the PI determine which model experiments to conduct.; This study was funded by the National Parks Service, Biological Resources Management Division. Comments and suggestions from Barry Noon, Ryan Monello, and Jenny Powers improved the manuscript. Any use of trade, firm, or product names is for descriptive purposes only and does not imply endorsement by the U.S. government.	Barlow ND, 1997, WILDLIFE RES, V24, P129, DOI 10.1071/WR95027; Bates S., 2006, WHITE TAILED DEER DE; Berliner LM, 1996, FUND THEOR, V79, P15; Bowman Jacob L., 2007, Proceedings of the Annual Conference Southeastern Association of Fish and Wildlife Agencies, V61, P76; Brinkman TJ, 2004, WILDLIFE SOC B, V32, P726, DOI 10.2193/0091-7648(2004)032[0726:SOWDIA]2.0.CO;2; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Buckland S. T., 1993, Distance sampling: estimating abundance of biological populations.; Buckland S.T., 2005, ENCY BIOSTATISTICS V, VWiley and Sons.; Campbell TA, 2005, WILDLIFE SOC B, V33, P212, DOI 10.2193/0091-7648(2005)33[212:PCOACA]2.0.CO;2; Caswell H., 2006, MATRIX POPULATION MO; Cote SD, 2004, ANNU REV ECOL EVOL S, V35, P113, DOI 10.1146/annurev.ecolsys.35.021103.105725; DePerno CS, 2000, WILDLIFE SOC B, V28, P1030; DIAMOND J, 1992, NAT HIST, P2; DUSEK GL, 1992, J WILDLIFE MANAGE, V56, P645, DOI 10.2307/3809455; FULLER TK, 1990, WILDLIFE MONOGR, P1; GARROTT RA, 1993, CONSERV BIOL, V7, P946, DOI 10.1046/j.1523-1739.1993.740946.x; Gelman A., 2013, BAYESIAN DATA ANAL M; Gelman A., 2007, DATA ANAL USING REGR, DOI 10.1017/CBO9780511790942; Grovenburg TW, 2011, AM MIDL NAT, V165, P426, DOI 10.1674/0003-0031-165.2.426; HEIDELBERGER P, 1983, OPER RES, V31, P1109, DOI 10.1287/opre.31.6.1109; Hobbs N.T., 2015, BAYESIAN MODELS, DOI [DOI 10.1515/9781400866557, 10.1515/9781400866557]; Hobbs NT, 2000, J WILDLIFE MANAGE, V64, P473, DOI 10.2307/3803245; Hobbs NT, 2015, ECOLOGICAL IN PRESS; HONE J, 1992, J APPL ECOL, V29, P695, DOI 10.2307/2404478; Jewell PA, 1981, PROBLEMS MANAGEMENT; Kery M, 2012, BAYESIAN POPULATION ANALYSIS USING WINBUGS: A HIERARCHICAL PERSPECTIVE, P1; Kilpatrick HJ, 2001, CAN J ZOOL, V79, P949, DOI 10.1139/cjz-79-6-949; Kirkpatrick JF, 1997, REPROD FERT DEVELOP, V9, P105, DOI 10.1071/R96052; Knight TM, 2009, FOREST ECOL MANAG, V257, P1095, DOI 10.1016/j.foreco.2008.11.018; Knowlton FF, 1972, J WILDLIFE MANAGEMEN, V36; LESLIE PH, 1948, BIOMETRIKA, V35, P213, DOI 10.1093/biomet/35.3-4.213; Malcolm KD, 2010, ANIM REPROD SCI, V117, P261, DOI 10.1016/j.anireprosci.2009.05.003; McCabe Thomas R., 1997, P11; McCullough D. R., 1979, GEORGE RESERVE DEER; McShea WJ, 1997, J WILDLIFE MANAGE, V61, P560, DOI 10.2307/3802615; Noon BR, 2001, WILDLIFE 2001 POPULA, P441; Pimentel D, 2005, ECOL ECON, V52, P273, DOI 10.1016/j.ecolecon.2004.10.002; Plummer M, 2012, JAGS VERSION 3 3 0 U; Plummer M, 2013, R PACKAGE VERSION 3; Plummer M, 2003, P 3 INT WORKSHOP DIS, P1; Burroughs JP, 2006, J WILDLIFE MANAGE, V70, P743, DOI 10.2193/0022-541X(2006)70[743:CMASOW]2.0.CO;2; R Core Team, 2021, R LANG ENV STAT COMP; Ransom JI, 2014, J APPL ECOL, V51, P259, DOI 10.1111/1365-2664.12166; Rubin D. B., 1992, STAT SCI, V7, P457, DOI DOI 10.1111/j.1469-8137.2011.03796.x; Russell FL, 2001, AM MIDL NAT, V146, P1, DOI 10.1674/0003-0031(2001)146[0001:EOWTDO]2.0.CO;2; Sinclair ARE, 2003, PHILOS T R SOC B, V358, P1729, DOI 10.1098/rstb.2003.1359; Stubben C, 2007, J STAT SOFTW, V22, P1, DOI 10.18637/jss.v022.i11; Thomas L, 2010, J APPL ECOL, V47, P5, DOI 10.1111/j.1365-2664.2009.01737.x; Todd CR, 2008, J APPL ECOL, V45, P568, DOI 10.1111/j.1365-2664.2007.01434.x; Van Der Peet S, 2007, AUSTRAL ECOLOGY, V32, P720, DOI [10.1111/j.1442-9993.2007.01786.x, DOI 10.1111/J.1442-9993.2007.01786.X]; VanDeelen TR, 1997, J WILDLIFE MANAGE, V61, P903, DOI 10.2307/3802199; VerCauteren K.C., 2003, USDA STAFF PUBLICATI, V281; Vreeland JK, 2004, WILDLIFE SOC B, V32, P542, DOI 10.2193/0091-7648(2004)32[542:SRMCAH]2.0.CO;2; WESTERN D, 1979, AFR J ECOL, V17, P185, DOI 10.1111/j.1365-2028.1979.tb00256.x; Whitlaw HA, 1998, J WILDLIFE MANAGE, V62, P1335, DOI 10.2307/3801999; Wickham Brian M., 1993, Proceedings of the Annual Conference Southeastern Association of Fish and Wildlife Agencies, V47, P222; Wright R, 1993, RENEWABLE RESOURCES, V11, P18	57	19	20	0	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2015	10	12							e0143122	10.1371/journal.pone.0143122	http://dx.doi.org/10.1371/journal.pone.0143122			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1YX	26650739	Green Submitted, Green Published, gold			2023-01-03	WOS:000366903300011
J	Karhson, DS; Mock, JR; Golob, EJ				Karhson, Debra S.; Mock, Jeffrey R.; Golob, Edward J.			The Role of Right Inferior Parietal Cortex in Auditory Spatial Attention: A Repetitive Transcranial Magnetic Stimulation Study	PLOS ONE			English	Article							EVENT-RELATED POTENTIALS; SOUND LOCALIZATION; UNILATERAL NEGLECT; VISUAL-ATTENTION; SIGNAL-DETECTION; DETECTION TASK; P300 LATENCY; HUMAN BRAIN; MECHANISMS; REPRESENTATIONS	Behavioral studies support the concept of an auditory spatial attention gradient by demonstrating that attentional benefits progressively diminish as distance increases from an attended location. Damage to the right inferior parietal cortex can induce a rightward attention bias, which implicates this region in the construction of attention gradients. This study used event-related potentials (ERPs) to define attention-related gradients before and after repetitive transcranial magnetic stimulation (rTMS) to the right inferior parietal cortex. Subjects (n = 16) listened to noise bursts at five azimuth locations (left to right: -90 degrees, -45 degrees, 0 degrees midline, +45 degrees, +90 degrees) and responded to stimuli at one target location (-90 degrees, +90 degrees, separate blocks). ERPs as a function of non-target location were examined before (baseline) and after 0.9 Hz rTMS. Results showed that ERP attention gradients were observed in three time windows (frontal 230-340, parietal 400-460, frontal 550-750 ms). Significant transient rTMS effects were seen in the first and third windows. The first window had a voltage decrease at the farthest location when attending to either the left or right side. The third window had on overall increase in positivity, but only when attending to the left side. These findings suggest that rTMS induced a small contraction in spatial attention gradients within the first time window. The asymmetric effect of attended location on gradients in the third time window may relate to neglect of the left hemispace after right parietal injury. Together, these results highlight the role of the right inferior parietal cortex in modulating frontal lobe attention network activity.	[Karhson, Debra S.; Golob, Edward J.] Tulane Univ, Program Neurosci, New Orleans, LA 70118 USA; [Mock, Jeffrey R.; Golob, Edward J.] Tulane Univ, Dept Psychol, New Orleans, LA 70118 USA; [Golob, Edward J.] Tulane Univ, Ctr Aging, New Orleans, LA 70118 USA	Tulane University; Tulane University; Tulane University	Golob, EJ (corresponding author), Tulane Univ, Program Neurosci, New Orleans, LA 70118 USA.	egolob@tulane.edu		Karhson, Debra/0000-0002-3850-3119; Mock, Jeffrey/0000-0003-0446-6687	National Science Foundation [BCS-0844961]; Southern Regional Education Board - Louisiana Board of Regents Doctoral Scholars Program	National Science Foundation(National Science Foundation (NSF)); Southern Regional Education Board - Louisiana Board of Regents Doctoral Scholars Program	This study was supported by funding from National Science Foundation (BCS-0844961) and the Southern Regional Education Board - Louisiana Board of Regents Doctoral Scholars Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank John Holmes, Michael Seay, Kelsey Ward, and Drs. Kate Yurgil and Jeremy Nelson for valuable discussions and help with this study. This work was supported by the National Science Foundation (BCS-0844961).	Adair JC, 2008, ANN NY ACAD SCI, V1142, P21, DOI 10.1196/annals.1444.008; Ahveninen J, 2006, P NATL ACAD SCI USA, V103, P14608, DOI 10.1073/pnas.0510480103; Arnott SR, 2002, PSYCHOPHYSIOLOGY, V39, P625, DOI 10.1017/S0048577202394149; At A, 2011, NEUROPSYCHOLOGIA, V49, P2794, DOI 10.1016/j.neuropsychologia.2011.05.024; Barrett AM, 1998, NEUROLOGY, V51, P972, DOI 10.1212/WNL.51.4.972; Barrick TR, 2007, CEREB CORTEX, V17, P591, DOI 10.1093/cercor/bhk004; Behrmann M, 1997, NEUROPSYCHOLOGIA, V35, P1445, DOI 10.1016/S0028-3932(97)00058-4; Bellmann A, 2001, BRAIN, V124, P676, DOI 10.1093/brain/124.4.676; Berardelli A, 1998, EXP BRAIN RES, V122, P79, DOI 10.1007/s002210050493; Blauert J., 1997, SPATIAL HEARING PSYC; CARLILE S, 1996, VIRTUAL AUDITORY SPA; Caspers S, 2006, NEUROIMAGE, V33, P430, DOI 10.1016/j.neuroimage.2006.06.054; Caspers S, 2011, NEUROIMAGE, V58, P362, DOI 10.1016/j.neuroimage.2011.06.027; Cave KR, 1999, PSYCHON B REV, V6, P204, DOI 10.3758/BF03212327; Chen R, 1997, ELECTROMYOGR MOTOR C, V105, P415, DOI 10.1016/S0924-980X(97)00036-2; Clarke S, 1998, NEUROREPORT, V9, P3433, DOI 10.1097/00001756-199810260-00018; Clarke S, 2004, CORTEX, V40, P291, DOI 10.1016/S0010-9452(08)70124-2; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Corbetta M, 2011, ANNU REV NEUROSCI, V34, P569, DOI 10.1146/annurev-neuro-061010-113731; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DOWNING CJ, 1988, J EXP PSYCHOL HUMAN, V14, P188, DOI 10.1037/0096-1523.14.2.188; Egeth HE, 1997, ANNU REV PSYCHOL, V48, P269, DOI 10.1146/annurev.psych.48.1.269; Egner T, 2007, COGN AFFECT BEHAV NE, V7, P380, DOI 10.3758/CABN.7.4.380; ERIKSEN CW, 1986, PERCEPT PSYCHOPHYS, V40, P225, DOI 10.3758/BF03211502; Friedman D, 2001, NEUROSCI BIOBEHAV R, V25, P355, DOI 10.1016/S0149-7634(01)00019-7; Golob EJ, 2016, PERCEPTION, V45, P165, DOI 10.1177/0301006615599906; Golob EJ, 2011, BRAIN RES, V1384, P128, DOI 10.1016/j.brainres.2011.01.089; Halgren E, 1998, ELECTROEN CLIN NEURO, V106, P156, DOI 10.1016/S0013-4694(97)00119-3; Hall DA, 2003, AUDIOL NEURO-OTOL, V8, P1, DOI 10.1159/000067894; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEILMAN KM, 1972, ARCH NEUROL-CHICAGO, V26, P32, DOI 10.1001/archneur.1972.00490070050007; Hilgetag CC, 2001, NAT NEUROSCI, V4, P953, DOI 10.1038/nn0901-953; Husain M, 2003, NAT REV NEUROSCI, V4, P26, DOI 10.1038/nrn1005; Karnath HO, 2012, NEUROPSYCHOLOGIA, V50, P1010, DOI 10.1016/j.neuropsychologia.2011.06.027; Kong LQ, 2014, CEREB CORTEX, V24, P773, DOI 10.1093/cercor/bhs359; LABERGE D, 1989, PSYCHOL REV, V96, P101, DOI 10.1037/0033-295X.96.1.101; Lewald J, 2004, NEUROPSYCHOLOGIA, V42, P1598, DOI 10.1016/j.neuropsychologia.2004.04.012; Lewald J, 2004, J COGNITIVE NEUROSCI, V16, P828, DOI 10.1162/089892904970834; Macaluso E, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00685; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; MIDDLEBROOKS JC, 1991, ANNU REV PSYCHOL, V42, P135, DOI 10.1146/annurev.ps.42.020191.001031; Middlebrooks JC, 1981, J NEUROSCI, V1; MILLS AW, 1958, J ACOUST SOC AM, V30, P237, DOI 10.1121/1.1909553; Mock JR, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00179; MONDOR TA, 1995, J EXP PSYCHOL HUMAN, V21, P387, DOI 10.1037/0096-1523.21.2.387; Muggleton NG, 2006, NEUROPSYCHOLOGIA, V44, P1222, DOI 10.1016/j.neuropsychologia.2005.10.004; NASH A, 1994, BIOL PSYCHOL, V37, P219, DOI 10.1016/0301-0511(94)90004-3; Pascual-Leone A, 1998, J CLIN NEUROPHYSIOL, V15, P333, DOI 10.1097/00004691-199807000-00005; POLICH J, 1983, PSYCHOPHYSIOLOGY, V20, P665, DOI 10.1111/j.1469-8986.1983.tb00936.x; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Pouget A, 2000, CURR OPIN NEUROBIOL, V10, P242, DOI 10.1016/S0959-4388(00)00077-5; Price CJ, 2001, J COGNITIVE NEUROSCI, V13, P419, DOI 10.1162/08989290152001853; PRITCHARD WS, 1986, PSYCHOPHYSIOLOGY, V23, P166, DOI 10.1111/j.1469-8986.1986.tb00611.x; Rader SK, 2008, CLIN NEUROPHYSIOL, V119, P1176, DOI 10.1016/j.clinph.2008.01.014; Recanzone GH, 2000, P NATL ACAD SCI USA, V97, P11829, DOI 10.1073/pnas.97.22.11829; ROHRBAUGH JW, 1978, ELECTROEN CLIN NEURO, V45, P551, DOI 10.1016/0013-4694(78)90156-6; Rorden C, 2001, EXP BRAIN RES, V137, P487, DOI 10.1007/s002210100679; Rothwell JC, 1997, J NEUROSCI METH, V74, P113, DOI 10.1016/S0165-0270(97)02242-5; RUCHKIN DS, 1980, ELECTROEN CLIN NEURO, V50, P35, DOI 10.1016/0013-4694(80)90321-1; Rushworth MFS, 2006, NEUROPSYCHOLOGIA, V44, P2700, DOI 10.1016/j.neuropsychologia.2005.12.007; SCHARF B, 1998, ATTENTION, P75; Siebner HR, 2009, BRAIN STIMUL, V2, P58, DOI 10.1016/j.brs.2008.11.002; Spencer KM, 2001, PSYCHOPHYSIOLOGY, V38, P343, DOI 10.1111/1469-8986.3820343; SQUIRES KC, 1975, J EXP PSYCHOL HUMAN, V1, P268, DOI 10.1037/0096-1523.1.3.268; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; Sur Shravani, 2009, Ind Psychiatry J, V18, P70, DOI 10.4103/0972-6748.57865; Teder-Salejarvi WA, 1998, PERCEPT PSYCHOPHYS, V60, P1228, DOI 10.3758/BF03206172; Teder-Salejarvi WA, 1999, COGNITIVE BRAIN RES, V8, P213, DOI 10.1016/S0926-6410(99)00023-3; Vallar G, 1997, PHILOS T ROY SOC B, V352, P1401, DOI 10.1098/rstb.1997.0126; Vallar G, 2007, CNS SPECTRUMS, V12, P527, DOI 10.1017/S1092852900021271; YUND EW, 1990, BRAIN COGNITION, V12, P42, DOI 10.1016/0278-2626(90)90003-7	75	9	9	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2015	10	12							e0144221	10.1371/journal.pone.0144221	http://dx.doi.org/10.1371/journal.pone.0144221			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY1CH	26636333	Green Published, gold, Green Submitted			2023-01-03	WOS:000366143800059
J	Padhi, S; Kemmis-Betty, S; Rajesh, S; Hill, J; Murphy, MF				Padhi, Smita; Kemmis-Betty, Sophia; Rajesh, Sharangini; Hill, Jennifer; Murphy, Michael F.		Guideline Dev Grp	GUIDELINES Blood transfusion: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Padhi, Smita; Kemmis-Betty, Sophia; Rajesh, Sharangini; Hill, Jennifer] Natl Clin Guideline Ctr, London, England; [Murphy, Michael F.] Univ Oxford, NHS Blood & Transplant, Oxford Univ Hosp NHS Fdn Trust, Oxford OX1 2JD, England	Oxford University Hospitals NHS Foundation Trust; University of Oxford	Murphy, MF (corresponding author), Natl Clin Guideline Ctr, London, England.	mike.murphy@nhsbt.nhs.uk		Wonderling, David/0000-0003-0315-6273				Goodnough LT, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6897; Murphy MF, 2014, 2013 NATL PATIENT BL; National Institute for Health and Care Excellence, 2009, MED ADH INV PAT DEC; National Institute for Health and Care Excellence, 2015, BLOOD TRANSF NICE GU; National Institute for Health and Care Excellence, 2011, AN MAN CHRON KIDN DI; National Institute for Health and Care Excellence, 2008, STROK TRANS ISCH ATT; National Institute for Health and Care Excellence, 2012, AC UPP GASTR BLEED 1; National Institute for Health and Care Excellence, 2012, PAT EXP AD NHS SERV; NHS Blood and Transplant, 2013, NAT COMP AUD BLOOD T; NHS Blood and Transplant, 2013, PAT INF LEAFL WILL I	10	79	79	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	2015	351								h5832	10.1136/bmj.h5832	http://dx.doi.org/10.1136/bmj.h5832			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW9XX	26581483				2023-01-03	WOS:000365352600003
J	White, RH				White, Richard H.			Review: In older patients with AF or acute VTE, some DOACs reduce thrombotic events and major bleeding	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[White, Richard H.] Univ Calif Davis, Davis, CA 95616 USA	University of California System; University of California Davis	White, RH (corresponding author), Univ Calif Davis, Davis, CA 95616 USA.							Cutler TW, 2014, J MANAG CARE SPEC PH, V20, P1028, DOI 10.18553/jmcp.2014.20.10.1028; Singer DE, 2009, ANN INTERN MED, V151, P297, DOI 10.7326/0003-4819-151-5-200909010-00003	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2015	163	10					JC4	JC4		10.7326/ACPJC-2015-163-10-004	http://dx.doi.org/10.7326/ACPJC-2015-163-10-004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX5MQ	26571258	Green Submitted			2023-01-03	WOS:000365746400005
J	Ruan, J; Martin, P; Shah, B; Schuster, SJ; Smith, SM; Furman, RR; Christos, P; Rodriguez, A; Svoboda, J; Lewis, J; Katz, O; Coleman, M; Leonard, JP				Ruan, Jia; Martin, Peter; Shah, Bijal; Schuster, Stephen J.; Smith, Sonali M.; Furman, Richard R.; Christos, Paul; Rodriguez, Amelyn; Svoboda, Jakub; Lewis, Jessica; Katz, Orel; Coleman, Morton; Leonard, John P.			Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; IN-VITRO; THERAPY; COMBINATION; INDOLENT; PHASE-2; CHOP; IMMUNOCHEMOTHERAPY; CYCLOPHOSPHAMIDE; MULTICENTER	BACKGROUND Mantle-cell lymphoma is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, an anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenalidomide plus rituximab as a first-line therapy. METHODS We conducted a single-group, multicenter, phase 2 study with induction and maintenance phases. During the induction phase, lenalidomide was administered at a dose of 20 mg daily on days 1 through 21 of every 28-day cycle for 12 cycles; the dose was escalated to 25 mg daily after the first cycle if no dose-limiting adverse events occurred during the first cycle and was reduced to 15 mg daily during the maintenance phase. Rituximab was administered once weekly for the first 4 weeks and then once every other cycle until disease progression. The primary end point was the overall response rate. Secondary end points included outcomes related to safety, survival, and quality of life. RESULTS A total of 38 participants were enrolled at four centers from July 2011 through April 2014. The median age was 65 years. On the basis of the Mantle Cell Lymphoma International Prognostic Index scores, the proportions of participants with low-risk, intermediate-risk, and high-risk disease at baseline were similar (34%, 34%, and 32%, respectively). The most common grade 3 or 4 adverse events were neutropenia (in 50% of the patients), rash (in 29%), thrombocytopenia (in 13%), an inflammatory syndrome ("tumor flare") (in 11%), anemia (in 11%), serum sickness (in 8%), and fatigue (in 8%). At the median follow-up of 30 months (through February 2015), the overall response rate among the participants who could be evaluated was 92% (95% confidence interval [CI], 78 to 98), and the complete response rate was 64% (95% CI, 46 to 79); median progression-free survival had not been reached. The 2-year progression-free survival was estimated to be 85% (95% CI, 67 to 94), and the 2-year overall survival 97% (95% CI, 79 to 99). A response to treatment was associated with improvement in quality of life. CONCLUSIONS Combination biologic therapy consisting of lenalidomide plus rituximab was active as initial therapy for mantle-cell lymphoma.	[Ruan, Jia; Martin, Peter; Furman, Richard R.; Rodriguez, Amelyn; Lewis, Jessica; Katz, Orel; Coleman, Morton; Leonard, John P.] Weill Cornell Med Coll, Meyer Canc Ctr, Div Hematol & Med Oncol, New York, NY USA; [Christos, Paul] Weill Cornell Med Coll, Div Biostat & Epidemiol, New York, NY USA; New York Presbyterian Hosp, New York, NY 10021 USA; [Shah, Bijal] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Schuster, Stephen J.; Svoboda, Jakub] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Smith, Sonali M.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA	Cornell University; Cornell University; NewYork-Presbyterian Hospital; H Lee Moffitt Cancer Center & Research Institute; University of Pennsylvania; Pennsylvania Medicine; University of Chicago; University of Chicago Medical Center	Ruan, J (corresponding author), New York Presbyterian Hosp, Weill Cornell Med Coll, Meyer Canc Ctr, Div Hematol & Med Oncol, 1305 York Ave,7th Fl, New York, NY 10021 USA.	jruan@med.cornell.edu; jpleonard@med.cornell.edu	Smith, Sonali/AAD-9328-2020; Ruan, Jia/AAH-4450-2019		Celgene; Weill Cornell Medical College; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000457, KL2TR000458] Funding Source: NIH RePORTER	Celgene(Bristol-Myers SquibbCelgene Corporation); Weill Cornell Medical College; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Funded by Celgene and Weill Cornell Medical College	Abrahamsson A, 2014, BLOOD, V124, P1288, DOI 10.1182/blood-2014-03-559930; Ahmadi T, 2014, CANCER-AM CANCER SOC, V120, P222, DOI 10.1002/cncr.28405; Bartlett JB, 2004, NAT REV CANCER, V4, P314, DOI 10.1038/nrc1323; Campo E, 2015, BLOOD, V125, P48, DOI 10.1182/blood-2014-05-521898; Chang JE, 2014, BLOOD, V123, P1665, DOI 10.1182/blood-2013-08-523845; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Chong EA, 2015, CLIN CANCER RES, V21, P1835, DOI 10.1158/1078-0432.CCR-14-2221; Delarue R, 2013, BLOOD, V121, P48, DOI 10.1182/blood-2011-09-370320; Forstpointner R, 2006, BLOOD, V108, P4003, DOI 10.1182/blood-2006-04-016725; Geisler CH, 2008, BLOOD, V112, P2687, DOI 10.1182/blood-2008-03-147025; Goy A, 2013, J CLIN ONCOL, V31, P3688, DOI 10.1200/JCO.2013.49.2835; Harrison CN, 2013, BRIT J HAEMATOL, V162, P229, DOI 10.1111/bjh.12375; Herrmann A, 2009, J CLIN ONCOL, V27, P511, DOI 10.1200/JCO.2008.16.8435; Howard OM, 2002, J CLIN ONCOL, V20, P1288, DOI 10.1200/JCO.20.5.1288; Kluin-Nelemans HC, 2012, NEW ENGL J MED, V367, P520, DOI 10.1056/NEJMoa1200920; Lenz G, 2005, J CLIN ONCOL, V23, P1984, DOI 10.1200/JCO.2005.08.133; Martin P, 2009, J CLIN ONCOL, V27, P1209, DOI 10.1200/JCO.2008.19.6121; Moros A, 2014, CLIN CANCER RES, V20, P393, DOI 10.1158/1078-0432.CCR-13-1569; Perez-Galan P, 2011, BLOOD, V117, P26, DOI 10.1182/blood-2010-04-189977; Reddy N, 2008, BRIT J HAEMATOL, V140, P36, DOI 10.1111/j.1365-2141.2007.06841.x; Robak T, 2015, NEW ENGL J MED, V372, P944, DOI 10.1056/NEJMoa1412096; Romaguera JE, 2005, J CLIN ONCOL, V23, P7013, DOI 10.1200/JCO.2005.01.1825; Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9; Smith SK, 2009, CANCER-AM CANCER SOC, V115, P3312, DOI 10.1002/cncr.24391; Song K, 2013, CANCER RES, V73, P7254, DOI 10.1158/0008-5472.CAN-13-0750; Till BG, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.149.149; Trneny M, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.626.626; Wang M, 2012, LANCET ONCOL, V13, P716, DOI 10.1016/S1470-2045(12)70200-0; Zhang L, 2009, AM J HEMATOL, V84, P553, DOI 10.1002/ajh.21468	30	179	191	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	2015	373	19					1835	1844		10.1056/NEJMoa1505237	http://dx.doi.org/10.1056/NEJMoa1505237			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV3FK	26535512	Green Accepted			2023-01-03	WOS:000364144000007
J	Marx, W; McKavanagh, D; McCarthy, AL; Bird, R; Ried, K; Chan, A; Isenring, L				Marx, Wolfgang; McKavanagh, Daniel; McCarthy, Alexandra L.; Bird, Robert; Ried, Karin; Chan, Alexandre; Isenring, Liz			The Effect of Ginger (Zingiber officinale) on Platelet Aggregation: A Systematic Literature Review	PLOS ONE			English	Review							ALTERNATIVE MEDICINE; ANTIPLATELET AGGREGATION; THROMBOXANE PRODUCTION; COMPLEMENTARY; CONSTITUENTS; NAUSEA; CONSUMPTION; NIFEDIPINE; COMPONENTS; WARFARIN	Background The potential effect of ginger on platelet aggregation is a widely-cited concern both within the published literature and to clinicians; however, there has been no systematic appraisal of the evidence to date. Methods Using the PRISMA guidelines, we systematically reviewed the results of clinical and observational trials regarding the effect of ginger on platelet aggregation in adults compared to either placebo or baseline data. Studies included in this review stipulated the independent variable was a ginger preparation or isolated ginger compound, and used measures of platelet aggregation as the primary outcome. Results Ten studies were included, comprising eight clinical trials and two observational studies. Of the eight clinical trials, four reported that ginger reduced platelet aggregation, while the remaining four reported no effect. The two observational studies also reported mixed findings. Discussion Many of the studies appraised for this review had moderate risks of bias. Methodology varied considerably between studies, notably the timeframe studied, dose of ginger used, and the characteristics of subjects recruited (e.g. healthy vs. patients with chronic diseases). Conclusion The evidence that ginger affects platelet aggregation and coagulation is equivocal and further study is needed to definitively address this question.	[Marx, Wolfgang; Isenring, Liz] Bond Univ, Hlth Sci & Med, Gold Coast, Qld, Australia; [McKavanagh, Daniel; McCarthy, Alexandra L.; Bird, Robert] Princess Alexandra Hosp, Div Canc Serv, Brisbane, Qld 4102, Australia; [McCarthy, Alexandra L.] Queensland Univ Technol, Inst Biomed Innovat, Brisbane, Qld 4001, Australia; [Bird, Robert] Griffith Univ, Sch Med, Nathan, Qld 4111, Australia; [Ried, Karin] Natl Inst Integrat Med, Melbourne, Vic, Australia; [Chan, Alexandre] Natl Univ Singapore, Fac Sci, Dept Pharm, Singapore 117548, Singapore; [Isenring, Liz] Princess Alexandra Hosp, Dept Nutr & Dietet, Brisbane, Qld 4102, Australia	Bond University; Queensland University of Technology (QUT); Griffith University; National University of Singapore	Marx, W (corresponding author), Bond Univ, Hlth Sci & Med, Gold Coast, Qld, Australia.	Wolfgang.marx@student.bond.edu.au	Marx, Wolfgang/AFO-7355-2022; Chan, Alexandre/D-5035-2016	Marx, Wolfgang/0000-0002-8556-8230; Chan, Alexandre/0000-0003-4391-4219; Bird, Robert/0000-0002-3110-1424; Isenring, Elizabeth/0000-0002-4478-9707				[Agricultural Research Service U.S. Department of Agriculture], 2014, USDA NAT NUTR DAT ST; Bordia A, 1997, PROSTAG LEUKOTR ESS, V56, P379, DOI 10.1016/S0952-3278(97)90587-1; Chaiyakunapruk N, 2006, AM J OBSTET GYNECOL, V194, P95, DOI 10.1016/j.ajog.2005.06.046; Chrubasik S, 2005, PHYTOMEDICINE, V12, P684, DOI 10.1016/j.phymed.2004.07.009; Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223; DORSO CR, 1980, NEW ENGL J MED, V303, P756; Elting LS, 2001, J CLIN ONCOL, V19, P1137, DOI 10.1200/JCO.2001.19.4.1137; FLYNN DL, 1986, PROSTAG LEUKOTR ESS, V24, P195, DOI 10.1016/0262-1746(86)90126-5; Heck AM, 2000, AM J HEALTH-SYST PH, V57, P1221, DOI 10.1093/ajhp/57.13.1221; Janssen PLTMK, 1996, EUR J CLIN NUTR, V50, P772; Jiang XM, 2005, BRIT J CLIN PHARMACO, V59, P425, DOI 10.1111/j.1365-2125.2005.02322.x; Koo KLK, 2001, THROMB RES, V103, P387, DOI 10.1016/S0049-3848(01)00338-3; Lesho EP, 2004, CLEV CLIN J MED, V71, P651, DOI 10.3949/ccjm.71.8.651; Leung VWY, 2009, ANN PHARMACOTHER, V43, P875, DOI 10.1345/aph.1L631; Liao YR, 2012, MOLECULES, V17, P8928, DOI 10.3390/molecules17088928; Lien HC, 2003, AM J PHYSIOL-GASTR L, V284, pG481, DOI 10.1152/ajpgi.00164.2002; LUMB AB, 1994, THROMB HAEMOSTASIS, V71, P110; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Marx WM, 2013, NUTR REV, V71, P245, DOI 10.1111/nure.12016; Miller LG, 1998, ARCH INTERN MED, V158, P2200, DOI 10.1001/archinte.158.20.2200; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; National Health and Medical Research Council, 2009, NHMRC LEV EV GRAD RE; Nie H, 2008, CHINESE MED J-PEKING, V121, P1226, DOI 10.1097/00029330-200807010-00015; Nievergelt A, 2011, J IMMUNOL, V187, P4140, DOI 10.4049/jimmunol.1100880; Nurtjahja-Tjendraputra E, 2003, THROMB RES, V111, P259, DOI 10.1016/j.thromres.2003.09.009; Ryan JL, 2012, SUPPORT CARE CANCER, V20, P1479, DOI 10.1007/s00520-011-1236-3; Schwertner HA, 2007, J CHROMATOGR B, V856, P41, DOI 10.1016/j.jchromb.2007.05.011; Schwertner HA, 2006, OBSTET GYNECOL, V107, P1337, DOI 10.1097/01.AOG.0000217697.33787.8c; Shalansky S, 2007, PHARMACOTHERAPY, V27, P1237, DOI 10.1592/phco.27.9.1237; Shih CY, 2014, J HYPERTENS, V32, P181, DOI 10.1097/HJH.0000000000000007; Srinivasan R, 2011, PLANTA MED, V77, P112, DOI [10.1055/s-0031-1273641, DOI 10.1055/S-0031-1273641]; SRIVASTAVA KC, 1989, PROSTAG LEUKOTR ESS, V35, P183, DOI 10.1016/0952-3278(89)90122-1; SRIVASTAVA KC, 1986, PROSTAG LEUKOTR ESS, V25, P187, DOI 10.1016/0262-1746(86)90065-X; SRIVASTAVA KC, 1984, BIOMED BIOCHIM ACTA, V43, pS335; Thomson M, 2002, PROSTAG LEUKOTR ESS, V67, P475, DOI 10.1054/plef.2002.0441; Thomson M, 2014, J AM BOARD FAM MED, V27, P115, DOI 10.3122/jabfm.2014.01.130167; Tjendraputra E, 2001, BIOORG CHEM, V29, P156, DOI 10.1006/bioo.2001.1208; VERMA SK, 1993, INDIAN J MED RES-B, V98, P240; Weidner MS, 2000, J ETHNOPHARMACOL, V73, P513, DOI 10.1016/S0378-8741(00)00340-8; Young HY, 2006, AM J CHINESE MED, V34, P545, DOI 10.1142/S0192415X06004089	40	33	34	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2015	10	10							e0141119	10.1371/journal.pone.0141119	http://dx.doi.org/10.1371/journal.pone.0141119			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0ZM	26488162	Green Published, gold, Green Submitted			2023-01-03	WOS:000363248400104
J	Yao, ZJ; Peng, Y; Chen, XF; Bi, JQ; Li, Y; Ye, XH; Shi, J				Yao, Zhenjiang; Peng, Yang; Chen, Xiaofeng; Bi, Jiaqi; Li, Ying; Ye, Xiaohua; Shi, Jing			Healthcare Associated Infections of Methicillin-Resistant Staphylococcus aureus: A Case-Control-Control Study	PLOS ONE			English	Article							RISK-FACTORS; ANTIMICROBIAL RESISTANCE; PATIENT OUTCOMES; BACTEREMIA; IMPACT; CHINA; COLONIZATION; MORTALITY; EPIDEMIOLOGY; SURVEILLANCE	Background Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most widespread and dangerous pathogens in healthcare settings. We carried out this case-control-control study at a tertiary care hospital in Guangzhou, China, to examine the antimicrobial susceptibility patterns, risk factors and clinical outcomes of MRSA infections. Methods A total of 57 MRSA patients, 116 methicillin-susceptible Staphylococcus aureus (MSSA) patients and 102 S. aureus negative patients were included in this study. We applied the disk diffusion method to compare the antimicrobial susceptibilities of 18 antibiotics between MRSA and MSSA isolates. Risk factors of MRSA infections were evaluated using univariate and multivariate logistic regression models. We used Cox proportional hazards models and logistic regression analysis to assess the hospital stay duration and fatality for patients with MRSA infections. Results The MRSA group had significantly higher resistance rates for most drugs tested compared with the MSSA group. Using MSSA patients as controls, the following independent risk factors of MRSA infections were identified: 3 or more prior hospitalizations (OR 2.8, 95% CI 1.3-5.8, P = 0.007), chronic obstructive pulmonary disease (OR 5.9, 95% CI 1.7-20.7, P = 0.006), and use of a respirator (OR 3.6, 95% CI 1.0-12.9, P = 0.046). With the S. aureus negative patients as controls, use of a respirator (OR 3.8, 95% CI 1.0-13.9, P = 0.047) and tracheal intubation (OR 8.2, 95% CI 1.5-45.1, P = 0.016) were significant risk factors for MRSA infections. MRSA patients had a longer hospital stay duration and higher fatality in comparison with those in the two control groups. Conclusions MRSA infections substantially increase hospital stay duration and fatality. Thus, MRSA infections are serious issues in this healthcare setting and should receive more attention from clinicians.	[Yao, Zhenjiang; Peng, Yang; Ye, Xiaohua] Guangdong Pharmaceut Univ, Dept Epidemiol & Hlth Stat, Guangzhou, Guangdong, Peoples R China; [Chen, Xiaofeng] Peoples Hosp Meizhou, Div Infect Dis, Meizhou, Peoples R China; [Bi, Jiaqi] Shajing Hlth Inspect Inst, Dept Environm, Shenzhen, Peoples R China; [Bi, Jiaqi] Shajing Hlth Inspect Inst, Sch Hlth, Shenzhen, Peoples R China; [Li, Ying] Guangdong Pharmaceut Univ, Div Environm Hlth, Publ Hlth Lab Ctr, Guangzhou, Guangdong, Peoples R China; [Shi, Jing] Hebei Univ Chinese Med, Dept Prevent Med, Shijiazhuang, Peoples R China	Guangdong Pharmaceutical University; Guangdong Pharmaceutical University; Hebei University of Chinese Medicine	Yao, ZJ (corresponding author), Guangdong Pharmaceut Univ, Dept Epidemiol & Hlth Stat, Guangzhou, Guangdong, Peoples R China.	zhjyao2001@yahoo.com	Peng, Yang/J-8980-2016; yao, zhenjiang/N-7450-2016	Peng, Yang/0000-0002-9119-5506; yao, zhenjiang/0000-0002-2156-7896	Natural Science Foundation of Guangdong Education Department [2013KJCX0112]	Natural Science Foundation of Guangdong Education Department	This study was supported by Natural Science Foundation of Guangdong Education Department (2013KJCX0112). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe Y, 2012, INT J ANTIMICROB AG, V40, P423, DOI 10.1016/j.ijantimicag.2012.07.005; Boucher HW, 2009, CLIN INFECT DIS, V48, P1, DOI 10.1086/595011; Chen CC, 2013, AM J INFECT CONTROL, V41, P1100, DOI 10.1016/j.ajic.2013.01.035; Clinical and Laboratory Standards Institute, 2013, M100S23 CLIN LAB STA; Cosgrove SE, 2006, CLIN INFECT DIS, V42, pS82, DOI 10.1086/499406; Cosgrove SE, 2005, INFECT CONT HOSP EP, V26, P166, DOI 10.1086/502522; ERIKSEN K R, 1961, Ugeskr Laeger, V123, P384; Fascia DTM, 2009, J BONE JOINT SURG BR, V91B, P249, DOI 10.1302/0301-620X.91B2.21339; Fuda C, 2004, J BIOL CHEM, V279, P40802, DOI 10.1074/jbc.M403589200; Ghirardi B, 2013, Pediatr Med Chir, V35, P263; Harinstein L, 2011, J HOSP INFECT, V79, P194, DOI 10.1016/j.jhin.2011.03.017; Jones RN, 2013, DIAGN MICROBIOL INFE, V77, P258, DOI DOI 10.1016/J.DIAGMICR0BI0.2013.07.003; Kaasch AJ, 2014, J INFECTION, V68, P242, DOI 10.1016/j.jinf.2013.10.015; Kahsay A, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-16; Li TM, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-153; Lodise TP, 2005, DIAGN MICR INFEC DIS, V52, P113, DOI 10.1016/j.diagmicrobio.2005.02.007; March A, 2010, CLIN MICROBIOL INFEC, V16, P934, DOI 10.1111/j.1469-0691.2009.03024.x; Park DA, 2013, INFECT CHEMOTHER, V45, P202, DOI 10.3947/ic.2013.45.2.202; Porto JP, 2013, REV SOC BRAS MED TRO, V46, P713, DOI 10.1590/0037-8682-0199-2013; Rasmussen G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114276; Rongpharpi SR, 2013, J CLIN DIAGN RES, V7, P257, DOI 10.7860/JCDR/2013/4320.2741; Sun DD, 2013, BRAZ J INFECT DIS, V17, P682, DOI 10.1016/j.bjid.2013.02.007; van Hal SJ, 2014, J ANTIMICROB CHEMOTH, V69, P363, DOI 10.1093/jac/dkt354; Whitby M, 2001, MED J AUSTRALIA, V175, P264, DOI 10.5694/j.1326-5377.2001.tb143562.x; Xiao M, 2013, J CLIN MICROBIOL, V51, P3638, DOI 10.1128/JCM.01375-13; Xiao YH, 2011, DRUG RESIST UPDATE, V14, P236, DOI 10.1016/j.drup.2011.07.001; Zhao CJ, 2012, DIAGN MICR INFEC DIS, V73, P174, DOI 10.1016/j.diagmicrobio.2012.03.003	27	6	8	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2015	10	10							e0140604	10.1371/journal.pone.0140604	http://dx.doi.org/10.1371/journal.pone.0140604			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0CX	26470023	Green Published, gold, Green Submitted			2023-01-03	WOS:000363184600084
J	Han, B; Compton, WM; Jones, CM; Cai, R				Han, Beth; Compton, Wilson M.; Jones, Christopher M.; Cai, Rong			Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANALGESIC ABUSE; PAIN RELIEVERS; TRENDS; FREQUENCY	IMPORTANCE Since 1999, the United States has experienced increases in morbidity and mortality associated with nonmedical use of prescription opioids. OBJECTIVE To assess national trends in and characteristics of nonmedical prescription opioid use and use disorders and the national trend in related mortality. DESIGN, SETTING, AND PARTICIPANTS Prevalence of nonmedical use and use disorders and related risk factors were based on data from 472 200 persons aged 18 through 64 years who participated in the 2003-2013 National Surveys on Drug Use and Health. Mortality was based on the 2003-2013 National Vital Statistics System's Multiple Cause of Death Files. EXPOSURES Prevalence of nonmedical use of prescription opioids. MAIN OUTCOMES AND MEASURES Nonmedical prescription opioid use and use disorders. RESULTS Among adults aged 18 through 64 years, the prevalence of nonmedical use of prescription opioids decreased from 5.4% (95% CI, 5.08%-5.70%) in 2003 to 4.9% (95% CI, 4.58%-5.22%) in 2013 (absolute difference, -0.5%; 95% CI, -0.11% to -0.89%), but the prevalence of prescription opioid use disorders increased from 0.6% (95% CI, 0.54%-0.76%) in 2003 to 0.9% (95% CI, 0.75%-1.01%) in 2013 (absolute difference, 0.3%; 95% CI, 0.03%-0.43%). The 12-month prevalence of high-frequency use (>= 200 days) also increased from 0.3% (95% CI, 0.19%-0.35%) in 2003 to 0.4% (95% CI, 0.31%-0.48%) in 2013 (absolute difference, 0.1%; 95% CI, 0.01%-0.29%). Mortality assessed by drug overdose death rates involving prescription opioids increased from 4.5 per 100 000 (95% CI, 4.42-4.61) in 2003 to 7.8 per 100 000 (95% CI, 7.64-7.89) in 2013 (absolute difference, 3.3; 95% CI, 3.09-3.41) among adults aged 18 through 64 years. The mean number of days of nonmedical use of prescription opioids increased from 2.1 (95% CI, 1.83-2.37) in 2003 to 2.6 (95% CI, 2.27-2.85) in 2013 (absolute difference, 0.5, 95% CI, 0.05-0.86). The model-adjusted prevalence of having prescription opioid use disorders among nonmedical users increased to 15.7% (95% CI, 13.87%-17.67%) in 2010,16.1% (95% CI, 14.36%-17.99%) in 2011, 17.0% (95% CI, 15.07%-19.12%) in 2012, and 16.9% (95% CI, 14.95%-19.03%) in 2013 from 12.7% (95% CI, 11.04%-14.53%) in 2003. CONCLUSIONS AND RELEVANCE During the 2003-2013 years, among adults aged 18 through 64 years, the percentage of nonmedical use of prescription opioids decreased. In contrast, the prevalence of prescription opioid use disorders, frequency of use, and related mortality increased.	[Han, Beth; Cai, Rong] Subst Abuse & Mental Hlth Serv Adm, Rockville, MD 20857 USA; [Compton, Wilson M.] NIDA, NIH, Bethesda, MD USA; [Jones, Christopher M.] US FDA, Silver Spring, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); US Food & Drug Administration (FDA)	Han, B (corresponding author), Subst Abuse & Mental Hlth Serv Adm, One Choke Cherry Rd,Room 2-1079, Rockville, MD 20857 USA.	beth.han@samhsa.hhs.gov			Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse; US Food and Drug Administration	Substance Abuse and Mental Health Services Administration(United States Department of Health & Human Services); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); US Food and Drug Administration	This study was jointly sponsored by the Substance Abuse and Mental Health Services Administration, the National Institute on Drug Abuse, and the US Food and Drug Administration. The National Surveys on Drug Use and Health were supported by contracts from the Substance Abuse and Mental Health Services Administration.	American Association for Public Opinion Research, 2015, STAND DEF FIN DISP C, V8th ed, P52; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Baumblatt JAG, 2014, JAMA INTERN MED, V174, P796, DOI 10.1001/jamainternmed.2013.12711; Bieler GS, 2010, AM J EPIDEMIOL, V171, P618, DOI 10.1093/aje/kwp440; Cai R., 2010, Morbidity and Mortality Weekly Report, V59, P705; Center for Behavioral Health Statistics and Quality, 2014, 2013 NAT SURV DRUG U; Center for Behavioral Health Statistics and Quality, 2014, NAT SURV DRUG US HLT; Centers for Disease Control and Prevention, 2014, MULT CAUS OF DEATH D; Centers for Disease Control and Prevention (CDC), 2012, MMWR MORB MORTAL WKL, V61, P10; Compton WM, 2015, PREV MED, V80, P5, DOI 10.1016/j.ypmed.2015.04.003; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Groves RM, 2006, PUBLIC OPIN QUART, V70, P646, DOI 10.1093/poq/nfl033; Hilbe J.M., 2007, NEGATIVE BINOMIAL RE; Jones CM, 2015, AM J PREV MED, V49, P493, DOI 10.1016/j.amepre.2015.03.040; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Jones CM, 2014, JAMA-J AM MED ASSOC, V312, P1733, DOI 10.1001/jama.2014.13480; Jones CM, 2014, JAMA INTERN MED, V174, P802, DOI 10.1001/jamainternmed.2013.12809; Jones CM, 2013, DRUG ALCOHOL DEPEN, V132, P95, DOI 10.1016/j.drugalcdep.2013.01.007; Jones CM, 2012, ARCH INTERN MED, V172, P1265, DOI 10.1001/archinternmed.2012.2533; Mack KA, 2015, J HEALTH CARE POOR U, V26, P182, DOI 10.1353/hpu.2015.0009; Modarai F, 2013, DRUG ALCOHOL DEPEN, V132, P81, DOI 10.1016/j.drugalcdep.2013.01.006; Murphy Sherry L, 2013, Natl Vital Stat Rep, V61, P1; National Vital Statistics System National Center for Health Statistics CDC, NAT VIT STAT SYST; Office of National Drug Control Policy, 2012, NAT DRUG CONTR STRAT; Olsen Y, 2014, JAMA-J AM MED ASSOC, V311, P1393, DOI 10.1001/jama.2014.2147; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Paulozzi LJ, 2013, J CLIN TOXICOL, V3, P175, DOI DOI 10.4172/2161-0495.1000175; Reifler LM, 2012, PAIN MED, V13, P434, DOI 10.1111/j.1526-4637.2012.01327.x; Research Triangle Institute, 2015, SUDAAN REL 11 0 1; Services USD of H and H, 2014, RESULTS 2013 NATL SU, V131, DOI 10.1002/ajmg.a.30231; Shiffman S, 2004, NICOTINE TOB RES, V6, P327, DOI 10.1080/1462220042000202481; StataCorp, 2014, STATA STAT SOFTW REL; Substance Abuse and Mental Health Services Administration, NAT SURV DRUG US HLT; Substance Abuse and Mental Health Services Administration, DRUG AB WARN NETW NA; Tourangeau R, 2013, NONRESPONSE SOCIAL S; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780	37	248	249	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2015	314	14					1468	1478		10.1001/jama.2015.11859	http://dx.doi.org/10.1001/jama.2015.11859			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT2QI	26461997	Bronze			2023-01-03	WOS:000362647800014
J	Vidic, J; Richard, CA; Pechoux, C; Da Costa, B; Bertho, N; Mazerat, S; Delmas, B; Chevalier, C				Vidic, Jasmina; Richard, Charles-Adrien; Pechoux, Christine; Da Costa, Bruno; Bertho, Nicolas; Mazerat, Sandra; Delmas, Bernard; Chevalier, Christophe			Amyloid Assemblies of Influenza A Virus PB1-F2 Protein Damage Membrane and Induce Cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ELECTROCHEMICAL DETECTION; MITOCHONDRIAL-MEMBRANE; MISFOLDING DISEASES; LIPID-MEMBRANES; ALPHA-SYNUCLEIN; INFECTED-CELLS; MESSENGER-RNA; MECHANISM; BINDING	PB1-F2 is a small accessory protein encoded by an alternative open reading frame in PB1 segments of most influenza A virus. PB1-F2 is involved in virulence by inducing mitochondria-mediated immune cells apoptosis, increasing inflammation, and enhancing predisposition to secondary bacterial infections. Using biophysical approaches we characterized membrane disruptive activity of the full-length PB1-F2 (90 amino acids), its N-terminal domain (52 amino acids), expressed by currently circulating H1N1 viruses, and its C-terminal domain (38 amino acids). Both full-length and N-terminal domain of PB1-F2 are soluble at pH values <= 6, whereas the C-terminal fragment was found soluble only at pH <= 3. All three peptides are intrinsically disordered. At pH >= 7, the C-terminal part of PB1-F2 spontaneously switches to amyloid oligomers, whereas full-length and the N-terminal domain of PB1-F2 aggregate to amorphous structures. When incubated with anionic liposomes at pH 5, full-length and the C-terminal part of PB1-F2 assemble into amyloid structures and disrupt membrane at nanomolar concentrations. PB1-F2 and its C-terminal exhibit no significant antimicrobial activity. When added in the culture medium of mammalian cells, PB1-F2 amorphous aggregates show no cytotoxicity, whereas PB1-F2 pre-assembled into amyloid oligomers or fragmented nanoscaled fibrils was highly cytotoxic. Furthermore, the formation of PB1-F2 amyloid oligomers in infected cells was directly reflected by membrane disruption and cell death as observed in U937 and A549 cells. Altogether our results demonstrate that membrane-lytic activity of PB1-F2 is closely linked to supramolecular organization of the protein.	[Vidic, Jasmina; Richard, Charles-Adrien; Da Costa, Bruno; Bertho, Nicolas; Delmas, Bernard; Chevalier, Christophe] INRA, Unite Virol & Immunol Mol, UR892, F-78350 Jouy En Josas, France; [Pechoux, Christine] INRA, Genet Anim & Biol Integrat, UMR1313, F-78350 Jouy En Josas, France; [Mazerat, Sandra] Univ Paris 11, Inst Chim Mol & Mat Orsay, CNRS, UMR 8182, F-91400 Orsay, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay	Vidic, J (corresponding author), INRA, Unite Virol & Immunol Mol, UR892, F-78350 Jouy En Josas, France.	jasmina.vidic@jouy.inra.fr	Chevalier, Christophe/AAW-5560-2020; Vidic, Jasmina/AFP-6747-2022; Chevalier, Christophe/AAK-4461-2020; Chevalier, Christophe/C-2575-2009; BERTHO, Nicolas/B-8167-2019	Vidic, Jasmina/0000-0002-8549-8199; Chevalier, Christophe/0000-0003-3231-9027; BERTHO, Nicolas/0000-0002-6732-3483; RICHARD, Charles-Adrien/0000-0001-5306-2297				Alymova IV, 2014, J VIROL, V88, P503, DOI 10.1128/JVI.01373-13; Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7; Biancalana M, 2010, BBA-PROTEINS PROTEOM, V1804, P1405, DOI 10.1016/j.bbapap.2010.04.001; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chakrabarti AK, 2013, VIROLOGY, V440, P97, DOI 10.1016/j.virol.2013.02.025; Chanturiya AN, 2004, J VIROL, V78, P6304, DOI 10.1128/JVI.78.12.6304-6312.2004; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Chevalier C, 2010, J BIOL CHEM, V285, P13233, DOI 10.1074/jbc.M109.067710; Conenello GM, 2011, J VIROL, V85, P652, DOI 10.1128/JVI.01987-10; Cremades N, 2012, CELL, V149, P1048, DOI 10.1016/j.cell.2012.03.037; Daude N, 2010, J NEUROCHEM, V113, P92, DOI 10.1111/j.1471-4159.2010.06575.x; Domanov YA, 2008, J MOL BIOL, V376, P42, DOI 10.1016/j.jmb.2007.11.077; Gibbs JS, 2003, J VIROL, V77, P7214, DOI 10.1128/JVI.77.13.7214-7224.2003; Goodchild SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104492; Henkel M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011112; Jagger BW, 2012, SCIENCE, V337, P199, DOI 10.1126/science.1222213; Kash JC, 2006, NATURE, V443, P578, DOI 10.1038/nature05181; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kosik I, 2013, VIROLOGY, V447, P1, DOI 10.1016/j.virol.2013.08.022; Krumbholz A, 2011, MED MICROBIOL IMMUN, V200, P69, DOI 10.1007/s00430-010-0176-8; La Gruta NL, 2007, IMMUNOL CELL BIOL, V85, P85, DOI 10.1038/sj.icb.7100026; Le Goffic R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002202; Le Goffic R, 2010, J IMMUNOL, V185, P4812, DOI 10.4049/jimmunol.0903952; Li QJ, 2013, BIOCHEM BIOPH RES CO, V438, P519, DOI 10.1016/j.bbrc.2013.07.104; Mazur I, 2008, CELL MICROBIOL, V10, P1140, DOI 10.1111/j.1462-5822.2008.01116.x; McAuley JL, 2007, CELL HOST MICROBE, V2, P240, DOI 10.1016/j.chom.2007.09.001; McAuley JL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003392; McAuley JL, 2010, J VIROL, V84, P558, DOI 10.1128/JVI.01785-09; Miodek A, 2014, ANAL CHEM, V86, P9098, DOI 10.1021/ac5018056; Miodek A, 2014, BIOSENS BIOELECTRON, V59, P6, DOI 10.1016/j.bios.2014.02.037; Muramoto Y, 2013, J VIROL, V87, P2455, DOI 10.1128/JVI.02656-12; Relini A, 2014, ADV COLLOID INTERFAC, V207, P81, DOI 10.1016/j.cis.2013.10.015; Reynolds NP, 2011, J AM CHEM SOC, V133, P19366, DOI 10.1021/ja2029848; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Steunou S, 2010, BIOSENS BIOELECTRON, V26, P1399, DOI 10.1016/j.bios.2010.07.064; Swaminathan R, 2011, ADV PROTEIN CHEM STR, V84, P63, DOI 10.1016/B978-0-12-386483-3.00003-3; Terakawa MS, 2015, J BIOL CHEM, V290, P815, DOI 10.1074/jbc.M114.592527; Varga ZT, 2012, J VIROL, V86, P8359, DOI 10.1128/JVI.01122-12; Varga ZT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002067; Vasin AV, 2014, VIRUS RES, V185, P53, DOI 10.1016/j.virusres.2014.03.015; Vermes I, 2000, J IMMUNOL METHODS, V243, P167, DOI 10.1016/S0022-1759(00)00233-7; Vidic J., 2013, J ANAL BIOANAL TECH, V4, P169; Walsh P, 2014, J BIOL CHEM, V289, P10419, DOI 10.1074/jbc.M113.515866; Weeks-Gorospe JN, 2012, J VIROL, V86, P9035, DOI 10.1128/JVI.00369-12; Wise HM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002998; Wise HM, 2009, J VIROL, V83, P8021, DOI 10.1128/JVI.00826-09; Wright P., 2007, ORTHOMYXOVIRUSES; Yamada H, 2004, FEBS LETT, V578, P331, DOI 10.1016/j.febslet.2004.11.017; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Yoshizumi T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5713; Zamarin D, 2006, J VIROL, V80, P7976, DOI 10.1128/JVI.00415-06; Zamarin Dmitriy, 2005, PLoS Pathogens, V1, P40	53	35	38	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2016	291	2					739	751		10.1074/jbc.M115.652917	http://dx.doi.org/10.1074/jbc.M115.652917			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DA5GF	26601953	Green Published, hybrid			2023-01-03	WOS:000367830500022
J	van Griensven, J; Edwards, T; de Lamballerie, X; Semple, MG; Gallian, P; Baize, S; Horby, PW; Raoul, H; Magassouba, N; Antierens, A; Lomas, C; Faye, O; Sall, AA; Fransen, K; Buyze, J; Ravinetto, R; Tiberghien, P; Claeys, Y; De Crop, M; Lynen, L; Bah, EI; Smith, PG; Delamou, A; De Weggheleire, A; Haba, N				van Griensven, J.; Edwards, T.; de Lamballerie, X.; Semple, M. G.; Gallian, P.; Baize, S.; Horby, P. W.; Raoul, H.; Magassouba, N.; Antierens, A.; Lomas, C.; Faye, O.; Sall, A. A.; Fransen, K.; Buyze, J.; Ravinetto, R.; Tiberghien, P.; Claeys, Y.; De Crop, M.; Lynen, L.; Bah, E. I.; Smith, P. G.; Delamou, A.; De Weggheleire, A.; Haba, N.		Ebola-Tx Consortium	Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONHUMAN-PRIMATES; HEMORRHAGIC-FEVER	BACKGROUND In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the World Health Organization prioritized the evaluation of treatment with convalescent plasma derived from patients who have recovered from the disease. We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea. METHODS In this nonrandomized, comparative study, 99 patients of various ages (including pregnant women) with confirmed EVD received two consecutive transfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained from a separate convalescent donor. The transfusions were initiated on the day of diagnosis or up to 2 days later. The level of neutralizing antibodies against Ebola virus in the plasma was unknown at the time of administration. The control group was 418 patients who had been treated at the same center during the previous 5 months. The primary outcome was the risk of death during the period from 3 to 16 days after diagnosis with adjustments for age and the baseline cycle-threshold value on polymerase- chain-reaction assay; patients who had died before day 3 were excluded. The clinically important difference was defined as an absolute reduction in mortality of 20 percentage points in the convalescent-plasma group as compared with the control group. RESULTS A total of 84 patients who were treated with plasma were included in the primary analysis. At baseline, the convalescent-plasma group had slightly higher cycle-threshold values and a shorter duration of symptoms than did the control group, along with a higher frequency of eye redness and difficulty in swallowing. From day 3 to day 16 after diagnosis, the risk of death was 31% in the convalescent-plasma group and 38% in the control group (risk difference, -7 percentage points; 95% confidence interval [CI], -18 to 4). The difference was reduced after adjustment for age and cycle-threshold value (adjusted risk difference, -3 percentage points; 95% CI, -13 to 8). No serious adverse reactions associated with the use of convalescent plasma were observed. CONCLUSIONS The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed EVD was not associated with a significant improvement in survival. (Funded by the European Union's Horizon 2020 Research and Innovation Program and others; ClinicalTrials. gov number, NCT02342171.)	[van Griensven, J.; Fransen, K.; Buyze, J.; Ravinetto, R.; Claeys, Y.; De Crop, M.; Lynen, L.; De Weggheleire, A.] Inst Trop Med, B-2000 Antwerp, Belgium; [Antierens, A.; Lomas, C.] Med Sans Frontieres, Brussels, Belgium; [Ravinetto, R.] Katholieke Univ Leuven, Clin Pharmacol & Pharmacotherapy Dept, Leuven, Belgium; [Edwards, T.; Smith, P. G.] London Sch Hyg & Trop Med, Med Res Council, Trop Epidemiol Grp, London WC1, England; [Semple, M. G.] Univ Liverpool, Inst Translat Med, Liverpool L69 3BX, Merseyside, England; [Semple, M. G.] Univ Liverpool, NIHR, Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool L69 3BX, Merseyside, England; [Horby, P. W.] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England; [de Lamballerie, X.; Gallian, P.] Aix Marseille Univ, Marseille, France; [de Lamballerie, X.] French Inst Res Dev, Marseille, France; [de Lamballerie, X.] Ecole Hautes Etud Sante Publ, Marseille, France; [de Lamballerie, X.; Gallian, P.] Inst Hosp Univ Mediterranee Infect, Marseille, France; [Gallian, P.; Tiberghien, P.] Etab Francais Sang, La Plaine St Denis, France; [Baize, S.] Inst Pasteur, Ctr Int Rech Infectiol, Unite Biol Infect Virales Emergentes, Lyon, France; [Raoul, H.] Lab P4 INSERM Jean Merieux, Lyon, France; [Tiberghien, P.] Univ Franche Comte, Etab Francais Sang, INSERM UMR 1098, F-25030 Besancon, France; [Magassouba, N.] Gamal Abdel Nasser Univ Conakry, Lab Viral Hemorrhag Fever, Conakry, Guinea; [Bah, E. I.] Hop Natl Donka, Serv Malad Infect & Trop, Conakry, Guinea; [Haba, N.] Natl Blood Transfus Ctr, Conakry, Guinea; [Delamou, A.] Natl Ctr Training & Res Rural Hlth Maferinyah, Forecariah, Guinea; [Faye, O.; Sall, A. A.] Inst Pasteur, Dakar, Senegal	Institute of Tropical Medicine (ITM); Doctors Without Borders; KU Leuven; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of London; London School of Hygiene & Tropical Medicine; University of Liverpool; University of Liverpool; University of Oxford; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Dakar	van Griensven, J (corresponding author), Inst Trop Med, Nationalestr 155, B-2000 Antwerp, Belgium.	jvangriensven@itg.be	Buyze, Jozefien/B-8550-2014; Tiberghien, Pierre/AAH-5878-2019; amsalu, ribka/G-8780-2019; De Weggheleire, Anja/C-7345-2018; Saez, Almudena M/AAU-9835-2021; Lynen, Lutgarde/A-1212-2014; Semple, Malcolm Gracie/A-8790-2008; Lynen, Lutgarde/AAT-9180-2020; smith, peter/ABH-9627-2020	Buyze, Jozefien/0000-0001-6780-380X; De Weggheleire, Anja/0000-0001-9377-4766; Saez, Almudena M/0000-0002-5429-8485; Lynen, Lutgarde/0000-0001-7183-4895; Semple, Malcolm Gracie/0000-0001-9700-0418; Lynen, Lutgarde/0000-0001-7183-4895; smith, peter/0000-0003-0080-7560; Ingelbeen, Brecht/0000-0002-2214-6858; Baize, Sylvain/0000-0002-3234-7477; Edwards, Tansy/0000-0002-6110-014X; Horby, Peter/0000-0002-9822-1586; Tiberghien, Pierre/0000-0002-9310-8322; Colebunders, Robert/0000-0002-1919-1340	European Union; Medical Research Council [MR/K012126/1] Funding Source: researchfish	European Union(European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Funded by the European Union's Horizon 2020 Research and Innovation Program and others; ClinicalTrials.gov number, NCT02342171.	Adebamowo C, 2014, LANCET, V384, P1423, DOI 10.1016/S0140-6736(14)61734-7; Agua-Agum J, 2015, NEW ENGL J MED, V372, P1274, DOI 10.1056/NEJMc1415318; [Anonymous], 2015, C RETR OPP INF SEATT; Bah EI, 2015, NEW ENGL J MED, V372, P40, DOI 10.1056/NEJMoa1411249; Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974; Dye JM, 2012, P NATL ACAD SCI USA, V109, P5034, DOI 10.1073/pnas.1200409109; Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396; Mora-Rillo M, 2015, LANCET RESP MED, V3, P554, DOI 10.1016/S2213-2600(15)00180-0; Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298; Mupapa K, 1999, J INFECT DIS, V179, pS11, DOI 10.1086/514289; Norton EC, 2013, STATA J, V13, P492, DOI 10.1177/1536867X1301300304; Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777; Schieffelin JS, 2014, NEW ENGL J MED, V371, P2092, DOI 10.1056/NEJMoa1411680; Sterck A, 2008, MED SANS FRONTIERES; World Health Organization, 2014, INT GUID NAT HLTH AU; World Health Organization, 2015, EB SIT REP WHO	16	349	360	0	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 7	2016	374	1					33	42		10.1056/NEJMoa1511812	http://dx.doi.org/10.1056/NEJMoa1511812			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA1UH	26735992	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000367580500006
J	Van Poucke, S; Zhang, ZH; Schmitz, M; Vukicevic, M; Vander Laenen, M; Celi, LA; De Deyne, C				Van Poucke, Sven; Zhang, Zhongheng; Schmitz, Martin; Vukicevic, Milan; Vander Laenen, Margot; Celi, Leo Anthony; De Deyne, Cathy			Scalable Predictive Analysis in Critically Ill Patients Using a Visual Open Data Analysis Platform	PLOS ONE			English	Article							ACUTE PHYSIOLOGY SCORE; SELECTION	With the accumulation of large amounts of health related data, predictive analytics could stimulate the transformation of reactive medicine towards Predictive, Preventive and Personalized (PPPM) Medicine, ultimately affecting both cost and quality of care. However, high-dimensionality and high-complexity of the data involved, prevents data-driven methods from easy translation into clinically relevant models. Additionally, the application of cutting edge predictive methods and data manipulation require substantial programming skills, limiting its direct exploitation by medical domain experts. This leaves a gap between potential and actual data usage. In this study, the authors address this problem by focusing on open, visual environments, suited to be applied by the medical community. Moreover, we review code free applications of big data technologies. As a showcase, a framework was developed for the meaningful use of data from critical care patients by integrating the MIMIC-II database in a data mining environment (RapidMiner) supporting scalable predictive analytics using visual tools (RapidMiner's Radoop extension). Guided by the CRoss-Industry Standard Process for Data Mining (CRISP-DM), the ETL process (Extract, Transform, Load) was initiated by retrieving data from the MIMIC-II tables of interest. As use case, correlation of platelet count and ICU survival was quantitatively assessed. Using visual tools for ETL on Hadoop and predictive modeling in RapidMiner, we developed robust processes for automatic building, parameter optimization and evaluation of various predictive models, under different feature selection schemes. Because these processes can be easily adopted in other projects, this environment is attractive for scalable predictive analytics in health research.	[Van Poucke, Sven; Vander Laenen, Margot; De Deyne, Cathy] Ziekenhuis Oost Limburg, Dept Anesthesiol Intens Care Emergency Med & Pain, Genk, Belgium; [Zhang, Zhongheng] Zhejiang Univ, Jinhua Hosp, Dept Crit Care Med, Hangzhou, Zhejiang, Peoples R China; [Schmitz, Martin] RapidMiner GmbH, Dortmund, Germany; [Vukicevic, Milan] Univ Belgrade, Dept Org Sci, Belgrade, Serbia; [Celi, Leo Anthony] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA; [De Deyne, Cathy] Univ Hasselt, Fac Med, Limburg Clin Res Program, Hasselt, Belgium	East Limburg Hospital; Zhejiang University; University of Belgrade; Massachusetts Institute of Technology (MIT); Hasselt University	Van Poucke, S (corresponding author), Ziekenhuis Oost Limburg, Dept Anesthesiol Intens Care Emergency Med & Pain, Genk, Belgium.	svanpoucke@gmail.com	Van Poucke, Sven/K-5999-2016; zhang, zh/GWV-4677-2022; Zhang, Zhongheng/E-1282-2011; PAN, ZEQIANG/X-6341-2018; Vukicevic, Milan/GOH-2563-2022; Vukicevic, Milan/X-3590-2019	Van Poucke, Sven/0000-0001-8070-8786; Zhang, Zhongheng/0000-0002-2336-5323; Vukicevic, Milan/0000-0002-1631-6531; 	National Institutes of Health (NIH) through National Institute of Biomedical Imaging and Bioengineering [R01 EB01720501A1]; Vancis B.V. (Amsterdam, NL); Xomnia B.V. (Amsterdam, NL); RapidMiner; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB017205] Funding Source: NIH RePORTER	National Institutes of Health (NIH) through National Institute of Biomedical Imaging and Bioengineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vancis B.V. (Amsterdam, NL); Xomnia B.V. (Amsterdam, NL); RapidMiner; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	LAC was funded by the National Institutes of Health (NIH) through National Institute of Biomedical Imaging and Bioengineering grant R01 EB01720501A1. Access, licenses and support for Hadoop/Hiveare were provided by Vancis B.V. (Amsterdam, NL) and Xomnia B.V. (Amsterdam, NL). Licenses for RapidMiner/Radoop were provided by RapidMiner (Cambridge, MA, USA). RapidMiner provides free or substantially discounted use of the commercial version of its platform to students, professors, researchers and other academics at educational institutions. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. RapidMiner provided support in the form of salary for author [MS], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the "author contributions" section.	[Anonymous], 2012, USENIX LOGIN; Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280; Breiman L, 1996, MACH LEARN, V24, P49; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1007/bf00058655; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chao CM, 2014, J MED SYST, V38, DOI 10.1007/s10916-014-0106-1; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Davis J, P 23 INT C MACH LEAR, P230, DOI [http://doi.acm.org/10.1145/1143844.1143874J, DOI 10.1145/1143844.1143874J]; Dean J, 2004, USENIX ASSOCIATION PROCEEDINGS OF THE SIXTH SYMPOSIUM ON OPERATING SYSTEMS DESIGN AND IMPLEMENTATION (OSDE '04), P137; Druss BG, 2000, AM J PSYCHIAT, V157, P1485, DOI 10.1176/appi.ajp.157.9.1485; Edwards DD., 2003, ARTIF INTELL, V2; Freund Y., 1999, Journal of Japanese Society for Artificial Intelligence, V14, P771; Friedrichs F, 2005, NEUROCOMPUTING, V64, P107, DOI 10.1016/j.neucom.2004.11.022; Ghassemi M, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0801-4; Goldberg DE, 1989, GENETIC ALGORITHMS S; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Golubnitschaja O, 2014, EPMA J, V5, DOI [10.1186/1878-5085-5-6, 10.1186/s13167-015-0026-2]; Grau J, 2015, PRECISION RECALL ROC; Hall M, 2013, WEKA AND HADOOP; Hand DJ, 2001, INT STAT REV, V69, P385, DOI 10.1111/j.1751-5823.2001.tb00465.x; Hastie T., 2009, ELEMENTS STAT LEARNI; Herschel G, MAGIC QUADRANT ADV A; Jovic A, 2014, 2014 37TH INTERNATIONAL CONVENTION ON INFORMATION AND COMMUNICATION TECHNOLOGY, ELECTRONICS AND MICROELECTRONICS (MIPRO), P1112, DOI 10.1109/MIPRO.2014.6859735; Kamkar I, 2015, J BIOMED INFORM, V53, P277, DOI 10.1016/j.jbi.2014.11.013; Kohavi R, 1997, ARTIF INTELL, V97, P273, DOI 10.1016/S0004-3702(97)00043-X; Koliopoulos AK, 2015, IEEE INT CONGR BIG, P9, DOI 10.1109/BigDataCongress.2015.12; Kononenko I., 1994, MACH LEARN ECML, P171, DOI 10.1007/3-540-57868-4_57; Kuncheva LI, 2003, MACH LEARN, V51, P181, DOI 10.1023/A:1022859003006; Landset S., 2015, J BIG DATA-GER, V2, P1; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEGALL JR, 1984, CRIT CARE MED, V12, P975; Mao KZ, 2004, IEEE T SYST MAN CY B, V34, P629, DOI 10.1109/TSMCB.2002.804363; Mohammadzadeh Niloofar, 2014, Acta Inform Med, V22, P263, DOI 10.5455/aim.2014.22.263-267; Mohammed EA, 2014, BIODATA MIN, V7, DOI 10.1186/1756-0381-7-22; Ni Z, 2013, THESIS; Nick RK, 2015, 18 INT C EXT DAT TEC, P671; Olston C., 2008, P 2008 ACM SIGMOD IN, P1099, DOI [DOI 10.1145/1376616.1376726, 10.1145/1376616.1376726]; Post RM, 2015, COMPR PSYCHIAT, V56, P21, DOI 10.1016/j.comppsych.2014.08.050; Quinlan J. R., 1986, Machine Learning, V1, P81, DOI 10.1007/BF00116251; Radovanovic S, 2015, P 15 C ART INT MED 2; Riley RD, 2015, STAT MED, P1097, DOI DOI 10.1002/SIM.6471/ABSTRACT; Rish I., 2001, IJCAI 2001 WORKSHOP, P41; Ritthoff O, 2001, TECHNICAL REPORT 763, V763, P84; Saeed M, 2011, CRIT CARE MED, V39, P952, DOI 10.1097/CCM.0b013e31820a92c6; Scott DJ, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-9; Shearer Colin, 2000, J DATA WAREHOUSING, V5, P13; Sparks ER, 2013, IEEE DATA MINING, P1187, DOI 10.1109/ICDM.2013.158; Thusoo A, 2010, PROC INT CONF DATA, P996, DOI 10.1109/ICDE.2010.5447738; Ting H, 2014, J MED SYST, V38, DOI 10.1007/s10916-014-0094-1; Van Poucke S, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0895-8; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Wimmer H, 2015, COMP OPEN SOURCE TOO, P1; Wolfson J, 2014, NAIVE BAYES MACHINE; Zhang ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095204; Zheng J, 2014, IEEE INT CONF BIG DA, P952, DOI 10.1109/BigData.2014.7004327	56	29	29	0	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2016	11	1							e0145791	10.1371/journal.pone.0145791	http://dx.doi.org/10.1371/journal.pone.0145791			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA4VZ	26731286	Green Published, gold, Green Submitted			2023-01-03	WOS:000367801400054
J	Kaleebu, P; Kirungi, W; Watera, C; Asio, J; Lyagoba, F; Lutalo, T; Kapaata, AA; Nanyonga, F; Parry, CM; Magambo, B; Nazziwa, J; Nannyonjo, M; Hughes, P; Hladik, W; Ruberantwari, A; Namuwenge, N; Musinguzi, J; Downing, R; Katongole-Mbidde, E				Kaleebu, Pontiano; Kirungi, Wilford; Watera, Christine; Asio, Juliet; Lyagoba, Fred; Lutalo, Tom; Kapaata, Anne A.; Nanyonga, Faith; Parry, Chris M.; Magambo, Brian; Nazziwa, Jamirah; Nannyonjo, Maria; Hughes, Peter; Hladik, Wolfgang; Ruberantwari, Anthony; Namuwenge, Norah; Musinguzi, Joshua; Downing, Robert; Katongole-Mbidde, Edward		HIV Drug Resistance Working Grp	Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; TRANSMISSION CLUSTERS; NAIVE INDIVIDUALS; SURVEILLANCE; PREVENTION; INITIATION; CLINICS	Background With the scale-up of antiretroviral therapy (ART), monitoring programme performance is needed to maximize ART efficacy and limit HIV drug resistance (HIVDR). Methods We implemented a WHO HIVDR prospective survey protocol at three treatment centers between 2012 and 2013. Data were abstracted from patient records at ART start (T1) and after 12 months (T2). Genotyping was performed in the HIV pol region at the two time points. Results Of the 425 patients enrolled, at T2, 20 (4.7%) had died, 66 (15.5%) were lost to follow-up, 313 (73.6%) were still on first-line, 8 (1.9%) had switched to second-line, 17 (4.0%) had transferred out and 1 (0.2%) had stopped treatment. At T2, 272 out of 321 on first and second line (84.7%) suppressed below 1000 copies/ml and the HIV DR prevention rate was 70.1%, just within the WHO threshold of >= 70%. The proportion of participants with potential HIVDR was 20.9%, which is higher than the 18.8% based on pooled analyses from African studies. Of the 35 patients with mutations at T2, 80% had M184V/I, 65.7% Y181C, and 48.6% (54.8% excluding those not on Tenofovir) had K65R mutations. 22.9% had Thymidine Analogue Mutations (TAMs). Factors significantly associated with HIVDR prevention at T2 were: baseline viral load (VL) <100,000 copies/ml [Adjusted odds ratio (AOR) 3.13, 95% confidence interval (CI): 1.36-7.19] and facility. Independent baseline predictors for HIVDR mutations at T2 were: CD4 count <250 cells/mu l (AOR 2.80, 95% CI: 1.08-7.29) and viral load >= 100,000 copies/ml (AOR 2.48, 95% CI: 1.00-6.14). Conclusion Strengthening defaulter tracing, intensified follow-up for patients with low CD4 counts and/or high VL at ART initiation together with early treatment initiation above 250 CD4 cells/ul and adequate patient counselling would improve ART efficacy and HIVDR prevention. The high rate of K65R and TAMs could compromise second line regimens including NRTIs.	[Kaleebu, Pontiano; Watera, Christine; Asio, Juliet; Lyagoba, Fred; Lutalo, Tom; Nanyonga, Faith; Magambo, Brian; Ruberantwari, Anthony; Downing, Robert; Katongole-Mbidde, Edward] Uganda Virus Res Inst, Entebbe, Uganda; [Kaleebu, Pontiano; Lyagoba, Fred; Kapaata, Anne A.; Parry, Chris M.; Magambo, Brian; Nazziwa, Jamirah; Nannyonjo, Maria; Hughes, Peter] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda; [Kaleebu, Pontiano] London Sch Hyg & Trop Med, London WC1, England; [Kirungi, Wilford; Namuwenge, Norah; Musinguzi, Joshua] Minist Hlth, AIDS Control Programme, Kampala, Uganda; [Hladik, Wolfgang] US Ctr Dis Control & Prevent, Entebbe, Uganda	Uganda Virus Research Institute; University of London; London School of Hygiene & Tropical Medicine	Kaleebu, P (corresponding author), Uganda Virus Res Inst, Entebbe, Uganda.	Pontiano.kaleebu@mrcuganda.org		Nazziwa, Jamirah/0000-0001-9029-7976; Ndagije, Helen/0000-0001-5802-4791; Nanyonga, Faith Elizabeth/0000-0003-2691-4401	PEPFAR [1U2GGH000785-01, 3U2GPS000586-05S1]; UK Medical Research Council (MRC); UK Department for International Development (DFID) under the MRC/DFID Concordat agreement; Medical Research Council [MC_U950080938] Funding Source: researchfish; MRC [MC_U950080938] Funding Source: UKRI	PEPFAR; UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department for International Development (DFID) under the MRC/DFID Concordat agreement; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by PEPFAR grant Nos. 1U2GGH000785-01 and 3U2GPS000586-05S1 to UVRI and by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement.	Barth RE, 2010, LANCET INFECT DIS, V10, P155, DOI 10.1016/S1473-3099(09)70328-7; Bennett DE, 2008, ANTIVIR THER, V13, P1; Billong SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072680; Commonwealth of Australia, 2015, NAT INV REP 2015, P1; Hamers RL, 2012, LANCET INFECT DIS, V12, P307, DOI 10.1016/S1473-3099(11)70255-9; Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9; Hamers RL, 2012, CLIN INFECTIOUS DIS; Hong SY, 2015, JAIDS-J ACQ IMM DEF, V68, P463, DOI 10.1097/QAI.0000000000000509; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Jordan MR, 2008, ANTIVIR THER, V13, P15; Kapaata A, 2013, AIDS RES HUM RETROV, V29, P520, DOI [10.1089/aid.2012.0170, 10.1089/AID.2012.0170]; Lahuerta M, 2013, CLIN INFECTIOUS DIS; Liegeois F, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17985; MOH, 2013, UG TREATM GUID ADD N; Nazziwa J, 2013, AIDS RES HUM RETROV, V29, P788, DOI [10.1089/aid.2012.0123, 10.1089/AID.2012.0123]; Ndembi N, 2008, AIDS RES HUM RETROV, V24, P889, DOI 10.1089/aid.2007.0317; Ndembi N, 2011, AIDS, V25, P905, DOI 10.1097/QAD.0b013e328346260f; Ssemwanga D, 2012, CLIN INFECT DIS, V54, pS339, DOI 10.1093/cid/cir937; Ugbena R, 2012, CLIN INFECT DIS, V54, pS375, DOI 10.1093/cid/cir1064; UNAIDS, 2014, UG HIV AIDS COUNTR P; UNAIDS, 2020, UNAIDS 2020 GLOB REP; Wadonda-Kabondo N, 2012, CLIN INFECT DIS, V54, pS355, DOI 10.1093/cid/cis004; Wensing Annemarie M, 2014, Top Antivir Med, V22, P642; WHO, 2012, WHO GLOB STRAT SURV; WHO, 2012, WHO HIV DRUG RES REP	25	20	20	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0145536	10.1371/journal.pone.0145536	http://dx.doi.org/10.1371/journal.pone.0145536			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SI	26700639	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000367092600094
J	Ruegger, J; Hodgkinson, S; Field-Smith, A; Ahmedzai, SH				Ruegger, Joshua; Hodgkinson, Sarah; Field-Smith, Antonia; Ahmedzai, Sam H.		Guideline Comm	GUIDELINES Care of adults in the last days of life: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Ruegger, Joshua; Hodgkinson, Sarah] Royal Coll Physicians, Natl Clin Guidelines Ctr, London NW1 4LE, England; [Field-Smith, Antonia] Royal Surrey Cty Hosp NHS Fdn Trust, Guildford, Surrey, England; [Ahmedzai, Sam H.] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England	Royal College of Physicians; Royal Surrey County Hospital; University of Sheffield	Ahmedzai, SH (corresponding author), Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.	s.ahmedzai@sheffield.ac.uk	Grocott, Michael/C-4394-2008	Grocott, Michael/0000-0002-9484-7581; Ahmedzai, Sam/0000-0002-2028-8510				Department of Health, 2013, MORE CARE LESS PATHW; General Medical Council, 2010, TREATM CAR END LIF G; General Medical Council, PRESCR GUID PRESCR U; National Archive, 2005, MENT CAP ACT; National Institute for Health and Care Excellence, 2014, DEV NICE GUID MAN 20; National Institute for Health and Care Excellence, 2015, CAR DYING AD LAST DA	6	9	9	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2015	351								h6631	10.1136/bmj.h6631	http://dx.doi.org/10.1136/bmj.h6631			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CZ4MP	26676374				2023-01-03	WOS:000367077600010
J	Lane, R				Lane, Richard			Yusuf Hamied: leader in the Indian generic drug industry	LANCET			English	Biographical-Item																			0	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	2015	386	10011					2385	2385		10.1016/S0140-6736(15)00839-9	http://dx.doi.org/10.1016/S0140-6736(15)00839-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CY3EE	26603926				2023-01-03	WOS:000366290400017
J	Kaye, KS; Patel, DA; Stephens, JM; Khachatryan, A; Patel, A; Johnson, K				Kaye, Keith S.; Patel, Dipen A.; Stephens, Jennifer M.; Khachatryan, Alexandra; Patel, Ayush; Johnson, Kenneth			Rising United States Hospital Admissions for Acute Bacterial Skin and Skin Structure Infections: Recent Trends and Economic Impact	PLOS ONE			English	Article							SOFT-TISSUE INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; PRACTICE GUIDELINES; DISEASES SOCIETY; EMERGENCE; AMERICA; VISITS	Background The number of ambulatory patients seeking treatment for skin and skin structure infections (SSSI) are increasing. The objective of this study is to determine recent trends in hospital admissions and healthcare resource utilization and identify covariates associated with hospital costs and mortality for hospitalized adult patients with a primary SSSI diagnosis in the United States. Methods We performed a retrospective cross-sectional analysis (years 2005-2011) of data from the US Healthcare Cost and Utilization Project National Inpatient Sample. Recent trends, patient characteristics, and healthcare resource utilization for patients hospitalized with a primary SSSI diagnosis were evaluated. Descriptive and bivariate analyses were conducted to assess patient and hospital characteristics. Results A total of 1.8% of hospital admissions for the years 2005 through 2011 were for adult patients with a SSSI primary diagnosis. SSSI-related hospital admissions significantly changed during the study period (P<.001 for trend) ranging from 1.6% (in 2005) to 2.0% (in 2011). Mean hospital length of stay (LOS) decreased from 5.4 days in the year 2005 to 5.0 days in the year 2011 (overall change, P<.001) with no change in hospital costs. Patients with postoperative wound infections had the longest hospital stays (adjusted mean, 5.81 days; 95% confidence interval (CI), 5.80-5.83) and highest total costs (adjusted mean, $9388; 95% CI, $9366-$9410). Year of hospital admission was strongly associated with mortality; infection type, all patient refined diagnosis related group severity of illness level, and LOS were strongly associated with hospital costs. Conclusions Hospital admissions for adult patients in the United States with a SSSI primary diagnosis continue to increase. Decreasing hospital inpatient LOS and mortality rate may be due to improved early treatment. Future research should focus on identifying alternative treatment processes for patients with SSSI that could shift management from inpatient to outpatient treatment settings.	[Kaye, Keith S.] Wayne State Univ, Detroit, MI USA; [Kaye, Keith S.] Detroit Med Ctr, Detroit, MI USA; [Patel, Dipen A.; Stephens, Jennifer M.; Khachatryan, Alexandra; Patel, Ayush] Pharmerit Int, Bethesda, MD 20814 USA; [Johnson, Kenneth] Durata Therapeut, Chicago, IL USA	Wayne State University; Detroit Medical Center	Stephens, JM (corresponding author), Pharmerit Int, Bethesda, MD 20814 USA.	jstephens@pharmerit.com	Kaye, Keith/AAF-1048-2019		Durata Therapeutics	Durata Therapeutics	This study was funded by Durata Therapeutics, and the funders had role in study conceptualization, design and manuscript writing. Pharmerit authors were involved with study design, data analysis and preparation of the manuscript.	Edelsberg J, 2008, INFECT CONT HOSP EP, V29, P160, DOI 10.1086/526444; Edelsberg J, 2009, EMERG INFECT DIS, V15, P1516, DOI 10.3201/eid1509.081228; [Food and Drug Administration Center for Drug Evaluation Research Guidance for industry US Department of Health and Human Services], 2013, GUID IND AC BACT SKI; HCUP Nationwide Inpatient Sample (NIS), 2012, HCUP NATIONWIDE INPA; Hersh AL, 2008, ARCH INTERN MED, V168, P1585, DOI 10.1001/archinte.168.14.1585; Liu C, 2011, CLIN INFECT DIS, V52, P285, DOI 10.1093/cid/cir034; Merritt C, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-26; Pallin DJ, 2008, ANN EMERG MED, V51, P291, DOI 10.1016/j.annemergmed.2007.12.004; Qualls ML, 2012, CLIN INFECT DIS, V55, P103, DOI 10.1093/cid/cis342; Stevens DL, 2014, CLIN INFECT DIS, V59, pE10, DOI [10.1093/cid/ciu296, 10.1093/cid/ciu444]; Suaya JA, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-296	11	63	64	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2015	10	11							e0143276	10.1371/journal.pone.0143276	http://dx.doi.org/10.1371/journal.pone.0143276			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7DU	26599005	Green Published, gold, Green Submitted			2023-01-03	WOS:000365862600043
J	Potestio, ML; Boyd, JM; Bagshaw, SM; Heyland, D; Oxland, P; Doig, CJ; Zygun, D; Stelfox, HT				Potestio, Melissa L.; Boyd, Jamie M.; Bagshaw, Sean M.; Heyland, Daren; Oxland, Peter; Doig, Christopher J.; Zygun, Dave; Stelfox, Henry T.			Engaging the Public to Identify Opportunities to Improve Critical Care: A Qualitative Analysis of an Open Community Forum	PLOS ONE			English	Article							OF-LIFE CARE; INTENSIVE-CARE; HOSPITALIZED-PATIENTS; FAMILY SATISFACTION; MORAL DISTRESS; FOCUS GROUPS; HEALTH-CARE; UNIT; ICU; DISCUSSIONS	Objective To engage the public to understand how to improve the care of critically ill patients. Design A qualitative content analysis of an open community forum (Cafe Scientifique). Setting Public venue in Calgary, Alberta, Canada. Participants Members of the general public including patients, families of patients, health care providers, and members of the community at large. Methods A panel of researchers, decision-makers, and a family member led a Cafe Scientifique, an informal dialogue between the populace and experts, over three-hours to engage the public to understand how to improve the care of critically ill patients. Conventional qualitative content analysis was used to analyze the data. The inductive analysis occurred in three phases: coding, categorizing, and developing themes. Results Thirty-eight members of the public (former ICU patients, family members of patients, providers, community members) attended. Participants focused the discussion and provided concrete suggestions for improvement around communication (family as surrogate voice, timing of conversations, decision tools) and provider well-being and engagement, as opposed to medical interventions in critical care. Conclusions Cafe participants believe patient and family centered care is important to ensure high-quality care in the ICU. A Cafe Scientifique is a valuable forum to engage the public to contribute to priority setting areas for research in critical care, as well as a platform to share lived experience. Research stakeholders including health care organizations, governments, and funding organizations should provide more opportunities for the public to engage in meaningful conversations about how to best improve healthcare.	[Potestio, Melissa L.] Alberta Hlth Serv, Res Prior & Implementat, Calgary, AB, Canada; [Potestio, Melissa L.; Boyd, Jamie M.; Stelfox, Henry T.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Boyd, Jamie M.] Univ Calgary, Res & Innovat Ctr W21C, Calgary, AB, Canada; [Bagshaw, Sean M.; Zygun, Dave] Univ Alberta, Div Crit Care Med, Fac Med & Dent, Alberta Hlth Serv, Edmonton, AB, Canada; [Heyland, Daren] Queens Univ, Kingston Gen Hosp, Dept Crit Care Med, Clin Evaluat Res Unit, Kingston, ON, Canada; [Oxland, Peter] Alberta Hlth Serv, Crit Care, Calgary, AB, Canada; [Oxland, Peter] Univ Calgary, Calgary, AB, Canada; [Doig, Christopher J.] Univ Calgary, Dept Crit Care Med, Alberta Hlth Serv, Calgary, AB, Canada	Alberta Health Services (AHS); University of Calgary; University of Calgary; University of Calgary; Alberta Health Services (AHS); University of Alberta; Queens University - Canada; Alberta Health Services (AHS); University of Calgary; University of Calgary; Alberta Health Services (AHS); University of Calgary	Stelfox, HT (corresponding author), Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada.	tstelfox@ucalgary.ca	Doig, Christopher/AAC-7949-2020	Doig, Christopher/0000-0002-8576-9139; Stelfox, Henry/0000-0003-1231-1490	Canadian Institutes of Health Research [SCI-131811]; O'Brien Institute for Public Health at the University of Calgary; Alberta Innovates [201300477, 201201137] Funding Source: researchfish	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); O'Brien Institute for Public Health at the University of Calgary; Alberta Innovates	This work was supported by an operating grant from Canadian Institutes of Health Research (SCI-131811). The funder had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.; We thank the O'Brien Institute for Public Health at the University of Calgary for their financial support of the Cafe Scientifique. We thank Dr. Day, Ms. Roe and Ms. Rabatach for assisting with coordination of the Cafe Scientifique.	Arnetz BB, 2001, SOC SCI MED, V52, P203, DOI 10.1016/S0277-9536(00)00220-3; Auriemma CL, 2014, JAMA INTERN MED, V174, P1085, DOI 10.1001/jamainternmed.2014.1183; Bagshaw SM, 2014, CAN MED ASSOC J, V186, pE95, DOI 10.1503/cmaj.130639; Beumer CM, 2008, DIMENS CRIT CARE NUR, V27, P263, DOI 10.1097/01.DCC.0000338871.77658.03; Brondani MA, 2010, ARCH SEX BEHAV, V39, P1453, DOI 10.1007/s10508-009-9578-3; Brown S, 2010, STRATEGY PATIENT ORI; Bryman A., 2008, SOCIAL RES METHODS; Corley MC, 2002, NURS ETHICS, V9, P636, DOI 10.1191/0969733002ne557oa; Cullen DJ, 1997, CRIT CARE MED, V25, P1289, DOI 10.1097/00003246-199708000-00014; Firth-Cozens J, 2001, SOC SCI MED, V52, P215, DOI 10.1016/S0277-9536(00)00221-5; FirthCozens J, 1997, SOC SCI MED, V44, P1017, DOI 10.1016/S0277-9536(96)00227-4; Gagliardi AR, 2014, J TRAUMA ACUTE CARE, V77, P749, DOI 10.1097/TA.0000000000000432; Glaser B., 1978, THEORETICAL SENSITIV; Guevara-Lopez U, 2015, BMC MED ETHICS, V16, DOI 10.1186/s12910-015-0003-2; Halpern NA, 2010, CRIT CARE MED, V38, P65, DOI 10.1097/CCM.0b013e3181b090d0; Hartog CS, 2014, J CRIT CARE, V29, P128, DOI 10.1016/j.jcrc.2013.08.024; Heyland DK, 2010, CAN MED ASSOC J, V182, pE747, DOI 10.1503/cmaj.100131; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSSING QUALITY CHA; Institute of Medicine Committee on the Quality of Health Care in America, 1990, MED STRAT QUAL ASS; Johnson AR, 2013, J PALLIAT CARE, V29, P99, DOI 10.1177/082585971302900206; Karanikola MNK, 2012, DIMENS CRIT CARE NUR, V31, P37, DOI 10.1097/DCC.0b013e31823a55b8; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Kompanje EJO, 2013, CURR OPIN CRIT CARE, V19, P630, DOI 10.1097/MCC.0000000000000026; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; Lind R, 2011, INTENS CARE MED, V37, P1143, DOI 10.1007/s00134-011-2253-x; MacQueen KM, 1998, CAM J, V10, P31, DOI [DOI 10.1177/1525822X980100020301, 10.1177/1525822X980100020301]; Miles M.B., 1994, QUALITATIVE DATA ANA; Morse Janice., 1995, QUALITATIVE RES METH; Moyen E, 2008, CRIT CARE, V12, DOI 10.1186/cc6813; Nelson JE, 2010, CRIT CARE MED, V38, P808, DOI 10.1097/CCM.0b013e3181c5887c; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Price Bob, 2010, Paediatr Nurs, V22, P26; Reimer-Kirkham S, 2015, HEALTH COMMUN, V30, P496, DOI 10.1080/10410236.2013.868398; Robinson R, 2010, DIMENS CRIT CARE NUR, V29, P197, DOI 10.1097/DCC.0b013e3181e6c344; Schenker Y, 2012, J GEN INTERN MED, V27, P1657, DOI 10.1007/s11606-012-2129-y; St Ledger U, 2013, J ADV NURS, V69, P1869, DOI 10.1111/jan.12053; Sundararajan K, 2012, ANAESTH INTENS CARE, V40, P159, DOI 10.1177/0310057X1204000120; Thelen Mary, 2005, Crit Care Nurse, V25, P28; Wall RJ, 2007, CHEST, V132, P1425, DOI 10.1378/chest.07-0419; Wiegand DL, 2015, AACN ADV CRIT CARE, V26, P142, DOI 10.1097/NCI.0000000000000085; Wiegand DL, 2013, J GERONTOL NURS, V39, P60, DOI 10.3928/00989134-20130530-04; Wong P, 2015, INTENS CRIT CARE NUR, V31, P51, DOI 10.1016/j.iccn.2014.06.005; You JJ, 2014, CMAJ, V186, P679, DOI DOI 10.1503/CMAJ.140673; You JJ, 2015, JAMA INTERN MED, V175, P549, DOI 10.1001/jamainternmed.2014.7732; You JJ, 2014, CAN MED ASSOC J, V186, P425, DOI 10.1503/cmaj.121274	46	20	20	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2015	10	11							e0143088	10.1371/journal.pone.0143088	http://dx.doi.org/10.1371/journal.pone.0143088			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CW7CD	26580406	Green Submitted, Green Published, gold			2023-01-03	WOS:000365154600080
J	Raihana, S; Dunsmuir, D; Huda, T; Zhou, GH; Rahman, QSU; Garde, A; Moinuddin, M; Karlen, W; Dumont, GA; Kissoon, N; El Arifeen, S; Larson, C; Ansermino, JM				Raihana, Shahreen; Dunsmuir, Dustin; Huda, Tanvir; Zhou, Guohai; Rahman, Qazi Sadeq-ur; Garde, Ainara; Moinuddin, Md; Karlen, Walter; Dumont, Guy A.; Kissoon, Niranjan; El Arifeen, Shams; Larson, Charles; Ansermino, J. Mark			Development and Internal Validation of a Predictive Model Including Pulse Oximetry for Hospitalization of Under-Five Children in Bangladesh	PLOS ONE			English	Article							CHILDHOOD PNEUMONIA; OXYGEN-SATURATION; CASE-MANAGEMENT; VITAL SIGNS; INFECTIONS; HYPOXEMIA; MORTALITY; ADMISSION; EMERGENCY; COUNTRIES	Background The reduction in the deaths of millions of children who die from infectious diseases requires early initiation of treatment and improved access to care available in health facilities. A major challenge is the lack of objective evidence to guide front line health workers in the community to recognize critical illness in children earlier in their course. Methods We undertook a prospective observational study of children less than 5 years of age presenting at the outpatient or emergency department of a rural tertiary care hospital between October 2012 and April 2013. Study physicians collected clinical signs and symptoms from the facility records, and with a mobile application performed recordings of oxygen saturation, heart rate and respiratory rate. Facility physicians decided the need for hospital admission without knowledge of the oxygen saturation. Multiple logistic predictive models were tested. Findings Twenty-five percent of the 3374 assessed children, with a median (interquartile range) age of 1.02 (0.42-2.24), were admitted to hospital. We were unable to contact 20% of subjects after their visit. A logistic regression model using continuous oxygen saturation, respiratory rate, temperature and age combined with dichotomous signs of chest indrawing, lethargy, irritability and symptoms of cough, diarrhea and fast or difficult breathing predicted admission to hospital with an area under the receiver operating characteristic curve of 0.89 (95% confidence interval -CI: 0.87 to 0.90). At a risk threshold of 25% for admission, the sensitivity was 77% (95% CI: 74% to 80%), specificity was 87% (95% CI: 86% to 88%), positive predictive value was 70% (95% CI: 67% to 73%) and negative predictive value was 91% (95% CI: 90% to 92%). Conclusion A model using oxygen saturation, respiratory rate and temperature in combination with readily obtained clinical signs and symptoms predicted the need for hospitalization of critically ill children. External validation of this model in a community setting will be required before adoption into clinical practice.	[Raihana, Shahreen; Huda, Tanvir; Rahman, Qazi Sadeq-ur; Moinuddin, Md; El Arifeen, Shams] Int Ctr Diarrhoeal Dis Res, Ctr Child & Adolescent Hlth, Dhaka 1000, Bangladesh; [Dunsmuir, Dustin; Dumont, Guy A.; Kissoon, Niranjan; Larson, Charles; Ansermino, J. Mark] British Columbia Childrens Hosp, Ctr Int Child Hlth, Vancouver, BC V6H 3V4, Canada; [Dunsmuir, Dustin; Ansermino, J. Mark] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Zhou, Guohai] Univ British Columbia, Dept Stat, Vancouver, BC V6T 1W5, Canada; [Garde, Ainara; Karlen, Walter; Dumont, Guy A.] Univ British Columbia, Dept Elect & Comp Engn, Vancouver, BC V5Z 1M9, Canada; [Kissoon, Niranjan; Larson, Charles] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada	International Centre for Diarrhoeal Disease Research (ICDDR); BC Childrens Hospital; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Ansermino, JM (corresponding author), British Columbia Childrens Hosp, Ctr Int Child Hlth, Vancouver, BC V6H 3V4, Canada.	anserminos@yahoo.ca	Karlen, Walter/AAN-9397-2020; Karlen, Walter/C-6290-2008; Moinuddin, Mohammed/AAP-4454-2021; Kissoon, Niranjan/AAC-6140-2021; Garde, Ainara/J-9442-2017	Karlen, Walter/0000-0001-8643-3074; Karlen, Walter/0000-0001-8643-3074; Moinuddin, Mohammed/0000-0001-9364-390X; Garde, Ainara/0000-0002-9503-6908; Kissoon, Niranjan/0000-0001-8847-9973; Zhou, Guohai/0000-0002-8826-403X; Dumont, Guy/0000-0003-2048-4391; Ansermino, J Mark/0000-0001-8427-2035; Dunsmuir, Dustin/0000-0001-9717-3685; Arifeen, Shams/0000-0002-5372-5932	Canadian Department of Foreign Affairs, Trade and Development's MUSKOKA Initiative on Maternal, Newborn and Child Health (MNCH) [S065353-001]	Canadian Department of Foreign Affairs, Trade and Development's MUSKOKA Initiative on Maternal, Newborn and Child Health (MNCH)	This study was a component of the project titled Interrupting Pathways to Maternal, Newborn and Early Childhood Sepsis (IPSI) (Project # S065353-001) that was funded by the Canadian Department of Foreign Affairs, Trade and Development's MUSKOKA Initiative on Maternal, Newborn and Child Health (MNCH), received by CL, http://www.international.gc.ca/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, UNICEF PROGR REPORT; [Anonymous], 2012, R LANG ENV STAT COMP; Ansermino JM, 2013, ANESTH ANALG, V117, P883, DOI 10.1213/ANE.0b013e3182a1f22f; Bang Abhay T, 2005, J Perinatol, V25 Suppl 1, pS92, DOI 10.1038/sj.jp.7211277; BENATAR SR, 1973, BRIT J ANAESTH, V45, P711, DOI 10.1093/bja/45.7.711; Berkley JA, 2003, BRIT MED J, V326, P361, DOI 10.1136/bmj.326.7385.361; Duke T, 2009, ANN TROP PAEDIATR, V29, P165, DOI 10.1179/027249309X12467994190011; Duke T, 2008, LANCET, V372, P1328, DOI 10.1016/S0140-6736(08)61164-2; Dunsmuir D, 2012, ANESTHESIA ANALGESIA, V115, pS21; Ginsburg AS, 2012, J TROP PEDIATRICS, V58, P389, DOI 10.1093/tropej/fmr103; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Janes H, 2008, ANN INTERN MED, V149, P751, DOI 10.7326/0003-4819-149-10-200811180-00009; Kallander K, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2130; Kalter HD, 1997, B WORLD HEALTH ORGAN, V75, P65; Karlen W, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone0099266, DOI 10.1371/J0URNAL.P0NE.0099266]; Keahey L, 2002, ANN EMERG MED, V40, P300, DOI 10.1067/mem.2002.126813; Laman M, 2005, ANN TROP PAEDIATR, V25, P23, DOI 10.1179/146532805X23317; Launay E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107286; Little R. J., 2019, STAT ANAL MISSING DA, V793; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Marsh DR, 2012, AM J TROP MED HYG, V87, P2, DOI 10.4269/ajtmh.2012.12-0504; Modi P, 2013, J EMERG MED, V45, P752, DOI 10.1016/j.jemermed.2013.04.041; Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1; Nijman RG, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4224; ONYANGO FE, 1993, BRIT MED J, V306, P612, DOI 10.1136/bmj.306.6878.612; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Petersen CL, 2013, ACM SIGPLAN NOTICES, V48, P357, DOI [10.1145/2500365.2500615, 10.1145/2544174.2500615]; Petersen CL, 2013, SENSORS-BASEL, V13, P16882, DOI 10.3390/s131216882; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; SEVERINGHAUS JW, 1979, J APPL PHYSIOL, V46, P599, DOI 10.1152/jappl.1979.46.3.599; Spruijt B, 2013, J CLIN EPIDEMIOL, V66, P453, DOI 10.1016/j.jclinepi.2012.09.014; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Subhi R, 2009, LANCET INFECT DIS, V9, P219, DOI 10.1016/S1473-3099(09)70071-4; Theodoratou E, 2010, INT J EPIDEMIOL, V39, P155, DOI 10.1093/ije/dyq032; Thompson M, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16150; Van den Bruel A, 2010, LANCET, V375, P834, DOI 10.1016/S0140-6736(09)62000-6; Walsh P, 2004, EUR J EMERG MED, V11, P265, DOI 10.1097/00063110-200410000-00005; West J. B., 2011, RESP PHYSL ESSENTIAL, V9th; WHO, 2014, REV WHO CLASS TREATM	40	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2015	10	11							e0143213	10.1371/journal.pone.0143213	http://dx.doi.org/10.1371/journal.pone.0143213			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW7CD	26580403	Green Published, gold, Green Submitted			2023-01-03	WOS:000365154600098
J	Rodriguez-Gutierrez, R; Shah, ND; Montori, VM				Rodriguez-Gutierrez, Rene; Shah, Nilay D.; Montori, Victor M.			Predicting the Overuse of PCSK-9 Inhibitors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HIGH CHOLESTEROL; STATIN THERAPY; GUIDELINES		[Rodriguez-Gutierrez, Rene; Shah, Nilay D.; Montori, Victor M.] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN 55905 USA; [Rodriguez-Gutierrez, Rene; Montori, Victor M.] Mayo Clin, Dept Med, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA; [Shah, Nilay D.] Mayo Clin, Dept Hlth Sci Res, Div Hlth Care Policy & Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Montori, VM (corresponding author), Mayo Clin, Knowledge & Evaluat Res Unit, Div Endocrinol Diabet Metab & Nutr, 200 First St SW, Rochester, MN 55905 USA.	montori.victor@mayo.edu		Montori, Victor/0000-0003-0595-2898				Boden WE, 2011, NEW ENGL J MED, V365, P2255, DOI 10.1056/NEJMoa1107579; Cannon CP, 2015, NEW ENGL J MED, V372, P2387, DOI 10.1056/NEJMoa1410489; Iglay K, 2015, CLIN THER, V37; Keech A, 2005, LANCET, V366, P1849, DOI 10.1016/S0140-6736(05)67667-2; Montori VM, 2014, JAMA-J AM MED ASSOC, V311, P465, DOI 10.1001/jama.2014.110; Navarese EP, 2015, ANN INTERN MED, V163, P40, DOI 10.7326/M14-2957; Shrank WH, 2015, JAMA-J AM MED ASSOC, V314, P1443, DOI 10.1001/jama.2015.10017; Zhang HB, 2013, ANN INTERN MED, V158, P526, DOI 10.7326/0003-4819-158-7-201304020-00004	8	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2015	314	18					1909	1910		10.1001/jama.2015.13414	http://dx.doi.org/10.1001/jama.2015.13414			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV7XQ	26547456				2023-01-03	WOS:000364490700007
J	Bhattacharjee, P; Bhattacharyya, D				Bhattacharjee, Payel; Bhattacharyya, Debasish			An Enzyme from Aristolochia indica Destabilizes Fibrin-beta Amyloid Co-Aggregate: Implication in Cerebrovascular Diseases	PLOS ONE			English	Article							PLASMINOGEN-ACTIVATOR; FRAGMENT-D; BINDING; THROMBOSIS; VENOM	Fibrinogen and beta-amyloid (A beta) peptide independently form ordered aggregates but in combination, they form disordered structures which are resistant to fibrinolytic enzymes like plasmin and cause severity in cerebral amyloid angiopathy (CAA). A novel enzyme of 31.3 kDa has been isolated from the root of the medicinal plant Aristolochia indica that showed fibrinolytic as well as fibrin-A beta co-aggregate destabilizing properties. This enzyme is functionally distinct from plasmin. Thrombolytic action of the enzyme was demonstrated in rat model. The potency of the plant enzyme in degrading fibrin and fibrin-plasma protein (A beta, human serum albumin, lysozyme, transthyretin and fibronectin) co-aggregates was demonstrated by atomic force microscopy, scanning electron microscopy and confocal microscopy that showed better potency of the plant enzyme as compared to plasmin. Moreover, the plant enzyme inhibited localization of the co-aggregate inside SH-SY5Y human neuroblastoma cells and also co-aggregate induced cytotoxicity. Plasmin was inefficient in this respect. In the background of limited options for fragmentation of these co-aggregates, the plant enzyme may appear as a potential proteolytic enzyme.	[Bhattacharjee, Payel; Bhattacharyya, Debasish] Indian Inst Chem Biol, CSIR, Div Struct Biol & Bioinformat, Kolkata 700032, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Bhattacharjee, P (corresponding author), Indian Inst Chem Biol, CSIR, Div Struct Biol & Bioinformat, Kolkata 700032, India.	payel.iicb@gmail.com; debasish@iicb.res.in			CSIR-Net Work Project [miND BSC0115]; Department of Science and Technology, Cognition Science Initiative, Project [SR/CSI/07/2009(G)]; UGC-NET fellowship	CSIR-Net Work Project(Council of Scientific & Industrial Research (CSIR) - India); Department of Science and Technology, Cognition Science Initiative, Project; UGC-NET fellowship	This work is supported by CSIR-Net Work Project (miND BSC0115) and the Department of Science and Technology, Cognition Science Initiative, Project No. SR/CSI/07/2009(G). P.B. was supported by UGC-NET fellowship.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adams RA, 2004, MOL INTERV, V4, P163; Ahn HJ, 2014, J EXP MED, V211, P1049, DOI 10.1084/jem.20131751; Ahn HJ, 2010, P NATL ACAD SCI USA, V107, P21812, DOI 10.1073/pnas.1010373107; ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; Bhattacharjee P, 2013, J BIOL CHEM, V288, P30559, DOI 10.1074/jbc.M113.511410; Bhattacharjee P, 2013, J ETHNOPHARMACOL, V145, P220, DOI 10.1016/j.jep.2012.10.056; Buchmann K, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00459; Charidimou A, 2012, J NEUROL NEUROSUR PS, V83, P124, DOI 10.1136/jnnp-2011-301308; Cortes-Canteli M, 2009, J THROMB HAEMOST, V7, P146, DOI 10.1111/j.1538-7836.2009.03376.x; Furie B, 2005, J CLIN INVEST, V115, P3355, DOI 10.1172/JCI26987; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; Hawkes C, 2012, J ADDICT RES THER S, VS5, pe001; Hoffman R, 1998, J INVEST DERMATOL, V111, P1140, DOI 10.1046/j.1523-1747.1998.00429.x; Johnson SM, 2012, J MOL BIOL, V421, P185, DOI 10.1016/j.jmb.2011.12.060; KACZMAREK E, 1993, J BIOL CHEM, V268, P2474; Killer M, 2010, DRUG DISCOV TODAY, V15, P640, DOI 10.1016/j.drudis.2010.04.007; Kim SH, 1998, ANAL BIOCHEM, V263, P115, DOI 10.1006/abio.1998.2816; Kolev K., 2014, FIBRINOLYSIS THROMBO, P3, DOI [10.5772/57353., DOI 10.5772/57353]; Lai Aaron Y, 2010, Int J Alzheimers Dis, V2011, P548380, DOI 10.4061/2011/548380; Levi M, 2001, THROMB HAEMOSTASIS, V86, P1331; Liu RM, 2011, NEUROBIOL AGING, V32, P1079, DOI 10.1016/j.neurobiolaging.2009.06.003; Longstaff C, 2011, BLOOD, V117, P661, DOI 10.1182/blood-2010-06-290338; Lord ST, 2011, ARTERIOSCL THROM VAS, V31, P494, DOI 10.1161/ATVBAHA.110.213389; Maity G, 2011, TOXICON, V57, P747, DOI 10.1016/j.toxicon.2011.02.008; McCarty SM, 2013, ADV WOUND CARE, V2, P438, DOI 10.1089/wound.2012.0370; Oliveira SB, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-21; OPRANDY JJ, 1988, AM J TROP MED HYG, V38, P181, DOI 10.4269/ajtmh.1988.38.181; Pontes-Neto Octavio M, 2012, Eur Neurol Rev, V7, P134; PRINCEN HMG, 1985, THROMB HAEMOSTASIS, V53, P212; Rego ROM, 2005, INSECT BIOCHEM MOLEC, V35, P991, DOI 10.1016/j.ibmb.2005.04.001; Sakono M, 2010, FEBS J, V277, P1348, DOI 10.1111/j.1742-4658.2010.07568.x; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Simkhada JR, 2010, PROCESS BIOCHEM, V45, P88, DOI 10.1016/j.procbio.2009.08.010; Smith EE, 2009, STROKE, V40, P2601, DOI 10.1161/STROKEAHA.108.536839; Stoffels JMJ, 2013, BRAIN, V136, P116, DOI 10.1093/brain/aws313; Talens S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041966; Taylor D, 2012, DRUG TREATMENTS ALZH, P1; Tucker HM, 2000, J NEUROSCI, V20, P3937; van Rooden S, 2009, STROKE, V40, P3022, DOI 10.1161/STROKEAHA.109.554378; Vieira MNN, 2006, CELL BIOCHEM BIOPHYS, V44, P549, DOI 10.1385/CBB:44:3:549; WILCHEK M, 1984, METHOD ENZYMOL, V104, P3; Yakovlev S, 2000, BIOCHEMISTRY-US, V39, P15730, DOI 10.1021/bi001847a; Yang Z, 2002, BIOCHEMISTRY-US, V41, P10218, DOI 10.1021/bi020299t; Zamolodchikov D, 2012, BLOOD, V119, P3342, DOI 10.1182/blood-2011-11-389668; ZHANG Y, 1995, J BIOL CHEM, V270, P10246, DOI 10.1074/jbc.270.17.10246	47	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2015	10	11							e0141986	10.1371/journal.pone.0141986	http://dx.doi.org/10.1371/journal.pone.0141986			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV6RT	26545113	Green Submitted, Green Published, gold			2023-01-03	WOS:000364398700067
J	Friedman, AA; Amzallag, A; Pruteanu-Malinici, I; Baniya, S; Cooper, ZA; Piris, A; Hargreaves, L; Igras, V; Frederick, DT; Lawrence, DP; Haber, DA; Flaherty, KT; Wargo, JA; Ramaswamy, S; Benes, CH; Fisher, DE				Friedman, Adam A.; Amzallag, Arnaud; Pruteanu-Malinici, Iulian; Baniya, Subash; Cooper, Zachary A.; Piris, Adriano; Hargreaves, Leeza; Igras, Vivien; Frederick, Dennie T.; Lawrence, Donald P.; Haber, Daniel A.; Flaherty, Keith T.; Wargo, Jennifer A.; Ramaswamy, Sridhar; Benes, Cyril H.; Fisher, David E.			Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment	PLOS ONE			English	Article							TYROSINE KINASE INHIBITOR; RAF INHIBITION; ACQUIRED-RESISTANCE; CONFERS RESISTANCE; CANCER; PATHWAY; MEK; GROWTH	A newer generation of anti-cancer drugs targeting underlying somatic genetic driver events have resulted in high single-agent or single-pathway response rates in selected patients, but few patients achieve complete responses and a sizeable fraction of patients relapse within a year. Thus, there is a pressing need for identification of combinations of targeted agents which induce more complete responses and prevent disease progression. We describe the results of a combination screen of an unprecedented scale in mammalian cells performed using a collection of targeted, clinically tractable agents across a large panel of melanoma cell lines. We find that even the most synergistic drug pairs are effective only in a discrete number of cell lines, underlying a strong context dependency for synergy, with strong, widespread synergies often corresponding to non-specific or off-target drug effects such as multidrug resistance protein 1 (MDR1) transporter inhibition. We identified drugs sensitizing cell lines that are BRAF(V600E) mutant but intrinsically resistant to BRAF inhibitor PLX4720, including the vascular endothelial growth factor receptor/kinase insert domain receptor (VEGFR/KDR) and platelet derived growth factor receptor (PDGFR) family inhibitor cediranib. The combination of cediranib and PLX4720 induced apoptosis in vitro and tumor regression in animal models. This synergistic interaction is likely due to engagement of multiple receptor tyrosine kinases (RTKs), demonstrating the potential of drug-rather than gene-specific combination discovery approaches. Patients with elevated biopsy KDR expression showed decreased progression free survival in trials of mitogen-activated protein kinase (MAPK) kinase pathway inhibitors. Thus, high-throughput unbiased screening of targeted drug combinations, with appropriate library selection and mechanistic follow-up, can yield clinically-actionable drug combinations.	[Friedman, Adam A.; Amzallag, Arnaud; Pruteanu-Malinici, Iulian; Baniya, Subash; Hargreaves, Leeza; Igras, Vivien; Frederick, Dennie T.; Lawrence, Donald P.; Haber, Daniel A.; Flaherty, Keith T.; Ramaswamy, Sridhar; Benes, Cyril H.; Fisher, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02163 USA; [Friedman, Adam A.; Baniya, Subash; Hargreaves, Leeza; Igras, Vivien; Fisher, David E.] Massachusetts Gen Hosp, Dermatol & Cutaneous Biol Res Ctr, Charlestown, MA USA; [Cooper, Zachary A.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Cooper, Zachary A.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Piris, Adriano] Massachusetts Gen Hosp, Div Dermatopathol, Boston, MA 02114 USA; [Haber, Daniel A.] Howard Hughes Med Inst, Chevy Chase, MD USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute	Friedman, AA (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02163 USA.	aafriedman@partners.org; cbenes@partners.org; dfisher3@partners.org	Fisher, David/AAH-2878-2019	Amzallag, Arnaud/0000-0001-7467-1227; Birdwell, Leeza/0000-0002-0137-3939; Cooper, Zachary/0000-0003-1059-0940	National Institutes of Health [P01CA163222, R21CA175907, 1K08CA160692-01A1, U54CA163125, 1U54HG006097-01]; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Doris Duke Medical Foundation; Elsa U. Pardee Foundation grant; Fred Lovejoy Resident Research and Education Award; Brigham and Women's Hospital Department of Dermatology NIH Training Grant [T32AR007098-38]; Wellcome Trust [086357, 102696]; NATIONAL CANCER INSTITUTE [P30CA016672, K08CA160692, R21CA175907, U54CA163125, P01CA163222] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG006097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007098, R01AR043369] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Doris Duke Medical Foundation(Doris Duke Charitable Foundation (DDCF)); Elsa U. Pardee Foundation grant; Fred Lovejoy Resident Research and Education Award; Brigham and Women's Hospital Department of Dermatology NIH Training Grant; Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the National Institutes of Health (P01CA163222 and R21CA175907 to D.E.F.; 1K08CA160692-01A1 and U54CA163125 to J.A.W., 1U54HG006097-01 to C.H.B.), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (D.E.F.), the Doris Duke Medical Foundation (D.E.F.), an Elsa U. Pardee Foundation grant (D.E.F.), a Fred Lovejoy Resident Research and Education Award (A.A.F.), a Brigham and Women's Hospital Department of Dermatology NIH Training Grant T32AR007098-38 (A.A.F.), and grants from the Wellcome Trust (086357 and 102696; C.H.B., D.A.H.).	Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cokol M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.71; Corcoran RB, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005753; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Erlichman C, 2001, CANCER RES, V61, P739; Fallahi-Sichani M, 2013, NAT CHEM BIOL, V9, P708, DOI [10.1038/NCHEMBIO.1337, 10.1038/nchembio.1337]; Flaherty K, 2014, ASCO M, V32, P9010; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; GRECO WR, 1995, PHARMACOL REV, V47, P331; Guertin AD, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-45; Gujral TS, 2014, P NATL ACAD SCI USA, V111, P5048, DOI 10.1073/pnas.1403080111; Haq R, 2013, P NATL ACAD SCI USA, V110, P4321, DOI 10.1073/pnas.1205575110; Held MA, 2013, CANCER DISCOV, V3, P52, DOI 10.1158/2159-8290.CD-12-0408; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kendrew J, 2013, CANCER CHEMOTH PHARM, V71, P1021, DOI 10.1007/s00280-013-2097-x; Kim KB, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8519; Lehar J, 2008, NAT CHEM BIOL, V4, P674, DOI 10.1038/nchembio.120; Lehar J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100116; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Noguchi K, 2009, CANCER SCI, V100, P1701, DOI 10.1111/j.1349-7006.2009.01213.x; Roller DG, 2012, MOL CANCER THER, V11, P2505, DOI 10.1158/1535-7163.MCT-12-0461; Sabbatino F, 2014, ONCOTARGET; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Takahashi O, 2012, CLIN CANCER RES, V18, P1641, DOI 10.1158/1078-0432.CCR-11-2324; Turajlic S, 2014, ANN ONCOL, V25, P959, DOI 10.1093/annonc/mdu049; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409	45	24	24	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2015	10	10							e0140310	10.1371/journal.pone.0140310	http://dx.doi.org/10.1371/journal.pone.0140310			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT6ZJ	26461489	gold, Green Published, Green Submitted			2023-01-03	WOS:000362962300078
J	Kamerow, D; Doodling, YK				Kamerow, Douglas; Doodling, Yankee			What's happening to cheap generic drugs?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Kamerow, Douglas] Robert Graham Ctr, Policy Studies Primary Care, Washington, DC 20036 USA; [Kamerow, Douglas] Georgetown Univ, Family Med, Washington, DC 20057 USA	Georgetown University	Kamerow, D (corresponding author), Robert Graham Ctr, Policy Studies Primary Care, Washington, DC 20036 USA.	dkamerow@aafp.org		Kamerow, Douglas/0000-0001-7000-9957				Alpern JD, 2014, NEW ENGL J MED, V371, P1859, DOI 10.1056/NEJMp1408376; Healy P, 2015, NY TIMES; Johnson Y, 2015, WASHINGTON POST; McCarthy M, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5114; Pollack A, 2015, NY TIMES, pB2; Saul S., 2007, NY TIMES; Tanne JH, 2003, BRIT MED J, V327, P565, DOI 10.1136/bmj.327.7414.565	7	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2015	351								h5329	10.1136/bmj.h5329	http://dx.doi.org/10.1136/bmj.h5329			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT3SC	26437788				2023-01-03	WOS:000362726200010
J	Wang, LX; Mogami, S; Yakabi, S; Karasawa, H; Yamada, C; Yakabi, K; Hattori, T; Tache, Y				Wang, Lixin; Mogami, Sachiko; Yakabi, Seiichi; Karasawa, Hiroshi; Yamada, Chihiro; Yakabi, Koji; Hattori, Tomohisa; Tache, Yvette			Patterns of Brain Activation and Meal Reduction Induced by Abdominal Surgery in Mice and Modulation by Rikkunshito	PLOS ONE			English	Article							CORTICOTROPIN-RELEASING-FACTOR; HYPOTHALAMIC ARCUATE NUCLEUS; STRESS-RELATED ALTERATIONS; POSTOPERATIVE GASTRIC ILEUS; CISPLATIN-INDUCED ANOREXIA; GHRELIN RECEPTOR AGONIST; COLONIC MOTOR FUNCTION; CENTRAL-NERVOUS-SYSTEM; FOOD-INTAKE; PARABRACHIAL NUCLEUS	Abdominal surgery inhibits food intake and induces c-Fos expression in the hypothalamic and medullary nuclei in rats. Rikkunshito (RKT), a Kampo medicine improves anorexia. We assessed the alterations in meal microstructure and c-Fos expression in brain nuclei induced by abdominal surgery and the modulation by RKT in mice. RKT or vehicle was gavaged daily for 1 week. On day 8 mice had no access to food for 6-7 h and were treated twice with RKT or vehicle. Abdominal surgery (laparotomy-cecum palpation) was performed 1-2 h before the dark phase. The food intake and meal structures were monitored using an automated monitoring system for mice. Brain sections were processed for c-Fos immunoreactivity (ir) 2-h after abdominal surgery. Abdominal surgery significantly reduced bouts, meal frequency, size and duration, and time spent on meals, and increased inter-meal interval and satiety ratio resulting in 92-86% suppression of food intake at 2-24 h post-surgery compared with control group (no surgery). RKT significantly increased bouts, meal duration and the cumulative 12-h food intake by 11%. Abdominal surgery increased c-Fos in the prelimbic, cingulate and insular cortexes, and autonomic nuclei, such as the bed nucleus of the stria terminalis, central amygdala, hypothalamic supraoptic (SON), paraventricular and arcuate nuclei, Edinger-Westphal nucleus (E-W), lateral periaqueduct gray (PAG), lateral parabrachial nucleus, locus coeruleus, ventrolateral medulla and nucleus tractus solitarius (NTS). RKT induced a small increase in c-Fos-ir neurons in the SON and E-W of control mice, and in mice with surgery there was an increase in the lateral PAG and a decrease in the NTS. These findings indicate that abdominal surgery inhibits food intake by increasing both satiation (meal duration) and satiety (meal interval) and activates brain circuits involved in pain, feeding behavior and stress that may underlie the alterations of meal pattern and food intake inhibition. RKT improves food consumption post-surgically that may involve modulation of pain pathway.	[Wang, Lixin; Yakabi, Seiichi; Karasawa, Hiroshi; Tache, Yvette] Univ Calif Los Angeles, CURE Digest Dis Ctr, Los Angeles, CA 90089 USA; [Wang, Lixin; Yakabi, Seiichi; Karasawa, Hiroshi; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA 90024 USA; [Wang, Lixin; Yakabi, Seiichi; Karasawa, Hiroshi; Tache, Yvette] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA; [Mogami, Sachiko; Yamada, Chihiro; Hattori, Tomohisa] Tsumura & Co, Kampo Sci Strategies Div, Tsumura Res Labs, Tsukuba, Ibaraki, Japan; [Yakabi, Koji] Saitama Med Univ, Saitama Med Ctr, Dept Gastroenterol & Hepatol, Saitama, Japan	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Tsumura & Company; Saitama Medical University	Wang, LX (corresponding author), Univ Calif Los Angeles, CURE Digest Dis Ctr, Los Angeles, CA 90089 USA.	lixinw@ucla.edu		Mogami, Sachiko/0000-0001-7914-4928; Yamada, Chihiro/0000-0002-3690-893X; Karasawa, Hiroshi/0000-0003-1798-2277	Veterans Administration Research Career Scientist Award; VA Merit Award; Tsumura Co.;  [NIHDDK-41303]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER	Veterans Administration Research Career Scientist Award; VA Merit Award(US Department of Veterans Affairs); Tsumura Co.(Tsumura & Company); ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The work was supported by NIHDDK-41303 (Animal core, YT, LW), Veterans Administration Research Career Scientist Award (YT), VA Merit Award (YT) and Tsumura & Co. Drs. SM, CY and TH are employees of Tsumura & Co. The funders of Tsumura & Co. had no role in study design, data collection and analysis, decision topublish, or preparation of the manuscript.	Abbott SBG, 2013, J NEUROSCI, V33, P3164, DOI 10.1523/JNEUROSCI.1046-12.2013; Alhadeff AL, 2014, NEUROPSYCHOPHARMACOL, V39, P2233, DOI 10.1038/npp.2014.74; Arai M, 2012, HEPATO-GASTROENTEROL, V59, P62, DOI 10.5754/hge11246; Augestad KM, 2010, WORLD J GASTROENTERO, V16, P2067, DOI 10.3748/wjg.v16.i17.2067; Barletta JF, 2014, WORLD J SURG, V38, P1966, DOI 10.1007/s00268-014-2506-2; Barquist E, 1996, AM J PHYSIOL-REG I, V270, pR888, DOI 10.1152/ajpregu.1996.270.4.R888; Becskei C, 2008, J NEUROENDOCRINOL, V20, P85, DOI 10.1111/j.1365-2826.2007.01619.x; BEHBEHANI MM, 1995, PROG NEUROBIOL, V46, P575, DOI 10.1016/0301-0082(95)00009-K; Benarroch EE, 2006, NEUROL SCI, V27, pS130, DOI 10.1007/s10072-006-0587-x; Bisgaard T, 2002, NUTRITION, V18, P944, DOI 10.1016/S0899-9007(02)00990-5; BLOCK CH, 1987, PEPTIDES, V8, P267, DOI 10.1016/0196-9781(87)90102-1; BONAZ B, 1994, J COMP NEUROL, V349, P212, DOI 10.1002/cne.903490205; Bonaz B, 1997, BRAIN RES, V748, P12, DOI 10.1016/S0006-8993(96)01281-4; Browning KN, 2011, AUTON NEUROSCI-BASIC, V161, P6, DOI 10.1016/j.autneu.2010.11.001; Cailotto C, 2012, NEUROGASTROENT MOTIL, V24, P191, DOI 10.1111/j.1365-2982.2011.01824.x; Card JP, 2006, J COMP NEUROL, V499, P840, DOI 10.1002/cne.21140; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; Chan RKW, 1998, J NEUROSCI, V18, P371; Costantino L, 2014, EXPERT OPIN THER PAT, V24, P1007, DOI 10.1517/13543776.2014.941531; De Jonge WJ, 2003, GASTROENTEROLOGY, V125, P1137, DOI 10.1016/S0016-5085(03)01197-1; Endo M, 2014, J PHARMACOL SCI, V124, P374, DOI 10.1254/jphs.13182FP; Franklin KBJ, 2008, MOUSE BRAIN STEROSTA; Fraser GL, 2009, EUR J PHARMACOL, V604, P132, DOI 10.1016/j.ejphar.2008.12.011; Fraser GL, 2008, ENDOCRINOLOGY, V149, P6280, DOI 10.1210/en.2008-0804; Fukuda H, 2005, NEUROGASTROENT MOTIL, V17, P245, DOI 10.1111/j.1365-2982.2004.00602.x; Furukawa N, 2013, AUTON NEUROSCI-BASIC, V179, P14, DOI 10.1016/j.autneu.2013.06.003; Greenwood-Van Meerveld B, 2011, PEPTIDES, V32, P2352, DOI 10.1016/j.peptides.2011.03.014; Hattori T, 2010, INT J PEPT, V2010, P2010; Heinricher MM, 2009, BRAIN RES REV, V60, P214, DOI 10.1016/j.brainresrev.2008.12.009; Joly-Amado A, 2014, BEST PRACT RES CL EN, V28, P725, DOI 10.1016/j.beem.2014.03.003; Karimnamazi H, 2002, BRAIN RES, V957, P193, DOI 10.1016/S0006-8993(02)03438-8; Kito Y, 2010, AM J PHYSIOL-GASTR L, V298, pG755, DOI 10.1152/ajpgi.00333.2009; Kozicz T, 1998, J COMP NEUROL, V391, P1, DOI 10.1002/(SICI)1096-9861(19980202)391:1<1::AID-CNE1>3.0.CO;2-6; Kozicz T, 2007, GEN COMP ENDOCR, V153, P235, DOI 10.1016/j.ygcen.2007.04.005; Kusunoki H, 2010, INTERNAL MED, V49, P2195, DOI 10.2169/internalmedicine.49.3803; LANTERIMINET M, 1993, NEUROSCIENCE, V55, P737, DOI 10.1016/0306-4522(93)90439-M; Li L, 2006, BRAIN RES, V1114, P41, DOI 10.1016/j.brainres.2006.07.042; Ll RX, 2007, CHIN J INTEGR MED, V13, P59, DOI 10.1007/s11655-007-0059-z; Lomax AE, 2010, NEUROGASTROENT MOTIL, V22, P7, DOI 10.1111/j.1365-2982.2009.01381.x; Luckey A, 2003, GASTROENTEROLOGY, V125, P654, DOI 10.1016/S0016-5085(03)01069-2; Martinez V, 1997, J PHARMACOL EXP THER, V280, P754; Mogami S, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/519035; Mueller MH, 2006, LANGENBECK ARCH SURG, V391, P88, DOI 10.1007/s00423-006-0042-8; Owyang C, 2011, J NEUROGASTROENTEROL, V17, P338, DOI 10.5056/jnm.2011.17.4.338; PACAK K, 1995, FRONT NEUROENDOCRIN, V16, P89, DOI 10.1006/frne.1995.1004; Richard S, 2005, J COMP NEUROL, V481, P210, DOI 10.1002/cne.20384; Sadakane C, 2011, BIOCHEM BIOPH RES CO, V412, P506, DOI 10.1016/j.bbrc.2011.08.002; Saegusa Y, 2011, AM J PHYSIOL-ENDOC M, V301, pE685, DOI 10.1152/ajpendo.00121.2011; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Stengel A, 2011, NEUROGASTROENT MOTIL, V23, pE294, DOI 10.1111/j.1365-2982.2011.01721.x; Stengel A, 2011, NEUROGASTROENT MOTIL, V23, pE223, DOI 10.1111/j.1365-2982.2011.01706.x; Stengel A, 2009, ENDOCRINOLOGY, V150, P153, DOI 10.1210/en.2008-0723; Stengel A, 2014, CURR OPIN PHARMACOL, V19, P31, DOI 10.1016/j.coph.2014.06.006; Stengel A, 2014, FRONT NEUROSCI-SWITZ, V8, DOI [10.3389/fnhum.2014.00595, 10.3389/fnins.2014.00052]; Stengel A, 2011, AM J PHYSIOL-GASTR L, V301, pG239, DOI 10.1152/ajpgi.00018.2011; Stengel A, 2010, PHYSIOL BEHAV, V101, P614, DOI 10.1016/j.physbeh.2010.09.009; Stengel A, 2010, PEPTIDES, V31, P263, DOI 10.1016/j.peptides.2009.11.015; Tache Y, 2007, J CLIN INVEST, V117, P33, DOI 10.1172/JCI30085; Tache Y, 2014, CURR PHARM DESIGN, V20, P2725, DOI 10.2174/13816128113199990578; Takeda H, 2008, GASTROENTEROLOGY, V134, P2004, DOI 10.1053/j.gastro.2008.02.078; Takeda H, 2012, METHOD ENZYMOL, V514, P333, DOI 10.1016/B978-0-12-381272-8.00021-0; TATSUTA M, 1993, ALIMENT PHARM THERAP, V7, P459; Tewari N, 2013, CURR OPIN CLIN NUTR, V16, P569, DOI 10.1097/MCO.0b013e3283638e97; Tominaga K, 2013, J GASTROENTEROL, V48, P452, DOI 10.1007/s00535-013-0788-z; Tsubouchi H, 2014, AM J PHYSIOL-LUNG C, V306, pL233, DOI 10.1152/ajplung.00096.2013; Vather R, 2014, CLIN EXP PHARMACOL P, V41, P358, DOI 10.1111/1440-1681.12220; Veenema AH, 2007, BRAIN BEHAV EVOLUT, V70, P274, DOI 10.1159/000105491; Venkova K, 2007, DIGEST DIS SCI, V52, P2241, DOI 10.1007/s10620-007-9783-7; Wang L, 2012, NEUROGASTROENT MOTIL, V24, pe425, DOI 10.1111/j.1365-2982.2012.01974.x; Wang L, 1998, BRAIN RES, V791, P157, DOI 10.1016/S0006-8993(98)00091-2; Wang LX, 2014, PEPTIDES, V55, P136, DOI 10.1016/j.peptides.2014.02.011; Wang LX, 2011, BRAIN RES, V1415, P34, DOI 10.1016/j.brainres.2011.07.024; Wang LX, 2011, PEPTIDES, V32, P51, DOI 10.1016/j.peptides.2010.10.017; Wang LX, 2002, NEUROSCI LETT, V325, P47; Warren J, 2011, NUTR CLIN PRACT, V26, P115, DOI 10.1177/0884533611400231; Wu QL, 2014, ENDOCRINOLOGY, V155, P840, DOI 10.1210/en.2013-1831; Wu ZQ, 2015, EUR SURG RES, V54, P127, DOI 10.1159/000369529; Yagi M, 2004, PEDIATR SURG INT, V19, P760, DOI 10.1007/s00383-003-1053-y; Yakabi K, 2011, AM J PHYSIOL-ENDOC M, V301, pE72, DOI 10.1152/ajpendo.00695.2010; Yamada C, 2015, PSYCHONEUROENDOCRINO, V55, P81, DOI 10.1016/j.psyneuen.2015.02.006; Yamada C, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/792940; Yamamoto T, 2009, ANN NY ACAD SCI, V1170, P378, DOI 10.1111/j.1749-6632.2009.03883.x; Yu DY, 1996, NEUROSCI LETT, V205, P21, DOI 10.1016/0304-3940(96)12383-1; Zittel TT, 1998, SURGERY, V123, P518, DOI 10.1067/msy.1998.88090; ZITTEL TT, 1993, NEUROSCI LETT, V159, P79, DOI 10.1016/0304-3940(93)90803-S	85	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2015	10	9							e0139325	10.1371/journal.pone.0139325	http://dx.doi.org/10.1371/journal.pone.0139325			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6GF	26421719	gold, Green Published, Green Submitted			2023-01-03	WOS:000362175700094
J	Zhou, P; Zhang, L; Li, JL; Luo, YQ; Zhang, BL; Xing, S; Zhu, YP; Sun, H; Gao, F; Zhou, GH				Zhou, Ping; Zhang, Lin; Li, Jiaolong; Luo, Yiqiu; Zhang, Bolin; Xing, Shen; Zhu, Yuping; Sun, Hui; Gao, Feng; Zhou, Guanghong			Effects of Dietary Crude Protein Levels and Cysteamine Supplementation on Protein Synthetic and Degradative Signaling in Skeletal Muscle of Finishing Pigs	PLOS ONE			English	Article							GROWTH-FACTOR-I; AMINO-ACIDS; HORMONE RECEPTOR; CARCASS TRAITS; PERFORMANCE; INSULIN; EXPRESSION; ATROPHY; BARROWS; PIGLETS	Dietary protein levels and cysteamine (CS) supplementation can affect growth performance and protein metabolism of pigs. However, the influence of dietary protein intake on the growth response of CS-treated pigs is unclear, and the mechanisms involved in protein metabolism remain unknown. Hence, we investigated the interactions between dietary protein levels and CS supplementation and the effects of dietary crude protein levels and CS supplementation on protein synthetic and degradative signaling in skeletal muscle of finishing pigs. One hundred twenty barrows (65.84 +/- 0.61 kg) were allocated to a 2 x 2 factorial arrangement with five replicates of six pigs each. The primary variations were dietary crude protein (CP) levels (14% or 10%) and CS supplemental levels (0 or 700 mg/kg). The low-protein (LP) diets (10% CP) were supplemented with enough essential amino acids (EAA) to meet the NRC AA requirements of pigs and maintain the balanced supply of eight EAA including lysine, methionine, threonine, tryptophan, valine, phenylalanine, isoleucine, and leucine. After 41 days, 10 pigs per treatment were slaughtered. We found that LP diets supplemented with EAA resulted in decreased concentrations of plasma somatostatin (SS) (P<0.01) and plasma urea nitrogen (PUN) (P<0.001), while dietary protein levels did not affect other traits. However, CS supplementation increased the average daily gain (P<0.001) and lean percentage (P<0.05), and decreased the feed conversion ratio (P<0.05) and back fat (P<0.05). CS supplementation also increased the concentrations of plasma insulin-like growth factor 1 (IGF-1) (P<0.001), and reduced the concentrations of leptin, SS, and PUN (P<0.001). Increased mRNA abundance of Akt1 and IGF-1 signaling (P<0.001) and decreased mRNA abundance of Forkhead Box O (FOXO) 4 (P<0.01) and muscle atrophy F-box (P<0.001) were observed in pigs receiving CS. Additionally, CS supplementation increased the protein levels for the phosphorylated mammalian target of rapamycin (mTOR), eIF-4E binding protein 1, and ribosomal protein S6 kinase 1 (P<0.001). There were no interactions between dietary protein levels and CS supplementation for all traits. In conclusion, dietary protein levels and CS supplementation influenced growth and protein metabolism through independent mechanisms in pigs. In addition, LP diets supplemented with EAA did not affect growth performance and other traits except the concentrations of SS and PUN probably through maintenance of protein synthesis and degradation signaling. Moreover, CS supplementation improved growth performance by increasing plasma IGF-1 concentrations possibly through alterations of mTOR and Akt/FOXO signaling pathways in skeletal muscle of finishing pigs.	[Zhou, Ping; Zhang, Lin; Li, Jiaolong; Luo, Yiqiu; Zhang, Bolin; Xing, Shen; Zhu, Yuping; Gao, Feng; Zhou, Guanghong] Nanjing Agr Univ, Synerget Innovat Ctr Food Safety & Nutr, Key Lab Anim Origin Food Prod & Safety Guarantee, Coll Anim Sci & Technol, Nanjing 210095, Jiangsu, Peoples R China; [Sun, Hui] Jilin Agr Univ, Coll Anim Sci & Technol, Changchun 130118, Peoples R China	Nanjing Agricultural University; Jilin Agricultural University	Gao, F (corresponding author), Nanjing Agr Univ, Synerget Innovat Ctr Food Safety & Nutr, Key Lab Anim Origin Food Prod & Safety Guarantee, Coll Anim Sci & Technol, Nanjing 210095, Jiangsu, Peoples R China.	gaofeng0629@sina.com	Zhang, bolin/GZN-2017-2022; Zhang, Lin/AAL-3573-2020	Zhang, Lin/0000-0003-1555-1086	National Key Basic Research Program of China [2013CB127306]	National Key Basic Research Program of China(National Basic Research Program of China)	The present study was supported by National Key Basic Research Program of China (no. 2013CB127306). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, NUTR REQ SWIN; Barb CR, 2001, DOMEST ANIM ENDOCRIN, V21, P297, DOI 10.1016/S0739-7240(01)00123-0; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brameld JM, 1996, J ANIM SCI, V74, P1832; Clemmons DR, 2009, TRENDS ENDOCRIN MET, V20, P349, DOI 10.1016/j.tem.2009.04.002; Deng D, 2007, LIVEST SCI, V109, P220, DOI 10.1016/j.livsci.2007.01.122; Deng D, 2007, LIVEST SCI, V109, P224, DOI 10.1016/j.livsci.2007.01.104; Deng D, 2009, J NUTR BIOCHEM, V20, P544, DOI 10.1016/j.jnutbio.2008.05.014; DEVOL DL, 1988, J ANIM SCI, V66, P385; ETHERTON TD, 1987, J ANIM SCI, V64, P433, DOI 10.2527/jas1987.642433x; Foletta VC, 2011, PFLUG ARCH EUR J PHY, V461, P325, DOI 10.1007/s00424-010-0919-9; Gomez RS, 2002, J ANIM SCI, V80, P644; Guay F, 2006, J ANIM SCI, V84, P3010, DOI 10.2527/jas.2005-559; Han B, 2008, MOL REPROD DEV, V75, P810, DOI 10.1002/mrd.20832; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Kendall D, 2000, THESIS PURDUE U W LA; KERR BJ, 1995, J ANIM SCI, V73, P433; Latres E, 2005, J BIOL CHEM, V280, P2737, DOI 10.1074/jbc.M407517200; Li YeGuo, 2006, Journal of Northwest Sci Tech University of Agriculture and Forestry - Natural Science Edition, V34, P27; Liu GM, 2008, J AGR FOOD CHEM, V56, P5422, DOI 10.1021/jf800575p; Liu GM, 2009, LIVEST SCI, V122, P86, DOI 10.1016/j.livsci.2008.07.027; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lordelo MM, 2008, J ANIM SCI, V86, P2936, DOI 10.2527/jas.2007-0222; Luo JQ, 2010, BRIT J NUTR, V104, P1421, DOI 10.1017/S000711451000231X; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; Madrid J, 2013, ANIM PROD SCI, V53, P146, DOI 10.1071/AN12067; Nyachoti CM, 2006, J ANIM SCI, V84, P125, DOI 10.2527/2006.841125x; O'Connor PMJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE40, DOI 10.1152/ajpendo.00563.2002; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sandri M, 2008, PHYSIOLOGY, V23, P160, DOI 10.1152/physiol.00041.2007; Shriver JA, 2003, J ANIM SCI, V81, P492; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Toledo JB, 2014, LIVEST SCI, V168, P94, DOI 10.1016/j.livsci.2014.07.006; Tse MCL, 2006, BRIT J NUTR, V96, P650, DOI 10.1079/BJN20061870; Wen C, 2014, BRIT J NUTR, V111, P201, DOI 10.1017/S0007114513002419; Wu GY, 2009, AMINO ACIDS, V37, P1, DOI 10.1007/s00726-009-0269-0; Wu GY, 2013, AMINO ACIDS, V45, P241, DOI 10.1007/s00726-013-1515-z; Xiong B H, 2012, CHINA FEED, V473, P33; Yang CM, 2006, POULTRY SCI, V85, P1912, DOI 10.1093/ps/85.11.1912; Yang CB, 2005, J SCI FOOD AGR, V85, P1947, DOI 10.1002/jsfa.2123; Yang X, 2008, J Anim Sci, V86, pE36; YOKOGOSHI H, 1980, J NUTR, V110, P375, DOI 10.1093/jn/110.3.375; Yuan YL, 2012, ANIM PROD SCI, V52, P911, DOI 10.1071/AN11222; Yue LY, 2008, LIVEST SCI, V115, P144, DOI 10.1016/j.livsci.2007.06.018; Zhang BL, 2015, NUTRITION, V31, P749, DOI 10.1016/j.nut.2014.11.010; Zhang SH, 2013, AMINO ACIDS, V45, P1191, DOI 10.1007/s00726-013-1577-y	49	12	20	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2015	10	9							e0139393	10.1371/journal.pone.0139393	http://dx.doi.org/10.1371/journal.pone.0139393			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6GF	26422009	Green Published, Green Submitted, gold			2023-01-03	WOS:000362175700111
J	Dalal, HM; Doherty, P; Taylor, RS				Dalal, Hasnain M.; Doherty, Patrick; Taylor, Rod S.			Cardiac rehabilitation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CORONARY-ARTERY-DISEASE; FAILURE SELF-CARE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; HEART-FAILURE; POSTMYOCARDIAL INFARCTION; PHYSICIAN FACTORS; EXERCISE; MANAGEMENT; ENROLLMENT		[Dalal, Hasnain M.] Univ Exeter, Med Sch Primary Care, Royal Cornwall Hosp, Exeter EX4 4QJ, Devon, England; [Doherty, Patrick] Univ York, Dept Hlth Sci, Cardiovasc Hlth, York YO10 5DD, N Yorkshire, England; [Doherty, Patrick] Univ York, Dept Hlth Sci, Natl Audit Cardiac Rehabil, York YO10 5DD, N Yorkshire, England; [Doherty, Patrick] Univ York, Dept Hlth Sci, Res, York YO10 5DD, N Yorkshire, England; [Taylor, Rod S.] Univ Exeter, Sch Med, Inst Hlth Res, Hlth Serv Res, Exeter EX1 2LU, Devon, England; [Taylor, Rod S.] Univ Exeter, Sch Med, Inst Hlth Res, Exeter Clin Trials Support Network, Exeter EX1 2LU, Devon, England	Royal Cornwall Hospital; University of Exeter; University of York - UK; University of York - UK; University of York - UK; University of Exeter; University of Exeter	Dalal, HM (corresponding author), Univ Exeter, Med Sch Primary Care, Royal Cornwall Hosp, Truro Campus,Knowledge Spa, Exeter EX4 4QJ, Devon, England.	hmdalal@doctors.org.uk	Dinnes, Jacqueline/Y-3673-2018; McGee, Hannah M/D-6480-2012; Taylor, Rod/R-9581-2019; Thompson, David R/C-6320-2009	Dinnes, Jacqueline/0000-0003-1343-7335; McGee, Hannah M/0000-0003-1417-993X; Taylor, Rod/0000-0002-3043-6011; Doherty, Patrick Joseph/0000-0002-1887-0237	National Institute for Health Research [NF-SI-0514-10155, RP-PG-1210-12004] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		ADES PA, 1992, ARCH INTERN MED, V152, P1033, DOI 10.1001/archinte.152.5.1033; Ades PA, 2013, JACC-HEART FAIL, V1, P540, DOI 10.1016/j.jchf.2013.09.002; Ades PA, 2009, CIRCULATION, V119, P2671, DOI 10.1161/CIRCULATIONAHA.108.834184; Anderson L, COCHRANE DA IN PRESS; Anderson L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011273.pub2; Balady GJ, 2007, J CARDIOPULM REHABIL, V27, P121; Balady GJ, 2011, CIRCULATION, V124, P2951, DOI 10.1161/CIR.0b013e31823b21e2; Beatty AL, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000568; Bjarnason-Wehrens B, 2010, EUR J CARDIOV PREV R, V17, P410, DOI [DOI 10.1097/HJR.0b013e328334f42d, 10.1097/HJR.0b013e328334f42d]; British Association for Cardiovascular Prevention and Rehabilitation, 2012, BACPR STAND COR COMP; British Heart Foundation, 2014, INP OUTP ACC PHIL; British Heart Foundation, EUROPEAN CARDIOVASCU; British Heart Foundation, HEART STAT; Brown JPR, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008895.pub2; Brown JP, 2010, COCHRANE DB SYST REV, V1; Buck HG, 2015, EUR J CARDIOVASC NUR, V14, P79, DOI 10.1177/1474515113518434; Clark AM, 2014, HEART, V100, P716, DOI 10.1136/heartjnl-2013-304852; Clark AM, 2005, ANN INTERN MED, V143, P659, DOI 10.7326/0003-4819-143-9-200511010-00010; Clark RA, 2015, EUR J PREV CARDIOL, V22, P35, DOI 10.1177/2047487313501093; Dalal H, 2004, BMJ-BRIT MED J, V328, P693, DOI 10.1136/bmj.328.7441.693; Dalal HM, 2007, INT J CARDIOL, V119, P202, DOI 10.1016/j.ijcard.2006.11.018; Dalal HM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000787; Dalal HM, 2003, BRIT MED J, V326, P481, DOI 10.1136/bmj.326.7387.481; Deanfield J, 2014, HEART, V100, P1, DOI 10.1136/heartjnl-2014-305693; Department of Health, 2010, CARD REH COMM PACK; Doherty P, 2012, HEART, V98, P605, DOI 10.1136/heartjnl-2012-301728; Forman DE, 2015, J AM COLL CARDIOL, V65, P2652, DOI 10.1016/j.jacc.2015.04.052; Ghisi GLM, 2013, CLIN CARDIOL, V36, P323, DOI 10.1002/clc.22126; Grace SL, 2008, EUR J CARDIOV PREV R, V15, P548, DOI 10.1097/HJR.0b013e328305df05; Healthcare Commission, 2004, COR HEART DIS SURV P; Heran BS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub3, 10.1002/14651858.CD001800.pub2]; Jelinek MV, 2015, INT J CARDIOL, V179, P153, DOI 10.1016/j.ijcard.2014.10.154; Jolly K, 2009, HEART, V95, P36, DOI 10.1136/hrt.2007.127209; Lavie CJ, 2006, ARCH INTERN MED, V166, P1878, DOI 10.1001/archinte.166.17.1878; LAVIE CJ, 1994, AM J CARDIOL, V74, P1192, DOI 10.1016/0002-9149(94)90546-0; Lawler PR, 2011, AM HEART J, V162, P571, DOI 10.1016/j.ahj.2011.07.017; Leon AS, 2005, CIRCULATION, V111, P369, DOI 10.1161/01.CIR.0000151788.08740.5C; LEWIN B, 1992, LANCET, V339, P1036, DOI 10.1016/0140-6736(92)90547-G; Lewin R, 2013, HEART, V99, P909, DOI 10.1136/heartjnl-2013-303704; Linden W, 1996, ARCH INTERN MED, V156, P745, DOI 10.1001/archinte.156.7.745; Mampuya WM, 2012, CARDIOVASC DIAGN THE, V2, P38, DOI 10.3978/j.issn.2223-3652.2012.01.02; Menezes AR, 2014, PROG CARDIOVASC DIS, V56, P522, DOI 10.1016/j.pcad.2013.09.018; Milani RV, 2011, AM J CARDIOL, V107, P64, DOI 10.1016/j.amjcard.2010.08.047; National Institute for Health and Care Excellence, 2010, EARL MAN UNST ANG NO; National Institute for Health and Care Excellence, 2010, MAN CHRON HEART FAIL; National Institute for Health and Care Excellence, 2013, SEC PREV PRIM SEC CA; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; Pack QR, 2014, J CARDIOPULM REHABIL, V34, P318, DOI 10.1097/HCR.0000000000000076; Pavy B, 2006, ARCH INTERN MED, V166, P2329, DOI 10.1001/archinte.166.21.2329; Piepoli MF, 2014, EUR J PREV CARDIOL, V21, P664, DOI 10.1177/2047487312449597; Sagar VA, 2015, OPEN HEART, V2, DOI 10.1136/openhrt-2014-000163; SCHULER G, 1992, J AM COLL CARDIOL, V19, P34, DOI 10.1016/0735-1097(92)90048-R; TAYLOR CB, 1986, J PSYCHOSOM RES, V30, P581, DOI 10.1016/0022-3999(86)90031-0; Anderson Lindsey, 2017, Cochrane Database Syst Rev, V6, pCD007130, DOI [10.1002/14651858.CD007130.pub3, 10.1002/14651858.CD007130.pub4]; Taylor RS, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003331.pub4; VANCAMP SP, 1986, JAMA-J AM MED ASSOC, V256, P1160, DOI 10.1001/jama.256.9.1160; Vanhees L, 2012, EUR J PREV CARDIOL, V19, P1333, DOI 10.1177/2047487312437063; Varnfield M, 2014, HEART, V100, P1770, DOI 10.1136/heartjnl-2014-305783; West R, 2013, HEART, V99, P911, DOI 10.1136/heartjnl-2013-303705; West RR, 2012, HEART, V98, P637, DOI 10.1136/heartjnl-2011-300302; Wingham Jenny, 2006, Eur J Cardiovasc Nurs, V5, P289, DOI 10.1016/j.ejcnurse.2006.02.002; Wood D, 2012, HEART, V98, P607, DOI 10.1136/heartjnl-2012-301811	62	205	214	2	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 29	2015	351								h5000	10.1136/bmj.h5000	http://dx.doi.org/10.1136/bmj.h5000			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CS9YU	26419744	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000362450900007
J	Wallace, E; Smith, SM; Fahey, T; Roland, M				Wallace, Emma; Smith, Susan M.; Fahey, Tom; Roland, Martin			Reducing emergency admissions through community based interventions	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RISK PREDICTION MODELS; PRIMARY-CARE; HOSPITAL READMISSIONS; GUIDED CARE; HEALTH-CARE; MANAGEMENT; OUTCOMES; QUALITY; IMPACT; ADULTS		[Wallace, Emma; Smith, Susan M.; Fahey, Tom] Royal Coll Surgeons Ireland, Dept Gen Practice, HRB Ctr Primary Care Res, 123 St Stephens Green, Dublin 2, Ireland; [Roland, Martin] Univ Cambridge, Cambridge Ctr Hlth Serv Res, Cambridge CB2 1TN, England	Health Research Board - Ireland; Royal College of Surgeons - Ireland; University of Cambridge	Wallace, E (corresponding author), Royal Coll Surgeons Ireland, Dept Gen Practice, HRB Ctr Primary Care Res, 123 St Stephens Green, Dublin 2, Ireland.	emmawallace@rcsi.ie	Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783; Smith, Susan/0000-0001-6027-2727; Roland, Martin/0000-0002-8533-3060; wallace, emma/0000-0002-9315-2956				Abualenain J, 2013, ANN EMERG MED, V61, P638, DOI 10.1016/j.annemergmed.2013.01.016; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Billings J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003352; Blunt I., 2013, FOCUS PREVENTABLE AD; BMA NHS England NHS Employers, 2014, AVOID UNPL ADM ENH S; Boult C, 2011, ARCH INTERN MED, V171, P460, DOI 10.1001/archinternmed.2010.540; Boyd CM, 2010, J GEN INTERN MED, V25, P235, DOI 10.1007/s11606-009-1192-5; Centers for Medicare and Medicaid Services, 2015, ACC CAR ORG 2015 PRO; Centers for Medicare and Medicaid services, 2014, SUMM FIN RUL PROV AC; Chitnis XA, 2013, BMJ SUPPORT PALLIAT, V3, P422, DOI 10.1136/bmjspcare-2012-000424; Deschodt M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-48; Dusheiko M, 2011, HEALTH SERV RES, V46, P27, DOI 10.1111/j.1475-6773.2010.01184.x; Gao J, 2014, MED CARE, V52, P164, DOI 10.1097/MLR.0000000000000041; Gravelle H, 2007, BMJ-BRIT MED J, V334, P31, DOI 10.1136/bmj.39020.413310.55; Harrison MJ, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6423; Hastings SN, 2005, ACAD EMERG MED, V12, P978, DOI 10.1197/j.aem.2005.05.032; Huntley AL, 2013, FAM PRACT, V30, P266, DOI 10.1093/fampra/cms081; IS Scotland, 2011, SCOTT PAT RISK READM; Jackson GL, 2013, ANN INTERN MED, V158, P169, DOI 10.7326/0003-4819-158-3-201302050-00579; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Keogh C, 2014, ANN FAM MED, V12, P359, DOI 10.1370/afm.1640; Kiran T, 2010, J EPIDEMIOL COMMUN H, V64, P927, DOI 10.1136/jech.2009.098806; Kruis AL, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009437.pub2; Leppin AL, 2014, JAMA INTERN MED, V174, P1095, DOI 10.1001/jamainternmed.2014.1608; Lewis GH, 2013, IMPACT VIRTUAL WARDS; Louis DZ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005223; Miani C, 2014, HLTH SERVICES DELIVE, V2, P52, DOI [DOI 10.3310/HSDR02520, 10.3310/hsdr02520]; Michalopoulos C, 2014, FINAL REPORT EVALUAT; National Audit Office, 2013, EM ADM HOSP MAN DEM; National Primary Care Research and Development Centre, 2006, EV EV FIN REP; NHS England, 2015, NEXT STEPS RISK STRA; Nuffield Trust Research Group, 2011, PRED RISK HEALTHC OV; O'Cathain A, 2013, HEALTH SERV MANAG RE, V26, P110, DOI 10.1177/0951484814525357; O'Cathain A, 2014, BMJ QUAL SAF, V23, P47, DOI 10.1136/bmjqs-2013-002003; Public Health Division, 2001, VICT AMB CAR SENS CO; Purdy S, 2009, PUBLIC HEALTH, V123, P169, DOI 10.1016/j.puhe.2008.11.001; Purdy S, 2012, INTERVENTIONS REDUCE; Simmonds RL, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X658278; Sinha SK, 2011, ANN EMERG MED, V57, P672, DOI 10.1016/j.annemergmed.2011.01.021; Stokes J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132340; Tian, 2012, DATA BRIEFING EMERGE; Verhaegh KJ, 2014, HEALTH AFFAIR, V33, P1531, DOI 10.1377/hlthaff.2014.0160; Wallace E, 2014, MED CARE, V52, P751, DOI 10.1097/MLR.0000000000000171	43	36	36	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	2016	352								h6817	10.1136/bmj.h6817	http://dx.doi.org/10.1136/bmj.h6817			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC6EX	26822070				2023-01-03	WOS:000369313700001
J	Rainone, V; Martelli, C; Ottobrini, L; Biasin, M; Borelli, M; Lucignani, G; Trabattoni, D; Clerici, M				Rainone, Veronica; Martelli, Cristina; Ottobrini, Luisa; Biasin, Mara; Borelli, Manuela; Lucignani, Giovanni; Trabattoni, Daria; Clerici, Mario			Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy	PLOS ONE			English	Article							IMMUNE-RESPONSES; EXPRESSION; MELANOMA; ANTIGENS; SUBSETS; CD4(+)	Introduction Dendritic cells play a key role as initiators of T-cell responses, and even if tumour antigen-loaded dendritic cells can induce anti-tumour responses, their efficacy has been questioned, suggesting a need to enhance immunization strategies. Matherials & Methods We focused on the characterization of bone marrow-derived dendritic cells pulsed with whole tumour lysate (TAA-DC), as a source of known and unknown antigens, in a mouse model of breast cancer (MMTV-Ras). Dendritic cells were evaluated for antigen uptake and for the expression of MHC class I/II and costimulatory molecules and markers associated with maturation. Results Results showed that antigen-loaded dendritic cells are characterized by a phenotypically semi-mature/mature profile and by the upregulation of genes involved in antigen presentation and T-cell priming. Activated dendritic cells stimulated T-cell proliferation and induced the production of high concentrations of IL-12p70 and IFN-gamma but only low levels of IL-10, indicating their ability to elicit a T(H)1-immune response. Furthermore, administration of Antigen loaded-Dendritic Cells in MMTV-Ras mice evoked a strong anti-tumour response in vivo as demonstrated by a general activation of immunocompetent cells and the release of T(H)1 cytokines. Conclusion Data herein could be useful in the design of antitumoral DC-based therapies, showing a specific activation of immune system against breast cancer.	[Rainone, Veronica; Biasin, Mara; Borelli, Manuela; Trabattoni, Daria] Univ Milan, Chair Immunol, Dept Biomed & Clin Sci L Sacco, Milan, Italy; [Martelli, Cristina; Ottobrini, Luisa; Clerici, Mario] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Martelli, Cristina; Ottobrini, Luisa; Lucignani, Giovanni] Univ Milan, Ctr Mol & Cellular Imaging IMAGO, Milan, Italy; [Ottobrini, Luisa] Natl Res Council CNR, Inst Mol Bioimaging & Physiol IBFM, Milan, Italy; [Lucignani, Giovanni] Univ Milan, Dept Hlth Sci, Milan, Italy; [Lucignani, Giovanni] San Paolo Hosp, Nucl Med Unit, Dept Diagnost Serv, Milan, Italy; [Clerici, Mario] Don C Gnocchi Fdn IRCCS, Milan, Italy	University of Milan; Luigi Sacco Hospital; University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioimmagini e Fisiologia Molecolare (IBFM-CNR); University of Milan; San Paolo-Polo Universitaria Hospital; IRCCS Fondazione Don Carlo Gnocchi Onlus	Clerici, M (corresponding author), Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.; Clerici, M (corresponding author), Don C Gnocchi Fdn IRCCS, Milan, Italy.	mario.clerici@unimi.it	Trabattoni, Daria/G-7424-2012; Lucignani, Giovanni/C-6773-2008; Ottobrini, Luisa/K-7608-2016; Martelli, Cristina/P-4426-2017; biasin, mara/G-7426-2012	Trabattoni, Daria/0000-0001-9535-3359; Lucignani, Giovanni/0000-0002-9674-8958; Ottobrini, Luisa/0000-0002-5002-6845; Martelli, Cristina/0000-0003-0023-9110; biasin, mara/0000-0003-3671-4235	PRIN (Progetti di Rilevante Interesse Nazionale, Health Ministry) [20082NHWH9_001]; AIRC (Associazione Italiana per la Ricerca sul Cancro) [IG-9311]; Italian program PRIN [20082NHWH9_001]	PRIN (Progetti di Rilevante Interesse Nazionale, Health Ministry)(Ministry of Education, Universities and Research (MIUR)); AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); Italian program PRIN	This work was supported by PRIN 2008 (Progetti di Rilevante Interesse Nazionale, Health Ministry, project no. 20082NHWH9_001) received by MC and AIRC (Associazione Italiana per la Ricerca sul Cancro; funded project no IG-9311) received by MC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was supported in part by the Italian program PRIN 2008 (project no. 20082NHWH9_001) and by AIRC (Associazione Italiana per la Ricerca sul Cancro) funded project no IG-9311. All the authors have read the manuscript and approve the final version herein attached.	Aerts-Toegaert C, 2007, EUR J IMMUNOL, V37, P686, DOI 10.1002/eji.200636535; Ahmad M, 2004, CANCER IMMUNOL IMMUN, V53, P844, DOI 10.1007/s00262-004-0540-x; Bai L, 2002, INT J ONCOL, V20, P247; Baker K, 2014, FRONT IMMUNOL, V5, DOI [10.3389/fimmu.2014.00664, 10.3389/fimmu.2014.00408]; Banchereau J, 2001, CANCER RES, V61, P6451; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; Caux C, 2002, TRANSPLANTATION, V73, pS7, DOI 10.1097/00007890-200201151-00005; Chiang CLL, 2010, SEMIN IMMUNOL, V22, P132, DOI 10.1016/j.smim.2010.02.004; Corinti S, 2001, J IMMUNOL, V166, P4312, DOI 10.4049/jimmunol.166.7.4312; De Vries IJ, 2008, CANCER RES, V63, P12; de Vries IJM, 2003, CLIN CANCER RES, V9, P5091; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Gilboa E, 2007, J CLIN INVEST, V117, P1195, DOI 10.1172/JCI31205; Goldszmid RS, 2003, J IMMUNOL, V171, P5940, DOI 10.4049/jimmunol.171.11.5940; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; Gunn MD, 2003, SEMIN IMMUNOL, V15, P271, DOI 10.1016/j.smim.2003.08.004; Hart JP, 2004, J IMMUNOL, V172, P70, DOI 10.4049/jimmunol.172.1.70; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kushwah R, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-20; Mackensen A, 2000, INT J CANCER, V86, P385, DOI 10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T; Malumbres M, 2003, NAT REV CANCER, V3, P708, DOI 10.1038/nrc1193; Martelli C, 2012, MOL IMAGING BIOL, V14, P183, DOI 10.1007/s11307-011-0496-0; Melero I, 2000, GENE THER, V7, P1167, DOI 10.1038/sj.gt.3301234; Mocellin S, 2005, J LEUKOCYTE BIOL, V78, P1043, DOI 10.1189/jlb.0705358; Mocellin S, 2001, J IMMUNOTHER, V24, P392, DOI 10.1097/00002371-200109000-00002; Morel S, 2000, IMMUNITY, V12, P107, DOI 10.1016/S1074-7613(00)80163-6; Neller MA, 2008, SEMIN IMMUNOL, V20, P286, DOI 10.1016/j.smim.2008.09.006; Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258; Ridolfi Ruggero, 2004, J Transl Med, V2, P27; Saito K, 2005, EXP CELL RES, V310, P229, DOI 10.1016/j.yexcr.2005.07.014; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sallusto F, 2018, J IMMUNOL, V200, P887, DOI 10.1084/jem.179.4.1109; Satthaporn S, 2001, J ROY COLL SURG EDIN, V46, P9; Shumway NM, 2009, BIODRUGS, V23, P277, DOI 10.2165/11313490-000000000-00000; Sogn JA, 1998, IMMUNITY, V9, P757, DOI 10.1016/S1074-7613(00)80641-X; Srivastava Pramod K, 2005, Curr Oncol Rep, V7, P104, DOI 10.1007/s11912-005-0035-8; Zanetti M, 2003, ANN NY ACAD SCI, V987, P249, DOI 10.1111/j.1749-6632.2003.tb06056.x; Zhan YF, 2012, MOL IMMUNOL, V52, P30, DOI 10.1016/j.molimm.2012.04.009; Zhang XS, 2005, J IMMUNOL, V175, P2931, DOI 10.4049/jimmunol.175.5.2931	43	22	24	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2016	11	1							e0146622	10.1371/journal.pone.0146622	http://dx.doi.org/10.1371/journal.pone.0146622			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB5CE	26795765	Green Published, gold, Green Submitted			2023-01-03	WOS:000368530300009
J	Szoboszlay, M; White-Monsant, A; Moe, LA				Szoboszlay, Marton; White-Monsant, Alison; Moe, Luke A.			The Effect of Root Exudate 7,4 '-Dihydroxyflavone and Naringenin on Soil Bacterial Community Structure	PLOS ONE			English	Article							GENE-INDUCING FLAVONOIDS; SP NOV.; MICROBIAL COMMUNITY; PHENOLIC-ACIDS; SEQUENCE DATA; PLANT-GROWTH; RHIZOSPHERE; ACTINOBACTERIA; ACIDOBACTERIA; DIVERSITY	Our goal was to investigate how root exudate flavonoids influence the soil bacterial community structure and to identify members of the community that change their relative abundance in response to flavonoid exudation. Using a model system that approximates flavonoid exudation of Medicago sativa roots, we treated a soil with 7,4'-dihydroxyflavone and naringenin in two separate experiments using three different rates: medium (equivalent to the exudation rate of 7,4'-dihydroxyflavone from M. sativa seedlings), high (10x the medium rate), and low (0.1x the medium rate). Controls received no flavonoid. Soil samples were subjected to ATP assays and 16S rRNA gene amplicon sequencing. The flavonoid treatments caused no significant change in the soil ATP content. With the high 7,4'-dihydroxyflavone treatment rate, operational taxonomic units (OTUs) classified as Acidobacteria subdivision 4 increased in relative abundance compared with the control samples, whereas OTUs classified as Gaiellales, Nocardioidaceae, and Thermomonosporaceae were more prevalent in the control. The naringenin treatments did not cause significant changes in the soil bacterial community structure. Our results suggest that the root exudate flavonoid 7,4'-dihydroxyflavone can interact with a diverse range of soil bacteria and may have other functions in the rhizosphere in addition to nod gene induction in legume-rhizobia symbiosis.	[Szoboszlay, Marton; Moe, Luke A.] Univ Kentucky, Dept Plant & Soil Sci, Lexington, KY 40506 USA; [White-Monsant, Alison] La Trobe Univ, Ctr AgriBiosci, Dept Anim Plant & Soil Sci, Melbourne, Vic, Australia	University of Kentucky; La Trobe University	Moe, LA (corresponding author), Univ Kentucky, Dept Plant & Soil Sci, Lexington, KY 40506 USA.	luke.moe@uky.edu		Moe, Luke/0000-0001-6864-4660; Szoboszlay, Marton/0000-0002-7264-3369	National Institute of Food and Agriculture of the United States Department of Agriculture [2011-67020-30195]	National Institute of Food and Agriculture of the United States Department of Agriculture	This work was supported by grant 2011-67020-30195 from the National Institute of Food and Agriculture of the United States Department of Agriculture to LAM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aitchison J, 1986, STAT ANAL COMPOSITIO, DOI [DOI 10.1007/978-94-009-4109-0, 10.1007/978-94-009-4109-0]; Albuquerque L, 2011, SYST APPL MICROBIOL, V34, P595, DOI 10.1016/j.syapm.2011.07.001; Anderson CR, 2011, PEDOBIOLOGIA, V54, P309, DOI 10.1016/j.pedobi.2011.07.005; BAI QY, 1988, CHEMOSPHERE, V17, P2461, DOI 10.1016/0045-6535(88)90156-7; Blagodatskaya E, 2013, SOIL BIOL BIOCHEM, V67, P192, DOI 10.1016/j.soilbio.2013.08.024; Cesco S, 2012, BIOL FERT SOILS, V48, P123, DOI 10.1007/s00374-011-0653-2; Cesco S, 2010, PLANT SOIL, V329, P1, DOI 10.1007/s11104-009-0266-9; Chen F, 2013, CURR MICROBIOL, V67, P177, DOI 10.1007/s00284-013-0347-0; Cole JR, 2014, NUCLEIC ACIDS RES, V42, pD633, DOI 10.1093/nar/gkt1244; Coombs JT, 2004, BIOL CONTROL, V29, P359, DOI 10.1016/j.biocontrol.2003.08.001; Coombs JT, 2003, APPL ENVIRON MICROB, V69, P5603, DOI 10.1128/AEM.69.9.5603-5608.2003; Cooper JE, 2004, ADV BOT RES, V41, P1; Crowe MA, 2014, INT J SYST EVOL MICR, V64, P220, DOI 10.1099/ijs.0.055079-0; da Rocha UN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082443; da Rocha UN, 2009, FEMS MICROBIOL ECOL, V69, P313, DOI 10.1111/j.1574-6941.2009.00702.x; Dakora FD, 1996, PHYSIOL MOL PLANT P, V49, P1, DOI 10.1006/pmpp.1996.0035; DeNobili M, 1996, SOIL BIOL BIOCHEM, V28, P1099, DOI 10.1016/0038-0717(96)00074-0; DHARMATILAKE AJ, 1992, APPL ENVIRON MICROB, V58, P1153, DOI 10.1128/AEM.58.4.1153-1158.1992; DJORDJEVIC MA, 1987, EMBO J, V6, P1173, DOI 10.1002/j.1460-2075.1987.tb02351.x; Drake JE, 2013, BIOGEOSCIENCES, V10, P821, DOI 10.5194/bg-10-821-2013; Eren AM, 2015, ISME J, V9, P968, DOI 10.1038/ismej.2014.195; Fattorusso E, 2001, PHYTOCHEMISTRY, V57, P565, DOI 10.1016/S0031-9422(01)00039-5; Fernandes AD, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-15; Foesel BU, 2013, SYST APPL MICROBIOL, V36, P82, DOI 10.1016/j.syapm.2012.11.002; Gremion F, 2003, ENVIRON MICROBIOL, V5, P896, DOI 10.1046/j.1462-2920.2003.00484.x; Griffiths BS, 1999, SOIL BIOL BIOCHEM, V31, P145, DOI 10.1016/S0038-0717(98)00117-5; HAMLEN RA, 1972, CAN J PLANT SCI, V52, P633, DOI 10.4141/cjps72-097; HARTWIG UA, 1991, PLANT PHYSIOL, V95, P797, DOI 10.1104/pp.95.3.797; Hassan S, 2012, J EXP BOT, V63, P3429, DOI 10.1093/jxb/err430; Hernandez M, 2015, APPL ENVIRON MICROB, V81, P2244, DOI 10.1128/AEM.03209-14; Huber KJ, 2014, INT J SYST EVOL MICR, V64, P1866, DOI 10.1099/ijs.0.060236-0; Jones RT, 2009, ISME J, V3, P442, DOI 10.1038/ismej.2008.127; Khamna S, 2009, WORLD J MICROB BIOT, V25, P649, DOI 10.1007/s11274-008-9933-x; Kim YE, 2014, J GEN APPL MICROBIOL, V60, P65, DOI 10.2323/jgam.60.65; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Kroppenstedt RM, 2006, PROKARYOTES: A HANDBOOK ON THE BIOLOGY OF BACTERIA, VOL 3, THIRD EDITION, P682, DOI 10.1007/0-387-30743-5_27; Kuzyakov Y, 2007, PLANT SOIL, V290, P293, DOI 10.1007/s11104-006-9162-8; Landi L, 2006, SOIL BIOL BIOCHEM, V38, P509, DOI 10.1016/j.soilbio.2005.05.021; Lesuffleur F, 2007, PLANT SOIL, V294, P235, DOI 10.1007/s11104-007-9249-x; Lewis CE, 1998, J SCI FOOD AGR, V77, P58, DOI 10.1002/(SICI)1097-0010(199805)77:1&lt;58::AID-JSFA2&gt;3.0.CO;2-J; Lewis CE, 1998, J SCI FOOD AGR, V77, P45, DOI [10.1002/(SICI)1097-0010(199805)77:1&lt;45::AID-JSFA1&gt;3.0.CO;2-S, 10.1002/(SICI)1097-0010(199805)77:1<45::AID-JSFA1>3.0.CO;2-S]; LIPTON DS, 1987, PLANT PHYSIOL, V85, P315, DOI 10.1104/pp.85.2.315; Llugany M, 2013, J PLANT NUTR SOIL SC, V176, P851, DOI 10.1002/jpln.201300096; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mandalari G, 2007, J APPL MICROBIOL, V103, P2056, DOI 10.1111/j.1365-2672.2007.03456.x; Mandalari G, 2010, LETT APPL MICROBIOL, V51, P83, DOI 10.1111/j.1472-765X.2010.02862.x; MARTENS R, 1982, SOIL BIOL BIOCHEM, V14, P315, DOI 10.1016/0038-0717(82)90046-3; Martens R, 2001, SOIL BIOL BIOCHEM, V33, P973, DOI 10.1016/S0038-0717(01)00001-3; MAXWELL CA, 1990, PLANT PHYSIOL, V93, P1552, DOI 10.1104/pp.93.4.1552; MAXWELL CA, 1989, PLANT PHYSIOL, V91, P842, DOI 10.1104/pp.91.3.842; McCune B., 2002, ANAL ECOLOGICAL COMM; McMurdie PJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003531; NANNIPIERI P, 1978, SOIL BIOL BIOCHEM, V10, P223, DOI 10.1016/0038-0717(78)90100-1; Nimnoi P, 2014, J PLANT NUTR, V37, P432, DOI 10.1080/01904167.2013.864308; Nimnoi P, 2010, WORLD J MICROB BIOT, V26, P193, DOI 10.1007/s11274-009-0159-3; ODHAM G, 1986, APPL ENVIRON MICROB, V52, P191, DOI 10.1128/AEM.52.1.191-196.1986; Paterson E, 2007, NEW PHYTOL, V173, P600, DOI 10.1111/j.1469-8137.2006.01931.x; Perez-Montano F, 2011, RES MICROBIOL, V162, P715, DOI 10.1016/j.resmic.2011.05.002; Probst TA, 2011, FORAGE GRAZINGLANDS, V9; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Qawasmeh A, 2012, J AGR FOOD CHEM, V60, P3381, DOI 10.1021/jf204105k; Rauha JP, 2000, INT J FOOD MICROBIOL, V56, P3, DOI 10.1016/S0168-1605(00)00218-X; Rozanov AS, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S12-S12; Ryu JY, 2005, J MICROBIOL BIOTECHN, V15, P1280; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Shaw LJ, 2008, SOIL BIOL BIOCHEM, V40, P528, DOI 10.1016/j.soilbio.2007.09.021; Shaw LJ, 2006, ENVIRON MICROBIOL, V8, P1867, DOI 10.1111/j.1462-2920.2006.01141.x; Shutsrirung A, 2013, SOIL SCI PLANT NUTR, V59, P322, DOI 10.1080/00380768.2013.776935; Sikora FJ, 2006, SOIL SCI SOC AM J, V70, P474, DOI 10.2136/sssaj2005.0164; Singh AK, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-122; Soininen TH, 2014, PHYTOCHEM ANALYSIS, V25, P220, DOI 10.1002/pca.2495; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tian XL, 2007, MICROB ECOL, V53, P700, DOI 10.1007/s00248-006-9163-4; Tomasi N, 2008, SOIL BIOL BIOCHEM, V40, P1971, DOI 10.1016/j.soilbio.2008.02.017; Toth E. M., 2014, PROKARYOTES ACTINOBA, P651, DOI [10.1007/978-3-642-30138-4_193, DOI 10.1007/978-3-642-30138-4_193]; Valdes M, 2005, APPL ENVIRON MICROB, V71, P460, DOI 10.1128/AEM.71.1.460-466.2005; Van Der Boogaart KG, 2006, GEOLOGICAL SOC SPECI; Vandeputte OM, 2011, MICROBIOL-SGM, V157, P2120, DOI 10.1099/mic.0.049338-0; Vandeputte OM, 2010, APPL ENVIRON MICROB, V76, P243, DOI 10.1128/AEM.01059-09; Ziegler M, 2013, J MICROBIOL METH, V94, P30, DOI 10.1016/j.mimet.2013.04.003	80	34	35	5	70	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0146555	10.1371/journal.pone.0146555	http://dx.doi.org/10.1371/journal.pone.0146555			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6CA	26752410	Green Published, Green Submitted, gold			2023-01-03	WOS:000367888100099
J	Kitzman, DW; Brubaker, P; Morgan, T; Haykowsky, M; Hundley, G; Kraus, WE; Eggebeen, J; Nicklas, BJ				Kitzman, Dalane W.; Brubaker, Peter; Morgan, Timothy; Haykowsky, Mark; Hundley, Gregory; Kraus, William E.; Eggebeen, Joel; Nicklas, Barbara J.			Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATRIURETIC PEPTIDE LEVELS; SINGLE-BLIND TRIAL; SKELETAL-MUSCLE; BARIATRIC SURGERY; PHYSICAL FUNCTION; WEIGHT-LOSS; ELDERLY-PATIENTS; INTOLERANCE; CAPACITY; ADULTS	IMPORTANCE More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese. Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL). OBJECTIVE To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF. DESIGN, SETTING, AND PARTICIPANTS Randomized, attention-controlled, 2 x 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center. Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation). INTERVENTIONS Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks. MAIN OUTCOMES AND MEASURES Exercise capacity measured as peak oxygen consumption ((V)over dotO(2), mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome). RESULTS Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control. Of these, 92 participants completed the trial. Exercise attendance was 84%(SD, 14%) and diet adherence was 99%(SD, 1%). By main effects analysis, peak (V)over dotO(2) was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001. The combination of exercise + diet was additive (complementary) for peak (V)over dotO(2) (joint effect, 2.5 mL/kg/min). There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08). The change in peak (V)over dotO(2) was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle: intermuscular fat ratio (r = 0.27; P = .02). There were no study-related serious adverse events. Body weight decreased by 7%(7 kg [SD, 1]) in the diet group, 3%(4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group. CONCLUSIONS AND RELEVANCE Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak (V)over dotO(2), and the effects may be additive. Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.	[Kitzman, Dalane W.; Hundley, Gregory] Wake Forest Sch Med, Dept Internal Med, Cardiol Sect, Winston Salem, NC 27157 USA; [Brubaker, Peter] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27109 USA; [Morgan, Timothy] Wake Forest Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; [Haykowsky, Mark] Univ Texas Arlington, Coll Nursing & Hlth Innovat, Arlington, TX USA; [Kraus, William E.] Duke Univ, Sch Med, Durham, NC USA; [Eggebeen, Joel] Emory Univ, Sch Med, Atlanta, GA USA; [Nicklas, Barbara J.] Wake Forest Sch Med, Geriatr & Gerontol Sect, Dept Internal Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; University of Texas System; University of Texas Arlington; Duke University; Emory University; Wake Forest University	Kitzman, DW (corresponding author), Wake Forest Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dkitzman@wfubmc.edu	Nicklas, Barbara/AAA-2781-2020	Haykowsky, Mark/0000-0002-7217-2747	National Institutes of Health [R01AG18915, P30AG021332, R01HL093713, R01AG020583]; Kermit Glenn Phillips II Chair in Cardiovascular Medicine at Wake Forest School of Medicine; Mortiz Chair in Geriatric Nursing Research in the College of Nursing and Health Innovation at The University of Texas at Arlington; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001420] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG021332, R01AG020583, R37AG018915, R01AG018915] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kermit Glenn Phillips II Chair in Cardiovascular Medicine at Wake Forest School of Medicine; Mortiz Chair in Geriatric Nursing Research in the College of Nursing and Health Innovation at The University of Texas at Arlington; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by research grants R01AG18915, P30AG021332, R01HL093713, and R01AG020583 from the National Institutes of Health. Also supported in part by the Kermit Glenn Phillips II Chair in Cardiovascular Medicine at Wake Forest School of Medicine (Dr Kitzman) and the Mortiz Chair in Geriatric Nursing Research in the College of Nursing and Health Innovation at The University of Texas at Arlington (Dr Haykowsky).	Anjan VY, 2012, AM J CARDIOL, V110, P870, DOI 10.1016/j.amjcard.2012.05.014; Beavers KM, 2013, AM J CLIN NUTR, V97, P552, DOI 10.3945/ajcn.112.047860; Beavers KM, 2013, J GERONTOL A-BIOL, V68, P80, DOI 10.1093/gerona/gls092; Bharadwaj M, 2013, GERONTOLOGIST, V53, P945; Bowen TS, 2015, EUR J HEART FAIL, V17, P263, DOI 10.1002/ejhf.239; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; Dhakal BP, 2015, CIRC-HEART FAIL, V8, P286, DOI 10.1161/CIRCHEARTFAILURE.114.001825; Edelmann F, 2011, J AM COLL CARDIOL, V58, P1780, DOI 10.1016/j.jacc.2011.06.054; Flynn KE, 2009, JAMA-J AM MED ASSOC, V301, P1451, DOI 10.1001/jama.2009.457; Haass M, 2011, CIRC-HEART FAIL, V4, P324, DOI 10.1161/CIRCHEARTFAILURE.110.959890; Haykowsky MJ, 2014, AM J CARDIOL, V113, P1211, DOI 10.1016/j.amjcard.2013.12.031; Haykowsky MJ, 2013, J GERONTOL A-BIOL, V68, P968, DOI 10.1093/gerona/glt011; Haykowsky MJ, 2012, J AM COLL CARDIOL, V60, P120, DOI 10.1016/j.jacc.2012.02.055; Haykowsky MJ, 2011, J AM COLL CARDIOL, V58, P265, DOI 10.1016/j.jacc.2011.02.055; Heinonen I, 2012, J APPL PHYSIOL, V112, P1059, DOI 10.1152/japplphysiol.00732.2011; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Kitzman DW, 2014, AM J PHYSIOL-HEART C, V306, pH1364, DOI 10.1152/ajpheart.00004.2014; Kitzman DW, 2013, J AM COLL CARDIOL, V62, P584, DOI 10.1016/j.jacc.2013.04.033; Kitzman DW, 2010, CIRC-HEART FAIL, V3, P659, DOI 10.1161/CIRCHEARTFAILURE.110.958785; Kitzman DW, 2002, JAMA-J AM MED ASSOC, V288, P2144, DOI 10.1001/jama.288.17.2144; Kritchevsky SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121993; Miranda WR, 2013, OBES SURG, V23, P1011, DOI 10.1007/s11695-013-0953-8; Morkedal B, 2014, J AM COLL CARDIOL, V63, P1071, DOI 10.1016/j.jacc.2013.11.035; Nicklas BJ, 2009, AM J CLIN NUTR, V89, P1043, DOI 10.3945/ajcn.2008.26938; Normandin Eve, 2015, Curr Nutr Rep, V4, P143, DOI 10.1007/s13668-015-0123-9; Owan TE, 2006, NEW ENGL J MED, V355, P251, DOI 10.1056/NEJMoa052256; Prior SJ, 2014, DIABETES CARE, V37, P1469, DOI 10.2337/dc13-2358; RECTOR TS, 1992, AM HEART J, V124, P1017, DOI 10.1016/0002-8703(92)90986-6; Redfield MM, 2013, JAMA-J AM MED ASSOC, V309, P1268, DOI 10.1001/jama.2013.2024; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Ryan D, 2014, OBESITY, V22, pS1, DOI 10.1002/oby.20819; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Scott JM, 2012, AM J CARDIOL, V110, P1809, DOI 10.1016/j.amjcard.2012.08.015; Sharma K, 2014, CIRC RES, V115, P79, DOI 10.1161/CIRCRESAHA.115.302922; Sjostrom L, 2012, JAMA-J AM MED ASSOC, V307, P56, DOI 10.1001/jama.2011.1914; Stavrakis S, 2013, AM J MED SCI, V345, P211, DOI 10.1097/MAJ.0b013e318271c012; Stehle JR, 2012, J GERONTOL A-BIOL, V67, P1212, DOI 10.1093/gerona/gls178; Villareal DT, 2011, NEW ENGL J MED, V364, P1218, DOI 10.1056/NEJMoa1008234; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilms B, 2013, OBES SURG, V23, P365, DOI 10.1007/s11695-012-0795-9; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019	41	411	417	5	76	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2016	315	1					36	46		10.1001/jama.2015.17346	http://dx.doi.org/10.1001/jama.2015.17346			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DA0YH	26746456	Green Accepted, Bronze			2023-01-03	WOS:000367523000013
J	Smith, RC; Amiaz, R; Si, TM; Maayan, L; Jin, H; Boules, S; Sershen, H; Li, CB; Ren, JJ; Liu, YH; Youseff, M; Lajtha, A; Guidotti, A; Weiser, M; Davis, JM				Smith, Robert C.; Amiaz, Revital; Si, Tian-Mei; Maayan, Lawrence; Jin, Hua; Boules, Sylvia; Sershen, Henry; Li, Chunbo; Ren, Juanjuan; Liu, Yanhong; Youseff, Mary; Lajtha, Abel; Guidotti, Alessandro; Weiser, Mark; Davis, John M.			Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial	PLOS ONE			English	Article							RECEPTOR PARTIAL AGONIST; SUSTAINED-RELEASE BUPROPION; NICOTINE NASAL SPRAY; ACETYLCHOLINE-RECEPTOR; TRANSDERMAL NICOTINE; CIGARETTE-SMOKING; GENERAL-PRACTICE; CESSATION; PLACEBO; ALPHA-4-BETA-2	Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains. Varenicline is a partial nicotinic agonist which is effective as an antismoking drug in cigarette smokers, although concerns have been raised about potential psychiatric side-effects. We conducted a double-blind placebo controlled study in 87 schizophrenic smokers to evaluate the effects of varenicline (2 mg/day) on measures of smoking, cognition, psychiatric symptoms, and side-effects in schizophrenic patients who were cigarette smokers. Varenicline significantly decreased cotinine levels (P<0.001), and other objective and subjective measures of smoking (P < .01), and responses on a smoking urges scale (P = .02), more than placebo. Varenicline did not improve scores on a cognitive battery designed to test the effect of drugs on cognitive performance in schizophrenia (the MATRICS battery), either in overall MATRICS battery Composite or individual Domain scores, more than placebo. There were no significant differences between varenicline vs. placebo effects on total symptom scores on psychiatric rating scales, PANSS, SANS, or Calgary Depression scales, and there were no significant drug effects in any of these scales sub-scores when we used Benjamin-Hochberg corrected significance levels (alpha = .05). Varenicline patients did not show greater side-effects than placebo treated patients at any time point when controlled for baseline side-effect scores. Our study supports the use of varenicline as a safe drug for smoking reduction in schizophrenia but not as a cognitive enhancer.	[Smith, Robert C.; Boules, Sylvia; Sershen, Henry; Youseff, Mary; Lajtha, Abel] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA; [Smith, Robert C.; Sershen, Henry; Lajtha, Abel] NYU, Dept Psychiat, Langone Med Ctr, New York, NY 10016 USA; [Amiaz, Revital; Weiser, Mark] Chaim Sheba Med Ctr, Ramat Gan, Israel; [Amiaz, Revital; Weiser, Mark] Sackler Sch Med, Tel Aviv, Israel; [Si, Tian-Mei; Liu, Yanhong] Peking Univ, Inst Mental Hlth, Key Lab Mental Hlth, Minist Hlth, Beijing 100871, Peoples R China; [Guidotti, Alessandro; Davis, John M.] Univ Illinois, Inst Psychiat, Chicago, IL USA; [Jin, Hua] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Jin, Hua] VA San Diego Healthcare Syst, San Diego, CA USA; [Li, Chunbo; Ren, Juanjuan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai Key Lab Psychot Disorders, Shanghai 200030, Peoples R China; [Maayan, Lawrence] Albany Med Ctr, Albany, NY USA	Nathan Kline Institute for Psychiatric Research; New York University; NYU Langone Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Peking University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Shanghai Jiao Tong University; Albany Medical College	Smith, RC (corresponding author), Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA.	rsmith@nki.rfmh.org	jin, hua/AAX-1569-2020; liu, yan/HGV-1365-2022; liu, yan/HCI-5542-2022; Amiaz, Revital/AAK-4576-2021	Li, Chunming/0000-0002-4159-7048	Stanley Medical Research Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH093348] Funding Source: NIH RePORTER	Stanley Medical Research Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by a grant from Stanley Medical Research Foundation (www.stanelyresearch.org). Pfizer Pharmaceuticals (Pfizer.com) supplied active and placebo varenicline. The design of the study and analysis of the data was done independently by the principal investigator. The Stanley Foundation and Pfizer received reports of the analysis of the study but had no other role in the presentation of data at meetings or writing of the paper for publication. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADDINGTON D, 1990, SCHIZOPHR RES, V3, P247, DOI 10.1016/0920-9964(90)90005-R; Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320; ADLER LE, 1993, AM J PSYCHIAT, V150, P1856; Andreasen NC, 1983, SCALE ASSESSMENT NEG; Anthenelli RM, 2013, ANN INTERN MED, V159, P390, DOI 10.7326/0003-4819-159-6-201309170-00005; Atbasoglu EC, 2003, PSYCHOPATHOLOGY, V36, P263, DOI 10.1159/000073452; Barr RS, 2008, NEUROPSYCHOPHARMACOL, V33, P480, DOI 10.1038/sj.npp.1301423; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Buggy Y, 2013, DRUG SAFETY, V36, P521, DOI 10.1007/s40264-013-0046-6; Coe JW, 2005, J MED CHEM, V48, P3474, DOI 10.1021/jm050069n; Cox L S, 2001, Nicotine Tob Res, V3, P7, DOI 10.1080/14622200020032051; Depatie L, 2002, NEUROPSYCHOPHARMACOL, V27, P1056, DOI 10.1016/S0893-133X(02)00372-X; Etter JF, 2003, NEUROPSYCHOPHARMACOL, V28, P359, DOI 10.1038/sj.npp.1300030; Evins AE, 2008, J CLIN PSYCHIAT, V69, P1016, DOI 10.4088/JCP.v69n0620a; Evins AE, 2007, J CLIN PSYCHOPHARM, V27, P380, DOI 10.1097/01.jcp.0b013e3180ca86fa; Evins AE, 2014, JAMA-J AM MED ASSOC, V311, P145, DOI 10.1001/jama.2013.285113; Evins AE, 2005, J CLIN PSYCHOPHARM, V25, P218, DOI 10.1097/01.jcp.0000162802.54076.18; Foulds J, 2013, NICOTINE TOB RES, V21, P21; FREEDMAN R, 1995, BIOL PSYCHIAT, V38, P22, DOI 10.1016/0006-3223(94)00252-X; Freedman R, 2000, J CHEM NEUROANAT, V20, P299, DOI 10.1016/S0891-0618(00)00109-5; Freedman R, 2007, AM J PSYCHIAT, V164, P1269, DOI 10.1176/appi.ajp.2007.07020326; George TP, 2002, NEUROPSYCHOPHARMACOL, V26, P75, DOI 10.1016/S0893-133X(01)00296-2; Gibbons RD, 2013, AM J PSYCHIAT, V170, P1460, DOI 10.1176/appi.ajp.2013.12121599; Gold JM, 1999, AM J PSYCHIAT, V156, P1944; Gonzales D, 2006, JAMA-J AM MED ASSOC, V296, P47, DOI 10.1001/jama.296.1.47; Hong LE, 2011, ARCH GEN PSYCHIAT, V68, P1195, DOI 10.1001/archgenpsychiatry.2011.83; Jorenby DE, 2006, JAMA-J AM MED ASSOC, V296, P56, DOI 10.1001/jama.296.1.56; Jubelt LE, 2008, PSYCHOPHARMACOLOGY, V199, P89, DOI 10.1007/s00213-008-1133-8; Kasliwal R, 2009, DRUG SAFETY, V32, P499, DOI 10.2165/00002018-200932060-00006; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Keefe RSE, 2011, SCHIZOPHR RES, V125, P161, DOI 10.1016/j.schres.2010.09.015; Kern R, 2008, MATRICS CONSENSUS 2; Kern RS, 2008, AM J PSYCHIAT, V165, P214, DOI 10.1176/appi.ajp.2007.07010043; Lancon C, 2000, SCHIZOPHR RES, V42, P231, DOI 10.1016/S0920-9964(99)00129-2; Leonard S, 2002, ARCH GEN PSYCHIAT, V59, P1085, DOI 10.1001/archpsyc.59.12.1085; Levin ED, 1996, NEUROPSYCHOPHARMACOL, V15, P429, DOI 10.1016/S0893-133X(96)00018-8; Liu ME, 2011, PSYCHIAT RES, V190, P79, DOI 10.1016/j.psychres.2011.04.018; Mihalak KB, 2006, MOL PHARMACOL, V70, P801, DOI 10.1124/mol.106.025130; Morstad AE, 2008, ANN PHARMACOTHER, V42, P288, DOI 10.1345/aph.1K511; Nides M, 2006, ARCH INTERN MED, V166, P1561, DOI 10.1001/archinte.166.15.1561; Pachas GN, 2012, J DUAL DIAGN, V8, P117, DOI 10.1080/15504263.2012.663675; Patterson F, 2009, BIOL PSYCHIAT, V65, P144, DOI 10.1016/j.biopsych.2008.08.028; Philip NS, 2009, J CLIN PSYCHIAT, V70, P1026, DOI 10.4088/JCP.08m04441; Rajji TK, 2013, AM J GERIAT PSYCHIAT, V21, P108, DOI 10.1016/j.jagp.2012.10.011; Roh S, 2014, PSYCHOPHARMACOLOGY, V231, P765, DOI 10.1007/s00213-013-3286-3; Rollema H, 2007, NEUROPHARMACOLOGY, V52, P985, DOI 10.1016/j.neuropharm.2006.10.016; Roseberry JE, 2014, SCHIZOPHR RES, V159, P188, DOI 10.1016/j.schres.2014.08.004; Shim JC, 2012, NEUROPSYCHOPHARMACOL, V37, P660, DOI 10.1038/npp.2011.238; Smith RC, 2006, NEUROPSYCHOPHARMACOL, V31, P637, DOI 10.1038/sj.npp.1300881; Smith RC, 2002, NEUROPSYCHOPHARMACOL, V27, P479, DOI 10.1016/S0893-133X(02)00324-X; Smith RC, 2002, SUBST ABUS, V22, P479; Smith RC, 2009, SCHIZOPHR RES, V110, P149, DOI 10.1016/j.schres.2009.02.001; Tonstad S, 2010, DRUG SAFETY, V33, P289, DOI 10.2165/11319180-000000000-00000; Wallace TL, 2013, EXPERT OPIN THER TAR, V17, P139, DOI 10.1517/14728222.2013.736498; Weiner E, 2010, NEUROPSYCHOPHARMACOL, V35, P2274, DOI 10.1038/npp.2010.101; Williams JM, 2012, J CLIN PSYCHIAT, V73, P654, DOI 10.4088/JCP.11m07522; Wing VC, 2013, SCHIZOPHR RES, V149, P190, DOI 10.1016/j.schres.2013.06.032	57	48	49	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2016	11	1							e0143490	10.1371/journal.pone.0143490	http://dx.doi.org/10.1371/journal.pone.0143490			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA4VZ	26730716	Green Submitted, gold, Green Published			2023-01-03	WOS:000367801400006
J	Cao, L; Yao, GY; Liu, MF; Chen, LJ; Hu, XL; Ye, CS				Cao, Li; Yao, Guang-yu; Liu, Min-feng; Chen, Lu-jia; Hu, Xiao-lei; Ye, Chang-sheng			Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials	PLOS ONE			English	Article							PATHOLOGICAL COMPLETE RESPONSE; SYSTEMIC TREATMENT; OPEN-LABEL; PHASE-3 TRIAL; DOCETAXEL; SURVIVAL; CYCLOPHOSPHAMIDE; ASSOCIATION; MASTECTOMY; THERAPY	Purpose Results from previous randomised controlled trials (RCTs) investigating whether the addition of bevacizumab to neoadjuvant chemotherapy (NAC) could statistically significantly increase the pathological complete response (pCR) and to identify which subgroup would benefit most from such regimens have produced conflicting results. This meta-analysis was designed to assess the efficacy and safety of bevacizumab plus chemotherapy compared with chemotherapy alone in the neoadjuvant setting. Methods A literature search of MEDLINE, EMBASE, Web of Science, and the Cochrane library was performed to identify eligible studies. The primary endpoint of interest was pCR. The secondary endpoints were clinical complete rate (cCR), surgery rate, breast-conserving surgery (BCS) rate, and toxicity. The meta-analysis was performed using Review Manager software version 5.3. Results Nine RCTs matched the selection criteria, yielding a total of 4967 patients (bevacizumab plus chemotherapy: 50.1%, chemotherapy alone: 49.9%). The results of this meta-analysis demonstrated that the addition of bevacizumab to NAC significantly increased the pCR rate (odds ratio [OR] = 1.34 [1.18-1.54]; P < 0.0001) compared with chemotherapy alone. Subgroup analysis showed that the effect of bevacizumab was more pronounced in patients with HER2-negative cancer (OR = 1.34 [1.17-1.54]; P < 0.0001) compared with HER2-positive cancer (OR = 1.69 [0.90-3.20]; P = 0.11). Similarly, in patients with HER2-negative cancer, the effect of bevacizumab was also more pronounced in patients with HR-negative cancer (OR = 1.38 [1.09-1.74]; P = 0.007) compared with HR-positive cancer (OR = 1.36 [0.78-2.35]; P = 0.27). No significant differences were observed between the groups with respect to cCR, surgery rate, or BCS rate. Additionally bevacizumab was associated with a higher incidence of neutropenia, febrile neutropenia, and hand-foot syndrome. Conclusions Higher proportions of patients achieved pCR when bevacizumab was added to NAC compared with when they received chemotherapy alone; acceptable toxicities were also found. Subgroup analysis demonstrated that patients with histologically confirmed HER2-negative and HR-negative breast cancer benefited the most.	[Cao, Li; Yao, Guang-yu; Liu, Min-feng; Chen, Lu-jia; Hu, Xiao-lei; Ye, Chang-sheng] Southern Med Univ, Nanfang Hosp, Breast Ctr, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China	Ye, CS (corresponding author), Southern Med Univ, Nanfang Hosp, Breast Ctr, Guangzhou, Guangdong, Peoples R China.	yechangsheng2015@126.com			President Foundation of Nanfang Hospital, Southern Medical University [2014B017]	President Foundation of Nanfang Hospital, Southern Medical University	The President Foundation of Nanfang Hospital, Southern Medical University (No. 2014B017). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adkisson CD, 2012, ANN SURG ONCOL, V19, P1129, DOI 10.1245/s10434-011-2080-x; Alvarez RH, 2011, ONCOLOGIST, V16, P1684, DOI 10.1634/theoncologist.2011-0113; Bear HD, 2012, NEW ENGL J MED, V366, P310, DOI 10.1056/NEJMoa1111097; Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005; Berruti A, 2014, J CLIN ONCOL, V32, P3883, DOI 10.1200/JCO.2014.55.2836; Berruti A, 2008, ONCOLOGIST, V13, P1137, DOI 10.1634/theoncologist.2008-0162; Brouwers B, 2008, TUMOR BIOL, V29, P211, DOI 10.1159/000152938; Brufsky AM, 2011, J CLIN ONCOL, V29, P4286, DOI 10.1200/JCO.2010.34.1255; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chia S, 2008, J CLIN ONCOL, V26, P786, DOI 10.1200/JCO.2008.15.0243; Colleoni M, 2004, CLIN CANCER RES, V10, P6622, DOI 10.1158/1078-0432.CCR-04-0380; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Coudert B, 2014, LANCET ONCOL, V15, P1493, DOI 10.1016/S1470-2045(14)70475-9; de Azambuja E, 2014, LANCET ONCOL, V15, P1137, DOI 10.1016/S1470-2045(14)70320-1; Earl HM, 2015, LANCET ONCOL, V16, P656, DOI 10.1016/S1470-2045(15)70137-3; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Engebraaten O, 2015, CANC RES, V75; Gerber B, 2013, ANN ONCOL, V24, P2978, DOI 10.1093/annonc/mdt361; Golshan M, 2015, ANN SURG, V262, P434, DOI 10.1097/SLA.0000000000001417; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Houssami N, 2012, EUR J CANCER, V48, P3342, DOI 10.1016/j.ejca.2012.05.023; Hurvitz SA, 2012, CANC RES, V72; Jebbink M, 2015, BREAST CANCER RES TR, V153, P145, DOI 10.1007/s10549-015-3510-4; Kaufmann M, 2006, J CLIN ONCOL, V24, P1940, DOI 10.1200/JCO.2005.02.6187; Killelea BK, 2015, J AM COLL SURGEONS, V220, P1063, DOI 10.1016/j.jamcollsurg.2015.02.011; Lohmann AE, 2012, CURR TREAT OPTION ON, V13, P249, DOI 10.1007/s11864-012-0181-9; Luangdilok S, 2014, J BREAST CANCER, V17, P376, DOI 10.4048/jbc.2014.17.4.376; Makris A, 1998, ANN ONCOL, V9, P1179, DOI 10.1023/A:1008400706949; Mauri D, 2005, JNCI-J NATL CANCER I, V97, P188, DOI 10.1093/jnci/dji021; Metcalfe KA, 2008, J CLIN ONCOL, V26, P1093, DOI 10.1200/JCO.2007.12.6078; Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Nahleh ZA, 2015, CANC RES, V75; Ring AE, 2004, BRIT J CANCER, V91, P2012, DOI 10.1038/sj.bjc.6602235; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Sikov WM, 2015, J CLIN ONCOL, V33, P13, DOI 10.1200/JCO.2014.57.0572; Steger GG, 2015, CANC RES, V75; Valachis A, 2014, BREAST CANCER RES TR, V144, P443, DOI 10.1007/s10549-014-2890-1; van der Hage JA, 2001, J CLIN ONCOL, V19, P4224, DOI 10.1200/JCO.2001.19.22.4224; von Minckwitz G, 2014, ANN ONCOL, V25, P2363, DOI 10.1093/annonc/mdu455; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; von Minckwitz G, 2012, NEW ENGL J MED, V366, P299, DOI 10.1056/NEJMoa1111065; Wang-Lopez Q, 2015, CRIT REV ONCOL HEMAT, V95, P88, DOI 10.1016/j.critrevonc.2015.02.011	43	18	19	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2015	10	12							e0145442	10.1371/journal.pone.0145442	http://dx.doi.org/10.1371/journal.pone.0145442			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0TN	26717149	Green Published, Green Submitted, gold			2023-01-03	WOS:000367510500035
J	Tanaka, Y; Aoyagi, K; Minashi, K; Komatsuzaki, R; Komatsu, M; Chiwaki, F; Tamaoki, M; Nishimura, T; Takahashi, N; Oda, I; Tachimori, Y; Arao, T; Nishio, K; Kitano, S; Narumi, K; Aoki, K; Fujii, S; Ochiai, A; Yoshida, T; Muto, M; Yamada, Y; Sasaki, H				Tanaka, Yosuke; Aoyagi, Kazuhiko; Minashi, Keiko; Komatsuzaki, Rie; Komatsu, Masayuki; Chiwaki, Fumiko; Tamaoki, Masashi; Nishimura, Takao; Takahashi, Naoki; Oda, Ichiro; Tachimori, Yuji; Arao, Tokuzo; Nishio, Kazuto; Kitano, Shigehisa; Narumi, Kenta; Aoki, Kazunori; Fujii, Satoshi; Ochiai, Atsushi; Yoshida, Teruhiko; Muto, Manabu; Yamada, Yasuhide; Sasaki, Hiroki			Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy	PLOS ONE			English	Article							DEFINITIVE CHEMORADIOTHERAPY; PHASE-II; CANCER; IRRADIATION; CHEMOTHERAPY; PHENOTYPE; PROGNOSIS; THERAPY; IMPACT	Definitive chemoradiotherapy (CRT) is a less invasive therapy for esophageal squamous cell carcinoma (ESCC). Five-year survival rate of locally advanced ESCC patients by definitive CRT were 37%. We previously reported that tumor-specific cytotoxic T-lymphocyte (CTL) activation signatures were preferentially found in long-term survivors. However, it is unknown whether the CTL activation is actually driven by CRT. We compared gene expression profiles among pre- and post-treatment biopsy specimens of 30 ESCC patients and 121 pre-treatment ESCC biopsy specimens. In the complete response (CR) cases, 999 overexpressed genes including at least 234 tumor-specific CTL-activation associated genes such as IFNG, PRF1, and GZMB, were found in post-treatment biopsy specimens. Clustering analysis using expression profiles of these 234 genes allowed us to distinguish the immune-activated cases, designating them as I-type, from other cases. However, despite the better CR rate in the I-type, overall survival was not significantly better in both these 30 cases and another 121 cases. Further comparative study identified a series of epithelial to mesenchymal transition-related genes overexpressed in the early relapse cases. Importantly, the clinical outcome of CDH2-negative cases in the I-type was significantly better than that of the CDH2-positive cases in the I-type. Furthermore, NK cells, which were activated by neutrophils-producing S100A8/S100A9, and CTLs were suggested to cooperatively enhance the effect of CRT in the CDH2-negative I-type. These results suggested that CTL gene activation may provide a prognostic advantage in ESCCs with epithelial characteristics.	[Tanaka, Yosuke; Takahashi, Naoki; Yamada, Yasuhide] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan; [Oda, Ichiro] Natl Canc Ctr, Dept Gastrointestinal Oncol & Endoscopy, Tokyo, Japan; [Tachimori, Yuji] Natl Canc Ctr, Dept Esophageal Surg, Tokyo, Japan; [Kitano, Shigehisa] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan; [Aoyagi, Kazuhiko; Komatsuzaki, Rie; Komatsu, Masayuki; Chiwaki, Fumiko; Tamaoki, Masashi; Nishimura, Takao; Sasaki, Hiroki] Natl Canc Ctr, Dept Translat Oncol, Tokyo, Japan; [Narumi, Kenta; Aoki, Kazunori] Natl Canc Ctr, Div Mol & Cellular Med, Tokyo, Japan; [Yoshida, Teruhiko] Natl Canc Ctr, Div Genet, Tokyo, Japan; [Fujii, Satoshi; Ochiai, Atsushi] Fundamental Innovat Oncol Core Ctr, Natl Canc Ctr Res Inst, Tokyo, Japan; [Arao, Tokuzo; Nishio, Kazuto] Kinki Univ, Fac Med, Dept Genome Biol, Osaka, Japan; [Minashi, Keiko] Chiba Canc Ctr, Dept Clin Trial Promot, Chiba 2608717, Japan; [Muto, Manabu] Kyoto Univ, Dept Therapeut Oncol, Kyoto, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Kindai University (Kinki University); Chiba Cancer Center; Kyoto University	Muto, M (corresponding author), Kyoto Univ, Dept Therapeut Oncol, Kyoto, Japan.	mmuto@kuhp.kyoto-u.ac.jp; yamada0304@aol.com; hksasaki@ncc.go.jp	Yamada, Yasuhide/AAH-9124-2020		National Institute of Biomedical Innovation (the Advanced Research for Medical Products Mining Programme); Japan Agency for Medical Research and Development (Practical Research for Innovative Cancer Control); National Cancer Center Research and Development Fund; Ministry of Education, Culture, Sports, Science and Technology of Japan; Princess Takamatsu Cancer Research Fund; Foundation of Promotion of Cancer Research in Japan; Grants-in-Aid for Scientific Research [15K14389] Funding Source: KAKEN	National Institute of Biomedical Innovation (the Advanced Research for Medical Products Mining Programme); Japan Agency for Medical Research and Development (Practical Research for Innovative Cancer Control)(Japan Agency for Medical Research and Development (AMED)); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Princess Takamatsu Cancer Research Fund; Foundation of Promotion of Cancer Research in Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by The National Institute of Biomedical Innovation (the Advanced Research for Medical Products Mining Programme), Japan Agency for Medical Research and Development (Practical Research for Innovative Cancer Control), National Cancer Center Research and Development Fund, The Ministry of Education, Culture, Sports, Science and Technology of Japan, and The Princess Takamatsu Cancer Research Fund. Dr M Komatsu was the recipient of a Research Resident Fellowship from the Foundation of Promotion of Cancer Research in Japan.	AKIYAMA H, 1994, ANN SURG, V220, P364, DOI 10.1097/00000658-199409000-00012; Ando N, 2012, ANN SURG ONCOL, V19, P68, DOI 10.1245/s10434-011-2049-9; Ashida A, 2006, INT J ONCOL, V28, P1345; Barrett DM, 2014, ANNU REV MED, V65, P333, DOI 10.1146/annurev-med-060512-150254; Chakraborty M, 2003, J IMMUNOL, V170, P6338, DOI 10.4049/jimmunol.170.12.6338; Cho Y, 2003, CANCER RES, V63, P1555; Costantini C, 2011, J LEUKOCYTE BIOL, V89, P221, DOI 10.1189/jlb.0510250; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Garnett CT, 2004, CANCER RES, V64, P7985, DOI 10.1158/0008-5472.CAN-04-1525; Gebski V, 2007, LANCET ONCOL, V8, P226, DOI 10.1016/S1470-2045(07)70039-6; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Ishikura S, 2003, J CLIN ONCOL, V21, P2697, DOI 10.1200/JCO.2003.03.055; Kato K, 2013, JPN J CLIN ONCOL, V43, P608, DOI 10.1093/jjco/hyt048; Kato K, 2011, INT J RADIAT ONCOL, V81, P684, DOI 10.1016/j.ijrobp.2010.06.033; Komatsu M, 2014, EPIGENOMICS-UK, V6, P567, DOI [10.2217/EPI.14.56, 10.2217/epi.14.56]; Lesokhin AM, 2012, CANCER RES, V72, P876, DOI 10.1158/0008-5472.CAN-11-1792; Mei Z, 2014, BRIT J CANCER, V110, P1595, DOI 10.1038/bjc.2014.46; Menetrier-Caux C, 2012, TARGET ONCOL, V7, P15, DOI 10.1007/s11523-012-0208-y; Narumi K, 2015, J IMMUNOL, V194, P5539, DOI 10.4049/jimmunol.1402301; Ohtsu A, 1999, J CLIN ONCOL, V17, P2915, DOI 10.1200/JCO.1999.17.9.2915; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; ROTH JA, 1994, SEMIN ONCOL, V21, P453; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Schumacher K, 2001, CANCER RES, V61, P3932; Tanabe S, 2014, INT J ONCOL, V44, P1955, DOI 10.3892/ijo.2014.2387; Tang C, 2014, CANCER IMMUNOL RES, V2, P831, DOI 10.1158/2326-6066.CIR-14-0069; Tsuchikawa T, 2012, ANN SURG ONCOL, V19, P1713, DOI 10.1245/s10434-011-1906-x	28	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2015	10	12							e0143804	10.1371/journal.pone.0143804	http://dx.doi.org/10.1371/journal.pone.0143804			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7OL	26625258	Green Published, gold			2023-01-03	WOS:000365891600053
J	Wolf, C; Pauly, A; Mayr, A; Gromer, T; Lenz, B; Kornhuber, J; Friedland, K				Wolf, Carolin; Pauly, Anne; Mayr, Andreas; Groemer, Teja; Lenz, Bernd; Kornhuber, Johannes; Friedland, Kristina			Pharmacist-Led Medication Reviews to Identify and Collaboratively Resolve Drug-Related Problems in Psychiatry - A Controlled, Clinical Trial	PLOS ONE			English	Article							APPROPRIATENESS INDEX; ERRORS; INTERVENTION; EVENTS; CARE; IDENTIFICATION; CLASSIFICATION; DOCUMENTATION; HOSPITALS; OUTCOMES	Aim of the study This prospective, controlled trial aimed to assess the effect of pharmacist-led medication reviews on the medication safety of psychiatric inpatients by the resolution of Drug-Related Problems (DRP). Both the therapy appropriateness measured with the Medication Appropriateness Index (MAI) and the number of unsolved DRP per patient were chosen as primary outcome measures. Methods Depending on their time of admission, 269 psychiatric patients that were admitted to a psychiatric university hospital were allocated in control (09/2012-03/2013) or intervention group (05/2013-12/2013). In both groups, DRP were identified by comprehensive medication reviews by clinical pharmacists at admission, during the hospital stay, and at discharge. In the intervention group, recommendations for identified DRP were compiled by the pharmacists and discussed with the therapeutic team. In the control group, recommendations were not provided except for serious or life threatening DRP. As a primary outcome measure, the changes in therapy appropriateness from admission to discharge as well as from admission to three months after discharge (follow-up) assessed with the MAI were compared between both groups. The second primary outcome was the number of unsolved DRP per patient after completing the study protocol. The DRP type, the relevance and the potential of drugs to cause DRP were also evaluated. Results The intervention led to a reduced MAI score by 1.4 points per patient (95% confidence interval [CI]: 0.8-2.0) at discharge and 1.3 points (95% CI: 0.7-1.9) at follow-up compared with controls. The number of unsolved DRP in the intervention group was 1.8 (95% CI: 1.5-2.1) less than in control. Conclusion The pharmaceutical medication reviews with interdisciplinary discussion of identified DRP appears to be a worthy strategy to improve medication safety in psychiatry as reflected by less unsolved DRP per patient and an enhanced appropriateness of therapy. The promising results of this trial likely warrant further research that evaluates direct clinical outcomes and health-related costs.	[Wolf, Carolin; Pauly, Anne; Friedland, Kristina] Univ Erlangen Nurnberg, Mol & Clin Pharm, D-91054 Erlangen, Germany; [Mayr, Andreas] Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, D-91054 Erlangen, Germany; [Groemer, Teja; Lenz, Bernd; Kornhuber, Johannes] Univ Erlangen Nurnberg, Dept Psychiat & Psychotherapy, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Friedland, K (corresponding author), Univ Erlangen Nurnberg, Mol & Clin Pharm, D-91054 Erlangen, Germany.	Kristina.leuner@fau.de	Kornhuber, Johannes/B-9613-2014; Friedland, Kristina/G-4651-2015	Kornhuber, Johannes/0000-0002-8096-3987; Mayr, Andreas/0000-0001-7106-9732; Friedland, Kristina/0000-0001-8603-5957; Lenz, Bernd/0000-0001-6086-0924	Forederinitiative Pharmazeutische Betreuung e.v	Forederinitiative Pharmazeutische Betreuung e.v	This work was supported by Forederinitiative Pharmazeutische Betreuung e.v, http://www.foerderinitiative.de/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alderman CP, 1997, J CLIN PHARM THER, V22, P27, DOI 10.1046/j.1365-2710.1997.95975959.x; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bondesson A, 2013, EUR J CLIN PHARMACOL, V69, P647, DOI 10.1007/s00228-012-1368-5; Brownlie K, 2014, INT J CLIN PHARM-NET, V36, P303, DOI 10.1007/s11096-013-9875-8; Burnett KM, 2009, AM J HEALTH-SYST PH, V66, P854, DOI 10.2146/ajhp080176; Campbell AR, 2011, AM J PHARM EDUC, V75; Dolder C, 2008, AM J HEALTH-SYST PH, V65, P1795, DOI 10.2146/ajhp060448; Fick DM, 2001, POTENTIALLY INAPPROP, V7; GANSO M, 2007, KRANKENHAUSPHARMAZIE, V28, P273; GANSO M, 2009, KRANKENHAUSPHARMAZIE, V30, P349; Gill-Banham S, 2003, PSYCHIAT B, V27, P208; Gillespie U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062401; Gillespie U, 2009, ARCH INTERN MED, V169, P894, DOI 10.1001/archinternmed.2009.71; Graabaek T, 2013, BASIC CLIN PHARMACOL, V112, P359, DOI 10.1111/bcpt.12062; Grasso B, 2007, J PHARM FINANC EC PO, V15, P73, DOI [10.1300/J371v15n0404, DOI 10.1300/J371V15N04_04]; Grasso BC, 2003, PSYCHIAT SERV, V54, P677, DOI 10.1176/appi.ps.54.5.677; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Haynes RB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub3; Hellstrom LM, 2011, EUR J CLIN PHARMACOL, V67, P741, DOI 10.1007/s00228-010-0982-3; Ito H, 2003, INT J QUAL HEALTH C, V15, P207, DOI 10.1093/intqhc/mzg038; Keers RN, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006084; Krahenbuhl-Melcher A, 2007, DRUG SAFETY, V30, P379; KUNKEL M, 2009, KRANKENHAUSPHARMAZIE, V30, P156; Mann K, 2008, WORLD J BIOL PSYCHIA, V9, P24, DOI 10.1080/15622970601178056; Muller F, 2014, EUR J CLIN PHARMACOL, V70, P727, DOI 10.1007/s00228-014-1665-2; National Coordinating Council for Medication Error Reporting and Prevention, WHAT IS MED ERR; Pharmaceutical Care Network Europe Foundation, PCNE CLASS V 6 2; Post TW, UPTODATE; Preston, STOCKLEYS DRUG INTER; Procyshyn RM, 2010, CNS DRUGS, V24, P595, DOI 10.2165/11533710-000000000-00000; Rothschild JM, 2007, GEN HOSP PSYCHIAT, V29, P156, DOI 10.1016/j.genhosppsych.2006.12.002; SAMSA GP, 1994, J CLIN EPIDEMIOL, V47, P891, DOI 10.1016/0895-4356(94)90192-9; Schaefer M, 2002, PHARM WORLD SCI, V24, P120, DOI 10.1023/A:1019543029936; SCHMADER K, 1994, J AM GERIATR SOC, V42, P1241; Schmader KE, 1997, ANN PHARMACOTHER, V31, P529, DOI 10.1177/106002809703100501; Senst BL, 2001, AM J HEALTH-SYST PH, V58, P1126, DOI 10.1093/ajhp/58.12.1126; Soerensen AL, 2013, RISK MANAG HEALTHC P, V6, P23, DOI 10.2147/RMHP.S47723; Spinewine A, 2006, J AM GERIATR SOC, V54, P720, DOI 10.1111/j.1532-5415.2006.00668_8.x; Spinewine A, 2007, J AM GERIATR SOC, V55, P658, DOI 10.1111/j.1532-5415.2007.01132.x; Stubbs J, 2004, HOSP PHARM, V11, P203; [Task Force on Patient Safety American Psychiatric Association], 2003, REC APA BOARD TRUST; van den Bemt PMLA, 2000, DRUG SAFETY, V22, P321, DOI 10.2165/00002018-200022040-00005; Viktil KK, 2008, BASIC CLIN PHARMACOL, V102, P275, DOI 10.1111/j.1742-7843.2007.00206.x; Viktil KK, 2006, PHARMACOEPIDEM DR S, V15, P667, DOI 10.1002/pds.1238	46	22	22	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2015	10	11							e0142011	10.1371/journal.pone.0142011	http://dx.doi.org/10.1371/journal.pone.0142011			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV6RT	26544202	Green Submitted, Green Published, gold			2023-01-03	WOS:000364398700070
J	Campbell, TC				Campbell, Toby C.			When Minutes Matter	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Campbell, Toby C.] Univ Wisconsin, Dept Med, Div Hematol Oncol, Madison, WI 53706 USA; [Campbell, Toby C.] Univ Wisconsin, Sch Nursing, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Campbell, TC (corresponding author), Univ Wisconsin, Dept Med, Div Hematol Oncol, Madison, WI 53706 USA.	tcc@medicine.wisc.edu	Campbell, Toby C/AAN-3249-2021	Campbell, Toby C/0000-0003-4910-1112					0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2015	314	17					1799	1800		10.1001/jama.2015.9204	http://dx.doi.org/10.1001/jama.2015.9204			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV0RO	26529156				2023-01-03	WOS:000363960200009
J	Wu, PY; Yang, SH; Wong, TC; Chen, TW; Chen, HH; Chen, TH; Chen, YT				Wu, Pei-Yu; Yang, Shwu-Huey; Wong, Te-Chih; Chen, Tzen-Wen; Chen, His-Hsien; Chen, Tso-Hsiao; Chen, Yu-Tong			Association of Processed Meat Intake with Hypertension Risk in Hemodialysis Patients: A Cross-Sectional Study	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; ARTERY CALCIFICATION; DIETARY ASSESSMENT; SODIUM-INTAKE; ENERGY-INTAKE; ALL-CAUSE; MORTALITY	In this cross-sectional study, we hypothesized that hemodialysis patients consuming greater processed meat is associated with hypertension risk, which can be partly explained by the high sodium content in processed meat. From September 2013 to May 2014, one hundred and four patients requiring chronic hemodialysis treatment were recruited from hemodialysis centers. Data on systolic blood pressure and diastolic blood pressure before receiving dialysis, and 3-day dietary records of the recruited patients were collected. HD patients with systolic and diastolic blood pressures greater than 140 mmHg and higher than 90 mmHg, respectively, were considered hypertension risk. Protein foods were divided into 4 categories: red meat, white meat, soybeans, and processed meat (e.g., sausage and ham). In a model adjusted for energy intake and hypertension history, additional servings of processed meats was positively associated to systolic blood pressure >140 mmHg (odds ratio [95% confidence interval]: 2.1 [1.0-4.3]), and diastolic blood pressure > 90 mmHg (odds ratio: 2.5 [1.2-5.5]). After adjustment for dietary sodium contents or body mass index (BMI), most associations were substantially attenuated and were no longer significant. In systolic blood pressure greater than140 mmHg, one serving per day of red meats (beta = -1.22, P < .05) and white meats (beta = -0. 75, P = .05) was associated with a reduced risk compared with one serving per day of processed meats. Similarly, compared with one serving per day of processed meat, a reduced risk of diastolic blood pressure higher than 90 mmHg was associated with one serving per day of red meat (beta = -1. 59, P < .05), white meat (beta = -0. 62, P < .05). Thus, in these hemodialysis patients, intake of processed meat is significantly positively associated with higher blood pressure risk, and both sodium contents in processed meat and BMI significantly contributes to this association.	[Wu, Pei-Yu; Yang, Shwu-Huey; Wong, Te-Chih; Chen, Yu-Tong] Taipei Med Univ, Sch Nutr & Hlth Sci, Taipei, Taiwan; [Chen, Tzen-Wen; Chen, His-Hsien] Taipei Med Univ Hosp, Dept Nephrol, Taipei, Taiwan; [Chen, Tso-Hsiao] Wan Fang Med Ctr, Dept Nephrol, Taipei, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Municipal WanFang Hospital	Yang, SH (corresponding author), Taipei Med Univ, Sch Nutr & Hlth Sci, Taipei, Taiwan.	sherry@tmu.edu.tw	Wong, Te-Chih/AAH-7667-2020	Wong, Te-Chih/0000-0002-5798-1060	Ministry of Science and Technology (Taiwan);  [NSC-102-2320-B-038-026]	Ministry of Science and Technology (Taiwan)(Ministry of Science and Technology, Taiwan); 	This study was funded by Ministry of Science and Technology (Taiwan), and the website is http://www.most.gov.tw/mp.aspx. The grant number is: NSC-102-2320-B-038-026. PYW, SHY, TCW, and YTC have received the funding.	Agarwal R, 2003, AM J MED, V115, P291, DOI 10.1016/S0002-9343(03)00366-8; [Anonymous], 2014, USRDS 2014 ANN DAT R; Appel LJ, 2006, HYPERTENSION, V47, P296, DOI 10.1161/01.HYP.0000202568.01167.B6; Bernstein AM, 2010, CIRCULATION, V122, P876, DOI 10.1161/CIRCULATIONAHA.109.915165; Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; Bross R, 2010, SEMIN DIALYSIS, V23, P359, DOI 10.1111/j.1525-139X.2010.00743.x; Brown IJ, 2009, INT J EPIDEMIOL, V38, P791, DOI 10.1093/ije/dyp139; Caro P, 2010, DIALYSIS TRANSPLANT, V39, P27, DOI 10.1002/dat.20399; Chang TY, 2007, CURR MED RES OPIN, V23, P1879, DOI 10.1185/030079907X218077; Chazot C, 2007, NEPHROL THER, V3, pS137, DOI 10.1016/S1769-7255(07)80022-8; Chen HS, 2014, HEMODIAL INT, V18, P799, DOI 10.1111/hdi.12165; Chen KH, 2008, KIDNEY BLOOD PRESS R, V31, P143, DOI 10.1159/000127388; Chiu YF, 2014, J RENAL NUTR, V24, P163, DOI 10.1053/j.jrn.2013.12.006; Chobanian AV, 2000, HYPERTENSION, V35, P858, DOI 10.1161/01.HYP.35.4.858; Collins Allan J, 2014, Am J Kidney Dis, V63, pA7, DOI 10.1053/j.ajkd.2013.11.001; Fogarty AW, 2009, AM J CLIN NUTR, V89, P1901, DOI 10.3945/ajcn.2008.27006; Gallardo JM, 2007, ARCH MED RES, V38, P34, DOI 10.1016/j.arcmed.2006.08.010; Grossman C, 2013, AM J HYPERTENS, V26, P13, DOI 10.1093/ajh/hps028; He FJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1325; Hecking M, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001750; Hecking M, 2014, AM J HYPERTENS, V27, P1160, DOI 10.1093/ajh/hpu040; Heidari B, 2013, CASP J INTERN MED, V4, P611; Huang JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126668; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Ikizler TA, 1996, KIDNEY INT, V50, P343, DOI 10.1038/ki.1996.323; Kalantar-Zadeh K, 2010, CLIN J AM SOC NEPHRO, V5, P519, DOI 10.2215/CJN.06080809; Kaluza J, 2014, CIRC-HEART FAIL, V7, P552, DOI 10.1161/CIRCHEARTFAILURE.113.000921; Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group, 2012, KIDNEY INT SUPPL, V2, P347; Kobayashi S, 2012, J EPIDEMIOL, V22, P151, DOI 10.2188/jea.JE20110075; Kopple JD, 2001, AM J KIDNEY DIS, V37, pS66, DOI 10.1053/ajkd.2001.20748; Lajous M, 2014, AM J CLIN NUTR, V100, P948, DOI 10.3945/ajcn.113.080598; Larsson SC, 2011, STROKE, V42, P324, DOI 10.1161/STROKEAHA.110.596510; Levin NW, 2010, KIDNEY INT, V77, P273, DOI 10.1038/ki.2009.469; Ley SH, 2014, AM J CLIN NUTR, V99, P352, DOI 10.3945/ajcn.113.075663; Lin HS, 2014, KAOHSIUNG J MED SCI, V30, P206, DOI 10.1016/j.kjms.2013.12.002; Luhrmann PM, 1999, EUR J NUTR, V38, P235, DOI 10.1007/s003940050066; Mafra D, 2012, J RENAL NUTR, V22, P578, DOI 10.1053/j.jrn.2011.10.037; Malluche HH, 2015, J AM SOC NEPHROL; Martinez-Maldonado M, 1998, KIDNEY INT, V54, pS67, DOI 10.1046/j.1523-1755.1998.06816.x; McCullough ML, 2002, AM J CLIN NUTR, V76, P1261, DOI 10.1093/ajcn/76.6.1261; Micha R, 2010, CIRCULATION, V121, P2271, DOI 10.1161/CIRCULATIONAHA.109.924977; Miller GE, 2002, HEALTH PSYCHOL, V21, P531, DOI 10.1037//0278-6133.21.6.531; Moriya H, 2008, CLIN J AM SOC NEPHRO, V3, P416, DOI 10.2215/CJN.03490807; Noori N, 2011, AM J NEPHROL, V33, P157, DOI 10.1159/000323972; Ortega RM, 2015, NUTR HOSP, V31, P38, DOI 10.3305/nh.2015.31.sup3.8749; Potter SM, 1998, NUTR REV, V56, P231, DOI 10.1111/j.1753-4887.1998.tb01754.x; Ravel VA, 2013, J NUTR, V143, P1084, DOI 10.3945/jn.112.169722; Renal Data System U.S, 2014, AM J KIDNEY DIS, V63, pe215; Ribeiro S, 1998, NEPHROL DIAL TRANSPL, V13, P2037, DOI 10.1093/ndt/13.8.2037; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rouhani MH, 2014, OBES REV, V15, P740, DOI 10.1111/obr.12172; Ruusunen M, 2005, MEAT SCI, V70, P531, DOI 10.1016/j.meatsci.2004.07.016; Santarelli RL, 2008, NUTR CANCER, V60, P131, DOI 10.1080/01635580701684872; Shapiro BB, 2015, J RENAL NUTR, V25, P357, DOI 10.1053/j.jrn.2014.12.004; Shinaberger CS, 2006, AM J KIDNEY DIS, V48, P37, DOI 10.1053/j.ajkd.2006.03.049; Sullivan C, 2009, JAMA-J AM MED ASSOC, V301, P629, DOI 10.1001/jama.2009.96; Takeda A, 2005, AM J KIDNEY DIS, V45, P112, DOI 10.1053/j.ajkd.2004.08.045; TERMAN DS, 1971, AM J MED, V50, P744, DOI 10.1016/0002-9343(71)90182-3; The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Workgroup, 2004, AM J KIDNEY DIS, V43, P11, DOI [10.1053/j.ajkd.2004.03.003, DOI 10.1053/J.AJKD.2004.03.003]; Therrien M, 2014, J RENAL NUTR, V24, P72, DOI 10.1053/j.jrn.2013.09.005; THOMPSON GR, 1994, LANCET, V343, P670, DOI 10.1016/S0140-6736(94)92664-6; Uribarri J, 2009, CLIN J AM SOC NEPHRO, V4, P1290, DOI 10.2215/CJN.03950609; Wang Y, 2009, INT J OBESITY, V33, P621, DOI 10.1038/ijo.2009.45; Wanner C, 2002, NEPHROL DIAL TRANSPL, V17, P29, DOI 10.1093/ndt/17.suppl_8.29; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wu M-S, 2012, ACTA NEPHROLOGICA, V26, P104; Wu PY, 2014, NEPHROLOGY, V19, P98; Wu SJ, 2011, ASIA PAC J CLIN NUTR, V20, P251; Zheng ZJ, 1999, AM J EPIDEMIOL, V150, P492, DOI 10.1093/oxfordjournals.aje.a010038	70	12	12	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2015	10	10							e0141917	10.1371/journal.pone.0141917	http://dx.doi.org/10.1371/journal.pone.0141917			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV0EH	26517837	Green Published, gold, Green Submitted			2023-01-03	WOS:000363920800093
J	Nakashima, H; Oniki, K; Nishimura, M; Ogusu, N; Shimomasuda, M; Ono, T; Matsuda, K; Yasui-Furukori, N; Nakagawa, K; Ishitsu, T; Saruwatari, J				Nakashima, Hiroo; Oniki, Kentaro; Nishimura, Miki; Ogusu, Naoki; Shimomasuda, Masatsugu; Ono, Tatsumasa; Matsuda, Kazuki; Yasui-Furukori, Norio; Nakagawa, Kazuko; Ishitsu, Takateru; Saruwatari, Junji			Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis	PLOS ONE			English	Article							ANTIEPILEPTIC DRUGS; POLYMORPHISMS; CARBAMAZEPINE; SCN1A; ASSOCIATION; RECEPTOR	Valproic acid (VPA) is one of the most widely prescribed antiepileptic drugs for the treatment of epileptic seizures. Although it is well known that the doses of VPA and its plasma concentrations are highly correlated, the plasma concentrations do not correlate well with the therapeutic effects of the VPA. In this study, we developed a population-based pharmacokinetic (PK)-pharmacodynamic (PD) model to determine the optimal concentration of VPA according to the clinical characteristics of each patient. This retrospective study included 77 VPA-treated Japanese patients with epilepsy. A nonlinear mixed-effects model best represented the relationship between the trough concentrations of VPA at steady-state and an over 50% reduction in seizure frequency. The model was fitted using a logistic regression model, in which the logit function of the probability was a linear function of the predicted trough concentration of VPA. The model showed that the age, seizure locus, the sodium channel neuronal type I alpha subunit rs3812718 polymorphism and co-administration of carbamazepine, clonazepam, phenytoin or topiramate were associated with an over 50% reduction in the seizure frequency. We plotted the receiver operating characteristic (ROC) curve for the logit(Pr) value of the model and the presence or absence of a more than 50% reduction in seizure frequency, and the areas under the curves with the 95% confidence interval from the ROC curve were 0.823 with 0.793-0.853. A logit(Pr) value of 0.1 was considered the optimal cut-off point (sensitivity = 71.8% and specificity = 80.4%), and we calculated the optimal trough concentration of VPA for each patient. Such parameters may be useful to determine the recommended therapeutic concentration of VPA for each patient, and the procedure may contribute to the further development of personalized pharmacological therapy for epilepsy.	[Nakashima, Hiroo; Oniki, Kentaro; Nishimura, Miki; Ogusu, Naoki; Shimomasuda, Masatsugu; Ono, Tatsumasa; Matsuda, Kazuki; Nakagawa, Kazuko; Saruwatari, Junji] Kumamoto Univ, Div Pharmacol & Therapeut, Grad Sch Pharmaceut Sci, Kumamoto, Japan; [Yasui-Furukori, Norio] Hirosaki Univ, Grad Sch Med, Dept Neuropsychiat, Hirosaki, Aomori, Japan; [Nakagawa, Kazuko; Saruwatari, Junji] Kumamoto Univ, Ctr Clin Pharmaceut Sci, Kumamoto, Japan; [Ishitsu, Takateru] Kumamoto Saishunso Natl Hosp, Kumamoto, Japan; [Ishitsu, Takateru] Kumamoto Ezuko Ryoiku Iryo Ctr, Kumamoto, Japan	Kumamoto University; Hirosaki University; Kumamoto University	Saruwatari, J (corresponding author), Kumamoto Univ, Div Pharmacol & Therapeut, Grad Sch Pharmaceut Sci, Kumamoto, Japan.	junsaru@gpo.kumamoto-u.ac.jp	Saruwatari, Junji/Q-7748-2019	Saruwatari, Junji/0000-0001-6266-1347	Ministry of Education, Culture, Sports, Science and Technology, Japan [25860117, 26360049, 15K18925]; Smoking Research Foundation	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Smoking Research Foundation	The work was supported in full by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (http://www.jsps.go.jp/english/index.html) Grant Numbers: 25860117, 26360049 and 15K18925, and in part by a grant from Smoking Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe T, 2008, BRIT J CLIN PHARMACO, V66, P304, DOI 10.1111/j.1365-2125.2008.03203.x; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Blanco-Serrano B, 1999, BIOPHARM DRUG DISPOS, V20, P233, DOI 10.1002/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5; Brunklaus A, 2014, EPILEPSIA, V55, P979, DOI 10.1111/epi.12652; Ding JJ, 2015, CLIN PHARMACOKINET, V54, P305, DOI 10.1007/s40262-014-0212-8; El Desoky ES, 2004, EUR J CLIN PHARMACOL, V59, P783, DOI 10.1007/s00228-003-0699-7; Fletcher EV, 2011, J BIOL CHEM, V286, P36700, DOI 10.1074/jbc.M111.250225; Ghodke-Puranik Y, 2013, PHARMACOGENET GENOM, V23, P236, DOI 10.1097/FPC.0b013e32835ea0b2; Haerian BS, 2015, GENOMICS, V105, P229, DOI 10.1016/j.ygeno.2015.02.001; Heinzen EL, 2007, AM J HUM GENET, V80, P876, DOI 10.1086/516650; Kalthoff S, 2010, GASTROENTEROLOGY, V139, P1699, DOI 10.1053/j.gastro.2010.06.048; Keizer RJ, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.24; Lin WW, 2015, THER DRUG MONIT, V37, P76, DOI 10.1097/FTD.0000000000000100; Ma CL, 2014, PHARMACOGENOMICS, V15, P1323, DOI [10.2217/pgs.14.89, 10.2217/PGS.14.89]; Moshe SL, 2015, LANCET, V385, P884, DOI 10.1016/S0140-6736(14)60456-6; Nanau RM, 2013, CLIN BIOCHEM, V46, P1323, DOI 10.1016/j.clinbiochem.2013.06.012; Ogusu N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111066; Saghazadeh A, 2014, REV NEUROSCIENCE, V25, P129, DOI 10.1515/revneuro-2013-0053; Saruwatari J, 2014, PHARMACOGENET GENOM, V24, P162, DOI 10.1097/FPC.0000000000000030; Schmidt D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g254; Sundqvist A, 1997, THER DRUG MONIT, V19, P153, DOI 10.1097/00007691-199704000-00006; Tate SK, 2005, P NATL ACAD SCI USA, V102, P5507, DOI 10.1073/pnas.0407346102; TURNBULL DM, 1983, ANN NEUROL, V14, P38, DOI 10.1002/ana.410140107; Vajda FJE, 2014, EPILEPTIC DISORD, V16, P395, DOI 10.1684/epd.2014.0704; Wassenaar M, 2013, EPILEPSY RES, V106, P301, DOI 10.1016/j.eplepsyres.2013.06.013; Yun WT, 2013, EPILEPSY RES, V107, P231, DOI 10.1016/j.eplepsyres.2013.09.011	26	24	26	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2015	10	10							e0141266	10.1371/journal.pone.0141266	http://dx.doi.org/10.1371/journal.pone.0141266			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT7XI	26484865	Green Published, gold, Green Submitted			2023-01-03	WOS:000363028100127
J	Borrelli, S; Leonardis, D; Minutolo, R; Chiodini, P; De Nicola, L; Esposito, C; Mallamaci, F; Zoccali, C; Conte, G				Borrelli, Silvio; Leonardis, Daniela; Minutolo, Roberto; Chiodini, Paolo; De Nicola, Luca; Esposito, Ciro; Mallamaci, Francesca; Zoccali, Carmine; Conte, Giuseppe			Epidemiology of CKD Regression in Patients under Nephrology Care	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; DOMINANT POLYCYSTIC KIDNEY; GLOMERULAR-FILTRATION-RATE; CHRONIC NEPHROPATHIES; RENAL-FUNCTION; DECLINE; RISK; GFR; PROGRESSION; PROGNOSIS	Chronic Kidney Disease (CKD) regression is considered as an infrequent renal outcome, limited to early stages, and associated with higher mortality. However, prevalence, prognosis and the clinical correlates of CKD regression remain undefined in the setting of nephrology care. This is a multicenter prospective study in 1418 patients with established CKD (eGFR: 60-15 ml/min/1.73m(2)) under nephrology care in 47 outpatient clinics in Italy from a least one year. We defined CKD regressors as a Delta GFR >= 0 ml/min/1.73 m(2)/year. Delta GFR was estimated as the absolute difference between eGFR measured at baseline and at follow up visit after 18-24 months, respectively. Outcomes were End Stage Renal Disease (ESRD) and overall-causes Mortality. 391 patients (27.6%) were identified as regressors as they showed an eGFR increase between the baseline visit in the renal clinic and the follow up visit. In multivariate regression analyses the regressor status was not associated with CKD stage. Low proteinuria was the main factor associated with CKD regression, accounting per se for 48% of the likelihood of this outcome. Lower systolic blood pressure, higher BMI and absence of autosomal polycystic disease (PKD) were additional predictors of CKD regression. In regressors, ESRD risk was 72% lower (HR: 0.28; 95% CI 0.14-0.57; p<0.0001) while mortality risk did not differ from that in non-regressors (HR: 1.16; 95% CI 0.73-1.83; p = 0.540). Spline models showed that the reduction of ESRD risk associated with positive Delta GFR was attenuated in advanced CKD stage. CKD regression occurs in about one-fourth patients receiving renal care in nephrology units and correlates with low proteinuria, BP and the absence of PKD. This condition portends better renal prognosis, mostly in earlier CKD stages, with no excess risk for mortality.	[Borrelli, Silvio; Minutolo, Roberto; De Nicola, Luca; Conte, Giuseppe] Univ Naples 2, Div Nephrol, Naples, Italy; [Leonardis, Daniela; Mallamaci, Francesca; Zoccali, Carmine] Inst Biomed & Mol Immunol Hosp, Ctr Natl Res, Nephrol Diis, Reggio Di Calabria, Italy; [Chiodini, Paolo] Univ Naples 2, Div Med Stat, Naples, Italy; [Esposito, Ciro] IRCCS Maugeri Inst Pavia, Div Nephrol, Pavia, Italy	Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); Universita della Campania Vanvitelli	Conte, G (corresponding author), Univ Naples 2, Div Nephrol, Naples, Italy.	giuseppe.conte@unina2.it	Chiodini, Paolo/E-7290-2014; De Nicola, Luca/AAB-7682-2019; Borrelli, Silvio/AAH-8549-2019; esposito, ciro/AAC-8023-2020; Zoccali, Carmine/AAR-4473-2020; Zoccali, Carmine/B-9445-2009	Chiodini, Paolo/0000-0003-0139-2264; Borrelli, Silvio/0000-0002-4414-4597; esposito, ciro/0000-0002-7906-1097; Zoccali, Carmine/0000-0002-6616-1996; Minutolo, Roberto/0000-0001-5686-2089				Al-Aly Z, 2010, J AM SOC NEPHROL, V21, P1961, DOI 10.1681/ASN.2009121210; Cianciaruso B, 2003, G Ital Nefrol, V20 Suppl 24, pS48; Coresh J, 2014, JAMA-J AM MED ASSOC, V311, P2518, DOI 10.1001/jama.2014.6634; De Nicola L, 2012, KIDNEY INT, V82, P482, DOI 10.1038/ki.2012.174; De Nicola L, 2011, CLIN J AM SOC NEPHRO, V6, P2421, DOI 10.2215/CJN.01180211; Dwyer J., 1993, NUTR KIDNEY, V2nd ed., P61; Ecder T, 2000, AM J KIDNEY DIS, V35, P427, DOI 10.1016/S0272-6386(00)70195-8; Eriksen BO, 2007, KIDNEY INT, V72, P1242, DOI 10.1038/sj.ki.5002472; Eriksen BO, 2006, KIDNEY INT, V69, P375, DOI 10.1038/sj.ki.5000058; Glymour MM, 2005, AM J EPIDEMIOL, V162, P267, DOI 10.1093/aje/kwi187; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; Hogan MC, 2010, J AM SOC NEPHROL, V21, P1052, DOI 10.1681/ASN.2009121291; Hu B, 2012, J AM SOC NEPHROL, V23, P706, DOI 10.1681/ASN.2011050456; Jones C, 2006, NEPHROL DIAL TRANSPL, V21, P2133, DOI 10.1093/ndt/gfl198; *K DOQI, 2004, AM J KIDNEY DIS S, V43, pS1; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leonardis D, 2012, J NEPHROL, V25, P1081, DOI 10.5301/jn.5000239; Levey AS, 2007, CLIN CHEM, V53, P766, DOI 10.1373/clinchem.2006.077180; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Li L, 2012, AM J KIDNEY DIS, V59, P504, DOI 10.1053/j.ajkd.2011.12.009; LINDEMAN RD, 1985, J AM GERIATR SOC, V33, P278, DOI 10.1111/j.1532-5415.1985.tb07117.x; Mallamaci F, 2013, KIDNEY INT, V84, P381, DOI 10.1038/ki.2013.132; Mancia G, 2007, J HYPERTENS, V25, P1105, DOI DOI 10.1097/HJH.0B013E3281FC975A; Matsushita K, 2009, J AM SOC NEPHROL, V20, P2617, DOI 10.1681/ASN.2009010025; Minutolo R, 2014, CLIN J AM SOC NEPHRO, V9, P1586, DOI 10.2215/CJN.10481013; Murthy K, 2005, KIDNEY INT, V68, P1884, DOI 10.1111/j.1523-1755.2005.00608.x; Perkins RM, 2011, CLIN J AM SOC NEPHRO, V6, P1879, DOI 10.2215/CJN.00470111; Poggio ED, 2009, KIDNEY INT, V75, P1079, DOI 10.1038/ki.2009.11; Remuzzi G, 2006, J CLIN INVEST, V116, P288, DOI 10.1172/JCI27699; Ruggenenti P, 1999, J AM SOC NEPHROL, V10, P997; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; Stevens LA, 2007, AM J KIDNEY DIS, V50, P21, DOI 10.1053/j.ajkd.2007.04.004; Tjur T, 2009, AM STAT, V63, P366, DOI 10.1198/tast.2009.08210; Tseng CL, 2008, ARCH INTERN MED, V168, P55, DOI 10.1001/archinternmed.2007.9; Turin TC, 2013, KIDNEY INT, V83, P684, DOI 10.1038/ki.2012.443; Weis L, 2013, PLOS ONE, V8; Wetzels JFM, 2007, KIDNEY INT, V72, P632, DOI 10.1038/sj.ki.5002374	39	24	26	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2015	10	10							e0140138	10.1371/journal.pone.0140138	http://dx.doi.org/10.1371/journal.pone.0140138			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT6ZJ	26462071	Green Published, Green Submitted, gold			2023-01-03	WOS:000362962300058
J	Tam, JCW; Ko, CH; Koon, CM; Cheng, Z; Lok, WH; Lau, CP; Leung, PC; Fung, KP; Chan, WY; Lau, CBS				Tam, Jacqueline Chor Wing; Ko, Chun Hay; Koon, Chi Man; Cheng, Zhang; Lok, Wong Hing; Lau, Ching Po; Leung, Ping Chung; Fung, Kwok Pui; Chan, Wai Yee; Lau, Clara Bik San			Identification of Target Genes Involved in Wound Healing Angiogenesis of Endothelial Cells with the Treatment of a Chinese 2-Herb Formula	PLOS ONE			English	Article							UBIQUITIN-PROTEASOME PATHWAY; CHEMOKINE RECEPTOR; MATRIX METALLOPROTEINASE-8; NATRIURETIC PEPTIDE; REHMANNIAE RADIX; ASTRAGALI RADIX; HERBAL FORMULA; BREAST-CANCER; UP-REGULATION; IN-VITRO	Angiogenesis is vitally important in diabetic wound healing. We had previously demonstrated that a Chinese 2-herb formula (NF3) significantly stimulated angiogenesis of HUVEC in wound healing. However, the molecular mechanism has not yet been elucidated. In line with this, global expression profiling of NF3-treated HUVEC was performed so as to assess the regulatory role of NF3 involved in the underlying signaling pathways in wound healing angiogenesis. The microarray results illustrated that different panels of differentially expressed genes were strictly governed in NF3-treated HUVEC in a time-regulated manner. The microarray analysis followed by qRT-PCR and western blotting verification of NF3-treated HUVEC at 6 h revealed the involvement of various genes in diverse biological process, e.g., MAP3K14 in anti-inflammation; SLC5A8 in anti-tumorogenesis; DNAJB7 in protein translation; BIRC5, EPCAM, INSL4, MMP8 and NPR3 in cell proliferation; CXCR7, EPCAM, HAND1 and MMP8 in migration; CXCR7, EPCAM and MMP8 in tubular formation; and BIRC5, CXCR7, EPCAM, HAND1, MMP8 and UBD in angiogenesis. After 16 h incubation of NF3, other sets of genes were shown with differential expression in HUVEC, e.g., IL1RAPL2 and NR1H4 in anti-inflammation; miR28 in anti-tumorogenesis; GRIN1 and LCN1 in anti-oxidation; EPB41 in intracellular signal transduction; PRL and TFAP2A in cell proliferation; miR28, PRL and SCG2 in cell migration; PRL in tubular formation; and miR28, NR1H4 and PRL in angiogenesis. This study provided concrete scientific evidence in support of the regulatory role of NF3 on endothelial cells involved in wound healing angiogenesis.	[Tam, Jacqueline Chor Wing; Ko, Chun Hay; Koon, Chi Man; Cheng, Zhang; Lok, Wong Hing; Lau, Ching Po; Leung, Ping Chung; Fung, Kwok Pui; Lau, Clara Bik San] Chinese Univ Hong Kong, Inst Chinese Med, Shatin, Hong Kong, Peoples R China; [Tam, Jacqueline Chor Wing; Ko, Chun Hay; Koon, Chi Man; Cheng, Zhang; Lok, Wong Hing; Lau, Ching Po; Leung, Ping Chung; Fung, Kwok Pui; Lau, Clara Bik San] Chinese Univ Hong Kong, State Key Lab Phytochem & Plant Resources West Ch, Shatin, Hong Kong, Peoples R China; [Fung, Kwok Pui; Chan, Wai Yee] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Lau, CBS (corresponding author), Chinese Univ Hong Kong, Inst Chinese Med, Shatin, Hong Kong, Peoples R China.	claralau@cuhk.edu.hk	Chan, Wai Yee/R-7442-2018; Fung, Kwok Pui/R-9708-2018; Lau, Clara Bik-San/AAF-3989-2020	Chan, Wai Yee/0000-0002-9714-0936; Fung, Kwok Pui/0000-0001-6214-5123; Lau, Clara Bik-San/0000-0002-7409-1270	UGC Area of Excellence project "Chinese Medicine Research and Further Development" [AoE/B-10/01]	UGC Area of Excellence project "Chinese Medicine Research and Further Development"	This study is supported by a grant from UGC Area of Excellence project "Chinese Medicine Research and Further Development" (Project No. AoE/B-10/01). The authors would like to thank Dr. Cao Hui of the National Engineering Research Centre for Modernization of Traditional Chinese Medicine, Zhuhai, Guangdong, China for his technical help in TCM authentication.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Born TL, 2000, J BIOL CHEM, V275, P29946, DOI 10.1074/jbc.M004077200; Brizzi MF, 1999, CIRC RES, V84, P785; Castilla A, 2010, J VASC RES, V47, P45, DOI 10.1159/000231720; Cioffi DL, 2005, CIRC RES, V97, P1164, DOI 10.1161/01.RES.0000193597.65217.00; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; Ding XF, 2013, INT J BIOCHEM CELL B, V45, P1647, DOI 10.1016/j.biocel.2013.04.024; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Fang CC, 2013, CARDIOVASC RES, V99, P146, DOI 10.1093/cvr/cvt060; Girardot M, 2010, BLOOD, V116, P437, DOI 10.1182/blood-2008-06-165985; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Kahler CM, 1996, EUR J PHARMACOL, V304, P135, DOI 10.1016/0014-2999(96)00135-5; Kahler CM, 1997, ARTERIOSCL THROM VAS, V17, P932, DOI 10.1161/01.ATV.17.5.932; Khambata RS, 2011, BRIT J PHARMACOL, V164, P584, DOI 10.1111/j.1476-5381.2011.01400.x; Ko CH, 2014, J DIABETES, V6, P323, DOI 10.1111/1753-0407.12117; Laurent A, 1998, MOL REPROD DEV, V51, P123, DOI 10.1002/(SICI)1098-2795(199810)51:2<123::AID-MRD1>3.0.CO;2-S; Lechner M, 2001, BIOCHEM J, V356, P129, DOI 10.1042/0264-6021:3560129; Li J, 2008, CARDIOVASC RES, V77, P169, DOI 10.1093/cvr/cvm016; Li YTY, 2007, ARTERIOSCL THROM VAS, V27, P2606, DOI 10.1161/ATVBAHA.107.152694; Liu CL, 2013, WOUND REPAIR REGEN, V21, P579, DOI 10.1111/wrr.12055; Liu JS, 2012, J BIOL CHEM, V287, P27326, DOI 10.1074/jbc.M112.366658; Madeddu P, 2005, EXP PHYSIOL, V90, P315, DOI 10.1113/expphysiol.2004.028571; Martin A, 2003, MED RES REV, V23, P117, DOI 10.1002/med.10024; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; Millar L, 2005, BIOL REPROD, V73, P695, DOI 10.1095/biolreprod.105.039859; Miyauchi S, 2004, J BIOL CHEM, V279, P13293, DOI 10.1074/jbc.C400059200; Morikawa Y, 2004, DEVELOPMENT, V131, P2195, DOI 10.1242/dev.01091; Or PMY, 2012, PHYTOMEDICINE, V19, P535, DOI 10.1016/j.phymed.2011.12.005; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Qiu XB, 2006, CELL MOL LIFE SCI, V63, P2560, DOI 10.1007/s00018-006-6192-6; Reuwer AQ, 2012, J CELL MOL MED, V16, P2035, DOI 10.1111/j.1582-4934.2011.01499.x; Sankpal NV, 2013, MOL CANCER RES, V11, P418, DOI 10.1158/1541-7786.MCR-12-0518; Shan YF, 2011, MED ONCOL, V28, P1012, DOI 10.1007/s12032-010-9600-6; Sharp CD, 2005, AM J PHYSIOL-HEART C, V288, pH1893, DOI 10.1152/ajpheart.01110.2003; Smart N, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1041; Stangl K, 2010, CARDIOVASC RES, V85, P281, DOI 10.1093/cvr/cvp315; Stangl V, 2004, FASEB J, V18, P272, DOI 10.1096/fj.03-0054com; Tam JCW, 2014, PROTEOMICS, V14, P2089, DOI 10.1002/pmic.201300547; Tam JCW, 2011, J ETHNOPHARMACOL, V134, P831, DOI 10.1016/j.jep.2011.01.032; Tam JCW, 2014, J DIABETES COMPLICAT, V28, P436, DOI 10.1016/j.jdiacomp.2014.03.004; Tam JC, 2014, J DIABETES; Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200; Wong M. W. N., 2001, Hong Kong Medical Journal, V7, P403; Wu SW, 2001, J CELL BIOL, V154, P1225, DOI 10.1083/jcb.200106156; Xiao QZ, 2013, CIRC RES, V112, P35, DOI 10.1161/CIRCRESAHA.112.274019; Yan XQ, 2012, J CELL BIOCHEM, V113, P1437, DOI 10.1002/jcb.24015; Yang MH, 2011, BREAST CANCER RES TR, V129, P983, DOI 10.1007/s10549-011-1604-1; Yang XH, 2013, J BIOL CHEM, V288, P21184, DOI 10.1074/jbc.M113.481119; Zampetaki A, 2010, CIRC RES, V107, P810, DOI 10.1161/CIRCRESAHA.110.226357; Zhang Q, 2012, PHYTOMEDICINE, V20, P9, DOI 10.1016/j.phymed.2012.09.006; Zheng K, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-31	52	5	5	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2015	10	10							e0139342	10.1371/journal.pone.0139342	http://dx.doi.org/10.1371/journal.pone.0139342			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6HH	26430762	Green Submitted, gold, Green Published			2023-01-03	WOS:000362178700045
J	Fukuyama, Y; Okada, K; Yamaguchi, M; Kiyono, H; Mori, K; Yuki, Y				Fukuyama, Yoshiko; Okada, Kazunari; Yamaguchi, Masahiro; Kiyono, Hiroshi; Mori, Kensaku; Yuki, Yoshikazu			Nasal Administration of Cholera Toxin as a Mucosal Adjuvant Damages the Olfactory System in Mice	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; PROTECTIVE IMMUNITY; ANTIBODY-RESPONSES; ODORANT RECEPTORS; NONHUMAN-PRIMATES; SENSORY MAP; TH2 CELLS; INTRANASAL; BULB; VIRUS	Cholera toxin (CT) induces severe diarrhea in humans but acts as an adjuvant to enhance immune responses to vaccines when administered orally. Nasally administered CT also acts as an adjuvant, but CT and CT derivatives, including the B subunit of CT (CTB), are taken up from the olfactory epithelium and transported to the olfactory bulbs and therefore may be toxic to the central nervous system. To assess the toxicity, we investigated whether nasally administered CT or CT derivatives impair the olfactory system. In mice, nasal administration of CT, but not CTB or a non-toxic CT derivative, reduced the expression of olfactory marker protein (OMP) in the olfactory epithelium and olfactory bulbs and impaired odor responses, as determined with behavioral tests and optical imaging. Thus, nasally administered CT, like orally administered CT, is toxic and damages the olfactory system in mice. However, CTB and a non-toxic CT derivative, do not damage the olfactory system. The optical imaging we used here will be useful for assessing the safety of nasal vaccines and adjuvants during their development for human use and CT can be used as a positive control in this test.	[Fukuyama, Yoshiko; Okada, Kazunari; Kiyono, Hiroshi; Yuki, Yoshikazu] Univ Tokyo, Inst Med Sci, Div Mucosal Immunol, Tokyo, Japan; [Yamaguchi, Masahiro; Mori, Kensaku] Univ Tokyo, Grad Sch Med, Dept Physiol, Tokyo, Japan; [Kiyono, Hiroshi; Yuki, Yoshikazu] Univ Tokyo, Inst Med Sci, Int Res & Dev Ctr Mucosal Vaccine, Tokyo, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Yuki, Y (corresponding author), Univ Tokyo, Inst Med Sci, Div Mucosal Immunol, Tokyo, Japan.	yukiy@ims.u-tokyo.ac.jp	Kiyono, Hiroshi/AAC-6735-2022; Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Mori, Kensaku/0000-0001-7853-9370	Ministry of Health, Labour, and Welfare of Japan; Global Center of Excellence Program "Center of Education and Research for the Advanced Genome - Based Medicine - For personalized medicine; control of worldwide infectious diseases - "MEXT" Japan; Grants-in-Aid for Scientific Research [26115506] Funding Source: KAKEN	Ministry of Health, Labour, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Global Center of Excellence Program "Center of Education and Research for the Advanced Genome - Based Medicine - For personalized medicine; control of worldwide infectious diseases - "MEXT" Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by the Ministry of Health, Labour, and Welfare of Japan to YY, and Global Center of Excellence Program "Center of Education and Research for the Advanced Genome - Based Medicine - For personalized medicine, the control of worldwide infectious diseases - "MEXT" Japan to HK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bepari AK, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-140; Bodewes R, 2011, AM J PATHOL, V179, P30, DOI 10.1016/j.ajpath.2011.03.026; Bracher M, 1995, Psychoanal Rev, V82, P655; Bracher M, 1995, PSYCHOANAL REV, V82, P703; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CANCALON P, 1982, TISSUE CELL, V14, P717, DOI 10.1016/0040-8166(82)90061-1; Czarnecki LA, 2011, NEUROTOXICOLOGY, V32, P441, DOI 10.1016/j.neuro.2011.03.007; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; DICKINSON BL, 1995, INFECT IMMUN, V63, P1617, DOI 10.1128/IAI.63.5.1617-1623.1995; EVANS J, 1992, FUND APPL TOXICOL, V19, P275, DOI 10.1016/0272-0590(92)90161-A; GOTTOFREY J, 1991, PHARMACOL TOXICOL, V69, P242, DOI 10.1111/bcpt.1991.69.4.242; Hagiwara Y, 2003, J IMMUNOL, V170, P1754, DOI 10.4049/jimmunol.170.4.1754; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; JACKSON RJ, 1993, INFECT IMMUN, V61, P4272, DOI 10.1128/IAI.61.10.4272-4279.1993; Katoh K, 1994, Neuroimage, V1, P199, DOI 10.1006/nimg.1994.1005; Kweon MN, 2002, J INFECT DIS, V186, P1261, DOI 10.1086/344526; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MARINARO M, 1995, J IMMUNOL, V155, P4621; Matsumoto H, 2010, J NEUROPHYSIOL, V103, P3490, DOI 10.1152/jn.00035.2010; MILEDI R, 1989, J PHYSIOL-LONDON, V417, P173, DOI 10.1113/jphysiol.1989.sp017796; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; Mori I, 2004, REV MED VIROL, V14, P209, DOI 10.1002/rmv.426; Mori I, 2002, MED MICROBIOL IMMUN, V191, P1, DOI 10.1007/s00430-002-0110-9; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Nagao H, 2002, MICROSC RES TECHNIQ, V58, P168, DOI 10.1002/jemt.10146; Nochi T, 2010, NAT MATER, V9, P572, DOI [10.1038/NMAT2784, 10.1038/nmat2784]; Park CH, 2002, ARCH VIROL, V147, P1425, DOI 10.1007/s00705-001-0750-x; Persson E, 2003, TOXICOL LETT, V145, P19, DOI 10.1016/S0378-4274(03)00266-2; Rasola A, 2011, CELL CALCIUM, V50, P222, DOI 10.1016/j.ceca.2011.04.007; Sanchez-Andrade G, 2005, J REPROD DEVELOP, V51, P547, DOI 10.1262/jrd.17031; Schrauwen EJA, 2012, J VIROL, V86, P3975, DOI 10.1128/JVI.06828-11; Shinya K, 2011, J VIROL, V85, P5202, DOI 10.1128/JVI.00239-11; Staats HF, 1996, J IMMUNOL, V157, P462; Takahashi YK, 2004, J NEUROPHYSIOL, V92, P2413, DOI 10.1152/jn.00236.2004; Taniguchi M, 2003, J NEUROSCI, V23, P1390, DOI 10.1523/JNEUROSCI.23-04-01390.2003; Tjalve H, 1996, PHARMACOL TOXICOL, V79, P347; Tjalve H, 1999, NEUROTOXICOLOGY, V20, P181; Uchida N, 2000, NAT NEUROSCI, V3, P1035, DOI 10.1038/79857; van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778; van Ginkel FW, 2005, INFECT IMMUN, V73, P6892, DOI 10.1128/IAI.73.10.6892-6902.2005; Wilson DA, 2008, J NEUROPHYSIOL, V100, P2, DOI 10.1152/jn.90479.2008; XUAMANO JC, 1993, J EXP MED, V178, P1309, DOI 10.1084/jem.178.4.1309; XUAMANO JC, 1994, VACCINE, V12, P903, DOI 10.1016/0264-410X(94)90033-7; Yamamoto M, 1998, J IMMUNOL, V161, P4115; Yamamoto S, 1997, J EXP MED, V185, P1203, DOI 10.1084/jem.185.7.1203; Yamamoto S, 1997, P NATL ACAD SCI USA, V94, P5267, DOI 10.1073/pnas.94.10.5267; Yoshida S, 2001, BRAIN RES, V892, P102, DOI 10.1016/S0006-8993(00)03240-6; Yoshino N, 2004, J IMMUNOL, V173, P6850, DOI 10.4049/jimmunol.173.11.6850; Yuki Y, 2003, REV MED VIROL, V13, P293, DOI 10.1002/rmv.398; Yuki Y, 2001, BIOTECHNOL BIOENG, V74, P62, DOI 10.1002/bit.1095; Yuki Y, 2010, J IMMUNOL, V185, P5436, DOI 10.4049/jimmunol.1001789	53	13	13	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2015	10	9							e0139368	10.1371/journal.pone.0139368	http://dx.doi.org/10.1371/journal.pone.0139368			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6GF	26422280	gold, Green Published, Green Submitted			2023-01-03	WOS:000362175700101
J	Vinit, S; Keomani, E; Deramaudt, TB; Bonay, M; Petitjean, M				Vinit, Stephane; Keomani, Emilie; Deramaudt, Therese B.; Bonay, Marcel; Petitjean, Michel			Reorganization of Respiratory Descending Pathways following Cervical Spinal Partial Section Investigated by Transcranial Magnetic Stimulation in the Rat	PLOS ONE			English	Article							CROSSED-PHRENIC PHENOMENON; MOTOR CORTICAL REPRESENTATION; CORD-INJURY; HUMAN DIAPHRAGM; TIDAL VOLUME; RECOVERY; HEMISECTION; MOTONEURONS; PLASTICITY; FACILITATION	High cervical spinal cord injuries lead to permanent respiratory deficits. One preclinical model of respiratory insufficiency in adult rats is the C2 partial injury which causes unilateral diaphragm paralysis. This model allows the investigation of a particular population of respiratory bulbospinal axons which cross the midline at C3-C6 spinal segment, namely the crossed phrenic pathway. Transcranial magnetic stimulation (TMS) is a non-invasive technique that can be used to study supraspinal descending respiratory pathways in the rat. Interestingly, a lateral C2 injury does not affect the amplitude and latency of the largest motor-evoked potential recorded from the diaphragm (MEPdia) ipsilateral to the injury in response to a single TMS pulse, compared to a sham animal. Although the rhythmic respiratory activity on the contralateral diaphragm is preserved at 7 days post-injury, no diaphragm activity can be recorded on the injured side. However, a profound reorganization of the MEPdia evoked by TMS can be observed. The MEPdia is reduced on the non-injured rather than the injured side. This suggests an increase in ipsilateral phrenic motoneurons excitability. Moreover, correlations between MEPdia amplitude and spontaneous contralateral diaphragmatic activity were observed. The larger diaphragm activity correlated with a larger MEPdia on the injured side, and a smaller MEPdia on the non-injured side. This suggests, for the first time, the occurrence of a functional neuroplasticity process involving changes in motoneuron excitability balance between the injured and non-injured sides at a short post-lesional delay.	[Vinit, Stephane; Keomani, Emilie; Deramaudt, Therese B.; Bonay, Marcel; Petitjean, Michel] Univ Versailles St Quentin En Yvelines, UFR Sci Sante Simone Veil, Montigny Le Bretonneux, France; [Vinit, Stephane; Keomani, Emilie; Deramaudt, Therese B.; Bonay, Marcel; Petitjean, Michel] Inserm U1179, Lab Physiol TITAN, End Icap, Montigny Le Bretonneux, France; [Deramaudt, Therese B.; Bonay, Marcel] CSM, LIA BAHN, 8 Quai Antoine Ier, MC-98000 Monaco, Monaco; [Bonay, Marcel; Petitjean, Michel] Grp Hosp Paris Ile de France Ouest, Hop Ambroise Pare, AP HP, Serv Physiol Explorat Fonctionnelles, Boulogne Billancourt, France	UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Petitjean, M (corresponding author), Univ Versailles St Quentin En Yvelines, UFR Sci Sante Simone Veil, Montigny Le Bretonneux, France.; Petitjean, M (corresponding author), Inserm U1179, Lab Physiol TITAN, End Icap, Montigny Le Bretonneux, France.; Petitjean, M (corresponding author), Grp Hosp Paris Ile de France Ouest, Hop Ambroise Pare, AP HP, Serv Physiol Explorat Fonctionnelles, Boulogne Billancourt, France.	michel.petitjean134@gmail.com	Bonay, Marcel/ABG-2039-2020	Bonay, Marcel/0000-0003-1446-7456; vinit, stephane/0000-0001-7013-1741	European Union [246556]	European Union(European Commission)	This work was supported by funding from the European Union Seventh framework Programme (FP7/2007-2013) under grant agreement No. 246556 (European project RBUCE-UP), HandiMedEx allocated by the French Public Investment Board, the Chancellerie des Universites de Paris (Legs Poix), the "Centre d'Assistance Respiratoire a Domicile d'Ile de France (CARDIF)", the "Fonds de Dotation de Recherche en Sante Respiratoire", LVL Medical, and Universite de Versailles Saint-Quentin-en-Yvelines. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aleksandrov VG, 2007, J PHYSIOL PHARMACOL, V58, P17; Alilain WJ, 2011, NATURE, V475, P196, DOI 10.1038/nature10199; Bonay M, 2014, NEURAL REGEN RES, V9, P1949, DOI 10.4103/1673-5374.145367; Boulenguez P, 2007, BRAIN RES, V1148, P96, DOI 10.1016/j.brainres.2007.02.060; Buttry JL, 2015, J NEUROSCI METH, V241, P137, DOI 10.1016/j.jneumeth.2014.12.013; Corfield DR, 1998, RESP PHYSIOL, V114, P109, DOI 10.1016/S0034-5687(98)00083-8; Darlot F, 2012, EXP NEUROL, V236, P88, DOI 10.1016/j.expneurol.2012.04.004; Davey NJ, 1996, RESP PHYSIOL, V106, P127, DOI 10.1016/S0034-5687(96)00069-2; Dougherty BJ, 2012, J APPL PHYSIOL, V112, P96, DOI 10.1152/japplphysiol.00690.2011; Ferrini F, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/429815; Fuller DD, 2009, RESP PHYSIOL NEUROBI, V165, P245, DOI 10.1016/j.resp.2008.12.010; Fuller DD, 2006, J APPL PHYSIOL, V100, P800, DOI 10.1152/japplphysiol.00960.2005; GANDEVIA SC, 1987, J PHYSIOL-LONDON, V384, P109, DOI 10.1113/jphysiol.1987.sp016445; Golder FJ, 2005, J NEUROSCI, V25, P2925, DOI 10.1523/JNEUROSCI.0148-05.2005; Golder FJ, 2003, J NEUROSCI, V23, P2494; Goshgarian HG, 2009, RESP PHYSIOL NEUROBI, V169, P85, DOI 10.1016/j.resp.2009.06.005; Goshgarian HG, 2003, J APPL PHYSIOL, V94, P795, DOI 10.1152/japplphysiol.00847.2002; Keomani E, 2014, JOVE-J VIS EXP, DOI 10.3791/51235; Khedr EM, 2001, EUR J APPL PHYSIOL, V85, P560, DOI 10.1007/s004210100504; Lane MA, 2011, RESP PHYSIOL NEUROBI, V179, P3, DOI 10.1016/j.resp.2011.07.004; Lane MA, 2009, RESP PHYSIOL NEUROBI, V169, P123, DOI 10.1016/j.resp.2009.08.007; LIPSKI J, 1986, EXP BRAIN RES, V61, P280; LISSENS MA, 1994, J NEUROL SCI, V124, P204, DOI 10.1016/0022-510X(94)90327-1; Lovett-Barr MR, 2012, J NEUROSCI, V32, P3591, DOI 10.1523/JNEUROSCI.2908-11.2012; Luft AR, 2001, EXP BRAIN RES, V140, P112, DOI 10.1007/s002210100805; Mantilla CB, 2014, EXP NEUROL, V261, P190, DOI 10.1016/j.expneurol.2014.05.027; MASKILL D, 1991, J PHYSIOL-LONDON, V443, P105, DOI 10.1113/jphysiol.1991.sp018825; Minor KH, 2006, EXP NEUROL, V200, P486, DOI 10.1016/j.expneurol.2006.02.125; Navarrete-Opazo A, 2015, EXP NEUROL, V266, P1, DOI 10.1016/j.expneurol.2015.02.007; Polentes J, 2004, NEUROBIOL DIS, V16, P638, DOI 10.1016/j.nbd.2004.04.009; Sharshar T, 2003, J APPL PHYSIOL, V95, P26, DOI 10.1152/japplphysiol.00918.2002; Shionoya K, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00128; SPERRY MA, 1993, EXP NEUROL, V120, P233, DOI 10.1006/exnr.1993.1058; Vinit S, 2006, J NEUROTRAUM, V23, P1137, DOI 10.1089/neu.2006.23.1137; Vinit S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113251; Vinit S, 2011, RESP PHYSIOL NEUROBI, V176, P130, DOI 10.1016/j.resp.2011.02.008; Vinit S, 2009, RESP PHYSIOL NEUROBI, V169, P115, DOI 10.1016/j.resp.2009.08.004; Vinit S, 2009, RESP PHYSIOL NEUROBI, V169, P210, DOI 10.1016/j.resp.2009.07.023; Windelborn JA, 2012, RESP PHYSIOL NEUROBI, V180, P61, DOI 10.1016/j.resp.2011.10.011; Winslow C, 2003, AM J PHYS MED REHAB, V82, P803, DOI 10.1097/01.PHM.0000078184.08835.01; Zimmer MB, 2015, J SPINAL CORD MED, V38, P224, DOI 10.1179/2045772314Y.0000000220	41	15	15	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2016	11	2							e0148180	10.1371/journal.pone.0148180	http://dx.doi.org/10.1371/journal.pone.0148180			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9NL	26828648	Green Submitted, Green Published, gold			2023-01-03	WOS:000369548200079
J	Follin, C; Gabery, S; Petersen, A; Sundgren, PC; Bjorkman-Burtcher, I; Latt, J; Mannfolk, P; Erfurth, EM				Follin, Cecilia; Gabery, Sanaz; Petersen, Asa; Sundgren, Pia C.; Bjorkman-Burtcher, Isabella; Latt, Jimmy; Mannfolk, Peter; Erfurth, Eva Marie			Associations between Metabolic Risk Factors and the Hypothalamic Volume in Childhood Leukemia Survivors Treated with Cranial Radiotherapy	PLOS ONE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CARDIOVASCULAR RISK; CIRCULATING GHRELIN; ADULT SURVIVORS; HORMONE; OBESITY; BRAIN; PREVALENCE; RESISTANCE; NUCLEUS	Metabolic complications are prevalent in individuals treated with cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia (ALL). The hypothalamus is a master regulator of endocrine and metabolic control. The aim of this study was to investigate whether the hypothalamic volume would be associated to metabolic parameters in ALL survivors. Thirty-eight (21 women) survivors participated in this study 34 years after diagnosis and with a median age of 38 (27-46) years. All were treated with a median CRT dose of 24 Gy and 11 years (3-13) of complete hormone supplementation. Comparisons were made to 31 matched controls. We performed analyses of fat mass, fat free mass, plasma (p)-glucose, p-insulin, Homa-Index (a measure of insulin resistance), serum (s)-leptin, s-ghrelin and of the hypothalamic volume in scans obtained by magnetic resonance imaging (MRI) at 3 Tesla. Serum leptin/kg fat mass (r = -0.4, P = 0.04) and fat mass (r = -0.4, P = 0.01) were negatively correlated with the HT volume among ALL survivors, but not among controls. We also detected significantly higher BMI, waist, fat mass, p-insulin, Homa-Index, leptin/kg fat mass and s-ghrelin and significantly lower fat free mass specifically among female ALL survivors (all P<0.01). Interestingly, s-ghrelin levels increased with time since diagnosis and with low age at diagnosis for childhood ALL. Our results showed that leptin/kg fat mass and fat mass were associated with a reduced HT volume 34 years after ALL diagnosis and that women treated with CRT after ALL are at high risk of metabolic abnormalities. Taken together our data suggest that the hypothalamus is involved in the metabolic consequences after CRT in ALL survivors.	[Follin, Cecilia; Erfurth, Eva Marie] Lund Univ, Dept Endocrinol, Skane Univ Hosp, Lund, Sweden; [Follin, Cecilia; Sundgren, Pia C.; Bjorkman-Burtcher, Isabella; Latt, Jimmy; Mannfolk, Peter; Erfurth, Eva Marie] Lund Univ, IKVL, Lund, Sweden; [Gabery, Sanaz; Petersen, Asa] Lund Univ, Translat Neuroendocrine Res Unit, Dept Expt Med Sci, Lund, Sweden; [Sundgren, Pia C.; Bjorkman-Burtcher, Isabella; Latt, Jimmy; Mannfolk, Peter] Lund Univ, Dept Diagnost Radiol, Skane Univ Hosp, Lund, Sweden; [Bjorkman-Burtcher, Isabella] Lund Univ, Lund Univ Bioimaging Ctr LBIC, Lund, Sweden	Lund University; Skane University Hospital; Lund University; Lund University; Lund University; Skane University Hospital; Lund University	Follin, C (corresponding author), Lund Univ, Dept Endocrinol, Skane Univ Hosp, Lund, Sweden.; Follin, C (corresponding author), Lund Univ, IKVL, Lund, Sweden.	Cecilia.follin@med.lu.se		Sundgren, Pia/0000-0001-9237-1236	Swedish Childhood Cancer Foundation	Swedish Childhood Cancer Foundation(European Commission)	This study was supported by the Swedish Childhood Cancer Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bao AM, 2005, BRAIN, V128, P1301, DOI 10.1093/brain/awh448; Brennan B, 1999, CLIN ENDOCRINOL, V61, P683; Briggs DI, 2014, ENDOCRINOLOGY, V155, P2411, DOI 10.1210/en.2013-1861; Date Y, 2002, DIABETES, V51, P124, DOI 10.2337/diabetes.51.1.124; DelPparigi A, 2002, J CLIN ENDOCR METAB, V87, P5461, DOI 10.1210/jc.2002-020871; Eden Engstrom B, 2003, J CLIN ENDOCR METAB, V88, P5093; Egido EM, 2002, EUR J ENDOCRINOL, V146, P241, DOI 10.1530/eje.0.1460241; Filippi BM, 2013, REV ENDOCR METAB DIS, V14, P365, DOI 10.1007/s11154-013-9258-4; Flanagan DE, 2003, AM J PHYSIOL-ENDOC M, V284, pE313, DOI 10.1152/ajpendo.00569.2001; Follin C, 2006, J CLIN ENDOCR METAB, V91, P1872, DOI 10.1210/jc.2005-2298; Follin C, 2010, J CLIN ENDOCR METAB, V95, P3726, DOI 10.1210/jc.2010-0117; Gabery S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117593; Gordon-Dseagu V, 2015, PLOS ONE, V18, P1; GUSTAFSSON G, 1981, ACTA PAEDIATR SCAND, V70, P609, DOI 10.1111/j.1651-2227.1981.tb05754.x; Ha J, 2013, DIS MARKERS, V2013, P249, DOI 10.1155/2013/531736; Hempel R, 2012, DIABETES-METAB RES, V28, P76, DOI 10.1002/dmrr.1230; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Holmer H, 2010, J CLIN ENDOCR METAB, V95, P5395, DOI 10.1210/jc.2010-0993; Horvath TL, 2001, ENDOCRINOLOGY, V142, P4163, DOI 10.1210/en.142.10.4163; Howlader N, 2011, SEER CANC STAT REV 1; Kamegai J, 2000, ENDOCRINOLOGY, V141, P4797, DOI 10.1210/en.141.12.4797; Kohno D, 2007, ENDOCRINOLOGY, V148, P2251, DOI 10.1210/en.2006-1240; Link K, 2004, J CLIN ENDOCR METAB, V89, P5003, DOI 10.1210/jc.2004-0126; Lustig RH, 2003, J CLIN ENDOCR METAB, V88, P611, DOI 10.1210/jc.2002-021180; Mai JK., 2008, ATLAS HUMAN BRAIN, V3rd ed; Maison P, J CLIN ENDOCRINOL ME, V89, P2192; Mayes J S, 2004, Obes Rev, V5, P197, DOI 10.1111/j.1467-789X.2004.00152.x; O'Brien LM, 2006, HARVARD REV PSYCHIAT, V14, P141, DOI 10.1080/10673220600784119; Peper JS, 2010, PSYCHONEUROENDOCRINO, V35, P133, DOI 10.1016/j.psyneuen.2009.05.025; Saad MF, 2002, J CLIN ENDOCR METAB, V87, P3997, DOI 10.1210/jc.87.8.3997; Salat DH, 2010, NEUROBIOL AGING, V31, P244, DOI 10.1016/j.neurobiolaging.2008.03.013; Schneeberger M, 2014, J ENDOCRINOL, V220, pT25, DOI 10.1530/JOE-13-0398; Sklar CA, 2000, MED PEDIATR ONCOL, V35, P91, DOI 10.1002/1096-911X(200008)35:2<91::AID-MPO1>3.0.CO;2-G; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Stahl R, 2007, RADIOLOGY, V243, P483, DOI 10.1148/radiol.2432051714; Tschop M, 2001, DIABETES, V50, P707, DOI 10.2337/diabetes.50.4.707; Vestergaard ET, 2007, J CLIN ENDOCR METAB, V92, P297, DOI 10.1210/jc.2006-1435	37	11	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2016	11	1							e0147575	10.1371/journal.pone.0147575	http://dx.doi.org/10.1371/journal.pone.0147575			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9GH	26824435	Green Submitted, Green Published, gold			2023-01-03	WOS:000369528600036
J	Li, ZY; Ren, BB; Tan, HY; Liu, SR; Wang, W; Pang, Y; Lin, JZ; Zeng, C				Li, Zhangyong; Ren, Binbin; Tan, Haiyan; Liu, Shengrong; Wang, Wei; Pang, Yu; Lin, Jinzhao; Zeng, Chen			Capsule Design for Blue Light Therapy against Helicobacter pylori	PLOS ONE			English	Article							ENDOSCOPY; SYSTEMS; SENSOR; CORE	A photo-medical capsule that emits blue light for Helicobacter pylori treatment was described in this paper. The system consists of modules for pH sensing and measuring, light-emitting diode driver circuit, radio communication and microcontroller, and power management. The system can differentiate locations by monitoring the pH values of the gastrointestinal tract, and turn on and off the blue light according to the preset range of pH values. Our experimental tests show that the capsule can operate in the effective light therapy mode for more than 32 minutes and the wireless communication module can reliably transmit the measured pH value to a receiver located outside the body.	[Li, Zhangyong; Ren, Binbin; Tan, Haiyan; Liu, Shengrong; Wang, Wei; Pang, Yu; Lin, Jinzhao; Zeng, Chen] Chongqing Univ Posts & Telecommun, Biomed Engn Res Ctr, Chongqing, Peoples R China; [Zeng, Chen] George Washington Univ, Dept Phys, Washington, DC 20052 USA	Chongqing University of Posts & Telecommunications; George Washington University	Li, ZY (corresponding author), Chongqing Univ Posts & Telecommun, Biomed Engn Res Ctr, Chongqing, Peoples R China.	lizy@cqupt.edu.cn			National Natural Science Foundation of China [60901045]; Science Fund of Chongqing China [cstc2012jjA10148, KJ1400427]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Fund of Chongqing China	This project is supported by the National Natural Science Foundation of China (No. 60901045), Science Fund of Chongqing China (No. cstc2012jjA10148 and No. KJ1400427). The author Zhangyong Li plays a role in charge for both the funders.	Banerjee SS, 2015, J MATER CHEM B, V3, P3931, DOI 10.1039/c5tb00534e; Chen WW, 2014, INT J MED ROBOT COMP, V10, P147, DOI 10.1002/rcs.1520; Dai TH, 2012, DRUG RESIST UPDATE, V15, P223, DOI 10.1016/j.drup.2012.07.001; Ganz RA, 2015, LASER SURG MED, V36, P260; Halbritter H, 2014, IEEE PHOTONIC TECH L, V26, P1871, DOI 10.1109/LPT.2014.2336732; Hamblin MR, 2005, ANTIMICROB AGENTS CH, V49, P2822, DOI 10.1128/AAC.49.7.2822-2827.2005; Jia ZW, 2015, AIP ADV, V5, DOI 10.1063/1.4907170; Jia Zhiwei, 2014, Journal of Medical Engineering & Technology, V38, P351, DOI 10.3109/03091902.2014.937835; Khan TH, 2014, SENSORS-BASEL, V14, P20779, DOI 10.3390/s141120779; Kwak SS, 2014, INT J ELECTRON, V101, P1683, DOI 10.1080/00207217.2014.888780; Lembo AJ, 2009, LASER SURG MED, V41, P337, DOI 10.1002/lsm.20770; Li J, 2013, J NANOPART RES, V15, P1; Majumdar D., 2015, MEDICINE, V43, P215, DOI [10.1016/j.mpmed.2015.01.008, DOI 10.1016/J.MPMED.2015.01.008]; Makobongo MO, 2014, J MICROBIOL, V52, P259, DOI 10.1007/s12275-014-3603-5; Nakamura T, 2008, J GASTROENTEROL, V43, P93, DOI 10.1007/s00535-007-2153-6; Pedersen PB, 2014, PHARM RES-DORDR, V31, P2044, DOI 10.1007/s11095-014-1306-6; Qi Shao, 2014, IEEE Sensors 2014. Proceedings, P339, DOI 10.1109/ICSENS.2014.6985003; Qin YX, 2010, IEEE T POWER ELECTR, V25, P507, DOI 10.1109/TPEL.2009.2026752; Sri LR, 2013, INT J ENG TECHNOLOGY, V1, P46; Taylor NAS, 2014, J THERM BIOL, V46, P72, DOI 10.1016/j.jtherbio.2014.10.006; Than TD, 2012, IEEE T BIO-MED ENG, V59, P2387, DOI 10.1109/TBME.2012.2201715; Woods SP, 2013, IEEE T BIO-MED ENG, V60, P945, DOI 10.1109/TBME.2012.2228647; Xu F, 2015, MEASUREMENT, V64, P49, DOI 10.1016/j.measurement.2014.12.044; Yamasue K, 2012, ADV BIOMED ENG, V1, P9, DOI 10.14326/abe.1.9; Yim S, 2014, INT J CONTROL AUTOM, V12, P383, DOI 10.1007/s12555-013-0078-9	25	7	12	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2016	11	1							e0147531	10.1371/journal.pone.0147531	http://dx.doi.org/10.1371/journal.pone.0147531			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9GD	26814481	gold, Green Published, Green Submitted			2023-01-03	WOS:000369528200038
J	Likanonsakul, S; Suntisuklappon, B; Nitiyanontakij, R; Prasithsirikul, W; Nakayama, EE; Shioda, T; Sangsajja, C				Likanonsakul, Sirirat; Suntisuklappon, Bussakorn; Nitiyanontakij, Ravee; Prasithsirikul, Wisit; Nakayama, Emi E.; Shioda, Tatsuo; Sangsajja, Chariya			A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection	PLOS ONE			English	Article							KIDNEY TUBULAR DYSFUNCTION; GLOMERULAR-FILTRATION-RATE; RENAL-FUNCTION; PLASMA-CONCENTRATIONS; ANTIRETROVIRAL-NAIVE; DRUG; SAFETY; NEPHROTOXICITY; TRANSPORTERS; THERAPY	Background In Thailand, the combined generic anti-retroviral drug stavudine/lamivudine/nevirapine (d4T/3TC/NVP) has been used to treat human immunodeficiency virus (HIV)-infected individuals since 2001. Due to relatively frequent adverse effects, d4T gradually has been replaced with tenofovir disoproxil fumarate (TDF). Although the frequency of adverse drug effects with TDF is lower than that with d4T, TDF is known to induce kidney dysfunction, especially in the proximal tubules. It has been reported that renal tubular transporters, including members of the multi-drug resistant (MDR) protein family, are implicated in tenofovir extrusion and may, therefore, confer susceptibility to TDF-induced kidney tubular dysfunction (KTD). We have explored the association between KTD and polymorphisms in genes that encode adenosine triphosphate-binding cassette (ABC)-type MDRs. Methods HIV-infected patients receiving TDF-containing antiretroviral regimens for at least one year were enrolled in the study. The levels of beta2-microglobulin in urine and creatinine (Cr) were measured. Three single-nucleotide polymorphisms, ABCC2 C-24T (rs717620), ABCC2 G1429A (rs2273697), and ABCC4 T4976C (rs1059751), were analyzed using Taq-Man SNP genotyping assays. Results A total of 273 HIV-infected patients were recruited. The median number of years of TDF treatment was 5.04 with interquartile range (IQR) of 3.9-6.7. Despite the length of treatment with TDF, 98.5% patients maintained an estimated glomerular filtration rate (eGFR) of >60 mL/min as calculated by the CKD-EPI formula. Fifty-four patients (19.8%) showed beta2-microglobulinuria (median 2636 mu g/g Cr with IQR of 1519-13197 mu g/g Cr). The allele frequency of ABCC4 T4976C among those 54 patients was 0.602, compared to 0.475 among the 219 remaining patients (p = 0.018). Conclusions Approximately 20% of HIV-infected patients receiving TDF showed beta2-microglobulinuria. The C allele at position 4976 of the ABCC4 gene was associated with beta2-microglobulinuria in this population. This polymorphism may help to identify patients at greater risk for developing TDF-associated KTD.	[Likanonsakul, Sirirat; Suntisuklappon, Bussakorn; Nitiyanontakij, Ravee; Prasithsirikul, Wisit; Sangsajja, Chariya] Minist Publ Hlth, Dept Dis Control, Bamrasnaradura Infect Dis Inst, Nonthaburi, Thailand; [Nakayama, Emi E.; Shioda, Tatsuo] Osaka Univ, Microbial Dis Res Inst, Dept Viral Infect, Suita, Osaka 565, Japan	Ministry of Public Health - Thailand; Osaka University	Shioda, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Viral Infect, Suita, Osaka 565, Japan.	shioda@biken.osaka-u.ac.jp	Prasithsirikul, Wisit/AAH-6284-2020	ying mei, zhong shan/0000-0002-0477-0980	Ministry of Health, Labor, and Welfare in Japan; Ministry of Education, Culture, Sports, Science, and Technology, Japan; Japan Initiative for Global Research Network on Infectious Diseases; Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand	Ministry of Health, Labor, and Welfare in Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Initiative for Global Research Network on Infectious Diseases(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand	This work was supported by the grant from the Ministry of Health, Labor, and Welfare in Japan, the Ministry of Education, Culture, Sports, Science, and Technology, Japan; the Japan Initiative for Global Research Network on Infectious Diseases, directed by the Ministry of Education, Culture, Sports, Science, and Technology of Japan and Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Calcagno A, 2016, PHARMACOGENOMICS J, V16, P514, DOI 10.1038/tpj.2015.71; Calcagno A, 2013, ANTIMICROB AGENTS CH, V57, P1840, DOI 10.1128/AAC.02434-12; Charoenpak R, 2014, J BAMRASNARADURA INF, V8, P94; Cihlar T, 2001, NUCLEOS NUCLEOT NUCL, V20, P641, DOI 10.1081/NCN-100002341; Ezinga M, 2014, ANTIVIR THER, V19, P765, DOI 10.3851/IMP2761; Gupta SK, 2008, AIDS PATIENT CARE ST, V22, P99, DOI 10.1089/apc.2007.0052; Horberg M, 2010, JAIDS-J ACQ IMM DEF, V53, P62, DOI 10.1097/QAI.0b013e3181be6be2; Izzedine H, 2004, AIDS, V18, P1074, DOI 10.1097/00002030-200404300-00019; Izzedine H, 2005, AM J KIDNEY DIS, V45, P804, DOI 10.1053/j.ajkd.2005.02.010; Izzedine H, 2006, J INFECT DIS, V194, P1481, DOI 10.1086/508546; Izzedine H, 2009, NAT REV NEPHROL, V5, P564, DOI 10.1038/nrneph.2009.142; Labarga P, 2009, AIDS, V23, P689, DOI 10.1097/QAD.0b013e3283262a64; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Lubomirov R, 2011, J INFECT DIS, V203, P246, DOI 10.1093/infdis/jiq043; Manosuthi W, 2014, J ANTIMICROB CHEMOTH, V69, P2195, DOI 10.1093/jac/dku129; Moss DM, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00248; Nelson MR, 2007, AIDS, V21, P1273, DOI 10.1097/QAD.0b013e3280b07b33; Nishijima T, 2012, CLIN INFECT DIS, V55, P1558, DOI 10.1093/cid/cis772; Perazella MA, 2010, KIDNEY INT, V78, P1060, DOI 10.1038/ki.2010.344; Peyriere H, 2004, JAIDS-J ACQ IMM DEF, V35, P269, DOI 10.1097/00126334-200403010-00007; Post FA, 2010, CURR OPIN HIV AIDS, V5, P524, DOI 10.1097/COH.0b013e32833f203e; Post FA, 2010, JAIDS-J ACQ IMM DEF, V55, P49, DOI 10.1097/QAI.0b013e3181dd911e; Pushpakom SP, 2011, J INFECT DIS, V204, P145, DOI 10.1093/infdis/jir215; Ray AS, 2006, ANTIMICROB AGENTS CH, V50, P3297, DOI 10.1128/AAC.00251-06; Robertson EE, 2006, PHARMACOL THERAPEUT, V109, P399, DOI 10.1016/j.pharmthera.2005.07.005; Rodriguez-Novoa S, 2010, AIDS, V24, P1064, DOI 10.1097/QAD.0b013e32833202e2; Rodriguez-Novoa S, 2009, CLIN INFECT DIS, V48, pE108, DOI 10.1086/598507; Uwai Y, 2007, PHARM RES, V24, P811, DOI 10.1007/s11095-006-9196-x; Van Aubel RAMH, 2005, AM J PHYSIOL-RENAL, V288, pF327, DOI 10.1152/ajprenal.00133.2004; Woodward CLN, 2009, HIV MED, V10, P482, DOI 10.1111/j.1468-1293.2009.00716.x; Zimmermann AE, 2006, CLIN INFECT DIS, V42, P283, DOI 10.1086/499048	31	22	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147724	10.1371/journal.pone.0147724	http://dx.doi.org/10.1371/journal.pone.0147724			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26807589	Green Published, Green Submitted, gold			2023-01-03	WOS:000369527800196
J	Chochinov, HM				Chochinov, Harvey Max			Physician-Assisted Death in Canada	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH-CARE; EUTHANASIA		[Chochinov, Harvey Max] Univ Manitoba, Winnipeg, MB, Canada	University of Manitoba	Chochinov, HM (corresponding author), CancerCare Manitoba, 3017-675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	hchochinov@cancercare.mb.ca		Chochinov, Harvey/0000-0003-2656-4704				Chochinov HM, 2014, CURR ONCOL, V21, pE668, DOI 10.3747/co.21.2239; Marcoux I, 2007, CAN J PUBLIC HEALTH, V98, P235, DOI 10.1007/BF03403719; Marcoux I, 2015, CAN FAM PHYSICIAN, V61, pE196; Schuklenk U, ROYAL SOC CANADA EXP; who, WHO DEF PALL CAR; Wilson KG, 2007, HEALTH PSYCHOL, V26, P314, DOI 10.1037/0278-6133.26.3.314	6	15	16	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					253	254		10.1001/jama.2015.17435	http://dx.doi.org/10.1001/jama.2015.17435			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784766				2023-01-03	WOS:000368371400015
J	Gulland, A				Gulland, Anne			HOMELESS HEALTH Keeping homeless patients off the streets	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												agulland@bmj.com						Crisis, 2011, HIDD TRUTH HOM ENGL; Department for Communities and Local Government, 2015, ROUGH SLEEP STAT ENG; Department of Health, 2010, HEALTHC SINGL HOM PE; Healthwatch England, 2015, SAF HOM WHAT HAPP PE; Institute for Health Equity, 2013, WORK HLTH EQ ROL HLT; Royal College of Emergency Medicine, 2015, INCL HLTH CLIN AUD	6	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 19	2016	352								i318	10.1136/bmj.i318	http://dx.doi.org/10.1136/bmj.i318			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC4ZO	26786634				2023-01-03	WOS:000369229700011
J	Oliver, D				Oliver, David			ACUTE PERSPECTIVE David Oliver: Rehabilitation is part of medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						Alzheimer's Society, 2009, COUNT COST CAR PEOPL; Blunt I, 2014, FOCUS A E ATTENDANCE; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; Ellis G, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6553; Hubbard RE, 2004, AGE AGEING, V33, P479, DOI 10.1093/ageing/afh164; Mudge AM, 2011, J HOSP MED, V6, P61, DOI 10.1002/jhm.811; NHS Benchmarking Network, 2014, NAT AUD INT CAR SUMM; NHS Benchmarking Network, 2015, RAIS STAND SHAR EXC; Oliver D, 2008, J ROY SOC MED, V101, P168, DOI 10.1258/jrsm.2008.080017; Royal College of Physicians, 2015, HOSP EDG TIM ACT; Young J., 2015, CHANGING CARE SYSTEM	11	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 19	2016	352								i270	10.1136/bmj.i270	http://dx.doi.org/10.1136/bmj.i270			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC4ZO	26786383	Bronze, Green Published			2023-01-03	WOS:000369229700005
J	Strnad, V; Ott, OJ; Hildebrandt, G; Kauer-Dorner, D; Knauerhase, H; Major, T; Lyczek, J; Guinot, JL; Dunst, J; Miguelez, CG; Slampa, P; Allgaeuer, M; Loessl, K; Polat, B; Kovacs, G; Fischedick, AR; Wendt, TG; Fietkau, R; Hindemith, M; Resch, A; Kulik, A; Arribas, L; Niehoff, P; Guedea, F; Schlamann, A; Poetter, R; Gall, C; Malzer, M; Uter, W; Polgar, C				Strnad, Vratislav; Ott, Oliver J.; Hildebrandt, Guido; Kauer-Dorner, Daniela; Knauerhase, Hellen; Major, Tibor; Lyczek, Jaroslaw; Guinot, Jose Luis; Dunst, Juergen; Gutierrez Miguelez, Cristina; Slampa, Pavel; Allgaeuer, Michael; Loessl, Kristina; Polat, Buelent; Kovacs, Gyoergy; Fischedick, Arnt-Rene; Wendt, Thomas G.; Fietkau, Rainer; Hindemith, Marion; Resch, Alexandra; Kulik, Anna; Arribas, Leo; Niehoff, Peter; Guedea, Fernando; Schlamann, Annika; Poetter, Richard; Gall, Christine; Malzer, Martina; Uter, Wolfgang; Polgar, Csaba		GEC ESTRO	5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial	LANCET			English	Article							LUMPECTOMY PLUS TAMOXIFEN; RADIATION-THERAPY; INTRAOPERATIVE RADIOTHERAPY; FOLLOW-UP; CANCER; WOMEN; MANAGEMENT; TOXICITY; SURVIVAL; OLDER	Background In a phase 3, randomised, non-inferiority trial, accelerated partial breast irradiation (APBI) for patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment was compared with whole-breast irradiation. Here, we present 5-year follow-up results. Methods We did a phase 3, randomised, non-inferiority trial at 16 hospitals and medical centres in seven European countries. 1184 patients with low-risk invasive and ductal carcinoma in situ treated with breast-conserving surgery were centrally randomised to either whole-breast irradiation or APBI using multicatheter brachytherapy. The primary endpoint was local recurrence. Analysis was done according to treatment received. This trial is registered with ClinicalTrials.gov, number NCT00402519. Findings Between April 20, 2004, and July 30, 2009, 551 patients had whole-breast irradiation with tumour-bed boost and 633 patients received APBI using interstitial multicatheter brachytherapy. At 5-year follow-up, nine patients treated with APBI and five patients receiving whole-breast irradiation had a local recurrence; the cumulative incidence of local recurrence was 1.44% (95% CI 0.51-2.38) with APBI and 0.92% (0.12-1.73) with whole-breast irradiation (difference 0. 52%, 95% CI -0.72 to 1.75; p=0.42). No grade 4 late side-effects were reported. The 5-year risk of grade 2-3 late side-effects to the skin was 3.2% with APBI versus 5.7% with whole-breast irradiation (p=0.08), and 5-year risk of grade 2-3 subcutaneous tissue late side-effects was 7.6% versus 6.3% (p=0.53). The risk of severe (grade 3) fibrosis at 5 years was 0.2% with whole-breast irradiation and 0% with APBI (p=0.46). Interpretation The difference between treatments was below the relevance margin of 3 percentage points. Therefore, adjuvant APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer is not inferior to adjuvant whole-breast irradiation with respect to 5-year local control, disease-free survival, and overall survival. Funding German Cancer Aid.	[Strnad, Vratislav; Ott, Oliver J.; Fietkau, Rainer] Univ Hosp Erlangen, Dept Radiat Oncol, D-91054 Erlangen, Germany; [Major, Tibor; Polgar, Csaba] Natl Inst Oncol, Ctr Radiotherapy, Budapest, Hungary; [Hildebrandt, Guido; Hindemith, Marion; Schlamann, Annika] Univ Hosp Leipzig, Dept Radiat Oncol, Leipzig, Germany; [Hildebrandt, Guido; Knauerhase, Hellen; Fietkau, Rainer] Univ Hosp Rostock, Dept Radiat Oncol, Rostock, Germany; [Kauer-Dorner, Daniela; Resch, Alexandra; Poetter, Richard] Univ Hosp AKH Wien, Dept Radiat Oncol, Vienna, Austria; [Lyczek, Jaroslaw; Kulik, Anna] Inst Marii Sklodowskej, Ctr Onkol, Brachytherapy Dept, Warsaw, Poland; [Lyczek, Jaroslaw] Podkarpacki Hosp, Canc Ctr Brzozow, Brzozow, Poland; [Guinot, Jose Luis; Arribas, Leo] Valencian Inst Oncol, Dept Radiat Oncol, Valencia, Spain; [Dunst, Juergen; Niehoff, Peter] Univ Hosp Kiel, Dept Radiat Oncol, Kiel, Germany; [Niehoff, Peter] Univ Witten Herdecke, Dept Radiotherapy, Municipal Hosp Cologne, Witten, Germany; [Gutierrez Miguelez, Cristina; Guedea, Fernando] Catalan Inst Oncol, Dept Radiat Oncol, Barcelona, Spain; [Slampa, Pavel] Masaryk Mem Canc Inst, Dept Radiat Oncol, Brno, Czech Republic; [Loessl, Kristina] Univ Hosp Bern, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland; [Allgaeuer, Michael] Hosp Barmherzige Bruder Regensburg, Dept Radiat Oncol, Regensburg, Germany; [Kovacs, Gyoergy] Med Univ Lubeck, Interdisciplinary Brachytherapy Unit, D-23538 Lubeck, Germany; [Fischedick, Arnt-Rene] Clemens Hosp, Dept Radiat Oncol, Munster, Germany; [Polat, Buelent] Univ Hosp Wurzburg, Dept Radiat Oncol, Wurzburg, Germany; [Wendt, Thomas G.] Univ Hosp Jena, Dept Radiat Oncol, Jena, Germany; [Gall, Christine; Malzer, Martina; Uter, Wolfgang] Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; National Institute of Oncology Hungary; Leipzig University; University of Rostock; University Hospital Vienna; Instituto Valenciano De Oncologia; University of Kiel; Schleswig Holstein University Hospital; Witten Herdecke University; Catalan Institute of Oncology; Masaryk Memorial Cancer Institute; University of Bern; University Hospital of Bern; University of Lubeck; University of Wurzburg; Friedrich Schiller University of Jena; University of Erlangen Nuremberg	Strnad, V (corresponding author), Univ Hosp Erlangen, Dept Radiat Oncol, D-91054 Erlangen, Germany.	vratislav.strnad@uk-erlangen.de	Fietkau, Rainer/A-9632-2017; Niehoff, Peter/Y-4535-2018; , Tibor/N-1003-2019; Dunst, Juergen/D-2138-2010; Ott, Oliver J./AAH-2608-2021; Polat, Bülent/R-1481-2019	Ott, Oliver J./0000-0001-5806-6158; Polat, Bülent/0000-0003-4677-424X; Potter, Richard/0000-0002-0703-572X; Major, Tibor/0000-0002-4672-6910; Resch, Alexandra/0000-0001-5413-6331	German Cancer Aid	German Cancer Aid(Deutsche Krebshilfe)	German Cancer Aid.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Abe O, 2005, LANCET, V366, P2087; Bartelink H, 2015, LANCET ONCOL, V16, P47, DOI 10.1016/S1470-2045(14)71156-8; Csaba P, 2010, RADIOTHER ONCOL, V94, P274, DOI 10.1016/j.radonc.2010.01.019; Dodwell DJ, 2005, CLIN ONCOL-UK, V17, P618, DOI 10.1016/j.clon.2005.07.018; Gilleard O, 2008, WORLD J SURG ONCOL, V6, DOI 10.1186/1477-7819-6-61; Hepel J, 2015, INT J RADIAT ONCOL, V91, P255, DOI 10.1016/j.ijrobp.2014.09.019; Hughes KS, 2013, J CLIN ONCOL, V31, P2382, DOI 10.1200/JCO.2012.45.2615; Khan AJ, 2012, ANN SURG ONCOL, V19, P1477, DOI 10.1245/s10434-011-2133-1; King TA, 2000, AM J SURG, V180, P299, DOI 10.1016/S0002-9610(00)00454-2; Kirova YM, 2007, INT J RADIAT ONCOL, V68, P359, DOI 10.1016/j.ijrobp.2006.12.011; Kunkler IH, 2015, LANCET ONCOL, V16, P266, DOI 10.1016/S1470-2045(14)71221-5; Lee LJ, 2009, BREAST, V18, pS103, DOI 10.1016/S0960-9776(09)70284-X; Lettmaier S, 2011, RADIOTHER ONCOL, V100, P189, DOI 10.1016/j.radonc.2010.07.011; Livi L, 2015, EUR J CANCER, V51, P451, DOI 10.1016/j.ejca.2014.12.013; Njeh CF, 2012, CRIT REV ONCOL HEMAT, V81, P1, DOI [10.1016/j.critrevonc.2011.01.01, 10.1016/j.critrevonc.2011.01.011]; Offersen BV, 2009, RADIOTHER ONCOL, V90, P1, DOI 10.1016/j.radonc.2008.08.005; Olivotto IA, 2013, J CLIN ONCOL, V31, P4038, DOI 10.1200/JCO.2013.50.5511; Potter R, 2007, INT J RADIAT ONCOL, V68, P334, DOI 10.1016/j.ijrobp.2006.12.045; Polgar C, 2013, RADIOTHER ONCOL, V108, P197, DOI 10.1016/j.radonc.2013.05.008; Polgar C, 2010, STRAHLENTHER ONKOL, V186, P113, DOI 10.1007/s00066-010-3001-9; Ragaz J, 2005, JNCI-J NATL CANCER I, V97, P116, DOI 10.1093/jnci/djh297; Rodriguez N, 2013, INT J RADIAT ONCOL, V87, P1051, DOI 10.1016/j.ijrobp.2013.08.046; RUBIN P, 1995, RADIOTHER ONCOL, V35, P5; Showalter SL, 2013, ANN SURG ONCOL, V20, P1287, DOI 10.1245/s10434-012-2693-8; Strnad V, 2011, INT J RADIAT ONCOL, V80, P17, DOI 10.1016/j.ijrobp.2010.01.020; Toutouzas K, 2013, NEW ENGL J MED, V368, P2524, DOI 10.1056/NEJMc1304601; Vaidya JS, 2014, LANCET, V383, P603, DOI 10.1016/S0140-6736(13)61950-9; Veronesi U, 2013, LANCET ONCOL, V14, P1269, DOI 10.1016/S1470-2045(13)70497-2; Vicini FA, 1997, INT J RADIAT ONCOL, V38, P301, DOI 10.1016/S0360-3016(97)00035-7	30	439	447	2	66	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	2016	387	10015					229	238		10.1016/S0140-6736(15)00471-7	http://dx.doi.org/10.1016/S0140-6736(15)00471-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA9LQ	26494415				2023-01-03	WOS:000368130700030
J	Zhou, H; Wang, FZ; Liu, L; Zhang, M; Chen, XZ; Jin, SY				Zhou Huan; Wang Fuzhi; Liu Lu; Zhang Min; Chen Xingzhi; Jin Shiyang			Comparisons of Adherence to Antiretroviral Therapy in a High- Risk Population in China: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							INCOME COUNTRIES; MIDDLE-INCOME; BIAS	Background Reports on antiretroviral therapy (ART) adherence are scare in China; we performed this meta-analysis to estimate ART adherence rates in different populations at high risk for HIV transmission in China. Methods We searched PubMed, Chinese Biomedical Literature Database (Chinese), China National Knowledge Infrastructure (Chinese), and Wanfang (Chinese) to identify studies published from January 1985 to May 2015. We used random-effects meta-analysis to calculate weighted mean estimates across studies and 95% CIs. Data were pooled with proportions transformed prior to pooling using the Freeman-Tukey double arcsine transformation and then back transformed to the original scale. We calculated the I-2 (and its 95% confidence intervals) and tau(2) to assess between-study heterogeneity. Results We identified 36 eligible articles, including 6885 HIV-positive individuals, reporting ART adherence. Pooled analysis produced an estimate of 77.61% (95% CI = 71.63-83.08) of patients with HIV with adequate adherence; however, high heterogeneity was observed between studies (I-2 = 96.60%, 95% CI = 96.00%-97.20%; tau(2) = 0.16). Three studies, which included 149 old HIV-infected patients, reported the highest ART adequate adherence rate (89.39%, 95% CI = 72.01-99.26) with high heterogeneity between the studies (I-2 = 86.20%, 95% CI = 60.00-95.20%; tau(2) = 0.13). While, only two studies, which included 143 heterosexual transmission group (HTG) patients, reported the lowest ART adequate adherence rate (51.55%, 95% CI = 41.33-61.71) with low heterogeneity between the studies (I-2 = 31.3%, tau(2) = 0.007). In the multivariable meta-regression model, high-risk populations was the main factor explaining heterogeneity (variance explained 28.14%). Conclusions ART adherence in some high-risk populations (e.g., heterosexual transmission group) is below the recommended levels for maintaining virologic suppression. It is crucial to develop comprehensive intervention strategies to promote ART adherence in high-risk populations and effectively prevent the spread of HIV/AIDS in China.	[Zhou Huan; Jin Shiyang] Bengbu Med Coll, Affiliated Hosp 1, Bengbu 233000, Anhui, Peoples R China; [Zhou Huan; Wang Fuzhi; Liu Lu; Zhang Min; Chen Xingzhi] Bengbu Med Coll, Dept Hlth Management, Bengbu 233000, Anhui, Peoples R China	Bengbu Medical College; Bengbu Medical College	Jin, SY (corresponding author), Bengbu Med Coll, Affiliated Hosp 1, Bengbu 233000, Anhui, Peoples R China.	jsybbmc@163.com						Ailika S, 2013, CHINESE J HLTH ED, P687; Brockwell SE, 2001, STAT MED, V20, P825, DOI 10.1002/sim.650; Chang YL, 2010, XINJIANG MED J, V11, P78; Chen S.-C., 2013, INT J ANTENN PROPAG, V2013, P1, DOI DOI 10.1103/PHYSREVLETT.110.155003; Dai F, 2014, J QILU NURSING, V20, P77; Deng MH, 2012, CHINESE FOREIGN MED, V10, P70; Dong XB, 2014, MED INFORM, V27, P612; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Feelemyer J, 2015, AIDS BEHAV, V19, P575, DOI 10.1007/s10461-014-0928-3; Gui XiuZhi, 2012, Maternal and Child Health Care of China, V27, P4683; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hu HH, 2012, EFFECT PREVENTION MO; Kicinski M, 2015, STAT MED, V34, P2781, DOI 10.1002/sim.6525; Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930; Lee SS, 2007, INT J STD AIDS, V18, P167, DOI 10.1258/095646207780132497; Li AiJie, 2012, Chinese Journal of Dermatovenereology, V26, P516; Li ZJ, 2015, MED INFORM, V28, P317; Liu AW, 2007, ANHUI J PREV MED, V20, P414; Liu J, 2013, CHIN J AIDS STD, V19, P2; Liu J.W., 2013, COMPUT MATH METHOD M, V2013, P10, DOI DOI 10.3724/SP.J.1146.2013.01820; Liu MR, 2014, MED PEOPLE, V27, P28; [刘霞 LIU Xia], 2011, [中华检验医学杂志, Chinese Journal of Laboratory Medicine], V34, P542; Lu J, 2008, CHIN J AIDS STD, V14, P569; Lu J, 2009, PROSPECTIVE COHORT S; Maartens G, 2014, LANCET, V384, P258, DOI 10.1016/S0140-6736(14)60164-1; Mhaskar Rahul, 2013, Indian J Community Med, V38, P74, DOI 10.4103/0970-0218.112435; MILLER JJ, 1978, AM STAT, V32, P138, DOI 10.2307/2682942; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Mittlbock M, 2006, STAT MED, V25, P4321, DOI 10.1002/sim.2692; Mountain E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105645; Nachega JB, 2012, AIDS, V26, P2039, DOI 10.1097/QAD.0b013e328359590f; Nachega Jean B., 2011, Infectious Disorders - Drug Targets, V11, P167; Ortego C, 2011, AIDS BEHAV, V15, P1381, DOI 10.1007/s10461-011-9942-x; Ortego C, 2011, GAC SANIT, V25, P282, DOI 10.1016/j.gaceta.2010.10.016; Pang J, 2009, YOUJIANG NATL MED J, V03, P432; Qiao JK, 2014, CHIN J AIDS STD, V20, P428; Qin YL, 2013, MOD HOSP, V13, P147; Rostom A, CELIAC DIS; Su FQ, 2011, GUANGXI MED J, V33, P1662; [王红红 WANG Honghong], 2008, [中国行为医学科学, Chinese Journal of Behavioral Medical Science], V17, P881; Wang LH, 2009, CHIN J AIDS STD, V15, P352; Wang Q., 2011, THESIS; Wang Q, 2013, CHIN J AIDS STD, V19, P393; Wang Yong-zhong, 2009, Zhonghua Yufang Yixue Zazhi, V43, P277, DOI 10.3760/cma.j.issn.0253-9624.2009.04.003; Wang YZ, 2008, CHINESE J MATERNAL C, V19, P407; Wei XB, 2012, CHINESE NURSING RES, V26, P842; Wu HongPing, 2013, Maternal and Child Health Care of China, V28, P1313; [杨成彬 Yang Chengbin], 2010, [中国全科医学, Chinese General Practice], V13, P3188; Ye HL, 2013, CHINESE NURSING RES, V27, P4055; Yu R., 2007, THESIS; Yuan Y., 2012, MODERN PREV MED, V39, P5954; Zeng H, 2016, SEX TRANSM INFECT, V92, P116, DOI 10.1136/sextrans-2014-051877; Zhang L, 2013, LANCET INFECT DIS, V13, P955, DOI 10.1016/S1473-3099(13)70245-7; Zhou, 2008, THESIS NE NORMAL U J; Zhou YF, 2012, CHIN J AIDS STD, V18, P746	55	3	8	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2016	11	1							e0146659	10.1371/journal.pone.0146659	http://dx.doi.org/10.1371/journal.pone.0146659			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6CG	26756336	Green Published, Green Submitted, gold			2023-01-03	WOS:000367888800023
J	Rebeiro, PF; Gange, SJ; Horberg, MA; Abraham, AG; Napravnik, S; Samji, H; Yehia, BR; Althoff, KN; Moore, RD; Kitahata, MM; Sterling, TR; Curriero, FC				Rebeiro, Peter F.; Gange, Stephen J.; Horberg, Michael A.; Abraham, Alison G.; Napravnik, Sonia; Samji, Hasina; Yehia, Baligh R.; Althoff, Keri N.; Moore, Richard D.; Kitahata, Mari M.; Sterling, Timothy R.; Curriero, Frank C.		North Amer AIDS Cohort	Geographic Variations in Retention in Care among HIV-Infected Adults in the United States	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; MEDICAL-CARE; ESTIMATING EQUATIONS; INFORMATION-SYSTEMS; CLINICAL COHORT; MISSED VISITS; CELL COUNTS; DISPARITIES; MORTALITY; HIV/AIDS	Objective To understand geographic variations in clinical retention, a central component of the HIV care continuum and key to improving individual-and population-level HIV outcomes. Design We evaluated retention by US region in a retrospective observational study. Methods Adults receiving care from 2000-2010 in 12 clinical cohorts of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) contributed data. Individuals were assigned to Centers for Disease Control and Prevention (CDC)-defined regions by residential data (10 cohorts) and clinic location as proxy (2 cohorts). Retention was >= 2 primary HIV outpatient visits within a calendar year, >90 days apart. Trends and regional differences were analyzed using modified Poisson regression with clustering, adjusting for time in care, age, sex, race/ethnicity, and HIV risk, and stratified by baseline CD4+ count. Results Among 78,993 adults with 444,212 person-years of follow-up, median time in care was 7 years (Interquartile Range: 4-9). Retention increased from 2000 to 2010: from 73% (5,000/6,875) to 85% (7,189/8,462) in the Northeast, 75% (1,778/2,356) to 87% (1,630/1,880) in the Midwest, 68% (8,451/12,417) to 80% (9,892/12,304) in the South, and 68% (5,147/7,520) to 72% (6,401/8,895) in the West. In adjusted analyses, retention improved over time in all regions (p<0.01, trend), although the average percent retained lagged in the West and South vs. the Northeast (p<0.01). Conclusions In our population, retention improved, though regional differences persisted even after adjusting for demographic and HIV risk factors. These data demonstrate regional differences in the US which may affect patient care, despite national care recommendations.	[Rebeiro, Peter F.; Sterling, Timothy R.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Gange, Stephen J.; Abraham, Alison G.; Althoff, Keri N.; Moore, Richard D.; Curriero, Frank C.] Johns Hopkins Univ, Baltimore, MD USA; [Horberg, Michael A.] Kaiser Permanente Midatlantic States, Midatlantic Permanente Res Inst, Rockville, MD USA; [Napravnik, Sonia] Univ N Carolina, Chapel Hill, NC USA; [Samji, Hasina] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Yehia, Baligh R.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Kitahata, Mari M.] Univ Washington, Sch Med, Seattle, WA USA	Vanderbilt University; Johns Hopkins University; Kaiser Permanente; University of North Carolina; University of North Carolina Chapel Hill; B.C. Centre for Excellence in HIV/AIDS; University of Pennsylvania; Pennsylvania Medicine; University of Washington; University of Washington Seattle	Rebeiro, PF (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.	p.rebeiro@vanderbilt.edu	Althoff, Keri N/HGC-5595-2022; Gange, Stephen/AGY-5004-2022	Gange, Stephen/0000-0001-7842-512X; Rebeiro, Peter/0000-0003-1951-9104; Althoff, Keri/0000-0002-5068-6595; Samji, Hasina/0000-0002-4555-7609	National Institutes of Health, USA [U01-AI069918, U01-AA013566, U24-AA020794, U01-AA020790, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI38855]; Center's for Disease Control and Prevention, USA [CDC200-2006-18797]; Agency for Healthcare Research and Quality, USA [90047713]; Health Resources and Services Administration, USA [90051652]; Canadian Institutes of Health Research, Canada [TGF-96118, HCP-97105, CBR-86906, CBR-94036]; Ontario Ministry of Health and Long Term Care; Government of Alberta, Canada;  [K01-AI071754];  [K01-AI093197];  [K23 EY013707];  [K24-AI065298];  [K24-00432];  [MO1-RR-00052];  [N02-CP55504];  [P30-AI027763];  [P30-AI094189];  [P30-AI27757];  [P30-AI27767];  [P30-AI50410];  [P30-AI54999];  [P30-AI036219];  [P30-MH62246];  [R01-CA165937];  [R01-AA16893];  [R01-DA11602];  [U01-DA0356935];  [R01-DA04334];  [F31-DA035713];  [G12-MD007583];  [U01-AI38858];  [U01-AI42590];  [U01-AI68634];  [U01-AI68636];  [U01-AI69432];  [U01-AI69434];  [U01-HD32632];  [U10-EY08057];  [U10-EY08052];  [U10-EY08067];  [R01-DA12568];  [R24-AI067039];  [R56-AI102622];  [Z01-CP010214];  [Z01-CP010176];  [UL1-RR024131];  [UL1-TR000083];  [U54-MD007587]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD032632] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA165937, Z01CP010176] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000083] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052, UL1RR024131] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [U10EY008057, K23EY013707, U10EY008067, U10EY008052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI037613, R56AI102622, U01AI037984, U01AI035042, U01AI038858, U01AI069918, P30AI036219, P30AI050410, U01AI031834, U01AI038855, U01AI042590, U01AI034989, P30AI027757, U01AI035043, U01AI035041, U01AI069432, P30AI027763, K01AI071754, U01AI069434, P30AI054999, U01AI068634, U01AI034993, U01AI035039, K01AI093197, P30AI094189, U01AI068636, U01AI034994, U01AI035004, P30AI045008, K24AI065298, R24AI067039, P30AI110527, U01AI035040, P30AI027767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [U01AA013566, R01AA016893, U24AA020794, U01AA020790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA035713, R01DA004334, R01DA011602, R01DA012568] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [G12MD007583, U54MD007587] Funding Source: NIH RePORTER	National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center's for Disease Control and Prevention, USA(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Agency for Healthcare Research and Quality, USA(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Health Resources and Services Administration, USA; Canadian Institutes of Health Research, Canada(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario); Government of Alberta, Canada; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by grants U01-AI069918, U01-AA013566, U24-AA020794, U01-AA020790, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636, U01-AI69432, U01-AI69434, U01-HD32632, U10-EY08057, U10-EY08052, U10-EY08067, UL1-RR024131, UL1-TR000083, U54-MD007587, F31-DA035713, G12-MD007583, K01-AI071754, K01-AI093197, K23 EY013707, K24-AI065298, K24-00432, MO1-RR-00052, N02-CP55504, P30-AI027763, P30-AI094189, P30-AI27757, P30-AI27767, P30-AI50410, P30-AI54999, P30-AI036219, P30-MH62246, R01-CA165937, R01-AA16893, R01-DA11602, U01-DA0356935, R01-DA04334, R01-DA12568, R24-AI067039, R56-AI102622, Z01-CP010214, and Z01-CP010176 from the National Institutes of Health, USA; contract CDC200-2006-18797 from the Center's for Disease Control and Prevention, USA; contract 90047713 from the Agency for Healthcare Research and Quality, USA; contract 90051652 from the Health Resources and Services Administration, USA; grants TGF-96118, HCP-97105, CBR-86906, CBR-94036 from the Canadian Institutes of Health Research, Canada; Ontario Ministry of Health and Long Term Care; and the Government of Alberta, Canada.	Althoff KN, 2014, CLIN INFECT DIS, V58, P1185, DOI 10.1093/cid/ciu044; Althoff KN, 2012, ANN INTERN MED, V157, P325, DOI 10.7326/0003-4819-157-5-201209040-00005; An Qian, 2012, Morbidity and Mortality Weekly Report, V61, P805; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2011, CLIN INFECT DIS, DOI DOI 10.1093/cid/ciq043; [Anonymous], RMS REGRESSION MODEL; [Anonymous], 2013, ACCELERATING IMPROVE; [Anonymous], 2011, NAT HIST GEOGR INF S; Baum CF, 2008, STATA J, V8, P299, DOI 10.1177/1536867X0800800212; Berg MB, 2005, AIDS CARE, V17, P902, DOI 10.1080/09540120500101658; Centers for Disease Control and Prevention, 2013, HIV SURV REP, V25; Cohen Stacy M., 2011, Morbidity and Mortality Weekly Report, V60, P1618; Eberhart MG, 2013, JAIDS-J ACQ IMM DEF, V64, pS42, DOI 10.1097/QAI.0b013e3182a90112; Edison L, 2014, MMWR-MORBID MORTAL W, V63, P55; Ford MA, 2012, MONITORING HIV CARE; Gange SJ, 2007, INT J EPIDEMIOL, V36, P294, DOI 10.1093/ije/dyl286; Gao S, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-8; Gardiner JC, 2009, STAT MED, V28, P221, DOI 10.1002/sim.3478; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Geanuracos CG, 2007, AM J PUBLIC HEALTH, V97, P1974, DOI 10.2105/AJPH.2005.076851; Gill MJ, 2009, INT J STD AIDS, V20, P540, DOI 10.1258/ijsa.2008.008422; Giordano TP, 2007, CLIN INFECT DIS, V44, P1493, DOI 10.1086/516778; Hanna DB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078952; Hanna DB, 2013, CLIN INFECT DIS, V56, P1174, DOI 10.1093/cid/cit003; Hanna DB, 2012, AIDS, V26, P95, DOI 10.1097/QAD.0b013e32834dcf87; Hixson BA, 2011, J URBAN HEALTH, V88, P129, DOI 10.1007/s11524-010-9510-0; Holtgrave DR, 2012, AIDS BEHAV, V16, P1365, DOI 10.1007/s10461-012-0207-0; Houle B, 2009, AM J PUBLIC HEALTH, V99, P308, DOI 10.2105/AJPH.2008.138750; Howe CJ, 2010, AIDS RES HUM RETROV, V26, P875, DOI 10.1089/aid.2009.0282; Hsu LC, 2011, AIDS CARE, V23, P383, DOI 10.1080/09540121.2010.507740; Hubbard AE, 2010, EPIDEMIOLOGY, V21, P467, DOI 10.1097/EDE.0b013e3181caeb90; Improving Outcomes, IMPR OUTC ACC PROGR; Jones SG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048036; Klassen AC, 2006, AM J PREV MED, V30, pS77, DOI 10.1016/j.amepre.2005.09.010; Klassen Ann Carroll, 2005, Int J Health Geogr, V4, P1, DOI 10.1186/1476-072X-4-1; Koch T, 2004, J GEOGR, V103, P76, DOI 10.1080/00221340408978578; Koch T., 2004, CARTOGRAPHICA, V39, P1, DOI DOI 10.3138/B123-8124-4390-5792; Kurth AE, 2012, JAIDS-J ACQ IMM DEF, V1; Lau B, 2007, AIDS RES HUM RETROV, V23, P769, DOI 10.1089/aid.2006.0171; Marks G, 2010, AIDS, V24, P2665, DOI 10.1097/QAD.0b013e32833f4b1b; Morris TP, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-75; Mugavero MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P100, DOI 10.1097/QAI.0b013e31818d5c37; Mugavero MJ, 2009, CLIN INFECT DIS, V48, P248, DOI 10.1086/595705; Musal M, 2013, STAT MED, V32, P267, DOI 10.1002/sim.5457; Namosha E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069279; Niyonsenga T, 2013, AIDS BEHAV, V17, P700, DOI 10.1007/s10461-012-0236-8; Pan W, 2002, STAT SINICA, V12, P475; Papke L.E., 1993, ECONOMETRIC METHODS; Park WB, 2007, J INTERN MED, V261, P268, DOI 10.1111/j.1365-2796.2006.01762.x; Rebeiro P, 2013, JAIDS-J ACQ IMM DEF, V62, P356, DOI 10.1097/QAI.0b013e31827f578a; Rebeiro PF, 2015, AM J EPIDEMIOL, V182, P952, DOI 10.1093/aje/kwv181; Rebeiro PF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111772; Reif S., 2011, HIV AIDS EPIDEMIC S; Richards TB, 1999, PUBLIC HEALTH REP, V114, P359, DOI 10.1093/phr/114.4.359; Shacham E, 2013, HIV MED, V14, P624, DOI 10.1111/hiv.12067; Stone VE, 2012, CURR INFECT DIS REP, V14, P53, DOI 10.1007/s11908-011-0226-4; Tanser F, 2009, INT J EPIDEMIOL, V38, P1008, DOI 10.1093/ije/dyp148; The White House, 2021, NAT HIV AIDS STRAT U; Torian LV, 2011, AIDS PATIENT CARE ST, V25, P79, DOI 10.1089/apc.2010.0151; Ulett KB, 2009, AIDS PATIENT CARE ST, V23, P41, DOI 10.1089/apc.2008.0132; Wallace RG, 2003, SOC SCI MED, V56, P1155, DOI 10.1016/S0277-9536(02)00121-1; Westergaard RP, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-10; Whiteside YO, 2014, MMWR-MORBID MORTAL W, V63, P85; Yan J, 2004, STAT MED, V23, P859, DOI 10.1002/sim.1650; Yehia Baligh, 2011, Am J Public Health, V101, pe4, DOI 10.2105/AJPH.2011.300259; Zou GY, 2013, STAT METHODS MED RES, V22, P661, DOI 10.1177/0962280211427759; [No title captured]	67	36	36	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0146119	10.1371/journal.pone.0146119	http://dx.doi.org/10.1371/journal.pone.0146119			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DA6CA	26752637	Green Published, Green Submitted, gold			2023-01-03	WOS:000367888100045
J	Varma, SR; Sivaprakasam, TO; Mishra, A; Kumar, LMS; Prakash, NS; Prabhu, S; Ramakrishnan, S				Varma, Sandeep R.; Sivaprakasam, Thiyagarajan O.; Mishra, Abheepsa; Kumar, L. M. Sharath; Prakash, N. S.; Prabhu, Sunil; Ramakrishnan, Shyam			Protective Effects of Triphala on Dermal Fibroblasts and Human Keratinocytes	PLOS ONE			English	Article							OXIDATIVE STRESS; IN-VITRO; SCAVENGING ACTIVITY; RAT ERYTHROCYTES; STRAND BREAKS; NITRIC-OXIDE; HUMAN SKIN; ANTIOXIDANT; TYROSINASE; EXTRACT	Human skin is body's vital organ constantly exposed to abiotic oxidative stress. This can have deleterious effects on skin such as darkening, skin damage, and aging. Plant-derived products having skin-protective effects are well-known traditionally. Triphala, a formulation of three fruit products, is one of the most important rasayana drugs used in Ayurveda. Several skin care products based on Triphala are available that claim its protective effects on facial skin. However, the skin protective effects of Triphala extract (TE) and its mechanistic action on skin cells have not been elucidated in vitro. Gallic acid, ellagic acid, and chebulinic acid were deduced by LC-MS as the major constituents of TE. The identified key compounds were docked with skin-related proteins to predict their binding affinity. The IC50 values for TE on human dermal fibroblasts (HDF) and human keratinocytes (HaCaT) were 204.90 +/- 7.6 and 239.13 +/- 4.3 mu g/mL respectively. The antioxidant capacity of TE was 481.33 +/- 1.5 mM Trolox equivalents in HaCaT cells. Triphala extract inhibited hydrogen peroxide (H2O2) induced RBC haemolysis (IC50 64.95 mu g/mL), nitric oxide production by 48.62 +/- 2.2%, and showed high reducing power activity. TE also rescued HDF from H2O2-induced damage; inhibited H2O2 induced cellular senescence and protected HDF from DNA damage. TE increased collagen-I, involucrin and filaggrin synthesis by 70.72 +/- 2.3%, 67.61 +/- 2.1% and 51.91 +/- 3.5% in HDF or HaCaT cells respectively. TE also exhibited anti-tyrosinase and melanin inhibition properties in a dose-dependent manner. TE increased the mRNA expression of collagen-I, elastin, superoxide dismutase (SOD-2), aquaporin-3 (AQP-3), filaggrin, involucrin, transglutaminase in HDF or HaCaT cells, and decreased the mRNA levels of tyrosinase in B16F10 cells. Thus, Triphala exhibits protective benefits on skin cells in vitro and can be used as a potential ingredient in skin care formulations.	[Varma, Sandeep R.; Sivaprakasam, Thiyagarajan O.; Mishra, Abheepsa; Kumar, L. M. Sharath; Prakash, N. S.; Prabhu, Sunil; Ramakrishnan, Shyam] Himalaya Drug Co, Res & Dev, Bangalore 562162, Karnataka, India	Himalaya Drug Company	Varma, SR (corresponding author), Himalaya Drug Co, Res & Dev, Bangalore 562162, Karnataka, India.	dr.sandeepvarma@himalayawellness.com	Mishra, Abheepsa/I-6872-2019	Mishra, Abheepsa/0000-0002-8242-6800	Himalaya Drug Company, India	Himalaya Drug Company, India	The funding for this project was done by The Himalaya Drug Company, India. All the authors of this study are regular employees of the Himalaya Drug Company. The study was conducted as part of the project work funded by the Himalaya drug Company, India. The company provided all the support to the study which include author salaries, study design, data collection, decision to publish, and preparation of the manuscript.	Ajila CM, 2008, FOOD CHEM TOXICOL, V46, P303, DOI 10.1016/j.fct.2007.08.024; Azhar-ul-Haq, 2006, PHYTOMEDICINE, V13, P255, DOI 10.1016/j.phymed.2004.09.001; Bag A, 2013, INDIAN J EXP BIOL, V51, P709; Baliga MS, 2012, CHIN J INTEGR MED, V18, P946, DOI 10.1007/s11655-012-1299-x; Baurin N, 2002, J ETHNOPHARMACOL, V82, P155, DOI 10.1016/S0378-8741(02)00174-5; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Bernard P., 2000, International Journal of Cosmetic Science, V22, P219, DOI 10.1046/j.1467-2494.2000.00019.x; Brenner M, 2008, PHOTOCHEM PHOTOBIOL, V84, P539, DOI 10.1111/j.1751-1097.2007.00226.x; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Chen QM, 2000, BIOGERONTOLOGY, V1, P335, DOI 10.1023/A:1026590501344; Chung YC, 2002, J AGR FOOD CHEM, V50, P2454, DOI 10.1021/jf011369q; Coleman JW, 2002, CLIN EXP IMMUNOL, V129, P4, DOI 10.1046/j.1365-2249.2002.01918.x; Cuppett SL, 1997, ANTIOXIDANT METHODOL, P41; Deep G, 2005, J EXP CLIN CANC RES, V24, P555; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ding HY, 2011, J MED PLANTS RES, V5, P237; Duncan EL, 2000, BIOGERONTOLOGY, V1, P103, DOI 10.1023/A:1010000132671; Fulop T, 2012, PATHOL BIOL, V60, P28, DOI 10.1016/j.patbio.2011.10.006; Furukawa A, 2007, CELL PHYSIOL BIOCHEM, V20, P45, DOI 10.1159/000104152; Gopaul R, 2011, INT J COSMETIC SCI, V33, P416, DOI 10.1111/j.1468-2494.2011.00645.x; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; Hitomi K, 2005, EUR J DERMATOL, V15, P313; Jagetia GC, 2004, PHYTOTHER RES, V18, P561, DOI 10.1002/ptr.1494; Jagetia GC, 2002, PHYTOMEDICINE, V9, P99, DOI 10.1078/0944-7113-00095; Janjetovic Z, 2014, J PINEAL RES, V57, P90, DOI 10.1111/jpi.12146; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Kaczvinsky JR, 2009, J DRUGS DERMATOL, V8, pS15; Kim YJ, 2006, BIOSCI BIOTECH BIOCH, V70, P532, DOI 10.1271/bbb.70.532; Kim YJ, 2013, BIOL PHARM BULL, V36, P1341, DOI 10.1248/bpb.b13-00276; Korhonen Riku, 2005, Current Drug Targets - Inflammation and Allergy, V4, P471, DOI 10.2174/1568010054526359; Kumar KJS, 2010, PHYTOTHER RES, V24, P1158, DOI 10.1002/ptr.3018; Kurtz A, 2012, PREV MED, V54, pS50, DOI 10.1016/j.ypmed.2012.01.003; Lee K. T., 1997, International Journal of Cosmetic Science, V19, P291, DOI 10.1046/j.1467-2494.1997.171725.x; Li J, 2010, AUSTRALAS J DERMATOL, V51, P106, DOI 10.1111/j.1440-0960.2010.00629.x; Lloyd DR, 1999, MUTAT RES-FUND MOL M, V424, P23, DOI 10.1016/S0027-5107(99)00005-6; Lu K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043934; Manayi A, 2014, EXPERT OPIN DRUG DIS, V9, P383, DOI 10.1517/17460441.2014.885014; Menon, 2012, INT J PHARM PHARM SC, V4, P714; Mensah AY, 2001, J ETHNOPHARMACOL, V77, P219, DOI 10.1016/S0378-8741(01)00297-5; Mias C, 2009, STEM CELLS, V27, P2734, DOI 10.1002/stem.169; Mishra A, 2014, PEPTIDES, V54, P148, DOI 10.1016/j.peptides.2014.01.023; Mora P.C., 2000, POLYM BIOMATERIALS, V2nd ed., P459; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mukherjee PK, 2011, PHYTOMEDICINE, V19, P64, DOI 10.1016/j.phymed.2011.10.003; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; Naik GH, 2006, CURR SCI INDIA, V90, P1100; Nakayama H, 2000, COSMET SCI TECHNOL S, P123; Pawar V, 2009, INDIAN J PHARM SCI, V71, P382, DOI 10.4103/0250-474X.57286; Pellati F, 2013, J ETHNOPHARMACOL, V147, P277, DOI 10.1016/j.jep.2013.02.025; Prota G, 1996, COSMET TOILETRIES, V111, P43; Qian ZJ, 2008, BIORESOURCE TECHNOL, V99, P1690, DOI 10.1016/j.biortech.2007.04.005; Rajesh KP, 2013, IND CROP PROD, V47, P186, DOI 10.1016/j.indcrop.2013.03.008; Reddy CSSS, 2007, TOXICOL IN VITRO, V21, P1355, DOI 10.1016/j.tiv.2007.06.010; Robinson MK, 2009, J DRUGS DERMATOL, V8, pS8; ROSS WM, 1982, CAN J OPHTHALMOL, V17, P61; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sandeep RV, 2014, SCI PHARM, V82, P375, DOI [10.3797/scipharm.1310-25, DOI 10.3797/SCIPHARM.1310-25]; Shimogaki H., 2000, International Journal of Cosmetic Science, V22, P291, DOI 10.1046/j.1467-2494.2000.00023.x; Shimogaki H, 1996, AM AC DERM 54 ANN M, P280; SHINDO Y, 1994, J INVEST DERMATOL, V102, P122, DOI 10.1111/1523-1747.ep12371744; Singh DP, 2008, PHYTOCHEM ANALYSIS, V19, P164, DOI 10.1002/pca.1032; Sivanandham V., 2011, PHARMACOLOGYONLINE, V1, P1062; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2012, PIGM CELL MELANOMA R, V25, P14, DOI 10.1111/j.1755-148X.2011.00898.x; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Slominski AT, 2014, INT J MOL SCI, V15, P17705, DOI 10.3390/ijms151017705; SLOMINSKI AT, 2014, ANTI-CANCER AGENT ME, V14, P77, DOI DOI 10.2174/18715206113139990308; SNYDER LM, 1985, J CLIN INVEST, V76, P1971, DOI 10.1172/JCI112196; Sung JH, 2009, BIOSCI BIOTECH BIOCH, V73, P552, DOI 10.1271/bbb.80601; Svobodova Alena, 2003, Biomedical Papers (Olomouc), V147, P137; Tanaka Y, 2001, PIGMENT CELL RES, V14, P495; Thomas C, 2009, REDOX REP, V14, P102, DOI 10.1179/135100009X392566; Tierra M, 1996, WONDERS TRIPHALA AYU; Tiwari AK, 2004, CURR SCI INDIA, V86, P1092; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P859, DOI 10.1016/0891-5849(95)02184-1; Treiber N, 2012, DERM-ENDOCRINOL, V4, DOI 10.4161/derm.21819; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Vasile E, 2001, FASEB J, V15, P458, DOI 10.1096/fj.00-0051com; Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019; WATT FM, 1983, J INVEST DERMATOL, V81, pS100, DOI 10.1111/1523-1747.ep12540786; Wolfe K, 2003, J AGR FOOD CHEM, V51, P609, DOI 10.1021/jf020782a; Zheng Q, 2013, CLIN COSMET INVESTI, V6, P317, DOI 10.2147/CCID.S51958; Zheng ZP, 2009, J AGR FOOD CHEM, V57, P6649, DOI 10.1021/jf9014685	83	29	31	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2016	11	1							e0145921	10.1371/journal.pone.0145921	http://dx.doi.org/10.1371/journal.pone.0145921			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA4VZ	26731545	Green Submitted, Green Published, gold			2023-01-03	WOS:000367801400065
J	Bouras, G; Burns, EM; Howell, AM; Bottle, A; Athanasiou, T; Darzi, A				Bouras, George; Burns, Elaine Marie; Howell, Ann-Marie; Bottle, Alex; Athanasiou, Thanos; Darzi, Ara			Risk of Post-Discharge Venous Thromboembolism and Associated Mortality in General Surgery: A Population-Based Cohort Study Using Linked Hospital and Primary Care Data in England	PLOS ONE			English	Article							CANCER; IMPACT; COMPLICATIONS; PROPHYLAXIS; DURATION	Background Trends towards day case surgery and enhanced recovery mean that postoperative venous thromboembolism (VTE) may increasingly arise after hospital discharge. However, hospital data alone are unable to capture adverse events that occur outside of the hospital setting. The National Institute for Health and Care Excellence has suggested the use of primary care data to quantify hospital care-related VTE. Data in surgical patients using these resources is lacking. The aim of this study was to measure VTE risk and associated mortality in general surgery using linked primary care and hospital databases, to improve our understanding of harm from VTE that arises beyond hospital stay. Methods This was a longitudinal cohort study using nationally linked primary care (Clinical Practice Research Datalink, CPRD), hospital administrative (Hospital Episodes Statistics, HES), population statistics (Office of National Statistics, ONS) and National Cancer Intelligence Network databases. Routinely collected information was used to quantify 90-day in-hospital VTE, 90-day post-discharge VTE and 90-day mortality in adults undergoing one of twelve general surgical procedures between 1st April 1997 and 31st March 2012. The earliest postoperative recording of deep vein thrombosis or pulmonary embolism in CPRD, HES and ONS was counted in each patient. Covariates from multiple datasets were combined to derive detailed prediction models for VTE and mortality. Limitation included the capture of VTE presenting to healthcare only and the lack of information on adherence to pharmacological thromboprophylaxis as there was no data linkage to hospital pharmacy records. Results There were 981 VTE events captured within 90 days of surgery in 168005 procedures (23.7/1000 patient-years). Overall, primary care data increased the detection of postoperative VTE by a factor of 1.38 (981/710) when compared with using HES and ONS only. Total VTE rates ranged between 3.2/1000 patient-years in haemorrhoidectomy to 118.3/1000 patient-years in esophagogastric resection. Predictors of VTE included emergency surgery (OR = 1.91 95% CI 1.60-2.28, p<0.001), age (OR = 1.02 95% CI 1.02-1.03, p<0.001), body mass index (OR = 1.03 95% CI 1.01-1.04, p<0.001), previous VTE (OR = 8.07 95% CI 6.61-9.83, p<0.001), length of stay (OR = 1.00 95% CI 1.00-1.00, p = 0.007) and cancer stages II (OR = 1.38 95% CI 1.03-1.87, p = 0.033), III (OR = 1.50 95% CI 1.11-2.01, p = 0.008) and IV (OR = 1.63 95% CI 1.03-2.59, p = 0.038). Major organ resections had the greatest odds of VTE when adjusted for other risk factors including length of hospital stay. Post-discharge VTE accounted for 64.8% (636/981) of all recorded VTE. In-hospital VTE (165.4/1000 patient-years) was recorded more frequently than post-discharge VTE (16.2/1000 patient-years). Both in-hospital (OR = 2.07 95% CI 1.51-2.85, p<0.001) and post-discharge (OR = 4.03 95% CI 2.95-5.51, p<0.001) VTE independently predicted 90-day mortality. In patients who died and VTE was recorded on HES or CPRD (n = 56), VTE was one of the causes of death in 37.5% (21/56) of cases. Conclusions A large proportion of postoperative VTE was detected in primary care. Evaluation of linked databases was a useful way of measuring postoperative VTE at population level. These resources identified a significant association between post-discharge VTE and mortality in general surgery.	[Bouras, George; Burns, Elaine Marie; Howell, Ann-Marie; Athanasiou, Thanos; Darzi, Ara] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Surg & Canc, London W2 1NY, England; [Bottle, Alex] Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Epidemiol & Publ Hlth, London EC4Y 8EN, England	Imperial College London; Imperial College London	Bouras, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Surg & Canc, Praed St, London W2 1NY, England.	g.bouras@imperial.ac.uk	Burns, Elaine/V-5416-2019		Sowerby Foundation; National Institute for Health Research [NF-SI-0510-10186] Funding Source: researchfish	Sowerby Foundation; National Institute for Health Research(National Institute for Health Research (NIHR))	This project was supported by the Sowerby Foundation.	Agnelli G, 2004, CIRCULATION, V110, P4, DOI 10.1161/01.CIR.0000150639.98514.6c; Bergqvist D, 2002, NEW ENGL J MED, V346, P975, DOI 10.1056/NEJMoa012385; Bottle A., UNDERSTANDING HSMRS; Bouras G, 2014, ANN SURG; Burns EM, 2012, J PUBLIC HEALTH-UK, V34, P138, DOI 10.1093/pubmed/fdr054; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017844, 10.1371/journal.pone.0017876, 10.1371/journal.pone.0027333, 10.1371/journal.pone.0021428, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0024144]; Darzi A, 2008, HIGH QUALITY CARE AL; Dyer J, 2013, ANN ROY COLL SURG, V95, P65, DOI 10.1308/003588413X13511609956219; Eaton SC, 2008, PHARMACOEPIDEMIOL DR, V17; Gangireddy C, 2007, J VASC SURG, V45, P335, DOI 10.1016/j.jvs.2006.10.034; Huerta C, 2007, ARCH INTERN MED, V167, P935, DOI 10.1001/archinte.167.9.935; Jameson SS, 2010, J BONE JOINT SURG BR, V92B, P123, DOI 10.1302/0301-620X.92B1.22751; Kazaure HS, 2012, ARCH SURG-CHICAGO, V147, P1000, DOI 10.1001/2013.jamasurg.114; Lawrenson R, 2000, BRIT J CLIN PHARMACO, V49, P591, DOI 10.1046/j.1365-2125.2000.00199.x; Lester W, 2013, HEART, V99, P1734, DOI 10.1136/heartjnl-2013-304479; LOWE GDO, 1992, BMJ-BRIT MED J, V305, P567; Majeed Azeem, 2004, Health Stat Q, P5; Merkow RP, 2013, CANCER-AM CANCER SOC, V119, P1412, DOI 10.1002/cncr.27891; Merkow RP, 2011, ANN SURG, V254, P131, DOI 10.1097/SLA.0b013e31821b98da; Muntz J, 2010, AM J SURG, V200, P413, DOI 10.1016/j.amjsurg.2009.05.045; National Institute for Health and Care Excellence, 2010, VEN THROMB DEEP VEIN, V92; Pannucci CJ, 2012, ANN SURG, V255, P1093, DOI 10.1097/SLA.0b013e3182519ccf; Raftery J, 2005, HEALTH TECHNOL ASSES, V9, pIII; Reinke CE, 2012, SURGERY, V152, P186, DOI 10.1016/j.surg.2012.05.003; Seaman HE, 2007, BJU INT, V99, P1398, DOI 10.1111/j.1464-410X.2007.06859.x; Sobin LH, 2009, TNM CLASSIFICATION M, V7th, DOI DOI 10.1002/9780471420194.TNMC26.PUB2; Sultan AA, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6099; Sutton PA, 2012, ANN ROY COLL SURG, V94, P481, DOI 10.1308/003588412X13171221592096; Sweetland S, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4583; Tsang C, 2013, BRIT J GEN PRACT, V63, pE534, DOI 10.3399/bjgp13X670660; Vinogradova Y, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004499; Walker AJ, 2014, J THROMB HAEMOST, V12, P641, DOI 10.1111/jth.12533; Walker AJ, 2013, EUR J CANCER, V49, P1404, DOI 10.1016/j.ejca.2012.10.021; White RH, 2003, THROMB HAEMOSTASIS, V90, P446, DOI 10.1160/TH03-03-0152	34	30	33	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2015	10	12							e0145759	10.1371/journal.pone.0145759	http://dx.doi.org/10.1371/journal.pone.0145759			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0IX	26713434	Green Published, gold, Green Submitted			2023-01-03	WOS:000367481900077
J	Bryan, R; Aronson, JK; ten Hacken, P; Williams, A; Jordan, S				Bryan, Rachel; Aronson, Jeffrey K.; ten Hacken, Pius; Williams, Alison; Jordan, Sue			Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names	PLOS ONE			English	Article							VISUAL WORD RECOGNITION; SOUND-ALIKE DRUGS; LOOK-ALIKE; DOUBLE-BLIND; ERRORS; MEDICINES; SIMILARITY; LENGTH	Background Confusion between look-alike and sound-alike (LASA) medication names (such as mercaptamine and mercaptopurine) accounts for up to one in four medication errors, threatening patient safety. Error reduction strategies include computerized physician order entry interventions, and 'Tall Man' lettering. The purpose of this study is to explore the medication name designation process, to elucidate properties that may prime the risk of confusion. Methods and Findings We analysed the formal and semantic properties of 7,987 International Non-proprietary Names (INNs), in relation to naming guidelines of the World Health Organization (WHO) INN programme, and have identified potential for errors. We explored: their linguistic properties, the underlying taxonomy of stems to indicate pharmacological interrelationships, and similarities between INNs. We used Microsoft Excel for analysis, including calculation of Levenshtein edit distance (LED). Compliance with WHO naming guidelines was inconsistent. Since the 1970s there has been a trend towards compliance in formal properties, such as word length, but longer names published in the 1950s and 1960s are still in use. The stems used to show pharmacological interrelationships are not spelled consistently and the guidelines do not impose an unequivocal order on them, making the meanings of INNs difficult to understand. Pairs of INNs sharing a stem (appropriately or not) often have high levels of similarity (< 5 LED), and thus have greater potential for confusion. Conclusions We have revealed a tension between WHO guidelines stipulating use of stems to denote meaning, and the aim of reducing similarities in nomenclature. To mitigate this tension and reduce the risk of confusion, the stem system should be made clear and well ordered, so as to avoid compounding the risk of confusion at the clinical level. The interplay between the different WHO INN naming principles should be further examined, to better understand their implications for the problem of LASA errors.	[Bryan, Rachel; Williams, Alison; Jordan, Sue] Swansea Univ, Swansea, W Glam, Wales; [Aronson, Jeffrey K.] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [ten Hacken, Pius] Univ Innsbruck, Inst Translat Studies, A-6020 Innsbruck, Austria	Swansea University; University of Oxford; University of Innsbruck	Bryan, R (corresponding author), Swansea Univ, Swansea, W Glam, Wales.	r.bryan@swansea.ac.uk	jordan, sue/O-1297-2019; Bryan, Rachel/Q-9347-2016; Hacken, Pius ten/AAJ-2641-2021	jordan, sue/0000-0002-5691-2987; Bryan, Rachel/0000-0001-8617-3882; 	Arts and Humanities Research Council; AHRC	Arts and Humanities Research Council(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC)); AHRC(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC))	The authors report no grants, no funding, no sponsors for the current work. R Bryan was funded by the Arts and Humanities Research Council between 2009 and 2012, for a Master's, during which time she developed an early incantation of this study and presented it in her thesis.; Rachel Bryan was funded by the Arts and Humanities Research Council (AHRC) between 2009 and 2012 to complete a Master's, during which she developed an early incantation of this study. The authors thank the AHRC for their support. We are particularly grateful for the critical remarks of Kent Vrana and an anonymous reviewer, whose suggestions enabled us to improve our paper considerably.	Aronson JK, 2009, QJM-INT J MED, V102, P513, DOI 10.1093/qjmed/hcp052; Bryan R, 2015, WORD FORMATION TRANS; Choi SH, 2002, J NEUROSCI RES, V67, P411, DOI 10.1002/jnr.10102; Coltheart M, 2001, PSYCHOL REV, V108, P204, DOI 10.1037//0033-295X.108.1.204; DAVE NK, 1990, ANN ALLERGY, V65, P298; Dogne Jean-Michel, 2002, Am J Respir Med, V1, P11; Emmerton LM, 2012, INT J CLIN PHARM-NET, V34, P4, DOI 10.1007/s11096-011-9595-x; Galanter WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101977; Garfield S., 2010, JUST MY TYPE BOOK FO; Ghaleb MA, 2010, ARCH DIS CHILD, V95, P113, DOI 10.1136/adc.2009.158485; Jordan S, 2014, J NURS MANAGE, V22, P271, DOI 10.1111/jonm.12238; Kaushal R, 2001, JAMA-J AM MED ASSOC, V285, P2114, DOI 10.1001/jama.285.16.2114; Kovacic Laurel, 2011, J Oncol Pharm Pract, V17, P104, DOI 10.1177/1078155209354135; Lambert BL, 2005, DRUG SAFETY, V28, P495, DOI 10.2165/00002018-200528060-00003; Lambert BL, 2003, SOC SCI MED, V57, P1939, DOI 10.1016/S0277-9536(03)00059-5; Lambert BL, 2001, DRUG INF J, V35, P163, DOI 10.1177/009286150103500119; Lambert BL, 1999, MED CARE, V37, P1214, DOI 10.1097/00005650-199912000-00005; Low JG, 2014, LANCET INFECT DIS, V14, P706, DOI 10.1016/S1473-3099(14)70730-3; [MHPRA Medicines and Healthcare Products Regulatory Agency], 2002, MERC MERC CONF DRUG; Moorman SM, 2008, GERONTOLOGIST, V48, P811, DOI 10.1093/geront/48.6.811; National Patient Safety Agency NPSA, 2006, GUID GRAPH DES MED P; National Reporting and Learning Service NRLS, 2009, SAF DOS IMPR US MED; New B, 2006, PSYCHON B REV, V13, P45, DOI 10.3758/BF03193811; Nute Christine, 2014, Nurs Stand, V29, P45, DOI 10.7748/ns.29.12.45.e9191; Ostini Remo, 2012, Int J Pharm Pract, V20, P349, DOI 10.1111/j.2042-7174.2012.00210.x; Rastle K, 1998, PSYCHON B REV, V5, P277, DOI 10.3758/BF03212951; Runciman WB, 2003, INT J QUAL HEALTH C, V15, pI49, DOI 10.1093/intqhc/mzg085; Sanders C, 2004, CAMBRIDGE COMPANION; Sauberan JB, 2010, AM J HEALTH-SYST PH, V67, P49, DOI 10.2146/ajhp090122; Tuohy N, 2005, J EMERG NURS, V31, P569, DOI 10.1016/j.jen.2005.07.012; WHO, 1997, GUID US INT NONPR NA; World Health Organization WHO, 2009, WHO STEMB 2009 US ST	32	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0145431	10.1371/journal.pone.0145431	http://dx.doi.org/10.1371/journal.pone.0145431			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CZ4SI	26701761	Green Published, Green Submitted, gold			2023-01-03	WOS:000367092600079
J	Maier, LJ; Liakoni, E; Schildmann, J; Schaub, MP; Liechti, ME				Maier, Larissa J.; Liakoni, Evangelia; Schildmann, Jan; Schaub, Michael P.; Liechti, Matthias E.			Swiss University Students' Attitudes toward Pharmacological Cognitive Enhancement	PLOS ONE			English	Article							NEUROENHANCEMENT; METHYLPHENIDATE	Pharmacological cognitive enhancement (PCE) refers to the nonmedical use of prescription or recreational drugs to enhance cognitive performance. Several concerns about PCE have been raised in the public. The aim of the present study was to investigate students' attitudes toward PCE. Students at three Swiss universities were invited by e-mail to participate in a web-based survey. Of the 29,282 students who were contacted, 3,056 participated. Of these students, 22% indicated that they had used prescription drugs (12%) or recreational substances including alcohol (14%) at least once for PCE. The use of prescription drugs or recreational substances including alcohol prior to the last exam was reported by 16%. Users of pharmacological cognitive enhancers were more likely to consider PCE fair (24%) compared with nonusers (11%). Only a minority of the participants agreed with the nonmedical use of prescription drugs by fellow students when assuming weak (7%) or hypothetically strong efficacy and availability to everyone (14%). Two-thirds (68%) considered performance that is obtained with PCE less worthy of recognition. Additionally, 80% disagreed that PCE is acceptable in a competitive environment. More than half (64%) agreed that PCE in academia is similar to doping in sports. Nearly half (48%) claimed that unregulated access to pharmacological cognitive enhancers increases the pressure to engage in PCE and educational inequality (55%). In conclusion, Swiss students' main concerns regarding PCE were related to coercion and fairness. As expected, these concerns were more prevalent among nonusers than among users of pharmacological cognitive enhancers. More balanced information on PCE should be shared with students, and future monitoring of PCE is recommended.	[Maier, Larissa J.; Schaub, Michael P.] Univ Zurich, Associated Inst, Swiss Res Inst Publ Hlth & Addict ISGF, Zurich, Switzerland; [Maier, Larissa J.; Schaub, Michael P.] WHO Collaborating Ctr, Zurich, Switzerland; [Liakoni, Evangelia; Liechti, Matthias E.] Univ Basel Hosp, Dept Clin Res, Div Clin Pharmacol & Toxicol, CH-4031 Basel, Switzerland; [Schildmann, Jan] Ruhr Univ Bochum, Inst Med Eth & Geschichte Med, Bochum, Germany	University of Zurich; World Health Organization; University of Basel; Ruhr University Bochum	Liechti, ME (corresponding author), Univ Basel Hosp, Dept Clin Res, Div Clin Pharmacol & Toxicol, CH-4031 Basel, Switzerland.	matthias.liechti@usb.ch	Schaub, Michael P./ABF-9468-2021; Maier, Larissa/P-8669-2014; Maier, Larissa J/C-2922-2017	Schaub, Michael P./0000-0002-8375-4005; Maier, Larissa/0000-0002-4302-0488; Maier, Larissa J/0000-0002-4302-0488; Schildmann, Jan/0000-0002-5755-7630	Division of Clinical Pharmacology & Toxicology, University Hospital Basel; Swiss Centre of Applied Human Toxicology (SCAHT); Swiss Research Institute for Public Health and Addiction (ISGF), Zurich	Division of Clinical Pharmacology & Toxicology, University Hospital Basel; Swiss Centre of Applied Human Toxicology (SCAHT); Swiss Research Institute for Public Health and Addiction (ISGF), Zurich	This study was supported by internal funds from the Division of Clinical Pharmacology & Toxicology, University Hospital Basel (ML), Swiss Centre of Applied Human Toxicology (SCAHT) (ML), and Swiss Research Institute for Public Health and Addiction (ISGF), Zurich (MS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bagot KS, 2014, ADDICTION, V109, P547, DOI 10.1111/add.12460; Bell S, 2013, NEUROETHICS-NETH, V6, P197, DOI 10.1007/s12152-012-9153-9; de Jongh R, 2008, NEUROSCI BIOBEHAV R, V32, P760, DOI 10.1016/j.neubiorev.2007.12.001; Dodge T, 2012, PSYCHOL ADDICT BEHAV, V26, P678, DOI 10.1037/a0027872; Faulmuller N, 2013, AM J BIOETHICS, V13, P45, DOI 10.1080/15265161.2013.794880; Forlini C, 2014, NEUROETHICS; Forlini C, 2009, BMC MED ETHICS, V10, DOI 10.1186/1472-6939-10-9; Franke AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040047; Franke AndreasG., 2012, AJOB PRIMARY RES, V3, P48, DOI [DOI 10.1080/21507716.2011.608411, 10.1080/21507716.2011.608411]; Goold I, 2015, MED LAW REV, V23, P427, DOI 10.1093/medlaw/fwu028; Hall W., 2012, AJOB PRIMARY RES, V3, P81, DOI [DOI 10.1080/21507716.2012.720639, 10.1080/21507716.2012.720639]; Maier LJ, 2015, EUR PSYCHOL, V20, P155, DOI 10.1027/1016-9040/a000228; Maier LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077967; Maslen H, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00107; Ott R, 2014, PHARMACOPSYCHIATRY, V47, P22, DOI 10.1055/s-0033-1358682; Partridge B., 2014, PERMANCE ENHANCEM, V3, P20, DOI [https://doi.org/10.1016/j.peh.2014.03.001, DOI 10.1016/J.PEH.2014.03.001]; Partridge B, 2013, DRUG ALCOHOL REV, V32, P295, DOI 10.1111/dar.12005; Repantis D, 2010, PHARMACOL RES, V62, P187, DOI 10.1016/j.phrs.2010.04.002; Sattler S, 2014, SUBST ABUSE TREAT PR, V9, DOI 10.1186/1747-597X-9-8; Sattler S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068821; Schelle KJ, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00010; Schelle KJ, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00053; Shook JR, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00228	23	17	17	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2015	10	12							e0144402	10.1371/journal.pone.0144402	http://dx.doi.org/10.1371/journal.pone.0144402			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CZ1YZ	26657300	Green Accepted, Green Published, gold			2023-01-03	WOS:000366903500026
J	Murakami, T; Qamar, S; Lin, JQ; Schierle, GSK; Rees, E; Miyashita, A; Costa, AR; Dodd, RB; Chan, FTS; Michel, CH; Kronenberg-Versteeg, D; Li, Y; Yang, SP; Wakutani, Y; Meadows, W; Ferry, RR; Dong, L; Tartaglia, GG; Favrin, G; Lin, WL; Dickson, DW; Zhen, M; Ron, D; Schmitt-Ulms, G; Fraser, PE; Shneider, NA; Holt, C; Vendruscolo, M; Kaminski, CF; St George-Hyslop, P				Murakami, Tetsuro; Qamar, Seema; Lin, Julie Qiaojin; Schierle, Gabriele S. Kaminski; Rees, Eric; Miyashita, Akinori; Costa, Ana R.; Dodd, Roger B.; Chan, Fiona T. S.; Michel, Claire H.; Kronenberg-Versteeg, Deborah; Li, Yi; Yang, Seung-Pil; Wakutani, Yosuke; Meadows, William; Ferry, Rodylyn Rose; Dong, Liang; Gaetano Tartaglia, Gian; Favrin, Giorgio; Lin, Wen-Lang; Dickson, Dennis W.; Zhen, Mei; Ron, David; Schmitt-Ulms, Gerold; Fraser, Paul E.; Shneider, Neil A.; Holt, Christine; Vendruscolo, Michele; Kaminski, Clemens F.; St George-Hyslop, Peter			ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function	NEURON			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; UNFOLDED PROTEIN RESPONSE; CELL-FREE FORMATION; CAENORHABDITIS-ELEGANS; STRESS GRANULES; MESSENGER-RNA; LOCAL TRANSLATION; IN-VIVO; AGGREGATION	The mechanisms by which mutations in FUS and other RNA binding proteins cause ALS and FTD remain controversial. We propose a model in which low-complexity (LC) domains of FUS drive its physiologically reversible assembly into membrane-free, liquid droplet and hydrogel-like structures. ALS/FTD mutations in LC or non-LC domains induce further phase transition into poorly soluble fibrillar hydrogels distinct from conventional amyloids. These assemblies are necessary and sufficient for neurotoxicity in a C. elegans model of FUS-dependent neurodegeneration. They trap other ribonucleoprotein (RNP) granule components and disrupt RNP granule function. One consequence is impairment of new protein synthesis by cytoplasmic RNP granules in axon terminals, where RNP granules regulate local RNA metabolism and translation. Nuclear FUS granules may be similarly affected. Inhibiting formation of these fibrillar hydrogel assemblies mitigates neurotoxicity and suggests a potential therapeutic strategy that may also be applicable to ALS/FTD associated with mutations in other RNA binding proteins.	[Murakami, Tetsuro; Miyashita, Akinori; Yang, Seung-Pil; Wakutani, Yosuke; Ferry, Rodylyn Rose; Schmitt-Ulms, Gerold; Fraser, Paul E.; St George-Hyslop, Peter] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; [Murakami, Tetsuro; Miyashita, Akinori; Yang, Seung-Pil; Wakutani, Yosuke; Ferry, Rodylyn Rose; Schmitt-Ulms, Gerold; Fraser, Paul E.; St George-Hyslop, Peter] Univ Toronto, Dept Med Med Biophys & Lab Med, Toronto, ON M5S 3H2, Canada; [Murakami, Tetsuro; Miyashita, Akinori; Yang, Seung-Pil; Wakutani, Yosuke; Ferry, Rodylyn Rose; Schmitt-Ulms, Gerold; Fraser, Paul E.; St George-Hyslop, Peter] Univ Toronto, Dept Pathobiol, Toronto, ON M5S 3H2, Canada; [Qamar, Seema; Costa, Ana R.; Dodd, Roger B.; Kronenberg-Versteeg, Deborah; Li, Yi; Meadows, William; Dong, Liang; St George-Hyslop, Peter] Univ Cambridge, Cambridge Inst Med Res, Cambridge Natl Inst Hlth Res, Biomed Res Unit Dementia, Cambridge CB2 0XY, England; [Lin, Julie Qiaojin; Holt, Christine] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3DY, England; [Schierle, Gabriele S. Kaminski; Rees, Eric; Chan, Fiona T. S.; Michel, Claire H.; Kaminski, Clemens F.] Univ Cambridge, Dept Chem Engn & Biotechnol, Cambridge CB2 3RA, England; [Gaetano Tartaglia, Gian; Vendruscolo, Michele] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; [Gaetano Tartaglia, Gian] Ctr Genom Regulat, Barcelona 08003, Spain; [Gaetano Tartaglia, Gian] Univ Pompeu Fabra, Barcelona 08003, Spain; [Gaetano Tartaglia, Gian] ICREA, Barcelona 08010, Spain; [Favrin, Giorgio] Univ Cambridge, Cambridge Syst Biol Ctr, Cambridge CB2 1GA, England; [Favrin, Giorgio] Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; [Lin, Wen-Lang; Dickson, Dennis W.] Mayo Clin, Coll Med, Dept Res, Neurosci, Jacksonville, FL 32224 USA; [Zhen, Mei] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Zhen, Mei] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1X5, Canada; [Ron, David] Univ Cambridge, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 0XY, England; [Shneider, Neil A.] Columbia Univ, Med Ctr, Ctr Motor Neuron Biol & Dis, Dept Neurol, New York, NY 10032 USA	University of Toronto; University of Toronto; University of Toronto; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; ICREA; University of Cambridge; University of Cambridge; Mayo Clinic; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Cambridge; Columbia University	St George-Hyslop, P (corresponding author), Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada.	phs22@cam.ac.uk	Shneider, Neil/ABF-5751-2020; Kronenberg-Versteeg, Deborah/AAW-5442-2020; Lin, Qiaojin/ABA-3382-2020; Chan, Felix/O-8875-2016; Kaminski, Clemens/G-7488-2016; Costa, Ana Rita AR/G-6341-2016; Lin, Julie Qiaojin/AAY-5309-2020; Vendruscolo, Michele/F-5901-2012; Zhen, Mei/A-4967-2012; Tartaglia, Gian Gaetano/K-1229-2014	Shneider, Neil/0000-0002-3223-7366; Kronenberg-Versteeg, Deborah/0000-0003-0965-9998; Lin, Qiaojin/0000-0002-2669-6478; Chan, Felix/0000-0001-7374-2396; Kaminski, Clemens/0000-0002-5194-0962; Costa, Ana Rita AR/0000-0002-2855-0472; Lin, Julie Qiaojin/0000-0002-2669-6478; Vendruscolo, Michele/0000-0002-3616-1610; Zhen, Mei/0000-0003-0086-9622; St George-Hyslop, Peter/0000-0003-0796-7209; Dodd, Roger/0000-0003-4268-1863; Ron, David/0000-0002-3014-5636; Holt, Christine Elizabeth/0000-0003-2829-121X; Rees, Eric/0000-0001-7478-5961; Tartaglia, Gian Gaetano/0000-0001-7524-6310; Yang, Seung-Pil/0000-0003-3980-7103	Canadian Institutes of Health Research; Alzheimer Society of Ontario; Wellcome Trust; Medical Research Council; NIH Research; Alzheimer Research UK; Gates Cambridge Scholarship; Engineering and Physical Sciences Research Council; European Research Council [RIBOMYLOME_309545]; European Research Council under the European Union's Seventh Framework Programme (FP)/ERC [322817]; National Institute of Neurological Disorders and Stroke [R01 NS07377]; EPSRC [EP/H018301/1] Funding Source: UKRI; MRC [G0902243, MC_G1000734, MR/K02292X/1] Funding Source: UKRI; ICREA Funding Source: Custom; Alzheimers Research UK [ARUK-EG2012A-1, ARUK-PG2013-14, ARUK-ESG2012-1] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/H018301/1] Funding Source: researchfish; Medical Research Council [G0902243, MR/K02292X/1, MC_G1000734] Funding Source: researchfish	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Alzheimer Society of Ontario; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIH Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimer Research UK(Alzheimer's Research UK (ARUK)); Gates Cambridge Scholarship; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); European Research Council(European Research Council (ERC)European Commission); European Research Council under the European Union's Seventh Framework Programme (FP)/ERC(European Research Council (ERC)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ICREA(ICREA); Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by Canadian Institutes of Health Research (P.E.F. and P.S.G.-H.), Alzheimer Society of Ontario (P.E.F., P.St.G.H.), Wellcome Trust (P.S.G.-H., M.V., C.F.K., G.S.K.S., D.R., and C.H.), Medical Research Council (P.S.G.-H., M.V., C.F.K., and G.S.K.S.), NIH Research, Alzheimer Research UK (C.F.K. and G.S.K.S.), Gates Cambridge Scholarship (J.Q.L.), Engineering and Physical Sciences Research Council (C.F.K. and G.S.K.S.), European Research Council Starting Grant RIBOMYLOME_309545 (G.G.T.), European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement no. 322817 (C.H.), and National Institute of Neurological Disorders and Stroke R01 NS07377 (N.A.S.). The authors thank Tom Cech and Roy Parker for helpful discussions.	Akbalik G, 2014, SCIENCE, V343, P375, DOI 10.1126/science.1249623; Alami NH, 2014, NEURON, V81, P536, DOI 10.1016/j.neuron.2013.12.018; Anderson P, 2002, CELL STRESS CHAPERON, V7, P213, DOI 10.1379/1466-1268(2002)007<0213:VSTROE>2.0.CO;2; [Anonymous], J MED CHEM, V55, P7193; Bosco DA, 2010, HUM MOL GENET, V19, P4160, DOI 10.1093/hmg/ddq335; Brangwynne CP, 2009, SCIENCE, V324, P1729, DOI 10.1126/science.1172046; Cairns NJ, 2007, ACTA NEUROPATHOL, V114, P5, DOI 10.1007/s00401-007-0237-2; Couthouis J, 2011, P NATL ACAD SCI USA, V108, P20881, DOI 10.1073/pnas.1109434108; Crocker JC, 1996, J COLLOID INTERF SCI, V179, P298, DOI 10.1006/jcis.1996.0217; DeJesus-Hernandez M, 2010, HUM MUTAT, V31, pE1377, DOI 10.1002/humu.21241; Dieck ST, 2015, NAT METHODS, V12, P411, DOI [10.1038/NMETH.3319, 10.1038/nmeth.3319]; Dixon SJ, 2006, DEVELOPMENT, V133, P1263, DOI 10.1242/dev.02300; Dormann D, 2009, J NEUROCHEM, V110, P1082, DOI 10.1111/j.1471-4159.2009.06211.x; Fang YS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5824; Gao SB, 2011, P NATL ACAD SCI USA, V108, P2557, DOI 10.1073/pnas.1012346108; Gendron TF, 2010, NEUROPATH APPL NEURO, V36, P97, DOI [10.1111/j.1365-2990.2009.01060.x, 10.1111/j.1365-2990.2010.01060.x]; Han TNW, 2012, CELL, V149, P768, DOI 10.1016/j.cell.2012.04.016; Hara M, 2012, J NEUROL, V259, P2237, DOI 10.1007/s00415-012-6542-2; Holt CE, 2013, NEURON, V80, P648, DOI 10.1016/j.neuron.2013.10.036; Jung H, 2014, CELL, V157, P26, DOI 10.1016/j.cell.2014.03.005; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kato M, 2012, CELL, V149, P753, DOI 10.1016/j.cell.2012.04.017; Kent L, 2014, AMYOTROPH LAT SCL FR, V15, P557, DOI 10.3109/21678421.2014.920033; Li YR, 2013, J CELL BIOL, V201, P361, DOI 10.1083/jcb.201302044; Lin AC, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-8; Liu-Yesucevitz L, 2014, J NEUROSCI, V34, P4167, DOI 10.1523/JNEUROSCI.2350-13.2014; Mao XR, 2010, MOL CELL BIOL, V30, P5033, DOI 10.1128/MCB.00922-10; Mitchell SF, 2014, MOL CELL, V54, P547, DOI 10.1016/j.molcel.2014.04.033; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Morita M, 2009, BRAIN RES, V1295, P186, DOI 10.1016/j.brainres.2009.08.002; Murakami T, 2012, HUM MOL GENET, V21, P1, DOI 10.1093/hmg/ddr417; Neumann M, 2007, ARCH NEUROL-CHICAGO, V64, P1388, DOI 10.1001/archneur.64.10.1388; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Rademakers R, 2012, NAT REV NEUROL, V8, P423, DOI 10.1038/nrneurol.2012.117; Ramaswami M, 2013, CELL, V154, P727, DOI 10.1016/j.cell.2013.07.038; Rees CE, 2013, MED EDUC, V47, P154, DOI 10.1111/medu.12055; Robinson JL, 2013, ACTA NEUROPATHOL, V125, P121, DOI 10.1007/s00401-012-1055-8; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schierle GSK, 2011, CHEMPHYSCHEM, V12, P673, DOI 10.1002/cphc.201000996; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Schwartz JC, 2013, CELL REP, V5, P918, DOI 10.1016/j.celrep.2013.11.017; Tartaglia GG, 2008, CHEM SOC REV, V37, P1395, DOI 10.1039/b706784b; Ticozzi N, 2010, CNS NEUROL DISORD-DR, V9, P285, DOI 10.2174/187152710791292585; Uchikado H, 2006, NEUROPATHOLOGY, V26, P417, DOI 10.1111/j.1440-1789.2006.00709.x; van der Zee J, 2014, NAT REV NEUROL, V10, P70, DOI 10.1038/nrneurol.2013.270; Wolozin B, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-56; Yan J, 2010, NEUROLOGY, V75, P807, DOI 10.1212/WNL.0b013e3181f07e0c	47	484	487	5	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	NOV 18	2015	88	4					678	690		10.1016/j.neuron.2015.10.030	http://dx.doi.org/10.1016/j.neuron.2015.10.030			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CX5TR	26526393	hybrid, Green Published			2023-01-03	WOS:000365765900010
J	Shanmuganathan, B; Malar, DS; Sathya, S; Devi, KP				Shanmuganathan, Balakrishnan; Malar, Dicson Sheeja; Sathya, Sethuraman; Devi, Kasi Pandima			Antiaggregation Potential of Padina gymnospora against the Toxic Alzheimer's Beta-Amyloid Peptide(25-35) and Cholinesterase Inhibitory Property of Its Bioactive Compounds	PLOS ONE			English	Article							PRECURSOR PROTEIN; IN-VITRO; BUTYRYLCHOLINESTERASE; AGGREGATION; EXTRACTS; DISEASE	Inhibition of beta-amyloid (A beta) aggregation in the cerebral cortex of the brain is a promising therapeutic and defensive strategy in identification of disease modifying agents for Alzheimer's disease (AD). Since natural products are considered as the current alternative trend for the discovery of AD drugs, the present study aims at the evaluation of anti-amyloidogenic potential of the marine seaweed Padina gymnospora. Prevention of aggregation and disaggregation of the mature fibril formation of A beta(25-35) by acetone extracts of P. gymnospora (ACTPG) was evaluated in two phases by Thioflavin T assay. The results were further confirmed by confocal laser scanning microscopy (CLSM) analysis and Fourier transform infrared (FTIR) spectroscopic analysis. The results of antiaggregation and disaggregation assay showed that the increase in fluorescence intensity of aggregated A beta and the co-treatment of ACTPG (250 mu g/ml) with A beta(25-35), an extensive decrease in the fluorescence intensity was observed in both phases, which suggests that ACTPG prevents the oligomers formation and disaggregation of mature fibrils. In addition, ACTPG was subjected to column chromatography and the bioactivity was screened based on the cholinesterase inhibitory activity. Finally, the active fraction was subjected to LC-MS/MS analysis for the identification of bioactive compounds. Overall, the results suggest that the bioactive compound alpha bisabolol present in the alga might be responsible for the observed cholinesterase inhibition with the IC50 value < 10 mu g/ml for both AChE and BuChE when compared to standard drug donepezil (IC50 value < 6 mu g/ml) and support its use for the treatment of neurological disorders.	[Shanmuganathan, Balakrishnan; Malar, Dicson Sheeja; Sathya, Sethuraman; Devi, Kasi Pandima] Alagappa Univ, Dept Biotechnol, Karaikkudi 630004, Tamil Nadu, India	Alagappa University	Devi, KP (corresponding author), Alagappa Univ, Dept Biotechnol, Sci Campus, Karaikkudi 630004, Tamil Nadu, India.	devikasi@yahoo.com	Devi, Kasi Pandima/J-9172-2012; Devi, Kasi Pandima/U-9565-2019	Devi, Kasi Pandima/0000-0002-6175-8961; Devi, Kasi Pandima/0000-0002-6175-8961; Sethuraman, Sathya/0000-0002-1819-2798; , Dicson Sheeja Malar/0000-0003-4253-9496	Department of Science and Technology, Government of India (DST) [SR/S0/AS-22/2012]; Bioinformatics Infrastructure Facility, Alagappa University - Department of Biotechnology, Ministry of Science and Technology, Government of India [BT/BI/25/015/2012]; DST	Department of Science and Technology, Government of India (DST)(Department of Science & Technology (India)); Bioinformatics Infrastructure Facility, Alagappa University - Department of Biotechnology, Ministry of Science and Technology, Government of India; DST(Department of Science & Technology (India))	This work was supported by Department of Science and Technology, Government of India through Major Research Grant (DST No: SR/S0/AS-22/2012, http://www.dst.gov.in/), Bioinformatics Infrastructure Facility, Alagappa University funded by the Department of Biotechnology, Ministry of Science and Technology, Government of India (No. BT/BI/25/015/2012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; KPD wishes to thank DST, India, for offering Major Research Grant (DST No: SR/S0/AS-22/2012). BS wishes to thank DST for providing fellowship in the form of project fellow. The authors also gratefully acknowledge the use of the Bioinformatics Infrastructure Facility, Alagappa University funded by the Department of Biotechnology, Ministry of Science and Technology, Government of India (No. BT/BI/25/015/2012).	Arendash GW, 2010, J ALZHEIMERS DIS, V20, pS117, DOI 10.3233/JAD-2010-091249; Chander M. P., 2014, International Journal of Current Microbiology and Applied Sciences, V3, P364; Choi EY, 2009, FOOD CHEM TOXICOL, V47, P134, DOI 10.1016/j.fct.2008.10.026; CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; Durairajan SSK, 2008, NEUROCHEM INT, V52, P741, DOI 10.1016/j.neuint.2007.09.006; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Fujiwara H, 2009, J NEUROCHEM, V109, P1648, DOI 10.1111/j.1471-4159.2009.06069.x; Galimberti Daniela, 2011, Ther Adv Neurol Disord, V4, P203, DOI 10.1177/1756285611404470; Ghahremanitamadon F, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/798535; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; Hipkiss AR, 2007, J ALZHEIMERS DIS, V11, P229; Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967; Joshi NVM., 2012, INT J BIO PHAR RES, V3, P956; Kamatou GPP, 2010, J AM OIL CHEM SOC, V87, P1, DOI 10.1007/s11746-009-1483-3; Kayalvizhi K., 2012, INT J PHARM APPL, V3, P306; Krishnamurthy V, 1970, CHECK LIST INDIAN MA, P1; Liu QA, 2011, NEUROCHEM INT, V58, P119, DOI 10.1016/j.neuint.2010.11.004; Mathew M, 2014, INDIAN J EXP BIOL, V52, P606; Mesulam MM, 2002, NEUROSCIENCE, V110, P627, DOI 10.1016/S0306-4522(01)00613-3; Munoz-Ruiz P, 2005, J MED CHEM, V48, P7223, DOI 10.1021/jm0503289; Murugan K, 2014, INDIAN J PHARM SCI, V76, P548; Nielson KA, 1996, BRAIN RES, V741, P284, DOI 10.1016/S0006-8993(96)00983-3; Oza RM, 2003, REVISED CHECKLIST IN, P1; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; Pryor NE, 2012, INT J MOL SCI, V13, P3038, DOI 10.3390/ijms13033038; Ramesh BN, 2010, NEUROSCI LETT, V475, P110, DOI 10.1016/j.neulet.2010.03.062; RATNASOORIYA WD, 1994, CONTRACEPTION, V50, P291, DOI 10.1016/0010-7824(94)90074-4; Rees T, 2003, NEUROBIOL AGING, V24, P777, DOI 10.1016/S0197-4580(02)00230-0; Reid GA, 2015, NEUROSCIENCE, V298, P424, DOI 10.1016/j.neuroscience.2015.04.039; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sun YD, 2008, BIOORGAN MED CHEM, V16, P7177, DOI 10.1016/j.bmc.2008.06.045; Szabo Z, 1999, BIOCHEM BIOPH RES CO, V265, P297, DOI 10.1006/bbrc.1999.1667; Tamagno E, 2012, IUBMB LIFE, V64, P943, DOI 10.1002/iub.1099; Vauzour D, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/914273; Wu HQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109438; Zubia M, 2007, J APPL PHYCOL, V19, P449, DOI 10.1007/s10811-006-9152-5	36	32	35	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2015	10	11							e0141708	10.1371/journal.pone.0141708	http://dx.doi.org/10.1371/journal.pone.0141708			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV5GZ	26536106	Green Submitted, Green Published, gold			2023-01-03	WOS:000364298400079
J	Yu, JB; Shi, J; Zhang, Y; Gong, LR; Dong, SA; Cao, XS; Wu, LL; Wu, LN				Yu, Jian-bo; Shi, Jia; Zhang, Yuan; Gong, Li-rong; Dong, Shu-an; Cao, Xin-shun; Wu, Li-li; Wu, Li-na			Electroacupuncture Ameliorates Acute Renal Injury in Lipopolysaccharide-Stimulated Rabbits via Induction of HO-1 through the PI3K/Akt/Nrf2 Pathways	PLOS ONE			English	Article							ACUTE KIDNEY INJURY; ACUTE LUNG INJURY; HEME OXYGENASE-1; ISCHEMIA-REPERFUSION; OXIDATIVE STRESS; LIVER-INJURY; FAILURE; SEPSIS; RATS; CELLS	Electroacupuncture at select acupoints have been verified to protect against organ dysfunctions during endotoxic shock. And, heme oxygenase (HO)-1 as a phase II enzyme and antioxidant contributed to the protection of kidney in septic shock rats. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway mediated the activation of NF-E2 related factor-2 (Nrf2), which was involved in HO-1 induction. To understand the efficacy of electroacupuncture stimulation in ameliorating acute kidney injury (AKI) through the PI3K/Akt/Nrf2 pathway and subsequent HO-1 upregulation, a dose of LPS 5mg/kg was administered intravenously to replicate the rabbit model of AKI induced by endotoxic shock. Electroacupuncture pretreatment was handled bilaterally at Zusanli and Neiguan acupoints for five consecutive days while sham electroacupuncture at non-acupoints as control. Results displayed that electroacupuncture stimulation significantly alleviated the morphologic renal damage, attenuated renal tubular apoptosis, suppressed the elevated biochemical indicators of AKI caused by LPS, enhanced the expressions of phospho-Akt, HO-1protein, Nrf2 total and nucleoprotein, and highlighted the proportions of Nrf2 nucleoprotein as a parallel. Furthermore, partial protective effects of elecroacupuncture were counteracted by preconditioning with wortmannin ( the selective PI3K inhibitor), indicating a direct involvement of PI3K/Akt pathway. Inconsistently, wortmannin pretreatment made little difference to the expressions of HO-1, Nrf2 nucleoprotein and total protein, which indicated that PI3K/Akt may be not the only pathway responsible for electroacupuncture-afforded protection against LPS-induced AKI. These findings provide new insights into the potential future clinical applications of electroacupuncture for AKI induced by endotoxic shock instead of traditional remedies.	[Yu, Jian-bo; Shi, Jia; Zhang, Yuan; Gong, Li-rong; Dong, Shu-an; Cao, Xin-shun; Wu, Li-li; Wu, Li-na] Tianjin Med Univ, Tianjin Nankai Hosp, Dept Anesthesiol, Tianjin, Peoples R China	Tianjin Medical University	Yu, JB (corresponding author), Tianjin Med Univ, Tianjin Nankai Hosp, Dept Anesthesiol, Tianjin, Peoples R China.	yujianbo11@126.com			National Natural Science Foundation of China, Beijing, China [81372096]; Key Projects in the Tianjin Science & Technology Pillar Program, Tianjin, China [12ZCZDSY013300]	National Natural Science Foundation of China, Beijing, China(National Natural Science Foundation of China (NSFC)); Key Projects in the Tianjin Science & Technology Pillar Program, Tianjin, China	Financial support for this research was provided by grant No. 81372096 from the National Natural Science Foundation of China, Beijing, China, and grant No. 12ZCZDSY013300 from the Key Projects in the Tianjin Science & Technology Pillar Program, Tianjin, China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Chen HH, 2012, FREE RADICAL BIO MED, V52, P1054, DOI 10.1016/j.freeradbiomed.2011.12.012; Chen XJ, 2013, RESP PHYSIOL NEUROBI, V188, P214, DOI 10.1016/j.resp.2013.04.014; Chiari PC, 2005, ANESTHESIOLOGY, V102, P102, DOI 10.1097/00000542-200501000-00018; Dear JW, 2006, KIDNEY INT, V69, P832, DOI 10.1038/sj.ki.5000165; Fenhammar J, 2011, ANESTHESIOLOGY, V114, P1130, DOI 10.1097/ALN.0b013e31820b8b44; Ferenbach DA, 2010, MOL THER, V18, P1706, DOI 10.1038/mt.2010.100; Gomez H, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000052; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Huang CL, 2007, ANESTH ANALG, V104, P646, DOI 10.1213/01.ane.0000255288.68199.eb; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Knotek M, 2001, KIDNEY INT, V59, P2243, DOI 10.1046/j.1523-1755.2001.00740.x; Kong XN, 2011, AM J RESP CRIT CARE, V184, P928, DOI 10.1164/rccm.201102-0271OC; Kuwana H, 2008, KIDNEY INT, V73, P430, DOI 10.1038/sj.ki.5002702; Langenberg C, 2014, CRIT CARE MED, V42, pE58, DOI 10.1097/CCM.0b013e3182a639da; Liu HW, 2011, ACUPUNCT MED, V29, P284, DOI 10.1136/aim.2010.003525; LOEWENBERG J. R., 1967, ANAL BIOCHEM, V19, P95, DOI 10.1016/0003-2697(67)90138-8; Lu CY, 2014, BIOCHEM PHARMACOL, V91, P40, DOI 10.1016/j.bcp.2014.06.024; MISRA HP, 1971, J BIOL CHEM, V246, P6886; Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Nath KA, 2014, CURR OPIN NEPHROL HY, V23, P17, DOI 10.1097/01.mnh.0000437613.88158.d3; Nemzek JA, 2004, SHOCK, V21, P17, DOI 10.1097/01.shk.0000101667.49265.fd; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ozyurt H, 2004, J APPL TOXICOL, V24, P269, DOI 10.1002/jat.983; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Schiffl H, 2012, MOL DIAGN THER, V16, P199, DOI 10.2165/11634310-000000000-00000; Schrier RW, 2004, NEW ENGL J MED, V351, P159, DOI 10.1056/NEJMra032401; Siu FKW, 2004, NEUROSCI LETT, V354, P158, DOI 10.1016/j.neulet.2003.10.009; Song JG, 2012, ANESTHESIOLOGY, V116, P406, DOI 10.1097/ALN.0b013e3182426ebd; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Tsai PS, 2006, ANESTHESIOLOGY, V105, P1201, DOI 10.1097/00000542-200612000-00020; Tsao CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108455; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Wang K, 2009, ANESTH ANALG, V109, P1666, DOI 10.1213/ANE.0b013e3181b5a234; Wang W, 2007, AM J PHYSIOL-RENAL, V293, pF1131, DOI 10.1152/ajprenal.00212.2007; WELLWOOD JM, 1975, BRIT MED J, V3, P408, DOI 10.1136/bmj.3.5980.408; Williams DL, 2004, J IMMUNOL, V172, P449, DOI 10.4049/jimmunol.172.1.449; Wulfert FM, 2012, ANESTHESIOLOGY, V117, P126, DOI 10.1097/ALN.0b013e31825b57c9; Yap SC, 2012, ANESTHESIOLOGY, V116, P1139, DOI 10.1097/ALN.0b013e31824f951b; Yu JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104924; Yu JB, 2009, TRANSL RES, V153, P283, DOI 10.1016/j.trsl.2009.01.002; Yu JB, 2013, EXP BIOL MED, V238, P705, DOI 10.1177/1535370213489487; Yu JB, 2013, ANESTH ANALG, V116, P239, DOI 10.1213/ANE.0b013e31826f0a4a; Zhang HX, 2009, CAN J CARDIOL, V25, P359, DOI 10.1016/S0828-282X(09)70095-9; Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101; Zhao HD, 2010, WORLD J GASTROENTERO, V16, P3002, DOI 10.3748/wjg.v16.i24.3002	47	22	30	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2015	10	11							e0141622	10.1371/journal.pone.0141622	http://dx.doi.org/10.1371/journal.pone.0141622			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV1PG	26524181	Green Submitted, Green Published, gold			2023-01-03	WOS:000364029800016
J	Poizot-Martin, I; Naqvi, A; Obry-Roguet, V; Valantin, MA; Cuzin, L; Billaud, E; Cheret, A; Rey, D; Jacomet, C; Duvivier, C; Pugliese, P; Pradat, P; Cotte, L				Poizot-Martin, Isabelle; Naqvi, Alissa; Obry-Roguet, Veronique; Valantin, Marc-Antoine; Cuzin, Lise; Billaud, Eric; Cheret, Antoine; Rey, David; Jacomet, Christine; Duvivier, Claudine; Pugliese, Pascal; Pradat, Pierre; Cotte, Laurent		Hepadat'AIDS Study Grp	Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients	PLOS ONE			English	Article							HEPATITIS-C VIRUS; SOFOSBUVIR PLUS RIBAVIRIN; HIV-INFECTED PATIENTS; GENOTYPE 1; NATURAL-HISTORY; OPEN-LABEL; THERAPY; TELAPREVIR	Objectives Development of direct acting antivirals (DAA) offers new benefits for patients with chronic hepatitis C. The combination of these drugs with antiretroviral treatment (cART) is a real challenge in HIV/HCV coinfected patients. The aim of this study was to describe potential drug-drug interactions between DAAs and antiretroviral drugs in a cohort of HIV/HCV coinfected patients. Methods Cross-sectional study of all HIV/HCV coinfected patients attending at least one visit in 2012 in the multicenter French Dat'AIDS cohort. A simulation of drug-drug interactions between antiretroviral treatment and DAAs available in 2015 was performed. Results Of 16,634 HIV-infected patients, 2,511 had detectable anti-HCV antibodies, of whom 1,196 had a detectable HCV-RNA and were not receiving HCV treatment at the time of analysis. 97.1% of these patients were receiving cART and 81.2% had a plasma HIV RNA <50 copies/mL. cART included combinations of nucleoside reverse transcriptase inhibitors with a boosted protease inhibitor in 43.6%, a non-nucleoside reverse transcriptase inhibitor in 17.3%, an integrase inhibitor in 15.4% and various combinations or antiretroviral drugs in 23.7% of patients. A previous treatment against HCV had been administered in 64.4% of patients. Contraindicated associations/potential interactions were expected between cART and respectively sofosbuvir (0.2%/0%), sofosbuvir/ledipasvir (0.2%/67.6%), daclatasvir (0%/49.4%), ombitasvir/boosted paritaprevir (with or without dasabuvir) (34.4%/52.2%) and simeprevir (78.8%/0%). Conclusions Significant potential drug-drug interactions are expected between cART and the currently available DAAs in the majority of HIV/HCV coinfected patients. Sofosbuvir/ledipasvir and sofosbuvir/daclatasvir with or without ribavirin appeared the most suitable combinations in our population. A close collaboration between hepatologists and HIV/AIDS specialists appears necessary for the management of HCV treatment concomitantly to cART.	[Poizot-Martin, Isabelle; Obry-Roguet, Veronique] Aix Marseille Univ, Hop St Marguerite, APHM, Immunohematol Clin, Marseille, France; [Poizot-Martin, Isabelle] INSERM, U912, SESSTIM, F-13258 Marseille, France; [Naqvi, Alissa; Pugliese, Pascal] CHU Nice, Hop Archet 1, Serv Malad Infect, Unite Virol Clin, F-06202 Nice, France; [Valantin, Marc-Antoine] Univ Paris 06, Sorbonne Univ, UMR S 1136, Inst Pierre Louis Epidemiol & Sante Publ, F-75013 Paris, France; [Valantin, Marc-Antoine] Univ Paris 06, Grp Hosp Pitie Salpetriere, AP HP, Serv Malad Infect & Trop, Paris, France; [Cuzin, Lise] INSERM, UMR 1027, F-31000 Toulouse, France; [Cuzin, Lise] Univ Toulouse 3, F-31000 Toulouse, France; [Cuzin, Lise] CHU Toulouse, COREVIH Toulouse, F-31000 Toulouse, France; [Billaud, Eric] CHU Nantes, Hotel Dieu, Serv Malad Infect, F-44035 Nantes 01, France; [Cheret, Antoine] Ctr Hosp Tourcoing, Serv Univ Malad Infect, Tourcoing, France; [Cheret, Antoine] CHU Bicetre, Serv Med Interne, Le Kremlin Bicetre, France; [Cheret, Antoine; Duvivier, Claudine] Univ Paris 05, Hop Necker, EA 7327, Lab Virol, Paris, France; [Rey, David] Hop Univ Strasbourg, Ctr HIV Care, Strasbourg, France; [Jacomet, Christine] CHU Clermont Ferrand, Serv Malad Infect & Trop, Clermont Ferrand, France; [Duvivier, Claudine] Hop Necker Enfants Malad, AP HP, Serv Malad Infect & Trop, Ctr Infectiol Necker Pasteur IHU Imagine, Paris, France; [Duvivier, Claudine] Inst Pasteur, Ctr Med, Ctr Infectiol Necker Pasteur, Paris, France; [Pradat, Pierre] Hosp Civils Lyon, Hop Croix Rousse, Serv Hepatol, Ctr Rech Clin, Lyon, France; [Pradat, Pierre; Cotte, Laurent] INSERM, U1052, F-69008 Lyon, France; [Cotte, Laurent] Hosp Civils Lyon, Hop Croix Rousse, Serv Malad Infect, Lyon, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; CHU Nice; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon	Cotte, L (corresponding author), INSERM, U1052, F-69008 Lyon, France.	laurent.cotte@chu-lyon.fr	Delobel, Pierre/K-3166-2014	Delobel, Pierre/0000-0002-2874-3581; ferry, tristan/0000-0003-3082-7001; MARCHOU, Bruno/0000-0002-0673-2945; ADER, Florence/0000-0002-4778-4338; Poizot-Martin, Isabelle/0000-0002-5676-5411	Gilead; MSD; BMS; Janssen-Cilag; Gilead Science; ViiV Healthcare; Bristol-Myers Squibb; Merck/Schering-Plough; Janssen; Merck; Roche; Mylan; Abbott	Gilead(Gilead Sciences); MSD; BMS(Bristol-Myers Squibb); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Gilead Science(Gilead Sciences); ViiV Healthcare; Bristol-Myers Squibb(Bristol-Myers Squibb); Merck/Schering-Plough(Merck & CompanySchering Plough Corporation); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck(Merck & Company); Roche(Roche Holding); Mylan; Abbott(Abbott Laboratories)	Isabelle POIZOT-MARTIN is member of advisory boards for GILEAD, BMS, and ABVIE. She received speaker fees from Gilead, MSD, and BMS, and travel/accommodation grants from BMS. Marc- Antoine VALANTIN has received honoraria for consulting/educational lectures and travel grants from Janssen-Cilag, Gilead Science, ViiV Healthcare, Bristol-Myers Squibb, and Merck/Schering-Plough. Lise CUZIN participated in advisory board meetings for BMS, ViiV Healthcare and received travel grants from BMS and MSD. Eric BILLAUD received travel grants from ViiV Healthcare, Janssen, Gilead, Merck, and BMS, and expertise fees from Gilead and BMS. He also participated in advisory board meetings for MSD. David REY is member of advisory board for Gilead, received speaker fees from MSD and travel grants from Gilead, BMS, and MSD. Christine JACOMET reports grants and nonfinancial support from MSD, nonfinancial support from ViiV, grants from Roche, grants, personal fees and non-financial support from Janssen, personal fees from Gilead, personal fees from BMS, personal fees from Mylan, personal fees and non-financial support from Abbott, outside the submitted work. Claudine DUVIVIER has received travel grants, honoraria or study grants from various pharmaceutical companies, including Bristol- Myers- Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare. Pascal PUGLIESE is member of advisory boards for Gilead and BMS. Laurent COTTE has received research grants from ViiV healthcare and MSD, personal fees from Mylan and non-financial support from BMS, Gilead Science, Janssen Cilag, MSD and ViiV healthcare. Alissa NAQVI, Veronique OBRY-ROGUET, Antoine CHERET, and Pierre PRADAT have no conflict of interest to disclose. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	Afdhal N, 2014, NEW ENGL J MED, V370, P1889, DOI 10.1056/NEJMoa1402454; Beste LA, 2015, EPIDEMIOL REV, V37, P131, DOI 10.1093/epirev/mxu002; Cachay ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102883; Cacoub P, 2015, LIVER INT, V35, P65, DOI 10.1111/liv.12639; Cope R, 2015, AIDS PATIENT CARE ST, V29, P379, DOI 10.1089/apc.2015.0004; Cotte L, 2014, CLIN INFECT DIS, V59, P1768, DOI 10.1093/cid/ciu659; Gane EJ, 2013, NEW ENGL J MED, V368, P34, DOI 10.1056/NEJMoa1208953; Graham CS, 2001, CLIN INFECT DIS, V33, P562, DOI 10.1086/321909; Grint D, 2013, HIV MED, V14, P614, DOI 10.1111/hiv.12068; Hernandez MD, 2011, CURR OPIN HIV AIDS, V6, P478, DOI 10.1097/COH.0b013e32834bd365; Hezode C, 2015, LANCET, V385, P2502, DOI 10.1016/S0140-6736(15)60159-3; [IDSA IAS-USA. AASLD], 2015, REC TEST MAN TREAT H, DOI 10.1002/hep.27950; Karageorgopoulos DE, 2014, CURR OPIN INFECT DIS, V27, P36, DOI 10.1097/QCO.0000000000000034; Klein MB, 2013, ANTIVIR THER, V18, P717, DOI 10.3851/IMP2484; Kovari H, 2015, J HEPATOL, V63, P573, DOI 10.1016/j.jhep.2015.04.019; Lawitz E, 2014, LANCET, V384, P1756, DOI 10.1016/S0140-6736(14)61036-9; Molina JM, 2015, LANCET, V385, P1098, DOI 10.1016/S0140-6736(14)62483-1; Morlat P., 2013, PRISE CHARGE MED PER; Operskalski Eva A, 2011, Curr HIV/AIDS Rep, V8, P12, DOI 10.1007/s11904-010-0071-3; Osinusi A, 2015, JAMA-J AM MED ASSOC, V313, P1232, DOI 10.1001/jama.2015.1373; Patel N, 2015, INFECT DIS THER, V4, P67, DOI 10.1007/s40121-015-0058-x; Patel N, 2015, AIDS RES HUM RETROV, V31, P189, DOI [10.1089/AID.2014.0215, 10.1089/aid.2014.0215]; Pawlotsky JM, 2015, J HEPATOL, V63, P199, DOI 10.1016/j.jhep.2015.03.025; Piroth L, 2010, HEPATOLOGY, V52, P1915, DOI 10.1002/hep.23959; Pugliese P, 2009, HIV MED, V10, P504, DOI 10.1111/j.1468-1293.2009.00719.x; Soriano V, 2015, EXPERT OPIN DRUG MET, V11, P333, DOI 10.1517/17425255.2015.998997; Sulkowski M, 2013, LANCET INFECT DIS, V13, P597, DOI 10.1016/S1473-3099(13)70149-X; Sulkowski MS, 2015, JAMA-J AM MED ASSOC, V313, P1223, DOI 10.1001/jama.2015.1328; Sulkowski MS, 2014, NEW ENGL J MED, V370, P211, DOI 10.1056/NEJMoa1306218; Sulkowski MS, 2013, ANN INTERN MED, V159, P86, DOI 10.7326/0003-4819-159-2-201307160-00654; Thein HH, 2008, AIDS, V22, P1979, DOI 10.1097/QAD.0b013e32830e6d51; van de Laar T, 2009, GASTROENTEROLOGY, V136, P1609, DOI 10.1053/j.gastro.2009.02.006; Yehia BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101554	33	32	33	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2015	10	10							e0141164	10.1371/journal.pone.0141164	http://dx.doi.org/10.1371/journal.pone.0141164			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0ZM	26488159	gold, Green Published, Green Submitted			2023-01-03	WOS:000363248400113
J	McCool, ME; Wahl, J; Schlecht, I; Apfelbacher, C				McCool, Megan E.; Wahl, Josepha; Schlecht, Inga; Apfelbacher, Christian			Evaluating Written Patient Information for Eczema in German: Comparing the Reliability of Two Instruments, DISCERN and EQIP	PLOS ONE			English	Article							ENSURING QUALITY INFORMATION; BRAIN-TUMOR INFORMATION; HEALTH INFORMATION; INTERNET; RESOURCES; LANGUAGE	Patients actively seek information about how to cope with their health problems, but the quality of the information available varies. A number of instruments have been developed to assess the quality of patient information, primarily though in English. Little is known about the reliability of these instruments when applied to patient information in German. The objective of our study was to investigate and compare the reliability of two validated instruments, DISCERN and EQIP, in order to determine which of these instruments is better suited for a further study pertaining to the quality of information available to German patients with eczema. Two independent raters evaluated a random sample of 20 informational brochures in German. All the brochures addressed eczema as a disorder and/or therapy options and care. Intra-rater and inter-rater reliability were assessed by calculating intraclass correlation coefficients, agreement was tested with weighted kappas, and the correlation of the raters' scores for each instrument was measured with Pearson's correlation coefficient. DISCERN demonstrated substantial intra-and inter-rater reliability. It also showed slightly better agreement than EQIP. There was a strong correlation of the raters' scores for both instruments. The findings of this study support the reliability of both DISCERN and EQIP. However, based on the results of the inter-rater reliability, agreement and correlation analyses, we consider DISCERN to be the more precise tool for our project on patient information concerning the treatment and care of eczema.	[McCool, Megan E.; Wahl, Josepha; Schlecht, Inga; Apfelbacher, Christian] Univ Regensburg, Dept Med, Inst Epidemiol & Prevent Med, D-93053 Regensburg, Germany	University of Regensburg	McCool, ME (corresponding author), Univ Regensburg, Dept Med, Inst Epidemiol & Prevent Med, D-93053 Regensburg, Germany.	megan.mccool@klinik.uni-regensburg.de	McCool-Myers, Megan/R-4873-2019; Apfelbacher, Christian/X-1051-2019	McCool-Myers, Megan/0000-0003-3000-9172; Apfelbacher, Christian/0000-0003-3805-8219				BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; Batchelor Jonathan M., 2009, Allergology International, V58, P141, DOI 10.2332/allergolint.08-SC-0022; Berth-Jones J, 2006, BRIT J DERMATOL, V155, P707, DOI 10.1111/j.1365-2133.2006.07389.x; BMA, 1997, PAT APPR FORM; Charnock D, 1999, J EPIDEMIOL COMMUN H, V53, P105, DOI 10.1136/jech.53.2.105; Charvet-Berard AI, 2008, PATIENT EDUC COUNS, V70, P407, DOI 10.1016/j.pec.2007.11.018; Coulter A., 2006, ASSESSING QUALITY IN; Dierks MLLM, 1999, PUBLIC HLTH F, P16; Elwyn G, 2006, BMJ-BRIT MED J, V333, P417, DOI 10.1136/bmj.38926.629329.AE; Goslin RA, 2013, LARYNGOSCOPE, V123, P1626, DOI 10.1002/lary.23773; Grewal P, 2013, INT J SURG, V11, P410, DOI 10.1016/j.ijsu.2013.03.006; GROVE WA, 1981, AM J PSYCHIAT, V138, P1644; Hargrave D, 2003, B CANCER, V90, P650; Hubner J, 2013, FORSCH KOMPLEMENTMED, V20, P120, DOI 10.1159/000350049; Kaicker J, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-59; Knapp TR, 1990, J ED PSYCHOL MEASURE, V50, P225; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Lau L, 2006, CHILD NERV SYST, V22, P346, DOI 10.1007/s00381-005-1238-x; Matsoukas Konstantina, 2008, AMIA Annu Symp Proc, P1048; Melloul E, 2012, LIVER TRANSPLANT, V18, P892, DOI 10.1002/lt.23442; Montoya A, 2011, Educ Health (Abingdon), V24, P577; Moult B, 2004, HEALTH EXPECT, V7, P165, DOI 10.1111/j.1369-7625.2004.00273.x; NUNNALLY JC, 1979, CC/SOC BEHAV SCI, P12; Perdaens S, 2011, Tijdschr Psychiatr, V53, P695; Saenger SHA, 2002, CHECK IN INSTRUMENT; Shrout P E, 1998, Stat Methods Med Res, V7, P301, DOI 10.1191/096228098672090967; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.1997.03540390074039; Steckelberg Anke, 2005, Z Arztl Fortbild Qualitatssich, V99, P343; Vaona A, 2011, PRIM CARE DIABETES, V5, P257, DOI 10.1016/j.pcd.2011.08.001; Zahedi Razieh, 2013, Acta Inform Med, V21, P46, DOI 10.5455/AIM.2012.21.46-50	31	25	25	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2015	10	10							e0139895	10.1371/journal.pone.0139895	http://dx.doi.org/10.1371/journal.pone.0139895			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CT0TP	26440612	Green Submitted, Green Published, gold			2023-01-03	WOS:000362510300071
J	Stone, A; Kartheiser, G; Hauser, PC; Petitto, LA; Allen, TE				Stone, Adam; Kartheiser, Geo; Hauser, Peter C.; Petitto, Laura-Ann; Allen, Thomas E.			Fingerspelling as a Novel Gateway into Reading Fluency in Deaf Bilinguals	PLOS ONE			English	Article							INDIVIDUAL-DIFFERENCES; COMPREHENSION; STUDENTS; ABILITY; READERS; MEMORY; PRINT	Studies have shown that American Sign Language (ASL) fluency has a positive impact on deaf individuals' English reading, but the cognitive and cross-linguistic mechanisms permitting the mapping of a visual-manual language onto a sound-based language have yet to be elucidated. Fingerspelling, which represents English orthography with 26 distinct hand configurations, is an integral part of ASL and has been suggested to provide deaf bilinguals with important cross-linguistic links between sign language and orthography. Using a hierarchical multiple regression analysis, this study examined the relationship of age of ASL exposure, ASL fluency, and fingerspelling skill on reading fluency in deaf college-age bilinguals. After controlling for ASL fluency, fingerspelling skill significantly predicted reading fluency, revealing for the first-time that fingerspelling, above and beyond ASL skills, contributes to reading fluency in deaf bilinguals. We suggest that both fingerspelling-in the visual-manual modality-and reading-in the visual-orthographic modality-are mutually facilitating because they share common underlying cognitive capacities of word decoding accuracy and automaticity of word recognition. The findings provide support for the hypothesis that the development of English reading proficiency may be facilitated through strengthening of the relationship among fingerspelling, sign language, and orthographic decoding en route to reading mastery, and may also reveal optimal approaches for reading instruction for deaf and hard of hearing children.	[Stone, Adam; Kartheiser, Geo; Petitto, Laura-Ann; Allen, Thomas E.] Gallaudet Univ, Educ Neurosci PEN Program, Washington, DC 20002 USA; [Stone, Adam; Kartheiser, Geo; Hauser, Peter C.; Petitto, Laura-Ann; Allen, Thomas E.] Gallaudet Univ, NSF Sci Learning Ctr Visual Language & Visual Lea, Washington, DC 20002 USA; [Hauser, Peter C.] Rochester Inst Technol, Natl Tech Inst Deaf, Deaf Studies Lab, Rochester, NY 14623 USA; [Petitto, Laura-Ann] Gallaudet Univ, Dept Psychol, Washington, DC 20002 USA; [Allen, Thomas E.] Gallaudet Univ, Dept Educ, Washington, DC 20002 USA	National Science Foundation (NSF); Rochester Institute of Technology; US Department of Education	Stone, A (corresponding author), Gallaudet Univ, Educ Neurosci PEN Program, Washington, DC 20002 USA.	adam.stone@gallaudet.edu		Stone, Adam/0000-0002-0319-4301; Stone, Adam/0000-0002-2026-309X	National Science Foundation [SBE-1041725]	National Science Foundation(National Science Foundation (NSF))	This work was supported by the National Science Foundation SBE-1041725, http://nsf.gov (LAP TEA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akamatsu C.T., 1985, SLR 83 P 3 INT S SIG, P126; Allen TE, 2012, ASSESSING LIT DEAF I, P21; Allen TE, 2015, SIGN LANG STUD, V15, P233, DOI 10.1353/sls.2015.0006; Andrew KN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089994; Brentari D, 2001, FOREIGN VOCABULARY IN SIGN LANGUAGES: CROSS-LINGUISTIC INVESTIGATION OF WORD FORMATION, P87; Chamberlain C, 2000, LANGUAGE ACQUISITION BY EYE, P221; Chamberlain C, 2008, APPL PSYCHOLINGUIST, V29, P367, DOI 10.1017/S014271640808017X; Corsi P., 1972, THESIS; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Easterbrooks SR, 2008, J DEAF STUD DEAF EDU, V13, P37, DOI 10.1093/deafed/enm030; Ehri LC, 2014, SCI STUD READ, V18, P5, DOI 10.1080/10888438.2013.819356; Emmorey K, 2012, J DEAF STUD DEAF EDU, V17, P194, DOI 10.1093/deafed/enr051; Enns C, 2007, AM ANN DEAF, V152, P63, DOI 10.1353/aad.2007.0011; Ensor A, 1997, J Deaf Stud Deaf Educ, V2, P61; Freel B.L., 2011, PSYCHOLOGY, V2, P18, DOI [DOI 10.4236/PSYCH.2011.21003, 10.4236/psych.2011.21003]; FUCHS LS, 1988, REM SPEC EDUC, V9, P20, DOI 10.1177/074193258800900206; Gough PB, 1986, REM SPEC EDUC, V7, P10; Grushkin DA, 1998, AM ANN DEAF, V143, P404, DOI 10.1353/aad.2012.0192; Haptonstall-Nykaza TS, 2007, J DEAF STUD DEAF EDU, V12, P172, DOI 10.1093/deafed/enm003; Hauser PC, 2008, SIGN LANGUAGES SPINN; Hermans D, 2008, J DEAF STUD DEAF EDU, V13, P518, DOI 10.1093/deafed/enn009; Hile A. E., 2009, THESIS U COLORADO BO; HIRSHPASEK K, 1987, READ RES QUART, V22, P455, DOI 10.2307/747702; Hoffmeister RJ, 2000, LANGUAGE ACQUISITION BY EYE, P143; HOOVER WA, 1990, READ WRIT, V2, P127, DOI 10.1007/BF00401799; Humphries T., 1999, VISUAL ANTHR REV, V15, P84, DOI DOI 10.1525/VAR.2000.15.2.84; JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122; Kaufman A.S., 2004, KBIT 2, Vsecond; KELLY LP, 1995, EXCEPT CHILDREN, V61, P318, DOI 10.1177/001440299506100402; Kovelman I, 2008, BILING-LANG COGN, V11, P203, DOI 10.1017/S1366728908003386; Luckner JL, 2012, COMMUN DISORD Q, V33, P230, DOI 10.1177/1525740111412582; Mayberry RI, 2011, J DEAF STUD DEAF EDU, V16, P164, DOI 10.1093/deafed/enq049; Mayberry RI, 2002, NATURE, V417, P38, DOI 10.1038/417038a; Mercer CD, 2000, LEARN DISABIL RES, V15, P177; Morere D., 2012, ASSESSING LITERACY D, DOI [10.1007/978-1-4614-5269-0, DOI 10.1007/978-1-4614-5269-0]; Morere D., 2012, ASSESSING LIT DEAF I, P159; Morere D, 2012, ASSESSING LIT DEAF I, P21; Morere D.A., 2012, ASSESSING LITERACY D; Morere D. A., 2012, ASSESSING LITERACY D, P179; National Reading Panel, 2000, REP NAT READ PAN TEA; Padden C, 1998, TOP LANG DISORD, V18, P30, DOI 10.1097/00011363-199808000-00005; Padden C. A., 1991, THEORETICAL ISSUES S, P193; Padden C.A., 2003, SIGN LANGUAGE STUDIE, V4, P10, DOI [DOI 10.1353/SLS.2003.0026, 10.1353/sls.2003.0026]; Padden CA, 2000, SIGNS OF LANGUAGE REVISITED, P435; Penner-Wilger M., 2008, READING FLUENCY BRID; Petitto LA, 2009, MIND BRAIN EDUC, V3, P185, DOI 10.1111/j.1751-228X.2009.01069.x; Pinnell G.S., 1995, LISTENING CHILDREN R; Ramus F, 2012, COGN NEUROPSYCHOL, V29, P104, DOI 10.1080/02643294.2012.677420; Samare Y, 1992, PHONETICS FARSI LANG; Samuels S.J., 2006, WHAT RES HAS SAY FLU, P24; Schick B., 2006, ADV SIGN LANGUAGE DE, P189, DOI DOI 10.1007/978-1-4614-5269-0; Schirmer B. R., 2009, READING IMPROVEMENT, V46, P168; Strong M, 1997, J Deaf Stud Deaf Educ, V2, P37; Torgesen JK., 2006, WHAT RES HAS SAY FLU, P130; Williams J, 2015, J LANG LIT, V6, P156; WILSON MD, 1973, J APPL BEHAV ANAL, V6, P231, DOI 10.1901/jaba.1973.6-231; Woodcock R, 2001, WOODCOCK JOHNSON TES	57	36	39	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2015	10	10							e0139610	10.1371/journal.pone.0139610	http://dx.doi.org/10.1371/journal.pone.0139610			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6GT	26427062	Green Published, gold, Green Submitted			2023-01-03	WOS:000362177100080
J	Press, MJ; Rajkumar, R; Conway, PH				Press, Matthew J.; Rajkumar, Rahul; Conway, Patrick H.			Medicare's New Bundled Payments Design, Strategy, and Evolution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Press, Matthew J.; Rajkumar, Rahul; Conway, Patrick H.] Ctr Medicare & Medicaid Serv, Baltimore, MD 21244 USA	Centers for Medicare & Medicaid Services	Rajkumar, R (corresponding author), Ctr Medicare & Medicaid Serv, 7500 Secur Blvd,Mailstop WB 06-05, Baltimore, MD 21244 USA.	Rahul.Rajkumar@cms.hhs.gov						Burwell SM, 2015, NEW ENGL J MED, V372, P897, DOI 10.1056/NEJMp1500445; Friedberg MW, 2018, EFFECTS HLTH CARE PA; Howell BL, 2015, JAMA-J AM MED ASSOC, V313, P2317, DOI 10.1001/jama.2015.2902; Rajkumar R, 2014, JAMA-J AM MED ASSOC, V311, P1967, DOI 10.1001/jama.2014.3703	4	119	119	1	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2016	315	2					131	132		10.1001/jama.2015.18161	http://dx.doi.org/10.1001/jama.2015.18161			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA6XO	26720889				2023-01-03	WOS:000367949200010
J	Das, P; Horton, R				Das, Pamela; Horton, Richard			Antibiotics: achieving the balance between access and excess	LANCET			English	Editorial Material									[Das, Pamela; Horton, Richard] The Lancet, London EC2Y 5AS, England		Das, P (corresponding author), The Lancet, London EC2Y 5AS, England.							[Anonymous], 2015, LANCET, DOI [http://dx.doi.org/10.1016/S0140-6736(15)00547-4, DOI 10.1016/S0140-6736(15)00547-4]; Ardal C, 2016, LANCET, V387, P296, DOI 10.1016/S0140-6736(15)00470-5; Dar OA, 2016, LANCET, V387, P285, DOI 10.1016/S0140-6736(15)00520-6; Holmes AH, 2016, LANCET, V387, P176, DOI 10.1016/S0140-6736(15)00473-0; Laxminarayan R, 2015, LANCET; Laxminarayan R, 2013, LANCET INFECT DIS, V13, P1057, DOI 10.1016/S1473-3099(13)70318-9; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; World Health Organization, 2015, GLOBAL ACTION PLAN A	8	15	16	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	2016	387	10014					102	104		10.1016/S0140-6736(15)00729-1	http://dx.doi.org/10.1016/S0140-6736(15)00729-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA8LF	26603923				2023-01-03	WOS:000368055500009
J	Wanzel, I; Vischedyk, JB; Gittler, MP; Gremke, N; Seiz, JR; Hefter, M; Noack, M; Savai, R; Mernberger, M; Charles, JP; Schneikert, J; Bretz, AC; Nist, A; Stiewe, T				Wanzel, Ichael; Vischedyk, Jonas B.; Gittler, Miriam P.; Gremke, Niklas; Seiz, Julia R.; Hefter, Mirjam; Noack, Magdalena; Savai, Rajkumar; Mernberger, Marco; Charles, Joel P.; Schneikert, Jean; Bretz, Anne Catherine; Nist, Andrea; Stiewe, Thorsten			CRISPR-Cas9-based target validation for p53-reactivating model compounds	NATURE CHEMICAL BIOLOGY			English	Article							SMALL-MOLECULE RITA; IN-VIVO; P53 RESTORATION; FANCD2 MONOUBIQUITINATION; CANCER-CELLS; MUTANT P53; DNA; ACTIVATION; RESISTANCE; PATHWAY	Inactivation of the p53 tumor suppressor by Mdm2 is one of the most frequent events in cancer, so compounds targeting the p53-Mdm2 interaction are promising for cancer therapy. Mechanisms conferring resistance to p53-reactivating compounds are largely unknown. Here we show using CRISPR-Cas9-based target validation in lung and colorectal cancer that the activity of nutlin, which blocks the p53-binding pocket of Mdm2, strictly depends on functional p53. In contrast, sensitivity to the drug RITA, which binds the Mdm2-interacting N terminus of p53, correlates with induction of DNA damage. Cells with primary or acquired RITA resistance display cross-resistance to DNA crosslinking compounds such as cisplatin and show increased DNA cross-link repair. Inhibition of FancD2 by RNA interference or pharmacological mTOR inhibitors restores RITA sensitivity. The therapeutic response to p53-reactivating compounds is therefore limited by compound-specific resistance mechanisms that can be resolved by CRISPR-Cas9-based target validation and should be considered when allocating patients to p53-reactivating treatments.	[Wanzel, Ichael; Vischedyk, Jonas B.; Gittler, Miriam P.; Gremke, Niklas; Seiz, Julia R.; Hefter, Mirjam; Noack, Magdalena; Mernberger, Marco; Charles, Joel P.; Schneikert, Jean; Bretz, Anne Catherine; Nist, Andrea; Stiewe, Thorsten] Univ Marburg, Inst Mol Oncol, Marburg, Germany; [Wanzel, Ichael; Savai, Rajkumar; Stiewe, Thorsten] UGMLC, German Ctr Lung Res DZL, Berlin, Germany; [Savai, Rajkumar] Max Planck Inst Heart & Lung Res, Dept Lung Dev & Remodeling, Bad Nauheim, Germany; [Savai, Rajkumar] Univ Giessen, Dept Internal Med, Giessen, Germany; [Nist, Andrea; Stiewe, Thorsten] Univ Marburg, Genom Core Facil, Marburg, Germany	Philipps University Marburg; Max Planck Society; Justus Liebig University Giessen; Philipps University Marburg	Wanzel, I (corresponding author), Univ Marburg, Inst Mol Oncol, Marburg, Germany.	thorsten.stiewe@uni-marburg.de		Stiewe, Thorsten/0000-0003-0134-7826; Vischedyk, Jonas Bernhard/0000-0001-7759-8934	Deutsche Forschungsgemeinschaft grants [WA 2725/1-1, TRR81, STI 182/3-2, STI 182/7-1]; European Research Council grant [P73CANCER 260431]; Deutsche Krebshilfe grant [111250]; Deutsche Jose Carreras Leukamie-Stiftung grant; Von-Behring-Rontgen-Stiftung grant; Rhon Klinikum AG grant; LOEWE Universities of Giessen and Marburg Lung Center grant	Deutsche Forschungsgemeinschaft grants(German Research Foundation (DFG)); European Research Council grant(European Research Council (ERC)); Deutsche Krebshilfe grant(Deutsche Krebshilfe); Deutsche Jose Carreras Leukamie-Stiftung grant; Von-Behring-Rontgen-Stiftung grant; Rhon Klinikum AG grant; LOEWE Universities of Giessen and Marburg Lung Center grant	We thank B. Vogelstein (John Hopkins University) for providing HCT116 p53<SUP>-/-</SUP> cells and A. Filmer for excellent technical assistance with next-generation sequencing. The authors are grateful to the members of the Stiewe laboratory for fruitful discussions and support of the project. This research was supported by Deutsche Forschungsgemeinschaft grants WA 2725/1-1 (M.W.), TRR81 (T.S.), STI 182/3-2 (T.S.) and STI 182/7-1 (T.S.); European Research Council grant P73CANCER 260431 (T.S.); Deutsche Krebshilfe grant 111250 (T.S.); Deutsche Jose Carreras Leukamie-Stiftung grant (T.S.), Von-Behring-Rontgen-Stiftung grant (T.S.), Rhon Klinikum AG grant (T.S.) and LOEWE Universities of Giessen and Marburg Lung Center grant (T.S.).	Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burmakin M, 2013, CLIN CANCER RES, V19, P5092, DOI 10.1158/1078-0432.CCR-12-2211; Charles JP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4981; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; de Lange J, 2012, CELL DEATH DIFFER, V19, P980, DOI 10.1038/cdd.2011.182; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Grinkevich VV, 2009, CANCER CELL, V15, P441, DOI 10.1016/j.ccr.2009.03.021; Guo F, 2013, LEUKEMIA, V27, P2040, DOI 10.1038/leu.2013.93; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Hedstrom E, 2009, CELL CYCLE, V8, P3584, DOI 10.4161/cc.8.21.9977; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Kachnic LA, 2011, CANCER LETT, V305, P86, DOI 10.1016/j.canlet.2011.02.030; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kasap C, 2014, NAT CHEM BIOL, V10, P626, DOI 10.1038/nchembio.1551; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kim H, 2012, GENE DEV, V26, P1393, DOI 10.1101/gad.195248.112; Krajewski M, 2005, NAT MED, V11, P1135, DOI 10.1038/nm1105-1135; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Meng XJ, 2009, ONCOL REP, V21, P995, DOI 10.3892/or_00000314; Michaelis M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.129; Michaelis M, 2009, CANCER RES, V69, P416, DOI 10.1158/0008-5472.CAN-08-1856; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; Nieves-Neira W, 1999, MOL PHARMACOL, V56, P478, DOI 10.1124/mol.56.3.478; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Park HK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013313; Pickering A, 2013, CELL CYCLE, V12, P3448, DOI 10.4161/cc.26387; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Schlereth K, 2010, MOL CELL, V38, P356, DOI 10.1016/j.molcel.2010.02.037; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shen CX, 2013, CANCER RES, V73, P3393, DOI 10.1158/0008-5472.CAN-12-4282; Smurnyy Y, 2014, NAT CHEM BIOL, V10, P623, DOI 10.1038/nchembio.1550; Song IY, 2010, J BIOL CHEM, V285, P31525, DOI 10.1074/jbc.M110.138206; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wei X, 2012, BIOINFORMATICS, V28, P301, DOI 10.1093/bioinformatics/btr676; Weilbacher A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.284; Williams SA, 2011, BLOOD, V117, P5078, DOI 10.1182/blood-2010-10-311761; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zhang J, 2008, CELL CYCLE, V7, P407, DOI 10.4161/cc.7.3.5156; Zhao CY, 2010, CELL CYCLE, V9, P1847, DOI 10.4161/cc.9.9.11545	51	59	63	0	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2016	12	1					22	+		10.1038/NCHEMBIO.1965	http://dx.doi.org/10.1038/NCHEMBIO.1965			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CY8QW	26595461	Green Accepted			2023-01-03	WOS:000366674400007
J	Martinez-Skinner, AL; Arainga, MA; Puligujja, P; Palandri, DL; Baldridge, HM; Edagwa, BJ; McMillan, JM; Mosley, RL; Gendelman, HE				Martinez-Skinner, Andrea L.; Arainga, Mariluz A.; Puligujja, Pavan; Palandri, Diana L.; Baldridge, Hannah M.; Edagwa, Benson J.; McMillan, JoEllyn M.; Mosley, R. Lee; Gendelman, Howard E.			Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy	PLOS ONE			English	Article							HIV-1-INFECTED HUMANIZED MICE; MONOCYTE-DERIVED MACROPHAGES; DRUG-DELIVERY; HIV-1 INFECTION; IN-VIVO; SUBCAPSULAR SINUS; LYMPH-NODE; NANOPARTICLES; PHARMACOKINETICS; PHARMACODYNAMICS	Long-acting nanoformulated antiretroviral therapy (nanoART) induces a range of innate immune migratory, phagocytic and secretory cell functions that perpetuate drug depots. While recycling endosomes serve as the macrophage subcellular depots, little is known of the dynamics of nanoART-cell interactions. To this end, we assessed temporal leukocyte responses, drug uptake and distribution following both intraperitoneal and intramuscular injection of nanoformulated atazanavir (nanoATV). Local inflammatory responses heralded drug distribution to peritoneal cell populations, regional lymph nodes, spleen and liver. This proceeded for three days in male Balb/c mice. NanoATV-induced changes in myeloid populations were assessed by fluorescence-activated cell sorting (FACS) with CD45, CD3, CD11b, F4180, and GR-1 antibodies. The localization of nanoATV within leukocyte cell subsets was determined by confocal microscopy. Combined FACS and ultra-performance liquid chromatography tandem mass-spectrometry assays determined nanoATV carriages by cell-based vehicles. A robust granulocyte, but not peritoneal macrophage nanoATV response paralleled zymosan A treatment. ATV levels were highest at sites of injection in peritoneal or muscle macrophages, dependent on the injection site. The spleen and liver served as nanoATV tissue depots while drug levels in lymph nodes were higher than those recorded in plasma. Dual polymer and cell labeling demonstrated a nearly exclusive drug reservoir in macrophages within the liver and spleen. Overall, nanoART induces innate immune responses coincident with rapid tissue macrophage distribution. Taken together, these works provide avenues for therapeutic development designed towards chemical eradication of human immunodeficiency viral infection.	[Martinez-Skinner, Andrea L.; Arainga, Mariluz A.; Puligujja, Pavan; Palandri, Diana L.; Baldridge, Hannah M.; Edagwa, Benson J.; McMillan, JoEllyn M.; Mosley, R. Lee; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; [Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	McMillan, JM (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.	jmmcmillan@unmc.edu			University of Nebraska Foundation; Vice Chancellor's office of the University of Nebraska Medical Center; ViiV Healthcare; National Institutes of Health [P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P01 NS43985, P30 MH062261, R01 AG043540]; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062261, P01MH064570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492, R01NS034239, P01NS043985, R01NS036126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG043540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA028555] Funding Source: NIH RePORTER	University of Nebraska Foundation; Vice Chancellor's office of the University of Nebraska Medical Center; ViiV Healthcare; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the University of Nebraska Foundation (https://nufoundation.org) which includes individual donations from Carol Swarts and Frances and Louie Blumkin; the Vice Chancellor's office of the University of Nebraska Medical Center; ViiV Healthcare; and National Institutes of Health grants P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P01 NS43985, P30 MH062261 and R01 AG043540.	Adams JL, 2012, CURR OPIN HIV AIDS, V7, P390, DOI 10.1097/COH.0b013e328356e91c; Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195; Allers K, 2014, J INFECT DIS, V209, P739, DOI 10.1093/infdis/jit547; [Anonymous], 2003, Proj Inf Perspect, P7; Azzam R, 2006, JAIDS-J ACQ IMM DEF, V42, P19; Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830; Balkundi Shantanu, 2010, J Vis Exp, DOI 10.3791/2460; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Bogdan C, 2008, CELL MICROBIOL, V10, P1221, DOI 10.1111/j.1462-5822.2008.01146.x; Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107; Bressani RF, 2011, NANOTOXICOLOGY, V5, P592, DOI 10.3109/17435390.2010.541292; Carter CA, 2008, ANNU REV MICROBIOL, V62, P425, DOI 10.1146/annurev.micro.62.081307.162758; Cash JL, 2009, METHOD ENZYMOL, V461, P379, DOI 10.1016/S0076-6879(09)05417-2; Chen RY, 2002, AIDS RES HUM RETROV, V18, P909, DOI 10.1089/088922202760265588; Chulamokha L, 2005, J NEUROVIROL, V11, P76, DOI 10.1080/13550280590931270; Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad; Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012; Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534; Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274; Edagwa BJ, 2014, FASEB J, V28, P5071, DOI 10.1096/fj.14-255786; Edagwa BJ, 2014, CURR MED CHEM, V21, P4186, DOI 10.2174/0929867321666140826114135; Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3; Fujiwara M, 1996, BBA-BIOMEMBRANES, V1278, P59, DOI 10.1016/0005-2736(95)00183-2; Gautam N, 2014, ANTIMICROB AGENTS CH, V58, P7510, DOI 10.1128/AAC.04108-14; Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13; Gent YYJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4191; Gordon S, 2014, IMMUNOL REV, V262, P36, DOI 10.1111/imr.12223; Hawkins T, 2006, AIDS PATIENT CARE ST, V20, P6, DOI 10.1089/apc.2006.20.6; Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032; Kadiu I, 2011, J NEUROIMMUNE PHARM, V6, P658, DOI 10.1007/s11481-011-9298-z; Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/NNM.11.27, 10.2217/nnm.11.27]; Kamaly N, 2013, P NATL ACAD SCI USA, V110, P6506, DOI 10.1073/pnas.1303377110; Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454; Kovarova M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005075; Lieberman-Blum SS, 2008, CLIN THER, V30, P1228, DOI 10.1016/S0149-2918(08)80048-3; Lu J, 2012, NANOMED-NANOTECHNOL, V8, P212, DOI 10.1016/j.nano.2011.06.002; Martinez-Skinner AL, 2013, J PROTEOME RES, V12, P2282, DOI 10.1021/pr400185w; Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/nnm.09.38; Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019; Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7; Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]; Nukolova NV, 2011, BIOMATERIALS, V32, P5417, DOI 10.1016/j.biomaterials.2011.04.006; Orenstein JM, 2007, ULTRASTRUCT PATHOL, V31, P151, DOI 10.1080/01913120701344343; Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488; Puligujja P, 2015, ANTIVIR RES, V120, P85, DOI 10.1016/j.antiviral.2015.05.009; Puligujja P, 2015, BIOMATERIALS, V41, P141, DOI 10.1016/j.biomaterials.2014.11.012; Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003; Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x; Ray Avijit, 2010, J Vis Exp, DOI 10.3791/1488; Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395; SAINTEMARIE G, 1985, CELL TISSUE RES, V239, P31, DOI 10.1007/BF00214899; Shehu-Xhilaga M, 2005, CURR MED CHEM, V12, P1705, DOI 10.2174/0929867054367211; Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P481, DOI 10.1097/QAI.0000000000000301; Strauss-Ayali D, 2007, J LEUKOCYTE BIOL, V82, P244, DOI 10.1189/jlb.0307191; SZAKAL AK, 1983, J IMMUNOL, V131, P1714; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541; Wang X, 2009, ACS NANO, V3, P3165, DOI 10.1021/nn900649v; Wegzyn CM, 2012, CURR OPIN PHARMACOL, V12, P556, DOI 10.1016/j.coph.2012.06.005; Zhao YL, 2011, NANOMEDICINE-UK, V6, P25, DOI [10.2217/nnm.10.129, 10.2217/NNM.10.129]	60	9	9	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2015	10	12							e0145966	10.1371/journal.pone.0145966	http://dx.doi.org/10.1371/journal.pone.0145966			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0TN	26716700	gold, Green Submitted, Green Published			2023-01-03	WOS:000367510500104
J	Schaapveld, M; Aleman, BMP; van Eggermond, AM; Janus, CPM; Krol, ADG; van der Maazen, RWM; Roesink, J; Raemaekers, JMM; de Boer, JP; Zijlstra, JM; van Imhoff, GW; Petersen, EJ; Poortmans, PMP; Beijert, M; Lybeert, ML; Mulder, I; Visser, O; Louwman, MWJ; Krul, IM; Lugtenburg, PJ; van Leeuwen, FE				Schaapveld, Michael; Aleman, Berthe M. P.; van Eggermond, Anna M.; Janus, Cecile P. M.; Krol, Augustinus D. G.; van der Maazen, Richard W. M.; Roesink, Judith; Raemaekers, John M. M.; de Boer, Jan Paul; Zijlstra, Josee M.; van Imhoff, Gustaaf W.; Petersen, Eefke J.; Poortmans, Philip M. P.; Beijert, Max; Lybeert, Marnix L.; Mulder, Ina; Visser, Otto; Louwman, Marieke W. J.; Krul, Inge M.; Lugtenburg, Pieternella J.; van Leeuwen, Flora E.			Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLLABORATIVE BRITISH COHORT; LUNG-CANCER; STOMACH-CANCER; FOLLOW-UP; DISEASE; RADIOTHERAPY; CHEMOTHERAPY; SURVIVORS; MALIGNANCY; NEOPLASMS	BACKGROUND Survivors of Hodgkin's lymphoma are at increased risk for treatment-related subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late 1980s, on the long-term risk of a second cancer remains unknown. METHODS We enrolled 3905 persons in the Netherlands who had survived for at least 5 years after the initiation of treatment for Hodgkin's lymphoma. Patients had received treatment between 1965 and 2000, when they were 15 to 50 years of age. We compared the risk of a second cancer among these patients with the risk that was expected on the basis of cancer incidence in the general population. Treatment-specific risks were compared within the cohort. RESULTS With a median follow-up of 19.1 years, 1055 second cancers were diagnosed in 908 patients, resulting in a standardized incidence ratio (SIR) of 4.6 (95% confidence interval [CI], 4.3 to 4.9) in the study cohort as compared with the general population. The risk was still elevated 35 years or more after treatment (SIR, 3.9; 95% CI, 2.8 to 5.4), and the cumulative incidence of a second cancer in the study cohort at 40 years was 48.5% (95% CI, 45.4 to 51.5). The cumulative incidence of second solid cancers did not differ according to study period (1965-1976, 1977-1988, or 1989-2000) (P = 0.71 for heterogeneity). Although the risk of breast cancer was lower among patients who were treated with supradiaphragmatic-field radiotherapy not including the axilla than among those who were exposed to mantle-field irradiation (hazard ratio, 0.37; 95% CI, 0.19 to 0.72), the risk of breast cancer was not lower among patients treated in the 1989-2000 study period than among those treated in the two earlier periods. A cumulative procarbazine dose of 4.3 g or more per square meter of body-surface area (which has been associated with premature menopause) was associated with a significantly lower risk of breast cancer (hazard ratio for the comparison with no chemotherapy, 0.57; 95% CI, 0.39 to 0.84) but a higher risk of gastrointestinal cancer (hazard ratio, 2.70; 95% CI, 1.69 to 4.30). CONCLUSIONS The risk of second solid cancers did not appear to be lower among patients treated in the most recent calendar period studied (1989-2000) than among those treated in earlier periods. The awareness of an increased risk of second cancer remains crucial for survivors of Hodgkin's lymphoma. (Funded by the Dutch Cancer Society.)	[Schaapveld, Michael; van Eggermond, Anna M.; Mulder, Ina; Krul, Inge M.; van Leeuwen, Flora E.] Netherlands Canc Inst, Dept Epidemiol, NL-1066 CX Amsterdam, Netherlands; [Aleman, Berthe M. P.] Netherlands Canc Inst, Dept Radiat Oncol, NL-1066 CX Amsterdam, Netherlands; [de Boer, Jan Paul] Netherlands Canc Inst, Dept Hematol, NL-1066 CX Amsterdam, Netherlands; [Zijlstra, Josee M.] Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands; [Schaapveld, Michael; Mulder, Ina; Visser, Otto; Louwman, Marieke W. J.] Univ Med Ctr Utrecht, Netherlands Comprehens Canc Org, Utrecht, Netherlands; [Roesink, Judith] Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands; [Petersen, Eefke J.] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands; [Janus, Cecile P. M.] Erasmus MC, Dept Radiat Oncol, Inst Canc, Rotterdam, Netherlands; [Lugtenburg, Pieternella J.] Erasmus MC, Dept Hematol, Inst Canc, Rotterdam, Netherlands; [Krol, Augustinus D. G.] Leiden Univ, Med Ctr, Dept Radiat Oncol, Leiden, Netherlands; [van der Maazen, Richard W. M.; Poortmans, Philip M. P.] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, NL-6525 ED Nijmegen, Netherlands; [Mulder, Ina] Canisius Wilhelmina Hosp, Dept Educ & Sci, Nijmegen, Netherlands; [Raemaekers, John M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, Arnhem, Netherlands; [van Imhoff, Gustaaf W.] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands; [Beijert, Max] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands; [Poortmans, Philip M. P.] Dr Bernard Verbeeten Inst, Dept Radiat Oncol, Tilburg, Netherlands; [Lybeert, Marnix L.] Catharina Hosp, Dept Radiotherapy, Eindhoven, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen; Canisius-Wilhelmina Hospital; Radboud University Nijmegen; University of Groningen; University of Groningen; Instituut Verbeeten; Catharina Hospital	van Leeuwen, FE (corresponding author), Netherlands Canc Inst, Dept Epidemiol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	f.v.leeuwen@nki.nl	Poortmans, P.M.P./L-4581-2015; van der Maazen, R.W.M./L-4498-2015; Schaapveld, Michael/ABC-9714-2020; Louwman, Marieke WJ/N-5267-2018	Louwman, Marieke WJ/0000-0001-9011-6741; Krol, Stijn/0000-0002-3257-3634; Janus, Cecile/0000-0003-3860-8698; Schaapveld, Michael/0000-0003-4390-7182	Dutch Cancer Society [2010-4720]	Dutch Cancer Society(KWF Kankerbestrijding)	Supported by a grant (2010-4720) from the Dutch Cancer Society.	Aleman BMP, 2007, BLOOD, V109, P1878, DOI 10.1182/blood-2006-07-034405; Bhatia S, 2003, J CLIN ONCOL, V21, P4386, DOI 10.1200/JCO.2003.11.059; Boshuizen Hendriek C, 2010, Epidemiol Perspect Innov, V7, P4, DOI 10.1186/1742-5573-7-4; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Cooke R, 2013, BRIT J CANCER, V108, P2399, DOI 10.1038/bjc.2013.219; De Bruin ML, 2009, J CLIN ONCOL, V27, P4239, DOI 10.1200/JCO.2008.19.9174; De Bruin ML, 2009, BLOOD, V113, P3679, DOI 10.1182/blood-2008-10-184705; Diehl V, 2004, LANCET ONCOL, V5, P19, DOI 10.1016/S1470-2045(03)01320-2; Dores GM, 2014, ANN ONCOL, V25, P2073, DOI 10.1093/annonc/mdu287; Dores GM, 2002, J CLIN ONCOL, V20, P3484, DOI 10.1200/JCO.2002.09.038; Ederer F., 1959, INSTRUCTIONS IBM 650; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Hodgson DC, 2007, J CLIN ONCOL, V25, P1489, DOI 10.1200/JCO.2006.09.0936; Kooistra HAM, 2015, LEUKEMIA LYMPHOMA, V56, P230, DOI 10.3109/10428194.2014.910658; Maraldo MV, 2013, ANN ONCOL, V24, P2113, DOI 10.1093/annonc/mdt156; Morton LM, 2014, HAEMATOLOGICA, V99, pE193, DOI 10.3324/haematol.2014.108258; Morton LM, 2013, J CLIN ONCOL, V31, P3369, DOI 10.1200/JCO.2013.50.6832; Ng AK, 2002, BLOOD, V100, P1989, DOI 10.1182/blood-2002-02-0634; Ng AK, 2013, J CLIN ONCOL, V31, P2282, DOI 10.1200/JCO.2012.46.5732; Specht L, 2014, INT J RADIAT ONCOL, V89, P854, DOI 10.1016/j.ijrobp.2013.05.005; Swerdlow AJ, 2000, J CLIN ONCOL, V18, P498, DOI 10.1200/JCO.2000.18.3.498; Swerdlow AJ, 2001, J CLIN ONCOL, V19, P1610, DOI 10.1200/JCO.2001.19.6.1610; Swerdlow AJ, 2012, J CLIN ONCOL, V30, P2745, DOI 10.1200/JCO.2011.38.8835; Swerdlow AJ, 2011, J CLIN ONCOL, V29, P4096, DOI 10.1200/JCO.2011.34.8268; Travis LB, 2003, JAMA-J AM MED ASSOC, V290, P465, DOI 10.1001/jama.290.4.465; Travis LB, 2002, JNCI-J NATL CANCER I, V94, P182, DOI 10.1093/jnci/94.3.182; van den Belt-Dusebout AW, 2009, INT J RADIAT ONCOL, V75, P1420, DOI 10.1016/j.ijrobp.2009.01.073; van Eggermond AM, 2014, BLOOD, V124, P319, DOI 10.1182/blood-2013-10-532184; van Leeuwen FE, 2000, J CLIN ONCOL, V18, P487, DOI 10.1200/JCO.2000.18.3.487; VANLEEUWEN FE, 1995, JNCI-J NATL CANCER I, V87, P1530, DOI 10.1093/jnci/87.20.1530; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P312, DOI 10.1200/JCO.1994.12.2.312; ZARATEOSORNO A, 1992, AM J SURG PATHOL, V16, P885, DOI 10.1097/00000478-199209000-00007	32	346	351	2	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	2015	373	26					2499	2511		10.1056/NEJMoa1505949	http://dx.doi.org/10.1056/NEJMoa1505949			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CZ7SG	26699166	Bronze, Green Published			2023-01-03	WOS:000367299700006
J	Mair, G; von Kummer, R; Lindley, RI; Sandercock, PAG; Wardlaw, JM				Mair, Grant; von Kummer, Ruediger; Lindley, Richard I.; Sandercock, Peter A. G.; Wardlaw, Joanna M.		IST-3 Collaborative Grp	Effect of X-Ray Attenuation of Arterial Obstructions on Intravenous Thrombolysis and Outcome after Ischemic Stroke	PLOS ONE			English	Article							PREDICTS SUCCESSFUL RECANALIZATION; TISSUE-PLASMINOGEN ACTIVATOR; THROMBUS ATTENUATION; COMPUTED-TOMOGRAPHY; TRIAL IST-3; CT; THROMBECTOMY; DENSITY; VESSEL; SIGN	Objective To assess whether the x-ray attenuation of intra-arterial obstruction measured on non-contrast CT in ischemic stroke can predict response to thrombolysis and subsequent functional outcome. Methods The Third International Stroke Trial (IST-3) was a multicenter randomized-controlled trial of intravenous thrombolysis (rt-PA) given within six hours of ischemic stroke. Ethical approval and informed consent were obtained. In a subgroup of 109 IST-3 patients (38 men, median age 82 years), a single reader, masked to all clinical and other imaging data, manually measured x-ray attenuation (Hounsfield Units, HU) on non-contrast CT at the location of angiographically-proven intra-arterial obstructions, pre-randomization and at 24-48 hour follow-up. We calculated change in attenuation between scans. We assessed the impact of pre-randomization arterial obstruction attenuation on six-month functional outcome. Results Most arterial obstructions (64/109, 59%) were hyperattenuating (mean 51.0 HU). Compared with control, treatment with rt-PA was associated with a greater, but non-significant, reduction in obstruction attenuation at follow-up (-8.0 HU versus -1.4 HU in patients allocated control, p = 0.117). In multivariable ordinal regression analysis controlled for patient age, stroke severity, location and extent of obstruction, time from stroke onset to baseline scan and rt-PA treatment allocation, the attenuation of pre-randomization arterial obstruction was not independently associated with six-month outcome (odds ratio = 0.99, 95% confidence interval = 0.94-1.03, p = 0.516). Conclusions In ischemic stroke, the x-ray attenuation of the arterial obstruction may decline more rapidly from baseline to 24-48 hours following treatment with thrombolysis but we found no evidence that baseline arterial obstruction attenuation predicts six-month outcome.	[Mair, Grant; Wardlaw, Joanna M.] Univ Edinburgh, Western Gen Hosp, Div Neuroimaging Sci, Edinburgh, Midlothian, Scotland; [von Kummer, Ruediger] Dresden Univ, Stroke Ctr, Univ Hosp, Dept Neuroradiol, Dresden, Germany; [Lindley, Richard I.] Univ Sydney, Westmead Hosp, Sch Clin, Sydney, NSW 2006, Australia; [Lindley, Richard I.] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia; [Sandercock, Peter A. G.] Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Edinburgh, Midlothian, Scotland	University of Edinburgh; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Sydney; George Institute for Global Health; University of Sydney; University of Edinburgh	Wardlaw, JM (corresponding author), Univ Edinburgh, Western Gen Hosp, Div Neuroimaging Sci, Edinburgh, Midlothian, Scotland.	joanna.wardlaw@ed.ac.uk	Mair, Grant/M-9071-2016; Hernandez, María/GYU-3543-2022; Zini, Andrea/K-1136-2014; Lueck, Christian Joseph/O-4031-2016; von Kummer, Rüdiger/AAA-4478-2019; Wardlaw, Joanna M/Y-3456-2019; Lindley, Richard/B-8148-2013; Hankey, Graeme J/H-4968-2014	Mair, Grant/0000-0003-2189-443X; Zini, Andrea/0000-0003-1486-4507; Lueck, Christian Joseph/0000-0003-1537-7612; von Kummer, Rüdiger/0000-0003-0119-4604; Wardlaw, Joanna M/0000-0002-9812-6642; Lindley, Richard/0000-0002-0104-5679; Hankey, Graeme J/0000-0002-6044-7328; Engelter, Stefan/0000-0003-3855-6234	Stroke Association, UK [TSA 04/99]; Health Foundation UK [2268/1282]; Chest, Heart & Stroke Scotland [R100/7]; UK Medical Research Council (MRC) [G0400069, EME 09-800-15]; Research Council of Norway; Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden; Swedish Heart Lung Fund; Foundation of Marianne and Marcus Wallenberg, Stockholm County Council; Karolinska Institute Joint ALF-project grants Sweden; Polish Ministry of Science and Education [2PO5B10928]; Australian Heart Foundation; Australian National Health and Medical Research Council (NHMRC); Swiss National Research Foundation; Swiss Heart Foundation; Foundation for Health and Cardio-/Neurovascular Research, Basel, Switzerland; Assessorato alla Sanita, Regione dell'Umbria, Italy; Danube University, Krems, Austria; Scottish Funding Council (SFC); Chief Scientist Office of the Scottish Executive (CSO); Chest Heart and Stroke Scotland; DesAcc; University of Edinburgh; Danderyd Hospital RD Department; Karolinska Institutet; Oslo University Hospital; Dalhousie University Internal Medicine Research Fund; National Institute for Health Research Efficacy and Mechanisms Evaluation Panel [EME 08-43-52]; Medical Research Council [MC_G1002455, G0400069] Funding Source: researchfish; MRC [MC_G1002455, G0400069] Funding Source: UKRI	Stroke Association, UK; Health Foundation UK; Chest, Heart & Stroke Scotland; UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Research Council of Norway(Research Council of Norway); Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden; Swedish Heart Lung Fund(Swedish Heart-Lung Foundation); Foundation of Marianne and Marcus Wallenberg, Stockholm County Council; Karolinska Institute Joint ALF-project grants Sweden; Polish Ministry of Science and Education(Ministry of Science and Higher Education, Poland); Australian Heart Foundation; Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Swiss National Research Foundation(Swiss National Science Foundation (SNSF)); Swiss Heart Foundation; Foundation for Health and Cardio-/Neurovascular Research, Basel, Switzerland; Assessorato alla Sanita, Regione dell'Umbria, Italy; Danube University, Krems, Austria; Scottish Funding Council (SFC); Chief Scientist Office of the Scottish Executive (CSO); Chest Heart and Stroke Scotland; DesAcc; University of Edinburgh; Danderyd Hospital RD Department; Karolinska Institutet(Karolinska Institutet); Oslo University Hospital; Dalhousie University Internal Medicine Research Fund; National Institute for Health Research Efficacy and Mechanisms Evaluation Panel; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The start-up phase of IST-3 was supported by a grant from the Stroke Association, UK (TSA 04/99, www.stroke.org.uk). The expansion phase was funded by the Health Foundation UK (2268/1282, www.health.org.uk). The scan reading development was funded by Chest, Heart & Stroke Scotland (R100/7, www.chss.org.uk). The main phase of the trial was funded by: UK Medical Research Council (MRC) (grant numbers G0400069 and EME 09-800-15, www.mrc.ac.uk) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership; the Research Council of Norway; Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden; the Swedish Heart Lung Fund; The Foundation of Marianne and Marcus Wallenberg, Stockholm County Council; Karolinska Institute Joint ALF-project grants Sweden, the Polish Ministry of Science and Education (grant number 2PO5B10928, www.nauka.gov.pl); the Australian Heart Foundation; Australian National Health and Medical Research Council (NHMRC); the Swiss National Research Foundation; the Swiss Heart Foundation; the Foundation for Health and Cardio-/Neurovascular Research, Basel, Switzerland; the Assessorato alla Sanita, Regione dell'Umbria, Italy; and, Danube University, Krems, Austria. Boehringer-Ingelheim GmbH donated drug and placebo for the 300 patients in the double-blind phase, but thereafter had no role whatsoever in the trial. The UK Stroke Research Network (SRN study ID 2135, www.uksrn.ac.uk) adopted the trial in 01/05/2006, supported the initiation of new UK sites, and in some centres, and, after that date, data collection was undertaken by staff funded by the network or working for associated NHS organizations. IST-3 gratefully acknowledges the extensive support of the NIHR Stroke Research Network, NHS Research Scotland (NRS), through the Scottish Stroke Research Network, and the National Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC). The central imaging work was undertaken at the Brain Imaging Research Centre, a member of the Scottish Imaging Network A Platform for Scientific Excellence (SINAPSE) collaboration, at the Division of Clinical Neurosciences, University of Edinburgh. SINAPSE is funded by the Scottish Funding Council (SFC) and the Chief Scientist Office of the Scottish Executive (CSO). Additional support was received from Chest Heart and Stroke Scotland, DesAcc, University of Edinburgh, Danderyd Hospital R&D Department, Karolinska Institutet, Oslo University Hospital, and the Dalhousie University Internal Medicine Research Fund. The IST-3 angiography substudy was funded by the National Institute for Health Research Efficacy and Mechanisms Evaluation Panel (EME 08-43-52, www.nets.nihr.ac.uk/programmes/eme). The views are those of the authors and not the funders. The funders played no role in study design, data analysis, decision to publish or preparation of the manuscript.	BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6; Froehler MT, 2013, J NEUROINTERV SURG, V5, P289, DOI 10.1136/neurintsurg-2012-010313; Nam HS, 2012, THROMB HAEMOSTASIS, V107, P786, DOI 10.1160/TH11-08-0585; Kirchhof K, 2003, RADIOLOGY, V228, P126, DOI 10.1148/radiol.2273020530; Liebeskind DS, 2011, STROKE, V42, P1237, DOI 10.1161/STROKEAHA.110.605576; Mair G, 2015, NEUROLOGY IN PRESS; Mair G, 2015, NEURORADIOLOGY, V57, P1, DOI 10.1007/s00234-014-1441-0; Mair G, 2015, STROKE, V46, P102, DOI 10.1161/STROKEAHA.114.007036; Moftakhar P, 2013, STROKE, V44, P243, DOI 10.1161/STROKEAHA.112.674127; Mokin M, 2015, J NEUROINTERV SURG, V7, P104, DOI 10.1136/neurintsurg-2013-011017; Niesten JM, 2014, CEREBROVASC DIS, V37, P116, DOI 10.1159/000357420; Niesten JM, 2013, NEURORADIOLOGY, V55, P1071, DOI 10.1007/s00234-013-1217-y; Niesten JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088882; Novotna J, 2014, J STROKE CEREBROVASC, V23, P2533, DOI 10.1016/j.jstrokecerebrovasdis.2014.04.034; Puig J, 2012, AM J NEURORADIOL, V33, P90, DOI 10.3174/ajnr.A2878; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Sandercock P, 2012, INT J STROKE, V7, P186, DOI 10.1111/j.1747-4949.2012.00782.x; Sandercock P, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-37; Spiotta AM, 2014, J NEUROINTERV SURG, V6, P423, DOI 10.1136/neurintsurg-2013-010765; Topcuoglu MA, 2014, J STROKE CEREBROVASC, V23, pE85, DOI 10.1016/j.jstrokecerebrovasdis.2013.08.026; Wardlaw JM, 2015, INT J STROKE, V10, P956, DOI 10.1111/j.1747-4949.2012.00946.x; Yilmaz U, 2013, AM J NEURORADIOL, V34, P2184, DOI 10.3174/ajnr.A3565; Zhu GM, 2015, INT J STROKE, V10, P28, DOI 10.1111/ijs.12312	24	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0145683	10.1371/journal.pone.0145683	http://dx.doi.org/10.1371/journal.pone.0145683			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SI	26701648	Green Submitted, Green Published, gold			2023-01-03	WOS:000367092600118
J	Al-Awaidy, S; Hamid, S; Al Obaidani, I; Al Baqlani, S; Al Busaidi, S; Bawikar, S; El-Shoubary, W; Dueger, EL; Said, MM; Elamin, E; Shah, P; Talaat, M				Al-Awaidy, Salah; Hamid, Sarah; Al Obaidani, Idris; Al Baqlani, Said; Al Busaidi, Suleiman; Bawikar, Shyam; El-Shoubary, Waleed; Dueger, Erica L.; Said, Mayar M.; Elamin, Emdeldin; Shah, Parag; Talaat, Maha			The Burden of Influenza-Associated Hospitalizations in Oman, January 2008-June 2013	PLOS ONE			English	Article							OUTPATIENTS; INFECTION	Introduction Acute respiratory infections (ARI), including influenza, comprise a leading cause of morbidity and mortality worldwide. Influenza surveillance provides important information to inform policy on influenza control and vaccination. While the epidemiology of influenza has been well characterized in western countries, few data exist on influenza epidemiology in the Eastern Mediterranean Region. We describe the epidemiology of influenza virus in Oman. Methods Using syndromic case definitions and protocols, patients from four regional hospitals in Oman were enrolled in a descriptive prospective study to characterize the burden of severe acute respiratory infections (SARI) and influenza. Eligible patients provided demographic information as well as oropharyngeal (OP) and nasopharyngeal (NP) swabs. Specimens were tested for influenza A and influenza B; influenza A viruses were subtyped using RT-PCR. Results From January 2008 through June 2013, a total of 5,147 cases were enrolled and tested for influenza. Influenza strains were detected in 8% of cases for whom samples were available. Annual incidence rates ranged from 0.5 to 15.4 cases of influenza-associated SARI per 100,000 population. The median age of influenza patients was 6 years with children 0-2 years accounting for 34% of all influenza-associated hospitalizations. By contrast, the median age of non-influenza SARI cases was 1 year with children 0-2 years comprising 59% of SARI. Compared to non-influenza SARI cases, a greater proportion of influenza cases had pre-existing chronic conditions and underwent ventilation during hospitalization. Conclusions Influenza virus is associated with a substantial proportion of SARI in Oman. Influenza in Oman approximately follows northern hemisphere seasonality, with major peaks in October to December and a lesser peak around April. The burden of influenza was greatest in children and the elderly. Future efforts should examine the burden of influenza in other potential risk groups such as pregnant women to inform interventions including targeted vaccination.	[Al-Awaidy, Salah; Al Obaidani, Idris; Al Baqlani, Said; Al Busaidi, Suleiman; Bawikar, Shyam; Elamin, Emdeldin; Shah, Parag] Minist Hlth, Muscat, Oman; [Hamid, Sarah; El-Shoubary, Waleed; Dueger, Erica L.; Talaat, Maha] US Naval Med Res, Global Dis Detect & Response Program, Unit 3, Cairo, Egypt; [Hamid, Sarah; El-Shoubary, Waleed; Talaat, Maha] Ctr Dis Control & Prevent, Global Dis Detect Ctr, Cairo, Egypt; [Dueger, Erica L.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Said, Mayar M.] US Naval Med Res, Unit 3, Cairo, Egypt	Naval Medical Research Center (NMRC); Naval Medical Research Unit - No. 3 (NAMRU-3); Centers for Disease Control & Prevention - USA; Naval Medical Research Center (NMRC); Naval Medical Research Unit - No. 3 (NAMRU-3)	Hamid, S (corresponding author), US Naval Med Res, Global Dis Detect & Response Program, Unit 3, Cairo, Egypt.	hamids@wpro.who.int	Awaidy, Salah Al/AAF-5884-2020	Awaidy, Salah Al/0000-0001-5112-3893; Hamid, Sarah/0000-0001-8164-0656	Global Emerging Infections Surveillance Program [GEIS847705.821000.25GB.E0018]; Centers of Disease Control (CDC) in Atlanta, Georgia	Global Emerging Infections Surveillance Program; Centers of Disease Control (CDC) in Atlanta, Georgia	This work was supported by the Global Emerging Infections Surveillance Program [GEIS847705.821000.25GB.E0018] and the Centers of Disease Control (CDC) in Atlanta, Georgia.	Ahmad Akhwand Shakeel, 2011, Oman Med J, V26, P329, DOI 10.5001/omj.2011.82; Al-Lawati J, 2010, SULTAN QABOOS U MED, V10, P326; Al-Mahrezi A, 2012, INT J INFECT DIS, V16, pE504, DOI 10.1016/j.ijid.2012.02.015; Al-Muharrmi Zakariya, 2010, Sultan Qaboos Univ Med J, V10, P187; [Anonymous], 2012, BACKGR SUMM NOV COR; Azziz-Baumgartner E, 2012, B WORLD HEALTH ORGAN, V90, P12, DOI 10.2471/BLT.11.090209; Central Intelligence Agency, WORLD FACTBOOK; Emukule GO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105543; International Emerging Infections Program-Thailand, ACT SURV PNEUM REQ H; Karageorgopoulos D. E., 2011, PLoS ONE, pe21690, DOI 10.1371/journal.pone.0021690; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Meerhoff TJ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-014-0722-x; Pajankar Sumant, 2012, Oman Med J, V27, P201, DOI 10.5001/omj.2012.46; Patrozou E, 2009, PUBLIC HEALTH REP, V124, P193, DOI 10.1177/003335490912400205; Radin JM, 2012, J INFECT DIS, V206, pS14, DOI 10.1093/infdis/jis606; Tallo VL, 2014, INFLUENZA OTHER RESP, V8, P159, DOI 10.1111/irv.12223; Tamfum JJM, 2012, J INFECT DIS, V206, pS36, DOI 10.1093/infdis/jis537; Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004; Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053; World Health Organization, 2011, WHO GLOB TECHN CONS; World Health Organization, 2015, FLUNET CHARTS; World Health Organization, 2012, INFL VIR ACT WORLD; World Health Organization, PAHO CDC GEN PROT IN; World Health Organization, 2015, INFL VIR UPD; World Health Organization, 2005, HDB IMCI	25	19	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2015	10	12							e0144186	10.1371/journal.pone.0144186	http://dx.doi.org/10.1371/journal.pone.0144186			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1YS	26642055	Green Published, Green Submitted, gold			2023-01-03	WOS:000366902700071
J	Lemiale, V; Mokart, D; Resche-Rigon, M; Pene, F; Mayaux, J; Faucher, E; Nyunga, M; Girault, C; Perez, P; Guitton, C; Ekpe, K; Kouatchet, A; Theodose, I; Benoit, D; Canet, E; Barbier, F; Rabbat, A; Bruneel, F; Vincent, F; Klouche, K; Loay, K; Mariotte, E; Bouadma, L; Moreau, AS; Seguin, A; Meert, AP; Reignier, J; Papazian, L; Mehzari, I; Cohen, Y; Schenck, M; Hamidfar, R; Darmon, M; Demoule, A; Chevret, S; Azoulay, E				Lemiale, Virginie; Mokart, Djamel; Resche-Rigon, Matthieu; Pene, Frederic; Mayaux, Julien; Faucher, Etienne; Nyunga, Martine; Girault, Christophe; Perez, Pierre; Guitton, Christophe; Ekpe, Kenneth; Kouatchet, Achille; Theodose, Igor; Benoit, Dominique; Canet, Emmanuel; Barbier, Francois; Rabbat, Antoine; Bruneel, Fabrice; Vincent, Francois; Klouche, Kada; Loay, Kontar; Mariotte, Eric; Bouadma, Lila; Moreau, Anne-Sophie; Seguin, Amelie; Meert, Anne-Pascale; Reignier, Jean; Papazian, Laurent; Mehzari, Ilham; Cohen, Yves; Schenck, Maleka; Hamidfar, Rebecca; Darmon, Michael; Demoule, Alexandre; Chevret, Sylvie; Azoulay, Elie		Grp Rech Reanimation Resp Patient	Effect of Noninvasive Ventilation vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION; ONCOLOGY PATIENTS; HEMATOLOGY; SURVIVAL; CANCER; ADMISSION	IMPORTANCE Noninvasive ventilation has been recommended to decrease mortality among immunocompromised patients with hypoxemic acute respiratory failure. However, its effectiveness for this indication remains unclear. OBJECTIVE To determine whether early noninvasive ventilation improved survival in immunocompromised patients with nonhypercapnic acute hypoxemic respiratory failure. DESIGN, SETTING, AND PARTICIPANTS Multicenter randomized trial conducted among 374 critically ill immunocompromised patients, of whom 317 (84.7%) were receiving treatment for hematologic malignancies or solid tumors, at 28 intensive care units (ICUs) in France and Belgium between August 12, 2013, and January 2, 2015. INTERVENTIONS Patients were randomly assigned to early noninvasive ventilation (n = 191) or oxygen therapy alone (n = 183). MAIN OUTCOMES AND MEASURES The primary outcome was day-28 mortality. Secondary outcomes were intubation, Sequential Organ Failure Assessment score on day 3, ICU-acquired infections, duration of mechanical ventilation, and ICU length of stay. RESULTS At randomization, median oxygen flow was 9 L/min (interquartile range, 5-15) in the noninvasive ventilation group and 9 L/min (interquartile range, 6-15) in the oxygen group. All patients in the noninvasive ventilation group received the first noninvasive ventilation session immediately after randomization. On day 28 after randomization, 46 deaths (24.1%) had occurred in the noninvasive ventilation group vs 50 (27.3%) in the oxygen group (absolute difference, -3.2 [95% CI, -12.1 to 5.6]; P = .47). Oxygenation failure occurred in 155 patients overall (41.4%), 73 (38.2%) in the noninvasive ventilation group and 82 (44.8%) in the oxygen group (absolute difference, -6.6 [95% CI, -16.6 to 3.4]; P = .20). There were no significant differences in ICU-acquired infections, duration of mechanical ventilation, or lengths of ICU or hospital stays. CONCLUSIONS AND RELEVANCE Among immunocompromised patients admitted to the ICU with hypoxemic acute respiratory failure, early noninvasive ventilation compared with oxygen therapy alone did not reduce 28-day mortality. However, study power was limited.	[Lemiale, Virginie; Chevret, Sylvie; Azoulay, Elie] St Louis Univ Hosp, Paris, France; [Mokart, Djamel] IPC, Lyon, France; [Resche-Rigon, Matthieu; Pene, Frederic; Theodose, Igor; Canet, Emmanuel; Rabbat, Antoine; Mariotte, Eric; Bouadma, Lila; Demoule, Alexandre] APHP, Paris, France; [Mayaux, Julien] Grp Hosp Pitie Salpetriere Charles Fox, AP HP, Serv Pneumol & Reanimat Med, Paris, France; [Faucher, Etienne] Hosp Civils Lyon, Lyon, France; [Girault, Christophe] Univ Rouen, Charles Nicolle Univ Hosp, Med Intens Care Unit, Rouen, France; [Perez, Pierre] Ctr Hosp Univ Nancy, Nancy, France; [Guitton, Christophe] Univ Hosp Nantes, Nantes, France; [Ekpe, Kenneth] Inst Gustave Roussy, Paris, France; [Kouatchet, Achille] CHRU Angers, Intens Care Unit, Angers, France; [Benoit, Dominique] Intens Care Med, Ghent, Belgium; [Barbier, Francois] La Source Hosp CHR Orleans, Med Intens Care Unit, Orleans, France; [Bruneel, Fabrice] Hop Andre Mignot Le Chesnay, Intens Care Unit, Paris, France; [Vincent, Francois; Cohen, Yves] Hop Avicenne, APHP, F-93009 Bobigny, France; [Klouche, Kada] Lapeyronie Univ Hosp, Montpellier, France; [Loay, Kontar] Ctr Hosp Univ Amiens, Amiens, France; [Moreau, Anne-Sophie] CHRU Lille, Ctr Reanimat, F-59037 Lille, France; [Seguin, Amelie] Ctr Hosp Univ Caen, Caen, France; [Meert, Anne-Pascale] Inst Jules Bordet, B-1000 Brussels, Belgium; [Reignier, Jean] CHU Nantes, Reanimat Med, F-44035 Nantes 01, France; [Papazian, Laurent] Hop Nord Marseille, Reanimat DRIS, Marseille, France; [Mehzari, Ilham] CHSF, Paris, France; [Schenck, Maleka] Hospices Civils Strasbourg, Strasbourg, France; [Hamidfar, Rebecca] CHU Grenoble, F-38043 Grenoble, France; [Darmon, Michael] St Etienne Univ Hosp, Med Surg ICU, St Etienne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Lyon; CHU de Rouen; Universite de Rouen Normandie; CHU de Nancy; Nantes Universite; CHU de Nantes; UNICANCER; Gustave Roussy; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Ghent University; Ghent University Hospital; Centre Hospitalier Regional d'Orleans; Centre Hospitalier de Versailles; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Avicenne - APHP; Universite Paris 13; Universite de Montpellier; CHU de Montpellier; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Universite de Lille - ISITE; CHU Lille; CHU de Caen NORMANDIE; Universite de Caen Normandie; Institut Jules Bordet; Nantes Universite; CHU de Nantes; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU de St Etienne	Azoulay, E (corresponding author), Hop St Louis, Med Intens Care Unit, 1 Ave Claude Vellefaux, F-75010 Paris, France.	elie.azoulay@sls.aphp.fr	Resche-Rigon, Matthieu/ABA-5374-2021; Lascarrou, Jean Baptiste/I-4079-2014; Demoule, Alexandre/ABG-4915-2021	Lascarrou, Jean Baptiste/0000-0003-3706-078X; Demoule, Alexandre/0000-0002-0432-7217; Mariotte, Eric/0000-0002-3614-0457; Nseir, Saad/0000-0002-7618-0357; Darmon, Michael/0000-0003-4198-8038; resche-rigon, matthieu/0000-0003-2220-5085; Chemouni, Frank/0000-0001-6834-1803; Pene, Frederic/0000-0003-3639-3849; chevret, sylvie/0000-0001-6449-4730; Mokart, D/0000-0003-1711-463X	Legs Poix (Chancellerie des Universites de Paris); OUTCOMEREA study group	Legs Poix (Chancellerie des Universites de Paris); OUTCOMEREA study group	The study was sponsored by 2 grants from the nonprofit organizations Legs Poix (Chancellerie des Universites de Paris) and the OUTCOMEREA study group.	Adda M, 2008, CRIT CARE MED, V36, P2766, DOI 10.1097/CCM.0b013e31818699f6; Azoulay E, 2012, BONE MARROW TRANSPL, V47, P469, DOI 10.1038/bmt.2011.232; Azoulay E, 2008, CRIT CARE MED, V36, P100, DOI 10.1097/01.CCM.0000295590.33145.C4; Azoulay E, 2014, INTENS CARE MED, V40, P1106, DOI 10.1007/s00134-014-3354-0; Azoulay E, 2013, J CLIN ONCOL, V31, P2810, DOI 10.1200/JCO.2012.47.2365; Azoulay E, 2013, INTENS CARE MED, V39, P292, DOI 10.1007/s00134-012-2746-2; Azoulay E, 2010, AM J RESP CRIT CARE, V182, P1038, DOI 10.1164/rccm.201001-0018OC; Canet E, 2011, CRIT CARE, V15, DOI 10.1186/cc10091; Depuydt PO, 2010, J CRIT CARE, V25, P30, DOI 10.1016/j.jcrc.2009.02.016; Depuydt PO, 2004, CHEST, V126, P1299, DOI 10.1378/chest.126.4.1299; Faguer S, 2013, EUR J INTERN MED, V24, pE40, DOI 10.1016/j.ejim.2012.11.018; Frat JP, 2015, RESP CARE, V60, P170, DOI 10.4187/respcare.03075; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Gristina GR, 2011, CRIT CARE MED, V39, P2232, DOI 10.1097/CCM.0b013e3182227a27; He HW, 2013, NEW ENGL J MED, V369, P980, DOI 10.1056/NEJMc1308895; Hilbert G, 2001, NEW ENGL J MED, V344, P481, DOI 10.1056/NEJM200102153440703; Keenan SP, 2011, CAN MED ASSOC J, V183, pE195, DOI 10.1503/cmaj.100071; Lemiale V, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-372; Lemiale V, 2014, RESP CARE, V59, P1517, DOI 10.4187/respcare.02693; Malhotra A, 2007, NEW ENGL J MED, V357, P1113, DOI 10.1056/NEJMct074213; Mokart D, 2015, INTENS CARE MED, V41, P296, DOI 10.1007/s00134-014-3615-y; Mokart D, 2014, INTENS CARE MED, V40, P1570, DOI 10.1007/s00134-014-3433-2; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Salvadori Maurizio, 2014, World J Transplant, V4, P243, DOI 10.5500/wjt.v4.i4.243; Cruz RS, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009098.pub2; Schellongowski P, 2011, HAEMATOL-HEMATOL J, V96, P231, DOI 10.3324/haematol.2010.031583; Soerjomataram I, 2012, LANCET, V380, P1840, DOI 10.1016/S0140-6736(12)60919-2; van Vliet M, 2014, INTENS CARE MED, V40, P1275, DOI 10.1007/s00134-014-3373-x; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	30	206	218	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2015	314	16					1711	1719		10.1001/jama.2015.12402	http://dx.doi.org/10.1001/jama.2015.12402			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CU7HC	26444879	Bronze			2023-01-03	WOS:000363706300020
J	Chen, HJ; Shen, YC; Shiao, YJ; Liou, KT; Hsu, WH; Hsieh, PH; Lee, CY; Chen, YR; Lin, YL				Chen, Hong-Jhang; Shen, Yuh-Chiang; Shiao, Young-Ji; Liou, Kuo-Tong; Hsu, Wei-Hsiang; Hsieh, Pei-Hsuan; Lee, Chi-Ying; Chen, Yet-Ran; Lin, Yun-Lian			Multiplex Brain Proteomic Analysis Revealed the Molecular Therapeutic Effects of Buyang Huanwu Decoction on Cerebral Ischemic Stroke Mice	PLOS ONE			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; TISSUE-PLASMINOGEN ACTIVATOR; CHINESE MEDICINE; ARTERY OCCLUSION; NEURONAL DEATH; STEM-CELLS; MODEL; RAT; RECEPTOR; INJURY	Stroke is the second-leading cause of death worldwide, and tissue plasminogen activator (TPA) is the only drug used for a limited group of stroke patients in the acute phase. Buyang Huanwu Decoction (BHD), a traditional Chinese medicine prescription, has long been used for improving neurological functional recovery in stroke. In this study, we characterized the therapeutic effect of TPA and BHD in a cerebral ischemia/reperfusion (CIR) injury mouse model using multiplex proteomics approach. After the iTRAQ-based proteomics analysis, 1310 proteins were identified from the mouse brain with <1% false discovery rate. Among them, 877 quantitative proteins, 10.26% (90/877), 1.71% (15/877), and 2.62% (23/877) of the proteins was significantly changed in the CIR, BHD treatment, and TPA treatment, respectively. Functional categorization analysis showed that BHD treatment preserved the integrity of the blood-brain barrier (BBB) (Alb, Fga, and Trf), suppressed excitotoxicity (Grm5, Gnai, and Gdi), and enhanced energy metabolism (Bdh), thereby revealing its multiple effects on ischemic stroke mice. Moreover, the neurogenesis marker doublecortin was upregulated, and the activity of glycogen synthase kinase 3 (GSK-3) and Tau was inhibited, which represented the neuroprotective effects. However, TPA treatment deteriorated BBB breakdown. This study highlights the potential of BHD in clinical applications for ischemic stroke.	[Chen, Hong-Jhang; Shen, Yuh-Chiang; Shiao, Young-Ji; Hsu, Wei-Hsiang; Lin, Yun-Lian] Natl Res Inst Chinese Med, Taipei, Taiwan; [Chen, Hong-Jhang] Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 10764, Taiwan; [Liou, Kuo-Tong] Chinese Culture Univ, Dept Chinese Martial Arts, Taipei, Taiwan; [Liou, Kuo-Tong] Chinese Culture Univ, Grad Inst Sport Coaching Sci, Taipei, Taiwan; [Hsieh, Pei-Hsuan; Lee, Chi-Ying; Chen, Yet-Ran] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan; [Lin, Yun-Lian] China Med Univ, Dept Chinese Pharmaceut Sci & Chinese Med Resourc, Taichung, Taiwan; [Lin, Yun-Lian] Natl Taiwan Univ, Sch Pharm, Taipei 10764, Taiwan	National Research Institute of Chinese Medicine; National Taiwan University; Chinese Culture University; Chinese Culture University; Academia Sinica - Taiwan; China Medical University Taiwan; National Taiwan University	Chen, YR (corresponding author), Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.	yetran@gate.sinica.edu.tw; yllin5212@gmail.com	Shiao, Young-Ji/AAA-9647-2022		National Science Council Taiwan [NSC-101-2325-B-077-001, NSC102-2325-B-077-001, NSC 103 2320-B-077-001]; Ministry of Science and Technology Taiwan (MOST) [103-2320-B-077-003-MY3]	National Science Council Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Science and Technology Taiwan (MOST)(Ministry of Science and Technology, Taiwan)	This work was supported by the grants from the National Science Council Taiwan (NSC-101-2325-B-077-001, NSC102-2325-B-077-001, and NSC 103 2320-B-077-001) and Ministry of Science and Technology Taiwan (MOST 103-2320-B-077-003-MY3).	Altamura C, 2009, STROKE, V40, P1282, DOI 10.1161/STROKEAHA.108.536714; Armogida M, 2012, BRIT J PHARMACOL, V166, P1211, DOI 10.1111/j.1476-5381.2012.01912.x; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Beschorner R, 2007, HISTOPATHOLOGY, V50, P897, DOI 10.1111/j.1365-2559.2007.02703.x; Cai GX, 2007, J ETHNOPHARMACOL, V113, P292, DOI 10.1016/j.jep.2007.06.007; Chang WH, 2013, ANAL CHEM, V85, P890, DOI 10.1021/ac302281j; Chen CJ, 2010, ANAL CHEM, V82, P8283, DOI 10.1021/ac1017937; Chen HJ, 2012, METABOLOMICS, V8, P974, DOI 10.1007/s11306-011-0394-0; Chen YS, 2001, AM J CHINESE MED, V29, P423, DOI 10.1142/S0192415X01000447; Chern CM, 2012, FREE RADICAL BIO MED, V52, P1634, DOI 10.1016/j.freeradbiomed.2012.01.030; Cho WCS, 2007, AM J CHINESE MED, V35, P911, DOI 10.1142/S0192415X07005375; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Datta A, 2011, J PROTEOME RES, V10, P5199, DOI 10.1021/pr200673y; DeSouza L, 2005, J PROTEOME RES, V4, P377, DOI 10.1021/pr049821j; Fan LZ, 2006, J FUTURES MARKETS, V26, P153, DOI 10.1002/fut.20191; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; Gao MX, 2007, J SEP SCI, V30, P785, DOI 10.1002/jssc.200600372; Gold AB, 2011, CURR DRUG TARGETS, V12, P243; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; Guo WX, 2012, HUM MOL GENET, V21, P681, DOI 10.1093/hmg/ddr501; Hao CZ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/630124; Hotta A, 2005, MOL BIOL CELL, V16, P32, DOI 10.1091/mbc.E04-08-0679; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Imhof A, 2006, NEUROBIOL DIS, V22, P274, DOI 10.1016/j.nbd.2005.11.009; Jin R, 2010, NEUROBIOL DIS, V38, P376, DOI 10.1016/j.nbd.2010.03.008; Kaur J, 2004, J CEREBR BLOOD F MET, V24, P945, DOI 10.1097/01.WCB.0000137868.50767.E8; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kelly S, 2004, EXP NEUROL, V188, P378, DOI 10.1016/j.expneurol.2004.04.004; Kim N, 2006, PROTEOMICS, V6, P1237, DOI 10.1002/pmic.200500291; Korshunova I, 2008, J NEUROSCI RES, V86, P2201, DOI 10.1002/jnr.21678; Kunz A, 2008, J NEUROSCI, V28, P1649, DOI 10.1523/JNEUROSCI.5205-07.2008; Lansberg MG, 2009, STROKE, V40, P2438, DOI 10.1161/STROKEAHA.109.552547; Leroy K, 1999, J CHEM NEUROANAT, V16, P279, DOI 10.1016/S0891-0618(99)00012-5; Li HL, 2013, ASN NEURO, V5, DOI 10.1042/AN20130002; Li XM, 2003, NEUROSCI LETT, V346, P29, DOI 10.1016/S0304-3940(03)00522-6; Lindvall O, 2011, STROKE, V42, P2369, DOI 10.1161/STROKEAHA.110.599654; Liu CP, 2003, ACTA PHARMACOL SIN, V24, P1205; Liu J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009622.pub2; Liu X, 2011, BIOCHEM SOC T, V39, P1348, DOI 10.1042/BST0391348; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Marchi N, 2003, J NEUROSCI, V23, P1949; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nelson TJ, 2009, TRENDS BIOCHEM SCI, V34, P136, DOI 10.1016/j.tibs.2008.11.006; Niswender CM, 2010, ANNU REV PHARMACOL, V50, P295, DOI 10.1146/annurev.pharmtox.011008.145533; Nochi R, 2012, EUR J NEUROSCI, V36, P2273, DOI 10.1111/j.1460-9568.2012.08128.x; Prajapati KD, 2010, BRAIN RES, V1327, P118, DOI 10.1016/j.brainres.2010.02.063; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Ryu JK, 2009, J THROMB HAEMOST, V7, P151, DOI 10.1111/j.1538-7836.2009.03438.x; Shimamura N, 2006, STROKE, V37, P1902, DOI 10.1161/01.STR.0000226991.27540.f2; Sirerol-Piquer M, 2011, HIPPOCAMPUS, V21, P910, DOI 10.1002/hipo.20805; Song B, 2010, J BIOL CHEM, V285, P41122, DOI 10.1074/jbc.M110.130351; Tan ZJ, 2013, STROKE, V44, P3490, DOI 10.1161/STROKEAHA.113.002411; Urich-Merzenich G, 2007, PHYTOMEDICINE, V14, P70, DOI 10.1016/j.phymed.2006.11.011; Wang HW, 2011, J ETHNOPHARMACOL, V138, P22, DOI 10.1016/j.jep.2011.06.033; Whiteley W, 2009, STROKE, V40, pE380, DOI 10.1161/STROKEAHA.108.528752; World Health Organization, 10 LEAD CAUS DEATH W; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1352, DOI 10.1038/sj.jcbfm.9600441; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zheng GQ, 2010, J CELL BIOCHEM, V109, P26, DOI 10.1002/jcb.22408; Ziegler G, 2009, BBA-MOL BASIS DIS, V1792, P1198, DOI 10.1016/j.bbadis.2009.10.003	65	19	22	3	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2015	10	10							e0140823	10.1371/journal.pone.0140823	http://dx.doi.org/10.1371/journal.pone.0140823			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0ZU	26492191	gold, Green Published, Green Submitted			2023-01-03	WOS:000363249300014
J	Chan, PM; Tan, YS; Chua, KH; Sabaratnam, V; Kuppusamy, UR				Chan, Pui-Mun; Tan, Yee-Shin; Chua, Kek-Heng; Sabaratnam, Vikineswary; Kuppusamy, Umah Rani			Attenuation of Inflammatory Mediators (TNF-alpha and Nitric Oxide) and Up-Regulation of IL-10 by Wild and Domesticated Basidiocarps of Amauroderma rugosum (Blume & T. Nees) Torrend in LPS-Stimulated RAW264.7 Cells	PLOS ONE			English	Article							NF-KAPPA-B; OXIDATIVE STRESS; PATHWAYS; ANTIOXIDANTS; CULTIVATION; ACTIVATION; CYTOKINES; SEIZURES; THERAPY; SYSTEM	Amauroderma rugosum, commonly known as "Jiazi" in China, is a wild mushroom traditionally used by the Chinese to reduce inflammation, to treat diuretic and upset stomach, and to prevent cancer. It is also used by the indigenous communities in Malaysia to prevent epileptic episodes and incessant crying by babies. The aim of this study was to compare the wild and domesticated basidiocarps of A. rugosum for antioxidant and in vitro anti-inflammatory effects in LPS-stimulated RAW264.7 cells. The wild basidiocarps of A. rugosum were collected from the Belum Forest, Perak, Malaysia and the domesticated basidiocarps of A. rugosum were cultivated in the mushroom house located in the University of Malaya, Kuala Lumpur, Malaysia. Both the wild and domesticated basidiocarps were subjected to ethanolic extraction and the extracts were tested for antioxidant and anti-inflammatory activities. In this study, the crude ethanolic extract of wild (WB) and domesticated (DB) basidiocarps of A. rugosum had comparable total phenolic content and DPPH scavenging activity. However, WB (EC50 = 222.90 mu g/mL) displayed a better ABTS cation radical scavenging activity than DB (EC50 = 469.60 mu g/mL). Both WB and DB were able to scavenge nitric oxide (NO) radical and suppress the NO production in LPS-stimulated RAW264.7 cells and this effect was mediated through the down-regulation of inducible nitric oxide synthase (iNOS) gene. In addition, both WB and DB caused down-regulation of the inflammatory gene TNF-alpha and the up-regulation of the anti-inflammatory gene IL-10. There was no inhibitory effect of WB and DB on nuclear translocation of NF-kappa B p65. In conclusion, the wild and domesticated basidiocarps of A. rugosum possessed antioxidant and in vitro anti-inflammatory properties. WB and DB inhibited downstream inflammatory mediators (TNF-alpha and NO) and induced anti-inflammatory cytokine IL-10 production. No inhibitory effects shown on upstream nuclear translocation of NF-kappa B p65. WB and DB exhibited antioxidant activity and attenuation of proinflammatory mediators and therefore, A. rugosum may serve as a potential therapeutic agent in the management of inflammation.	[Chan, Pui-Mun; Tan, Yee-Shin; Chua, Kek-Heng; Sabaratnam, Vikineswary; Kuppusamy, Umah Rani] Univ Malaya, Mushroom Res Ctr, Kuala Lumpur 50603, Malaysia; [Chan, Pui-Mun; Tan, Yee-Shin; Sabaratnam, Vikineswary] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur 50603, Malaysia; [Chua, Kek-Heng; Kuppusamy, Umah Rani] Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur 50603, Malaysia	Universiti Malaya; Universiti Malaya; Universiti Malaya	Kuppusamy, UR (corresponding author), Univ Malaya, Mushroom Res Ctr, Kuala Lumpur 50603, Malaysia.	umah@um.edu.my	YEE SHIN, TAN/B-9922-2010; CHUA, KEK HENG/B-5261-2010; KUPPUSAMY, UMAH RANI/B-9981-2010; SABARATNAM, S. VIKINESWARY/B-9648-2010	YEE SHIN, TAN/0000-0001-5478-1015; CHUA, KEK HENG/0000-0002-0452-9994; SABARATNAM, S. VIKINESWARY/0000-0003-3966-3701	Ministry of Education, Malaysia [UM.C/625/1/HIR/MOHE/ASH/01 (UM.0000106/HIR.C3), UM-MOHE UM.C/625/1/HIR/MOHE/SC/02 (HIR F00002-21001), PG071-2012B, RP005B-13AFR]	Ministry of Education, Malaysia	This work was funded by University of Malaya for Postgraduate Research Grant (PG071-2012B) [http://www.ippp.um.edu.my/], University of Malaya Research Grant RP005B-13AFR [http://www.ippp.um.edu.my/] and University of Malaya High Impact Research MoE Grant UM.C/625/1/HIR/MOHE/ASH/01 (UM.0000106/HIR.C3) [http://www.ippp.um.edu.my/] and UM-MOHE UM.C/625/1/HIR/MOHE/SC/02 (HIR F00002-21001) [http://www.ippp.um.edu.my/] from the Ministry of Education, Malaysia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdullah N, 2013, IND CROP PROD, V47, P256, DOI 10.1016/j.indcrop.2013.03.012; Adesina FC, 2011, AFR J BIOTECHNOL, V10, P4608; Alvarez-Parrilla E, 2007, CIENC TEC ALIMENTAR, V5, P329, DOI 10.1080/11358120709487708; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Azliza MA, 2012, STUD ETHNO-MED, V6, P17, DOI 10.1080/09735070.2012.11886415; Barros KV, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-68; Bartfai T, 2007, ANN NY ACAD SCI, V1113, P173, DOI 10.1196/annals.1391.022; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Bi Z-S, 1993, MACROFUNGUS FLORA CH, P127; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Chan PM, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/304713; Chang YS, 2004, FUNGAL DIVERS, V15, P15; Chen S, 2005, INT J MED MUSHROOMS, V7, P342; Christ-Crain M, 2010, CRIT CARE, V14, DOI 10.1186/cc8155; [戴玉成 DAI YuCheng], 2008, [菌物学报, Mygosystema], V27, P801; De Silva DD, 2012, FUNGAL DIVERS, V56, P1, DOI 10.1007/s13225-012-0187-4; Desai PB, 2010, EUR REV MED PHARMACO, V14, P959; Ferreira ICFR, 2009, CURR MED CHEM, V16, P1543, DOI 10.2174/092986709787909587; Floegel A, 2011, J FOOD COMPOS ANAL, V24, P1043, DOI 10.1016/j.jfca.2011.01.008; Galic MA, 2008, J NEUROSCI, V28, P6904, DOI 10.1523/JNEUROSCI.1901-08.2008; Gan C. H., 2013, International Food Research Journal, V20, P1095; Gill S.K, 2008, CAN J CLIN PHARM, V15, P275; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Hakansson A, 2011, NUTRIENTS, V3, P637, DOI 10.3390/nu3060637; Hovsepian E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079445; Huang GH, 2009, CYTOKINE, V48, P161, DOI 10.1016/j.cyto.2009.08.002; Jedinak A, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-52; Jiao C, 2013, PLOS ONE, V8, P1; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kanagasabapathy G, 2011, J AGR FOOD CHEM, V59, P2618, DOI 10.1021/jf104133g; Kanagasabapathy G, 2012, BMC COMPLEM ALTERN M, V12, P1; Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371; Lee KH, 2012, INT J MOL SCI, V13, P2985, DOI 10.3390/ijms13032985; Lee TH, 2012, INT IMMUNOPHARMACOL, V13, P264, DOI 10.1016/j.intimp.2012.05.005; Liang Y, 2004, CELL MOL IMMUNOL, V1, P343; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Magingo FS, 2004, MYCOLOGIA, V96, P197, DOI 10.2307/3762053; Martin KR, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-29; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Moonmoon Mahbuba, 2010, Saudi J Biol Sci, V17, P341, DOI 10.1016/j.sjbs.2010.05.004; Pathmashini L., 2008, Ceylon Journal of Science, Biological Sciences, V37, P177; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Shah Z. A., 2004, Pakistan Journal of Nutrition, V3, P158; Sharif O, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-1; Sheena N., 2005, Natural Product Radiance, V4, P382; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Theoharides TC, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-168; Tripathy A, 2011, BOT RES INT, V4, P19; Tsai TT, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-40; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Virta M, 2002, EPILEPSIA, V43, P920, DOI 10.1046/j.1528-1157.2002.02002.x; Wan-Ibrahim WI, 2010, FOOD CHEM, V122, P1139, DOI 10.1016/j.foodchem.2010.03.101; Wen CL, 2011, J ETHNOPHARMACOL, V137, P575, DOI 10.1016/j.jep.2011.06.009; Yang Eun-Jin, 2009, Interdiscip Toxicol, V2, P245, DOI 10.2478/v10102-009-0022-2	54	32	34	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2015	10	10							e0139593	10.1371/journal.pone.0139593	http://dx.doi.org/10.1371/journal.pone.0139593			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6GT	26427053	Green Submitted, Green Published, gold			2023-01-03	WOS:000362177100079
J	Pinto, A; Mace, Y; Drouet, F; Bony, E; Boidot, R; Draoui, N; Lobysheva, I; Corbet, C; Polet, F; Martherus, R; Deraedt, Q; Rodriguez, J; Lamy, C; Schicke, O; Delvaux, D; Louis, C; Kiss, R; Kriegsheim, AV; Dessy, C; Elias, B; Quetin-Leclercq, J; Riant, O; Feron, O				Pinto, A.; Mace, Y.; Drouet, F.; Bony, E.; Boidot, R.; Draoui, N.; Lobysheva, I.; Corbet, C.; Polet, F.; Martherus, R.; Deraedt, Q.; Rodriguez, J.; Lamy, C.; Schicke, O.; Delvaux, D.; Louis, C.; Kiss, R.; Kriegsheim, A. V.; Dessy, C.; Elias, B.; Quetin-Leclercq, J.; Riant, O.; Feron, O.			A new ER-specific photosensitizer unravels O-1(2)-driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; PHOTODYNAMIC THERAPY; MAMMALIAN TARGET; HYPOXIA; MTOR; PHOTOEXCITATION; MULTIMERIZATION; SENSITIZERS	Photosensitizers (PS) are ideally devoid of any activity in the absence of photoactivation, and rely on molecular oxygen for the formation of singlet oxygen (O-1(2)) to produce cellular damage. Off-targets and tumor hypoxia therefore represent obstacles for the use of PS for cancer photodynamic therapy. Herein, we describe the characterization of OR141, a benzophenazine compound identified through a phenotypic screening for its capacity to be strictly activated by light and to kill a large variety of tumor cells under both normoxia and hypoxia. This new class of PS unraveled an unsuspected common mechanism of action for PS that involves the combined inhibition of the mammalian target of rapamycin (mTOR) signaling pathway and proteasomal deubiquitinases (DUBs) USP14 and UCH37. Oxidation of mTOR and other endoplasmic reticulum (ER)-associated proteins drives the early formation of high molecular weight (MW) complexes of multimeric proteins, the concomitant blockade of DUBs preventing their degradation and precipitating cell death. Furthermore, we validated the antitumor effects of OR141 in vivo and documented its highly selective accumulation in the ER, further increasing the ER stress resulting from O-1(2) generation upon light activation.	[Pinto, A.; Draoui, N.; Lobysheva, I.; Corbet, C.; Polet, F.; Martherus, R.; Delvaux, D.; Louis, C.; Dessy, C.; Feron, O.] Catholic Univ Louvain, IREC, Pole Pharmacol & Therapeut FATH, Brussels, Belgium; [Mace, Y.; Drouet, F.; Boidot, R.; Deraedt, Q.; Lamy, C.; Schicke, O.; Elias, B.; Riant, O.] Catholic Univ Louvain, Inst Condensed Matter & Nanosci Mol Solids & Reac, 1 Pl Louis Pasteur,Bte 3, B-1348 Louvain La Neuve, Belgium; [Bony, E.; Quetin-Leclercq, J.] Catholic Univ Louvain, LDRI, Pharmacognosy Res Grp GNOS, Louvain La Neuve, Belgium; [Rodriguez, J.; Kriegsheim, A. V.] Conway Inst, Syst Biol Ireland, Dublin 4, Ireland; [Kiss, R.] Univ Libre Bruxelles, Fac Pharm, Lab Cancerol & Toxicol Expt, Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Universite Libre de Bruxelles	Riant, O (corresponding author), Catholic Univ Louvain, Inst Condensed Matter & Nanosci Mol Solids & Reac, 1 Pl Louis Pasteur,Bte 3, B-1348 Louvain La Neuve, Belgium.; Feron, O (corresponding author), UCLouvain, IREC, Pole Pharmacol & Therapeut FATH, 53 Ave E Mounier,B1-53-09, B-1200 Brussels, Belgium.	olivier.riant@uclouvain.be; olivier.feron@uclouvain.be	von Kriegsheim, Alex/C-2371-2016; FERON, Olivier/AAM-6395-2020; rodriguez, javier/AAB-1131-2019; riant, olivier/AAU-3567-2021	von Kriegsheim, Alex/0000-0002-4952-8573; FERON, Olivier/0000-0001-5360-0286; rodriguez, javier/0000-0001-7467-8533; Deraedt, Quentin/0000-0001-9226-2777; riant, olivier/0000-0003-4852-6469; Leclercq, Joelle/0000-0002-2278-6206	Region Bruxelles Capitale (Innoviris); Fonds national de la Recherche Scientifique (FRS-FNRS); Belgian Foundation against cancer; J Maisin Foundation; Belgian Science Policy Office (Belspo) [UP7-03]; Action de Recherche Concertee [ARC 14/19]	Region Bruxelles Capitale (Innoviris)(Innoviris); Fonds national de la Recherche Scientifique (FRS-FNRS)(Fonds de la Recherche Scientifique - FNRS); Belgian Foundation against cancer; J Maisin Foundation; Belgian Science Policy Office (Belspo)(Belgian Federal Science Policy Office); Action de Recherche Concertee	This work was supported by grants from the Region Bruxelles Capitale (Innoviris), the Fonds national de la Recherche Scientifique (FRS-FNRS), the Belgian Foundation against cancer, the J Maisin Foundation, the interuniversity attraction pole (IUAP) research program #UP7-03 from the Belgian Science Policy Office (Belspo) and an Action de Recherche Concertee (ARC 14/19).	Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Altun M, 2011, CHEM BIOL, V18, P1401, DOI 10.1016/j.chembiol.2011.08.018; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brodsky JL, 2012, CELL, V151, P1163, DOI 10.1016/j.cell.2012.11.012; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Cao YT, 2005, CANCER RES, V65, P5498, DOI 10.1158/0008-5472.CAN-04-4553; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Corbet C, 2014, CANCER RES, V74, P5507, DOI 10.1158/0008-5472.CAN-14-0705; Davies MJ, 2004, PHOTOCH PHOTOBIO SCI, V3, P17, DOI 10.1039/b307576c; Davies MJ, 2005, BBA-PROTEINS PROTEOM, V1703, P93, DOI 10.1016/j.bbapap.2004.08.007; Diao YR, 2010, P NATL ACAD SCI USA, V107, P20974, DOI 10.1073/pnas.1007225107; Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915; Draoui N, 2014, MOL CANCER THER, V13, P1410, DOI 10.1158/1535-7163.MCT-13-0653; Hiraoka W, 2006, ULTRASON SONOCHEM, V13, P535, DOI 10.1016/j.ultsonch.2005.10.001; Hwang JY, 2012, J CONTROL RELEASE, V163, P368, DOI 10.1016/j.jconrel.2012.09.015; Jain A, 2014, P NATL ACAD SCI USA, V111, P17833, DOI 10.1073/pnas.1419425111; Li WM, 2007, CIRC RES, V100, P79, DOI 10.1161/01.RES.0000253094.03023.3f; Liu XY, 2007, MOL BIOL CELL, V18, P1073, DOI 10.1091/mbc.E06-05-0406; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516; Nadeau PJ, 2007, MOL BIOL CELL, V18, P3903, DOI 10.1091/mbc.E07-05-0491; Nakatsukasa K, 2008, TRAFFIC, V9, P861, DOI 10.1111/j.1600-0854.2008.00729.x; Nau W., 2011, CHEMPHYSCHEM, V12, P2496; Ng WY, 2007, J CELL SCI, V120, P682, DOI 10.1242/jcs.03351; Ormond AB, 2013, MATERIALS, V6, P817, DOI 10.3390/ma6030817; Poon E, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001173; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Seront E, 2013, BRIT J CANCER, V109, P1586, DOI 10.1038/bjc.2013.505; Sueishi Y, 2014, J CLIN BIOCHEM NUTR, V54, P67, DOI 10.3164/jcbn.13-53; Takahara T, 2006, J BIOL CHEM, V281, P28605, DOI 10.1074/jbc.M606087200; Udeshi ND, 2013, NAT PROTOC, V8, P1950, DOI 10.1038/nprot.2013.120; van der Wijk T, 2004, J BIOL CHEM, V279, P44355, DOI 10.1074/jbc.M407483200; Wilson BC, 2008, PHYS MED BIOL, V53, pR61, DOI 10.1088/0031-9155/53/9/R01; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Yoshii H, 2012, BIOCHEM BIOPH RES CO, V417, P640, DOI 10.1016/j.bbrc.2011.12.024	37	22	22	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3976	3985		10.1038/onc.2015.474	http://dx.doi.org/10.1038/onc.2015.474			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26686091				2023-01-03	WOS:000381013100009
J	Vera, B; Martinez-Velez, N; Xipell, E; de la Rocha, AA; Patino-Garcia, A; Saez-Castresana, J; Gonzalez-Huarriz, M; Cascallo, M; Alemany, R; Alonso, MM				Vera, Beatriz; Martinez-Velez, Naiara; Xipell, Enric; Acanda de la Rocha, Arlet; Patino-Garcia, Ana; Saez-Castresana, Javier; Gonzalez-Huarriz, Marisol; Cascallo, Manel; Alemany, Ramon; Alonso, Marta M.			Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01	PLOS ONE			English	Article							MOUSE MACROPHAGES; HYALURONAN FRAGMENTS; GENE-EXPRESSION; BRAIN-TUMOR; TOXICITY; PROMOTER; SURVIVAL; GLIOMA; GLIOBLASTOMA; TEMOZOLOMIDE	Despite the recent advances in the development of antitumor therapies, the prognosis for patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is emerging as a treatment option for this devastating disease. In this study we characterize the anti-glioma effect of VCN-01, an improved hyaluronidase-armed pRB-pathway-selective oncolytic adenovirus that has proven safe and effective in the treatment of several solid tumors. VCN-01 displayed a significant cytotoxic effect on glioma cells in vitro. In vivo, in two different orthotopic glioma models, a single intra-tumoral administration of VCN-01 increased overall survival significantly and led to long-term survivors free of disease.	[Vera, Beatriz; Martinez-Velez, Naiara; Xipell, Enric; Acanda de la Rocha, Arlet; Patino-Garcia, Ana; Saez-Castresana, Javier; Gonzalez-Huarriz, Marisol; Alonso, Marta M.] Navarras Hlth Res Inst IDISNA, Pamplona, Spain; [Vera, Beatriz; Martinez-Velez, Naiara; Xipell, Enric; Acanda de la Rocha, Arlet; Gonzalez-Huarriz, Marisol; Alonso, Marta M.] Fdn Appl Med Res, Program Solid Tumors & Biomarkers, Pamplona, Spain; [Vera, Beatriz; Martinez-Velez, Naiara; Xipell, Enric; Acanda de la Rocha, Arlet; Gonzalez-Huarriz, Marisol; Alonso, Marta M.] Univ Hosp Navarra, Dept Med Oncol, Pamplona 31008, Spain; [Patino-Garcia, Ana] Univ Hosp Navarra, Dept Pediat, Pamplona 31008, Spain; [Saez-Castresana, Javier] Univ Navarra, Sch Sci, Brain Tumor Biol Unit, Pamplona 31008, Spain; [Cascallo, Manel] VCN Biosci, Barcelona 08174, Spain; [Alemany, Ramon] Hosp Llobregat, IDIBELL Inst Catala Oncol, Translat Res Lab, Barcelona 08907, Spain	Servicio Navarro de Salud - Osasunbidea; University of Navarra; Servicio Navarro de Salud - Osasunbidea; University of Navarra; University of Navarra; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Alonso, MM (corresponding author), Navarras Hlth Res Inst IDISNA, Pamplona, Spain.; Alonso, MM (corresponding author), Fdn Appl Med Res, Program Solid Tumors & Biomarkers, Pamplona, Spain.; Alonso, MM (corresponding author), Univ Hosp Navarra, Dept Med Oncol, Pamplona 31008, Spain.	mmalonso@unav.es	Patiño-Garcia, Ana/I-4299-2012; Alonso, Marta M/AAI-9457-2020	Patiño-Garcia, Ana/0000-0002-4066-8203; Alonso, Marta M/0000-0002-7520-7351; Castresana, Javier S./0000-0002-2373-482X; gonzalez-huarriz, marisol/0000-0002-0438-0077; Martinez-Velez, Naiara/0000-0003-2248-7692	European Union (Marie Curie) [IRG270459]; Instituto de Salud Carlos III y los Fondos Feder Europeos [PI13/125]; Spanish Ministry of Science and Innovation [RYC-2009-05571]; L'OREAL-Unesco Foundation; Department of Health of the Government of Navarra; Basque Foundation for Health Research (BIOEF) [BIO13/CI/005]; Caja Navarra Foundation; Credit Andorra Foundation; University of Navarra; Spanish Ministry of Education and Science [BIO2011-30299-C02-01]; VCN bioscience	European Union (Marie Curie)(European Commission); Instituto de Salud Carlos III y los Fondos Feder Europeos; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); L'OREAL-Unesco Foundation(L'Oreal Group); Department of Health of the Government of Navarra; Basque Foundation for Health Research (BIOEF); Caja Navarra Foundation; Credit Andorra Foundation; University of Navarra; Spanish Ministry of Education and Science(Spanish Government); VCN bioscience	This work was supported by the European Union (Marie Curie IRG270459 to MMA), the Instituto de Salud Carlos III y los Fondos Feder Europeos (PI13/125 to MMA), the Spanish Ministry of Science and Innovation (Ramon y Cajal contract RYC-2009-05571 to MMA), The L'OREAL-Unesco Foundation (to MMA), The Department of Health of the Government of Navarra (to MMA), The Basque Foundation for Health Research (BIOEF, BIO13/CI/005) and the Caja Navarra Foundation (to MMA). EX is supported by a fellowship from the Credit Andorra Foundation. AAR is supported by a fellowship from Friends of the University of Navarra (ADA). RA is supported by BIO2011-30299-C02-01 from the Spanish Ministry of Education and Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. VCN bioscience provided support in the form of salaries or research support for authors MC and RA, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.; This work was supported by the European Union (Marie Curie IRG270459 to MMA), the Instituto de Salud Carlos III y los Fondos Feder Europeos (PI13/125 to MMA), the Spanish Ministry of Science and Innovation (Ramon y Cajal contract RYC-2009-05571 to MMA), The L'OREAL-Unesco Foundation (to MMA), The Department of Health of the Government of Navarra (to MMA), The Basque Foundation for Health Research (BIOEF, BIO13/CI/005) and the Caja Navarra Foundation (to MMA). EX is supported by a fellowship from the Credit Andorra Foundation. AAR is supported by a fellowship from Friends of the University of Navarra (ADA). RA is supported by BIO2011-30299-C02-01 from the Spanish Ministry of Education and Science.	Alemany R, 2007, MOL ASPECTS MED, V28, P42, DOI 10.1016/j.mam.2006.12.002; Alonso MM, 2007, CANCER RES, V67, P11499, DOI 10.1158/0008-5472.CAN-07-5312; Alonso MM, 2007, CANCER RES, V67, P8255, DOI 10.1158/0008-5472.CAN-06-4675; Alonso MM, 2005, JNCI-J NATL CANCER I, V97, P1589, DOI 10.1093/jnci/dji340; Baier C, 2007, MATRIX BIOL, V26, P348, DOI 10.1016/j.matbio.2007.02.002; Ballman KV, 2007, NEURO-ONCOLOGY, V9, P29, DOI 10.1215/15228517-2006-025; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Cascallo M, 2007, MOL THER, V15, P1607, DOI 10.1038/sj.mt.6300239; Cascallo M, 2006, HUM GENE THER, V17, P929, DOI 10.1089/hum.2006.17.929; Chiarella P, 2013, HUM GENE THER, V24, P406, DOI 10.1089/hum.2012.215; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Horton MR, 1999, J IMMUNOL, V162, P4171; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; Horton MR, 1998, J IMMUNOL, V160, P3023; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Majem M, 2006, CANCER GENE THER, V13, P696, DOI 10.1038/sj.cgt.7700940; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Rodriguez-Garcia A, 2015, CLIN CANCER RES, V21, P1406, DOI 10.1158/1078-0432.CCR-14-2213; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Ulasov IV, 2009, INT J ONCOL, V34, P729, DOI 10.3892/ijo_00000199	26	21	21	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147211	10.1371/journal.pone.0147211	http://dx.doi.org/10.1371/journal.pone.0147211			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26808201	gold, Green Published, Green Submitted			2023-01-03	WOS:000369527800061
J	Clodfelter, RP; Adashi, EY				Clodfelter, Ryan P.; Adashi, Eli Y.			The Liberty to Die California Enacts Physician Aid-in-Dying Law	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Clodfelter, Ryan P.; Adashi, Eli Y.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02905 USA	Brown University	Adashi, EY (corresponding author), Brown Univ, Dept Obstet & Gynecol, Warren Alpert Med Sch, 101 Dudley St, Providence, RI 02905 USA.	eli_adashi@brown.edu						Annas GJ, 1997, NEW ENGL J MED, V337, P1098, DOI 10.1056/NEJM199710093371523; [Anonymous], STRONG VOT SUPP END; Boudreau J Donald, 2013, N Engl J Med, V368, P1450, DOI 10.1056/NEJMclde1302615; Dugan Andrew, GALLUP; Meisel A, 2014, RIGHT DIE LAE END OF; Patients Rights Council, ATT LEG EUTH ASS SUI	6	14	14	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					251	252		10.1001/jama.2015.16242	http://dx.doi.org/10.1001/jama.2015.16242			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784765				2023-01-03	WOS:000368371400014
J	Kang, SH; Choi, EW; Park, JW; Cho, KH; Do, JY				Kang, Seok Hui; Choi, Eun Woo; Park, Jong Won; Cho, Kyu Hyang; Do, Jun Young			Clinical Significance of the Edema Index in Incident Peritoneal Dialysis Patients	PLOS ONE			English	Article							RESIDUAL RENAL-FUNCTION; EXTRACELLULAR FLUID VOLUME; HEMODIALYSIS-PATIENTS; BODY-COMPOSITION; SODIUM REMOVAL; BLOOD-PRESSURE; ULTRAFILTRATION; DECLINE; CAPD; PREDICTORS	Background Proper monitoring for volume overload is important to improve prognosis in peritoneal dialysis (PD) patients. The association between volume status and residual renal function (RRF) remains an unresolved issue. The aim of the present study was to evaluate the association between the edema index and survival or RRF in incident PD patients. Patients and Methods We identified all adults who underwent PD. The edema index was defined as the ratio of extracellular fluid to total body fluid. Participants with available data regarding survivorship or non-survivorship during the first year after PD initiation were included in the area under the receiver operating characteristic curve analysis. The cutoff value of the edema index for 1-year mortality was >0.371 in men and >0.372 in women. Participants were divided into two groups according to the cutoff value of their baseline edema indices: High (>cutoff value) and Low (<= cutoff value). Survivors during the first year after PD initiation were divided into two groups according to the initial and 1-year edema index: Non-improvement (maintenance of criteria in the initial Low group during the year) and Other (all participants except those in the Non-improvement group). Results In total, 631 patients were enrolled in the present study. The cutoff value of the edema index for 1-year mortality was >0.371 in men and >0.372 in women. The respective mean initial RRF values (mL.min(-1).1.73 m(-2)) in the Low and High groups, respectively, were 4.88 +/- 4.09 and 4.21 +/- 3.28 in men (P = 0.108), and 3.19 +/- 2.57 and 2.98 +/- 2.70 in women (P = 0.531). There were no significant differences between groups in either sex. The respective mean RRF values at 1 year after PD initiation in the Low and High groups, respectively, were 3.56 +/- 4.35 and 2.73 +/- 2.53 in men, and 2.80 +/- 2.36 and 1.85 +/- 1.51 in women. RRF at 1 year after PD initiation was higher in the Low group than in the High group (men: P = 0.027; women: P = 0.001). In men, the cumulative 5-year survival rates were 78.7% and 46.2% in the Low and High groups, respectively, whereas in women, rates were 77.2% and 58.8% in the Low and High groups, respectively. For survivors during the first year after PD initiation, the Non-improvement group was associated with a poor survival rate compared with the Other group for both sexes. Conclusion A high edema index was associated with mortality in incident PD patients at baseline and follow-up. The edema index may be used as a new marker for predicting mortality in PD patients.	[Kang, Seok Hui; Choi, Eun Woo; Park, Jong Won; Cho, Kyu Hyang; Do, Jun Young] Yeungnam Univ Hosp, Dept Internal Med, Div Nephrol, Daegu, South Korea	Yeungnam University; Yeungnam University Hospital	Do, JY (corresponding author), Yeungnam Univ Hosp, Dept Internal Med, Div Nephrol, Daegu, South Korea.	jydo@med.yu.ac.kr	Barretti, Pasqual/AAK-7934-2021; Barretti, Pasqual/K-4156-2012	Barretti, Pasqual/0000-0003-4979-4836; Barretti, Pasqual/0000-0003-4979-4836	Medical Research Center Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [2015R1A5A2009124]	Medical Research Center Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning	This work was supported by the Medical Research Center Program (2015R1A5A2009124) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asci G, 2006, PERITON DIALYSIS INT, V26, P85; Bedogni G, 2002, EUR J CLIN NUTR, V56, P1143, DOI 10.1038/sj.ejcn.1601466; Castillo AA, 2002, AM J KIDNEY DIS, V40, P1301, DOI 10.1053/ajkd.2002.36907; Chamney PW, 2002, KIDNEY INT, V61, P2250, DOI 10.1046/j.1523-1755.2002.00377.x; Charra B, 1996, AM J NEPHROL, V16, P35, DOI 10.1159/000168968; Cheng LT, 2008, PERITON DIALYSIS INT, V28, P397; Cheng LT, 2005, AM J KIDNEY DIS, V45, P891, DOI 10.1053/j.ajkd.2005.01.037; Davies SJ, 2002, NEPHROL DIAL TRANSPL, V17, P1085, DOI 10.1093/ndt/17.6.1085; Dou YN, 2012, SEMIN DIALYSIS, V25, P377, DOI 10.1111/j.1525-139X.2012.01095.x; Dumler F, 2003, ASAIO J, V49, P282, DOI 10.1097/01.MAT.0000065465.52748.BB; Ellis KJ, 2000, PHYSIOL REV, V80, P649, DOI 10.1152/physrev.2000.80.2.649; Gao N, 2011, CLIN NEPHROL, V76, P16, DOI 10.5414/CN106896; Goff DC, 2014, CIRCULATION, V129, pS49, DOI 10.1161/01.cir.0000437741.48606.98; Gunal AI, 2001, AM J KIDNEY DIS, V37, P588, DOI 10.1053/ajkd.2001.22085; HEIMBURGER O, 1990, KIDNEY INT, V38, P495, DOI 10.1038/ki.1990.231; Hufnagel C, 1999, NEPHROL DIAL TRANSPL, V14, P1224, DOI 10.1093/ndt/14.5.1224; Hur SM, 2014, KOREAN J INTERN MED, V29, P489, DOI 10.3904/kjim.2014.29.4.489; Jansen MAM, 2002, KIDNEY INT, V62, P1046, DOI 10.1046/j.1523-1755.2002.00505.x; Jones CH, 2002, AM J KIDNEY DIS, V39, P872, DOI 10.1053/ajkd.2002.32010; Karopadi AN, 2013, NEPHROL DIAL TRANSPL, V28, P2553, DOI 10.1093/ndt/gft214; Kausz AT, 2000, J AM SOC NEPHROL, V11, P2351, DOI 10.1681/ASN.V11122351; Kawaguchi Y, 1997, KIDNEY INT, V52, pS105; Koc M, 2002, NEPHROL DIAL TRANSPL, V17, P1661, DOI 10.1093/ndt/17.9.1661; Koh ES, 2015, AM J NEPHROL, V42, P91, DOI 10.1159/000439060; Konings CJAM, 2002, PERITON DIALYSIS INT, V22, P477; Kraemer M, 2006, KIDNEY INT, V69, P1609, DOI 10.1038/sj.ki.5000286; Lee SW, 2003, AM J KIDNEY DIS, V41, P1257, DOI 10.1016/S0272-6386(03)00358-5; Liao CT, 2008, PERITON DIALYSIS INT, V28, pS191; Liao CT, 2009, NEPHROL DIAL TRANSPL, V24, P2909, DOI 10.1093/ndt/gfp056; Lu YH, 2015, PERITON DIALYSIS INT, V35, P172, DOI 10.3747/pdi.2013.00060; Lysaght M J, 1991, ASAIO Trans, V37, P598; Mandelbaum A, 1996, NEPHROL DIAL TRANSPL, V11, P24; Mujais S, 2000, PERITON DIALYSIS INT, V20, pS5; Mujais S., 2009, NOLPH GOKALS TXB PER, V3, P505, DOI [10.1007/978-0-387-78940-8_17, DOI 10.1007/978-0-387-78940-8_17]; O'Lone EL, 2014, NEPHROL DIAL TRANSPL, V29, P1430, DOI 10.1093/ndt/gfu049; Papakrivopoulou E, 2012, NEPHROL DIAL TRANSPL, V27, P396, DOI 10.1093/ndt/gfr338; *PER DIAL AD WORK, 2006, AM J KIDNEY DIS S, V48, pS98; Rodriguez-Carmona A, 2004, AM J KIDNEY DIS, V44, P132, DOI 10.1053/j.ajkd.2004.03.035; Rodriguez-Carmona A, 2002, PERITON DIALYSIS INT, V22, P705; Sartorio A, 2005, EUR J CLIN NUTR, V59, P155, DOI 10.1038/sj.ejcn.1602049; Smit W, 2004, PERITON DIALYSIS INT, V24, P562; US Renal Data System, 2013, USRDS 2013 ANN DAT R; WANG ZM, 1992, AM J CLIN NUTR, V56, P19, DOI 10.1093/ajcn/56.1.19; WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27; Wilson B, 2004, HEMODIAL INT, V11, P263; Woodrow G, 2007, PERITON DIALYSIS INT, V27, pS143; Wright S, 2010, CLIN J AM SOC NEPHRO, V5, P1828, DOI 10.2215/CJN.06230909; Yonova C, 2004, Minerva Urol Nefrol, V56, P367	48	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2016	11	1							e0147070	10.1371/journal.pone.0147070	http://dx.doi.org/10.1371/journal.pone.0147070			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB5BP	26785259	Green Submitted, Green Published, gold			2023-01-03	WOS:000368528400105
J	Sridharan, B; Lin, SM; Hwu, AT; Laflin, AD; Detamore, MS				Sridharan, BanuPriya; Lin, Staphany M.; Hwu, Alexander T.; Laflin, Amy D.; Detamore, Michael S.			Stem Cells in Aggregate Form to Enhance Chondrogenesis in Hydrogels	PLOS ONE			English	Article							HUMAN UMBILICAL-CORD; MESENCHYMAL STROMAL CELLS; WHARTONS JELLY CELLS; IN-VITRO; CARTILAGE FORMATION; HYALURONIC-ACID; CHONDROCYTES; DIFFERENTIATION; SCAFFOLDS; AGAROSE	There are a variety of exciting hydrogel technologies being explored for cartilage regenerative medicine. Our overall goal is to explore whether using stem cells in an aggregate form may be advantageous in these applications. 3D stem cell aggregates hold great promise as they may recapitulate the in vivo skeletal tissue condensation, a property that is not typically observed in 2D culture. We considered two different stem cell sources, human umbilical cord Wharton's jelly cells (hWJCs, currently being used in clinical trials) and rat bone marrow-derived mesenchymal stem cells (rBMSCs). The objective of the current study was to compare the influence of cell phenotype, aggregate size, and aggregate number on chondrogenic differentiation in a generic hydrogel (agarose) platform. Despite being differing cell sources, both rBMSC and hWJC aggregates were consistent in outperforming cell suspension control groups in biosynthesis and chondrogenesis. Higher cell density impacted biosynthesis favorably, and the number of aggregates positively influenced chondrogenesis. Therefore, we recommend that investigators employing hydrogels consider using cells in an aggregate form for enhanced chondrogenic performance.	[Sridharan, BanuPriya; Detamore, Michael S.] Univ Kansas, Bioengn Grad Program, Lawrence, KS 66045 USA; [Lin, Staphany M.; Hwu, Alexander T.; Laflin, Amy D.; Detamore, Michael S.] Univ Kansas, Dept Chem & Petr Engn, Lawrence, KS 66045 USA	University of Kansas; University of Kansas	Detamore, MS (corresponding author), Univ Kansas, Bioengn Grad Program, Lawrence, KS 66045 USA.	detamore@ku.edu			National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R01 AR056347]; Kansas Bioscience Authority Rising Star Award; State of Kansas Umbilical Cord Matrix Project; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056347] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Kansas Bioscience Authority Rising Star Award; State of Kansas Umbilical Cord Matrix Project; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01 AR056347 supported research reported in this publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors would also like to recognize support from the Kansas Bioscience Authority Rising Star Award, as well as the State of Kansas Umbilical Cord Matrix Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bailey MM, 2007, TISSUE ENG, V13, P2003, DOI 10.1089/ten.2006.0150; Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006-0709; Batsali AK, 2013, CURR STEM CELL RES T, V8, P144; Benders KEM, 2013, TRENDS BIOTECHNOL, V31, P169, DOI 10.1016/j.tibtech.2012.12.004; Bhakta G, 2012, BIOMATERIALS, V33, P6113, DOI 10.1016/j.biomaterials.2012.05.030; Bhumiratana S, 2014, P NATL ACAD SCI USA, V111, P6940, DOI 10.1073/pnas.1324050111; Centola M, 2013, STEM CELLS DEV, V22, P2849, DOI 10.1089/scd.2013.0216; Craft AM, 2013, DEVELOPMENT, V140, P2597, DOI 10.1242/dev.087890; Dang PN, 2014, TISSUE ENG PT A, V20, P3163, DOI [10.1089/ten.TEA.2012.0551, 10.1089/ten.tea.2012.0551]; Declercq HA, 2013, BIOMATERIALS, V34, P1004, DOI 10.1016/j.biomaterials.2012.10.051; DeKosky BJ, 2010, TISSUE ENG PART C-ME, V16, P1533, DOI 10.1089/ten.tec.2009.0761; Detamore MS, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt353; Devarajan K, 2013, CELL REPROGRAM, V15, P43, DOI 10.1089/cell.2011.0097; Dikina AD, 2015, BIOMATERIALS, V52, P452, DOI 10.1016/j.biomaterials.2015.01.073; Dormer NH, 2010, ANN BIOMED ENG, V38, P2167, DOI 10.1007/s10439-010-0028-0; DuRaine GD, 2015, ANN BIOMED ENG, V43, P543, DOI 10.1007/s10439-014-1161-y; Fennema E, 2013, TRENDS BIOTECHNOL, V31, P108, DOI 10.1016/j.tibtech.2012.12.003; Ferreira LS, 2007, BIOMATERIALS, V28, P2706, DOI 10.1016/j.biomaterials.2007.01.021; Florine EM, 2013, CARTILAGE, V4, P63, DOI 10.1177/1947603512455196; Goude MC, 2014, CELLS TISSUES ORGANS, V199, P117, DOI 10.1159/000365966; Huang CC, 2013, BIOMATERIALS, V34, P9441, DOI 10.1016/j.biomaterials.2013.09.010; Huey DJ, 2013, CELL TRANSPLANT, V22, P331, DOI 10.3727/096368912X657648; Lei J, 2014, BIOMATER SCI-UK, V2, P666, DOI 10.1039/c3bm60271k; Levato R, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/3/035020; Lima AC, 2013, TISSUE ENG PT A, V19, P1175, DOI [10.1089/ten.tea.2012.0249, 10.1089/ten.TEA.2012.0249]; Liu SY, 2014, J BIOSCI BIOENG, V117, P229, DOI 10.1016/j.jbiosc.2013.07.001; Mellott AJ, 2015, TISSUE ENG PT A, V21, P1795, DOI [10.1089/ten.tea.2014.0340, 10.1089/ten.TEA.2014.0340]; Mellott AJ, 2014, CELL REPROGRAM, V16, P91, DOI 10.1089/cell.2013.0069; Moriguchi Y, 2013, BIOMATERIALS, V34, P2185, DOI 10.1016/j.biomaterials.2012.11.039; Raghothaman D, 2014, BIOMATERIALS, V35, P2607, DOI 10.1016/j.biomaterials.2013.12.008; Rettinger CL, 2014, CELL TISSUE RES, V358, P395, DOI 10.1007/s00441-014-1939-0; Ruan DK, 2012, TISSUE ENG PT A, V18, P167, DOI [10.1089/ten.tea.2011.0186, 10.1089/ten.TEA.2011.0186]; Sart S, 2013, TISSUE ENG B; Skaalure SC, 2014, ACTA BIOMATER, V10, P3409, DOI 10.1016/j.actbio.2014.04.013; Suzuki S, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3869; Teixeira LSM, 2012, EUR CELLS MATER, V23, P387, DOI 10.22203/eCM.v023a30; Wang Limin, 2013, Recent Pat Regen Med, V3, P182, DOI 10.2174/22102965113039990020; Wang LM, 2011, REGEN MED, V6, P95, DOI [10.2217/rme.10.98, 10.2217/RME.10.98]; Wang LM, 2009, TISSUE ENG PT A, V15, P2259, DOI 10.1089/ten.tea.2008.0393; Winter A, 2003, ARTHRITIS RHEUM-US, V48, P418, DOI 10.1002/art.10767; Yu Y, 2012, LIVER TRANSPLANT, V18, P9, DOI 10.1002/lt.22467	41	17	17	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2015	10	12							e0141479	10.1371/journal.pone.0141479	http://dx.doi.org/10.1371/journal.pone.0141479			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0TR	26719986	Green Published, Green Submitted, gold			2023-01-03	WOS:000367510900001
J	Munoz-Rivas, N; Mendez-Bailon, M; Hernandez-Barrera, V; de Miguel-Yanes, JM; Jimenez-Garcia, R; Esteban-Hernandez, J; Jimenez-Trujillo, I; Alvaro-Meca, A; Carrasco-Garrido, P; de Miguel-Diez, J; Lopez-de-Andres, A				Munoz-Rivas, Nuria; Mendez-Bailon, Manuel; Hernandez-Barrera, Valentin; Ma de Miguel-Yanes, Jose; Jimenez-Garcia, Rodrigo; Esteban-Hernandez, Jesus; Jimenez-Trujillo, Isabel; Alvaro-Meca, Alejandro; Carrasco-Garrido, Pilar; de Miguel-Diez, Javier; Lopez-de-Andres, Ana			Time Trends in Ischemic Stroke among Type 2 Diabetic and Non-Diabetic Patients: Analysis of the Spanish National Hospital Discharge Data (2003-2012)	PLOS ONE			English	Article							RISK-FACTORS; CASE-FATALITY; CEREBROVASCULAR-DISEASE; SEX-DIFFERENCES; EPIDEMIOLOGY; MELLITUS; MORTALITY; SPAIN; METAANALYSIS; WOMEN	Background Type 2 Diabetes (T2DM) is the most rapidly increasing risk factor for ischemic stroke. We aimed to compare trends in outcomes for ischemic stroke in people with or without diabetes in Spain between 2003 and 2012. Methods We selected all patients hospitalized for ischemic stroke using national hospital discharge data. We evaluated annual incident rates stratified by T2DM status. We analyzed trends in the use of diagnostic and therapeutic procedures, patient comorbidities, and in-hospital outcomes. We calculated in-hospital mortality (IHM), length of hospital stay (LOHS) and readmission rate in one month after discharge. Time trend on the incidence of hospitalization was estimated fitting Poisson regression models by sex and diabetes variables. In-hospital mortality was analyzed using logistic regression models separate for men and women. LOHS were compared with ANOVA or Kruskal-Wallis when necessary. Results We identified a total of 423,475 discharges of patients (221,418 men and 202,057 women) admitted with ischemic stroke as primary diagnosis. Patients with T2DM accounted for 30.9% of total. The estimated incidence rates of discharges increased significantly in all groups. The incidence of hospitalization due to stroke (with ICD9 codes for stroke as main diagnosis at discharge) was higher among those with than those without diabetes in all the years studied. T2DM was positively associated with ischemic stroke with an adjusted incidence rate ratio (IRR) of 2.27 (95% CI 2.24-2.29) for men and 2.15 (95% CI 2.13-2.17) for women. Over the 10 year period LOHS decreased significantly in men and women with and without diabetes. Readmission rate remained stable in diabetic and non diabetic men (around 5%) while slightly increased in women with and without diabetes. We observed a significant increase in the use of fibrinolysis from 2002-2013. IHM was positively associated with older age in all groups, with Charlson Comorbidity Index > 3 and atrial fibrillation as risk factors. The IHM did not change significantly over time among T2DM men and women ranging from 9.25% to 10.56% and from 13.21% to 14.86%, respectively; neither did among non-diabetic women. However, in men without T2DM IHM decreased significantly over time. Diabetes was associated to higher IHM only in women (OR 1.07; 95% CI, 1.05-1.11). Conclusions Our national data show that incidence rate of ischemic stroke hospitalization increased significantly during the period of study (2003-2012). People with T2DM have more than double the risk of ischemic stroke after adjusting for other risk factors. Women with T2DM had poorer outcomes-IHM and readmission rates-than diabetic men. Diabetes was an independent factor for IHM only in women.	[Munoz-Rivas, Nuria] Hosp Univ Infanta Leonor, Dept Med, Madrid, Spain; [Mendez-Bailon, Manuel] Hosp Clin San Carlos, Dept Med, Madrid, Comunidad De Ma, Spain; [Hernandez-Barrera, Valentin; Jimenez-Garcia, Rodrigo; Esteban-Hernandez, Jesus; Jimenez-Trujillo, Isabel; Alvaro-Meca, Alejandro; Carrasco-Garrido, Pilar; Lopez-de-Andres, Ana] Rey Juan Carlos Univ, Fac Hlth Sci, Prevent Med & Publ Hlth Teaching & Res Unit, Alcorcon, Comunidad De Ma, Spain; [Ma de Miguel-Yanes, Jose] Hosp Gregorio Maranon, Dept Med, Comunidad De Madrid, Spain; [de Miguel-Diez, Javier] Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Dept Pneumol, Madrid, Spain	Hospital Universitario Infanta Leonor; Hospital Clinico San Carlos; Universidad Rey Juan Carlos; General University Gregorio Maranon Hospital; Complutense University of Madrid; General University Gregorio Maranon Hospital	Munoz-Rivas, N (corresponding author), Hosp Univ Infanta Leonor, Dept Med, Madrid, Spain.	nmunozr@salud.madrid.org	Jimenez-Trujillo, Isabel/AAP-7746-2021; Lopez-de-Andres, Ana/D-4498-2019; Jimenez-Garcia, Rodrigo/D-4953-2019; Lopez-de-Andres, Ana/AAD-8703-2019; Esteban-Hernandez, Jesus/B-6816-2009; Esteban-Hernández, Jesús/ABG-4660-2020	Jimenez-Trujillo, Isabel/0000-0002-9394-6799; Lopez-de-Andres, Ana/0000-0001-5551-5181; Jimenez-Garcia, Rodrigo/0000-0001-5906-9393; Lopez-de-Andres, Ana/0000-0001-5551-5181; Esteban-Hernández, Jesús/0000-0002-6013-1091; Hernandez-Barrera, Valentin/0000-0001-5790-1959; de Miguel-Yanes, Jose M./0000-0003-2802-033X; de Miguel-Diez, Javier/0000-0003-4543-573X; Alvaro-Meca, Alejandro/0000-0003-1315-4386	FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, Instituto de Salud Carlos III) [PI13/00118]; Grupo de Excelencia Investigadora URJC-Banco Santander [30VCPIGI03]	FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, Instituto de Salud Carlos III); Grupo de Excelencia Investigadora URJC-Banco Santander	This study forms part of research funded by the FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, grant no. PI13/00118, Instituto de Salud Carlos III) and partly funded by the Grupo de Excelencia Investigadora URJC-Banco Santander No30VCPIGI03: Investigacion traslacional en el proceso de salud - enfermedad (ITPSE). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.; This study forms part of research funded by the FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, grant no. PI13/00118, Instituto de Salud Carlos III) and by the Grupo de Excelencia Investigadora URJC-Banco Santander No30VCPIGI03: Investigacion traslacional en el proceso de salud-enfermedad (ITPSE).	Aleman JA, 2011, MED CLIN-BARCELONA, V136, P329, DOI 10.1016/j.medcli.2010.04.035; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011; [Anonymous], SERV SOC LGUALD ENC; Arboix A, 2014, CLIN NEUROL NEUROSUR, V127, P19, DOI 10.1016/j.clineuro.2014.09.024; Banerjee C, 2012, STROKE, V43, P1212, DOI 10.1161/STROKEAHA.111.641381; Basterra-Gortari FJ, 2007, MED CLIN-BARCELONA, V129, P405; Bejot Y, 2007, J NEUROL SCI, V262, P85, DOI 10.1016/j.jns.2007.06.025; Brea A, 2013, CLIN INVEST ARTERIOS, V25, P211, DOI 10.1016/j.arteri.2013.10.006; Cayuela A, ANALISIS TENDENCIAS; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Diaz-Guzman J, 2008, REV NEUROLOGIA, V47, P617, DOI 10.33588/rn.4712.2008576; Diaz-Guzman J, 2012, CEREBROVASC DIS, V34, P272, DOI 10.1159/000342652; Eriksson M, 2012, CEREBROVASC DIS, V34, P153, DOI 10.1159/000339763; EVANS RW, 1994, METABOLISM, V43, P1196, DOI 10.1016/0026-0495(94)90065-5; Feigin VL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134609; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Giampaoli S, 2015, EUR J PREV CARDIOL, V22, P9, DOI 10.1177/2047487315589011; Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238; Grysiewicz RA, 2008, NEUROL CLIN, V26, P871, DOI 10.1016/j.ncl.2008.07.003; Howard BV, 1998, DIABETES CARE, V21, P1258, DOI 10.2337/diacare.21.8.1258; Icks A, 2012, DIABETES CARE, V35, P1868, DOI 10.2337/dc11-2159; Idris I, 2006, INT J CLIN PRACT, V60, P48, DOI 10.1111/j.1368-5031.2006.00682.x; Instituto Nacional de Estadistica, 2004, DEF SEG CAUS MUERT 2; Caballero PEJ, 2013, J STROKE CEREBROVASC, V22, pE214, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.014; Khalessi AA, 2011, JACC-CARDIOVASC INTE, V4, P261, DOI 10.1016/j.jcin.2010.11.015; Lindley RI, 2015, STROKE, V46, P746, DOI 10.1161/STROKEAHA.114.006573; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lopez-De-Andres A, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-3; Luitse MJA, 2012, LANCET NEUROL, V11, P261, DOI 10.1016/S1474-4422(12)70005-4; Mansfield MW, 1996, ARTERIOSCL THROM VAS, V16, P160, DOI 10.1161/01.ATV.16.1.160; Marini C, 2003, STROKE, V34, pE13, DOI 10.1161/01.STR.0000065429.56621.6E; Marrugat J, 2007, REV ESP CARDIOL, V60, P573, DOI 10.1157/13107113; Nwaneri C., 2013, BRIT J DIABETES VASC, V13, P192, DOI [10.1177/1474651413495703, DOI 10.1177/1474651413495703]; Palacio S, 2014, STROKE, V45, P2689, DOI 10.1161/STROKEAHA.114.005018; Peters SAE, 2014, LANCET, V383, P1973, DOI 10.1016/S0140-6736(14)60040-4; Ramalle-Gomara E, 2013, J STROKE CEREBROVASC, V22, pE441, DOI 10.1016/j.jstrokecerebrovasdis.2013.04.039; Rodriguez T, 2006, HEART, V92, P453, DOI 10.1136/hrt.2004.059295; Sandercock P, 2013, LANCET NEUROL, V12, P768, DOI 10.1016/S1474-4422(13)70130-3; Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9; Shah AD, 2015, LANCET DIABETES ENDO, V3, P105, DOI 10.1016/S2213-8587(14)70219-0; Soriguer F, 2012, DIABETOLOGIA, V55, P88, DOI 10.1007/s00125-011-2336-9; Steinberg HO, 2000, CIRCULATION, V101, P2040, DOI 10.1161/01.CIR.101.17.2040; Stevens R, 2004, DIABETES CARE, V27, P201, DOI 10.2337/diacare.27.1.201; Strbian D, 2011, NEUROLOGY, V77, P341, DOI 10.1212/WNL.0b013e3182267b8c; Garcia JT, 2010, AV DIABETOL, V26, P397; Thomsen Reimar Wernich, 2012, Clin Epidemiol, V4, P43, DOI 10.2147/CLEP.S30083; Vasiliadis AV, 2014, NEUROL NEUROCHIR POL, V48, P449, DOI 10.1016/j.pjnns.2014.11.001; Vega T, 2009, J STROKE CEREBROVASC, V18, P11, DOI 10.1016/j.jstrokecerebrovasdis.2008.06.010; Wannamethee SG, 2012, DIABETOLOGIA, V55, P80, DOI 10.1007/s00125-011-2284-4; Wardlaw JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub2; Whiteley WN, 2012, STROKE, V43, P2904, DOI 10.1161/STROKEAHA.112.665331; Zhang PL, 2015, EUR REV MED PHARMACO, V19, P1001	52	23	24	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2015	10	12							e0145535	10.1371/journal.pone.0145535	http://dx.doi.org/10.1371/journal.pone.0145535			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0IX	26713435	gold, Green Published, Green Submitted			2023-01-03	WOS:000367481900053
J	Wang, Z; Zhao, SM; Zhao, LM; Chen, XQ; Zeng, GZ; Tan, NH				Wang, Zhe; Zhao, Si-Meng; Zhao, Li-Mei; Chen, Xiao-Qiang; Zeng, Guang-Zhi; Tan, Ning-Hua			Rubipodanin A, the First Natural N-Desmonomethyl Rubiaceae-Type Cyclopeptide from Rubia podantha, Indicating an Important Role of the N-9-Methyl Group in the Conformation and Bioactivity	PLOS ONE			English	Article							ANTITUMOR CYCLIC HEXAPEPTIDES; CYTOTOXIC BICYCLIC HEXAPEPTIDES; BREAST-CANCER CELLS; RA-VII; CORDIFOLIA; DEOXYBOUVARDIN; IDENTIFICATION; RUBIYUNNANINS; PHARMACOPHORE; YUNNANENSIS	One new cyclic hexapeptide named rubipodanin A (1), which is the first identified natural N-desmonomethyl Rubiaceae-type cyclopeptide, together with six known Rubiaceae-type cyclopeptides (2-7) were obtained using the TLC cyclopeptide protosite detection method with ninhydrin from the roots and rhizomes of Rubia podantha. The cyclopeptide structures were elucidated by extensive spectroscopic analysis, including 1D-NMR, 2D-NMR, IR, UV and MS. The solution conformation and biological activities of 1 and RA-V (4) were evaluated, and the results demonstrated that the N-9-methyl group plays a vital role in the maintenance of the conformation and bioactivity.	[Wang, Zhe; Zhao, Si-Meng; Zhao, Li-Mei; Chen, Xiao-Qiang; Zeng, Guang-Zhi; Tan, Ning-Hua] Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Peoples R China; [Tan, Ning-Hua] China Pharmaceut Univ, Dept Nat Med Chem, Nanjing 210009, Jiangsu, Peoples R China; [Tan, Ning-Hua] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China; [Wang, Zhe] Univ Chinese Acad Sci, Beijing 100049, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Botany, CAS; China Pharmaceutical University; China Pharmaceutical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zeng, GZ (corresponding author), Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Peoples R China.	gzh_zeng@mail.kib.ac.cn; nhtan@mail.kib.ac.cn			National Basic Research Program of China [2013CB127505]; Foundation of Chinese Academy of Sciences (Hundred Talents Program) [XDA09030301-4]; National Natural Science Foundation of China [U1032602, 91013002, 31470428]; National New Drug Innovation Major Project of China [2011ZX09307-002-02]; Natural Science Foundation of Yunnan Province [2012GA003]	National Basic Research Program of China(National Basic Research Program of China); Foundation of Chinese Academy of Sciences (Hundred Talents Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National New Drug Innovation Major Project of China; Natural Science Foundation of Yunnan Province(Natural Science Foundation of Yunnan Province)	This work was supported by the National Basic Research Program of China (2013CB127505), the Foundation of Chinese Academy of Sciences (Hundred Talents Program, XDA09030301-4), the National Natural Science Foundation of China (U1032602, 91013002, 31470428), the National New Drug Innovation Major Project of China (2011ZX09307-002-02), and the Natural Science Foundation of Yunnan Province (2012GA003).	AEBI JD, 1990, J MED CHEM, V33, P999, DOI 10.1021/jm00165a018; Bik-San C, 2015, SCIENCE, V347, pS45; BOGER DL, 1994, J AM CHEM SOC, V116, P8544, DOI 10.1021/ja00098a015; BOGER DL, 1992, J ORG CHEM, V57, P1319, DOI 10.1021/jo00031a001; BOGER DL, 1993, J AM CHEM SOC, V115, P3420, DOI 10.1021/ja00062a004; BOGER DL, 1995, J AM CHEM SOC, V117, P7364, DOI 10.1021/ja00133a010; Fan JT, 2010, TETRAHEDRON LETT, V51, P6810, DOI 10.1016/j.tetlet.2010.07.066; Fan JT, 2010, BIOORGAN MED CHEM, V18, P8226, DOI 10.1016/j.bmc.2010.10.019; Fang XY, 2013, TOXICOL APPL PHARM, V267, P95, DOI 10.1016/j.taap.2012.12.010; Fujiwara H, 2004, CANCER LETT, V209, P223, DOI 10.1016/j.canlet.2003.12.022; Hitotsuyanagi Y, 2012, PHYTOCHEM LETT, V5, P335, DOI 10.1016/j.phytol.2012.02.014; Hitotsuyanagi Y, 2012, CHEM-EUR J, V18, P2839, DOI 10.1002/chem.201103185; Huang MB, 2014, TETRAHEDRON, V70, P7627, DOI 10.1016/j.tet.2014.07.105; ITOKAWA H, 1983, CHEM PHARM BULL, V31, P1424; ITOKAWA H, 1986, CHEM PHARM BULL, V34, P3762; JOLAD SD, 1977, J AM CHEM SOC, V99, P8040, DOI 10.1021/ja00466a043; Kuang Bin, 2012, Zhongguo Zhong Yao Za Zhi, V37, P2563; Lee JE, 2008, CHEM PHARM BULL, V56, P730, DOI 10.1248/cpb.56.730; Lee JE, 2008, TETRAHEDRON, V64, P4117, DOI 10.1016/j.tet.2008.01.094; Lee JE, 2008, BIOORG MED CHEM LETT, V18, P808, DOI 10.1016/j.bmcl.2007.11.030; Leung HW, 2015, BBA-MOL CELL RES, V1853, P1827, DOI 10.1016/j.bbamcr.2015.04.020; Liu NN, 2014, TETRAHEDRON, V70, P6630, DOI 10.1016/j.tet.2014.06.108; MORITA H, 1993, CHEM PHARM BULL, V41, P781, DOI 10.1248/cpb.41.781; MORITA H, 1992, CHEM PHARM BULL, V40, P1352, DOI 10.1248/cpb.40.1352; Morita H, 2010, HETEROCYCLES, V80, P739, DOI 10.3987/REV-09-SR(S)7; Otrubova K, 2008, J MED CHEM, V51, P530, DOI 10.1021/jm070731a; Tan NH, 2006, CHEM REV, V106, P840, DOI 10.1021/cr040699h; Tao J, 2003, CHEM PHARM BULL, V51, P654, DOI 10.1248/cpb.51.654; Yan H, 2009, EUR J MED CHEM, V44, P3425, DOI 10.1016/j.ejmech.2009.02.005; Yue GGL, 2011, BRIT J PHARMACOL, V164, P1883, DOI 10.1111/j.1476-5381.2011.01458.x; Zeng GZ, 2009, PHYTOTHER RES, V23, P885, DOI 10.1002/ptr.2671; Zhao SM, 2011, CHIMIA, V65, P952, DOI 10.2533/chimia.2011.952; Zhao SM, 2014, ORG LETT, V16, P5576, DOI 10.1021/ol502603f; Zhou T, 2000, CHINESE SCI BULL, V45, P1825	34	18	18	0	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2015	10	12							e0144950	10.1371/journal.pone.0144950	http://dx.doi.org/10.1371/journal.pone.0144950			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SH	26694544	Green Published, Green Submitted, gold			2023-01-03	WOS:000367092500017
J	Chouchou, F; Chauny, JM; Rainville, P; Lavigne, GJ				Chouchou, Florian; Chauny, Jean-Marc; Rainville, Pierre; Lavigne, Gilles J.			Selective REM Sleep Deprivation Improves Expectation-Related Placebo Analgesia	PLOS ONE			English	Article							EYE-MOVEMENT SLEEP; INDIVIDUAL-DIFFERENCES; CLONIDINE; PAIN; RESPONSES; BRAIN; REWARD; HUMANS; SUPPRESSION; EXPERIENCE	The placebo effect is a neurobiological and psychophysiological process known to influence perceived pain relief. Optimization of placebo analgesia may contribute to the clinical efficacy and effectiveness of medication for acute and chronic pain management. We know that the placebo effect operates through two main mechanisms, expectations and learning, which is also influenced by sleep. Moreover, a recent study suggested that rapid eye movement (REM) sleep is associated with modulation of expectation-mediated placebo analgesia. We examined placebo analgesia following pharmacological REM sleep deprivation and we tested the hypothesis that relief expectations and placebo analgesia would be improved by experimental REM sleep deprivation in healthy volunteers. Following an adaptive night in a sleep laboratory, 26 healthy volunteers underwent classical experimental placebo analgesic conditioning in the evening combined with pharmacological REM sleep deprivation (clonidine: 13 volunteers or inert control pill: 13 volunteers). Medication was administered in a double-blind manner at bedtime, and placebo analgesia was tested in the morning. Results revealed that 1) placebo analgesia improved with REM sleep deprivation; 2) pain relief expectations did not differ between REM sleep deprivation and control groups; and 3) REM sleep moderated the relationship between pain relief expectations and placebo analgesia. These results support the putative role of REM sleep in modulating placebo analgesia. The mechanisms involved in these improvements in placebo analgesia and pain relief following selective REM sleep deprivation should be further investigated.	[Chouchou, Florian; Rainville, Pierre; Lavigne, Gilles J.] Univ Montreal, Fac Med Dent, Montreal, PQ H3C 3J7, Canada; [Chouchou, Florian; Rainville, Pierre; Lavigne, Gilles J.] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada; [Chouchou, Florian; Lavigne, Gilles J.] Hop Sacre Coeur, Ctr Adv Res Sleep Med, Montreal, PQ H4J 1C5, Canada; [Chauny, Jean-Marc; Lavigne, Gilles J.] Hop Sacre Coeur, Emergency Dept, Montreal, PQ H4J 1C5, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Lavigne, GJ (corresponding author), Univ Montreal, Fac Med Dent, Montreal, PQ H3C 3J7, Canada.	gilles.lavigne@umontreal.ca	Rainville, Pierre/M-5480-2015; Chouchou, Florian/AAS-5499-2021	Rainville, Pierre/0000-0001-9801-757X; 	Network for Oral and Bone Health Research (Quebec, Canada); Rhone-Alpes Region (France)	Network for Oral and Bone Health Research (Quebec, Canada); Rhone-Alpes Region (France)(Region Auvergne-Rhone-Alpes)	GJL holds a Canada Research Chair on Pain, Sleep and Traumatic Injuries. FC received a grant from the Network for Oral and Bone Health Research (Quebec, Canada) and from the Rhone-Alpes Region (France).	Atlas Lauren Y, 2014, Handb Exp Pharmacol, V225, P37, DOI 10.1007/978-3-662-44519-8_3; AUTRET A, 1976, CR ACAD SCI D NAT, V283, P955; Azevedo E, 2011, PAIN, V152, P2052, DOI 10.1016/j.pain.2011.04.032; Benedetti F, 2003, J NEUROSCI, V23, P4315; Benedetti F, 2014, NEURON, V84, P623, DOI 10.1016/j.neuron.2014.10.023; Benedict C, 2012, J CLIN ENDOCR METAB, V97, pE443, DOI 10.1210/jc.2011-2759; Chesson A., 2007, AASM MANUAL SCORING; Chouchou F, 2014, SLEEP MED REV, V18, P273, DOI 10.1016/j.smrv.2013.07.002; Clement O, 2012, J NEUROSCI, V32, P16763, DOI 10.1523/JNEUROSCI.1885-12.2012; Colloca L, 2008, PAIN, V139, P306, DOI 10.1016/j.pain.2008.04.021; Drummond SPA, 1999, NEUROREPORT, V10, P3745, DOI 10.1097/00001756-199912160-00004; Eippert F, 2009, SCIENCE, V326, P404, DOI 10.1126/science.1180142; Enck P, 2008, NEURON, V59, P195, DOI 10.1016/j.neuron.2008.06.030; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Gentili A, 1996, EUR J CLIN PHARMACOL, V50, P463, DOI 10.1007/s002280050141; Geuter S, 2013, NEUROIMAGE, V67, P227, DOI 10.1016/j.neuroimage.2012.11.029; GILLBERG M, 1994, SLEEP, V17, P236, DOI 10.1093/sleep/17.3.236; Gujar N, 2011, J NEUROSCI, V31, P4466, DOI 10.1523/JNEUROSCI.3220-10.2011; Hanlon EC, 2005, BEHAV BRAIN RES, V163, P58, DOI 10.1016/j.bbr.2005.04.017; Hauck M, 2006, EUR J PAIN, V10, P757, DOI 10.1016/j.ejpain.2005.12.003; Hayes A. F., 2013, MEDIATION MODERATION; HORNE JA, 1988, SLEEP, V11, P528, DOI 10.1093/sleep/11.6.528; Huynh N, 2006, SLEEP, V29, P307, DOI 10.1093/sleep/29.3.307; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Klinger R, 2014, PAIN, V155, P1055, DOI 10.1016/j.pain.2013.12.007; Laverdure-Dupont D, 2010, REV NEUROSCIENCE, V21, P381; Laverdure-Dupont D, 2009, J NEUROSCI, V29, P11745, DOI 10.1523/JNEUROSCI.1224-09.2009; Loh S, 2004, BEHAV RES METH INS C, V36, P339, DOI 10.3758/BF03195580; Maquet P, 2000, NAT NEUROSCI, V3, P831, DOI 10.1038/77744; Marshall AJ, 2014, J NEUROSCI, V34, P11754, DOI 10.1523/JNEUROSCI.0478-14.2014; Mckenna BS, 2007, J SLEEP RES, V16, P245, DOI 10.1111/j.1365-2869.2007.00591.x; Mitchell A, 2005, CARDIOVASC DRUG THER, V19, P49, DOI 10.1007/s10557-005-6890-6; Montgomery GH, 1997, PAIN, V72, P107, DOI 10.1016/S0304-3959(97)00016-X; Pace-Schott E.F., 2015, PSYCHOL B; Peigneux P, 2003, NEUROIMAGE, V20, P125, DOI 10.1016/S1053-8119(03)00278-7; PORCHET HC, 1990, LIFE SCI, V46, P991, DOI 10.1016/0024-3205(90)90022-J; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; Spoormaker VI, 2014, EXP BRAIN RES, V232, P1547, DOI 10.1007/s00221-014-3831-2; Spoormaker VI, 2012, HUM BRAIN MAPP, V33, P2362, DOI 10.1002/hbm.21369; Steinberg EE, 2013, NAT NEUROSCI, V16, P966, DOI 10.1038/nn.3413; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; Tracey I, 2010, NAT MED, V16, P1277, DOI 10.1038/nm.2229; Venkatraman V, 2007, SLEEP, V30, P603, DOI 10.1093/sleep/30.5.603; Wager TD, 2011, J NEUROSCI, V31, P439, DOI 10.1523/JNEUROSCI.3420-10.2011; Watts A, 2012, J NEUROSCI, V32, P13411, DOI 10.1523/JNEUROSCI.0170-12.2012; Wong MM, 2009, SLEEP MED, V10, P787, DOI 10.1016/j.sleep.2008.06.015; Wu JC, 2006, NEUROPSYCHOPHARMACOL, V31, P2783, DOI 10.1038/sj.npp.1301166; Yoo SS, 2007, CURR BIOL, V17, pR877, DOI 10.1016/j.cub.2007.08.007	50	9	9	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2015	10	12							e0144992	10.1371/journal.pone.0144992	http://dx.doi.org/10.1371/journal.pone.0144992			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9JO	26678391	Green Submitted, Green Published, gold			2023-01-03	WOS:000366723400040
J	Smirni, D; Turriziani, P; Mangano, GR; Cipolotti, L; Oliveri, M				Smirni, Daniela; Turriziani, Patrizia; Mangano, Giuseppa Renata; Cipolotti, Lisa; Oliveri, Massimiliano			Modulating Memory Performance in Healthy Subjects with Transcranial Direct Current Stimulation Over the Right Dorsolateral Prefrontal Cortex	PLOS ONE			English	Article							LONG-TERM-MEMORY; NONINVASIVE BRAIN-STIMULATION; VERBAL EPISODIC MEMORY; MAGNETIC STIMULATION; RECOGNITION MEMORY; ALZHEIMERS-DISEASE; INHIBITORY CONTROL; FRONTAL-CORTEX; OLDER-ADULTS; RETRIEVAL	Objective The role of the Dorsolateral Prefrontal Cortex (DLPFC) in recognition memory has been well documented in lesion, neuroimaging and repetitive Transcranial Magnetic Stimulation (rTMS) studies. The aim of the present study was to investigate the effects of transcranial Direct Current Stimulation (tDCS) over the left and the right DLPFC during the delay interval of a non-verbal recognition memory task. Method 36 right-handed young healthy subjects participated in the study. The experimental task was an Italian version of Recognition Memory Test for unknown faces. Study included two experiments: in a first experiment, each subject underwent one session of sham tDCS and one session of left or right cathodal tDCS; in a second experiment each subject underwent one session of sham tDCS and one session of left or right anodal tDCS. Results Cathodal tDCS over the right DLPFC significantly improved non verbal recognition memory performance, while cathodal tDCS over the left DLPFC had no effect. Anodal tDCS of both the left and right DLPFC did not modify non verbal recognition memory performance. Conclusion Complementing the majority of previous studies, reporting long term memory facilitations following left prefrontal anodal tDCS, the present findings show that cathodal tDCS of the right DLPFC can also improve recognition memory in healthy subjects.	[Smirni, Daniela; Turriziani, Patrizia; Mangano, Giuseppa Renata; Cipolotti, Lisa; Oliveri, Massimiliano] Univ Palermo, Dipartimento Sci Psicol Pedag & Formaz, Palermo, Italy; [Smirni, Daniela; Turriziani, Patrizia; Mangano, Giuseppa Renata; Cipolotti, Lisa; Oliveri, Massimiliano] NeuroTeam Life & Sci, Palermo, Italy; [Cipolotti, Lisa] Natl Hosp Neurol & Neurosurg, Dept Neuropsychol, London WC1N 3BG, England; [Oliveri, Massimiliano] IRCCS Fdn SantaLucia, Rome, Italy	University of Palermo; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Smirni, D (corresponding author), Univ Palermo, Dipartimento Sci Psicol Pedag & Formaz, Palermo, Italy.	daniela.smirni@unipa.it	Oliveri, Massimiliano/HDO-5602-2022; Smirni, Daniela/R-3445-2019	Smirni, Daniela/0000-0002-4410-2047; cipolotti, lisa/0000-0001-5838-3647; Turriziani, Patrizia/0000-0003-4802-280X				Acevedo A, 2007, J GERIATR PSYCH NEUR, V20, P239, DOI 10.1177/0891988707308808; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Bestmann S, 2003, NEUROIMAGE, V20, P1685, DOI 10.1016/j.neuroimage.2003.07.028; Bilek E, 2013, J NEUROSCI, V33, P7050, DOI 10.1523/JNEUROSCI.3081-12.2013; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Boggio PS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004959; Boggio PS, 2012, BRAIN STIMUL, V5, P223, DOI 10.1016/j.brs.2011.06.006; Boggio PS, 2011, NEUROPSYCHOL REHABIL, V21, P703, DOI 10.1080/09602011.2011.617943; Buckner RL, 2001, NAT REV NEUROSCI, V2, P624, DOI 10.1038/35090048; Chi RP, 2010, BRAIN RES, V1353, P168, DOI 10.1016/j.brainres.2010.07.062; Cipolotti L, 2008, NEUROPSYCHOLOGIA, V46, P2745, DOI 10.1016/j.neuropsychologia.2008.05.009; Cipolotti L, 2001, NEUROPSYCHOLOGIA, V39, P151, DOI 10.1016/S0028-3932(00)00103-2; Cotelli M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00038; De Neys W, 2008, PSYCHOL SCI, V19, P483, DOI 10.1111/j.1467-9280.2008.02113.x; Ferrucci R, 2008, NEUROLOGY, V71, P493, DOI 10.1212/01.wnl.0000317060.43722.a3; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Floel A, 2004, CEREB CORTEX, V14, P404, DOI 10.1093/cercor/bhh002; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Habib R, 2003, TRENDS COGN SCI, V7, P241, DOI 10.1016/S1364-6613(03)00110-4; Hammer A, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-72; Jacobs HIL, 2015, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00344; Jacobson TK, 2013, J NEUROPHYSIOL, V109, P1852, DOI 10.1152/jn.00409.2012; Javadi AH, 2013, BRAIN STIMUL, V6, P668, DOI 10.1016/j.brs.2012.10.007; Javadi AH, 2012, BRAIN STIMUL, V5, P468, DOI 10.1016/j.brs.2011.08.003; Javadi AH, 2012, BRAIN STIMUL, V5, P231, DOI 10.1016/j.brs.2011.06.007; Juan CH, 2012, BRAIN STIMUL, V5, P63, DOI 10.1016/j.brs.2012.03.012; Kamida T, 2011, BEHAV BRAIN RES, V217, P99, DOI 10.1016/j.bbr.2010.08.050; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kincses TZ, 2004, NEUROPSYCHOLOGIA, V42, P113, DOI 10.1016/S0028-3932(03)00124-6; Kirchhoff BA, 2000, J NEUROSCI, V20, P6173, DOI 10.1523/JNEUROSCI.20-16-06173.2000; Knoch D, 2006, J NEUROSCI, V26, P6469, DOI 10.1523/JNEUROSCI.0804-06.2006; Manenti R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00049; Manenti R, 2012, BRAIN STIMUL, V5, P103, DOI 10.1016/j.brs.2012.03.004; McDermott KB, 1999, J COGNITIVE NEUROSCI, V11, P631, DOI 10.1162/089892999563698; MILNER B, 1991, NEUROPSYCHOLOGIA, V29, P601, DOI 10.1016/0028-3932(91)90013-X; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Oliveri M, 1999, BRAIN, V122, P1731, DOI 10.1093/brain/122.9.1731; Penolazzi B, 2014, J NEUROSCI, V34, P6606, DOI 10.1523/JNEUROSCI.0349-14.2014; Penolazzi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010623; Pisoni A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123085; Rossi S, 2001, NAT NEUROSCI, V4, P948, DOI 10.1038/nn0901-948; Rounis E, 2006, J NEUROSCI, V26, P9629, DOI 10.1523/JNEUROSCI.2657-06.2006; Sandrini M, 2003, J COGNITIVE NEUROSCI, V15, P855, DOI 10.1162/089892903322370771; Sandrini M, 2013, CURR BIOL, V23, P2181, DOI 10.1016/j.cub.2013.08.045; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Smirni D., 2010, G ITAL PSICOL, V1, P227; Spaniol J, 2009, NEUROPSYCHOLOGIA, V47, P1765, DOI 10.1016/j.neuropsychologia.2009.02.028; Squire LR, 2004, NEUROBIOL LEARN MEM, V82, P171, DOI 10.1016/j.nlm.2004.06.005; Tomita H, 1999, NATURE, V401, P699, DOI 10.1038/44372; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; Turriziani P, 2008, BEHAV NEUROL, V19, P23, DOI 10.1155/2008/568057; Turriziani P, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00062; Turriziani P, 2010, NEUROIMAGE, V52, P348, DOI 10.1016/j.neuroimage.2010.04.007; van Kesteren MTR, 2010, P NATL ACAD SCI USA, V107, P7550, DOI 10.1073/pnas.0914892107; Wagner AD, 1998, BRAIN, V121, P1985, DOI 10.1093/brain/121.10.1985; Warrington E.K., 1984, RECOGNITION MEMORY T; Warrington EK, 1996, CAMDEN MEMORY TEST; Wermke M, 2008, EUR J NUCL MED MOL I, V35, pS12, DOI 10.1007/s00259-007-0698-5; Williams JA, 2010, PHYS THER, V90, P398, DOI 10.2522/ptj.20090075; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Zwissler B, 2014, J NEUROSCI, V34, P4022, DOI 10.1523/JNEUROSCI.5407-13.2014	62	38	39	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2015	10	12							e0144838	10.1371/journal.pone.0144838	http://dx.doi.org/10.1371/journal.pone.0144838			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9JO	26679936	Green Published, gold, Green Submitted			2023-01-03	WOS:000366723400030
J	Ioannides, KLH; Mamtani, M; Shofer, FS; Small, DS; Hennessy, S; Abella, BS; Scott, KR				Ioannides, Kimon L. H.; Mamtani, Mira; Shofer, Frances S.; Small, Dylan S.; Hennessy, Sean; Abella, Benjamin S.; Scott, Kevin R.			Medical Students in the Emergency Department and Patient Length of Stay	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RESIDENTS		[Ioannides, Kimon L. H.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Mamtani, Mira; Shofer, Frances S.; Abella, Benjamin S.; Scott, Kevin R.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Small, Dylan S.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA; [Hennessy, Sean] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Scott, KR (corresponding author), Dept Emergency Med, 3400 Spruce St, Philadelphia, PA 19104 USA.	kevin.scott@uphs.upenn.edu	Scott, Kevin/ABE-5066-2020; Ioannides, Kimon/R-7211-2019	Ioannides, Kimon/0000-0002-6384-2235; Abella, Benjamin/0000-0003-2521-0891; Scott, Kevin/0000-0003-1862-2855; Mamtani, Mira/0000-0002-5927-2532				Dehon E, 2015, SOUTH MED J, V108, P245, DOI 10.14423/SMJ.0000000000000264; DeLaney M, 2013, ACAD MED, V88, P1723, DOI 10.1097/ACM.0b013e3182a7f1f8; Goldfarb S, 2013, NEW ENGL J MED, V369, P1087, DOI 10.1056/NEJMp1306457; Hiller K, 2014, J EMERG MED, V47, P216, DOI 10.1016/j.jemermed.2013.09.040; Pines JM, 2012, ANN EMERG MED, V60, P293, DOI 10.1016/j.annemergmed.2012.01.024; Pitts SR, 2014, JAMA-J AM MED ASSOC, V312, P2394, DOI 10.1001/jama.2014.16172	6	4	4	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	2015	314	22					2411	2413		10.1001/jama.2015.16476	http://dx.doi.org/10.1001/jama.2015.16476			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX8XT	26647265	Green Published, Bronze			2023-01-03	WOS:000365989100018
J	Bacharier, LB; Guilbert, TW; Mauger, DT; Boehmer, S; Beigelman, A; Fitzpatrick, AM; Jackson, DJ; Baxi, SN; Benson, M; Burnham, CAD; Cabana, M; Castro, M; Chmiel, JF; Covar, R; Daines, M; Gaffin, JM; Gentile, DA; Holguin, F; Israel, E; Kelly, HW; Lazarus, SC; Lemanske, RF; Ly, N; Meade, K; Morgan, W; Moy, J; Olin, T; Peters, SP; Phipatanakul, W; Pongracic, JA; Raissy, HH; Ross, K; Sheehan, WJ; Sorkness, C; Szefler, SJ; Teague, WG; Thyne, S; Martinez, FD				Bacharier, Leonard B.; Guilbert, Theresa W.; Mauger, David T.; Boehmer, Susan; Beigelman, Avraham; Fitzpatrick, Anne M.; Jackson, Daniel J.; Baxi, Sachin N.; Benson, Mindy; Burnham, Carey-Ann D.; Cabana, Michael; Castro, Mario; Chmiel, James F.; Covar, Ronina; Daines, Michael; Gaffin, Jonathan M.; Gentile, Deborah Ann; Holguin, Fernando; Israel, Elliot; Kelly, H. William; Lazarus, Stephen C.; Lemanske, Robert F., Jr.; Ly, Ngoc; Meade, Kelley; Morgan, Wayne; Moy, James; Olin, Tod; Peters, Stephen P.; Phipatanakul, Wanda; Pongracic, Jacqueline A.; Raissy, Hengameh H.; Ross, Kristie; Sheehan, William J.; Sorkness, Christine; Szefler, Stanley J.; Teague, W. Gerald; Thyne, Shannon; Martinez, Fernando D.		Natl Heart Lung & Blood Inst	Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-RISK; RHINOVIRUS ILLNESSES; ASTHMA; CHILDHOOD; CORTICOSTEROIDS; INTERLEUKIN-8; ASSOCIATION; INFECTIONS; SYMPTOMS; BACTERIA	IMPORTANCE Many preschool children develop recurrent, severe episodes of lower respiratory tract illness (LRTI). Although viral infections are often present, bacteria may also contribute to illness pathogenesis. Strategies that effectively attenuate such episodes are needed. OBJECTIVE To evaluate if early administration of azithromycin, started prior to the onset of severe LRTI symptoms, in preschool children with recurrent severe LRTIs can prevent the progression of these episodes. DESIGN, SETTING, AND PARTICIPANTS A randomized, double-blind, placebo-controlled, parallel-group trial conducted across 9 academic US medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network, with enrollment starting in April 2011 and follow-up complete by December 2014. Participants were 607 children aged 12 through 71 months with histories of recurrent, severe LRTIs and minimal day-to-day impairment. INTERVENTION Participants were randomly assigned to receive azithromycin (12mg/kg/d for 5 days; n = 307) or matching placebo (n = 300), started early during each predefined RTI (child's signs or symptoms prior to development of LRTI), based on individualized action plans, over a 12-through 18-month period. MAIN OUTCOMES AND MEASURES The primary outcome measure was the number of RTIs not progressing to a severe LRTI, measured at the level of the RTI, that would in clinical practice trigger the prescription of oral corticosteroids. Presence of azithromycin-resistant organisms in oropharyngeal samples, along with adverse events, were among the secondary outcome measures. RESULTS A total of 937 treated RTIs (azithromycin group, 473; placebo group, 464) were experienced by 443 children (azithromycin group, 223; placebo group, 220), including 92 severe LRTIs (azithromycin group, 35; placebo group, 57). Azithromycin significantly reduced the risk of progressing to severe LRTI relative to placebo (hazard ratio, 0.64 [95% CI, 0.41-0.98], P =.04; absolute risk for first RTI: 0.05 for azithromycin, 0.08 for placebo; risk difference, 0.03 [95% CI, 0.00-0.06]). Induction of azithromycin-resistant organisms and adverse events were infrequently observed. CONCLUSIONS AND RELEVANCE Among young children with histories of recurrent severe LRTIs, the use of azithromycin early during an apparent RTI compared with placebo reduced the likelihood of severe LRTI. More information is needed on the development of antibiotic-resistant pathogens with this strategy.	[Bacharier, Leonard B.; Beigelman, Avraham; Castro, Mario] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Guilbert, Theresa W.] Cincinnati Childrens Hosp & Med Ctr, Cincinnati, OH USA; [Mauger, David T.; Boehmer, Susan] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Fitzpatrick, Anne M.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Pediat Sect Allergy Immunol & Rheumatol, Madison, WI 53706 USA; [Baxi, Sachin N.; Phipatanakul, Wanda; Sheehan, William J.] Boston Childrens Hosp, Div Allergy Immunol, Boston, MA USA; [Benson, Mindy; Meade, Kelley] Benioff Childrens Hosp, Oakland, CA USA; [Burnham, Carey-Ann D.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Cabana, Michael; Lazarus, Stephen C.] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA; [Chmiel, James F.; Ross, Kristie] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Covar, Ronina; Olin, Tod] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Daines, Michael; Morgan, Wayne] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Gaffin, Jonathan M.] Boston Childrens Hosp, Div Resp Dis, Boston, MA USA; [Gentile, Deborah Ann] Allegheny Gen Hosp, Dept Pediat, Pittsburgh, PA 15212 USA; [Holguin, Fernando] Univ Pittsburgh, Asthma Inst, Pittsburgh, PA USA; [Israel, Elliot] Brigham & Womens Hosp, Boston, MA 02115 USA; [Kelly, H. William] Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Ly, Ngoc] Univ Calif San Francisco, Airway Clin Res Ctr, San Francisco, CA 94143 USA; [Moy, James] Stroger Hosp Cook Cty Pediat Serv, Chicago, IL USA; [Peters, Stephen P.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Pongracic, Jacqueline A.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Raissy, Hengameh H.] Univ New Mexico, Dept Pediat Pulm, Albuquerque, NM 87131 USA; [Sorkness, Christine] Univ Wisconsin, Madison, WI 53706 USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Breathing Inst, Denver, CO USA; [Teague, W. Gerald] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; [Thyne, Shannon] San Francisco Gen Hosp, Dept Pediat, San Francisco, CA 94110 USA; [Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA	Washington University (WUSTL); Cincinnati Children's Hospital Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Emory University; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Boston Children's Hospital; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Washington University (WUSTL); University of California System; University of California San Francisco; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; National Jewish Health; University of Arizona; Harvard University; Boston Children's Hospital; Allegheny General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Brigham & Women's Hospital; University of New Mexico; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; John H Stroger Junior Hospital Cook County; Wake Forest University; Wake Forest Baptist Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; University of New Mexico; University of Wisconsin System; University of Wisconsin Madison; Children's Hospital Colorado; University of Virginia; San Francisco General Hospital Medical Center; University of Arizona	Bacharier, LB (corresponding author), Washington Univ, Sch Med, Dept Pediat, Campus Box 8116,660 S Euclid Ave, St Louis, MO 63110 USA.	bacharier_l@kidswustl.edu		GAFFIN, JONATHAN/0000-0003-2213-4504; Bacharier, Leonard/0000-0003-0432-2704; Fitzpatrick, Anne/0000-0002-2933-5926; Szefler, Stanley/0000-0002-6911-3199	National Heart, Lung, and Blood Institute (NHLBI) as part of AsthmaNet [HL098102, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, HL098103, HL098115, TR001082, TR000439, TR000448, TR000454]; NHLBI; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001449, UL1TR000448, UL1TR000454, UL1TR001082, UL1TR000439, UL1TR000041] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098102, U10HL098090, U10HL098103, U10HL098075, U10HL098096, U10HL098112, U10HL098107, U10HL098177, U10HL098115, U10HL098098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI106945, K23AI104780] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI) as part of AsthmaNet; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The study was funded by grants HL098102, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, HL098103, HL098115, TR001082, TR000439, TR000448, and TR000454 from the National Heart, Lung, and Blood Institute (NHLBI) as part of AsthmaNet, a clinical trials network supported by a cooperative agreement with NHLBI. GlaxoSmithKline, Merck, Teva, Boehringer Ingelheim, and Sunovion provided products for NHLBI AsthmaNet studies.	Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Beigelman A, 2015, J ALLERGY CLIN IMMUN, V135, P1171, DOI 10.1016/j.jaci.2014.10.001; Beigelman A, 2013, J ALLERGY CLIN IMMUN, V131, P1518, DOI 10.1016/j.jaci.2013.01.034; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; De Boeck K, 2011, PEDIATRICS, V127, P1022, DOI 10.1542/peds.2009-3068; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Hersh AL, 2013, PEDIATRICS, V132, P1146, DOI 10.1542/peds.2013-3260; Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Klein JP, 2003, SURVIVAL ANAL TECHNI, V2nd, DOI DOI 10.1007/B97377; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853; Kozyrskyj AL, 2006, PEDIATRICS, V117, pE1104, DOI 10.1542/peds.2005-2443; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Ly NP, 2006, PEDIATRICS, V117, pE1132, DOI 10.1542/peds.2005-2271; Marguet C, 1999, AM J RESP CRIT CARE, V159, P1533, DOI 10.1164/ajrccm.159.5.9805028; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; Panickar J, 2009, NEW ENGL J MED, V360, P329, DOI 10.1056/NEJMoa0804897; Paul IM, 2011, PEDIATRICS, V127, P1014, DOI 10.1542/peds.2011-0218; Program NAEaP, 2007, PROGR NAEAP PUBL, V08-4051; Rivera-Spoljaric K, 2009, J PEDIATR-US, V154, P877, DOI 10.1016/j.jpeds.2008.12.029; Sarpong EM, 2015, HEALTH SERV RES, V50, P830, DOI 10.1111/1475-6773.12260; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647	33	179	184	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2015	314	19					2034	2044		10.1001/jama.2015.13896	http://dx.doi.org/10.1001/jama.2015.13896			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW1PR	26575060	Bronze, Green Accepted			2023-01-03	WOS:000364764200018
J	McCartney, M				McCartney, Margaret			NO HOLDS BARRED Margaret McCartney: Is Jeremy Hunt our colleague?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Rimmer A, 2015, BMJ CAREERS	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2015	351								h5995	10.1136/bmj.h5995	http://dx.doi.org/10.1136/bmj.h5995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV6PO	26546585	Bronze			2023-01-03	WOS:000364392500007
J	Calado, GP; Lopes, AJO; Costa, LM; Lima, FDA; Silva, LA; Pereira, WS; do Amaral, FMM; Garcia, JBS; Cartagenes, MDD; Nascimento, FRF				Calado, Gustavo P.; Lopes, Alberto Jorge O.; Costa Junior, Livio M.; Lima, Francisco das Chagas A.; Silva, Lucilene A.; Pereira, Wanderson S.; do Amaral, Flavia M. M.; Garcia, Joao Batista S.; Cartagenes, Maria do Socorro de S.; Nascimento, Flavia R. F.			Chenopodium ambrosioides L. Reduces Synovial Inflammation and Pain in Experimental Osteoarthritis	PLOS ONE			English	Article							RAT MODEL; DOCKING	The chronicity of osteoarthritis (OA), characterized by pain and inflammation in the joints, is linked to a glutamate receptor, N-methyl-D-aspartate (NMDA). The use of plant species such as Chenopodium ambrosioides L. (Amaranthaceae) as NMDA antagonists offers a promising perspective. This work aims to analyze the antinociceptive and anti-inflammatory responses of the crude hydroalcoholic extract (HCE) of C. ambrosioides leaves in an experimental OA model. Wistar rats were separated into six groups (n = 24): clean (C), negative control (CTL-), positive control (CTL+), HCE0.5, HCE5 and HCE50. The first group received no intervention. The other groups received an intra-articular injection of sodium monoiodoacetate (MIA) (8 mg/kg) on day 0. After six hours, they were orally treated with saline, Maxicam plus (meloxicam + chondroitin sulfate) and HCE at doses of 0.5 mg/kg, 5 mg/kg and 50 mg/kg, respectively. After three, seven and ten days, clinical evaluations were performed (knee diameter, mechanical allodynia, mechanical hyperalgesia and motor activity). On the tenth day, after euthanasia, synovial fluid and draining lymph node were collected for cellular quantification, and cartilage was collected for histopathological analysis. Finally, molecular docking was performed to evaluate the compatibility of ascaridole, a monoterpene found in HCE, with the NMDA receptor. After the third day, HCE reduced knee edema. HCE5 showed less cellular infiltrate in the cartilage and synovium and lower intensities of allodynia from the third day and of hyperalgesia from the seventh day up to the last treatment day. The HCE5 and HCE50 groups improved in forced walking. In relation to molecular docking, ascaridole showed NMDA receptor binding affinity. C. ambrosioides HCE was effective in the treatment of OA because it reduced synovial inflammation and behavioral changes due to pain. This effect may be related to the antagonistic effect of ascaridole on the NMDA receptor.	[Calado, Gustavo P.; Lopes, Alberto Jorge O.; Costa Junior, Livio M.; Silva, Lucilene A.; Pereira, Wanderson S.; do Amaral, Flavia M. M.; Garcia, Joao Batista S.; Cartagenes, Maria do Socorro de S.; Nascimento, Flavia R. F.] Univ Fed Maranhao, Biol & Hlth Sci Ctr, Hlth Sci Grad Program, BR-6508580 Sao Luis, MA, Brazil; [Lima, Francisco das Chagas A.] Univ Estadual Piaui, Dept Chem, Quantum Chem Computat Grp, Chem Grad Program, BR-64002150 Teresina, PI, Brazil	Universidade Federal do Maranhao; Universidade Estadual do Piaui (UESPI)	Nascimento, FRF (corresponding author), Univ Fed Maranhao, Biol & Hlth Sci Ctr, Hlth Sci Grad Program, Av Portugueses 1966, BR-6508580 Sao Luis, MA, Brazil.	nascimentofrf@yahoo.com.br	Lima, Francisco das Chagas das Chagas Alves/D-8730-2017; Costa-Junior, Livio M/H-7530-2012; LOPES, ALBERTO JORGE OLIVEIRA/AAS-9995-2020; Nascimento, Flavia/F-8173-2016	Lima, Francisco das Chagas das Chagas Alves/0000-0002-0447-4911; Costa-Junior, Livio M/0000-0002-1475-049X; LOPES, ALBERTO JORGE OLIVEIRA/0000-0001-5267-9500; Nascimento, Flavia/0000-0001-9328-1806	Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do Maranhao (FAPEMA); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento em Pesquisa (CNPq)	Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do Maranhao (FAPEMA)(Fundacao de Amparo a Pesquisa e Desenvolvimento Cientifico do Maranhao (FAPEMA)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Desenvolvimento em Pesquisa (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by grants from Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do Maranhao (FAPEMA), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and Conselho Nacional de Desenvolvimento em Pesquisa (CNPq).	Castro RR, 2008, OSTEOARTHRIITIS CART, V14, P769; Dembitsky V, 2008, BIOMED PAP, V152, P209, DOI 10.5507/bp.2008.032; Fernihough J, 2004, PAIN, V112, P83, DOI 10.1016/j.pain.2004.08.004; Goh JZ, 2015, INT J NANOMED, V10, P297, DOI 10.2147/IJN.S75545; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; Ibironke G. F., 2007, IJP - International Journal of Pharmacology, V3, P111; Ishizuka Pedro, 2007, Rev. Bras. Anestesiol., V57, P19, DOI 10.1590/S0034-70942007000100003; Kiselycznyk C, 2015, BEHAV BRAIN RES, V287, P89, DOI 10.1016/j.bbr.2015.03.023; Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549; Kumar R, 2007, INT J FOOD MICROBIOL, V115, P159, DOI 10.1016/j.ijfoodmicro.2006.10.017; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Lee CH, 2009, OSTEOARTHR CARTILAGE, V17, P1485, DOI 10.1016/j.joca.2009.05.006; Liu GW, 2011, IMMUNOL CELL BIOL, V89, P130, DOI 10.1038/icb.2010.70; Lorenzi H, 2002, PLANTAS MED BRASIL N; Mannelli LD, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-228; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; Matos F.J.A., 1997, INTRO FITOQUIMICA EX, V2a; Moller KA, 1998, J NEUROSCI METH, V84, P41, DOI 10.1016/S0165-0270(98)00083-1; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nascimento FRF, 2006, LIFE SCI, V78, P2650, DOI 10.1016/j.lfs.2005.10.006; Neiva VS, 2011, REV CIENCIAS SAUDE, V13, P155; Olajide O. A., 1997, Fitoterapia, V68, P529; Pastor J, 2015, ACTA TROP, V145, P31, DOI 10.1016/j.actatropica.2015.02.002; Patricio FJ, 2008, J ETHNOPHARMACOL, V115, P313, DOI 10.1016/j.jep.2007.10.009; Pereira WS, 2010, J ETHNOPHARMACOL, V127, P602, DOI 10.1016/j.jep.2009.12.018; PINHEIRO VF, 2005, J BRASILEIRO FITOMED, V3, P62; Rahman W, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0509-x; Ramos RM, 2012, J MOL MODEL, V18, P4013, DOI 10.1007/s00894-012-1383-6; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Rocha FAC, 2003, REV BRAS REUMATOL, V43, P206; Sousa LHA, 2012, REV CIENC SAUDE, V14; Stierand K, 2010, ACS MED CHEM LETT, V1, P540, DOI 10.1021/ml100164p; TrivellatoGrassi L, 2013, J ETHNOPHARMACOL, V145, P127, DOI 10.1016/j.jep.2012.10.040; Yassin NZ, 2015, DRUG DES DEV THER, V9, P1491, DOI 10.2147/DDDT.S79957; Ye H, 2015, WORLD J GASTROENTERO, V21, P4178, DOI 10.3748/wjg.v21.i14.4178	35	25	26	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2015	10	11							e0141886	10.1371/journal.pone.0141886	http://dx.doi.org/10.1371/journal.pone.0141886			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV1PG	26524084	Green Published, gold, Green Submitted			2023-01-03	WOS:000364029800027
J	Young, P; Bailey, M; Beasley, R; Henderson, S; Mackle, D; McArthur, C; MGuinness, S; Mehrtens, J; Myburgh, J; Psirides, A; Reddy, S; Bellomo, R				Young, Paul; Bailey, Michael; Beasley, Richard; Henderson, Seton; Mackle, Diane; McArthur, Colin; MGuinness, Shay; Mehrtens, Jan; Myburgh, John; Psirides, Alex; Reddy, Sumeet; Bellomo, Rinaldo		SPLIT Investigators ANZICS CTG	Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit The SPLIT Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL ADULTS; IN-HOSPITAL MORTALITY; FLUID THERAPY SPLIT; PLASMA-LYTE 148; 0.9-PERCENT SALINE; RESUSCITATION; CHLORIDE; ASSOCIATION	IMPORTANCE Saline (0.9% sodium chloride) is the most commonly administered intravenous fluid; however, its use may be associated with acute kidney injury (AKI) and increased mortality. OBJECTIVE To determine the effect of a buffered crystalloid compared with saline on renal complications in patients admitted to the intensive care unit (ICU). DESIGN AND SETTING Double-blind, cluster randomized, double-crossover trial conducted in 4 ICUs in New Zealand from April 2014 through October 2014. Three ICUs were general medical and surgical ICUs; 1 ICU had a predominance of cardiothoracic and vascular surgical patients. PARTICIPANTS All patients admitted to the ICU requiring crystalloid fluid therapy were eligible for inclusion. Patients with established AKI requiring renal replacement therapy (RRT) were excluded. All 2278 eligible patients were enrolled; 1152 of 1162 patients (99.1%) receiving buffered crystalloid and 1110 of 1116 patients (99.5%) receiving saline were analyzed. INTERVENTIONS Participating ICUs were assigned a masked study fluid, either saline or a buffered crystalloid, for alternating 7-week treatment blocks. Two ICUs commenced using 1 fluid and the other 2 commenced using the alternative fluid. Two crossovers occurred so that each ICU used each fluid twice over the 28 weeks of the study. The treating clinician determined the rate and frequency of fluid administration. MAIN OUTCOMES AND MEASURES The primary outcome was proportion of patients with AKI (defined as a rise in serum creatinine level of at least 2-fold or a serum creatinine level of >= 3.96mg/dL with an increase of >= 0.5mg/dL); main secondary outcomes were incidence of RRT use and in-hospital mortality. RESULTS In the buffered crystalloid group, 102 of 1067 patients (9.6%) developed AKI within 90 days after enrollment compared with 94 of 1025 patients (9.2%) in the saline group (absolute difference, 0.4%[95% CI, -2.1% to 2.9%]; relative risk [RR], 1.04 [95% CI, 0.80 to 1.36]; P=.77). In the buffered crystalloid group, RRT was used in 38 of 1152 patients (3.3%) compared with 38 of 1110 patients (3.4%) in the saline group (absolute difference, -0.1% [95% CI, -1.6% to 1.4%]; RR, 0.96 [95% CI, 0.62 to 1.50]; P = .91). Overall, 87 of 1152 patients (7.6%) in the buffered crystalloid group and 95 of 1110 patients (8.6%) in the saline group died in the hospital (absolute difference, -1.0% [95% CI, -3.3% to 1.2%]; RR, 0.88 [95% CI, 0.67 to 1.17]; P=.40). CONCLUSIONS AND RELEVANCE Among patients receiving crystalloid fluid therapy in the ICU, use of a buffered crystalloid compared with saline did not reduce the risk of AKI. Further large randomized clinical trials are needed to assess efficacy in higher-risk populations and to measure clinical outcomes such as mortality.	[Young, Paul; Beasley, Richard; Henderson, Seton; Mackle, Diane; McArthur, Colin; MGuinness, Shay; Reddy, Sumeet] Med Res Inst New Zealand, Wellington 6242, New Zealand; [Young, Paul; Psirides, Alex] Wellington Reg Hosp, Intens Care Unit, Wellington, New Zealand; [Bailey, Michael; McArthur, Colin; MGuinness, Shay; Bellomo, Rinaldo] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia; [Henderson, Seton; Mehrtens, Jan] Christchurch Hosp, Dept Intens Care Med, Christchurch, New Zealand; [McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [MGuinness, Shay] Auckland City Hosp, Cardiothorac & Vasc Intens Care Unit, Auckland, New Zealand; [Myburgh, John] St George Hosp, Intens Care Unit, Sydney, NSW, Australia; [Myburgh, John] George Inst Global Hlth, Crit Care Div, Sydney, NSW, Australia; [Bellomo, Rinaldo] Austin Hosp, Intens Care Unit, Melbourne, Vic 3084, Australia	Medical Research Institute Of New Zealand; Monash University; Christchurch Hospital New Zealand; Auckland City Hospital; Auckland City Hospital; St George Hospital; George Institute for Global Health; University of Sydney; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Young, P (corresponding author), Med Res Inst New Zealand, Private Bag 7902, Wellington 6242, New Zealand.	paul.young@ccdhb.org.nz	Bailey, Michael J/A-4499-2012; Beasley, Richard/AAH-3908-2019	Bailey, Michael J/0000-0002-5551-1401; Beasley, Richard/0000-0003-0337-406X; McGuinness, Shay/0000-0003-0620-4787; Forbes, Andrew/0000-0003-4269-914X; Young, Paul/0000-0002-3428-3083; Myburgh, John/0000-0003-4088-7016; Psirides, Alex/0000-0002-5925-2478; Bellomo, Rinaldo/0000-0002-1650-8939	Health Research Council of New Zealand; Baxter Healthcare Corporation	Health Research Council of New Zealand(Health Research Council of New Zealand); Baxter Healthcare Corporation	This study was funded by the Health Research Council of New Zealand through a Research Partnership for Health Delivery grant and by Baxter Healthcare Corporation.	Bayer O, 2011, CRIT CARE MED, V39, P1335, DOI 10.1097/CCM.0b013e318212096a; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Chowdhury AH, 2012, ANN SURG, V256, P18, DOI 10.1097/SLA.0b013e318256be72; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krajewski ML, 2015, BRIT J SURG, V102, P24, DOI 10.1002/bjs.9651; Myburgh JA, 2013, NEW ENGL J MED, V369, P1243, DOI 10.1056/NEJMra1208627; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Pilcher D, APD DATA DICT SOFTWA; Raghunathan K, 2014, CRIT CARE MED, V42, P1585, DOI 10.1097/CCM.0000000000000305; Reddy SK, 2015, CRIT CARE RESUSC, V17, P29; Reddy SK, 2014, CRIT CARE RESUSC, V16, P274; Shaw AD, 2014, INTENS CARE MED, V40, P1897, DOI 10.1007/s00134-014-3505-3; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Young P, STAT ANAL PLAN 0 9 S; Young PJ, 2014, INTENS CARE MED, V40, P1966, DOI 10.1007/s00134-014-3531-1; Yunos NM, 2015, INTENS CARE MED, V41, P257, DOI 10.1007/s00134-014-3593-0; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Yunos NM, 2010, CRIT CARE, V14, DOI 10.1186/cc9052	21	401	423	2	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2015	314	16					1701	1710		10.1001/jama.2015.12334	http://dx.doi.org/10.1001/jama.2015.12334			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CU7HC	26444692	Bronze			2023-01-03	WOS:000363706300019
J	Appleby, J				Appleby, John			DATA BRIEFING The rise and rise of generic prescribing	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Fund, London, England		Appleby, J (corresponding author), Kings Fund, London, England.	j.appleby@kingsfund.org.uk						Aitken M, 2014, MED USE SHIFTING COS; Alderwick H, 2015, BETTER VALUE NHS ROL; Department of Health, 1998, PRESCR DISP COMM; Department of Health, 1987, STAT PRESCR DISP FAM; Department of Health and Social Security, 1988, ENGLAND 1976 1986 B; Health and Social Care Information Centre, 2015, PRESCR DIS COMM STAT; Monitor, 2015, PERFORMANCE FDN TRUS; Smyth C., 2015, TIMES; Trust Development Authority, 2015, NHS TRUSTS FIN POS Q	9	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 20	2015	351								h5507	10.1136/bmj.h5507	http://dx.doi.org/10.1136/bmj.h5507			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV3FJ	26486378				2023-01-03	WOS:000364143900008
J	Aronson, SJ; Rehm, HL				Aronson, Samuel J.; Rehm, Heidi L.			Building the foundation for genomics in precision medicine	NATURE			English	Review							IMPLEMENTATION CONSORTIUM GUIDELINES; SEQUENCE VARIATION; EMERGE NETWORK; LUNG-CANCER; BIG DATA; DATABASE; RECORDS; ASSOCIATION; INFORMATION; PREDICTION	Precision medicine has the potential to profoundly improve the practice of medicine. However, the advances required will take time to implement. Genetics is already being used to direct clinical decision-making and its contribution is likely to increase. To accelerate these advances, fundamental changes are needed in the infrastructure and mechanisms for data collection, storage and sharing. This will create a continuously learning health-care system with seamless cycling between clinical care and research. Patients must be educated about the benefits of sharing data. The building blocks for such a system are already forming and they will accelerate the adoption of precision medicine.	[Aronson, Samuel J.; Rehm, Heidi L.] Partners HealthCare Personalized Med, Boston, MA 02115 USA; [Aronson, Samuel J.] Partners HealthCare Res Informat Serv & Comp, Charlestown, MA 02129 USA; [Rehm, Heidi L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Rehm, Heidi L.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Rehm, Heidi L.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA	Partners Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Rehm, HL (corresponding author), Partners HealthCare Personalized Med, Boston, MA 02115 USA.	hrehm@partners.org		Rehm, Heidi L./0000-0002-6025-0015	NIH [U41HG006834, U01HG006500, U19HD077671]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U19HD077671] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U41HG006834, U01HG006500] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	H.L.R. was supported in part by NIH grants U41HG006834, U01HG006500 and U19HD077671. S.J.A. was supported in part by U41HG006834.	Abdallah K, 2015, ONCOLOGIST, V20, P459, DOI 10.1634/theoncologist.2015-0054; Abina SHB, 2015, JAMA-J AM MED ASSOC, V313, P1550, DOI 10.1001/jama.2015.3253; Allen NL, 2014, MAYO CLIN PROC, V89, P738, DOI 10.1016/j.mayocp.2014.03.015; Almalki M, 2015, HEALTH INF SCI SYST, V3, DOI 10.1186/2047-2501-3-S1-S1; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Aronson SJ, 2012, GENET MED, V14, P713, DOI 10.1038/gim.2012.19; Aronson SJ, 2011, HUM MUTAT, V32, P532, DOI 10.1002/humu.21470; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Beroud C, 2000, HUM MUTAT, V15, P86, DOI 10.1002/(SICI)1098-1004(200001)15:1<86::AID-HUMU16>3.0.CO;2-4; Buske O. J., 2015, HUM MUTAT; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Cutting GR, 2015, NAT REV GENET, V16, P45, DOI 10.1038/nrg3849; Del Fiol Guilherme, 2006, AMIA Annu Symp Proc, P904; Domchek SM, 2010, JAMA-J AM MED ASSOC, V304, P967, DOI 10.1001/jama.2010.1237; Firth HV, 2009, AM J HUM GENET, V84, P524, DOI 10.1016/j.ajhg.2009.03.010; Gargis AS, 2012, NAT BIOTECHNOL, V30, P1033, DOI 10.1038/nbt.2403; Gottesman O, 2013, GENET MED, V15, P761, DOI 10.1038/gim.2013.72; Hoffman MA, 2011, HUM GENET, V130, P33, DOI 10.1007/s00439-011-0992-y; Jarchum I, 2015, NAT BIOTECHNOL, V33, P49, DOI 10.1038/nbt.3115; Jian XQ, 2014, GENET MED, V16, P497, DOI 10.1038/gim.2013.176; Joyner MJ, 2015, JAMA-J AM MED ASSOC, V314, P999, DOI 10.1001/jama.2015.7725; Kho AN, 2013, GENET MED, V15, P772, DOI 10.1038/gim.2013.131; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Knoppers Bartha Maria, 2014, Hugo J, V8, P3, DOI 10.1186/s11568-014-0003-1; Korf BR, 2013, JAMA-J AM MED ASSOC, V309, P1511, DOI 10.1001/jama.2013.3239; Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113; Lerner-Ellis J, 2015, J MED GENET, V52, P438, DOI 10.1136/jmedgenet-2014-102933; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Martin MA, 2014, CLIN PHARMACOL THER, V95, P499, DOI 10.1038/clpt.2014.38; McCarty CA, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-13; Milani L, 2015, J INTERN MED, V277, P188, DOI 10.1111/joim.12320; Miller DT, 2010, AM J HUM GENET, V86, P749, DOI 10.1016/j.ajhg.2010.04.006; Morell CF, 2009, EXPERT OPIN BIOL TH, V9, P631, DOI [10.1517/14712590902902296, 10.1517/14712590902902296 ]; Murphy SN, 2015, J DIGIT IMAGING, V28, P194, DOI 10.1007/s10278-014-9733-9; O'Driscoll A, 2013, J BIOMED INFORM, V46, P774, DOI 10.1016/j.jbi.2013.07.001; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Philippakis A. A., 2015, HUM MUTAT; Rehm HL, 2015, NEW ENGL J MED, V372, P2235, DOI 10.1056/NEJMsr1406261; Relling MV, 2013, CLIN PHARMACOL THER, V93, P324, DOI 10.1038/clpt.2013.4; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Riggs ER, 2012, HUM MUTAT, V33, P787, DOI 10.1002/humu.22052; Schilsky RL, 2014, J CLIN ONCOL, V32, P2373, DOI 10.1200/JCO.2014.56.2124; Sosnay PR, 2013, NAT GENET, V45, P1160, DOI 10.1038/ng.2745; Spurdle AB, 2012, HUM MUTAT, V33, P2, DOI 10.1002/humu.21628; Starren J, 2013, JAMA-J AM MED ASSOC, V309, P1237, DOI 10.1001/jama.2013.1579; Stenson PD, 2014, HUM GENET, V133, P1, DOI 10.1007/s00439-013-1358-4; Thompson BA, 2014, NAT GENET, V46, P107, DOI 10.1038/ng.2854; Thusberg J, 2011, HUM MUTAT, V32, P358, DOI 10.1002/humu.21445; Toledo JB, 2014, ALZHEIMERS DEMENT, V10, P477, DOI 10.1016/j.jalz.2013.06.003; Tryka KA, 2014, NUCLEIC ACIDS RES, V42, pD975, DOI 10.1093/nar/gkt1211; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; US Department of Veterans Affairs Office of Research & Development, 2002, INF CONS HUM SUBJ RE; Wraith J. E., 2013, COCHRANE DB SYST REV, V11; Xue W, 2011, NATURE, V473, P544, DOI 10.1038/nature09909; Zhang JJ, 2011, DATABASE-OXFORD, DOI [10.1093/database/bar026, 10.1155/2011/958381]	55	280	292	15	199	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 15	2015	526	7573					336	342		10.1038/nature15816	http://dx.doi.org/10.1038/nature15816			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT3TQ	26469044	Green Accepted			2023-01-03	WOS:000362730200036
J	Wang, M; Bjorkenstam, C; Alexanderson, K; Runeson, B; Tinghog, P; Mittendorfer-Rutz, E				Wang, Mo; Bjoerkenstam, Charlotte; Alexanderson, Kristina; Runeson, Bo; Tinghoeg, Petter; Mittendorfer-Rutz, Ellenor			Trajectories of Work-Related Functional Impairment prior to Suicide	PLOS ONE			English	Article							4.9 MILLION INHABITANTS; TERM SICKNESS ABSENCE; DISABILITY PENSIONERS; MENTAL-DISORDERS; RISK-FACTORS; FOLLOW-UP; ALL-CAUSE; MORTALITY; HEALTH; BEHAVIOR	Background Work-related functional impairment in terms of sickness absence and disability pension (SA/DP) has been reported to be associated with subsequent suicide. However, there is only limited knowledge on SA/DP patterns prior to suicide. The aim was to identify trajectories of work-related functional impairment prior to suicide and to describe associations of socio-demographic and medical factors with such trajectories. Methods This is a population-based retrospective cohort study of the 4 209 individuals aged 22-65 years who committed suicide during 2007-2010 in Sweden. Work-related functional impairment was measured as mean annual number of months of SA/DP. We analyzed trajectories of SA/DP during five years prior to suicide (i.e., 2002-2009) by a group-based trajectory method. Associations between socio-demographic and medical factors with different groups of trajectories were estimated by chi(2)-test and multinomial logistic regression. Results Five different functional impairment trajectory groups were identified prior to suicide. One group had constant low levels of SA/DP (46%), while 30% had constant high levels of SA/DP. Two groups (16%) showed increasing number of SA/DP months. The remaining 7% showed decreasing number of SA/DP months before the suicide. Sex, age, educational level, family situation, and diagnosis-specific healthcare were significantly associated with different trajectory groups (Likelihood ratio X-2 tests <0.05). A larger proportion of higher educated and younger men with a lower proportion of previous suicide attempts were found in the group with constant low levels. Opposite characteristics were displayed in the group with constant high levels. Conclusions This study identified five different groups of work-related functional impairment trajectories before suicide. These differences might be partly explained by the variations in socio-demographic profiles and health care consumptions five years before suicide.	[Wang, Mo; Bjoerkenstam, Charlotte; Alexanderson, Kristina; Tinghoeg, Petter; Mittendorfer-Rutz, Ellenor] Karolinska Inst, Dept Clin Neurosci, Div Insurance Med, Stockholm, Sweden; [Runeson, Bo] Karolinska Inst, Ctr Psychiat Res, Dept Clin Neurosci, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Wang, M (corresponding author), Karolinska Inst, Dept Clin Neurosci, Div Insurance Med, Stockholm, Sweden.	mo.wang@ki.se	Wang, Mo/AAJ-9414-2020		Swedish Research Council [522-2010-2683]; Karolinska Institutet funds for doctoral education, the Swedish Research Council for Health, Working Life and Welfare	Swedish Research Council(Swedish Research CouncilEuropean Commission); Karolinska Institutet funds for doctoral education, the Swedish Research Council for Health, Working Life and Welfare	This work was supported by the Swedish Research Council (grant number 522-2010-2683) and Karolinska Institutet funds for doctoral education, the Swedish Research Council for Health, Working Life and Welfare.	Alexanderson K, 2004, SCAND J PUBLIC HEALT, V32, P12, DOI 10.1080/14034950410021808; ALLEBECK P, 1991, SCAND J SOC MED, V19, P242, DOI 10.1177/140349489101900405; Angst J, 2002, EUR ARCH PSY CLIN N, V252, P201, DOI 10.1007/s00406-002-0381-6; [Anonymous], 2013, SOC INS FIG 2013; Bjorkenstam Charlotte, 2015, Mult Scler J Exp Transl Clin, V1, p2055217315595638, DOI 10.1177/2055217315595638; Bjorkenstam C, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1247; Blakely TA, 2003, J EPIDEMIOL COMMUN H, V57, P594, DOI 10.1136/jech.57.8.594; Bryngelson A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067887; Burns BJ, 2000, INT J PSYCHIAT MED, V30, P127, DOI 10.2190/TLXJ-YXLX-F4YA-6PHA; Chen Q, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3769; Ejlertsson G, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-20; Elliott Jane, 2013, LIFE COURSE APPROACH, P118; Ferrie JE, 2011, OCCUP ENVIRON MED, V68, P729, DOI 10.1136/oem.2010.060210; Floderus B, 2005, J REHABIL MED, V37, P291, DOI 10.1080/16501970510034422; Gjesdal S, 2009, SCAND J PUBLIC HEALT, V37, P168, DOI 10.1177/1403494808100937; Goldston K, 2008, CLIN PSYCHOL REV, V28, P288, DOI 10.1016/j.cpr.2007.05.005; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; Ishtiak-Ahmed K, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-492; Janssens H, 2014, EUR J PUBLIC HEALTH, V24, P428, DOI 10.1093/eurpub/cku009; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Jonsson U, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002286; Karlsson NE, 2007, SCAND J PUBLIC HEALT, V35, P341, DOI 10.1080/14034940601159229; Kivimaki M, 2003, BRIT MED J, V327, P364, DOI 10.1136/bmj.327.7411.364; Knudsen AK, 2013, ACTA PSYCHIAT SCAND, V127, P287, DOI 10.1111/j.1600-0447.2012.01902.x; Leone SS, 2010, BRIT J PSYCHIAT, V197, P86, DOI 10.1192/bjp.bp.109.076604; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Mittendorfer-Rutz E, 2004, LANCET, V364, P1135, DOI 10.1016/S0140-6736(04)17099-2; Mittendorfer-Rutz E., 2012, PLOS ONE, V7, P1; Runeson BS, 1996, ACTA PSYCHIAT SCAND, V93, P35, DOI 10.1111/j.1600-0447.1996.tb10616.x; Socialstyrelsen, 2009, CAUS DEATH REG; STANSFELD S, 1995, SOC SCI MED, V40, P189, DOI 10.1016/0277-9536(94)E0064-Y; TAYLOR PJ, 1972, P ROY SOC MED, V65, P577, DOI 10.1177/003591577206500634; Taylor R, 1998, SOC SCI MED, V47, P1677, DOI 10.1016/S0277-9536(98)00243-3; Thorsen SV, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-115; Virtanen M, 2015, DIABET MED; Wallman T, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-103; Wang M, 2014, OCCUP ENVIRON MED, V71, P12, DOI 10.1136/oemed-2013-101462; World Health Organization, 2009, EUR HLTH ALL DAT	38	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2015	10	10							e0139937	10.1371/journal.pone.0139937	http://dx.doi.org/10.1371/journal.pone.0139937			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CT0TS	26444997	Green Published, Green Submitted, gold			2023-01-03	WOS:000362510600109
J	Schroder, H; Komljenovic, D; Hecker, M; Korff, T				Schroeder, Hannes; Komljenovic, Dorde; Hecker, Markus; Korff, Thomas			Transdermal drug targeting and functional imaging of tumor blood vessels in the mouse auricle	FASEB JOURNAL			English	Article						angiogenesis; blood vessel growth; bortezomib; mouse model; perfusion	UBIQUITIN-PROTEASOME SYSTEM; FLOW-INDUCED DILATION; ANTIANGIOGENIC THERAPY; DOPPLER ULTRASOUND; MULTIPLE-MYELOMA; MULTICELLULAR SPHEROIDS; COMPUTED-TOMOGRAPHY; ACTIVATOR PROTEIN-1; GENE-EXPRESSION; MICRO-CT	Subcutaneously growing tumors are widely utilized to study tumor angiogenesis and the efficacy of antiangiogenic therapies in mice. To additionally assess functional and morphologic alterations of the vasculature in the periphery of a growing tumor, we exploited the easily accessible and hierarchically organized vasculature of the mouse auricle. By site-specific subcutaneous implantation of a defined preformed mouse B16/F0 melanoma aggregate, a solid tumor nodule developed within 14 d. Growth of the tumor nodule was accompanied by a 4-fold increase in its perfusion as well as a 2-to 4-fold elevated diameter and perfusion of peripheral blood vessels that had connected to the tumor capillary microvasculature. By transdermal application of the anticancer drug bortezomib, tumor growth was significantly diminished by about 50% without provoking side effects. Moreover, perfusion and tumor microvessel diameter as well as growth and perfusion of arterial or venous blood vessels supplying or draining the tumor microvasculature were decreased under these conditions by up to 80%. Collectively, we observed that the progressive tumor growth is accompanied by the enlargement of supplying and draining extratumoral blood vessels. This process was effectively suppressed by bortezomib, thereby restricting the perfusion capacity of both extra and intratumoral blood vessels.	[Schroeder, Hannes; Hecker, Markus; Korff, Thomas] Heidelberg Univ, Div Cardiovasc Physiol, Inst Physiol & Pathophysiol, Neuenheimer Feld 326, D-69120 Heidelberg, Germany; [Komljenovic, Dorde] German Canc Res Ctr, Dept Med Phys Radiol, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Korff, T (corresponding author), Heidelberg Univ, Div Cardiovasc Physiol, Inst Physiol & Pathophysiol, Neuenheimer Feld 326, D-69120 Heidelberg, Germany.	korff@physiologie.uni-heidelberg.de			Deutsche Forschungsgemeinschaft [SFB TR 23]; Heidelberg University Faculty of Medicine; Krebs und Scharlach Stiftung Mannhein	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Heidelberg University Faculty of Medicine; Krebs und Scharlach Stiftung Mannhein	This work was supported in part by a grant from the Deutsche Forschungsgemeinschaft (SFB TR 23, project sections C5, C6, and Z1, Ursula M. Handel Animal Welfare Award), the Postdoc Fellowship Program of the Heidelberg University Faculty of Medicine, and the Krebs und Scharlach Stiftung Mannhein. The authors acknowledge the excellent technical assistance of G. Scheib (Heidelberg University) and K. Oehme (DKFZ, Heidelberg). Y. Sun (DKFZ, Heidelberg) is acknowledged for help in CT image processing.	Amiri KI, 2004, CANCER RES, V64, P4912, DOI 10.1158/0008-5472.CAN-04-0673; Barringhaus Kurt G, 2007, Exp Clin Cardiol, V12, P119; Brahimi-Horn C, 2001, TRENDS CELL BIOL, V11, pS32, DOI 10.1016/S0962-8924(01)02126-2; Bzyl J, 2013, EUR RADIOL, V23, P468, DOI 10.1007/s00330-012-2594-z; Carew JS, 2008, CANCER RES, V68, P4783, DOI 10.1158/0008-5472.CAN-07-6483; Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873; Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476; Demicheva E, 2008, CIRC RES, V103, P477, DOI 10.1161/CIRCRESAHA.108.177782; Drews O, 2010, CIRC RES, V107, P1094, DOI 10.1161/CIRCRESAHA.110.222364; Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21; Ehling J, 2014, AM J PATHOL, V184, P431, DOI 10.1016/j.ajpath.2013.10.014; Eisa F, 2012, EUR RADIOL, V22, P900, DOI 10.1007/s00330-011-2318-9; FALCONE JC, 1993, AM J PHYSIOL, V264, pH653, DOI 10.1152/ajpheart.1993.264.2.H653; Feldner A, 2011, FASEB J, V25, P3613, DOI 10.1096/fj.11-185975; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Goertz DE, 2002, CANCER RES, V62, P6371; Gomez-Bougie P, 2007, CANCER RES, V67, P5418, DOI 10.1158/0008-5472.CAN-06-4322; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kiessling F, 2004, NAT MED, V10, P1133, DOI 10.1038/nm1101; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; KUO L, 1990, AM J PHYSIOL, V259, pH1063, DOI 10.1152/ajpheart.1990.259.4.H1063; Lashinger LM, 2005, CANCER RES, V65, P4902, DOI 10.1158/0008-5472.CAN-04-3701; Lesinski GB, 2008, CANCER RES, V68, P8351, DOI 10.1158/0008-5472.CAN-08-0426; Limbourg A, 2009, NAT PROTOC, V4, P1737, DOI 10.1038/nprot.2009.185; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; MUELLERKLIESER W, 1987, J CANCER RES CLIN, V113, P101, DOI 10.1007/BF00391431; Pagan J, 2013, CIRC RES, V112, P1046, DOI 10.1161/CIRCRESAHA.112.300521; Palmowski M, 2008, CANCER RES, V68, P7042, DOI 10.1158/0008-5472.CAN-08-0285; Pascarella L, 2005, J VASC SURG, V41, P303, DOI 10.1016/j.jvs.2004.10.038; Patan S, 2001, CIRC RES, V89, P732, DOI 10.1161/hh2001.097872; Pfisterer L, 2014, FASEB J, V28, P3518, DOI 10.1096/fj.14-250464; Pfisterer L, 2012, CARDIOVASC RES, V96, P120, DOI 10.1093/cvr/cvs247; Pipp F, 2004, ARTERIOSCL THROM VAS, V24, P1664, DOI 10.1161/01.ATV.0000138028.14390.e4; Prior BM, 2004, AM J PHYSIOL-HEART C, V287, pH2434, DOI 10.1152/ajpheart.00398.2004; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Savai R, 2009, NEOPLASIA, V11, P48, DOI 10.1593/neo.81036; Scholz Dimitri, 2001, Angiogenesis, V4, P247, DOI 10.1023/A:1016094004084; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soriano GP, 2014, ANTIOXID REDOX SIGN, V21, P2419, DOI 10.1089/ars.2013.5794; Tung D, 2011, PHARMACOLOGY, V88, P100, DOI 10.1159/000330067; Tydlacka S, 2008, J NEUROSCI, V28, P13285, DOI 10.1523/JNEUROSCI.4393-08.2008; van Es RJJ, 1999, LAB ANIM-UK, V33, P175, DOI 10.1258/002367799780578372; Weathington NM, 2013, AM J RESP CRIT CARE, V188, P530, DOI 10.1164/rccm.201304-0754PP; Xuan JW, 2007, CANCER RES, V67, P2830, DOI 10.1158/0008-5472.CAN-06-3944; YUHAS JM, 1977, CANCER RES, V37, P3639; ZAMORA PO, 1980, CANCER RES, V40, P4631	47	2	2	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2016	30	2					923	932		10.1096/fj.15-279240	http://dx.doi.org/10.1096/fj.15-279240			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DC7IA	26546130				2023-01-03	WOS:000369391900039
J	Natsume, Y; Toyota, T				Natsume, Yuno; Toyota, Taro			Asymmetrical Polyhedral Configuration of Giant Vesicles Induced by Orderly Array of Encapsulated Colloidal Particles	PLOS ONE			English	Article							EQUATION-OF-STATE; HARD-SPHERES; EMULSION	Giant vesicles (GVs) encapsulating colloidal particles by a specific volume fraction show a characteristic configuration under a hypertonic condition. Several flat faces were formed in GV membrane with orderly array of inner particles. GV shape changed from the spherical to the asymmetrical polyhedral configuration. This shape deformation was derived by entropic interaction between inner particles and GV membrane. Because a part of inner particles became to form an ordered phase in the region neighboring the GV membrane, free volume for the other part of particles increased. Giant vesicles encapsulating colloidal particles were useful for the model of "crowding effect" which is the entropic interaction in the cell.	[Natsume, Yuno] Japan Womens Univ, Fac Sci, Dept Math & Phys Sci, Tokyo 112, Japan; [Toyota, Taro] Univ Tokyo, Res Ctr Complex Syst Biol, Tokyo, Japan; [Toyota, Taro] Univ Tokyo, Grad Sch Arts & Sci, Dept Basic Sci, Tokyo, Japan	Japan Womens University; University of Tokyo; University of Tokyo	Toyota, T (corresponding author), Univ Tokyo, Res Ctr Complex Syst Biol, Tokyo, Japan.	cttoyota@mail.ecc.u-tokyo.ac.jp			Science Research Promotion Fund [23];  [24104004]	Science Research Promotion Fund; 	The Science Research Promotion Fund (YN, No. 23), Grant-in-Aid for Scientific Research on Innovative Areas "Molecular Robotics" (TT, No. 24104004).	CARNAHAN NF, 1969, J CHEM PHYS, V51, P635, DOI 10.1063/1.1672048; Castellana ET, 2006, SURF SCI REP, V61, P429, DOI 10.1016/j.surfrep.2006.06.001; Cook PR, 2009, J CELL BIOL, V186, P825, DOI 10.1083/jcb.200903083; Dinsmore AD, 1998, PHYS REV LETT, V80, P409, DOI 10.1103/PhysRevLett.80.409; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Ellis RJ, 2003, NATURE, V425, P27, DOI 10.1038/425027a; Fujiwara K, 2014, ACS SYNTH BIOL, V3, P870, DOI 10.1021/sb4001917; HALL KR, 1972, J CHEM PHYS, V57, P2252, DOI 10.1063/1.1678576; HOOVER WG, 1968, J CHEM PHYS, V49, P3609, DOI 10.1063/1.1670641; Kinoshita Masahiro, 2013, Biophys Rev, V5, P283, DOI 10.1007/s12551-013-0100-8; Miyoshi D, 2008, BIOCHIMIE, V90, P1040, DOI 10.1016/j.biochi.2008.02.009; Natsume Y, 2013, CHEM LETT, V42, P295, DOI 10.1246/cl.2013.295; Natsume Y, 2010, SOFT MATTER, V6, P5359, DOI 10.1039/c0sm00396d; Negishi M, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.061921; Pautot S, 2003, P NATL ACAD SCI USA, V100, P10718, DOI 10.1073/pnas.1931005100; Pautot S, 2003, LANGMUIR, V19, P2870, DOI 10.1021/la026100v; Terasawa H, 2012, P NATL ACAD SCI USA, V109, P5942, DOI 10.1073/pnas.1120327109; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	18	5	5	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0146683	10.1371/journal.pone.0146683	http://dx.doi.org/10.1371/journal.pone.0146683			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6CA	26752650	Green Submitted, Green Published, gold			2023-01-03	WOS:000367888100129
J	Riggare, S				Riggare, Sara			Self referral to physiotherapy and other services would empower patients and doctors	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Riggare, Sara] Karolinska Inst, Hlth Informat Ctr, Dept Learning Informat Management & Eth, S-17177 Stockholm, Sweden	Karolinska Institutet	Riggare, S (corresponding author), Karolinska Inst, Hlth Informat Ctr, Dept Learning Informat Management & Eth, S-17177 Stockholm, Sweden.	sara.riggare@ki.se		Riggare, Sara/0000-0002-2256-7310				DOSHAY LJ, 1962, NEW ENGL J MED, V266, P878, DOI 10.1056/NEJM196204262661709; Ferguson T, 2004, BMJ-BRIT MED J, V328, P1148, DOI 10.1136/bmj.328.7449.1148; Fox S, 2008, ENGAGED E PATIENT PO; Kremer JAM, 2011, MINERVA MED, V102, P505; Krey J, 2015, DAGENS MED; Marshall M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2117; Stockholm County Council, 2015, PROJ 4D ARTR	7	1	1	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 5	2016	352								h6977	10.1136/bmj.h6977	http://dx.doi.org/10.1136/bmj.h6977			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA8MA	26733363				2023-01-03	WOS:000368057800007
J	Rad, SK; Kanthimathi, MS; Abd Malek, SN; Lee, GS; Looi, CY; Wong, WF				Rad, Sima Kianpour; Kanthimathi, M. S.; Abd Malek, Sri Nurestri; Lee, Guan Serm; Looi, Chung Yeng; Wong, Won Fen			Cinnamomum cassia Suppresses Caspase-9 through Stimulation of AKT1 in MCF-7 Cells but Not in MDA-MB-231 Cells	PLOS ONE			English	Article							INDUCED APOPTOSIS; GLUTATHIONE-PEROXIDASE; MITOCHONDRIAL DAMAGE; SUPEROXIDE-DISMUTASE; ANTIOXIDANT ACTIVITY; CANCER; BARK; P53; INHIBITORS; INDUCTION	Background Cinnamomum cassia bark is a popular culinary spice used for flavoring and in traditional medicine. C. cassia extract (CE) induces apoptosis in many cell lines. In the present study, particular differences in the mechanism of the anti-proliferative property of C. cassia on two breast cancer cell lines, MCF-7 and MDA-MB-231, were elucidated. Methodology/Principal Findings The hexane extract of C. cassia demonstrated high anti-proliferative activity against MCF-7 and MDA-MB-231 cells (IC50, 34 +/- 3.52 and 32.42 +/- 0.37 mu g/ml, respectively). Oxidative stress due to disruption of antioxidant enzyme (SOD, GPx and CAT) activity is suggested as the probable cause for apoptosis initiation. Though the main apoptosis pathway in both cell lines was found to be through caspase-8 activation, caspase-9 was also activated in MDA-MB-231 cells but suppressed in MCF-7 cells. Gene expression studies revealed that AKT1, the caspase-9 suppressor, was up-regulated in MCF-7 cells while down-regulated in MDA-MB-231 cells. Although, AKT1 protein expression in both cell lines was down-regulated, a steady increase in MCF-7 cells was observed after a sharp decrease of suppression of AKT1. Trans-cinnamaldehyde and coumarin were isolated and identified and found to be mainly responsible for the observed anti-proliferative activity of CE (Cinnamomum cassia). Conclusion Activation of caspase-8 is reported for the first time to be involved as the main apoptosis pathway in breast cancer cell lines upon treatment with C. cassia. The double effects of C. cassia on AKT1 gene expression in MCF-7 cells is reported for the first time in this study.	[Rad, Sima Kianpour; Kanthimathi, M. S.] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur, Malaysia; [Kanthimathi, M. S.] Univ Malaya, Fac Med, UMCPR, Ctr Prote Res, Kuala Lumpur, Malaysia; [Abd Malek, Sri Nurestri; Lee, Guan Serm] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur, Malaysia; [Looi, Chung Yeng] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia; [Wong, Won Fen] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia	Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya	Kanthimathi, MS (corresponding author), Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur, Malaysia.	kanthi@ummc.edu.my	Malek, Sri Nurestri Abd/B-9834-2010; Kianpour Rad, Sima/AAC-5642-2022; Wong, Won Fen/D-3087-2012; Malek, Sri Nurestri/W-8556-2019; LEE, GUAN SERM/B-8833-2010	Malek, Sri Nurestri Abd/0000-0001-6278-8559; Wong, Won Fen/0000-0003-1082-1956; Malek, Sri Nurestri/0000-0001-6278-8559; LEE, GUAN SERM/0000-0002-8386-4976	University of Malaya Research University [UMRG RG290-14AFR, RP027A-14HTM]; University of Malaya	University of Malaya Research University; University of Malaya(Universiti Malaya)	This research was supported by University of Malaya Research University grants, UMRG RG290-14AFR and RP027A-14HTM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors wish to thank the University of Malaya for financial support.	Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; Amaral JD, 2010, DISCOV MED, V9, P145; Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Araujo JR, 2011, NUTR RES, V31, P77, DOI 10.1016/j.nutres.2011.01.006; Arbab IA, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/856029; Assadollahi V, 2013, ADV BIOMEDICAL RES, P2; Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]; Blanc C, 2000, CANCER RES, V60, P4386; Cardo-Vila M, 2003, MOL CELL, V11, P1151, DOI 10.1016/S1097-2765(03)00138-2; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chuang JY, 2007, IN VIVO, V21, P1003; Ciapetti G, 2002, BIOMATERIALS, V23, P617, DOI 10.1016/S0142-9612(01)00149-1; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; D'Archivio M, 2008, INT J MOL SCI, V9, P213, DOI 10.3390/ijms9030213; de Fatima A, 2006, BIOORGAN MED CHEM, V14, P622, DOI 10.1016/j.bmc.2005.08.036; Dejean LM, 2006, CELL DEATH DIFFER, V13, P1387, DOI 10.1038/sj.cdd.4401949; Downward J, 2004, SEMINARS CELL DEV BI; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Evens AM, 2005, BLOOD, V105, P1265, DOI 10.1182/blood-2004-03-0964; Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x; Fesik SW, 2001, SCIENCE, V294, P1477, DOI 10.1126/science.1062236; Franco-Molina MA, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-148; Frydman-Marom A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016564; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Gerhauser C, 2003, MUTAT RES-FUND MOL M, V523, P163, DOI 10.1016/S0027-5107(02)00332-9; GONZALES R, 1984, CANCER RES, V44, P4137; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; Kim IG, 2008, ENVIRON TOXICOL PHAR, V25, P75, DOI 10.1016/j.etap.2007.09.002; Koppikar SJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-210; Kuete V, 2010, FRONT PHARMACOL, V1, DOI 10.3389/fphar.2010.00123; Lahiry L, 2008, APOPTOSIS, V13, P771, DOI 10.1007/s10495-008-0213-x; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Lee KH, 2006, PHYTOTHER RES, V20, P952, DOI 10.1002/ptr.1984; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lopez-Gonzalez JS, 2004, LUNG CANCER-J IASLC, V43, P275, DOI 10.1016/j.lungcan.2003.09.005; Lopez-Lazaro M, 2007, CANCER LETT, V252, P1, DOI 10.1016/j.canlet.2006.10.029; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND SL, 1982, CANCER RES, V42, P1955; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; O'Mahony R, 2005, WORLD J GASTROENTERO, V11, P7499, DOI 10.3748/wjg.v11.i47.7499; Peter K. V, 2006, HDB HERBS SPICES, V3; Rashad AE, 2010, ARCH PHARM, V343, P440, DOI 10.1002/ardp.201000002; Rasul A, 2011, ASIAN PAC J CANCER P, V12, P1219; Riveiro ME, 2008, BIOORGAN MED CHEM, V16, P2665, DOI 10.1016/j.bmc.2007.11.038; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Shklyar B, 2013, MOL CELL BIOL, V33, P3191, DOI 10.1128/MCB.00233-13; Tang ELH, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-347; Tomaino A, 2005, FOOD CHEM, V89, P549, DOI 10.1016/j.foodchem.2004.03.011; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tsuji-Naito K, 2008, BIOORGAN MED CHEM, V16, P9176, DOI 10.1016/j.bmc.2008.09.036; Watanabe Y, 2013, J ALLERGY CLIN IMMUN, V132, P648, DOI 10.1016/j.jaci.2013.03.046; Wondrak GT, 2010, MOLECULES, V15, P3338, DOI 10.3390/molecules15053338; Wu SJ, 2007, FOOD CHEM TOXICOL, V45, P2446, DOI 10.1016/j.fct.2007.05.032; Yang PM, 2012, INT J ONCOL, V40, P469, DOI 10.3892/ijo.2011.1203; Yu YB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009339; Zhang JH, 2010, ACTA PHARMACOL SIN, V31, P861, DOI 10.1038/aps.2010.76; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zu YG, 2010, MOLECULES, V15, P3200, DOI 10.3390/molecules15053200	60	19	20	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0145216	10.1371/journal.pone.0145216	http://dx.doi.org/10.1371/journal.pone.0145216			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SI	26700476	Green Published, gold			2023-01-03	WOS:000367092600053
J	Young, R; Gill, JJ				Young, Ry; Gill, Jason J.			Phage therapy redux - What is to be done?	SCIENCE			English	Editorial Material							BACTERIOPHAGE		[Young, Ry; Gill, Jason J.] Texas A&M Univ, Ctr Phage Technol, College Stn, TX 77843 USA; [Young, Ry] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; [Gill, Jason J.] Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Young, R (corresponding author), Texas A&M Univ, Ctr Phage Technol, College Stn, TX 77843 USA.	ryland@tamu.edu; jason.gill@tamu.edu		Young, Ry/0000-0001-8001-2914; Gill, Jason/0000-0002-9494-6053	NIAID NIH HHS [R13 AI069717] Funding Source: Medline; NIGMS NIH HHS [R37 GM027099, R01 GM027099] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R13AI069717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027099, R37GM027099] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando H, 2015, CELL SYST, V1, P187, DOI 10.1016/j.cels.2015.08.013; Barr JJ, 2015, P NATL ACAD SCI USA, V112, P13675, DOI 10.1073/pnas.1508355112; Brussow H, 2002, CELL, V108, P13, DOI 10.1016/S0092-8674(01)00637-7; Fischetti VA, 2008, CURR OPIN MICROBIOL, V11, P393, DOI 10.1016/j.mib.2008.09.012; Ge P, 2015, NAT STRUCT MOL BIOL, V22, P377, DOI 10.1038/nsmb.2995; Ghequire MGK, 2015, TRENDS MICROBIOL, V23, P587, DOI 10.1016/j.tim.2015.07.011; Gill J, 2011, EMERGING TRENDS IN ANTIBACTERIAL DISCOVERY: ANSWERING THE CALL TO ARMS, P367; Nannapaneni R, 2015, BIOFILMS FOOD ENV, P131; Nobrega FL, 2015, TRENDS MICROBIOL, V23, P185, DOI 10.1016/j.tim.2015.01.006; Reyes A, 2013, P NATL ACAD SCI USA, V110, P20236, DOI 10.1073/pnas.1319470110; Summers WC, 2001, ANNU REV MICROBIOL, V55, P437, DOI 10.1146/annurev.micro.55.1.437; Williams SR, 2008, APPL ENVIRON MICROB, V74, P3868, DOI 10.1128/AEM.00141-08	12	79	87	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	2015	350	6265					1163	1164		10.1126/science.aad6791	http://dx.doi.org/10.1126/science.aad6791			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX4WG	26785457	Green Accepted			2023-01-03	WOS:000365700500042
J	Kuzmina, A; Vaknin, K; Gdalevsky, G; Vyazmensky, M; Marks, RS; Taube, R; Engel, S				Kuzmina, Alona; Vaknin, Karin; Gdalevsky, Garik; Vyazmensky, Maria; Marks, Robert S.; Taube, Ran; Engel, Stanislav			Functional Mimetics of the HIV-1 CCR5 Co-Receptor Displayed on the Surface of Magnetic Liposomes	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GP120 ENVELOPE GLYCOPROTEIN; SOLUBLE CD4; N-TERMINUS; CHEMOKINE; BINDING; ENTRY; RECEPTOR; PEPTIDE; COMPLEX	Chemokine G protein coupled receptors, principally CCR5 or CXCR4, function as co-receptors for HIV-1 entry into CD4(+) T cells. Initial binding of the viral envelope glycoprotein (Env) gp120 subunit to the host CD4 receptor induces a cascade of structural conformational changes that lead to the formation of a high-affinity co-receptor-binding site on gp120. Interaction between gp120 and the co-receptor leads to the exposure of epitopes on the viral gp41 that mediates fusion between viral and cell membranes. Soluble CD4 (sCD4) mimetics can act as an activation-based inhibitor of HIV-1 entry in vitro, as it induces similar structural changes in gp120, leading to increased virus infectivity in the short term but to virus Env inactivation in the long term. Despite promising clinical implications, sCD4 displays low efficiency in vivo, and in multiple HIV strains, it does not inhibit viral infection. This has been attributed to the slow kinetics of the sCD4-induced HIV Env inactivation and to the failure to obtain sufficient sCD4 mimetic levels in the serum. Here we present uniquely structured CCR5 co-receptor mimetics. We hypothesized that such mimetics will enhance sCD4-induced HIV Env inactivation and inhibition of HIV entry. Co-receptor mimetics were derived from CCR5 gp120-binding epitopes and functionalized with a palmitoyl group, which mediated their display on the surface of lipid-coated magnetic beads. CCR5-peptido-liposome mimetics bound to soluble gp120 and inhibited HIV-1 infectivity in a sCD4-dependent manner. We concluded that CCR5-peptidoliposomes increase the efficiency of sCD4 to inhibit HIV infection by acting as bait for sCD4-primed virus, catalyzing the premature discharge of its fusion potential.	[Kuzmina, Alona; Taube, Ran] Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol & Immunol, Beer Sheva, Israel; [Vaknin, Karin; Gdalevsky, Garik; Engel, Stanislav] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem & Pharmacol, Beer Sheva, Israel; [Vyazmensky, Maria; Marks, Robert S.; Engel, Stanislav] Natl Inst Biotechnol Negev, Beer Sheva, Israel; [Marks, Robert S.] Ben Gurion Univ Negev, Fac Engn, Dept Biotechnol Engn, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University; Ben Gurion University	Taube, R (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol & Immunol, Beer Sheva, Israel.	engels@bgu.ac.il; rantaube@bgu.ac.il	TAUBE, RAN/F-2029-2012; MARKS, ROBERT/AAS-4746-2020; Engel, Stanislav/G-2799-2013	TAUBE, RAN/0000-0002-2062-4537; Engel, Stanislav/0000-0001-5916-5190; Marks, Robert/0000-0002-9697-3805	Chief Scientist Office of the Ministry of Health, Israel [3-00000-7445]; HEZNEK grant from Ben-Gurion University of the Negev, Israel	Chief Scientist Office of the Ministry of Health, Israel; HEZNEK grant from Ben-Gurion University of the Negev, Israel	This study was supported by grant no. 3-00000-7445 from the Chief Scientist Office of the Ministry of Health, Israel and the HEZNEK grant from Ben-Gurion University of the Negev, Israel. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Babcock GJ, 2001, J BIOL CHEM, V276, P38433, DOI 10.1074/jbc.M106229200; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; Cormier EG, 2002, J VIROL, V76, P8953, DOI 10.1128/JVI.76.17.8953-8957.2002; Cormier EG, 2001, J VIROL, V75, P5541, DOI 10.1128/JVI.75.12.5541-5549.2001; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; De Feo CJ, 2012, VIRUSES-BASEL, V4, P3859, DOI 10.3390/v4123859; Devesa F, 2002, EUR J BIOCHEM, V269, P5163, DOI 10.1046/j.1432-1033.2002.03213.x; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Gardner MR, 2015, NATURE, V519, P87, DOI 10.1038/nature14264; Haim H, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000360; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; Huang CC, 2005, STRUCTURE, V13, P755, DOI 10.1016/j.str.2005.03.006; Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373; Hutchings CJ, 2010, MABS-AUSTIN, V2, P594, DOI 10.4161/mabs.2.6.13420; Khurana S, 2005, J VIROL, V79, P6791, DOI 10.1128/JVI.79.11.6791-6800.2005; Kitagawa K, 2001, J ORG CHEM, V66, P1, DOI 10.1021/jo000895y; Klasse PJ, 2012, CELL MICROBIOL, V14, P1183, DOI 10.1111/j.1462-5822.2012.01812.x; Kolchinsky P, 2001, J VIROL, V75, P3435, DOI 10.1128/JVI.75.7.3435-3443.2001; Kuzmina A, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-51; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lam SN, 2008, BIOORGAN MED CHEM, V16, P10113, DOI 10.1016/j.bmc.2008.10.005; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Lee H, 2009, J PHYS CHEM B, V113, P13186, DOI 10.1021/jp9058966; Lobritz MA, 2010, VIRUSES-BASEL, V2, P1069, DOI 10.3390/v2051069; Madani N, 2008, STRUCTURE, V16, P1689, DOI 10.1016/j.str.2008.09.005; Martin G, 2008, VIROLOGY, V381, P241, DOI 10.1016/j.virol.2008.08.039; Mirzabekov T, 2000, NAT BIOTECHNOL, V18, P649, DOI 10.1038/76501; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; Moseri A, 2014, FEBS J, V281, P3019, DOI 10.1111/febs.12839; ORLOFF SL, 1993, J VIROL, V67, P1461, DOI 10.1128/JVI.67.3.1461-1471.1993; Rizzuto C, 2000, AIDS RES HUM RETROV, V16, P741, DOI 10.1089/088922200308747; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Schnur E, 2011, J MOL BIOL, V410, P778, DOI 10.1016/j.jmb.2011.04.023; Schon A, 2006, BIOCHEMISTRY-US, V45, P10973, DOI 10.1021/bi061193r; Selhorst P, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-12; Tan QX, 2013, SCIENCE, V341, P1387, DOI 10.1126/science.1241475; Van Herrewege Y, 2008, J ANTIMICROB CHEMOTH, V61, P818, DOI 10.1093/jac/dkn042; Xiang SH, 2010, J VIROL, V84, P3147, DOI 10.1128/JVI.02587-09; Young T, 2002, ANGEW CHEM INT EDIT, V41, P3449, DOI 10.1002/1521-3773(20020916)41:18<3449::AID-ANIE3449>3.0.CO;2-U; Zhukovsky MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013249	44	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2015	10	12							e0144043	10.1371/journal.pone.0144043	http://dx.doi.org/10.1371/journal.pone.0144043			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX8BI	26629902	gold, Green Submitted, Green Published			2023-01-03	WOS:000365926300144
J	Ming, X; Feng, YM; Liu, H; Zhang, Y; Zhou, L; Deng, J				Ming, Xin; Feng, Yuanming; Liu, Huan; Zhang, Ying; Zhou, Li; Deng, Jun			Cardiac Exposure in the Dynamic Conformal Arc Therapy, Intensity-Modulated Radiotherapy and Volumetric Modulated Arc Therapy of Lung Cancer	PLOS ONE			English	Article							BODY RADIATION-THERAPY; EARLY BREAST-CANCER; HEART-DISEASE; LONG-TERM; CARDIOVASCULAR-DISEASE; CHILDHOOD-CANCER; HODGKIN LYMPHOMA; RISK; MORTALITY; TOXICITY	Purpose To retrospectively evaluate the cardiac exposure in three cohorts of lung cancer patients treated with dynamic conformal arc therapy (DCAT), intensity-modulated radiotherapy (IMRT), or volumetric modulated arc therapy (VMAT) at our institution in the past seven years. Methods and Materials A total of 140 lung cancer patients were included in this institutional review board approved study: 25 treated with DCAT, 70 with IMRT and 45 with VMAT. All plans were generated in a same commercial treatment planning system and have been clinically accepted and delivered. The dose distribution to the heart and the effects of tumor laterality, the irradiated heart volume and the beam-to-heart distance on the cardiac exposure were investigated. Results The mean dose to the heart among all 140 plans was 4.5 Gy. Specifically, the heart received on average 2.3, 5.2 and 4.6 Gy in the DCAT, IMRT and VMAT plans, respectively. The mean heart doses for the left and right lung tumors were 4.1 and 4.8 Gy, respectively. No patients died with evidence of cardiac disease. Three patients (2%) with preexisting cardiac condition developed cardiac disease after treatment. Furthermore, the cardiac exposure was found to increase linearly with the irradiated heart volume while decreasing exponentially with the beam-to-heart distance. Conclusions Compared to old technologies for lung cancer treatment, modern radiotherapy treatment modalities demonstrated better heart sparing. But the heart dose in lung cancer radiotherapy is still higher than that in the radiotherapy of breast cancer and Hodgkin's disease where cardiac complications have been extensively studied. With strong correlations of mean heart dose with beam-to-heart distance and irradiated heart volume, cautions should be exercised to avoid long-term cardiac toxicity in the lung cancer patients undergoing radiotherapy.	[Ming, Xin; Feng, Yuanming; Zhang, Ying] Tianjin Univ, Dept Biomed Engn, Tianjin 300072, Peoples R China; [Ming, Xin; Zhang, Ying; Deng, Jun] Yale Univ, Dept Therapeut Radiol, New Haven, CT 06520 USA; [Liu, Huan; Deng, Jun] Yale New Haven Med Ctr, Dept Therapeut Radiol, New Haven, CT 06504 USA; [Zhou, Li] Sichuan Univ, West China Hosp, Ctr Canc, Ctr Radiat Phys & Technol, Chengdu 610064, Peoples R China	Tianjin University; Yale University; Yale University; Sichuan University	Deng, J (corresponding author), Yale Univ, Dept Therapeut Radiol, New Haven, CT 06520 USA.	jun.deng@yale.edu			Fellowship of China Scholarship Council [201206250086]	Fellowship of China Scholarship Council	This work was supported by the Fellowship of China Scholarship Council #201206250086.	Adams MJ, 2003, CRIT REV ONCOL HEMAT, V45, P55, DOI 10.1016/S1040-8428(01)00227-X; Aleman BMP, 2007, BLOOD, V109, P1878, DOI 10.1182/blood-2006-07-034405; American Cancer Society, 2015, CANC FACTS FIG 2015; Andratschke N, 2011, RADIOTHER ONCOL, V100, P160, DOI 10.1016/j.radonc.2010.08.010; Belliere A, 2009, CANCER RADIOTHER, V13, P298, DOI 10.1016/j.canrad.2009.04.004; Bezjak A, 2014, NRG ONCOLOGY RTOG 08; Borger JH, 2007, INT J RADIAT ONCOL, V69, P1131, DOI 10.1016/j.ijrobp.2007.04.042; Bradley J, 2014, RAD THERAPY ONCOLOGY; Brenner DJ, 2014, JAMA INTERN MED, V174, P158, DOI 10.1001/jamainternmed.2013.11790; Carr ZA, 2005, INT J RADIAT ONCOL, V61, P842, DOI 10.1016/j.ijrobp.2004.07.708; Castellino SM, 2011, BLOOD, V117, P1806, DOI 10.1182/blood-2010-04-278796; Chargari Cyrus, 2013, Presse Med, V42, pe342, DOI 10.1016/j.lpm.2013.06.012; Darby S, 2003, BRIT MED J, V326, P256, DOI 10.1136/bmj.326.7383.256; Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825; Darby SC, 2010, INT J RADIAT ONCOL, V76, P656, DOI 10.1016/j.ijrobp.2009.09.064; Darby SC, 2005, LANCET ONCOL, V6, P557, DOI 10.1016/S1470-2045(05)70251-5; Demirci S, 2009, INT J RADIAT ONCOL, V73, P980, DOI 10.1016/j.ijrobp.2008.11.016; Fakiris AJ, 2009, INT J RADIAT ONCOL, V75, P677, DOI 10.1016/j.ijrobp.2008.11.042; Gagliardi G, 2010, INT J RADIAT ONCOL, V76, pS77, DOI 10.1016/j.ijrobp.2009.04.093; Gai J, 2014, MED PHYS, V41, DOI [10.1118/1.4856175, DOI 10.1118/1.4856175]; Gayed I, 2009, INT J CARDIOVAS IMAG, V25, P487, DOI 10.1007/s10554-009-9440-7; Grills IS, 2003, INT J RADIAT ONCOL, V57, P875, DOI 10.1016/S0360-3016(03)00743-0; Hardy D, 2010, ANN ONCOL, V21, P1825, DOI 10.1093/annonc/mdq042; Holt A, 2011, INT J RADIAT ONCOL, V81, P1560, DOI 10.1016/j.ijrobp.2010.09.014; Hooning MJ, 2007, JNCI-J NATL CANCER I, V99, P365, DOI 10.1093/jnci/djk064; Jaworski C, 2013, J AM COLL CARDIOL, V61, P2319, DOI 10.1016/j.jacc.2013.01.090; Lally BE, 2007, CANCER-AM CANCER SOC, V110, P911, DOI 10.1002/cncr.22845; Lilenbaum R, 2008, RAD THERAPY ONCOLOGY; Little MP, 2012, INT J RADIAT ONCOL, V84, P1101, DOI 10.1016/j.ijrobp.2012.01.053; Marks LB, 2010, INT J RADIAT ONCOL, V76, pS10, DOI 10.1016/j.ijrobp.2009.07.1754; Martel MK, 1998, INT J RADIAT ONCOL, V40, P155, DOI 10.1016/S0360-3016(97)00584-1; McGale P, 2011, RADIOTHER ONCOL, V100, P167, DOI 10.1016/j.radonc.2011.06.016; Merrow CE, 2012, J APPL CLIN MED PHYS, V14, P4110; Mulrooney DA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4606; Prosnitz RG, 2005, SEMIN ONCOL, V32, pS71, DOI 10.1053/j.seminoncol.2005.03.013; Schytte T, 2010, ACTA ONCOL, V49, P1058, DOI 10.3109/0284186X.2010.504736; Steingart RM, 2013, SEMIN ONCOL, V40, P690, DOI 10.1053/j.seminoncol.2013.09.010; Swerdlow AJ, 2007, J NATL CANCER I, V99, P206, DOI 10.1093/jnci/djk029; Takeda A, 2009, INT J RADIAT ONCOL, V74, P363, DOI 10.1016/j.ijrobp.2008.08.012; Taylor CW, 2009, INT J RADIAT ONCOL, V73, P1061, DOI 10.1016/j.ijrobp.2008.05.066; Taylor CW, 2008, INT J RADIAT ONCOL, V72, P501, DOI 10.1016/j.ijrobp.2007.12.058; Taylor CW, 2007, INT J RADIAT ONCOL, V69, P1484, DOI 10.1016/j.ijrobp.2007.05.034; Taylor CW, 2011, RADIOTHER ONCOL, V100, P176, DOI 10.1016/j.radonc.2011.01.020; Timmerman R, 2010, JAMA-J AM MED ASSOC, V303, P1070, DOI 10.1001/jama.2010.261; Tukenova M, 2010, J CLIN ONCOL, V28, P1308, DOI 10.1200/JCO.2008.20.2267; Videtic GMM, 2012, NRG ONCOLOGY RTOG 09; Wei X, 2008, INT J RADIAT ONCOL, V70, P707, DOI 10.1016/j.ijrobp.2007.10.056	47	7	7	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2015	10	12							e0144211	10.1371/journal.pone.0144211	http://dx.doi.org/10.1371/journal.pone.0144211			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX8BI	26630566	Green Submitted, Green Published, gold			2023-01-03	WOS:000365926300170
J	Tomaszewski, P				Tomaszewski, Piotr			Constraints on Negative Prefixation in Polish Sign Language	PLOS ONE			English	Article								The aim of this article is to describe a negative prefix, NEG-, in Polish Sign Language (PJM) which appears to be indigenous to the language. This is of interest given the relative rarity of prefixes in sign languages. Prefixed PJM signs were analyzed on the basis of both a corpus of texts signed by 15 deaf PJM users who are either native or near-native signers, and material including a specified range of prefixed signs as demonstrated by native signers in dictionary form (i.e. signs produced in isolation, not as part of phrases or sentences). In order to define the morphological rules behind prefixation on both the phonological and morphological levels, native PJM users were consulted for their expertise. The research results can enrich models for describing processes of grammaticalization in the context of the visual-gestural modality that forms the basis for sign language structure.	[Tomaszewski, Piotr] Univ Warsaw, Fac Psychol, Warsaw, Poland	University of Warsaw	Tomaszewski, P (corresponding author), Univ Warsaw, Fac Psychol, Warsaw, Poland.	piotr.tomaszewski@psych.uw.edu.pl		Tomaszewski, Piotr/0000-0002-4083-067X	Principal Research Fund of the Faculty of Psychology, University of Warsaw [BST 171223/2014, BST 174419/2015]	Principal Research Fund of the Faculty of Psychology, University of Warsaw	The author's work was supported by the Principal Research Fund of the Faculty of Psychology, University of Warsaw (BST 171223/2014, BST 174419/2015). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2005, PORADNIK JEZYKOWY, V3, P44; Antzakas K, 2006, THESIS; Aronoff M, 2005, LANGUAGE, V81, P301, DOI 10.1353/lan.2005.0043; Aronoff M, 2003, PERSPECTIVES ON CLASSIFIER CONSTRUCTIONS IN SIGN LANGUAGES, P53; Aronoff M, 2000, U MARYLAND WORKING P, V10, P1; Aronoff M, 2008, INTERACT STUD, V9, P133, DOI 10.1075/is.9.1.10aro; Aronoff M, 2005, YEARB MORPHOL, P19, DOI 10.1007/1-4020-2900-4_2; Battison R, 1974, SIGN LANGUAGE STUDIE, V5, P1, DOI DOI 10.1353/SLS.1974.0005; Battison R., 1978, LEXICAL BORROWING AM; Bauer Laurie, 2001, MORPHOLOGICAL PRODUC, DOI 10.1017/CBO9780511486210; Brennan M., 1992, DICT BRIT SIGN LANGU, P1, DOI DOI 10.1017/CBO9781139167048.002; Brennan Mary., 1990, WORD FORMATION BRIT; Brentari D., 1998, PROSODIC MODEL SIGN; Bybee Joan L., 1994, EVOLUTION GRAMMAR TE; Coulter G., 1990, LINGUISTICS, V1, P109; Heine Bernd., 2002, WORLD LEXICON GRAMMA; Hendriks B., 2008, JORDANIAN SIGN LANGU; Hollak J., 1879, SLOWNIK MIMICZNY GLU; Johnston T., 2007, AUSTR SIGN LANGUAGE; Kennedy G, 2002, CONCISE DICT NZ SIGN; Klima E.S., 1979, SIGNS LANGUAGE; Lesson L, 2012, IRISH SIGN LANGUAGE; Liddell Scott, 1989, SIGN LANG STUD, V64, P195, DOI DOI 10.1353/SLS.1989.0027; LIDDELL SK, 1984, LANGUAGE, V60, P372, DOI 10.2307/413645; Mathur G., 2014, OXFORD HDB LANGUAGE, P379, DOI [10.1093/oxfordhb/9780199735471.013.005, DOI 10.1093/OXFORDHB/9780199735471.013.005]; Meir I., 2004, SIGN LANG LING, V7, P97, DOI [DOI 10.1075/SLL.7.2.03MEI, 10.1075/sll.7.2.03mei]; Meir I., 2012, SIGN LANGUAGE INT HD, P77, DOI DOI 10.1515/9783110261325.77; Meir I, 2010, AMST STUD THEORY HIS, V311, P301; Meir Irit, 2008, LANGUAGE SPACE STORY; PADDEN CA, 1990, SIGN LANGUAGE RESEARCH, P118; Padden CA, 1988, OUTSTANDING DISSER 4; Pfau Roland., 2006, LINGUISTICS POTSDAM, V24, P3; Sandler W, 2006, SIGN LANGUAGE AND LINGUISTIC UNIVERSALS, P1, DOI 10.2277/ 0521483956; Sandler W, 1996, LINGUA, V98, P197, DOI 10.1016/0024-3841(95)00038-0; Sandler W, 2005, CONT LINGUISTICS INT, P343; Sandler W., 1989, PHONOLOGICAL REPRESE; Sandler W, 1990, LINGUISTICS, V1, P7; Sandler W, 2011, NAT LANG LINGUIST TH, V29, P503, DOI 10.1007/s11049-011-9128-2; Sandler W, 2010, T PHILOL SOC, V108, P298, DOI 10.1111/j.1467-968X.2010.01242.x; Sandler Wendy., 1999, STUDIES PHONOLOGICAL, P223, DOI DOI 10.1075/CILT.174.09SAN; Sandler Wendy, 2010, BLACKWELL COMPANION, P577; Sutton-Spence R., 1999, LINGUISTICS BRIT SIG; Sutton-Spence R., 2001, HANDS ARE HEAD MOUTH, P1; Tomaszewski P., 2005, PORADNIK JEZYKOWY, V2, P59; Tomaszewski P., 2010, STUDIES PSYCHOL LANG, P289; Tomaszewski P., 2010, FONOLOGIA WIZUALNA P; Valli Clayton., 2006, GALLAUDET DICT AM SI; Wilbur R., 1987, AM SIGN LANGUAGE SIG; Wilbur RB, 1999, LANG SPEECH, V42, P229, DOI 10.1177/00238309990420020501; Wojda P., 2010, SIGN LANGUAGES, P131, DOI [10.1017/cbo9780511712203.008, DOI 10.1017/CBO9780511712203.008]; WOODWARD J, 1977, LANG SOC, V6, P379, DOI 10.1017/S0047404500005078; Woodward James, 1974, SIGN LANGUAGE STUDIE, V5, P20, DOI DOI 10.1353/SLS.1974.0006; Yang J.H., 2002, SIGN LANG LINGUIST, V5, P167, DOI [https://doi.org/10.1075/sll.5.2.05yan, DOI 10.1075/SLL.5.2.05YAN, 10.1075/sll.5.2.05yan]; Zeshan U., 2004, LINGUIST TYPOL, V8, P1, DOI [10.1515/lity.2004.003, DOI 10.1515/LITY.2004.003]; Zeshan U., 2006, INTERROGATIVE NEGATI, P28, DOI 10.26530/OAPEN_453832; Zeshan Ulrike, 2000, SIGN LANGUAGE INDO P; Zipf G. K., 1949, HUMAN BEHAV PRINCIPL; ZWICKY AM, 1983, LANGUAGE, V59, P502, DOI 10.2307/413900	58	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2015	10	11							e0143574	10.1371/journal.pone.0143574	http://dx.doi.org/10.1371/journal.pone.0143574			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	CX7NW	26619066	Green Submitted, Green Published, gold			2023-01-03	WOS:000365889800048
J	Bae, MN; Kim, SH; Kim, YO; Jin, DC; Song, HC; Choi, EJ; Kim, YL; Kim, YS; Kang, SW; Kim, NH; Yang, CW; Kim, YK				Bae, Myoung Nam; Kim, Su Hyun; Kim, Young Ok; Jin, Dong Chan; Song, Ho Chul; Choi, Euy Jin; Kim, Yong-Lim; Kim, Yon-Su; Kang, Shin-Wook; Kim, Nam-Ho; Yang, Chul Woo; Kim, Yong Kyun			Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients	PLOS ONE			English	Article							LEFT-VENTRICULAR MASS; KIDNEY-DISEASE; ANEMIA; INDEX; HEMOGLOBIN; RESISTANCE; OUTCOMES; REGISTRY; THERAPY; COHORT	Erythropoiesis-stimulating agent (ESA) responsiveness has been reported to be associated with increased mortality in hemodialysis (HD) patients. ESA requirement to obtain the same hemoglobin (Hb) level is different between HD and peritoneal dialysis (PD) patients. In this study, we investigated the impact of ESA responsiveness on mortality between both HD and PD patients. Prevalent HD and PD patients were selected from the Clinical Research Center registry for end-stage renal disease, a prospective cohort study in Korea. ESA responsiveness was estimated using an erythropoietin resistant index (ERI) (U/kg/week/g/dL). Patients were divided into three groups by tertiles of ERI. ESA responsiveness was also assessed based on a combination of ESA dosage and hemoglobin (Hb) levels. The primary outcome was all-cause mortality. A total of 1,594 HD and 876 PD patients were included. The median ESA dose and ERI were lower in PD patients compared with HD patients (ESA dose: 4000 U/week vs 6000 U/week, respectively. P<0.001, ERI: 7.0 vs 10.4 U/kg/week/g/dl, respectively. P<0.001). The median follow-up period was 40 months. In HD patients, the highest ERI tertile was significantly associated with higher risk for all-cause mortality (HR 1.96, 95% CI, 1.07 to 3.59, P = 0.029). HD patients with high-dose ESA and low Hb levels (ESA hypo-responsiveness) had a significantly higher risk of all-cause mortality (HR 2.24, 95% CI, 1.16 to 4.31, P = 0.016). In PD patients, there was no significant difference in all-cause mortality among the ERI groups (P = 0.247, log-rank test). ESA hypo-responsiveness was not associated with all-cause mortality (HR = 1.75, 95% CI, 0.58 to 5.28, P = 0.319). Our data showed that ESA hypo-responsiveness was associated with an increased risk of all-cause mortality in HD patients. However, in PD patients, ESA hypo-responsiveness was not related to all-cause mortality. These finding suggest the different prognostic value of ESA responsiveness between HD and PD patients.	[Bae, Myoung Nam; Kim, Young Ok; Jin, Dong Chan; Song, Ho Chul; Choi, Euy Jin; Yang, Chul Woo; Kim, Yong Kyun] Catholic Univ Korea, Dept Internal Med, Coll Med, Seoul, South Korea; [Kim, Su Hyun] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul 156756, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu, South Korea; [Kim, Yon-Su] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Sch Med, Dept Internal Med, Kwangju, South Korea; [Kim, Yong Kyun] Catholic Univ Korea, MRC Cell Death Dis Res Ctr, Seoul, South Korea	Catholic University of Korea; Chung Ang University; Chung Ang University Hospital; Kyungpook National University; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Chonnam National University; Catholic University of Korea	Kim, YK (corresponding author), Catholic Univ Korea, Dept Internal Med, Coll Med, Seoul, South Korea.	drkimyk@catholic.ac.kr			Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI10C2020]	Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea	This work was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020).	Al-Hilali N, 2007, MED PRIN PRACT, V16, P63, DOI 10.1159/000096143; [Anonymous], 2006, AM J KIDNEY DIS, DOI [10.1053/j.ajkd.2006.03.051, DOI 10.1053/J.AJKD.2006.03.051.MEDLINE]; Blake PG, 2011, PERITON DIALYSIS INT, V31, P218, DOI 10.3747/pdi.2011.00026; Chung S, 2012, HEMODIAL INT, V16, P181, DOI 10.1111/j.1542-4758.2011.00644.x; Coronel F, 2003, J NEPHROL, V16, P697; Cotter DJ, 2004, SEMIN DIALYSIS, V17, P181, DOI 10.1111/j.0894-0959.2004.17317.x; DEPAEPE MBJ, 1983, KIDNEY INT, V23, P744, DOI 10.1038/ki.1983.88; Duong U, 2012, AM J NEPHROL, V35, P198, DOI 10.1159/000335685; Frank H, 2004, KIDNEY INT, V66, P832, DOI 10.1111/j.1523-1755.2004.00810.x; Fukuma S, 2012, AM J KIDNEY DIS, V59, P108, DOI 10.1053/j.ajkd.2011.07.014; GOLDBERG N, 1992, AM HEART J, V124, P424, DOI 10.1016/0002-8703(92)90608-X; HALSTENSON CE, 1991, CLIN PHARMACOL THER, V50, P702, DOI 10.1038/clpt.1991.210; Kaysen GA, 2006, AM J KIDNEY DIS, V47, P157, DOI 10.1053/j.ajkd.2005.09.013; Kim YK, 2014, PERITON DIALYSIS INT, V34, P383, DOI 10.3747/pdi.2013.00008; KORBET SM, 1993, KIDNEY INT, V43, pS111; Locatelli Francesco, 2007, Ther Clin Risk Manag, V3, P433; Lopez-Gomez JM, 2008, KIDNEY INT, V74, pS75, DOI 10.1038/ki.2008.523; MACDOUGALL IC, 1990, LANCET, V335, P489, DOI 10.1016/0140-6736(90)90733-L; McFarlane PA, 2010, KIDNEY INT, V78, P215, DOI 10.1038/ki.2010.108; Ogawa T, 2014, INT UROL NEPHROL, V46, P151, DOI 10.1007/s11255-013-0494-z; Parfrey PS, 2009, CLIN J AM SOC NEPHRO, V4, P755, DOI 10.2215/CJN.02730608; Rao A, 2013, NEPHRON CLIN PRACT, V125, P183, DOI 10.1159/000360029; Rattanasompattikul M, 2013, NEPHROL DIAL TRANSPL, V28, P1936, DOI 10.1093/ndt/gfs368; Sklar AH, 1998, NEW ENGL J MED, V339, P2023; Solomon SD, 2010, NEW ENGL J MED, V363, P1146, DOI 10.1056/NEJMoa1005109; Suttorp MM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-200; Vega A, 2014, RENAL FAILURE, V36, P1073, DOI 10.3109/0886022X.2014.917937; Wetmore JB, 2015, AM J NEPHROL, V41, P354, DOI 10.1159/000431335	28	27	28	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2015	10	11							e0143348	10.1371/journal.pone.0143348	http://dx.doi.org/10.1371/journal.pone.0143348			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW8LQ	26588085	Green Published, Green Submitted, gold			2023-01-03	WOS:000365251500054
J	Ye, P; Zhang, MZ; Fan, SQ; Zhang, TW; Fu, HH; Su, XY; Gavine, PR; Liu, Q; Yin, XL				Ye, Peng; Zhang, Meizhuo; Fan, Shuqiong; Zhang, Tianwei; Fu, Haihua; Su, Xinying; Gavine, Paul R.; Liu, Qiang; Yin, Xiaolu			Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis	PLOS ONE			English	Article							KINASE-ACTIVITY; MET; INHIBITOR; AMPLIFICATION; SENSITIVITY; EXPRESSION; THERAPY; GROWTH; CELLS	Current drug development efforts on gastric cancer are directed against several molecular targets driving the growth of this neoplasm. Intra-tumoral biomarker heterogeneity however, commonly observed in gastric cancer, could lead to biased selection of patients. MET, ATM, FGFR2, and HER2 were profiled on gastric cancer biopsy samples. An innovative pathological assessment was performed through scoring of individual biopsies against whole biopsies from a single patient to enable heterogeneity evaluation. Following this, false negative risks for each biomarker were estimated in silico. 166 gastric cancer cases with multiple biopsies from single patients were collected from Shanghai Renji Hospital. Following pre-set criteria, 56 similar to 78% cases showed low, 15 similar to 35% showed medium and 0 similar to 11% showed high heterogeneity within the biomarkers profiled. If 3 biopsies were collected from a single patient, the false negative risk for detection of the biomarkers was close to 5% (exception for FGFR2: 12.2%). When 6 biopsies were collected, the false negative risk approached 0%. Our study demonstrates the benefit of multiple biopsy sampling when considering personalized healthcare biomarker strategy, and provides an example to address the challenge of intra-tumoral biomarker heterogeneity using alternative pathological assessment and statistical methods.	[Ye, Peng; Fan, Shuqiong; Zhang, Tianwei; Fu, Haihua; Su, Xinying; Gavine, Paul R.; Yin, Xiaolu] AstraZeneca R&D, Asia & Emerging Markets iMed, Shanghai, Peoples R China; [Zhang, Meizhuo] AstraZeneca R&D, Res & Dev Informat, Shanghai, Peoples R China; [Liu, Qiang] Shanghai Jiao Tong Univ, Dept Pathol, Ren Ji Hosp, Sch Med, Shanghai 200030, Peoples R China	AstraZeneca; AstraZeneca; Shanghai Jiao Tong University	Liu, Q (corresponding author), Shanghai Jiao Tong Univ, Dept Pathol, Ren Ji Hosp, Sch Med, Shanghai 200030, Peoples R China.	liuq1963@sohu.com; lucy.yin@astrazeneca.com	Liu, Qiang/HHZ-3181-2022		AstraZeneca	AstraZeneca(AstraZeneca)	Funding: AstraZeneca has sponsored this study. The funder provided support in the form of salaries for authors [PY, MZ, SF, TZ, HF, XS, PG and XY] and provided facility and resources for completing this study. The specific roles of these authors are articulated in the "author contributions" section.	Bang YJ, 2010, LANCET, V376, P1302; Cunningham D, 2013, J CLIN ON S IN PRESS, V31; DEARETXABALA X, 1989, CANCER, V63, P791, DOI 10.1002/1097-0142(19890215)63:4<791::AID-CNCR2820630431>3.0.CO;2-W; Feng Y, 2011, CANCER DISCOV, V1, P550, DOI 10.1158/2159-8290.CD-11-0289; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gavine PR, 2015, MOL ONCOL, V9, P323, DOI 10.1016/j.molonc.2014.08.015; Gerlinger M, 2010, BRIT J CANCER, V103, P1139, DOI 10.1038/sj.bjc.6605912; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gilardini Montani MS, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-95; Guo XN, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-B42; Inskip HM, 1999, BRIT J CANCER, V79, P1304, DOI 10.1038/sj.bjc.6690209; Kim HS, 2013, PATHOBIOLOGY, V80, P127, DOI 10.1159/000346034; Kubota E, 2014, CELL CYCLE, V13, P2129, DOI 10.4161/cc.29212; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lee J, 2013, DISCOV MED, V16, P7; Liu YJ, 2014, BRIT J CANCER, V110, P1169, DOI 10.1038/bjc.2014.61; McGranahan N, 2012, EMBO REP, V13, P528, DOI 10.1038/embor.2012.61; Min A, 2013, MOL CANCER THER, V12, P865, DOI 10.1158/1535-7163.MCT-12-0950; NALDINI L, 1991, ONCOGENE, V6, P501; Pourhoseingholi Mohamad Amin, 2015, Gastroenterol Hepatol Bed Bench, V8, P19; Power DG, 2010, CANCER TREAT REV, V36, P384, DOI 10.1016/j.ctrv.2010.01.005; Reimers MS, 2013, GASTROENTEROL REP, V1, P166, DOI 10.1093/gastro/got022; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Su X, 2014, BRIT J CANCER, V110, P967, DOI 10.1038/bjc.2013.802; Tai WY, 2010, J CONTROL RELEASE, V146, P264, DOI 10.1016/j.jconrel.2010.04.009; Xie L, 2013, CLIN CANCER RES, V19, P2572, DOI 10.1158/1078-0432.CCR-12-3898; Yang JY, 2012, CELL BIOCHEM BIOPHYS, V62, P221, DOI 10.1007/s12013-011-9286-1; Ye QQ, 2014, PATHOL ONCOL RES, V20, P931, DOI 10.1007/s12253-014-9776-8; YONEMURA Y, 1992, ANAL CELL PATHOL, V4, P61	29	21	21	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2015	10	11							e0143207	10.1371/journal.pone.0143207	http://dx.doi.org/10.1371/journal.pone.0143207			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW8LQ	26587992	Green Submitted, Green Published, gold			2023-01-03	WOS:000365251500037
J	Xu, SY; Wang, DY; Zhou, DS; Lin, Y; Che, LQ; Fang, ZF; Wu, D				Xu, Shengyu; Wang, Dingyue; Zhou, Dongsheng; Lin, Yan; Che, Lianqiang; Fang, Zhengfeng; Wu, De			Reproductive Hormone and Transcriptomic Responses of Pituitary Tissue in Anestrus Gilts Induced by Nutrient Restriction	PLOS ONE			English	Article							GROWTH; GENE; OVULATION; ACTIVATION; RECEPTOR; GPR54	The onset of estrus is a critical sign of female sexual maturity. The pituitary plays a vital role in this process by the secretion of reproductive hormones. To investigate the effects of nutrient restriction on reproductive function and the underlying mechanisms involved, deep RNA sequencing of pituitary gland tissue was carried out to determine the differentially expressed genes (DEGs) between gilts in normal estrus, and gilts in which anestrus was induced by nutrient restriction. Gilts which had gone through two estrus cycles were fed a normal (CON, 2.86kg/d, n = 10) or nutrient restricted (NR, 1kg/d, n = 10) diet. The NR gilts experienced another three estrus cycles, but did not express estrus symptoms at the anticipated 6th and 7th cycles. Body weight gain in NR gilts was significantly decreased by nutrient restriction. Gilts were considered as anestrus when blood progesterone concentrations lower than 1.0 ng/mL from three consecutive blood samples were recorded. Circulating concentrations of progesterone (< 1.0 ng/mL vs. 2.1 ng/mL) and estradiol (208.6 ng/mL vs. 371.8 ng/mL) were significantly lower in the NR gilts than in the CON gilts. Between 5,360,000 and 5,370,000 sequence reads per sample from the CON and NR gilts' pituitaries were obtained and mapped to the porcine genome. Analysis of read counts revealed 185 DEGs. Expression of selected genes was validated by the use of quantitative real-time RTPCR. Bioinformatic analysis identified that the genes identified were enriched in the GO terms "neuroactive ligand-receptor interaction", "GnRH signaling pathway" and "immune response system". Our findings provide a new perspective for understanding the nutrient restriction-induced reproductive impairment at the pituitary transcriptional level, and how this is linked to hormone secretion. Moreover, the transcriptomic changes in anestrus gilts associated with nutrient restriction could be a resource for targeted studies of genes and pathways potentially involved in the regulation of reproductive function and animal health.	[Wu, De] Sichuan Agr Univ, Key Lab Anim Dis Resistance Nutr, Minist Educ, Yaan 625014, Peoples R China; Sichuan Agr Univ, Inst Anim Nutr, Yaan 625014, Peoples R China	Sichuan Agricultural University; Sichuan Agricultural University	Wu, D (corresponding author), Sichuan Agr Univ, Key Lab Anim Dis Resistance Nutr, Minist Educ, Yaan 625014, Peoples R China.	pig2pig@sina.com.cn			National Natural Science Foundation of P.R. China [30871804]; Program for Changjiang Scholars and Innovative Research Team in University [IRT13083]; Program form Feed Industry and Technology Research Institute of Sichuan Province [2013NZ0054]	National Natural Science Foundation of P.R. China(National Natural Science Foundation of China (NSFC)); Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); Program form Feed Industry and Technology Research Institute of Sichuan Province	This work was supported by National Natural Science Foundation (30871804) of P.R. China, Program for Changjiang Scholars and Innovative Research Team in University (IRT13083) and Program form Feed Industry and Technology Research Institute of Sichuan Province (2013NZ0054). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARMSTRONG JD, 1987, J ANIM SCI, V65, P508, DOI 10.2527/jas1987.652508x; Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; BERGENDAHL M, 1991, BIOL REPROD, V44, P413, DOI 10.1095/biolreprod44.3.413; Bliss SP, 2010, FRONT NEUROENDOCRIN, V31, P322, DOI 10.1016/j.yfrne.2010.04.002; BOOTH PJ, 1994, J ANIM SCI, V72, P2415, DOI 10.2527/1994.7292415x; BOYAR RM, 1978, ANNU REV MED, V29, P509; Breen SM, 2012, ANIM REPROD SCI, V132, P193, DOI 10.1016/j.anireprosci.2012.05.013; Brooks AJ, 2010, NAT REV ENDOCRINOL, V6, P515, DOI 10.1038/nrendo.2010.123; Castellano JM, 2009, PEPTIDES, V30, P139, DOI 10.1016/j.peptides.2008.06.007; Colledge WH, 2004, TRENDS ENDOCRIN MET, V15, P448, DOI 10.1016/j.tem.2004.09.008; Coskun M, 2013, PHARMACOL RES, V76, P1, DOI 10.1016/j.phrs.2013.06.007; de la Iglesia HO, 2006, ENDOCRINOLOGY, V147, P1148, DOI 10.1210/en.2005-1311; DYCK GW, 1979, CAN J ANIM SCI, V59, P649, DOI 10.4141/cjas79-084; Fasler-Kan E, 2013, XENOTRANSPLANTATION, V20, P469, DOI 10.1111/xen.12070; Ge XJ, 2007, J RES ADOLESCENCE, V17, P767, DOI 10.1111/j.1532-7795.2007.00546.x; Hillier SG, 2001, MOL CELL ENDOCRINOL, V179, P39, DOI 10.1016/S0303-7207(01)00469-5; HILLIER SG, 1994, MOL CELL ENDOCRINOL, V100, P51, DOI 10.1016/0303-7207(94)90278-X; Hirose M, 2013, ANIM SCI J, V84, P693, DOI 10.1111/asj.12061; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Kiu H, 2012, GROWTH FACTORS, V30, P88, DOI 10.3109/08977194.2012.660936; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loisel F, 2015, DOMEST ANIM ENDOCRIN, V53, P35, DOI 10.1016/j.domaniend.2015.04.005; Macklon NS, 2001, ARCH MED RES, V32, P595, DOI 10.1016/S0188-4409(01)00327-7; Mastorakos G, 2010, ANN NY ACAD SCI, V900, P65; Mekchay S, 2003, GENET SEL EVOL, V35, pS83, DOI 10.1051/gse:2003018; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; National Research Council, 1998, NUTR REQ SWIN, Vtenth; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; POMERANTZ SH, 1987, GAMETE RES, V17, P267, DOI 10.1002/mrd.1120170310; ROZEBOOM DW, 1993, J ANIM SCI, V71, P426, DOI 10.2527/1993.712426x; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Stouffer RL, 2007, FRONT BIOSCI, V12, P297, DOI 10.2741/2065; Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342; Tena-Sempere M, 2006, HUM REPROD UPDATE, V12, P631, DOI 10.1093/humupd/dml023; Viswanathan G, 2014, J CLIN ENDOCR METAB, V99, pE1050, DOI 10.1210/jc.2013-3062; Zhou DS, 2014, MOL BIOL REP, V41, P4733, DOI 10.1007/s11033-014-3344-x	37	7	8	5	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2015	10	11							e0143219	10.1371/journal.pone.0143219	http://dx.doi.org/10.1371/journal.pone.0143219			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW7CD	26580562	gold, Green Published, Green Submitted			2023-01-03	WOS:000365154600099
J	Eissa, MM; El-Moslemany, RM; Ramadan, AA; Amer, EI; El-Azzouni, MZ; El-Khordagui, LK				Eissa, Maha M.; El-Moslemany, Riham M.; Ramadan, Alyaa A.; Amer, Eglal I.; El-Azzouni, Mervat Z.; El-Khordagui, Labiba K.			Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study	PLOS ONE			English	Article							IN-VIVO EVALUATION; VISCERAL LEISHMANIASIS; ARACHIDONIC-ACID; AMPHOTERICIN-B; HEXADECYLPHOSPHOCHOLINE; NANOPARTICLES; NANOCARRIERS; STABILITY; LIPOSOMES; MEMBRANES	Miltefosine (MFS) is an alkylphosphocholine used for the local treatment of cutaneous metastases of breast cancer and oral therapy of visceral leishmaniasis. Recently, the drug was reported in in vitro and preclinical studies to exert significant activity against different developmental stages of schistosomiasis mansoni, a widespread chronic neglected tropical disease (NTD). This justified MFS repurposing as a potential antischistosomal drug. However, five consecutive daily 20 mg/kg doses were needed for the treatment of schistosomiasis mansoni in mice. The present study aims at enhancing MFS efficacy to allow for a single 20mg/kg oral dose therapy using a nanotechnological approach based on lipid nanocapsules (LNCs) as oral nanovectors. MFS was incorporated in LNCs both as membrane-active structural alkylphospholipid component and active antischistosomal agent. MFS-LNC formulations showed high entrapment efficiency (EE%), good colloidal properties, sustained release pattern and physical stability. Further, LNCs generally decreased MFS-induced erythrocyte hemolytic activity used as surrogate indicator of membrane activity. While MFS-free LNCs exerted no antischistosomal effect, statistically significant enhancement was observed with all MFS-LNC formulations. A maximum effect was achieved with MFS-LNCs incorporating CTAB as positive charge imparting agent or oleic acid as membrane permeabilizer. Reduction of worm load, ameliorated liver pathology and extensive damage of the worm tegument provided evidence for formulation-related efficacy enhancement. Non-compartmental analysis of pharmacokinetic data obtained in rats indicated independence of antischistosomal activity on systemic drug exposure, suggesting possible gut uptake of the stable LNCs and targeting of the fluke tegument which was verified by SEM. The study findings put forward MFS-LNCs as unique oral nanovectors combining the bioactivity of MFS and biopharmaceutical advantages of LNCs, allowing targeting via the oral route. From a clinical point of view, data suggest MFS-LNCs as a potential single dose oral nanomedicine for enhanced therapy of schistosomiasis mansoni and possibly other diseases.	[Eissa, Maha M.; Amer, Eglal I.; El-Azzouni, Mervat Z.] Univ Alexandria, Fac Med, Dept Med Parasitol, Alexandria, Egypt; [El-Moslemany, Riham M.; Ramadan, Alyaa A.; El-Khordagui, Labiba K.] Univ Alexandria, Fac Pharm, Dept Pharmaceut, Alexandria, Egypt	Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge Bank (EKB); Alexandria University	El-Khordagui, LK (corresponding author), Univ Alexandria, Fac Pharm, Dept Pharmaceut, Alexandria, Egypt.	lakhalil@gmail.com	Eissa, M M/S-4230-2019; Ramadan, Alyaa/AAL-5073-2021	Eissa, M M/0000-0003-4723-6427; Ramadan, Alyaa/0000-0003-2143-7909; El-Moslemany, Riham/0000-0001-5594-4314; Eissa, Maha/0000-0001-9572-2820				Akhtar F, 2012, BIOTECHNOL ADV, V30, P310, DOI 10.1016/j.biotechadv.2011.05.009; Azzouz S, 2006, J PARASITOL, V92, P877, DOI 10.1645/GE-632R1.1; Bertao HG, 2012, PARASITOL RES, V110, P2465, DOI 10.1007/s00436-011-2786-5; Botros S, 2003, ANTIMICROB AGENTS CH, V47, P3853, DOI 10.1128/AAC.47.12.3853-3858.2003; BREISER A, 1987, LIPIDS, V22, P925, DOI 10.1007/BF02535556; de Araujo SC, 2007, INT J PHARMACEUT, V337, P307, DOI 10.1016/j.ijpharm.2007.01.009; Cho WS, 2014, NANOTOXICOLOGY, V8, P202, DOI 10.3109/17435390.2013.773465; da Costa AV, 2008, REV SOC BRAS MED TRO, V41, P424, DOI 10.1590/S0037-86822008000400022; Date AA, 2007, ADV DRUG DELIVER REV, V59, P505, DOI 10.1016/j.addr.2007.04.009; de Sa MM, 2014, MOL INFORM, V33, P53, DOI 10.1002/minf.201300124; Dorlo TPC, 2008, J CHROMATOGR B, V865, P55, DOI 10.1016/j.jchromb.2008.02.005; Dorlo TPC, 2012, J ANTIMICROB CHEMOTH, V67, P2576, DOI 10.1093/jac/dks275; Du WW, 2013, BIOMATERIALS, V34, P794, DOI 10.1016/j.biomaterials.2012.10.003; Eissa MM, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-73; Eissa MM, 2011, INT J PARASITOL, V41, P235, DOI 10.1016/j.ijpara.2010.09.010; El Ridi R, 2010, ANTIMICROB AGENTS CH, V54, P3383, DOI 10.1128/AAC.00173-10; Freitas-Junior LH, 2012, INT J PARASITOL-DRUG, V2, P11, DOI 10.1016/j.ijpddr.2012.01.003; Groo AC, 2015, NANOMEDICINE-UK, V10, P589, DOI 10.2217/nnm.14.124; Groo AC, 2014, PHARM RES-DORDR, V31, P1753, DOI 10.1007/s11095-013-1280-4; Groo AC, 2013, INT J NANOMED, V8, P4291, DOI 10.2147/IJN.S51837; Huynh NT, 2009, INT J PHARMACEUT, V379, P201, DOI 10.1016/j.ijpharm.2009.04.026; Jumaa M, 2000, EUR J PHARM SCI, V9, P285, DOI 10.1016/S0928-0987(99)00071-8; Kepczynski M, 2011, CHEM PHYS LIPIDS, V164, P359, DOI 10.1016/j.chemphyslip.2011.04.007; Khalil NM, 2013, CURR PHARM DESIGN, V19, P7316, DOI 10.2174/138161281941131219135458; Kolenyak-Santos F., 2014, J NANOSCI NANOTECHNO, V14, P1, DOI DOI 10.1166/JNN.2014.9186; Kopetzki D, 2009, SOFT MATTER, V5, P4212, DOI 10.1039/b907339f; Lacoeuille F, 2007, INT J PHARM, V344, P143, DOI 10.1016/j.ijpharm.2007.06.014; Lamprecht A, 2002, J CONTROL RELEASE, V84, P59, DOI 10.1016/S0168-3659(02)00258-4; Lindenberg M, 2004, EUR J PHARM BIOPHARM, V58, P265, DOI 10.1016/j.ejpb.2004.03.001; LOWRY JB, 1979, J PHARM SCI, V68, P110, DOI 10.1002/jps.2600680138; Lukac ML, 2008, ACTA FACULT PHARM U, V55, P142; Mally M, 2013, J PHYS CHEM B, V117, P12086, DOI 10.1021/jp404135g; Menez C, 2006, BIOCHEM PHARMACOL, V71, P486, DOI 10.1016/j.bcp.2005.11.008; Mishra A, 2014, J NANOTECHNOL, V2014, DOI 10.1155/2014/351693; More B, 2003, J Postgrad Med, V49, P101; Moreira RA, 2014, ANTIMICROB AGENTS CH, V58, P3021, DOI 10.1128/AAC.01332-13; Morigaki K, 2007, CURR OPIN COLLOID IN, V12, P75, DOI 10.1016/j.cocis.2007.05.005; Morille M, 2010, BIOMATERIALS, V31, P321, DOI 10.1016/j.biomaterials.2009.09.044; Munoz C, 2013, TOXICOL IN VITRO, V27, P1913, DOI 10.1016/j.tiv.2013.06.010; Oliveira CNF De, 2013, PARASITIC DIS SCHIST; Olliaro P, 2014, J ANTIMICROB CHEMOTH, V69, P863, DOI 10.1093/jac/dkt491; Pabla D, 2010, EUR J PHARM SCI, V40, P466, DOI 10.1016/j.ejps.2010.05.002; Padmanabhan P, 2013, EJNMMI RES, V3, DOI 10.1186/2191-219X-3-60; Palumbo E, 2008, BRAZ J INFECT DIS, V12, P2, DOI 10.1590/S1413-86702008000100002; Papagiannaros A, 2006, BIOMED PHARMACOTHER, V60, P36, DOI 10.1016/j.biopha.2005.09.001; Peltier S, 2006, PHARM RES-DORDR, V23, P1243, DOI 10.1007/s11095-006-0022-2; Perrier T, 2010, INT J PHARMACEUT, V396, P204, DOI 10.1016/j.ijpharm.2010.06.019; Pisarcik M, 2012, COLLOID SURFACE A, V407, P169, DOI 10.1016/j.colsurfa.2012.05.028; Pollastri MP, 2011, FUTURE MED CHEM, V3, P1307, DOI [10.4155/FMC.11.92, 10.4155/fmc.11.92]; Ramadan A, 2011, INT J NANOMED, V6, P2941, DOI 10.2147/IJN.S25791; Roger E, 2009, J CONTROL RELEASE, V140, P174, DOI 10.1016/j.jconrel.2009.08.010; Roger E, 2009, INT J PHARMACEUT, V379, P260, DOI 10.1016/j.ijpharm.2009.05.069; Selim S, 2014, AM J TROP MED HYG, V91, P973, DOI 10.4269/ajtmh.14-0328; Serrano DR, 2015, MOL PHARMACEUT, V12, P420, DOI 10.1021/mp500527x; Sharma V, 2009, BRIT J PHARMACOL, V157, P907, DOI 10.1111/j.1476-5381.2009.00267.x; SHAW MK, 1987, PARASITOLOGY, V94, P243, DOI 10.1017/S0031182000053920; Sindermann H, 2006, T ROY SOC TROP MED H, V100, pS17, DOI 10.1016/j.trstmh.2006.02.010; SMITHERS SR, 1965, PARASITOLOGY, V55, P695, DOI 10.1017/S0031182000086248; Talegaonkar Sushama, 2008, Recent Pat Drug Deliv Formul, V2, P238; Thakur A, 2013, CANCER LETT, V334, P274, DOI 10.1016/j.canlet.2012.08.022; Trinconi CT, 2014, ANTIMICROB AGENTS CH, V58, P2608, DOI 10.1128/AAC.01315-13; Zeisig R, 1996, BBA-BIOMEMBRANES, V1283, P177, DOI 10.1016/0005-2736(96)00090-9; Zhang Y, 2010, COMPUT METH PROG BIO, V99, P306, DOI 10.1016/j.cmpb.2010.01.007; Zhukova MV, 2010, PHARM CHEM J+, V44, P507, DOI 10.1007/s11094-010-0504-8	64	51	51	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2015	10	11							e0141788	10.1371/journal.pone.0141788	http://dx.doi.org/10.1371/journal.pone.0141788			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW7BR	26574746	Green Submitted, gold, Green Published			2023-01-03	WOS:000365153400008
J	Shiraishi, Y; Kohsaka, S; Harada, K; Sakai, T; Takagi, A; Miyamoto, T; Iida, K; Tanimoto, S; Fukuda, K; Nagao, K; Sato, N; Takayama, M				Shiraishi, Yasuyuki; Kohsaka, Shun; Harada, Kazumasa; Sakai, Tetsuro; Takagi, Atsutoshi; Miyamoto, Takamichi; Iida, Kiyoshi; Tanimoto, Shuzou; Fukuda, Keiichi; Nagao, Ken; Sato, Naoki; Takayama, Morimasa		Sci Comm Tokyo CCU Network	Time Interval from Symptom Onset to Hospital Care in Patients with Acute Heart Failure: A Report from the Tokyo Cardiac Care Unit Network Emergency Medical Service Database	PLOS ONE			English	Article							RISK STRATIFICATION; TASK-FORCE; MORTALITY; ASSOCIATION; GUIDELINES; MANAGEMENT; THERAPY; LENGTH; DELAY; ESC	Aims There seems to be two distinct patterns in the presentation of acute heart failure (AHF) patients; early-vs. gradual-onset. However, whether time-dependent relationship exists in outcomes of patients with AHF remains unclear. Methods The Tokyo Cardiac Care Unit Network Database prospectively collects information of emergency admissions via EMS service to acute cardiac care facilities from 67 participating hospitals in the Tokyo metropolitan area. Between 2009 and 2011, a total of 3811 AHF patients were registered. The documentation of symptom onset time was mandated by the on-site ambulance team. We divided the patients into two groups according to the median on-set-to-hospitalization (OH) time for those patients (2h); early-(presenting <= 2h after symptom onset) vs. gradual-onset (late) group (>2h). The primary outcome was in-hospital mortality. Results The early OH group had more urgent presentation, as demonstrated by a higher systolic blood pressure (SBP), respiratory rate, and higher incidence of pulmonary congestion (48.6% vs. 41.6%; P<0.001); whereas medical comorbidities such as stroke (10.8% vs. 7.9%; P<0.001) and atrial fibrillation (30.0% vs. 26.0%; P<0.001) were more frequently seen in the late OH group. Overall, 242 (6.5%) patients died during hospitalization. Notably, a shorter OH time was associated with a better in-hospital mortality rate (odds ratio, 0.71; 95% confidence interval, 0.51 - 0.99; P = 0.043). Conclusions Early-onset patients had rather typical AHF presentations (e.g., higher SBP or pulmonary congestion) but had a better in-hospital outcome compared to gradual-onset patients.	[Shiraishi, Yasuyuki; Kohsaka, Shun; Harada, Kazumasa; Sakai, Tetsuro; Takagi, Atsutoshi; Miyamoto, Takamichi; Iida, Kiyoshi; Tanimoto, Shuzou; Fukuda, Keiichi; Nagao, Ken; Sato, Naoki; Takayama, Morimasa; Sci Comm Tokyo CCU Network] Tokyo CCU Network Sci Comm, Tokyo, Japan; [Shiraishi, Yasuyuki] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan	Keio University	Kohsaka, S (corresponding author), Tokyo CCU Network Sci Comm, Tokyo, Japan.	kohsaka@cpnet.med.keio.ac.jp	Fukuda, Keiichi/L-3777-2013	Kohsaka, Shun/0000-0003-3779-2972; Shibui, Takashi/0000-0002-0676-5595	Pfizer Japan Inc.; Department of Cardiology, Keio University School of Medicine from Bayer Pharmaceutical Co., Ltd.	Pfizer Japan Inc.(Pfizer); Department of Cardiology, Keio University School of Medicine from Bayer Pharmaceutical Co., Ltd.	Dr. Kohsaka received lecture fees from Pfizer Japan Inc., and he received unrestricted research grant for Department of Cardiology, Keio University School of Medicine from Bayer Pharmaceutical Co., Ltd. Other authors have no conflicts of interest to disclose. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.	Brodie BR, 2006, J AM COLL CARDIOL, V48, P2600, DOI 10.1016/j.jacc.2006.09.023; Chen J, 2011, JAMA-J AM MED ASSOC, V306, P1669, DOI 10.1001/jama.2011.1474; Collins S, 2008, ANN EMERG MED, V51, P45, DOI 10.1016/j.annemergmed.2007.07.007; Cotter G, 2008, EUR J HEART FAIL, V10, P165, DOI 10.1016/j.ejheart.2008.01.007; Cotter G, 2008, AM HEART J, V155, P9, DOI 10.1016/j.ahj.2006.02.038; Dib JE, 2012, J EMERG MED, V42, P553, DOI 10.1016/j.jemermed.2011.06.002; Fonarow GC, 2005, JAMA-J AM MED ASSOC, V293, P572, DOI 10.1001/jama.293.5.572; Gravely-Witte S, 2010, EUR J HEART FAIL, V12, P1122, DOI 10.1093/eurjhf/hfq122; Johnson W, 2002, J AM COLL CARDIOL, V39, P1623, DOI 10.1016/S0735-1097(02)01814-4; Kawaguchi M, 2003, CIRCULATION, V107, P714, DOI 10.1161/01.CIR.0000048123.22359.A0; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; Maggioni AP, 2013, EUR J HEART FAIL, V15, P808, DOI 10.1093/eurjhf/hft050; Magid DJ, 2005, JAMA-J AM MED ASSOC, V294, P803, DOI 10.1001/jama.294.7.803; Maisel AS, 2008, J AM COLL CARDIOL, V52, P534, DOI 10.1016/j.jacc.2008.05.010; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Mebazaa Alexandre, 2008, Crit Care Med, V36, pS129, DOI 10.1097/01.CCM.0000296274.51933.4C; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; O'Connor CM, 2012, EUR J HEART FAIL, V14, P605, DOI 10.1093/eurjhf/hfs029; Obayashi T, 2010, CIRC J, V74, P289, DOI 10.1253/circj.CJ-09-0623; Ohta T, 1974, No Shinkei Geka, V2, P623; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Peacock William Frank, 2009, Congest Heart Fail, V15, P256, DOI 10.1111/j.1751-7133.2009.00112.x; Peterson PN, 2010, CIRC-CARDIOVASC QUAL, V3, P25, DOI 10.1161/CIRCOUTCOMES.109.854877; Takahashi M, 2011, J CARD FAIL, V17, P742, DOI 10.1016/j.cardfail.2011.05.005; Wong YW, 2013, AM HEART J, V166, P349, DOI 10.1016/j.ahj.2013.05.014; WUERZ RC, 1992, ANN EMERG MED, V21, P669, DOI 10.1016/S0196-0644(05)82777-5; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019	27	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2015	10	11							e0142017	10.1371/journal.pone.0142017	http://dx.doi.org/10.1371/journal.pone.0142017			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV7UL	26562780	gold, Green Submitted, Green Published			2023-01-03	WOS:000364480900011
J	MacPherson, H; Tilbrook, H; Richmond, S; Woodman, J; Ballard, K; Atkin, K; Bland, M; Eldred, J; Essex, H; Hewitt, C; Hopton, A; Keding, A; Lansdown, H; Parrott, S; Torgerson, D; Wenham, A; Watt, I				MacPherson, Hugh; Tilbrook, Helen; Richmond, Stewart; Woodman, Julia; Ballard, Kathleen; Atkin, Karl; Bland, Martin; Eldred, Janet; Essex, Holly; Hewitt, Catherine; Hopton, Ann; Keding, Ada; Lansdown, Harriet; Parrott, Steve; Torgerson, David; Wenham, Aniela; Watt, Ian			Alexander Technique Lessons or Acupuncture Sessions for Persons With Chronic Neck Pain A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							TRADITIONAL ACUPUNCTURE; USUAL PHYSIOTHERAPY; CARE; EXERCISE; ADVICE; PRACTITIONERS; QUESTIONNAIRE; DISABILITY; MANAGEMENT; DISORDERS	Background: Management of chronic neck pain may benefit from additional active self-care-oriented approaches. Objective: To evaluate clinical effectiveness of Alexander Technique lessons or acupuncture versus usual care for persons with chronic, nonspecific neck pain. Design: Three-group randomized, controlled trial. (Current Controlled Trials: ISRCTN15186354) Setting: U.K. primary care. Participants: Persons with neck pain lasting at least 3 months, a score of at least 28% on the Northwick Park Questionnaire (NPQ) for neck pain and associated disability, and no serious underlying pathology. Intervention: 12 acupuncture sessions or 20 one-to-one Alexander lessons (both 600 minutes total) plus usual care versus usual care alone. Measurements: NPQ score (primary outcome) at 0, 3, 6, and 12 months (primary end point) and Chronic Pain Self-Efficacy Scale score, quality of life, and adverse events (secondary outcomes). Results: 517 patients were recruited, and the median duration of neck pain was 6 years. Mean attendance was 10 acupuncture sessions and 14 Alexander lessons. Between-group reductions in NPQ score at 12 months versus usual care were 3.92 percent-age points for acupuncture (95% CI, 0.97 to 6.87 percentage points) (P = 0.009) and 3.79 percentage points for Alexander lessons (CI, 0.91 to 6.66 percentage points) (P = 0.010). The 12-month reductions in NPQ score from baseline were 32% for acupuncture and 31% for Alexander lessons. Participant self-efficacy improved for both interventions versus usual care at 6 months (P < 0.001) and was significantly associated (P < 0.001) with 12-month NPQ score reductions (acupuncture, 3.34 percentage points [CI, 2.31 to 4.38 percentage points]; Alexander lessons, 3.33 percentage points [CI, 2.22 to 4.44 percentage points]). No reported serious adverse events were considered probably or definitely related to either intervention. Limitation: Practitioners belonged to the 2 main U.K.-based professional associations, which may limit generalizability of the findings. Conclusion: Acupuncture sessions and Alexander Technique lessons both led to significant reductions in neck pain and associated disability compared with usual care at 12 months. Enhanced self-efficacy may partially explain why longer-term benefits were sustained.	[MacPherson, Hugh; Tilbrook, Helen; Atkin, Karl; Bland, Martin; Eldred, Janet; Essex, Holly; Hewitt, Catherine; Hopton, Ann; Keding, Ada; Lansdown, Harriet; Parrott, Steve; Torgerson, David; Wenham, Aniela; Watt, Ian] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Woodman, Julia; Ballard, Kathleen] Alexander Tech, Soc Teachers, London N17 9TA, England; British Acupuncture Council, London, England	University of York - UK	MacPherson, H (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	hugh.macpherson@york.ac.uk	Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Eldred, Janet/0000-0003-2858-8240; Parrott, Steven James/0000-0002-0165-1150; Hewitt, Catherine Elizabeth/0000-0002-0415-3536	University of York; Arthritis Research UK [19702]; Versus Arthritis [19702] Funding Source: researchfish	University of York(European Commission); Arthritis Research UK(Versus Arthritis); Versus Arthritis(Versus Arthritis)	The trial was sponsored by the University of York. This research was funded by clinical studies grant 19702 from Arthritis Research UK.	ANDERSON KO, 1995, PAIN, V63, P77, DOI 10.1016/0304-3959(95)00021-J; Andersson S, 2012, ALTERN THER HEALTH M, V18, P25; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Bertozzi L, 2013, PHYS THER, V93, P1026, DOI 10.2522/ptj.20120412; Cacciatore TW, 2011, HUM MOVEMENT SCI, V30, P74, DOI 10.1016/j.humov.2010.10.002; Cacciatore TW, 2014, J NEUROPHYSIOL, V112, P719, DOI 10.1152/jn.00617.2013; Cacciatore TW, 2011, GAIT POSTURE, V34, P496, DOI 10.1016/j.gaitpost.2011.06.026; Dziedzic K, 2005, ARTHRIT RHEUM-ARTHR, V53, P214, DOI 10.1002/art.21087; Evans M, 2011, J ALTERN COMPLEM MED, V17, P519, DOI 10.1089/acm.2010.0749; Ferrari R, 2003, BEST PRACT RES CL RH, V17, P57, DOI 10.1016/S1521-6942(02)00097-9; Furlan AD, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/953139; Gross A, 2010, MANUAL THER, V15, P315, DOI 10.1016/j.math.2010.04.002; Haldeman S, 2009, J MANIP PHYSIOL THER, V32, pS10, DOI 10.1016/j.jmpt.2008.11.006; Hewitt CE, 2006, CAN MED ASSOC J, V175, P347, DOI 10.1503/cmaj.051625; Hoy D, 2014, ANN RHEUM DIS, V73, P1309, DOI 10.1136/annrheumdis-2013-204431; Hurwitz EL, 2006, DISABIL REHABIL, V28, P1319, DOI 10.1080/09638280600641509; Jull G., 2008, WHIPLASH HEADACHE NE; Klaber Moffett J, 2006, RHEUMATOLOGY, V45, P1514, DOI 10.1093/rheumatology/kel339; Lauche R, 2016, CLIN REHABIL, V30, P247, DOI 10.1177/0269215515578699; LEAK AM, 1994, BRIT J RHEUMATOL, V33, P469; Little P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a884; MacPherscon H, 2008, COMPLEMENT THER MED, V16, P101, DOI 10.1016/j.ctim.2008.02.010; MacPherson H, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-209; McClean S, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0966-1; McLean SM, 2013, MANUAL THER, V18, P199, DOI 10.1016/j.math.2012.09.005; Miller J, 2010, MANUAL THER, V15, P334, DOI 10.1016/j.math.2010.02.007; Moffett JAK, 2005, BRIT MED J, V330, P75, DOI 10.1136/bmj.38286.493206.82; National Institute for Health and Care Excellence, 2009, LOW BACK PAIN EARL M, P4; National Institute for Health and Care Excellence, 2012, HEAD DIAGN MAN HEAD; Robinson N, 2012, J ETHNOPHARMACOL, V140, P604, DOI 10.1016/j.jep.2012.01.052; Salter GC, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-99; Sim J, 2006, CLIN J PAIN, V22, P820, DOI 10.1097/01.ajp.0000210937.58439.39; Skills for Health, 2010, CNH3 DEL AL TECHN TE; Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C; Thomas KJ, 2001, COMPLEMENT THER MED, V9, P2, DOI 10.1054/ctim.2000.0407; Trinh KV, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004870.pub3; Tsakitzidis G, 2009, KCE REPORTS C; Vernon H, 2007, Eura Medicophys, V43, P91; White IR, 2011, STAT MED, V30, P3192, DOI 10.1002/sim.4360; Witt CM, 2006, PAIN, V125, P98, DOI 10.1016/j.pain.2006.05.013; Woodman JP, 2012, INT J CLIN PRACT, V66, P98, DOI 10.1111/j.1742-1241.2011.02817.x	41	59	62	0	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 3	2015	163	9					653	+		10.7326/M15-0667	http://dx.doi.org/10.7326/M15-0667			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX3PF	26524571				2023-01-03	WOS:000365610600001
J	Stingl, JC; Welker, S; Hartmann, G; Damann, V; Gerzer, R				Stingl, Julia C.; Welker, Susanne; Hartmann, Gunther; Damann, Volker; Gerzer, Ruppert			Where Failure Is Not an Option - Personalized Medicine in Astronauts	PLOS ONE			English	Article							DRUG-METABOLIZING-ENZYMES; PROTON PUMP INHIBITORS; GENETIC POLYMORPHISMS; CYTOCHROME-P450 2D6; ULTRARAPID METABOLIZER; CLINICAL CONSEQUENCES; CYP2C19 GENOTYPE; CYP2D6 GENOTYPE; CYP1A2 GENE; IN-VITRO	Drug safety and efficacy are highly variable among patients. Most patients will experience the desired drug effect, but some may suffer from adverse drug reactions or gain no benefit. Pharmacogenetic testing serves as a pre-treatment diagnostic option in situations where failure or adverse events should be avoided at all costs. One such situation is human space flight. On the international space station (ISS), a list of drugs is available to cover typical emergency settings, as well as the long-term treatment of common conditions for the use in self-medicating common ailments developing over a definite period. Here, we scrutinized the list of the 78 drugs permanently available at the ISS (year 2014) to determine the extent to which their metabolism may be affected by genetic polymorphisms, potentially requiring genotype-specific dosing or choice of an alternative drug. The purpose of this analysis was to estimate the potential benefit of pharmacogenetic diagnostics in astronauts to prevent therapy failure or side effects.	[Stingl, Julia C.; Welker, Susanne] Fed Inst Drugs & Med Devices, Div Res, Bonn, Germany; [Stingl, Julia C.] Univ Bonn, Fac Med, Ctr Translat Med, Bonn, Germany; [Hartmann, Gunther] Univ Bonn, Inst Clin Chem & Clin Pharmacol, Bonn, Germany; [Damann, Volker] European Space Agcy, Space Med Off, Cologne, Germany; [Gerzer, Ruppert] German Aerosp Ctr, Inst Aerosp Med, Cologne, Germany	University of Bonn; University of Bonn; European Space Agency; Helmholtz Association; German Aerospace Centre (DLR)	Stingl, JC (corresponding author), Fed Inst Drugs & Med Devices, Div Res, Bonn, Germany.	Julia.stingl@bfarm.de	Stingl, Julia C./ABA-7201-2020; Hartmann, Gunther/P-7492-2017	Stingl, Julia C./0000-0002-1566-8156; Hartmann, Gunther/0000-0003-1021-2018				Batty JA, 2014, CLIN PHARMACOL THER, V95, P321, DOI 10.1038/clpt.2013.193; BERTILSSON L, 1995, CLIN PHARMACOKINET, V29, P192, DOI 10.2165/00003088-199529030-00005; Bijl MJ, 2009, CLIN PHARMACOL THER, V85, P45, DOI 10.1038/clpt.2008.172; Candiotti KA, 2005, ANESTHESIOLOGY, V102, P543, DOI 10.1097/00000542-200503000-00011; Choi CI, 2012, J CLIN PHARMACOL, V52, P1934, DOI 10.1177/0091270011432168; Chung WH, 2014, JAMA-J AM MED ASSOC, V312, P525, DOI 10.1001/jama.2014.7859; de Leon J, 2008, CNS SPECTRUMS, V13, P133, DOI 10.1017/S109285290001628X; Dong HJ, 2000, DRUG METAB DISPOS, V28, P1397; Eichler HG, 2011, NAT REV DRUG DISCOV, V10, P495, DOI [10.1038/nrd3501, 10.1038/nrd3348]; Foster Adriana, 2007, Pain Pract, V7, P352, DOI 10.1111/j.1533-2500.2007.00153.x; Fukuda T, 1999, BRIT J CLIN PHARMACO, V47, P450, DOI 10.1046/j.1365-2125.1999.00913.x; Furuta K, 2010, J INT MED RES, V38, P1473, DOI 10.1177/147323001003800430; Furuta T, 2002, CLIN PHARMACOL THER, V72, P453, DOI 10.1067/mcp.2002.127637; Gaedigk A, 2008, CLIN PHARMACOL THER, V83, P234, DOI 10.1038/sj.clpt.6100406; Garcia-Martin E, 2004, CLIN PHARMACOL THER, V76, P119, DOI 10.1016/j.clpt.2004.04.006; Garcia-Martin E, 2006, MOL DIAGN THER, V10, P29, DOI 10.1007/BF03256440; Ghosal Anima, 2009, Drug Metab Lett, V3, P162; Gill HJ, 1999, PHARMACOGENETICS, V9, P43, DOI 10.1097/00008571-199902000-00007; Hartter S, 2006, BASIC CLIN PHARMACOL, V99, P300, DOI 10.1111/j.1742-7843.2006.pto_491.x; Hamadeh IS, 2014, CLIN PHARMACOL THER, V96, P175, DOI 10.1038/clpt.2014.62; Hendset M, 2007, EUR J CLIN PHARMACOL, V63, P1147, DOI 10.1007/s00228-007-0373-6; Hijazi Y, 2002, DRUG METAB DISPOS, V30, P853, DOI 10.1124/dmd.30.7.853; Hutchinson MR, 2004, BRIT J CLIN PHARMACO, V57, P287, DOI 10.1111/j.1365-2125.2003.02002.x; Ingelman-Sundberg M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/sj.tpj.6500285; Ingelman-Sundberg M, 2007, PHARMACOL THERAPEUT, V116, P496, DOI 10.1016/j.pharmthera.2007.09.004; Inomata S, 2005, CLIN PHARMACOL THER, V78, P647, DOI 10.1016/j.clpt.2005.08.020; Kawamura M, 2003, ALIMENT PHARM THER, V17, P965, DOI 10.1046/j.1365-2036.2003.01539.x; Kawamura M, 2007, J GASTROEN HEPATOL, V22, P222, DOI 10.1111/j.1440-1746.2006.04419.x; Kim KA, 2004, EUR J CLIN PHARMACOL, V60, P575, DOI 10.1007/s00228-004-0815-3; Kirchheiner J, 2005, NAT REV DRUG DISCOV, V4, P639, DOI 10.1038/nrd1801; Kirchheiner J, 2005, CLIN PHARMACOL THER, V77, P1, DOI 10.1016/j.clpt.2004.08.009; Kirchheiner J, 2004, MOL PSYCHIATR, V9, P442, DOI 10.1038/sj.mp.4001494; Kirchheiner J, 2004, CLIN PHARMACOL THER, V76, P302, DOI 10.1016/j.clpt.2004.07.002; Klotz U, 2004, BASIC CLIN PHARMACOL, V95, P2, DOI 10.1111/j.1600-0773.2004.pto950102.x; Lessard E, 1999, PHARMACOGENETICS, V9, P435; Nakajima M, 1999, J BIOCHEM-TOKYO, V125, P803, DOI 10.1093/oxfordjournals.jbchem.a022352; Nelson DR, 2011, CYTOCHROME P450 CYP; Nicolas JM, 1999, CHEM-BIOL INTERACT, V123, P63, DOI 10.1016/S0009-2797(99)00131-3; Olkkola K. T., 2008, V182, P335, DOI 10.1007/978-3-540-74806-9_16; Otton SV, 1996, BRIT J CLIN PHARMACO, V41, P149, DOI 10.1111/j.1365-2125.1996.tb00173.x; Palikhe NS, 2011, ALLERGY ASTHMA IMMUN, V3, P273, DOI 10.4168/aair.2011.3.4.273; Park MW, 2013, PHARMACOGENET GENOM, V23, P558, DOI 10.1097/FPC.0b013e328364eb92; Phillips KA, 2001, JAMA-J AM MED ASSOC, V286, P2270, DOI 10.1001/jama.286.18.2270; Rasmussen BB, 2002, PHARMACOGENETICS, V12, P473, DOI 10.1097/00008571-200208000-00008; Relling MV, 2011, CLIN PHARMACOL THER, V89, P464, DOI 10.1038/clpt.2010.279; Renwick AB, 1998, XENOBIOTICA, V28, P337, DOI 10.1080/004982598239452; Sachse C, 1999, BRIT J CLIN PHARMACO, V47, P445, DOI 10.1046/j.1365-2125.1999.00898.x; Schwab M, 2004, CLIN PHARMACOL THER, V76, P201, DOI 10.1016/j.clpt.2004.05.002; Shams MEE, 2006, J CLIN PHARM THER, V31, P493, DOI 10.1111/j.1365-2710.2006.00763.x; Shen M, 2013, FORENSIC SCI INT, V227, P77, DOI 10.1016/j.forsciint.2012.08.035; Siegle I, 2001, PHARMACOGENETICS, V11, P237, DOI 10.1097/00008571-200104000-00007; Sim SC, 2006, CLIN PHARMACOL THER, V79, P103, DOI 10.1016/j.clpt.2005.10.002; Stingl JC, 2013, MOL PSYCHIATR, V18, P273, DOI 10.1038/mp.2012.42; Swen JJ, 2008, CLIN PHARMACOL THER, V83, P781, DOI 10.1038/sj.clpt.6100507; Swen JJ, 2011, CLIN PHARMACOL THER, V89, P662, DOI 10.1038/clpt.2011.34; Veefkind AH, 2000, THER DRUG MONIT, V22, P202, DOI 10.1097/00007691-200004000-00011; Wang JS, 2000, DRUG METAB DISPOS, V28, P959; Wang ZJ, 2012, J CLIN PHARMACOL, V52, P1343, DOI 10.1177/0091270011414575	58	14	16	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2015	10	10							e0140764	10.1371/journal.pone.0140764	http://dx.doi.org/10.1371/journal.pone.0140764			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0ZM	26489089	Green Published, gold			2023-01-03	WOS:000363248400067
J	Fu, JZ; Huang, J; Lei, M; Luo, ZM; Zhong, XY; Huang, YH; Zhang, H; Liu, RG; Tong, JR; He, F				Fu, Junzhou; Huang, Jun; Lei, Ming; Luo, Zhengmao; Zhong, Xianyang; Huang, Yuanhang; Zhang, Hong; Liu, Riguang; Tong, Junrong; He, Feng			Prevalence and Impact on Stroke in Patients Receiving Maintenance Hemodialysis versus Peritoneal Dialysis: A Prospective Observational Study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; CARDIOVASCULAR RISK-FACTORS; AMERICAN-HEART-ASSOCIATION; ISCHEMIC-STROKE; SINGLE-CENTER; ALL-CAUSE; MORTALITY; EVENTS; UPDATE; COHORT	Background Patients undergoing maintenance dialysis are at increased risk of stroke, however, less is known about the prevalence and impact on stroke in the patients. Methods In this prospective cohort study, 590 patients undergoing hemodialysis (HD; n = 285) or peritoneal dialysis (PD; n = 305) from January 1, 2008 to December 31, 2012 were recruited. Baseline demographic, clinical, and laboratory data were collected. Timeline incidence data were analyzed using a Poisson model. The Cox proportional hazards regression assessed adjusted differences in stroke risk, a multivariate analysis was also performed. Results 62 strokes occurred during 1258 total patient-years of follow-up. Stroke occurred at a rate of 49.2/1,000 patient-years with a predominance in HD patients compared with PD patients (74.0 vs. 31.8/1,000 patient-years). The cumulative hazard of developing stroke was significantly higher in HD patients (hazard ratio [HR], 1.75; 95% confidence interval [CI], 1.15-3.62; p = 0.046) after adjusting for potential confounders. HD patients had an increased risk of ischemic stroke (HR, 2.62; 95% CI, 1.56-4.58; p = 0.002). The risk of hemorrhagic stroke was not significantly different between PD and HD patients. On multivariate Cox analysis, risk factors of stroke in both HD and PD patients were older age, diabetes, and cardiovascular disease. Other independent risk factors of stroke were lower albumin-corrected calcium in HD patients and higher triglycerides in PD patients. Conclusions Patients undergoing PD were less likely to develop ischemic stroke than those undergoing HD. Comprehensive control of diabetes, cardiovascular disease, calcium-phosphorus metabolism, and triglyceride levels may be useful preventive strategies for stroke in dialysis patients.	[Fu, Junzhou; Liu, Riguang; He, Feng] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Nephrol, Guangzhou 510180, Guangdong, Peoples R China; [Huang, Jun] Southern Med Univ, Grad Sch, Guangzhou 510515, Guangdong, Peoples R China; [Lei, Ming; Luo, Zhengmao; Zhong, Xianyang; Huang, Yuanhang; Zhang, Hong; Tong, Junrong] PLA, Guangzhou Mil Command, Gen Hosp, Dept Nephrol, Guangzhou 510010, Guangdong, Peoples R China	Guangzhou Medical University; Southern Medical University - China; Southern Theater Command General Hospital	Tong, JR (corresponding author), PLA, Guangzhou Mil Command, Gen Hosp, Dept Nephrol, Guangzhou 510010, Guangdong, Peoples R China.	tongjr63@163.com; hefengmm@163.com			National Natural Science Foundation of China [81270895, 81360137]; Guangdong Natural Science Foundation [2014A030310060]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province)	This study was funded by the National Natural Science Foundation of China (Grant No. 81270895; 81360137), and the Guangdong Natural Science Foundation (Grant No. 2014A030310060). The funders had no role in the design or conduct of this research.	Soriano LC, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0204-5; Chan KE, 2009, J AM SOC NEPHROL, V20, P2223, DOI 10.1681/ASN.2009030319; Cheung AK, 2009, CLIN J AM SOC NEPHRO, V4, pS95, DOI 10.2215/CJN.04780709; Goldfarb-Rumyantzev AS, 2007, AM J KIDNEY DIS, V50, P791, DOI 10.1053/j.ajkd.2007.07.023; He F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061497; Herzog CA, 2011, KIDNEY INT, V80, P572, DOI 10.1038/ki.2011.223; Iseki K, 2000, NEPHROL DIAL TRANSPL, V15, P1808, DOI 10.1093/ndt/15.11.1808; ISEKI K, 1993, KIDNEY INT, V44, P1086, DOI 10.1038/ki.1993.352; Karopadi AN, 2014, NEPHROL DIAL TRANSPL, V29, P885, DOI 10.1093/ndt/gft528; Kawamura M, 1998, AM J KIDNEY DIS, V31, P991, DOI 10.1053/ajkd.1998.v31.pm9631844; Liu XH, 2014, CLIN J AM SOC NEPHRO, V9, P771, DOI 10.2215/CJN.08280813; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; Losito A, 2012, NEPHROL DIAL TRANSPL, V27, P1054, DOI 10.1093/ndt/gfr378; Miller M, 2011, CIRCULATION, V123, P2292, DOI 10.1161/CIR.0b013e3182160726; Power A, 2012, AM J KIDNEY DIS, V59, P249, DOI 10.1053/j.ajkd.2011.07.016; Sanchez-Perales C, 2010, NEPHROL DIAL TRANSPL, V25, P3343, DOI 10.1093/ndt/gfq220; Seliger SL, 2003, J AM SOC NEPHROL, V14, P2623, DOI 10.1097/01.ASN.0000088722.56342.A8; Seliger SL, 2003, KIDNEY INT, V64, P603, DOI 10.1046/j.1523-1755.2003.00101.x; Slinin Y, 2005, J AM SOC NEPHROL, V16, P1788, DOI 10.1681/ASN.2004040275; Sozio SM, 2009, AM J KIDNEY DIS, V54, P468, DOI 10.1053/j.ajkd.2009.01.261; Sudlow CLM, 1996, STROKE, V27, P550, DOI 10.1161/01.STR.27.3.550; Toyoda K, 2005, AM J KIDNEY DIS, V45, P1058, DOI 10.1053/j.ajkd.2005.02.028; Wang HH, 2014, AM J KIDNEY DIS, V63, P604, DOI 10.1053/j.ajkd.2013.10.013; Westra WM, 2007, PERITON DIALYSIS INT, V27, P192; Xia X, 2014, AM J KIDNEY DIS, V64, P257, DOI 10.1053/j.ajkd.2013.08.027; Zoccali C, 2003, KIDNEY INT, V63, pS105, DOI 10.1046/j.1523-1755.63.s85.25.x	26	14	17	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2015	10	10							e0140887	10.1371/journal.pone.0140887	http://dx.doi.org/10.1371/journal.pone.0140887			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT7XI	26485155	Green Published, Green Submitted, gold			2023-01-03	WOS:000363028100085
J	Sanna, G; Madeddu, S; Giliberti, G; Ntalli, NG; Cottiglia, F; De Logu, A; Agus, E; Caboni, P				Sanna, Giuseppina; Madeddu, Silvia; Giliberti, Gabriele; Ntalli, Nikoletta G.; Cottiglia, Filippo; De Logu, Alessandro; Agus, Emanuela; Caboni, Pierluigi			Limonoids from Melia azedarach Fruits as Inhibitors of Flaviviruses and Mycobacterium tubercolosis	PLOS ONE			English	Article							CYTOTOXIC LIMONOIDS; DENGUE VIRUS; L. DIPTERA; EXTRACTS; ANTIMYCOBACTERIAL; TRITERPENOIDS; LEAVES; ENTRY	The biological diversity of nature is the source of a wide range of bioactive molecules. The natural products, either as pure compounds or as standardized plant extracts, have been a successful source of inspiration for the development of new drugs. The present work was carried out to investigate the cytotoxicity, antiviral and antimycobacterial activity of the methanol extract and of four identified limonoids from the fruits of Melia azedarach (Meliaceae). The extract and purified limonoids were tested in cell-based assays for antiviral activity against representatives of ssRNA, dsRNA and dsDNA viruses and against Mycobacterium tuberculosis. Very interestingly, 3-alpha-tigloyl-melianol and melianone showed a potent antiviral activity (EC50 in the range of 3-11 mu M) against three important human pathogens, belonging to Flaviviridae family, West Nile virus, Dengue virus and Yellow Fever virus. Mode of action studies demonstrated that title compounds were inhibitors of West Nile virus only when added during the infection, acting as inhibitors of the entry or of a very early event of life cycle. Furthermore, 3-alpha-tigloyl-melianol and methyl kulonate showed interesting antimycobacterial activity (with MIC values of 29 and 70 mu M respectively). The limonoids are typically lipophilic compounds present in the fruits of Melia azeradach. They are known as cytotoxic compounds against different cancer cell lines, while their potential as antiviral and antibacterial was poorly investigated. Our studies show that they may serve as a good starting point for the development of novel drugs for the treatment of infections by Flaviviruses and Mycobacterium tuberculosis, for which there is a continued need.	[Sanna, Giuseppina; Madeddu, Silvia; Giliberti, Gabriele] Univ Cagliari, Dept Biomed Sci, Sect Microbiol & Virol, I-09124 Cagliari, Italy; [Ntalli, Nikoletta G.; Cottiglia, Filippo; Caboni, Pierluigi] Univ Cagliari, Dept Life & Environm Sci, High Resolut Mass Spectrometry Lab, I-09124 Cagliari, Italy; [De Logu, Alessandro; Agus, Emanuela] Univ Cagliari, Dept Life & Environm Sci, Sect Med Microbiol, I-09124 Cagliari, Italy	University of Cagliari; University of Cagliari; University of Cagliari	Giliberti, G (corresponding author), Univ Cagliari, Dept Biomed Sci, Sect Microbiol & Virol, I-09124 Cagliari, Italy.	ggiliberti@unica.it	Sanna, Giuseppina/AAR-5370-2020	Sanna, Giuseppina/0000-0002-3999-4263; Ntalli, Nikoletta/0000-0002-2017-2972				Akihisa T, 2013, PHYTOCHEMISTRY, V89, P59, DOI 10.1016/j.phytochem.2013.01.015; Balestrieri E, 2011, BIOORGAN MED CHEM, V19, P2084, DOI 10.1016/j.bmc.2011.01.024; Barrett ADT, 2009, CURR OPIN IMMUNOL, V21, P308, DOI 10.1016/j.coi.2009.05.018; Bueno CA, 2010, BIOCHEM BIOPH RES CO, V393, P32, DOI 10.1016/j.bbrc.2010.01.068; Bueno CA, 2009, VIRUS RES, V141, P47, DOI 10.1016/j.virusres.2008.12.013; Cabral MMO, 2008, REV BRAS FARMACOGN, V18, P699, DOI 10.1590/S0102-695X2008000500011; Cantrell CL, 1999, J NAT PROD, V62, P546, DOI 10.1021/np980288u; Cheng YB, 2014, J NAT PROD, V77, P2367, DOI 10.1021/np5002829; Chu JJH, 2004, J VIROL, V78, P10543, DOI 10.1128/JVI.78.19.10543-10555.2004; Coria C, 2008, BIORESOURCE TECHNOL, V99, P3066, DOI 10.1016/j.biortech.2007.06.012; Della Bona A, 2015, J MED FOOD, V18, P259, DOI 10.1089/jmf.2013.0181; Diosa-Toro M, 2013, ADV VIRUS RES, V85, P91, DOI 10.1016/B978-0-12-408116-1.00004-5; Gould EA, 2008, LANCET, V371, P500, DOI 10.1016/S0140-6736(08)60238-X; Gubler D, 2007, FIELDS VIROLOGY, P1155; ITOKAWA H, 1995, CHEM PHARM BULL, V43, P1171, DOI 10.1248/cpb.43.1171; Li Y, 2007, PHYTOTHER RES, V21, P466, DOI 10.1002/ptr.1962; Liang CQ, 2013, J NAT PROD, V76, P2350, DOI 10.1021/np400546z; Lim SP, 2013, VIRUSES-BASEL, V5, P2977, DOI 10.3390/v5122977; Maneerata W, 2008, PHYTOMEDICINE, V15, P1130, DOI 10.1016/j.phymed.2008.05.004; Ntalli NG, 2010, MOLECULES, V15, P5866, DOI 10.3390/molecules15095866; Pan X, 2014, CHEM BIODIVERS, V11, P1121, DOI 10.1002/cbdv.201400190; Pan X, 2014, CHEM BIODIVERS, V11, P987, DOI 10.1002/cbdv.201400052; Parida MM, 2002, J ETHNOPHARMACOL, V79, P273, DOI 10.1016/S0378-8741(01)00395-6; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; Perera-Lecoin M, 2014, VIRUSES-BASEL, V6, P69, DOI 10.3390/v6010069; Rahman AKMS, 2009, J NAT MED-TOKYO, V63, P41, DOI 10.1007/s11418-008-0287-3; Roy A, 2006, BIOL PHARM BULL, V29, P191, DOI 10.1248/bpb.29.191; Sanna G, 2015, NAT PROD RES, V23, P1; Solomon T, 2001, J INFECTION, V42, P104, DOI 10.1053/jinf.2001.0802; Szewczuk VD, 2006, PHYTOTHER RES, V20, P993, DOI 10.1002/ptr.1929; Talarico LB, 2005, ANTIVIR RES, V66, P103, DOI 10.1016/j.antiviral.2005.02.001; Vila S, 2010, BIOCELL, V34, P7; Vila SK, 2004, BIOCELL, V28, P35; Xiao J, 2014, NAT PROD RES, V28, P1388, DOI 10.1080/14786419.2014.904308; Yuan CM, 2013, PLANTA MED, V79, P163, DOI 10.1055/s-0032-1328069; Zahoor M, 2014, NAT PROD RES, V26, P1; Zhao JQ, 2014, NAT PRODUCT BIOPROSP, V4, P233, DOI 10.1007/s13659-014-0026-2; Zhou HL, 2005, CHEM PHARM BULL, V53, P1362, DOI 10.1248/cpb.53.1362	38	16	18	1	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2015	10	10							e0141272	10.1371/journal.pone.0141272	http://dx.doi.org/10.1371/journal.pone.0141272			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT7XI	26485025	Green Published, gold, Green Submitted			2023-01-03	WOS:000363028100128
J	Tung, CW; Hsu, YC; Shih, YH; Lin, CL				Tung, Chun-Wu; Hsu, Yung-Chien; Shih, Ya-Hsueh; Lin, Chun-Liang			Association of Adiponectin with High-Sensitivity C-Reactive Protein and Clinical Outcomes in Peritoneal Dialysis Patients: A 3.5-Year Follow-Up Study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; ALL-CAUSE MORTALITY; HEMODIALYSIS-PATIENTS; CARDIOVASCULAR-DISEASE; PLASMA ADIPONECTIN; CIRCULATING ADIPONECTIN; RECIPROCAL ASSOCIATION; INSULIN-RESISTANCE; ADIPOSE-TISSUE; KIDNEY-DISEASE	Introduction Adiponectin (ADPN), one of most abundant fat-derived biologically active substances, plays an important role in anti-atherosclerotic process. There are conflicting results about the impact of ADPN on cardiovascular (CV) outcomes and mortality, particularly in patients undergoing peritoneal dialysis (PD). Moreover, the relationship between ADPN and inflammatory mediators has been seldom explored in this population. Therefore, we examined the relationship between ADPN and longitudinal high-sensitivity C-reactive protein (hs-CRP) changes and investigated whether ADPN or hs-CRP levels could predict CV outcomes and mortality in prevalent PD patients after comprehensive adjustment of possible confounders. Methods In this prospective cohort study, 78 PD patients were enrolled and followed from February 2009 to August 2012. During follow-up, CV events and all-cause mortality were recorded. Results The mean baseline ADPN value was 29.46 +/- 18.01 mu g/ml and duration of PD treatment was 37.76 +/- 36.96 months. In multiple linear regression analysis, plasma ADPN levels positively correlated with high-density lipoprotein and negatively associated with hs-CRP, body mass index, D4/D0 glucose, triglyceride, and duration of PD treatment. After stratified by genders, the inverse association between baseline ADPN and hs-CRP was more significant in the female group. The hs-CRP levels were followed up annually and remained significantly lower in the high ADPN group in the first 2 years. Patients were then stratified into two groups according to the median ADPN value (23.8 mu g/ml). The results of Kaplan-Meier survival analysis demonstrated less CV events and better survival in high ADPN group. On multivariate Cox regression analysis, only ADPN level (HR: 0.93, 95% CI: 0.88-0.98, p = 0.02), age and history of CV diseases were independent risk factors for future CV events. Furthermore, hs-CRP (HR: 1.11, 95% CI: 1.001-1.22, p = 0.04) was identified as independent predictor of all-cause mortality. Conclusions Serum hs-CRP levels were consistently lower in the high ADPN group during 2-year follow-up. We also demonstrated the importance of ADPN and hs-CRP in predicting CV events and all-cause mortality in PD population during 3.5-year follow-up.	[Tung, Chun-Wu; Hsu, Yung-Chien; Shih, Ya-Hsueh; Lin, Chun-Liang] Chang Gung Mem Hosp, Dept Nephrol, Chiayi, Taiwan; [Tung, Chun-Wu] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan, Taiwan; [Tung, Chun-Wu; Hsu, Yung-Chien; Shih, Ya-Hsueh; Lin, Chun-Liang] Chang Gung Mem Hosp, Dept Kidney & Diabet Complicat Res Team KDCRT, Chiayi, Taiwan; [Tung, Chun-Wu; Hsu, Yung-Chien; Shih, Ya-Hsueh; Lin, Chun-Liang] Chang Gung Mem Hosp, Chron Kidney Dis Ctr, Chiayi, Taiwan; [Lin, Chun-Liang] Chang Gung Univ, Sch Tradit Chinese Med, Coll Med, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University	Lin, CL (corresponding author), Chang Gung Mem Hosp, Dept Nephrol, Chiayi, Taiwan.	linchunliang@cgmh.org.tw			Chang Gung Memorial Hospital at Chiayi, Taiwan [CMRPG690191]	Chang Gung Memorial Hospital at Chiayi, Taiwan	This work was supported by grants from Chang Gung Memorial Hospital at Chiayi, Taiwan (CMRPG690191, to CWT), https://www.cgmh.org.tw/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Hamodi Z, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-99; Alemzadeh R, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/2251-6581-13-35; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Chandran M, 2003, DIABETES CARE, V26, P2442, DOI 10.2337/diacare.26.8.2442; Chaudhary K, 2011, CLIN J AM SOC NEPHRO, V6, P447, DOI 10.2215/CJN.07920910; Disthabanchong S, 2011, NEPHROL DIAL TRANSPL, V26, P592, DOI 10.1093/ndt/gfq410; Ducloux D, 2002, KIDNEY INT, V62, P1417, DOI 10.1111/j.1523-1755.2002.kid562.x; Fasshauer M, 2002, BIOCHEM BIOPH RES CO, V290, P1084, DOI 10.1006/bbrc.2001.6307; Funahashi T, 1999, INTERNAL MED, V38, P202, DOI 10.2169/internalmedicine.38.202; Huang JW, 2004, AM J KIDNEY DIS, V43, P1047, DOI 10.1053/j.ajkd.2004.02.017; Huh JY, 2012, PERITON DIALYSIS INT, V32, P20, DOI 10.3747/pdi.2009.00228; Ignacy W, 2005, NEPHRON CLIN PRACT, V101, pC18, DOI 10.1159/000085707; James LR, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0052350, DOI 10.1371/JOURNAL.PONE.0052350]; Johnson DW, 2009, CLIN J AM SOC NEPHRO, V4, P1620, DOI 10.2215/CJN.01750309; Kalantar-Zadeh K, 2005, AM J KIDNEY DIS, V46, P489, DOI 10.1053/j.ajkd.2005.05.020; Kalantar-Zadeh K, 2006, CONTRIB NEPHROL, V151, P57, DOI 10.1159/000095319; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Lai KN, 2012, PERITON DIALYSIS INT, V32, P280, DOI 10.3747/pdi.2010.00176; Li Y, 2012, PERITON DIALYSIS INT, V32, P507, DOI 10.3747/pdi.2011.00116; Liu SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093063; Lui SL, 2012, AM J KIDNEY DIS, V60, P966, DOI 10.1053/j.ajkd.2012.05.018; Matsushita K, 2006, ATHEROSCLEROSIS, V188, P184, DOI 10.1016/j.atherosclerosis.2005.10.031; Mcdonald SP, 2003, J AM SOC NEPHROL, V14, P2894, DOI 10.1097/01.ASN.0000091587.55159.5F; Menon V, 2006, J AM SOC NEPHROL, V17, P2599, DOI 10.1681/ASN.2006040331; Ohashi N, 2008, INTERNAL MED, V47, P485, DOI 10.2169/internalmedicine.47.0614; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Ouchi N, 2003, CIRCULATION, V107, P671, DOI 10.1161/01.CIR.0000055188.83694.B3; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Ozdemir FN, 2001, ARTIF ORGANS, V25, P448, DOI 10.1046/j.1525-1594.2001.025006448.x; Pilz S, 2006, J CLIN ENDOCR METAB, V91, P4277, DOI 10.1210/jc.2006-0836; Pischon T, 2004, JAMA-J AM MED ASSOC, V291, P1730, DOI 10.1001/jama.291.14.1730; Pliakogiannis T, 2007, INT UROL NEPHROL, V39, P281, DOI 10.1007/s11255-006-9142-1; Prichard S, 1999, PERITON DIALYSIS INT, V19, pS133; Rhee CM, 2015, AM J KIDNEY DIS, V66, P313, DOI 10.1053/j.ajkd.2015.02.325; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rodriguez-Carmona A, 2012, NEPHROL DIAL TRANSPL, V27, P369, DOI 10.1093/ndt/gfr244; Ryo M, 2004, CIRC J, V68, P975, DOI 10.1253/circj.68.975; Selby NM, 2007, NEPHROL DIAL TRANSPL, V22, P870, DOI 10.1093/ndt/gfl654; Takeguchi F, 2008, THER APHER DIAL, V12, P243, DOI 10.1111/j.1744-9987.2008.00581.x; Tan CC, 2005, KIDNEY INT, V67, pS19, DOI 10.1111/j.1523-1755.2005.09405.x; Tsao YT, 2008, J NEPHROL, V21, P744; Tsigalou C, 2013, J RENAL NUTR, V23, P45, DOI 10.1053/j.jrn.2011.12.007; TWARDOWSKI ZJ, 1989, BLOOD PURIFICAT, V7, P95, DOI 10.1159/000169582; US Renal Data System, USRDS 2013 ANN DAT R; Wannamethee SG, 2007, ARCH INTERN MED, V167, P1510, DOI 10.1001/archinte.167.14.1510; Wu ZJ, 2014, METABOLISM, V63, P1157, DOI 10.1016/j.metabol.2014.05.001; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yeun JY, 2000, AM J KIDNEY DIS, V35, P469, DOI 10.1016/S0272-6386(00)70200-9; Yu ZZ, 2008, BLOOD PURIFICAT, V26, P386, DOI 10.1159/000141930; Zoccali C, 2005, J RENAL NUTR, V15, P125, DOI 10.1053/j.jrn.2004.09.036; Zoccali C, 2002, J AM SOC NEPHROL, V13, P134, DOI 10.1681/ASN.V131134	51	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2015	10	10							e0141058	10.1371/journal.pone.0141058	http://dx.doi.org/10.1371/journal.pone.0141058			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0DF	26474473	gold, Green Published, Green Submitted			2023-01-03	WOS:000363185500143
J	Moritz, ML; Ayus, JC				Moritz, Michael L.; Ayus, Juan C.			DISORDERS OF FLUIDS AND ELECTROLYTES Maintenance Intravenous Fluids in Acutely Ill Patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HOSPITAL-ACQUIRED HYPONATREMIA; RANDOMIZED CONTROLLED-TRIAL; PERMANENT BRAIN-DAMAGE; POSTOPERATIVE HYPONATREMIA; CHILDREN; THERAPY; SODIUM; WATER; ENCEPHALOPATHY; MANAGEMENT		[Moritz, Michael L.] Univ Pittsburgh, Sch Med, Dept Pediat, Childrens Hosp Pittsburgh,Univ Pittsburgh Med Ctr, Pittsburgh, PA 15261 USA; [Moritz, Michael L.] Univ Pittsburgh, Sch Med, Div Nephrol, Childrens Hosp Pittsburgh,Univ Pittsburgh Med Ctr, Pittsburgh, PA 15261 USA; [Ayus, Juan C.] Renal Consultants Houston, Houston, TX USA; [Ayus, Juan C.] Hosp Italiano Buenos Aires, Div Nephrol, Buenos Aires, DF, Argentina	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hospital Italiano de Buenos Aires; University of Buenos Aires	Moritz, ML (corresponding author), UPMC, Div Nephrol, Childrens Hosp Pittsburgh, 1 Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA.	moritzml@upmc.edu			Otsuka	Otsuka(Otsuka Pharmaceutical)	Drs. Moritz and Ayus report receiving consulting fees from Otsuka and a continuing medical education honorarium from the Global Education Group. No other potential conflict of interest relevant to this article was reported.	Amin A, 2012, J HOSP MED, V7, P634, DOI 10.1002/jhm.1973; ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; [Anonymous], 2009, ISMP CANADA SAFETY B, V9, P1; [Anonymous], 2011, BRIT CONSENSUS GUIDE; ARIEFF AI, 1992, BRIT MED J, V304, P1218, DOI 10.1136/bmj.304.6836.1218; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; Aronson D, 2002, AM J KIDNEY DIS, V40, P940, DOI 10.1053/ajkd.2002.36324; Au AK, 2008, J PEDIATR, V152, P33, DOI 10.1016/j.jpeds.2007.08.040; Ayus JC, 2006, KIDNEY INT, V69, P1319, DOI 10.1038/sj.ki.5000187; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; Ayus JC, 1999, JAMA-J AM MED ASSOC, V281, P2299, DOI 10.1001/jama.281.24.2299; Ayus JC, 2015, AM J KIDNEY DIS, V65, P435, DOI 10.1053/j.ajkd.2014.09.021; Ayus JC, 2010, CLIN J AM SOC NEPHRO, V5, P167, DOI 10.2215/CJN.09281209; BOMBERGER RA, 1986, J VASC SURG, V4, P164, DOI 10.1067/mva.1986.avs0040164; Carandang F, 2013, J PEDIATR-US, V163, P1646, DOI 10.1016/j.jpeds.2013.07.020; Ayus JC, 2012, NEPHROL DIAL TRANSPL, V27, P3725, DOI 10.1093/ndt/gfs412; Chawla G, 2008, MED EDUC, V42, P613, DOI 10.1111/j.1365-2923.2008.03009.x; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; Corona G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080451; Coulthard MG, 2007, BRIT J ANAESTH, V98, P146, DOI 10.1093/bja/ael297; Danziger J, 2015, CLIN J AM SOC NEPHRO, V10, P852, DOI 10.2215/CJN.10741013; Davies Polly, 2008, BMC Surg, V8, P10, DOI 10.1186/1471-2482-8-10; Drysdale SB, 2010, EUR J PEDIATR, V169, P813, DOI 10.1007/s00431-009-1117-7; Ellison DH, 2007, NEW ENGL J MED, V356, P2064, DOI 10.1056/NEJMcp066837; Foster BA, 2014, J PEDIAT, V165; Freeman MA, 2012, ACTA PAEDIATR, V101, pE465, DOI 10.1111/j.1651-2227.2012.02780.x; Friedman JN, 2015, JAMA PEDIATR, V169, P445, DOI 10.1001/jamapediatrics.2014.3809; Gankam-Kengne F, 2013, KIDNEY INT, V83, P700, DOI 10.1038/ki.2012.459; Greenberg A, 2015, KIDNEY INT, V88, P167, DOI 10.1038/ki.2015.4; Grissinger Matthew, 2013, P T, V38, P575; Halberthal M, 2001, BRIT MED J, V322, P780, DOI 10.1136/bmj.322.7289.780; Hanna M, 2010, PEDIATR NEPHROL, V25, P1471, DOI 10.1007/s00467-009-1428-y; Hatherill M, 2004, ARCH DIS CHILD, V89, P414, DOI 10.1136/adc.2003.045047; HOLLIDAY MA, 1957, PEDIATRICS, V19, P823; Holliday MA, 2007, ARCH DIS CHILD, V92, P546, DOI 10.1136/adc.2006.106377; Hoorn EJ, 2013, AM J KIDNEY DIS, V62, P139, DOI 10.1053/j.ajkd.2012.09.019; Institute for Safe Medication Practices, 2009, ISMP MED SAFETY ALER, V14, P1; Issa VS, 2013, INT J CARDIOL, V167, P34, DOI 10.1016/j.ijcard.2011.11.087; Rodriguez MJ, 2014, ACTA PAEDIATR, V103, pE7, DOI 10.1111/apa.12439; Kannan L, 2010, PEDIATR NEPHROL, V25, P2303, DOI 10.1007/s00467-010-1600-4; Kinsella S, 2010, CLIN J AM SOC NEPHRO, V5, P275, DOI 10.2215/CJN.06120809; Knepper MA, 2015, NEW ENGL J MED, V372, P1349, DOI 10.1056/NEJMra1404726; Lobo DN, 2014, KIDNEY INT, V86, P1096, DOI 10.1038/ki.2014.105; McNab S, 2014, COCHRANE DB SYST REV, V12, P1; Mcnab S, 2015, LANCET, V385, P1190, DOI 10.1016/S0140-6736(14)61459-8; Mohan S, 2013, AM J MED, V126, P1127, DOI 10.1016/j.amjmed.2013.07.021; Moritz M, 2005, PEDIATR NEPHROL, V20, P1687, DOI 10.1007/s00467-005-1933-6; Moritz ML, 2008, PEDIATR NEPHROL, V23, P955, DOI 10.1007/s00467-008-0757-6; Moritz ML, 2007, NAT CLIN PRACT NEPHR, V3, P374, DOI 10.1038/ncpneph0526; Moritz ML, 2011, CURR OPIN PEDIATR, V23, P186, DOI 10.1097/MOP.0b013e3283440fd9; Moritz ML, 2010, PEDIATR NEPHROL, V25, P1225, DOI 10.1007/s00467-009-1323-6; Moritz ML, 2003, PEDIATRICS, V111, P227, DOI 10.1542/peds.111.2.227; Moro N, 2007, SURG NEUROL, V68, P387, DOI 10.1016/j.surneu.2006.11.052; Musch W, 1998, QJM-MON J ASSOC PHYS, V91, P749, DOI 10.1093/qjmed/91.11.749; Mythen MG, 2012, PERIOPER MED, V1, DOI 10.1186/2047-0525-1-2; Nair V, 2007, AM J NEPHROL, V27, P184, DOI 10.1159/000100866; National Patient Safety Agency (NPSA), 2007, PAT SAF AL RED RISK; Neville KA, 2005, PEDIATRICS, V116, P1401, DOI 10.1542/peds.2004-2376; Neville KA, 2010, J PEDIAT, V156; Nigro N, 2015, J AM GERIATR SOC, V63, P470, DOI 10.1111/jgs.13325; Oster JR, 1997, ARCH INTERN MED, V157, P721, DOI 10.1001/archinte.157.7.721; Padhi S, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7073; Renneboog B, 2006, AM J MED, V119, DOI [10.1016/j.amjmed.2005.09.026, DOI 10.1016/J.AMJMED.2005.09.026]; Saba TG, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-82; Schrier RW, 2006, J AM SOC NEPHROL, V17, P1820, DOI 10.1681/ASN.2006030240; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1127, DOI 10.1056/NEJM198810273191705; Severs D, 2015, NEPHROL DIAL TRANSPL, V30, P178, DOI 10.1093/ndt/gfu005; Shafiee MAS, 2003, QJM-INT J MED, V96, P601, DOI 10.1093/qjmed/hcg101; Shamim A, 2014, INDIAN PEDIATR, V51, P969, DOI 10.1007/s13312-014-0542-5; Spasovski G, 2014, NEPHROL DIAL TRANSPL, V29, P1, DOI 10.1093/ndt/gfu040; Steele A, 1997, ANN INTERN MED, V126, P20, DOI 10.7326/0003-4819-126-1-199701010-00003; TALBOT NB, 1953, NEW ENGL J MED, V248, P1100, DOI 10.1056/NEJM195306252482605; Taylor D, 2004, ARCH DIS CHILD, V89, P411, DOI 10.1136/adc.2003.045302; Upadhyay A, 2006, AM J MED, V119, pS30, DOI 10.1016/j.amjmed.2006.05.005; Verbalis JG, 2010, J BONE MINER RES, V25, P554, DOI 10.1359/jbmr.090827; Yung M, 2009, J PAEDIATR CHILD H, V45, P9, DOI 10.1111/j.1440-1754.2007.01254.x	76	94	99	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 1	2015	373	14					1350	1360		10.1056/NEJMra1412877	http://dx.doi.org/10.1056/NEJMra1412877			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CS3CI	26422725				2023-01-03	WOS:000361948600009
J	Rewatkar, PV; Parekh, HS; Parat, MO				Rewatkar, Prarthana V.; Parekh, Harendra S.; Parat, Marie-Odile			Molecular Determinants of the Cellular Entry of Asymmetric Peptide Dendrimers and Role of Caveolae	PLOS ONE			English	Article							ARGININE-RICH PEPTIDES; SURFACE-CHARGE; ANIONIC SITES; DIFFERENTIATED MICRODOMAINS; TRANSLOCATION MECHANISMS; CAPILLARY ENDOTHELIUM; PAMAM DENDRIMERS; LUMINAL SURFACE; DELIVERY; MEMBRANE	Caveolae are flask-shaped plasma membrane subdomains abundant in most cell types that participate in endocytosis. Caveola formation and functions require membrane proteins of the caveolin family, and cytoplasmic proteins of the cavin family. Cationic peptide dendrimers are non-vesicular chemical carriers that can transport pharmacological agents or genetic material across the plasma membrane. We prepared a panel of cationic dendrimers and investigated whether they require caveolae to enter into cells. Cell-based studies were performed using wild type or caveola-deficient i.e. caveolin-1 or PTRF gene-disrupted cells. There was a statistically significant difference in entry of cationic dendrimers between wild type and caveola-deficient cells. We further unveiled differences between dendrimers with varying charge density and head groups. Our results show, using a molecular approach, that (i) expression of caveola-forming proteins promotes cellular entry of cationic dendrimers and (ii) dendrimer structure can be modified to promote endocytosis in caveola-forming cells.	[Rewatkar, Prarthana V.; Parekh, Harendra S.; Parat, Marie-Odile] Univ Queensland, Sch Pharm, 20 Cornwall St, Woolloongabba, Qld 4102, Australia	University of Queensland	Parekh, HS; Parat, MO (corresponding author), Univ Queensland, Sch Pharm, 20 Cornwall St, Woolloongabba, Qld 4102, Australia.	h.parekh@uq.edu.au; m.parat@uq.edu.au	Parekh, Harendra S/D-6846-2011; Parekh, Harendra/P-3964-2019; Parat, Marie-Odile/G-4410-2010	Parekh, Harendra S/0000-0001-8792-4318; Parekh, Harendra/0000-0001-8792-4318; Parat, Marie-Odile/0000-0003-4895-7381	School of Pharmacy	School of Pharmacy	This study was entirely funded by internal funds from the School of Pharmacy to MOP and HSP.	Albertazzi L, 2012, BIOMACROMOLECULES, V13, P4089, DOI 10.1021/bm301384y; Billiet L, 2012, BIOMATERIALS, V33, P2980, DOI 10.1016/j.biomaterials.2011.12.027; Biswas S, 2013, PHARMACEUTICALS-BASE, V6, P161, DOI 10.3390/ph6020161; Buczkowski A, 2011, INT J PHARMACEUT, V408, P266, DOI 10.1016/j.ijpharm.2011.02.014; Bugno J, 2015, BIOMATER SCI-UK, V3, P1025, DOI 10.1039/c4bm00351a; Chaudhary N, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001832; Cheng ZJ, 2010, J BIOL CHEM, V285, P15119, DOI 10.1074/jbc.M109.069427; Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027; Cordes H, 2007, BIOMACROMOLECULES, V8, P3578, DOI 10.1021/bm7006168; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808; Frohlich E, 2012, INT J NANOMED, V7, P5577, DOI 10.2147/IJN.S36111; Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009; Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Hill MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043041; Kaneshiro TL, 2009, BIOMATERIALS, V30, P5660, DOI 10.1016/j.biomaterials.2009.06.026; Kim TI, 2007, BIOMATERIALS, V28, P2061, DOI 10.1016/j.biomaterials.2006.12.013; Liu LB, 2008, CELL METAB, V8, P310, DOI 10.1016/j.cmet.2008.07.008; Liu LB, 2008, J BIOL CHEM, V283, P4314, DOI 10.1074/jbc.M707890200; Liu XX, 2015, NANOSCALE, V7, P3867, DOI 10.1039/c4nr04759a; Maiti PK, 2004, MACROMOLECULES, V37, P6236, DOI 10.1021/ma035629b; Naka K, 2012, POLYM J, V44, P353, DOI 10.1038/pj.2011.145; Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824; Parat MO, 2001, J BIOL CHEM, V276, P15776, DOI 10.1074/jbc.M006722200; Parton RG, 2013, NAT REV MOL CELL BIO, V14, P98, DOI 10.1038/nrm3512; Perumal OP, 2008, BIOMATERIALS, V29, P3469, DOI 10.1016/j.biomaterials.2008.04.038; Rewatkar PV, 2015, ADV DRUG DELIVER REV, V91, P92, DOI 10.1016/j.addr.2015.01.003; Richter T, 2008, TRAFFIC, V9, P893, DOI 10.1111/j.1600-0854.2008.00733.x; Schlormann W, 2010, HISTOCHEM CELL BIOL, V133, P223, DOI 10.1007/s00418-009-0651-8; Shah N, 2011, J PEPT SCI, V17, P470, DOI 10.1002/psc.1347; Shah ND, 2014, PHARM RES-DORDR, V31, P3150, DOI 10.1007/s11095-014-1408-1; SIMIONESCU D, 1983, MICROVASC RES, V25, P85, DOI 10.1016/0026-2862(83)90045-6; SIMIONESCU M, 1981, J CELL BIOL, V90, P614, DOI 10.1083/jcb.90.3.614; SIMIONESCU N, 1981, J CELL BIOL, V90, P605, DOI 10.1083/jcb.90.3.605; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Topp A, 1999, MACROMOLECULES, V32, P7232, DOI 10.1021/ma9901240; Xiao K, 2011, BIOMATERIALS, V32, P3435, DOI 10.1016/j.biomaterials.2011.01.021	38	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2016	11	1							e0147491	10.1371/journal.pone.0147491	http://dx.doi.org/10.1371/journal.pone.0147491			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB5BW	26788849	Green Published, gold, Green Submitted			2023-01-03	WOS:000368529100089
J	Moore, KA; Rubin, EB; Halpern, SD				Moore, Kendra A.; Rubin, Emily B.; Halpern, Scott D.			The Problems With Physician Orders for Life-Sustaining Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Moore, Kendra A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Moore, Kendra A.; Rubin, Emily B.; Halpern, Scott D.] Univ Penn, Fostering Improvement End Of Life Decis Sci FIELD, Philadelphia, PA 19104 USA; [Rubin, Emily B.; Halpern, Scott D.] Univ Penn, Div Pulm Allergy & Crit Care Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Halpern, SD (corresponding author), Univ Penn, 719 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	shalpern@exchange.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL098054] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL098054] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], PHYS ORD LIF SUST TR; [Anonymous], 2006, NAT FRAM PREF PRACT; Auriemma CL, 2014, JAMA INTERN MED, V174, P1085, DOI 10.1001/jamainternmed.2014.1183; Fromme EK, 2014, J AM GERIATR SOC, V62, P1246, DOI 10.1111/jgs.12889; Hickman SE, 2015, J AM GERIATR SOC, V63, P341, DOI 10.1111/jgs.13248; Hickman SE, 2011, J AM GERIATR SOC, V59, P2091, DOI 10.1111/j.1532-5415.2011.03656.x; Mirarchi FL, 2015, J PATIENT SAF, V11, P9, DOI 10.1097/PTS.0000000000000164; Mirarchi FL, 2015, J PATIENT SAF, V11, P1, DOI 10.1097/PTS.0000000000000165	8	32	32	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					259	260		10.1001/jama.2015.17362	http://dx.doi.org/10.1001/jama.2015.17362			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DB2WN	26784769	Green Accepted			2023-01-03	WOS:000368371400018
J	Compton, WM; Jones, CM; Baldwin, GT				Compton, Wilson M.; Jones, Christopher M.; Baldwin, Grant T.			Relationship between Nonmedical Prescription-Opioid Use and Heroin Use	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							UNITED-STATES; RISK BEHAVIORS; DRUG-USERS; ABUSE; OVERDOSE; EPIDEMIC; MISUSE; INJECTION; DIVERSION; NALOXONE		[Compton, Wilson M.] NIDA, NIH, Silver Spring, MD USA; [Jones, Christopher M.] US FDA, Silver Spring, MD USA; [Baldwin, Grant T.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); US Food & Drug Administration (FDA); Centers for Disease Control & Prevention - USA	Compton, WM (corresponding author), NIDA, NIH, 6001 Execut Blvd,MSC 9581, Bethesda, MD 20892 USA.	wcompton@nida.nih.gov						[Anonymous], 2013, ADDR PRESCR DRUG AB; [Anonymous], 2015, PUB DEP JUST, VDEA-DCT-DIR-002-15; [Anonymous], 2013, CBHSQ DATA REV; [Anonymous], 2013, DAWN REP HIGHL 2011; [Anonymous], 2014, HHS PUBL; Association of State and Territorial Health Officials, 2013, ASTHO PRESCR DRUG MI; Becker WC, 2008, DRUG ALCOHOL DEPEN, V94, P38, DOI 10.1016/j.drugalcdep.2007.09.018; Cassidy TA, 2014, PAIN MED, V15, P440, DOI 10.1111/pme.12295; Center for Behavioral Health Statistics and Quality, 2015, 2014 NAT SURV DRUG U; Centers for Disease Control and Prevention, 2015, WID RANG ONL DAT EP; Centers for Disease Control and Prevention National Center for Injury Prevention and Control Division of Unintentional Injury Prevention, COMM EL GUID PRESCR; Cicero TJ, 2015, JAMA PSYCHIAT, V72, P424, DOI 10.1001/jamapsychiatry.2014.3043; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Cicero TJ, 2012, NEW ENGL J MED, V367, P187, DOI 10.1056/NEJMc1204141; Coffin PO, 2013, ANN INTERN MED, V158, P1, DOI 10.7326/0003-4819-158-1-201301010-00003; Comer SD, 2008, NEUROPSYCHOPHARMACOL, V33, P1179, DOI 10.1038/sj.npp.1301479; Compton WM, 2013, ANN INTERN MED, V158, P65, DOI 10.7326/0003-4819-158-1-201301010-00013; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Dasgupta N, 2014, DRUG ALCOHOL DEPEN, V145, P238, DOI 10.1016/j.drugalcdep.2014.10.005; Davis WR, 2008, DRUG ALCOHOL DEPEN, V92, P267, DOI 10.1016/j.drugalcdep.2007.08.008; Dick AW, 2015, HEALTH AFFAIR, V34, P1028, DOI 10.1377/hlthaff.2014.1205; Franklin G, 2015, AM J PUBLIC HEALTH, V105, P463, DOI 10.2105/AJPH.2014.302367; George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002; Grau LE, 2007, AM J ADDICTION, V16, P166, DOI 10.1080/10550490701375293; Han B, 2015, JAMA-J AM MED ASSOC, V314, P1468, DOI 10.1001/jama.2015.11859; Havens JR, 2009, AM J DRUG ALCOHOL AB, V35, P18, DOI 10.1080/00952990802326298; Inciardi JA, 2009, PAIN MED, V10, P537, DOI 10.1111/j.1526-4637.2009.00603.x; Institute of Medicine, 2011, REL PAIN AM BLUEPR T; Johnson H, 2014, MMWR-MORBID MORTAL W, V63, P569; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Jones CM, 2013, DRUG ALCOHOL DEPEN, V132, P95, DOI 10.1016/j.drugalcdep.2013.01.007; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Jones JD, 2011, AM J ADDICTION, V20, P190, DOI 10.1111/j.1521-0391.2011.00120.x; Khosla N, 2011, ADDICT BEHAV, V36, P1282, DOI 10.1016/j.addbeh.2011.07.046; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Kreek MJ., 2002, NEUROPSYCHOPHARMACOL, P1491; Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI 10.1016/j.drugpo.2011.05.014; Levy B, 2015, AM J PREV MED; Maher CE, 2005, LIFE SCI, V77, P1140, DOI 10.1016/j.lfs.2005.03.004; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Mars SG, 2015, SOC SCI MED, V140, P44, DOI 10.1016/j.socscimed.2015.06.032; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; Mateu-Gelabert P, 2015, J SUBST ABUSE TREAT, V48, P13, DOI 10.1016/j.jsat.2014.07.002; Meiman J, 2015, DRUG ALCOHOL DEPEN, V152, P177, DOI 10.1016/j.drugalcdep.2015.04.002; National Governors Association, 2012, 6 STRAT RED PRESCR D; National Institute on Drug Abuse Community Epidemiology Working Group, 2014, EP TRENDS DRUG AB P; Office of National Drug Control Policy US Executive Office of the President, 2011, EP RESP AM PRESCR DR; Paone D, 2015, MMWR-MORBID MORTAL W, V64, P491; Paulozzi LJ, 2012, J SAFETY RES, V43, P283, DOI 10.1016/j.jsr.2012.08.009; Peavy KM, 2012, J PSYCHOACTIVE DRUGS, V44, P259, DOI 10.1080/02791072.2012.704591; Pollini RA, 2011, SUBST ABUSE REHABIL, V2, P173, DOI 10.2147/SAR.S24800; Pud D, 2006, EUR J PAIN, V10, P103, DOI 10.1016/j.ejpain.2005.01.010; Rudd RA., 2014, MMWR MORB MORTAL WKL, V63, P849; Siegal HA, 2003, AM FAM PHYSICIAN, V67, P942; Spoth R, 2013, AM J PUBLIC HEALTH, V103, P665, DOI 10.2105/AJPH.2012.301209; Surratt HL, 2014, PHARMACOEPIDEM DR S, V23, P314, DOI 10.1002/pds.3553; Surratt Hilary L, 2006, J Opioid Manag, V2, P283; TERNES J W, 1990, Advances in Alcohol and Substance Abuse, V9, P27; Unick G, 2014, ADDICTION, V109, P1889, DOI 10.1111/add.12664; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; Volkow ND, 1999, J PHARMACOL EXP THER, V291, P409; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Weiss RD, 2011, ARCH GEN PSYCHIAT, V68, P1238, DOI 10.1001/archgenpsychiatry.2011.121	65	765	765	0	151	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 14	2016	374	2					154	163		10.1056/NEJMra1508490	http://dx.doi.org/10.1056/NEJMra1508490			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DA7PQ	26760086	Bronze			2023-01-03	WOS:000367996700010
J	Hajek, A; Brettschneider, C; Lange, C; Posselt, T; Wiese, B; Steinmann, S; Weyerer, S; Werle, J; Pentzek, M; Fuchs, A; Stein, J; Luck, T; Bickel, H; Mosch, E; Wagner, M; Jessen, F; Maier, W; Scherer, M; Riedel-Heller, SG; Konig, HH				Hajek, Andre; Brettschneider, Christian; Lange, Carolin; Posselt, Tina; Wiese, Birgitt; Steinmann, Susanne; Weyerer, Siegfried; Werle, Jochen; Pentzek, Michael; Fuchs, Angela; Stein, Janine; Luck, Tobias; Bickel, Horst; Moesch, Edelgard; Wagner, Michael; Jessen, Frank; Maier, Wolfgang; Scherer, Martin; Riedel-Heller, Steffi G.; Koenig, Hans-Helmut		AgeCoDe Study Grp	Longitudinal Predictors of Institutionalization in Old Age	PLOS ONE			English	Article							NURSING-HOME PLACEMENT; RISK-FACTORS; DEMENTIA; IMPAIRMENT; ADMISSION; HEALTH; LONELINESS; COMMUNITY; DISEASES; FRAILTY	Objective To investigate time-dependent predictors of institutionalization in old age using a longitudinal approach. Methods In a representative survey of the German general population aged 75 years and older predictors of institutionalization were observed every 1.5 years over six waves. Conditional fixed-effects logistic regressions (with 201 individuals and 960 observations) were performed to estimate the effects of marital status, depression, dementia, and physical impairments (mobility, hearing and visual impairments) on the risk of admission to old-age home or nursing home. By exploiting the longitudinal data structure using panel econometric models, we were able to control for unobserved heterogeneity such as genetic predisposition and personality traits. Results The probability of institutionalization increased significantly with occurrence of widowhood, depression, dementia, as well as walking and hearing impairments. In particular, the occurrence of widowhood (OR = 78.3), dementia (OR = 154.1) and substantial mobility impairment (OR = 36.7) were strongly associated with institutionalization. Conclusion Findings underline the strong influence of loss of spouse as well as dementia on institutionalization. This is relevant as the number of old people (a) living alone and (b) suffering from dementia is expected to increase rapidly in the next decades. Consequently, it is supposed that the demand for institutionalization among the elderly will increase considerably. Practitioners as well as policy makers should be aware of these upcoming challenges.	[Hajek, Andre; Brettschneider, Christian; Koenig, Hans-Helmut] Univ Med Ctr Hamburg Eppendorf, Dept Hlth Econ & Hlth Serv Res, Hamburg Ctr Hlth Econ, Hamburg, Germany; [Lange, Carolin; Posselt, Tina; Scherer, Martin] Univ Med Ctr Hamburg Eppendorf, Dept Primary Med Care, Ctr Psychosocial Med, Hamburg, Germany; [Wiese, Birgitt; Steinmann, Susanne] Hannover Med Sch, WG Med Stat & IT Infrastruct, Inst Gen Practice, Hannover, Germany; [Weyerer, Siegfried; Werle, Jochen] Heidelberg Univ, Cent Inst Mental Hlth, Med Fac Mannheim, Mannheim, Germany; [Pentzek, Michael; Fuchs, Angela] Univ Dusseldorf, Inst Gen Practice, Fac Med, Dusseldorf, Germany; [Stein, Janine; Luck, Tobias; Riedel-Heller, Steffi G.] Univ Leipzig, Inst Social Med Occupat Hlth & Publ Hlth, D-04109 Leipzig, Germany; [Bickel, Horst; Moesch, Edelgard] Tech Univ Munich, Dept Psychiat, D-80290 Munich, Germany; [Wagner, Michael; Jessen, Frank; Maier, Wolfgang] Univ Bonn, Dept Psychiat, Bonn, Germany; [Wagner, Michael; Maier, Wolfgang] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany; [Jessen, Frank] Univ Cologne, Dept Psychiat & Psychotherapy, D-50931 Cologne, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Hannover Medical School; Central Institute of Mental Health; Ruprecht Karls University Heidelberg; Heinrich Heine University Dusseldorf; Leipzig University; Technical University of Munich; University of Munich; University of Bonn; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Cologne	Hajek, A (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Hlth Econ & Hlth Serv Res, Hamburg Ctr Hlth Econ, Hamburg, Germany.	a.hajek@uke.de	Wagner, Michael/E-2325-2011; Jessen, Frank/AAK-6170-2020; König, Hans-Helmut/P-1211-2018; Riedel-Heller, Steffi/ABG-1537-2021; Brettschneider, Christian/H-5920-2019	Wagner, Michael/0000-0003-2589-6440; König, Hans-Helmut/0000-0001-5711-6862; Brettschneider, Christian/0000-0002-5280-1075; Luck, Tobias/0000-0001-7551-4397; Pentzek, Michael/0000-0001-6538-0241; Hajek, Andre/0000-0002-6886-2745	German Federal Ministry of Education and Research [KND 01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 01GI0434, KNDD 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715, 01GI0716, AgeQualiDe 01GY1322A, 01GY1322B, 01GY1322C, 01GY1322D, 01GY1322E, 01GY1322F, 01GY1322G]	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	This publication is part of the German Research Network on Dementia (KND), the German Research Network on Degenerative Dementia (KNDD), and the Study on Needs, Health Service Use, Costs and Health-related Quality of Life in a large Sample of Oldest-old Primary Care Patients (85 +) (AgeQualiDe) and was funded by the German Federal Ministry of Education and Research (grants KND 01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433 and 01GI0434; grants KNDD 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715 and 01GI0716; and grants AgeQualiDe 01GY1322A, 01GY1322B, 01GY1322C, 01GY1322D, 01GY1322E, 01GY1322F, 01GY1322G). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguero-Torres H, 2001, J CLIN EPIDEMIOL, V54, P795, DOI 10.1016/S0895-4356(00)00371-1; Andel R, 2007, J AGING HEALTH, V19, P213, DOI 10.1177/0898264307299359; Banaszak-Holl J, 2004, ALZ DIS ASSOC DIS, V18, P83, DOI 10.1097/01.wad.0000126619.80941.91; Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262; Bharucha AJ, 2004, J AM GERIATR SOC, V52, P434, DOI 10.1111/j.1532-5415.2004.52118.x; Bickel H., 2012, DEMENZEN, V2, P18; Brauns H., 1999, ZUMA NACHRICHTEN, V44, P7; Brderl J., 2015, SAGE HDB REGRESSION, V327, P357, DOI DOI 10.4135/9781446288146.N15; Eaker ED, 2002, J CLIN EPIDEMIOL, V55, P462, DOI 10.1016/S0895-4356(01)00498-X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fydrich T., 2009, Z MEDIZINISCHE PSYCH, V18, P43; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; Grenade L, 2008, AUST HEALTH REV, V32, P468, DOI 10.1071/AH080468; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; Jee J, 2005, OPHTHAL EPIDEMIOL, V12, P199, DOI 10.1080/09286580590969707; Kinsella K, 2009, INT POPULATION REPOR; Lachs M, 2006, GERONTOLOGIST, V46, P583, DOI 10.1093/geront/46.5.583; Lachs MS, 2002, GERONTOLOGIST, V42, P734, DOI 10.1093/geront/42.6.734; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Luck T, 2010, ACTA PSYCHIAT SCAND, V121, P260, DOI 10.1111/j.1600-0447.2009.01481.x; Luck T, 2008, NEUROEPIDEMIOLOGY, V31, P100, DOI 10.1159/000146251; Luppa M, 2008, DEMENT GERIATR COGN, V26, P65, DOI 10.1159/000144027; Luppa M, 2012, SOC PSYCH PSYCH EPID, V47, P263, DOI 10.1007/s00127-010-0333-9; Luppa M, 2010, AGE AGEING, V39, P31, DOI 10.1093/ageing/afp202; Luppa M, 2009, INT PSYCHOGERIATR, V21, P1015, DOI 10.1017/S1041610209990238; MAHONEY F I, 1965, Md State Med J, V14, P61; Matthews Z, 2006, NOTES WORKFORCE IMPL; McCallum J, 2005, AUSTRALAS J AGEING, V24, P169, DOI 10.1111/j.1741-6612.2005.00116.x; Miller DK, 2008, J GERONTOL A-BIOL, V63, P487, DOI 10.1093/gerona/63.5.487; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Pollak C P, 1990, J Community Health, V15, P123, DOI 10.1007/BF01321316; Prieto-Flores ME, 2011, J AGING HEALTH, V23, P177, DOI 10.1177/0898264310382658; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Sarma S, 2009, SOC SCI MED, V68, P1106, DOI 10.1016/j.socscimed.2008.12.046; Shapiro E., 1985, CAN J AGING, V4, P11, DOI [10.1017/S0714980800015798, DOI 10.1017/S0714980800015798]; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; STATISTISCHES BUNDESAMT, 2009, BEV DTSCH 2060 12 KO; Stock JH, 2008, ECONOMETRICA, V76, P155, DOI 10.1111/j.0012-9682.2008.00821.x; Tomiak M, 2000, J GERONTOL A-BIOL, V55, pM279, DOI 10.1093/gerona/55.5.M279; Tsai HJ, 2013, GERIATR GERONTOL INT, V13, P597, DOI 10.1111/j.1447-0594.2012.00944.x; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Victor CR, 2012, AGING HLTH, V8, P637, DOI DOI 10.2217/AHE.12.65; von Bonsdorff M, 2006, GERONTOLOGY, V52, P359, DOI 10.1159/000094985; Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773; Wang SY, 2013, ARCH GERONTOL GERIAT, V57, P16, DOI 10.1016/j.archger.2013.03.007; WOLINSKY FD, 1993, J GERONTOL, V48, pS93	47	106	110	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2015	10	12							e0144203	10.1371/journal.pone.0144203	http://dx.doi.org/10.1371/journal.pone.0144203			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CY9GR	26658776	gold, Green Submitted, Green Published			2023-01-03	WOS:000366715900031
J	Shirmanova, M; Yuzhakova, D; Snopova, L; Perelman, G; Serebrovskaya, E; Lukyanov, K; Turchin, I; Subochev, P; Lukyanov, S; Kamensky, V; Zagaynova, E				Shirmanova, Marina; Yuzhakova, Diana; Snopova, Ludmila; Perelman, Gregory; Serebrovskaya, Ekaterina; Lukyanov, Konstantin; Turchin, Ilya; Subochev, Pavel; Lukyanov, Sergey; Kamensky, Vladislav; Zagaynova, Elena			Towards PDT with Genetically Encoded Photosensitizer KillerRed: A Comparison of Continuous and Pulsed Laser Regimens in an Animal Tumor Model	PLOS ONE			English	Article							CONTINUOUS-WAVE LIGHT; PHOTODYNAMIC THERAPY; IN-VIVO; FLUORESCENT PROTEINS; CELL CARCINOMAS; CANCER-CELLS; DYE-LASER; ACTIVATION; MECHANISMS; DELIVERY	The strong phototoxicity of the red fluorescent protein KillerRed allows it to be considered as a potential genetically encoded photosensitizer for the photodynamic therapy (PDT) of cancer. The advantages of KillerRed over chemical photosensitizers are its expression in tumor cells transduced with the appropriate gene and direct killing of cells through precise damage to any desired cell compartment. The ability of KillerRed to affect cell division and to induce cell death has already been demonstrated in cancer cell lines in vitro and HeLa tumor xenografts in vivo. However, the further development of this approach for PDT requires optimization of the method of treatment. In this study we tested the continuous wave (593 nm) and pulsed laser (584 nm, 10 Hz, 18 ns) modes to achieve an antitumor effect. The research was implemented on CT26 subcutaneous mouse tumors expressing KillerRed in fusion with histone H2B. The results showed that the pulsed mode provided a higher rate of photobleaching of KillerRed without any temperature increase on the tumor surface. PDT with the continuous wave laser was ineffective against CT26 tumors in mice, whereas the pulsed laser induced pronounced histopathological changes and inhibition of tumor growth. Therefore, we selected an effective regimen for PDT when using the genetically encoded photosensitizer KillerRed and pulsed laser irradiation.	[Shirmanova, Marina; Yuzhakova, Diana; Snopova, Ludmila; Serebrovskaya, Ekaterina; Lukyanov, Konstantin; Lukyanov, Sergey; Zagaynova, Elena] Nizhny Novgorod State Med Acad, Nizhnii Novgorod, Russia; [Yuzhakova, Diana; Perelman, Gregory] Lobachevsky State Univ Nizhny Novgorod, Nizhnii Novgorod, Russia; [Serebrovskaya, Ekaterina; Lukyanov, Konstantin; Lukyanov, Sergey] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia; [Turchin, Ilya; Subochev, Pavel; Kamensky, Vladislav] Russian Acad Sci, Inst Appl Phys, Nizhnii Novgorod, Russia; [Lukyanov, Sergey] Pirogov Russian Natl Res Med Univ, Moscow, Russia	Privolzhsky Research Medical University; Lobachevsky State University of Nizhni Novgorod; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Institute of Applied Physics of the Russian Academy of Sciences; Pirogov Russian National Research Medical University	Shirmanova, M (corresponding author), Nizhny Novgorod State Med Acad, Nizhnii Novgorod, Russia.	Shirmanovam@mail.ru	Shirmanova, Marina V./M-7635-2016; Serebrovskaya, Ekaterina/AAN-8121-2020; Subochev, Pavel/E-4918-2014; Yuzhakova, Diana V/F-8990-2017; Turchin, Ilya/E-3863-2014; Lukyanov, Sergey/HIU-0305-2022; Lukyanov, Konstantin A/D-4030-2013	Subochev, Pavel/0000-0001-5803-5773; Turchin, Ilya/0000-0002-8471-7361; Lukyanov, Konstantin A/0000-0001-9845-2088; Shirmanova, Marina/0000-0002-3207-7227; Perelman, Grigory/0000-0003-2512-247X	Russian Scientific Foundation [14-25-00129]; Russian Foundation for Basic Research [14-02-00860]; Russian Science Foundation [14-25-00129] Funding Source: Russian Science Foundation	Russian Scientific Foundation(Russian Science Foundation (RSF)); Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Russian Science Foundation(Russian Science Foundation (RSF))	This work was supported by the Russian Scientific Foundation (#14-25-00129) to KL, and the Russian Foundation for Basic Research (#14-02-00860) to VK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; Anbil S, 2013, PROC SPIE, V8568, DOI 10.1117/12.2010840; BARR H, 1989, Lasers in Medical Science, V4, P7, DOI 10.1007/BF02032503; Bulina ME, 2006, NAT PROTOC, V1, P947, DOI 10.1038/nprot.2006.89; Bulina ME, 2006, NAT BIOTECHNOL, V24, P95, DOI 10.1038/nbt1175; Chen B, 2008, INT J CANCER, V123, P695, DOI 10.1002/ijc.23538; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; FERRARIO A, 1991, LASER SURG MED, V11, P404, DOI 10.1002/lsm.1900110504; Grecco C, 2013, LASER MED SCI, V28, P1177, DOI 10.1007/s10103-012-1216-y; Henderson BW, 2000, CANCER RES, V60, P525; Jarvi MT, 2012, BIOPHYS J, V102, P661, DOI 10.1016/j.bpj.2011.12.043; Jimenez-Banzo A, 2008, BIOPHYS J, V94, P168, DOI 10.1529/biophysj.107.107128; Kawauchi S, 2004, LASER MED SCI, V18, P179, DOI 10.1007/s10103-004-0288-8; Kimura H, 2010, J CELL BIOCHEM, V110, P1439, DOI 10.1002/jcb.22693; Klimenko VV, 2014, J PHYS CONF SER, V541, DOI 10.1088/1742-6596/541/1/012040; Kuznetsova DS, 2015, J BIOPHOTONICS, V8, P952, DOI 10.1002/jbio.201400130; Lan L, 2014, NUCLEIC ACIDS RES, V42, P2330, DOI 10.1093/nar/gkt1233; LAPLANT M, 1987, LASER SURG MED, V7, P336, DOI 10.1002/lsm.1900070407; Liao ZX, 2014, J CONTROL RELEASE, V193, P304, DOI 10.1016/j.jconrel.2014.04.024; MIMURA S, 1995, P SOC PHOTO-OPT INS, V2371, P522; Mitra S, 2011, LASER SURG MED, V43, P632, DOI 10.1002/lsm.21108; Miyamoto Y, 1999, J PHOTOCH PHOTOBIO B, V53, P53, DOI 10.1016/S1011-1344(99)00125-6; Momiyama M, 2012, ANTICANCER RES, V32, P4327; Muthiah M, 2014, COLLOID SURFACE B, V116, P284, DOI 10.1016/j.colsurfb.2014.01.001; OKUNAKA T, 1992, JPN J CANCER RES, V83, P226, DOI 10.1111/j.1349-7006.1992.tb00090.x; Pletnev S, 2009, J BIOL CHEM, V284, P32028, DOI 10.1074/jbc.M109.054973; Pogue BW, 1999, BRIT J CANCER, V80, P344, DOI 10.1038/sj.bjc.6690361; Pogue BW, 1997, APPL OPTICS, V36, P7257, DOI 10.1364/AO.36.007257; RAUSCH PC, 1993, EUR ARCH OTO-RHINO-L, V250, P82; Roy A, 2010, PHOTOCH PHOTOBIO SCI, V9, P1342, DOI 10.1039/c0pp00141d; Sato K, 2015, THERANOSTICS, V5, P698, DOI 10.7150/thno.11559; Serebrovskaya EO, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.7.071403; Serebrovskaya EO, 2011, BIOCHEM J, V435, P65, DOI 10.1042/BJ20101217; Serebrovskaya EO, 2009, P NATL ACAD SCI USA, V106, P9221, DOI 10.1073/pnas.0904140106; Sheng C, 2007, PHOTOCHEM PHOTOBIOL, V83, P738, DOI 10.1562/2006-09-07-RA-1033; Shirmanova MV, 2013, J BIOPHOTONICS, V6, P283, DOI 10.1002/jbio.201200056; Sterenborg HJCM, 1996, PHYS MED BIOL, V41, P835, DOI 10.1088/0031-9155/41/5/002; Takehara K, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-706; Teh C, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-110; Tseng SJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7456; Vegh RB, 2014, J PHYS CHEM B, V118, P4527, DOI 10.1021/jp500919a; Vegh RB, 2011, CHEM COMMUN, V47, P4887, DOI 10.1039/c0cc05713d; Waldeck W, 2011, INT J MED SCI, V8, P97, DOI 10.7150/ijms.8.97	43	14	15	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2015	10	12							e0144617	10.1371/journal.pone.0144617	http://dx.doi.org/10.1371/journal.pone.0144617			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1ZA	26657001	gold, Green Published, Green Submitted			2023-01-03	WOS:000366903600069
J	Hasegawa, Y; Tanino, H; Horiguchi, J; Miura, D; Ishikawa, T; Hayashi, M; Takao, S; Kim, SJ; Yamagami, K; Miyashita, M; Konishi, M; Shigeoka, Y; Suzuki, M; Taguchi, T; Kubota, T; Akazawa, K; Kohno, N				Hasegawa, Yoshie; Tanino, Hirokazu; Horiguchi, Jun; Miura, Daishu; Ishikawa, Takashi; Hayashi, Mitsuhiro; Takao, Shintaro; Kim, Seung Jin; Yamagami, Kazuhiko; Miyashita, Masaru; Konishi, Muneharu; Shigeoka, Yasushi; Suzuki, Masato; Taguchi, Tetsuya; Kubota, Tomoyuki; Akazawa, Kouhei; Kohno, Norio		JONIE Study Grp	Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)	PLOS ONE			English	Article							ANTITUMOR-ACTIVITY; TUMOR RESPONSE; WOMEN; THERAPY; BISPHOSPHONATE; LETROZOLE	Purpose Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption by inhibiting the mevalonate pathway. Its benefit for the prevention of skeletal complications due to bone metastases has been established. However, the antitumor efficacy of ZOL, although suggested by multiple preclinical and clinical studies, has not yet been clinically proven. We performed the present randomized Phase 2 trial to investigate the antitumor effect of ZOL with chemotherapy (CT). Methods Asian patients with HER2-negative invasive breast cancer were randomly assigned to either the CT or CT+ZOL (CTZ) group. One hundred and eighty-eight patients were randomized to either the CT group (n = 95) or the CTZ group (n = 93) from March 2010 to April 2012, and 180 patients were assessed. All patients received four cycles of FEC100 (fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2)), followed by 12 cycles of paclitaxel at 80 mg/m(2) weekly. ZOL (4 mg) was administered three to four times weekly for 7 weeks to the patients in the CTZ group. The primary endpoint was the pathological complete response (pCR) rate, which was defined as no invasive cancer in the breast tissue specimen. Safety was assessed in all patients who received at least one dose of the study drug. Results This randomized controlled trial indicated that the rates of pCR in CTZ group (14.8%) was doubled to CT group (7.7%), respectively (one-sided chi-square test, p = 0.068), though the additional efficacy of zoledronic acid was not demonstrated statistically. The pCR rate in postmenopausal patients was 18.4% and 5.1% in the CTZ and CT groups, respectively (one-sided Fisher's exact test, p = 0.071), and that in patients with triple-negative breast cancer was 35.3% and 11.8% in the CTZ and CT groups, respectively (one-sided Fisher's exact test, p = 0.112). Thus the addition of ZOL to neoadjuvant CT has potential anticancer benefits in postmenopausal patients and patients with triple-negative breast cancer. Further investigation is warranted.	[Hasegawa, Yoshie] Hirosaki Municipal Hosp, Dept Breast Surg, Aomori, Japan; [Tanino, Hirokazu] Kitasato Univ Hosp, Dept Breast & Thyroid Surg, Sagamihara, Kanagawa, Japan; [Horiguchi, Jun] Gunma Univ Hosp, Dept Breast & Endocrine Surg, Gunma, Japan; [Miura, Daishu] Toranomon Gen Hosp, Dept Breast & Endocrine Surg, Tokyo, Japan; [Ishikawa, Takashi] Yokohama City Univ, Med Ctr, Dept Breast & Thyroid Surg, Yokohama, Kanagawa, Japan; [Hayashi, Mitsuhiro] Tokyo Med Univ, Hachioji Med Ctr, Dept Breast Oncol, Tokyo 1608402, Japan; [Takao, Shintaro] Hyogo Canc Ctr, Dept Breast Surg, Akashi, Hyogo, Japan; [Kim, Seung Jin] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, Osaka, Japan; [Yamagami, Kazuhiko] Shinko Hosp, Dept Breast Oncol, Kobe, Hyogo, Japan; [Miyashita, Masaru] Konan Hosp, Dept Surg, Kobe, Hyogo, Japan; [Konishi, Muneharu] Hyogo Prefectural Nishinomiya Hosp, Dept Surg, Kobe, Hyogo, Japan; [Shigeoka, Yasushi] Yodogawa Christians Hosp, Dept Med Oncol, Osaka, Japan; [Suzuki, Masato] Teikyo Univ, Chiba Med Ctr, Dept Surg, Chiba, Japan; [Taguchi, Tetsuya] Kyoto Prefectural Univ Med, Dept Endocrine & Breast Surg, Kyoto, Japan; [Kubota, Tomoyuki] Kamiiida Daiichi Gen Hosp, Dept Breast Surg, Nagoya, Aichi, Japan; [Akazawa, Kouhei] Niigata Univ, Med & Dent Hosp, Dept Med Informat, Niigata, Japan; [Kohno, Norio] Kobe Kaisei Hosp, Dept Breast Oncol, Kobe, Hyogo, Japan	Kitasato University; Gunma University; Toranomon Hospital; Yokohama City University; Tokyo Medical University; Hyogo Cancer Center; Osaka University; Teikyo University; Kyoto Prefectural University of Medicine; Niigata University	Hasegawa, Y (corresponding author), Hirosaki Municipal Hosp, Dept Breast Surg, Aomori, Japan.	vo-irene.yoshie@nifty.com	Tanino, Hirokazu/AAN-4455-2021; Kohno, Norio/Q-5594-2019		Novaltis Pharma	Novaltis Pharma	This study was supported by Novaltis Pharma. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470-2045(10)70054-1; Almubarak Hussain, 2011, J Carcinog, V10, P2, DOI 10.4103/1477-3163.75723; Charehbili A, 2014, ANN ONCOL, V25, P998, DOI 10.1093/annonc/mdu102; Coleman R, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-S4-07; Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277; Coleman R, 2011, BREAST CANCER RES TR, V127, P429, DOI 10.1007/s10549-011-1429-y; Coleman RE, 2010, BRIT J CANCER, V102, P1099, DOI 10.1038/sj.bjc.6605604; Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195; Fehm T, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-308; Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414; Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470-2045(11)70122-X; Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285; Green JR, 2011, CRIT REV ONCOL HEMAT, V77, pS3, DOI 10.1016/S1040-8428(11)70003-8; Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116; Neville-Webbe HL, 2010, BRIT J CANCER, V102, P1010, DOI 10.1038/sj.bjc.6605579; Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756	16	18	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2015	10	12							e0143643	10.1371/journal.pone.0143643	http://dx.doi.org/10.1371/journal.pone.0143643			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX9QI	26633806	gold, Green Published, Green Submitted			2023-01-03	WOS:000366040000019
J	Kamerow, D				Kamerow, Douglas			YANKEE DOODLING An unexpected headline: more US white people are dying	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Kamerow, Douglas] Robert Graham Ctr Policy Studies Primary Care, Washington, DC 20052 USA; [Kamerow, Douglas] Georgetown Univ, Family Med, Washington, DC 20057 USA	Georgetown University	Kamerow, D (corresponding author), Robert Graham Ctr Policy Studies Primary Care, Washington, DC 20052 USA.	dkamerow@aafp.org		Kamerow, Douglas/0000-0001-7000-9957				[Anonymous], 2015, NY TIMES; Ashenbach J, 2015, WASHINGTON POST; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; Kolata G, 2015, NY TIMES, pA1; Ma JM, 2015, JAMA-J AM MED ASSOC, V314, P1731, DOI 10.1001/jama.2015.12319; McKay B, 2015, WALL STREET J, pA1	6	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2015	351								h6180	10.1136/bmj.h6180	http://dx.doi.org/10.1136/bmj.h6180			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW9XV	26578225				2023-01-03	WOS:000365352400006
J	Akilimali, PZ; Kashala-Abotnes, E; Musumari, PM; Kayembe, PK; Tylleskar, T; Mapatano, MA				Akilimali, Pierre Zalagile; Kashala-Abotnes, Esperance; Musumari, Patou Masika; Kayembe, Patrick Kalambayi; Tylleskar, Thorkild; Mapatano, Mala Ali			Predictors of Persistent Anaemia in the First Year of Antiretroviral Therapy: A Retrospective Cohort Study from Goma, the Democratic Republic of Congo	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; SUB-SAHARAN AFRICA; SCALE-UP; PREVALENCE; ZIDOVUDINE; MORTALITY; PROGNOSIS; DISEASE; COMPLEX; RISK	Background Anaemia is associated with adverse outcomes including early death in the first year of anti-retroviral therapy (ART). This study reports on the factors associated with persistent anaemia among HIV-infected patients initiating ART in the Democratic Republic of Congo (DR Congo). Methods We conducted a retrospective cohort study and analyzed data from patients receiving HIV care between January 2004 and December 2012 at two major hospitals in Goma, DR Congo. Haemoglobin concentrations of all patients on ART regimen were obtained prior to and within one year of ART initiation. A logistic regression model was used to identify the predictors of persistent anaemia after 12 months of ART. Results Of 756 patients, 69% of patients were anaemic (IC95%: 65.7-72.3) at baseline. After 12 months of follow up, there was a 1.2 g/dl average increase of haemoglobin concentration (P < 0.001) with differences depending on the therapeutic regimen. Patients who received zidovudine (AZT) gained less than those who did not receive AZT (0.99 g/dl vs 1.33 g/dl; p < 0.001). Among 445 patient who had anaemia at the beginning, 33% (147/445) had the condition resolved. Among patients with anaemia at ART initiation, those who did not receive cotrimoxazole prophylaxis before starting ART(AOR 3.89; 95% CI 2.09-7.25; P < 0.001) and a AZT initial regimen (AOR 2.19; 95% CI 1.36-3.52; P < 0.001) were significantly at risk of persistent anaemia. Conclusions More than two thirds of patients had anaemia at baseline. The AZT-containing regimen and absence of cotrimoxazole prophylaxis before starting ART were associated with persistent anaemia 12 months, after initiation of treatment. Considering the large proportion of patients with persistence of anaemia at 12 months, we suggest that it is necessary to conduct a large study to assess anaemia among HIV-infected patients in Goma.	[Akilimali, Pierre Zalagile; Kayembe, Patrick Kalambayi; Mapatano, Mala Ali] Univ Kinshasa, Kinshasa Univ Sch Publ Hlth, Kinshasa, DEM REP CONGO; [Kashala-Abotnes, Esperance; Tylleskar, Thorkild] Univ Bergen, Ctr Int Hlth, Bergen, Norway; [Musumari, Patou Masika] Kyoto Univ, Sch Publ Hlth, Dept Global Hlth & Socioepidemiol, Kyoto, Japan	Universite de Kinshasa; University of Bergen; Kyoto University	Akilimali, PZ (corresponding author), Univ Kinshasa, Kinshasa Univ Sch Publ Hlth, Kinshasa, DEM REP CONGO.	pierretulanefp@gmail.com	Akilimali, Pierre Z/D-2564-2018; Tylleskär, Thorkild/S-5529-2017	Akilimali, Pierre Z/0000-0002-3828-6214; Tylleskär, Thorkild/0000-0003-4801-4324				Adane Asfaw, 2012, Ethiop Med J, V50, P13; Akilimali PZ, 2014, REV EPIDEMIOL SANTE, V62, P201, DOI 10.1016/j.respe.2014.03.004; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; DOUKAS MA, 1992, MED CLIN N AM, V76, P699, DOI 10.1016/S0025-7125(16)30348-0; Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01; Forna Fatu, 2009, J Int Assoc Physicians AIDS Care (Chic), V8, P128, DOI 10.1177/1545109709333081; FRASER I, 1994, CLIN INFECT DIS, V19, P211, DOI 10.1093/clinids/19.1.211; GELMON K, 1989, AIDS, V3, P555, DOI 10.1097/00002030-198909000-00001; GROOPMAN JE, 1990, REV INFECT DIS, V12, P931; Johannessen A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-52; Johannessen A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-190; KEISU M, 1990, J INTERN MED, V228, P353, DOI 10.1111/j.1365-2796.1990.tb00245.x; Kerkhoff AD, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0702-1; Kiragga AN, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-42; Laurent C, 2008, AIDS RES HUM RETROV, V24, P393, DOI 10.1089/aid.2007.0219; Levine AM, 2001, J ACQ IMMUN DEF SYND, V26, P28, DOI 10.1097/00126334-200101010-00004; May M, 2010, LANCET, V376, P449, DOI 10.1016/S0140-6736(10)60666-6; Ministere du Plan, 2014, ENQ DEM SANT 2013 20; MIR N, 1989, EUR J HAEMATOL, V42, P339; Mocroft A, 1999, AIDS, V13, P943, DOI 10.1097/00002030-199905280-00010; Moore RD, 2002, J ACQ IMMUN DEF SYND, V29, P54, DOI 10.1097/00042560-200201010-00007; Mugisha JO, 2008, TROP MED INT HEALTH, V13, P788, DOI 10.1111/j.1365-3156.2008.02069.x; Obirikorang C, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-102; [Republique Democratique du Congo Ministere de la Sante], 2005, PROGR NAT LUTT VIH G; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; Russell EC, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-433; Semba RD, 2001, AIDS PATIENT CARE ST, V15, P473, DOI 10.1089/108729101753145466; Semba RD, 2002, CLIN INFECT DIS, V34, P260, DOI 10.1086/338151; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Subbaraman R, 2007, CLIN INFECT DIS, V45, P1093, DOI 10.1086/521150; Sullivan PS, 1998, BLOOD, V91, P301, DOI 10.1182/blood.V91.1.301.301_301_308; WHO, 2010, ANT THER HIV INF AD; Wills Todd S, 2004, AIDS Read, V14, P305; World Health Organization, 2011, SER FERR CONC ASS IR; World Health Organization, 2006, ANT THER HIV INF AD; Zhou JL, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-5	36	10	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2015	10	10							e0140240	10.1371/journal.pone.0140240	http://dx.doi.org/10.1371/journal.pone.0140240			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0DF	26474481	Green Published, Green Submitted, gold			2023-01-03	WOS:000363185500033
J	Wang, JH; Guo, Q; Ma, ZX; Ma, QL; Yu, MX; Yin, XF; Lu, SS; Xie, HQ; Jiang, YH; Shen, D; Ma, LY; Shi, H; Yu, WJ; Lou, YJ; Li, Y; Yang, M; Xu, GX; Mao, LP; Li, JH; Wang, HP; Wang, DM; Wei, JY; Tong, HY; Huang, J; Jin, J				Wang, Jing-Han; Guo, Qi; Ma, Zhi-Xin; Ma, Qiu-Ling; Yu, Meng-Xia; Yin, Xiu-Feng; Lu, Sha-Sha; Xie, Hong-Qiong; Jiang, Yue-Hong; Shen, Dan; Ma, Li-Ya; Shi, Hui; Yu, Wen-Juan; Lou, Ye-Jiang; Li, Ying; Yang, Min; Xu, Gai-Xiang; Mao, Li-Ping; Li, Jian-Hu; Wang, Huan-Ping; Wang, Dong-Mei; Wei, Ju-Ying; Tong, Hong-Yan; Huang, Jian; Jin, Jie			Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients	PLOS ONE			English	Article							ACUTE MYELOID-LEUKEMIA; PROGNOSTIC-SIGNIFICANCE; INITIATION; DIAGNOSIS; YOUNGER; OLDER; TIME	The effect of time from diagnosis to treatment (TDT) on overall survival of patients with acute myeloid leukemia (AML) remains obscure. Furthermore, whether chemotherapy delay impacts overall survival (OS) of patients with a special molecular subtype has not been investigated. Here, we enrolled 364 cases of AML to assess the effect of TDT on OS by fractional polynomial regression in the context of clinical parameters and genes of FLT3ITD, NPM1, CEBPA, DNMT3a, and IDH1/2 mutations. Results of the current study show IDH1/2 mutations are associated with older age, M0 morphology, an intermediate cytogenetic risk group, and NPM1 mutations. TDT associates with OS for AML patients in a nonlinear pattern with a J shape. Moreover, adverse effect of delayed treatment on OS was observed in patients with IDH1/2 mutations, but not in those with IDH1/2 wildtype. Therefore, initiating chemotherapy as soon as possible after diagnosis might be a potential strategy to improve OS in AML patients with IDH1/2 mutations.	[Wang, Jing-Han; Ma, Zhi-Xin; Ma, Qiu-Ling; Yu, Meng-Xia; Yin, Xiu-Feng; Lu, Sha-Sha; Xie, Hong-Qiong; Jiang, Yue-Hong; Shen, Dan; Ma, Li-Ya; Shi, Hui; Yu, Wen-Juan; Lou, Ye-Jiang; Li, Ying; Yang, Min; Xu, Gai-Xiang; Mao, Li-Ping; Li, Jian-Hu; Wang, Huan-Ping; Wang, Dong-Mei; Wei, Ju-Ying; Tong, Hong-Yan; Huang, Jian; Jin, Jie] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China; [Wang, Jing-Han; Ma, Zhi-Xin; Ma, Qiu-Ling; Yu, Meng-Xia; Yin, Xiu-Feng; Lu, Sha-Sha; Xie, Hong-Qiong; Jiang, Yue-Hong; Shen, Dan; Ma, Li-Ya; Shi, Hui; Yu, Wen-Juan; Lou, Ye-Jiang; Li, Ying; Yang, Min; Xu, Gai-Xiang; Mao, Li-Ping; Li, Jian-Hu; Wang, Huan-Ping; Wang, Dong-Mei; Wei, Ju-Ying; Tong, Hong-Yan; Huang, Jian; Jin, Jie] Zhejiang Univ, Affiliated Hosp 1, Inst Hematol, Hangzhou 310003, Zhejiang, Peoples R China; [Wang, Jing-Han; Ma, Qiu-Ling; Tong, Hong-Yan; Huang, Jian; Jin, Jie] Key Lab Hematopoiet Malignancies, Hangzhou, Zhejiang, Peoples R China; [Guo, Qi] Zhejiang Univ, Affiliated Hosp 1, Dept Nephrol, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Wei, JY (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China.	weijuy@hotmail.com; hongyantong@aliyun.com; househuang@hotmail.com; zjuhematology@163.com			National Natural Science Foundation of China [81470305]; National Public Health Grant Research Foundation [201202017]; Foundation of Innovation Team for Basic and Clinical Research of Zhejiang Province [2011R50015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Public Health Grant Research Foundation; Foundation of Innovation Team for Basic and Clinical Research of Zhejiang Province	This work was supported by National Natural Science Foundation of China grants (81470305), National Public Health Grant Research Foundation (201202017) and the Foundation of Innovation Team for Basic and Clinical Research of Zhejiang Province (2011R50015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bertoli S, 2013, BLOOD, V121, P2618, DOI 10.1182/blood-2012-09-454553; Brothman AR, 2009, CYTOGENET GENOME RES, V127, P1, DOI 10.1159/000279442; Chen WL, 2014, BLOOD, V124, P1645, DOI 10.1182/blood-2014-02-554204; Feng JH, 2012, AM J BLOOD RES, V2, P254; Im AP, 2014, LEUKEMIA, V28, P1774, DOI 10.1038/leu.2014.124; Jin J, 2013, LANCET ONCOL, V14, P599, DOI 10.1016/S1470-2045(13)70152-9; Ma QL, 2015, INT J CANCER, V137, P1058, DOI 10.1002/ijc.29395; O'Donnell MR, 2012, J NATL COMPR CANC NE, V10, P984, DOI 10.6004/jnccn.2012.0103; Ostgard LSG, 2014, LEUKEMIA, V28, P1926, DOI 10.1038/leu.2014.157; Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762; Rakheja D, 2012, HUM PATHOL, V43, P1541, DOI 10.1016/j.humpath.2012.05.003; Royston P, 2004, STAT MED, V23, P2509, DOI 10.1002/sim.1815; Sauerbrei WM-H C, 2006, COMPUTATIONAL STAT D, V50, P464; Sekeres MA, 2009, BLOOD, V113, P28, DOI 10.1182/blood-2008-05-157065; Wang JH, 2013, P NATL ACAD SCI USA, V110, P17017, DOI 10.1073/pnas.1315558110; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020	16	3	4	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2015	10	10							e0140622	10.1371/journal.pone.0140622	http://dx.doi.org/10.1371/journal.pone.0140622			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0CK	26466372	Green Published, gold, Green Submitted			2023-01-03	WOS:000363183100154
J	Huang, CW; Lee, MJ; Lee, PT; Hsu, CY; Huang, WC; Chen, CL; Chou, KJ; Fang, HC				Huang, Chien-Wei; Lee, Min-Jing; Lee, Po-Tsang; Hsu, Chih-Yang; Huang, Wei-Chieh; Chen, Chien-Liang; Chou, Kang-Ju; Fang, Hua-Chang			Low Potassium Dialysate as a Protective Factor of Sudden Cardiac Death in Hemodialysis Patients with Hyperkalemia	PLOS ONE			English	Article							ARRHYTHMIAS; RISK; VARIABLES; SURVIVAL; ARREST; SERUM	Aim Hyperkalemia increases the risk of sudden cardiac death (SCD) in hemodialysis patients. Our objective was to determine the association between administering low potassium dialysate to hyperkalemic hemodialysis patients and SCD. Methods We conducted a retrospective cohort study with patients undergoing maintenance hemodialysis from May 1, 2006, through December 31, 2013. The dialysate composition was adjusted over time according to monthly laboratory results. A 1.0 mEq/L potassium dialysate was applied in patients with predialysis hyperkalemia (>5.5 mEq/L) and was included as a time-dependent confounding factor. The clinical characteristics of enrolled patients, the incidence and timing of SCD and risk factors for all-cause mortality and SCD were analyzed. Results There were 312 patients on maintenance hemodialysis during the study period. One hundred and fifty-seven patients had been dialyzed against a 1.0 mEq/L potassium dialysate at least once. The rates of all-cause mortality and SCD were 48.17 and 20.74 per 1000 patient-years, respectively. A 1.12-fold increase in the risk of SCD in the 24-hour period starting with the hemodialysis procedure and a 1.36-fold increase in the 24 hours preceding a weekly cycle were found (p = 0.017). Multivariate Cox proportional hazards models showed that age, diabetes mellitus and predialysis hyperkalemia (>5.0 mEq/L) were significant predictors of all-cause mortality and SCD. Exposure to 1.0 mEq/L potassium dialysate, Kt/V, and serum albumin were independent protective factors against all-cause mortality. Only exposure to 1.0 mEq/L potassium dialysate significantly prevented SCD (hazard ratio = 0.33, 95% CI = 0.13-0.85). Conclusions Using low potassium dialysate in hyperkalemic hemodialysis patients may prevent SCD.	[Huang, Chien-Wei; Lee, Po-Tsang; Hsu, Chih-Yang; Huang, Wei-Chieh; Chen, Chien-Liang; Chou, Kang-Ju; Fang, Hua-Chang] Kaohsiung Vet Gen Hosp, Div Nephrol, Dept Internal Med, Kaohsiung, Taiwan; [Lee, Min-Jing] Kaohsiung Chang Gung Mem Hosp, Dept Child & Adolescent Psychiat, Kaohsiung, Taiwan; [Lee, Min-Jing] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Lee, Po-Tsang; Chen, Chien-Liang; Chou, Kang-Ju; Fang, Hua-Chang] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan	Kaohsiung Veterans General Hospital; Chang Gung Memorial Hospital; Chang Gung University; National Yang Ming Chiao Tung University	Fang, HC (corresponding author), Kaohsiung Vet Gen Hosp, Div Nephrol, Dept Internal Med, Kaohsiung, Taiwan.	hcfang@vghks.gov.tw	Huang, Chien-Wei/AAN-9838-2020; chen, chien-liang/I-6192-2015	Huang, Chien-Wei/0000-0001-5753-9654; chen, chien-liang/0000-0002-9508-8396				Basile C, 2012, J NEPHROL, V25, P506, DOI 10.5301/jn.5000023; Bleyer AJ, 2006, KIDNEY INT, V69, P2268, DOI 10.1038/sj.ki.5000446; Buemi M, 2005, NEPHROL DIAL TRANSPL, V20, P1148, DOI 10.1093/ndt/gfh770; DAUGIRDAS JT, 1989, INT J ARTIF ORGANS, V12, P420; Di Iorio B, 2012, J NEPHROL, V25, P653, DOI 10.5301/jn.5000036; Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272-6386(03)00111-2; Genovesi S, 2008, EUROPACE, V10, P771, DOI 10.1093/europace/eun028; Genovesi S, 2009, NEPHROL DIAL TRANSPL, V24, P2529, DOI 10.1093/ndt/gfp104; Green D, 2011, AM J KIDNEY DIS, V57, P921, DOI 10.1053/j.ajkd.2011.02.376; Herzog CA, 2008, SEMIN DIALYSIS, V21, P300, DOI 10.1111/j.1525-139X.2008.00455.x; HOU S, 1989, AM J KIDNEY DIS, V13, P137, DOI 10.1016/S0272-6386(89)80132-5; Iseki K, 1996, AM J KIDNEY DIS, V28, P541, DOI 10.1016/S0272-6386(96)90465-5; Jadoul M, 2014, SEMIN DIALYSIS, V27, P16, DOI 10.1111/sdi.12158; Jadoul M, 2012, CLIN J AM SOC NEPHRO, V7, P765, DOI 10.2215/CJN.08850811; Karnik JA, 2001, KIDNEY INT, V60, P350, DOI 10.1046/j.1523-1755.2001.00806.x; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Kovesdy CP, 2007, CLIN J AM SOC NEPHRO, V2, P999, DOI 10.2215/CJN.04451206; Labriola L, 2014, SEMIN DIALYSIS, V27, P463, DOI 10.1111/sdi.12252; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MORRISON G, 1980, KIDNEY INT, V17, P811, DOI 10.1038/ki.1980.93; Parekh RS, 2008, KIDNEY INT, V74, P1335, DOI 10.1038/ki.2008.449; Pun PH, 2012, BLOOD PURIFICAT, V33, P183, DOI 10.1159/000334154; Pun PH, 2011, KIDNEY INT, V79, P218, DOI 10.1038/ki.2010.315; RAMIREZ G, 1984, NEPHRON, V36, P212, DOI 10.1159/000183156; Redaelli B, 1996, KIDNEY INT, V50, P609, DOI 10.1038/ki.1996.356; Redaelli B, 2001, J NEPHROL, V14, pS7; Ritz E, 2008, CLIN J AM SOC NEPHRO, V3, P920, DOI 10.2215/CJN.04571007; Santoro A, 2008, NEPHROL DIAL TRANSPL, V23, P1415, DOI 10.1093/ndt/gfm730; SARAGOCA MA, 1991, J CARDIOVASC PHARM, V17, pS136, DOI 10.1097/00005344-199117002-00032; SFORZINI S, 1992, LANCET, V339, P212, DOI 10.1016/0140-6736(92)90008-Q; Stecker EC, 2014, CIRC-ARRHYTHMIA ELEC, V7, P212, DOI 10.1161/CIRCEP.113.001034; US Renal Data System, 2013, USRDS 2013 ANN DAT R	32	15	17	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2015	10	10							e0139886	10.1371/journal.pone.0139886	http://dx.doi.org/10.1371/journal.pone.0139886			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TP	26440515	Green Submitted, gold, Green Published			2023-01-03	WOS:000362510300070
J	Wang, CC; Wang, YC; Wang, GJ; Shen, MY; Chang, YL; Liou, SY; Chen, HC; Chang, CT				Wang, Chun-Cheng; Wang, Yao-Chang; Wang, Guei-Jane; Shen, Ming-Yi; Chang, Yen-Lin; Liou, Show-Yih; Chen, Hung-Chih; Chang, Chiz-Tzung			Skin Autofluorescence Is Associated with Endothelial Dysfunction in Uremic Subjects on Hemodialysis	PLOS ONE			English	Article							GLYCATION END-PRODUCTS; INTIMA-MEDIA THICKNESS; BRACHIAL-ARTERY; PENTOSIDINE; DISEASE; COMPLICATIONS; GLYCOXIDATION; ACCUMULATION; PRAVASTATIN; MORTALITY	Background Elevated levels of advanced glycation end products (AGEs) within tissues may contribute to endothelial dysfunction, an early indicator of atherosclerosis. We aimed to investigate whether levels of skin AGEs could be a useful marker to predict endothelial dysfunction in uremic subjects on hemodialysis. Methods and Results One hundred and nineteen uremic patients on hemodialysis and 57 control subjects with moderate-to-high cardiovascular risk factors and without chronic kidney disease (CKD) were enrolled. We used ultrasound tomeasure flow-mediated vasodilation (FMD). An AGE reader measured skin autoflurorescence (AF). We then compared differences in FMD and skin AF values between the two groups. The uremic subjects had significantly higher levels of skin AF (3.47 +/- 0.76 AU vs. 2.21 +/- 0.45 arbitrary units; P<0.01) and significantly lower levels of FMD (4.79%+/- 1.88% vs. 7.19%+/- 2.17%; P<0.01) than the non-CKD subjects. After adjusting for all potential covariates, we found that skin AF level independently predicted FMD in both the hemodialysis and the non-CKD groups. In the hemodialysis group, skin AF >= +/- 3.05 arbitrary units predicted abnormal FMD at a sensitivity of 87.9% and a specificity of 78.6%(P<0.01). Conclusions Skin AF could be a useful marker to predict endothelial dysfunction in uremic subjects on hemodialysis.	[Wang, Chun-Cheng; Wang, Guei-Jane; Shen, Ming-Yi] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Wang, Chun-Cheng] Buddhist Tzuchi Med Fdn, Taichung Tzuchi Hosp, Dept Internal Med, Div Cardiol, Taichung, Taiwan; [Wang, Yao-Chang] Chang Gung Mem Hosp, Keelung Branch, Div Cardiothorac Surg, Keelung, Taiwan; [Wang, Guei-Jane] China Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Wang, Guei-Jane] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan; [Chang, Yen-Lin] Chung Yuan Christian Univ, Dept Biomed Engn, Taoyuan, Taiwan; [Liou, Show-Yih] Formosan Blood Purificat Fdn, Taipei, Taiwan; [Chen, Hung-Chih; Chang, Chiz-Tzung] China Med Univ Hosp, Dept Internal Med, Div Nephrol, Taichung, Taiwan; [Chang, Chiz-Tzung] China Med Univ, Coll Med, Taichung, Taiwan; [Wang, Chun-Cheng; Chang, Chiz-Tzung] China Med Univ Hosp, Cardiovas Res Lab, Taichung, Taiwan	China Medical University Taiwan; Chang Gung Memorial Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan; Chung Yuan Christian University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Chang, CT (corresponding author), China Med Univ Hosp, Dept Internal Med, Div Nephrol, Taichung, Taiwan.; Chang, CT (corresponding author), China Med Univ, Coll Med, Taichung, Taiwan.; Chang, CT (corresponding author), China Med Univ Hosp, Cardiovas Res Lab, Taichung, Taiwan.	d19863@mail.cmuh.org.tw	Shen, Ming-Yi/L-6861-2019	Shen, Ming-Yi/0000-0002-9351-1912; Chen, Hung-Chih/0000-0001-7666-9729	Tzu-chi General Hospital [TTCRD 103-16]; China Medical University Hospital [DMR-104-014]; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW105-TDU-B-212-133019]	Tzu-chi General Hospital; China Medical University Hospital; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This study was supported by Taichung Tzu-chi General Hospital (grant number TTCRD 103-16), China Medical University Hospital (grant number DMR-104-014), Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019).	Brunet P, 2011, KIDNEY BLOOD PRESS R, V34, P284, DOI 10.1159/000327131; Contreras I, 1997, DIABETES CARE, V20, P832, DOI 10.2337/diacare.20.5.832; de Vos LC, 2013, ARTERIOSCL THROM VAS, V33, P131, DOI 10.1161/ATVBAHA.112.300016; Deng HF, 2005, ACTA PHARMACOL SIN, V26, P92, DOI 10.1111/j.1745-7254.2005.00013.x; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Foley RN, 2005, J AM SOC NEPHROL, V16, P489, DOI 10.1681/ASN.2004030203; Himmelfarb J, 2002, KIDNEY INT, V62, P1524, DOI 10.1046/j.1523-1755.2002.00600.x; Iwamoto Y, 2012, ARTERIOSCL THROM VAS, V32, P2295, DOI 10.1161/ATVBAHA.112.249680; Jadoul M, 1999, KIDNEY INT, V55, P2487, DOI 10.1046/j.1523-1755.1999.00468.x; Kocak H, 2009, NEPHROLOGY, V14, P273, DOI 10.1111/j.1440-1797.2008.01062.x; Meerwaldt R, 2004, DIABETOLOGIA, V47, P1324, DOI 10.1007/s00125-004-1451-2; Miyata T, 2001, NEPHROL DIAL TRANSPL, V16, P8, DOI 10.1093/ndt/16.suppl_4.8; Miyazawa T, 2012, AMINO ACIDS, V42, P1163, DOI 10.1007/s00726-010-0772-3; Monnier VM, 2005, ANN NY ACAD SCI, V1043, P567, DOI 10.1196/annals.1333.065; Monnier VM, 1999, DIABETES, V48, P870, DOI 10.2337/diabetes.48.4.870; Mulder DJ, 2009, NETH HEART J, V17, P162, DOI 10.1007/BF03086239; Mulder DJ, 2008, ATHEROSCLEROSIS, V197, P217, DOI 10.1016/j.atherosclerosis.2007.03.027; Nazratuna N, 2006, VASC MED, V11, P245, DOI 10.1177/1358863x06072202; Noordzij MJ, 2012, INT J CARDIOVAS IMAG, V28, P431, DOI 10.1007/s10554-011-9805-6; Parfrey PS, 1999, J AM SOC NEPHROL, V10, P1606; Raitakari OT, 2000, BRIT J CLIN PHARMACO, V50, P397, DOI 10.1046/j.1365-2125.2000.00277.x; Raj DSC, 2000, AM J KIDNEY DIS, V35, P365, DOI 10.1016/S0272-6386(00)70189-2; Sakata N, 2003, NEPHROL DIAL TRANSPL, V18, P1601, DOI 10.1093/ndt/gfg200; Schwedler SB, 2002, KIDNEY INT, V62, P301, DOI 10.1046/j.1523-1755.2002.00423.x; Shafi T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126048; Shechter M, 2009, INT J CARDIOL, V134, P52, DOI 10.1016/j.ijcard.2008.01.021; Soro-Paavonen A, 2010, J HYPERTENS, V28, P780, DOI 10.1097/HJH.0b013e328335043e; Suliman ME, 2003, J AM SOC NEPHROL, V14, P1614, DOI 10.1097/01.ASN.0000067413.32377.CF; Tanaka K, 2012, DIABETIC MED, V29, P492, DOI 10.1111/j.1464-5491.2011.03448.x; Teragawa H, 2001, AM J CARDIOL, V88, P1147, DOI 10.1016/S0002-9149(01)02051-3; U. S. Renal Data system, 2015, USRDS 2013 ANN DAT R, V4, P2; Ueno H, 2008, METABOLISM, V57, P1452, DOI 10.1016/j.metabol.2008.05.016; Uydes-Dogan BS, 2005, LIFE SCI, V76, P1771, DOI 10.1016/j.lfs.2004.11.002; Wagner Z, 2006, AM J KIDNEY DIS, V47, P294, DOI 10.1053/j.ajkd.2005.10.010; Weiss MF, 2000, KIDNEY INT, V57, P2571, DOI 10.1046/j.1523-1755.2000.00117.x; Widlansky ME, 2003, J AM COLL CARDIOL, V42, P1149, DOI 10.1016/S0735-1097(03)00994-X; Zhou YL, 2010, ARTIF ORGANS, V34, P193, DOI 10.1111/j.1525-1594.2009.00801.x	37	5	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147771	10.1371/journal.pone.0147771	http://dx.doi.org/10.1371/journal.pone.0147771			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26809145	Green Submitted, Green Published, gold			2023-01-03	WOS:000369527800209
J	Larochelle, MR; Liebschutz, JM; Zhang, F; Ross-Degnan, D; Wharam, JF				Larochelle, Marc R.; Liebschutz, Jane M.; Zhang, Fang; Ross-Degnan, Dennis; Wharam, J. Frank			Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC NONCANCER PAIN; UNITED-STATES; CONTROLLED SUBSTANCES; RISK-FACTORS; THERAPY; DEPENDENCE; DEATHS; ABUSE; PRESCRIPTIONS; GUIDELINES	Background: Nonfatal opioid overdose is an opportunity to identify and treat substance use disorders, but treatment patterns after the overdose are unknown. Objective: To determine prescribed opioid dosage after an opioid overdose and its association with repeated overdose. Design: Retrospective cohort study. Setting: A large U.S. health insurer. Participants: 2848 commercially insured patients aged 18 to 64 years who had a nonfatal opioid overdose during long-term opioid therapy for noncancer pain between May 2000 and December 2012. Measurements: Nonfatal opioid overdose was identified using International Classification of Diseases, Ninth Revision, Clinical Modification, codes from emergency department or inpatient claims. The primary outcome was daily morphine-equivalent dosage (MED) of opioids dispensed from 60 days before to up to 730 days after the index overdose. We categorized dosages as large (>= 100 mg MED), moderate (50 to <100 mg MED), low (<50 mg MED), or none (0 mg MED). Secondary outcomes included time to repeated overdose stratified by daily dosage as a time-varying covariate. Results: Over a median follow-up of 299 days, opioids were dispensed to 91% of patients after an overdose. Seven percent of patients (n = 212) had a repeated opioid overdose. At 2 years, the cumulative incidence of repeated overdose was 17% (95% CI, 14% to 20%) for patients receiving high dosages of opioids after the index overdose, 15% (CI, 10% to 21%) for those receiving moderate dosages, 9% (CI, 6% to 14%) for those receiving low dosages, and 8% (CI, 6% to 11%) for those receiving no opioids. Limitation: The cohort was limited to commercially insured adults. Conclusion: Almost all patients continue to receive prescription opioids after an overdose. Opioid discontinuation after overdose is associated with lower risk for repeated overdose.	[Larochelle, Marc R.; Liebschutz, Jane M.; Zhang, Fang; Ross-Degnan, Dennis; Wharam, J. Frank] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Larochelle, Marc R.; Liebschutz, Jane M.; Zhang, Fang; Ross-Degnan, Dennis; Wharam, J. Frank] Boston Univ, Sch Med, Boston, MA 02118 USA; [Larochelle, Marc R.; Liebschutz, Jane M.; Zhang, Fang; Ross-Degnan, Dennis; Wharam, J. Frank] Boston Med Ctr, Boston, MA 02118 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Boston University; Boston Medical Center	Larochelle, MR (corresponding author), Boston Med Ctr, 801 Massachusetts Ave,2nd Floor, Boston, MA 02118 USA.	marc.larochelle@bmc.org	Zhang, Fang/HHN-2153-2022	Wharam, James/0000-0003-2053-0757	Health Resources and Services Administration	Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA))	Health Resources and Services Administration.	Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bohnert ASB, 2011, MED CARE, V49, P393, DOI 10.1097/MLR.0b013e318202aa27; Boscarino JA, 2010, ADDICTION, V105, P1776, DOI 10.1111/j.1360-0443.2010.03052.x; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Cai R., 2010, Morbidity and Mortality Weekly Report, V59, P705; Caudill-Slosberg MA, 2004, PAIN, V109, P514, DOI 10.1016/j.pain.2004.03.006; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Coolen P., 2009, Morbidity and Mortality Weekly Report, V58, P1171; Daubresse M, 2014, PHARMACOEPIDEM DR S, V23, P419, DOI 10.1002/pds.3487; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Edlund MJ, 2007, PAIN, V129, P355, DOI 10.1016/j.pain.2007.02.014; Edlund MJ, 2010, DRUG ALCOHOL DEPEN, V112, P90, DOI 10.1016/j.drugalcdep.2010.05.017; Garcia AM, 2013, J LAW MED ETHICS, V41, P42, DOI 10.1111/jlme.12037; Injury Surveillance Workgroup, 2012, CONS REC NAT STAT PO; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pS67; Mattick RP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub4; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Snapinn SM, 2005, AM STAT, V59, P301, DOI 10.1198/000313005X70371; Sullivan MD, 2008, PAIN, V138, P440, DOI 10.1016/j.pain.2008.04.027; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174	24	119	121	2	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	2016	164	1					1	+		10.7326/M15-0038	http://dx.doi.org/10.7326/M15-0038			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA4WC	26720742				2023-01-03	WOS:000367801700005
J	Mateescu, M; Baixe, S; Garnier, T; Jierry, L; Ball, V; Haikel, Y; Metz-Boutigue, MH; Nardin, M; Schaaf, P; Etienne, O; Lavalle, P				Mateescu, Mihaela; Baixe, Sebastien; Garnier, Tony; Jierry, Loic; Ball, Vincent; Haikel, Youssef; Metz-Boutigue, Marie Helene; Nardin, Michel; Schaaf, Pierre; Etienne, Olivier; Lavalle, Philippe			Antibacterial Peptide-Based Gel for Prevention of Medical Implanted-Device Infection	PLOS ONE			English	Article							RELEASE-INHIBITORY PEPTIDE; IN-VITRO; CHROMOGRANIN-A; DENTAL IMPLANTS; SOL-GEL; CATESTATIN; HYDROGELS; SURFACES; VIVO; ANTIBIOTICS	Implanted medical devices are prone to infection. Designing new strategies to reduce infection and implant rejection are an important challenge for modern medicine. To this end, in the last few years many hydrogels have been designed as matrices for antimicrobial molecules destined to fight frequent infection found in moist environments like the oral cavity. In this study, two types of original hydrogels containing the antimicrobial peptide Cateslytin have been designed. The first hydrogel is based on alginate modified with catechol moieties (AC gel). The choice of these catechol functional groups which derive from mussel's catechol originates from their strong adhesion properties on various surfaces. The second type of gel we tested is a mixture of alginate catechol and thiol-terminated Pluronic (AC/PlubisSH), a polymer derived from Pluronic, a well-known biocompatible polymer. This PlubisSH polymer has been chosen for its capacity to enhance the cohesion of the composition. These two gels offer new clinical uses, as they can be injected and jellify in a few minutes. Moreover, we show these gels strongly adhere to implant surfaces and gingiva. Once gelled, they demonstrate a high level of rheological properties and stability. In particular, the dissipative energy of the (AC/PlubisSH) gel detachment reaches a high value on gingiva (10 J.m(-2)) and on titanium alloys (4 J.m(-2)), conferring a strong mechanical barrier. Moreover, the Cateslytin peptide in hydrogels exhibited potent antimicrobial activities against P. gingivalis, where a strong inhibition of bacterial metabolic activity and viability was observed, indicating reduced virulence. Gel biocompatibility tests indicate no signs of toxicity. In conclusion, these new hydrogels could be ideal candidates in the prevention and/or management of periimplant diseases.	[Mateescu, Mihaela; Baixe, Sebastien; Ball, Vincent; Haikel, Youssef; Metz-Boutigue, Marie Helene; Schaaf, Pierre; Etienne, Olivier; Lavalle, Philippe] INSERM, UMR S 1121, Biomat & Bioingn, Strasbourg, France; [Mateescu, Mihaela; Baixe, Sebastien; Ball, Vincent; Haikel, Youssef; Metz-Boutigue, Marie Helene; Schaaf, Pierre; Etienne, Olivier; Lavalle, Philippe] Univ Strasbourg, Fac Chirurg Dent, Strasbourg, France; [Garnier, Tony; Jierry, Loic; Schaaf, Pierre] Univ Strasbourg, CNRS, Inst Charles Sadron, Strasbourg, France; [Nardin, Michel] CNRS, LRC 7228, Inst Sci Mat Mulhouse, Mulhouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Universites de Strasbourg Etablissements Associes; Universite de Haute-Alsace (UHA)	Etienne, O (corresponding author), INSERM, UMR S 1121, Biomat & Bioingn, Strasbourg, France.	olivier.etienne@unistra.fr	ETIENNE, olivier/D-1601-2013; SCHAAF, Pierre/J-2751-2016; etienne, olivier/D-9542-2011; Lavalle, Philippe/E-6328-2016; BALL, Vincent VB/E-8500-2016	ETIENNE, olivier/0000-0001-8870-4659; SCHAAF, Pierre/0000-0001-7423-5492; etienne, olivier/0000-0001-8870-4659; Lavalle, Philippe/0000-0001-8798-912X; JIERRY, Loic/0000-0002-7541-1360	Projet MICA Dopaglue	Projet MICA Dopaglue	This work was supported by Projet MICA Dopaglue (http://www.instituts-carnot.eu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdullah Al N, 2011, MACROMOLECULAR BIOSC, V11, P1264, DOI [10.1002/mabi.201100083, DOI 10.1002/MABI.201100083]; Akaddar A, 2010, CELL MOL LIFE SCI, V67, P1005, DOI 10.1007/s00018-009-0235-8; Bahar AA, 2013, PHARMACEUTICALS-BASE, V6, P1543, DOI 10.3390/ph6121543; Ben-Nissan B, 2006, NANOMEDICINE-UK, V1, P311, DOI 10.2217/17435889.1.3.311; Besimo CE, 1999, INT J ORAL MAX IMPL, V14, P654; Brandl F, 2010, J CONTROL RELEASE, V142, P221, DOI 10.1016/j.jconrel.2009.10.030; Briolat J, 2005, CELL MOL LIFE SCI, V62, P377, DOI 10.1007/s00018-004-4461-9; Cado G, 2012, LANGMUIR, V28, P8470, DOI 10.1021/la300563s; Chae JJ, 2014, MIL MED, V179, P686, DOI 10.7205/MILMED-D-13-00360; D'Ercole S, 2009, INT J IMMUNOPATH PH, V22, P1019, DOI 10.1177/039463200902200417; Ding FY, 2013, CARBOHYD POLYM, V98, P1547, DOI 10.1016/j.carbpol.2013.07.042; Etienne O, 2006, J DENT RES, V85, P44, DOI 10.1177/154405910608500107; Glinel K, 2012, ACTA BIOMATER, V8, P1670, DOI 10.1016/j.actbio.2012.01.011; Gupta H, 2015, J PHARM BIOALLIED SC, V7, P9, DOI 10.4103/0975-7406.149810; Johnson DW, 2009, PERITON DIALYSIS INT, V29, P303; Kastrup CJ, 2012, P NATL ACAD SCI USA, V109, P21444, DOI 10.1073/pnas.1217972110; Kennedy BP, 1998, PEPTIDES, V19, P1241, DOI 10.1016/S0196-9781(98)00086-2; Lee C, 2013, BIOMACROMOLECULES, V14, P2004, DOI 10.1021/bm400352d; Lee Y, 2010, SOFT MATTER, V6, P977, DOI 10.1039/b919944f; Lin HR, 2004, BIOMACROMOLECULES, V5, P2358, DOI 10.1021/bm0496965; Mahata SK, 2000, MOL ENDOCRINOL, V14, P1525, DOI 10.1210/me.14.10.1525; Matsuno H, 2006, J ORTHOP SCI, V11, P497, DOI 10.1007/s00776-006-1059-0; Nayak AG, 2014, J ORAL IMPLANTOL, V40, P11, DOI 10.1563/AAID-JOI-D-10-00167; Nguyen LT, 2011, TRENDS BIOTECHNOL, V29, P464, DOI 10.1016/j.tibtech.2011.05.001; O'Connor DT, 2002, J HYPERTENS, V20, P1335, DOI 10.1097/00004872-200207000-00020; Paolantonio M, 2008, J PERIODONTOL, V79, P1419, DOI [10.1902/jop.2008.070660, 10.1902/jop.2008.070660 ]; Pingel LC, 2008, IMMUNOL CELL BIOL, V86, P643, DOI 10.1038/icb.2008.56; Radin S, 2001, J BIOMED MATER RES, V57, P313, DOI 10.1002/1097-4636(200111)57:2<313::AID-JBM1173>3.0.CO;2-E; Risbud MV, 2000, J CONTROL RELEASE, V68, P23, DOI 10.1016/S0168-3659(00)00208-X; Ryu JH, 2011, BIOMACROMOLECULES, V12, P2653, DOI 10.1021/bm200464x; van Winkelhoff AJ, 2012, EUR J ORAL IMPLANTOL, V5, pS43; Wang GS, 2015, PHARMACEUTICALS-BASE, V8, P123, DOI 10.3390/ph8010123; Wang GS, 2014, PHARMACEUTICALS-BASE, V7, P545, DOI 10.3390/ph7050545; Xu JK, 2012, LANGMUIR, V28, P14010, DOI 10.1021/la3025414; Zitzmann NU, 2008, J CLIN PERIODONTOL, V35, P286, DOI 10.1111/j.1600-051X.2008.01274.x	35	46	47	2	110	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2015	10	12							e0145143	10.1371/journal.pone.0145143	http://dx.doi.org/10.1371/journal.pone.0145143			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9GR	26659616	Green Published, gold, Green Submitted			2023-01-03	WOS:000366715900187
J	Singam, A; Ytterberg, C; Tham, K; von Koch, L				Singam, Avvai; Ytterberg, Charlotte; Tham, Kerstin; von Koch, Lena			Participation in Complex and Social Everyday Activities Six Years after Stroke: Predictors for Return to Pre-Stroke Level	PLOS ONE			English	Article							FRENCHAY ACTIVITIES INDEX; FUNCTIONAL STATUS; REHABILITATION; DETERMINANTS; DISCHARGE; RECOVERY; IMPACT; LIFE	Background Long-term disability following stroke can lead to participation restrictions in complex and social everyday activities, yet information is lacking on to what extent stroke survivors return to their pre-stroke levels of participation. Objectives The objectives of this study were to investigate the level of participation in complex and social everyday activities 6 years after stroke, to compare this with pre-stroke participation and to identify predictors of returning to pre-stroke levels of participation. Method All patients admitted to Karolinska University Hospital's stroke units during a 1-year period were eligible to participate and 349 patients were recruited. Assessments were made at base-line, 3 months and 6 years using self-reported outcome measures. Participation was assessed using the Frenchay Activities Index (FAI). The 6-year score for each participant was compared to the pre-stroke score, both for the total score and for each domain (domestic chores, leisure/work and outdoor activities). Predictors of having the same or better level of participation at 6 years were identified using logistic regression. Results At 6 years, 121 participants were followed up, 166 were deceased, 44 declined to take part and 18 could not be traced. At 6 years 84% could be described as active (FAI >= 15). The same level of participation or better than pre-stroke was found in 35% of participants, in 65% the level was lower. Similar predictors were identified for achieving the same or better level of participation at 6 years for FAI total and the three domains; ability to walk without aids and a lower age at stroke onset, and perceived mobility, participation and recovery at 3 months. Conclusion Six years after stroke, 35% of participants had the same or better level of participation as pre-stroke. Rehabilitation after stroke to improve walking ability and participation might improve long-term participation in complex and social everyday activities.	[Singam, Avvai] Nykopings Hosp, Nykoping, Sweden; [Singam, Avvai; Ytterberg, Charlotte; Tham, Kerstin; von Koch, Lena] Karolinska Inst, Stockholm, Sweden; [Ytterberg, Charlotte; Tham, Kerstin; von Koch, Lena] Karolinska Univ Hosp, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Ytterberg, C (corresponding author), Karolinska Inst, Stockholm, Sweden.	charlotte.ytterberg@ki.se	von Koch, Lena/P-2310-2018; Tham, Kerstin/T-3964-2018	von Koch, Lena/0000-0002-8560-3016; Tham, Kerstin/0000-0001-7025-5226; Ytterberg, Charlotte/0000-0003-3704-8887	Swedish Research Council [2007-3087, 2013-2806]; Stockholms Lans Landsting [2006-0700]; Swedish Stroke Association	Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholms Lans Landsting; Swedish Stroke Association	Swedish Research Council 2007-3087 and 2013-2806 http://www.vr.se/, Stockholms Lans Landsting 2006-0700 https://www.sll.se/, Swedish Stroke Association www.strokeforbundet.se/AS CY KT LvK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2006, ANN REPORT; ASPLUND K, 1985, STROKE, V16, P885; BOND MJ, 1995, DISABIL REHABIL, V17, P63, DOI 10.3109/09638289509166629; De Wit L, 2007, STROKE, V38, P2101, DOI 10.1161/STROKEAHA.107.482869; Desrosiers J, 2006, DISABIL REHABIL, V28, P221, DOI 10.1080/09638280500158372; Desrosiers Johanne, 2005, Can J Occup Ther, V72, P195; Dijkerman HC, 1996, J ROY COLL PHYS LOND, V30, P538; Dobkin BH, 2004, LANCET NEUROL, V3, P528, DOI 10.1016/S1474-4422(04)00851-8; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; Ellwardt L, 2014, EUR SOCIOL REV, V30, P413, DOI 10.1093/esr/jcu046; Feigin VL, 2010, NEUROLOGY, V75, P1597, DOI 10.1212/WNL.0b013e3181fb44b3; Gadidi V, 2011, ARCH PHYS MED REHAB, V92, P1802, DOI 10.1016/j.apmr.2011.06.014; Gall SL, 2009, CEREBROVASC DIS, V27, P123, DOI 10.1159/000177919; Govan L, 2009, STROKE, V40, P3396, DOI 10.1161/STROKEAHA.109.557645; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Jonsson AC, 2014, STROKE, V45, P1784, DOI 10.1161/STROKEAHA.114.005164; Kumlien S, 1999, DISABIL REHABIL, V21, P31, DOI 10.1080/096382899298070; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Liman TG, 2012, J NEUROL, V259, P1125, DOI 10.1007/s00415-011-6312-6; Lu WS, 2012, ARCH PHYS MED REHAB, V93, P1097, DOI 10.1016/j.apmr.2012.01.015; Norrving B., 2010, FOREKOMST BEFOLKNING; Patel MD, 2002, J AM GERIATR SOC, V50, P700, DOI 10.1046/j.1532-5415.2002.50165.x; Piercy W, 2000, CLIN REHABIL, V14, P433, DOI 10.1191/0269215500cr327oa; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; Spitzer J, 2011, OTJR THOROFARE N J, V31, P8; Tse T, 2013, ARCH PHYS MED REHAB, V94, P177, DOI 10.1016/j.apmr.2012.09.002; Turnbull JC, 2000, ARCH PHYS MED REHAB, V81, P1034, DOI 10.1053/apmr.2000.7162; von Koch L, 2000, CLIN REHABIL, V14, P574, DOI 10.1191/0269215500cr364oa; Wade D T, 1985, Int Rehabil Med, V7, P176; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; Wilkinson PR, 1997, QUAL HEALTH CARE, V6, P125, DOI 10.1136/qshc.6.3.125; Wolfe C, 2011, PLOS MED, V8, P1; World Health Organisation, 2001, ICF INT CLASFUNCT; Young J, 2001, CEREBROVASC DIS, V12, P114, DOI 10.1159/000047690	34	58	59	5	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2015	10	12							e0144344	10.1371/journal.pone.0144344	http://dx.doi.org/10.1371/journal.pone.0144344			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1YZ	26658735	Green Submitted, Green Published, gold			2023-01-03	WOS:000366903500022
J	Chaudhuri, D; Ghate, NB; Panja, S; Das, A; Mandal, N				Chaudhuri, Dipankar; Ghate, Nikhil Baban; Panja, Sourav; Das, Abhishek; Mandal, Nripendranath			Wild Edible Fruit of Prunus nepalensis Ser. (Steud), a Potential Source of Antioxidants, Ameliorates Iron Overload-Induced Hepatotoxicity and Liver Fibrosis in Mice	PLOS ONE			English	Article							HEPATOPROTECTIVE ACTIVITY; SUPEROXIDE; EXTRACTS; FERRITIN; ASSAY; ACID; L.; HYDROXYPROLINE; LEAVES; RATS	The antioxidant and restoration potentials of hepatic injury by Prunus nepalensis Ser. (Steud), a wild fruit plant from the Northeastern region of India, were investigated. The fruit extract (PNME) exhibited excellent antioxidant and reducing properties and also scavenged the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical (IC50 = 30.92 +/- 0.40 mu g/ml). PNME demonstrated promising scavenging potency, as assessed by the scavenging of different reactive oxygen and nitrogen species. Moreover, the extract revealed an exceptional iron chelation capacity with an IC50 of 25.64 +/- 0.60 mu g/ml. The extract induced significant improvement of hepatic injury and liver fibrosis against iron overload induced hepatotoxicity in mice in a dose-dependent manner, and this effect was supported by different histopathological studies. The phytochemical constitutions and their identification by HPLC confirmed the presence of purpurin, tannic acid, methyl gallate, reserpine, gallic acid, ascorbic acid, catechin and rutin. The identified compounds were investigated for their individual radical scavenging and iron chelation activity; some compounds exhibited excellent radical scavenging and iron chelation properties, but most were toxic towards normal cells (WI-38). On the other hand, crude PNME was found to be completely nontoxic to normal cells, suggesting its feasibility as a safe oral drug. The above study suggests that different phytochemicals in PNME contributed to its free radical scavenging and iron chelation activity; however, further studies are required to determine the pathway in which PNME acts to treat iron-overload diseases.	[Chaudhuri, Dipankar; Ghate, Nikhil Baban; Panja, Sourav; Das, Abhishek; Mandal, Nripendranath] Bose Inst, Div Mol Med, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Mandal, N (corresponding author), Bose Inst, Div Mol Med, P 1-12,CIT Rd, Kolkata 700054, W Bengal, India.	mandaln@rediffmail.com	Chudhuri, Dipankar/AAU-6215-2021; Mandal, Nripendranath/ABC-3918-2020; Ghate, Nikhil/T-4153-2017; PANJA, SOURAV/AAA-7163-2022; Panja, Sourav/AFO-5798-2022	Mandal, Nripendranath/0000-0002-8733-3566; Ghate, Nikhil/0000-0002-4447-3737; Panja, Sourav/0000-0001-8540-5266; Chaudhuri, Dipankar/0000-0001-7991-0469				Adikwu E., 2013, Pharmacology and Pharmacy, V4, P84; Afdhal NH, 2004, AM J GASTROENTEROL, V99, P1160, DOI 10.1111/j.1572-0241.2004.30110.x; Agrahar-Murugkar D, 2005, ECOL FOOD NUTR, V44, P207, DOI 10.1080/03670240590953025; Anusha M, 2011, INDIAN J PHARMACOL, V43, P563, DOI 10.4103/0253-7613.84973; Arabshahi-Delouee S, 2007, FOOD CHEM, V102, P1233, DOI 10.1016/j.foodchem.2006.07.013; Arthur MJP, 1996, J GASTROEN HEPATOL, V11, P1124, DOI 10.1111/j.1440-1746.1996.tb01840.x; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BARRY M, 1971, LANCET, V1, P100; Begum S, 2012, NAT PROD RES, V26, P2084, DOI 10.1080/14786419.2011.625502; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BONAVENTURA J, 1972, ARCH BIOCHEM BIOPHYS, V150, P606, DOI 10.1016/0003-9861(72)90080-X; Bothwell T.H., 1979, IRON METABOLISM MAN; Buege J A, 1978, Methods Enzymol, V52, P302; Chatha SAS, 2006, GRASAS ACEITES, V57, P328; Chaudhuri D, 2012, ASIAN J PHARM CLIN R, V5, P193, DOI DOI 10.1186/0717-6287-47-24; Dalle-Donne I, 2003, CLIN CHIM ACTA, V329, P23, DOI 10.1016/S0009-8981(03)00003-2; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Ercal Nuran, 2001, Current Topics in Medicinal Chemistry, V1, P529, DOI 10.2174/1568026013394831; Galleano Monica, 2004, Molecular Aspects of Medicine, V25, P141, DOI 10.1016/j.mam.2004.02.015; Ghate NB., 2013, INT J PHARM BIO SCI, V4, P373; Ghate NB, 2014, CYTOTECHNOLOGY, V66, P209, DOI 10.1007/s10616-013-9553-7; Ghate NB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082293; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Harborne J.B., 1995, PHYTOCHEMICAL DICT H; HARRISON PM, 1977, SEMIN HEMATOL, V14, P55; Hassan S, 2009, TOXICOL LETT, P189; Hazra B, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-63; HERSHKO C, 1994, IRON METABOLISM HLTH, P391; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Hynes MJ, 2002, J INORG BIOCHEM, V90, P18, DOI 10.1016/S0162-0134(02)00383-5; Janbaz KH, 2002, FITOTERAPIA, V73, P557, DOI 10.1016/S0367-326X(02)00217-4; KAKKAR P, 1984, INDIAN J BIOCHEM BIO, V21, P130; Khatri A, 2009, J ETHNOPHARMACOL, V122, P1, DOI 10.1016/j.jep.2008.10.043; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; Kochevar IE, 2000, METHOD ENZYMOL, V319, P20; Kokate C.K., 2003, TXB PHARMACOGNOSY; Koncic MZ, 2011, MOLECULES, V16, P6232, DOI 10.3390/molecules16086232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lushchak VI, 2011, COMP BIOCHEM PHYS C, V153, P175, DOI 10.1016/j.cbpc.2010.10.004; OBRIEN RT, 1974, ANN NY ACAD SCI, V232, P221, DOI 10.1111/j.1749-6632.1974.tb20588.x; Peschel W, 2006, FOOD CHEM, V97, P137, DOI 10.1016/j.foodchem.2005.03.033; Ramm GA, 2005, SEMIN LIVER DIS, V25, P433, DOI 10.1055/s-2005-923315; Reddy ACP, 1996, TOXICOLOGY, V107, P39, DOI 10.1016/0300-483X(95)03199-P; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; RICEEVANS CA, 1995, FREE RADICAL RES, V22, P375, DOI 10.3109/10715769509145649; ROTHMAN RJ, 1992, MOL PHARMACOL, V42, P703; Ryan T. P., 1992, REV TOXICOL, V22, P119; Sabir SM, 2012, FOOD CHEM, V131, P741, DOI 10.1016/j.foodchem.2011.09.026; Saukkonen JJ, 2006, AM J RESP CRIT CARE, V174, P935, DOI 10.1164/rccm.200510-1666ST; Sayre Lawrence M, 2005, Ann Ist Super Sanita, V41, P143; Stief TW, 2003, MED HYPOTHESES, V60, P567, DOI 10.1016/S0306-9877(03)00026-4; Sudha G., 2011, INT J CURR PHARM RES, V3, P137; Tam TF, 2003, CURR MED CHEM, V10, P983, DOI 10.2174/0929867033457593; Tapan S., 2011, INT J PHARM PHARM SC, V3, P233; Taylor BS, 1997, ARCH SURG-CHICAGO, V132, P1177; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; VILE GF, 1995, FREE RADICAL BIO MED, V18, P721, DOI 10.1016/0891-5849(94)00192-M; Visioli F, 1998, BIOCHEM BIOPH RES CO, V247, P60, DOI 10.1006/bbrc.1998.8735; YATES WR, 1987, DRUG ALCOHOL DEPEN, V20, P155, DOI 10.1016/0376-8716(87)90065-2; Yildirim A, 2001, J AGR FOOD CHEM, V49, P4083, DOI 10.1021/jf0103572; Zhou J., 2011, ENCY TRADITIONAL CHI	61	19	19	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2015	10	12							e0144280	10.1371/journal.pone.0144280	http://dx.doi.org/10.1371/journal.pone.0144280			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX9QI	26633891	Green Submitted, Green Published, gold			2023-01-03	WOS:000366040000076
J	Peng, M; Ding, YL; Yu, L; Deng, YL; Lai, WS; Hu, Y; Zhang, HW; Wu, XQ; Fan, H; Ding, H; Wu, YL; Tao, GS				Peng, Mei; Ding, Yiling; Yu, Ling; Deng, Yali; Lai, Weisi; Hu, Yun; Zhang, Hongwen; Wu, Xianqing; Fan, Hong; Ding, Hui; Wu, Yilin; Tao, Guangshi			Tegafur Substitution for 5-Fu in Combination with Actinomycin D to Treat Gestational Trophoblastic Neoplasm	PLOS ONE			English	Article							HYDATIDIFORM MOLE; MANAGEMENT; DIAGNOSIS; DISEASE; S-1; UFT	Although 5-fluorouracil (5-Fu) combination chemotherapy provides a satisfactory therapeutic response in patients with gestational trophoblastic neoplasms (GTNs), it has severe side effects. The current study analyzed the therapeutic effects and side effects of tegafur plus actinomycin D (Act-D) vs. 5-Fu plus Act-D for the treatment of GTNs based on controlled historical records. A total of 427 GTN cases that received tegafur and Act-D combination chemotherapy at the Second Xiangya Hospital of XiangYa Medical School between August 2003 and July 2013 were analyzed based on historical data. A total of 393 GTN cases that received 5-Fu plus Act-D between August 1993 and July 2003 at the same hospital were also analyzed, which constituted the control group. The therapeutic effects, toxicity and side effects after chemotherapy were compared between the groups. The overall response rate was 90.63% in the tegafur+Act-D group (tegafur group) and 92.37% in the 5-Fu+Act-D group (5-Fu group); these rates were not significantly different (P > 0.05). However, the incidence rates of myelosuppression (white blood cell decline), gastrointestinal reactions (nausea, vomiting, dental ulcer, and diarrhea), skin lesions and phlebitis were lower in the tegafur group than in the 5-Fu group (P < 0.05). The results of this study may provide useful data for the clinical application of tegafur in GTN treatment.	[Peng, Mei; Ding, Yiling; Yu, Ling; Deng, Yali; Lai, Weisi; Hu, Yun; Zhang, Hongwen; Wu, Xianqing; Fan, Hong; Ding, Hui; Wu, Yilin; Tao, Guangshi] Cent S Univ, Dept Obstet & Gynaecol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China	Central South University	Ding, YL (corresponding author), Cent S Univ, Dept Obstet & Gynaecol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.	dingylcn@yeah.net						Ajani JA, 2005, J CLIN ONCOL, V24, P663; Berkowitz RS, 2002, NOVAKS GYNECOLOGY, P1353; Cao J, 2007, WORLD PHARM NEWSLETT, P38; Chalouhi GE, 2009, AM J OBSTET GYNECOL, P643; Chen XQ, 2003, NEW PHARM, P673; Eiriksson L, 2012, GYNECOL ONCOL, V124, P553, DOI 10.1016/j.ygyno.2011.10.036; Feng YJ, 2010, OBSTET GYNECOLOGY 8; Goldstein DP, 2012, HEMATOL ONCOL CLIN N, V26, P111, DOI 10.1016/j.hoc.2011.10.007; Komatsu T, 2001, CLIN CANCER RES, V7, P675; LI MC, 1971, ANN INTERN MED, V74, P102, DOI 10.7326/0003-4819-74-1-102; LI MC, 1956, P SOC EXP BIOL MED, V93, P361; Li ZY, 2009, CLIN ONCOLOGY, Vl14, P1022; Malet-Martino M, 2002, ONCOLOGIST, V7, P288, DOI 10.1634/theoncologist.7-4-288; Manopunya M, 2012, ASIAN PAC J CANCER P, V13, P387, DOI 10.7314/APJCP.2012.13.1.387; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Ngan HYS, 2002, INT J GYNECOL OBSTET, V77, P285; Ngan S, 2007, CURR OPIN ONCOL, V19, P486, DOI 10.1097/CCO.0b013e3282dc94e5; Rodriguez N, 2010, EXPERT OPIN PHARMACO, V11, P3027, DOI 10.1517/14656566.2010.512288; Shi YF, 2006, HYDATID MOLE CHORIOC; Shi YF, 2000, CHINESE J CLIN OBSTE, V1, P29; Song HZ, 2004, DIAGNOSIS TREATMENT; Soper JT, 2004, GYNECOL ONCOL, V93, P575, DOI 10.1016/j.ygyno.2004.05.013; Sun Y, 2001, ONCOLOGY INTERNAL ME, P523; Takayama K, 2008, RESPIROLOGY, V13, P103, DOI 10.1111/j.1440-1843.2007.01190.x; Tsuburaya A, 2014, LANCET ONCOL, V15, P886, DOI 10.1016/S1470-2045(14)70025-7; Wan XR, 2002, CHINESE J PRACTICAL, V17, P398; Wang CM, 2009, J MED GENET, V46, P569, DOI 10.1136/jmg.2008.064196; Wang FM, 2007, PRACTICAL J CANC, P77; WANG SL, 1991, CHINESE MED J-PEKING, V104, P156; World Health Organization, 1979, WHO HDB REP RES CANC; Zhao YF, 2007, CHINESE CLIN ONCOLOG, V12, P699; Zhou JC, 2003, PRACTICAL TUMOR INTE; Zhou JC, CLIN APPL ANTITUMOR; Zhou X, 2012, ONCOL LETT, V3, P659, DOI 10.3892/ol.2011.542	34	7	7	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2015	10	11							e0143531	10.1371/journal.pone.0143531	http://dx.doi.org/10.1371/journal.pone.0143531			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7AW	26599757	Green Published, gold, Green Submitted			2023-01-03	WOS:000365853900138
J	Huang, Q; Ma, QF; Feng, J; Cheng, WY; Jia, JP; Song, HQ; Chang, H; Wu, J				Huang, Qiang; Ma, Qing-feng; Feng, Juan; Cheng, Wei-yang; Jia, Jian-ping; Song, Hai-qing; Chang, Hong; Wu, Jian			Factors Associated with In-Hospital Delay in Intravenous Thrombolysis for Acute Ischemic Stroke: Lessons from China	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; TO-NEEDLE TIMES; IMAGING TIME; CARE; IMPROVEMENT; WINDOW; TRIAL	In-hospital delay reduces the benefit of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS), while factors affecting in-hospital delay are less well known in Chinese. We are aiming at determining the specific factors associated with in-hospital delay through a hospital based cohort. In-hospital delay was defined as door-to-needle time (DTN) >= 60min (standard delay criteria) or >= 75% percentile of all DTNs (severe delay criteria). Demographic data, time intervals [onset-to-door time (OTD), DTN, door-to-examination time (DTE), door-to-imaging time (DTI), door-to-laboratory time (DTL) and final-test-to-needle time (FTN, the time interval between the time obtaining the result of the last screening test and the needle time)], medical history and additional variables were calculated using Mann-Whitney U or Pearson Chi-Square tests for group comparison, and multivariate linear regression analysis was performed to identify independent variables of in-hospital delay. A total of 202 IVT cases were enrolled. The median age was 61 years and 25.2% were female. The cutoff points for the upper quartile of DTN (severe delay criteria) was 135min. When compared with the reference group without in-hospital delay, older age, shorter OTD and less referral were found in the standard delay group and male sex, presence with transient ischemic attacks or rapidly improving symptom, and with multi-model CT imaging were more frequent in the severe delay group. In the multivariate linear regression analysis, FTN (P<0.001) and DTL (P = 0.002) were significantly associated with standard delay; while DTE (P = 0.005), DTI (P = 0.033), DTL (P<0.001), and FTN (P<0.001) were positively associated with severe delay. There was not a significant change in the trend of DTNs during the study period (P = 0.054). In-hospital delay was due to multifactors in China, in which time delays of decision-making process and laboratory tests contributed the most. Efforts aiming at reducing the delay should be focused on the optimization for the items of screening tests and improvement of the pathway organization.	[Huang, Qiang; Ma, Qing-feng; Feng, Juan; Cheng, Wei-yang; Jia, Jian-ping; Song, Hai-qing; Wu, Jian] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China; [Chang, Hong] Capital Med Univ, Xuanwu Hosp, Dept Nursing, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Wu, J (corresponding author), Capital Med Univ, Shijingshan Teaching Hosp, Dept Neurol, Beijing Shijingshan Hosp, Beijing, Peoples R China.	wujianxuanwu@126.com			National Natural Science Foundation of China [81371291]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (Grant No. 81371291).	Blumenthal D, 2015, NEW ENGL J MED, V372, P1281, DOI 10.1056/NEJMp1410425; Bogardus ST, 1999, JAMA-J AM MED ASSOC, V281, P1037, DOI 10.1001/jama.281.11.1037; Breuer L, 2013, EUR NEUROL, V69, P317, DOI 10.1159/000345702; Casaubon LK, 2015, INT J STROKE, V10, P924, DOI 10.1111/ijs.12551; Cunningham VL, 2008, CAN J EMERG MED, V10, P545; Dirks M, 2011, STROKE, V42, P1325, DOI 10.1161/STROKEAHA.110.596940; Ebinger M, 2014, JAMA-J AM MED ASSOC, V311, P1622, DOI 10.1001/jama.2014.2850; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Fang K, 2014, J STROKE CEREBROVASC, V23, P427, DOI 10.1016/j.jstrokecerebrovasdis.2013.03.029; Fonarow GC, 2014, JAMA-J AM MED ASSOC, V311, P1632, DOI 10.1001/jama.2014.3203; Fonarow GC, 2011, STROKE, V42, P2983, DOI 10.1161/STROKEAHA.111.621342; Ford AL, 2012, STROKE, V43, P3395, DOI 10.1161/STROKEAHA.112.670687; Hacke W, 2004, LANCET, V363, P768; Huang P, 2011, ACAD EMERG MED, V18, P273, DOI 10.1111/j.1553-2712.2011.01006.x; Huang Q, 2014, NEUROL SCI, V35, P1321, DOI 10.1007/s10072-014-1859-5; Huang Qiang, 2013, Zhonghua Yi Xue Za Zhi, V93, P3419; Jin HQ, 2012, STROKE, V43, P362, DOI 10.1161/STROKEAHA.111.623512; Liu LP, 2011, STROKE, V42, P3651, DOI 10.1161/STROKEAHA.111.635755; Meretoja A, 2012, NEUROLOGY, V79, P306, DOI 10.1212/WNL.0b013e31825d6011; Ming Liu, 2010, CHINESE GUIDELINES D, P146; Nolte CH, 2013, J STROKE CEREBROVASC, V22, P149, DOI 10.1016/j.jstrokecerebrovasdis.2011.07.004; Noorian AR, 2014, J STROKE CEREBROVASC, V23, P220, DOI 10.1016/j.jstrokecerebrovasdis.2012.12.008; Pitt M, 2012, STROKE, V43, P2992, DOI 10.1161/STROKEAHA.111.638650; Rizos T, 2009, STROKE, V40, P3547, DOI 10.1161/STROKEAHA.109.562769; Sauser K, 2014, JAMA NEUROL, V71, P1155, DOI 10.1001/jamaneurol.2014.1528; Scott PA, 2013, LANCET NEUROL, V12, P139, DOI 10.1016/S1474-4422(12)70311-3; Thortveit ET, 2014, ACTA NEUROL SCAND, V130, P248, DOI 10.1111/ane.12204; Yang T, 2013, LANCET, V382, P1703, DOI 10.1016/S0140-6736(13)62401-0	28	13	18	4	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2015	10	11							e0143145	10.1371/journal.pone.0143145	http://dx.doi.org/10.1371/journal.pone.0143145			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW7BR	26575839	gold, Green Published, Green Submitted			2023-01-03	WOS:000365153400045
J	Masic, A; Hernandez, AMV; Hazra, S; Glaser, J; Holzgrabe, U; Hazra, B; Schurigt, U				Masic, Anita; Hernandez, Ana Maria Valencia; Hazra, Sudipta; Glaser, Jan; Holzgrabe, Ulrike; Hazra, Banasri; Schurigt, Uta			Cinnamic Acid Bornyl Ester Derivatives from Valeriana wallichii Exhibit Antileishmanial In Vivo Activity in Leishmania major-Infected BALB/c Mice	PLOS ONE			English	Article							APOPTOTIC CELL-DEATH; DRUG DISCOVERY; CUTANEOUS LEISHMANIASIS; CHALCONES; VITRO; PROLIFERATION; AMAZONENSIS; RESISTANCE; INHIBITORS; DONOVANI	Human leishmaniasis covers a broad spectrum of clinical manifestations ranging from self-healing cutaneous leishmaniasis to severe and lethal visceral leishmaniasis caused among other species by Leishmania major or Leishmania donovani, respectively. Some drug candidates are in clinical trials to substitute current therapies, which are facing emerging drug-resistance accompanied with serious side effects. Here, two cinnamic acid bornyl ester derivatives (1 and 2) were assessed for their antileishmanial activity. Good selectivity and antileishmanial activity of bornyl 3-phenylpropanoate (2) in vitro prompted the antileishmanial assessment in vivo. For this purpose, BALB/c mice were infected with Leishmania major promastigotes and treated with three doses of 50 mg/kg/day of compound 2. The treatment prevented the characteristic swelling at the site of infection and correlated with reduced parasite burden. Transmitted light microscopy and transmission electron microscopy of Leishmania major promastigotes revealed that compounds 1 and 2 induce mitochondrial swelling. Subsequent studies on Leishmania major promastigotes showed the loss of mitochondrial transmembrane potential (Delta psi(m)) as a putative mode of action. As the cinnamic acid bornyl ester derivatives 1 and 2 had exhibited antileishmanial activity in vitro, and compound 2 in Leishmania major-infected BALB/c mice in vivo, they can be regarded as possible lead structures for the development of new antileishmanial therapeutic approaches.	[Masic, Anita; Hernandez, Ana Maria Valencia; Schurigt, Uta] Univ Wurzburg, Inst Mol Infect Biol, Wurzburg, Germany; [Hazra, Sudipta; Hazra, Banasri] Jadavpur Univ, Dept Pharmaceut Technol, Kolkata, India; [Glaser, Jan; Holzgrabe, Ulrike] Univ Wurzburg, Inst Pharm & Food Chem, Wurzburg, Germany	University of Wurzburg; Jadavpur University; University of Wurzburg	Glaser, J (corresponding author), Univ Wurzburg, Inst Pharm & Food Chem, Wurzburg, Germany.	jan.glaser@uni-wuerzburg.de; uta.schurigt@uni-wuerzburg.de		Holzgrabe, Ulrike/0000-0002-0364-7278	Deutsche Forschungsgemeinschaft (DFG), Collaborative Research Center [630 (SFB 630)]; Indian Council of Medical Research, New Delhi, India [3/1/3/WL/JRF-2008/MPD]; Deutsche Forschungsgemeinschaft (DFG); University of Wuerzburg	Deutsche Forschungsgemeinschaft (DFG), Collaborative Research Center(German Research Foundation (DFG)); Indian Council of Medical Research, New Delhi, India(Indian Council of Medical Research (ICMR)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); University of Wuerzburg	Funding: This work was supported by a grant of the Deutsche Forschungsgemeinschaft (DFG), Collaborative Research Center 630 (SFB 630), "Recognition, Preparation and Functional Analysis of Agents against Infectious Diseases" (projects A1 and B3; www.sfb630.uni-wuerzburg.de). SH was awarded a fellowship from the Indian Council of Medical Research, New Delhi, India (3/1/3/WL/JRF-2008/MPD). This publication was funded by the Deutsche Forschungsgemeinschaft (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Aponte JC, 2010, BIOORG MED CHEM LETT, V20, P100, DOI 10.1016/j.bmcl.2009.11.033; Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a; BOGDAN C, 1990, EUR J IMMUNOL, V20, P1131, DOI 10.1002/eji.1830200528; Bozic DD, 2014, INDIAN J MED RES, V140, P130; Bringmann G, 2013, ANTIMICROB AGENTS CH, V57, P3003, DOI 10.1128/AAC.02201-12; Britta EA, 2014, BMC MICROBIOL, V14, DOI 10.1186/s12866-014-0236-0; Castanys-Munoz E, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.113; CHRISTENSEN SB, 1994, PLANTA MED, V60, P121, DOI 10.1055/s-2006-959431; Corware K, 2011, BIOMATERIALS, V32, P8029, DOI 10.1016/j.biomaterials.2011.07.021; Croft SL, 2006, INDIAN J MED RES, V123, P399; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI 10.1128/CMR.19.1.111-126.2006; CROFT SL, 1993, T ROY SOC TROP MED H, V87, P217, DOI 10.1016/0035-9203(93)90499-G; Cruz AK, 2009, CURR DRUG TARGETS, V10, P178, DOI 10.2174/138945009787581177; Dao TTH, 2011, PHYTOCHEM REV, V10, P397, DOI 10.1007/s11101-011-9211-7; de Mello TFP, 2014, EXP PARASITOL, V136, P27, DOI 10.1016/j.exppara.2013.11.003; de Souza W, 2009, INT J BIOCHEM CELL B, V41, P2069, DOI 10.1016/j.biocel.2009.04.007; Rodrigues JCF, 2008, CURR PHARM DESIGN, V14, P925, DOI 10.2174/138161208784041033; Ferreira ME, 2002, J ETHNOPHARMACOL, V80, P199, DOI 10.1016/S0378-8741(02)00025-9; FOURNET A, 1992, J ETHNOPHARMACOL, V37, P159, DOI 10.1016/0378-8741(92)90074-2; Garcia M, 2011, ASIAN PAC J TROP MED, V4, P836, DOI 10.1016/S1995-7645(11)60204-6; Ghosh S, 2011, PARASITOL RES, V108, P861, DOI 10.1007/s00436-010-2127-0; Glaser J, 2015, MOLECULES, V20, P5740, DOI 10.3390/molecules20045740; Glaser J, 2014, MOLECULES, V19, P1394, DOI 10.3390/molecules19021394; Gumy A, 2004, INT J PARASITOL, V34, P433, DOI 10.1016/j.ijpara.2003.11.021; Gupta S, 2014, EUR J MED CHEM, V81, P359, DOI 10.1016/j.ejmech.2014.05.034; GUY RA, 1995, CLIN EXP IMMUNOL, V100, P440; Hacker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193; Hazra S, 2013, EXP PARASITOL, V135, P407, DOI 10.1016/j.exppara.2013.07.021; Hazra S, 2012, PARASITOL RES, V111, P195, DOI 10.1007/s00436-012-2818-9; Inacio JDF, 2012, EXP PARASITOL, V132, P151, DOI 10.1016/j.exppara.2012.06.008; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khademvatan S, 2011, KOREAN J PARASITOL, V49, P17, DOI 10.3347/kjp.2011.49.1.17; Khuda F, 2012, PAK J PHARM SCI, V25, P715; Kingston DGI, 2005, IDRUGS, V8, P990; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Lima HC, 1997, PARASITOL TODAY, V13, P80, DOI 10.1016/S0169-4758(96)40010-2; Masic A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001721; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakayama H, 2007, BIOMED PHARMACOTHER, V61, P186, DOI 10.1016/j.biopha.2007.02.001; Narender T, 2005, BIOORG MED CHEM LETT, V15, P2453, DOI 10.1016/j.bmcl.2005.03.081; Narender T, 2004, BIOORG MED CHEM LETT, V14, P3913, DOI 10.1016/j.bmcl.2004.05.071; Ponte-Sucre A, 2006, ANTIMICROB AGENTS CH, V50, P2439, DOI 10.1128/AAC.01430-05; Proto WR, 2013, NAT REV MICROBIOL, V11, P58, DOI 10.1038/nrmicro2929; Rodrigues IA, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-249; Rosa MDS, 2003, ANTIMICROB AGENTS CH, V47, P1895, DOI 10.1128/AAC.47.6.1895-1901.2003; Sati S. C., 2011, Research Journal of Microbiology, V6, P289, DOI 10.3923/jm.2011.289.296; Schurigt U, 2010, ANTIMICROB AGENTS CH, V54, P5028, DOI 10.1128/AAC.00327-10; Simpson L, 1997, MOL BIOCHEM PARASIT, V87, P71, DOI 10.1016/S0166-6851(97)00044-3; Singh Sarman, 2004, Journal of Infection and Chemotherapy, V10, P307, DOI 10.1007/s10156-004-0348-9; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; SOLBACH W, 1986, INFECT IMMUN, V54, P909, DOI 10.1128/IAI.54.3.909-912.1986; Sundar S, 2008, EXPERT OPIN INV DRUG, V17, P787, DOI [10.1517/13543784.17.5.787, 10.1517/13543784.17.5.787 ]; Vermes I, 2000, J IMMUNOL METHODS, V243, P167, DOI 10.1016/S0022-1759(00)00233-7; Weingartner A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042070; ZHAI L, 1995, ANTIMICROB AGENTS CH, V39, P2742, DOI 10.1128/AAC.39.12.2742; Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01	57	16	16	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2015	10	11							e0142386	10.1371/journal.pone.0142386	http://dx.doi.org/10.1371/journal.pone.0142386			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV7CT	26554591	gold, Green Submitted, Green Published			2023-01-03	WOS:000364430700095
J	Ti, LP; Milloy, MJ; Buxton, J; McNeil, R; Dobrer, S; Hayashi, K; Wood, E; Kerr, T				Ti, Lianping; Milloy, M-J; Buxton, Jane; McNeil, Ryan; Dobrer, Sabina; Hayashi, Kanna; Wood, Evan; Kerr, Thomas			Factors Associated with Leaving Hospital against Medical Advice among People Who Use Illicit Drugs in Vancouver, Canada	PLOS ONE			English	Article							COMMUNITY REENTRY; PAIN MANAGEMENT; RISK; DISCHARGE; THERAPY; COHORT; HOME; READMISSION; EMPLOYMENT; MORTALITY	Background Leaving hospital against medical advice (AMA) is common among people who use illicit drugs (PWUD) and is associated with severe health-related harms and costs. However, little is known about the prevalence of and factors associated with leaving AMA among PWUD. Methods Data were collected through two Canadian prospective cohort studies involving PWUD between September 2005 and July 2011 and linked to a hospital admission/discharge database. Bivariable and multivariable generalized estimating equations were used to examine factors associated with leaving hospital AMA among PWUD who were hospitalized. Results Among 488 participants who experienced at least one hospitalization, 212 (43.4%) left the hospital AMA at least once during the study period. In multivariable analyses, factors positively and significantly associated with leaving hospital AMA included: unstable employment (AOR = 1.92; 95% confidence interval [CI]: 1.22-3.03); recent incarceration (AOR = 1.63; 95% CI: 1.07-2.49); >= daily heroin injection (AOR = 1.49; 95% CI: 1.05-2.11); and younger age per year younger (adjusted odds ratio [AOR] = 1.04; 95% CI: 1.02-1.06). Conclusions We found a substantial proportion of PWUD in this setting left hospital AMA and that various markers of risk and vulnerability were associated with this phenomenon. Our findings highlight the need to address substance abuse issues early following hospital admission. These findings further suggest a need to develop novel interventions to minimize PWUD leaving hospital prematurely.	[Ti, Lianping; Milloy, M-J; McNeil, Ryan; Dobrer, Sabina; Hayashi, Kanna; Wood, Evan; Kerr, Thomas] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; [Ti, Lianping; Milloy, M-J; Hayashi, Kanna; Wood, Evan; Kerr, Thomas] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada; [Buxton, Jane] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V6T 1Z3, Canada; [Buxton, Jane] British Columbia Ctr Dis Control, Vancouver, BC V5Z 4R4, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; University of British Columbia	Kerr, T (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	uhri-tk@cfenet.ubc.ca	Dobrer, Sabina/AAD-1070-2021; Milloy, M-J/AAY-3618-2020; Dobrer, Sabina/S-4401-2019		US National Institutes of Health [R01DA011591, U01DA038886, R01DA021525]; Canadian Institutes of Health Research; Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA021525, U01DA038886, R01DA011591, R01DA033147] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine(Canada Research Chairs); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The VIDUS study was supported by the US National Institutes of Health (R01DA011591, U01DA038886; http://www.drugabuse.gov/). The ACCESS study was supported by the US National Institutes of Health (R01DA021525; http://www.drugabuse.gov/). LT and KH are supported by the Canadian Institutes of Health Research (http://www.cihr.ca/). This research was undertaken, in part, thanks to funding from the Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine which supports EW (http://www.chairs-chaires.gc. ca/home-accueil-eng.aspx). M-JM is supported, in part, by the US National Institutes of Health (R01DA021525; http://www.drugabuse.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexandre PK, 2004, CONTEMP ECON POLICY, V22, P382, DOI 10.1093/cep/byh028; Alfandre DJ, 2009, MAYO CLIN PROC, V84, P255, DOI 10.1016/S0025-6196(11)61143-9; Aliyu Z, 2002, INT J CLIN PRACT, V56, P325; Anis AH, 2002, CAN MED ASSOC J, V167, P633; Binswanger IA, 2000, CLIN INFECT DIS, V30, P579, DOI 10.1086/313703; Carroll IR, 2004, REGION ANESTH PAIN M, V29, P576, DOI 10.1016/j.rapm.2004.06.009; Chan ACH, 2004, JAIDS-J ACQ IMM DEF, V35, P56, DOI 10.1097/00126334-200401010-00008; Choi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024459; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; de Sa LC, 2013, REV LAT-AM ENFERM, V21, P1195, DOI 10.1590/0104-1169.3126.2354; DeBeck K, 2007, DRUG ALCOHOL DEPEN, V91, P50, DOI 10.1016/j.drugalcdep.2007.05.003; DeSimone J, 2002, J LABOR ECON, V20, P952, DOI 10.1086/342893; Fairbairn N, 2012, J EMERG MED, V43, P236, DOI 10.1016/j.jemermed.2011.05.020; Freudenberg N, 2005, AM J PUBLIC HEALTH, V95, P1725, DOI 10.2105/AJPH.2004.056325; Garland A, 2013, CAN MED ASSOC J, V185, P1207, DOI 10.1503/cmaj.130029; Glasgow JM, 2010, J GEN INTERN MED, V25, P926, DOI 10.1007/s11606-010-1371-4; Hines S, 2008, DRUG ALCOHOL REV, V27, P519, DOI 10.1080/09595230802245519; Huxtable CA, 2011, ANAESTH INTENS CARE, V39, P804, DOI 10.1177/0310057X1103900505; Lloyd-Smith Elisa, 2005, Harm Reduct J, V2, P24, DOI 10.1186/1477-7517-2-24; Lloyd-Smith E, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-327; McCreaddie M, 2010, J CLIN NURS, V19, P2730, DOI 10.1111/j.1365-2702.2010.03284.x; McNeil R, 2014, SOC SCI MED, V105, P59, DOI 10.1016/j.socscimed.2014.01.010; Palepu A, 2001, CAN MED ASSOC J, V165, P415; Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x; Rhodes T., 2002, INT J DRUG POLICY, V13, P85, DOI [10.1016/S0955-3959(02)00007-5, DOI 10.1016/S0955-3959(02)00007-5]; Richardson L, 2010, DRUG ALCOHOL REV, V29, P293, DOI 10.1111/j.1465-3362.2009.00141.x; Sordo L, 2014, DRUG ALCOHOL DEPEN, V142, P1, DOI 10.1016/j.drugalcdep.2014.06.041; Southern WN, 2012, AM J MED, V125, P594, DOI 10.1016/j.amjmed.2011.12.017; Steensma C, 2005, J URBAN HEALTH, V82, P622, DOI 10.1093/jurban/jti121; Strathdee SA, 1998, JAMA-J AM MED ASSOC, V280, P547, DOI 10.1001/jama.280.6.547; Tawk R, 2013, ADM POLICY MENT HLTH, V40, P124, DOI 10.1007/s10488-011-0382-8; Ti L, 2014, DRUG ALCOHOL DEPEND; Tompkins CNE, 2007, INT J PRISON HEALTH, V3, P189, DOI 10.1080/17449200701520123; Tyndall MW, 2003, AIDS, V17, P887, DOI 10.1097/00002030-200304110-00014; van Olphen J, 2006, J URBAN HEALTH, V83, P372, DOI 10.1007/s11524-006-9047-4; van Olphen J, 2009, SUBST ABUSE TREAT PR, V4, DOI 10.1186/1747-597X-4-10; Voon P, 2014, PAIN MANAG, V4, P27, DOI [10.2217/PMT.13.62, 10.2217/pmt.13.62]	37	42	42	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2015	10	10							e0141594	10.1371/journal.pone.0141594	http://dx.doi.org/10.1371/journal.pone.0141594			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV0DL	26509447	Green Published, Green Submitted, gold			2023-01-03	WOS:000363918100111
J	Kotchen, TA; Cowley, AW; Liang, MY				Kotchen, Theodore A.; Cowley, Allen W., Jr.; Liang, Mingyu			Ushering Hypertension Into a New Era of Precision Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EPIGENETICS		[Kotchen, Theodore A.] Med Coll Wisconsin, Dept Med, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Cowley, Allen W., Jr.; Liang, Mingyu] Med Coll Wisconsin, Dept Physiol, Ctr Syst Mol Med, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kotchen, TA (corresponding author), Med Coll Wisconsin, Dept Med, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	tkotchen@mcw.edu	Liang, Mingyu/A-2331-2008		NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001436] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL082798] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1TR001436, UL1 TR001436] Funding Source: Medline; NHLBI NIH HHS [P01 HL082798, HL-082798] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cowley AW, 2012, HYPERTENSION, V59, P899, DOI 10.1161/HYPERTENSIONAHA.111.190116; Feinberg AP, 2015, JAMA-J AM MED ASSOC, V314, P1129, DOI 10.1001/jama.2015.10414; Friso S, 2015, TRANSL RES, V165, P154, DOI 10.1016/j.trsl.2014.06.007; Go AS, 2014, HYPERTENSION, V63, P878, DOI 10.1161/HYP.0000000000000003; Joyner MJ, 2015, JAMA-J AM MED ASSOC, V314, P999, DOI 10.1001/jama.2015.7725; Laragh JH, 2011, AM J HYPERTENS, V24, P1164, DOI 10.1038/ajh.2011.171; Liang MY, 2013, SEMIN NEPHROL, V33, P392, DOI [10.1016/j.semnephro1.2013.05.011, 10.1016/j.semnephrol.2013.05.011]; PICKERING GW, 1955, ANN INTERN MED, V43, P1153, DOI 10.7326/0003-4819-43-6-1153	9	54	55	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2016	315	4					343	344		10.1001/jama.2015.18359	http://dx.doi.org/10.1001/jama.2015.18359			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB5YI	26769233	Green Accepted			2023-01-03	WOS:000368589500008
J	Cripe, LD				Cripe, Larry D.			Hope Is the Thing With Feathers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Cripe, Larry D.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA; [Cripe, Larry D.] Indiana Univ Sch Med, Div Hematol Oncol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington	Cripe, LD (corresponding author), Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.	lcripe@iu.edu							0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					265	266		10.1001/jama.2015.18557	http://dx.doi.org/10.1001/jama.2015.18557			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784772				2023-01-03	WOS:000368371400021
J	Quill, TE; Back, AL; Block, SD				Quill, Timothy E.; Back, Anthony L.; Block, Susan D.			Responding to Patients Requesting Physician-Assisted Death Physician Involvement at the Very End of Life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SUICIDE; CARE		[Quill, Timothy E.] Univ Rochester, Med Ctr, Palliat Care Div, Dept Med, Rochester, NY 14642 USA; [Back, Anthony L.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Back, Anthony L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Back, Anthony L.] Univ Washington, Cambia Palliat Care Ctr Excellence, Seattle, WA 98195 USA; [Block, Susan D.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA; [Block, Susan D.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA; [Block, Susan D.] Harvard Univ, Brigham & Womens Hosp, Sch Publ Hlth, Ariadne Labs, Boston, MA 02115 USA	University of Rochester; Harborview Medical Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard T.H. Chan School of Public Health	Quill, TE (corresponding author), Univ Rochester, Med Ctr, Ctr Eth, POB 687,601 Elmwood Ave,Room G-7824, Rochester, NY 14642 USA.	timothy_quill@urmc.rochester.edu						BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Ganzini L, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1682; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Oregon Health Authority, DEATH DIGN ACT; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Tolle SW, 2004, J CLIN ETHIC, V15, P111	7	55	55	0	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					245	246		10.1001/jama.2015.16210	http://dx.doi.org/10.1001/jama.2015.16210			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784762				2023-01-03	WOS:000368371400011
J	Jun, JC; Unnikrishnan, D; Schneider, H; Kirkness, J; Schwartz, AR; Smith, PL; Polotsky, VY				Jun, Jonathan C.; Unnikrishnan, Dileep; Schneider, Hartmut; Kirkness, Jason; Schwartz, Alan R.; Smith, Philip L.; Polotsky, Vsevolod Y.			Effect of Acute Intermittent CPAP Depressurization during Sleep in Obese Patients	PLOS ONE			English	Article							AIRWAY PRESSURE THERAPY; RESPIRATORY EVENTS; APNEA SYNDROME; NIGHT; VARIABILITY; WITHDRAWAL	Background Obstructive Sleep Apnea (OSA) describes intermittent collapse of the airway during sleep, for which continuous positive airway pressure (CPAP) is often prescribed for treatment. Prior studies suggest that discontinuation of CPAP leads to a gradual, rather than immediate return of baseline severity of OSA. The objective of this study was to determine the extent of OSA recurrence during short intervals of CPAP depressurization during sleep. Methods Nine obese (BMI = 40.4 +/- 3.5) subjects with severe OSA (AHI = 88.9 +/- 6.8) adherent to CPAP were studied during one night in the sleep laboratory. Nasal CPAP was delivered at therapeutic (11.1 +/- 0.6 cm H2O) or atmospheric pressure, in alternating fashion for 1-hour periods during the night. We compared sleep architecture and metrics of OSA during CPAP-on and CPAP-off periods. Results 8/9 subjects tolerated CPAP withdrawal. The average AHI during CPAP-on and CPAP-off periods was 3.6 +/- 0.6 and 15.8 +/- 3.6 respectively (p<0.05). The average 3% ODI during CPAP-on and CPAP-off was 4.7 +/- 2 and 20.4 +/- 4.7 respectively (p<0.05). CPAP depressurization also induced more awake (p<0.05) and stage N1 (p<0.01) sleep, and less stage REM (p<0.05) with a trend towards decreased stage N3 (p = 0.064). Conclusion Acute intermittent depressurization of CPAP during sleep led to deterioration of sleep architecture but only partial re-emergence of OSA. These observations suggest carryover effects of CPAP.	[Jun, Jonathan C.; Unnikrishnan, Dileep; Schneider, Hartmut; Kirkness, Jason; Schwartz, Alan R.; Smith, Philip L.; Polotsky, Vsevolod Y.] Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA	Johns Hopkins University	Jun, JC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA.	jjun2@jhmi.edu	C Unnikrishnan, Dileep/P-3048-2018	C Unnikrishnan, Dileep/0000-0001-6743-4792	National Institutes of Health [K08HL109475]; American Academy of Sleep Medicine Foundation [106-JF-14]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL109475] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Sleep Medicine Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Institutes of Health K08HL109475 (JCJ), and American Academy of Sleep Medicine Foundation 106-JF-14 (JCJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmadi N, 2009, SLEEP BREATH, V13, P221, DOI 10.1007/s11325-008-0234-2; Berry RB, 2012, J CLIN SLEEP MED, V8, P597, DOI 10.5664/jcsm.2172; Chediak AD, 1996, SLEEP, V19, P589, DOI 10.1093/sleep/19.7.589; Corda L, 2009, SLEEP BREATH, V13, P187, DOI 10.1007/s11325-008-0219-1; Daulatzai Mak Adam, 2011, Sleep Disord, V2011, P596879, DOI 10.1155/2011/596879; Eckert DJ, 2013, AM J RESP CRIT CARE, V188, P996, DOI 10.1164/rccm.201303-0448OC; Hon QYBMS, 2006, SLEEP, V29, P545, DOI 10.1093/sleep/29.4.545; Kohler M, 2011, AM J RESP CRIT CARE, V184, P1192, DOI 10.1164/rccm.201106-0964OC; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; Le Bon O, 2000, CHEST, V118, P353, DOI 10.1378/chest.118.2.353; Loewen A, 2009, SLEEP, V32, P1355, DOI 10.1093/sleep/32.10.1355; McSharry D, 2012, RESP PHYSIOL NEUROBI, V183, P59, DOI 10.1016/j.resp.2012.05.024; Rossi VA, 2014, EUR RESPIR J, V43, P1387, DOI 10.1183/09031936.00180213; RYAN CF, 1991, AM REV RESPIR DIS, V144, P939, DOI 10.1164/ajrccm/144.4.939; SFORZA E, 1995, SLEEP, V18, P195; SMITH PL, 1988, J APPL PHYSIOL, V64, P789, DOI 10.1152/jappl.1988.64.2.789; Strohl KP, 2014, EUR RESPIR J, V43, P1227, DOI 10.1183/09031936.00003614; White LH, 2015, J CLIN SLEEP MED, V11, P149, DOI 10.5664/jcsm.4462; WOODSON BT, 1991, LARYNGOSCOPE, V101, P1318, DOI 10.1002/lary.5541011211	20	4	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2016	11	1							e0146606	10.1371/journal.pone.0146606	http://dx.doi.org/10.1371/journal.pone.0146606			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA4VZ	26731735	Green Submitted, gold, Green Published			2023-01-03	WOS:000367801400192
J	Murphy, KC; Stilhano, RS; Mitra, D; Zhou, DJ; Batarni, S; Silva, EA; Leach, JK				Murphy, Kaitlin C.; Stilhano, Roberta S.; Mitra, Debika; Zhou, Dejie; Batarni, Samir; Silva, Eduardo A.; Leach, J. Kent			Hydrogel biophysical properties instruct coculture-mediated osteogenic potential	FASEB JOURNAL			English	Article						fibrin; mesenchymal stem cell; ECFC; BMP-2; osteogenesis	ENDOTHELIAL PROGENITOR CELLS; COLONY-FORMING CELLS; ACID-BASED HYDROGEL; BONE REGENERATION; STEM-CELLS; IN-VIVO; BIOACTIVE GLASS; STROMAL CELLS; FIBRIN GELS; DIFFERENTIATION	Cell-based approaches for bone formation require instructional cues from the surrounding environment. As an alternative to pharmacological strategies or transplanting single cell populations, one approach is to coimplant populations that can establish a new vasculature and differentiate to bone-forming osteoblasts. Mesenchymal stem/stromal cells (MSCs) possess osteogenic potential and produce numerous angiogenic growth factors. Endothelial colony-forming cells (ECFCs) are a subpopulation of endothelial progenitor cells capable of vasculogenesis in vivo and may provide endogenous cues to support MSC function. We investigated the contribution of the carrier biophysical properties to instruct entrapped human MSCs and ECFCs to simultaneously promote their osteogenic and proangiogenic potential. Compared with gels containing MSCs alone, fibrin gels engineered with increased compressive stiffness simultaneously increased the osteogenic and proangiogenic potential of entrapped cocultured cells. ECFCs produced bone morphogenetic protein-2 (BMP-2), a potent osteoinductive molecule, and increases in BMP-2 secretion correlated with gel stiffness. Coculture of MSCs with ECFCs transduced to knockdown BMP-2 production abrogated the osteogenic response to levels observed with MSCs alone. These results demonstrate that physical properties of engineered hydrogels modulate the function of cocultured cells in the absence of inductive cues, thus increasing the translational potential of coimplantation to speed bone formation and repair.	[Murphy, Kaitlin C.; Stilhano, Roberta S.; Mitra, Debika; Zhou, Dejie; Batarni, Samir; Silva, Eduardo A.; Leach, J. Kent] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; [Leach, J. Kent] Univ Calif Davis, Sch Med, Dept Orthopaed Surg, Davis, CA 95616 USA; [Stilhano, Roberta S.] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil	University of California System; University of California Davis; University of California System; University of California Davis; Universidade Federal de Sao Paulo (UNIFESP)	Leach, JK (corresponding author), Univ Calif Davis, Dept Biomed Engn, 451 Hlth Sci Dri, Davis, CA 95616 USA.	jkleach@ucdavis.edu	Silva, Eduardo A./M-2711-2015; STILHANO, roberta/F-6923-2015	Silva, Eduardo A./0000-0003-3173-7622; STILHANO, roberta/0000-0002-0653-5968; Fogg, Kaitlin/0000-0003-3572-778X	U.S. National Institutes of Health; National Institute of Dental and Craniofacial Research [R03-DE021704]; AO Foundation (Davos, Switzerland) [C10-39L]; American Heart Association Western States Affiliate Pre-doctoral Fellowship; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R03DE021704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T34GM083894] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); AO Foundation (Davos, Switzerland); American Heart Association Western States Affiliate Pre-doctoral Fellowship(American Heart Association); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a U.S. National Institutes of Health, National Institute of Dental and Craniofacial Research Grant R03-DE021704, and the AO Foundation (Davos, Switzerland) (C10-39L to J.K.L.). K.M. was supported by the American Heart Association Western States Affiliate Pre-doctoral Fellowship. The authors declare no conflicts of interest.	American Academy of Orthopaedic Surgeons, 2000, MUSC INJ REP INC RIS; Bajada S, 2008, J TISSUE ENG REGEN M, V2, P169, DOI 10.1002/term.83; Binder BYK, 2014, TISSUE ENG PT A, V20, P1156, DOI [10.1089/ten.tea.2013.0487, 10.1089/ten.TEA.2013.0487]; Chen YC, 2012, ADV FUNCT MATER, V22, P2027, DOI 10.1002/adfm.201101662; Chung YI, 2007, J CONTROL RELEASE, V121, P91, DOI 10.1016/j.jconrel.2007.05.029; Das A, 2011, TISSUE ENG PART B-RE, V17, P403, DOI [10.1089/ten.TEB.2011.0190, 10.1089/ten.teb.2011.0190]; Davis HE, 2011, ACTA BIOMATER, V7, P691, DOI 10.1016/j.actbio.2010.09.007; Decaris ML, 2011, ANN BIOMED ENG, V39, P1174, DOI 10.1007/s10439-010-0217-x; Decaris ML, 2009, ANGIOGENESIS, V12, P303, DOI 10.1007/s10456-009-9152-6; Dyer LA, 2014, TRENDS ENDOCRIN MET, V25, P472, DOI 10.1016/j.tem.2014.05.003; Edgar CM, 2007, BONE, V40, P1389, DOI 10.1016/j.bone.2007.01.001; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fierro FA, 2011, STEM CELLS, V29, P1727, DOI 10.1002/stem.720; Fioretta ES, 2012, J BIOMECH, V45, P736, DOI 10.1016/j.jbiomech.2011.11.013; Ghajar CM, 2008, BIOPHYS J, V94, P1930, DOI 10.1529/biophysj.107.120774; Ghajar CM, 2006, TISSUE ENG, V12, P2875, DOI 10.1089/ten.2006.12.2875; Ghajar CM, 2010, EXP CELL RES, V316, P813, DOI 10.1016/j.yexcr.2010.01.013; Grellier M, 2009, BIOMATERIALS, V30, P3271, DOI 10.1016/j.biomaterials.2009.02.033; He JW, 2012, TISSUE ENG PT A, V18, P1520, DOI [10.1089/ten.tea.2011.0127, 10.1089/ten.TEA.2011.0127]; Herzog DPE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/320123; Hoch AI, 2014, STEM CELL TRANSL MED, V3, P643, DOI 10.5966/sctm.2013-0196; Hoch AI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035579; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Janmey PA, 2009, J R SOC INTERFACE, V6, P1, DOI 10.1098/rsif.2008.0327; Joo HJ, 2015, INT J CARDIOL, V197, P33, DOI 10.1016/j.ijcard.2015.06.013; Kaigler D, 2006, J DENT RES, V85, P633, DOI 10.1177/154405910608500710; Kaigler D, 2005, FASEB J, V19, P665, DOI 10.1096/fj.04-2529fje; Kim J, 2007, BIOMATERIALS, V28, P1830, DOI 10.1016/j.biomaterials.2006.11.050; Kim J, 2009, J BIOMED MATER RES A, V88A, P967, DOI 10.1002/jbm.a.31947; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Leach JK, 2006, BIOMATERIALS, V27, P3249, DOI 10.1016/j.biomaterials.2006.01.033; Leu A, 2009, TISSUE ENG PT A, V15, P877, DOI 10.1089/ten.tea.2008.0018; Lin RZ, 2014, P NATL ACAD SCI USA, V111, P10137, DOI 10.1073/pnas.1405388111; Melero-Martin JM, 2008, CIRC RES, V103, P194, DOI 10.1161/CIRCRESAHA.108.178590; Melero-Martin JM, 2007, BLOOD, V109, P4761, DOI 10.1182/blood-2006-12-062471; Murphy KC, 2015, ANN BIOMED ENG, V43, P2010, DOI 10.1007/s10439-014-1227-x; Murphy Kaitlin C, 2012, BMC Res Notes, V5, P423, DOI 10.1186/1756-0500-5-423; Oelker AM, 2011, BIOMACROMOLECULES, V12, P1658, DOI 10.1021/bm200039s; Saleh FA, 2011, STEM CELLS DEV, V20, P391, DOI 10.1089/scd.2010.0168; Seebach C, 2012, CELL TRANSPLANT, V21, P1667, DOI 10.3727/096368912X638937; Smadja DM, 2008, ARTERIOSCL THROM VAS, V28, P2137, DOI 10.1161/ATVBAHA.108.168815; Spotnitz William D, 2014, ISRN Surg, V2014, P203943, DOI 10.1155/2014/203943; Wingate K, 2012, ACTA BIOMATER, V8, P1440, DOI 10.1016/j.actbio.2011.12.032; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Young S, 2009, TISSUE ENG PT A, V15, P2347, DOI 10.1089/ten.tea.2008.0510; Yu HY, 2009, BIOMATERIALS, V30, P508, DOI 10.1016/j.biomaterials.2008.09.047	46	16	16	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2016	30	1					477	486		10.1096/fj.15-279984	http://dx.doi.org/10.1096/fj.15-279984			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DA2JL	26443826	Green Published			2023-01-03	WOS:000367621000044
J	Cao, SJ; Yu, L; Mao, JY; Wang, Q; Ruan, JS				Cao, Shujuan; Yu, Liang; Mao, Jingyuan; Wang, Quan; Ruan, Jishou			Uncovering the Molecular Mechanism of Actions between Pharmaceuticals and Proteins on the AD Network	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; ACE; TAU; ACTIVATION; HYPOTHESIS; INHIBITORS; AFFINITY; RECEPTOR; PROGRESS; BINDING	This study begins with constructing the mini metabolic networks (MMNs) of beta amyloid (A beta) and acetylcholine (ACh) which stimulate the Alzheimer's Disease (AD). Then we generate the AD network by incorporating MMNs of A beta and ACh, and other MMNs of stimuli of AD. The panel of proteins contains 49 enzymes/receptors on the AD network which have the 3D-structure in PDB. The panel of drugs is formed by 5 AD drugs and 5 AD nutraceutical drugs, and 20 non-AD drugs. All of these complexes formed by these 30 drugs and 49 proteins are transformed into dyadic arrays. Utilizing the prior knowledge learned from the drug panel, we propose a statistical classification (dry-lab). According to the wet-lab for the complex of amiloride and insulin degrading enzyme, and the complex of amiloride and neutral endopeptidase, we are confident that this dry-lab is reliable. As the consequences of the dry-lab, we discover many interesting implications. Especially, we show that possible causes of Tacrine, donepezil, galantamine and huperzine A cannot improve the level of ACh which is against to their original design purpose but they still prevent AD to be worse as A beta deposition appeared. On the other hand, we recommend Miglitol and Atenolol as the safe and potent drugs to improve the level of ACh before A beta deposition appearing. Moreover, some nutrients such as NADH and Vitamin E should be controlled because they may harm health if being used in wrong way and wrong time. Anyway, the insights shown in this study are valuable to be developed further.	[Cao, Shujuan; Yu, Liang; Ruan, Jishou] Nankai Univ, Coll Math Sci, Tianjin 300071, Peoples R China; [Cao, Shujuan; Yu, Liang; Ruan, Jishou] Nankai Univ, LPMC, Tianjin 300071, Peoples R China; [Mao, Jingyuan] Tianjin Univ Tradit Chinese Med, Internal Med Heart, Tianjin, Peoples R China; [Wang, Quan] Chinese Acad Sci, Inst Biophys, Natl Lab Macromol, Beijing 100080, Peoples R China; [Wang, Quan] TEDA, Tianjin Int Joint Acad Biomed, High Throughput Mol Drug Discovery Ctr, Tianjin, Peoples R China; [Ruan, Jishou] Nankai Univ, State Key Lab Med Chem & Biol, Tianjin 300071, Peoples R China	Nankai University; Nankai University; Tianjin University of Traditional Chinese Medicine; Chinese Academy of Sciences; Institute of Biophysics, CAS; Tianjin International Joint Academy of Biomedicine; Nankai University	Ruan, JS (corresponding author), Nankai Univ, Coll Math Sci, Tianjin 300071, Peoples R China.	jsruan@nankai.edu.cn			Natural Science Funding of China [10671100, 11101226, 31050110432, 31150110577]; International Development Research Center in Ottawa, Canada [104519010]	Natural Science Funding of China; International Development Research Center in Ottawa, Canada	J.R. and his research group are thankful for the financial support from the Natural Science Funding of China (grants 10671100, 11101226, 31050110432, and 31150110577). J.R. also expresses gratitude to the International Development Research Center in Ottawa, Canada (grant 104519010).	Amtul Z, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.07.014; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Bartzokis G, 2011, NEUROBIOL AGING, V32, P1341, DOI 10.1016/j.neurobiolaging.2009.08.007; Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006; Birks J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005593; Bourne KZ, 2007, J NEUROSCI RES, V85, P1194, DOI 10.1002/jnr.21252; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; Chen CH, 2012, INT J NEUROPSYCHOPH, V15, P77, DOI 10.1017/S1461145711000149; Cui W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037790; Glenn ND, 1981, BRIT J CLIN PHARMACO, V11, P549; Gohlke P, 2001, J PHARMACOL EXP THER, V298, P62; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Grommes C, 2013, CANCER CHEMOTH PHARM, V71, P929, DOI 10.1007/s00280-013-2084-2; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heneka MT, 2010, P NATL ACAD SCI USA, V107, P6058, DOI 10.1073/pnas.0909586107; Hu G, 2012, STRUCTURE, V20, P1815, DOI 10.1016/j.str.2012.09.011; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Itzhaki RF, 2008, J ALZHEIMERS DIS, V13, P393; Jandeleit-Dahm KAM, 2006, J HUM HYPERTENS, V20, P478, DOI 10.1038/sj.jhh.1002018; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Jouquey S, 1995, NEUROPHARMACOLOGY, V34, P1689, DOI 10.1016/0028-3908(95)00146-8; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Kuhn W, 1996, J NEURAL TRANSM, V103, P1187, DOI 10.1007/BF01271203; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8; Mellin V, 2005, J CARDIOVASC PHARM, V46, P390, DOI 10.1097/01.fjc.0000175457.48031.8b; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Rosendoff C, 2007, AM J GERIATR CARDIOL, V16, P143, DOI 10.1111/j.1076-7460.2007.06696.x; Rossi GP, 2003, CARDIOVASC DRUG REV, V21, P51; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Szekely Christine A, 2007, Subcell Biochem, V42, P229; Thathiah A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.293re8; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang HY, 2000, J NEUROCHEM, V75, P1155, DOI 10.1046/j.1471-4159.2000.0751155.x; Wang K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033709; Wang R, 2006, ACTA PHARMACOL SIN, V27, P1, DOI 10.1111/j.1745-7254.2006.00255.x; Yorulmaz H, 2011, NEUROPHYSIOLOGY+, V42, P349, DOI 10.1007/s11062-011-9168-6	42	4	4	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2015	10	12							e0144387	10.1371/journal.pone.0144387	http://dx.doi.org/10.1371/journal.pone.0144387			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1YX	26650760	gold, Green Published, Green Submitted			2023-01-03	WOS:000366903300047
J	Luo, P; Dong, GT; Liu, L; Zhou, H				Luo, Pei; Dong, Gengting; Liu, Liang; Zhou, Hua			The Long-Term Consumption of Ginseng Extract Reduces the Susceptibility of Intermediate-Aged Hearts to Acute Ischemia Reperfusion Injury	PLOS ONE			English	Article							MYOCARDIAL-INFARCTION; CARDIAC-HYPERTROPHY; PANAX-GINSENG; MOLECULAR-MECHANISMS; OXIDATIVE STRESS; RATS; FAILURE; ANGIOGENESIS; DISEASE; YOUNG	Background A large number of experimental studies using young adult subjects have shown that ginseng (Panax ginseng C.A. Meyer) protects against ischemia heart disease. However, ginseng has not been explored for its anti-I/R effect and mechanism of action in the aged myocardium. The present study was designed to evaluate the effects of the long-term consumption of ginseng extract on myocardial I/R in an in vivo rat model and explore the potential underlying mechanism. Methods and Results Young (6-mo-old) and intermediate-aged (18-mo-old) rats were gavaged with either standardized ginseng extract (RSE) at 80 mg/kg or vehicle for 90 days. The rats were sacrificed after LAD coronary artery ligation was performed to induce 30 min of ischemia, followed by 90 min of reperfusion. The myocardial infarct size was measured. Left ventricular function was evaluated using pressure-volume loops. The levels of survival, apoptotic and longevity protein expression were assessed through Western blot analysis. Myocardial pathology was detected through H&E or Masson's trichrome staining. We observed higher infarct expansion with impairment in the LV functional parameters, such as LVSP and LVEDP, in aged rats compared with young rats. Enhanced Akt phosphorylation and eNOS expression in RSE-treated aged hearts were accompanied with reduced infarct size, improved cardiac performance, and inducted survival signals. In contrast, p-Erk and caspase 7 were significantly downregulated in aged rats, suggesting that cardiomyocyte apoptosis was suppressed after RSE treatment. RSE also inhibited caspase-3/7 activation and decreased Bax/Bcl-2 ratio. Consistent with the results of apoptosis, Sirt1 and Sirt3 were significantly increased in the RSE-treated aged heart compared with vehicle-treated I/R, suggesting that the anti-aging effect was correlated with the anti-apoptotic activity of RSE. Conclusion These findings suggest that the long-term consumption of ginseng extract reduced the susceptibility of intermediate-aged hearts to acute ischemia reperfusion injury in rats. These effects might be mediated through the activation of Akt/eNOS, suppression of Erk/caspase 7 and upregulation of Sirt1 and Sirt3 in intermediate-aged rats.	[Luo, Pei; Dong, Gengting; Liu, Liang; Zhou, Hua] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Taipa, Macau, Peoples R China; [Luo, Pei; Liu, Liang; Zhou, Hua] Hong Kong Baptist Univ, Sch Chinese Med, Kowloon, Hong Kong, Peoples R China	Macau University of Science & Technology; Hong Kong Baptist University	Liu, L (corresponding author), Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Ave Wai Long, Taipa, Macau, Peoples R China.	lliu@must.edu.mo; hzhou@must.edu.mo			Macao Science and Technology Development Fund [071/2011/A3, 073/2011/A3, 052/2013/A2]; Faculty Research Grant of Hong Kong Baptist University [FRG 08-09 II-18]	Macao Science and Technology Development Fund; Faculty Research Grant of Hong Kong Baptist University	This research was supported by the Macao Science and Technology Development Fund (Grant numbers: 071/2011/A3, 073/2011/A3, www.fdct.gov.mo) and the Faculty Research Grant of Hong Kong Baptist University (Grant numbers: FRG 08-09 II-18; URL: www.hkbu.edu.hk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was supported by the Macao Science and Technology Development Fund (Grant numbers: 071/2011/A3, 073/2011/A3, 052/2013/A2; URL: www.fdct.gov.mo) and the Faculty Research Grant of Hong Kong Baptist University (Grant numbers: FRG 08-09 II-18; URL: www.hkbu.edu.hk).	Arbab-Zadeh A, 2004, CIRCULATION, V110, P1799, DOI 10.1161/01.CIR.0000142863.71285.74; Braidy N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019194; Choi KT, 2008, ACTA PHARMACOL SIN, V29, P1109, DOI 10.1111/j.1745-7254.2008.00869.x; Dai DF, 2012, ANTIOXID REDOX SIGN, V16, P1492, DOI 10.1089/ars.2011.4179; de Souza RR, 2002, BIOGERONTOLOGY, V3, P325, DOI 10.1023/A:1021312027486; Forman DE, 1997, J AM COLL CARDIOL, V30, P1872, DOI 10.1016/S0735-1097(97)00411-7; Fromm Annette, 2014, BMC Res Notes, V7, P176, DOI 10.1186/1756-0500-7-176; Fu Y, 2003, J NUTR, V133, P3603, DOI 10.1093/jn/133.11.3603; Gould KE, 2002, AM J PHYSIOL-HEART C, V282, pH615, DOI 10.1152/ajpheart.00206.2001; Hacker TA, 2006, AM J PHYSIOL-HEART C, V290, pH304, DOI 10.1152/ajpheart.00290.2005; HOIT BD, 1986, CIRCULATION, V74, P712, DOI 10.1161/01.CIR.74.4.712; Im DS, 2013, ACTA PHARMACOL SIN, V34, P1367, DOI 10.1038/aps.2013.100; Joukar S, 2010, CARDIOVASC TOXICOL, V10, P66, DOI 10.1007/s12012-010-9063-1; Karmazyn M, 2011, DRUGS, V71, P1989, DOI 10.2165/11594300-000000000-00000; Kim JH, 2012, J GINSENG RES, V36, P16, DOI 10.5142/jgr.2012.36.1.16; Kris-Etherton PM, 2004, CIRCULATION, V110, P637, DOI 10.1161/01.CIR.0000137822.39831.F1; Lindsey ML, 2006, AM J PHYSIOL-HEART C, V290, pH232, DOI 10.1152/ajpheart.00457.2005; Lindsey ML, 2005, CARDIOVASC RES, V66, P410, DOI 10.1016/j.cardiores.2004.11.029; Nadal-Ginard B, 2003, CIRC RES, V92, P139, DOI 10.1161/01.RES.0000053618.86362.DF; Phaneuf S, 2002, AM J PHYSIOL-REG I, V282, pR423, DOI 10.1152/ajpregu.00296.2001; Pillai VB, 2014, CIRC RES, V114, P368, DOI 10.1161/CIRCRESAHA.113.300536; Ramesh T, 2012, EXP GERONTOL, V47, P77, DOI 10.1016/j.exger.2011.10.007; Rich MW, 2006, AM J GERIATR CARDIOL, V15, P7, DOI 10.1111/j.1076-7460.2006.05273.x; Shiojima I, 2005, J CLIN INVEST, V115, P2108, DOI 10.1172/JCI24682; Song JQ, 2009, APOPTOSIS, V14, P1299, DOI 10.1007/s10495-009-0398-7; Sulaiman M, 2010, AM J PHYSIOL-HEART C, V298, pH833, DOI 10.1152/ajpheart.00418.2009; Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162; Turer AT, 2010, AM J CARDIOL, V106, P360, DOI 10.1016/j.amjcard.2010.03.032; Weiss RG, 2005, P NATL ACAD SCI USA, V102, P808, DOI 10.1073/pnas.0408962102; Xiang YZ, 2008, PHYTOTHER RES, V22, P851, DOI 10.1002/ptr.2384; Yang B, 1999, AM J PHYSIOL-HEART C, V277, pH1906, DOI 10.1152/ajpheart.1999.277.5.H1906; Yang YN, 2008, AM J PHYSIOL-HEART C, V294, pH1815, DOI 10.1152/ajpheart.00831.2007; Zhou H, 2011, J ETHNOPHARMACOL, V135, P287, DOI 10.1016/j.jep.2011.03.015	33	22	23	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2015	10	12							e0144733	10.1371/journal.pone.0144733	http://dx.doi.org/10.1371/journal.pone.0144733			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1YX	26650753	Green Published, gold, Green Submitted			2023-01-03	WOS:000366903300071
J	Flores-Gonzalez, JC; Matamala-Morillo, MA; Rodriguez-Campoy, P; Perez-Guerrero, JJ; Serrano-Moyano, B; Comino-Vazquez, P; Palma-Zambrano, E; Bulo-Concellon, R; Santos-Sanchez, V; Lechuga-Sancho, AM				Carlos Flores-Gonzalez, J.; Matamala-Morillo, Miguel A.; Rodriguez-Campoy, Patricia; Perez-Guerrero, Juan J.; Serrano-Moyano, Belen; Comino-Vazquez, Paloma; Palma-Zambrano, Encarnacion; Bulo-Concellon, Rocio; Santos-Sanchez, Vanessa; Lechuga-Sancho, Alfonso M.		Bronchiolitis Cadiz Study Grp	Epinephrine Improves the Efficacy of Nebulized Hypertonic Saline in Moderate Bronchiolitis: A Randomised Clinical Trial	PLOS ONE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; HOSPITALIZED INFANTS; VIRAL BRONCHIOLITIS; ALBUTEROL; MULTICENTER; POPULATION; SALBUTAMOL; CHILDREN	Background and Aims There is no evidence that the epinephrine-3% hypertonic saline combination is more effective than 3% hypertonic saline alone for treating infants hospitalized with acute bronchiolitis. We evaluated the efficacy of nebulized epinephrine in 3% hypertonic saline. Patients and Methods We performed a randomized, double-blind, placebo-controlled clinical trial in 208 infants hospitalized with acute moderate bronchiolitis. Infants were randomly assigned to receive nebulized 3% hypertonic saline with either 3 mL of epinephrine or 3 mL of placebo, administered every four hours. The primary outcome measure was the length of hospital stay. Results A total of 185 infants were analyzed: 94 in the epinephrine plus 3% hypertonic saline group and 91 in the placebo plus 3% hypertonic saline group. Baseline demographic and clinical characteristics were similar in both groups. Length of hospital stay was significantly reduced in the epinephrine group as compared with the placebo group (3.94 +/- 1.88 days vs. 4.82 +/- 2.30 days, P = 0.011). Disease severity also decreased significantly earlier in the epinephrine group (P = 0.029 and P = 0.036 on days 3 and 5, respectively). Conclusions In our setting, nebulized epinephrine in 3% hypertonic saline significantly shortens hospital stay in hospitalized infants with acute moderate bronchiolitis compared to 3% hypertonic saline alone, and improves the clinical scores of severity from the third day of treatment, but not before.	[Carlos Flores-Gonzalez, J.; Matamala-Morillo, Miguel A.; Rodriguez-Campoy, Patricia; Perez-Guerrero, Juan J.; Serrano-Moyano, Belen; Comino-Vazquez, Paloma; Palma-Zambrano, Encarnacion; Lechuga-Sancho, Alfonso M.] Hosp Univ Puerta del Mar, Dept Clin Pediat, Cadiz, Spain; [Bulo-Concellon, Rocio] Hosp Univ Puerta del Mar, Dept Pharm, Cadiz, Spain; [Santos-Sanchez, Vanessa] Fdn Biomed Res Management, Cadiz, Spain; [Lechuga-Sancho, Alfonso M.] Univ Cadiz, Dept Maternal & Child Hlth Care & Radiol, Cadiz, Spain	Universidad de Cadiz; Hospital Universitario Puerta del Mar; Universidad de Cadiz; Hospital Universitario Puerta del Mar; Universidad de Cadiz	Flores-Gonzalez, JC (corresponding author), Hosp Univ Puerta del Mar, Dept Clin Pediat, Cadiz, Spain.	carlosflogon@gmail.com	Lechuga-Sancho, Alfonso/M-2712-2015; Gonzalez, Jose Carlos Flores/AAL-8848-2020	Lechuga-Sancho, Alfonso/0000-0001-5861-6041; Gonzalez, Jose Carlos Flores/0000-0002-3900-125X	Spanish Ministry of Health, Social Politics and Equality [EC10-180]	Spanish Ministry of Health, Social Politics and Equality	This work was supported by grants from the Spanish Ministry of Health, Social Politics and Equality for the promotion of independent clinical research of 2010 (EC10-180). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASSOULINE G, 1977, EUR J PHARMACOL, V44, P271, DOI 10.1016/0014-2999(77)90073-5; Bertrand P, 2001, PEDIATR PULM, V31, P284, DOI 10.1002/ppul.1040; Castro-Rodriguez JA, 2015, PAEDIAT RESP REV; Del Giudice MM, 2012, INT J IMMUNOPATH PH, V25, P485, DOI 10.1177/039463201202500218; Dobson JV, 1998, PEDIATRICS, V101, P361, DOI 10.1542/peds.101.3.361; Everard ML, 2014, THORAX, V69, P1105, DOI 10.1136/thoraxjnl-2014-205953; Flores G, 1997, PEDIATRICS, V100, P233, DOI 10.1542/peds.100.2.233; Flores-Gonzalez JC, 2014, MINERVA PEDIAT; Gadomski AM, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001266.pub2, 10.1002/14651858.CD001266.pub3]; Gonzalez Caballero D, 2001, An Esp Pediatr, V55, P355; Grewal S, 2015, CAN FAM PHYSICIAN, V61, P531; Grewal S, 2009, ARCH PEDIAT ADOL MED, V163, P1007, DOI 10.1001/archpediatrics.2009.196; Grupo de trabajo de la Guia de Practica Clinica sobre la Bronquiolitis Aguda, 2007, GUIA DE PRACTICA CLI; Hartling L, 2003, ARCH PEDIAT ADOL MED, V157, P957, DOI 10.1001/archpedi.157.10.957; Hartling L, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003123.pub3; Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758; Kuzik BA, 2007, J PEDIATR-US, V151, P266, DOI 10.1016/j.jpeds.2007.04.010; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; Langley Joanne M, 2005, BMC Pediatr, V5, P7, DOI 10.1186/1471-2431-5-7; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Mandelberg A, 2010, PEDIATR PULM, V45, P36, DOI 10.1002/ppul.21185; MENON K, 1995, J PEDIATR-US, V126, P1004, DOI 10.1016/S0022-3476(95)70234-2; Mull CC, 2004, ARCH PEDIAT ADOL MED, V158, P113, DOI 10.1001/archpedi.158.2.113; Patel H, 2002, J PEDIATR-US, V141, P818, DOI 10.1067/mpd.2002.129844; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3; Stockman LJ, 2012, PEDIATR INFECT DIS J, V31, P5, DOI 10.1097/INF.0b013e31822e68e6; Tal G, 2006, ISR MED ASSOC J, V8, P169; Tinsa Faten, 2014, Tunis Med, V92, P674; Vicente D, 2003, EPIDEMIOL INFECT, V131, P867, DOI 10.1017/S0950268803008926; Wainwright C, 2003, NEW ENGL J MED, V349, P27, DOI 10.1056/NEJMoa022226; WOHL MEB, 1978, AM REV RESPIR DIS, V118, P759, DOI 10.1164/arrd.1978.118.4.759; Wu SS, 2014, JAMA PEDIATR, V168, P657, DOI 10.1001/jamapediatrics.2014.301; Zhang LJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006458.pub3; Ziment I., 1978, RESP PHARM THERAPEUT	37	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2015	10	11							e0142847	10.1371/journal.pone.0142847	http://dx.doi.org/10.1371/journal.pone.0142847			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW7BR	26575036	Green Published, Green Submitted, gold			2023-01-03	WOS:000365153400019
J	Oueslati, A; Lovisa, B; Perrin, J; Wagnieres, G; van den Bergh, H; Tardy, Y; Lashuel, HA				Oueslati, Abid; Lovisa, Blaise; Perrin, John; Wagnieres, Georges; van den Bergh, Hubert; Tardy, Yanik; Lashuel, Hilal A.			Photobiomodulation Suppresses Alpha-Synuclein-Induced Toxicity in an AAV-Based Rat Genetic Model of Parkinson's Disease	PLOS ONE			English	Article							LOW-LEVEL LASER; MITOCHONDRIAL DYSFUNCTION; PHOSPHORYLATION; MECHANISMS; PREVENT; MICE	Converging lines of evidence indicate that near-infrared light treatment, also known as photobiomodulation (PBM), may exert beneficial effects and protect against cellular toxicity and degeneration in several animal models of human pathologies, including neurodegenerative disorders. In the present study, we report that chronic PMB treatment mitigates dopaminergic loss induced by unilateral overexpression of human alpha-synuclein (alpha-syn) in the substantia nigra of an AAV-based rat genetic model of Parkinson's disease (PD). In this model, daily exposure of both sides of the rat's head to 808-nm near-infrared light for 28 consecutive days alleviated alpha-syn-induced motor impairment, as assessed using the cylinder test. This treatment also significantly reduced dopaminergic neuronal loss in the injected substantia nigra and preserved dopaminergic fibers in the ipsilateral striatum. These beneficial effects were sustained for at least 6 weeks after discontinuing the treatment. Together, our data point to PBM as a possible therapeutic strategy for the treatment of PD and other related synucleinopathies.	[Oueslati, Abid; Perrin, John; Lashuel, Hilal A.] Swiss Fed Inst Technol EPFL, Brain Mind Inst, Lab Mol & Chem Biol Neurodegenerat, CH-1015 Lausanne, Switzerland; [Oueslati, Abid] Univ Laval, Ctr Rech, Ctr Hosp Quebec, Axe Neurosci, Quebec City, PQ G1V 4G2, Canada; [Oueslati, Abid] Univ Laval, Dept Med Mol, Quebec City, PQ G1V 4G2, Canada; [Lovisa, Blaise; Wagnieres, Georges; van den Bergh, Hubert] Swiss Fed Inst Technol EPFL, Inst Chem Sci & Engn, CH-1015 Lausanne, Switzerland; [Lovisa, Blaise; Tardy, Yanik] Medos Int Sarl, CH-2400 Le Locle, Switzerland; [Lashuel, Hilal A.] Hamad Bin Khalifa Univ, Qatar Fdn, Qatar Biomed Res Inst, Doha, Qatar	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Laval University; Laval University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Qatar Foundation (QF); Hamad Bin Khalifa University-Qatar; Qatar Biomedical Research Institute (QBRI)	Oueslati, A (corresponding author), Swiss Fed Inst Technol EPFL, Brain Mind Inst, Lab Mol & Chem Biol Neurodegenerat, CH-1015 Lausanne, Switzerland.	Abid.Oueslati@crchudequebec.ulaval.ca; hilal.lashuel@epfl.ch	Lashuel, Hilal/M-3500-2017; Oueslati, Abid/ABG-8116-2020	Oueslati, Abid/0000-0003-1122-7086; Wagnieres, Georges/0000-0002-9082-3099	Medos International Sarl, a JohnsonJohnson company; Ecole Polytechnique Federal de Lausanne; Commission for Technology and Innovation (CTI); CTI projects [13758.1, 14660.1]; Swiss National Science Foundation (SNSF) [205320_147141, CR32I3_159746]	Medos International Sarl, a JohnsonJohnson company; Ecole Polytechnique Federal de Lausanne; Commission for Technology and Innovation (CTI); CTI projects; Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF))	This work was in part supported by Medos International Sarl, a Johnson&Johnson company. The funder provided support in the form of salaries for authors [BL, YT], but did not have any additional role in the study design, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. HAL, GW, HvdB and AO were supported by the Ecole Polytechnique Federal de Lausanne and JP and BL were supported by the Commission for Technology and Innovation (CTI). Additional supports were provided by the CTI projects 13758.1 and 14660.1, and the Swiss National Science Foundation (SNSF) projects No 205320_147141 and CR32I3_159746.	Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; da Silveira SA, 2009, HUM MOL GENET, V18, P872, DOI 10.1093/hmg/ddn417; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Decressac M, 2012, EXP NEUROL, V235, P306, DOI 10.1016/j.expneurol.2012.02.012; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Gupta A, 2014, LASER MED SCI, V29, P257, DOI 10.1007/s10103-013-1319-0; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Jankovic Joseph, 2008, Neuropsychiatr Dis Treat, V4, P743; Karu T, 2010, PHOTOMED LASER SURG, V28, P159, DOI 10.1089/pho.2010.2789; Kirik D, 2002, P NATL ACAD SCI USA, V99, P4708, DOI 10.1073/pnas.062047599; Lashuel HA, 2013, NAT REV NEUROSCI, V14, P38, DOI 10.1038/nrn3406; Lee VMY, 2006, NEURON, V52, P33, DOI 10.1016/j.neuron.2006.09.026; McCormack AL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012122; Mullin S, 2013, MOL NEUROBIOL, V47, P587, DOI 10.1007/s12035-013-8394-x; Nash KR, 2015, MOL THER, V23, P17, DOI 10.1038/mt.2014.175; Obeso JA, 2010, NAT MED, V16, P653, DOI 10.1038/nm.2165; Olanow CW, 2013, ANN NEUROL, V74, P337, DOI 10.1002/ana.24011; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oueslati A, 2013, P NATL ACAD SCI USA, V110, pE3945, DOI 10.1073/pnas.1309991110; Oueslati A, 2012, J NEUROSCI, V32, P1536, DOI 10.1523/JNEUROSCI.3784-11.2012; Paleologou KE, 2010, J NEUROSCI, V30, P3184, DOI 10.1523/JNEUROSCI.5922-09.2010; Peoples Cassandra, 2012, ISRN Neurol, V2012, P850150, DOI 10.5402/2012/850150; Peoples C, 2012, PARKINSONISM RELAT D, V18, P469, DOI 10.1016/j.parkreldis.2012.01.005; Purushothuman S, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt232; Purushothuman S, 2013, BRAIN RES, V1535, P61, DOI 10.1016/j.brainres.2013.08.047; Putcha P, 2010, J PHARMACOL EXP THER, V332, P849, DOI 10.1124/jpet.109.158436; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207; Spatola Marianna, 2014, Parkinsonism Relat Disord, V20 Suppl 1, pS35, DOI 10.1016/S1353-8020(13)70011-7; Trancikova A, 2012, ANTIOXID REDOX SIGN, V16, P896, DOI 10.1089/ars.2011.4200; Trinh J, 2013, NAT REV NEUROL, V9, P445, DOI 10.1038/nrneurol.2013.132; Ulusoy Ayse, 2010, Prog Brain Res, V184, P89, DOI 10.1016/S0079-6123(10)84005-1; Vos M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078562; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; Wilden L, 1998, J CLIN LASER MED SUR, V16, P159, DOI 10.1089/clm.1998.16.159; Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011	38	32	33	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2015	10	10							e0140880	10.1371/journal.pone.0140880	http://dx.doi.org/10.1371/journal.pone.0140880			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT7XI	26484876	Green Submitted, Green Published, gold			2023-01-03	WOS:000363028100083
J	Sarker, MR; Franks, S; Sumien, N; Thangthaeng, N; Filipetto, F; Forster, M				Sarker, Marjana Rahman; Franks, Susan; Sumien, Nathalie; Thangthaeng, Nopporn; Filipetto, Frank; Forster, Michael			Curcumin Mimics the Neurocognitive and Anti-Inflammatory Effects of Caloric Restriction in a Mouse Model of Midlife Obesity	PLOS ONE			English	Article							C-REACTIVE PROTEIN; MILD COGNITIVE IMPAIRMENT; LIFE-SPAN; OXIDATIVE STRESS; INFLAMMATORY CYTOKINES; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION; GENE-EXPRESSION; WEIGHT-LOSS; OVERWEIGHT	Dietary curcumin was studied for its potential to decrease adiposity and reverse obesity-associated cognitive impairment in a mouse model of midlife sedentary obesity. We hypothesized that curcumin intake, by decreasing adiposity, would improve cognitive function in a manner comparable to caloric restriction (CR), a weight loss regimen. 15-month-old male C57BL/6 mice were assigned in groups to receive the following dietary regimens for 12 weeks: (i) a base diet (Ain93M) fed ad libitum (AL), (ii) the base diet restricted to 70% of ad libitum (CR) or (iii) the base diet containing curcumin fed AL (1000 mg/kg diet, CURAL). Blood markers of inflammation, interleukin 6 (IL-6) and C-reactive protein (CRP), as well as an indicator of redox stress (GSH: GSSG ratio), were determined at different time points during the treatments, and visceral and subcutaneous adipose tissue were measured upon completion of the experiment. After 8 weeks of dietary treatment, the mice were tested for spatial cognition (Morris water maze) and cognitive flexibility (discriminated active avoidance). The CR group showed significant weight loss and reduced adiposity, whereas CURAL mice had stable weight throughout the experiment, consumed more food than the AL group, with no reduction of adiposity. However, both CR and CURAL groups took fewer trials than AL to reach criterion during the reversal sessions of the active avoidance task, suggesting an improvement in cognitive flexibility. The AL mice had higher levels of CRP compared to CURAL and CR, and GSH as well as the GSH: GSSG ratio were increased during curcumin intake, suggesting a reducing shift in the redox state. The results suggest that, independent of their effects on adiposity; dietary curcumin and caloric restriction have positive effects on frontal cortical functions that could be linked to anti-inflammatory or anti-oxidant actions.	[Sarker, Marjana Rahman; Sumien, Nathalie; Thangthaeng, Nopporn; Forster, Michael] Univ N Texas, Hlth Sci Ctr, IAADR, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA; [Franks, Susan; Filipetto, Frank] Univ N Texas, Texas Coll Osteopath Med, Hlth Sci Ctr, Family Med, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Forster, M (corresponding author), Univ N Texas, Hlth Sci Ctr, IAADR, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA.	Michael.forster@unthsc.edu	Sarker, Marjana/J-7214-2019	Sarker, Marjana/0000-0001-6766-6737	National Institutes of Health, National Institute on Aging [AG022550]; University of North Texas Health Science Center, Faculty seed grant [RI6039]; NATIONAL INSTITUTE ON AGING [P01AG022550] Funding Source: NIH RePORTER	National Institutes of Health, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); University of North Texas Health Science Center, Faculty seed grant; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by P01 (Program project grant) AG022550 National Institutes of Health, National Institute on Aging; and RI6039, University of North Texas Health Science Center, Faculty seed grant.	Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x; Arfanakis K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073107; Banerjee M, 2003, IMMUNOPHARM IMMUNOT, V25, P213, DOI 10.1081/IPH-120020471; Bar-Sela G, 2010, CURR MED CHEM, V17, P190, DOI 10.2174/092986710790149738; Becskei C, 2009, NEUROENDOCRINOLOGY, V90, P371, DOI 10.1159/000251723; Begum AN, 2008, J PHARMACOL EXP THER, V326, P196, DOI 10.1124/jpet.108.137455; Bermejo P, 2008, FREE RADICAL RES, V42, P162, DOI 10.1080/10715760701861373; Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200; Bradford PG, 2013, BIOFACTORS, V39, P78, DOI 10.1002/biof.1074; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Burke LE, 2008, J AM DIET ASSOC, V108, P640, DOI 10.1016/j.jada.2008.01.012; Calabro P, 2003, CIRCULATION, V108, P1930, DOI 10.1161/01.CIR.0000096055.62724.C5; Chaudhari K, 2014, J SPORT HEALTH SCI, V3, P196, DOI 10.1016/j.jshs.2014.04.004; Chaudhari N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00213; Cohen AN, 2009, ARCH OTOLARYNGOL, V135, P190, DOI 10.1001/archotol.135.2.190; Cooke D, 2006, NAT REV DRUG DISCOV, V5, P919, DOI 10.1038/nrd2136; de Fiebre NC, 2006, AGE, V28, P235, DOI 10.1007/s11357-006-9027-3; Deckers K, 2015, INT J GERIATR PSYCH, V30, P234, DOI 10.1002/gps.4245; Dixit S, 2015, ACS CHEM NEUROSCI; Dubey A, 1996, ARCH BIOCHEM BIOPHYS, V333, P189, DOI 10.1006/abbi.1996.0380; Ejaz A, 2009, J NUTR, V139, P919, DOI 10.3945/jn.108.100966; Forster MJ, 1999, NEUROBIOL AGING, V20, P167, DOI 10.1016/S0197-4580(99)00041-X; Forster MJ, 2000, J GERONTOL A-BIOL, V55, pB522, DOI 10.1093/gerona/55.11.B522; Garcia-Ptacek S, 2014, EUR J CLIN NUTR, V68, P1204, DOI 10.1038/ejcn.2014.199; Guerreiro RJ, 2007, NEURODEGENER DIS, V4, P406, DOI 10.1159/000107700; Gupta A, 2015, NEUROIMAGE-CLIN, V7, P506, DOI 10.1016/j.nicl.2015.01.005; Gupta SC, 2013, BIOFACTORS, V39, P2, DOI 10.1002/biof.1079; Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123; Harvie MN, 2011, INT J OBESITY, V35, P714, DOI 10.1038/ijo.2010.171; Kim T, 2009, BIOCHEM BIOPH RES CO, V388, P377, DOI 10.1016/j.bbrc.2009.08.018; Kim YW, 2013, J MOL MED, V91, P323, DOI 10.1007/s00109-013-1007-3; Latham JR, 2009, DIABETES, V58, P2656, DOI 10.2337/db08-1763; Lee BC, 2014, BBA-MOL BASIS DIS, V1842, P446, DOI 10.1016/j.bbadis.2013.05.017; Lekander M, 2011, SCAND J PSYCHOL, V52, P229, DOI 10.1111/j.1467-9450.2010.00865.x; Madeo F, 2014, NAT REV DRUG DISCOV, V13, P727, DOI 10.1038/nrd4391; Martin B, 2006, AGEING RES REV, V5, P332, DOI 10.1016/j.arr.2006.04.002; Mazzetti AP, 2015, NEUROCHEM INT, V82, P10, DOI 10.1016/j.neuint.2015.01.008; Mcdonald SR, 2005, FREE RADICAL BIO MED, V38, P729, DOI 10.1016/j.freeradbiomed.2004.11.014; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Pires RC, 2014, APPL PHYSIOL NUTR ME, V39, P895, DOI 10.1139/apnm-2013-0520; Priyadarsini KI, 2013, CURR PHARM DESIGN, V19, P2093; Priyadarsini KI, 2003, FREE RADICAL BIO MED, V35, P475, DOI 10.1016/S0891-5849(03)00325-3; Pu YF, 2013, CELL PHYSIOL BIOCHEM, V32, P1167, DOI 10.1159/000354516; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rebrin I, 2011, FREE RADICAL BIO MED, V51, P225, DOI 10.1016/j.freeradbiomed.2011.04.006; Shen LR, 2013, AGE, V35, P1133, DOI 10.1007/s11357-012-9438-2; Sohal RS, 2014, FREE RADICAL BIO MED, V73, P366, DOI 10.1016/j.freeradbiomed.2014.05.015; Spangler EL, 2010, CALORIE RESTRICTION, AGING AND LONGEVITY, P177, DOI 10.1007/978-90-481-8556-6_10; Sperling RA, 2010, NEUROMOL MED, V12, P27, DOI 10.1007/s12017-009-8109-7; Spindler SR, 2005, MECH AGEING DEV, V126, P960, DOI 10.1016/j.mad.2005.03.016; Strong R, 2013, J GERONTOL A-BIOL, V68, P6, DOI 10.1093/gerona/gls070; Sturm R, 2013, INT J OBESITY, V37, P889, DOI 10.1038/ijo.2012.159; Sumien N, 2006, AGE, V28, P265, DOI 10.1007/s11357-006-9015-7; Sweat V, 2008, INFLAMMATION, V31, P198, DOI 10.1007/s10753-008-9065-3; Sykiotis GP, 2011, CURR OPIN CLIN NUTR, V14, P41, DOI 10.1097/MCO.0b013e32834136f2; Tang YC, 2014, LAB INVEST, V94, P503, DOI 10.1038/labinvest.2014.42; TAYLOR AW, 1990, J IMMUNOL, V145, P2507; Thangthaeng N, 2008, EXP GERONTOL, V43, P1077, DOI 10.1016/j.exger.2008.08.045; Torres LL, 2011, J ALZHEIMERS DIS, V26, P59, DOI 10.3233/JAD-2011-110284; Trujillo J, 2014, ARCH PHARM, V347, P873, DOI 10.1002/ardp.201400266; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Wang J, 2013, NUTR METAB, V10; Wang S, 2014, J NUTR BIOCHEM, V25, P1, DOI 10.1016/j.jnutbio.2013.09.001; West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421; Weuve J, 2006, EPIDEMIOLOGY, V17, P183, DOI 10.1097/01.ede.0000198183.60572.c9; Xu WL, 2011, NEUROLOGY, V76, P1568, DOI 10.1212/WNL.0b013e3182190d09; Zheng DM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-138	67	21	21	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2015	10	10							e0140431	10.1371/journal.pone.0140431	http://dx.doi.org/10.1371/journal.pone.0140431			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0DF	26473740	Green Submitted, gold, Green Published			2023-01-03	WOS:000363185500047
J	Singh, VK; Dwivedi, P; Chaudhary, BR; Singh, R				Singh, Vineet Kumar; Dwivedi, Padmanabh; Chaudhary, B. R.; Singh, Ramesh			Immunomodulatory Effect of Gymnema sylvestre (R.Br.) Leaf Extract: An In Vitro Study in Rat Model	PLOS ONE			English	Article							VISCUM-ALBUM EXTRACTS; STIMULATES INSULIN-SECRETION; AQUEOUS EXTRACT; DIABETES-MELLITUS; PERITONEAL-MACROPHAGES; SEXUAL-DIMORPHISM; HUMAN ISLETS; VIVO; GLUCOSE; CELLS	Gymnema sylvestre Wild R.Br (family: Asclepidaceae) is a valuable medicinal plant used in folk medicine to treat diabetes, obesity, asthma etc. in India for antiquity. Diabetes mellitus is a syndrome characterized immunologically by lymphocyte apoptosis and reduced cell-mediated and humoral immunity. Modulation of immune responses to alleviate diseases has been of interest, and traditional herbal medicines may play an important role in this regard. In this study, we aim to evaluate the immunomodulatory potential of methanolic extract of G. sylvestre leaf using rat model. HPLC analysis of leaf extract was carried out for gymnemic acid. The method involves the initial hydrolysis of gymnemic acids, the active ingredients, to a common aglycone followed by the quantitative estimation of gymnemagenin, using gymnemagenin as reference standard. Gymnemic acid content was 2.40% (w/w) in G. sylvestre leaf extract. In vitro immunomodulatory activity of the methanolic extract of G. sylvestre leaf (1-200 mu g/ml) was evaluated by gauging its effects on nitroblue tetrazolium reduction and nitrite release in rat peritoneal macrophages and on mitogen (ConA, PHA and LPS) induced splenic lymphocyte proliferation. G. sylvestre leaf extract showed significant (<0.05) enhancement in NO and ROS generation in macrophages and in proliferation of lymphocytes in dose dependent manner. EC50 value was 3.10, 3.75 and 2.68 mu g/ml for NBT reduction, nitrite release and lymphoproliferation, respectively. Potential effect was observed at 100 mu g/ml in NO and ROS generation in macrophages and 20 mu g/ml in lymphocyte proliferation. G. sylvestre leaf extract stimulates macrophage reactivity, increasing the level of activity even higher when combined with PMA or LPS. These findings suggest the presence of active compounds, gymnemic acid, in methanolic extract of G. sylvestre leaf that stimulates both myeloid and lymphoid components of immune system, and therefore can restore the innate immune function. Through this study, the traditional knowledge of anti-diabetic property of G. sylvestre is scientifically supplemented with its immunomodulatory properties.	[Singh, Vineet Kumar; Chaudhary, B. R.] Banaras Hindu Univ, Ctr Adv Study Bot, Varanasi 221005, UP, India; [Dwivedi, Padmanabh] Banaras Hindu Univ, Inst Agr Sci, Dept Plant Physiol, Varanasi 221005, UP, India; [Singh, Ramesh] Udai Pratap Autonomous Coll, Dept Zool, Varanasi, UP, India	Banaras Hindu University (BHU); Banaras Hindu University (BHU); Udai Pratap College, Varanasi	Singh, R (corresponding author), Udai Pratap Autonomous Coll, Dept Zool, Varanasi, UP, India.	upcrsingh@yahoo.com	Dwivedi, Padmanabh/L-5307-2019; Dwivedi, Padmanabh/AAJ-8808-2020					Al-Romaiyan A, 2013, PHYTOTHER RES, V27, P1006, DOI 10.1002/ptr.4815; Al-Romaiyan A, 2010, PHYTOTHER RES, V24, P1370, DOI 10.1002/ptr.3125; BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BASKARAN K, 1990, J ETHNOPHARMACOL, V30, P295, DOI 10.1016/0378-8741(90)90108-6; Berger J., 2003, COMP CLIN PATHOL, V12, P84; Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7; Bishayi Biswadev, 2002, J Toxicol Sci, V27, P139, DOI 10.2131/jts.27.139; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Cruz GVB, 2007, J ETHNOPHARMACOL, V111, P148, DOI 10.1016/j.jep.2006.11.006; DING AH, 1988, J IMMUNOL, V141, P2407; Diwanay S, 2004, J ETHNOPHARMACOL, V90, P49, DOI 10.1016/j.jep.2003.09.023; ELIASHIV A, 1978, ARCH SURG-CHICAGO, V113, P1180; Elluru SR, 2015, TRANSL RES BIOMED, V4, P67, DOI 10.1159/000375427; Elluru SR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-161; Elluru SR, 2009, ANTICANCER RES, V29, P2945; Elluru S, 2007, MEDICINA-BUENOS AIRE, V67, P85; Elluru S, 2006, ARZNEIMITTEL-FORSCH, V56, P461; Flanagan KL, 2014, T ROY SOC TROP MED H, V108, P385, DOI 10.1093/trstmh/tru079; FUSHIKI T, 1992, J NUTR, V122, P2367, DOI 10.1093/jn/122.12.2367; Gautam M, 2009, J ETHNOPHARMACOL, V121, P41, DOI 10.1016/j.jep.2008.10.028; Geerlings SE, 1999, FEMS IMMUNOL MED MIC, V26, P259, DOI 10.1111/j.1574-695X.1999.tb01397.x; GIENI RS, 1995, J IMMUNOL METHODS, V187, P85, DOI 10.1016/0022-1759(95)00170-F; Hegde P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026312; Jayathirtha MG, 2004, PHYTOMEDICINE, V11, P361, DOI 10.1078/0944711041495236; Jeong SC, 2006, J MED FOOD, V9, P175, DOI 10.1089/jmf.2006.9.175; Khanna V, 2009, INT J GREEN PHARM, V3, P227, DOI DOI 10.4103/0973-8258.56280; Leach MJ, 2007, J ALTERN COMPLEM MED, V13, P977, DOI 10.1089/acm.2006.6387; Liu B, 2009, CELL PHYSIOL BIOCHEM, V23, P125, DOI 10.1159/000204101; Mandal S.C., 2007, BIODIVERSITY ENV BIO, P177; Manosroi A, 2005, J ETHNOPHARMACOL, V102, P5, DOI 10.1016/j.jep.2005.04.033; Manosroi A, 2005, J ETHNOPHARMACOL, V101, P90, DOI 10.1016/j.jep.2005.03.031; Manosroi A, 2004, FITOTERAPIA, V75, P302, DOI 10.1016/j.fitote.2004.01.009; Manosroi A, 2003, J ETHNOPHARMACOL, V89, P155, DOI 10.1016/S0378-8741(03)00278-2; Manosroi A, 2006, FITOTERAPIA, V77, P189, DOI 10.1016/j.fitote.2006.01.003; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nunn CL, 2009, PHILOS T R SOC B, V364, P61, DOI 10.1098/rstb.2008.0148; Otton R, 2004, J ENDOCRINOL, V182, P145, DOI 10.1677/joe.0.1820145; Persaud SJ, 1999, J ENDOCRINOL, V163, P207, DOI 10.1677/joe.0.1630207; Porchezhian E, 2003, PHARMAZIE, V58, P5; Sabu MC, 2002, J ETHNOPHARMACOL, V81, P155, DOI 10.1016/S0378-8741(02)00034-X; Saha C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114965; Saravanan S, 2012, J ETHNOPHARMACOL, V140, P239, DOI 10.1016/j.jep.2012.01.010; Sengupta M, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-102; Sengupta Mahuya, 2011, Asian Pacific Journal of Tropical Biomedicine, V1, P193, DOI 10.1016/S2221-1691(11)60026-9; SHANMUGASUNDARAM ERB, 1990, J ETHNOPHARMACOL, V30, P281, DOI 10.1016/0378-8741(90)90107-5; SHANMUGASUNDARAM ERB, 1990, J ETHNOPHARMACOL, V30, P265, DOI 10.1016/0378-8741(90)90106-4; Sharma U, 2012, J ETHNOPHARMACOL, V141, P918, DOI 10.1016/j.jep.2012.03.027; Toffoli-Kadri MC, 2014, J ETHNOPHARMACOL, V153, P461, DOI 10.1016/j.jep.2014.03.008; Tripathi MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116588; Tripathi MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104431; Van Huyen JPD, 2003, CHEMOTHERAPY, V49, P298, DOI 10.1159/000074530; Van Huyen JPD, 2002, MOL MED, V8, P600, DOI 10.1007/BF03402170; Van Huyen JPD, 2001, CHEMOTHERAPY, V47, P366, DOI 10.1159/000048545; VANDERNAT JM, 1987, J ETHNOPHARMACOL, V19, P125, DOI 10.1016/0378-8741(87)90036-5; Weissenstein U, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-6; WHO, 2011, QUAL CONTR METH HERB, P1; Wu XY, 2012, FOOD RES INT, V48, P935, DOI [10.1016/j.foodres.2012.02.006, 10.1016/j.foodres.2011.01.031]	57	10	10	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2015	10	10							e0139631	10.1371/journal.pone.0139631	http://dx.doi.org/10.1371/journal.pone.0139631			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0DF	26474420	Green Submitted, Green Published, gold			2023-01-03	WOS:000363185500012
J	Povitz, M; Hanly, PJ; Pendharkar, SR; James, MT; Tsai, WH				Povitz, Marcus; Hanly, Patrick J.; Pendharkar, Sachin R.; James, Matthew T.; Tsai, Willis H.			Treatment of Sleep Disordered Breathing Liberates Obese Hypoxemic Patients from Oxygen	PLOS ONE			English	Article							POSITIVE-PRESSURE VENTILATION; HYPOVENTILATION SYNDROME; SUPPLEMENTAL OXYGEN; HYPERCAPNIA; COPD; ADHERENCE; APNEA; CPAP; TERM	Background Obese hypoxemic patients have a high prevalence of sleep disordered breathing (SDB). It is unclear to what extent treatment of SDB can improve daytime hypoxemia. Methods We performed a retrospective cohort study of obese hypoxemic individuals, all of whom underwent polysomnography, arterial blood gas analysis, and subsequent initiation of positive airway pressure (PAP) therapy for SDB. Patients were followed for one year for change in partial pressure of arterial oxygen and the need for supplemental oxygen. Results One hundred and seventeen patients were treated with nocturnal PAP and had follow-up available. Adherence to PAP was satisfactory in 60%, and was associated with a significant improvement in daytime hypoxemia and hypercapnea; 56% of these patients were able to discontinue supplemental oxygen. Adherence to PAP therapy and the baseline severity of OSA predicted improvement in hypoxemia, but only adherence to PAP therapy predicted liberation from supplemental oxygen. Conclusions The identification and treatment of SDB in obese hypoxemic patients improves daytime hypoxemia. It is important to identify SDB in these patients, since supplemental oxygen can frequently be discontinued following treatment with PAP therapy.	[Povitz, Marcus; Pendharkar, Sachin R.; James, Matthew T.; Tsai, Willis H.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Povitz, Marcus] Univ Western Ontario, Dept Med, London, ON, Canada; [Hanly, Patrick J.; Pendharkar, Sachin R.; James, Matthew T.; Tsai, Willis H.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Hanly, Patrick J.; Pendharkar, Sachin R.; Tsai, Willis H.] Foothills Med Ctr, Sleep Ctr, Calgary, AB, Canada	University of Calgary; Western University (University of Western Ontario); University of Calgary; University of Calgary	Tsai, WH (corresponding author), Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada.	tsai@ucalgary.ca	Pendharkar, Sachin R./AAS-5513-2020; Povitz, Marcus/F-6615-2018; Pendharkar, Sachin R./AAS-5520-2020	Pendharkar, Sachin R./0000-0002-4693-0831; Pendharkar, Sachin R./0000-0002-4693-0831				[Anonymous], 2011, RESP POLICIES PROCED, P1; Bahammam A, 1999, SLEEP, V22, P740, DOI 10.1093/sleep/22.6.740; Bardwell Wayne A, 2007, Behav Sleep Med, V5, P21, DOI 10.1207/s15402010bsm0501_2; Berg G, 2001, CHEST, V120, P377, DOI 10.1378/chest.120.2.377; Berry RB, 2012, J CLIN SLEEP MED, V8, P597, DOI 10.5664/jcsm.2172; Budweiser S, 2007, J INTERN MED, V261, P375, DOI 10.1111/j.1365-2796.2007.01765.x; de Llano LAP, 2005, CHEST, V128, P587, DOI 10.1378/chest.128.2.587; Drager LF, 2015, THORAX, V70, P258, DOI 10.1136/thoraxjnl-2014-205361; Fleetham John, 2006, Can Respir J, V13, P387; Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39; Gotay CC, 2013, CAN J PUBLIC HEALTH, V104, pE64, DOI 10.1007/BF03405657; Gottlieb DJ, 2014, NEW ENGL J MED, V370, P2276, DOI 10.1056/NEJMoa1306766; Hollier CA, 2014, THORAX, V69, P346, DOI 10.1136/thoraxjnl-2013-204389; Kohnlein T, 2014, LANCET RESP MED, V2, P698, DOI 10.1016/S2213-2600(14)70153-5; LEMIEUX S, 1993, AM J CLIN NUTR, V58, P463, DOI 10.1093/ajcn/58.4.463; Lumachi F, 2010, IN VIVO, V24, P329; McEvoy RD, 2009, THORAX, V64, P561, DOI 10.1136/thx.2008.108274; McNicholas WT, 2013, EUR RESPIR REV, V22, P365, DOI 10.1183/09059180.00003213; Mokhlesi B, 2006, J CLIN SLEEP MED, V2, P57; Pepin JL, 2012, AM J RESP CRIT CARE, V186, P1205, DOI 10.1164/rccm.201210-1922ED; Piper AJ, 2011, AM J RESP CRIT CARE, V183, P292, DOI 10.1164/rccm.201008-1280CI; Povitz M, 2015, ANN AM THORAC SOC, V12, P921, DOI 10.1513/AnnalsATS.201412-551OC; Priou P, 2010, CHEST, V138, P84, DOI 10.1378/chest.09-2472; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Reid J, 2014, TOBACCO USE CANADA; Ronksley PE, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-50; Struik FM, 2014, THORAX, V69, P826, DOI 10.1136/thoraxjnl-2014-205126; Villar I, 2009, SLEEP, V32, P623, DOI 10.1093/sleep/32.5.623; Wijesinghe M, 2011, CHEST, V139, P1018, DOI 10.1378/chest.10-1280; Zavorsky GS, 2008, OBES REV, V9, P326, DOI 10.1111/j.1467-789X.2008.00471.x	30	7	7	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2015	10	10							e0140135	10.1371/journal.pone.0140135	http://dx.doi.org/10.1371/journal.pone.0140135			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TY	26451835	Green Published, Green Submitted, gold			2023-01-03	WOS:000362511200040
J	Ficker, M; Petersen, JF; Hansen, JS; Christensen, JB				Ficker, Mario; Petersen, Johannes F.; Hansen, Jon S.; Christensen, Jorn B.			Guest-Host Chemistry with Dendrimers-Binding of Carboxylates in Aqueous Solution	PLOS ONE			English	Article							ISOTHERMAL TITRATION CALORIMETRY; PAMAM DENDRIMERS; SIRNA DELIVERY; IN-VITRO; SOLUBILITY	Recognition and binding of anions in water is difficult due to the ability of water molecules to form strong hydrogen bonds and to solvate the anions. The complexation of two different carboxylates with 1-(4-carbomethoxypyrrolidone)-terminated PAMAM dendrimers was studied in aqueous solution using NMR and ITC binding models. Sodium 2-naphthoate and sodium 3-hydroxy-2-naphthoate were chosen as carboxylate model compounds, since they carry structural similarities to many non-steroidal anti-inflammatory drugs and they possess only a limited number of functional groups, making them ideal to study the carboxylate-dendrimer interaction selectively. The binding stoichiometry for 3-hydroxy-2-naphthoate was found to be two strongly bound guest molecules per dendrimer and an additional 40 molecules with weak binding affinity. The NOESY NMR showed a clear binding correlation of sodium 3-hydroxy-2-naphthoate with the lyophilic dendrimer core, possibly with the two high affinity guest molecules. In comparison, sodium 2-naphthoate showed a weaker binding strength and had a stoichiometry of two guests per dendrimer with no additional weakly bound guests. This stronger dendrimer interaction with sodium 3-hydroxy-2-naphthoate is possibly a result of the additional interactions of the dendrimer with the extra hydroxyl group and an internal stabilization of the negative charge due to the hydroxyl group. These findings illustrate the potential of the G4 1-(4-carbomethoxy) pyrrolidone dendrimer to complex carboxylate guests in water and act as a possible carrier of such molecules.	[Ficker, Mario; Petersen, Johannes F.; Hansen, Jon S.; Christensen, Jorn B.] Univ Copenhagen, Dept Chem, DK-1871 Frederiksberg C, Denmark	University of Copenhagen	Christensen, JB (corresponding author), Univ Copenhagen, Dept Chem, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	jbc@chem.ku.dk	Christensen, Jørn B./J-8124-2012	Christensen, Jørn B./0000-0002-7641-8302	University of Copenhagen; Lundbeck Foundation [R48-2009-4618] Funding Source: researchfish	University of Copenhagen; Lundbeck Foundation(Lundbeckfonden)	For financial support the authors would like to thank the University of Copenhagen. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnusch CJ, 2007, BIOCHEMISTRY-US, V46, P13437, DOI 10.1021/bi7015553; Avila-Salas F, 2012, J PHYS CHEM B, V116, P2031, DOI 10.1021/jp2069122; Biswas T, 2010, ANAL BIOCHEM, V406, P91, DOI 10.1016/j.ab.2010.06.050; Caminade AM, 2008, CHEM-EUR J, V14, P7422, DOI 10.1002/chem.200800584; Cheng YY, 2007, EUR J MED CHEM, V42, P1032, DOI 10.1016/j.ejmech.2006.12.035; Ciolkowski M, 2012, NANOMED-NANOTECHNOL, V8, P815, DOI 10.1016/j.nano.2012.03.009; Donald A., 2012, DENDRIMERS DENDRONS; Ficker M, 2015, CHEM COMMUN, V51, P9957, DOI 10.1039/c5cc00347d; Fielding L, 2003, CURR TOP MED CHEM, V3, P39, DOI 10.2174/1568026033392705; Freire E., 1990, ANAL CHEM, V62, P950; Freyer MW, 2008, METHOD CELL BIOL, V84, P79, DOI 10.1016/S0091-679X(07)84004-0; Gramage-Doria R, 2013, CHEMISTRYOPEN, V2, P176, DOI 10.1002/open.201300033; Gupta U, 2007, J PHARM PHARM SCI, V10, P358; Hansen JS, 2013, J PHYS CHEM B, V117, P14865, DOI 10.1021/jp408613z; Hu JJ, 2012, CHEM REV, V112, P3856, DOI 10.1021/cr200333h; Janaszewska A, 2015, NANOMED-NANOTECHNOL, V11, P409, DOI 10.1016/j.nano.2014.09.011; Janaszewska A, 2013, NANOMED-NANOTECHNOL, V9, P461, DOI 10.1016/j.nano.2013.01.010; Kang SO, 2010, CHEM SOC REV, V39, P3980, DOI 10.1039/c0cs00083c; Kim SK, 2010, CHEM SOC REV, V39, P3784, DOI 10.1039/c002694h; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171; Liu XX, 2009, CHEMMEDCHEM, V4, P1302, DOI 10.1002/cmdc.200900076; Morgan MT, 2006, CANCER RES, V66, P11913, DOI 10.1158/0008-5472.CAN-06-2066; Pavan GM, 2010, CHEM-EUR J, V16, P7781, DOI 10.1002/chem.200903258; Tarazona-Vasquez F, 2007, J PHYS CHEM A, V111, P945, DOI 10.1021/jp065016b; Tomalia D. A., 2001, DENDRIMERS OTHER DEN; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; Wu L. P., 2015, BIOCONJUGATE CHEM; Yang K, 2011, J PHYS CHEM B, V115, P2185, DOI 10.1021/jp111044k; Zeng FW, 1997, CHEM REV, V97, P1681, DOI 10.1021/cr9603892	30	7	7	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2015	10	10							e0138706	10.1371/journal.pone.0138706	http://dx.doi.org/10.1371/journal.pone.0138706			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TW	26448138	Green Published, Green Submitted, gold			2023-01-03	WOS:000362511000011
J	Crespo, I; Toledo, D; Soldevila, N; Jordan, I; Solano, R; Castilla, J; Cayla, JA; Godoy, P; Munoz-Almagro, C; Dominguez, A				Crespo, Inma; Toledo, Diana; Soldevila, Nuria; Jordan, Iolanda; Solano, Ruben; Castilla, Jesus; Cayla, Joan A.; Godoy, Pere; Munoz-Almagro, Carmen; Dominguez, Angela		Working Grp Transmission Pertussis	Characteristics of Hospitalized Cases of Pertussis in Catalonia and Navarra, Two Regions in the North of Spain	PLOS ONE			English	Article							BORDETELLA-PERTUSSIS; VACCINE; CHILDREN; SURVEILLANCE; INFECTIONS; RESURGENCE; EPIDEMIC	Pertussis causes a large number of cases and hospitalizations in Catalonia and Navarra. We made a study of household cases of pertussis during 2012 and 2013 in order to identify risk factors for hospitalization in pertussis cases. Each primary case reported triggered the study of their contacts. Close contacts at home and people who were in contact for >2 hours during the transmission period of cases were included. The adjusted OR and 95% confidence intervals ( CI) was calculated using logistic regression. A total of 1124 pertussis cases were detected, of which 14.9% were hospitalized. Inspiratory whoop (aOR: 1.64; CI: 1.02-2.65), apnoea (aOR: 2.47; CI: 1.51-4.03) and cyanosis (aOR: 15.51; CI: 1.87-128.09) were more common in hospitalized than in outpatient cases. Hospitalization occurred in 8.7% of correctly-vaccinated cases, 41.1% of non-vaccinated cases and 9.4% of partially-vaccinated cases. In conclusion, inspiratory whoop, apnoea and cyanosis were associated factors to hospitalization while vaccination reduced hospitalizations due to pertussis.	[Crespo, Inma; Soldevila, Nuria; Solano, Ruben; Castilla, Jesus; Cayla, Joan A.; Godoy, Pere; Dominguez, Angela] CIBER Epidemiol & Publ Hlth, Barcelona, Spain; [Crespo, Inma; Toledo, Diana; Soldevila, Nuria; Solano, Ruben; Dominguez, Angela] Univ Barcelona, Dept Publ Hlth, Barcelona, Spain; [Toledo, Diana; Solano, Ruben; Cayla, Joan A.] Publ Hlth Agcy, Barcelona, Spain; [Jordan, Iolanda] Hosp St Joan de Deu, Paediat Intens Care Med, Barcelona, Spain; [Castilla, Jesus] Navarra Inst Hlth Res, Inst Publ Hlth, Pamplona, Spain; [Godoy, Pere] Agcy Publ Hlth Catalonia, Barcelona, Spain; [Munoz-Almagro, Carmen] Hosp St Joan de Deu, Dept Mol Microbiol, Barcelona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Barcelona; Public Health Agency of Barcelona; University of Barcelona; University of Barcelona	Crespo, I (corresponding author), CIBER Epidemiol & Publ Hlth, Barcelona, Spain.	inma.crespo@hotmail.com	Muñoz-Almagro, Carmen/N-7248-2015; Castilla, Jesus/B-9048-2008; Solano, Ruben/H-5104-2017	Muñoz-Almagro, Carmen/0000-0001-5586-404X; Castilla, Jesus/0000-0002-6396-7265; Godoy, Pere/0000-0002-2896-7286; Cayla, Joan A./0000-0003-3891-111X; Hozbor, Daniela/0000-0001-6379-0482	Institute of Health Carlos III [PI11/02557]; Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa); Catalan Agency for the Management of Grants for University Research (AGAUR Grant) [2014/SGR 1403]; Agency of Public Health of Catalonia; Public Health Agency; Institute of Public Health of Navarra; Ministry of Science and Innovation	Institute of Health Carlos III(Instituto de Salud Carlos III); Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa)(European Commission); Catalan Agency for the Management of Grants for University Research (AGAUR Grant); Agency of Public Health of Catalonia; Public Health Agency; Institute of Public Health of Navarra; Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This study was supported by the Ministry of Science and Innovation, Institute of Health Carlos III (Project PI11/02557) and Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa); the Catalan Agency for the Management of Grants for University Research (AGAUR Grant number 2014/SGR 1403). Agency of Public Health of Catalonia provided support in the form of salaries for author P. Godoy, Public Health Agency provided support in the form of salaries for author J. Cayla and Institute of Public Health of Navarra provided support in the form of salaries for author J. Castilla, but none of the companies had any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Other authors have no other funding or conflicts of interest to disclose.	Amirthalingam G, 2013, EUROSURVEILLANCE, V18, P19, DOI 10.2807/1560-7917.ES2013.18.38.20587; [Anonymous], 2013, VACCINES 6; Barlow RS, 2014, CLIN INFECT DIS, V58, P1523, DOI 10.1093/cid/ciu156; Briand V, 2007, VACCINE, V25, P7224, DOI 10.1016/j.vaccine.2007.07.020; Cardenosa N, 2009, VACCINE, V27, P3489, DOI 10.1016/j.vaccine.2009.01.046; Centro Nacional de Epidemiologia, 2012, SIT EP TOS FER ESP; Cherry JD, 2012, NEW ENGL J MED, V367, P785, DOI 10.1056/NEJMp1209051; Cherry JD, 2009, TXB PEDIAT INFECT DI, P1683; Chiappini E, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-151; Cortese MM, 2008, PEDIATRICS, V121, P484, DOI 10.1542/peds.2007-1393; Fernandez IC, 2013, HUM VACC IMMUNOTHER, V9, P667, DOI 10.4161/hv.23263; Crespo I, 2013, VACUNAS, V14, P155; Crespo I, 2011, VACCINE, V29, P4244, DOI 10.1016/j.vaccine.2011.03.065; de Greeff SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014183; Departament de Salut, VACC SCHED 2014; DeVincenzo JP, 2013, DIAGN MICR INFEC DIS, V76, P10, DOI 10.1016/j.diagmicrobio.2012.12.015; Fingermann M, 2006, VACCINE, V24, P3513, DOI 10.1016/j.vaccine.2006.02.026; Generalitat de Catalunya, 2006, DEP SAN SEG SOC MAN; Grupo de trabajo de tos ferina, 2012, PON PROGR REG VAC RE; Hochwald O, 2006, ISR MED ASSOC J, V8, P301; Fernandez-Cano MI, 2014, EUR J PEDIATR, V173, P721, DOI 10.1007/s00431-013-2228-8; Juretzko P, 2002, CLIN INFECT DIS, V35, P162, DOI 10.1086/341027; Klein NP, 2012, NEW ENGL J MED, V367, P1012, DOI 10.1056/NEJMoa1200850; Lavine JS, 2012, VACCINE, V30, P544, DOI 10.1016/j.vaccine.2011.11.065; Lurie G, 2009, ACAD PEDIATR, V9, P118, DOI 10.1016/j.acap.2009.01.004; Miyashita N, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-129; Roorda Lieuwe, 2011, BMC Res Notes, V4, P11, DOI 10.1186/1756-0500-4-11; Servicio de Epidemiologia, VACC SCHED 2014; Shapiro ED, 2012, JAMA-J AM MED ASSOC, V308, P2149, DOI 10.1001/jama.2012.65031; Sheridan SL, 2014, MED J AUSTRALIA, V200, P334, DOI 10.5694/mja13.11069; Skowronski DM, 2012, CLIN INFECT DIS, V54, P318, DOI 10.1093/cid/cir836; van den Brink G, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-526; van Gent M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046407; von Konig CHW, 2002, LANCET INFECT DIS, V2, P744, DOI 10.1016/S1473-3099(02)00452-8; Waters V, 2015, PRINCIPLES PRACTICE, P2619; Wymann MN, 2006, EUR J PUBLIC HEALTH, V16, P29	36	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2015	10	10							e0139993	10.1371/journal.pone.0139993	http://dx.doi.org/10.1371/journal.pone.0139993			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TP	26440655	Green Submitted, Green Published, gold			2023-01-03	WOS:000362510300091
J	Vazquez-Guillen, JM; Palacios-Saucedo, GC; Rivera-Morales, LG; Garcia-Campos, J; Ortiz-Lopez, R; Noguera-Julian, M; Paredes, R; Vielma-Ramirez, HJ; Ramirez, TJ; Chavez-Garcia, M; Lopez-Guillen, P; Briones-Lara, E; Sanchez-Sanchez, LM; Vazquez-Martinez, CA; Rodriguez-Padilla, C				Manuel Vazquez-Guillen, Jose; Palacios-Saucedo, Gerardo C.; Rivera-Morales, Lydia G.; Garcia-Campos, Jorge; Ortiz-Lopez, Rocio; Noguera-Julian, Marc; Paredes, Roger; Vielma-Ramirez, Herlinda J.; Ramirez, Teresa J.; Chavez-Garcia, Marcelino; Lopez-Guillen, Paulo; Briones-Lara, Evangelina; Sanchez-Sanchez, Luz M.; Vazquez-Martinez, Carlos A.; Rodriguez-Padilla, Cristina			Mutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAART	PLOS ONE			English	Article							REVERSE-TRANSCRIPTASE; HIV-1; VIRUS; PROTEASE; POPULATIONS; THERAPY; FAILURE; NAIVE	Although Structured Treatment Interruptions (STI) are currently not considered an alternative strategy for antiretroviral treatment, their true benefits and limitations have not been fully established. Some studies suggest the possibility of improving the quality of life of patients with this strategy; however, the information that has been obtained corresponds mostly to studies conducted in adults, with a lack of knowledge about its impact on children. Furthermore, mutations associated with antiretroviral resistance could be selected due to sub-therapeutic levels of HAART at each interruption period. Genotyping methods to determine the resistance profiles of the infecting viruses have become increasingly important for the management of patients under STI, thus low-abundance antiretroviral drug-resistant mutations (DRM's) at levels under limit of detection of conventional genotyping (< 20% of quasispecies) could increase the risk of virologic failure. In this work, we analyzed the protease and reverse transcriptase regions of the pol gene by ultra-deep sequencing in pediatric patients under STI with the aim of determining the presence of high-and low-abundance DRM's in the viral rebounds generated by the STI. High-abundance mutations in protease and high- and low-abundance mutations in reverse transcriptase were detected but no one of these are directly associated with resistance to antiretroviral drugs. The results could suggest that the evaluated STI program is virologically safe, but strict and carefully planned studies, with greater numbers of patients and interruption/ restart cycles, are still needed to evaluate the selection of DRM's during STI.	[Manuel Vazquez-Guillen, Jose; Rivera-Morales, Lydia G.; Vielma-Ramirez, Herlinda J.; Rodriguez-Padilla, Cristina] Univ Autonoma Nuevo Leon, Fac Ciencias Biol, Lab Inmunol & Virol, Monterrey, Nuevo Leon, Mexico; [Palacios-Saucedo, Gerardo C.; Garcia-Campos, Jorge; Chavez-Garcia, Marcelino; Briones-Lara, Evangelina; Sanchez-Sanchez, Luz M.; Vazquez-Martinez, Carlos A.] Hosp Especialidades 25, Unidad Med Alta Especialidad, Dept Pediat & Infectol Pediat, Inst Mexicano Seguro Social,Div Invest, Monterrey, Nuevo Leon, Mexico; [Ortiz-Lopez, Rocio] Univ Autonoma Nuevo Leon, Dept Bioquim & Med Mol, Fac Med, Monterrey, Nuevo Leon, Mexico; [Ortiz-Lopez, Rocio] Univ Autonoma Nuevo Leon, Ctr Invest Desarrollo Ciencias Salud, Monterrey, Nuevo Leon, Mexico; [Noguera-Julian, Marc; Paredes, Roger] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Inst Recerca SIDA, IrsiCaixa, Badalona, Spain; [Noguera-Julian, Marc; Paredes, Roger] Univ Vic, Catedra SIDA, Vic, Spain; [Ramirez, Teresa J.] Lab Estatal Salud Publ Estado Nuevo Leon, Secretaria Salud, Nuevo Leon, Mexico; [Lopez-Guillen, Paulo] Hosp Gen Reg 45, Inst Mexicano Seguro Social, Unidad Infectol Dr Juan I Menchaca, Jalisco, Mexico	Universidad Autonoma de Nuevo Leon; Instituto Mexicano del Seguro Social; Universidad Autonoma de Nuevo Leon; Universidad Autonoma de Nuevo Leon; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); Instituto Mexicano del Seguro Social	Palacios-Saucedo, GC (corresponding author), Hosp Especialidades 25, Unidad Med Alta Especialidad, Dept Pediat & Infectol Pediat, Inst Mexicano Seguro Social,Div Invest, Monterrey, Nuevo Leon, Mexico.	palsaugc@gmail.com	Vazquez-Guillen, Jose Manuel/W-6886-2019; Ortiz-Lopez, Rocio/N-4827-2018; Noguera-Julian, Marc/F-8651-2016	Vazquez-Guillen, Jose Manuel/0000-0001-8256-4253; Ortiz-Lopez, Rocio/0000-0002-7783-026X; Noguera-Julian, Marc/0000-0002-6194-1395; Sanchez-Sanchez, Luz Maria/0000-0001-5973-3530; Rivera-Morales, Lydia Guadalupe/0000-0001-7329-0449	Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico [44519]	Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This study was supported by the grant 44519 from the Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico. We thank to Ramses Medina-Gonzalez for his help and collaboration in the technical work of sequencing experiments, to the Laboratorio de Inmunologia y Virologia from Facultad de Ciencias Biologicas UANL for providing all the necessary facilities for the research, and to the Red Tematica de Inmunologia en Cancer y Enfermedades Infecciosas (INMUNOCANEI-CONACYT) for all its collaboration.	Alteri C, 2011, J ANTIMICROB CHEMOTH, V66, P2615, DOI 10.1093/jac/dkr354; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; Borkowsky W, 2008, AIDS RES HUM RETROV, V24, P401, DOI 10.1089/aid.2007.0110; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Eriksson N, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000074; Hedskog C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011345; Ji HZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009263; Kalmar EMN, 2012, INT J STD AIDS, V23, P120, DOI 10.1258/ijsa.2011.011124; Lauring AS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001005; Le T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006079; Lori F, 2000, LANCET, V355, P287, DOI 10.1016/S0140-6736(99)03515-1; Metzner KJ, 2009, CLIN INFECT DIS, V48, P239, DOI 10.1086/595703; Metzner KJ, 2003, J INFECT DIS, V188, P1433, DOI 10.1086/379215; Monpoux F, 2004, AIDS, V18, P2401; O'Meara D, 2001, J CLIN MICROBIOL, V39, P464, DOI 10.1128/JCM.39.2.464-473.2001; Palacios GC, 2010, INT J INFECT DIS, V14, pE34, DOI 10.1016/j.ijid.2009.03.003; Palacios-Saucedo GC, 2011, CURR HIV RES, V9, P154, DOI 10.2174/157016211795945250; Pennings PS, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002527; Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P298, DOI 10.1093/nar/gkg100; Saitoh A, 2008, PEDIATRICS, V121, pE513, DOI 10.1542/peds.2007-1086; Valle-Bahena OM, 2006, ARCH MED RES, V37, P1022, DOI 10.1016/j.arcmed.2006.05.014; Van Rompay KKA, 2006, J VIROL, V80, P6399, DOI 10.1128/JVI.02308-05; Wang CL, 2007, GENOME RES, V17, P1195, DOI 10.1101/gr.6468307; Wensing Annemarie M, 2014, Top Antivir Med, V22, P642	24	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147591	10.1371/journal.pone.0147591	http://dx.doi.org/10.1371/journal.pone.0147591			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26807922	Green Published, Green Submitted, gold			2023-01-03	WOS:000369527800143
J	Angus, DC; Truog, RD				Angus, Derek C.; Truog, Robert D.			Toward Better ICU Use at the End of Life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTENSIVE-CARE; UNITED-STATES; MEDICARE; GROWTH; TRENDS		[Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, Sch Med, Pittsburgh, PA 15261 USA; [Truog, Robert D.] Harvard Univ, Sch Med, Ctr Bioeth, Boston, MA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School	Angus, DC (corresponding author), Univ Pittsburgh, Dept Crit Care Med, 3550 Terrace St,614 Scaife Hall, Pittsburgh, PA 15261 USA.	angusdc@upmc.edu	Angus, Derek C/E-9671-2012					Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; Arnold RM, 2015, J CRIT CARE, V30, P250, DOI 10.1016/j.jcrc.2014.11.016; Emanuel EJ, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2015.18603, DOI 10.1001/JAMA.2015.18603]; Milbrandt EB, 2008, CRIT CARE MED, V36, P2504, DOI 10.1097/CCM.0b013e318183ef84; Riley GF, 2010, HEALTH SERV RES, V45, P565, DOI 10.1111/j.1475-6773.2010.01082.x; Schenker Y, 2015, JAMA-J AM MED ASSOC, V314, P1565, DOI 10.1001/jama.2015.11217; Wallace DJ, 2015, AM J RESP CRIT CARE, V191, P410, DOI 10.1164/rccm.201409-1746OC; Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8	8	48	48	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					255	256		10.1001/jama.2015.18681	http://dx.doi.org/10.1001/jama.2015.18681			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB2WN	26784767				2023-01-03	WOS:000368371400016
J	Wright, AA; Keating, NL; Ayanian, JZ; Chrischilles, EA; Kahn, KL; Ritchie, CS; Weeks, JC; Earle, CC; Landrum, MB				Wright, Alexi A.; Keating, Nancy L.; Ayanian, John Z.; Chrischilles, Elizabeth A.; Kahn, Katherine L.; Ritchie, Christine S.; Weeks, Jane C.; Earle, Craig C.; Landrum, Mary B.			Family Perspectives on Aggressive Cancer Care Near the End of Life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE; MEDICARE BENEFICIARIES; ETHNIC-DIFFERENCES; OUTCOMES RESEARCH; DEATH; QUALITY; HEALTH; PLACE; ASSOCIATIONS; HOSPICE	IMPORTANCE Patients with advanced-stage cancer are receiving increasingly aggressive medical care near death, despite growing concerns that this reflects poor-quality care. OBJECTIVE To assess the association of aggressive end-of-life care with bereaved family members' perceptions of the quality of end-of-life care and patients' goal attainment. DESIGN, SETTING, AND PARTICIPANTS Interviews with 1146 family members of Medicare patients with advanced-stage lung or colorectal cancer in the Cancer Care Outcomes Research and Surveillance study (a multiregional, prospective, observational study) who died by the end of 2011 (median, 144.5 days after death; interquartile range, 85.0-551.0 days). EXPOSURES Claims-based quality measures of aggressive end-of-life care (ie, intensive care unit [ICU] admission or repeated hospitalizations or emergency department visits during the last month of life; chemotherapy <= 2 weeks of death; no hospice or <= 3 days of hospice services; and deaths occurring in the hospital). MAIN OUTCOMES AND MEASURES Family member-reported quality rating of "excellent" for end-of-life care. Secondary outcomes included patients' goal attainment (ie, end-of-life care congruent with patients' wishes and location of death occurred in preferred place). RESULTS Of 1146 patients with cancer (median age, 76.0 years [interquartile range, 65.0-87.0 years]; 55.8% male), bereaved family members reported excellent end-of-life care for 51.3%. Family members reported excellent end-of-life care more often for patients who received hospice care for longer than 3 days (58.8% [352/599]) than those who did not receive hospice care or received 3 or fewer days (43.1% [236/547]) (adjusted difference, 16.5 percentage points [95% CI, 10.7 to 22.4 percentage points]). In contrast, family members of patients admitted to an ICU within 30 days of death reported excellent end-of-life care less often (45.0% [68/151]) than those who were not admitted to an ICU within 30 days of death (52.3% [520/995]) (adjusted difference, -9.4 percentage points [95% CI, -18.2 to -0.6 percentage points]). Similarly, family members of patients who died in the hospital reported excellent end-of-life care less often (42.2% [194/460]) than those who did not die in the hospital (57.4% [394/686]) (adjusted difference, -17.0 percentage points [95% CI, -22.9 to -11.1 percentage points]). Family members of patients who did not receive hospice care or received 3 or fewer days were less likely to report that patients died in their preferred location (40.0% [152/380]) than those who received hospice care for longer than 3 days (72.8% [287/394]) (adjusted difference, -34.4 percentage points [95% CI, -41.7 to -27.0 percentage points]). CONCLUSIONS AND RELEVANCE Among family members of older patients with fee-for service Medicare who died of lung or colorectal cancer, earlier hospice enrollment, avoidance of ICU admissions within 30 days of death, and death occurring outside the hospital were associated with perceptions of better end-of-life care. These findings are supportive of advance care planning consistent with the preferences of patients.	[Wright, Alexi A.; Weeks, Jane C.] Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Sch Med, Boston, MA 02215 USA; [Keating, Nancy L.; Landrum, Mary B.] Harvard Univ, Dept Hlth Care Policy, Sch Med, Boston, MA 02215 USA; [Keating, Nancy L.] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; [Ayanian, John Z.] Univ Michigan, Inst Healthcare Policy & Innovat, Div Gen Med, Ann Arbor, MI 48109 USA; [Ayanian, John Z.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA; [Ayanian, John Z.] Univ Michigan, Gerald R Ford Sch Publ Policy, Ann Arbor, MI 48109 USA; [Chrischilles, Elizabeth A.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; [Kahn, Katherine L.] RAND Corp, Santa Monica, CA USA; [Kahn, Katherine L.] Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA USA; [Ritchie, Christine S.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA; [Earle, Craig C.] Inst Clin Evaluat Sci, Toronto, ON, Canada	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Iowa; RAND Corporation; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; University of Toronto	Wright, AA (corresponding author), Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Sch Med, 450 Brookline Ave,Dana 1133, Boston, MA 02215 USA.	alexi_wright@dfci.harvard.edu	Kahn, Katherine/AAE-2857-2020	Kahn, Katherine/0000-0002-6605-1455; Chrischilles, Elizabeth/0000-0002-1843-1955	National Cancer Institute [R01 CA91753, 5U01CA093344-08, K24 CA181510]; Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium [U01 CA093344, U01 CA093324, U01 CA093332, U01 CA093348, U01 CA093329, U01 CA093339, U01 CA093326, R01 CA1604021];  [K07 166210]; NATIONAL CANCER INSTITUTE [U01CA093329, R01CA091753, P30CA086862, R01CA164021, U01CA093326, U01CA093339, R01CA104021, K07CA166210, U01CA093324, K24CA181510, U01CA093332, U01CA093344, U01CA093348] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant R01 CA91753 from the National Cancer Institute (awarded to Dr Earle) and grants U01 CA093344 (awarded to Dana-Farber Cancer Institute), U01 CA093324 (awarded to Harvard Medical School and Northern California Cancer Center), U01 CA093332 (awarded to Dana-Farber Cancer Institute and Cancer Research Network), U01 CA093348 (awarded to RAND Corporation and University of California, Los Angeles), U01 CA093329 (awarded to University of Alabama, Birmingham), U01 CA093339 (awarded to University of Iowa), U01 CA093326 (awarded to the University of North Carolina), and R01 CA1604021 (awarded to Dr Keating) from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium. CanCORS II work was funded by grant 5U01CA093344-08 from the National Cancer Institute (awarded to the CanCORS Consortium Statistical Coordinating Center). Dr Wright is supported by grant K07 166210 and Dr Keating is supported by K24 CA181510 from the National Cancer Institute.	Ayanian JZ, 2010, J CLIN ONCOL, V28, P4154, DOI 10.1200/JCO.2009.27.3268; Ayanian JZ, 2004, J CLIN ONCOL, V22, P2992, DOI 10.1200/JCO.2004.06.020; Barnato AE, 2009, J GEN INTERN MED, V24, P695, DOI 10.1007/s11606-009-0952-6; Catalano PJ, 2013, MED CARE, V51, pE9, DOI 10.1097/MLR.0b013e318222a711; Cutler D, PHYS BELIEFS PATIENT; DiBiasio EL, 2015, J PAIN SYMPTOM MANAG, V50, P17, DOI 10.1016/j.jpainsymman.2015.01.006; Earle CC, 2005, INT J QUAL HEALTH C, V17, P505, DOI 10.1093/intqhc/mzi061; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; He Y, 2010, STAT METHODS MED RES, V19, P653, DOI 10.1177/0962280208101273; Higginson I J, 2000, J Palliat Med, V3, P287, DOI 10.1089/jpm.2000.3.287; Jacobson Joseph O, 2012, Am Soc Clin Oncol Educ Book, pe70, DOI 10.14694/EdBook_AM.2012.32.e70; Obermeyer Z, 2014, JAMA, V312, P1888; Obermeyer Z, 2015, HEALTH AFFAIR, V34, P993, DOI 10.1377/hlthaff.2014.1055; Smith AK, 2010, J PAIN SYMPTOM MANAG, V39, P972, DOI 10.1016/j.jpainsymman.2009.10.004; Smith AK, 2009, J AM GERIATR SOC, V57, P153, DOI 10.1111/j.1532-5415.2008.02081.x; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, 2015, J PALLIAT MED, V18, P662, DOI 10.1089/jpm.2015.0039; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Wright AA, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1219; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	31	272	276	4	48	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2016	315	3					284	292		10.1001/jama.2015.18604	http://dx.doi.org/10.1001/jama.2015.18604			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DB2WN	26784776	Bronze, Green Accepted			2023-01-03	WOS:000368371400025
J	Iannaccone, A; Giorgianni, F; New, DD; Hollingsworth, TJ; Umfress, A; Alhatem, AH; Neeli, I; Lenchik, NI; Jennings, BJ; Calzada, JI; Satterfield, S; Mathews, D; Diaz, RI; Harris, T; Johnson, KC; Charles, S; Kritchevsky, SB; Gerling, IC; Beranova-Giorgianni, S; Radic, MZ				Iannaccone, Alessandro; Giorgianni, Francesco; New, David D.; Hollingsworth, T. J.; Umfress, Allison; Alhatem, Albert H.; Neeli, Indira; Lenchik, Nataliya I.; Jennings, Barbara J.; Calzada, Jorge I.; Satterfield, Suzanne; Mathews, Dennis; Diaz, Rocio I.; Harris, Tamara; Johnson, Karen C.; Charles, Steve; Kritchevsky, Stephen B.; Gerling, Ivan C.; Beranova-Giorgianni, Sarka; Radic, Marko Z.		Hlth ABC Study	Circulating Autoantibodies in Age-Related Macular Degeneration Recognize Human Macular Tissue Antigens Implicated in Autophagy, Immunomodulation, and Protection from Oxidative Stress and Apoptosis	PLOS ONE			English	Article							RETINAL-PIGMENT EPITHELIUM; SUBRETINAL DRUSENOID DEPOSITS; CANCER-ASSOCIATED RETINOPATHY; ALPHA-ENOLASE AUTOANTIBODIES; FACTOR-H POLYMORPHISM; HEAT-SHOCK-RESPONSE; BRUCHS MEMBRANE; OPTICAL-DENSITY; EYE DISEASE; CHOROIDAL NEOVASCULARIZATION	Background We investigated sera from elderly subjects with and without age-related macular degeneration (AMD) for presence of autoantibodies (AAbs) against human macular antigens and characterized their identity. Methods Sera were collected from participants in the Age-Related Maculopathy Ancillary (ARMA) Study, a cross-sectional investigation ancillary to the Health ABC Study, enriched with participants from the general population. The resulting sample (mean age: 79.2 +/- 3.9 years old) included subjects with early to advanced AMD (n = 131) and controls (n = 231). Sera were tested by Western blots for immunoreactive bands against human donor macular tissue homogenates. Immunoreactive bands were identified and graded, and odds ratios (OR) calculated. Based on these findings, sera were immunoprecipitated, and subjected to 2D gel electrophoresis (GE). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to identify the targets recognized by circulating AAbs seen on 2D-GE, followed by ELI-SAs with recombinant proteins to confirm LC-MS/MS results, and quantify autoreactivities. Results In AMD, 11 immunoreactive bands were significantly more frequent and 13 were significantly stronger than in controls. Nine of the more frequent bands also showed stronger reactivity. OR estimates ranged between 4.06 and 1.93, and all clearly excluded the null value. Following immunoprecipitation, 2D-GE and LC-MS/MS, five of the possible autoreactivity targets were conclusively identified: two members of the heat shock protein 70 (HSP70) family, HSPA8 and HSPA9; another member of the HSP family, HSPB4, also known as alpha-crystallin A chain (CRYAA); Annexin A5 (ANXA5); and Protein S100-A9, also known as calgranulin B that, when complexed with S100A8, forms calprotectin. ELISA testing with recombinant proteins confirmed, on average, significantly higher reactivities against all targets in AMD samples compared to controls. Conclusions Consistent with other evidence supporting the role of inflammation and the immune system in AMD pathogenesis, AAbs were identified in AMD sera, including early-stage disease. Identified targets may be mechanistically linked to AMD pathogenesis because the identified proteins are implicated in autophagy, immunomodulation, and protection from oxidative stress and apoptosis. In particular, a role in autophagy activation is shared by all five autoantigens, raising the possibility that the detected AAbs may play a role in AMD via autophagy compromise and downstream activation of the inflammasome. Thus, we propose that the detected AAbs provide further insight into AMD pathogenesis and have the potential to contribute to disease biogenesis and progression.	[Iannaccone, Alessandro; New, David D.; Hollingsworth, T. J.; Umfress, Allison; Alhatem, Albert H.; Neeli, Indira; Lenchik, Nataliya I.; Jennings, Barbara J.; Calzada, Jorge I.; Diaz, Rocio I.; Charles, Steve] Univ Tennessee, Ctr Hlth Sci, Hamilton Eye Inst, Dept Ophthalmol, Memphis, TN 38163 USA; [Giorgianni, Francesco; Beranova-Giorgianni, Sarka] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA; [Neeli, Indira; Radic, Marko Z.] Univ Tennessee, Ctr Hlth Sci, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA; [Lenchik, Nataliya I.; Gerling, Ivan C.] Univ Tennessee, Ctr Hlth Sci, Dept Internal Med Endocrinol, Memphis, TN 38163 USA; [Calzada, Jorge I.; Diaz, Rocio I.; Charles, Steve] Charles Retina Inst, Memphis, TN USA; [Satterfield, Suzanne; Johnson, Karen C.; Kritchevsky, Stephen B.] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA; [Mathews, Dennis] Eye Specialty Grp, Memphis, TN USA; [Mathews, Dennis] Southern Coll Optometry, Memphis, TN USA; [Harris, Tamara] NIA, NIH, Bethesda, MD 20892 USA; [Kritchevsky, Stephen B.] Wake Forest Univ, Sticht Ctr Aging, Winston Salem, NC 27109 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Wake Forest University	Iannaccone, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Hamilton Eye Inst, Dept Ophthalmol, Memphis, TN 38163 USA.	aiannacc@yahoo.com	Hollingsworth, T.J./AAD-2814-2022	Radic, Marko/0000-0002-8004-282X; Hollingsworth, T.J./0000-0002-2119-521X; Iannaccone, Alessandro/0000-0001-5737-8424; Alhatem, Albert/0000-0003-1826-6854	National Institutes of Health/National Eye Institute [K23 EY000409, R21 EY018416, R01 EY022706]; International Retinal Research Foundation; Research to Prevent Blindness, Inc. New York, NY; University of Tennessee Health Science Center College of Pharmacy; University of Tennessee Health Science Center, Neuroscience Undergraduate Merit Fellowship Award; National Institutes of Health/National Institute on Aging, Intramural Research Program; National Institutes of Health/National Institute on AgingH [N01 AG-62101, N01 AG-62103, N01-AG-62106]; NATIONAL EYE INSTITUTE [R01EY022706, K23EY000409, R21EY018416] Funding Source: NIH RePORTER	National Institutes of Health/National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); International Retinal Research Foundation; Research to Prevent Blindness, Inc. New York, NY(Research to Prevent Blindness (RPB)); University of Tennessee Health Science Center College of Pharmacy; University of Tennessee Health Science Center, Neuroscience Undergraduate Merit Fellowship Award; National Institutes of Health/National Institute on Aging, Intramural Research Program; National Institutes of Health/National Institute on AgingH; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was funded by: National Institutes of Health/National Eye Institute grants K23 EY000409 (AI), R21 EY018416 (AI, PI; ICG and MRZ, co-investigators) and R01 EY022706 (AI, PI; MRZ, FG, ICG, and SBG, co-investigators) (https://nei.nih.gov); International Retinal Research Foundation (AI) (http://www.irrfonline.org); Research to Prevent Blindness, Inc. New York, NY (Career Development Award and Physician Scientist Award to AI and unrestricted grant to the UTHSC Hamilton Eye Institute, Memphis, TN, USA) (https://www.rpbusa.org/rpb/?); University of Tennessee Health Science Center College of Pharmacy, Intramural grant (FG and SBG) (http://www.uthsc.edu/pharmacy/); University of Tennessee Health Science Center, Neuroscience Undergraduate Merit Fellowship Award (AU) (http://www.uthsc.edu/neuroscience/); National Institutes of Health/National Institute on Aging, Intramural Research Program (TH) (https://www.nia.nih.gov). The Health ABC study was supported by: National Institutes of Health/National Institute on AgingH Contracts N01 AG-62101 (SBK, PI: SS and KCJ, co-investigators), N01 AG-62103 (SBK, PI: SS and KCJ, co-investigators), and N01-AG-62106 (Health ABC Coordinating Center) (https://www.nia.nih.gov). The Health ABC Publications Committee and the National Institute on Aging reviewed and approved the manuscript for publication before submission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamus G, 1998, J AUTOIMMUN, V11, P523, DOI 10.1006/jaut.1998.0221; Adamus G, 1997, INVEST OPHTH VIS SCI, V38, P283; Adamus G, 1998, J AUTOIMMUN, V11, P671, DOI 10.1006/jaut.1998.0239; Adamus G, 2003, AUTOIMMUN REV, V2, P63, DOI 10.1016/S1568-9972(02)00127-1; Adamus Grazyna, 2004, BMC Ophthalmol, V4, P5, DOI 10.1186/1471-2415-4-5; Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154; Adamus G, 2011, J OPHTHALMIC INFLAMM, V1, P111, DOI 10.1007/s12348-011-0028-8; Adamus G, 2009, J AUTOIMMUN, V32, P133, DOI 10.1016/j.jaut.2009.02.001; Adamus G, 2009, AUTOIMMUN REV, V8, P410, DOI 10.1016/j.autrev.2009.01.002; Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668; Alessandri C, 2011, AUTOIMMUN REV, V10, P609, DOI 10.1016/j.autrev.2011.04.011; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003; Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018; Bakar F, 2014, J CLIN ENDOCR METAB, V99, P932, DOI 10.1210/jc.2013-2592; BERBERIAN PA, 1990, AM J PATHOL, V136, P71; Bernstein SL, 2000, INVEST OPHTH VIS SCI, V41, P2857; Bjork P, 2009, PLOS BIOL, V7, P800, DOI 10.1371/journal.pbio.1000097; Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102; Borges TJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00095; Casola C, 2015, J MOL NEUROSCI, V56, P228, DOI 10.1007/s12031-014-0485-2; Cederholm A, 2005, IMMUNOBIOLOGY, V210, P761, DOI 10.1016/j.imbio.2005.10.007; Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172; Cesaro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045478; Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0; Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804; Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484; Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006; Dhas D. B. B., 2012, Current Pediatric Research, V16, P83; Dokladny K, 2015, AUTOPHAGY, V11, P200, DOI 10.1080/15548627.2015.1009776; Dokladny K, 2013, J BIOL CHEM, V288, P14959, DOI 10.1074/jbc.M113.462408; Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001; Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Ethen CM, 2007, FEBS LETT, V581, P885, DOI 10.1016/j.febslet.2007.01.061; Ferrington D., 2015, PROG RETIN EYE RES; Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570; FOUQUERAY B, 1992, EUR J IMMUNOL, V22, P2983, DOI 10.1002/eji.1830221133; Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737; Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564; Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399; Gallaher KT, 2007, VISION RES, V47, P1253, DOI 10.1016/j.visres.2007.01.013; Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724; Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18; Ghavami S, 2010, CELL RES, V20, P314, DOI 10.1038/cr.2009.129; Ghislat G, 2012, J CELL SCI, V125, P92, DOI 10.1242/jcs.086728; Giorgianni F, 2004, ANAL CHEM, V76, P7028, DOI 10.1021/ac0493368; Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750; Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979; Grus FH, 2004, MOL VIS, V10, P132; Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47; Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200; Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200; Hageman Gregory S., 2011, Human Genomics, V5, P420; Hageman GS, 1999, MOL VIS, V5; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730; Hawkins BS, 1999, MOL VIS, V5; Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83; Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709; Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z; Hughes AE, 2006, NAT GENET; Iaccarino L, 2011, AUTOIMMUN REV, V10, P553, DOI 10.1016/j.autrev.2011.04.007; Iannaccone A, 2007, INVEST OPHTH VIS SCI, V48, P1458, DOI 10.1167/iovs.06-0438; Iannaccone A, 2012, ADV EXP MED BIOL, V723, P11, DOI 10.1007/978-1-4614-0631-0_2; Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103; Jablonski MM, 2001, EXP EYE RES, V72, P573, DOI 10.1006/exer.2001.0987; Jablonski MM, 2007, INVEST OPHTH VIS SCI, V48, P479, DOI 10.1167/iovs.06-0972; Jia J, 2014, CELL, V159, P623, DOI 10.1016/j.cell.2014.09.032; Joachim SC, 2007, CURR EYE RES, V32, P501, DOI 10.1080/02713680701375183; Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399; Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z; Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546; Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001; Kannan R, 2015, BIOCH BIOPHYS ACTA; Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Koike A, 2012, INFLAMMATION, V35, P409, DOI 10.1007/s10753-011-9330-8; Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18; Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019; Li CS, 2009, BIOCHEM J, V422, P363, DOI 10.1042/BJ20090465; Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871; Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13; Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022; Magrys A, 2007, J CLIN IMMUNOL, V27, P181, DOI 10.1007/s10875-006-9065-8; Mak SK, 2010, J BIOL CHEM, V285, P13621, DOI 10.1074/jbc.M109.074617; Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873; Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704; Matsumura Y, 2013, J BIOL CHEM, V288, P31069, DOI 10.1074/jbc.M113.479345; McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008; McGeer Patrick L, 2002, Sci Aging Knowledge Environ, V2002, pre3, DOI 10.1126/sageke.2002.29.re3; McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007; Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216; Minoia M, 2014, MOL CELL BIOL, V34, P3570, DOI 10.1128/MCB.00698-14; Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007; Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011; Nakatani Y, 2005, MEDIAT INFLAMM, P280, DOI 10.1155/MI.2005.280; Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025; Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434; Ohguro H, 1999, INVEST OPHTH VIS SCI, V40, P3160; Pabst MJ, 2008, PROTEOME SCI, V6, DOI 10.1186/1477-5956-6-13; Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9; Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x; PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23; PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808; PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364; PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948; PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033; Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2; Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625; Philip LP, 2004, JAMA-J AM MED ASSOC, V292, P43, DOI 10.1001/jama.292.1.43-a; Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049; Rayborn ME, 2006, ADV EXP MED BIOL, V572, P75; Ren GY, 2004, J AUTOIMMUN, V23, P161, DOI 10.1016/j.jaut.2004.06.003; Riva M, 2012, IMMUNOLOGY, V137, P172, DOI 10.1111/j.1365-2567.2012.03619.x; Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x; Saraswathy S, 2010, INVEST OPHTH VIS SCI, V51, P3680, DOI 10.1167/iovs.09-4575; Schaumberg DA, 2014, JAMA OPHTHALMOL, V132, P84, DOI 10.1001/jamaophthalmol.2013.5506; Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141; Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143; Shiraga S, 2002, J NEUROIMMUNOL, V132, P72, DOI 10.1016/S0165-5728(02)00314-4; Simard JC, 2011, J IMMUNOL, V186, P3622, DOI 10.4049/jimmunol.1002956; Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065; Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075; Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369; Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784; Sreekumar PG, 2013, INVEST OPHTH VIS SCI, V54, P2787, DOI 10.1167/iovs.12-11571; Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369; Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212; Tahiri F, 2008, HEPATOLOGY, V47, P937, DOI 10.1002/hep.22149; Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151; Thanos S, 2014, PROG RETIN EYE RES, V42, P145, DOI 10.1016/j.preteyeres.2014.06.004; Tulapurkar ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118010; Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432; Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Vishwanathan R, 2014, AGE AGEING, V43, P271, DOI 10.1093/ageing/aft210; Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001; Yang Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088; Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699; Yaung J, 2007, MOL VIS, V13, P566; Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657; Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200; Zetterstrom P, 2011, J BIOL CHEM, V286, P20130, DOI 10.1074/jbc.M111.218842; Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790; Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014	155	34	35	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2015	10	12							e0145323	10.1371/journal.pone.0145323	http://dx.doi.org/10.1371/journal.pone.0145323			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0TN	26717306	gold, Green Published, Green Submitted			2023-01-03	WOS:000367510500028
J	Huang, HR; Chen, X; Li, DL; He, Y; Li, Y; Du, ZY; Zhang, K; DiPaola, R; Goodin, S; Zheng, X				Huang, Huarong; Chen, Xuan; Li, Dongli; He, Yan; Li, Yu; Du, Zhiyun; Zhang, Kun; DiPaola, Robert; Goodin, Susan; Zheng, Xi			Combination of alpha-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells	PLOS ONE			English	Article							FACTOR-KAPPA-B; CULTURED IN-VITRO; NUCLEAR-LOCALIZATION; SIGNALING PATHWAYS; PANCREATIC-CANCER; ANALOGS; CHEMOPREVENTION; ADENOCARCINOMA; BCL-2; CHEMOTHERAPY	alpha-Tomatine is a glycoalkaloid found in tomatoes and curcumin is a major yellow pigment of turmeric. In the present study, the combined effect of these two compounds on prostate cancer cells was studied. Treatment of different prostate cancer cells with curcumin or alpha-tomatine alone resulted in growth inhibition and apoptosis in a concentration-dependent manner. Combinations of alpha-tomatine and curcumin synergistically inhibited the growth and induced apoptosis in prostate cancer PC-3 cells. Effects of the alpha-tomatine and curcumin combination were associated with synergistic inhibition of NF-kappa B activity and a potent decrease in the expression of its downstream gene Bcl-2 in the cells. Moreover, strong decreases in the levels of phospho-Akt and phosphor-ERK1/2 were found in PC-3 cells treated with alpha-tomatine and curcumin in combination. In animal experiment, SCID mice with PC-3 xenograft tumors were treated with alpha-tomatine and curcumin. Combination of alpha-tomatine and curcumin more potently inhibited the growth of PC-3 tumors than either agent alone. Results from the present study indicate that alpha-tomatine in combination with curcumin may be an effective strategy for inhibiting the growth of prostate cancer.	[Huang, Huarong; Chen, Xuan; He, Yan; Du, Zhiyun; Zhang, Kun; Zheng, Xi] Guangdong Univ Technol, Allan H Conney Lab Anticanc Res, Guangzhou, Guangdong, Peoples R China; [Li, Dongli] Wuyi Univ, Dept Chem & Environm Engn, Jiangmen City, Guangdong, Peoples R China; [Li, Yu] Guangdong Ind Tech Coll, Dept Environm Engn, Guangzhou, Guangdong, Peoples R China; [DiPaola, Robert; Goodin, Susan] Canc Inst New Jersey, New Brunswick, NJ USA	Guangdong University of Technology; Wuyi University; Guangdong Industry Polytechnic; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Zheng, X (corresponding author), Guangdong Univ Technol, Allan H Conney Lab Anticanc Res, Guangzhou, Guangdong, Peoples R China.	xizhengch2006@163.com			Guangdong Province, Leadership grant; National Natural Science Foundation of China [81272452, 21102020, 21272043]; National Cancer Institute [P30-CA072720]; NATIONAL CANCER INSTITUTE [P30CA072720] Funding Source: NIH RePORTER	Guangdong Province, Leadership grant; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Guangdong Province, Leadership grant 2011 (http://pro.gdstc.gov.cn/egrantweb/), National Natural Science Foundation of China, 81272452, 21102020 and 21272043 (http://www.nsfc.gov.cn/), National Cancer Institute, P30-CA072720 (http://www.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal BB, 2009, TRENDS PHARMACOL SCI, V30, P85, DOI 10.1016/j.tips.2008.11.002; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Bommareddy A, 2013, ANTICANCER RES, V33, P4163; Boztas AO, 2013, MOL PHARMACEUT, V10, P2676, DOI 10.1021/mp400101k; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Choi SH, 2012, J AGR FOOD CHEM, V60, P3891, DOI 10.1021/jf3003027; Connors SK, 2012, NUTR CANCER, V64, P4, DOI 10.1080/01635581.2012.630158; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Fradet V, 2004, CLIN CANCER RES, V10, P8460, DOI 10.1158/1078-0432.CCR-04-0764; Friedman M, 2002, J AGR FOOD CHEM, V50, P5751, DOI 10.1021/jf020560c; Gioeli D, 1999, CANCER RES, V59, P279; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Guo JL, 2013, MOL CELL BIOCHEM, V382, P103, DOI 10.1007/s11010-013-1723-6; Hasima Noor, 2012, Int J Biochem Mol Biol, V3, P328; Huang HR, 2014, J AGR FOOD CHEM, V62, P10752, DOI 10.1021/jf504058f; Khor TO, 2006, CANCER RES, V66, P613, DOI 10.1158/0008-5472.CAN-05-2708; Kunnumakkara AB, 2007, CANCER RES, V67, P3853, DOI 10.1158/0008-5472.CAN-06-4257; Lee KH, 2009, EUR J MED CHEM, V44, P3195, DOI 10.1016/j.ejmech.2009.03.020; Lee ST, 2013, PHYTOMEDICINE, V20, P1297, DOI 10.1016/j.phymed.2013.07.002; Lee ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057708; Lee ST, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018915; Lessard L, 2003, BJU INT, V91, P417, DOI 10.1046/j.1464-410X.2003.04104.x; Li YW, 2014, CANCER METAST REV, V33, P629, DOI 10.1007/s10555-013-9478-9; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Nambiar D, 2013, NUTR CANCER, V65, P12, DOI 10.1080/01635581.2013.785006; Pan MH, 2001, J AGR FOOD CHEM, V49, P1464, DOI 10.1021/jf001129v; Paule B, 2007, WORLD J UROL, V25, P477, DOI 10.1007/s00345-007-0175-6; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3; Seruga B, 2011, J CLIN ONCOL, V29, P3686, DOI 10.1200/JCO.2010.34.3996; Shankar S, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-16; Shankar S, 2007, INT J ONCOL, V30, P905; Shieh JM, 2011, CELL BIOCHEM BIOPHYS, V60, P297, DOI 10.1007/s12013-011-9152-1; Shih YW, 2009, FOOD CHEM TOXICOL, V47, P1985, DOI 10.1016/j.fct.2009.05.011; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Somers-Edgar TJ, 2011, INVEST NEW DRUG, V29, P87, DOI 10.1007/s10637-009-9339-0; Stein MN, 2012, CLIN CANCER RES, V18, P1848, DOI 10.1158/1078-0432.CCR-11-1805; Su CC, 2010, INT J MOL MED, V26, P217, DOI 10.3892/ijmm_00000455; Subramaniam D, 2008, CANCER RES, V68, P1962, DOI 10.1158/0008-5472.CAN-07-6011; Thomas BM, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0719-0; Tomsik P, 2013, BIOMED PAP, V157, P153, DOI 10.5507/bp.2013.031; Uzgare AR, 2005, INT J BIOCHEM CELL B, V37, P707, DOI 10.1016/j.biocel.2004.11.018; Wei XC, 2013, ANTICANCER RES, V33, P1343; Wei XC, 2012, ONCOL LETT, V4, P279, DOI 10.3892/ol.2012.710; Xi Z, 2007, CLIN CANCER RES, V13, P5480, DOI 10.1158/1078-0432.CCR-07-0242; Yang CF, 2013, CURR PHARM DESIGN, V19, P1966; Yang JY, 2015, INT J CLIN EXP PATHO, V8, P9272; Zhao CG, 2010, BIOORGAN MED CHEM, V18, P2388, DOI 10.1016/j.bmc.2010.03.001; Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078-0432.CCR-04-1087; Zheng X, 2012, INT J ONCOL, V41, P2269, DOI 10.3892/ijo.2012.1651; Zhou DY, 2014, MOL MED REP, V10, P1315, DOI 10.3892/mmr.2014.2380	52	27	28	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2015	10	12							e0144293	10.1371/journal.pone.0144293	http://dx.doi.org/10.1371/journal.pone.0144293			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX8BI	26630272	Green Published, Green Submitted, gold			2023-01-03	WOS:000365926300177
J	Harris, CS; Campbell, NKJ; Raz, A				Harris, Cory S.; Campbell, Natasha K. J.; Raz, Amir			Placebo Trends across the Border: US versus Canada	PLOS ONE			English	Article							CLINICAL-PRACTICE; QUESTIONNAIRE SURVEY; DELIBERATE USE; INTERVENTIONS; ATTITUDES	Background Physicians around the world report to using placebos in a variety of situations and with varying degrees of frequency. Inconsistent methodologies, however, complicate interpretation and prevent direct comparisons across studies. While US-and Canada-based physicians share similar professional standards, Canada harbours a less-litigious universal healthcare model with no formal placebo-related policy-factors that may impact how physicians view and use placebos. Methods To compare American and Canadian data, we circulated an online survey to academic physicians practicing in Canada, collected anonymous responses, and extracted those of internists and rheumatologists for comparison to US data obtained through parallel methodologies. Results Whereas our data show overall concordance across the border-from definitions to ethical limitations and therapeutic potential-differences between American-and Canadian-based placebo practices merit acknowledgement. For example, compared to 45%-80% among US-based respondents, only 23 +/- 7% of Canada-based respondents reported using placebos in clinical practice. However, 79 +/- 7% of Canada-respondents-a figure comparable to US data-professed to prescribing at least one form of treatment without proven or expected efficacy. Placebo interventions including unwarranted vitamins and herbal supplements (impure placebos) as well as sugar pills and saline injections (pure placebos) appear more common in Canada, where more doctors described placebos as "placebos" (rather than "medications") and used them as a "diagnostic" tool (rather than a means of placating patient demands for treatment). Interpretation Cross-border variation in the use of clinical placebos appears minor despite substantial differences in health care delivery system, malpractice climate, and placebo-related policy. The prevalence of impure placebos in both Canadian and US clinics raises ethical and practical questions currently unaddressed by policy and warranting investigation.	[Harris, Cory S.] Univ Ottawa, Dept Biol, Ottawa, ON, Canada; [Campbell, Natasha K. J.; Raz, Amir] McGill Univ, Dept Psychiat, Montreal, PQ, Canada; [Raz, Amir] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	University of Ottawa; McGill University; Lady Davis Institute; McGill University	Raz, A (corresponding author), McGill Univ, Dept Psychiat, Montreal, PQ, Canada.	amir.raz@mcgill.ca			Canadian Institutes of Health Research Banting Postdoctoral Fellowship; Canada Research Chair Program	Canadian Institutes of Health Research Banting Postdoctoral Fellowship(Canadian Institutes of Health Research (CIHR)); Canada Research Chair Program(Canada Research Chairs)	CSH was initially supported by a Canadian Institutes of Health Research Banting Postdoctoral Fellowship (http://banting.fellowships-bourses.gc.ca/home-accueil-eng.html). AR acknowledges the support of the Canada Research Chair Program (http://www.charis-chaires.gc.ca/home-accueil-eng.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the Educational Technologies team at McGill University for their technical support and maintenance of the online survey. In addition, we appreciate contributions from the Statistical Consultation Service and the Centre for Clinical Epidemiology and Community Studies at the Jewish General Hospital as well as members of the Raz Lab at McGill University. CSH was initially supported by a Canadian Institutes of Health Research Banting Postdoctoral Fellowship (http://banting.fellowships-bourses.gc.ca/home-accueil-eng.html). AR acknowledges the support of the Canada Research Chair Program (http://www.charis-chaires.gc.ca/homeaccueil-eng.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Medical Association Council on Ethical and Judicial Affairs, 2006, COD MED ETH 2006 200; Babel P, 2012, EVAL HEALTH PROF, V35, P447, DOI 10.1177/0163278711420285; Canadian Institute for Health Information, 2008, SUPPL DISTR MIGR CAN, P154; Cook C, 2000, EDUC PSYCHOL MEAS, V60, P821, DOI 10.1177/00131640021970934; COYTE PC, 1991, NEW ENGL J MED, V324, P89, DOI 10.1056/NEJM199101103240204; Crawford SD, 2001, SOC SCI COMPUT REV, V19, P146, DOI 10.1177/089443930101900202; der Bundesarztekammer H., 2010, DTSCH ARZTEBL, V107, pB1253; Fassler M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-15; Fassler M, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-144; Gallagher TH, 2006, ARCH INTERN MED, V166, P1605, DOI 10.1001/archinte.166.15.1605; GRAY G, 1981, GEN HOSP PSYCHIAT, V3, P199, DOI 10.1016/0163-8343(81)90002-5; Harris CS, 2012, J MED ETHICS, V38, P406, DOI 10.1136/medethics-2012-100695; Hrobjartsson A, 2003, EVAL HEALTH PROF, V26, P153, DOI 10.1177/0163278703026002002; Krosnick JA, 1999, ANNU REV PSYCHOL, V50, P537, DOI 10.1146/annurev.psych.50.1.537; Linde K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092938; Louhiala P, 2012, J MED ETHICS, V38, P403, DOI 10.1136/medethics-2011-100420; Meissner K, 2012, FAM PRACT, V29, P79, DOI 10.1093/fampra/cmr045; Nitzan U, 2004, BMJ-BRIT MED J, V329, P944, DOI 10.1136/bmj.38236.646678.55; Patented Medicine Prices Review Board, 2010, PAT MED PRIC REV BOA; Raz A, PLACEBO TALKS MODERN; Raz A, 2011, CAN J PSYCHIAT, V56, P198, DOI 10.1177/070674371105600403; Shermon R, 2008, J GEN INTERN MED, V23, P7, DOI 10.1007/s11606-007-0332-z; Smith CB., 1997, J COMPUTER MEDIATED, V3; Tilburt JC, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1938	24	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2015	10	11							e0142804	10.1371/journal.pone.0142804	http://dx.doi.org/10.1371/journal.pone.0142804			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CX7ES	26606749	Green Submitted, Green Published, gold			2023-01-03	WOS:000365865300031
J	Roldan-Jimenez, C; Bennett, P; Cuesta-Vargas, AI				Roldan-Jimenez, Cristina; Bennett, Paul; Cuesta-Vargas, Antonio I.			Muscular Activity and Fatigue in Lower-Limb and Trunk Muscles during Different Sit-To-Stand Tests	PLOS ONE			English	Article							PHYSICAL-FITNESS; OLDER-ADULTS; 5-TIMES-SIT-TO-STAND TEST; LOWER-EXTREMITY; MOVEMENT CYCLE; HIP ABDUCTION; STRENGTH; CHAIR; ACTIVATION; BALANCE	Sit-to-stand (STS) tests measure the ability to get up from a chair, reproducing an important component of daily living activity. As this functional task is essential for human independence, STS performance has been studied in the past decades using several methods, including electromyography. The aim of this study was to measure muscular activity and fatigue during different repetitions and speeds of STS tasks using surface electromyography in lower-limb and trunk muscles. This cross-sectional study recruited 30 healthy young adults. Average muscle activation, percentage of maximum voluntary contraction, muscle involvement in motion and fatigue were measured using surface electrodes placed on the medial gastrocnemius (MG), biceps femoris (BF), vastus medialis of the quadriceps (QM), the abdominal rectus (AR), erector spinae (ES), rectus femoris (RF), soleus (SO) and the tibialis anterior (TA). Five-repetition STS, 10-repetition STS and 30-second STS variants were performed. MG, BF, QM, ES and RF muscles showed differences in muscle activation, while QM, AR and ES muscles showed significant differences in MVC percentage. Also, significant differences in fatigue were found in QM muscle between different STS tests. There was no statistically significant fatigue in the BF, MG and SO muscles of the leg although there appeared to be a trend of increasing fatigue. These results could be useful in describing the functional movements of the STS test used in rehabilitation programs, notwithstanding that they were measured in healthy young subjects.	[Roldan-Jimenez, Cristina; Cuesta-Vargas, Antonio I.] Univ Malaga, Fac Hlth Sci, Dept Physiotherapy, E-29071 Malaga, Spain; [Bennett, Paul; Cuesta-Vargas, Antonio I.] Queensland Univ Technol, Fac Hlth Sci, Sch Clin Sci, Brisbane, Qld 4001, Australia	Universidad de Malaga; Queensland University of Technology (QUT)	Cuesta-Vargas, AI (corresponding author), Univ Malaga, Fac Hlth Sci, Dept Physiotherapy, E-29071 Malaga, Spain.	acuesta.var@gmail.com	Jiménez, Cristina Roldán/AAT-1415-2020	Cuesta-Vargas, Antonio I/0000-0002-8880-4315; /0000-0002-7355-9740				Alcock L, 2015, PHYSIOTHERAPY, V101, P204, DOI 10.1016/j.physio.2014.09.001; BAER GD, 1995, ARCH PHYS MED REHAB, V76, P844, DOI 10.1016/S0003-9993(95)80550-8; Barbero M., 2012, ATLAS MUSCLE INNERVA, DOI [DOI 10.1017/CBO9781107415324.004, 10.1007/978-88-470-2463-2, DOI 10.1007/978-88-470-2463-2]; Bidargaddi N, 2007, P ANN INT IEEE EMBS, P1884, DOI 10.1109/IEMBS.2007.4352683; Bonato P, 2001, IEEE T BIO-MED ENG, V48, P745, DOI 10.1109/10.930899; Boukadida A, 2015, ANN PHYS REHABIL MED, V58, P167, DOI 10.1016/j.rehab.2015.04.007; Burnfield JM, 2012, GAIT POSTURE, V36, P516, DOI 10.1016/j.gaitpost.2012.05.002; Choi B, 2015, J PHYS THER SCI, V27, P893, DOI 10.1589/jpts.27.893; Criswell E., 2011, CRAMS INTRO SURFACE; CSUKA M, 1985, AM J MED, V78, P77, DOI 10.1016/0002-9343(85)90465-6; Cuesta-Vargas AI, 2013, J ELECTROMYOGR KINES, V23, P1446, DOI 10.1016/j.jelekin.2013.06.001; Cuesta-Vargas AI, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/173148; Daniels L., 1995, MUSCLE TESTING TECHN; Davidson BS, 2013, J ELECTROMYOGR KINES, V23, P1485, DOI 10.1016/j.jelekin.2013.06.008; Dehail P, 2007, CLIN BIOMECH, V22, P1096, DOI 10.1016/j.clinbiomech.2007.07.015; Doheny EP, 2013, GAIT POSTURE, V38, P1021, DOI 10.1016/j.gaitpost.2013.05.013; Doheny EP, 2011, IEEE ENG MED BIO, P3063, DOI 10.1109/IEMBS.2011.6090837; Duncan RP, 2011, ARCH PHYS MED REHAB, V92, P1431, DOI 10.1016/j.apmr.2011.04.008; Fujimoto M, 2012, J BIOMECH, V45, P543, DOI 10.1016/j.jbiomech.2011.11.037; Galli M, 2008, GAIT POSTURE, V28, P80, DOI 10.1016/j.gaitpost.2007.10.003; Gillette JC, 2012, GAIT POSTURE, V35, P78, DOI 10.1016/j.gaitpost.2011.08.010; Goulart FR, 1999, CLIN NEUROPHYSIOL, V110, P1634, DOI 10.1016/S1388-2457(99)00109-1; Hatton AL, 2013, GAIT POSTURE, V37, P506, DOI 10.1016/j.gaitpost.2012.09.004; Helbostad JL, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-56; Huffman KD, 2015, GAIT POSTURE, V41, P640, DOI 10.1016/j.gaitpost.2015.01.014; Hughes MA, 1996, J BIOMECH, V29, P1509, DOI 10.1016/0021-9290(96)00083-8; Jang EM, 2015, J PHYS THER SCI, V27, P375, DOI 10.1589/jpts.27.375; Janssen WGM, 2002, PHYS THER, V82, P866, DOI 10.1093/ptj/82.9.866; Kerr K., 1994, GAIT POSTURE, V2, P173, DOI [DOI 10.1016/0966-6362(94)90005-1, 10.1016/0966-6362(94)90005-1]; KERR KM, 1994, GAIT POSTURE, V2, P182, DOI DOI 10.1016/0966-6362(94)90006-X; Marschollek M, 2009, Z GERONTOL GERIATR, V42, P317, DOI 10.1007/s00391-009-0035-7; Mazza C, 2005, GAIT POSTURE, V21, P425, DOI 10.1016/j.gaitpost.2004.05.006; Moseng T, 2014, PHYSIOTHERAPY, V100, P319, DOI 10.1016/j.physio.2013.11.005; Najafi B, 2002, IEEE T BIO-MED ENG, V49, P843, DOI 10.1109/TBME.2002.800763; Nam I, 2015, J PHYS THER SCI, V27, P571, DOI 10.1589/jpts.27.571; Paillard T, 2012, NEUROSCI BIOBEHAV R, V36, P162, DOI 10.1016/j.neubiorev.2011.05.009; Perotto A.O., 2005, ANATOMICAL GUIDE ELE, V4th; Ploutz-Snyder LL, 2002, J GERONTOL A-BIOL, V57, pB144, DOI 10.1093/gerona/57.4.B144; RILEY PO, 1991, J BIOMECH, V24, P77, DOI 10.1016/0021-9290(91)90328-K; Savelberg HHCM, 2007, CLIN BIOMECH, V22, P805, DOI 10.1016/j.clinbiomech.2007.05.002; SCHENKMAN M, 1990, PHYS THER, V70, P638, DOI 10.1093/ptj/70.10.638; Schurr K, 2012, CLIN REHABIL, V26, P656, DOI 10.1177/0269215511427323; Spyropoulos G, 2013, GAIT POSTURE, V38, P62, DOI 10.1016/j.gaitpost.2012.10.013; Tully EA, 2005, GAIT POSTURE, V22, P338, DOI 10.1016/j.gaitpost.2004.11.007; Tveter AT, 2014, ARCH PHYS MED REHAB, V95, P1366, DOI 10.1016/j.apmr.2014.02.016; Tveter AT, 2014, J ORTHOP SPORT PHYS, V44, P206, DOI 10.2519/jospt.2014.5042; Van der Heijden MMP, 2009, GAIT POSTURE, V30, P110, DOI 10.1016/j.gaitpost.2009.04.002; Van Lummel RC, 2013, GAIT POSTURE, V38, P153, DOI 10.1016/j.gaitpost.2012.10.008; Whitney SL, 2005, PHYS THER, V85, P1034, DOI 10.1093/ptj/85.10.1034; Yoshioka S, 2012, J BIOMECH, V45, P699, DOI 10.1016/j.jbiomech.2011.11.054	50	48	48	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2015	10	10							e0141675	10.1371/journal.pone.0141675	http://dx.doi.org/10.1371/journal.pone.0141675			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU8PC	26506612	gold, Green Published, Green Submitted			2023-01-03	WOS:000363804200095
J	Chui, PL; Abdullah, KL; Wong, LP; Taib, NA				Chui, Ping Lei; Abdullah, Khatijah Lim; Wong, Li Ping; Taib, Nur Aishah			Quality of Life in CAM and Non-CAM Users among Breast Cancer Patients during Chemotherapy in Malaysia	PLOS ONE			English	Article							ALTERNATIVE MEDICINE USE; COMPLEMENTARY/ALTERNATIVE MEDICINE; EORTC QLQ-C30; WOMEN; VALIDATION; VERSION; TRIALS; IMPACT	Background Complementary and alternative medicine (CAM) use has become increasingly popular among patients with cancer. The purposes of this study were to compare the QOL in CAM users and non-CAM users and to determine whether CAM use influences QOL among breast cancer patients during chemotherapy. Methodology A cross-sectional survey was conducted at two outpatient chemotherapy centers. A total of 546 patients completed the questionnaires on CAM use. QOL was evaluated based on the European Organization for Research and Treatment of Cancer (EORTC) core quality of life (QLQ-C30) and breast cancer-specific quality of life (QLQ-BR23) questionnaires. Results A total of 70.7% of patients were identified as CAM users. There was no significant difference in global health status scores and in all five subscales of the QLQ C30 functional scales between CAM users and non-CAM users. On the QLQ-C30 symptom scales, CAM users (44.96 +/- 3.89) had significantly (p = 0.01) higher mean scores for financial difficulties than non-CAM users (36.29 +/- 4.81). On the QLQ-BR23 functional scales, CAM users reported significantly higher mean scores for sexual enjoyment (6.01 +/- 12.84 vs. 4.64 +/- 12.76, p = 0.04) than non-CAM users. On the QLQ-BR23 symptom scales, CAM users reported higher systemic therapy side effects (41.34 +/- 2.01 vs. 37.22 +/- 2.48, p = 0.04) and breast symptoms (15.76 +/- 2.13 vs. 11.08 +/- 2.62, p = 0.02) than non-CAM users. Multivariate logistic regression analysis indicated that the use of CAM modality was not significantly associated with higher global health status scores (p = 0.71). Conclusion While the findings indicated that there was no significant difference between users and nonusers of CAM in terms of QOL, CAM may be used by health professionals as a surrogate to monitor patients with higher systemic therapy side effects and breast symptoms. Furthermore, given that CAM users reported higher financial burdens (which may have contributed to increased distress), patients should be encouraged to discuss the potential benefits and/or disadvantages of using CAM with their healthcare providers.	[Chui, Ping Lei; Abdullah, Khatijah Lim] Univ Malaya, Fac Med, Dept Nursing Sci, Kuala Lumpur, Malaysia; [Wong, Li Ping] Univ Malaya, Fac Med, Dept Social & Prevent Med, Kuala Lumpur, Malaysia; [Taib, Nur Aishah] Univ Malaya, Dept Surg, Fac Med, Kuala Lumpur, Malaysia	Universiti Malaya; Universiti Malaya; Universiti Malaya	Chui, PL (corresponding author), Univ Malaya, Fac Med, Dept Nursing Sci, Kuala Lumpur, Malaysia.	chuipinglei@um.edu.my	Chui, Ping Lei/B-8417-2010; WONG, LI PING/B-2782-2010; Abdullah, Khatijah Lim/B-8782-2010; Taib, Nur Aishah Mohd/B-2370-2010	Chui, Ping Lei/0000-0002-6918-1204; WONG, LI PING/0000-0002-0107-0532; Abdullah, Khatijah Lim/0000-0002-7185-6004; Taib, Nur Aishah Mohd/0000-0001-8419-0478	University Malaya Research Grant, Health and Translational Medicine Cluster [RG238/10HTM]	University Malaya Research Grant, Health and Translational Medicine Cluster	This study was funded by a University Malaya Research Grant, Health and Translational Medicine Cluster, Project No. RG238/10HTM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn E, 2009, BREAST CANCER RES TR, V116, P609, DOI 10.1007/s10549-008-0209-9; Al-Naggar RA., 2013, WORLD J MED SCI, V8, P157; Ashing-Giwa K. T, 2009, ONCOL NURS FORUM; Balneaves LG, 2006, J ALTERN COMPLEM MED, V12, P459, DOI 10.1089/acm.2006.12.459; Bautista C., 2011, APPL CLIN TRIALS, V6; Calhoun EA, 2003, BLOOD, V102, p749A; Can G, 2011, EUR J ONCOL NURS, V15, P3, DOI 10.1016/j.ejon.2009.10.010; Centers for Disease Control and Prevention, 2010, NUTRITION; Chang O, 2014, ASIAN PAC J CANCER P, V15, P8607, DOI 10.7314/APJCP.2014.15.20.8607; Chie WC, 2003, PSYCHO-ONCOLOGY, V12, P729, DOI 10.1002/pon.727; Efficace F, 2007, ANN ONCOL, V18, P775, DOI 10.1093/annonc/mdl494; Er O, 2008, TUMORI, V94, P833; Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O; Farooqui M., 2013, ALTERN INTEGR MED, V2, P121, DOI 10.4172/2327-5162.1000121; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; Frenkel M, 2010, INTEGR CANCER THER, V9, P177, DOI 10.1177/1534735410363706; Gopal RR, 2013, MAL J PUB HLTH MED, V13, P11; Hasan Syed Shahzad, 2009, Complement Ther Clin Pract, V15, P152, DOI 10.1016/j.ctcp.2009.02.003; Hlubocky FJ, 2007, J CLIN ONCOL, V25, P548, DOI 10.1200/JCO.2005.03.9800; Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920; Jassim GA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-212; Kang E, 2012, SUPPORT CARE CANCER, V20, P461, DOI 10.1007/s00520-011-1094-z; Kremser T, 2008, BREAST, V17, P387, DOI 10.1016/j.breast.2007.12.006; Kresevic DM, 2014, AM J ORTHOP, V31, P24; Lee PY, 2007, ASIA PACIFIC FAMILY, V6; Lim CL, 2006, MALAYSIAN J NUTR S, V12, pS102; Lim MK, 2005, COMPLEMENT THER MED, V13, P16, DOI 10.1016/j.ctim.2004.11.002; Longman A J, 1999, Oncol Nurs Forum, V26, P909; Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110; National Center for Complementary and Integrative Health, 2013, COMPL ALT INT HLTH W; Ngelangel CA, 2008, ASIA PACIFIC OCOLOGY, V1, P18; Pinar R, 2003, TURKISH J CANC, V33, P96; Power M, 1998, SOC SCI MED, V46, P1569, DOI 10.1016/s0277-9536(98)00009-4; Puataweepong P, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/670408; Saghatchian M, 2014, BREAST, V23, P279, DOI 10.1016/j.breast.2014.01.009; Saibul N, 2012, ASIAN PAC J CANCER P, V13, P4081, DOI 10.7314/APJCP.2012.13.8.4081; Saini A, 2011, QUAL LIFE RES, V20, P683, DOI 10.1007/s11136-010-9795-1; Salonen P, 2009, CANCER NURS, V32, P177, DOI 10.1097/NCC.0b013e31819b5b65; Saw Jun Tze, 2006, Complement Ther Clin Pract, V12, P236, DOI 10.1016/j.ctcp.2006.06.002; Shen FR, 2012, ASIAN PAC J CANCER P, V13, P3747, DOI 10.7314/APJCP.2012.13.8.3747; Shih V, 2009, ANN ONCOL, V20, P752, DOI 10.1093/annonc/mdn659; Soraya HS, 2011, ALTERN THER HEALTH M, V17, P50; SPSS I, 2009, PASW STAT 18; Tan ML, 2014, ASIA-PAC J ONCOL NUR, V1, P22, DOI 10.4103/2347-5625.135817; Tarhan O, 2009, J BUON, V14, P265; Tautz E, 2012, EUR J CANCER, V48, P3133, DOI 10.1016/j.ejca.2012.04.021; Wyatt G, 2010, NURS RES, V59, P58, DOI 10.1097/NNR.0b013e3181c3bd26; Yong D, 2009, PALLIATIVE MED, P1; Yusoff N, 2010, INT MED J MALAYS, V9, P45	49	22	22	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2015	10	10							e0139952	10.1371/journal.pone.0139952	http://dx.doi.org/10.1371/journal.pone.0139952			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CT0TY	26451732	Green Submitted, Green Published, gold			2023-01-03	WOS:000362511200023
J	Yang, F; Khin, LW; Lau, T; Chua, HR; Vathsala, A; Lee, E; Luo, N				Yang, Fan; Khin, Lay-Wai; Lau, Titus; Chua, Horng-Ruey; Vathsala, A.; Lee, Evan; Luo, Nan			Hemodialysis versus Peritoneal Dialysis: A Comparison of Survival Outcomes in South-East Asian Patients with End-Stage Renal Disease	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; MORTALITY; NETHERLANDS; MODALITY; TAIWAN; MODELS; KOREA; RISK	Background Studies comparing patient survival of hemodialysis (HD) and peritoneal dialysis (PD) have yielded conflicting results and no such study was from South-East Asia. This study aimed to compare the survival outcomes of patients with end-stage renal disease (ESRD) who started dialysis with HD and PD in Singapore. Methods Survival data for a maximum of 5 years from a single-center cohort of 871 ESRD patients starting dialysis with HD (n = 641) or PD (n = 230) from 2005-2010 was analyzed using the flexible Royston-Parmar (RP) model. The model was also applied to a subsample of 225 propensity-score-matched patient pairs and subgroups defined by age, diabetes mellitus, and cardiovascular disease. Results After adjusting for the effect of socio-demographic and clinical characteristics, the risk of death was higher in patients initiating dialysis with PD than those initiating dialysis with HD (hazard ratio [HR]: 2.08; 95% confidence interval [CI]: 1.67-2.59; p<0.001), although there was no significant difference in mortality between the two modalities in the first 12 months of treatment. Consistently, in the matched subsample, patients starting PD had a higher risk of death than those starting HD (HR: 1.73, 95% CI: 1.30-2.28, p<0.001). Subgroup analysis showed that PD may be similar to or better than HD in survival outcomes among young patients (<= 65 years old) without diabetes or cardiovascular disease. Conclusion ESRD patients who initiated dialysis with HD experienced better survival outcomes than those who initiated dialysis with PD in Singapore, although survival outcomes may not differ between the two dialysis modalities in young and healthier patients. These findings are potentially confounded by selection bias, as patients were not randomized to the two dialysis modalities in this cohort study.	[Yang, Fan; Khin, Lay-Wai; Luo, Nan] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore; [Lau, Titus; Chua, Horng-Ruey; Vathsala, A.; Lee, Evan] Natl Univ Hlth Syst, Univ Med Cluster, Div Nephrol, Singapore, Singapore	National University of Singapore; National University of Singapore	Luo, N (corresponding author), Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.	nan_luo@nuhs.edu.sg		Yang, Fan/0000-0003-4689-265X				Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Chang YK, 2012, MEDICINE, V91, P144, DOI 10.1097/MD.0b013e318256538e; Choo JCJ FM, 2012, P SINGAPORE HEALTHCA, V21; Frankenfield DL, 2003, KIDNEY INT, V64, P623, DOI 10.1046/j.1523-1755.2003.00121.x; Grassmann A, 2005, NEPHROL DIAL TRANSPL, V20, P2587, DOI 10.1093/ndt/gfi159; Hall YN, 2005, KIDNEY INT, V68, P2310, DOI 10.1111/j.1523-1755.2005.00691.x; Heaf JG, 2002, NEPHROL DIAL TRANSPL, V17, P112, DOI 10.1093/ndt/17.1.112; Huang CC, 2008, PERITON DIALYSIS INT, V28, pS15; Jaar BG, 2005, ANN INTERN MED, V143, P174, DOI 10.7326/0003-4819-143-3-200508020-00003; Kim H, 2014, KIDNEY INT, V86, P991, DOI 10.1038/ki.2014.163; Letsios A, 2011, HIPPOKRATIA, V15, P16; Liem YS, 2007, KIDNEY INT, V71, P153, DOI 10.1038/sj.ki.5002014; McDonald SP, 2009, J AM SOC NEPHROL, V20, P155, DOI 10.1681/ASN.2007111188; Mehrotra R, 2011, ARCH INTERN MED, V171, P110, DOI 10.1001/archinternmed.2010.352; Miladinovic B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047804; Molsted S, 2007, NEPHRON CLIN PRACT, V106, pC24, DOI 10.1159/000101481; National Registry of Diseases Office HPB, 2014, SING REN REG ANN REG; Noordzij M, 2014, KIDNEY INT, V86, P877, DOI 10.1038/ki.2014.194; Norris KC, 2005, KIDNEY INT, V68, P914, DOI 10.1111/j.1523-1755.2005.00485.x; Pacheco A, 2007, PERITON DIALYSIS INT, V27, P359; Polkinghorne KR, 2004, J AM SOC NEPHROL, V15, P477, DOI 10.1097/01.ASN.0000109668.05157.05; Rooney J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074733; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Shahab Irum, 2006, Adv Perit Dial, V22, P180; Tan CC, 2005, KIDNEY INT, V67, pS19, DOI 10.1111/j.1523-1755.2005.09405.x; Termorshuizen F, 2003, J AM SOC NEPHROL, V14, P2851, DOI 10.1097/01.ASN.0000091585.45723.9E; van de Luijtgaarden MWM, 2011, NEPHROL DIAL TRANSPL, V26, P2940, DOI 10.1093/ndt/gfq845; Vonesh EF, 2004, KIDNEY INT, V66, P2389, DOI 10.1111/j.1523-1755.2004.66028.x; Weinhandl ED, 2010, J AM SOC NEPHROL, V21, P499, DOI 10.1681/ASN.2009060635; Yang F, 2015, QUAL LIFE RES, V24, P2163, DOI 10.1007/s11136-015-0964-0; Yeates K, 2012, NEPHROL DIAL TRANSPL, V27, P3568, DOI 10.1093/ndt/gfr674	32	25	28	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2015	10	10							e0140195	10.1371/journal.pone.0140195	http://dx.doi.org/10.1371/journal.pone.0140195			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TS	26444003	Green Submitted, Green Published, gold			2023-01-03	WOS:000362510600151
J	Jiang, SY; Du, JC; Kong, QH; Li, CC; Li, Y; Sun, HD; Pu, JX; Mao, BY				Jiang, Shiyou; Du, Jiacheng; Kong, Qinghua; Li, Chaocui; Li, Yan; Sun, Handong; Pu, Jianxin; Mao, Bingyu			A Group of ent-Kaurane Diterpenoids Inhibit Hedgehog Signaling and Induce Cilia Elongation	PLOS ONE			English	Article							SMALL-MOLECULE INHIBITORS; BASAL-CELL CARCINOMA; TRITERPENE DILACTONES; PATHWAY INHIBITOR; PROTEIN KIF7; MITOSIS; MEDULLOBLASTOMA; CILIOGENESIS; SUPPRESSOR; BINDING	The Hedgehog (Hh) signaling pathway plays important roles in the tumorigenesis of multiple cancers and is a key target for drug discovery. In a screen of natural products extracted from Chinese herbs, we identified eight ent-Kaurane diterpenoids and two triterpene dilactones as novel Hh pathway antagonists. Epistatic analyses suggest that these compounds likely act at the level or downstream of Smoothened (Smo) and upstream of Suppressor of Fused (Sufu). The ent-Kauranoid-treated cells showed elongated cilia, suppressed Smo trafficking to cilia, and mitotic defects, while the triterpene dilactones had no effect on the cilia and ciliary Smo. These ent-Kaurane diterpenoids provide new prototypes of Hh inhibitors, and are valuable probes for deciphering the mechanisms of Smo ciliary transport and ciliogenesis.	[Jiang, Shiyou; Du, Jiacheng; Li, Chaocui; Mao, Bingyu] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming, Peoples R China; [Kong, Qinghua; Li, Yan; Sun, Handong; Pu, Jianxin] Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming, Peoples R China; [Jiang, Shiyou; Du, Jiacheng] Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; Kunming Institute of Botany, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Pu, JX (corresponding author), Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming, Peoples R China.	pujianxin@mail.kib.ac.cn; mao@mail.kiz.ac.cn		Mao, Bingyu/0000-0002-7993-3158; Jiang, Shi-You/0000-0001-9406-4934	NSFC-Yunnan [U1302226, U1302223]; National Natural Science Foundation of China [21322204]	NSFC-Yunnan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by NSFC-Yunnan Joint Funds (U1302226 and U1302223), and National Natural Science Foundation of China (21322204). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Besschetnova TY, 2010, CURR BIOL, V20, P182, DOI 10.1016/j.cub.2009.11.072; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Buglio D, 2012, BLOOD, V120, P347, DOI 10.1182/blood-2011-07-369397; Chang ALS, 2012, ARCH DERMATOL, V148, P1324, DOI 10.1001/archdermatol.2012.2354; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; CHEN Y, 1990, Acta Botanica Yunnanica, V12, P211; Cheung HOL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000405; Clarke PR, 2008, NAT REV MOL CELL BIO, V9, P464, DOI 10.1038/nrm2410; Cooper AF, 2005, DEVELOPMENT, V132, P4407, DOI 10.1242/dev.02021; Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008; Delaval B, 2011, NAT CELL BIOL, V13, P461, DOI 10.1038/ncb2202; Dishinger JF, 2010, NAT CELL BIOL, V12, P703, DOI 10.1038/ncb2073; Endoh-Yamagami S, 2009, CURR BIOL, V19, P1320, DOI 10.1016/j.cub.2009.06.046; Fan SL, 2011, MOL BIOL CELL, V22, P4539, DOI 10.1091/mbc.E11-03-0267; Firestone AJ, 2012, NATURE, V484, P125, DOI 10.1038/nature10936; Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208; Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Haraguchi K, 2006, J BIOL CHEM, V281, P4094, DOI 10.1074/jbc.M507028200; He M, 2014, NAT CELL BIOL, V16, P663, DOI 10.1038/ncb2988; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106; Ishikawa H, 2011, NAT REV MOL CELL BIO, V12, P222, DOI 10.1038/nrm3085; Jiang B, 2002, J NAT PROD, V65, P1111, DOI 10.1021/np020084k; Kee HL, 2012, NAT CELL BIOL, V14, P431, DOI 10.1038/ncb2450; Kim J, 2010, NATURE, V464, P1048, DOI 10.1038/nature08895; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Li X, 2006, PHYTOCHEMISTRY, V67, P1336, DOI 10.1016/j.phytochem.2006.05.002; Li XY, 2013, NAT PRODUCT BIOPROSP, V3, P24, DOI 10.1007/s13659-012-0094-0; Liem KF, 2009, P NATL ACAD SCI USA, V106, P13377, DOI 10.1073/pnas.0906944106; Nachtergaele S, 2013, ELIFE, V2, DOI 10.7554/eLife.01340; Nozawa YI, 2013, CURR OPIN GENET DEV, V23, P429, DOI 10.1016/j.gde.2013.04.008; Pu JX, 2006, TETRAHEDRON, V62, P6073, DOI 10.1016/j.tet.2006.03.108; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Rundle NT, 2006, ACS CHEM BIOL, V1, P443, DOI 10.1021/cb600196w; Sharpe HJ, 2015, NAT CHEM BIOL, V11, P246, DOI [10.1038/NCHEMBIO.1776, 10.1038/nchembio.1776]; Sharpe HJ, 2015, CANCER CELL, V27, P327, DOI 10.1016/j.ccell.2015.02.001; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Wang L, 2011, MINI-REV MED CHEM, V11, P910, DOI 10.2174/138955711796575416; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Wu JQ, 2013, ACS CHEM BIOL, V8, P643, DOI 10.1021/cb3005897; Xie JW, 2010, U.S. patent, Patent No. [20100111955 A1, 20100111955]; Yang JH, 2013, J NAT PROD, V76, P256, DOI 10.1021/np300772e; Yang JH, 2010, J NAT PROD, V73, P12, DOI 10.1021/np900506g; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yoshio T, 1987, J CHEM SOC PERK T, V1, P2403; Yue S, 2009, ONCOGENE, V28, P492, DOI 10.1038/onc.2008.403	51	0	2	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2015	10	10							e0139830	10.1371/journal.pone.0139830	http://dx.doi.org/10.1371/journal.pone.0139830			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TP	26439749	Green Submitted, gold, Green Published			2023-01-03	WOS:000362510300064
J	Muller, L; Meyer, M; Bauer, RN; Zhou, HB; Zhang, HT; Jones, S; Robinette, C; Noah, TL; Jaspers, I				Mueller, Loretta; Meyer, Megan; Bauer, Rebecca N.; Zhou, Haibo; Zhang, Hongtao; Jones, Shannon; Robinette, Carole; Noah, Terry L.; Jaspers, Ilona			Effect of Broccoli Sprouts and Live Attenuated Influenza Virus on Peripheral Blood Natural Killer Cells: A Randomized, Double-Blind Study	PLOS ONE			English	Article							BRAUN-TYPE LIPOPROTEINS; NASAL EPITHELIAL-CELLS; SULFORAPHANE; VACCINES; SMOKERS; CANCER; ISOTHIOCYANATE; EXPRESSION; INDUCTION; INFECTION	Enhancing antiviral host defense responses through nutritional supplementation would be an attractive strategy in the fight against influenza. Using inoculation with live attenuated influenza virus (LAIV) as an infection model, we have recently shown that ingestion of sulforaphane-containing broccoli sprout homogenates (BSH) reduces markers of viral load in the nose. To investigate the systemic effects of short-term BSH supplementation in the context of LAIV-inoculation, we examined peripheral blood immune cell populations in non-smoking subjects from this study, with a particular focus on NK cells. We carried out a randomized, double-blinded, placebo-controlled study measuring the effects of BSH (N = 13) or placebo (alfalfa sprout homogenate, ASH; N = 16) on peripheral blood mononuclear cell responses to a standard nasal vaccine dose of LAIV in healthy volunteers. Blood was drawn prior to (day-1) and post (day2, day21) LAIV inoculation and analyzed for neutrophils, monocytes, macrophages, T cells, NKT cells, and NK cells. In addition, NK cells were enriched, stimulated, and assessed for surface markers, intracellular markers, and cytotoxic potential by flow cytometry. Overall, LAIV significantly reduced NKT (day2 and day21) and T cell (day2) populations. LAIV decreased NK cell CD56 and CD158b expression, while significantly increasing CD16 expression and cytotoxic potential (on day2). BSH supplementation further increased LAIV-induced granzyme B production (day2) in NK cells compared to ASH and in the BSH group granzyme B levels appeared to be negatively associated with influenza RNA levels in nasal lavage fluid cells. We conclude that nasal influenza infection may induce complex changes in peripheral blood NK cell activation, and that BSH increases virus-induced peripheral blood NK cell granzyme B production, an effect that may be important for enhanced antiviral defense responses.	[Mueller, Loretta; Bauer, Rebecca N.; Jones, Shannon; Robinette, Carole; Noah, Terry L.; Jaspers, Ilona] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA; [Mueller, Loretta] Univ Childrens Hosp Basel, Basel, Switzerland; [Meyer, Megan] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; [Bauer, Rebecca N.] Stanford Univ, Dept Pediat Allergy & Immunol, Stanford, CA 94305 USA; [Zhou, Haibo; Zhang, Hongtao] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA; [Noah, Terry L.; Jaspers, Ilona] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of Basel; University of North Carolina; University of North Carolina Chapel Hill; Stanford University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Jaspers, I (corresponding author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA.; Jaspers, I (corresponding author), Univ N Carolina, Dept Pediat, Chapel Hill, NC USA.	Ilona-Jaspers@med.unc.edu	ZHOU, Haibo/M-7373-2017; Jaspers, Ilona/AAZ-5035-2020		NIH [R01 HL095163]; Swiss National Science Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, R01ES013611, T32ES007126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM000678] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by NIH R01 HL095163. Loretta Muller was supported by a personal grant from the Swiss National Science Foundation.	Amin PJ, 2015, LIFE SCI, V126, P19, DOI 10.1016/j.lfs.2015.01.026; Broder K., 2009, Morbidity and Mortality Weekly Report, V58, P1351; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8; Cho HY, 2009, AM J RESP CRIT CARE, V179, P138, DOI 10.1164/rccm.200804-535OC; Dinkova-Kostova AT, 2007, CANCER EPIDEM BIOMAR, V16, P847, DOI 10.1158/1055-9965.EPI-06-0934; Dou YL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121258; Egner PA, 2014, CANCER PREV RES, V7, P813, DOI 10.1158/1940-6207.CAPR-14-0103; Guerrero-Beltran CE, 2012, EXP TOXICOL PATHOL, V64, P503, DOI 10.1016/j.etp.2010.11.005; Fan X, 2013, AM J PHYSIOL-LUNG C, V305, P1267, DOI 10.1152/ajplung.00288.2012; Gregoire C, 2007, IMMUNOL REV, V220, P169, DOI 10.1111/j.1600-065X.2007.00563.x; Harvey CJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002042; He XS, 2008, J INFECT DIS, V197, P803, DOI 10.1086/528804; He XS, 2006, J VIROL, V80, P11756, DOI 10.1128/JVI.01460-06; Heber D, 2014, FOOD FUNCT, V5, P35, DOI 10.1039/c3fo60277j; Horvath KM, 2012, CLIN IMMUNOL, V142, P232, DOI 10.1016/j.clim.2011.12.013; Horvath KM, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-102; Jaspers I, 2010, AM J RESP CELL MOL, V43, P368, DOI 10.1165/rcmb.2009-0254OC; Kesic MJ, 2011, FREE RADICAL BIO MED, V51, P444, DOI 10.1016/j.freeradbiomed.2011.04.027; Meyer M, 2013, RESP MED, V107, P472, DOI 10.1016/j.rmed.2012.11.006; Muller L, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-16; Muller L, 2013, AM J PHYSIOL-LUNG C, V304, pL332, DOI 10.1152/ajplung.00256.2012; Nielsen CH, 2010, PLANTA MED, V76, P1802, DOI 10.1055/s-0030-1250043; Noah TL, 2011, ENVIRON HEALTH PERSP, V119, P78, DOI 10.1289/ehp.1002258; Noah TL, 2014, PLOS ONE, V9; Paich HA, 2013, OBESITY, V21, P2377, DOI 10.1002/oby.20383; Peng H, 2014, CLIN REV ALLERG IMMU, V47, P119, DOI 10.1007/s12016-013-8400-0; Pugh ND, 2008, INT IMMUNOPHARMACOL, V8, P1023, DOI 10.1016/j.intimp.2008.03.007; Pugh ND, 2015, PHYTOMEDICINE, V22, P271, DOI 10.1016/j.phymed.2014.12.006; Riedl MA, 2009, CLIN IMMUNOL, V130, P244, DOI 10.1016/j.clim.2008.10.007; Robertson MJ, 2002, J LEUKOCYTE BIOL, V71, P173; Rudenko L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087962; Singh SV, 2009, CANCER RES, V69, P2117, DOI 10.1158/0008-5472.CAN-08-3502; Thejass P, 2006, IMMUNOPHARM IMMUNOT, V28, P443, DOI 10.1080/08923970600928049; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Wu CC, 2013, MOL CARCINOGEN, V52, P946, DOI 10.1002/mc.21926	36	28	29	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2016	11	1							e0147742	10.1371/journal.pone.0147742	http://dx.doi.org/10.1371/journal.pone.0147742			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9GF	26820305	Green Submitted, Green Published, gold			2023-01-03	WOS:000369528400040
J	Stadlbauer, V; Haselgrubler, R; Lanzerstorfer, P; Plochberger, B; Borgmann, D; Jacak, J; Winkler, SM; Schroder, K; Hoglinger, O; Weghuber, J				Stadlbauer, Verena; Haselgruebler, Renate; Lanzerstorfer, Peter; Plochberger, Birgit; Borgmann, Daniela; Jacak, Jaroslaw; Winkler, Stephan M.; Schroeder, Klaus; Hoeglinger, Otmar; Weghuber, Julian			Biomolecular Characterization of Putative Antidiabetic Herbal Extracts	PLOS ONE			English	Article							PORTULACA-OLERACEA L.; HYPOGLYCEMIC ACTIVITY; GLUCOSE-UPTAKE; ADIPOCYTE DIFFERENTIATION; GLUT4 TRANSLOCATION; INSULIN-RESISTANCE; MEDICINAL-PLANTS; CELL-SURFACE; PURSLANE; OBESITY	Induction of GLUT4 translocation in the absence of insulin is considered a key concept to decrease elevated blood glucose levels in diabetics. Due to the lack of pharmaceuticals that specifically increase the uptake of glucose from the blood circuit, application of natural compounds might be an alternative strategy. However, the effects and mechanisms of action remain unknown for many of those substances. For this study we investigated extracts prepared from seven different plants, which have been reported to exhibit anti-diabetic effects, for their GLUT4 translocation inducing properties. Quantitation of GLUT4 translocation was determined by total internal reflection fluorescence (TIRF) microscopy in insulin sensitive CHO-K1 cells and adipocytes. Two extracts prepared from purslane (Portulaca oleracea) and tindora (Coccinia grandis) were found to induce GLUT4 translocation, accompanied by an increase of intracellular glucose concentrations. Our results indicate that the PI3K pathway is mainly responsible for the respective translocation process. Atomic force microscopy was used to prove complete plasma membrane insertion. Furthermore, this approach suggested a compound mediated distribution of GLUT4 molecules in the plasma membrane similar to insulin stimulated conditions. Utilizing a fluorescent actin marker, TIRF measurements indicated an impact of purslane and tindora on actin remodeling as observed in insulin treated cells. Finally, in-ovo experiments suggested a significant reduction of blood glucose levels under tindora and purslane treated conditions in a living organism. In conclusion, this study confirms the anti-diabetic properties of tindora and purslane, which stimulate GLUT4 translocation in an insulin-like manner.	[Stadlbauer, Verena; Haselgruebler, Renate; Lanzerstorfer, Peter; Hoeglinger, Otmar; Weghuber, Julian] Univ Appl Sci Upper Austria, Wels, Austria; [Plochberger, Birgit; Jacak, Jaroslaw] Univ Appl Sci Upper Austria, Linz, Austria; [Borgmann, Daniela; Winkler, Stephan M.] Univ Appl Sci Upper Austria, Hagenberg, Austria; [Schroeder, Klaus] BioMed Zet Life Sci GmbH, Linz, Austria; [Plochberger, Birgit] Vienna Univ Technol, A-1040 Vienna, Austria	Technische Universitat Wien	Weghuber, J (corresponding author), Univ Appl Sci Upper Austria, Wels, Austria.	julian.weghuber@fh-wels.at	Jacak, Jarosław/AAM-9987-2021	Jacak, Jarosław/0000-0002-4989-1276; Lanzerstorfer, Peter/0000-0003-4512-7964	Austrian Research Promotion Agency (FFG) [850681]; University of Applied Sciences Upper Austria Basic Funding initiative; federal state auf Upper Austria; BioMed zet Life Science GmbH	Austrian Research Promotion Agency (FFG); University of Applied Sciences Upper Austria Basic Funding initiative; federal state auf Upper Austria; BioMed zet Life Science GmbH	This work was funded by the Austrian Research Promotion Agency (FFG; project number 850681) and University of Applied Sciences Upper Austria Basic Funding initiative (project GlucoSTAR). BioMed zet Life Science GmbH is funded by the federal state auf Upper Austria. BioMed zet Life Science GmbH provided support in the form of salaries for author KS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the author contributions section.	Almqvist N, 2004, BIOPHYS J, V86, P1753, DOI 10.1016/S0006-3495(04)74243-5; Bouderba S, 2014, J DIABETES, V6, P184, DOI 10.1111/1753-0407.12083; Bunkrongcheap R, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-88; Chen Y, 2012, J CELL BIOL, V198, P545, DOI 10.1083/jcb.201111091; Creager MA, 2003, CIRCULATION, V108, P1527, DOI 10.1161/01.CIR.0000091257.27563.32; de Souza CJ, 2001, DIABETES, V50, P1863, DOI 10.2337/diabetes.50.8.1863; El-Sayed MIK, 2011, J ETHNOPHARMACOL, V137, P643, DOI 10.1016/j.jep.2011.06.020; Esmaillzadeh A, 2015, J RES MED SCI, V20, P47; Gu JF, 2015, J ETHNOPHARMACOL, V161, P214, DOI 10.1016/j.jep.2014.12.002; He YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110711; Heyman L, 2014, J NUTR METAB, V2014, DOI 10.1155/2014/403041; Huyen VTT, 2013, J NUTR METAB, V2013, DOI 10.1155/2013/765383; Jacak J, 2015, MICROSC MICROANAL, V21, P826, DOI 10.1017/S1431927615013513; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Jung CH, 2015, NUTRIENTS, V7, P4851, DOI 10.3390/nu7064851; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kar A, 2003, J ETHNOPHARMACOL, V84, P105, DOI 10.1016/S0378-8741(02)00144-7; Kroll DJ, 2007, INTEGR CANCER THER, V6, P110, DOI 10.1177/1534735407301825; Lanzerstorfer P, 2015, FEBS J, V282, P987, DOI 10.1111/febs.13213; Lanzerstorfer P, 2014, BRIT J PHARMACOL, V171, P5237, DOI 10.1111/bph.12845; Lee AS, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/741824; Lee JO, 2015, J CELL BIOCHEM, V116, P1401, DOI 10.1002/jcb.25100; Li YM, 2012, PLANTA MED, V78, P1549, DOI 10.1055/s-0032-1315041; Lim Chun-Yan, 2014, Bioarchitecture, V4, P210, DOI 10.1080/19490992.2015.1031949; Liu LX, 2000, J CHROMATOGR A, V893, P207, DOI 10.1016/S0021-9673(00)00747-0; Lokman EF, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/120572; Lopez JA, 2009, MOL BIOL CELL, V20, P3918, DOI 10.1091/mbc.E09-03-0187; Megalli S, 2006, J PHARM PHARM SCI, V9, P281; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mozaffari-Khosravi H, 2014, COMPLEMENT THER MED, V22, P9, DOI 10.1016/j.ctim.2013.12.017; Munasinghe MAAK, 2011, EXP DIABETES RES, DOI 10.1155/2011/978762; Naowaboot J, 2012, AM J CHINESE MED, V40, P163, DOI 10.1142/S0192415X12500139; Norberg A, 2004, J BIOL CHEM, V279, P41361, DOI 10.1074/jbc.M403435200; OMARAALWALA TR, 1991, J AM OIL CHEM SOC, V68, P198, DOI 10.1007/BF02657769; Patel D. K., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P320, DOI 10.1016/S2221-1691(12)60032-X; Prabhakar PK, 2011, THER ADV ENDOCRINOL, V2, P103, DOI 10.1177/2042018811411356; Purintrapiban J, 2006, BIOL PHARM BULL, V29, P1995, DOI 10.1248/bpb.29.1995; Qin ZY, 2012, J BIOENERG BIOMEMBR, V44, P579, DOI 10.1007/s10863-012-9460-1; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; SHIBIB BA, 1993, BIOCHEM J, V292, P267, DOI 10.1042/bj2920267; SIMOPOULOS AP, 1992, J AM COLL NUTR, V11, P374; Smyth S, 2006, NAT MED, V12, P75, DOI 10.1038/nm0106-75; Stefanut MN, 2013, PLANT FOOD HUM NUTR, V68, P378, DOI 10.1007/s11130-013-0380-y; Stenkula KG, 2010, CELL METAB, V12, P250, DOI 10.1016/j.cmet.2010.08.005; Stockli J, 2011, J CELL SCI, V124, P4147, DOI 10.1242/jcs.097063; Turmelle YP, 2006, FASEB J, V20, P2609, DOI 10.1096/fj.06-6511fje; Ueda M, 2010, FOOD FUNCT, V1, P167, DOI 10.1039/c0fo00105h; Vijayakumar MV, 2010, J BIOSCIENCES, V35, P525, DOI 10.1007/s12038-010-0060-0; Vijayakumar MV, 2005, BRIT J PHARMACOL, V146, P41, DOI 10.1038/sj.bjp.0706312; Weghuber J, 2011, BBA-BIOMEMBRANES, V1808, P2581, DOI 10.1016/j.bbamem.2011.06.007; Yoshiyama Y, 2005, BIOL PHARM BULL, V28, P1986, DOI 10.1248/bpb.28.1986; Zhan TZ, 2011, J CELL BIOCHEM, V112, P849, DOI 10.1002/jcb.22984; Zhang Z, 1993, J SHANXI U NATURAL S, V16, P307; Zidan Y, 2014, PHYTOMEDICINE, V21, P1504, DOI 10.1016/j.phymed.2014.07.010	55	14	15	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2016	11	1							e0148109	10.1371/journal.pone.0148109	http://dx.doi.org/10.1371/journal.pone.0148109			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9GF	26820984	Green Submitted, gold, Green Published			2023-01-03	WOS:000369528400067
J	Johnson, MJ; Allgar, V; Macleod, U; Jones, A; Oliver, S; Currow, D				Johnson, Miriam J.; Allgar, Victoria; Macleod, Una; Jones, Annie; Oliver, Steven; Currow, David			Family Caregivers Who Would Be Unwilling to Provide Care at the End of Life Again: Findings from the Health Survey for England Population Survey	PLOS ONE			English	Article							PALLIATIVE CARE; HEART-FAILURE; SERVICES; DEATH; PROFESSIONALS; MORTALITY; OUTCOMES; PEOPLE; TRENDS	Background Family caregivers provide significant care at the end of life. We aimed to describe caregiver characteristics, and of those unwilling to repeat this role under the same circumstances. Methods Observational study of adults in private households (Health Survey for England [HSE]). Caregiving questions included: whether someone close to them died within past 5 years; relationship to the deceased; provision, intensity and duration of care; supportive/palliative care services used; willingness to care again; able to carry on with life. Comparison between those willing to care again or not used univariable analyses and an exploratory multiple logistic regression. A descriptive comparison with Health Omnibus Survey (Australia) data was conducted. Findings HSE response was 64%. 2167/8861 (25%) respondents had someone close to them die in the previous 5 years. Some level of personal care was provided by 645/8861 (7.3%). 57/632 (9%) former caregivers would be unwilling to provide care again irrespective of time since the death, duration of care, education and income. Younger age (<= 65; odds ratio [OR] 2.79; 95% CI 136, 5.74) and use of palliative care services (odds ratio: 1.95, 95% CI: 1.09, 3.48) showed greater willingness to provide care again. Apart from use of palliative care services, findings were remarkably similar to the Australian data. Conclusions A significant group of caregivers would be unwilling to provide care again. Older people and those who had not used palliative care services were more likely to be unwilling to care again. Barriers preventing access for disadvantaged groups need to be overcome.	[Johnson, Miriam J.; Macleod, Una; Jones, Annie] Univ Hull, Hull York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England; [Allgar, Victoria; Oliver, Steven] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England; [Currow, David] Flinders Univ S Australia, Discipline Palliat & Support Serv, Adelaide, SA 5001, Australia	University of Hull; University of York - UK; University of Hull; University of York - UK; Flinders University South Australia	Johnson, MJ (corresponding author), Univ Hull, Hull York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England.	miriam.johnson@hyms.ac.uk		Allgar, Victoria/0000-0002-5228-2623; Currow, David/0000-0003-1988-1250; Johnson, Miriam/0000-0001-6204-9158	North East Yorkshire, North Lincolnshire (NEYNL) Local Clinical Research Network	North East Yorkshire, North Lincolnshire (NEYNL) Local Clinical Research Network	The work was funded by palliative care speciality group lead (MJ) general support funding provided by the North East Yorkshire, North Lincolnshire (NEYNL) Local Clinical Research Network who were independent of the study and the funding unrelated to the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abernethy A, 2009, PALLIATIVE MED, V23, P66, DOI 10.1177/0269216308098793; Abernethy AP, 2008, SUPPORT CARE CANCER, V16, P585, DOI 10.1007/s00520-007-0342-8; Ahmed N, 2004, PALLIATIVE MED, V18, P525, DOI 10.1191/0269216304pm921oa; [Anonymous], 2015, MDS FULL REP YEAR 20; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Boodhna G, 2014, METHODS DOCUMENTATIO, V2; Boyd KJ, 2009, PALLIATIVE MED, V23, P767, DOI 10.1177/0269216309346541; Buckner L, 2011, VALUING CARERS 2011; Burns CM, 2013, PALLIATIVE MED, V27, P608, DOI 10.1177/0269216313483664; Candy B, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007617.pub2; Cantwell P, 2000, J PALLIATIVE CARE, V16, P23, DOI 10.1177/082585970001600105; Carers UK tvoc, 2012, FACTS CAR 2012; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Currow DC, 2011, J PAIN SYMPTOM MANAG, V41, P661, DOI 10.1016/j.jpainsymman.2010.06.017; Davidson PM, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-342; Department of Health, 2008, CAR HEART 21 CENT FA; Funk L, 2010, PALLIATIVE MED, V24, P594, DOI 10.1177/0269216310371411; Gadoud A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113188; Gelfman LP, 2014, J PALLIAT MED, V17, P753, DOI 10.1089/jpm.2013.0675; Gomes B, 2008, PALLIATIVE MED, V22, P33, DOI 10.1177/0269216307084606; Gomes B, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007760.pub2, 10.1590/1516-3180.20161341T2]; Gomes B, 2012, PALLIATIVE MED, V26, P102, DOI 10.1177/0269216311432329; Grande G, 2009, PALLIATIVE MED, V23, P339, DOI 10.1177/0269216309104875; Grande G, 2008, PALLIATIVE MED, V22, P971, DOI 10.1177/0269216308098805; Grande GE, 2006, AGE AGEING, V35, P267, DOI 10.1093/ageing/afj071; Hauser JM, 2004, CLIN GERIATR MED, V20, P671, DOI 10.1016/j.cger.2004.07.003; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Hudson PL, 2010, PALLIATIVE MED, V24, P656, DOI 10.1177/0269216310373167; Morris SM, 2015, PALLIATIVE MED, V29, P487, DOI 10.1177/0269216314565706; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; National Institute of Cancer Research, 2010, RAP REV RES SURV CAN; NHS The Information Centre for Health and Social Care, 2010, SURV CAR HOUSEH 2009; Office for National Statistics, 2014, STAT B; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Pinnock Hilary, 2011, BMJ Support Palliat Care, V1, P174, DOI 10.1136/bmjspcare.d142rep; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Schulz R, 2008, GERIATRICS, V63, P20; Seaman JB, 2014, AM J HOSP PALLIAT CA; Simpson B, 2010, DOH CARERS PERSONALI; Stajduhar KI, 2010, PALLIATIVE MED, V24, P573, DOI 10.1177/0269216310371412; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476	41	13	13	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0146960	10.1371/journal.pone.0146960	http://dx.doi.org/10.1371/journal.pone.0146960			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26809029	Green Published, gold, Green Accepted			2023-01-03	WOS:000369527800041
J	Iglehart, JK				Iglehart, John K.			Future of Long-Term Care and the Expanding Role of Medicaid Managed Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SERVICES											[Anonymous], 2011, COMMUNICATION; [Anonymous], 1991, NAT LONG TERM CAR CH; Barry C, 2015, EARLY INSIGHTS ONE C; Bernstein N., 2014, NY TIMES, pA1; Bipartisan Policy Center, 2014, AM LONG TERM CAR CRI; Butler L, 2013, COMMISSION LONG TERM; Congressional Budget Office, 2013, RIS DEM LONG TERM SE; Department of Health and Human Services, 2011, REP ACT MARK LEG AN; Eiken S, 2015, MED EXPENDITURES LON; Eiken S, 2013, J AGING SOC POLICY, V25, P134, DOI 10.1080/08959420.2013.766054; Favreault MM, 2015, HEALTH AFFAIR, V34, P2181, DOI 10.1377/hlthaff.2015.1226; FEDER J, 2014, ST LOUIS U J HLTH LA, V8, P47; Frank RG, 2013, MAKING PROGR EXPADIN; Genworth Financial Inc., 2015, GENW 2015 COST CAR S; Goldberg L, 2013, SOCIAL INSURANCE CRI; Kemper P, 2005, INQUIRY-J HEALTH CAR, V42, P335, DOI 10.5034/inquiryjrnl_42.4.335; Medicaid and CHIP Payment and Access Commission, 2014, C MED CHIP WASH DC M; Ng T., 2014, MED HOME COMMUNITY B; OShaughnessy Carol, 2014, BASICS NATL SPENDING; Pear R, 2015, NY TIMES, pA14; Reaves E., 2015, MED LONG TERM CARE S MED LONG TERM CARE S; Redfoot D., 2013, AGING BABY BOOM GROW; Reinhard S, 2015, AARP            0716; Reinhard SC, 2014, RAISING EXPECTATIONS; Social Security and Medicare Boards of Trustees, SUMM 2015 ANN REP; Stevenson DG, 2008, NEW ENGL J MED, V358, P1985, DOI 10.1056/NEJMp0802347; Stevenson DG, 2010, HEALTH AFFAIR, V29, P96, DOI 10.1377/hlthaff.2009.0920; Stone RI, 2015, FAMILY CAREGIVING NE, P57, DOI DOI 10.1016/B978-0-12-417046-9.00006-4; The Associated Press-NORC Center for Public Affairs Research, 2015, REP LONG TERM CAR AM; Weil AR, 2015, HEALTH AFFAIR, V34, P2015, DOI 10.1377/hlthaff.2015.1450	30	4	4	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 14	2016	374	2					182	187		10.1056/NEJMhpr1510026	http://dx.doi.org/10.1056/NEJMhpr1510026			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DA7PQ	26760091				2023-01-03	WOS:000367996700017
J	Gustafson, CT; Boakye-Agyeman, F; Brinkman, CL; Reid, JM; Patel, R; Bajzer, Z; Dadsetan, M; Yaszemski, MJ				Gustafson, Carl T.; Boakye-Agyeman, Felix; Brinkman, Cassandra L.; Reid, Joel M.; Patel, Robin; Bajzer, Zeljko; Dadsetan, Mahrokh; Yaszemski, Michael J.			Controlled Delivery of Vancomycin via Charged Hydrogels	PLOS ONE			English	Article							SURGICAL-SITE INFECTION; CONTROLLED-RELEASE; IN-VITRO; RESISTANCE; SUSCEPTIBILITY; MECHANISMS; DIAGNOSIS; SYSTEM	Surgical site infection (SSI) remains a significant risk for any clean orthopedic surgical procedure. Complications resulting from an SSI often require a second surgery and lengthen patient recovery time. The efficacy of antimicrobial agents delivered to combat SSI is diminished by systemic toxicity, bacterial resistance, and patient compliance to dosing schedules. We submit that development of localized, controlled release formulations for antimicrobial compounds would improve the effectiveness of prophylactic surgical wound antibiotic treatment while decreasing systemic side effects. Our research group developed and characterized oligo(poly(ethylene glycol) fumarate) / sodium methacrylate (OPF/SMA) charged copolymers as biocompatible hydrogel matrices. Here, we report the engineering of this copolymer for use as an antibiotic delivery vehicle in surgical applications. We demonstrate that these hydrogels can be efficiently loaded with vancomycin (over 500 mu g drug per mg hydrogel) and this loading mechanism is both time-and charge-dependent. Vancomycin release kinetics are shown to be dependent on copolymer negative charge. In the first 6 hours, we achieved as low as 33.7% release. In the first 24 hours, under 80% of total loaded drug was released. Further, vancomycin release from this system can be extended past four days. Finally, we show that the antimicrobial activity of released vancomycin is equivalent to stock vancomycin in inhibiting the growth of colonies of a clinically derived strain of methicillin-resistant Staphylococcus aureus. In summary, our work demonstrates that OPF/SMA hydrogels are appropriate candidates to deliver local antibiotic therapy for prophylaxis of surgical site infection.	[Gustafson, Carl T.; Reid, Joel M.; Yaszemski, Michael J.] Mayo Clin, Coll Med, Mayo Grad Sch, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55902 USA; [Boakye-Agyeman, Felix] Duke Clin Res Inst, Pharmacometr Ctr, Durham, NC 27705 USA; [Brinkman, Cassandra L.; Patel, Robin] Mayo Clin, Infect Dis Res Lab, Dept Lab Med & Pathol, Div Clin Microbiol, Rochester, MN 55902 USA; [Bajzer, Zeljko] Mayo Clin, Coll Med, Div Biomath, Dept Biochem & Mol Biol, Rochester, MN 55902 USA; [Bajzer, Zeljko] Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, Div Biomath, Rochester, MN 55902 USA; [Dadsetan, Mahrokh; Yaszemski, Michael J.] Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, Div Orthopaed Res, Rochester, MN 55902 USA	Mayo Clinic; Duke University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Gustafson, CT (corresponding author), Mayo Clin, Coll Med, Mayo Grad Sch, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55902 USA.	Gustafson.carl@mayo.edu			Orthopedic Surgery and Biomedical Engineering; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056647, T32AR056950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM072474] Funding Source: NIH RePORTER	Orthopedic Surgery and Biomedical Engineering; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funding for this work was provided by The John and Posy Krehbiel Endowed Professorship of Orthopedic Surgery and Biomedical Engineering. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson DJ, 2014, INFECT CONT HOSP EP, V35, P605, DOI [10.1086/676022, 10.1017/S0899823X00193869]; Bakhsheshian J, 2015, WORLD NEUROSURG, V83, P816, DOI 10.1016/j.wneu.2014.12.033; Boyanova L, 2015, ANAEROBE, V31, P4, DOI 10.1016/j.anaerobe.2014.05.004; Brooks BD, 2014, ADV DRUG DELIVER REV, V78, P14, DOI 10.1016/j.addr.2014.10.027; Cavallaro A, 2014, BIOINTERPHASES, V9, DOI 10.1116/1.4866697; Costerton JW, 2005, CLIN ORTHOP RELAT R, P7, DOI 10.1097/01.blo.0000175128.44966.d9; Dadsetan M, 2013, ACTA BIOMATER, V9, P5438, DOI 10.1016/j.actbio.2012.09.019; Dadsetan M, 2010, BIOMATERIALS, V31, P8051, DOI 10.1016/j.biomaterials.2010.06.054; Dadsetan M, 2009, BIOMATERIALS, V30, P3874, DOI 10.1016/j.biomaterials.2009.04.018; Daly WT, 2013, BIOMATERIALS, V34, P8630, DOI 10.1016/j.biomaterials.2013.07.086; Dhawan S, 2002, PEPTIDES, V23, P2099, DOI 10.1016/S0196-9781(02)00253-X; Esposito S, 2008, INT J ANTIMICROB AG, V32, P287, DOI 10.1016/j.ijantimicag.2008.03.010; Fish R, 2012, PERITON DIALYSIS INT, V32, P332, DOI 10.3747/pdi.2010.00294; Gardete S, 2014, J CLIN INVEST, V124, P2836, DOI 10.1172/JCI68834; Golden AL, 2010, BIOCONJUGATE CHEM, V21, P1820, DOI 10.1021/bc100169y; Hamada Y, 2015, J ANTIMICROB CHEMOTH, V70, P2064, DOI 10.1093/jac/dkv074; Hetrick EM, 2006, CHEM SOC REV, V35, P780, DOI 10.1039/b515219b; Hill BW, 2014, ACTA NEUROCHIR, V156, P749, DOI 10.1007/s00701-014-2022-z; Howden BP, 2010, CLIN MICROBIOL REV, V23, P99, DOI 10.1128/CMR.00042-09; Joglekar M, 2013, BIOTECHNOL J, V8, P931, DOI 10.1002/biot.201300073; Kazanowski M, 2014, TECH COLOPROCTOL, V18, P223, DOI 10.1007/s10151-013-1081-0; Khan NR, 2014, J NEUROSURG-SPINE, V21, P974, DOI 10.3171/2014.8.SPINE1445; Kinard LA, 2012, NAT PROTOC, V7, P1219, DOI 10.1038/nprot.2012.055; Koppula S, 2015, AM J MED SCI, V349, P137, DOI 10.1097/MAJ.0000000000000368; Koyamatsu Y, 2014, J CONTROL RELEASE, V173, P89, DOI 10.1016/j.jconrel.2013.10.035; Kurtz SM, 2012, J ARTHROPLASTY, V27, P61, DOI 10.1016/j.arth.2012.02.022; Lakes AL, 2014, BIOMACROMOLECULES, V15, P3009, DOI 10.1021/bm5006323; Laxminarayan R, 2014, SCIENCE, V345, P1299, DOI 10.1126/science.1254163; Leone S, 2010, INT J INFECT DIS, V14, pS67, DOI 10.1016/j.ijid.2010.05.005; Lodise TP, 2011, ANTIMICROB AGENTS CH, V55, P5507, DOI 10.1128/AAC.00712-11; Nakayama M, 2014, J DRUG TARGET, V22, P584, DOI 10.3109/1061186X.2014.936872; Noren T, 2010, CLIN MICROBIOL INFEC, V16, P1104, DOI 10.1111/j.1469-0691.2009.03048.x; Overstreet D, 2015, CLIN ORTHOP RELAT R, V473, P337, DOI 10.1007/s11999-014-3935-9; Press WH, 2007, NUMERICAL RECIPES AR, Vxxi; Rineh A, 2014, EXPERT REV ANTI-INFE, V12, P131, DOI 10.1586/14787210.2014.866515; Rubinstein E, 2014, FRONT PUBLIC HLTH, V2, P217, DOI DOI 10.3389/FPUBH.2014.00217; Runge MB, 2010, BIOMACROMOLECULES, V11, P2845, DOI 10.1021/bm100526a; SANDERS WE, 1979, ANNU REV PHARMACOL, V19, P53, DOI 10.1146/annurev.pa.19.040179.000413; Seltman Ann K, 2012, Clin Colon Rectal Surg, V25, P204, DOI 10.1055/s-0032-1329390; Sievert DM, 2013, INFECT CONT HOSP EP, V34, P1, DOI 10.1086/668770; Soontornworajit B, 2011, BIOMATERIALS, V32, P6839, DOI 10.1016/j.biomaterials.2011.05.074; STAYTON PS, 1995, NATURE, V378, P472, DOI 10.1038/378472a0; Strom RG, 2013, CLIN NEUROL NEUROSUR, V115, P1766, DOI 10.1016/j.clineuro.2013.04.005; Tian HY, 2014, J CONTROL RELEASE, V174, P117, DOI 10.1016/j.jconrel.2013.11.008; Trouche E, 2010, CELL TRANSPLANT, V19, P1623, DOI 10.3727/096368910X514297; van Dishoeck AM, 2013, BRIT J SURG, V100, P628, DOI 10.1002/bjs.9039; Venkatesh MP, 2013, CURR DRUG DELIV, V10, P188, DOI 10.2174/1567201811310020005; Wang SF, 2006, BIOMATERIALS, V27, P832, DOI 10.1016/j.biomaterials.2005.07.013; Zhang XL, 2012, BIOMACROMOLECULES, V13, P2202, DOI 10.1021/bm3006227; Zhou X, 2010, J AM CHEM SOC, V132, P4161, DOI 10.1021/ja9081827; Zimmerli W, 2004, NEW ENGL J MED, V351, P1645, DOI 10.1056/NEJMra040181	51	45	46	2	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2016	11	1							e0146401	10.1371/journal.pone.0146401	http://dx.doi.org/10.1371/journal.pone.0146401			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA8CX	26760034	Green Published, gold, Green Submitted			2023-01-03	WOS:000368033100032
J	Jueng, RN; Tsai, DC; Chen, IJ				Jueng, Ruo-Nan; Tsai, Der-Chong; Chen, I-Ju			Sense of Coherence among Older Adult Residents of Long-Term Care Facilities in Taiwan: A Cross-Sectional Analysis	PLOS ONE			English	Article							NURSING-HOME RESIDENTS; QUALITY-OF-LIFE; COGNITIVE IMPAIRMENT; ANTONOVSKYS SENSE; MENTAL-HEALTH; FOLLOW-UP; SCALE; SELF; EXPERIENCES; EDUCATION	Background Growing evidence shows that sense of coherence (SOC) is related to health promotion. Knowledge of SOC among older adults in Taiwan is limited. The present study aimed to investigate SOC status and its relationship to personal and environmental factors among older adult residents of long-term care facilities (LTCFs) in northeastern Taiwan. Methods This cross-sectional study was performed in Yilan, Taiwan. With face-to-face interviews, we obtained data from 104 LTCF residents (aged 65 years and older) using the Chinese version of Antonovsky's short 13-item SOC scale. We also collected the information on personal characteristics, physical and social environmental resources. Multiple linear regression was used to analyze factors potentially influencing SOC. Results Of the participants, the mean score (+/- standard deviation) of SOC was 58.3 (+/- 8.8), while scores on SOC subscales (comprehensibility, manageability, and meaningfulness) were 23.4 +/- 4.5, 17.9 +/- 3.8, and 17.0 +/- 3.2, respectively. Education level, activities of daily living and number of LTCF staff were found to be independently associated with SOC status after adjusting for demographic characteristics, health status, and environmental resources. In addition, interactions between personal and environmental factors had a crucial influence on SOC status. Conclusions Participants in this study had relatively low SOC scores compared to their counterparts in Western countries. In addition to personal factors, environmental factors can play a significant role in SOC status among older adult LTCF residents. Comprehensive evaluation of SOC status should consider person-environment interaction effects.	[Jueng, Ruo-Nan; Chen, I-Ju] Natl Yang Ming Univ, Inst & Dept Nursing, Taipei 112, Taiwan; [Jueng, Ruo-Nan] Natl Yang Ming Univ Hosp, Dept Nursing, Yilan, Taiwan; [Tsai, Der-Chong] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Tsai, Der-Chong] Natl Yang Ming Univ Hosp, Dept Ophthalmol, Yilan, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chen, IJ (corresponding author), Natl Yang Ming Univ, Inst & Dept Nursing, Taipei 112, Taiwan.	ijchen@ym.edu.tw			National Yang-Ming University Hospital [2010B045]	National Yang-Ming University Hospital	This work was supported by the National Yang-Ming University Hospital under Grant 2010B045. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Antonovsky, 1987, UNRAVELING MYSTERY H; ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Antonovsky A, 1996, HEALTH PROMOT INT, V11, P11, DOI 10.1093/heapro/11.1.11; Antonovsky A., 1979, HLTH STRESS COPING N; Borglin G, 2006, HEALTH SOC CARE COMM, V14, P136, DOI 10.1111/j.1365-2524.2006.00603.x; Calkins M.P., 2003, J HOUS ELDER, V17, P67, DOI [10.1300/J081v17n01_06, DOI 10.1300/J081V17N01_06]; Chang EC, 2003, J PERS SOC PSYCHOL, V84, P569, DOI 10.1037/0022-3514.84.3.569; Cole CS, 2007, J HOLIST NURS, V25, P96, DOI 10.1177/0898010106295187; Drageset J, 2014, AGING MENT HEALTH, V18, P889, DOI 10.1080/13607863.2014.896866; Drageset J, 2012, J CLIN NURS, V21, P965, DOI 10.1111/j.1365-2702.2011.03932.x; Drageset J, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-85; Eriksson M, 2005, J EPIDEMIOL COMMUN H, V59, P460, DOI 10.1136/jech.2003.018085; Eriksson M, 2006, J EPIDEMIOL COMMUN H, V60, P376, DOI 10.1136/jech.2005.041616; Eriksson M, 2008, HEALTH PROMOT INT, V23, P190, DOI 10.1093/heapro/dan014; Giglio RE, 2015, INT PSYCHOGERIATR, V27, P621, DOI 10.1017/S1041610214002440; Helvik AS, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-82; Hill EE, 2009, RES GERONTOL NURS, V2, P287, DOI 10.3928/19404921-20090527-02; Hwang HL, 2013, SCAND J CARING SCI, V27, P695, DOI 10.1111/j.1471-6712.2012.01082.x; Lawton M.P., 1982, AGING ENV, P33; Lee DTF, 2002, J ADV NURS, V37, P19, DOI 10.1046/j.1365-2648.2002.02060.x; Lindstrom B, 2005, J EPIDEMIOL COMMUN H, V59, P440, DOI 10.1136/jech.2005.034777; Lovheim H, 2013, SCAND J CARING SCI, V27, P13, DOI 10.1111/j.1471-6712.2012.00988.x; Meeks S, 2001, J AGING HEALTH, V13, P92, DOI 10.1177/089826430101300105; Ministry of Health and Welfare, EST STAND SEN CIT WE; Murrell SA, 2002, J AGING HEALTH, V14, P527, DOI 10.1177/089826402237182; Naaldenberg J, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-37; Nilsson B, 2000, SCAND J PRIM HEALTH, V18, P14; Nygren B, 2005, AGING MENT HEALTH, V9, P354, DOI 10.1080/1360500114415; Posadzki P, 2010, SCAND J PSYCHOL, V51, P246, DOI 10.1111/j.1467-9450.2009.00764.x; Shiu ATY, 2004, INT J NURS STUD, V41, P387, DOI 10.1016/j.ijnurstu.2003.10.010; Soderhamn Olle, 2010, Br J Community Nurs, V15, P376; Tang Siew Tzuh, 2002, J Nurs Meas, V10, P59, DOI 10.1891/jnum.10.1.59.52544; Thygesen E, 2009, INT J OLDER PEOPLE N, V4, P12, DOI 10.1111/j.1748-3743.2008.00132.x; Thygesen E, 2009, AGING MENT HEALTH, V13, P319, DOI 10.1080/13607860802534591; Tsuno YS, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1107; Wang Chia-Hui, 2006, J Nurs Res, V14, P123; Wiesmann U, 2008, AGING MENT HEALTH, V12, P56, DOI 10.1080/13607860701365998; Wiesmann U, 2009, BRIT J HEALTH PSYCH, V14, P767, DOI 10.1348/135910709X413124; Xu DJ, 2013, ARCH GERONTOL GERIAT, V57, P127, DOI 10.1016/j.archger.2013.03.015; Young HM, 2006, GERIATR NURS, V27, P346, DOI 10.1016/j.gerinurse.2006.08.014	41	6	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2016	11	1							e0146912	10.1371/journal.pone.0146912	http://dx.doi.org/10.1371/journal.pone.0146912			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DA6CA	26751949	Green Published, gold, Green Submitted			2023-01-03	WOS:000367888100179
J	Lv, HQ; Zhang, ZM; Wu, XY; Wang, YX; Li, CL; Gong, WH; Gui, L; Wang, X				Lv, Huiqing; Zhang, Zhongmin; Wu, Xiaoyu; Wang, Yaoxia; Li, Chenglin; Gong, Weihong; Gui, Liang; Wang, Xin			Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent	PLOS ONE			English	Article							INDUCED APOPTOSIS; IN-VITRO; CANCER; INHIBITION; ACTIVATION; EXPRESSION; PERIFOSINE; MELANOMA; PATHWAY; GROWTH	Hepatocellular carcinoma (HCC) remains a global health threat. The search for novel anti-HCC agents is urgent. In the current study, we synthesized a liposomal C8 ceramide, and analyzed its anti-tumor activity in pre-clinical HCC models. The liposomal C8 (ceramide) potently inhibited HCC cell (HepG2, SMMC-7721 and Huh-7 lines) survival and proliferation, more efficiently than free C8 ceramide. Yet, non-cancerous HL7702 human hepatocytes were resistant to the liposomal C8 treatment. Liposomal C8 activated caspase-dependent apoptosis in HCC cells, and HCC cytotoxicity by liposomal C8 was significantly attenuated with co-treatment of caspase inhibitors. At the molecular level, we showed that liposomal C8 activated ASK1 (apoptosis signal-regulating kinase 1)-JNK (Jun N-terminal protein kinase) signaling in HCC cells. On the other hand, JNK pharmacological inhibition or dominant negative mutation, as well as ASK1 shRNA-knockdown remarkably inhibited liposomal C8-induced apoptosis in HCC cells. Further studies showed that liposomal C8 inhibited AKT-mTOR (mammalian target of rapamycin) activation in HCC cells. Restoring AKT-mTOR activation by introducing a constitutively-active AKT alleviated HepG2 cytotoxicity by liposomal C8. In vivo, intravenous (i.v.) injection of liposomal C8 significantly inhibited HepG2 xenograft growth in severe combined immuno-deficient (SCID) mice, and mice survival was significantly improved. These preclinical results suggest that liposomal C8 could be further studied as a valuable anti-HCC agent.	[Lv, Huiqing] Lin Yi Peoples Hosp, Dept Hyperbar Oxygen, Lin Yi, Peoples R China; [Zhang, Zhongmin; Wang, Yaoxia; Li, Chenglin; Gong, Weihong; Wang, Xin] Lin Yi Peoples Hosp, Dept Oncol, Lin Yi, Peoples R China; [Wu, Xiaoyu; Gui, Liang] Nanjing Med Univ, Affiliated Hosp, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University	Gui, L (corresponding author), Nanjing Med Univ, Affiliated Hosp, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China.	drguiliangnhc12@163.com; drwangxinlinyi8@163.com	wu, xiaoyu/HIK-3475-2022		National science foundation of China [81373990]	National science foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by National science foundation of China (81373990). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Averous J, 2008, ONCOGENE, V27, P1106, DOI 10.1038/sj.onc.1210715; Chen MB, 2015, CARCINOGENESIS, V36, P1061, DOI 10.1093/carcin/bgv094; Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026; Dimanche-Boitrel MT, 2011, RECENT PAT ANTI-CANC, V6, P284, DOI 10.2174/157489211796957838; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Gomez-Pinillos A, 2012, HEMATOL ONCOL CLIN N, V26, P483, DOI 10.1016/j.hoc.2012.02.014; Henry B., 2011, CANC LETT; Ji C, 2012, CELL SIGNAL, V24, P1781, DOI 10.1016/j.cellsig.2012.05.003; Kester M, 2015, BIOL CHEM, V396, P737, DOI 10.1515/hsz-2015-0129; Lin CF, 2006, CURR MED CHEM, V13, P1609, DOI 10.2174/092986706777441986; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Morales A, 2012, ANTI-CANCER AGENT ME, V12, P364, DOI 10.2174/187152012800228689; Mullen TD, 2012, ANTI-CANCER AGENT ME, V12, P340, DOI 10.2174/187152012800228661; Radin NS, 2003, BIOCHEM J, V371, P243, DOI 10.1042/BJ20021878; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Singh S, 2014, NAT REV GASTRO HEPAT, V11, P45, DOI 10.1038/nrgastro.2013.143; Stover TC, 2005, CLIN CANCER RES, V11, P3465, DOI 10.1158/1078-0432.CCR-04-1770; Sun H, 2011, CANCER LETT, V310, P118, DOI 10.1016/j.canlet.2011.06.010; Tagaram HRS, 2011, GUT, V60, P695, DOI 10.1136/gut.2010.216671; Tanaka S, 2012, SEMIN ONCOL, V39, P486, DOI 10.1053/j.seminoncol.2012.05.005; Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200; Tran MA, 2008, CLIN CANCER RES, V14, P3571, DOI 10.1158/1078-0432.CCR-07-4881; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Xavier CPR, 2013, J NUTR BIOCHEM, V24, P706, DOI 10.1016/j.jnutbio.2012.04.004; Xu D, 2013, ONCOL REP, V29, P653, DOI 10.3892/or.2012.2138; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yang L, 2015, EXP CELL RES; Yu T, 2013, BIOCHEM BIOPH RES CO, V441, P53, DOI 10.1016/j.bbrc.2013.10.008; Zheng QY, 2012, BIOCH BIOPHYS RES CO; Zolnik BS, 2008, DRUG METAB DISPOS, V36, P1709, DOI 10.1124/dmd.107.019679	30	13	13	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2016	11	1							e0145195	10.1371/journal.pone.0145195	http://dx.doi.org/10.1371/journal.pone.0145195			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA3FF	26727592	Green Submitted, Green Published, gold			2023-01-03	WOS:000367681500011
J	Burtin, C; Langer, D; van Remoortel, H; Demeyer, H; Gosselink, R; Decramer, M; Dobbels, F; Janssens, W; Troosters, T				Burtin, Chris; Langer, Daniel; van Remoortel, Hans; Demeyer, Heleen; Gosselink, Rik; Decramer, Marc; Dobbels, Fabienne; Janssens, Wim; Troosters, Thierry			Physical Activity Counselling during Pulmonary Rehabilitation in Patients with COPD: A Randomised Controlled Trial	PLOS ONE			English	Article							LIFE; BEHAVIOR; DISEASE; HEALTH; STYLE; PEDOMETER; STEPS/DAY; EFFICACY; PROGRAM; PEOPLE	Background Pulmonary rehabilitation programs only modestly enhance daily physical activity levels in patients with chronic obstructive pulmonary disease (COPD). This randomised controlled trial investigates the additional effect of an individual activity counselling program during pulmonary rehabilitation on physical activity levels in patients with moderate to very severe COPD. Methods Eighty patients (66 +/- 7 years, 81% male, forced expiratory volume in 1 second 45 +/- 16% of predicted) referred for a six-month multidisciplinary pulmonary rehabilitation program were randomised. The intervention group was offered an additional eight-session activity counselling program. The primary outcomes were daily walking time and time spent in at least moderate intense activities. Results Baseline daily walking time was similar in the intervention and control group (median 33 [interquartile range 16-47] vs 29 [17-44]) whereas daily time spent in at least moderate intensity was somewhat higher in the intervention group (17[4-50] vs 12[2-26] min). No significant intervention*time interaction effects were observed in daily physical activity levels. In the whole group, daily walking time and time spent in at least moderate intense activities did not significantly change over time. Conclusions The present study identified no additional effect of eight individual activity counselling sessions during pulmonary rehabilitation to enhance physical activity levels in patients with COPD.	[Burtin, Chris; Langer, Daniel; van Remoortel, Hans; Demeyer, Heleen; Gosselink, Rik; Troosters, Thierry] Katholieke Univ Leuven, Fac Kinesiol & Rehabil Sci, Leuven, Belgium; [Burtin, Chris; Langer, Daniel; van Remoortel, Hans; Demeyer, Heleen; Gosselink, Rik; Decramer, Marc; Janssens, Wim; Troosters, Thierry] Katholieke Univ Leuven, Resp Rehabil & Resp Div, Univ Hosp, Leuven, Belgium; [Burtin, Chris] Hasselt Univ, Fac Med & Life Sci, Rehabil Res Ctr, Biomed Res Inst, Diepenbeek, Belgium; [Dobbels, Fabienne] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Leuven, Belgium	KU Leuven; KU Leuven; Hasselt University; KU Leuven	Troosters, T (corresponding author), Katholieke Univ Leuven, Fac Kinesiol & Rehabil Sci, Leuven, Belgium.	thierry.troosters@med.kuleuven.be	Gosselink, Rik/AAK-4655-2020; Van Remoortel, Hans/AAH-2425-2019; Langer, Daniel/B-7307-2014; burtin, chris/B-3343-2015	Langer, Daniel/0000-0001-8738-9482; Janssens, Wim/0000-0003-1830-2982; Gosselink, Rik/0000-0003-0444-8606; Dobbels, Fabienne/0000-0002-9502-7374; Demeyer, Heleen/0000-0001-8925-0564				Altenburg WA, 2015, RESP MED, V109, P112, DOI 10.1016/j.rmed.2014.10.020; Avery L, 2012, DIABETES CARE, V35, P2681, DOI 10.2337/dc11-2452; Bennett JA, 2007, NURS RES, V56, P18, DOI 10.1097/00006199-200701000-00003; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Bravata DM, 2007, JAMA-J AM MED ASSOC, V298, P2296, DOI 10.1001/jama.298.19.2296; Brodie DA, 2005, J ADV NURS, V50, P518, DOI 10.1111/j.1365-2648.2005.03422.x; Brug J, 2007, J NUTR EDUC BEHAV, V39, P8, DOI 10.1016/j.jneb.2006.08.010; Carels RA, 2007, HEALTH PSYCHOL, V26, P369, DOI 10.1037/0278-6133.26.3.369; de Blok BMJ, 2006, PATIENT EDUC COUNS, V61, P48, DOI 10.1016/j.pec.2005.02.005; Decramer M, 2005, RESP MED, V99, pS3, DOI 10.1016/j.rmed.2005.09.010; DECRAMER M, 1994, AM J RESP CRIT CARE, V150, P11, DOI 10.1164/ajrccm.150.1.8025735; Demeyer H, 2014, CHEST, V146, P318, DOI 10.1378/chest.13-1968; Doig GS, 2005, J CRIT CARE, V20, P187, DOI 10.1016/j.jcrc.2005.04.005; Garcia-Aymerich J, 2006, THORAX, V61, P772, DOI 10.1136/thx.2006.060145; Groeneveld IF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-836; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; GUYATT GH, 1984, THORAX, V39, P818, DOI 10.1136/thx.39.11.818; Hardcastle SJ, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-40; Harland J, 1999, BRIT MED J, V319, P828, DOI 10.1136/bmj.319.7213.828; Heckman CJ, 2010, TOB CONTROL, V19, P410, DOI 10.1136/tc.2009.033175; Hill K, 2015, INTERN MED J, V45, P474, DOI 10.1111/imj.12570; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Kang M, 2009, RES Q EXERCISE SPORT, V80, P131, DOI 10.1080/02701367.2009.10599546; KAPLAN RM, 1994, HEALTH PSYCHOL, V13, P366, DOI 10.1037/0278-6133.13.4.366; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; Langer D, 2009, THORAX, V64, P641, DOI 10.1136/thx.2008.112102; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Michie S, 2011, ADDICT BEHAV, V36, P315, DOI 10.1016/j.addbeh.2010.11.016; Miller William R, 2005, J Cardiopulm Rehabil, V25, P207, DOI 10.1097/00008483-200507000-00005; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; Ng LWC, 2012, CHRON RESP DIS, V9, P17, DOI 10.1177/1479972311430335; O'Halloran PD, 2014, CLIN REHABIL, V28, P1159, DOI 10.1177/0269215514536210; Patel Sanjay A, 2007, COPD, V4, P107, DOI 10.1080/15412550701246658; Pitta F, 2005, AM J RESP CRIT CARE, V171, P972, DOI 10.1164/rccm.200407-855OC; Pitta F, 2008, CHEST, V134, P273, DOI 10.1378/chest.07-2655; Puhan MA, 2008, EUR RESPIR J, V32, P637, DOI 10.1183/09031936.00140507; Puhan MA, 2011, EUR RESPIR J, V37, P784, DOI 10.1183/09031936.00063810; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Sjoling Mats, 2011, BMC Res Notes, V4, P352, DOI 10.1186/1756-0500-4-352; Smedslund G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008063.pub2; Thorpe O, 2012, J CARDIOPULM REHABIL, V32, P359, DOI 10.1097/HCR.0b013e318262d7df; Troosters T, 2005, AM J RESP CRIT CARE, V172, P19, DOI 10.1164/rccm.200408-1109SO; Troosters T, 2010, EUR RESPIR REV, V19, P24, DOI 10.1183/09059180.00007809; Troosters T, 2000, AM J MED, V109, P207, DOI 10.1016/S0002-9343(00)00472-1; Tudor-Locke C, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-80; Tudor-Locke C, 2009, PREV MED, V49, P3, DOI 10.1016/j.ypmed.2009.04.012; van Keulen HM, 2011, ANN BEHAV MED, V41, P104, DOI 10.1007/s12160-010-9231-3; Van Remoortel H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039198; Vorrink SNW, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-33; Watz H, 2014, EUR RESPIR J, V44, P1521, DOI 10.1183/09031936.00046814	50	34	34	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0144989	10.1371/journal.pone.0144989	http://dx.doi.org/10.1371/journal.pone.0144989			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CZ4SI	26697853	Green Submitted, Green Published, gold			2023-01-03	WOS:000367092600040
J	Lin, YJ; Ho, TJ; Yeh, YC; Cheng, CF; Shiao, YT; Wang, CB; Chien, WK; Chen, JH; Liu, X; Tsang, H; Lin, TH; Liao, CC; Huang, SM; Li, JP; Lin, CW; Pang, HY; Lin, JG; Lan, YC; Liu, YH; Chen, SY; Tsai, FJ; Liang, WM				Lin, Ying-Ju; Ho, Tsung-Jung; Yeh, Yi-Chun; Cheng, Chi-Fung; Shiao, Yi-Tzone; Wang, Chang-Bi; Chien, Wen-Kuei; Chen, Jin-Hua; Liu, Xiang; Tsang, Hsinyi; Lin, Ting-Hsu; Liao, Chiu-Chu; Huang, Shao-Mei; Li, Ju-Pi; Lin, Cheng-Wen; Pang, Hao-Yu; Lin, Jaung-Geng; Lan, Yu-Ching; Liu, Yu-Huei; Chen, Shih-Yin; Tsai, Fuu-Jen; Liang, Wen-Miin			Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell Contractility	PLOS ONE			English	Article							TANSHINONE IIA SULFONATE; BLOOD-PRESSURE CONTROL; SALVIANOLIC ACID B; CARDIOVASCULAR EVENTS; DOUBLE-BLIND; BREAST-CANCER; RISK; MELLITUS; THERAPY; COMPLICATIONS	Type 2 diabetes (T2D) is a chronic, multifactorial, and metabolic disorder accounting for 90% diabetes cases worldwide. Among them, almost half of T2D have hypertension, which is responsible for cardiovascular disease, morbidity, and mortality in these patients. The Chinese herbal medicine (CHM) prescription patterns of hypertension individuals among T2D patients have yet to be characterized. This study, therefore, aimed to determine their prescription patterns and evaluate the CHM effect. A cohort of one million randomly sampled cases from the National Health Insurance Research Database (NHIRD) was used to investigate the overall survival rate of CHM users, and prescription patterns. After matching CHM and non-CHM users for age, gender and date of diagnosis of hypertension, 980 subjects for each group were selected. The CHM users were characterized with slightly longer duration time from diabetes to hypertension, and more cases for hyperlipidaemia. The cumulative survival probabilities were higher in CHM users than in non-CHM users. Among these top 12 herbs, Liu-Wei-Di-Huang-Wan, Jia-Wei-Xiao-Yao-San, Dan-Shen, and Ge-Gen were the most common herbs and inhibited in vitro smooth muscle cell contractility. Our study also provides a CHM comprehensive list that may be useful in future investigation of the safety and efficacy for individuals with hypertension among type 2 diabetes patients.	[Lin, Ying-Ju; Ho, Tsung-Jung; Li, Ju-Pi; Lin, Jaung-Geng; Chen, Shih-Yin; Tsai, Fuu-Jen] China Med Univ, Sch Chinese Med, Taichung, Taiwan; [Lin, Ying-Ju; Lin, Ting-Hsu; Liao, Chiu-Chu; Huang, Shao-Mei; Liu, Yu-Huei; Chen, Shih-Yin; Tsai, Fuu-Jen] China Med Univ Hosp, Genet Ctr, Dept Med Res, Taichung, Taiwan; [Ho, Tsung-Jung] China Med Univ, Beigang Hosp, Div Chinese Med, Peikang, Yunlin, Taiwan; [Ho, Tsung-Jung] China Med Univ, Tainan Municipal An Nan Hosp, Div Chinese Med, Tainan, Taiwan; [Yeh, Yi-Chun; Cheng, Chi-Fung; Wang, Chang-Bi; Liang, Wen-Miin] China Med Univ, Grad Inst Biostat, Sch Publ Hlth, Taichung, Taiwan; [Shiao, Yi-Tzone] China Med Univ Hosp, Ctr Heart, Taichung, Taiwan; [Chien, Wen-Kuei; Chen, Jin-Hua] Taipei Med Univ, Biostat Ctr, Coll Management, Taipei, Taiwan; [Chen, Jin-Hua] Taipei Med Univ, Sch Hlth Care Adm, Coll Management, Taipei, Taiwan; [Liu, Xiang; Tsang, Hsinyi] NIAID, NIH, Bethesda, MD 20892 USA; [Li, Ju-Pi] China Med Univ Hosp, Rheumatism Res Ctr, Taichung, Taiwan; [Lin, Cheng-Wen; Pang, Hao-Yu] China Med Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan; [Lan, Yu-Ching] China Med Univ, Dept Hlth Risk Management, Taichung, Taiwan; [Liu, Yu-Huei] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Tsai, Fuu-Jen] Asia Univ, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Taipei Medical University; Taipei Medical University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan	Tsai, FJ (corresponding author), China Med Univ, Sch Chinese Med, Taichung, Taiwan.	d0704@mail.cmuh.org.tw; wmliang.cmu@gmail.com	Lan, Yu-Ching/F-2449-2017; Liu, Yu-Huei/D-2539-2014; Li, Ju-Pi/AAS-8866-2021	Lan, Yu-Ching/0000-0003-4781-6405; Liu, Yu-Huei/0000-0002-3603-868X; Li, Ju-Pi/0000-0003-3406-4865	Ministry of Science and Technology [MOST 103-2320-B-039 -006 -MY3]; China Medical University [CMU102-PH-01]; China Medical University Hospital [DMR-104-029, DMR-104-089]; China Medical University Beigang Hospital [CMUBH R103-008, CMUBH R104-007]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); China Medical University(China Medical University); China Medical University Hospital; China Medical University Beigang Hospital(China Medical University)	This study was funded by Ministry of Science and Technology (MOST 103-2320-B-039 -006 -MY3; YJL), China Medical University (CMU102-PH-01; YJL and FJT), China Medical University Hospital (DMR-104-029; FJT; DMR-104-089; YJL), and China Medical University Beigang Hospital (CMUBH R103-008; TJH; CMUBH R104-007; TJH).	Bhadriraju K, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-43; Cai HB, 2014, EXP THER MED, V8, P1127, DOI 10.3892/etm.2014.1919; Ceylan-Isik AF, 2008, CURR DIABETES REV, V4, P320, DOI 10.2174/157339908786241142; Chang CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135417; Chao TH, 2014, J ETHNOPHARMACOL, V155, P702, DOI 10.1016/j.jep.2014.06.012; Chen FP, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-26; Chen LC, 2003, MATURITAS, V44, P55, DOI 10.1016/S0378-5122(02)00314-6; Chen MJ, 2016, INT J CANCER, V138, P594, DOI 10.1002/ijc.29813; Chen YC, 2015, THER CLIN RISK MANAG, V11, P1315, DOI 10.2147/TCRM.S91513; Chien SC, 2014, SCI WORLD J, DOI 10.1155/2014/217525; Estacio RO, 2000, DIABETES CARE, V23, pB54; Fang RC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/591391; Geneva WHO, 1999, WHONCDNCS992; Grant SJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006690.pub2; Hsieh CM, 2014, ANN RHEUM DIS, V73, P495, DOI 10.1136/annrheumdis-2014-eular.4676; Hu F, 2012, PHYTOMEDICINE, V19, P1051, DOI 10.1016/j.phymed.2012.07.007; Huang CY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/201329; Huang MA, 2015, PHARM BIOL, V53, P1058, DOI 10.3109/13880209.2014.959611; Huang TP, 2013, ALLERGY, V68, P1610, DOI 10.1111/all.12273; Hui Hongxiang, 2009, Chin Med, V4, P11, DOI 10.1186/1749-8546-4-11; Jiang BH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059621; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Koo M, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0220-3; Lai JN, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/891893; LEBOVITZ HE, 1984, PEDIATR CLIN N AM, V31, P521; Lee YC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-225; Li GQ, 2013, ADV EXP MED BIOL, V771, P396; Li SY, 2003, PHARMACOL RES, V48, P127, DOI 10.1016/S1043-6618(03)00099-9; Li WL, 2004, J ETHNOPHARMACOL, V92, P1, DOI 10.1016/j.jep.2003.12.031; Lian FM, 2015, J ETHNOPHARMACOL, V164, P71, DOI 10.1016/j.jep.2015.01.048; Lian FM, 2014, J CLIN ENDOCR METAB, V99, P648, DOI 10.1210/jc.2013-3276; Lin CH, 2013, J INTERN MED, V273, P102, DOI 10.1111/joim.12000; Lin HC, 2008, COMPLEMENT THER MED, V16, P336, DOI 10.1016/j.ctim.2007.11.001; Lin K, 2014, J DIABETES COMPLICAT, V28, P234, DOI 10.1016/j.jdiacomp.2013.09.008; Lincoff AM, 2007, JAMA-J AM MED ASSOC, V298, P1180, DOI 10.1001/jama.298.10.1180; Liu XA, 2010, ACTA BIOCH BIOPH SIN, V42, P496, DOI 10.1093/abbs/gmq043; Liu XA, 2010, FEBS LETT, V584, P3185, DOI 10.1016/j.febslet.2010.06.002; Loke YK, 2009, CAN MED ASSOC J, V180, P32, DOI 10.1503/cmaj.080486; Mehler PS, 2003, CIRCULATION, V107, P753, DOI 10.1161/01.CIR.0000049640.46039.52; Pan JC, 2014, J ETHNOPHARMACOL, V152, P314, DOI 10.1016/j.jep.2014.01.002; Qian Yi, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P21; Qian Yi, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P34; QICHENG F, 1980, J ETHNOPHARMACOL, V2, P57, DOI 10.1016/0378-8741(80)90031-8; Qu Y, 2010, PHYTOTHER RES, V24, P245, DOI 10.1002/ptr.2920; Rao AD, 2008, DIABETES CARE, V31, P1672, DOI 10.2337/dc08-0167; Raoufi S, 2015, PHARM BIOL, V53, P1803, DOI 10.3109/13880209.2015.1008148; Roumie CL, 2012, ANN INTERN MED, V157, P601, DOI 10.7326/0003-4819-157-9-201211060-00003; Saquib N, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-434; Shera AS, 1999, DIABETES RES CLIN PR, V44, P49, DOI 10.1016/S0168-8227(99)00017-0; Singh S, 2011, THORAX, V66, P383, DOI 10.1136/thx.2010.152777; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X; Teng Y, 2009, MOL BIOL REP, V36, P1129, DOI 10.1007/s11033-008-9288-2; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Turner RM, 2014, BRIT J CLIN PHARMACO, V78, P258, DOI 10.1111/bcp.12306; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Wietmarschen HA, 2013, J ETHNOPHARMACOL, V150, P851, DOI 10.1016/j.jep.2013.09.041; Wang BR, 2014, PATIENT PREFER ADHER, V8, P671, DOI 10.2147/PPA.S61280; Wang B, 2012, J DIABETES, V4, P22, DOI 10.1111/j.1753-0407.2011.00167.x; Wang J, 2013, J THORAC DIS, V5, P169, DOI 10.3978/j.issn.2072-1439.2013.02.04; Wang J, 2013, AM J RESP CELL MOL, V48, P125, DOI 10.1165/rcmb.2012-0071OC; Wang J, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/714805; Wang SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131122; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Woo KS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/132912; Xue YM, 2006, NAN FANG YI KE DA XU, V26, P1446; Yang TY, 2012, PHYTOTHER RES, V26, P291, DOI 10.1002/ptr.3548; Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292; Yu MC, 2014, J ETHNOPHARMACOL, V155, P435, DOI 10.1016/j.jep.2014.05.049; Zhang TT, 2014, PHYTOMEDICINE, V21, P1137, DOI 10.1016/j.phymed.2014.05.003	70	15	18	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0145109	10.1371/journal.pone.0145109	http://dx.doi.org/10.1371/journal.pone.0145109			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SI	26699542	Green Submitted, gold, Green Published			2023-01-03	WOS:000367092600047
J	Hai, X; Landeras, V; Dobre, MA; DeOreo, P; Meyer, TW; Hostetter, TH				Hai, Xin; Landeras, Veeda; Dobre, Mirela A.; DeOreo, Peter; Meyer, Timothy W.; Hostetter, Thomas H.			Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; GUT MICROBIOTA; N-OXIDE; METABOLISM; UREMIA; BLOOD; UREA; PHOSPHATIDYLCHOLINE; CREATININE; SOLUTES	Large size, protein binding and intracellular sequestration are well known to limit dialytic removal of compounds. In studying the normal renal and dialytic handling of trimethylamine oxide (TMAO), a molecule associated with cardiovascular disease in the general population, we discovered two largely unrecognized additional limitations to sustained reduction of a solute by chronic hemodialysis. We measured solute levels and handling in subjects on chronic hemodialysis (ESRD, n = 7) and compared these with levels and clearance in normal controls (NLS, n = 6). The ESRD patients had much higher peak predialysis plasma levels of TMAO than NLS (77 +/- 26 vs 2 +/- 1 mu M, mean +/- SD, p<0.05). For comparison, predialysis BUN levels in ESRD subjects were 45 +/- 11 mg/dl and 15 +/- 3 mg/dl in NLS. Thus TMAO levels in ESRD average about 40 fold those in NLS while BUN is 3 fold NLS. However, the fractional reduction of TMAO concentration during dialysis, was in fact greater than that of urea (86 +/- 3 vs 74 +/- 6%, TMAO vs urea, p < 0.05) and its dialytic clearance while somewhat lower than that of urea was comparable to creatinine's. Also production rates were similar (533 +/- 272 vs 606 +/- 220 mu moles/day, ESRD vs NLS, p>0.05). However, TMAO has a volume of distribution about one half that of urea. Also in NLS the urinary clearance of TMAO was high (219 +/- 78 ml/min) compared to the urinary urea and creatinine clearances (55 +/- 14 and 119 +/- 21 ml/min, respectively). Thus, TMAO levels achieve multiples of normal much greater than those of urea due mainly to 1) TMAO's high clearance by the normal kidney relative to urea and 2) its smaller volume of distribution. Modelling suggests that only much more frequent dialysis would be required to lower levels Thus, additional strategies such as reducing production should be explored. Furthermore, using urea as the sole marker of dialysis adequacy may be misleading since a molecule, TMAO, that is dialyzed readily accumulates to much higher multiples of normal with urea based dialysis prescriptions.	[Hai, Xin; Landeras, Veeda; Dobre, Mirela A.; DeOreo, Peter; Hostetter, Thomas H.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; [Meyer, Timothy W.] Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA	Case Western Reserve University; Stanford University	Hostetter, TH (corresponding author), Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA.	thomas.hostetter@uhhospitals.org	Dobre, Mirela/ABC-8901-2021	Dobre, Mirela/0000-0002-9059-9998	National Institutes of Health [RO1 DK 080123]; American Heart Association [FTF 15920005]; Rosenberg Foundation of the Centers for Dialysis Care; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080123] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Rosenberg Foundation of the Centers for Dialysis Care; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by the National Institutes of Health RO1 DK 080123, THH and TWM; American Heart Association FTF 15920005, MAD; Rosenberg Foundation of the Centers for Dialysis Care, THH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bain MA, 2006, NEPHROL DIAL TRANSPL, V21, P1300, DOI 10.1093/ndt/gfk056; Chasis H, 1938, J CLIN INVEST, V17, P347, DOI 10.1172/JCI100959; DESCOMBES E, 1993, CLIN NEPHROL, V40, P286; Eloot S, 2009, NEPHROL DIAL TRANSPL, V24, P2225, DOI 10.1093/ndt/gfp059; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; LANGSDORF LJ, 1993, BLOOD, V81, P820; Meyer TW, 2007, NEW ENGL J MED, V357, P1316, DOI 10.1056/NEJMra071313; Meyer TW, 2007, J AM SOC NEPHROL, V18, P868, DOI 10.1681/ASN.2006080863; Meyer TW, 2014, J AM SOC NEPHROL, V25, P2151, DOI 10.1681/ASN.2013121264; Schneditz D, 2009, HEMODIAL INT, V13, P215, DOI 10.1111/j.1542-4758.2009.00351.x; Sirich TL, 2014, J AM SOC NEPHROL, V25, P615, DOI 10.1681/ASN.2013060597; Tang WHW, 2015, CIRC RES, V116, P448, DOI 10.1161/CIRCRESAHA.116.305360; Tang WHW, 2014, J CLIN INVEST, V124, P4204, DOI 10.1172/JCI72331; Tang WHW, 2013, NEW ENGL J MED, V368, P1575, DOI 10.1056/NEJMoa1109400; Vanholder R, 2015, SEMIN DIALYSIS, V28, P114, DOI 10.1111/sdi.12331; Walther JL, 2006, KIDNEY INT, V69, P1056, DOI 10.1038/sj.ki.5000196; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922	17	60	63	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2015	10	12							e0143731	10.1371/journal.pone.0143731	http://dx.doi.org/10.1371/journal.pone.0143731			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1YX	26650937	Green Published, gold, Green Submitted			2023-01-03	WOS:000366903300025
J	Nakashima, A; Ohkido, I; Yokoyama, K; Mafune, A; Urashima, M; Yokoo, T				Nakashima, Akio; Ohkido, Ichiro; Yokoyama, Keitaro; Mafune, Aki; Urashima, Mitsuyoshi; Yokoo, Takashi			Proton Pump Inhibitor Use and Magnesium Concentrations in Hemodialysis Patients: A Cross-Sectional Study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; LOW SERUM MAGNESIUM; RESIDUAL RENAL-FUNCTION; BONE-MINERAL DENSITY; VASCULAR CALCIFICATION; ATRIAL-FIBRILLATION; HYPOMAGNESEMIA; RISK; DIALYSIS; EXPRESSION	Magnesium concentration is a proven predictor of mortality in hemodialysis patients. Recent reports have indicated that proton pump inhibitor (PPI) use affects serum magnesium levels, however few studies have investigated the relationship between PPI use and magnesium levels in hemodialysis patients. This study aimed to clarify the association between PPI use and serum magnesium levels in hemodialysis patients. We designed this cross sectional study and included 1189 hemodialysis patients in stable condition. Associations between PPI and magnesium-related factors, as well as other possible confounders, were evaluated using a multiple regression model. We defined hypomagnesemia as a value <2.0 mg/dL, and created comparable logistic regression models to assess the association between PPI use and hypomagnesemia. PPI use is associated with a significantly lower mean serum magnesium level than histamine 2 (H2) receptor antagonists or no acid-suppressive medications (mean [SD] PPI: 2.52 [0.45] mg/dL; H2 receptor antagonist: 2.68 [0.41] mg/dL; no acid suppressive medications: 2.68 [0.46] mg/dL; P = 0.001). Hypomagnesemia remained significantly associated with PPI (adjusted OR, OR: 2.05; 95% CI: 1.14-3.69; P = 0.017). PPI use is associated with an increased risk of hypomagnesemia in hemodialysis patients. Future prospective studies are needed to explore magnesium replacement in PPI users on hemodialysis.	[Nakashima, Akio; Ohkido, Ichiro; Yokoyama, Keitaro; Mafune, Aki; Yokoo, Takashi] Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan; [Nakashima, Akio; Mafune, Aki; Urashima, Mitsuyoshi] Jikei Univ, Sch Med, Div Mol Epidemiol, Tokyo, Japan	Jikei University; Jikei University	Nakashima, A (corresponding author), Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan.	a-nakashima@jikei.ac.jp	Mafune, Aki/AAL-2293-2021	Mafune, Aki/0000-0002-6160-2879; Nakashima, Akio/0000-0002-3730-0301				Agus ZS, 1999, J AM SOC NEPHROL, V10, P1616; Alhosaini M, 2014, AM J NEPHROL, V39, P204, DOI 10.1159/000360011; Bai JPF, 2012, MOL PHARMACEUT, V9, P3495, DOI 10.1021/mp300323q; Bailie George R, 2006, Hemodial Int, V10, P180, DOI 10.1111/j.1542-4758.2006.00092.x; Blaine J, 2015, CLIN J AM SOC NEPHRO, V10, P1257, DOI 10.2215/CJN.09750913; Broeren MAC, 2009, ANN INTERN MED, V151, P755, DOI 10.7326/0003-4819-151-10-200911170-00016; Cano AE, 2007, AM J GASTROENTEROL, V102, P1990, DOI 10.1111/j.1572-0241.2007.01321.x; Castiglioni S, 2013, NUTRIENTS, V5, P3022, DOI 10.3390/nu5083022; Cundy T, 2008, CLIN ENDOCRINOL, V69, P338, DOI 10.1111/j.1365-2265.2008.03194.x; Cundy T, 2011, CURR OPIN GASTROEN, V27, P180, DOI 10.1097/MOG.0b013e32833ff5d6; Danziger J, 2008, CLIN J AM SOC NEPHRO, V3, P1504, DOI 10.2215/CJN.00770208; Danziger J, 2013, KIDNEY INT, V83, P692, DOI 10.1038/ki.2012.452; Epstein M, 2006, NEW ENGL J MED, V355, P1834, DOI 10.1056/NEJMc066308; Ethier J, 2007, AM J KIDNEY DIS, V50, P602, DOI 10.1053/j.ajkd.2007.07.007; Fusaro M, 2013, DRUG SAFETY, V36, P635, DOI 10.1007/s40264-013-0062-6; Hess MW, 2012, ALIMENT PHARM THER, V36, P405, DOI 10.1111/j.1365-2036.2012.05201.x; Hou JH, 2008, J CLIN INVEST, V118, P619, DOI 10.1172/JCI33970; Joosten MM, 2013, HYPERTENSION, V61, P1161, DOI 10.1161/HYPERTENSIONAHA.113.01333; Khan AM, 2013, CIRCULATION, V127, P33, DOI 10.1161/CIRCULATIONAHA.111.082511; Kirkpantur A, 2009, INT J CLIN PRACT, V63, P261, DOI 10.1111/j.1742-1241.2008.01883.x; Lameris ALL, 2013, PFLUG ARCH EUR J PHY, V465, P1613, DOI 10.1007/s00424-013-1306-0; Lau AN, 2015, ENDOCRINE, V49, P606, DOI 10.1007/s12020-015-0576-z; Lemes HP, 2011, CLIN EXP NEPHROL, V15, P554, DOI 10.1007/s10157-011-0427-z; Liao JN, 2015, KIDNEY INT, V87, P1209, DOI 10.1038/ki.2014.393; Lim H, 2015, J GASTROEN HEPATOL, V30, P478, DOI 10.1111/jgh.12780; Lopez-Ridaura R, 2004, DIABETES CARE, V27, P134, DOI 10.2337/diacare.27.1.134; Louvet L, 2013, NEPHROL DIAL TRANSPL, V28, P869, DOI 10.1093/ndt/gfs520; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Mehrotra R, 1997, AM J KIDNEY DIS, V29, P106, DOI 10.1016/S0272-6386(97)90016-0; Navarro-Gonzalez JF, 2009, SEMIN DIALYSIS, V22, P37, DOI 10.1111/j.1525-139X.2008.00530.x; Okuno S, 2007, NEW PERSPECTIVES IN MAGNESIUM RESEARCH: NUTRITION AND HEALTH, P316, DOI 10.1007/978-1-84628-483-0_26; Orchard TS, 2014, AM J CLIN NUTR, V99, P926, DOI 10.3945/ajcn.113.067488; Paloian NJ, 2014, AM J PHYSIOL-RENAL, V307, pF891, DOI 10.1152/ajprenal.00163.2014; Pilkey RM, 2007, AM J KIDNEY DIS, V49, P432, DOI 10.1053/j.ajkd.2006.11.041; Quamme GA, 2008, CURR OPIN GASTROEN, V24, P230, DOI 10.1097/MOG.0b013e3282f37b59; Reffelmann T, 2011, ATHEROSCLEROSIS, V219, P280, DOI 10.1016/j.atherosclerosis.2011.05.038; Romani AMP, 2011, ARCH BIOCHEM BIOPHYS, V512, P1, DOI 10.1016/j.abb.2011.05.010; Rondon LJ, 2008, AM J PHYSIOL-REG I, V294, pR2001, DOI 10.1152/ajpregu.00153.2007; Sakaguchi Y, 2014, KIDNEY INT, V85, P174, DOI 10.1038/ki.2013.327; Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754, DOI 10.1093/ajcn/83.4.754; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Shabajee N, 2008, BMJ-BRIT MED J, DOI [10.1136/j.bmj.2008.39505.738981, DOI 10.1136/J.BMJ.2008.39505.738981]; Strid H, 2009, EUR J GASTROEN HEPAT, V21, P137, DOI 10.1097/MEG.0b013e3283200047; Van Laecke S, 2012, NEPHROL DIAL TRANSPL, V27, P4003, DOI 10.1093/ndt/gfs126; Wang AYM, 2006, KIDNEY INT, V69, P1726, DOI 10.1038/sj.ki.5000382; William JH, 2014, NEPHROLOGY, V19, P798, DOI 10.1111/nep.12330; Wu LL, 2014, ACTA BIOMATER, V10, P2843, DOI 10.1016/j.actbio.2014.02.010; Yang YX, 2006, JAMA-J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947; Zipursky J, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001736	49	30	31	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2015	10	11							e0143656	10.1371/journal.pone.0143656	http://dx.doi.org/10.1371/journal.pone.0143656			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7NW	26618538	gold, Green Published, Green Submitted			2023-01-03	WOS:000365889800054
J	Peng, DJ; Kryczek, I; Nagarsheth, N; Zhao, LL; Wei, S; Wang, WM; Sun, YQ; Zhao, ED; Vatan, L; Szeliga, W; Kotarski, J; Tarkowski, R; Dou, YL; Cho, K; Hensley-Alford, S; Munkarah, A; Liu, R; Zou, WP				Peng, Dongjun; Kryczek, Ilona; Nagarsheth, Nisha; Zhao, Lili; Wei, Shuang; Wang, Weimin; Sun, Yuqing; Zhao, Ende; Vatan, Linda; Szeliga, Wojciech; Kotarski, Jan; Tarkowski, Rafal; Dou, Yali; Cho, Kathleen; Hensley-Alford, Sharon; Munkarah, Adnan; Liu, Rebecca; Zou, Weiping			Epigenetic silencing of T(H)1-type chemokines shapes tumour immunity and immunotherapy	NATURE			English	Article							T-CELLS; CANCER; BLOCKADE; INHIBITION; SURVIVAL; DEATH; MODEL; EZH2; UTX	Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism(1). However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (T(H)1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade(2-4) and adoptive T-cell transfusion(5) in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of T(H)1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape(6) in cancer and may enhance the clinical efficacy of cancer therapy.	[Peng, Dongjun; Kryczek, Ilona; Nagarsheth, Nisha; Wei, Shuang; Wang, Weimin; Zhao, Ende; Vatan, Linda; Szeliga, Wojciech; Zou, Weiping] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA; [Kryczek, Ilona; Nagarsheth, Nisha; Zou, Weiping] Univ Michigan, Grad Program Immunol, Ann Arbor, MI 48109 USA; [Zhao, Lili] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA; [Sun, Yuqing; Dou, Yali; Cho, Kathleen] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Kotarski, Jan; Tarkowski, Rafal] Med Univ Lublin, Dept Gynecol Oncol & Gynecol 1, PL-20081 Lublin, Poland; [Cho, Kathleen; Liu, Rebecca; Zou, Weiping] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Hensley-Alford, Sharon; Munkarah, Adnan] Henry Ford Hlth Syst, Dept Womens Hlth Serv, Detroit, MI 48202 USA; [Liu, Rebecca] Univ Michigan, Sch Med, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; [Zou, Weiping] Univ Michigan, Grad Program Tumor Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Medical University of Lublin; University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Zou, WP (corresponding author), Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA.	wzou@med.umich.edu	Zhao, Ende/B-9851-2013; Tarkowski, Rafał/GQQ-9740-2022	Zhao, Ende/0000-0002-1355-6919; Nagarsheth, Nisha/0000-0002-9508-1530; Cho, Kathleen/0000-0003-0500-9998	NIH [CA190176, CA123088, CA099985, CA156685, CA193136, CA152470, CA171306, 5P30CA46592]; Rivkin Ovarian Cancer Center; Ovarian Cancer Research Fund; NATIONAL CANCER INSTITUTE [P30CA046592, R01CA099985, F31CA189440, R01CA171306, R01CA123088, R01CA156685, R01CA152470, R01CA193136, R01CA190176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM082856] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rivkin Ovarian Cancer Center; Ovarian Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is supported (in part) by the NIH grants (CA190176; CA123088; CA099985; CA156685; CA193136; CA152470; CA171306; 5P30CA46592), the Rivkin Ovarian Cancer Center, and the Ovarian Cancer Research Fund. We appreciate discussion with B. Richardson. We thank L. Cabrera, D. Postiff, M. Vinco, R. Craig and J. Barikdar for their technical assistance. We are grateful for the professional help from W. Wu and C. Johnson in our Microarray Core and Bioinformatics Core. We particularly appreciate the support of B. Leclair and D. Leclair.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Doege CA, 2012, NATURE, V488, P652, DOI 10.1038/nature11333; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773; Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kryczek I., 2014, IMMUNITY; Kryczek I, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002949; Kryczek I, 2012, INT J CANCER, V130, P29, DOI 10.1002/ijc.25967; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; Mansour AA, 2012, NATURE, V488, P409, DOI 10.1038/nature11272; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Park S, 2010, CANCER CELL, V18, P160, DOI 10.1016/j.ccr.2010.06.014; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Scholler J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003761; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang YX, 2014, BLOOD, V124, P737, DOI 10.1182/blood-2013-12-544106; Zitvogel L, 2010, CELL, V140, P798, DOI 10.1016/j.cell.2010.02.015; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326; Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339	35	653	683	11	150	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	2015	527	7577					249	+		10.1038/nature15520	http://dx.doi.org/10.1038/nature15520			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV6RC	26503055	Green Accepted			2023-01-03	WOS:000364396700048
J	Faigle, R; Marsh, EB; Llinas, RH; Urrutia, VC				Faigle, Roland; Marsh, Elisabeth B.; Llinas, Rafael H.; Urrutia, Victor C.			Critical Care Needs in Patients with Diffusion-Weighted Imaging Negative MRI after tPA - Does One Size Fit All?	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; GLOMERULAR-FILTRATION-RATE; TRANSIENT ISCHEMIC ATTACK; STROKE MIMICS; SERUM CREATININE; RT-PA; THROMBOLYSIS; RISK; ASSOCIATION; MANAGEMENT	Background and Purpose Patients who receive intravenous (IV) tissue plasminogen activator (tPA) for ischemic stroke are currently monitored in an intensive care unit (ICU) or a comparable stroke unit for at least 24 hours due to the high frequency of neurological exams and vital sign checks. The present study evaluates ICU needs in patients with diffusion-weighted imaging (DWI) negative MRI after IV tPA. Methods A retrospective chart review was performed for 209 patients who received IV tPA for acute stroke. Data on stroke risk factors, physiologic parameters, stroke severity, MRI characteristics, and final diagnosis were collected. The timing and nature of ICU interventions, if needed, was recorded. Multivariable logistic regression was used to determine factors associated with subsequent ICU needs. Results Patients with cerebral infarct on MRI after tPA had over 9 times higher odds of requiring ICU care compared to patients with DWI negative MRI (OR 9.2, 95% CI 2.49-34.15). All DWI negative patients requiring ICU care did so by the end of tPA infusion (p = 0.006). Among patients with DWI negative MRI, need for ICU interventions was associated with higher NIH Stroke Scale (NIHSS) scores (p < 0.001), uncontrolled hypertension (p < 0.001), seizure at onset (p = 0.002), and reduced estimated glomerular filtration rate (eGFR) (p = 0.010). Conclusions Only a small number of DWI negative patients required ICU care. In patients without critical care needs by the end of thrombolysis, post-tPA MRI may be considered for triaging DWI negative patients to a less resource intense monitoring environment.	[Faigle, Roland; Marsh, Elisabeth B.; Llinas, Rafael H.; Urrutia, Victor C.] Johns Hopkins Univ, Dept Neurol, Sch Med, Baltimore, MD 21218 USA	Johns Hopkins University	Faigle, R (corresponding author), Johns Hopkins Univ, Dept Neurol, Sch Med, Baltimore, MD 21218 USA.	rfaigle1@jhmi.edu	Faigle, Roland/ABB-9082-2020; Urrutia, Victor/AAH-6683-2021	Faigle, Roland/0000-0002-9074-1915; Urrutia, Victor/0000-0002-4995-6949; Marsh, Elisabeth/0000-0002-2385-5074; Llinas, Rafael/0000-0002-9161-2699	R25 NINDS Research Education Program for Residents and Fellows in Neurology and Neurosurgery [RFA-NS-09-001]	R25 NINDS Research Education Program for Residents and Fellows in Neurology and Neurosurgery	RF was supported by a R25 NINDS Research Education Program for Residents and Fellows in Neurology and Neurosurgery (RFA-NS-09-001); (http://www.ninds.nih.gov/funding/r25_institutions.htm). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chernyshev OY, 2010, NEUROLOGY, V74, P1340, DOI 10.1212/WNL.0b013e3181dad5a6; Faigle R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088652; Freeman JW, 2013, STROKE, V44, P1629, DOI 10.1161/STROKEAHA.111.000486; Gensicke H, 2013, NEUROLOGY, V81, P1780, DOI 10.1212/01.wnl.0000435550.83200.9e; Giraldo EA, 2011, NEUROCRIT CARE, V15, P76, DOI 10.1007/s12028-011-9523-x; Hacke W, 2004, LANCET, V363, P768; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Larrue V, 2001, STROKE, V32, P438, DOI 10.1161/01.STR.32.2.438; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Marsh EB, 2013, MEDICINE, V92, P317, DOI 10.1097/MD.0000000000000006; Naganuma M, 2011, CEREBROVASC DIS, V31, P123, DOI 10.1159/000321516; Oppenheim C, 2000, AM J NEURORADIOL, V21, P1434; Sylaja PN, 2008, STROKE, V39, P1898, DOI 10.1161/STROKEAHA.107.497453; Uchino K, 2010, CEREBROVASC DIS, V29, P57, DOI 10.1159/000255975; Winkler DT, 2009, STROKE, V40, P1522, DOI 10.1161/STROKEAHA.108.530352; Zinkstok SM, 2013, STROKE, V44, P1080, DOI 10.1161/STROKEAHA.111.000126	16	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2015	10	10							e0141204	10.1371/journal.pone.0141204	http://dx.doi.org/10.1371/journal.pone.0141204			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV0EH	26517543	Green Published, gold, Green Submitted			2023-01-03	WOS:000363920800027
J	Kaiser, M; Kirsch, B; Hauser, H; Schneider, D; Seuss-Baum, I; Goycoolea, FM				Kaiser, Mathias; Kirsch, Benedikt; Hauser, Hannah; Schneider, Desiree; Seuss-Baum, Ingrid; Goycoolea, Francisco M.			In Vitro and Sensory Evaluation of Capsaicin-Loaded Nanoformulations	PLOS ONE			English	Article							ALPHA-AMYLASE; CHITOSAN; MECHANISMS	Capsaicin has known health beneficial and therapeutic properties. It is also able to enhance the permeability of drugs across epithelial tissues. Unfortunately, due to its pungency the oral administration of capsaicin is limited. To this end, we assessed the effect of nanoencapsulation of capsaicin, under the hypothesis that this would reduce its pungency. Core-shell nanocapsules with an oily core and stabilized with phospholipids were used. This system was used with or without chitosan coating. In this work, we investigated the in vitro release behavior of capsaicin-loaded formulations in different physiological media (including simulated saliva fluid). We also evaluated the influence of encapsulation of capsaicin on the cell viability of buccal cells (TR146). To study the changes in pungency after encapsulation we carried out a sensory analysis with a trained panel of 24 students. The in vitro release study showed that the systems discharged capsaicin slowly in a monotonic manner and that the chitosan coating had an effect on the release profile. The cytotoxic response of TR146 cells to capsaicin at a concentration of 500 mu M, which was evident for the free compound, was reduced following its encapsulation. The sensory study revealed that a chitosan coating results in a lower threshold of perception of the formulation. The nanoencapsulation of capsaicin resulted in attenuation of the sensation of pungency significantly. However, the presence of a chitosan shell around the nanoformulations did not mask the pungency, when compared with uncoated systems.	[Kaiser, Mathias; Goycoolea, Francisco M.] Univ Munster, IBBP, D-48149 Munster, North Rhine Wes, Germany; [Kirsch, Benedikt; Hauser, Hannah; Schneider, Desiree; Seuss-Baum, Ingrid] Univ Appl Sci Fulda, Dept Food Technol, Fulda, Hesse, Germany	University of Munster	Goycoolea, FM (corresponding author), Univ Munster, IBBP, D-48149 Munster, North Rhine Wes, Germany.	goycoole@uni-muenster.de	Goycoolea, Francisco M./Q-5841-2017; Goycoolea, Francisco M. M/G-5755-2017	Goycoolea, Francisco M./0000-0001-7949-5429; Goycoolea, Francisco M. M/0000-0001-7949-5429	DFG, Germany [GRK 1549]; Danish Agency for Science, Technology and Innovation, Denmark (FENAMI project) [10-093456]; European Union [613931]	DFG, Germany(German Research Foundation (DFG)); Danish Agency for Science, Technology and Innovation, Denmark (FENAMI project); European Union(European Commission)	The authors acknowledge support from DFG, Germany (Project GRK 1549 International Research Training Group 'Molecular and Cellular GlycoSciences'), and from The Danish Agency for Science, Technology and Innovation, Denmark (FENAMI project 10-093456). The research leading to these results has also received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 613931.	[Anonymous], 13301200209 ISO; [Anonymous], 10970200209 DIN; [Anonymous], 10962199710 DIN; Arhakis A, 2013, OPEN DENT J, V7, P7, DOI 10.2174/1874210601307010007; Calvo P, 1997, INT J PHARM, V153, P41, DOI 10.1016/S0378-5173(97)00083-5; Chien PJ, 2007, J FOOD ENG, V78, P225, DOI 10.1016/j.jfoodeng.2005.09.022; Choi AJ, 2011, FOOD BIOPROCESS TECH, V4, P1119, DOI 10.1007/s11947-011-0568-9; Choi AY, 2013, J AGR FOOD CHEM, V61, P2096, DOI 10.1021/jf3052708; Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1; Davidov-Pardo G., 2008, American Journal of Food Technology, V3, P384; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DIN-EN-ISO, 2014, 8586201405 DIN EN IS; GOVINDARAJAN VS, 1991, CRIT REV FOOD SCI, V29, P435, DOI 10.1080/10408399109527536; Goycoolea FM, 2012, COLLOID POLYM SCI, V290, P1423, DOI 10.1007/s00396-012-2669-z; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Kaiser M, 2015, SCI REP-UK, V5, DOI 10.1038/srep10048; Kean T, 2010, ADV DRUG DELIVER REV, V62, P3, DOI 10.1016/j.addr.2009.09.004; Kim JH, 2014, J AGR FOOD CHEM, V62, P725, DOI 10.1021/jf404220n; Korel F, 2002, J AGR FOOD CHEM, V50, P3257, DOI 10.1021/jf010537b; KORSMEYER RW, 1983, INT J PHARM, V15, P25, DOI 10.1016/0378-5173(83)90064-9; KRAJEWSKA AM, 1988, J FOOD SCI, V53, P902, DOI 10.1111/j.1365-2621.1988.tb08981.x; Kurita S, 2002, BIOSCI BIOTECH BIOCH, V66, P532, DOI 10.1271/bbb.66.532; Meghvansi MK, 2010, J ETHNOPHARMACOL, V132, P1, DOI 10.1016/j.jep.2010.08.034; Menchicchi B, 2014, BIOMACROMOLECULES, V15, P3550, DOI 10.1021/bm5007954; Nascimento PLA, 2014, MOLECULES, V19, P5434, DOI 10.3390/molecules19045434; Peh KK, 1999, J PHARM PHARM SCI, V2, P53; RINAUDO M, 1993, INT J BIOL MACROMOL, V15, P281, DOI 10.1016/0141-8130(93)90027-J; Rodriguez MS, 2003, J FOOD SCI, V68, P665, DOI 10.1111/j.1365-2621.2003.tb05728.x; Schneider D., 2014, ADV J FOOD SCI TECHN, V6, P36; Schneider DJ, 2014, FOOD QUAL PREFER, V38, P98, DOI 10.1016/j.foodqual.2014.05.017; Schneider DJ, 2011, 6 DLG LEB DARMST; Shiobara T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079954; SIZER F, 1985, CHEM SENSES, V10, P279, DOI 10.1093/chemse/10.3.279; Tsukura Y, 2007, BIOL PHARM BULL, V30, P1982, DOI 10.1248/bpb.30.1982; Turgut C, 2004, ENVIRON SCI POLLUT R, V11, P7, DOI 10.1065/espr2003.12.180; Wang JC, 2010, J APPL POLYM SCI, V116, P2234, DOI 10.1002/app.31684; Wu SJ, 2011, FOOD CHEM, V128, P769, DOI 10.1016/j.foodchem.2011.03.111; Xing FB, 2004, J APPL POLYM SCI, V91, P2669, DOI 10.1002/app.13449; Xing FB, 2006, J APPL POLYM SCI, V102, P1318, DOI 10.1002/app.23766; Yeh TH, 2011, BIOMATERIALS, V32, P6164, DOI 10.1016/j.biomaterials.2011.03.056; Yi EJ, 2014, INT J PHARMACEUT, V466, P286, DOI 10.1016/j.ijpharm.2014.03.001; Zhang LL, 2007, CIRC RES, V100, P1063, DOI 10.1161/01.RES.0000262653.84850.8b; Zhu Y, 2014, J FUNCT FOODS, V8, P358, DOI 10.1016/j.jff.2014.04.001	43	19	19	3	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2015	10	10							e0141017	10.1371/journal.pone.0141017	http://dx.doi.org/10.1371/journal.pone.0141017			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0ZU	26492045	Green Published, Green Submitted, gold			2023-01-03	WOS:000363249300021
J	Stelfox, HT; Niven, DJ; Clement, FM; Bagshaw, SM; Cook, DJ; McKenzie, E; Potestio, ML; Doig, CJ; O'Neill, B; ZygunDavid				Stelfox, Henry T.; Niven, Daniel J.; Clement, Fiona M.; Bagshaw, Sean M.; Cook, Deborah J.; McKenzie, Emily; Potestio, Melissa L.; Doig, Christopher J.; O'Neill, Barbara; ZygunDavid		Critical Care Strategic Clinical N; Alberta Hlth Serv	Stakeholder Engagement to Identify Priorities for Improving the Quality and Value of Critical Care	PLOS ONE			English	Article							LONGITUDINAL DATA-ANALYSIS; TOP 5 LIST; ILL PATIENTS; VENOUS THROMBOEMBOLISM; KNOWLEDGE TRANSLATION; HEALTH; TRIAL; IMPROVEMENT; MEDICINE; OUTCOMES	Background Large amounts of scientific evidence are generated, but not implemented into patient care (the 'knowledge-to-care' gap). We identified and prioritized knowledge-to-care gaps in critical care as opportunities to improve the quality and value of healthcare. Methods We used a multi-method community-based participatory research approach to engage a Network of all adult (n = 14) and pediatric (n = 2) medical-surgical intensive care units (ICUs) in a fully integrated geographically defined healthcare system serving 4 million residents. Participants included Network oversight committee members (n = 38) and frontline providers (n = 1,790). Network committee members used a modified RAND/University of California Appropriateness Methodology, to serially propose, rate (validated 9 point scale) and revise potential knowledge-to-care gaps as priorities for improvement. The priorities were sent to frontline providers for evaluation. Results were relayed back to all frontline providers for feedback. Results Initially, 68 knowledge-to-care gaps were proposed, rated and revised by the committee (n = 32 participants) over 3 rounds of review and resulted in 13 proposed priorities for improvement. Then, 1,103 providers (62% response rate) evaluated the priorities, and rated 9 as 'necessary' (median score 7-9). Several factors were associated with rating priorities as necessary in multivariable logistic regression, related to the provider (experience, teaching status of ICU) and topic (strength of supporting evidence, potential to benefit the patient, potential to improve patient/family experience, potential to decrease costs). Conclusions A community-based participatory research approach engaged a diverse group of stakeholders to identify 9 priorities for improving the quality and value of critical care. The approach was time and cost efficient and could serve as a model to prioritize areas for research quality improvement across other settings.	[Stelfox, Henry T.; Niven, Daniel J.; Doig, Christopher J.] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Stelfox, Henry T.; Niven, Daniel J.; Clement, Fiona M.; McKenzie, Emily; Potestio, Melissa L.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Stelfox, Henry T.; Niven, Daniel J.; Bagshaw, Sean M.; Potestio, Melissa L.; Doig, Christopher J.; O'Neill, Barbara; ZygunDavid] Alberta Hlth Serv, Calgary, AB, Canada; [Bagshaw, Sean M.; ZygunDavid] Univ Alberta, Fac Med & Dent, Div Crit Care Med, Edmonton, AB, Canada; [Cook, Deborah J.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Cook, Deborah J.] McMaster Univ, Dept Crit Care, Hamilton, ON, Canada; [Cook, Deborah J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Cook, Deborah J.] St Josephs Healthcare, Hamilton, ON, Canada; [Clement, Fiona M.] Univ Calgary, OBrien Inst Publ Hlth, Calgary, AB, Canada	University of Calgary; University of Calgary; Alberta Health Services (AHS); University of Calgary; University of Alberta; McMaster University; McMaster University; McMaster University; University of Calgary	Stelfox, HT (corresponding author), Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada.	tstelfox@ucalgary.ca	Doig, Christopher/AAC-7949-2020; Zuege, Danny J./L-5368-2017	Doig, Christopher/0000-0002-8576-9139; Zuege, Danny J./0000-0003-2033-5847; Yipp, Bryan/0000-0002-5887-9551; Stelfox, Henry/0000-0003-1231-1490	Partnerships for Research and Innovation in Health System Improvement Grant from Alberta Innovates Health Solutions [201309 AIHS PRIHS]; Alberta Innovates [201300477] Funding Source: researchfish	Partnerships for Research and Innovation in Health System Improvement Grant from Alberta Innovates Health Solutions; Alberta Innovates	The project was supported by a Partnerships for Research and Innovation in Health System Improvement Grant ( 201309 AIHS PRIHS, www.aihealthsolutions.ca) from Alberta Innovates Health Solutions. Funding sources had no role in the design, conduct, or reporting of this study.	Alberta Health Services, 2014, CRIT CAR STRAT CLIN; Alberta Innovates Health Solutions, 2013, PARTN RES INN HLTH S; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Atkinson AA, 1997, SLOAN MANAGE REV, V38, P25; Bartlett Susan J, 2014, Ann Am Thorac Soc, V11 Suppl 2, pS112, DOI 10.1513/AnnalsATS.201309-327RM; Brody H, 2010, NEW ENGL J MED, V362, P283, DOI 10.1056/NEJMp0911423; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Carlin J B, 2001, Biostatistics, V2, P397, DOI 10.1093/biostatistics/2.4.397; Chalmers I, 2014, LANCET, V383, P156, DOI 10.1016/S0140-6736(13)62229-1; Davis D, 2003, BMJ-BRIT MED J, V327, P33, DOI 10.1136/bmj.327.7405.33; Finfer S, 2012, NEW ENGL J MED, V367, P1108, DOI 10.1056/NEJMoa1204942; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Fowler RA, 2014, JAMA-J AM MED ASSOC, V312, P2135, DOI 10.1001/jama.2014.15101; Gill M, 2015, PATIENT FAMILY UNPUB; Grady D, 2014, JAMA INTERN MED, V174, P498, DOI 10.1001/jamainternmed.2013.8272; Graham Ian D, 2004, Can J Nurs Res, V36, P89; Grimshaw JM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-50; Halpern SD, 2014, AM J RESP CRIT CARE, V190, P818, DOI 10.1164/rccm.201407-1317ST; Horowitz CR, 2009, CIRCULATION, V119, P2633, DOI 10.1161/CIRCULATIONAHA.107.729863; Hu FB, 1998, AM J EPIDEMIOL, V147, P694; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSSING QUALITY CHA; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; Kahn JM, 2009, CRIT CARE MED, V37, pS147, DOI 10.1097/CCM.0b013e3181920fa3; Kiefe CI, 2001, JAMA-J AM MED ASSOC, V285, P2871, DOI 10.1001/jama.285.22.2871; Kitson AL, 2013, KNOWLEDGE TRANSLATION IN HEALTH CARE: MOVING FROM EVIDENCE TO PRACTICE, 2ND EDITION, P97; Kucher N, 2005, NEW ENGL J MED, V352, P969, DOI 10.1056/NEJMoa041533; Langley GL., 2009, IMPROVEMENT GUIDE PR, V2nd; Lauzier F, 2014, CRIT CARE, V18, DOI 10.1186/cc13844; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; McDonnell J., 2001, RANDUCLA APPROPRIATE; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Niven DJ, 2015, JAMA INTERN MED, V175, P801, DOI 10.1001/jamainternmed.2015.0157; Ovretveit J, 2014, J HEALTH ORGAN MANAG, V28, P115, DOI 10.1108/JHOM-08-2013-0164; Scales DC, 2011, JAMA-J AM MED ASSOC, V305, P363, DOI 10.1001/jama.2010.2000; Schuur JD, 2014, JAMA INTERN MED, V174, P509, DOI 10.1001/jamainternmed.2013.12688; Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607; Sort P, 1999, NEW ENGL J MED, V341, P403, DOI 10.1056/NEJM199908053410603; Tilburt JC, 2013, JAMA-J AM MED ASSOC, V310, P380, DOI 10.1001/jama.2013.8278; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	40	24	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2015	10	10							e0140141	10.1371/journal.pone.0140141	http://dx.doi.org/10.1371/journal.pone.0140141			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0ZU	26492196	gold, Green Published, Green Submitted			2023-01-03	WOS:000363249300005
J	Relling, MV; Evans, WE				Relling, Mary V.; Evans, William E.			Pharmacogenomics in the clinic	NATURE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; IMPLEMENTATION CONSORTIUM GUIDELINES; ELECTRONIC MEDICAL-RECORDS; ADVERSE DRUG-REACTIONS; PERSONALIZED MEDICINE; GENOMIC MEDICINE; RESEARCH NETWORK; PREEMPTIVE PHARMACOGENOMICS; MERCAPTOPURINE INTOLERANCE; COMPANION DIAGNOSTICS	After decades of discovery, inherited variations have been identified in approximately 20 genes that affect about 80 medications and are actionable in the clinic. And some somatically acquired genetic variants direct the choice of 'targeted' anticancer drugs for individual patients. Current efforts that focus on the processes required to appropriately act on pharmacogenomic variability in the clinic are moving away from discovery and towards implementation of an evidenced-based strategy for improving the use of medications, thereby providing a cornerstone for precision medicine.	[Relling, Mary V.; Evans, William E.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Relling, MV (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	mary.relling@stjude.org	Relling, Mary/N-5032-2018; Evans, William E./C-2069-2012	Evans, William E./0000-0002-9333-5322; Loh, Mignon/0000-0003-4099-4700	NIH [P50 GM115279, RO1 CA36401, R24 GM115264, RO1 CA142665, P30 CA21765]; American Lebanese Syrian Associated Charities; NATIONAL CANCER INSTITUTE [R01CA036401, R01CA142665, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115279, R24GM115264] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Associated Charities(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank their many colleagues who have collaborated in research to elucidate the pharmacogenomics of medications used to treat their patients, as well as those who have collaborated to translate pharmacogenomics to optimize the care of patients. They also thank the many patients and parents who have willingly participated in their research. This work was supported in part by NIH grants P50 GM115279, RO1 CA36401, R24 GM115264, RO1 CA142665, P30 CA21765 and by the American Lebanese Syrian Associated Charities.	Abrams J, 2014, 2014 AM SOC CLIN ONC, P71; Agundez JAG, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00188; Becquement L, 2011, PHARMACOGENOMICS, V12, P113, DOI 10.2217/PGS.10.147; Bell GC, 2014, J AM MED INFORM ASSN, V21, pE93, DOI 10.1136/amiajnl-2013-001993; BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613; Bielinski SJ, 2014, MAYO CLIN PROC, V89, P25, DOI 10.1016/j.mayocp.2013.10.021; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; Bonifaz-Pena V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112640; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; Brauch H, 2014, BRIT J CLIN PHARMACO, V77, P695, DOI 10.1111/bcp.12229; Brauch H, 2013, J CLIN ONCOL, V31, P176, DOI 10.1200/JCO.2012.44.6625; Buchanan J, 2013, PHARMACOGENOMICS, V14, P1833, DOI 10.2217/pgs.13.183; Burke W, 2009, CURRENT PROTOCOLS HU; Carr DF, 2014, GENES-BASEL, V5, P430, DOI 10.3390/genes5020430; CARSON PE, 1956, SCIENCE, V124, P484, DOI 10.1126/science.124.3220.484-a; Caudle KE, 2014, CURR DRUG METAB, V15, P209, DOI 10.2174/1389200215666140130124910; Caulfield T, 2012, CLIN GENET, V81, P4, DOI 10.1111/j.1399-0004.2011.01799.x; Cavallari LH, 2014, CLIN PHARMACOL THER, V96, P22, DOI 10.1038/clpt.2014.78; Chan NC, 2014, BLOOD, V124, P689, DOI 10.1182/blood-2014-01-512723; Chen ZB, 2014, NEUROLOGY, V83, P2077, DOI 10.1212/WNL.0000000000001034; Cheng Q, 2005, NAT GENET, V37, P878, DOI 10.1038/ng1612; Cooper DN, 2014, PERS MED, V11, P615, DOI 10.2217/pme.14.59; Crawford DC, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00184; Crews KR, 2014, CLIN PHARMACOL THER, V95, P376, DOI 10.1038/clpt.2013.254; Dalabira E, 2014, PUBLIC HEALTH GENOM, V17, P265, DOI 10.1159/000365895; Dunnenberger HM, 2015, ANNU REV PHARMACOL, V55, P89, DOI 10.1146/annurev-pharmtox-010814-124835; Ehmann F, 2015, PHARMACOGENOMICS J, V15, P201, DOI 10.1038/tpj.2014.86; EVANS DAP, 1960, BRIT MED J, V2, P485, DOI 10.1136/bmj.2.5197.485; Evans WE, 2004, NATURE, V429, P464, DOI 10.1038/nature02626; Fernandez CA, 2012, CLIN PHARMACOL THER, V92, P360, DOI 10.1038/clpt.2012.95; Flockhart DA, 2009, CLIN PHARMACOL THER, V86, P109, DOI 10.1038/clpt.2009.39; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; Gordon AS, 2014, HUM MOL GENET, V23, P1957, DOI 10.1093/hmg/ddt588; Gottesman O, 2013, CLIN PHARMACOL THER, V94, P214, DOI 10.1038/clpt.2013.72; Gottesman O, 2013, GENET MED, V15, P761, DOI 10.1038/gim.2013.72; Grosse SD, 2006, GENET MED, V8, P448, DOI 10.1097/01.gim.0000227935.26763.c6; Haga SB, 2012, CLIN GENET, V82, P388, DOI 10.1111/j.1399-0004.2012.01908.x; Haga SB, 2012, CLIN GENET, V82, P115, DOI 10.1111/j.1399-0004.2012.01848.x; Hayden EC, 2013, NATURE, V498, P16, DOI 10.1038/498017a; Hughes D, 2015, NAT REV GENET, V16, P459, DOI 10.1038/nrg3922; HUGHES HB, 1954, AM REV TUBERC PULM, V70, P266; Ingelman-Sundberg M, 2008, NEW ENGL J MED, V358, P637, DOI 10.1056/NEJMe0708842; Irvin WJ, 2011, J CLIN ONCOL, V29, P3232, DOI 10.1200/JCO.2010.31.4427; Ishiguro A, 2013, J HUM GENET, V58, P313, DOI 10.1038/jhg.2013.36; Johnson JA, 2012, CLIN PHARMACOL THER, V92, P437, DOI 10.1038/clpt.2012.125; KALOW W, 1957, CAN J BIOCHEM PHYS, V35, P339, DOI 10.1139/o57-041; Kinch MS, 2014, DRUG DISCOV TODAY, V19, P1033, DOI 10.1016/j.drudis.2014.03.018; Korf BR, 2014, GENET MED, V16, P804, DOI 10.1038/gim.2014.35; Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113; Levy KD, 2014, CLIN PHARMACOL THER, V96, P307, DOI 10.1038/clpt.2014.101; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Manolio TA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0194; Manolio TA, 2014, GENET MED, V16, P571, DOI 10.1038/gim.2014.6; Manolio TA, 2014, AM J MED GENET C, V166, P1, DOI 10.1002/ajmg.c.31384; Marshall E, 2003, SCIENCE, V302, P588, DOI 10.1126/science.302.5645.588; Martin MA, 2014, CLIN PHARMACOL THER, V95, P499, DOI 10.1038/clpt.2014.38; McCarthy JJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005785; McLeod HL, 2013, SCIENCE, V339, P1563, DOI 10.1126/science.1234139; Mega JL, 2010, JAMA-J AM MED ASSOC, V304, P1821, DOI 10.1001/jama.2010.1543; Minarro-Gimenez JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093769; MOTULSKY AG, 1957, JAMA-J AM MED ASSOC, V165, P835, DOI 10.1001/jama.1957.72980250010016; O'Donnell PH, 2014, AM J MED GENET C, V166, P68, DOI 10.1002/ajmg.c.31385; Oetjens MT, 2013, PHARMACOGENOMICS, V14, P735, DOI [10.2217/pgs.13.64, 10.2217/PGS.13.64]; Overby CL, 2014, J PERS MED, V4, P35, DOI 10.3390/jpm4010035; Overby CL, 2013, GENET MED, V15, P817, DOI 10.1038/gim.2013.128; Percha Bethany, 2013, AMIA Annu Symp Proc, V2013, P1123; PharmGKB, 2015, CPIC GEN DRUGS; Pignatti F, 2014, CLIN CANCER RES, V20, P1458, DOI 10.1158/1078-0432.CCR-13-1571; Pirmohamed M, 2015, TRENDS PHARMACOL SCI, V36, P153, DOI 10.1016/j.tips.2015.01.003; Prainsack B, 2013, PHARMACOGENOMICS, V14, P403, DOI [10.2217/PGS.13.10, 10.2217/pgs.13.10]; Province MA, 2014, CLIN PHARMACOL THER, V96, P144, DOI 10.1038/clpt.2014.100; Province MA, 2014, CLIN PHARMACOL THER, V95, P216, DOI 10.1038/clpt.2013.186; PUI CH, 1990, BLOOD, V76, P1449; Pulley JM, 2012, CLIN PHARMACOL THER, V92, P87, DOI 10.1038/clpt.2011.371; Rasmussen-Torvik LJ, 2014, CLIN PHARMACOL THER, V96, P482, DOI 10.1038/clpt.2014.137; Ratain MJ, 2013, CLIN PHARMACOL THER, V94, P184, DOI 10.1038/clpt.2013.66; Rattanavipapong W, 2013, EPILEPSIA, V54, P1628, DOI 10.1111/epi.12325; Rehm HL, 2015, NEW ENGL J MED, V372, P2235, DOI 10.1056/NEJMsr1406261; Relling MV, 2014, CLIN PHARMACOL THER, V96, P169, DOI 10.1038/clpt.2014.97; Relling MV, 2011, CLIN PHARMACOL THER, V89, P464, DOI 10.1038/clpt.2010.279; ROLLHANSEN N, 1989, BIOL PHILOS, V4, P303, DOI 10.1007/BF02426630; Samwald M, 2013, PHARMACOGENOMICS, V14, P1529, DOI 10.2217/pgs.13.121; Schroeder SA, 2013, NEW ENGL J MED, V368, P2029, DOI 10.1056/NEJMsb1302322; Scott SA, 2011, GENET MED, V13, P987, DOI 10.1097/GIM.0b013e318238b38c; Senderowicz AM, 2014, CLIN CANCER RES, V20, P1445, DOI 10.1158/1078-0432.CCR-13-1761; Shuldiner AR, 2013, CLIN PHARMACOL THER, V94, P207, DOI 10.1038/clpt.2013.59; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Stanek EJ, 2012, CLIN PHARMACOL THER, V91, P450, DOI 10.1038/clpt.2011.306; Stocco G, 2009, CLIN PHARMACOL THER, V85, P164, DOI 10.1038/clpt.2008.154; Sukasem C, 2014, ASIAN PAC J ALLERGY, V32, P111; Swen JJ, 2008, CLIN PHARMACOL THER, V83, P781, DOI 10.1038/sj.clpt.6100507; Swen JJ, 2011, CLIN PHARMACOL THER, V89, P662, DOI 10.1038/clpt.2011.34; Toh DSL, 2014, PHARMACOGENOMICS J, V14, P316, DOI 10.1038/tpj.2013.46; Tutton R, 2014, PHARMACOGENOMICS, V15, P297, DOI 10.2217/pgs.13.198; US FDA, 2015, TABL PHARM BIOM DRUG; Van Allen EM, 2013, J CLIN ONCOL, V31, P1825, DOI 10.1200/JCO.2013.48.7215; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; VESELL ES, 1968, SCIENCE, V161, P72, DOI 10.1126/science.161.3836.72; Vogel F., 1959, ERG INN MED KINDERHK, P52; Wang LW, 2011, NEW ENGL J MED, V364, P1144, DOI 10.1056/NEJMra1010600; Weber GM, 2014, JAMA-J AM MED ASSOC, V311, P2479, DOI 10.1001/jama.2014.4228; Wheeler HE, 2013, NAT REV GENET, V14, P23, DOI 10.1038/nrg3352; Whirl-Carrillo M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/clpt.2012.96; Wiener CM, 2010, ACAD MED, V85, P498, DOI 10.1097/ACM.0b013e3181ccbebf; Yang JJ, 2015, J CLIN ONCOL, V33, P1235, DOI 10.1200/JCO.2014.59.4671; Yang SK, 2014, NAT GENET, V46, P1017, DOI 10.1038/ng.3060; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003; Yeh P, 2013, CLIN CANCER RES, V19, P1894, DOI 10.1158/1078-0432.CCR-12-1894; Zhu Q, 2013, J BIOMED INFORM, V46, P286, DOI 10.1016/j.jbi.2012.11.004	111	451	467	9	168	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 15	2015	526	7573					343	350		10.1038/nature15817	http://dx.doi.org/10.1038/nature15817			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT3TQ	26469045	Green Accepted			2023-01-03	WOS:000362730200037
J	Marshall, PWM; Finn, HT; Siegler, JC				Marshall, Paul W. M.; Finn, Harrison T.; Siegler, Jason C.			The Magnitude of Peripheral Muscle Fatigue Induced by High and Low Intensity Single-Joint Exercise Does Not Lead to Central Motor Output Reductions in Resistance Trained Men	PLOS ONE			English	Article							EVOKED CONTRACTILE PROPERTIES; ISOMETRIC CONTRACTIONS; NEURAL ADAPTATION; H-REFLEX; V-WAVE; HUMANS; MECHANISMS; VOLUNTARY; STRENGTH; FORCE	Purpose To examine quadriceps muscle fatigue and central motor output during fatiguing single joint exercise at 40% and 80% maximal torque output in resistance trained men. Method Ten resistance trained men performed fatiguing isometric knee extensor exercise at 40% and 80% of maximal torque output. Maximal torque, rate of torque development, and measures of central motor output and peripheral muscle fatigue were recorded at two matched volumes of exercise, and after a final contraction performed to exhaustion. Central motor output was quantified from changes in voluntary activation, normalized surface electromyograms (EMG), and V-waves. Quadriceps muscle fatigue was assessed from changes in the size and shape of the resting potentiated twitch (Q.(pot.tw)). Central motor output during the exercise protocols was estimated from EMG and interpolated twitches applied during the task (VA(sub)). Results Greater reductions in maximal torque and rate of torque development were observed during the 40% protocol (p<0.05). Maximal central motor output did not change for either protocol. For the 40% protocol reductions from pre-exercise in rate and amplitude variables calculated from the Q.(pot.tw) between 66.2 to 70.8% (p<0.001) exceeded those observed during the 80% protocol (p<0.01). V-waves only declined during the 80% protocol between 56.8 +/- 35.8% to 53.6 +/- 37.4%(p<0.05). At the end of the final 80% contraction VA(sub) had increased from 91.2 +/- 6.2% to 94.9 +/- 4.7% (p = 0.005), but a greater increase was observed during the 40% contraction where VAsub had increased from 67.1 +/- 6.1% to 88.9 +/- 9.6%(p<0.001). Conclusion Maximal central motor output in resistance trained men is well preserved despite varying levels of peripheral muscle fatigue. Upregulated central motor output during the 40% contraction protocol appeared to elicit greater peripheral fatigue. V-waves declines during the 80% protocol suggest intensity dependent modulation of the Ia afferent pathway.	[Marshall, Paul W. M.; Finn, Harrison T.; Siegler, Jason C.] Univ Western Sydney, Sch Sci & Hlth, Human Performance Lab, Sydney, NSW, Australia; [Finn, Harrison T.] NeuRA, Sydney, NSW, Australia	Western Sydney University; Neuroscience Research Australia	Marshall, PWM (corresponding author), Univ Western Sydney, Sch Sci & Hlth, Human Performance Lab, Sydney, NSW, Australia.	p.marshall@uws.edu.au		Siegler, Jason/0000-0003-1346-4982; Finn, Harrison/0000-0003-3412-0273	School of Science and Health, University of Western Sydney	School of Science and Health, University of Western Sydney	Funding for this project was provided by the School of Science and Health, University of Western Sydney.	Aagaard P, 2002, J APPL PHYSIOL, V92, P2309, DOI 10.1152/japplphysiol.01185.2001; Aagaard P, 2002, J APPL PHYSIOL, V93, P1318, DOI 10.1152/japplphysiol.00283.2002; Adam A, 2005, J APPL PHYSIOL, V99, P268, DOI 10.1152/japplphysiol.01344.2004; Allen DG, 2008, PHYSIOL REV, V88, P287, DOI 10.1152/physrev.00015.2007; Allison GT, 2008, J ORTHOP SPORT PHYS, V38, P228, DOI 10.2519/jospt.2008.2703; Amann M, 2011, MED SCI SPORT EXER, V43, P2039, DOI 10.1249/MSS.0b013e31821f59ab; Baudry S, 2011, J NEUROPHYSIOL, V106, P265, DOI 10.1152/jn.00954.2010; Behm DG, 1997, J APPL PHYSIOL, V82, P1654, DOI 10.1152/jappl.1997.82.5.1654; Behm DG, 2002, J STRENGTH COND RES, V16, P209; Carroll TJ, 2009, ACTA PHYSIOL, V197, P161, DOI 10.1111/j.1748-1716.2009.01992.x; Carroll TJ, 2002, J PHYSIOL-LONDON, V544, P641, DOI 10.1113/jphysiol.2002.024463; Christian RJ, 2014, J APPL PHYSIOL, V117, P1063, DOI 10.1152/japplphysiol.00988.2013; Christie A, 2009, EUR J APPL PHYSIOL, V107, P177, DOI 10.1007/s00421-009-1113-7; del Olmo MF, 2006, EUR J APPL PHYSIOL, V96, P722, DOI 10.1007/s00421-006-0153-5; Dideriksen JL, 2011, J APPL PHYSIOL, V111, P485, DOI 10.1152/japplphysiol.00186.2011; Ekblom MMN, 2010, J APPL PHYSIOL, V109, P19, DOI 10.1152/japplphysiol.01307.2009; Farina D, 2008, J NEUROPHYSIOL, V100, P431, DOI 10.1152/jn.90365.2008; Gabriel DA, 2006, SPORTS MED, V36, P133, DOI 10.2165/00007256-200636020-00004; Gandevia SC, 2001, PHYSIOL REV, V81, P1725, DOI 10.1152/physrev.2001.81.4.1725; Gauche E, 2009, J ELECTROMYOGR KINES, V19, pE481, DOI 10.1016/j.jelekin.2009.01.006; Harridge SDR, 1996, PFLUG ARCH EUR J PHY, V432, P913, DOI 10.1007/s004240050215; HENNEMAN E, 1957, SCIENCE, V126, P1345, DOI 10.1126/science.126.3287.1345; Johnson ST, 2015, SCAND J MED SCI SPOR, V25, P623, DOI 10.1111/sms.12283; KOMI PV, 1979, EUR J APPL PHYSIOL, V42, P41, DOI 10.1007/BF00421103; MERTON PA, 1954, J PHYSIOL-LONDON, V123, P553, DOI 10.1113/jphysiol.1954.sp005070; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; Misiaszek JE, 2003, MUSCLE NERVE, V28, P144, DOI 10.1002/mus.10372; Mitchell CJ, 2012, J APPL PHYSIOL, V113, P71, DOI 10.1152/japplphysiol.00307.2012; Nordlund MM, 2004, J APPL PHYSIOL, V96, P218, DOI 10.1152/japplphysiol.00650.2003; Rossman MJ, 2014, AM J PHYSIOL-REG I, V306, pR934, DOI 10.1152/ajpregu.00043.2014; Siegler JC, 2015, EXP PHYSIOL, V100, P519, DOI 10.1113/EP085054; Siegler JC, 2015, EUR J APPL PHYSIOL, V115, P565, DOI 10.1007/s00421-014-3027-2; Strojnik V, 1998, J APPL PHYSIOL, V84, P344, DOI 10.1152/jappl.1998.84.1.344; Vila-Cha C, 2012, J APPL PHYSIOL, V112, P54, DOI 10.1152/japplphysiol.00802.2011; Yoon T, 2007, MUSCLE NERVE, V36, P515, DOI 10.1002/mus.20844	35	16	16	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2015	10	10							e0140108	10.1371/journal.pone.0140108	http://dx.doi.org/10.1371/journal.pone.0140108			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TP	26439261	Green Published, gold, Green Submitted			2023-01-03	WOS:000362510300098
J	Oliver, D				Oliver, David			ACUTE PERSPECTIVE David Oliver: Why I let some patients stay longer in hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						Appleby J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1563; College of Emergency Medicine, 2014, CROWD EM DEP; GILLON R, 1994, BRIT MED J, V309, P184, DOI 10.1136/bmj.309.6948.184; Hall K, 2012, UNDERSTANDING IMPROV; HealthWatch England, 2015, SAF HOM WHAT HAPP OL; King's Fund, 2015, 16 KINGS FUND; NHS England, 2015, TRANSF URG EM CAR SE; Oliver D, 2014, MAKING HLTH CARE SYS	8	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 2	2015	351								h5225	10.1136/bmj.h5225	http://dx.doi.org/10.1136/bmj.h5225			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT0AK	26432800	Bronze			2023-01-03	WOS:000362455900005
J	Wens, I; Dalgas, U; Vandenabeele, F; Grevendonk, L; Verboven, K; Hansen, D; Eijnde, BO				Wens, Inez; Dalgas, Ulrik; Vandenabeele, Frank; Grevendonk, Lotte; Verboven, Kenneth; Hansen, Dominique; Eijnde, Bert O.			High Intensity Exercise in Multiple Sclerosis: Effects on Muscle Contractile Characteristics and Exercise Capacity, a Randomised Controlled Trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; TRAINING IMPROVES; CHRONOTROPIC INCOMPETENCE; MODERATE EXERCISE; STRENGTH; HEART; IMPACT; DISABILITY; MOBILITY; FITNESS	Introduction Low-to-moderate intensity exercise improves muscle contractile properties and endurance capacity in multiple sclerosis (MS). The impact of high intensity exercise remains unknown. Methods Thirty-four MS patients were randomized into a sedentary control group (SED, n = 11) and 2 exercise groups that performed 12 weeks of a high intensity interval (HITR, n = 12) or high intensity continuous cardiovascular training (HCTR, n = 11), both in combination with resistance training. M. vastus lateralis fiber cross sectional area (CSA) and proportion, kneeflexor/ extensor strength, body composition, maximal endurance capacity and self-reported physical activity levels were assessed before and after 12 weeks. Results Compared to SED, 12 weeks of high intensity exercise increased mean fiber CSA (HITR: + 21 +/- 7%, HCTR: + 23 +/- 5%). Furthermore, fiber type I CSA increased in HCTR (+ 29 +/- 6%), whereas type II (+ 23 +/- 7%) and IIa (+ 23 +/- 6%,) CSA increased in HITR. Muscle strength improved in HITR and HCTR (between + 13 +/- 7% and + 45 +/- 20%) and body fat percentage tended to decrease (HITR: -3.9 +/- 2.0% and HCTR: -2.5 +/- 1.2%). Furthermore, endurance capacity (Wmax + 21 +/- 4%, time to exhaustion + 24 +/- 5%, VO2max + 17 +/- 5%) and lean tissue mass (+ 1.4 +/- 0.5%) only increased in HITR. Finally self-reported physical activity levels increased 73 +/- 19% and 86 +/- 27% in HCTR and HITR, respectively. Conclusion High intensity cardiovascular exercise combined with resistance training was safe, well tolerated and improved muscle contractile characteristics and endurance capacity in MS.	[Wens, Inez; Vandenabeele, Frank; Grevendonk, Lotte; Verboven, Kenneth; Hansen, Dominique; Eijnde, Bert O.] Hasselt Univ, Fac Med & Life Sci, REVAL Rehabil Res Ctr, BIOMED Biomed Res Inst, Diepenbeek, Belgium; [Dalgas, Ulrik] Aarhus Univ, Dept Publ Hlth, Sect Sport Sci, DK-8000 Aarhus C, Denmark	Hasselt University; Aarhus University	Wens, I (corresponding author), Hasselt Univ, Fac Med & Life Sci, REVAL Rehabil Res Ctr, BIOMED Biomed Res Inst, Agoralaan Bldg A, Diepenbeek, Belgium.	inez.wens@uhasselt.be	Hansen, Dominique/AAH-5883-2021; Verboven, Kenneth/AAB-2007-2019; Op 't Eijnde, Bert/AHA-6777-2022; Vandenabeele, Frank/G-9292-2019	Op 't Eijnde, Bert/0000-0002-2262-4661; Vandenabeele, Frank/0000-0001-5556-8937; Cleeren TEST, Hilde/0000-0002-8756-8904; Wens, Inez/0000-0002-8171-5686; Hansen, Dominique/0000-0003-3074-2737; Grevendonk, Lotte/0000-0001-9540-1832; Dalgas, Ulrik/0000-0003-4132-2789	MS Fund, Limburg, Flanders, Belgium; Biogen Idec; Merck Serono; Sanofi Aventis; Biogen	MS Fund, Limburg, Flanders, Belgium; Biogen Idec(Biogen); Merck Serono(Merck & Company); Sanofi Aventis(Sanofi-Aventis); Biogen(Biogen)	This work was supported by MS Fund, Limburg, Flanders, Belgium. Ulrik Dalgas has received research support, travel grants and/or teaching honorary from Biogen Idec, Merck Serono and Sanofi Aventis and further serves as PI for the ongoing Biogen sponsored ACTIMS study. This does not alter our adherence to Plos One policies on sharing data and materials. Furthermore, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boutcher SH, 2011, J OBES, V2011, DOI 10.1155/2011/868305; Boyne P, 2013, TOP STROKE REHABIL, V20, P317, DOI 10.1310/tsr2004-317; Broekmans T, 2011, MULT SCLER J, V17, P468, DOI 10.1177/1352458510391339; BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; Brubaker Peter H, 2007, Curr Cardiol Rep, V9, P229, DOI 10.1007/BF02938355; Brubaker PH, 2011, CIRCULATION, V123, P1010, DOI 10.1161/CIRCULATIONAHA.110.940577; Ciolac EG, 2010, HYPERTENS RES, V33, P836, DOI 10.1038/hr.2010.72; Ciolac EG, 2012, AM J CARDIOVASC DIS, V2, P102; Collett J, 2011, MULT SCLER; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Dalgas U, 2008, MULT SCLER J, V14, P35, DOI 10.1177/1352458507079445; Dalgas U, 2009, Int MS J, V16, P5; Dalgas U, 2009, NEUROLOGY, V73, P1478, DOI 10.1212/WNL.0b013e3181bf98b4; Dalgas U, 2010, MULT SCLER; Dettmers C, 2009, ACTA NEUROL SCAND, V120, P251, DOI 10.1111/j.1600-0404.2008.01152.x; GREEN HJ, 1979, EUR J APPL PHYSIOL O, V41, P109, DOI 10.1007/BF00421658; Guimaraes GV, 2010, HYPERTENS RES, V33, P627, DOI 10.1038/hr.2010.42; Hakkinen K, 1998, J GERONTOL A-BIOL, V53, pB415, DOI 10.1093/gerona/53A.6.B415; Hansen D, 2014, EUR J PHYS REHABIL M; Hansen D, 2013, NEUROREHABILITATION, V33, P139, DOI 10.3233/NRE-130938; Hikida RS, 2000, J GERONTOL A-BIOL, V55, pB347, DOI 10.1093/gerona/55.7.B347; Kemi OJ, 2010, J CARDIOPULM REHABIL, V30, P2, DOI 10.1097/HCR.0b013e3181c56b89; Keteyian SJ, 1999, AM HEART J, V138, P233, DOI 10.1016/S0002-8703(99)70106-7; Kjolhede T, 2012, MULT SCLER J, V18, P1215, DOI 10.1177/1352458512437418; Langeskov-Christensen M, 2014, J NEUROL SCI, V342, P79, DOI 10.1016/j.jns.2014.04.028; LEXELL J, 1989, CLIN PHYSIOL, V9, P333, DOI 10.1111/j.1475-097X.1989.tb00987.x; Miossi R, 2012, ARTHRIT CARE RES, V64, P1159, DOI 10.1002/acr.21678; Mitranun W, 2014, SCAND J MED SCI SPOR, V24, pE69, DOI 10.1111/sms.12112; Morton RD, 2010, J SPORT SCI, V28, P93, DOI 10.1080/02640410903365685; Motl RW, 2008, MULT SCLER J, V14, P129, DOI 10.1177/1352458507080464; Motl RW, 2008, J NERV MENT DIS, V196, P492, DOI 10.1097/NMD.0b013e318177351b; Motl RW, 2012, J NEUROL PHYS THER, V36, P32, DOI 10.1097/NPT.0b013e3182477c92; Petajan JH, 1996, ANN NEUROL, V39, P432, DOI 10.1002/ana.410390405; Raymond MJ, 2013, ARCH PHYS MED REHAB, V94, P1458, DOI 10.1016/j.apmr.2013.02.022; Romberg A, 2004, NEUROLOGY, V63, P2034, DOI 10.1212/01.WNL.0000145761.38400.65; Schulz KH, 2004, J NEUROL SCI, V225, P11, DOI 10.1016/j.jns.2004.06.009; Simoneau JA, 1985, EUR J APPL PHYSL OCC, P250; Sloth M, 2013, SCAND J MED SCI SPOR, V23, pE341, DOI 10.1111/sms.12092; Smith RM, 2006, ARCH PHYS MED REHAB, V87, P723, DOI 10.1016/j.apmr.2006.01.015; Stuifbergen A K, 1997, J Neurosci Nurs, V29, P238; Stuifbergen AK, 2006, ARCH PHYS MED REHAB, V87, P935, DOI 10.1016/j.apmr.2006.04.003; Surakka J, 2004, CLIN REHABIL, V18, P737, DOI 10.1191/0269215504cr780oa; Terzis G, 2008, J STRENGTH COND RES, V22, P1198, DOI 10.1519/JSC.0b013e31816d5c97; Thoumie P, 2005, MULT SCLER J, V11, P485, DOI 10.1191/1352458505ms1176oa; Tjonna AE, 2008, CIRCULATION, V118, P346, DOI 10.1161/CIRCULATIONAHA.108.772822; Washburn RA, 2002, ARCH PHYS MED REHAB, V83, P193, DOI 10.1053/apmr.2002.27467; Wens I, 2012, MULT SCLER J, V18, pS35; Wens I, 2014, AM J PHYS MED REHABI; Wens I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108158	49	53	54	3	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2015	10	9							e0133697	10.1371/journal.pone.0133697	http://dx.doi.org/10.1371/journal.pone.0133697			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6EV	26418222	gold, Green Published, Green Submitted			2023-01-03	WOS:000362171400001
J	Zauderer, MG				Zauderer, Marjorie G.			A new standard for malignant pleural mesothelioma	LANCET			English	Editorial Material							PHASE-II TRIAL; MULTICENTER; TARGETS; THERAPY		[Zauderer, Marjorie G.] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, Div Solid Tumor Oncol, New York, NY 10065 USA; [Zauderer, Marjorie G.] Weill Cornell Med Coll, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Zauderer, MG (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, Div Solid Tumor Oncol, New York, NY 10065 USA.; Zauderer, MG (corresponding author), Weill Cornell Med Coll, New York, NY 10065 USA.	zauderem@mskcc.org			NCI NIH HHS [P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Buikhuisen WA, 2013, LANCET ONCOL, V14, P543, DOI 10.1016/S1470-2045(13)70125-6; Dubey S, 2010, J THORAC ONCOL, V5, P1655, DOI 10.1097/JTO.0b013e3181ec18db; Hellmann MD, 2016, JAMA ONCOL, V2, P167, DOI 10.1001/jamaoncol.2015.4345; Jahan T, 2012, LUNG CANCER, V76, P393, DOI 10.1016/j.lungcan.2011.11.014; Kindler HL, 2012, J CLIN ONCOL, V30, P2509, DOI 10.1200/JCO.2011.41.5869; Ladanyi M, 2012, CLIN CANCER RES, V18, P4485, DOI 10.1158/1078-0432.CCR-11-2375; Nowak AK, 2012, J THORAC ONCOL, V7, P1449, DOI 10.1097/JTO.0b013e31825f22ee; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Pastan I, 2014, CANCER RES, V74, P2907, DOI 10.1158/0008-5472.CAN-14-0337; Stahel RA, 2015, ANN ONCOL, V26, P1649, DOI 10.1093/annonc/mdv101; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Zalcman G, 2015, LANCET	13	7	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	2016	387	10026					1352	1354		10.1016/S0140-6736(15)01311-2	http://dx.doi.org/10.1016/S0140-6736(15)01311-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DI0WH	26719231	Green Accepted			2023-01-03	WOS:000373217500009
J	Glenn, AE; Davis, CB; Gao, ML; Gold, SE; Mitchell, TR; Proctor, RH; Stewart, JE; Snook, ME				Glenn, Anthony E.; Davis, C. Britton; Gao, Minglu; Gold, Scott E.; Mitchell, Trevor R.; Proctor, Robert H.; Stewart, Jane E.; Snook, Maurice E.			Two Horizontally Transferred Xenobiotic Resistance Gene Clusters Associated with Detoxification of Benzoxazolinones by Fusarium Species	PLOS ONE			English	Article							ASPERGILLUS-KAWACHII; FUMONISIN PRODUCTION; FUNGAL ENDOPHYTES; BETA-LACTAMASES; VERTICILLIOIDES; ECOLOGY; BIOTRANSFORMATION; IDENTIFICATION; PHYTOALEXINS; DEGRADATION	Microbes encounter a broad spectrum of antimicrobial compounds in their environments and often possess metabolic strategies to detoxify such xenobiotics. We have previously shown that Fusarium verticillioides, a fungal pathogen of maize known for its production of fumonisin mycotoxins, possesses two unlinked loci, FDB1 and FDB2, necessary for detoxification of antimicrobial compounds produced by maize, including the gamma-lactam 2-benzoxazolinone ( BOA). In support of these earlier studies, microarray analysis of F. verticillioides exposed to BOA identified the induction of multiple genes at FDB1 and FDB2, indicating the loci consist of gene clusters. One of the FDB1 cluster genes encoded a protein having domain homology to the metallo-beta-lactamase (MBL) superfamily. Deletion of this gene ( MBL1) rendered F. verticillioides incapable of metabolizing BOA and thus unable to grow on BOA-amended media. Deletion of other FDB1 cluster genes, in particular AMD1 and DLH1, did not affect BOA degradation. Phylogenetic analyses and topology testing of the FDB1 and FDB2 cluster genes suggested two horizontal transfer events among fungi, one being transfer of FDB1 from Fusarium to Colletotrichum, and the second being transfer of the FDB2 cluster from Fusarium to Aspergillus. Together, the results suggest that plant-derived xenobiotics have exerted evolutionary pressure on these fungi, leading to horizontal transfer of genes that enhance fitness or virulence.	[Glenn, Anthony E.; Davis, C. Britton; Gold, Scott E.; Mitchell, Trevor R.; Snook, Maurice E.] USDA, ARS, Richard B Russell Res Ctr, Toxicol & Mycotoxin Res Unit, Athens, GA USA; [Gao, Minglu] Univ Georgia, Dept Plant Pathol, Athens, GA 30602 USA; [Proctor, Robert H.] USDA, ARS, Natl Ctr Agr Utilizat Res, Mycotoxin Prevent & Appl Microbiol Res Unit, Peoria, IL USA; [Stewart, Jane E.] Colorado State Univ, Bioagr Sci & Pest Management, Ft Collins, CO 80523 USA; [Davis, C. Britton] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA	United States Department of Agriculture (USDA); University System of Georgia; University of Georgia; United States Department of Agriculture (USDA); Colorado State University; University System of Georgia; University of Georgia	Glenn, AE (corresponding author), USDA, ARS, Richard B Russell Res Ctr, Toxicol & Mycotoxin Res Unit, Athens, GA USA.	anthony.glenn@ars.usda.gov		Glenn, Anthony/0000-0001-8329-1306				Abbas HK, 2009, TOXIN REV, V28, P142, DOI 10.1080/15569540903081590; Allen HK, 2009, ISME J, V3, P243, DOI 10.1038/ismej.2008.86; Baldwin TT, 2014, J AGR FOOD CHEM, V62, P2118, DOI 10.1021/jf5001106; Brown DW, 2012, FUNGAL GENET BIOL, V49, P521, DOI 10.1016/j.fgb.2012.05.010; Bulder AS, 2012, P 74 M JOINT FAOWHO, P325; Bush K, 2010, CRIT CARE, V14, DOI 10.1186/cc8892; Butchko RAE, 2012, FUNGAL GENET BIOL, V49, P602, DOI 10.1016/j.fgb.2012.06.003; Dong YH, 2001, NATURE, V411, P813, DOI 10.1038/35081101; Futagami T, 2015, APPL ENVIRON MICROB, V81, P1353, DOI 10.1128/AEM.03483-14; Gardiner DM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002952; Geiser DM, 2004, EUR J PLANT PATHOL, V110, P473, DOI 10.1023/B:EJPP.0000032386.75915.a0; Glenn AE, 2009, J APPL MICROBIOL, V107, P657, DOI 10.1111/j.1365-2672.2009.04246.x; Glenn AE, 2003, APPL ENVIRON MICROB, V69, P3165, DOI 10.1128/AEM.69.6.3165-3169.2003; Glenn AE, 2002, MOL PLANT MICROBE IN, V15, P91, DOI 10.1094/MPMI.2002.15.2.91; Glenn AE, 2001, APPL ENVIRON MICROB, V67, P2973, DOI 10.1128/AEM.67.7.2973-2981.2001; Glenn AE, 2008, MOL PLANT MICROBE IN, V21, P87, DOI 10.1094/MPMI-21-1-0087; Glenn AE, 2010, FEBS LETT, V584, P3158, DOI 10.1016/j.febslet.2010.05.063; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Karagianni EP, 2015, SCI REP-UK, V5, DOI 10.1038/srep12900; Kettle AJ, 2015, MOL PLANT PATHOL, V16, P946, DOI 10.1111/mpp.12250; Kettle AJ, 2015, FUNGAL GENET BIOL, V83, P1, DOI 10.1016/j.fgb.2015.08.005; Leslie JF, 2006, FUSARIUM LAB MANUAL; Lim FY, 2012, APPL ENVIRON MICROB, V78, P4117, DOI 10.1128/AEM.07710-11; Marasas WFO, 2004, J NUTR, V134, P711, DOI 10.1093/jn/134.4.711; Morgavi DP, 2007, ANIM FEED SCI TECH, V137, P201, DOI 10.1016/j.anifeedsci.2007.06.002; Nesme J, 2015, ENVIRON MICROBIOL, V17, P913, DOI 10.1111/1462-2920.12631; NIEMEYER HM, 1988, PHYTOCHEMISTRY, V27, P3349, DOI 10.1016/0031-9422(88)80731-3; O'Donnell K, 2013, FUNGAL GENET BIOL, V52, P20, DOI 10.1016/j.fgb.2012.12.004; Saunders M, 2008, APPL ENVIRON MICROB, V74, P136, DOI 10.1128/AEM.01538-07; Saunders M, 2010, EVOL APPL, V3, P525, DOI 10.1111/j.1752-4571.2010.00141.x; Saunders M, 2009, NEW PHYTOL, V182, P229, DOI 10.1111/j.1469-8137.2008.02746.x; Schliep KP, 2011, BIOINFORMATICS, V27, P592, DOI 10.1093/bioinformatics/btq706; Schulz B, 2005, MYCOL RES, V109, P661, DOI 10.1017/S095375620500273X; Solovyev V, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s10; Stone JK, 2000, BOOK SOIL P, P3; Sugimoto T, 2012, J IND MICROBIOL BIOT, V39, P605, DOI 10.1007/s10295-011-1053-1; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]; Vagena E, 2008, CURR DRUG METAB, V9, P628, DOI 10.2174/138920008785821729; VANETTEN HD, 1994, PLANT CELL, V6, P1191; Vilich V, 1999, MYCOL RES, V103, P1529, DOI 10.1017/S0953756299008862; Voss KA, 2007, ANIM FEED SCI TECH, V137, P299, DOI 10.1016/j.anifeedsci.2007.06.007; Williams LD, 2007, J AGR FOOD CHEM, V55, P2937, DOI 10.1021/jf0635614; Williams LD, 2006, J AGR FOOD CHEM, V54, P5694, DOI 10.1021/jf0610209; Yim G, 2007, PHILOS T R SOC B, V362, P1195, DOI 10.1098/rstb.2007.2044; Yu JH, 2004, FUNGAL GENET BIOL, V41, P973, DOI 10.1016/j.fgb.2004.08.001	46	24	50	3	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147486	10.1371/journal.pone.0147486	http://dx.doi.org/10.1371/journal.pone.0147486			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DC9FZ	26808652	gold, Green Published, Green Submitted			2023-01-03	WOS:000369527800108
J	Storm, EE; Durinck, S; Melo, FDE; Tremayne, J; Kljavin, N; Tan, C; Ye, XF; Chiu, C; Pham, T; Hongo, JA; Bainbridge, T; Firestein, R; Blackwood, E; Metcalfe, C; Stawiski, EW; Yauch, RL; Wu, Y; de Sauvage, FJ				Storm, Elaine E.; Durinck, Steffen; de Sousa e Melo, Felipe; Tremayne, Jarrod; Kljavin, Noelyn; Tan, Christine; Ye, Xiaofen; Chiu, Cecilia; Thinh Pham; Hongo, Jo-Anne; Bainbridge, Travis; Firestein, Ron; Blackwood, Elizabeth; Metcalfe, Ciara; Stawiski, Eric W.; Yauch, Robert L.; Wu, Yan; de Sauvage, Frederic J.			Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function	NATURE			English	Article							COLORECTAL-CANCER; WNT/BETA-CATENIN; SMALL-INTESTINE; READ ALIGNMENT; IN-VITRO; CRYPT; IDENTIFICATION; MAINTENANCE; HOMEOSTASIS	Colorectal cancer remains a major unmet medical need, prompting large-scale genomics efforts in the field to identify molecular drivers for which targeted therapies might be developed(1-3). We previously reported the identification of recurrent translocations in R-spondin genes present in a subset of colorectal tumours(4). Here we show that targeting RSPO3 in PTPRK-RSPO3-fusion-positive human tumour xenografts inhibits tumour growth and promotes differentiation. Notably, genes expressed in the stem-cell compartment of the intestine were among those most sensitive to anti-RSPO3 treatment. This observation, combined with functional assays, suggests that a stem-cell compartment drives PTPRK-RSPO3 colorectal tumour growth and indicates that the therapeutic targeting of stem-cell properties within tumours may be a clinically relevant approach for the treatment of colorectal tumours.	[Storm, Elaine E.; de Sousa e Melo, Felipe; Kljavin, Noelyn; de Sauvage, Frederic J.] Genentech Inc, Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA; [Durinck, Steffen; Stawiski, Eric W.] Genentech Inc, Mol Biol, 1 DNA Way, San Francisco, CA 94080 USA; [Tremayne, Jarrod; Blackwood, Elizabeth; Metcalfe, Ciara] Genentech Inc, Translat Oncol, 1 DNA Way, San Francisco, CA 94080 USA; [Tan, Christine; Chiu, Cecilia; Hongo, Jo-Anne; Wu, Yan] Genentech Inc, Antibody Engn, 1 DNA Way, San Francisco, CA 94080 USA; [Ye, Xiaofen; Yauch, Robert L.] Genentech Inc, Discovery Oncol, 1 DNA Way, San Francisco, CA 94080 USA; [Thinh Pham; Firestein, Ron] Genentech Inc, Res Pathol, 1 DNA Way, San Francisco, CA 94080 USA; [Bainbridge, Travis] Genentech Inc, Prot Chem, 1 DNA Way, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	de Sauvage, FJ (corresponding author), Genentech Inc, Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	desauvage.fred@gene.com	de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Fu WQ, 2013, NATURE, V493, P216, DOI 10.1038/nature11690; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Jung P, 2011, NAT MED, V17, P1225, DOI 10.1038/nm.2470; Kim KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/cc.5.1.2305; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Madan B., 2015, ONCOGENE; Metcalfe C, 2014, CELL STEM CELL, V14, P149, DOI 10.1016/j.stem.2013.11.008; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sadanandam A, 2014, CELL CYCLE, V13, P353, DOI 10.4161/cc.27769; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Scholer-Dahirel A, 2011, P NATL ACAD SCI USA, V108, P17135, DOI 10.1073/pnas.1104182108; Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; Tso KY, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1172; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wu CJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4149; Yan KS, 2012, P NATL ACAD SCI USA, V109, P466, DOI 10.1073/pnas.1118857109	36	154	162	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 7	2016	529	7584					97	+		10.1038/nature16466	http://dx.doi.org/10.1038/nature16466			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA6VY	26700806				2023-01-03	WOS:000367944900034
J	Lu, JY; Zheng, J; Zhang, WZ; Huang, BT				Lu, Jia-Yang; Zheng, Jing; Zhang, Wu-Zhe; Huang, Bao-Tian			Flattening Filter-Free Beams in Intensity-Modulated Radiotherapy and Volumetric Modulated Arc Therapy for Sinonasal Cancer	PLOS ONE			English	Article							PARANASAL SINUS CANCER; UNFLATTENED PHOTON BEAMS; NASAL CAVITY; RADIATION-THERAPY; LINEAR-ACCELERATOR; MAXILLARY SINUS; PROSTATE-CANCER; IMRT; CARCINOMA; ACCURACY	Purpose To evaluate the dosimetric impacts of flattening filter-free (FFF) beams in intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) for sinonasal cancer. Methods For fourteen cases, IMRT and VMAT planning was performed using 6-MV photon beams with both conventional flattened and FFF modes. The four types of plans were compared in terms of target dose homogeneity and conformity, organ-at-risk (OAR) sparing, number of monitor units (MUs) per fraction, treatment time and pure beam-on time. Results FFF beams led to comparable target dose homogeneity, conformity, increased number of MUs and lower doses to the spinal cord, brainstem and normal tissue, compared with flattened beams in both IMRT and VMAT. FFF beams in IMRT resulted in improvements by up to 5.4% for sparing of the contralateral optic structures, with shortened treatment time by 9.5%. However, FFF beams provided comparable overall OAR sparing and treatment time in VMAT. With FFF mode, VMAT yielded inferior homogeneity and superior conformity compared with IMRT, with comparable overall OAR sparing and significantly shorter treatment time. Conclusions Using FFF beams in IMRT and VMAT is feasible for the treatment of sinonasal cancer. Our results suggest that the delivery mode of FFF beams may play an encouraging role with better sparing of contralateral optic OARs and treatment efficiency in IMRT, but yield comparable results in VMAT.	[Lu, Jia-Yang; Zhang, Wu-Zhe; Huang, Bao-Tian] Shantou Univ, Dept Radiat Oncol, Canc Hosp, Coll Med, Shantou, Guangdong, Peoples R China; [Zheng, Jing] Sun Yat Sen Univ, Affiliated Shantou Hosp, Shantou Cent Hosp, Dept Lab, Shantou, Guangdong, Peoples R China	Shantou University; Sun Yat Sen University	Huang, BT (corresponding author), Shantou Univ, Dept Radiat Oncol, Canc Hosp, Coll Med, Shantou, Guangdong, Peoples R China.	tianjia2025@163.com			Shantou Medical Science and Technology Project [(2015)123]; Medical Scientific Research Foundation of Guangdong Province [A2015534]	Shantou Medical Science and Technology Project; Medical Scientific Research Foundation of Guangdong Province	This work was supported by Shantou Medical Science and Technology Project [Grant No. (2015)123] and Medical Scientific Research Foundation of Guangdong Province (Grant No. A2015534). No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ainsbury EA, 2009, RADIAT RES, V172, P1, DOI 10.1667/RR1688.1; Cashmore J, 2008, PHYS MED BIOL, V53, P1933, DOI 10.1088/0031-9155/53/7/009; Chi A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-4; Dogan N, 2006, MED PHYS, V33, P4033, DOI 10.1118/1.2357835; Duprez F, 2012, INT J RADIAT ONCOL, V83, P252, DOI 10.1016/j.ijrobp.2011.06.1977; Dzierma Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094371; Gasic D, 2014, ACTA ONCOL, V53, P1005, DOI 10.3109/0284186X.2014.925578; Gay HA, 2007, PHYS MEDICA, V23, P115, DOI 10.1016/j.ejmp.2007.07.001; Hall EJ, 2003, INT J RADIAT ONCOL, V56, P83, DOI 10.1016/S0360-3016(03)00073-7; Hodapp N, 2012, STRAHLENTHER ONKOL, V188, P97, DOI 10.1007/s00066-011-0015-x; Hoppe BS, 2007, INT J RADIAT ONCOL, V67, P691, DOI 10.1016/j.ijrobp.2006.09.023; Hrbacek J, 2014, MED PHYS, V41, DOI 10.1118/1.4866231; Jeong Y, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-193; Kan Monica W K, 2012, J Appl Clin Med Phys, V13, P3887, DOI 10.1120/jacmp.v13i6.3887; Nguyen K, 2013, MED DOSIM, V38, P225, DOI 10.1016/j.meddos.2013.01.006; Kragl G, 2011, RADIOTHER ONCOL, V100, P417, DOI 10.1016/j.radonc.2011.09.001; Kry SF, 2010, PHYS MED BIOL, V55, P2155, DOI 10.1088/0031-9155/55/8/003; Le QT, 1999, CANCER, V86, P1700, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1700::AID-CNCR11>3.3.CO;2-W; Lu JY, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20140654; Mahalingappa YB, 2014, J LARYNGOL OTOL, V128, P654, DOI 10.1017/S0022215114001066; McGrath SD, 2010, RADIOTHER ONCOL, V95, P153, DOI 10.1016/j.radonc.2009.12.039; Mock U, 2004, INT J RADIAT ONCOL, V58, P147, DOI 10.1016/S0360-3016(03)01452-4; Murray LJ, 2015, PHYS MED BIOL, V60, P1237, DOI 10.1088/0031-9155/60/3/1237; Nicolini G, 2012, INT J RADIAT ONCOL, V84, P553, DOI 10.1016/j.ijrobp.2011.12.041; Ning ZH, 2015, STRAHLENTHER ONKOL, V191, P34, DOI 10.1007/s00066-014-0760-8; Orlandi E, 2014, RADIOTHER ONCOL, V113, P260, DOI 10.1016/j.radonc.2014.11.024; Paddick I, 2000, J NEUROSURG, V93, P219, DOI 10.3171/jns.2000.93.supplement_3.0219; Sheng K, 2007, RADIOTHER ONCOL, V82, P174, DOI 10.1016/j.radonc.2007.01.008; Siala W, 2009, CANCER RADIOTHER, V13, P709, DOI 10.1016/j.canrad.2009.05.006; Spruijt KH, 2013, INT J RADIAT ONCOL, V85, P506, DOI 10.1016/j.ijrobp.2012.03.040; Tiwari R, 2000, HEAD NECK-J SCI SPEC, V22, P164, DOI 10.1002/(SICI)1097-0347(200003)22:2<164::AID-HED8>3.0.CO;2-#; Vassiliev ON, 2006, PHYS MED BIOL, V51, P1907, DOI 10.1088/0031-9155/51/7/019; Zhuang MZ, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-120; Zwahlen DR, 2012, INT J RADIAT ONCOL, V83, P1655, DOI 10.1016/j.ijrobp.2011.10.019	34	4	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2016	11	1							e0146604	10.1371/journal.pone.0146604	http://dx.doi.org/10.1371/journal.pone.0146604			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA4XE	26734731	Green Published, Green Submitted, gold			2023-01-03	WOS:000367805100055
J	Nagy, VK; Szeplaki, G; Apor, A; Kutyifa, V; Kovacs, A; Kosztin, A; Becker, D; Boros, AM; Geller, L; Merkely, B				Nagy, Vivien Klaudia; Szeplaki, Gabor; Apor, Astrid; Kutyifa, Valentina; Kovacs, Attila; Kosztin, Annamaria; Becker, David; Boros, Andras Mihaly; Geller, Laszlo; Merkely, Bela			Role of Right Ventricular Global Longitudinal Strain in Predicting Early and Long-Term Mortality in Cardiac Resynchronization Therapy Patients	PLOS ONE			English	Article							ADVANCED HEART-FAILURE; EUROPEAN-SOCIETY; ESC GUIDELINES; EJECTION FRACTION; TASK-FORCE; SURVIVAL; ASSOCIATION; COLLABORATION; DYSFUNCTION; CARDIOLOGY	Background Right ventricular (RV) dysfunction has been associated with poor prognosis in chronic heart failure (HF). However, less data is available about the role of RV dysfunction in patients with cardiac resynchronization therapy (CRT). We aimed to investigate if RV dysfunction would predict outcome in CRT. Design We enrolled prospectively ninety-three consecutive HF patients in this single center observational study. All patients underwent clinical evaluation and echocardiography before CRT and 6 months after implantation. We assessed RV geometry and function by using speckle tracking imaging and calculated strain parameters. We performed multivariable Cox regression models to test mortality at 6 months and at 24 months. Results RV dysfunction, characterized by decreased RVGLS (RV global longitudinal strain) [10.2 (7.0-12.8) vs. 19.5 (15.0-23.9) %, p<0.0001] and RVFWS (RV free wall strain) [15.6 (10.0-19.3) vs. 17.4 (10.5-22.2) %, p = 0.04], improved 6 months after CRT implantation. Increasing baseline RVGLS and RVFWS predicted survival independent of other parameters at 6 months [hazard ratio (HR) = 0.37 (0.15-0.90), p = 0.02 and HR = 0.42 (0.19-0.89), p = 0.02; per 1 standard deviation increase, respectively]. RVGLS proved to be a significant independent predictor of mortality at 24 months [HR = 0.53 (0.32-0.86), p = 0.01], and RVFWS showed a strong tendency [HR = 0.64 (0.40-1.00), p = 0.05]. The 24-month survival was significantly impaired in patients with RVGLS below 10.04% before CRT implantation [area under the curve = 0.72 (0.60-0.84), p = 0.002, log-rank p = 0.0008; HR = 5.23 (1.76-15.48), p = 0.003]. Conclusions Our findings indicate that baseline RV dysfunction is associated with poor short-term and long-term prognosis after CRT implantation.	[Nagy, Vivien Klaudia; Szeplaki, Gabor; Apor, Astrid; Kutyifa, Valentina; Kovacs, Attila; Kosztin, Annamaria; Becker, David; Boros, Andras Mihaly; Geller, Laszlo; Merkely, Bela] Semmelweis Univ, Heart & Vasc Ctr, H-1085 Budapest, Hungary	Semmelweis University	Merkely, B (corresponding author), Semmelweis Univ, Heart & Vasc Ctr, H-1085 Budapest, Hungary.	merkely.bela@gmail.com	Kovács, Attila/AAE-7467-2019	Kovács, Attila/0000-0003-2320-6434; Szeplaki, Gabor/0000-0003-3795-1240; Kosztin MD, PhD, Annamaria/0000-0001-6647-2623	Hungarian Foundation Programs: Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences; Hungarian Scientific Research Foundation [OTKA 105555]	Hungarian Foundation Programs: Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences; Hungarian Scientific Research Foundation(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA))	This work was supported by Hungarian Foundation Programs: Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences (GSZ, LG) and the Hungarian Scientific Research Foundation (OTKA 105555). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We are grateful to all the patients who participated in our study. We are thankful to Semmelweis University for the professional assistance background. This work was supported by Hungarian Foundation Programs: Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences (GSZ, LG) and the Hungarian Scientific Research Foundation (OTKA 105555).	Alpendurada F, 2011, J CARDIOVASC MAGN R, V13, DOI 10.1186/1532-429X-13-68; Brignole M, 2013, EUR HEART J, V34, P2281, DOI 10.1093/eurheartj/eht150; Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165; Cameli M, 2012, J CARD FAIL, V18, P208, DOI 10.1016/j.cardfail.2011.12.002; Campbell P, 2013, CIRC-HEART FAIL, V6, P435, DOI 10.1161/CIRCHEARTFAILURE.112.000127; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Damy T, 2013, J AM COLL CARDIOL, V61, P2153, DOI 10.1016/j.jacc.2013.02.049; de Groote P, 1998, J AM COLL CARDIOL, V32, P948, DOI 10.1016/S0735-1097(98)00337-4; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; DISALVO TG, 1995, J AM COLL CARDIOL, V25, P1143, DOI 10.1016/0735-1097(94)00511-N; Field ME, 2006, J CARD FAIL, V12, P616, DOI 10.1016/j.cardfail.2006.06.472; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Leong DP, 2013, HEART, V99, P722, DOI 10.1136/heartjnl-2012-303076; Linde C, 2002, J AM COLL CARDIOL, V40, P111, DOI 10.1016/S0735-1097(02)01932-0; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Padeletti L, 2012, HEART FAIL REV, V17, P97, DOI 10.1007/s10741-011-9250-6; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010; Sade LE, 2013, J AM SOC ECHOCARDIOG, V26, P706, DOI 10.1016/j.echo.2013.03.013; Sutherland GR, 2004, J AM SOC ECHOCARDIOG, V17, P788, DOI 10.1016/j.echo.2004.03.027; Taylor J, 2010, EUR HEART J, V31, P2559, DOI 10.1093/eurheartj/ehq358; Vardas PE, 2007, EUR HEART J, V28, P2256, DOI 10.1093/eurheartj/ehm305; Vizzardi E, 2012, ECHOCARDIOGR-J CARD, V29, P773, DOI 10.1111/j.1540-8175.2012.01703.x	22	22	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0143907	10.1371/journal.pone.0143907	http://dx.doi.org/10.1371/journal.pone.0143907			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SI	26700308	Green Submitted, Green Published, gold			2023-01-03	WOS:000367092600012
J	Aoun, SM; Deas, K; Howting, D; Lee, G				Aoun, Samar M.; Deas, Kathleen; Howting, Denise; Lee, Gabriel			Exploring the Support Needs of Family Caregivers of Patients with Brain Cancer Using the CSNAT: A Comparative Study with Other Cancer Groups	PLOS ONE			English	Article							HIGH-GRADE GLIOMA; ASSESSMENT TOOL CSNAT; OF-LIFE CARE; PALLIATIVE CARE; HOME; BEREAVEMENT; VALIDATION; THERAPY; TUMOR; END	A substantial burden is placed on family caregivers of patients diagnosed with brain cancers. Despite this, the support needs of the caregivers are often under-recognised and not addressed adequately in current routine and patient centred clinical care. The Care Support Needs Assessment Tool (CSNAT) is a validated instrument designed to systematically identify and address caregiver needs. It has been trialled in an Australian palliative care community setting using a stepped wedge cluster design involving 322 family carers of terminally ill patients. The current article reports on a subset from this trial, 29 caregivers of patients with primary brain cancer, and compares their profile and outcomes to those of other cancer groups. Caregiver strain was assessed using the Family Appraisal of Caregiving Questionnaire, caregiver physical and mental wellbeing using SF12 and caregiver workload using a questionnaire on support with activities of daily living (ADL). In comparison to caregivers of patients with all other cancers, the primary brain cancer group had significantly higher levels of caregiver strain, lower levels of mental wellbeing and a higher level of ADL workload. Their physical wellness also deteriorated significantly over time. An action plan approach led to practical solutions for addressing highlighted concerns. Four themes evolved from the family caregivers' feedback interviews: The extremely challenging caregiver experience with brain cancer; the systematic and practical approach of the CSNAT during rapid changes; connection with health professionals, feeling acknowledged and empowered; and timely advice and assurance of support during the caregiving journey. This preliminary study has demonstrated that the CSNAT provides a practical and useful tool for assessing the support needs of family caregivers of patients with brain cancer and has provided the basis for a larger scale, longitudinal study that allows a more detailed characterisation of the evolving caregiver needs at different stages of the disease.	[Aoun, Samar M.; Deas, Kathleen; Howting, Denise] Curtin Univ, Sch Nursing Midwifery & Paramed, Perth, WA, Australia; [Lee, Gabriel] St John Of God Hosp, Subiaco, WA, Australia; [Lee, Gabriel] Univ Western Australia, Sch Surg, Nedlands, WA 6009, Australia	Curtin University; St John of God Health Care; University of Western Australia	Aoun, SM (corresponding author), Curtin Univ, Sch Nursing Midwifery & Paramed, Perth, WA, Australia.	s.aoun@curtin.edu.au	Howting, Denise Ann/GWU-5045-2022	Howting, Denise Ann/0000-0001-8753-5849; Aoun, Samar/0000-0002-4073-4805	Australian Research Council linkage grant; Silver Chain [LP110100622]	Australian Research Council linkage grant(Australian Research Council); Silver Chain	This research was financially supported by an Australian Research Council linkage grant and Silver Chain (LP110100622).; This research was financially supported by an Australian Research Council linkage grant and Silver Chain (LP110100622). The authors gratefully acknowledge the contribution of the Silver Chain Hospice Care Service nurses in recruitment, data collection and valuable advice and the contribution of family caregivers to enriching the project with their feedback considering their difficult circumstances.	Aoun S, 2015, PALLIAT MED; Aoun S, 2015, PALLIATIVE MED, P1; Aoun S, 2015, PLOS ONE, P10; Aoun SM, 2015, J PALLIAT MED, V18, P31, DOI 10.1089/jpm.2014.0213; Aoun SM, 2005, PALLIATIVE MED, V19, P551, DOI 10.1191/0269216305pm1053oa; Arber A., 2010, BR J NEUROSCI NURS, V6, P329, DOI [10.12968/bjnn.2010.6.7.79227, DOI 10.12968/BJNN.2010.6.7.79227]; Arber A, 2013, EUR J ONCOL NURS, V17, P52, DOI 10.1016/j.ejon.2012.01.008; Catt S, 2008, LANCET ONCOL, V9, P884, DOI 10.1016/S1470-2045(08)70230-4; Collins A, 2014, BMJ SUPPORT PALLIAT, V4, P68, DOI 10.1136/bmjspcare-2012-000419; Cooper B, 2006, PSYCHO-ONCOLOGY, V15, P613, DOI 10.1002/pon.1001; Damodaran O, 2014, J CLIN NEUROSCI, V21, P478, DOI 10.1016/j.jocn.2013.07.042; Ewing G, 2013, J PAIN SYMPTOM MANAG, V46, P395, DOI 10.1016/j.jpainsymman.2012.09.008; Ewing G, 2013, PALLIATIVE MED, V27, P244, DOI 10.1177/0269216312440607; Fabi A, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-10; Ferrario SR, 2004, PALLIATIVE MED, V18, P129, DOI 10.1191/0269216304pm870oa; Grande G, 2009, PALLIATIVE MED, V23, P339, DOI 10.1177/0269216309104875; Grande GE, 2004, J PALLIATIVE CARE, V20, P69, DOI 10.1177/082585970402000202; Guest G, 2011, APPL THEMATIC ANAL, DOI [10.4135/9781483384436, DOI 10.4135/9781483384436]; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Hudson PL, 2010, PALLIATIVE MED, V24, P656, DOI 10.1177/0269216310373167; Janda M, 2008, PATIENT EDUC COUNS, V71, P251, DOI 10.1016/j.pec.2008.01.020; Kissane DW, 2006, AM J PSYCHIAT, V163, P1208, DOI 10.1176/appi.ajp.163.7.1208; Madsen K, 2011, EUR J CANCER CARE, V20, P33, DOI 10.1111/j.1365-2354.2010.01184.x; McConigley R, 2010, PALLIAT MED; Moore G, 2013, PATIENT EDUC COUNS, V91, P141, DOI 10.1016/j.pec.2012.11.002; Northouse LL, 2010, CA-CANCER J CLIN, V60, P317, DOI 10.3322/caac.20081; Parvataneni R, 2011, J NEURO-ONCOL, V104, P737, DOI 10.1007/s11060-011-0534-4; Payne S., 2013, SUPPORTING FAMILY CA; Sanderson K, 2002, AUST NZ J PUBL HEAL, V26, P343, DOI 10.1111/j.1467-842X.2002.tb00182.x; Schubart JR, 2008, NEURO-ONCOLOGY, V10, P61, DOI 10.1215/15228517-2007-040; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Sherwood Paula R, 2004, Int J Palliat Nurs, V10, P67; Stajduhar KI, 2010, PALLIATIVE MED, V24, P573, DOI 10.1177/0269216310371412; Sterckx W, 2013, EUR J ONCOL NURS, V17, P107, DOI 10.1016/j.ejon.2012.04.006	34	22	25	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2015	10	12							e0145106	10.1371/journal.pone.0145106	http://dx.doi.org/10.1371/journal.pone.0145106			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CY9JO	26679505	Green Published, gold			2023-01-03	WOS:000366723400048
J	Zhang, Y; Feng, YM; Ahmad, M; Ming, X; Zhou, L; Deng, J				Zhang, Ying; Feng, Yuanming; Ahmad, Munir; Ming, Xin; Zhou, Li; Deng, Jun			Intermediate Megavoltage Photon Beams for Improved Lung Cancer Treatments	PLOS ONE			English	Article							BODY RADIATION-THERAPY; DOSE CALCULATION TOOL; BREAST-CANCER; RADIOTHERAPY; ENERGY; MV; TARGETS; PLANAR; IMRT	The goal of this study is to evaluate the effects of intermediate megavoltage (3-MV) photon beams on SBRT lung cancer treatments. To start with, a 3-MV virtual beam was commissioned on a commercial treatment planning system based on Monte Carlo simulations. Three optimized plans (6-MV, 3-MV and dual energy of 3-and 6-MV) were generated for 31 lung cancer patients with identical beam configuration and optimization constraints for each patient. Dosimetric metrics were evaluated and compared among the three plans. Overall, planned dose conformity was comparable among three plans for all 31 patients. For 21 thin patients with average short effective path length (< 10 cm), the 3-MV plans showed better target coverage and homogeneity with dose spillage index R-50% = 4.68 +/- 0.83 and homogeneity index = 1.26 +/- 0.06, as compared to 4.95 +/- 1.01 and 1.31 +/- 0.08 in the 6-MV plans (p < 0.001). Correspondingly, the average/maximum reductions of lung volumes receiving 20 Gy (V-20Gy), 5 Gy (V-5Gy), and mean lung dose (MLD) were 7%/20%, 9%/30% and 5%/10%, respectively in the 3-MV plans (p < 0.05). The doses to 5% volumes of the cord, esophagus, trachea and heart were reduced by 9.0%, 10.6%, 11.4% and 7.4%, respectively (p < 0.05). For 10 thick patients, dual energy plans can bring dosimetric benefits with comparable target coverage, integral dose and reduced dose to the critical structures, as compared to the 6-MV plans. In conclusion, our study indicated that 3-MV photon beams have potential dosimetric benefits in treating lung tumors in terms of improved tumor coverage and reduced doses to the adjacent critical structures, in comparison to 6-MV photon beams. Intermediate megavoltage photon beams (< 6-MV) may be considered and added into current treatment approaches to reduce the adjacent normal tissue doses while maintaining sufficient tumor dose coverage in lung cancer radiotherapy.	[Zhang, Ying; Feng, Yuanming; Ming, Xin] Tianjin Univ, Dept Biomed Engn, Tianjin 300072, Peoples R China; [Zhang, Ying; Ming, Xin; Deng, Jun] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA; [Ahmad, Munir] William W Backus Hosp, Dept Radiat Oncol, Norwich, CT USA; [Zhou, Li] Sichuan Univ, West China Hosp, Ctr Radiat Phys & Technol, Ctr Canc, Chengdu 610064, Peoples R China	Tianjin University; Yale University; Sichuan University	Deng, J (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA.	jun.deng@yale.edu			China Scholarship Council [201206250087]	China Scholarship Council(China Scholarship Council)	YZ was supported by China Scholarship Council (no. 201206250087). There was no other funding support for YZ or any co-author of this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AHNESJO A, 1989, MED PHYS, V16, P577, DOI 10.1118/1.596360; Benedict SH, 2010, MED PHYS, V37, P4078, DOI 10.1118/1.3438081; Bjorn Hardemark A L, 2004, P3IMRT DIRECT MACHIN; Darby SC, 2005, LANCET ONCOL, V6, P557, DOI 10.1016/S1470-2045(05)70251-5; Deng J, 2000, PHYS MED BIOL, V45, P411, DOI 10.1088/0031-9155/45/2/311; Dong P, 2014, MED PHYS, V41, DOI [10.1118/1.4868464, 10.1118/1.4888003]; Doyle JJ, 2007, INT J RADIAT ONCOL, V68, P82, DOI 10.1016/j.ijrobp.2006.12.019; Fox C, 2008, PHYS MED BIOL, V53, P3175, DOI 10.1088/0031-9155/53/12/007; Gong YL, 2008, RADIAT ONCOL, V3, DOI 10.1186/1748-717X-3-11; Guckenberger M, 2007, RADIOTHER ONCOL, V85, P435, DOI 10.1016/j.radonc.2007.10.044; HALPERIN E, 2005, PEDIAT RAD ONCOLOGY; Kataria T, 2012, J MED PHYS, V37, P207, DOI 10.4103/0971-6203.103606; Keller BM, 2007, MED PHYS, V34, P3996, DOI 10.1118/1.2775666; Li JS, 2000, PHYS MED BIOL, V45, P2969, DOI 10.1088/0031-9155/45/10/316; Lu XQ, 2000, FEASIBILITY STUDY US, V441, P449; Ma C.-M., 1995, 509D NRC PIRS; Ma CM, 1998, RADIAT PHYS CHEM, V53, P329, DOI 10.1016/S0969-806X(98)00113-3; Ma CM, 2002, PHYS MED BIOL, V47, P1671, DOI 10.1088/0031-9155/47/10/305; Madani I, 2007, RADIOTHER ONCOL, V82, P63, DOI 10.1016/j.radonc.2006.11.016; Meeks SL, 2005, MED PHYS, V32, P2673, DOI 10.1118/1.1990289; Nelson W. R., 1985, EGS4 CODE SYSTEM; Organization W.H., 2014, GLOBOCAN 2012 EST CA; Park JM, 2012, MED PHYS, V39, P1265, DOI 10.1118/1.3682172; Park JM, 2011, J APPL CLIN MED PHYS, V12, P147, DOI 10.1120/jacmp.v12i4.3563; Parsons D, 2012, MED PHYS, V39, P4568, DOI 10.1118/1.4730503; Robar JL, 2009, MED PHYS, V36, P3955, DOI 10.1118/1.3183499; ROGERS DWO, 1995, MED PHYS, V22, P503, DOI 10.1118/1.597552; Seco J., 2013, MONTE CARLO TECHNIQU; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; St-Hilaire J, 2009, J APPL CLIN MED PHYS, V10, P36, DOI 10.1120/jacmp.v10i4.3012; Stevens SW, 2011, PHYS MED BIOL, V56, P3809, DOI 10.1088/0031-9155/56/13/005; Timmerman RD, 2005, CURRENT PROBLEMS CAN; Timmerman R, 2010, JAMA-J AM MED ASSOC, V303, P1070, DOI 10.1001/jama.2010.261; Yartsev S, 2007, Biomed Imaging Interv J, V3, pe17, DOI 10.2349/biij.3.1.e17; Zhang Ying, 2015, British Journal of Medicine and Medical Research, V6, P661, DOI 10.9734/BJMMR/2015/15040	35	5	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2015	10	12							e0145117	10.1371/journal.pone.0145117	http://dx.doi.org/10.1371/journal.pone.0145117			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY9JH	26672752	Green Published, Green Submitted, gold			2023-01-03	WOS:000366722700102
J	Cramer, CK; Yoon, SW; Reinsvold, M; Joo, KM; Norris, H; Hood, RC; Adamson, JD; Klein, RC; Kirsch, DG; Oldham, M				Cramer, C. K.; Yoon, S. W.; Reinsvold, M.; Joo, K. M.; Norris, H.; Hood, R. C.; Adamson, J. D.; Klein, R. C.; Kirsch, D. G.; Oldham, M.			Treatment Planning and Delivery of Whole Brain Irradiation with Hippocampal Avoidance in Rats	PLOS ONE			English	Article							RADIOTHERAPY; METASTASES; RADIATION; ACCURACY; MEMORY	Background Despite the clinical benefit of whole brain radiotherapy (WBRT), patients and physicians are concerned by the long-term impact on cognitive functioning. Many studies investigating the molecular and cellular impact of WBRT have used rodent models. However, there has not been a rodent protocol comparable to the recently reported Radiation Therapy Oncology Group (RTOG) protocol for WBRT with hippocampal avoidance (HA) which is intended to spare cognitive function. The aim of this study was to develop a hippocampal-sparing WBRT protocol in Wistar rats. Methods The technical and clinical challenges encountered in hippocampal sparing during rat WBRT are substantial. Three key challenges were identified: hippocampal localization, treatment planning, and treatment localization. Hippocampal localization was achieved with sophisticated imaging techniques requiring deformable registration of a rat MRI atlas with a high resolution MRI followed by fusion via rigid registration to a CBCT. Treatment planning employed a Monte Carlo dose calculation in SmART-Plan and creation of 0.5cm thick lead blocks custom-shaped to match DRR projections. Treatment localization necessitated the on-board image-guidance capability of the XRAD C225Cx micro-CT/micro-irradiator (Precision X-Ray). Treatment was accomplished with opposed lateral fields with 225 KVp X-rays at a current of 13mA filtered through 0.3mm of copper using a 40x40mm square collimator and the lead blocks. A single fraction of 4Gy was delivered (2Gy per lateral field) with a 41 second beam on time per field at a dose rate of 304.5 cGy/min. Dosimetric verification of hippocampal sparing was performed using radiochromic film. In vivo verification of HA was performed after delivery of a single 4Gy fraction either with or without HA using gamma-H2Ax staining of tissue sections from the brain to quantify the amount of DNA damage in rats treated with HA, WBRT, or sham-irradiated (negative controls). Results The mean dose delivered to radiochromic film beneath the hippocampal block was 0.52Gy compared to 3.93Gy without the block, indicating an 87% reduction in the dose delivered to the hippocampus. This difference was consistent with doses predicted by Monte Carlo dose calculation. The Dose Volume Histogram (DVH) generated via Monte Carlo simulation showed an underdose of the target volume (brain minus hippocampus) with 50% of the target volume receiving 100% of the prescription isodose as a result of the lateral blocking techniques sparing some midline thalamic and subcortical tissue. Staining of brain sections with anti-phospho-Histone H2A.X (reflecting double-strand DNA breaks) demonstrated that this treatment protocol limited radiation dose to the hippocampus in vivo. The mean signal intensity from gamma-H2Ax staining in the cortex was not significantly different from the signal intensity in the cortex of rats treated with WBRT (5.40 v. 5.75, P = 0.32). In contrast, the signal intensity in the hippocampus of rats treated with HA was significantly lower than rats treated with WBRT (4.55 v. 6.93, P = 0.012). Conclusion Despite the challenges of planning conformal treatments for small volumes in rodents, our dosimetric and in vivo data show that WBRT with HA is feasible in rats. This study provides a useful platform for further application and refinement of the technique.	[Cramer, C. K.; Yoon, S. W.; Reinsvold, M.; Joo, K. M.; Norris, H.; Adamson, J. D.; Klein, R. C.; Kirsch, D. G.; Oldham, M.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27708 USA; [Klein, R. C.] Durham VA, Dept Psychiat, Durham, NC USA; [Kirsch, D. G.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA; [Joo, K. M.] Sungkyunkwan Univ, Sch Med, Dept Anat & Cell Biol, Seoul, South Korea; [Klein, R. C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA	Duke University; Duke University; Sungkyunkwan University (SKKU); Duke University	Cramer, CK (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27708 USA.	Christina.Cramer@duke.edu	Adamson, Justus/AAM-5335-2021	Adamson, Justus/0000-0002-7868-5631; Yoon, Suk Whan "Paul"/0000-0002-0313-8131	NIAID [K02AI093866]; Radiation Oncology departmental support; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI093866] Funding Source: NIH RePORTER	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Radiation Oncology departmental support; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was partially supported by K02AI093866 from the NIAID (awarded to DGK). The remainder of the research was funded by Radiation Oncology departmental support (start up funds) awarded to DGK.	Bache ST, 2015, MED PHYS, V42, P846, DOI 10.1118/1.4905489; Barlind A, 2010, EXP BRAIN RES, V201, P781, DOI 10.1007/s00221-009-2095-8; Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3; Gondi V, 2014, J CLIN ONCOL, V32, P3810, DOI 10.1200/JCO.2014.57.2909; Johnson GA, 2012, NEUROIMAGE, V62, P1848, DOI 10.1016/j.neuroimage.2012.05.041; Li J, 2007, J CLIN ONCOL, V25, P1260, DOI 10.1200/JCO.2006.09.2536; Linninger AA, 2008, IEEE T BIOMEDICAL EN, V55; Marsh JC, 2010, INT J RADIAT ONCOL, V76, P504, DOI 10.1016/j.ijrobp.2009.02.038; Meyers CA, 2004, J CLIN ONCOL, V22, P157, DOI 10.1200/JCO.2004.05.128; Monje ML, 2007, ANN NEUROL, V62, P515, DOI 10.1002/ana.21214; Newton J, 2011, MED PHYS, V38, P6754, DOI 10.1118/1.3663675; Parihar VK, 2014, TRANSL CANCER RES, V3, P124, DOI 10.3978/j.issn.2218-676X.2013.06.02; Parihar VK, 2013, P NATL ACAD SCI USA, V110, P12822, DOI 10.1073/pnas.1307301110; Patchell RA, 1998, JAMA-J AM MED ASSOC, V280, P1485, DOI 10.1001/jama.280.17.1485; Rankine LJ, 2013, PHYS MED BIOL, V58, P7791, DOI 10.1088/0031-9155/58/21/7791; Welzel G, 2008, INT J RADIAT ONCOL, V72, P1311, DOI 10.1016/j.ijrobp.2008.03.009; Wolf OT, 2002, BRAIN RES PROTOC, V10, P41	17	16	16	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2015	10	12							e0143208	10.1371/journal.pone.0143208	http://dx.doi.org/10.1371/journal.pone.0143208			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CY1CH	26636762	gold, Green Published, Green Submitted			2023-01-03	WOS:000366143800006
J	Busche, MA; Grienberger, C; Keskin, AD; Song, B; Neumann, U; Staufenbiel, M; Forstl, H; Konnerth, A				Busche, Marc Aurel; Grienberger, Christine; Keskin, Aylin D.; Song, Beomjong; Neumann, Ulf; Staufenbiel, Matthias; Foerstl, Hans; Konnerth, Arthur			Decreased amyloid-beta and increased neuronal hyperactivity by immunotherapy in Alzheimer's models	NATURE NEUROSCIENCE			English	Article							MOUSE MODEL; DISEASE; ANTIBODIES; PATHOLOGY; SEIZURES; TRIALS	Among the most promising approaches for treating Alzheimer's disease is immunotherapy with amyloid-beta (A beta)-targeting antibodies. Using in vivo two-photon imaging in mouse models, we found that two different antibodies to A beta used for treatment were ineffective at repairing neuronal dysfunction and caused an increase in cortical hyperactivity. This unexpected finding provides a possible cellular explanation for the lack of cognitive improvement by immunotherapy in human studies.	[Busche, Marc Aurel; Grienberger, Christine; Keskin, Aylin D.; Song, Beomjong; Konnerth, Arthur] Tech Univ Munich, Inst Neurosci, D-80290 Munich, Germany; [Busche, Marc Aurel; Foerstl, Hans] Tech Univ Munich, Dept Psychiat & Psychotherapy, D-80290 Munich, Germany; [Busche, Marc Aurel; Konnerth, Arthur] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Grienberger, Christine] Howard Hughes Med Inst, Janelia Farm Res Campus, Ashburn, VA USA; [Neumann, Ulf] Novartis Inst BioMed Res, Basel, Switzerland; [Staufenbiel, Matthias] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Cellular Neurol, Tubingen, Germany	Technical University of Munich; Technical University of Munich; University of Munich; University of Munich; Howard Hughes Medical Institute; Novartis; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Konnerth, A (corresponding author), Tech Univ Munich, Inst Neurosci, D-80290 Munich, Germany.	aurel.busche@tum.de; arthur.konnerth@tum.de		Forstl, Hans/0000-0002-6188-6883; Grienberger, Christine/0000-0002-7774-4062; Song, Beomjong/0000-0001-8820-7310; Busche, Marc Aurel/0000-0002-4416-7553	Advanced ERG grant; EU FP7 program (Project Corticonic); Deutsche Forschungsgemeinschaft [IRTG 1373, SFB870]; Hans und Klementia Langmatz Stiftung	Advanced ERG grant; EU FP7 program (Project Corticonic); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Hans und Klementia Langmatz Stiftung	We thank H. Adelsberger, P. Apostolopoulos, T. Starc, K. Kratz and C. Karrer for excellent technical assistance. We thank Janssen Alzheimer Immunotherapy for providing the PDAPP mice and the 3D6 antibodies. We thank F. Bard for advice and comments on the manuscript. The work was funded by an Advanced ERG grant to A.K., the EU FP7 program (Project Corticonic) and the Deutsche Forschungsgemeinschaft (IRTG 1373 and SFB870). M.A.B. was supported by the Hans und Klementia Langmatz Stiftung.	Amatniek JC, 2006, EPILEPSIA, V47, P867, DOI 10.1111/j.1528-1167.2006.00554.x; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Busche MA, 2008, SCIENCE, V321, P1686, DOI 10.1126/science.1162844; Busche MA, 2015, BIOESSAYS, V37, P624, DOI 10.1002/bies.201500004; Busche MA, 2012, P NATL ACAD SCI USA, V109, P8740, DOI 10.1073/pnas.1206171109; Buttini M, 2005, J NEUROSCI, V25, P9096, DOI 10.1523/JNEUROSCI.1697-05.2005; Chatham WW, 2001, LUPUS, V10, P140, DOI 10.1191/096120301675075008; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Golde TE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt233; Green KN, 2006, J NEUROSCI, V26, P9047, DOI 10.1523/JNEUROSCI.2797-06.2006; Grienberger C, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1783; Jones TLS, 2009, NEUROBIOL DIS, V33, P213, DOI 10.1016/j.nbd.2008.10.011; Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505; Liu YH, 2012, NAT REV NEUROL, V8, P465, DOI 10.1038/nrneurol.2012.118; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Sperling R, 2014, NEURON, V84, P608, DOI 10.1016/j.neuron.2014.10.038; Vossel KA, 2013, JAMA NEUROL, V70, P1158, DOI 10.1001/jamaneurol.2013.136; Zago W, 2012, J NEUROSCI, V32, P2696, DOI 10.1523/JNEUROSCI.1676-11.2012	20	88	98	0	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	DEC	2015	18	12					1725	1727		10.1038/nn.4163	http://dx.doi.org/10.1038/nn.4163			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CX1LV	26551546				2023-01-03	WOS:000365458600008
J	Riera, CE; Dillin, A				Riera, Celine E.; Dillin, Andrew			Can aging be 'drugged'?	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-KINASE; LIFE-SPAN EXTENSION; GENETICALLY HETEROGENEOUS MICE; INDUCED INSULIN-RESISTANCE; DIETARY RESTRICTION; CALORIC RESTRICTION; ENERGY-EXPENDITURE; MEDIATES LONGEVITY; ADIPOSE-TISSUE; RHESUS-MONKEYS	The engines that drive the complex process of aging are being identified by model-organism research, thereby providing potential targets and rationale for drug studies. Several studies of small molecules have already been completed in animal models with the hope of finding an elixir for aging, with a few compounds showing early promise. What lessons can we learn from drugs currently being tested, and which pitfalls can we avoid in our search for a therapeutic for aging? Finally, we must also ask whether an elixir for aging would be applicable to everyone, or whether we age differently, thus potentially shortening lifespan in some individuals.	[Riera, Celine E.; Dillin, Andrew] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Riera, Celine E.; Dillin, Andrew] Howard Hughes Med Inst, Chevy Chase, MD USA; [Riera, Celine E.; Dillin, Andrew] Univ Calif Berkeley, Glenn Ctr Res Aging, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Dillin, A (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	dillin@berkeley.edu			Howard Hughes Medical Institute; Glenn Center for Research on Aging; American Diabetes Association Pathway to Stop Diabetes [1-15-INI-12 (CER)]	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Glenn Center for Research on Aging; American Diabetes Association Pathway to Stop Diabetes	We apologize to those investigators whose important work we were unable to cite or describe in depth, owing to the limited scope and space constraints of this Perspective. We are supported by the Howard Hughes Medical Institute, the Glenn Center for Research on Aging and the American Diabetes Association Pathway to Stop Diabetes (grant no. 1-15-INI-12 (CER)).	Adams AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065763; Andrzejewski S, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-12; Anisimov VN, 2011, CELL CYCLE, V10, P4230, DOI 10.4161/cc.10.24.18486; Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; BARON SH, 1982, DIABETES CARE, V5, P64, DOI 10.2337/diacare.5.1.64; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Beher D, 2009, CHEM BIOL DRUG DES, V74, P619, DOI 10.1111/j.1747-0285.2009.00901.x; Bigal ME, 2014, CNS DRUGS, V28, P389, DOI 10.1007/s40263-014-0156-4; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Bosi E, 2009, DIABETES OBES METAB, V11, P3, DOI 10.1111/j.1463-1326.2008.01031.x; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Bruunsgaard H, 2000, CLIN EXP IMMUNOL, V121, P255, DOI 10.1046/j.1365-2249.2000.01281.x; Bruunsgaard H, 1999, J GERONTOL A-BIOL, V54, pM357, DOI 10.1093/gerona/54.7.M357; Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296; Cabreiro F, 2013, CELL, V153, P228, DOI 10.1016/j.cell.2013.02.035; Campbell RK, 1996, CLIN THER, V18, P360, DOI 10.1016/S0149-2918(96)80017-8; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Conover CA, 2007, AGING CELL, V6, P727, DOI 10.1111/j.1474-9726.2007.00328.x; Conover CA, 2010, AGING CELL, V9, P942, DOI 10.1111/j.1474-9726.2010.00630.x; Conover CA, 2010, J GERONTOL A-BIOL, V65, P590, DOI 10.1093/gerona/glq032; Cornu M, 2013, CURR OPIN GENET DEV, V23, P53, DOI 10.1016/j.gde.2012.12.005; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; de Cabo R, 2014, CELL, V157, P1515, DOI 10.1016/j.cell.2014.05.031; Fang YM, 2013, CELL METAB, V17, P456, DOI 10.1016/j.cmet.2013.02.008; FINK RI, 1983, J CLIN INVEST, V71, P1523, DOI 10.1172/JCI110908; Fiori JL, 2013, DIABETES, V62, P3500, DOI 10.2337/db13-0266; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Flurkey K, 2002, MECH AGEING DEV, V123, P121, DOI 10.1016/S0047-6374(01)00339-6; Flynn JM, 2013, AGING CELL, V12, P851, DOI 10.1111/acel.12109; Foukas LC, 2013, EMBO MOL MED, V5, P563, DOI 10.1002/emmm.201201953; Gaich G, 2013, CELL METAB, V18, P333, DOI 10.1016/j.cmet.2013.08.005; Gandini S, 2014, CANCER PREV RES, V7, P867, DOI 10.1158/1940-6207.CAPR-13-0424; Goldfine AB, 2013, ANN INTERN MED, V159, P1, DOI 10.7326/0003-4819-159-1-201307020-00003; Grandison RC, 2009, NATURE, V462, P1061, DOI 10.1038/nature08619; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hayden EC, 2015, NATURE, V522, P265, DOI 10.1038/522265a; Hine C, 2015, CELL, V160, P132, DOI 10.1016/j.cell.2014.11.048; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jagannath C, 2012, METHODS MOL BIOL, V821, P295, DOI 10.1007/978-1-61779-430-8_18; Jeck WR, 2012, AGING CELL, V11, P727, DOI 10.1111/j.1474-9726.2012.00871.x; Jimenez-Gomez Y, 2013, CELL METAB, V18, P533, DOI 10.1016/j.cmet.2013.09.004; Johnson JE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097729; Kabil H, 2011, P NATL ACAD SCI USA, V108, P16831, DOI 10.1073/pnas.1102008108; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kennedy BK, 2014, CELL, V159, P708, DOI 10.1016/j.cell.2014.10.039; Kim EB, 2011, NATURE, V479, P223, DOI 10.1038/nature10533; Kobilo T, 2014, LEARN MEMORY, V21, P119, DOI 10.1101/lm.033332.113; Komninou D, 2006, NUTR CANCER, V54, P202, DOI 10.1207/s15327914nc5402_6; Koska J, 2009, DIABETOLOGIA, V52, P385, DOI 10.1007/s00125-008-1239-x; Kulkarni SS, 2015, BBA-MOL BASIS DIS, V1852, P1114, DOI 10.1016/j.bbadis.2014.10.005; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lamberts SWJ, 1997, SCIENCE, V278, P419, DOI 10.1126/science.278.5337.419; Lamming DW, 2012, SCIENCE, V335, P1638, DOI 10.1126/science.1215135; Lawton KA, 2008, PHARMACOGENOMICS, V9, P383, DOI 10.2217/14622416.9.4.383; Liao CY, 2013, EXP GERONTOL, V48, P1025, DOI 10.1016/j.exger.2013.03.010; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Mair W, 2011, NATURE, V470, P404, DOI 10.1038/nature09706; Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892; Marcolin Éder, 2011, Arq. Gastroenterol., V48, P72, DOI 10.1590/S0004-28032011000100015; Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; McCarty MF, 2009, MED HYPOTHESES, V72, P125, DOI 10.1016/j.mehy.2008.07.044; MELNYK A, 1995, OBES RES, V3, P337, DOI 10.1002/j.1550-8528.1995.tb00159.x; Miller DL, 2007, P NATL ACAD SCI USA, V104, P20618, DOI 10.1073/pnas.0710191104; Miller RA, 2007, AGING CELL, V6, P565, DOI 10.1111/j.1474-9726.2007.00311.x; Miller RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/gerona/glq178; Narici MV, 2003, J APPL PHYSIOL, V95, P2229, DOI 10.1152/japplphysiol.00433.2003; Nojima A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069178; Ortega-Molina A, 2012, CELL METAB, V15, P382, DOI 10.1016/j.cmet.2012.02.001; Park TJ, 2008, PLOS BIOL, V6, P156, DOI 10.1371/journal.pbio.0060013; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Potthoff MJ, 2012, GENE DEV, V26, P312, DOI 10.1101/gad.184788.111; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; Riera CE, 2014, CELL, V157, P1023, DOI 10.1016/j.cell.2014.03.051; ROWE JW, 1983, J CLIN INVEST, V71, P1581, DOI 10.1172/JCI110914; Rowe JW, 1997, GERONTOLOGIST, V37, P433, DOI 10.1093/geront/37.4.433; Roy J, 2002, ANTIMICROB AGENTS CH, V46, P3447, DOI 10.1128/AAC.46.11.3447-3455.2002; Salvioli S, 2013, CURR PHARM DESIGN, V19, P1675; Selman C, 2008, FASEB J, V22, P807, DOI 10.1096/fj.07-9261com; Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221; Shiozaki M, 2008, NEUROSCIENCE, V152, P924, DOI 10.1016/j.neuroscience.2008.01.032; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Smith R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061432; Strong R, 2008, AGING CELL, V7, P641, DOI 10.1111/j.1474-9726.2008.00414.x; Sun LY, 2013, ELIFE, V2, DOI 10.7554/eLife.01098; Taguchi A, 2007, SCIENCE, V317, P369, DOI 10.1126/science.1142179; Tanner SJ, 2008, J BONE MINER RES, V23, P655, DOI 10.1359/JBMR.071210; Tilg H, 2011, J CLIN INVEST, V121, P2126, DOI 10.1172/JCI58109; Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Walter S, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2011.05.026; Weiss HJ, 2003, J THROMB HAEMOST, V1, P1869, DOI 10.1046/j.1538-7836.2003.00433.x; Wilicox BJ, 2008, P NATL ACAD SCI USA, V105, P13987, DOI 10.1073/pnas.0801030105; Wilkinson JE, 2012, AGING CELL, V11, P675, DOI 10.1111/j.1474-9726.2012.00832.x; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Woods JA, 2012, AGING DIS, V3, P130; Wu JJ, 2013, CELL REP, V4, P913, DOI 10.1016/j.celrep.2013.07.030; Xu J, 2014, AGING CELL, V13, P19, DOI 10.1111/acel.12145; Xue QL, 2008, J GERONTOL A-BIOL, V63, P984, DOI 10.1093/gerona/63.9.984; Yie JM, 2009, FEBS LETT, V583, P19, DOI 10.1016/j.febslet.2008.11.023; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zampieri M, 2015, MECH AGEING DEV, V151, P60, DOI 10.1016/j.mad.2015.02.002; Zapata HJ, 2015, J AM GERIATR SOC, V63, P776, DOI 10.1111/jgs.13310; Zhang G, 2013, NATURE, V497, P211, DOI 10.1038/nature12143; Zhang Y, 2012, ELIFE, V1, DOI 10.7554/eLife.00065; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	114	39	39	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2015	21	12					1400	1405		10.1038/nm.4005	http://dx.doi.org/10.1038/nm.4005			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	CX9EV	26646496				2023-01-03	WOS:000366008700010
J	Fraveto, A; Cardinale, V; Bragazzi, MC; Giuliante, F; De Rose, AM; Grazi, GL; Napoletano, C; Semeraro, R; Lustri, AM; Costantini, D; Nevi, L; Di Matteo, S; Renzi, A; Carpino, G; Gaudio, E; Alvaro, D				Fraveto, Alice; Cardinale, Vincenzo; Bragazzi, Maria Consiglia; Giuliante, Felice; De Rose, Agostino Maria; Grazi, Gian Luca; Napoletano, Chiara; Semeraro, Rossella; Lustri, Anna Maria; Costantini, Daniele; Nevi, Lorenzo; Di Matteo, Sabina; Renzi, Anastasia; Carpino, Guido; Gaudio, Eugenio; Alvaro, Domenico			Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures	PLOS ONE			English	Article							BILIARY-TRACT CANCER; TYROSINE KINASE INHIBITORS; STEM-CELLS; CHOLANGIOCELLULAR CARCINOMA; LIVER-CANCER; PHASE-II; GEMCITABINE; GROWTH; OXALIPLATIN; COMBINATION	We investigated the sensitivity of intrahepatic cholangiocarcinoma (IHCCA) subtypes to chemotherapeutics and molecular targeted agents. Primary cultures of mucin-and mixed-IHCCA were prepared from surgical specimens (N. 18 IHCCA patients) and evaluated for cell proliferation (MTS assay) and apoptosis (Caspase 3) after incubation (72 hours) with increasing concentrations of different drugs. In vivo, subcutaneous human tumor xenografts were evaluated. Primary cultures of mucin-and mixed-IHCCA were characterized by a different pattern of expression of cancer stem cell markers, and by a different drug sensitivity. Gemcitabine and the Gemcitabine-Cisplatin combination were more active in inhibiting cell proliferation in mixed-IHCCA while Cisplatin or Abraxane were more effective against mucin-IHCCA, where Abraxane also enhances apoptosis. 5-Fluoracil showed a slight inhibitory effect on cell proliferation that was more significant in mixed-than mucin-IHCCA primary cultures and, induced apoptosis only in mucin-IHCCA. Among Hg inhibitors, LY2940680 and Vismodegib showed slight effects on proliferation of both IHCCA subtypes. The tyrosine kinase inhibitors, Imatinib Mesylate and Sorafenib showed significant inhibitory effects on proliferation of both mucin-and mixed-IHCCA. The MEK 1/2 inhibitor, Selumetinib, inhibited proliferation of only mucin-IHCCA while the aminopeptidase-N inhibitor, Bestatin was more active against mixed-IHCCA. The c-erbB2 blocking antibody was more active against mixed-IHCCA while, the Wnt inhibitor, LGK974, similarly inhibited proliferation of mucin-and mixed-IHCCA. Either mucin-or mixed-IHCCA showed high sensitivity to nanomolar concentrations of the dual PI3-kinase/mTOR inhibitor, NVP-BEZ235. In vivo, in subcutaneous xenografts, either NVP-BEZ235 or Abraxane, blocked tumor growth. In conclusion, mucin-and mixed-IHCCA are characterized by a different drug sensitivity. Cisplatin, Abraxane and the MEK 1/2 inhibitor, Selumetinib were more active against mucin-IHCCA while, Gemcitabine, Gemcitabine-Cisplatin combination, the c-erbB2 blocking antibody and bestatin worked better against mixed-IHCCA. Remarkably, we identified a dual PI3-kinase/mTOR inhibitor that both in vitro and in vivo, exerts dramatic antiproliferative effects against both mucin- and mixed-IHCCA.	[Fraveto, Alice; Cardinale, Vincenzo; Bragazzi, Maria Consiglia; Semeraro, Rossella; Lustri, Anna Maria; Costantini, Daniele; Nevi, Lorenzo; Di Matteo, Sabina; Alvaro, Domenico] Univ Roma La Sapienza, Dept Medicosurg Sci & Biotechnol, I-00185 Rome, Italy; [Carpino, Guido] Univ Rome Foro Italico, Hlth Sci, Rome, Italy; [Renzi, Anastasia; Gaudio, Eugenio] Univ Roma La Sapienza, SAIMLAL, I-00185 Rome, Italy; [Giuliante, Felice; De Rose, Agostino Maria] Univ Cattolica Sacro Cuore, Sch Med, Hepatobiliary Unit, Surg, I-00168 Rome, Italy; [Napoletano, Chiara] Univ Roma La Sapienza, Expt Med, I-00185 Rome, Italy; [Grazi, Gian Luca] Regina Elena Inst Canc Res, Hepatobiliary Surg, Rome, Italy	Sapienza University Rome; Foro Italico University of Rome; Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Alvaro, D (corresponding author), Univ Roma La Sapienza, Dept Medicosurg Sci & Biotechnol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	domenico.alvaro@uniroma1.it	Cardinale, Vincenzo/AAB-9296-2019; De Rose, Agostino Maria/V-4910-2019; Grazi, Gian Luca/J-7215-2018; Nevi, Lorenzo/B-3289-2017; Napoletano, Chiara/AAO-1691-2021; Di Matteo, Sabina/D-1876-2017; ALVARO, Domenico/J-8600-2018; De Rose, Agostino/J-8414-2016; Carpino, Guido/AAB-9692-2019; GIULIANTE, FELICE/AAC-5066-2020; COSTANTINI, DANIELE/C-3898-2017	Cardinale, Vincenzo/0000-0003-0234-3341; De Rose, Agostino Maria/0000-0003-3310-8088; Grazi, Gian Luca/0000-0002-3279-0313; Nevi, Lorenzo/0000-0003-0924-2551; Di Matteo, Sabina/0000-0002-2586-7159; ALVARO, Domenico/0000-0003-3771-9644; De Rose, Agostino/0000-0003-3310-8088; GIULIANTE, FELICE/0000-0003-2087-2589; CARPINO, Guido/0000-0001-8570-2519; COSTANTINI, DANIELE/0000-0001-7438-4578	University "Sapienza" of Rome; Consorzio Interuniversitario Trapianti d'Organo	University "Sapienza" of Rome; Consorzio Interuniversitario Trapianti d'Organo	Funded by University "Sapienza" of Rome (DA, EG) and Consorzio Interuniversitario Trapianti d'Organo (DA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen JB, 2012, GASTROENTEROLOGY, V142, P1021, DOI 10.1053/j.gastro.2011.12.005; Bekaii-Saab T, 2011, J CLIN ONCOL, V29, P2357, DOI 10.1200/JCO.2010.33.9473; Bengala C, 2010, BRIT J CANCER, V102, P68, DOI 10.1038/sj.bjc.6605458; Boulter L, 2015, J CLIN INVEST, V125, P1269, DOI 10.1172/JCI76452; Burkholder Tanya, 2012, Curr Protoc Mouse Biol, V2, P145; Cardinale V, 2015, AM J PATHOL, V185, P1724, DOI 10.1016/j.ajpath.2015.02.010; Cardinale V, 2012, WORLD J GASTRO ONCOL, V4, P94, DOI 10.4251/wjgo.v4.i5.94; Chen MH, 2014, ONCOTARGET, V5, P2372, DOI 10.18632/oncotarget.1706; Dealis C, 2008, J CLIN ONCOL, P4590; El Khatib M, 2013, HEPATOLOGY, V57, P1035, DOI 10.1002/hep.26147; Ewald F, 2013, INT J CANCER, V133, P2065, DOI 10.1002/ijc.28214; Green MR, 2006, ANN ONCOL, V17, P1263, DOI 10.1093/annonc/mdl104; Gruenberger B, 2010, LANCET ONCOL, V11, P1142, DOI 10.1016/S1470-2045(10)70247-3; Grujic M, 2002, CANCER LETT, V182, P113, DOI 10.1016/S0304-3835(02)00086-1; Heinemann V, 2012, CANCER TREAT REV, V38, P843, DOI 10.1016/j.ctrv.2011.12.004; Komuta M, 2012, HEPATOLOGY, V55, P1876, DOI 10.1002/hep.25595; Law LY, 2012, J CLIN ONCOL, V30, pE271, DOI 10.1200/JCO.2012.42.3061; Levitzki A, 2013, ANNU REV PHARMACOL, V53, P161, DOI 10.1146/annurev-pharmtox-011112-140341; Lin TL, 2012, ONCOTARGETS THER, V5, P47, DOI 10.2147/OTT.S21957; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Malka D, 2014, LANCET ONCOL, V15, P819, DOI 10.1016/S1470-2045(14)70212-8; Martins MG, 2014, INVESTIGACAO, P1, DOI 10.14195/978-989-26-0696-5; Nanda Shreeya, 2010, Nat Rev Gastroenterol Hepatol, V7, P591, DOI 10.1038/nrgastro.2010.163; Oishi N, 2011, INT J BIOL SCI, V7, P517, DOI 10.7150/ijbs.7.517; Okusaka T, 2010, BRIT J CANCER, V103, P469, DOI 10.1038/sj.bjc.6605779; Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0; Razumilava N, 2014, J HEPATOL, V60, P599, DOI 10.1016/j.jhep.2013.11.005; Roskoski R, 2014, PHARMACOL RES, V87, P42, DOI 10.1016/j.phrs.2014.06.001; Roth A, 2011, ONKOLOGIE, V34, P469, DOI 10.1159/000331065; Roth Joshua A, 2012, J Gastrointest Cancer, V43, P215, DOI 10.1007/s12029-010-9242-0; Strumberg D, 2005, DRUGS TODAY, V41, P773, DOI 10.1358/dot.2005.41.12.937959; Tang L, 2013, CLIN CANCER RES, V19, P2014, DOI 10.1158/1078-0432.CCR-12-0349; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yamashita T, 2013, HEPATOLOGY, V57, P1484, DOI 10.1002/hep.26168; Yothaisong S, 2013, TUMOR BIOL, V34, P3637, DOI 10.1007/s13277-013-0945-2; Zhang ZC, 2010, HEPATOLOGY, V52, P975, DOI 10.1002/hep.23773	38	25	27	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2015	10	11							e0142124	10.1371/journal.pone.0142124	http://dx.doi.org/10.1371/journal.pone.0142124			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW5XP	26571380	Green Submitted, Green Published, gold			2023-01-03	WOS:000365070700019
J	Lim, S; Park, SH; Park, HK; Hur, MH; Oh, SJ; Suh, YJ				Lim, SeungTaek; Park, Se Ho; Park, Heong Kyu; Hur, Min Hee; Oh, Se Jeong; Suh, Young Jin			Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population	PLOS ONE			English	Article							RISK-FACTORS; CARCINOMA; THERAPY; SURVIVAL; FEATURES; CYCLOPHOSPHAMIDE; METHOTREXATE; PATTERNS; TRIALS; BASAL	Background Despite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negative (TN) MBC patients. Methods We included data from 252 patients with N0 TN MBC, obtained from the Korean Breast Cancer Registry database. Patients were categorized as those who did not undergo adjuvant chemotherapy (group I) or those who did (group II). Clinicopathological characteristics, breast cancer-specific survival (BCSS), and overall survival (OS) were compared between the groups. In addition, a subgroup analysis for survival based on tumor size was conducted. Results A total of 252 N0 TN MBC patients with tumor sizes >1 cm who were diagnosed between April 1997 andMarch 2011 were enrolled. The median age was 44.95 years (range, 25-72 years), and the median follow-up period was 93.94months (range, 23-195months). Overall, the BCSS and OS in group II (97.3% and 97.3%, respectively) were significantly better compared with those in group I (89.2% and 86.2%, respectively). In the subgroup analysis, in patients with tumors >2 cmin size, those in group II had significant better BCSS and OS (97.5% and 97.5%, respectively) compared with those in group I (78.3% and 73.9%, respectively). In contrast in those with tumors 1-2 cmin size, there were no significant differences in BCSS and OS between the groups (both 97.1% for group I, and 95.2% and 92.9%, respectively for group II). Multivariate analysis revealed that adjuvant chemotherapy significantly improved BCSS (P = 0.009) and OS (P = 0.007), but only for patients with larger tumors (> 2 cm). Conclusions In patients with N0 TN MBC, adjuvant chemotherapy had a significant clinical survival benefit, but only in those with tumors >2 cm.	[Lim, SeungTaek; Suh, Young Jin] Catholic Univ Korea, St Vincents Hosp, Div Breast & Thyroid Surg Oncol, Dept Surg,Coll Med, Suwon 442723, Gyeonggi Do, South Korea; [Park, Se Ho] Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea; [Park, Heong Kyu] Gachon Univ, Gill Hosp, Dept Surg, Breast Canc Ctr, Inchon 405760, South Korea; [Hur, Min Hee] Dankook Univ, Coll Med, Cheil Gen Hosp, Dept Surg, Seoul 100380, South Korea; [Hur, Min Hee] Dankook Univ, Coll Med, Womens Healthcare Ctr, Seoul 100380, South Korea; [Oh, Se Jeong] Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Surg, Inchon 403720, South Korea	Catholic University of Korea; Yonsei University; Yonsei University Health System; Gachon University; Dankook University; Dankook University; Catholic University of Korea	Suh, YJ (corresponding author), Catholic Univ Korea, St Vincents Hosp, Div Breast & Thyroid Surg Oncol, Dept Surg,Coll Med, Jungbu Daero 93, Suwon 442723, Gyeonggi Do, South Korea.	yjsuh@catholic.ac.kr		Oh, Se Jeong/0000-0002-2583-4218				Anderson WF, 2004, CANCER EPIDEM BIOMAR, V13, P1128; Bertucci F, 2006, CANCER RES, V66, P4636, DOI 10.1158/0008-5472.CAN-06-0031; BLOOM HJG, 1970, BMJ-BRIT MED J, V3, P181, DOI 10.1136/bmj.3.5716.181; Cao AY, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-91; Chu ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111493; Colleoni M, 2010, J CLIN ONCOL, V28, P2966, DOI 10.1200/JCO.2009.25.9549; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Foschini MP, 2009, PATHOLOGY, V41, P48, DOI 10.1080/00313020802563528; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Gradishar WJ, 2015, J NATL COMPR CANC NE, V13, P448, DOI 10.6004/jnccn.2015.0060; Huober J, 2012, ANN ONCOL, V23, P2843, DOI 10.1093/annonc/mds105; Huober J, 2010, BREAST CANCER RES TR, V124, P133, DOI 10.1007/s10549-010-1103-9; Jensen ML, 1997, HISTOPATHOLOGY, V30, P523; Li Christopher I., 2010, Hormones & Cancer, V1, P156, DOI 10.1007/s12672-010-0016-8; Li CI, 2005, BRIT J CANCER, V93, P1046, DOI 10.1038/sj.bjc.6602787; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Malyuchik S. S., 2008, Experimental Oncology, V30, P96; Martinez SR, 2011, MED ONCOL, V28, P738, DOI 10.1007/s12032-010-9526-z; Moon HG, 2009, J CLIN ONCOL, V27, P5899, DOI 10.1200/JCO.2009.22.4436; Munzone E, 2012, BREAST CANCER RES TR, V134, P277, DOI 10.1007/s10549-012-2040-6; Orlando L, 2005, ANN ONCOL, V16, P1094, DOI 10.1093/annonc/mdi213; Park I, 2013, J BREAST CANCER, V16, P417, DOI 10.4048/jbc.2013.16.4.417; Pedersen L, 1995, EUR J CANCER, V31A, P2289, DOI 10.1016/0959-8049(95)00408-4; PEDERSEN L, 1989, BREAST CANCER RES TR, V14, P91, DOI 10.1007/BF01805979; PERTSCHUK LP, 1990, CANCER, V66, P1663, DOI 10.1002/1097-0142(19901015)66:8<1663::AID-CNCR2820660802>3.0.CO;2-C; Rakha EA, 2009, EUR J CANCER, V45, P1780, DOI 10.1016/j.ejca.2009.02.014; Rakha EA, 2006, J PATHOL, V208, P495, DOI 10.1002/path.1916; RIDOLFI RL, 1977, CANCER, V40, P1365, DOI 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N; ROSEN PP, 1995, CANCER, V75, P1320, DOI 10.1002/1097-0142(19950315)75:6<1320::AID-CNCR2820750614>3.0.CO;2-C; Vu-Nishino H, 2005, INT J RADIAT ONCOL, V62, P1040, DOI 10.1016/j.ijrobp.2005.01.008; Wu CE, 2014, ANTICANCER RES, V34, P1301	31	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2015	10	11							e0140208	10.1371/journal.pone.0140208	http://dx.doi.org/10.1371/journal.pone.0140208			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV7UL	26562837	Green Published, gold, Green Submitted			2023-01-03	WOS:000364480900003
J	Tissot, A; Jaffre, S; Gagnadoux, F; Levaillant, M; Corne, F; Chollet, S; Blanc, FX; Goupil, F; Priou, P; Trzepizur, W; Magnan, A				Tissot, Adrien; Jaffre, Sandrine; Gagnadoux, Frederic; Levaillant, Marc; Corne, Frederic; Chollet, Sylvaine; Blanc, Francois-Xavier; Goupil, Franois; Priou, Pascaline; Trzepizur, Wojciech; Magnan, Antoine		IRSR NIV Cohort Grp	Home Non-Invasive Ventilation Fails to Improve Quality of Life in the Elderly: Results from a Multicenter Cohort Study	PLOS ONE			English	Article							POSITIVE-PRESSURE VENTILATION; OBESITY HYPOVENTILATION SYNDROME; STABLE HYPERCAPNIC COPD; MECHANICAL VENTILATION; RESPIRATORY INSUFFICIENCY; TRIAL; AGE	Background Home non-invasive ventilation (NIV) is a widely used treatment for chronic hypoventilation but little is known on its impact in the elderly. In a multicenter prospective cohort study, we studied tolerance and efficacy of domiciliary NIV in patients aged 75 or more compared to younger ones. Methods and Results 264 patients with at least a six-month follow-up were analyzed. Among them, 82 were elderly. In the elderly and the younger, we found an improvement of arterial blood gas, the Epworth sleepiness scale and the Pittsburgh sleep quality index at 6 months. Mean daily use of NIV at 6 months was 7 hours and the rate of non-adherent patients was similar in both group. Health-related quality of life (HRQL) assessed by SF-36 questionnaires did not change significantly after NIV initiation in the elderly whereas HRQL improved in the less than 75. On univariate analysis, we found that diabetes was a predictive factor for non-adherence in the elderly (Odds ratio: 3.95% confidence interval: 1.06-8.52). Conclusion NIV was efficient in the elderly while evaluation at 6 months showed a good adherence but failed to improve HRQL.	[Tissot, Adrien; Jaffre, Sandrine; Corne, Frederic; Chollet, Sylvaine; Blanc, Francois-Xavier; Magnan, Antoine] CHU Nantes, Inst Thorax, Serv Pneumol, F-44035 Nantes 01, France; [Gagnadoux, Frederic; Priou, Pascaline; Trzepizur, Wojciech] CHU Angers, Dept Pneumol, Angers, France; [Levaillant, Marc] CERMES, CNRS UMR8211, Inserm U988, EHESS, Villejuif, France; [Goupil, Franois] Ctr Hosp Mans, Serv Pneumol, Le Mans, France	Nantes Universite; CHU de Nantes; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Humanities & Social Sciences (INSHS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Le Mans	Tissot, A (corresponding author), CHU Nantes, Inst Thorax, Serv Pneumol, F-44035 Nantes 01, France.	adrientissot@hotmail.com	Blanc, François-Xavier/D-7425-2015; MAGNAN, ANTOINE/GVT-4308-2022	Blanc, François-Xavier/0000-0001-7644-2188; 	Institut de Recherche en Sante Respiratoire des Pays de Loire	Institut de Recherche en Sante Respiratoire des Pays de Loire	The study was funded by the Institut de Recherche en Sante Respiratoire des Pays de Loire. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Andersen-Ranberg K, 1999, AGE AGEING, V28, P373, DOI 10.1093/ageing/28.4.373; [Anonymous], 1999, CHEST, V116, P521; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Dreher M, 2010, THORAX, V65, P303, DOI 10.1136/thx.2009.124263; Farrero E, 2007, RESP MED, V101, P1068, DOI 10.1016/j.rmed.2006.10.005; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Heinemann F, 2007, RESP MED, V101, P1229, DOI 10.1016/j.rmed.2006.10.027; Hung WW, 2012, MED CARE, V50, P501, DOI 10.1097/MLR.0b013e318245a0e0; Janssens JP, 1998, RESP MED, V92, P1311, DOI 10.1016/S0954-6111(98)90135-4; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Klein BEK, 2005, ARCH GERONTOL GERIAT, V41, P141, DOI 10.1016/j.archger.2005.01.002; LEGER P, 1994, CHEST, V105, P100, DOI 10.1378/chest.105.1.100; Lloyd-Owen SJ, 2005, EUR RESPIR J, V25, P1025, DOI 10.1183/09031936.05.00066704; Marti S, 2010, RESP MED, V104, P1843, DOI 10.1016/j.rmed.2010.08.013; McEvoy RD, 2009, THORAX, V64, P561, DOI 10.1136/thx.2008.108274; McKim DA, 2011, CAN RESPIR J, V18, P197, DOI 10.1155/2011/139769; Olson AL, 2005, AM J MED, V118, P948, DOI 10.1016/j.amjmed.2005.03.042; Priou P, 2010, CHEST, V138, P84, DOI 10.1378/chest.09-2472; SIMONDS AK, 1995, THORAX, V50, P604, DOI 10.1136/thx.50.6.604; Tsuboi T, 2010, RESP MED, V104, P1850, DOI 10.1016/j.rmed.2010.04.027; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Windisch W, 2003, J CLIN EPIDEMIOL, V56, P752, DOI 10.1016/S0895-4356(03)00088-X	22	17	17	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2015	10	10							e0141156	10.1371/journal.pone.0141156	http://dx.doi.org/10.1371/journal.pone.0141156			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0ZM	26489014	Green Published, gold, Green Submitted			2023-01-03	WOS:000363248400111
J	Knoos, P; Svensson, AV; Ulvenlund, S; Wahlgren, M				Knoos, Patrik; Svensson, Anna V.; Ulvenlund, Stefan; Wahlgren, Marie			Release of a Poorly Soluble Drug from Hydrophobically Modified Poly (Acrylic Acid) in Simulated Intestinal Fluids	PLOS ONE			English	Article							IN-VIVO PERFORMANCE; POLY(ACRYLIC ACID); DOSAGE FORMS; DISSOLUTION MEDIA; MATRIX TABLETS; SOLUBILITY; SURFACTANT; BIOAVAILABILITY; FORMULATIONS; MECHANISM	A large part of new pharmaceutical substances are characterized by a poor solubility and high hydrophobicity, which might lead to a difference in drug adsorption between fasted and fed patients. We have previously evaluated the release of hydrophobic drugs from tablets based on Pemulen TR2 and showed that the release can be manipulated by adding surfactants. Here we further evaluate the possibility to use Pemulen TR2 in controlled release tablet formulations containing a poorly soluble substance, griseofulvin. The release is evaluated in simulated intestinal media that model the fasted state (FaSSIF medium) or fed state (FeSSIF). The rheology of polymer gels is studied in separate experiments, in order to gain more information on possible interactions. The release of griseofulvin in tablets without surfactant varied greatly and the slowest release were observed in FeSSIF. Addition of SDS to the tablets eliminated the differences and all tablets showed a slow linear release, which is of obvious relevance for robust drug delivery. Comparing the data from the release studies and the rheology experiment showed that the effects on the release from the different media could to a large extent be rationalised as a consequence of the interactions between the polymer and the surfactants in the media. The study shows that Pemulen TR2 is a candidate for controlled release formulations in which addition of surfactant provides a way to eliminate food effects on the release profile. However, the formulation used needs to be designed to give a faster release rate than the tablets currently investigated.	[Knoos, Patrik] Lund Univ, Div Phys Chem, Dept Chem, Lund, Sweden; [Svensson, Anna V.] Teknol Inst, Taastrup, Denmark; [Ulvenlund, Stefan] CR Competence AB, Lund, Sweden; [Wahlgren, Marie] Lund Univ, Dept Food Technol Engn & Nutr, Lund, Sweden	Lund University; Lund University	Wahlgren, M (corresponding author), Lund Univ, Dept Food Technol Engn & Nutr, Lund, Sweden.	marie.wahlgren@food.lth.se		Wahlgren, Marie/0000-0002-1705-3964	FLAK Research School of Pharmaceutics Lund University	FLAK Research School of Pharmaceutics Lund University	This work was funded by FLAK Research School of Pharmaceutics Lund University (no grant number available) to Patrik Knoos.	Abrahamsson B, 2004, EUR J PHARM SCI, V22, P165, DOI 10.1016/j.ejps.2004.03.004; Adler J, 1999, J PHARM SCI, V88, P371, DOI 10.1021/js970376j; AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288; Bettini R, 2001, J CONTROL RELEASE, V70, P383, DOI 10.1016/S0168-3659(00)00366-7; Borgquist P, 2006, J CONTROL RELEASE, V113, P216, DOI 10.1016/j.jconrel.2006.05.004; Colombo, 2000, Pharm Sci Technol Today, V3, P198, DOI 10.1016/S1461-5347(00)00269-8; COLOMBO P, 1993, ADV DRUG DELIVER REV, V11, P37, DOI 10.1016/0169-409X(93)90026-Z; Dressman JB, 1998, PHARMACEUT RES, V15, P11, DOI 10.1023/A:1011984216775; DUALEH AJ, 1990, MACROMOLECULES, V23, P251, DOI 10.1021/ma00203a043; Galia E, 1998, PHARMACEUT RES, V15, P698, DOI 10.1023/A:1011910801212; Holmberg K., 2003, SURFACTANTS POLYM AQ, DOI DOI 10.1002/0470856424; Jantratid E, 2008, PHARM RES-DORDR, V25, P1663, DOI 10.1007/s11095-008-9569-4; Kavanagh N, 2004, INT J PHARMACEUT, V279, P141, DOI 10.1016/j.ijpharm.2004.04.016; Kleberg K, 2010, J PHARM PHARMACOL, V62, P1656, DOI 10.1111/j.2042-7158.2010.01023.x; Knoos P, 2013, LANGMUIR; Knoos Patrik, 2013, Results Pharma Sci, V3, P7, DOI 10.1016/j.rinphs.2013.08.001; Korner A, 2005, J PHYS CHEM B, V109, P11530, DOI 10.1021/jp044332s; Kostewicz ES, 2014, EUR J PHARM SCI, V57, P342, DOI 10.1016/j.ejps.2013.08.024; Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6; Magny B., 1992, TRENDS COLLOID INTER, P118; Marques EF, 2000, LANGMUIR, V16, P5178, DOI 10.1021/la9912803; MAZER NA, 1979, BIOCHEMISTRY-US, V18, P3064, DOI 10.1021/bi00581a024; Miller-Chou BA, 2003, PROG POLYM SCI, V28, P1223, DOI 10.1016/S0079-6700(03)00045-5; Mithani SD, 1996, PHARMACEUT RES, V13, P163, DOI 10.1023/A:1016062224568; Mylonas Y, 1999, POLYMER, V40, P6841, DOI 10.1016/S0032-3861(98)00861-1; Philippova OE, 1997, MACROMOLECULES, V30, P8278, DOI 10.1021/ma970957v; Piculell I, 2001, POLYM ADVAN TECHNOL, V12, P44; Porter CJH, 2007, NAT REV DRUG DISCOV, V6, P231, DOI 10.1038/nrd2197; Reynolds TD, 1998, J PHARM SCI, V87, P1115, DOI 10.1021/js980004q; Simovic S, 1999, INT J PHARMACEUT, V184, P207, DOI 10.1016/S0378-5173(99)00097-6; SKOUG JW, 1993, J CONTROL RELEASE, V27, P227, DOI 10.1016/0168-3659(93)90154-W; Stegemann S, 2007, EUR J PHARM SCI, V31, P249, DOI 10.1016/j.ejps.2007.05.110; Tabandeh H, 2014, PAK J PHARM SCI, V27, P495; TAHARA K, 1995, J CONTROL RELEASE, V35, P59, DOI 10.1016/0168-3659(95)00021-Y; Tajarobi F, 2011, J PHARM SCI-US, V100, P275, DOI 10.1002/jps.22248; Wahlgren M, 2009, DRUG DEV IND PHARM, V35, P922, DOI 10.1080/03639040802698810; Weitschies W, 2005, J CONTROL RELEASE, V108, P375, DOI 10.1016/j.jconrel.2005.08.018; Wilson C.G., 2011, CONTROLLED RELEASE O, P27; Woo JS, 2008, EUR J PHARM SCI, V33, P159, DOI 10.1016/j.ejps.2007.11.001	39	3	3	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2015	10	10							e0140709	10.1371/journal.pone.0140709	http://dx.doi.org/10.1371/journal.pone.0140709			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0DF	26473964	Green Published, Green Submitted, gold			2023-01-03	WOS:000363185500088
J	Maybury, CM; Pink, A; Lewis, F				Maybury, Catriona M.; Pink, Andrew; Lewis, Fiona			CASE REVIEW A persistent vulval ulcer	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							NICORANDIL; ULCERATIONS		[Maybury, Catriona M.; Lewis, Fiona] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England; [Maybury, Catriona M.; Lewis, Fiona] Kings Coll London, London WC2R 2LS, England; [Pink, Andrew] Kings Coll London, Dept Med & Mol Genet, London WC2R 2LS, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; University of London; King's College London	Maybury, CM (corresponding author), Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England.	Catriona.maybury@kcl.ac.uk		Pink, Andrew/0000-0001-5151-5539	National Institute for Health Research [CL-2014-17-002] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Chhabra S, 2014, J OBSTET GYNAECOL, V34, P165, DOI 10.3109/01443615.2013.834310; Claeys A, 2006, BRIT J DERMATOL, V155, P494, DOI 10.1111/j.1365-2133.2006.07363.x; Edwards SK, 2015, INT J STD AIDS, V26, P611, DOI 10.1177/0956462414554271; Egred M, 2007, EUR J GASTROEN HEPAT, V19, P395, DOI 10.1097/MEG.0b013e328010b184; El-Dars LD, 2009, J OBSTET GYNAECOL, V29, P674, DOI 10.1080/01443610903104486; Fraser SJ, 2009, BJOG-INT J OBSTET GY, V116, P1400, DOI 10.1111/j.1471-0528.2009.02260.x; Goldsmith L, 2012, FITZPATRICKS DERMATO, V1; Healy CM, 2004, HEART, V90, DOI 10.1136/hrt.2003.031831; Hoang MP, 2014, AM J DERMATOPATH, V36, P689, DOI 10.1097/DAD.0000000000000149; Lee BC, 2011, DIGEST DIS SCI, V56, P2404, DOI 10.1007/s10620-011-1634-x; Lewis FM, 2005, CLIN OBSTET GYNECOL, V48, P824, DOI 10.1097/01.grf.0000179669.21811.8f; Malik R, 2005, BRIT J DERMATOL, V152, P809, DOI 10.1111/j.1365-2133.2005.06501.x; McKenna DJ, 2007, BRIT J DERMATOL, V156, P394, DOI 10.1111/j.1365-2133.2006.07643.x; Oyama N, 2003, LANCET, V362, P118, DOI 10.1016/S0140-6736(03)13863-9; Reichert S, 1997, EUR J DERMATOL, V7, P132; Spencer RJ, 2011, MENOPAUSE, V18, P1067, DOI 10.1097/gme.0b013e3182175a68; Trechot P, 2015, INT WOUND J, V12, P527, DOI 10.1111/iwj.12147; Watson A, 2002, LANCET, V360, P546, DOI 10.1016/S0140-6736(02)09710-6	18	0	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	2015	351								h5421	10.1136/bmj.h5421	http://dx.doi.org/10.1136/bmj.h5421			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT8YC	26475594				2023-01-03	WOS:000363101800001
J	Konstantopoulos, A; Tan, XW; Goh, GTW; Saraswathi, P; Chen, LY; Nyein, CL; Zhou, L; Beuerman, R; Tan, DTH; Mehta, J				Konstantopoulos, Aris; Tan, Xiao Wei; Goh, Gwendoline Tze Wei; Saraswathi, Padmanabhan; Chen, Liyan; Nyein, Chan Lwin; Zhou, Lei; Beuerman, Roger; Tan, Donald Tiang Hwee; Mehta, Jod			Prophylactic Vancomycin Drops Reduce the Severity of Early Bacterial Keratitis in Keratoprosthesis	PLOS ONE			English	Article							BOSTON TYPE-1 KERATOPROSTHESIS; CORNEAL GRAFT FAILURE; RISK-FACTORS; STAPHYLOCOCCUS-AUREUS; ENDOPHTHALMITIS; GLAUCOMA; OUTCOMES; EYES	Background Artificial cornea transplantation, keratoprosthesis, improves vision for patients at high risk of failure with human cadaveric cornea. However, post-operative infection can cause visual loss and implant extrusion in 3.2-17% of eyes. Long-term vancomycin drops are recommended following keratoprosthesis to prevent bacterial keratitis. Evidence, though, in support of this practice is poor. We investigated whether prophylactic vancomycin drops prevented bacterial keratitis in an animal keratoprosthesis model. Methodology Twenty-three rabbits were assigned either to a prophylactic group (n = 13) that received vancomycin 1.4% drops 5 times/day from keratoprosthesis implantation to sacrifice, or a non-prophylactic group (n = 10) that received no drops. All rabbits had Staphylococcus aureus inoculation into the cornea at 7-12 days post-implantation and were sacrificed at predetermined time-points. Prophylactic and non-prophylactic groups were compared with slit-lamp photography (SLP), anterior segment optical coherence tomography (AS-OCT), and histology, immunohistochemistry and bacterial quantification of excised corneas. Corneal vancomycin pharmacokinetics were studied in 8 additional rabbits. Results On day 1 post-inoculation, the median SLP score and mean +/- SEM AS-OCT corneal thickness (CT) were greater in the non-prophylactic than the prophylactic group (11 vs. 1, rho = 0.049 and 486.9 +/- 61.2 vs. 327.4 +/- 37.1 mu m, rho = 0.029 respectively). On days 2 and 4, SLP scores and CT were not significantly different. Immunohistochemistry showed a greater CD11b+ve/non-CD11b+ve cell ratio in the non-prophylactic group (1.45 vs. 0.71) on day 2. Bacterial counts were not significantly different between the two groups. Corneal vancomycin concentration (2.835 +/- 0.383 mu g/ml) exceeded minimum inhibitory concentration (MIC) for Staphylococcus aureus only after 16 days of vancomycin drops. Two of 3 rabbits still developed infection despite bacterial inoculation after 16 days of prophylactic drops. Conclusions Prophylactic vancomycin drops provided short-term benefit, but did not prevent infection. Achieving MIC in the cornea was not sufficient to prevent Staphylococcus aureus keratitis. Patients should continue to be counselled regarding the risk of infection following keratoprosthesis.	[Konstantopoulos, Aris; Tan, Xiao Wei; Goh, Gwendoline Tze Wei; Saraswathi, Padmanabhan; Chen, Liyan; Nyein, Chan Lwin; Zhou, Lei; Beuerman, Roger; Tan, Donald Tiang Hwee; Mehta, Jod] Singapore Eye Res Inst, Singapore, Singapore; [Konstantopoulos, Aris; Tan, Donald Tiang Hwee; Mehta, Jod] Singapore Natl Eye Ctr, Singapore, Singapore; [Tan, Donald Tiang Hwee; Mehta, Jod] Duke NUS Grad Med Sch, Dept Clin Sci, Singapore, Singapore; [Mehta, Jod] Nanyang Technol Univ, Singapore 639798, Singapore	National University of Singapore; Singapore National Eye Center; Singapore National Eye Center; National University of Singapore; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Mehta, J (corresponding author), Singapore Eye Res Inst, Singapore, Singapore.			Zhou, Lei/0000-0001-5893-6002	Singapore National Research Foundation under its Translational and Clinical Research (TCR) Programme [NMRC/TCR/008-SERI/2013]; LZ; RWB; DTT; JSM	Singapore National Research Foundation under its Translational and Clinical Research (TCR) Programme; LZ; RWB; DTT; JSM	This research was supported by the Singapore National Research Foundation under its Translational and Clinical Research (TCR) Programme (NMRC/TCR/008-SERI/2013) and administered by the Singapore Ministry of Health's National Medical Research Council. Authors that received funding: LZ, RWB, DTT, JSM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akpek EK, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009561.pub2; Aldave AJ, 2009, OPHTHALMOLOGY, V116, P640, DOI 10.1016/j.ophtha.2008.12.058; Alves D, 2014, BIOFOULING, V30, P483, DOI 10.1080/08927014.2014.889120; Avadhanam VS, 2015, BRIT J OPHTHALMOL, V99, P878, DOI 10.1136/bjophthalmol-2014-305359; Barnes SD, 2007, CORNEA, V26, P9, DOI 10.1097/01.ico.0000224650.19837.25; Bradley JC, 2009, CORNEA, V28, P321, DOI 10.1097/ICO.0b013e31818b8bfa; Chan CC, 2012, CORNEA, V31, P1128, DOI 10.1097/ICO.0b013e318245c02a; Chew HF, 2009, CORNEA, V28, P989, DOI 10.1097/ICO.0b013e3181a186dc; Crnej A, 2014, CORNEA, V33, P349, DOI 10.1097/ICO.0000000000000067; Dohlman Claes H., 2002, CLAO Journal, V28, P72; Durand ML, 2009, CORNEA, V28, P896, DOI 10.1097/ICO.0b013e3181983982; Harissi-Dagher M, 2007, CORNEA, V26, P564, DOI 10.1097/ICO.0b013e318041f0a6; Hicks CR, 2006, CORNEA, V25, P1034, DOI 10.1097/01.ico.0000229982.23334.6b; Jin XM, 2009, MOL VIS, V15, P2435; JOHNSON MK, 1990, CURR EYE RES, V9, P1107, DOI 10.3109/02713689008997584; Kim MJ, 2013, OPHTHALMOLOGY, V120, P2209, DOI 10.1016/j.ophtha.2013.05.001; Konstantopoulos A, 2008, AM J OPHTHALMOL, V146, P534, DOI 10.1016/j.ajo.2008.05.030; Konstantopoulos A, 2011, INVEST OPHTH VIS SCI, V52, P1093, DOI 10.1167/iovs.10-6067; LaPlante KL, 2004, ANTIMICROB AGENTS CH, V48, P4665, DOI 10.1128/AAC.48.12.4665-4672.2004; Li Q, 2008, MICROB PATHOGENESIS, V44, P426, DOI 10.1016/j.micpath.2007.11.006; Magalhaes FP, 2013, CORNEA, V32, P407, DOI 10.1097/ICO.0b013e31824a8b9b; MAGUIRE MG, 1994, OPHTHALMOLOGY, V101, P1536; Natarajan JV, 2014, ACS NANO, V8, P419, DOI 10.1021/nn4046024; Okeke CO, 2009, OPHTHALMOLOGY, V116, P191, DOI 10.1016/j.ophtha.2008.09.004; Olthoff CMG, 2005, OPHTHALMOLOGY, V112, P953, DOI 10.1016/j.ophtha.2004.12.035; Pascolini D, 2010, BR J OPHTHALMOL, V96, P614, DOI DOI 10.1136/BJ0PHTHALM0L-2011-300539; Ramchandran RS, 2012, OPHTHALMOLOGY, V119, P674, DOI 10.1016/j.ophtha.2011.10.009; Rybak MJ, 2006, CLIN INFECT DIS, V42, pS35, DOI 10.1086/491712; Sivaraman KR, 2013, AM J OPHTHALMOL, V155, P814, DOI 10.1016/j.ajo.2012.11.019; Srikumaran D, 2014, OPHTHALMOLOGY, V121, P2159, DOI 10.1016/j.ophtha.2014.05.030; Tan XW, 2014, ANTIMICROB AGENTS CH, V58, P5229, DOI 10.1128/AAC.02859-14; Thiagarajah JR, 2002, J BIOL CHEM, V277, P19139, DOI 10.1074/jbc.M202071200; Tullos NA, 2013, CURR EYE RES, V38, P1036, DOI 10.3109/02713683.2013.804094; von Fischern T, 1998, GRAEF ARCH CLIN EXP, V236, P553, DOI 10.1007/s004170050120; Whitcher JP, 2001, B WORLD HEALTH ORGAN, V79, P214; Williams KA, 2008, TRANSPLANTATION, V86, P1720, DOI 10.1097/TP.0b013e3181903b0a; Zerbe BL, 2006, OPHTHALMOLOGY, V113, P1779, DOI 10.1016/j.ophtha.2006.05.015	37	5	5	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2015	10	10							e0139653	10.1371/journal.pone.0139653	http://dx.doi.org/10.1371/journal.pone.0139653			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT6ZJ	26460791	Green Published, gold			2023-01-03	WOS:000362962300018
J	Kwon, O; Jang, HM; Jung, HY; Kim, YS; Kang, SW; Yang, CW; Kim, NH; Choi, JY; Cho, JH; Kim, CD; Kim, YL; Park, SH				Kwon, Owen; Jang, Hye Min; Jung, Hee-Yeon; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Choi, Ji-Young; Cho, Jang-Hee; Kim, Chan-Duck; Kim, Yong-Lim; Park, Sun-Hee		Clinical Res Ctr For End-Stage	The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; SECONDARY ANALYSIS; DIALYSIS OUTCOMES; ANEMIA MANAGEMENT; EPOETIN-ALPHA; MORBIDITY; TRIAL; LEVEL	Background Anemia is an important risk factor for mortality in hemodialysis (HD) patients. However, higher hemoglobin (Hb) is not necessarily better, as seen in several studies. This study aimed to validate the clinical use of an Hb target of 10-11 g/dL in Korean HD patients. Methods A total of 1,276 HD patients from the Clinical Research Center (CRC) for End-Stage Renal Disease (ESRD) were investigated in a prospective observational study. Cox proportional hazard analysis was conducted for each category of time-dependent Hb level and erythropoiesis-stimulating agent (ESA) dose, with subgroup analysis stratified by age and diabetes status. Results Using a reference Hb level of 10-11 g/dL, the hazard ratios (HRs) of death were 5.12 (95% confidence interval [CI], 2.62-10.02, P < 0.05) for Hb level < 9.0 g/dL, and 2.03 (CI, 1.16-3.69, P < 0.05) for Hb level 9.0-10.0 g/dL, after adjustment for multiple clinical variables. However, an Hb level >= 11 g/dL was not associated with decreased mortality risk. In an adjusted model categorized by Hb and ESA dose, the risk of death at an Hb level <10 g/dL and a higher dose of ESA (>= 126 U/kg/week) had an HR of 2.25 (CI, 1.03-4.92, P < 0.05), as compared to Hb level 10-11 g/dL and a lower dose of ESA. In subgroup analysis, those older than 65 years or who were diabetic had greater risk for mortality only in Hb category < 9.0 g/dL. However, there was no significant interaction between age or diabetes status and Hb. Conclusion Using CRC-ESRD data, we validated the association between Hb and ESA dose and mortality in Korean HD patients. The clinical practice target of an Hb of 10-11 g/dL before the new KDIGO guideline era seems reasonable considering its survival benefit in HD patients.	[Kwon, Owen; Jung, Hee-Yeon; Choi, Ji-Young; Cho, Jang-Hee; Kim, Chan-Duck; Kim, Yong-Lim; Park, Sun-Hee] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Dept Stat, Daegu, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120749, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea; Chonnam Natl Univ, Sch Med, Dept Internal Med, Gwangju, South Korea; [Kwon, Owen; Jang, Hye Min; Jung, Hee-Yeon; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Choi, Ji-Young; Cho, Jang-Hee; Kim, Chan-Duck; Kim, Yong-Lim; Park, Sun-Hee; Clinical Res Ctr For End-Stage] Clin Res Ctr End Stage Renal Dis Korea, Daegu, South Korea	Kyungpook National University; Kyungpook National University; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Catholic University of Korea; Chonnam National University	Kim, YL (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea.	ylkim@knu.ac.kr; sh-park@knu.ac.kr	Cho, Jang-hee/ABD-3534-2020	Cho, Jang-hee/0000-0002-7031-5214; Ryu, Dong-Ryeol/0000-0002-5309-7606; Jung, Hee-Yeon/0000-0003-0232-7202; Park, Jung Tak/0000-0002-2325-8982	Korean Healthcare Technology RD Project; Ministry for Health, Welfare and Family Affairs, Republic of Korea [A102065, A111345]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health & Welfare, Republic of Korea [HI15C0001]	Korean Healthcare Technology RD Project; Ministry for Health, Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health & Welfare, Republic of Korea	This study was supported by grants from the Korean Healthcare Technology R&D Project and Ministry for Health, Welfare and Family Affairs, Republic of Korea (A102065 and A111345) as well as by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Ministry of Health & Welfare, Republic of Korea (HI15C0001).	Bellinghieri G, 2015, J RENAL NUTR, V25, P164, DOI 10.1053/j.jrn.2014.10.012; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Coyne DW, 2012, KIDNEY INT, V82, P235, DOI 10.1038/ki.2012.76; Drueke TB, 2012, KIDNEY INT, V82, P952, DOI 10.1038/ki.2012.270; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Foley RN, 1996, AM J KIDNEY DIS, V28, P53, DOI 10.1016/S0272-6386(96)90130-4; Fort J, 2010, NEPHROL DIAL TRANSPL, V25, P2702, DOI 10.1093/ndt/gfq073; Fukuma S, 2012, AM J KIDNEY DIS, V59, P108, DOI 10.1053/j.ajkd.2011.07.014; Hanafusa N, 2014, NEPHROL DIAL TRANSPL, V29, P2316, DOI 10.1093/ndt/gfu272; Hung SC, 2014, NEPHROLOGY, V19, P735, DOI 10.1111/nep.12332; Inaba M, 2012, NEPHRON CLIN PRACT, V120, pC91, DOI 10.1159/000335979; Koulouridis I, 2013, AM J KIDNEY DIS, V61, P44, DOI 10.1053/j.ajkd.2012.07.014; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P121, DOI 10.1093/ndt/gfg458; Ma JZ, 1999, J AM SOC NEPHROL, V10, P610; Palmer SC, 2010, ANN INTERN MED, V153, P23, DOI 10.7326/0003-4819-153-1-201007060-00252; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Regidor DL, 2006, J AM SOC NEPHROL, V17, P1181, DOI 10.1681/ASN.2005090997; Robinson BM, 2005, KIDNEY INT, V68, P2323, DOI 10.1111/j.1523-1755.2005.00693.x; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Szczech LA, 2008, KIDNEY INT, V74, P791, DOI 10.1038/ki.2008.295; Szczech LA, 2010, KIDNEY INT, V77, P239, DOI 10.1038/ki.2009.415; Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809; Xia H, 1999, J AM SOC NEPHROL, V10, P1309; Zhang Y, 2004, AM J KIDNEY DIS, V44, P866, DOI 10.1053/j.ajkd.2004.08.002	24	6	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2015	10	10							e0140241	10.1371/journal.pone.0140241	http://dx.doi.org/10.1371/journal.pone.0140241			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TY	26452232	Green Submitted, Green Published, gold			2023-01-03	WOS:000362511200052
J	Mok, TSK; Loong, HH				Mok, Tony S. K.; Loong, Herbert H.			Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?	LANCET			English	Editorial Material							ADENOCARCINOMA; DOCETAXEL; NIVOLUMAB; GEFITINIB		[Mok, Tony S. K.; Loong, Herbert H.] Chinese Univ Hong Kong, State Key Lab Oncol South China, Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; State Key Lab Oncology South China	Mok, TSK (corresponding author), Chinese Univ Hong Kong, State Key Lab Oncol South China, Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.	tony@clo.cuhk.edu.hk	Mok, Tony Shu Kam/B-2310-2019; Loong, Herbert/J-5413-2017	Mok, Tony Shu Kam/0000-0002-8251-0551; Loong, Herbert/0000-0002-6607-1106				Ahamadi M, 2014, ANN M POP APPR GROUP; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Herbst RS, 2015, LANCET; Lindauer A, 2014, ANN M POP APPR GROUP; Lopes GD, 2012, CANCER-AM CANCER SOC, V118, P1032, DOI 10.1002/cncr.26372; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; *US FDA, 2015, FDA APPR KEYTR ADV N	10	8	8	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2016	387	10027					1488	1490		10.1016/S0140-6736(15)01308-2	http://dx.doi.org/10.1016/S0140-6736(15)01308-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DI8HH	26712085				2023-01-03	WOS:000373741600006
J	Takaschima, A; Marchioro, P; Sakae, TM; Porporatti, AL; Mezzomo, LA; Canto, GD				Takaschima, Augusto; Marchioro, Patricia; Sakae, Thiago M.; Porporatti, Andre L.; Mezzomo, Luis Andre; Canto, Graziela De Luca			Risk of Hemorrhage during Needle-Based Ophthalmic Regional Anesthesia in Patients Taking Antithrombotics: A Systematic Review	PLOS ONE			English	Article							ANTIPLATELET THERAPY; NONCARDIAC SURGERY; PERIOPERATIVE MANAGEMENT; CORONARY STENT; ANTICOAGULANT; PERIBULBAR; BLOCK; CONTINUATION; AGENTS; AUDIT	Background Patients undergoing ophthalmic surgery are usually elderly and, due to systemic disease, may be on long-term therapy, such as antithrombotic agents. Rates of hemorrhagic complications associated with invasive procedures may be increased by the use of anticoagulants and antiplatelet agents. Objective To compare the incidence of hemorrhagic complications in patients undergoing needle-based ophthalmic regional anesthesia between patients on antithrombotic therapy and those not on such therapy. Methods A systematic review was conducted by two independent reviewers based on searches of Cochrane, LILACS, PubMed, Scopus, Web of Science, and the "gray" literature (Google Scholar). The end search date was May 8, 2015, across all databases. Results Five studies met the eligibility criteria. In three studies, individual risk of bias was low, and in two of them, moderate. In all studies, no differences regarding mild to moderate incidence of hemorrhagic complications were found between patients using antithrombotics (aspirin, clopidogrel, and warfarin) and those not using them. Rates of severe hemorrhagic complication were very low (0.04%) in both groups, supporting the safety of needle blocks, even in patients using antithrombotics. High heterogeneity across studies prevented meta-analysis. Limitations to these results include low statistical power in three experimental studies and a large 95% confidence interval in the two retrospective cohorts. Conclusion In this review, none of the selected studies showed significant bleeding related to needle-based ophthalmic regional anesthesia in association with the use of aspirin, clopidogrel, or vitamin K inhibitors. Since the available data is not powerful enough to provide a reliable evaluation of the true effect of antithrombotics in this setting, new studies to address these limitations are necessary.	[Takaschima, Augusto; Marchioro, Patricia] Florianopolis Hosp, Florianopolis, SC, Brazil; [Takaschima, Augusto] Sianest Anesthesiol Serv, Florianopolis, SC, Brazil; [Takaschima, Augusto; Porporatti, Andre L.] Univ Fed Santa Catarina, Brazilian Ctr Evidence Based Res, Hlth Sci Ctr, Florianopolis, SC, Brazil; [Sakae, Thiago M.; Mezzomo, Luis Andre; Canto, Graziela De Luca] Unisul Univ Santa Catarina, Tubarao, Brazil; [Porporatti, Andre L.] Univ Sao Paulo, Bauru, Brazil; [Canto, Graziela De Luca] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada	Universidade Federal de Santa Catarina (UFSC); Universidade do Sul de Santa Catarina; Universidade de Sao Paulo; University of Alberta	Takaschima, A (corresponding author), Florianopolis Hosp, Florianopolis, SC, Brazil.; Takaschima, A (corresponding author), Sianest Anesthesiol Serv, Florianopolis, SC, Brazil.; Takaschima, A (corresponding author), Univ Fed Santa Catarina, Brazilian Ctr Evidence Based Res, Hlth Sci Ctr, Florianopolis, SC, Brazil.	takaschima@gmail.com	De Luca Canto, Graziela/AAW-5234-2021; Porporatti, Andre/D-5280-2012; Sakae, Thiago/AAN-5573-2020	Sakae, Thiago/0000-0002-0603-3685; De Luca Canto, Graziela/0000-0002-7986-8317; Porporatti, Andre/0000-0003-4379-9695				Alhassan MB, 2008, COCHRANE DB SYST REV, V3; Baron TH, 2013, NEW ENGL J MED, V368, P2113, DOI 10.1056/NEJMra1206531; Benzimra JD, 2009, EYE, V23, P10, DOI 10.1038/sj.eye.6703069; Bonhomme F, 2013, EUR J ANAESTH, V30, P449, DOI 10.1097/EJA.0b013e328360c442; Burger W, 2005, J INTERN MED, V257, P399, DOI 10.1111/j.1365-2796.2005.01477.x; Calenda E, 2014, INT J OPHTHALMOL-CHI, V7, P110, DOI 10.3980/j.issn.2222-3959.2014.01.20; Calenda E, 2012, J ANESTH, V26, P779, DOI 10.1007/s00540-012-1406-6; Calenda Emile, 2011, Acta Anaesthesiol Taiwan, V49, P141, DOI 10.1016/j.aat.2011.11.003; Darvish-Kazem S, 2013, CHEST, V144, P1848, DOI 10.1378/chest.13-0459; Douketis JD, 2015, NEW ENGL J MED, V373, P823, DOI 10.1056/NEJMoa1501035; Fleisher LA, 2015, J NUCL CARDIOL, V22, P162, DOI 10.1007/s12350-014-0025-z; Grzybowski A, 2015, CURR OPIN OPHTHALMOL, V26, P28, DOI 10.1097/ICU.0000000000000117; Kallio H, 2000, BRIT J ANAESTH, V85, P708, DOI 10.1093/bja/85.5.708; Katz J, 2003, OPHTHALMOLOGY, V110, P1784, DOI 10.1016/S0161-6420(03)00785-1; Kiire CA, 2014, BRIT J OPHTHALMOL, V98, P1320, DOI 10.1136/bjophthalmol-2014-304902; Kobayashi H, 2010, J CATARACT REFR SURG, V36, P1115, DOI 10.1016/j.jcrs.2010.01.017; Kong KL, 2015, BRIT J OPHTHALMOL, V99, P1025, DOI 10.1136/bjophthalmol-2014-306036; Levine GN, 2012, CATHETER CARDIO INTE, V79, P453, DOI 10.1002/ccd.23438; Levine M, 2001, PHARMACOTHERAPY, V21, P405, DOI 10.1592/phco.21.5.405.34503; Mason JO, 2011, OPHTHALMOLOGY, V118, P543, DOI 10.1016/j.ophtha.2010.07.005; Mather SJ, 2010, CURR ANAESTH CRIT CA, V21, P158; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nouvellon E, 2010, ANESTHESIOLOGY, V113, P1236, DOI 10.1097/ALN.0b013e3181f7a78e; Riad W, 2012, J CLIN ANESTH, V24, P193, DOI 10.1016/j.jclinane.2011.07.012; Rizk SN, 2014, EGYPT J ANAESTH, V30, P255, DOI 10.1016/j.egja.2014.01.002; Rossini R, 2015, THROMB HAEMOSTASIS, V113, P272, DOI 10.1160/TH14-05-0436; Saumier N, 2010, ANN FR ANESTH, V29, P878, DOI 10.1016/j.annfar.2010.08.009; Schouten O, 2007, J AM COLL CARDIOL, V49, P122, DOI 10.1016/j.jacc.2006.10.004; Smart S, 2007, BJA EDUC, V7, P157, DOI 10.1093/bjaceaccp/mkm030; The Joanna Briggs Institute, 2014, J BRIGGS I SYST REV; Windecker S, 2014, EUR HEART J, V35, P2541, DOI [10.5603/KP.2014.0224, 10.1093/eurheartj/ehu278, 10.1093/ejcts/ezu366]	31	6	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2016	11	1							e0147227	10.1371/journal.pone.0147227	http://dx.doi.org/10.1371/journal.pone.0147227			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB6WB	26800356	Green Published, Green Submitted, gold			2023-01-03	WOS:000368655300076
J	Coles, CE; Yarnold, JR				Coles, C. E.; Yarnold, J. R.			Accelerated partial breast irradiation: the new standard?	LANCET			English	Editorial Material							RADIATION-THERAPY; CANCER; RADIOTHERAPY; TRIALS; WOMEN		[Coles, C. E.] Cambridge Univ NHS Fdn Trust, Ctr Oncol, Cambridge CB2 0QQ, England; [Yarnold, J. R.] Inst Canc Res, London SW3 6JB, England; [Yarnold, J. R.] Royal Marsden Hosp NHS Fdn Trust, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Coles, CE (corresponding author), Cambridge Univ NHS Fdn Trust, Ctr Oncol, Cambridge CB2 0QQ, England.	charlotte.coles@addenbrookes.nhs.uk		Yarnold, John/0000-0002-9010-1854	Cancer Research UK [19727] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10026] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))		Bellon JR, 2015, J CLIN ONCOL, V33, P1998, DOI 10.1200/JCO.2015.61.2069; Coles C, 2006, CLIN ONCOL-UK, V18, P587, DOI 10.1016/j.clon.2006.07.010; Coles CE, 2013, CLIN ONCOL-UK, V25, P127, DOI 10.1016/j.clon.2012.10.013; Haviland JS, 2015, INT J RADIAT ONCOL, V92, P954, DOI 10.1016/j.ijrobp.2015.05.026; Haviland JS, 2013, LANCET ONCOL, V14, P1086, DOI 10.1016/S1470-2045(13)70386-3; Marta GN, 2015, RADIOTHER ONCOL, V114, P42, DOI 10.1016/j.radonc.2014.11.014; Olivotto IA, 2013, J CLIN ONCOL, V31, P4038, DOI 10.1200/JCO.2013.50.5511; Strnad V, 2015, LANCET; Taylor CW, 2015, CLIN ONCOL-UK, V27, P621, DOI 10.1016/j.clon.2015.06.007; Whelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260; Yarnold J, 2011, INT J RADIAT ONCOL, V79, P1, DOI 10.1016/j.ijrobp.2010.08.035	11	8	8	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	2016	387	10015					201	202		10.1016/S0140-6736(15)00518-8	http://dx.doi.org/10.1016/S0140-6736(15)00518-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA9LQ	26494414	Green Submitted			2023-01-03	WOS:000368130700004
J	Sokol, DK				Sokol, Daniel K.			Cautionary tales about DNACPR	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material											Sokol, DK (corresponding author), 112 Kings Bench Walk, London, England.							Dreaper J., 2015, BBC NEWS; Dyer C, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g4094; Dyer C, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e7503; Fins J, 2006, PALLIATIVE ETHIC CAR; Varney M, 2015, LETS TALK DNRS	5	9	9	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 5	2016	352								i26	10.1136/bmj.i26	http://dx.doi.org/10.1136/bmj.i26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DA8MA	26733107				2023-01-03	WOS:000368057800002
J	Chiang, Y; Yang, JCH; Hsu, FM; Chen, YH; Shih, JY; Lin, ZZ; Lan, KH; Cheng, AL; Kuo, SH				Chiang, Yun; Yang, James Chih-Hsin; Hsu, Feng-Ming; Chen, Yu-Hsuan; Shih, Jin-Yuan; Lin, Zhong-Zhe; Lan, Keng-Hsueh; Cheng, Ann-Lii; Kuo, Sung-Hsin			The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases	PLOS ONE			English	Article							PHASE-III; RADIATION-THERAPY; SUPPORTIVE CARE; CHEMOTHERAPY; SURVIVAL; TRIAL; SINGLE; IMPACT; LIFE	Background and Purpose For metastatic non-small cell lung cancer (NSCLC) patients with controlled extrathoracic disease after systemic treatment, stable or progressive primary lung lesions may cause respiratory symptoms and increase comorbidities. In the present study, we sought to investigate whether aggressive palliative thoracic radiotherapy (RT) can enhance local control and improve the survival for this subgroup of patients. Materials and Methods Between March 2006 and December 2014, 56 patients with metastatic NSCLC who had responsive or stable extrathoracic diseases after chemotherapy and/or molecular targets, and received thoracic RT for stable and progressive primary lung lesions were included. RT with a median dose of 55 Gy (range, 40-62 Gy) was administered in 1.8-2.5 Gy fractions to primary lung tumor and regional mediastinal lymph nodes using modern RT technique. Overall survival (OS) from diagnosis, and locoregional progression-free survival (LRPFS), and survival calculated from radiotherapy (OS-RT) were estimated using the Kaplan-Meier method. Results There were 37 men and 19 women with a median age of 60 years at diagnosis. The median interval from the diagnosis of metastatic disease to thoracic RT was 8 months. Following thoracic RT, 26 patients (46%) achieved complete or partial response (overall response rate, ORR). Patients with squamous cell carcinoma or poorly-differentiated carcinoma had a higher ORR than those with adenocarcinoma (63% vs. 34%, P = 0.034). EGFR mutations was closely associated with a better ORR (45% vs. 29%, P = 0.284). At a median follow-up time of 44 months, the median OS, LRPFS after RT, and OS-RT were 50 months, 15 months, and 18 months. Conclusion Radical palliative throractic RT is safe and might be beneficial for primary lung lesions of metastatic NSCLC patients with controlled extrathoracic diseases.	[Chiang, Yun; Hsu, Feng-Ming; Chen, Yu-Hsuan; Lan, Keng-Hsueh; Kuo, Sung-Hsin] Natl Taiwan Univ Hosp, Dept Oncol, Div Radiat Oncol, Taipei, Taiwan; [Shih, Jin-Yuan; Lin, Zhong-Zhe] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Yang, James Chih-Hsin; Lin, Zhong-Zhe; Cheng, Ann-Lii; Kuo, Sung-Hsin] Natl Taiwan Univ, Coll Med, Canc Res Ctr, Taipei 10764, Taiwan; [Yang, James Chih-Hsin; Lin, Zhong-Zhe; Cheng, Ann-Lii; Kuo, Sung-Hsin] Natl Taiwan Univ, Ctr Canc, Taipei 10764, Taiwan; [Yang, James Chih-Hsin; Cheng, Ann-Lii; Kuo, Sung-Hsin] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University	Kuo, SH (corresponding author), Natl Taiwan Univ Hosp, Dept Oncol, Div Radiat Oncol, Taipei, Taiwan.	shkuo101@ntu.edu.tw	Yang, James Chih-Hsin/W-1587-2019; Chiang, Yun/GRJ-5251-2022	Kuo, Sung-Hsin/0000-0003-0054-887X; Yang, James Chih-Hsin/0000-0002-5586-5138; Cheng, Ann-Lii/0000-0002-9152-6512	Ministry of Science and Technology, Taiwan [MOST 104-2314-B-002-189-MY3, MOST 104-2811-B-002-058]; National Health Research Institutes, Taiwan [NHRI-EX104-10239BI]; National Taiwan University Hospital [NTUH 104-S2710]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); National Taiwan University Hospital(National Taiwan University)	The authors thank the Cancer Registry, Office of Medical Records, National Taiwan University Hospital for providing the necessary patient information. Grant Support: This study was supported by research grants MOST 104-2314-B-002-189-MY3 and MOST 104-2811-B-002-058 from the Ministry of Science and Technology, Taiwan, NHRI-EX104-10239BI from the National Health Research Institutes, Taiwan, and NTUH 104-S2710 from National Taiwan University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arrieta O, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-166; Bezjak A, 2002, INT J RADIAT ONCOL, V54, P719, DOI 10.1016/S0360-3016(02)02989-9; Burdett S, 2008, J CLIN ONCOL, V26, P4617, DOI 10.1200/JCO.2008.17.7162; Chan C, 2014, J THORAC ONCOL, V9, P1598, DOI 10.1097/JTO.0000000000000346; Cheruvu P, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-80; De Ruysscher D, 2012, J THORAC ONCOL, V7, P1547, DOI 10.1097/JTO.0b013e318262caf6; De Ruysscher D, 2010, J CLIN ONCOL, V28, P5301, DOI 10.1200/JCO.2010.30.3271; Dehing-Oberije C, 2009, RADIOTHER ONCOL, V91, P421, DOI 10.1016/j.radonc.2008.12.002; Di BS, 2014, ASIAN PAC J CANCER P, V15, P3419, DOI 10.7314/APJCP.2014.15.8.3419; Ettinger DS, 2010, J NATL COMPR CANC NE, V8, P740, DOI 10.6004/jnccn.2010.0056; Fairchild A, 2008, J CLIN ONCOL, V26, P4001, DOI 10.1200/JCO.2007.15.3312; Genestreti G, 2015, EXPERT REV ANTICANC, V15, P839, DOI 10.1586/14737140.2015.1052410; Gerber DE, 2013, J CLIN ONCOL, V31, P1009, DOI 10.1200/JCO.2012.43.7459; Gow CH, 2008, CLIN CANCER RES, V14, P162, DOI 10.1158/1078-0432.CCR-07-1468; Helsing M, 1998, EUR J CANCER, V34, P1036, DOI 10.1016/S0959-8049(97)10122-8; Kao HF, 2013, FUTURE ONCOL, V9, P991, DOI [10.2217/FON.13.56, 10.2217/fon.13.56]; Kramer GWPM, 2005, J CLIN ONCOL, V23, P2962, DOI 10.1200/JCO.2005.01.685; Kuo SH, 2005, LUNG CANCER, V48, P275, DOI 10.1016/j.lungcan.2004.10.004; Lee CK, 2013, JNCI-J NATL CANCER I, V105, P595, DOI 10.1093/jnci/djt072; Guerra JLL, 2012, INT J RADIAT ONCOL, V84, pE61, DOI 10.1016/j.ijrobp.2012.02.054; Macbeth F R, 1996, Clin Oncol (R Coll Radiol), V8, P167, DOI 10.1016/S0936-6555(96)80041-0; Nichols L, 2012, ARCH PATHOL LAB MED, V136, P1552, DOI 10.5858/arpa.2011-0521-OA; Parikh RB, 2014, INT J RADIAT ONCOL, V89, P880, DOI 10.1016/j.ijrobp.2014.04.007; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Scagliotti GV, 2002, J CLIN ONCOL, V20, P4285, DOI 10.1200/JCO.2002.02.068; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Sirzen F, 2003, ACTA ONCOL, V42, P493, DOI 10.1080/02841860310014453; Spiro SG, 2004, THORAX, V59, P828, DOI 10.1136/thx.2003.020164; Su SF, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-474; US Department of Health and Human Services National Institutes of Health NCI, COMMON TERMINOLOGY C; van Baardwijk A, 2010, J CLIN ONCOL, V28, P1380, DOI 10.1200/JCO.2009.24.7221; Werner-Wasik M, 2010, INT J RADIAT ONCOL, V76, pS86, DOI 10.1016/j.ijrobp.2009.05.070; Zhong CX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058466	33	9	10	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2015	10	12							e0145936	10.1371/journal.pone.0145936	http://dx.doi.org/10.1371/journal.pone.0145936			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DA0TR	26720170	gold, Green Submitted, Green Published			2023-01-03	WOS:000367510900027
J	Westbom, C; Thompson, JK; Leggett, A; MacPherson, M; Beuschel, S; Pass, H; Vacek, P; Shukla, A				Westbom, Catherine; Thompson, Joyce K.; Leggett, Alan; MacPherson, Maximilian; Beuschel, Stacie; Pass, Harvey; Vacek, Pamela; Shukla, Arti			Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma	PLOS ONE			English	Article							NLRP3 INFLAMMASOME; PROSTATE-CANCER; CELLS; CASPASE-1; PROMOTES; IL-1-BETA; RELEASE; GROWTH; DOXORUBICIN; RESISTANCE	Malignant mesothelioma (MM) is a fatal disease in dire need of therapy. The role of inflammasomes in cancer is not very well studied, however, literature supports both pro- and antitumorigenic effects of inflammasomes on cancer depending upon the type of cancer. Asbestos is a causative agent for MM and we have shown before that it causes inflammasome priming and activation in mesothelial cells. MM tumor cells/tissues showed decreased levels of inflammasome components like NLRP3 and caspase-1 as compared to human mesothelial cells or normal tissue counterpart of tumor. Based on our preliminary findings we hypothesized that treatment of MMs with chemotherapeutic drugs may elevate the levels of NLRP3 and caspase-1 resulting in increased cell death by pyroptosis while increasing the levels of IL-1 beta and other pro-inflammatory molecules. Therefore, a combined strategy of chemotherapeutic drug and IL-1R antagonist may play a beneficial role in MM therapy. To test our hypothesis we used two human MM tumor cell lines (Hmeso, H2373) and two chemotherapeutic drugs (doxorubicin, cisplatin). Through a series of experiments we showed that both chemotherapeutic drugs caused increases in NLRP3 levels, caspase-1 activation, pyroptosis and pro-inflammatory molecules released from MM cells. In vivo studies using SCID mice and Hmeso cells showed that tumors were smaller in combined treatment group of cisplatin and IL-1R antagonist (Anakinra) as compared to cisplatin alone or untreated control groups. Taken together our study suggests that chemotherapeutic drugs in combination with IL-1R antagonist may have a beneficial role in MM treatment.	[Westbom, Catherine; Thompson, Joyce K.; Leggett, Alan; MacPherson, Maximilian; Beuschel, Stacie; Shukla, Arti] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT 05405 USA; [Vacek, Pamela] Univ Vermont, Coll Med, Dept Med Biostat, Burlington, VT USA; [Pass, Harvey] NYU, Hosp Joint Dis, Dept Cardiothorac Surg, New York, NY USA	University of Vermont; University of Vermont; New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC	Shukla, A (corresponding author), Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT 05405 USA.	Arti.Shukla@med.uvm.edu		Pass, Harvey/0000-0003-3222-3471; Thompson, Joyce/0000-0001-7898-0078	NIH [RO1 ES021110]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES021110] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by NIH RO1 ES021110.	Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Antonopoulos C, 2015, J BIOL CHEM, V290, P20167, DOI 10.1074/jbc.M115.652321; Antonopoulos C, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27499; Antonopoulos C, 2013, J IMMUNOL, V191, P4789, DOI 10.4049/jimmunol.1300645; Bauer C, 2010, GUT, V59, P1192, DOI 10.1136/gut.2009.197822; Bruchard M, 2014, B CANCER, V101, P605, DOI 10.1684/bdc.2014.1936; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Creagh EM, 2014, TRENDS IMMUNOL, V35, P631, DOI 10.1016/j.it.2014.10.004; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Hillegass JM, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-39; Hillegass JM, 2011, INT J CANCER, V129, P233, DOI 10.1002/ijc.25666; Hillegass JM, 2010, ANN NY ACAD SCI, V1203, P7, DOI 10.1111/j.1749-6632.2010.05554.x; Hillegass JM, 2010, WIRES NANOMED NANOBI, V2, P219, DOI 10.1002/wnan.54; Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001; Idris Adi, 2015, Biomark Cancer, V7, P25, DOI 10.4137/BIC.S25375; Krelin Y, 2007, CANCER RES, V67, P1062, DOI 10.1158/0008-5472.CAN-06-2956; Lamkanfi M, 2008, MOL CELL PROTEOMICS, V7, P2350, DOI 10.1074/mcp.M800132-MCP200; Lee DW, 2015, RENAL FAILURE, V37, P144, DOI 10.3109/0886022X.2014.970194; Newick K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039404; Palomo J, 2015, CYTOKINE, V76, P25, DOI 10.1016/j.cyto.2015.06.017; Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165; Park MS, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134858; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; REALE FR, 1987, CANCER RES, V47, P3199; Schwarznau A, 2009, J CELL PHYSIOL, V220, P341, DOI 10.1002/jcp.21770; Shukla A, 2006, FASEB J, V20, P997, DOI 10.1096/fj.05-4554fje; Shukla A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-314; Shukla A, 2013, CLIN CANCER RES, V19, P2071, DOI 10.1158/1078-0432.CCR-12-3202; Shukla A, 2011, INT J CANCER, V129, P1075, DOI 10.1002/ijc.25763; Shukla A, 2009, AM J PATHOL, V175, P2197, DOI 10.2353/ajpath.2009.090400; Siegmund B, 2001, P NATL ACAD SCI USA, V98, P13249, DOI 10.1073/pnas.231473998; Smythe W Roy, 2002, Curr Oncol Rep, V4, P305, DOI 10.1007/s11912-002-0006-2; Wang YH, 2004, INT J ONCOL, V25, P173; Westbom CM, 2014, AM J PATHOL, V184, P2816, DOI 10.1016/j.ajpath.2014.06.008; Winter RN, 2004, ANTICANCER RES, V24, P1377; Winter RN, 2001, CANCER RES, V61, P1227; Wong J, 2014, CANCER BIOL THER, V15, P1395, DOI 10.4161/cbt.29922; Zaki MH, 2011, CANCER CELL, V20, P649, DOI 10.1016/j.ccr.2011.10.022; Zhang YY, 2014, TOXICOL APPL PHARM, V281, P1, DOI 10.1016/j.taap.2014.09.016	41	24	26	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2015	10	12							e0145404	10.1371/journal.pone.0145404	http://dx.doi.org/10.1371/journal.pone.0145404			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SF	26689911	Green Published, Green Submitted, gold			2023-01-03	WOS:000367092300072
J	Duong, M; Moles, RJ; Chaar, B; Chen, TF				Duong, Mai; Moles, Rebekah J.; Chaar, Betty; Chen, Timothy F.		World Hosp Pharm Res Consortium	Essential Medicines in a High Income Country: Essential to Whom?	PLOS ONE			English	Article								Objective To explore the perspectives of a diverse group of stakeholders engaged in medicines decision making around what constitutes an "essential" medicine, and how the Essential Medicines List (EML) concept functions in a high income country context. Methods In-depth qualitative semi-structured interviews were conducted with 32 Australian stakeholders, recognised as decision makers, leaders or advisors in the area of medicines reimbursement or supply chain management. Participants were recruited from government, pharmaceutical industry, pharmaceutical wholesale/distribution companies, medicines non-profit organisations, academic health disciplines, hospitals, and consumer groups. Perspectives on the definition and application of the EML concept in a high income country context were thematically analysed using grounded theory approach. Findings Stakeholders found it challenging to describe the EML concept in the Australian context because many perceived it was generally used in resource scarce settings. Stakeholders were unable to distinguish whether nationally reimbursed medicines were essential medicines in Australia. Despite frequent generic drug shortages and high prices paid by consumers, many struggled to describe how the EML concept applied to Australia. Instead, broad inclusion of consumer needs, such as rare and high cost medicines, and consumer involvement in the decision making process, has led to expansive lists of nationally subsidised medicines. Therefore, improved communication and coordination is needed around shared interests between stakeholders regarding how medicines are prioritised and guaranteed in the supply chain. Conclusions This study showed that decision-making in Australia around reimbursement of medicines has strayed from the fundamental utilitarian concept of essential medicines. Many stakeholders involved in medicine reimbursement decisions and management of the supply chain did not consider the EML concept in their approach. The wide range of views of what stakeholders considered were essential medicines, challenges whether the EML concept is out-dated or underutilised in high income countries.	[Duong, Mai; Moles, Rebekah J.; Chaar, Betty; Chen, Timothy F.; World Hosp Pharm Res Consortium] Univ Sydney, Discipline Pharm Practice, Fac Pharm, Sydney, NSW 2006, Australia	University of Sydney	Duong, M (corresponding author), Univ Sydney, Discipline Pharm Practice, Fac Pharm, Sydney, NSW 2006, Australia.	mai.duong@sydney.edu.au	Chen, Timothy/X-3684-2019	Chen, Timothy/0000-0003-4189-8403					0	15	15	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2015	10	12							e0143654	10.1371/journal.pone.0143654	http://dx.doi.org/10.1371/journal.pone.0143654			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ1YX	26650544	Green Published, gold, Green Submitted			2023-01-03	WOS:000366903300021
J	Park, BY; Lee, H; Woo, S; Yoon, M; Kim, J; Hong, Y; Lee, HS; Park, EK; Hahm, JC; Kim, JW; Shin, SS; Kim, MY; Yoon, M				Park, Byung Young; Lee, Hyunghee; Woo, Sangee; Yoon, Miso; Kim, Jeongjun; Hong, Yeonhee; Lee, Hee Suk; Park, Eun Kyu; Hahm, Jong Cheon; Kim, Jin Woo; Shin, Soon Shik; Kim, Min-Young; Yoon, Michung			Reduction of Adipose Tissue Mass by the Angiogenesis Inhibitor ALS-L1023 from Melissa officinalis	PLOS ONE			English	Article							MATRIX-METALLOPROTEINASE INHIBITION; COMPOSITION OB-X; INSULIN-RESISTANCE; GELATINASE-A; PPAR-ALPHA; MORUS-ALBA; OBESITY; GROWTH; EXPRESSION; ADIPOGENESIS	It has been suggested that angiogenesis modulates adipogenesis and obesity. This study was undertaken to determine whether ALS-L1023 (ALS) prepared by a two-step organic solvent fractionation from Melissa leaves, which exhibits antiangiogenic activity, can regulate adipose tissue growth. The effects of ALS on angiogenesis and extracellular matrix remodeling were measured using in vitro assays. The effects of ALS on adipose tissue growth were investigated in high fat diet-induced obese mice. ALS inhibited VEGF-and bFGF-induced endothelial cell proliferation and suppressed matrix metalloproteinase (MMP) activity in vitro. Compared to obese control mice, administration of ALS to obese mice reduced body weight gain, adipose tissue mass and adipocyte size without affecting appetite. ALS treatment decreased blood vessel density and MMP activity in adipose tissues. ALS reduced the mRNA levels of angiogenic factors (VEGF-A and FGF-2) and MMPs (MMP-2 and MMP-9), whereas ALS increased the mRNA levels of angiogenic inhibitors (TSP-1, TIMP-1, and TIMP-2) in adipose tissues. The protein levels of VEGF, MMP-2 and MMP-9 were also decreased by ALS in adipose tissue. Metabolic changes in plasma lipids, liver triglycerides, and hepatic expression of fatty acid oxidation genes occurred during ALS-induced weight loss. These results suggest that ALS, which has antiangiogenic and MMP inhibitory activities, reduces adipose tissue mass in nutritionally obese mice, demonstrating that adipose tissue growth can be regulated by angiogenesis inhibitors.	[Park, Byung Young; Kim, Jin Woo] Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon, South Korea; [Park, Byung Young; Lee, Hee Suk; Park, Eun Kyu; Hahm, Jong Cheon; Kim, Min-Young] AngioLab Inc, Daejeon, South Korea; [Lee, Hyunghee; Woo, Sangee; Yoon, Miso; Kim, Jeongjun; Hong, Yeonhee; Yoon, Michung] Mokwon Univ, Dept Biomed Engn, Daejeon, South Korea; [Shin, Soon Shik] Dong Eui Univ, Dept Formula Sci, Coll Oriental Med, Busan, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Mokwon University; Dong-Eui University	Kim, MY (corresponding author), AngioLab Inc, Daejeon, South Korea.	mykim@angiolab.co.kr; yoon60@mokwon.ac.kr	KIM, JIN WOO/C-1655-2011	KIM, JIN WOO/0000-0003-0767-1918	National Research Foundation of Korea Grant - Korea Government (MEST), Korea [2012R1A1A3002100, 2012R1A2A2A01004508, 2015R1A1A3A04001016]; AngioLab Inc	National Research Foundation of Korea Grant - Korea Government (MEST), Korea; AngioLab Inc	This work was supported by the National Research Foundation of Korea [http://www.nrf.re.kr/] Grants funded by the Korea Government (MEST) (2012R1A1A3002100, 2012R1A2A2A01004508, and 2015R1A1A3A04001016), Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funder AngioLab Inc provided support in the form of salaries for authors [HL SW MY JK] and reagent materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhondzadeh S, 2003, J NEUROL NEUROSUR PS, V6, P625; [Anonymous], [No title captured]; Armstrong LC, 2003, MATRIX BIOL, V22, P63, DOI 10.1016/S0945-053X(03)00005-2; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Blumenthal M, 2000, HERBAL MED EXPANDED, V123, P230; Bouloumie A, 2002, ANN ENDOCRINOL-PARIS, V63, P91; Bouloumie A, 2001, DIABETES, V50, P2080, DOI 10.2337/diabetes.50.9.2080; Brakenhielm E, 2004, CIRC RES, V94, P1579, DOI 10.1161/01.RES.0000132745.76882.70; Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798; Cao Y, 2007, J CLIN INVEST, V117, P2362, DOI 10.1172/JCI32239; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chavey C, 2003, J BIOL CHEM, V278, P11888, DOI 10.1074/jbc.M209196200; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; Croissandeau G, 2002, BIOCHEM J, V364, P739, DOI 10.1042/BJ20011158; Demeulemeester D, 2005, BIOCHEM BIOPH RES CO, V329, P105, DOI 10.1016/j.bbrc.2005.01.103; Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Fukumura D, 2003, CIRC RES, V93, pE88, DOI 10.1161/01.RES.0000099243.20096.FA; GALARDY RE, 1994, CANCER RES, V54, P4715; Hawinkels LJAC, 2008, EUR J CANCER, V44, P1904, DOI 10.1016/j.ejca.2008.06.031; Hong Y, 2011, PHARM BIOL, V49, P775, DOI 10.3109/13880209.2010.547208; Itoh T, 1998, CANCER RES, V58, P1048; Jeong S, 2009, EXP MOL MED, V41, P397, DOI 10.3858/emm.2009.41.6.045; Kim MY, 2010, INT J OBESITY, V34, P820, DOI 10.1038/ijo.2010.13; Kim YM, 2007, J MOL ENDOCRINOL, V38, P455, DOI 10.1677/jme.1.02165; Lee H, 2013, FOOD CHEM TOXICOL, V53, P402, DOI 10.1016/j.fct.2012.11.052; Li JP, 2002, AM J PHYSIOL-ENDOC M, V282, pE1334, DOI 10.1152/ajpendo.00516.2001; Lijnen HR, 2002, ARTERIOSCL THROM VAS, V22, P374, DOI 10.1161/hq0302.104522; Lijnen HR, 2001, THROMB HAEMOSTASIS, V85, P1111; Maquoi E, 2002, DIABETES, V51, P1093, DOI 10.2337/diabetes.51.4.1093; Miksztowicz V, 2014, NUTR METAB CARDIOVAS, V24, P294, DOI 10.1016/j.numecd.2013.08.007; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Rundhaug JE, 2003, CLIN CANCER RES, V9, P551; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Silha JV, 2005, INT J OBESITY, V29, P1308, DOI 10.1038/sj.ijo.0802987; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Valentino MA, 2010, CLIN PHARMACOL THER, V87, P652, DOI 10.1038/clpt.2010.57; Van Hul M, 2008, J THROMB HAEMOST, V6, P1198, DOI 10.1111/j.1538-7836.2008.02988.x; Van Hul M, 2011, ENDOCR J, V58, P101, DOI 10.1507/endocrj.K10E-267; Yoon M, 2011, PHARM BIOL, V49, P614, DOI 10.3109/13880209.2010.539617; Yoon M, 2009, PHARMACOL RES, V60, P151, DOI 10.1016/j.phrs.2009.02.004	46	23	23	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2015	10	11							e0141612	10.1371/journal.pone.0141612	http://dx.doi.org/10.1371/journal.pone.0141612			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CX7AW	26599360	Green Published, gold			2023-01-03	WOS:000365853900013
J	Lieske, NV; Tonby, K; Kvale, D; Dyrhol-Riise, AM; Tasken, K				Lieske, Nora V.; Tonby, Kristian; Kvale, Dag; Dyrhol-Riise, Anne M.; Tasken, Kjetil			Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE-RESPONSES; MEK INHIBITORS; TNF-ALPHA; ACTIVATION; BLOOD; DISEASE; IL-2; INTERLEUKIN-2; HOMEOSTASIS	Human regulatory T cells (Tregs) are essential in maintaining immunological tolerance and suppress effector T cells. Tregs are commonly up-regulated in chronic infectious diseases such as tuberculosis (TB) and human immunodeficiency virus (HIV) infection and thereby hamper disease-specific immune responses and eradication of pathogens. The MEK/ERK signaling pathway is involved in regulation of the FoxP3 transcription factor, which directs a lineage-specific transcriptional program to define Tregs and control their suppressive function. Here, we aimed to target activation of disease-specific Tregs by inhibition of the MEK/ERK signaling pathway based on the hypothesis that this would improve anti-HIV and anti-TB immunity. Stimulation of T cells from untreated TB (n = 12) and HIV (n = 8) patients with disease-specific antigens in vitro in the presence of the MEK inhibitor (MEKI) trametinib (GSK1120212) resulted in significant down-regulation of both FoxP3 levels (MFI) and fractions of resting (CD45RA(+)FoxP3(+)) and activated (CD45RA(-)FoxP3(++)) Tregs. MEKI also reduced the levels of specific T effector cells expressing the pro-inflammatory cytokines (IFN-gamma, TNF-alpha and IL-2) in both HIV and TB patients. In conclusion, MEKIs modulate disease antigen-specific Treg activation and may have potential application in new treatment strategies in chronic infectious diseases where reduction of Treg activity would be favorable. Whether MEKIs can be used in current HIV or TB therapy regimens needs to be further investigated.	[Lieske, Nora V.; Tasken, Kjetil] Univ Oslo, Nord EMBL Partnership, Ctr Mol Med Norway, Oslo, Norway; [Tonby, Kristian; Kvale, Dag; Dyrhol-Riise, Anne M.] Univ Oslo, Inst Clin Med, Oslo, Norway; [Tonby, Kristian; Kvale, Dag; Dyrhol-Riise, Anne M.; Tasken, Kjetil] Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway; [Kvale, Dag; Dyrhol-Riise, Anne M.; Tasken, Kjetil] Univ Oslo, Kristian Gerhard Jebsen Inflammat Res Ctr, Oslo, Norway; [Tasken, Kjetil] Univ Oslo, Ctr Biotechnol, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo	Tasken, K (corresponding author), Univ Oslo, Nord EMBL Partnership, Ctr Mol Med Norway, Oslo, Norway.	kjetil.tasken@ncmm.uio.no		Tasken, Kjetil/0000-0003-2841-4697; Kvale, Dag/0000-0001-6410-2530	Research Council of Norway [RCN204784, RCN187615]; South Eastern Norway Regional Health Authority [11/01137-144, 2013074]; Kristian Gerhard Jebsen Inflammation Research Centre [2012/23]	Research Council of Norway(Research Council of Norway); South Eastern Norway Regional Health Authority; Kristian Gerhard Jebsen Inflammation Research Centre	This work was supported by the Research Council of Norway (RCN204784 and RCN187615, http://www.forskningsradet.no/en/Home_page/1177315753906, N.L., Kj.T.), the South Eastern Norway Regional Health Authority (11/01137-144 and 2013074, http://www.helse-sorost.no/omoss_/english_/, Kr.T and Kj.T respectively) and the Kristian Gerhard Jebsen Inflammation Research Centre (2012/23, http://www.stiftkgj.no/?lang = en, K.T.).	Abrams D, 2009, NEW ENGL J MED, V361, P1548, DOI 10.1056/NEJMoa0903175; Appay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276; Arruvito L, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0057336, DOI 10.1371/J0URNAL.P0NE.0052580]; Aukrust P, 1999, J INFECT DIS, V179, P74, DOI 10.1086/314572; Barnes PF, 2003, AM J RESP CRIT CARE, V168, P142, DOI 10.1164/rccm.2305001; Beiranvand E, 2014, INFLAMMATION ALLERGY; Belkaid Y, 2009, ANNU REV IMMUNOL, V27, P551, DOI 10.1146/annurev.immunol.021908.132723; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Bi X, 2009, EUR J IMMUNOL, V39, P301, DOI 10.1002/eji.200838667; Boaz MJ, 2003, CLIN EXP IMMUNOL, V134, P454, DOI 10.1111/j.1365-2249.2003.02307.x; Brazille P, 2003, CLIN EXP IMMUNOL, V131, P304, DOI 10.1046/j.1365-2249.2003.02064.x; Caccamo N, 2010, EUR J IMMUNOL, V40, P2211, DOI 10.1002/eji.201040455; Chatt JA, 2002, AIDS RES HUM RETROV, V18, P1367, DOI 10.1089/088922202320935447; Chen XC, 2007, CLIN IMMUNOL, V123, P50, DOI 10.1016/j.clim.2006.11.009; Chevalier MF, 2013, BLOOD, V121, P29, DOI 10.1182/blood-2012-07-409755; Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703; Day CL, 2011, J IMMUNOL, V187, P2222, DOI 10.4049/jimmunol.1101122; Feruglio SL, 2015, CLIN EXP IMMUNOL, V179, P454, DOI 10.1111/cei.12468; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Giovannetti A, 2001, CLIN EXP IMMUNOL, V124, P21, DOI 10.1046/j.1365-2249.2001.01502.x; Gonzalez-Juarrereo M, 2012, IMMUNOTHERAPY-UK, V4, P187, DOI [10.2217/IMT.11.168, 10.2217/imt.11.168]; Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC; Haraguchi Soichi, 2006, AIDS Res Ther, V3, P8, DOI 10.1186/1742-6405-3-8; Harari A, 2011, NAT MED, V17, P372, DOI 10.1038/nm.2299; HOBER D, 1992, CLIN IMMUNOL IMMUNOP, V62, P168, DOI 10.1016/0090-1229(92)90069-Z; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Horta A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057336; Hougardy JM, 2007, AM J RESP CRIT CARE, V176, P409, DOI 10.1164/rccm.200701-084OC; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; JOHNSON BJ, 1995, CYTOKINES MOL THER, V1, P185; Johnson JL, 2003, AM J RESP CRIT CARE, V168, P185, DOI 10.1164/rccm.200211-1359OC; Kalland ME, 2011, J IMMUNOL, V187, P5233, DOI 10.4049/jimmunol.1101804; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Kim JM, 2011, IMMUNOTHERAPY-UK, V3, P247, DOI 10.2217/IMT.10.91; Kursar M, 2007, J IMMUNOL, V178, P2661, DOI 10.4049/jimmunol.178.5.2661; Lintermans LL, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00504; Marin ND, 2010, TUBERCULOSIS, V90, P252, DOI 10.1016/j.tube.2010.05.003; Marriott JB, 1997, AIDS RES HUM RETROV, V13, P1625, DOI 10.1089/aid.1997.13.1625; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Moreno-Fernandez ME, 2012, J VIROL, V86, P10262, DOI 10.1128/JVI.00993-12; Pastrana Jahaira Lopez, 2012, J Clin Exp Cardiolog, V2012, P2; Popik W, 2000, J VIROL, V74, P2558, DOI 10.1128/JVI.74.6.2558-2566.2000; Prezzemolo T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00180; Ribeiro-Rodrigues R, 2006, CLIN EXP IMMUNOL, V144, P25, DOI 10.1111/j.1365-2249.2006.03027.x; Robbs BK, 2013, BBA-MOL CELL RES, V1833, P2016, DOI 10.1016/j.bbamcr.2013.04.003; Roberts L, 2010, AIDS, V24, P819, DOI 10.1097/QAD.0b013e3283367836; Roca FJ, 2013, CELL, V153, P521, DOI 10.1016/j.cell.2013.03.022; Rolf J, 2010, J IMMUNOL, V184, P6563, DOI 10.4049/jimmunol.1000202; Rouse BT, 2006, IMMUNOL REV, V212, P272, DOI 10.1111/j.0105-2896.2006.00412.x; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Shafiani S, 2010, J EXP MED, V207, P1409, DOI 10.1084/jem.20091885; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Shindo T, 2013, BLOOD, V121, P4617, DOI 10.1182/blood-2012-12-476218; Simonetta F, 2012, J INFECT DIS, V205, P1510, DOI 10.1093/infdis/jis235; Trujillo JI, 2011, EXPERT OPIN THER PAT, V21, P1045, DOI 10.1517/13543776.2011.577068; Uhlin M, 2012, J INFECT DIS, V205, pS325, DOI 10.1093/infdis/jis197; Vella LJ, 2014, CANCER IMMUNOL RES, V2, P351, DOI 10.1158/2326-6066.CIR-13-0181; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; VONSYDOW M, 1991, AIDS RES HUM RETROV, V7, P375, DOI 10.1089/aid.1991.7.375; Wallis RS, 1996, J INFECT DIS, V174, P727, DOI 10.1093/infdis/174.4.727; Wallis RS, 2004, CLIN INFECT DIS, V39, P1254, DOI 10.1086/424455; Wang D, 2007, BBA-MOL CELL RES, V1773, P1248, DOI 10.1016/j.bbamcr.2006.11.009; Weiss L, 2004, BLOOD, V104, P3249, DOI 10.1182/blood-2004-01-0365; Wergeland I, 2011, SCAND J IMMUNOL, V73, P234, DOI 10.1111/j.1365-3083.2010.02496.x; Westby M, 1998, CLIN EXP IMMUNOL, V111, P257; World Health Organization, 2014, GLOB TUB REP; Yamane H, 2013, IMMUNOL REV, V252, P12, DOI 10.1111/imr.12032; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563	72	9	9	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2015	10	11							e0141903	10.1371/journal.pone.0141903	http://dx.doi.org/10.1371/journal.pone.0141903			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV6RT	26544592	Green Submitted, gold, Green Published			2023-01-03	WOS:000364398700063
J	Santamarina, AB; Oliveira, JL; Silva, FP; Carnier, J; Mennitti, LV; Santana, AA; de Souza, GHI; Ribeiro, EB; do Nascimento, CMO; Lira, FS; Oyama, LM				Santamarina, Aline B.; Oliveira, Juliana L.; Silva, Fernanda P.; Carnier, June; Mennitti, Lais V.; Santana, Aline A.; de Souza, Gabriel H. I.; Ribeiro, Eliane B.; Oller do Nascimento, Claudia M.; Lira, Fabio S.; Oyama, Lila M.			Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet	PLOS ONE			English	Article							PROTEIN-KINASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; OXIDATIVE STRESS; NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS; ENERGY-METABOLISM; LIPID-METABOLISM; RECENT PROGRESS; RAT MODEL	Supplementation with epigallocatechin-3-gallate has been determined to aid in the prevention of obesity. Decaffeinated green tea extract appears to restore a normal hepatic metabolic profile and attenuate high-fat diet (HFD)-induced effects, thereby preventing nonalcoholic fatty liver disease in mice. Mice were maintained on either a control diet (CD) or HFD for 16 weeks and supplemented with either water or green tea extract (50 mg/kg/day). The body mass increase, serum adiponectin level, and lipid profile were measured over the course of the treatment. Furthermore, the AMPK pathway protein expression in the liver was measured. From the fourth week, the weight gain in the CD + green tea extract (CE) group was lower than that in the CD + water (CW) group. From the eighth week, the weight gain in the HFD + water (HFW) group was found to be higher than that in the CW group. Moreover, the weight gain in the HFD + green tea extract (HFE) group was found to be lower than that in the HFW group. Carcass lipid content was found to be higher in the HFW group than that in the CW and HFE groups. Serum analysis showed reduced non-esterified fatty acid level in the CE and HFE groups as compared with their corresponding placebo groups. Increased adiponectin level was observed in the same groups. Increased VLDL-TG secretion was observed in the HFW group as compared with the CW and HFE groups. Increased protein expression of AdipoR2, SIRT1, pLKB1, and pAMPK was observed in the HFE group, which explained the reduced expression of ACC, FAS, SREBP-1, and ChREBP in this group. These results indicate that the effects of decaffeinated green tea extract may be related to the activation of AMPK via LKB1 in the liver of HFD-fed mice.	[Santamarina, Aline B.; Oliveira, Juliana L.; Silva, Fernanda P.; Carnier, June; Santana, Aline A.; Ribeiro, Eliane B.; Oller do Nascimento, Claudia M.; Oyama, Lila M.] Univ Fed Sao Paulo, Dept Fisiol, Sao Paulo, Brazil; [Mennitti, Lais V.] Univ Fed Sao Paulo, Programa Posgrad Interdisciplinar Ciencias Saude, Santos, Brazil; [de Souza, Gabriel H. I.] Univ Sao Judas Tadeu, Lab Movimento Humano, Sao Paulo, Brazil; [Lira, Fabio S.] Univ Estadual Paulista, UNESP, Dept Phys Educ, Exercise & Immunometab Res Grp, Presidente Prudente, SP, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Universidade Sao Judas Tadeu; Universidade Estadual Paulista	Oyama, LM (corresponding author), Univ Fed Sao Paulo, Dept Fisiol, Sao Paulo, Brazil.	lmoyama@gmail.com	Lira, Fábio/N-7299-2019; Ribeiro, Eliane B/C-8124-2012; Lira, Fábio Santos/Q-7581-2016; Oyama, Lila M/B-7609-2012; Santamarina, Aline/AAI-7639-2020	Lira, Fábio/0000-0002-9645-1003; Ribeiro, Eliane B/0000-0002-3071-9134; Lira, Fábio Santos/0000-0002-9645-1003; Silva, Fernanda/0000-0003-3758-5797; Lopez de Oliveira, Juliana/0000-0003-2841-5980; Mennitti, Lais Vales/0000-0002-9326-7649	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2014/19508-7]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was funded by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo 2014/19508-7 - grant to: Dr Lila Missae Oyama and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - grant to Aline Boveto Santamarina.	Banerjee S, 2012, NUTR RES, V32, P985, DOI 10.1016/j.nutres.2012.10.005; Bijland S, 2013, CLIN SCI, V124, P491, DOI 10.1042/CS20120536; Blachnio-Zabielska A, 2010, J CELL PHYSIOL, V225, P786, DOI 10.1002/jcp.22283; Blagih J, 2012, IMMUNOL REV, V249, P59, DOI 10.1111/j.1600-065X.2012.01157.x; Bollheimer LC, 2012, BIOGERONTOLOGY, V13, P609, DOI 10.1007/s10522-012-9405-4; Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677; BRAZIL C, 2013, DIRETRIZ BRASILEIRA, P1; Buettner R, 2006, J MOL ENDOCRINOL; Burd N, 2014, PUBLIC HEALTH NUTR, P1; Byrne CD, 2013, P NUTR SOC, P1; Byun EH, 2010, J IMMUNOL, V185, P33, DOI 10.4049/jimmunol.0903742; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Carillon J, 2013, FREE RADICAL BIO MED, V65, P254, DOI 10.1016/j.freeradbiomed.2013.06.022; Ceddia RB, 2013, MOL CELL ENDOCRINOL, V366, P194, DOI 10.1016/j.mce.2012.06.014; Chacko Sabu M, 2010, Chin Med, V5, P13, DOI 10.1186/1749-8546-5-13; Charlton MR, 2011, GASTROENTEROLOGY, V141, P1249, DOI 10.1053/j.gastro.2011.06.061; Chen YK, 2011, J AGR FOOD CHEM, V59, P11862, DOI 10.1021/jf2029016; Choi KM, 2014, J CELL BIOCH; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; Costa S, 2007, FOOD CHEM TOXICOL, V45, P1910, DOI 10.1016/j.fct.2007.04.008; Cunha CA, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/635470; Darnton-Hill I, 2004, PUBLIC HEALTH NUTR, V7, P101, DOI 10.1079/PHN2003584; Davaatseren M, 2013, FOOD CHEM TOXICOL, V58, P30, DOI 10.1016/j.fct.2013.04.023; De Rosa E, 2014, NUTRITION; Derdemezis CS, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/285618; DONASCIMENTO CMO, 1986, BIOCHEM J, V239, P233; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI23621; Duval C, 2010, DIABETES, V59, P3181, DOI 10.2337/db10-0224; Fellner C, 2014, GERONTOLOGY, V60, P530, DOI 10.1159/000360289; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Fujimura Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037942; Gan RY, 2014, INT J MOL SCI, V15, P16698, DOI 10.3390/ijms150916698; Gillum MP, 2011, DIABETES, V60, P3235, DOI 10.2337/db11-0616; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Hasenour CM, 2013, MOL CELL ENDOCRINOL, V366, P152, DOI 10.1016/j.mce.2012.06.018; Hegarty BD, 2003, ACTA PHYSIOL SCAND, V178, P373, DOI 10.1046/j.1365-201X.2003.01162.x; Henriksen BS, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-29; Hill AM, 2007, J AM COLL NUTR, V26, p396S, DOI 10.1080/07315724.2007.10719628; Horton JD, 2004, MOL MEDIATORS HEPATI, P114; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Iizuka K, 2013, ENDOCR J, V60, P543, DOI 10.1507/endocrj.EJ13-0121; Jiang ZA, 2015, ALCOHOL CLIN EXP RES, V39, P424, DOI 10.1111/acer.12641; Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109; Kim EY, 2011, J AGR FOOD CHEM, V59, P3606, DOI 10.1021/jf104260j; Kim HS, 2014, REDOX BIOL, V2, P187, DOI 10.1016/j.redox.2013.12.022; Kobayashi-Hattori K, 2005, BIOSCI BIOTECH BIOCH, V69, P2219, DOI 10.1271/bbb.69.2219; Kohjima M, 2008, INT J MOL MED, V21, P507; Kurimoto Y, 2013, J AGR FOOD CHEM, V61, P5558, DOI 10.1021/jf401190y; Lambert JD, 2010, FOOD CHEM TOXICOL, V48, P409, DOI 10.1016/j.fct.2009.10.030; Latif R, 2013, NETH J MED, V71, P63; Lee J, 2012, DIABETES METAB J, V36, P262, DOI 10.4093/dmj.2012.36.4.262; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Liang XM, 2011, ANTIOXID REDOX SIGN, V15, P425, DOI 10.1089/ars.2010.3780; Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138; Ma QY, 2011, J FOOD SCI, V76, pH143, DOI 10.1111/j.1750-3841.2011.02184.x; Martins SV, 2010, BRIT J NUTR, V103, P869, DOI 10.1017/S000711450999256X; Masuoka HC, 2013, ANN NY ACAD SCI, V1281, P106, DOI 10.1111/nyas.12016; MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613; O'Neill HM, 2013, MOL CELL ENDOCRINOL, V366, P135, DOI 10.1016/j.mce.2012.06.019; Ratto E, 2006, J AM SOC NEPHROL, V17, pS120, DOI 10.1681/ASN.2005121328; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Sabu MC, 2002, J ETHNOPHARMACOL, V83, P109; Seo HY, 2013, ENDOCRINOLOGY, V154, P1722, DOI 10.1210/en.2012-2009; Seo MS, 2015, TOXICOL APPL PHARM, V284, P113, DOI 10.1016/j.taap.2015.02.020; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shafiei MS, 2011, AM J PATHOL, V178, P2690, DOI 10.1016/j.ajpath.2011.02.035; Shearn CT, 2013, J NUTR BIOCH, V1, P1, DOI DOI 10.1016/J.JNUTBI0.2012.12.002; Shen L, 2013, J LIPID RES, V54, P1430, DOI 10.1194/jlr.M035907; Shen Z, 2010, AM J PHYSIOL-GASTR L, V298, pG364, DOI 10.1152/ajpgi.00456.2009; Shiniada M, 2007, BIOSCI BIOTECH BIOCH, V71, P2079, DOI 10.1271/bbb.70174; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Song CY, 2013, TOXICOL IN VITRO, V27, P1065, DOI 10.1016/j.tiv.2013.01.020; Stanhope KL, 2008, CURR OPIN LIPIDOL, V19, P16, DOI 10.1097/MOL.0b013e3282f2b24a; STANSBIE D, 1976, BIOCHEM J, V154, P225, DOI 10.1042/bj1540225; Tachibana H, 2011, P JPN ACAD B-PHYS, V87, P66, DOI 10.2183/pjab.87.66; Tian C, 2013, PLOS ONE, P8; Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002; Turner N, 2013, DIABETOLOGIA, V56, P1638, DOI 10.1007/s00125-013-2913-1; Vigouroux C, 2011, INT J BIOCHEM CELL B, V43, P862, DOI 10.1016/j.biocel.2011.03.002; Viollet B, 2009, ACTA PHYSIOL, V196, P81, DOI 10.1111/j.1748-1716.2009.01970.x; Wang CT, 2009, MOL NUTR FOOD RES, V53, P349, DOI 10.1002/mnfr.200800013; Wang S, 2014, J NUTR BIOCHEM, V25, P1, DOI 10.1016/j.jnutbio.2013.09.001; Weng SY, 2013, J HEPATOL, V58, P619, DOI 10.1016/j.jhep.2012.09.031; Wu AH, 2011, NUTR CANCER, V63, P549, DOI 10.1080/01635581.2011.551986; Xiao J, 2014, EUR J NUTR, V53, P187, DOI 10.1007/s00394-013-0516-8; Yang ZG, 2010, J BIOL CHEM, V285, P19051, DOI 10.1074/jbc.M110.123620; Zang MW, 2006, DIABETES, V55, P2180, DOI 10.2337/db05-1188; Zhang WY, 2012, DIABETES, V61, P3114, DOI 10.2337/db11-1373; Zhou JH, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0084724, 10.1371/journal.pone.0096989, 10.1371/journal.pone.0087161]	90	58	62	2	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2015	10	11							e0141227	10.1371/journal.pone.0141227	http://dx.doi.org/10.1371/journal.pone.0141227			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV5GZ	26536464	Green Published, gold, Green Submitted			2023-01-03	WOS:000364298400055
J	Liakoni, E; Schaub, MP; Maier, LJ; Glauser, GV; Liechti, ME				Liakoni, Evangelia; Schaub, Michael P.; Maier, Larissa J.; Glauser, Gaelle-Vanessa; Liechti, Matthias E.			The Use of Prescription Drugs, Recreational Drugs, and "Soft Enhancers" for Cognitive Enhancement among Swiss Secondary School Students	PLOS ONE			English	Article							DEFICIT-HYPERACTIVITY DISORDER; NONMEDICAL USE; COLLEGE-STUDENTS; UNITED-STATES; STIMULANTS; NEUROENHANCEMENT; MISUSE; ADHD; METHYLPHENIDATE; MEDICATIONS	The use of prescription or recreational drugs for cognitive enhancement (CE) is prevalent among students. However, the prevalence of CE among Swiss school students is unknown. We therefore performed a cross-sectional online survey including >= 16-year-old students from bridge-year schools (10th grade), vocational schools, and upper secondary schools (10th-12th grade) in the Canton of Zurich to investigate the prevalence of and motives for the use of prescription drugs, recreational drugs, and/or freely available soft enhancers for CE. A total of 1,139 students were included. Of these, 54.5% reported the use of prescription drugs (9.2%), recreational drugs including alcohol (6.2%), or soft enhancers (51.3%) explicitly for CE at least once in their lives. The last-year and last-month prevalence for CE considering all substances was 45.5% and 39.5%, respectively. Soft enhancers were the substances that were most commonly used (ever, last-year, and last-month, respectively), including energy drinks (33.3%, 28.4%, and 24.6%), coffee (29.8%, 25.1%, and 21.9%), and tobacco (12.6%, 9.3%, and 8.3%). CE with methylphenidate was less prevalent (4.0%, 2.8%, and 2.0%). However, the use of prescription drugs, alcohol, or illegal drugs for CE was reported by 13.3% of the participants. The most common motives for use were to stay awake and improve concentration. CE was more prevalent among students who reported higher levels of stress or performance pressure and students with psychiatric disorders. In conclusion, half of the school students had used a substance at least once in their lives to improve school performance. Soft enhancers were most commonly used. Prevalence rates were similar to those reported by Swiss university students, indicating that the use of prescription or recreational drugs for CE already occurs before starting higher education. Performance pressure, stress, and psychiatric disorders may be associated with CE.	[Liakoni, Evangelia; Liechti, Matthias E.] Univ Basel Hosp, Dept Clin Res, Div Clin Pharmacol & Toxicol, CH-4031 Basel, Switzerland; [Schaub, Michael P.; Maier, Larissa J.; Glauser, Gaelle-Vanessa] Univ Zurich, Swiss Res Inst Publ Hlth & Addict ISGF, Zurich, Switzerland; [Schaub, Michael P.; Maier, Larissa J.; Glauser, Gaelle-Vanessa] WHO Collaborating Ctr, Zurich, Switzerland	University of Basel; University of Zurich; World Health Organization	Liakoni, E (corresponding author), Univ Basel Hosp, Dept Clin Res, Div Clin Pharmacol & Toxicol, CH-4031 Basel, Switzerland.	evangelia.liakoni@usb.ch	Maier, Larissa/P-8669-2014; Maier, Larissa J/C-2922-2017; Schaub, Michael P./ABF-9468-2021	Maier, Larissa/0000-0002-4302-0488; Maier, Larissa J/0000-0002-4302-0488; Schaub, Michael P./0000-0002-8375-4005	Division of Clinical Pharmacology & Toxicology, University Hospital Basel; Swiss Centre of Applied Human Toxicology (SCAHT); Swiss Research Institute for Public Health and Addiction (ISGF), Zurich	Division of Clinical Pharmacology & Toxicology, University Hospital Basel; Swiss Centre of Applied Human Toxicology (SCAHT); Swiss Research Institute for Public Health and Addiction (ISGF), Zurich	This study was supported by internal funds from the Division of Clinical Pharmacology & Toxicology, University Hospital Basel (to ML), Swiss Centre of Applied Human Toxicology (SCAHT) (to ML), and Swiss Research Institute for Public Health and Addiction (ISGF), Zurich (to MS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arria AM, 2008, PHARMACOTHERAPY, V28, P156, DOI 10.1592/phco.28.2.156; Bagot KS, 2014, ADDICTION, V109, P547, DOI 10.1111/add.12460; Cohen S, 2012, J APPL SOC PSYCHOL, V42, P1320, DOI 10.1111/j.1559-1816.2012.00900.x; de Jongh R, 2008, NEUROSCI BIOBEHAV R, V32, P760, DOI 10.1016/j.neubiorev.2007.12.001; Farah MJ, 2014, WIRES COGN SCI, V5, P95, DOI 10.1002/wcs.1250; Forlini C, 2014, NEUROETHICS; Forlini C, 2009, BMC MED ETHICS, V10, DOI 10.1186/1472-6939-10-9; Franke AG, 2011, PHARMACOPSYCHIATRY, V44, P60, DOI 10.1055/s-0030-1268417; Franke AG, 2010, BUNDESGESUNDHEITSBLA, V53, P853, DOI 10.1007/s00103-010-1105-0; Hall W., 2012, AJOB PRIMARY RES, V3, P81, DOI [DOI 10.1080/21507716.2012.720639, 10.1080/21507716.2012.720639]; Husain M, 2011, TRENDS COGN SCI, V15, P28, DOI 10.1016/j.tics.2010.11.002; Kroutil LA, 2006, DRUG ALCOHOL DEPEN, V84, P135, DOI 10.1016/j.drugalcdep.2005.12.011; Lieb K, 2010, HIMDOPING WARUM WIR; Mache S, 2012, WIEN MED WOCHENSCHR, V162, P440, DOI [10.1007/s10354-012-0144-6, 10.1007/s10354-012-0115-y]; Maier LJ, 2015, EUR PSYCHOL, V20, P155, DOI 10.1027/1016-9040/a000228; Maier LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129805; Maier LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077967; McCabe SE, 2005, ADDICTION, V100, P96, DOI 10.1111/j.1360-0443.2005.00944.x; McCabe SE, 2011, ARCH PEDIAT ADOL MED, V165, P729, DOI 10.1001/archpediatrics.2011.114; McCabe SE, 2009, DRUG ALCOHOL DEPEN, V102, P63, DOI 10.1016/j.drugalcdep.2009.01.007; Middendorff E, 2012, HISBUS BEFRAGUNG VER, V1; Novak SP, 2007, SUBST ABUSE TREAT PR, V2, DOI 10.1186/1747-597X-2-32; Ott R, 2014, PHARMACOPSYCHIATRY, V47, P22, DOI 10.1055/s-0033-1358682; Partridge B, 2012, AUST NZ J PSYCHIAT, V46, P958, DOI 10.1177/0004867412450755; Ragan CI, 2013, NEUROPHARMACOLOGY, V64, P588, DOI 10.1016/j.neuropharm.2012.06.016; Repantis D, 2010, PHARMACOL RES, V62, P187, DOI 10.1016/j.phrs.2010.04.002; Schelle KJ, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00053; Schermer M, 2009, NEUROETHICS-NETH, V2, P75, DOI 10.1007/s12152-009-9032-1; Vrecko Scott, 2013, AJOB Neurosci, V4, P4; Wilens TE, 2008, J AM ACAD CHILD PSY, V47, P21, DOI 10.1097/chi.0b013e31815a56f1; Wood S, 2014, PHARMACOL REV, V66, P193, DOI 10.1124/pr.112.007054	31	34	34	3	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2015	10	10							e0141289	10.1371/journal.pone.0141289	http://dx.doi.org/10.1371/journal.pone.0141289			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CU8PC	26505633	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000363804200043
J	Jolley, CJ; Bell, J; Rafferty, GF; Moxham, J; Strang, J				Jolley, Caroline J.; Bell, James; Rafferty, Gerrard F.; Moxham, John; Strang, John			Understanding Heroin Overdose: A Study of the Acute Respiratory Depressant Effects of Injected Pharmaceutical Heroin	PLOS ONE			English	Article							MAINTENANCE TREATMENT; SYMPTOMATIC THERAPY; DRIVE; ADDICTS; VENTILATION; METHADONE; TRIAL; HYPERCAPNIA; PREVALENCE; ACTIVATION	Opioids are respiratory depressants and heroin/opioid overdose is a major contributor to the excess mortality of heroin addicts. The individual and situational variability of respiratory depression caused by intravenous heroin is poorly understood. This study used advanced respiratory monitoring to follow the time course and severity of acute opioid-induced respiratory depression. 10 patients (9/10 with chronic airflow obstruction) undergoing supervised injectable opioid treatment for heroin addiction received their usual prescribed dose of injectable opioid (diamorphine or methadone) (IOT), and their usual prescribed dose of oral opioid (methadone or sustained release oral morphine) after 30 minutes. The main outcome measures were pulse oximetry (SpO(2)%), end-tidal CO2% (ETCO2%) and neural respiratory drive (NRD) (quantified using parasternal intercostal muscle electromyography). Significant respiratory depression was defined as absence of inspiratory airflow > 10s, SpO(2)% < 90% for > 10s and ETCO2% per breath > 6.5%. Increases in ETCO2% indicated significant respiratory depression following IOT in 8/10 patients at 30 minutes. In contrast, SpO(2)% indicated significant respiratory depression in only 4/10 patients, with small absolute changes in SpO(2)% at 30 minutes. A decline in NRD from baseline to 30 minutes post IOT was also observed, but was not statistically significant. Baseline NRD and opioid-induced drop in SpO(2)% were inversely related. We conclude that significant acute respiratory depression is commonly induced by opioid drugs prescribed to treat opioid addiction. Hypoventilation is reliably detected by capnography, but not by SpO(2)% alone. Chronic suppression of NRD in the presence of underlying lung disease may be a risk factor for acute opioid-induced respiratory depression.	[Jolley, Caroline J.; Rafferty, Gerrard F.; Moxham, John] Kings Coll London, Kings Hlth Partners, Fac Life Sci & Med, Div Asthma Allergy & Lung Biol, London WC2R 2LS, England; [Bell, James; Strang, John] Kings Coll London, Inst Psychiat Psychol & Neurosci, Natl Addict Ctr, Kings Hlth Partners, London WC2R 2LS, England; [Bell, James; Strang, John] South London & Maudsley NHS Fdn Trust, Kings Hlth Partners, Addict Serv, London, England	University of London; King's College London; University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London	Jolley, CJ (corresponding author), Kings Coll London, Kings Hlth Partners, Fac Life Sci & Med, Div Asthma Allergy & Lung Biol, Denmark Hill, London WC2R 2LS, England.	caroline.jolley@kcl.ac.uk	Rafferty, Gerrard F/B-2826-2011; Strang, John/H-5460-2011	Rafferty, Gerrard F/0000-0001-9520-6500; Strang, John/0000-0002-5413-2725; Jolley, Caroline/0000-0003-3538-2451	Kings Health Partners Biomedical Research Centre; NIHR Academic Clinical Lectureship in Respiratory Medicine; National Institute for Health Research [CL-2012-17-007] Funding Source: researchfish	Kings Health Partners Biomedical Research Centre; NIHR Academic Clinical Lectureship in Respiratory Medicine; National Institute for Health Research(National Institute for Health Research (NIHR))	This research was supported by a grant from Kings Health Partners Biomedical Research Centre. Dr. Caroline Jolley is supported by a NIHR Academic Clinical Lectureship in Respiratory Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Clemens KE, 2008, J PALLIAT MED, V11, P204, DOI 10.1089/jpm.2007.0131; Clemens KE, 2007, J PAIN SYMPTOM MANAG, V33, P473, DOI 10.1016/j.jpainsymman.2006.09.015; Conti G, 2002, ANAESTHESIA, V57, P540, DOI 10.1046/j.1365-2044.2002.02573.x; Cornish R, 2010, RISK DEATH OPIATE SU, V23; Cronin AJ, 2003, BRIT J ANAESTH, V91, P805, DOI 10.1093/bja/aeg273; Dalchow S, 2013, INT J OBSTET ANESTH, V22, P217, DOI 10.1016/j.ijoa.2013.04.003; Darke S, 1996, ADDICTION, V91, P1765, DOI 10.1111/j.1360-0443.1996.tb03800.x; Duiverman ML, 2004, J APPL PHYSIOL, V96, P1723, DOI 10.1152/japplphysiol.00914.2003; Dursteler-Mac Farland KM, 2000, ADDICTION, V95, P285; Fugelstad A, 2003, ADDICTION, V98, P463, DOI 10.1046/j.1360-0443.2003.00330.x; GILBERT R, 1972, J APPL PHYSIOL, V33, P252, DOI 10.1152/jappl.1972.33.2.252; Guydish J, 2011, NICOTINE TOB RES, V13, P401, DOI 10.1093/ntr/ntr048; Haasen C, 2007, BRIT J PSYCHIAT, V191, P55, DOI 10.1192/bjp.bp.106.026112; Hall W, 1998, DRUG ALCOHOL DEPEN, V52, P71, DOI 10.1016/S0376-8716(98)00044-1; Herman NL, 1999, ANESTH ANALG, V89, P378, DOI 10.1097/00000539-199908000-00024; Jolley CJ, 2009, EUR RESPIR J, V33, P289, DOI 10.1183/09031936.00093408; Jolley CJ, 2015, EUR RESPIR J, V45, P355, DOI 10.1183/09031936.00063014; Kopka A, 2007, BRIT J ANAESTH, V99, P567, DOI 10.1093/bja/aem206; Maarsingh EJW, 2002, RESP PHYSIOL NEUROBI, V133, P89, DOI 10.1016/S1569-9048(02)00130-1; MacBean V, 2014, THORAX, V69, pA170, DOI 10.1136/thoraxjnl-2014-206260.341; Madadi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060600; March JC, 2006, J SUBST ABUSE TREAT, V31, P203, DOI 10.1016/j.jsat.2006.04.007; Murphy PB, 2011, THORAX, V66, P602, DOI 10.1136/thx.2010.151332; Office for National Statistics, 2015, STAT B; Oviedo-Joekes E, 2009, NEW ENGL J MED, V361, P777, DOI 10.1056/NEJMoa0810635; Palmer F, 2012, PRIM CARE RESP J, V21, P377, DOI 10.4104/pcrj.2012.00069; Passarino G, 2005, AM J FOREN MED PATH, V26, P106, DOI 10.1097/01.paf.0000159990.54730.4b; Perneger TV, 1998, BMJ-BRIT MED J, V317, P13, DOI 10.1136/bmj.317.7150.13; Pierdominici S, 1997, Acta Anaesthesiol Belg, V48, P85; Reilly CC, 2012, EUR RESPIR J, V40, P977, DOI 10.1183/09031936.00163111; Reilly CC, 2011, THORAX, V66, P240, DOI 10.1136/thx.2010.142646; Reimer J, 2011, ADDICTION, V106, P1647, DOI 10.1111/j.1360-0443.2011.03463.x; Rook EJ, 2006, BASIC CLIN PHARM TOX, V98, P00; Sinderby C, 2001, AM J RESP CRIT CARE, V163, P1637, DOI 10.1164/ajrccm.163.7.2007033; Sinderby C, 1998, J APPL PHYSIOL, V85, P2146, DOI 10.1152/jappl.1998.85.6.2146; Steier J, 2011, THORAX, V66, P609, DOI 10.1136/thx.2010.152462; Stoermer R, 2003, BIOL PSYCHIAT, V54, P854, DOI 10.1016/S0006-3223(03)00290-7; Strang J, 2015, BRIT J PSYCHIAT, V207, P5, DOI 10.1192/bjp.bp.114.149195; Strang J, 2010, LANCET, V375, P1885, DOI 10.1016/S0140-6736(10)60349-2; TABATABAI M, 1989, ANESTHESIOLOGY, V70, P489, DOI 10.1097/00000542-198903000-00020; Teichtahl H, 2005, CHEST, V128, P1339, DOI 10.1378/chest.128.3.1339; van den Brink W, 2003, BRIT MED J, V327, P310, DOI 10.1136/bmj.327.7410.310; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x; WEIL JV, 1975, NEW ENGL J MED, V292, P1103, DOI 10.1056/NEJM197505222922106; World Health Organization (WHO), 2014, COMM MAN OP OV	45	36	36	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2015	10	10							e0140995	10.1371/journal.pone.0140995	http://dx.doi.org/10.1371/journal.pone.0140995			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU1VG	26495843	Green Published, gold			2023-01-03	WOS:000363309200049
J	Mohammed, A; Chiruvella, KK; Rao, YK; Geethangili, M; Raghavan, SC; Ghanta, RG				Mohammed, Arifullah; Chiruvella, Kishore K.; Rao, Yerra Koteswara; Geethangili, Madamanchi; Raghavan, Sathees C.; Ghanta, Rama Gopal			In Vitro Production of Echioidinin, 7-O-Methywogonin from Callus Cultures of Andrographis lineata and Their Cytotoxicity on Cancer Cells	PLOS ONE			English	Article							HAIRY ROOT; SUSPENSION CULTURES; FLAVONOIDS; PANICULATA; INHIBITION; APOPTOSIS; GROWTH; NEES	Andrographis lineata is an herbal medicinal plant used in traditional medicine as a substitute for Andrographis paniculata. Here, using mature leaf explants of A. lineata we demonstrate for the first time the callus induction established on MS medium containing 1.0 mg l(-1) IAA. Dried callus was subjected to solvent extraction with acetone. Further the acetone residue was separated by silica gel column chromatography, crystallized and characterized on the basis of nuclear magnetic resonance (proton and c13) and liquid chromatographic mass spectroscopy. This analysis revealed the occurrence of two known flavones namely, 7-O-methylwogonin (MW) and Echioidinin (ED). Furthermore, these compounds were tested for their cytotoxicity against leukemic cell line, CEM. We identify that ED and MW induced cytotoxicity in a time-and concentration-dependent manner. Further increase in the LDH release upon treatment with ED and MW further confirmed our cytotoxicity results against leukemic cell line. Strikingly, MW was more potent than ED when compared by trypan blue and MTT assays. Our results recapitulate the utility of callus cultures for the production of plant specific bioactive secondary metabolites instead of using wild plants. Together, our in vitro studies provide new insights of A. lineata callus cultures serving as a source for cancer chemotherapeutic agents.	[Mohammed, Arifullah] Univ Malaysia Kelantan, Fac Agrobased Ind, Jeli 17600, Kelantan, Malaysia; [Chiruvella, Kishore K.; Raghavan, Sathees C.] Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; [Mohammed, Arifullah; Chiruvella, Kishore K.; Ghanta, Rama Gopal] Sri Venkateswara Univ, Dept Bot, Div Plant Tissue Culture, Tirupati 517502, Andhra Pradesh, India; [Rao, Yerra Koteswara; Geethangili, Madamanchi] Chaoyang Univ Technol, Dept Appl Chem, Taichung, Taiwan	Universiti Malaysia Kelantan; Indian Institute of Science (IISC) - Bangalore; Sri Venkateswara University; Chaoyang University of Technology	Mohammed, A (corresponding author), Univ Malaysia Kelantan, Fac Agrobased Ind, Jeli Campus,Locked Bag 100, Jeli 17600, Kelantan, Malaysia.	arifullahmd@gmail.com	Chiruvella, Kishore Kumar/AAH-3131-2022; Yerra, Rao Koteswara/D-1954-2011; Madamanchi, Geethangili/W-6088-2019; Chiruvella, Kishore Kumar/AEU-8773-2022	Yerra, Rao Koteswara/0000-0001-6063-904X; Chiruvella, Kishore Kumar/0000-0002-4997-5875; Mohammed, Arifullah/0000-0001-7793-8134				Abdullah MA, 1998, PLANT CELL TISS ORG, V54, P173, DOI 10.1023/A:1006108717255; Akbar S, 2011, ALTERN MED REV, V16, P66; Alagesaboopathi C., 2012, INT J RECENT SCI RES, V3, P71; Bieker R, 2003, ONCOL REP, V10, P915; Cheng SY, 2014, NOT BOT HORTI AGROBO, V42, P88; Chiruvella KK, 2011, INVEST NEW DRUG, V29, P583, DOI 10.1007/s10637-010-9393-7; Chiruvella Kishore K, 2007, Int J Biomed Sci, V3, P269; Chiruvella KK, 2008, FEBS LETT, V582, P4066, DOI 10.1016/j.febslet.2008.11.001; D'Angiolillo F, 2014, NAT PROD COMMUN, V9, P477; Nicasio-Torres MD, 2012, ACTA PHYSIOL PLANT, V34, P307, DOI 10.1007/s11738-011-0830-9; Dias ACP, 1998, PHYTOCHEMISTRY, V48, P1165, DOI 10.1016/S0031-9422(97)00963-1; Dias ACP, 2000, PLANT SCI, V150, P93, DOI 10.1016/S0168-9452(99)00178-8; Enaksha RMW, 1993, PLANT CELL TISSUE OR, V35, P181; Filova A., 2014, Research Journal of Agricultural Science, V46, P236; Goleniowski ME, 2000, BIOCELL, V24, P139; GUPTA KK, 1983, PHYTOCHEMISTRY, V22, P314, DOI 10.1016/S0031-9422(00)80122-3; Hagendoorn MJM, 1997, J PLANT PHYSIOL, V150, P325, DOI 10.1016/S0176-1617(97)80128-9; Hussain MS, 2012, J PHARM BIOALLIED SC, V4, P10, DOI 10.4103/0975-7406.92725; IINUMA M, 1989, PHYTOCHEMISTRY, V28, P681, DOI 10.1016/0031-9422(89)80094-9; JALAL MAF, 1979, PHYTOCHEMISTRY, V18, P149, DOI 10.1016/S0031-9422(00)90934-8; Januario AH, 2005, CHEM PHARM BULL, V53, P740, DOI 10.1248/cpb.53.740; Jayaprakasam B, 1999, PHYTOCHEMISTRY, V52, P935, DOI 10.1016/S0031-9422(99)00295-2; KAMADA H, 1986, PLANT CELL REP, V5, P239, DOI 10.1007/BF00269811; Kavitha CV, 2009, BIOCHEM PHARMACOL, V77, P348, DOI 10.1016/j.bcp.2008.10.018; Kishore PH, 2003, PHYTOCHEMISTRY, V63, P457, DOI 10.1016/S031-9422(02)00702-1; Kittipongpatana N, 1998, PLANT CELL TISS ORG, V52, P133, DOI 10.1023/A:1005974611043; Kumar A, 2008, INVEST NEW DRUG, V26, P425, DOI 10.1007/s10637-008-9116-5; Kumar M, 2016, CYTOTECHNOLOGY, V68, P531, DOI 10.1007/s10616-015-9897-2; KUROYANAGI M, 1987, CHEM PHARM BULL, V35, P4429; Li W, 2002, PHYTOCHEMISTRY, V60, P351, DOI 10.1016/S0031-9422(02)00093-6; Luczkiewicz M, 2014, PLANT CELL TISS ORG, V118, P419, DOI 10.1007/s11240-014-0494-4; Maneechai S, 2012, PHYTOCHEMISTRY, V81, P42, DOI 10.1016/j.phytochem.2012.05.031; Matkowski A, 2004, J PLANT PHYSIOL, V161, P343, DOI 10.1078/0176-1617-01145; NIKAIDO T, 1988, CHEM PHARM BULL, V36, P654; Parixit B, 2012, INT J PHARM SCI, V4, P1835; Piovan A, 2014, NAT PROD COMMUN, V9, P489; Rech SB, 1998, PLANT CELL TISS ORG, V54, P61, DOI 10.1023/A:1006118220785; Renugadevi G, 2013, ASIAN PAC J TROP MED, V6, P176, DOI 10.1016/S1995-7645(13)60019-X; Roy HK, 2001, FEBS LETT, V496, P143, DOI 10.1016/S0014-5793(01)02420-6; Sangameswaran B., 2007, Nigerian Journal of Natural Products and Medicine, V11, P61; Sangameswaran B, 2008, PHYTOTHER RES, V22, P124, DOI 10.1002/ptr.2250; Santhi R., 2006, Advances in Plant Sciences, V19, P371; Sareer O, 2014, NAT PROD RES, V28, P2081, DOI 10.1080/14786419.2014.924004; Somasagara RR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047021; Srivastava M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06147; Tarbeeva DV, 2013, NAT PROD COMMUN, V8, P1419; Varma A, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep135; Wewetzer A, 1998, PHYTOPARASITICA, V26, P47, DOI 10.1007/BF02981265; Yamamoto H, 2002, PHYTOCHEMISTRY, V60, P263, DOI 10.1016/S0031-9422(02)00111-5; YAMAMOTO O, 1986, PLANT CELL REP, V5, P50, DOI 10.1007/BF00269717	50	8	8	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2015	10	10							e0141154	10.1371/journal.pone.0141154	http://dx.doi.org/10.1371/journal.pone.0141154			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0ZM	26488879	Green Published, Green Submitted, gold			2023-01-03	WOS:000363248400110
J	Guo, JQ; Huang, XM; Wang, H; Yang, HJ				Guo, Jianquan; Huang, Xuemei; Wang, Hui; Yang, Huanjie			Celastrol Induces Autophagy by Targeting AR/miR-101 in Prostate Cancer Cells	PLOS ONE			English	Article							ANDROGEN RECEPTOR; ENZALUTAMIDE; DEPRIVATION; EXPRESSION; MICRORNA-101; RESISTANCE; INHIBITOR; MECHANISM	Autophagy is an evolutionarily conserved process responsible for the degradation and recycling of cytoplasmic components through autolysosomes. Targeting AR axis is a standard strategy for prostate cancer treatment; however, the role of AR in autophagic processes is still not fully understood. In the present study, we found that AR played a negative role in AR degrader celastrol-induced autophagy. Knockdown of AR in AR-positive prostate cancer cells resulted in enhanced autophagy. Ectopic expression of AR in AR-negative prostate cancer cells, or gain of function of the AR signaling in AR-positive cells, led to suppression of autophagy. Since miR-101 is an inhibitor of autophagy and its expression was decreased along with AR in the process of celastrol-induced autophagy, we hypothesize that AR inhibits autophagy through transactivation of miR-101. AR binding site was defined in the upstream of miR-101 gene by luciferase reporter and ChIP assays. MiR-101 expression correlated with AR status in prostate cancer cell lines. The inhibition of celastrol-induced autophagy by AR was compromised by blocking miR-101; while transfection of miR-101 led to inhibition of celastrol-induced autophagy in spite of AR depletion. Furthermore, mutagenesis of the AR binding site in miR-101 gene led to decreased suppression of autophagy by AR. Finally, autophagy inhibition by miR-101 mimic was found to enhance the cytotoxic effect of celastrol in prostate cancer cells. Our results demonstrate that AR inhibits autophagy via transactivation of miR-101, thus combination of miR-101 mimics with celastrol may represent a promising therapeutic approach for treating prostate cancer.	[Guo, Jianquan; Huang, Xuemei; Wang, Hui; Yang, Huanjie] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Peoples R China	Harbin Institute of Technology	Yang, HJ (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Peoples R China.	yanghj@hit.edu.cn			Natural Science Foundation of Heilongjiang Province, China [C201432]; Innovation Research Project of Harbin, China [2012RFLXS011]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry	Natural Science Foundation of Heilongjiang Province, China(Natural Science Foundation of Heilongjiang Province); Innovation Research Project of Harbin, China; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry(Scientific Research Foundation for the Returned Overseas Chinese Scholars)	This work was partially supported by Natural Science Foundation of Heilongjiang Province, China (C201432), Innovation Research Project of Harbin, China (2012RFLXS011) and Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry.	Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Bennett HL, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.50; Boutin B, 2013, PROSTATE, V73, P1090, DOI 10.1002/pros.22658; Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108; Castoria G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.497; Chhipa RR, 2011, CELL SIGNAL, V23, P1466, DOI 10.1016/j.cellsig.2011.04.008; Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331; Frezza M, 2011, J CELL PHYSIOL, V226, P2731, DOI 10.1002/jcp.22758; Han XQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100380; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hoy SM, 2013, DRUGS, V73, P2077, DOI 10.1007/s40265-013-0150-z; Huang WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032960; Jiang Q, 2012, J UROLOGY, V188, P1361, DOI 10.1016/j.juro.2012.06.004; Kung Hsing-Jien, 2011, Hormones & Cancer, V2, P38, DOI 10.1007/s12672-010-0053-3; Li MQ, 2008, AUTOPHAGY, V4, P54, DOI 10.4161/auto.5209; Lippai M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/832704; Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82; Nguyen HG, 2014, ONCOGENE, V33, P4521, DOI 10.1038/onc.2014.25; Reddy GPV, 2006, J CELL BIOCHEM, V98, P1408, DOI 10.1002/jcb.20927; Shao LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058391; Shi R, 2005, BIOTECHNIQUES, V39, P519, DOI 10.2144/000112010; Tombal B, 2014, LANCET ONCOL, V15, P592, DOI 10.1016/S1470-2045(14)70129-9; Yang HJ, 2004, CANCER BIOL THER, V3, P1277, DOI 10.4161/cbt.3.12.1370; Yang HJ, 2008, J CELL PHYSIOL, V217, P569, DOI 10.1002/jcp.21565; Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529; Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1; Zhao X, 2014, CURR MOL MED, V14, P555, DOI 10.2174/1566524014666140414211223	27	49	58	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2015	10	10							e0140745	10.1371/journal.pone.0140745	http://dx.doi.org/10.1371/journal.pone.0140745			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0DF	26473737	Green Published, gold, Green Submitted			2023-01-03	WOS:000363185500097
J	Hunger, SP; Mullighan, CG				Hunger, Stephen P.; Mullighan, Charles G.			Acute Lymphoblastic Leukemia in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MINIMAL RESIDUAL DISEASE; INTRACHROMOSOMAL AMPLIFICATION; PROGNOSTIC-FACTORS; CHILDHOOD; THERAPY; ADOLESCENTS; MUTATIONS; RISK; RELAPSE; IMATINIB	Approximately 6000 cases of acute lymphoblastic leukemia (ALL) are diagnosed in the United States annually; half the cases occur in children and teenagers. In the United States, ALL is the most common cancer among children and the most frequent cause of death from cancer before 20 years of age. 1,2 Presenting symptoms of ALL include bruising or bleeding due to thrombocytopenia, pallor and fatigue from anemia, and infection caused by neutropenia. Leukemic infiltration of the liver, spleen, lymph nodes, and mediastinum is common at diagnosis. Extramedullary leukemia in the central nervous system (CNS) or testicles may require specific modifications in therapy. Since the first description in 1948 of temporary remission of leukemia induced by chemotherapy, 3 pediatric ALL has provided a model for improvement of survival among patients with cancer by progressive improvements in the efficacy of multi-agent chemotherapy regimens and by stratification of treatment intensity according to the clinical features of the patient, the biologic features of the leukemia cells, and the early response to treatment, all of which are predictive of the risk of relapse. Collectively, these advances have increased the survival rate from less than 10% in the 1960s to 90% today (Fig. 1). New discoveries are revealing the promise and challenges of precision-medicine strategies that integrate leukemia genomics into contemporary therapy.	[Hunger, Stephen P.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Oncol, Philadelphia, PA 19104 USA; [Hunger, Stephen P.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Mullighan, Charles G.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Mullighan, Charles G.] St Jude Childrens Res Hosp, Hematol Malignancies Program, Memphis, TN 38105 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Hunger, SP (corresponding author), Childrens Hosp Philadelphia, 3060 Colket Translat Res Bldg,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	charles.mullighan@stjude.org	Pui, Ching-Hon/N-8076-2018; Mullighan, Charles/H-3253-2011	Pui, Ching-Hon/0000-0003-0303-5658; Mullighan, Charles/0000-0002-1871-1850	Spectrum Pharmaceuticals; Amgen; Incyte Pharmaceuticals; Amgen Pharmaceuticals; Jazz Pharmaceuticals; Sigma-Tau Pharmaceuticals	Spectrum Pharmaceuticals; Amgen(Amgen); Incyte Pharmaceuticals; Amgen Pharmaceuticals(Amgen); Jazz Pharmaceuticals(Jazz Pharmaceuticals); Sigma-Tau Pharmaceuticals	Dr. Hunger reports receiving consulting fees from Jazz Pharmaceuticals, Sigma-Tau Pharmaceuticals, and Spectrum Pharmaceuticals and owning stock in Amgen; Dr. Mullighan, receiving consulting fees from Incyte Pharmaceuticals and speaking fees from Amgen Pharmaceuticals; and Drs. Hunger and Mullighan, being named as inventors on a pending patent application related to gene-expression signatures for detection of underlying Philadelphia chromosome-like events and therapeutic targeting in leukemia (PCT/US2012/069228). No other potential conflict of interest relevant to this article was reported.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230; Arico M, 2010, J CLIN ONCOL, V28, P4755, DOI 10.1200/JCO.2010.30.1325; AUR RJA, 1971, BLOOD-J HEMATOL, V37, P272, DOI 10.1182/blood.V37.3.272.272; Bhatia S, 2014, BLOOD, V124, P2345, DOI 10.1182/blood-2014-01-552166; Biondi A, 2012, LANCET ONCOL, V13, P936, DOI 10.1016/S1470-2045(12)70377-7; Blanco E, 2012, LEUKEMIA LYMPHOMA, V53, P878, DOI 10.3109/10428194.2011.639018; Borowitz MJ, 2008, BLOOD, V111, P5477, DOI 10.1182/blood-2008-01-132837; Buitenkamp TD, 2014, BLOOD, V123, P70, DOI 10.1182/blood-2013-06-509463; Campana D, 2012, CURR OPIN HEMATOL, V19, P313, DOI 10.1097/MOH.0b013e3283543d5c; Clappier E, 2014, LEUKEMIA, V28, P70, DOI 10.1038/leu.2013.277; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Conter V, 2010, BLOOD, V115, P3206, DOI 10.1182/blood-2009-10-248146; Coustan-Smith E, 2000, BLOOD, V96, P2691, DOI 10.1182/blood.V96.8.2691; Coustan-Smith E, 2009, LANCET ONCOL, V10, P147, DOI 10.1016/S1470-2045(08)70314-0; DeAngelo DJ, 2015, LEUKEMIA, V29, P526, DOI 10.1038/leu.2014.229; Den Boer ML, 2009, LANCET ONCOL, V10, P125, DOI 10.1016/S1470-2045(08)70339-5; Domenech C, 2014, HAEMATOLOGICA, V99, P1220, DOI 10.3324/haematol.2014.103507; Faham M, 2012, BLOOD, V120, P5173, DOI 10.1182/blood-2012-07-444042; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; GEORGE P, 1968, J PEDIATR-US, V72, P399, DOI 10.1016/S0022-3476(68)80217-3; Harrison CJ, 2014, LEUKEMIA, V28, P1015, DOI 10.1038/leu.2013.317; Harrison CJ, 2009, BRIT J HAEMATOL, V144, P147, DOI 10.1111/j.1365-2141.2008.07417.x; Harvey RC, 2010, BLOOD, V115, P5312, DOI 10.1182/blood-2009-09-245944; Heerema NA, 2013, J CLIN ONCOL, V31, P3397, DOI 10.1200/JCO.2013.49.1308; Holmfeldt L, 2013, NAT GENET, V45, P242, DOI 10.1038/ng.2532; Hunger SP, 2015, BLOOD; Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Krull KR, 2013, J CLIN ONCOL, V31, P4407, DOI 10.1200/JCO.2012.48.2315; Kuiper RP, 2007, LEUKEMIA, V21, P1258, DOI 10.1038/sj.leu.2404691; Kuiper RP, 2010, LEUKEMIA, V24, P1258, DOI 10.1038/leu.2010.87; Li BS, 2015, NAT MED, V21, P563, DOI 10.1038/nm.3840; Lim JYS, 2014, CANCER-AM CANCER SOC, V120, P955, DOI 10.1002/cncr.28531; Linabery AM, 2008, CANCER, V112, P416, DOI 10.1002/cncr.23169; Liu GJ, 2014, GENE DEV, V28, P1337, DOI 10.1101/gad.240416.114; Ma XT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7604; Mattano LA, 2012, LANCET ONCOL, V13, P906, DOI 10.1016/S1470-2045(12)70274-7; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Meyer JA, 2013, NAT GENET, V45, P290, DOI 10.1038/ng.2558; Moorman AV, 2010, LANCET ONCOL, V11, P429, DOI 10.1016/S1470-2045(10)70066-8; Moriyama T, 2015, BLOOD; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Nachman JB, 2007, BLOOD, V110, P1112, DOI 10.1182/blood-2006-07-038299; Navarrete M, 2014, PEDIATR BLOOD CANCER, V61, P803, DOI 10.1002/pbc.24911; Nguyen K, 2008, LEUKEMIA, V22, P2142, DOI 10.1038/leu.2008.251; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Papaemmanuil E, 2009, NAT GENET, V41, P1006, DOI 10.1038/ng.430; Perez-Andreu V, 2013, NAT GENET, V45, P1494, DOI 10.1038/ng.2803; Peters C, 2015, J CLIN ONCOL, V33, P1265, DOI 10.1200/JCO.2014.58.9747; Pui CH, 2003, JAMA-J AM MED ASSOC, V290, P2001, DOI 10.1001/jama.290.15.2001; Pui CH, 2015, LANCET ONCOL, V16, P465, DOI 10.1016/S1470-2045(15)70082-3; Pui CH, 2009, NEW ENGL J MED, V360, P2730, DOI 10.1056/NEJMoa0900386; Pulte D, 2009, BLOOD, V113, P1408, DOI 10.1182/blood-2008-06-164863; Raetz EA, 2012, HEMATOL-AM SOC HEMAT, P129, DOI 10.1182/asheducation-2012.1.129; RIEHM H, 1980, AM J PEDIAT HEMATOL, V2, P299; Ries L.A.G., 1999, CANC INCIDENCE SURVI; Roberts KG, 2014, NEW ENGL J MED, V371, P1005, DOI 10.1056/NEJMoa1403088; Ross DM, 2013, BLOOD, V122, P515, DOI 10.1182/blood-2013-02-483750; Russell LJ, 2009, LEUKEMIA, V23, P614, DOI 10.1038/leu.2008.250; Russell LJ, 2009, BLOOD, V114, P2688, DOI 10.1182/blood-2009-03-208397; Schmiegelow K, 2010, LEUKEMIA, V24, P345, DOI 10.1038/leu.2009.251; Schrappe M, 2011, BLOOD, V118, P2077, DOI 10.1182/blood-2011-03-338707; Schultz KR, 2014, LEUKEMIA, V28, P1467, DOI 10.1038/leu.2014.30; Schultz KR, 2009, J CLIN ONCOL, V27, P5175, DOI 10.1200/JCO.2008.21.2514; Schwickert TA, 2014, NAT IMMUNOL, V15, P283, DOI 10.1038/ni.2828; Shah S, 2013, NAT GENET, V45, P1226, DOI 10.1038/ng.2754; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; Smith MA, 2010, J CLIN ONCOL, V28, P2625, DOI 10.1200/JCO.2009.27.0421; Stary J, 2014, J CLIN ONCOL, V32, P174, DOI 10.1200/JCO.2013.48.6522; Stock W, 2010, HEMATOL-AM SOC HEMAT, P21, DOI 10.1182/asheducation-2010.1.21; te Winkel ML, 2014, HAEMATOLOGICA, V99, P430, DOI 10.3324/haematol.2013.095562; Topp MS, 2015, LANCET ONCOL, V16, P57, DOI 10.1016/S1470-2045(14)71170-2; Trevino LR, 2009, NAT GENET, V41, P1001, DOI 10.1038/ng.432; Tzoneva G, 2013, NAT MED, V19, P368, DOI 10.1038/nm.3078; Van der Meulen J, 2015, BLOOD, V125, P13, DOI 10.1182/blood-2014-05-577270; Van Vlierberghe P, 2010, NAT GENET, V42, P338, DOI 10.1038/ng.542; Veerman AJ, 2009, LANCET ONCOL, V10, P957, DOI 10.1016/S1470-2045(09)70228-1; Vora A, 2014, LANCET ONCOL, V15, P809, DOI 10.1016/S1470-2045(14)70243-8; Vora A, 2013, LANCET ONCOL, V14, P199, DOI 10.1016/S1470-2045(12)70600-9; Vrooman LM, 2013, J CLIN ONCOL, V31, P1202, DOI 10.1200/JCO.2012.43.2070; Weston BW, 2013, J CLIN ONCOL, V31, pE413, DOI 10.1200/JCO.2012.47.6770; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yeoh AEJ, 2013, LANCET ONCOL, V14, pE508, DOI 10.1016/S1470-2045(13)70452-2; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhang JH, 2011, BLOOD, V118, P3080, DOI 10.1182/blood-2011-03-341412; Zhang MY, 2015, NAT GENET, V47, P180, DOI 10.1038/ng.3177	92	975	1029	19	192	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	2015	373	16					1541	1552		10.1056/NEJMra1400972	http://dx.doi.org/10.1056/NEJMra1400972			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT5VX	26465987	Green Accepted, Green Submitted			2023-01-03	WOS:000362880300010
J	Bao, JL; Huang, BR; Zou, LD; Chen, SH; Zhang, C; Zhang, YL; Chen, MW; Wan, JB; Su, HX; Wang, YT; He, CW				Bao, Jiaolin; Huang, Borong; Zou, Lidi; Chen, Shenghui; Zhang, Chao; Zhang, Yulin; Chen, Meiwan; Wan, Jian-Bo; Su, Huanxing; Wang, Yitao; He, Chengwei			Hormetic Effect of Berberine Attenuates the Anticancer Activity of Chemotherapeutic Agents	PLOS ONE			English	Article							RADIATION HORMESIS; STRESS; CELLS; PATHWAYS; GROWTH; CANCER; RESVERATROL; EXPRESSION; INDUCTION	Hormesis is a phenomenon of biphasic dose response characterized by exhibiting stimulatory or beneficial effects at low doses and inhibitory or toxic effects at high doses. Increasing numbers of chemicals of various types have been shown to induce apparent hormetic effect on cancer cells. However, the underlying significance and mechanisms remain to be elucidated. Berberine, one of the major active components of Rhizoma coptidis, has been manifested with notable anticancer activities. This study aims to investigate the hormetic effect of berberine and its influence on the anticancer activities of chemotherapeutic agents. Our results demonstrated that berberine at low dose range (1.25 similar to 5 mu M) promoted cell proliferation to 112% similar to 170% of the untreated control in various cancer cells, while berberine at high dose rage (10 similar to 80 mu M) inhibited cell proliferation. Further, we observed that co-treatment with low dose berberine could significantly attenuate the anticancer activity of chemotherapeutic agents, including fluorouracil (5-FU), camptothecin (CPT), and paclitaxel (TAX). The hormetic effect and thereby the attenuated anticancer activity of chemotherapeutic drugs by berberine may attributable to the activated protective stress response in cancer cells triggered by berberine, as evidenced by up-regulated MAPK/ERK1/2 and PI3K/AKT signaling pathways. These results provided important information to understand the potential side effects of hormesis, and suggested cautious application of natural compounds and relevant herbs in adjuvant treatment of cancer.	[Bao, Jiaolin; Huang, Borong; Chen, Shenghui; Zhang, Chao; Zhang, Yulin; Chen, Meiwan; Wan, Jian-Bo; Su, Huanxing; Wang, Yitao; He, Chengwei] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa, Peoples R China; [Zou, Lidi] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China	University of Macau; China Academy of Chinese Medical Sciences; Institute of Chinese Materia Medica, CACMS	He, CW (corresponding author), Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa, Peoples R China.	chengweihe@umac.mo	Su, Huanxing/X-3980-2019; Su, Huanxing/X-3954-2019; Bao, Jiaolin/GRJ-8416-2022; Wang, Yitao/O-5184-2016; Wan, Jian-Bo/D-8368-2014	Su, Huanxing/0000-0002-0513-4943; Su, Huanxing/0000-0003-3254-825X; He, Chengwei/0000-0003-4701-2984; Wan, Jian-Bo/0000-0002-6750-2617; Bao, Jiaolin/0000-0003-0630-071X	Macao Science and Technology Development Fund [074/2013/A]; Research Fund of the University of Macau [MYRG107(Y1-L3)-ICMS13-HCW, MYRG2015-00081-ICMS-QRCM, MRG013/HCW/2014/ICMS]; Institute of Chinese Materia Medica at China Academy of Chinese Medical Sciences	Macao Science and Technology Development Fund; Research Fund of the University of Macau; Institute of Chinese Materia Medica at China Academy of Chinese Medical Sciences	This study was supported by the Macao Science and Technology Development Fund (code: 074/2013/A to CH) (http://www.fdct.gov.mo/) and the Research Fund of the University of Macau (code: MYRG107(Y1-L3)-ICMS13-HCW to CH, MYRG2015-00081-ICMS-QRCM to CH, and MRG013/HCW/2014/ICMS to CH) (www.umac.mo) in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Co-author Lidi Zou is employed by Institute of Chinese Materia Medica at China Academy of Chinese Medical Sciences, where provided support in the form of salary for author LZ, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	ALLEY MC, 1991, CANCER RES, V51, P1247; Berna MJ, 2009, CELL SIGNAL, V21, P622, DOI 10.1016/j.cellsig.2009.01.003; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864; Calabrese EJ, 2008, BRIT J CLIN PHARMACO, V66, P594, DOI 10.1111/j.1365-2125.2008.03243.x; Calabrese EJ, 2007, TOXICOL APPL PHARM, V222, P122, DOI 10.1016/j.taap.2007.02.015; Calabrese EJ, 2013, CRIT REV TOXICOL, V43, P580, DOI 10.3109/10408444.2013.808172; Calabrese E, 2008, INT J TOXICOL, V27, P369, DOI 10.1080/10915810802503735; Calabrese EJ, 2005, CRIT REV TOXICOL, V35, P463, DOI 10.1080/10408440591034502; Calabrese EJ, 2003, CRIT REV TOXICOL, V33, P305, DOI 10.1080/713611041; Calabrese EJ, 2002, HUM EXP TOXICOL, V21, P91, DOI 10.1191/0960327102ht217oa; Demirovic D, 2011, BIOGERONTOLOGY, V12, P437, DOI 10.1007/s10522-011-9326-7; Gomez-Pinilla F, 2008, AGEING RES REV, V7, P49, DOI 10.1016/j.arr.2007.04.003; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Juan SH, 2005, BIOCHEM PHARMACOL, V69, P41, DOI 10.1016/j.bcp.2004.09.015; Kaboli PJ, 2014, EUR J PHARMACOL, V740, P584, DOI 10.1016/j.ejphar.2014.06.025; Lee WK, 2012, BBA-MOL CELL RES, V1823, P1864, DOI 10.1016/j.bbamcr.2012.06.003; Li F, 2002, AM J PHYSIOL-CELL PH, V283, pC917, DOI 10.1152/ajpcell.00517.2001; Lu JJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/485042; Mattson MP, 2008, AGEING RES REV, V7, P1, DOI 10.1016/j.arr.2007.08.007; Mattson MP, 2006, TRENDS NEUROSCI, V29, P632, DOI 10.1016/j.tins.2006.09.001; Mizoguchi M, 1996, BUNSEKI KAGAKU, V45, P111; Ortiz LMG, 2014, MOLECULES, V19, P12349, DOI 10.3390/molecules190812349; Pallas M, 2013, CURR PHARM DESIGN, V19, P6726, DOI 10.2174/1381612811319380005; Qi HY, 2012, NEUROPHARMACOLOGY, V62, P1659, DOI 10.1016/j.neuropharm.2011.11.012; Ranzato E, 2010, J CELL BIOCHEM, V110, P783, DOI 10.1002/jcb.22591; Ranzato E, 2009, MOL CELL BIOCHEM, V332, P199, DOI 10.1007/s11010-009-0192-4; Rithidech KN, 2008, DOSE-RESPONSE, V6, P252, DOI 10.2203/dose-response.07-024.Rithidech; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Szumiel I, 2012, INT J RADIAT BIOL, V88, P619, DOI 10.3109/09553002.2012.699698; Tang J, 2009, J ETHNOPHARMACOL, V126, P5, DOI 10.1016/j.jep.2009.08.009; Tong NN, 2012, ONCOL LETT, V3, P1263, DOI 10.3892/ol.2012.644; Vezmar M, 2000, BIOCHEM PHARMACOL, V59, P1245, DOI 10.1016/S0006-2952(00)00270-7; VICHI P, 1989, CANCER RES, V49, P2679; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yu ML, 2014, MOL MED REP, V9, P249, DOI 10.3892/mmr.2013.1762; Zhang Q, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-98; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105	38	41	41	1	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2015	10	9							e0139298	10.1371/journal.pone.0139298	http://dx.doi.org/10.1371/journal.pone.0139298			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6GF	26421434	gold, Green Submitted, Green Published			2023-01-03	WOS:000362175700092
J	Wang-Gillam, A; Li, CP; Bodoky, G; Dean, A; Shan, YS; Jameson, G; Macarulla, T; Lee, KH; Cunningham, D; Blanc, JF; Hubner, RA; Chiu, CF; Schwartsmann, G; Siveke, JT; Braiteh, F; Moyo, V; Belanger, B; Dhindsa, N; Bayever, E; Von Hoff, DD; Chen, LT				Wang-Gillam, Andrea; Li, Chung-Pin; Bodoky, Gyoergy; Dean, Andrew; Shan, Yan-Shen; Jameson, Gayle; Macarulla, Teresa; Lee, Kyung-Hun; Cunningham, David; Blanc, Jean F.; Hubner, Richard A.; Chiu, Chang-Fang; Schwartsmann, Gilberto; Siveke, Jens T.; Braiteh, Fadi; Moyo, Victor; Belanger, Bruce; Dhindsa, Navreet; Bayever, Eliel; Von Hoff, Daniel D.; Chen, Li-Tzong		NAPOLI-1 Study Grp	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial	LANCET			English	Article							2ND-LINE CHEMOTHERAPY; PLUS GEMCITABINE; ADENOCARCINOMA; OXALIPLATIN; DOCETAXEL; FOLFIRI; PEP02; 5-FLUOROURACIL; CARCINOMA; SURVIVAL	Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population. Methods We did a global, phase 3, randomised, open-label trial at 76 sites in 14 countries. Eligible patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy were randomly assigned (1: 1) using an interactive web response system at a central location to receive either nanoliposomal irinotecan monotherapy (120 mg/m(2) every 3 weeks, equivalent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid. A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1: 1: 1), in a protocol amendment. Randomisation was stratified by baseline albumin, Karnofsky performance status, and ethnic origin. Treatment was continued until disease progression or intolerable toxic effects. The primary endpoint was overall survival, assessed in the intention-to-treat population. The primary analysis was planned after 305 events. Safety was assessed in all patients who had received study drug. This trial is registered at ClinicalTrials.gov, number NCT01494506. Findings Between Jan 11, 2012, and Sept 11, 2013, 417 patients were randomly assigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or fluorouracil and folinic acid (n=149). After 313 events, median overall survival in patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8-8.9) vs 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI 0.49-0.92; p=0.012). Median overall survival did not differ between patients assigned nanoliposomal irinotecan monotherapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4.2 months [3.6-4.9]; 0.99, 0.77-1.28; p=0.94). The grade 3 or 4 adverse events that occurred most frequently in the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]). Interpretation Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy. This agent represents a new treatment option for this population.	[Wang-Gillam, Andrea] Washington Univ, Sch Med, St Louis, MO USA; [Li, Chung-Pin] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Taipei, Taiwan; [Li, Chung-Pin] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Bodoky, Gyoergy] St Laszlo Teaching Hosp, Budapest, Hungary; [Dean, Andrew] St John God Hosp, Subiaco, WA, Australia; [Chen, Li-Tzong] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan 704, Taiwan; [Chen, Li-Tzong] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan; [Shan, Yan-Shen; Chen, Li-Tzong] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Tainan 701, Taiwan; [Jameson, Gayle; Von Hoff, Daniel D.] TGen, Phoenix, AZ USA; [Jameson, Gayle; Von Hoff, Daniel D.] HonorHlth, Scottsdale, AZ USA; [Macarulla, Teresa] HUVH, Barcelona, Spain; [Macarulla, Teresa] VHIO, Barcelona, Spain; [Lee, Kyung-Hun] Seoul Natl Univ Hosp, Seoul 110744, South Korea; [Cunningham, David] Royal Marsden Hosp, London SW3 6JJ, England; [Blanc, Jean F.] Hop St Andre, Bordeaux, France; [Hubner, Richard A.] Christie NHS Fdn Trust, Manchester, Lancs, England; [Chiu, Chang-Fang] China Med Univ Hosp, Taichung, Taiwan; [Schwartsmann, Gilberto] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Siveke, Jens T.] Tech Univ Munich, Klinikum Rechts Isar, Munich, Germany; [Braiteh, Fadi] Comprehens Canc Ctr Nevada, Las Vegas, NV USA; [Moyo, Victor; Belanger, Bruce; Dhindsa, Navreet; Bayever, Eliel] Merrimack Pharmaceut, Cambridge, MA USA	Washington University (WUSTL); Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; St John of God Health Care; National Health Research Institutes - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Translational Genomics Research Institute; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Seoul National University (SNU); Seoul National University Hospital; Royal Marsden NHS Foundation Trust; CHU Bordeaux; Christie NHS Foundation Trust; China Medical University Taiwan; China Medical University Hospital - Taiwan; Technical University of Munich; Comprehensive Cancer Centers of Nevada	Chen, LT (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Tainan 704, Taiwan.	leochen@nhri.org.tw	Schwartsmann, Gilberto/G-4256-2016; Macarulla, Teresa/AAG-9230-2019; Siveke, Jens/AAQ-6170-2021; Miquel, Josep Maria/AAG-3508-2019	Schwartsmann, Gilberto/0000-0002-7850-1644; Raoul, Jean-Luc/0000-0001-6305-8953; Moyo, Victor/0000-0001-8470-5347; Macarulla, Teresa/0000-0002-5856-4082; Cunningham, David/0000-0001-5158-1069	Merrimack Pharmaceuticals	Merrimack Pharmaceuticals	This study was funded by Merrimack Pharmaceuticals. We thank the patients and their families who participated in this study; C Grace Yeh (PharmaEngine) and John Fitzgerald (Merrimack Pharmaceuticals) for input on the design and analysis of the study and review of the manuscript; Deyaa Adib (Baxalta) for review of the data and contributions to the manuscript; Istvan Molnar for analysis and review of the data and review of the report; and Khalid Mamlouk (Merrimack Pharmaceuticals) for help with the content and coordination of revisions of this manuscript. Medical writing support (funded by Merrimack Pharmaceuticals) was provided by Beth Kamp.	American Cancer Society, 2015, CANC FACTS FIG 2015; Assaf E, 2011, ONCOLOGY-BASEL, V80, P301, DOI 10.1159/000329803; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cantore M, 2004, ONCOLOGY-BASEL, V67, P93, DOI 10.1159/000080993; Cereda S, 2010, ANTICANCER RES, V30, P4785; Chang TC, 2015, CANCER CHEMOTH PHARM, V75, P579, DOI 10.1007/s00280-014-2671-x; Chibaudel B, 2015, P AM SOC CLIN ONC S3, V33; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Gebbia V, 2010, AM J CLIN ONCOL-CANC, V33, P461, DOI 10.1097/COC.0b013e3181b4e3b0; Gill S, 2014, P AM SOC CLIN ONC S5, V32; Kalra AV, 2014, CANCER RES, V74, P7003, DOI 10.1158/0008-5472.CAN-14-0572; Ko AH, 2013, BRIT J CANCER, V109, P920, DOI 10.1038/bjc.2013.408; Ko AH, 2008, CANCER INVEST, V26, P47, DOI 10.1080/07357900701681483; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; National Comprehensive Cancer Network, 2015, NCCN GUID TREATM CAN; Neuzillet C, 2012, WORLD J GASTROENTERO, V18, P4533, DOI 10.3748/wjg.v18.i33.4533; Oettle H, 2014, J CLIN ONCOL, V32, P2423, DOI 10.1200/JCO.2013.53.6995; Oh SY, 2010, INVEST NEW DRUG, V28, P343, DOI 10.1007/s10637-009-9265-1; Ramanathan RK, 26 EORTC NCI AACR S; Reni M, 2004, CANCER INVEST, V22, P688, DOI 10.1081/CNV-200032929; Roy AC, 2013, ANN ONCOL, V24, P1567, DOI 10.1093/annonc/mdt002; Smith NF, 2006, TOXICOL IN VITRO, V20, P163, DOI 10.1016/j.tiv.2005.06.045; Storniolo AM, 1999, CANCER, V85, P1261, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T; Ulrich-Pur H, 2003, BRIT J CANCER, V88, P1180, DOI 10.1038/sj.bjc.6600883; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Walker EJ, 2014, WORLD J GASTROENTERO, V20, P2224, DOI 10.3748/wjg.v20.i9.2224; Yi SY, 2009, CANCER CHEMOTH PHARM, V63, P1141, DOI 10.1007/s00280-008-0839-y; Yoo C, 2009, BRIT J CANCER, V101, P1658, DOI 10.1038/sj.bjc.6605374; Zaniboni A, 2012, CANCER CHEMOTH PHARM, V69, P1641, DOI 10.1007/s00280-012-1875-1	29	649	678	2	75	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	2016	387	10018					545	557		10.1016/S0140-6736(15)00986-1	http://dx.doi.org/10.1016/S0140-6736(15)00986-1			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DD3PV	26615328				2023-01-03	WOS:000369835800033
J	Ee, C; Xue, C; Chondros, P; Myers, SP; French, SD; Teede, H; Pirotta, M				Ee, Carolyn; Xue, Charlie; Chondros, Patty; Myers, Stephen P.; French, Simon D.; Teede, Helena; Pirotta, Marie			Acupuncture for Menopausal Hot Flashes A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; VASOMOTOR SYMPTOMS; FLUSHES; HEALTH; PERIMENOPAUSAL; MEDICINE; MANAGEMENT; SEVERITY; ACUFLASH	Background: Hot flashes (HFs) affect up to 75% of menopausal women and pose a considerable health and financial burden. Evidence of acupuncture efficacy as an HF treatment is conflicting. Objective: To assess the efficacy of Chinese medicine acupuncture against sham acupuncture for menopausal HFs. Design: Stratified, blind (participants, outcome assessors, and investigators, but not treating acupuncturists), parallel, randomized, sham-controlled trial with equal allocation. (Australia New Zealand Clinical Trials Registry: ACTRN12611000393954) Setting: Community in Australia. Participants: Women older than 40 years in the late menopausal transition or postmenopause with at least 7 moderate HFs daily, meeting criteria for Chinese medicine diagnosis of kidney yin deficiency. Interventions: 10 treatments over 8 weeks of either standardized Chinese medicine needle acupuncture designed to treat kidney yin deficiency or noninsertive sham acupuncture. Measurements: The primary outcome was HF score at the end of treatment. Secondary outcomes included quality of life, anxi-ety, depression, and adverse events. Participants were assessed at 4 weeks, the end of treatment, and then 3 and 6 months after the end of treatment. Intention-to-treat analysis was conducted with linear mixed-effects models. Results: 327 women were randomly assigned to acupuncture (n = 163) or sham acupuncture (n = 164). At the end of treatment, 16% of participants in the acupuncture group and 13% in the sham group were lost to follow-up. Mean HF scores at the end of treatment were 15.36 in the acupuncture group and 15.04 in the sham group (mean difference, 0.33 [95% CI, -1.87 to 2.52]; P = 0.77). No serious adverse events were reported. Limitation: Participants were predominantly Caucasian and did not have breast cancer or surgical menopause. Conclusion: Chinese medicine acupuncture was not superior to noninsertive sham acupuncture for women with moderately severe menopausal HFs.	[Ee, Carolyn; Pirotta, Marie] Univ Melbourne, Dept Gen Practice, 200 Berkeley St, Carlton, Vic 3053, Australia; [Xue, Charlie] Royal Melbourne Inst Technol RMIT Univ, Sch Hlth Sci, POB 71, Bundoora, Vic 3083, Australia; [Myers, Stephen P.] So Cross Univ, NatMed Res Unit, POB 157, Lismore, Qld 2480, Australia; [French, Simon D.] Queens Univ, Sch Rehabil Therapy, Louise D Acton Bldg,3 George St, Kingston, ON K7L 3N6, Canada; [Teede, Helena] Monash Ctr Hlth Res & Implementat, Sch Publ Hlth & Prevent Med, Level 1,43-51 Kanooka Grove, Clayton, Vic 3168, Australia	University of Melbourne; Royal Melbourne Institute of Technology (RMIT); Southern Cross University; Queens University - Canada	Ee, C (corresponding author), Univ Melbourne, Dept Gen Practice, 200 Berkeley St, Carlton, Vic 3053, Australia.	ccee@unimelb.edu.au	Xue, Charlie C/F-1244-2014; Chondros, Patty/AAT-6426-2020; Ee, Carolyn/V-5070-2019	Ee, Carolyn/0000-0002-3363-9199; Xue, Charlie/0000-0001-6937-9088; Teede, Helena/0000-0001-7609-577X; Chondros, Patty/0000-0003-0393-8734; French, Simon/0000-0002-7061-7706	National Health and Medical Research Council (NHMRC) of Australia [APP 1004406]; NHMRC Career Development Fellowship; NHMRC Postgraduate Scholarship; NHMRC Practitioner Fellowship	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Career Development Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Postgraduate Scholarship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	By the National Health and Medical Research Council (NHMRC) of Australia (project grant APP 1004406). Dr. Pirotta is supported by an NHMRC Career Development Fellowship. Dr. Ee is supported by an NHMRC Postgraduate Scholarship. Dr. Teede is supported by an NHMRC Practitioner Fellowship.	Archer DF, 2011, CLIMACTERIC, V14, P515, DOI 10.3109/13697137.2011.608596; Australian Bureau of Statistics, 2011, 65230 AUSTR BUR STAT; Bang HJ, 2004, CONTROL CLIN TRIALS, V25, P143, DOI 10.1016/j.cct.2003.10.016; Bordeleau L, 2007, CLIN THER, V29, P230, DOI 10.1016/j.clinthera.2007.02.006; Borud E, 2010, AUTON NEUROSCI-BASIC, V157, P57, DOI 10.1016/j.autneu.2010.04.004; Borud E, 2010, MATURITAS, V66, P131, DOI 10.1016/j.maturitas.2009.12.010; Borud EK, 2009, ACUPUNCT MED, V27, P101, DOI 10.1136/aim.2009.000612; Borud EK, 2009, MENOPAUSE, V16, P484, DOI 10.1097/gme.0b013e31818c02ad; Butt DA, 2007, MENOPAUSE, V14, P203, DOI 10.1097/01.gme.0000235370.32103.4c; Chiu HY, 2015, MENOPAUSE, V22, P234, DOI [10.1097/GME.0000000000000260, 10.1097/gme.0000000000000260]; Cho SH, 2009, MENOPAUSE, V16, P1065, DOI 10.1097/gme.0b013e3181a48abd; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4; Dodin S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007410.pub2; Eriksson I, 2001, INT J EPIDEMIOL, V30, P326, DOI 10.1093/ije/30.2.326; Fitzmaurice G.M., 2011, APPL LONGITUDINAL AN; Freeman EW, 2007, CLIMACTERIC, V10, P197, DOI 10.1080/13697130601181486; Freeman EW, 2007, OBSTET GYNECOL, V110, P230, DOI 10.1097/01.AOG.0000270153.59102.40; Gerlinger C, 2012, MENOPAUSE, V19, P799, DOI 10.1097/gme.0b013e31823de8ba; Keenan NL, 2003, MENOPAUSE, V10, P507, DOI 10.1097/01.GME.0000064865.58809.3E; Kim DI, 2011, ACUPUNCT MED, V29, P249, DOI 10.1136/aim.2011.004085; Kim KH, 2010, MENOPAUSE, V17, P269, DOI 10.1097/gme.0b013e3181bfac3b; Lee MS, 2009, CLIMACTERIC, V12, P16, DOI 10.1080/13697130802566980; Leung L, 2012, J ACUPUNCT MERIDIAN, V5, P261, DOI 10.1016/j.jams.2012.07.017; Lewis JE, 2005, MATURITAS, V50, P209, DOI 10.1016/j.maturitas.2004.06.015; LITTLE RJA, 1993, J AM STAT ASSOC, V88, P125, DOI 10.1080/01621459.1993.10594302; Loprinzi CL, 2009, MENOPAUSE, V16, P621, DOI 10.1097/gme.0b013e3181a85107; Lund Irene, 2006, Acupunct Med, V24, P13; Lundeberg T, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep049; Maciocia G, 1998, OBSTET GYNECOLOGY CH; Nahin Richard L, 2009, Natl Health Stat Report, P1; Nir Y, 2007, MATURITAS, V56, P383, DOI 10.1016/j.maturitas.2006.11.001; Painovich JM, 2012, MENOPAUSE, V19, P54, DOI 10.1097/gme.0b013e31821f9171; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Park Jongbae, 2002, Acupunct Med, V20, P168; Pirotta M, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-224; Riley EH, 2004, J GEN INTERN MED, V19, P740, DOI 10.1007/s11606-004-0002-3; Sassarini J, 2013, CLIMACTERIC, V16, P31, DOI 10.3109/13697137.2013.805525; Sloan JA, 2001, J CLIN ONCOL, V19, P4280, DOI 10.1200/JCO.2001.19.23.4280; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Soules M R, 2001, Climacteric, V4, P267; van der Sluijs CP, 2007, MENOPAUSE, V14, P397, DOI 10.1097/01.gme.0000236937.36078.f4; Villaseca P, 2012, CLIMACTERIC, V15, P115, DOI 10.3109/13697137.2011.624214; Vincent A, 2007, MENOPAUSE, V14, P45, DOI 10.1097/01.gme.0000227854.27603.7d; White A, 2008, ACUPUNCT MED, V26, P111, DOI 10.1136/aim.26.2.111; White AR, 2001, COMPLEMENT THER MED, V9, P237, DOI 10.1054/ctim.2001.0489; White IR, 2012, CLIN TRIALS, V9, P396, DOI 10.1177/1740774512450098; Whiteley J, 2013, MENOPAUSE, V20, P518, DOI [10.1097/gme.0b013e31827d38a5, 10.1097/GME.0b013e31827d38a5]; Whiteman MK, 2003, J WOMEN HEALTH GEN-B, V12, P459, DOI 10.1089/154099903766651586; Whiteman MK, 2003, OBSTET GYNECOL, V101, P264, DOI 10.1016/S0029-7844(02)02593-0; Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315; Wyrwich KW, 2008, MENOPAUSE, V15, P698, DOI 10.1097/gme.0b013e31815f892d; Zell B, 2000, MENOPAUSE, V7, P129, DOI 10.1097/00042192-200007020-00010	53	48	54	1	51	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 2	2016	164	3					146	U135		10.7326/M15-1380	http://dx.doi.org/10.7326/M15-1380			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC4DD	26784863				2023-01-03	WOS:000369169400003
J	Weingarden, AR; Dosa, PI; DeWinter, E; Steer, CJ; Shaughnessy, MK; Johnson, JR; Khoruts, A; Sadowsky, MJ				Weingarden, Alexa R.; Dosa, Peter I.; DeWinter, Erin; Steer, Clifford J.; Shaughnessy, Megan K.; Johnson, James R.; Khoruts, Alexander; Sadowsky, Michael J.			Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth	PLOS ONE			English	Article							SPORE GERMINATION; PATHOGENICITY LOCUS; INFECTION; EPIDEMIOLOGY; POLYMORPHISM; STRAIN; SALTS	Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent Clostridium difficile infection (R-CDI), but its mechanisms remain poorly understood. Emerging evidence suggests that gut bile acids have significant influence on the physiology of C. difficile, and therefore on patient susceptibility to recurrent infection. We analyzed spore germination of 10 clinical C. difficile isolates exposed to combinations of bile acids present in patient feces before and after FMT. Bile acids at concentrations found in patients' feces prior to FMT induced germination of C. difficile, although with variable potency across different strains. However, bile acids at concentrations found in patients after FMT did not induce germination and inhibited vegetative growth of all C. difficile strains. Sequencing of the newly identified germinant receptor in C. difficile, CspC, revealed a possible correspondence of variation in germination responses across isolates with mutations in this receptor. This may be related to interstrain variability in spore germination and vegetative growth in response to bile acids seen in this and other studies. These results support the idea that intra-colonic bile acids play a key mechanistic role in the success of FMT, and suggests that novel therapeutic alternatives for treatment of R-CDI may be developed by targeted manipulation of bile acid composition in the colon.	[Weingarden, Alexa R.] Univ Minnesota, Dept Microbiol & Immunol, St Paul, MN 55108 USA; [Weingarden, Alexa R.; DeWinter, Erin; Khoruts, Alexander; Sadowsky, Michael J.] Univ Minnesota, Inst Biotechnol, St Paul, MN 55108 USA; [Dosa, Peter I.] Univ Minnesota, Dept Med Chem, Inst Therapeut Discovery & Dev, Minneapolis, MN 55455 USA; [Steer, Clifford J.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA; [Steer, Clifford J.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN USA; [Shaughnessy, Megan K.; Johnson, James R.] Univ Minnesota, Dept Med, Div Infect Dis, Box 736 UMHC, Minneapolis, MN 55455 USA; [Shaughnessy, Megan K.; Johnson, James R.] Minneapolis Vet Affairs VA Healthcare Syst, Div Infect Dis, Minneapolis, MN USA; [Khoruts, Alexander] Univ Minnesota, Dept Med, Div Gastroenterol, Box 736 UMHC, Minneapolis, MN 55455 USA; [Khoruts, Alexander] Univ Minnesota, Ctr Immunol, Minneapolis, MN USA; [Sadowsky, Michael J.] Univ Minnesota, Dept Soil Water & Climate, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Sadowsky, MJ (corresponding author), Univ Minnesota, Inst Biotechnol, St Paul, MN 55108 USA.; Sadowsky, MJ (corresponding author), Univ Minnesota, Dept Soil Water & Climate, St Paul, MN 55108 USA.	Sadowsky@umn.edu	Sadowsky, Michael/J-2507-2016; Khoruts, Alexander/ABF-5119-2020	Sadowsky, Michael/0000-0001-8779-2781; Khoruts, Alexander/0000-0002-3205-3188; Dosa, Peter/0000-0002-0081-3867; Weingarden, Alexa/0000-0002-1567-1320	NIH [1R21-AI114722-01, UL1TR00114]; NIAID [R21AI-091907]; National Center for Allergy and Infectious Diseases [2T32AI055433-06A1]; Office of Research and Development, Medical Research Service, Department of Veterans Affairs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI114722, T32AI055433, R21AI091907] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Allergy and Infectious Diseases; Office of Research and Development, Medical Research Service, Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by NIH grant 1R21-AI114722-01 (AK, MJS, CC) and NIH Training Grant UL1TR00114 to University of Minnesota CTSI (ARW). Research reported in this publication was also supported, in part, by NIAID Grant R21AI-091907 (AK and MJS). MKS was supported by training grant award 2T32AI055433-06A1 from the National Center for Allergy and Infectious Diseases and the Office of Research and Development, Medical Research Service, Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ananthakrishnan AN, 2011, NAT REV GASTRO HEPAT, V8, P17, DOI 10.1038/nrgastro.2010.190; Arroyo LG, 2005, J CLIN MICROBIOL, V43, P5341, DOI 10.1128/JCM.43.10.5341-5343.2005; Borody TJ, 2012, NAT REV GASTRO HEPAT, V9, P88, DOI 10.1038/nrgastro.2011.244; Braun V, 1996, GENE, V181, P29, DOI 10.1016/S0378-1119(96)00398-8; Buffie CG, 2015, NATURE, V517, P205, DOI 10.1038/nature13828; Chitnis AS, 2013, JAMA INTERN MED, V173, P1359, DOI 10.1001/jamainternmed.2013.7056; Francis MB, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003356; Fuentes S, 2014, ISME J, V8, P1621, DOI 10.1038/ismej.2014.13; Giel JL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008740; Gough E, 2011, CLIN INFECT DIS, V53, P994, DOI 10.1093/cid/cir632; Hamilton MJ, 2013, GUT MICROBES, V4, P125, DOI 10.4161/gmic.23571; Hamilton MJ, 2012, AM J GASTROENTEROL, V107, P761, DOI 10.1038/ajg.2011.482; Heeg D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032381; Kelly Ciaran P, 2008, N Engl J Med, V359, P1932, DOI 10.1056/NEJMra0707500; Khanna S, 2012, AM J GASTROENTEROL, V107, P89, DOI 10.1038/ajg.2011.398; Khoruts A, 2015, CLIN GASTROENTEROL H, V13, P246, DOI 10.1016/j.cgh.2014.11.014; Khoruts A, 2010, J CLIN GASTROENTEROL, V44, P354, DOI 10.1097/MCG.0b013e3181c87e02; Killgore G, 2008, J CLIN MICROBIOL, V46, P431, DOI 10.1128/JCM.01484-07; Koenigsknecht MJ, 2015, INFECT IMMUN, V83, P934, DOI 10.1128/IAI.02768-14; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMc1505190, 10.1056/NEJMoa1408913]; Lessa FC, 2012, CLIN INFECT DIS, V55, pS65, DOI 10.1093/cid/cis319; Louie TJ, 2011, NEW ENGL J MED, V364, P422, DOI 10.1056/NEJMoa0910812; McDonald LC, 2005, NEW ENGL J MED, V353, P2433, DOI 10.1056/NEJMoa051590; MEKHJIAN HS, 1979, DIGEST DIS SCI, V24, P545, DOI 10.1007/BF01489324; Miller BA, 2011, INFECT CONT HOSP EP, V32, P387, DOI 10.1086/659156; MOIR A, 1990, ANNU REV MICROBIOL, V44, P531, DOI 10.1146/annurev.mi.44.100190.002531; Ridlon JM, 2006, J LIPID RES, V47, P241, DOI 10.1194/jlr.R500013-JLR200; Rupnik M, 1998, J CLIN MICROBIOL, V36, P2240, DOI 10.1128/JCM.36.8.2240-2247.1998; Seekatz AM, 2014, MBIO, V5, DOI 10.1128/mBio.00893-14; Shahinas D, 2012, MBIO, V3, DOI 10.1128/mBio.00338-12; Shankar V, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-13; Sorg JA, 2008, J BACTERIOL, V190, P2505, DOI 10.1128/JB.01765-07; Sorg JA, 2010, J BACTERIOL, V192, P4983, DOI 10.1128/JB.00610-10; Sorg JA, 2009, J BACTERIOL, V191, P1115, DOI 10.1128/JB.01260-08; Spigaglia P, 2002, J CLIN MICROBIOL, V40, P3470, DOI 10.1128/JCM.40.9.3470-3475.2002; Surawicz CM, 2011, NAT REV GASTRO HEPAT, V8, P330, DOI 10.1038/nrgastro.2011.59; Theriot CM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4114; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Walker AS, 2013, CLIN INFECT DIS, V56, P1589, DOI 10.1093/cid/cit127; Weingarden A, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0070-0; Weingarden AR, 2014, AM J PHYSIOL-GASTR L, V306, pG310, DOI 10.1152/ajpgi.00282.2013; WILSON KH, 1983, J CLIN MICROBIOL, V18, P1017, DOI 10.1128/JCM.18.4.1017-1019.1983; Youngster I, 2014, CLIN INFECT DIS, V58, P1515, DOI 10.1093/cid/ciu135	44	109	113	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2016	11	1							e0147210	10.1371/journal.pone.0147210	http://dx.doi.org/10.1371/journal.pone.0147210			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB5BW	26789728	Green Submitted, Green Published, gold			2023-01-03	WOS:000368529100069
J	Sacks, HS				Sacks, Henry S.			Preexposure tenofovir-emtricitabine reduced HIV infection in men who have unprotected anal sex with men	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ANTIRETROVIRAL PROPHYLAXIS; PREVENTION		[Sacks, Henry S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sacks, HS (corresponding author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.							Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Centers for Disease Control and Prevention, 2014, PREEXP PROPH PREV HI, P1; Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7; Marrazzo JM, 2014, JAMA-J AM MED ASSOC, V312, P390, DOI 10.1001/jama.2014.7999; Schackman BR, 2015, MED CARE, V53, P293, DOI 10.1097/MLR.0000000000000308; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Young J, 2012, AIDS, V26, P567, DOI 10.1097/QAD.0b013e32834f337c	7	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	2016	164	2					JC3	JC3		10.7326/ACPJC-2016-164-2-003	http://dx.doi.org/10.7326/ACPJC-2016-164-2-003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB0CI	26784493				2023-01-03	WOS:000368175800002
J	Sobotka, KS; Hooper, SB; Crossley, KJ; Ong, T; Schmolzer, GM; Barton, SK; McDougall, ARA; Miller, SL; Tolcos, M; Klingenberg, C; Polglase, GR				Sobotka, Kristina S.; Hooper, Stuart B.; Crossley, Kelly J.; Ong, Tracey; Schmoelzer, Georg M.; Barton, Samantha K.; McDougall, Annie R. A.; Miller, Suzie L.; Tolcos, Mary; Klingenberg, Claus; Polglase, Graeme R.			Single Sustained Inflation followed by Ventilation Leads to Rapid Cardiorespiratory Recovery but Causes Cerebral Vascular Leakage in Asphyxiated Near-Term Lambs	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; FUNCTIONAL RESIDUAL CAPACITY; BIRTH-WEIGHT INFANTS; BLOOD-FLOW VELOCITY; PRETERM INFANTS; FETAL SHEEP; DELIVERY ROOM; BRAIN-INJURY; INTRAVENTRICULAR HEMORRHAGE; NEWBORN-INFANT	Background A sustained inflation (SI) rapidly restores cardiac function in asphyxic, bradycardic newborns but its effects on cerebral haemodynamics and brain injury are unknown. We determined the effect of different SI strategies on carotid blood flow (CaBF) and cerebral vascular integrity in asphyxiated near-term lambs. Methods Lambs were instrumented and delivered at 139 +/- 2 d gestation and asphyxia was induced by delaying ventilation onset. Lambs were randomised to receive 5 consecutive 3 s SI (multiple SI; n = 6), a single 30 s SI (single SI; n = 6) or conventional ventilation (no SI; n = 6). Ventilation continued for 30 min in all lambs while CaBF and respiratory function parameters were recorded. Brains were assessed for gross histopathology and vascular leakage. Results CaBF increased more rapidly and to a greater extent during a single SI (p = 0.01), which then decreased below both other groups by 10 min, due to a higher cerebral oxygen delivery (p = 0.01). Blood brain barrier disruption was increased in single SI lambs as indicated by increased numbers of blood vessel profiles with plasma protein extravasation (p = 0.001) in the cerebral cortex. There were no differences in CaBF or cerebral oxygen delivery between the multiple SI and no SI lambs. Conclusions Ventilation with an initial single 30 s SI improves circulatory recovery, but is associated with greater disruption of blood brain barrier function, which may exacerbate brain injury suffered by asphyxiated newborns. This injury may occur as a direct result of the initial SI or to the higher tidal volumes delivered during subsequent ventilation.	[Sobotka, Kristina S.; Hooper, Stuart B.; Crossley, Kelly J.; Ong, Tracey; Barton, Samantha K.; McDougall, Annie R. A.; Miller, Suzie L.; Tolcos, Mary; Polglase, Graeme R.] Monash Univ, Ritchie Ctr, Melbourne, Vic 3004, Australia; [Sobotka, Kristina S.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Gothenburg, Sweden; [Hooper, Stuart B.; Crossley, Kelly J.; Miller, Suzie L.; Tolcos, Mary; Polglase, Graeme R.] Monash Univ, Dept Obstet & Gynaecol, Melbourne, Vic 3004, Australia; [Schmoelzer, Georg M.] Med Univ, Dept Pediat, Graz, Austria; [Schmoelzer, Georg M.] Royal Alexandra Hosp, Neonatal Res Unit, Ctr Studies Asphyxia & Resuscitat, Edmonton, AB, Canada; [Schmoelzer, Georg M.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Klingenberg, Claus] Univ Hosp North Norway, Dept Paediat, Tromso, Norway; [Klingenberg, Claus] Univ Tromso, Fac Hlth Sci, Paediat Res Grp, Tromso, Norway	Monash University; University of Gothenburg; Monash University; Medical University of Graz; Royal Alexandra Hospital; University of Alberta; UiT The Arctic University of Tromso; University Hospital of North Norway; UiT The Arctic University of Tromso	Sobotka, KS (corresponding author), Monash Univ, Ritchie Ctr, Melbourne, Vic 3004, Australia.	kristina.sobotka@gu.se	Klingenberg, Claus/AAH-4467-2019; Crossley, Kelly J/I-7407-2013; Schmölzer, Georg M/E-7883-2010	Crossley, Kelly J/0000-0002-1580-1156; Schmölzer, Georg M/0000-0001-9798-2415; Miller, Suzanne/0000-0002-0451-8304; Polglase, Graeme/0000-0002-8906-614X; McDougall, Annie/0000-0003-1182-6679; Barton, Samantha/0000-0001-7601-0238; Tolcos, Mary/0000-0001-6105-4553; Hooper, Stuart/0000-0003-1676-4825	National Health and Medical Research Council (NHMRC) of Australia [384100, 1026890, APP1043294, 545921]; Rebecca L. Cooper Medical Research Foundation Fellowship; Victorian Government's Operational Infrastructure Support Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD072848] Funding Source: NIH RePORTER	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Rebecca L. Cooper Medical Research Foundation Fellowship; Victorian Government's Operational Infrastructure Support Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by the National Health and Medical Research Council (NHMRC) of Australia program grant (No. 384100), fellowship (GRP: 1026890, TJM: APP1043294, SBH: 545921), a Rebecca L. Cooper Medical Research Foundation Fellowship (GRP), and the Victorian Government's Operational Infrastructure Support Program.	Bennet L, 1998, PEDIATR RES, V44, P951, DOI 10.1203/00006450-199812000-00022; Boyle DW, 2008, SEMIN FETAL NEONAT M, V13, P392, DOI 10.1016/j.siny.2008.04.026; Covert RF, 1996, REPROD FERT DEVELOP, V8, P157, DOI 10.1071/RD9960157; Crossley KJ, 2009, J PHYSIOL-LONDON, V587, P4695, DOI 10.1113/jphysiol.2009.174870; DELTORO J, 1991, PEDIATR NEUROL, V7, P3, DOI 10.1016/0887-8994(91)90098-6; Fellman V, 1997, PEDIATR RES, V41, P599, DOI 10.1203/00006450-199705000-00001; Fuchs H, 2011, PEDIATR RES, V70, P176, DOI 10.1203/PDR.0b013e318220c1e0; Fujii EY, 2003, AM J OBSTET GYNECOL, V188, P413, DOI 10.1067/mob.2003.40; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; Grasso C, 2015, EARLY HUM DEV, V91, P71, DOI 10.1016/j.earlhumdev.2014.12.002; Hillman NH, 2007, AM J RESP CRIT CARE, V176, P575, DOI 10.1164/rccm.200701-051OC; HOSKYNS EW, 1987, ARCH DIS CHILD, V62, P376, DOI 10.1136/adc.62.4.376; Klingenberg C, 2013, ARCH DIS CHILD-FETAL, V98, pF222, DOI 10.1136/archdischild-2012-301787; Kluckow M, 2000, ARCH DIS CHILD-FETAL, V82, pF188, DOI 10.1136/fn.82.3.F188; Lindner W, 2005, ACTA PAEDIATR, V94, P303, DOI 10.1080/08035250410023647; Lindner W, 1999, PEDIATRICS, V103, P961, DOI 10.1542/peds.103.5.961; Lista G, 2011, NEONATOLOGY, V99, P45, DOI 10.1159/000298312; LISTER G, 1979, AM J PHYSIOL, V237, pH668, DOI 10.1152/ajpheart.1979.237.6.H668; LOU HC, 1979, J PEDIATR-US, V94, P118, DOI 10.1016/S0022-3476(79)80373-X; LOU HC, 1979, ACTA PAEDIATR SCAND, V68, P57, DOI 10.1111/j.1651-2227.1979.tb04430.x; MASON DT, 1971, CIRCULATION, V44, P47, DOI 10.1161/01.CIR.44.1.47; Perlman JM, 2010, CIRCULATION, V122, P8516, DOI 10.1161/CIRCULATIONAHA.110.971127; PERLMAN JM, 1983, NEW ENGL J MED, V309, P204, DOI 10.1056/NEJM198307283090402; Polglase GR, 2004, PEDIATR RES, V56, P932, DOI 10.1203/01.PDR.0000145254.66447.C0; Polglase GR, 2014, PEDIATR RES, V75, P682, DOI 10.1038/pr.2014.40; Polglase GR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039535; Polglase GR, 2009, J APPL PHYSIOL, V106, P1347, DOI 10.1152/japplphysiol.91445.2008; Rees S, 2010, J NEUROPATH EXP NEUR, V69, P306, DOI 10.1097/NEN.0b013e3181d27138; Richmond S, 2010, RESUSCITATION, V81, P1389, DOI 10.1016/j.resuscitation.2010.08.018; Sobotka KS, 2011, PEDIATR RES, V70, P56, DOI 10.1203/PDR.0b013e31821d06a1; Pas ABT, 2007, PEDIATRICS, V120, P322, DOI 10.1542/peds.2007-0114; te Pas AB, 2009, PEDIATR RES, V66, P295, DOI 10.1203/PDR.0b013e3181b1bca4; te Pas AB, 2009, PEDIATR RES, V65, P537, DOI 10.1203/PDR.0b013e31819da21b; VANBEL F, 1994, PEDIATR RES, V35, P329; VANBEL F, 1987, DEV MED CHILD NEUROL, V29, P601; VANBEL F, 1990, ACTA PAEDIATR SCAND, V79, P756; VYAS H, 1981, J PEDIATR-US, V99, P635, DOI 10.1016/S0022-3476(81)80279-X	37	21	21	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2016	11	1							e0146574	10.1371/journal.pone.0146574	http://dx.doi.org/10.1371/journal.pone.0146574			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB4CC	26765258	Green Submitted, Green Published, gold			2023-01-03	WOS:000368459300029
J	Sitbon, O; Channick, R; Chin, KM; Frey, A; Gaine, S; Galie, N; Ghofrani, HA; Hoeper, MM; Lang, IM; Preiss, R; Rubin, LJ; Di Scala, L; Tapson, V; Adzerikho, I; Liu, JM; Moiseeva, O; Zeng, XF; Simonneau, G; McLaughlin, VV				Sitbon, Olivier; Channick, Richard; Chin, Kelly M.; Frey, Aline; Gaine, Sean; Galie, Nazzareno; Ghofrani, Hossein-Ardeschir; Hoeper, Marius M.; Lang, Irene M.; Preiss, Ralph; Rubin, Lewis J.; Di Scala, Lilla; Tapson, Victor; Adzerikho, Igor; Liu, Jinming; Moiseeva, Olga; Zeng, Xiaofeng; Simonneau, Gerald; McLaughlin, Vallerie V.		GRIPHON Investigators	Selexipag for the Treatment of Pulmonary Arterial Hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROSTACYCLIN RECEPTOR AGONIST; 5 INHIBITOR THERAPY; ORAL TREPROSTINIL; DIAGNOSIS; MANAGEMENT; ANTAGONIST; SURVIVAL; TIME	BACKGROUND In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension. METHODS In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patients with pulmonary arterial hypertension to receive placebo or selexipag in individualized doses (maximum dose, 1600 mu g twice daily). Patients were eligible for enrollment if they were not receiving treatment for pulmonary arterial hypertension or if they were receiving a stable dose of an endothelin-receptor antagonist, a phosphodiesterase type 5 inhibitor, or both. The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of the treatment period (defined for each patient as 7 days after the date of the last intake of selexipag or placebo). RESULTS A primary end-point event occurred in 397 patients -41.6% of those in the placebo group and 27.0% of those in the selexipag group (hazard ratio in the selexipag group as compared with the placebo group, 0.60; 99% confidence interval, 0.46 to 0.78; P< 0.001). Disease progression and hospitalization accounted for 81.9% of the events. The effect of selexipag with respect to the primary end point was similar in the subgroup of patients who were not receiving treatment for the disease at baseline and in the subgroup of patients who were already receiving treatment at baseline (including those who were receiving a combination of two therapies). By the end of the study, 105 patients in the placebo group and 100 patients in the selexipag group had died from any cause. Overall, 7.1% of patients in the placebo group and 14.3% of patients in the selexipag group discontinued their assigned regimen prematurely because of adverse events. The most common adverse events in the selexipag group were consistent with the known side effects of prostacyclin, including headache, diarrhea, nausea, and jaw pain. CONCLUSIONS Among patients with pulmonary arterial hypertension, the risk of the primary composite end point of death or a complication related to pulmonary arterial hypertension was significantly lower with selexipag than with placebo. There was no significant difference in mortality between the two study groups. (Funded by Actelion Pharmaceuticals; GRIPHON ClinicalTrials.gov number, NCT01106014.)	[Sitbon, Olivier; Simonneau, Gerald] Univ Paris Saclay, Univ Paris Sud, INSERM, Unite Mixte Rech Sante 999,Hop Bicetre,AP HP, Le Kremlin Bicetre, France; [Channick, Richard] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Chin, Kelly M.] UT Southwestern Med Ctr, Dallas, TX USA; [Frey, Aline; Preiss, Ralph; Di Scala, Lilla] Actel Pharmaceut, Allschwil, Switzerland; [Gaine, Sean] Mater Misericordiae Univ Hosp, Natl Pulm Hypertens Unit, Dublin, Ireland; [Galie, Nazzareno] Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy; [Ghofrani, Hossein-Ardeschir] Univ Giessen, D-35390 Giessen, Germany; [Ghofrani, Hossein-Ardeschir] German Ctr Lung Res, Marburg Lung Ctr, Giessen, Germany; [Hoeper, Marius M.] Hannover Med Sch, Dept Resp Med, Hannover, Germany; [Hoeper, Marius M.] German Ctr Lung Res, Hannover, Germany; [Ghofrani, Hossein-Ardeschir] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2AZ, England; [Lang, Irene M.] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Allgemeines Krankenhaus, Vienna, Austria; [Rubin, Lewis J.] Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA; [Tapson, Victor] Cedars Sinai Med Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90048 USA; [Adzerikho, Igor] Minsk Reg Clin Hosp, Minsk, BELARUS; [Liu, Jinming] Shanghai Pulm Hosp, Dept Pulm Circulat, Shanghai, Peoples R China; [Zeng, Xiaofeng] Peking Union Med Coll Hosp, Dept Rheumatol, Beijing, Peoples R China; [Moiseeva, Olga] Fed Almazov North West Med Res Ctr, St Petersburg, Russia; [McLaughlin, Vallerie V.] Univ Michigan Hlth Syst, Div Cardiovasc Med, Dept Internal Med, Ann Arbor, MI USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Harvard University; Massachusetts General Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; Actelion Pharmaceuticals Ltd; Mater Misericordiae University Hospital; University College Dublin; University of Bologna; Justus Liebig University Giessen; Hannover Medical School; Imperial College London; Medical University of Vienna; University of California System; University of California San Diego; Cedars Sinai Medical Center; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Almazov National Medical Research Centre; University of Michigan System; University of Michigan	Sitbon, O (corresponding author), CHU Bicetre, Serv Pneumol & Soins Intensifs, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	olivier.sitbon@bct.aphp.fr	Evtushenko, Alexey/J-4544-2017; Schulman, Sam/I-7559-2019; Chazova, Irina/B-8688-2017; HACHULLA, ERIC/R-8488-2018; Evtushenko, Alexey/H-8346-2014; Sitbon, Olivier/I-3623-2019; Ghofrani, Hossein Ardeschir/AAD-2856-2022; Söderberg, Stefan/AAG-3881-2019; Moiseeva, Olga/AAN-1762-2020; Austin, Eric Douglas/A-6070-2013; Simonneau, Gerald/ABE-6614-2020; Ghofrani, Ardeschir/AAD-5293-2020; Hoeper, Marius C/Z-1546-2019	Evtushenko, Alexey/0000-0001-8475-4667; Schulman, Sam/0000-0002-8512-9043; Chazova, Irina/0000-0002-9822-4357; HACHULLA, ERIC/0000-0001-7432-847X; Evtushenko, Alexey/0000-0002-0519-783X; Sitbon, Olivier/0000-0002-1942-1951; Söderberg, Stefan/0000-0001-9225-1306; Moiseeva, Olga/0000-0002-7817-3847; Austin, Eric Douglas/0000-0002-1709-9022; Ghofrani, Ardeschir/0000-0002-2029-4419; Hoeper, Marius C/0000-0001-9086-2293; Chin, Kelly/0000-0002-1214-6723; Lang, Irene/0000-0003-0485-2692; Olschewski, Horst/0000-0002-2834-7466; Williams, Paul Graham/0000-0001-7940-8081; Adzeriho, Igor'/0000-0001-6572-8842; JAIS, XAVIER/0000-0002-4104-7994; Hubbert, Laila/0000-0002-6578-8826; Gaine, Sean/0000-0002-5941-684X; Brutsche, Martin/0000-0002-1612-3609; sharma, kamal/0000-0001-5866-2566	Actelion Pharmaceuticals; Actelion; GlaxoSmithKline; Bayer; Pfizer; United Therapeutics; Gilead Sciences; GeNO; Daiichi Sankyo; Novartis; Daiichi-Sankyo; Merck; Arena; Lung Biotechnology; Janssen; Eli Lilly; Ikaria	Actelion Pharmaceuticals; Actelion; GlaxoSmithKline(GlaxoSmithKline); Bayer(Bayer AG); Pfizer(Pfizer); United Therapeutics; Gilead Sciences(Gilead Sciences); GeNO; Daiichi Sankyo(Daiichi Sankyo Company Limited); Novartis(Novartis); Daiichi-Sankyo(Daiichi Sankyo Company Limited); Merck(Merck & Company); Arena(Australian Renewable Energy Agency (ARENA)); Lung Biotechnology; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Eli Lilly(Eli Lilly); Ikaria	Supported by Actelion Pharmaceuticals.; Dr. Sitbon reports receiving fees for serving on a steering committee from Actelion, fees for writing assistance from Actelion and GlaxoSmithKline, consulting and lecture fees from Actelion, Bayer, GlaxoSmithKline, Pfizer, and United Therapeutics, and fees for serving on advisory boards and grant support from Actelion, Bayer, GlaxoSmithKline, and Pfizer; Dr. Channick, receiving fees for serving on advisory boards from Bayer and Actelion, consulting fees from Bayer, and grant support from United Therapeutics and Actelion; Dr. Chin, receiving consulting fees from Actelion, Bayer, and Gilead Sciences and grant support from Actelion, Gilead Sciences, and GeNO; Dr. Frey, Dr. Preiss, and Dr. Di Scalla, being employees of Actelion; Dr. Gaine, receiving fees for serving on advisory boards from Bayer, Actelion, Novartis, Pfizer, and Daiichi Sankyo, fees for serving on data and safety monitoring boards from GlaxoSmithKline, United Therapeutics, and Novartis, fees for serving on a steering committee from Actelion, lecture fees from Bayer, GlaxoSmithKline, United Therapeutics, and Actelion, and travel support from Bayer, GlaxoSmithKline, Actelion, Novartis, and Daiichi-Sankyo; Dr. Galie, receiving personal fees and grant support from Actelion, Bayer, GlaxoSmithKline, and Pfizer; Dr. Ghofrani, receiving fees for serving on steering committees from Bayer, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, and Pfizer, consulting fees from Actelion, Bayer, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, and Pfizer, lecture fees from Actelion, Bayer, GlaxoSmithKline, Novartis, and Pfizer, and grant support from Actelion, Bayer, Novartis, and Pfizer; Dr. Hoeper, receiving consulting and lecture fees from Pfizer, Bayer, and GlaxoSmithKline; Dr. Lang, receiving fees for serving on a data and safety monitoring board from Novartis, lecture fees from Actelion, Bayer, GlaxoSmithKline, and United Therapeutics, and grant support from Actelion, Bayer, and United Therapeutics; Dr. Rubin, receiving fees for serving on an advisory board from United Therapeutics and consulting fees and travel support from Actelion, Arena, GeNO, Lung Biotechnology, Gilead Sciences, and United Therapeutics; Dr. Tapson, receiving fees for serving on steering committees from Actelion, Bayer, and United Therapeutics, consulting fees from Actelion, Gilead Sciences, Bayer, Daiichi Sankyo, and Janssen, lecture fees from Gilead Sciences and Janssen, and grant support from Actelion, Bayer, United Therapeutics, and Janssen; Dr. Moiseeva, receiving lecture fees and grant support from Actelion and Bayer; Dr. Zeng, receiving grant and travel support and study drugs and equipment from Actelion; Dr. Simonneau, receiving consulting fees, lecture fees, and travel support from Actelion, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, and Pfizer, and grant support from Actelion and Bayer; and Dr. McLaughlin, receiving fees for serving on advisory boards and steering committees, consulting fees, and travel support from Bayer, Gilead Sciences, United Therapeutics, Actelion, and Ikaria, and grant support from Bayer, Actelion, Ikaria, and Novartis. No other potential conflict of interest relevant to this article was reported.	Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; Benza RL, 2012, CHEST, V142, P448, DOI 10.1378/chest.11-1460; Cuzick J, 2005, LANCET, V365, P1308, DOI 10.1016/S0140-6736(05)61026-4; Farber HW, 2013, J HEART LUNG TRANSPL, V32, P1114, DOI 10.1016/j.healun.2013.08.010; Galie N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317; Galie N, 2013, J AM COLL CARDIOL, V62, pD60, DOI 10.1016/j.jacc.2013.10.031; Galie N, 2009, CIRCULATION, V119, P2894, DOI 10.1161/CIRCULATIONAHA.108.839274; Ghofrani HA, 2013, NEW ENGL J MED, V369, P319, DOI 10.1056/NEJMoa1209657; Humbert M, 2010, CIRCULATION, V122, P156, DOI 10.1161/CIRCULATIONAHA.109.911818; Kuwano K, 2008, J PHARMACOL EXP THER, V326, P691, DOI 10.1124/jpet.108.138305; Kuwano K, 2007, J PHARMACOL EXP THER, V322, P1181, DOI 10.1124/jpet.107.124248; McLaughlin VV, 2006, AM J RESP CRIT CARE, V174, P1257, DOI 10.1164/rccm.200603-358OC; McLaughlin VV, 2013, CLIN CHEST MED, V34, P825, DOI 10.1016/j.ccm.2013.09.003; McLaughlin VV, 2013, CHEST, V143, P324, DOI 10.1378/chest.11-3060; McLaughlin VV, 2010, J AM COLL CARDIOL, V55, P1915, DOI 10.1016/j.jacc.2010.01.027; McLaughlin VV, 2009, J AM COLL CARDIOL, V54, pS97, DOI 10.1016/j.jacc.2009.04.007; McMurray JJV, 2014, NEW ENGL J MED, V371, P993, DOI 10.1056/NEJMoa1409077; Morrison K, 2012, J PHARMACOL EXP THER, V343, P547, DOI 10.1124/jpet.112.197152; Morrison K, 2010, J PHARMACOL EXP THER, V335, P249, DOI 10.1124/jpet.110.169748; Pulido T, 2013, NEW ENGL J MED, V369, P809, DOI 10.1056/NEJMoa1213917; Rajkumar R, 2010, AM J PHYSIOL-HEART C, V298, pH1235, DOI 10.1152/ajpheart.00254.2009; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Simonneau G, 2012, EUR RESPIR J, V40, P874, DOI 10.1183/09031936.00137511; Tapson VE, 2012, CHEST, V142, P1383, DOI 10.1378/chest.11-2212; Tapson VF, 2013, CHEST, V144, P952, DOI 10.1378/chest.12-2875	25	527	564	2	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	2015	373	26					2522	2533		10.1056/NEJMoa1503184	http://dx.doi.org/10.1056/NEJMoa1503184			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CZ7SG	26699168	Green Published			2023-01-03	WOS:000367299700008
J	Tin, STW; Iro, G; Gadabu, E; Colagiuri, R				Tin, Si Thu Win; Iro, George; Gadabu, Eva; Colagiuri, Ruth			Counting the Cost of Diabetes in the Solomon Islands and Nauru	PLOS ONE			English	Article							CARE; PREVALENCE; PEOPLE; BURDEN	Aim To determine the costs associated with diabetes to governments, people with diabetes and their carers, and its impact on quality of life in two Pacific Island countries-the Solomon Islands and Nauru. Materials and Methods This cross-sectional cost of illness study was conducted on 330 people with type 2 diabetes (197 from the Solomon Islands and 133 from Nauru) using a structured cost of illness survey questionnaire adapted from the Australian DiabCo$t study. Quality of life was measured by the EQ-5D Visual Analogue Scale. Results There were 330 respondents (50% female; mean duration of diabetes 10.9 years; mean age 52.6 years). The estimated annual national cost of diabetes incurred by the Solomon Islands government was AUD12.8 million (AUD281 per person/year) and by Nauru government was AUD1.2 million (AUD747 per person/year). The major contribution to the government costs was inpatient services cost (71% in the Solomon Islands and 83% in Nauru). Annual expenditure for diabetes was approximately 20% of the governments' annual health care expenditure. Considerable absenteeism and retirement from work due to diabetes was found. Conclusions This study found substantial public and personal costs associated with diabetes. The findings provide objective data on which health policy, funding and planning decisions about the prevention and control of diabetes in the Solomon Islands and Nauru can be reliably based and subsequently evaluated.	[Tin, Si Thu Win] Univ Sydney, Boden Inst Obes Nutr Exercise & Eating Disorders, Sydney, NSW 2006, Australia; [Iro, George] Minist Hlth & Med Serv, Natl Diabet Ctr, Honiara, Solomon Islands; [Gadabu, Eva] Minist Hlth & Med Serv, Natl Diabet Ctr, Yaren, Nauru; [Tin, Si Thu Win; Colagiuri, Ruth] Univ Sydney, Menzies Ctr Hlth Policy, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Tin, STW (corresponding author), Univ Sydney, Boden Inst Obes Nutr Exercise & Eating Disorders, Sydney, NSW 2006, Australia.	si.wintin@sydney.edu.au			World Diabetes Foundation; Solomon Islands MHMS; Nauru MHMS; International Centre for Eyecare Education at the University of New South Wales and the Australia; New Zealand Society of Nephrologists	World Diabetes Foundation; Solomon Islands MHMS; Nauru MHMS; International Centre for Eyecare Education at the University of New South Wales and the Australia; New Zealand Society of Nephrologists	This study was conducted as part of a broader diabetes capacity building project in the Solomon Islands and Nauru funded by the World Diabetes Foundation (http://www.worlddiabetesfoundation.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was conducted as part of a broader World Diabetes Foundation funded project in partnership with the Solomon Islands MHMS, Nauru MHMS, the International Centre for Eyecare Education at the University of New South Wales and the Australia and New Zealand Society of Nephrologists.	Amer Diabet Assoc, 2013, DIABETES CARE, V36, P1033, DOI 10.2337/dc12-2625; [Anonymous], 2009, REP 2009 POP HOUS CE; [Anonymous], 2011, DIAB ATL; [Anonymous], 2011, SOL ISL GOV 2011 201; [Anonymous], 2011, NAT REP POP HOUS REP; [Anonymous], 2013, SOL ISL BUDG BUDG ST; [Anonymous], EUROQOL EQ 5D US GUI; Barcelo A, 2003, B WORLD HEALTH ORGAN, V81, P19; Bruno G, 2008, DIABETOLOGIA, V51, P795, DOI 10.1007/s00125-008-0957-4; Central Intelligence Agency, WORLD FACTBOOK; Clarke P, 2006, J DIABETES COMPLICAT, V20, P349, DOI 10.1016/j.jdiacomp.2005.08.004; Colagiuri R, 2006, PRACT DIAB INT, V23, P343; Colagiuri SCR, 2003, DIABCOST AUSTR ASSES; COLLINS VR, 1995, DIABETES CARE, V18, P1140, DOI 10.2337/diacare.18.8.1140; Dall TM, 2010, HEALTH AFFAIR, V29, DOI 10.1377/hlthaff.2009.0155; Doran C, 2003, EC ASS INP NCD COSTS; Falconer DG, 2010, DIABETES RES CLIN PR, V87, P92, DOI 10.1016/j.diabres.2009.09.022; Fu AZ, 2009, DIABETES CARE, V32, P2187, DOI 10.2337/dc09-1128; Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002; *INT DIAB FED, 2006, DIAB ATL; International diabetes federation, 2010, CALL ACT DIAB; International Diabetes Federation IDF, 2013, DIAB ATL; Javanbakht M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026864; Jonsson B, 2002, DIABETOLOGIA, V45, pS5, DOI 10.1007/s00125-002-0858-x; Khowaja LA, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-189; Koster I, 2006, DIABETOLOGIA, V49, P1498, DOI 10.1007/s00125-006-0277-5; Lee CMY, 2013, DIABETES RES CLIN PR, V99, P385, DOI 10.1016/j.diabres.2012.12.002; McBrien KA, 2013, DIABETES CARE, V36, P1172, DOI 10.2337/dc12-0862; Ministry of Health and Medical Services, 2010, STRAT PLAN REP NAUR; Petersen M, 2008, DIABETES CARE, V31, P1271, DOI 10.2337/dc08-9017; Shemilt I, 2010, EVID POLICY, V6, P51, DOI 10.1332/174426410X482999; Tin STW, 2014, DIABETES RES CLIN PR, V103, P114, DOI 10.1016/j.diabres.2013.09.017; Tin STW, 2013, DIABETES RES CLIN PR, V100, P230, DOI 10.1016/j.diabres.2013.03.012; *WHO, 2005, PREV CHR DIS VIT INV; World Bank, 2014, SKILLS SOL ISL OP NE; Yang WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039513; Zhang P, 2010, DIABETES RES CLIN PR, V87, P293, DOI 10.1016/j.diabres.2010.01.026	37	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2015	10	12							e0145603	10.1371/journal.pone.0145603	http://dx.doi.org/10.1371/journal.pone.0145603			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SI	26698575	Green Published, gold, Green Submitted			2023-01-03	WOS:000367092600103
J	Xu, XM; Cai, GY; Bu, R; Wang, WJ; Bai, XY; Sun, XF; Chen, XM				Xu, Xiao-meng; Cai, Guang-yan; Bu, Ru; Wang, Wen-juan; Bai, Xue-yuan; Sun, Xue-feng; Chen, Xiang-mei			Beneficial Effects of Caloric Restriction on Chronic Kidney Disease in Rodent Models: A Meta-Analysis and Systematic Review	PLOS ONE			English	Article							DIETARY RESTRICTION; LIFE-SPAN; RENAL-DISEASE; PROTEIN; RATS	Background Numerous studies have demonstrated the life-extending effect of caloric restriction. It is generally accepted that caloric restriction has health benefits, such as prolonging lifespan and delaying the onset and progression of CKD in various species, especially in rodent models. Although many studies have tested the efficacy of caloric restriction, no complete quantitative analysis of the potential beneficial effects of reducing caloric intake on the development and progression of CKD has been published. Methods All studies regarding the relationship between caloric restriction and chronic kidney diseases were searched in electronic databases, including PubMed/MEDLINE, EMBASE, Science Citation Index (SCI), OVID evidence-based medicine, Chinese Bio-medical Literature and Chinese science and technology periodicals (CNKI, VIP, and Wan Fang). The pooled odds ratios (OR) and 95% confidence intervals (95% CI) were calculated by using fixed- or random-effects models. Results The data from 27 of all the studies mentioned above was used in the Meta analysis. Through the meta-analysis, we found that the parameter of blood urea nitrogen, serum creatinine and urinary protein levels of the AL group was significant higher than that of the CR group, which are 4.11 mg/dl, 0.08mg/dl and 33.20mg/kg/24h, respectively. The incidence of the nephropathy in the caloric restriction (CR) group was significantly lower than that in the ad libitum-fed (AL) group. We further introduced the subgroup analysis and found that the effect of caloric restriction on the occurrence of kidney disease was only significant with prolonged intervention; the beneficial effects of CR on the 60%-caloric-restriction group were greater than on the less-than-60%-caloric-restriction group, and caloric restriction did not show obvious protective effects in genetically modified strains. Moreover, survival rate of the caloric restriction group is much higher than that of the ad libitum-fed (AL) group. Conclusions Our findings demonstrate for the first time that compared with the AL group, the caloric restriction indeed decreased urea nitrogen, creatinine, urine protein, incidence of kidney diseases and increased the survival rate on 700 similar to 800 days.	[Xu, Xiao-meng; Cai, Guang-yan; Bu, Ru; Wang, Wen-juan; Bai, Xue-yuan; Sun, Xue-feng; Chen, Xiang-mei] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Kidney Dis, Chinese PLA Inst Nephrol, Dept Nephrol,State Key Lab Kidney Dis, Beijing 100853, Peoples R China; [Xu, Xiao-meng; Wang, Wen-juan] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China	Chinese People's Liberation Army General Hospital; Nankai University	Cai, GY (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Kidney Dis, Chinese PLA Inst Nephrol, Dept Nephrol,State Key Lab Kidney Dis, Beijing 100853, Peoples R China.	caiguangyan@sina.com			Aging Biology of Individual and Organs and Risk Evaluation System of Geriatric Diseases; National Key Basic Research Program of China (973 Program) [2013CB530805]; Beijing Municipal Natural Science Foundation (CN) [81171645]	Aging Biology of Individual and Organs and Risk Evaluation System of Geriatric Diseases; National Key Basic Research Program of China (973 Program)(National Basic Research Program of China); Beijing Municipal Natural Science Foundation (CN)	This work was funded by Aging Biology of Individual and Organs and Risk Evaluation System of Geriatric Diseases, National Key Basic Research Program of China (973 Program), No. 2013CB530805 (to Prof. Cai Guangyan), and Beijing Municipal Natural Science Foundation (CN) 81171645. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	[Anonymous], 2008, HORMONES ATHENS; [Anonymous], 2009, AGING CELL, V8, P514, DOI [10.1111/j.1474-9726.2009.00497.x, DOI 10.1111/J.1474-9726.2009.00497.X]; [Anonymous], 2010, PHILOS T ROYAL SOC B, V365, P147; [Anonymous], 2009, AM J KIDNEY DIS, V53, P208, DOI [10.1053/j.ajkd.2008.08.009, DOI 10.1053/J.AJKD.2008.08.009]; [Anonymous], 1997, FASEB J, V11, P573; [Anonymous], 2003, AM J KIDNEY DIS OFFI, V41, P319; [Anonymous], 1995, J GERONTOL A, V50, pB337; [Anonymous], 2014, TRANSLATIONAL RES J, V164, P302; [Anonymous], 2004, STROKE, V35, P1203; [Anonymous], 2012, AGING CELL, V11, P401; [Anonymous], 2010, SCIENCE, V328, P321, DOI [10.1126/science.1172539, DOI 10.1126/SCIENCE.1172539]; [Anonymous], 2014, DIABETES METABOLISM, V40, P158; Bourg EL, 2010, AGEING RES REV, V9, P289, DOI [10.1016/j.arr.2010.01.001, DOI 10.1016/J.ARR.2010.01.001]; DAVIS TA, 1983, EXP GERONTOL, V18, P427, DOI 10.1016/0531-5565(83)90021-9; FD L M., 2009, COCHRANE DATABASE SY, V6; GUMPRECHT LA, 1993, TOXICOL PATHOL, V21, P528, DOI 10.1177/019262339302100602; Hong-mei A, 2008, J PRACTICAL MED TECH; Kilkenny C, 2010, VET CLIN PATHOL, V1, P27; LETO S, 1976, J GERONTOL, V31, P144, DOI 10.1093/geronj/31.2.144; LG H, 2004, J AM SOC NEPHROLOGY, V15, P1363; MASORO EJ, 1989, AM J CLIN NUTR, V49, P1217; Masoro EJ, 2005, MECH AGEING DEV, P126; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Mulder W J., 2001, Eur J Intern Med, V12, P86, DOI 10.1016/S0953-6205(01)00121-2; Partridge L, 2005, MECH AGEING DEV, V126, P911, DOI 10.1016/j.mad.2005.04.003; Phelan J, 2005, AGEING RES REV; Piper MDW, 2011, CELL METAB, V14, P154, DOI 10.1016/j.cmet.2011.06.013; Rigaud M, 2008, PAIN, V136, P188, DOI 10.1016/j.pain.2008.01.016; Soare A, 2014, DIABETES-METAB RES, V30, P41, DOI 10.1002/dmrr.2517; WE H, 2003, KIDNEY INT, V63, pS31	31	24	24	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2015	10	12							e0144442	10.1371/journal.pone.0144442	http://dx.doi.org/10.1371/journal.pone.0144442			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CZ4SH	26695411	gold, Green Published, Green Submitted			2023-01-03	WOS:000367092500004
J	Nichol, G; Leroux, B; Wang, H; Callaway, CW; Sopko, G; Weisfeldt, M; Stiell, I; Morrison, LJ; Aufderheide, TP; Cheskes, S; Christenson, J; Kudenchuk, P; Vaillancourt, C; Rea, TD; Idris, AH; Colella, R; Isaacs, M; Straight, R; Stephens, S; Richardson, J; Condle, J; Schmicker, RH; Egan, D; May, S; Ornato, JP				Nichol, Graham; Leroux, Brian; Wang, Henry; Callaway, Clifton W.; Sopko, George; Weisfeldt, Myron; Stiell, Ian; Morrison, Laurie J.; Aufderheide, Tom P.; Cheskes, Sheldon; Christenson, Jim; Kudenchuk, Peter; Vaillancourt, Christian; Rea, Thomas D.; Idris, Ahamed H.; Colella, Riccardo; Isaacs, Marshal; Straight, Ron; Stephens, Shannon; Richardson, Joe; Condle, Joe; Schmicker, Robert H.; Egan, Debra; May, Susanne; Ornato, Joseph P.		ROC Investigators	Trial of Continuous or Interrupted Chest Compressions during CPR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; EMERGENCY CARDIOVASCULAR CARE; HEART-ASSOCIATION GUIDELINES; CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; LAY RESCUERS; SURVIVAL; OUTCOMES; CATHETERIZATION; RATIONALE	BACKGROUND During cardiopulmonary resuscitation (CPR) in patients with out-of-hospital cardiac arrest, the interruption of manual chest compressions for rescue breathing reduces blood flow and possibly survival. We assessed whether outcomes after continuous compressions with positive-pressure ventilation differed from those after compressions that were interrupted for ventilations at a ratio of 30 compressions to two ventilations. METHODS This cluster-randomized trial with crossover included 114 emergency medical service (EMS) agencies. Adults with non-trauma-related cardiac arrest who were treated by EMS providers received continuous chest compressions (intervention group) or interrupted chest compressions (control group). The primary outcome was the rate of survival to hospital discharge. Secondary outcomes included the modified Rankin scale score (on a scale from 0 to 6, with a score of <= 3 indicating favorable neurologic function). CPR process was measured to assess compliance. RESULTS Of 23,711 patients included in the primary analysis, 12,653 were assigned to the intervention group and 11,058 to the control group. A total of 1129 of 12,613 patients with available data (9.0%) in the intervention group and 1072 of 11,035 with available data (9.7%) in the control group survived until discharge (difference, -0.7 percentage points; 95% confidence interval [CI], -1.5 to 0.1; P = 0.07); 7.0% of the patients in the intervention group and 7.7% of those in the control group survived with favorable neurologic function at discharge (difference, -0.6 percentage points; 95% CI, -1.4 to 0.1, P = 0.09). Hospital-free survival was significantly shorter in the intervention group than in the control group (mean difference, -0.2 days; 95% CI, -0.3 to -0.1; P = 0.004). CONCLUSIONS In patients with out-of-hospital cardiac arrest, continuous chest compressions during CPR performed by EMS providers did not result in significantly higher rates of survival or favorable neurologic function than did interrupted chest compressions. (Funded by the National Heart, Lung, and Blood Institute and others; ROC CCC ClinicalTrials.gov number, NCT01372748.)	[Nichol, Graham] Univ Washington, Harborview Ctr Prehospital Emergency Care, Seattle, WA 98195 USA; [Nichol, Graham; Leroux, Brian; Schmicker, Robert H.; May, Susanne] Clin Trial Ctr, Seattle, WA USA; [Kudenchuk, Peter; Rea, Thomas D.] Univ Washington, Seattle King Cty Ctr Resuscitat Res, Seattle, WA 98195 USA; [Wang, Henry; Stephens, Shannon] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; [Richardson, Joe] Birmingham Fire & Rescue Serv, Birmingham, AL USA; [Callaway, Clifton W.; Condle, Joe] Univ Pittsburgh, Pittsburgh Resuscitat Network, Pittsburgh, PA USA; [Sopko, George; Egan, Debra] NHLBI, Bethesda, MD 20892 USA; [Weisfeldt, Myron] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Stiell, Ian; Vaillancourt, Christian] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa Ontario Prehosp Adv Life Support Resuscita, Ottawa, ON, Canada; [Morrison, Laurie J.; Cheskes, Sheldon] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Christenson, Jim; Straight, Ron] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Aufderheide, Tom P.; Colella, Riccardo] Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; [Idris, Ahamed H.; Isaacs, Marshal] Univ Texas SW Med Ctr Dallas, Dallas Ft Worth Ctr Resuscitat Res, Dallas, TX 75390 USA; [Ornato, Joseph P.] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of British Columbia; Medical College of Wisconsin; University of Texas System; University of Texas Southwestern Medical Center Dallas; Virginia Commonwealth University	Nichol, G (corresponding author), Box 359727,325 Ninth Ave, Seattle, WA 98104 USA.	nichol@uw.edu	Christian, Michael/AAZ-4452-2020; Ferguson, Niall/D-7619-2019; McLeod, Shelley/AAE-9636-2019; Christian, Mike/AAO-6338-2020; Morrison, Laurie Jean/A-6325-2012; Cheskes, Sheldon/I-4456-2015; Nichol, Graham/Z-4996-2019; colella, riccardo/AAA-4306-2020; Welsford, Michelle/H-5535-2017	Christian, Michael/0000-0001-9644-9950; Ferguson, Niall/0000-0002-6213-5264; McLeod, Shelley/0000-0003-2686-6307; Christian, Mike/0000-0001-9644-9950; Morrison, Laurie Jean/0000-0001-8369-9774; Cheskes, Sheldon/0000-0001-7835-3074; colella, riccardo/0000-0001-9764-5179; Welsford, Michelle/0000-0003-2682-641X; Zelnick, Leila/0000-0002-8461-5111; MENA, JORGE/0000-0002-4421-2764; Guffey, Danielle/0000-0003-3721-614X; Gruen, Danielle/0000-0003-1019-4390; Stephens, Shannon/0000-0001-5898-5170	National Heart, Lung, and Blood Institute; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL077871, U01HL077867, U01HL077866, U01HL077872, U01HL077887, U01HL077885, U01HL077863, U01HL077881] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funded by the National Heart, Lung, and Blood Institute and others	Agarwal R, 2006, AM J RESP CRIT CARE, V174, P1055; Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Aufderheide TP, 2011, NEW ENGL J MED, V365, P798, DOI 10.1056/NEJMoa1010821; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Berg RA, 2000, CIRCULATION, V101, P1743; Berg RA, 2010, CIRCULATION, V122, pS685, DOI 10.1161/CIRCULATIONAHA.110.970939; Bobrow BJ, 2008, JAMA-J AM MED ASSOC, V299, P1158, DOI 10.1001/jama.299.10.1158; Bobrow BJ, 2010, JAMA-J AM MED ASSOC, V304, P1447, DOI 10.1001/jama.2010.1392; Bobrow BJ, 2009, ANN EMERG MED, V54, P656, DOI 10.1016/j.annemergmed.2009.06.011; Brown SP, 2015, AM HEART J, V169, P334, DOI 10.1016/j.ahj.2014.11.011; Callaway CW, 2014, RESUSCITATION, V85, P657, DOI 10.1016/j.resuscitation.2013.12.028; CAMPBELL JP, 1995, ANN EMERG MED, V26, P590, DOI 10.1016/S0196-0644(95)70009-9; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Garza AG, 2009, CIRCULATION, V119, P2597, DOI 10.1161/CIRCULATIONAHA.108.815621; Hollenbeck RD, 2014, RESUSCITATION, V85, P88, DOI 10.1016/j.resuscitation.2013.07.027; Hostler David, 2011, BMJ, V342, pd512, DOI 10.1136/bmj.d512; Huber P. J., 1967, PROCESSING 5 BERKELE; Kellum MJ, 2006, AM J MED, V119, P335, DOI 10.1016/j.amjmed.2005.11.014; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Kudenchuk PJ, 2014, AM HEART J, V167, P653, DOI 10.1016/j.ahj.2014.02.010; Link MS, 2010, CIRCULATION, V122, pS706, DOI 10.1161/CIRCULATIONAHA.110.970954; Little R. J., 2019, STAT ANAL MISSING DA, V793; Panchal AR, 2013, RESUSCITATION, V84, P435, DOI 10.1016/j.resuscitation.2012.07.038; Stiell IG, 2011, NEW ENGL J MED, V365, P787, DOI 10.1056/NEJMoa1010076; Strote JA, 2012, AM J CARDIOL, V109, P451, DOI 10.1016/j.amjcard.2011.09.036; Stub D, 2015, RESUSCITATION, V92, P45, DOI 10.1016/j.resuscitation.2015.04.015; Vaillancourt C, 2011, RESUSCITATION, V82, P1501, DOI 10.1016/j.resuscitation.2011.07.011; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526; Young P, 2014, RESUSCITATION, V85, P1686, DOI 10.1016/j.resuscitation.2014.09.011	32	186	191	1	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	2015	373	23					2203	2214		10.1056/NEJMoa1509139	http://dx.doi.org/10.1056/NEJMoa1509139			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX5LM	26550795	Bronze			2023-01-03	WOS:000365743100004
J	Pillay, J; Armstrong, MJ; Butalia, S; Donovan, LE; Sigal, RJ; Vandermeer, B; Chordiya, P; Dhakal, S; Hartling, L; Nuspl, M; Featherstone, R; Dryden, DM				Pillay, Jennifer; Armstrong, Marni J.; Butalia, Sonia; Donovan, Lois E.; Sigal, Ronald J.; Vandermeer, Ben; Chordiya, Pritam; Dhakal, Sanjaya; Hartling, Lisa; Nuspl, Megan; Featherstone, Robin; Dryden, Donna M.			Behavioral Programs for Type 2 Diabetes Mellitus A Systematic Review and Network Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							SELF-MANAGEMENT EDUCATION; RANDOMIZED CONTROLLED-TRIAL; AFRICAN-AMERICAN WOMEN; COMMUNITY-HEALTH WORKER; LIFE-STYLE INTERVENTION; QUALITY-OF-LIFE; WEIGHT-LOSS PROGRAM; GLYCEMIC CONTROL; MEXICAN-AMERICANS; PATIENT EDUCATION	Background: Behavioral programs may improve outcomes for individuals with type 2 diabetes mellitus, but there is a large diversity of behavioral interventions and uncertainty about how to optimize the effectiveness of these programs. Purpose: To identify factors moderating the effectiveness of behavioral programs for adults with type 2 diabetes. Data Sources: 6 databases (1993 to January 2015), conference proceedings (2011 to 2014), and reference lists. Study Selection: Duplicate screening and selection of 132 randomized, controlled trials evaluating behavioral programs compared with usual care, active controls, or other behavioral programs. Data Extraction: One reviewer extracted and another verified data. Two reviewers independently assessed risk of bias. Data Synthesis: Behavioral programs were grouped on the basis of program content and delivery methods. A Bayesian network meta-analysis showed that most lifestyle and diabetes self-management education and support programs (usually offering >= 11 contact hours) led to clinically important improvements in glycemic control (>= 0.4% reduction in hemoglobin A1c [HbA1c]), whereas most diabetes self-management education programs without added support-especially those offering 10 or fewer contact hours-provided little benefit. Programs with higher effect sizes were more often delivered in person than via technology. Lifestyle programs led to the greatest reductions in body mass index. Reductions in HbA1c seemed to be greater for participants with a baseline HbA1c level of 7.0% or greater, adults younger than 65 years, and minority persons (subgroups with >= 75% nonwhite participants). Limitations: All trials had medium or high risk of bias. Subgroup analyses were indirect, and therefore exploratory. Most outcomes were reported immediately after the interventions. Conclusion: Diabetes self-management education offering 10 or fewer hours of contact with delivery personnel provided little benefit. Behavioral programs seem to benefit persons with suboptimal or poor glycemic control more than those with good control.	Univ Alberta, Evidence Based Practice Ctr, Edmonton, AB T6G 1C9, Canada; [Pillay, Jennifer; Vandermeer, Ben; Chordiya, Pritam; Dhakal, Sanjaya; Hartling, Lisa; Nuspl, Megan; Featherstone, Robin; Dryden, Donna M.] Univ Alberta, Alberta Res Ctr Hlth Evidence, Dept Pediat, Edmonton Clin Hlth Acad, Edmonton, AB T6G 1C9, Canada; Alberta Hlth Serv, Calgary Zone, AB, Canada; [Armstrong, Marni J.; Butalia, Sonia; Donovan, Lois E.; Sigal, Ronald J.] Univ Calgary, Richmond Rd Diagnost & Treatment Ctr, Div Endocrinol & Metab, Calgary, AB T2T 5C7, Canada	University of Alberta; University of Alberta; Alberta Health Services (AHS); University of Calgary	Pillay, J (corresponding author), Univ Alberta, Alberta Res Ctr Hlth Evidence, Dept Pediat, Edmonton Clin Hlth Acad, 4th Floor,11405 87th Ave, Edmonton, AB T6G 1C9, Canada.	jpillay@ualberta.ca	Sigal, Ron/AAK-7627-2020; Sigal, Ronald/AAU-6081-2020; Featherstone, Robin/J-5165-2014	Featherstone, Robin/0000-0003-2517-2258; Butalia, Sonia/0000-0001-7865-9161	Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Agency for Healthcare Research and Quality. (PROSPERO registration number: CRD42014010515)	Adachi M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-467; AgursCollins TD, 1997, DIABETES CARE, V20, P1503, DOI 10.2337/diacare.20.10.1503; Amoako E, 2008, WESTERN J NURS RES, V30, P928, DOI 10.1177/0193945908320465; Anderson DR, 2010, J GEN INTERN MED, V25, P1116, DOI 10.1007/s11606-010-1419-5; ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943; Anderson RM, 2005, ETHNIC DIS, V15, P671; Anderson Robert M, 2009, Ther Patient Educ, V1, P3; Anderson-Loftin W, 2005, DIABETES EDUCATOR, V31, P555, DOI 10.1177/0145721705278948; [Anonymous], 2008, DIABETES EDUCATOR, V34, P445, DOI 10.1177/0145721708316625; Baksi AK, 2008, DIABETIC MED, V25, P1076, DOI 10.1111/j.1464-5491.2008.02542.x; Barratt R, 2008, BRIT J NUTR, V99, P1025, DOI 10.1017/S0007114507839018; Beverly EA, 2013, DIABETES EDUCATOR, V39, P504, DOI 10.1177/0145721713486837; Bond GE, 2007, DIABETES TECHNOL THE, V9, P52, DOI 10.1089/dia.2006.0057; Bozzetto L, 2014, ACTA DIABETOL, V51, P385, DOI 10.1007/s00592-013-0522-6; Bradshaw BG, 2007, DIABETES EDUCATOR, V33, P650, DOI 10.1177/0145721707303809; Brown SA, 2005, DIABETES CARE, V28, P527, DOI 10.2337/diacare.28.3.527; Brown SA, 2002, DIABETES CARE, V25, P259, DOI 10.2337/diacare.25.2.259; Brown SA, 2011, ETHNIC DIS, V21, P20; Castejon AM, 2013, J HEALTH CARE POOR U, V24, P48, DOI 10.1353/hpu.2014.0003; Centers for Disease Control and Prevention, 2014, NAT DIAB STAT REP; Chan JCN, 2014, JAMA INTERN MED, V174, P972, DOI 10.1001/jamainternmed.2014.655; Chan LS, 2012, DISS ABSTR INT B, V74, P4; Cheong SH, 2009, J AM DIET ASSOC, V109, P1411, DOI 10.1016/j.jada.2009.05.012; Chlebowy DO, 2015, WESTERN J NURS RES, V37, P566, DOI 10.1177/0193945914530522; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Clark M, 2004, BRIT J HEALTH PSYCH, V9, P365, DOI 10.1348/1359107041557066; Cooper H, 2008, DIABETES RES CLIN PR, V82, P165, DOI 10.1016/j.diabres.2008.07.013; Corkery E, 1997, DIABETES CARE, V20, P254, DOI 10.2337/diacare.20.3.254; Cramer JS, 2007, DIABETES EDUCATOR, V33, P503, DOI 10.1177/0145721707301680; Dall TM, 2010, HEALTH AFFAIR, V29, DOI 10.1377/hlthaff.2009.0155; Dasgupta K, 2006, DIABETES RES CLIN PR, V72, P53, DOI 10.1016/j.diabres.2005.09.010; Davis RM, 2010, DIABETES CARE, V33, P1712, DOI 10.2337/dc09-1919; Deakin TA, 2006, DIABETIC MED, V23, P944, DOI 10.1111/j.1464-5491.2006.01906.x; Duke SAS, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005268.pub2; Dunstan DW, 2005, DIABETES CARE, V28, P3, DOI 10.2337/diacare.28.1.3; Dunstan DW, 1997, DIABETES CARE, V20, P913, DOI 10.2337/diacare.20.6.913; Eakin EG, 2014, DIABETES CARE, V37, P2177, DOI 10.2337/dc13-2427; Edelman D, 2015, J GEN INTERN MED, V30, P626, DOI 10.1007/s11606-014-3154-9; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ellis SE, 2004, PATIENT EDUC COUNS, V52, P97, DOI 10.1016/S0738-3991(03)00016-8; Ettenhofer, 2002, AM J HLTH ED, V33, P161, DOI DOI 10.1080/19325037.2002.10604732; Fan LF, 2009, CAN J DIABETES, V33, P18, DOI 10.1016/S1499-2671(09)31005-9; Fisher L, 2013, DIABETES CARE, V36, P2551, DOI 10.2337/dc12-2493; Foster GD, 2013, NUTR DIABETES, V3, DOI 10.1038/nutd.2013.3; Foster GD, 2009, POSTGRAD MED, V121, P113, DOI 10.3810/pgm.2009.09.2046; Frosch DL, 2011, ARCH INTERN MED, V171, P2011, DOI 10.1001/archinternmed.2011.497; Funnell M, 2013, DIABETIC MED, V30, P765, DOI 10.1111/dme.12244; Gagliardino JJ, 2013, DIABETIC MED, V30, P1102, DOI 10.1111/dme.12230; Giannopoulou I, 2005, METABOLISM, V54, P866, DOI 10.1016/j.metabol.2005.01.033; Glasgow RE, 2006, AM J MANAG CARE, V12, P137; Glasgow RE, 2006, CHRONIC ILLN, V2, P27, DOI 10.1179/174592006X93851; Glasgow RE, 2012, PATIENT EDUC COUNS, V87, P81, DOI 10.1016/j.pec.2011.07.024; Glazier RH, 2006, DIABETES CARE, V29, P1675, DOI 10.2337/dc05-1942; Goudswaard AN, 2004, DIABETIC MED, V21, P491, DOI 10.1111/j.1464-5491.2004.01153.x; Hawkins SY, 2010, RES THEOR NURS PRACT, V24, P217, DOI 10.1891/1541-6577.24.4.217; Hemmingsen B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008143.pub3; Hendricks LE, 2000, DIABETES EDUCATOR, V26, P995, DOI 10.1177/014572170002600612; Hermanns N, 2012, PATIENT EDUC COUNS, V86, P226, DOI 10.1016/j.pec.2011.05.017; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hill-Briggs F, 2011, J GEN INTERN MED, V26, P972, DOI 10.1007/s11606-011-1689-6; Holmen H, 2014, JMIR MHEALTH UHEALTH, V2, DOI 10.2196/mhealth.3882; Huisman S, 2009, PATIENT EDUC COUNS, V75, P84, DOI 10.1016/j.pec.2008.09.027; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Ip S, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-15; Izquierdo RE, 2003, DIABETES CARE, V26, P1002, DOI 10.2337/diacare.26.4.1002; Johnson ST, 2009, DIABETES OBES METAB, V11, P836, DOI 10.1111/j.1463-1326.2009.01050.x; Jones H, 2003, DIABETES CARE, V26, P732, DOI 10.2337/diacare.26.3.732; Gagliardino JJ, 2013, DIABETES-METAB RES, V29, P152, DOI 10.1002/dmrr.2368; Keyserling TC, 2002, DIABETES CARE, V25, P1576, DOI 10.2337/diacare.25.9.1576; Kim MT, 2009, DIABETES EDUCATOR, V35, P986, DOI 10.1177/0145721709345774; Kim SH, 2006, METABOLISM, V55, P1053, DOI 10.1016/j.metabol.2006.03.017; Kim SH, 2014, CLIN ENDOCRINOL, V80, P825, DOI 10.1111/cen.12249; Knight KM, 2006, DIABETIC MED, V23, P485, DOI 10.1111/j.1464-5491.2005.01802.x; Koo BK, 2010, DIABETIC MED, V27, P1088, DOI 10.1111/j.1464-5491.2010.03045.x; Kulzer B, 2007, DIABETIC MED, V24, P415, DOI 10.1111/j.1464-5491.2007.02089.x; Lee A, 2011, POSTGRAD MED J, V87, P688, DOI 10.1136/pgmj.2011.118885; Lorig K, 2008, DIABETES CARE, V31, P408, DOI 10.2337/dc07-1313; Lorig K, 2010, DIABETES CARE, V33, P1275, DOI 10.2337/dc09-2153; Lorig K, 2009, DIABETES EDUCATOR, V35, P641, DOI 10.1177/0145721709335006; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lujan J, 2007, DIABETES EDUCATOR, V33, P660, DOI 10.1177/0145721707304080; Lynch EB, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.130349; Mandel SE, 2013, DIABETES EDUCATOR, V39, P568, DOI 10.1177/0145721713492216; Mayer-Davis EJ, 2004, AM J PUBLIC HEALTH, V94, P1736, DOI 10.2105/AJPH.94.10.1736; McGowan P, 2011, CAN J DIABETES, V35, P46, DOI 10.1016/S1499-2671(11)51008-1; Melkus GD, 2010, BIOL RES NURS, V12, P7, DOI 10.1177/1099800410369825; Miller CK, 2014, HEALTH EDUC BEHAV, V41, P145, DOI 10.1177/1090198113493092; Moher D, 2000, J CLIN EPIDEMIOL, V53, P964, DOI 10.1016/S0895-4356(00)00188-8; Moncrieft AE, 2014, DISS ABSTR INT B, V75, P1; Moriyama M, 2009, JPN J NURS SCI, V6, P51, DOI 10.1111/j.1742-7924.2009.00120.x; MUCHMORE DB, 1994, ACTA DIABETOL, V31, P215, DOI 10.1007/BF00571954; Murrock CJ, 2009, DIABETES EDUCATOR, V35, P995, DOI 10.1177/0145721709343322; Nam S, 2012, J CARDIOVASC NURS, V27, P505, DOI 10.1097/JCN.0b013e31822375a5; Nishita C, 2013, HEALTH EDUC BEHAV, V40, P581, DOI 10.1177/1090198112465088; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Norris SL, 2004, AM J MED, V117, P762, DOI 10.1016/j.amjmed.2004.05.024; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; Palmas W, 2014, DIABETES CARE, V37, P963, DOI 10.2337/dc13-2142; Philis-Tsimikas A, 2011, DIABETES CARE, V34, P1926, DOI 10.2337/dc10-2081; Pimouguet C, 2011, CAN MED ASSOC J, V183, pE115, DOI 10.1503/cmaj.091786; Plotnikoff RC, 2011, J PHYS ACT HEALTH, V8, P944, DOI 10.1123/jpah.8.7.944; Prezio EA, 2013, DIABETES RES CLIN PR, V100, P19, DOI 10.1016/j.diabres.2013.01.027; Reaney M, 2013, DIABETES SPECTR, V26, P236, DOI DOI 10.2337/DIASPECT.26.4.236; Revicki D, 2008, J CLIN EPIDEMIOL, V61, P102, DOI 10.1016/j.jclinepi.2007.03.012; Rickheim PL, 2002, DIABETES CARE, V25, P269, DOI 10.2337/diacare.25.2.269; Ridgeway NA, 1999, SOUTHERN MED J, V92, P667, DOI 10.1097/00007611-199907000-00004; Rock CL, 2014, DIABETES CARE, V37, P1573, DOI 10.2337/dc13-2900; Rosal MC, 2005, ANN BEHAV MED, V29, P225, DOI 10.1207/s15324796abm2903_9; Rosal MC, 2014, JMIR RES PROTOC, V3, DOI 10.2196/resprot.3412; Rosal MC, 2011, DIABETES CARE, V34, P838, DOI 10.2337/dc10-1981; Rothschild SK, 2014, AM J PUBLIC HEALTH, V104, P1540, DOI 10.2105/AJPH.2013.301439; Ruggiero L, 2014, WESTERN J NURS RES, V36, P1052, DOI 10.1177/0193945914522862; Ruggiero L, 2010, DIABETES EDUCATOR, V36, P127, DOI 10.1177/0145721709355487; Sacco WP, 2009, J BEHAV MED, V32, P349, DOI 10.1007/s10865-009-9209-4; Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037; Salinero-Fort MA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-267; Samuel-Hodge CD, 2009, DIABETES EDUCATOR, V35, P439, DOI 10.1177/0145721709333270; Sarkadi A, 2004, PATIENT EDUC COUNS, V53, P291, DOI 10.1016/j.pec.2003.10.009; Sevick MA, 2012, J ACAD NUTR DIET, V112, P1147, DOI 10.1016/j.jand.2012.05.008; Shibayama T, 2007, DIABETES RES CLIN PR, V76, P265, DOI 10.1016/j.diabres.2006.09.017; Sidik K, 2002, STAT MED, V21, P3153, DOI 10.1002/sim.1262; Sigurdardottir AK, 2009, J ADV NURS, V65, P2118, DOI 10.1111/j.1365-2648.2009.05040.x; Siminerio L, 2013, DIABETES EDUCATOR, V39, P705, DOI 10.1177/0145721713492570; Sinclair KA, 2013, ANN BEHAV MED, V45, P24, DOI 10.1007/s12160-012-9422-1; Sixta CS, 2008, DIABETES EDUCATOR, V34, P299, DOI 10.1177/0145721708314490; Skelly AH, 2005, APPL NURS RES, V18, P213, DOI 10.1016/j.apnr.2004.08.008; Skelly AH, 2009, NURS RES, V58, P410, DOI 10.1097/NNR.0b013e3181bee597; Smith DE, 1997, DIABETES CARE, V20, P52, DOI 10.2337/diacare.20.1.52; Sorkin DH, 2014, HEALTH PSYCHOL, V33, P566, DOI 10.1037/hea0000063; Spencer MS, 2011, AM J PUBLIC HEALTH, V101, P2253, DOI 10.2105/AJPH.2010.300106; Sperl-Hillen J, 2013, AM J MANAG CARE, V19, P104; Steed L, 2005, J HEALTH PSYCHOL, V10, P261, DOI 10.1177/1359105305049775; Sung K, 2012, NURS HEALTH SCI, V14, P438, DOI 10.1111/j.1442-2018.2012.00690.x; Tang TS, 2014, DIABETES CARE, V37, P1525, DOI 10.2337/dc13-2161; Thoolen B, 2007, DIABETES CARE, V30, P2832, DOI 10.2337/dc07-0777; Adolfsson ET, 2007, DIABETES RES CLIN PR, V76, P341, DOI 10.1016/j.diabres.2006.09.018; Toobert DJ, 2011, TRANSL BEHAV MED, V1, P416, DOI 10.1007/s13142-010-0011-1; Toobert DJ, 2003, DIABETES CARE, V26, P2288, DOI 10.2337/diacare.26.8.2288; Tricco AC, 2012, LANCET, V379, P2252, DOI 10.1016/S0140-6736(12)60480-2; Trief P, 2011, FAM SYST HEALTH, V29, P253, DOI 10.1037/a0024564; Tucker CM, 2014, J HEALTH CARE POOR U, V25, P292, DOI 10.1353/hpu.2014.0044; U.S. Department of Health and Human Services; U.S. Food and Drug Administration; Center for Drug Evaluation and Research, 2008, GUID IND DIAB MELL D; Utz SW, 2008, DIABETES EDUCATOR, V34, P854, DOI 10.1177/0145721708323642; Vadstrup ES, 2011, PATIENT EDUC COUNS, V84, P185, DOI 10.1016/j.pec.2010.06.031; Varney JE, 2014, INTERN MED J, V44, P890, DOI 10.1111/imj.12515; Vazquez IM, 1998, AM J HEALTH PROMOT, V13, P116, DOI 10.4278/0890-1171-13.2.116; Veroniki AA, 2013, INT J EPIDEMIOL, V42, P332, DOI 10.1093/ije/dys222; Vincent D, 2007, BIOL RES NURS, V9, P130, DOI 10.1177/1099800407304980; Walker EA, 2011, DIABETES CARE, V34, P2, DOI 10.2337/dc10-1005; Weinger K, 2011, ARCH INTERN MED, V171, P1990, DOI 10.1001/archinternmed.2011.502; Welch G, 2011, DIABETES RES CLIN PR, V91, P54, DOI 10.1016/j.diabres.2010.09.036; Welschen LMC, 2013, J BEHAV MED, V36, P556, DOI 10.1007/s10865-012-9451-z; West DS, 2007, DIABETES CARE, V30, P1081, DOI 10.2337/dc06-1966; WIERENGA ME, 1994, PATIENT EDUC COUNS, V23, P33; Wing R, 2013, NEW ENGL J MED, V369, P145, DOI 10.1056/NEJMoa1212914; Wolever RQ, 2010, DIABETES EDUCATOR, V36, P629, DOI 10.1177/0145721710371523; Wolf AM, 2004, DIABETES CARE, V27, P1570, DOI 10.2337/diacare.27.7.1570; Yoo JS, 2007, ASIAN NURS RES, V1, P106, DOI 10.1016/S1976-1317(08)60013-4; Yuan C, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/789761	159	139	140	0	51	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	2015	163	11					848	+		10.7326/M15-1400	http://dx.doi.org/10.7326/M15-1400			45	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CX7FB	26414227				2023-01-03	WOS:000365866500008
J	Adams, JU				Adams, Jill U.			Genetics: Big hopes for big data	NATURE			English	Editorial Material																		Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Liao S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0618-8	3	27	29	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	2015	527	7578					S108	S109		10.1038/527S108a	http://dx.doi.org/10.1038/527S108a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW9ZN	26580158	Bronze			2023-01-03	WOS:000365356800003
J	Benda, NMM; Seeger, JPH; Stevens, GGCF; Hijmans-Kersten, BTP; van Dijk, APJ; Bellersen, L; Lamfers, EJP; Hopman, MTE; Thijssen, DHJ				Benda, Nathalie M. M.; Seeger, Joost P. H.; Stevens, Guus G. C. F.; Hijmans-Kersten, Bregina T. P.; van Dijk, Arie P. J.; Bellersen, Louise; Lamfers, Evert J. P.; Hopman, Maria T. E.; Thijssen, Dick H. J.			Effects of High-Intensity Interval Training versus Continuous Training on Physical Fitness, Cardiovascular Function and Quality of Life in Heart Failure Patients	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; FLOW-MEDIATED DILATION; CHRONOTROPIC INCOMPETENCE; ENDOTHELIAL DYSFUNCTION; EXERCISE CAPACITY; HEALTHY-ADULTS; OXYGEN-UPTAKE; METAANALYSIS; REHABILITATION; HUMANS	Introduction Physical fitness is an important prognostic factor in heart failure (HF). To improve fitness, different types of exercise have been explored, with recent focus on high-intensity interval training (HIT). We comprehensively compared effects of HIT versus continuous training (CT) in HF patients NYHA II-III on physical fitness, cardiovascular function and structure, and quality of life, and hypothesize that HIT leads to superior improvements compared to CT. Methods Twenty HF patients (male: female 19: 1, 64 +/- 8 yrs, ejection fraction 38 +/- 6%) were allocated to 12-weeks of HIT (10*1-minute at 90% maximal workload-alternated by 2.5 minutes at 30% maximal workload) or CT (30 minutes at 60-75% of maximal workload). Before and after intervention, we examined physical fitness (incremental cycling test), cardiac function and structure (echocardiography), vascular function and structure (ultrasound) and quality of life (SF-36, Minnesota living with HF questionnaire (MLHFQ)). Results Training improved maximal workload, peak oxygen uptake (VO2peak) related to the predicted VO2peak, oxygen uptake at the anaerobic threshold, and maximal oxygen pulse (all P < 0.05), whilst no differences were present between HIT and CT (N.S.). We found no major changes in resting cardiovascular function and structure. SF-36 physical function score improved after training (P < 0.05), whilst SF-36 total score and MLHFQ did not change after training (N.S.). Conclusion Training induced significant improvements in parameters of physical fitness, although no evidence for superiority of HIT over CT was demonstrated. No major effect of training was found on cardiovascular structure and function or quality of life in HF patients NYHA II-III.	[Benda, Nathalie M. M.; Seeger, Joost P. H.; Stevens, Guus G. C. F.; Hijmans-Kersten, Bregina T. P.; Hopman, Maria T. E.; Thijssen, Dick H. J.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Physiol, Nijmegen, Netherlands; [van Dijk, Arie P. J.; Bellersen, Louise] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Cardiol, Nijmegen, Netherlands; [Lamfers, Evert J. P.] Canisius Wilhelmina Hosp, Dept Cardiol, Nijmegen, Netherlands; [Seeger, Joost P. H.; Thijssen, Dick H. J.] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Liverpool L3 5UX, Merseyside, England	Radboud University Nijmegen; Radboud University Nijmegen; Canisius-Wilhelmina Hospital; Liverpool John Moores University	Thijssen, DHJ (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Physiol, Nijmegen, Netherlands.	dick.thijssen@radboudumc.nl	Thijssen, Dick/D-3430-2009; Thijssen, Dick HJ/E-8731-2016; Stefanadis, Christodoulos/ABH-2232-2020; van Dijk, Arie/L-4272-2015; Hopman, Maria/A-4205-2014	Thijssen, Dick HJ/0000-0002-7707-5567; Stefanadis, Christodoulos/0000-0001-5974-6454; van Dijk, Arie/0000-0002-7843-8251; Lamfers, Evert/0000-0002-5582-3720	Netherlands Heart Foundation [2009T064]	Netherlands Heart Foundation(Netherlands Heart Foundation)	DHJT is financially supported by the Netherlands Heart Foundation (E Dekker-stipend, 2009T064).	Aksoy S, 2015, AM J PHYS MED REHABI; Arena R, 2013, HEART FAIL REV, V18, P95, DOI 10.1007/s10741-012-9333-z; Atkinson G, 2013, ATHEROSCLEROSIS, V226, P425, DOI 10.1016/j.atherosclerosis.2012.11.027; Barbour KA, 2008, HEART FAIL REV, V13, P81, DOI 10.1007/s10741-007-9054-x; BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020, DOI 10.1152/jappl.1986.60.6.2020; Belardinelli R, 2012, J AM COLL CARDIOL, V60, P1521, DOI 10.1016/j.jacc.2012.06.036; Benda NM, 2015, EXP PHYSL; Bleumink GS, 2004, EUR HEART J, V25, P1614, DOI 10.1016/j.ehj.2004.06.038; BORG G, 1987, EUR J APPL PHYSIOL O, V56, P679, DOI 10.1007/BF00424810; Bouchard C, 1999, J APPL PHYSIOL, V87, P1003, DOI 10.1152/jappl.1999.87.3.1003; Briasoulis Alexandros, 2012, Recent Pat Cardiovasc Drug Discov, V7, P21; Buchheit M, 2013, SPORTS MED, V43, P313, DOI 10.1007/s40279-013-0029-x; Cahalin LP, 2013, HEART FAIL REV, V18, P79, DOI 10.1007/s10741-012-9332-0; Chrysohoou C, 2014, QJM-INT J MED, V107, P25, DOI 10.1093/qjmed/hct194; de Groot E, 2004, CIRCULATION, V109, P33, DOI 10.1161/01.CIR.0000131516.65699.ba; Dimopoulos S, 2006, EUR J CARDIOV PREV R, V13, P67, DOI 10.1097/00149831-200602000-00010; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; Fletcher GF, 2013, CIRCULATION, V128, P873, DOI 10.1161/CIR.0b013e31829b5b44; Fu TC, 2013, INT J CARDIOL, V167, P41, DOI 10.1016/j.ijcard.2011.11.086; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Green DJ, 2014, J APPL PHYSIOL, V117, P345, DOI 10.1152/japplphysiol.00354.2014; Hambrecht R, 2000, J AM COLL CARDIOL, V35, P706, DOI 10.1016/S0735-1097(99)00602-6; Haykowsky MJ, 2007, J AM COLL CARDIOL, V49, P2329, DOI 10.1016/j.jacc.2007.02.055; Haykowsky MJ, 2013, AM J CARDIOL, V111, P1466, DOI 10.1016/j.amjcard.2013.01.303; Hobbs FDR, 2002, EUR HEART J, V23, P1867, DOI 10.1053/euhj.2002.3255; Iellamo F, 2014, INTERN EMERG MED, V9, P547, DOI 10.1007/s11739-013-0980-4; Iellamo F, 2013, INT J CARDIOL, V167, P2561, DOI 10.1016/j.ijcard.2012.06.057; Ismail H, 2013, JACC-HEART FAIL, V1, P514, DOI 10.1016/j.jchf.2013.08.006; Kemps HM, 2008, AM J CARDIOL, V102, P1073, DOI 10.1016/j.amjcard.2008.05.054; Koufaki P, 2014, J REHABIL MED, V46, P348, DOI 10.2340/16501977-1278; Koukoui F, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000544; Lavie CJ, 2015, CIRC RES, V117, P207, DOI 10.1161/CIRCRESAHA.117.305205; Lavie CJ, 2013, J HEART LUNG TRANSPL, V32, P1056, DOI 10.1016/j.healun.2013.08.001; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Linke A, 2001, J AM COLL CARDIOL, V37, P392, DOI 10.1016/S0735-1097(00)01108-6; McCullough PA, 2002, J AM COLL CARDIOL, V39, P60, DOI 10.1016/S0735-1097(01)01700-4; Meyer K, 1997, AM J CARDIOL, V80, P56, DOI 10.1016/S0002-9149(97)00283-X; Myers J, 1998, ANN INTERN MED, V129, P286, DOI 10.7326/0003-4819-129-4-199808150-00004; Naylor LH, 2005, J APPL PHYSIOL, V98, P2311, DOI 10.1152/japplphysiol.01047.2004; Nilsson BB, 2008, AM J CARDIOL, V102, P1361, DOI 10.1016/j.amjcard.2008.07.016; Norton K, 2010, J SCI MED SPORT, V13, P496, DOI 10.1016/j.jsams.2009.09.008; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Piepoli MF, 2011, EUR J HEART FAIL, V13, P347, DOI 10.1093/eurjhf/hfr017; Ramos JS, 2015, SPORTS MED, V45, P679, DOI 10.1007/s40279-015-0321-z; RECTOR TS, 1992, AM HEART J, V124, P1017, DOI 10.1016/0002-8703(92)90986-6; Roditis P, 2007, EUR J CARDIOV PREV R, V14, P304, DOI 10.1097/HJR.0b013e32808621a3; Schmid JP, 2013, EUR J PREV CARDIOL, V20, P585, DOI 10.1177/2047487312444368; Schreuder THA, 2014, HIGH ALT MED BIOL, V15, P349, DOI 10.1089/ham.2013.1144; Skaug EA, 2013, EUR J PREV CARDIOL, V20, P531, DOI 10.1177/2047487312444234; Smart NA, 2013, INT J CARDIOL, V166, P352, DOI 10.1016/j.ijcard.2011.10.075; Swank AM, 2012, CIRC-HEART FAIL, V5, P579, DOI 10.1161/CIRCHEARTFAILURE.111.965186; Taylor RS, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003331.pub4; Thijssen DHJ, 2011, AM J PHYSIOL-HEART C, V300, pH2, DOI 10.1152/ajpheart.00471.2010; van Tol BAF, 2006, EUR J HEART FAIL, V8, P841, DOI 10.1016/j.ejheart.2006.02.013; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wasserman K., 1987, PRINCIPLES EXERCISE; Wisloff U, 2007, CIRCULATION, V115, P3086, DOI 10.1161/CIRCULATIONAHA.106.675041; Witte KKA, 2006, HEART, V92, P481, DOI 10.1136/hrt.2004.058073; Zarrinkoub R, 2013, EUR J HEART FAIL, V15, P995, DOI 10.1093/eurjhf/hft064	59	40	46	1	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2015	10	10							e0141256	10.1371/journal.pone.0141256	http://dx.doi.org/10.1371/journal.pone.0141256			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV0EH	26517867	Green Submitted, Green Published, gold			2023-01-03	WOS:000363920800030
J	Gernand, AD; Schulze, KJ; Nanayakkara-Bind, A; Arguello, M; Shamim, AA; Ali, H; Wu, L; West, KP; Christian, P				Gernand, Alison D.; Schulze, Kerry J.; Nanayakkara-Bind, Ashika; Arguello, Margia; Shamim, Abu Ahmed; Ali, Hasmot; Wu, Lee; West, Keith P., Jr.; Christian, Parul			Effects of Prenatal Multiple Micronutrient Supplementation on Fetal Growth Factors: A Cluster-Randomized, Controlled Trial in Rural Bangladesh	PLOS ONE			English	Article							PLACENTAL-LACTOGEN EXPRESSION; BIRTH-WEIGHT; IGF-I; PREGNANCY; OUTCOMES; ACID; ZINC	Prenatal multiple micronutrient (MM) supplementation improves birth weight through increased fetal growth and gestational age, but whether maternal or fetal growth factors are involved is unclear. Our objective was to examine the effect of prenatal MM supplementation on intrauterine growth factors and the associations between growth factors and birth outcomes in a rural setting in Bangladesh. In a double-blind, cluster-randomized, controlled trial of MM vs. iron and folic acid (IFA) supplementation, we measured placental growth hormone (PGH) at 10 weeks and PGH and human placental lactogen (hPL) at 32 weeks gestation in maternal plasma (n = 396) and insulin, insulin-like growth factor-1 (IGF-1), and IGF binding protein-1 (IGFBP-1) in cord plasma (n = 325). Birth size and gestational age were also assessed. Early pregnancy mean (SD) BMI was 19.5 (2.4) kg/m(2) and birth weight was 2.68 (0.41) kg. There was no effect of MM on concentrations of maternal hPL or PGH, or cord insulin, IGF-1, or IGFBP-1. However, among pregnancies of female offspring, hPL concentration was higher by 1.1 mg/L in the third trimester (95% CI: 0.2, 2.0 mg/L; p = 0.09 for interaction); and among women with height < 145 cm, insulin was higher by 59% (95% CI: 3, 115%; p = 0.05 for interaction) in the MM vs. IFA group. Maternal hPL and cord blood insulin and IGF-1 were positively, and IGFBP-1 was negatively, associated with birth weight z score and other measures of birth size (all p < 0.05). IGF-1 was inversely associated with gestational age (p < 0.05), but other growth factors were not associated with gestational age or preterm birth. Prenatal MM supplementation had no overall impact on intrauterine growth factors. MM supplementation altered some growth factors differentially by maternal early pregnancy nutritional status and sex of the offspring, but this should be examined in other studies.	[Gernand, Alison D.; Schulze, Kerry J.; Nanayakkara-Bind, Ashika; Arguello, Margia; Wu, Lee; West, Keith P., Jr.; Christian, Parul] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Human Nutr, Baltimore, MD 21205 USA; [Gernand, Alison D.] Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA; [Shamim, Abu Ahmed; Ali, Hasmot] JiVitA Project, Gaibandha, Bangladesh	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Christian, P (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Human Nutr, Baltimore, MD 21205 USA.	pchristi@jhsph.edu	Gernand, Alison/W-8158-2019; Ali, Hasmot/I-8700-2019	Gernand, Alison/0000-0002-5661-7785; Ali, Hasmot/0000-0003-0044-1992; Abu Ahmed, Shamim/0000-0002-7071-8558	Bill and Melinda Gates Foundation, Seattle, WA, USA [GHOPP614]; Thrasher Research Fund [9179]; Sight and Life Research Institute, Baltimore, MD; National Institutes of Health [T32HD046405]; Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH [K12HD055882]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055882] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD046405] Funding Source: NIH RePORTER	Bill and Melinda Gates Foundation, Seattle, WA, USA(Bill & Melinda Gates Foundation); Thrasher Research Fund; Sight and Life Research Institute, Baltimore, MD; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The parent trial and field data collection for the substudy was funded through Grant GHOPP614 (Global Control of Micronutrient Deficiency) from the Bill and Melinda Gates Foundation, Seattle, WA, USA (http://www.gatesfoundation.org/). The laboratory study and analysis of maternal and fetal growth factors was funded by Thrasher Research Fund grant award 9179 (https://www.thrasherresearch.org/default.aspx). DSM N.V., Kaiseraugst Switzerland provided micronutrient premixes and tested supplement potency throughout the trial gratis. Beximco Pharmaceuticals, Ltd, Dhaka produced, bottled, labeled and delivered to the field site gratis. Additional support was received from the Sight and Life Research Institute, Baltimore, MD. National Institutes of Health grant T32HD046405 provided doctoral support to ADG. Dr. Gernand's research is supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH under BIRCWH award number K12HD055882, "Career Development Program in Women's Health Research at Penn State." The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akram SK, 2008, ACTA PAEDIATR, V97, P1443, DOI 10.1111/j.1651-2227.2008.00930.x; Ameri P, 2013, CLIN ENDOCRINOL, V79, P457, DOI 10.1111/cen.12268; Boyne MS, 2003, J CLIN ENDOCR METAB, V88, P1687, DOI 10.1210/jc.2002-020633; Chimienti F, 2013, NUTR RES REV, V26, P1, DOI 10.1017/S0954422412000212; Christian P, 2010, ANNU REV NUTR, V30, P83, DOI 10.1146/annurev.nutr.012809.104813; Eriksson JG, 2010, AM J HUM BIOL, V22, P330, DOI 10.1002/ajhb.20995; Fall CHD, 2009, FOOD NUTR BULL, V30, pS533, DOI 10.1177/15648265090304S408; Fuglsang J, 2006, GROWTH HORM IGF RES, V16, P67, DOI 10.1016/j.ghir.2006.03.010; Gernand AD, 2013, AM J CLIN NUTR, V98, P383, DOI 10.3945/ajcn.112.055426; Gernand AD, 2012, J NUTR, V142, P2010, DOI 10.3945/jn.112.163634; Gernand AD, 2012, J NUTR, V142, P1109, DOI 10.3945/jn.111.155978; Gluckman PD, 2003, J NUTR, V133, p1741S, DOI 10.1093/jn/133.5.1741S; Gray B, 2011, NUTR REV, V69, P155, DOI 10.1111/j.1753-4887.2011.00377.x; Haider BA, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004905.pub3; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; Lee ACC, 2013, LANCET GLOB HEALTH, V1, pE26, DOI 10.1016/S2214-109X(13)70006-8; MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S; MIRLESSE V, 1993, PEDIATR RES, V34, P439, DOI 10.1203/00006450-199310000-00011; Moller UK, 2013, OSTEOPOROSIS INT, V24, P1307, DOI 10.1007/s00198-012-2062-2; Murphy VE, 2006, ENDOCR REV, V27, P141, DOI 10.1210/er.2005-0011; Ong S, 2000, BEST PRACT RES CL OB, V14, P969, DOI 10.1053/beog.2000.0138; Ozaki T, 2001, J PHYSIOL-LONDON, V530, P141, DOI 10.1111/j.1469-7793.2001.0141m.x; Ramakrishnan U, 2012, PAEDIATR PERINAT EP, V26, P153, DOI 10.1111/j.1365-3016.2012.01276.x; Ravelli ACJ, 1999, AM J CLIN NUTR, V70, P811; Roberfroid D, 2010, AM J CLIN NUTR, V91, P1649, DOI 10.3945/ajcn.2009.28855; STEPHANOU A, 1995, ENDOCRINOLOGY, V136, P933, DOI 10.1210/en.136.3.933; STEPHANOU A, 1994, ENDOCRINOLOGY, V135, P2651, DOI 10.1210/en.135.6.2651; UNICEF/ WHO/UNU, 1999, COMP MULT SUPPL BE U; Watson CS, 2006, ENDOCRINOLOGY, V147, P1175, DOI 10.1210/en.2005-0606; West KP, 2014, JAMA-J AM MED ASSOC, V312, P2649, DOI 10.1001/jama.2014.16819	30	10	10	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2015	10	10							e0137269	10.1371/journal.pone.0137269	http://dx.doi.org/10.1371/journal.pone.0137269			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6HH	26431336	Green Published, gold, Green Submitted			2023-01-03	WOS:000362178700007
J	Chochinov, HM; Johnston, W; McClement, SE; Hack, TF; Dufault, B; Enns, M; Thompson, G; Harlos, M; Damant, RW; Ramsey, CD; Davison, S; Zacharias, J; Milke, D; Strang, D; Campbell-Enns, HJ; Kredentser, MS				Chochinov, Harvey Max; Johnston, Wendy; McClement, Susan E.; Hack, Thomas F.; Dufault, Brenden; Enns, Murray; Thompson, Genevieve; Harlos, Mike; Damant, Ronald W.; Ramsey, Clare D.; Davison, Sara; Zacharias, James; Milke, Doris; Strang, David; Campbell-Enns, Heather J.; Kredentser, Maia S.			Dignity and Distress towards the End of Life across Four Non-Cancer Populations	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; PALLIATIVE CARE NEEDS; ADVANCED CANCER; SYMPTOM BURDEN; TERMINALLY-ILL; OF-LIFE; PERSPECTIVE; INVENTORY; DYSPNEA; HOPE	Objective The purpose of this study was to identify four non-cancer populations that might benefit from a palliative approach; and describe and compare the prevalence and patterns of dignity related distress across these diverse clinical populations. Design A prospective, multi-site approach was used. Setting Outpatient clinics, inpatient facilities or personal care homes, located in Winnipeg, Manitoba and Edmonton, Alberta, Canada. Participants Patients with advanced Amyotrophic Lateral Sclerosis (ALS), Chronic Obstructive Pulmonary Disease (COPD), End Stage Renal Disease (ESRD); and the institutionalized alert frail elderly. Main Outcome Measure In addition to standardized measures of physical, psychological and spiritual aspects of patient experience, the Patient Dignity Inventory (PDI). Results Between February 2009 and December 2012, 404 participants were recruited (ALS, 101; COPD, 100; ESRD, 101; and frail elderly, 102). Depending on group designation, 35% to 58% died within one year of taking part in the study. While moderate to severe loss of sense of dignity did not differ significantly across the four study populations (4-11%), the number of PDI items reported as problematic was significantly different i.e. ALS 6.2 (5.2), COPD 5.6 (5.9), frail elderly 3.0 (4.4) and ESRD 2.3 (3.9) [p < .0001]. Each of the study populations also revealed unique and distinct patterns of physical, psychological and existential distress. Conclusion People with ALS, COPD, ESRD and the frail elderly face unique challenges as they move towards the end of life. Knowing the intricacies of distress and how they differ across these groups broadens our understanding of end-of-life experience within non-cancer populations and how best to meet their palliative care needs.	[Chochinov, Harvey Max; Enns, Murray] Univ Manitoba, Coll Med, Fac Hlth Sci, Dept Psychiat, Winnipeg, MB, Canada; [Chochinov, Harvey Max; McClement, Susan E.; Thompson, Genevieve; Campbell-Enns, Heather J.; Kredentser, Maia S.] CancerCare Manitoba, Manitoba Palliat Care Res Unit, Winnipeg, MB, Canada; [Johnston, Wendy] Univ Alberta, Fac Med, Dept Med, Neurol, Edmonton, AB, Canada; [McClement, Susan E.; Hack, Thomas F.; Thompson, Genevieve] Univ Manitoba, Fac Hlth Sci, Coll Nursing, Winnipeg, MB, Canada; [Dufault, Brenden] Univ Manitoba, Dept Community Hlth Sci, George & Fay Yee Ctr Healthcare Innovat, Winnipeg, MB R3T 2N2, Canada; [Harlos, Mike] Winnipeg Reg Hlth Author, Palliat Care Program, Winnipeg, MB, Canada; [Damant, Ronald W.] Univ Alberta, Div Pulm Med, Edmonton, AB, Canada; [Ramsey, Clare D.] Univ Manitoba, Fac Hlth Sci, Coll Med, Dept Internal Med, Winnipeg, MB, Canada; [Ramsey, Clare D.; Zacharias, James] Univ Manitoba, Community Hlth Sci, Winnipeg, MB, Canada; [Davison, Sara] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Zacharias, James] Univ Manitoba, Fac Hlth Sci, Coll Med, Nephrol Sect, Winnipeg, MB, Canada; [Milke, Doris] CapitalCare, Edmonton, AB, Canada; [Milke, Doris] Univ Alberta, Fac Nursing, Edmonton, AB, Canada; [Milke, Doris] Univ Alberta, Dept Psychol, Edmonton, AB, Canada; [Strang, David] Univ Manitoba, Geriatr Med, Winnipeg, MB, Canada; [Strang, David] Winnipeg Reg Hlth Author, Geriatr Program, Winnipeg, MB, Canada; [Campbell-Enns, Heather J.] Univ Manitoba, Fac Grad Studies, Fac Hlth Sci, Interdisciplinary Canc Control, Winnipeg, MB, Canada; [Kredentser, Maia S.] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; CancerCare Manitoba Foundation; University of Alberta; University of Manitoba; University of Manitoba; University of Alberta; University of Manitoba; University of Manitoba; University of Alberta; University of Manitoba; University of Alberta; University of Alberta; University of Manitoba; University of Manitoba; University of Manitoba	Chochinov, HM (corresponding author), Univ Manitoba, Coll Med, Fac Hlth Sci, Dept Psychiat, Winnipeg, MB, Canada.; Chochinov, HM (corresponding author), CancerCare Manitoba, Manitoba Palliat Care Res Unit, Winnipeg, MB, Canada.	hchochinov@cancercare.mb.ca	Johnston, Wendy S/E-2491-2013; McClement, Susan E/H-7031-2016	Johnston, Wendy S/0000-0002-4330-5563; McClement, Susan E/0000-0002-9537-9900; Enns, Murray/0000-0002-8375-0151; Zacharias, James/0000-0002-4887-5338; Campbell-Enns, Heather J./0000-0002-9920-5254; Thompson, Genevieve/0000-0003-2558-9926; Chochinov, Harvey/0000-0003-2656-4704	Canadian Institutes for Health Research [93640]	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR))	Funding provided by Canadian Institutes for Health Research, http://www.cihr-irsc.gc.ca, Grant # 93640. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albers G, 2013, J PALLIAT MED, V16, P1108, DOI 10.1089/jpm.2012.0307; BENGTSON VL, 1977, J GERONTOL, V32, P76, DOI 10.1093/geronj/32.1.76; Benzein E, 2001, PALLIATIVE MED, V15, P117, DOI 10.1191/026921601675617254; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Chochinov HM, 2012, J PALLIAT MED, V15, P998, DOI 10.1089/jpm.2012.0066; Chochinov HM, 2009, J PAIN SYMPTOM MANAG, V38, P641, DOI 10.1016/j.jpainsymman.2009.04.021; Chochinov HM, 2008, J PAIN SYMPTOM MANAG, V36, P559, DOI 10.1016/j.jpainsymman.2007.12.018; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; Chochinov HM, 2004, J CLIN ONCOL, V22, P1336, DOI 10.1200/JCO.2004.12.095; Chochinov HM, 2002, SOC SCI MED, V54, P433, DOI 10.1016/S0277-9536(01)00084-3; Cohen J., 2013, STAT POWER ANAL BEHA; Cohen LM, 2007, J PALLIAT MED, V10, P1262, DOI 10.1089/jpm.2007.0054; Cohen LM, 2003, JAMA-J AM MED ASSOC, V289, P2113, DOI 10.1001/jama.289.16.2113; Cohen LM, 2002, PSYCHOSOM MED, V64, P889, DOI 10.1097/01.PSY.0000028828.64279.84; Davison SN, 2010, CLIN J AM SOC NEPHRO, V5, P195, DOI 10.2215/CJN.05960809; Davison SN, 2014, BMJ SUPPORT PALLIAT; DUFAULT K, 1985, NURS CLIN N AM, V20, P379; Edmonds P, 2001, PALLIATIVE MED, V15, P287, DOI 10.1191/026921601678320278; Elkington H, 2005, PALLIATIVE MED, V19, P485, DOI 10.1191/0269216305pm1056oa; Fitzsimons D, 2007, PALLIATIVE MED, V21, P313, DOI 10.1177/0269216307077711; Gesser G., 1988, OMEGA, V18, P113, DOI DOI 10.2190/0DQB-7Q1E-2BER-H6YC; Gott M, 2009, PALLIATIVE MED, V23, P642, DOI 10.1177/0269216309106790; Hall S, 2013, PSYCHO-ONCOLOGY, V22, P1748, DOI 10.1002/pon.3206; Hall S, 2012, PALLIATIVE MED, V26, P703, DOI 10.1177/0269216311418145; HERTH K, 1992, J ADV NURS, V17, P1251, DOI 10.1111/j.1365-2648.1992.tb01843.x; Johnston B, 2012, INT J PALLIAT NURS, V18, P483, DOI 10.12968/ijpn.2012.18.10.483; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P94, DOI DOI 10.1001/JAMA.1963.03060120024016; Kimmel PL, 2003, AM J KIDNEY DIS, V42, P713, DOI 10.1016/S0272-6386(03)00907-7; Luddington L, 2001, Int J Palliat Nurs, V7, P221; Maessen M, 2010, J NEUROL, V257, P1192, DOI 10.1007/s00415-010-5474-y; McCarthy EP, 2000, J AM GERIATR SOC, V48, pS110, DOI 10.1111/j.1532-5415.2000.tb03120.x; McIlfatrick S, 2007, J ADV NURS, V57, P77, DOI 10.1111/j.1365-2648.2006.04062.x; McVey P, 2014, HEALTH SOC CARE COMM, V22, P197, DOI 10.1111/hsc.12077; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Murray AM, 2006, CLIN J AM SOC NEPHRO, V1, P1248, DOI 10.2215/CJN.00970306; Neimeyer RA, 1995, DYING FACING FACTS; Neuman A, 2006, RESP MED, V100, P1843, DOI 10.1016/j.rmed.2006.01.016; O'Donnell Denis E, 2007, Proc Am Thorac Soc, V4, P145, DOI 10.1513/pats.200611-159CC; Oechsle K, 2014, J PAIN SYMPTOM MANAG, V48, P313, DOI 10.1016/j.jpainsymman.2013.10.022; Pinnock H, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d142; Reynolds Kimberly, 2002, J Palliat Med, V5, P895, DOI 10.1089/10966210260499087; Sautier LP, 2014, J PAIN SYMPTOM MANAG, V47, P181, DOI 10.1016/j.jpainsymman.2013.02.023; Skilbeck JK, 2005, J ADV NURS, V51, P325, DOI 10.1111/j.1365-2648.2005.03503.x; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Tamura Keiko, 2006, Palliat Support Care, V4, P189; Thompson Genevieve N, 2008, Curr Opin Support Palliat Care, V2, P49, DOI 10.1097/SPC.0b013e3282f4cb15; Thorson J.A., 2000, DEATH ATTITUDES OLDE, P123, DOI DOI 10.1108/09534810210449550; Vehling S, 2014, PSYCHO-ONCOLOGY, V23, P283, DOI 10.1002/pon.3417; von Leupoldt A, 2013, CURR OPIN PSYCHIATR, V26, P458, DOI 10.1097/YCO.0b013e328363c1fc; Watanabe SM, 2011, J PAIN SYMPTOM MANAG, V41, P456, DOI 10.1016/j.jpainsymman.2010.04.020; Wilson KG, 2004, CAN J PSYCHIAT, V49, P350, DOI 10.1177/070674370404900603; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	54	58	60	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0147607	10.1371/journal.pone.0147607	http://dx.doi.org/10.1371/journal.pone.0147607			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DC9FZ	26808530	Green Published, gold			2023-01-03	WOS:000369527800148
J	Podolsky, SH; Kesselheim, AS				Podolsky, Scott H.; Kesselheim, Aaron S.			Regulating Homeopathic Products - A Century of Dilute Interest	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Podolsky, Scott H.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA; [Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, PORTAL, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Podolsky, SH (corresponding author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA.							Haller J., 2009, HIST AM HOMEOPATHY R	1	7	7	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	2016	374	3					201	203		10.1056/NEJMp1513393	http://dx.doi.org/10.1056/NEJMp1513393			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DB3IS	26789866	Bronze			2023-01-03	WOS:000368404800002
J	Hirsch, M; Carli, P; Nizard, R; Riou, B; Baroudjian, B; Baubet, T; Chhor, V; Chollet-Xemard, C; Dantchev, N; Fleury, N; Fontaine, JP; Yordanov, Y; Raphael, M; Burtz, CP; Lafont, A				Hirsch, Martin; Carli, Pierre; Nizard, Remy; Riou, Bruno; Baroudjian, Barouyr; Baubet, Thierry; Chhor, Vibol; Chollet-Xemard, Charlotte; Dantchev, Nicolas; Fleury, Nadia; Fontaine, Jean-Paul; Yordanov, Youri; Raphael, Maurice; Burtz, Catherine Paugam; Lafont, Antoine		Hlth Professionals Assistance	The medical response to multisite terrorist attacks in Paris	LANCET			English	Editorial Material							DAMAGE CONTROL; RESUSCITATION		[Hirsch, Martin] AP HP, Paris, France; [Carli, Pierre] Univ Paris 05, Hop Necker Enfants Malad, SAMU Paris, Paris, France; [Nizard, Remy] Univ Paris Diderot, Hop Lariboisiere, Paris, France; [Riou, Bruno] Univ Paris 06, Hop La Pitie Salpetriere, Paris, France; [Baroudjian, Barouyr; Fontaine, Jean-Paul] Hop St Louis, Paris, France; [Baubet, Thierry] Univ Paris 13, Hop Avicenne, Paris, France; [Chhor, Vibol] Hop Europeen Georges Pompidou, Paris, France; [Chollet-Xemard, Charlotte] Hop Henri Mondor, F-94010 Creteil, France; [Dantchev, Nicolas] Hop Hotel Dieu, Paris, France; [Fleury, Nadia] Hop La Pitie Salpetriere, Paris, France; [Yordanov, Youri] Hop St Antoine, F-75571 Paris, France; [Raphael, Maurice] Hop Bicetre, Paris, France; [Burtz, Catherine Paugam] Univ Paris Diderot, Hop Beaujon, Paris, France; [Lafont, Antoine] Univ Paris 05, Hop Europeen Georges Pompidou, Paris, France	Assistance Publique Hopitaux Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Lafont, A (corresponding author), Hop Europeen Georges Pompidou, Dept Cardiol, Paris, France.	antoine.lafont@inserm.fr	Nizard, Remy/R-5845-2019	Baubet, Thierry/0000-0002-4112-1592; Paugam-Burtz, Catherine/0000-0002-8168-7152				Aylwin CJ, 2006, LANCET, V368, P2219, DOI 10.1016/S0140-6736(06)69896-6; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Gates JD, 2014, ANN SURG, V260, P960, DOI 10.1097/SLA.0000000000000914; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107, DOI 10.1097/01.CCM.0000151072.17826.72; Jenkins DH, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000140; Katz JD, 2007, J CLIN ANESTH, V19, P152, DOI 10.1016/j.jclinane.2006.07.007; Mathieu L, 2014, INT ORTHOP, V38, P1569, DOI 10.1007/s00264-014-2305-2; RAID (Research Assistance Intervention Dissuasion) Medical Service, 2015, ANN FR MED URG, V5, P166; Regnier MA, 2012, ANESTHESIOLOGY, V117, P1276, DOI 10.1097/ALN.0b013e318273349d; Rochkind S, 2014, ACTA NEUROCHIR, V156, P1567, DOI 10.1007/s00701-014-2139-0; Tourtier JP, 2013, ANN FR ANESTH, V32, P520, DOI 10.1016/j.annfar.2013.07.012	11	183	185	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 19	2015	386	10012					2535	2538		10.1016/S0140-6736(15)01063-6	http://dx.doi.org/10.1016/S0140-6736(15)01063-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CZ1LD	26628327	Bronze			2023-01-03	WOS:000366866400028
J	Wiske, CP; Ogbechie, OA; Schulman, KA				Wiske, Clay P.; Ogbechie, Oluwatobi A.; Schulman, Kevin A.			Options to Promote Competitive Generics Markets in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHARMACEUTICALS; ENTRY		[Wiske, Clay P.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Wiske, Clay P.; Ogbechie, Oluwatobi A.; Schulman, Kevin A.] Harvard Univ, Sch Business, Boston, MA 02163 USA; [Ogbechie, Oluwatobi A.] Harvard Univ, Sch Med, Boston, MA USA; [Schulman, Kevin A.] Duke Clin Res Inst, Durham 17969, NC USA; [Schulman, Kevin A.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA	Brown University; Harvard University; Harvard University; Harvard Medical School; Duke University; Duke University	Schulman, KA (corresponding author), Duke Clin Res Inst, POB 17696, Durham 17969, NC USA.	kevin.schulman@duke.edu						Committee on Oversight and Government Reform, CUMM SAND INV STAGG; Frank RG, 1997, J ECON MANAGE STRAT, V6, P75, DOI 10.1162/105864097567039; GRABOWSKI HG, 1992, J LAW ECON, V35, P331, DOI 10.1086/467257; IMS Institute for Healthcare Informatics, MED US SHIFT COST HE; US Government Accountability Office, DRUG SHORT PUBL HLTH	5	13	13	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2015	314	20					2129	2130		10.1001/jama.2015.13498	http://dx.doi.org/10.1001/jama.2015.13498			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW9XQ	26513309	Bronze			2023-01-03	WOS:000365351900013
J	Coid, JW; Kallis, C; Doyle, M; Shaw, J; Ullrich, S				Coid, Jeremy W.; Kallis, Constantinos; Doyle, Mike; Shaw, Jenny; Ullrich, Simone			Identifying Causal Risk Factors for Violence among Discharged Patients	PLOS ONE			English	Article							PSYCHIATRIC MORBIDITY; ANTISOCIAL-BEHAVIOR; CRIMINAL RECIDIVISM; DYNAMIC PREDICTION; MENTAL-DISORDER; OFFENDERS; DELUSIONS; ILLNESS; HCR-20; NEEDS	Background Structured Professional Judgement (SPJ) is routinely administered in mental health and criminal justice settings but cannot identify violence risk above moderate accuracy. There is no current evidence that violence can be prevented using SPJ. This may be explained by routine application of predictive instead of causal statistical models when standardising SPJ instruments. Methods We carried out a prospective cohort study of 409 male and female patients discharged from medium secure services in England and Wales to the community. Measures were taken at baseline (pre-discharge), 6 and 12 months post-discharge using the Historical, Clinical and Risk-20 items version 3 (HCR-20v3) and Structural Assessment of Protective Factors (SAPROF). Information on violence was obtained via the McArthur community violence instrument and the Police National Computer. Results In a lagged model, HCR-20v3 and SAPROF items were poor predictors of violence. Eight items of the HCR-20v3 and 4 SAPROF items did not predict violent behaviour better than chance. In re-analyses considering temporal proximity of risk/protective factors (exposure) on violence (outcome), risk was elevated due to violent ideation (OR 6.98, 95% CI 13.85-12.65, P<0.001), instability (OR 5.41, 95% CI 3.44-8.50, P<0.001), and poor coping/stress (OR 8.35, 95% CI 4.21-16.57, P<0.001). All 3 risk factors were explanatory variables which drove the association with violent outcome. Self-control (OR 0.13, 95% CI 0.08-0.24, P< 0.001) conveyed protective effects and explained the association of other protective factors with violence. Conclusions Using two standardised SPJ instruments, predictive (lagged) methods could not identify risk and protective factors which must be targeted in interventions for discharged patients with severe mental illness. Predictive methods should be abandoned if the aim is to progress from risk assessment to effective risk management and replaced by methods which identify factors causally associated with violence.	[Coid, Jeremy W.; Kallis, Constantinos; Ullrich, Simone] Queen Mary Univ London, Violence Prevent Res Unit, Wolfson Inst Prevent Med, London E1 2AD, England; [Doyle, Mike; Shaw, Jenny] Univ Manchester, Inst Brain Behav & Mental Hlth, Manchester M13 9PL, Lancs, England	University of London; Queen Mary University London; University of Manchester	Ullrich, S (corresponding author), Queen Mary Univ London, Violence Prevent Res Unit, Wolfson Inst Prevent Med, Garrod Bldg,Turner St, London E1 2AD, England.	s.ullrich@qmul.ac.uk		Kallis, Constantinos/0000-0003-0866-5421; Kallis, Constantinos/0000-0002-4584-8844	UK National Institute for Health Research (NIHR) [RP-PG-0407-10500]; National Institute for Health Research [RP-PG-0407-10500] Funding Source: researchfish	UK National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	Funding: This study was funded by the UK National Institute for Health Research (NIHR) under its Programme Grants for Applied Research funding scheme (RP-PG-0407-10500). The views expressed in this manuscript are those of the authors and not necessarily those of the UK National Health Service (NHS), the NIHR or the UK Department of Health. There was no editorial direction or censorship from the funders.	Appelbaum PS, 2000, AM J PSYCHIAT, V157, P566, DOI 10.1176/appi.ajp.157.4.566; Bonta J, 1998, PSYCHOL BULL, V123, P123, DOI 10.1037/0033-2909.123.2.123; Borum R, 2010, INT PERSP FOREN MENT, P63; Brown SL, 2009, LAW HUMAN BEHAV, V33, P25, DOI 10.1007/s10979-008-9139-7; Coid J, 2006, AM J EPIDEMIOL, V164, P1199, DOI 10.1093/aje/kwj339; Coid JW, 2013, AM J PSYCHIAT, V170, P985, DOI 10.1176/appi.ajp.2013.12091188; Coid JW, 2011, J FORENSIC PSYCHI PS, V22, P3, DOI 10.1080/14789949.2010.495990; Cooke D, 2014, J THREAT ASSESSMENT, V1, P42, DOI DOI 10.1037/tam0000004; Douglas KS, 2010, INT PERSP FOREN MENT, P147; Doyle M, 2014, BRIT J PSYCHIAT, V205, P177, DOI 10.1192/bjp.bp.113.136622; Elbogen EB, 2009, ARCH GEN PSYCHIAT, V66, P152, DOI 10.1001/archgenpsychiatry.2008.537; Falzer PR, 2013, BEHAV SCI LAW, V31, P40, DOI 10.1002/bsl.2043; Fazel S, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4692; Fazel S, 2009, J CLIN PSYCHIAT, V70, P362, DOI 10.4088/JCP.08m04274; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Hart SD, 2013, BEHAV SCI LAW, V31, P81, DOI 10.1002/bsl.2049; Hart SD, 2010, INT PERSP FOREN MENT, P269; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Howard PD, 2013, LAW HUMAN BEHAV, V37, P163, DOI 10.1037/lhb0000012; Jones NJ, 2010, CRIM JUSTICE BEHAV, V37, P860, DOI 10.1177/0093854810368924; Kroner DG, 2005, INT J LAW PSYCHIAT, V28, P360, DOI 10.1016/j.ijlp.2004.01.011; Kropp PR, 2010, INT PERSP FOREN MENT, P227; Large MM, 2015, AUST NZ J PSYCHIAT, V49, P91, DOI 10.1177/0004867414539570; Large MM, 2011, PSYCHIATR BULL, V35, P413, DOI 10.1192/pb.bp.110.033910; Monahan J, 2005, PSYCHIAT SERV, V56, P810, DOI 10.1176/appi.ps.56.7.810; O'Shea LE, 2015, COMPR PSYCHIAT, V62, P132, DOI 10.1016/j.comppsych.2015.07.009; Peterson JK, 2014, LAW HUMAN BEHAV, V38, P439, DOI 10.1037/lhb0000075; Prins SJ, 2014, LAW HUM BEHAV; Quinsey VL, 2006, J INTERPERS VIOLENCE, V21, P1539, DOI 10.1177/0886260506294238; Schlager MD, 2011, CRIM JUSTICE BEHAV, V38, P541, DOI 10.1177/0093854811402300; Skeem JL, 2014, LAW HUMAN BEHAV, V38, P212, DOI 10.1037/lhb0000054; Troquete NAC, 2013, BRIT J PSYCHIAT, V202, P365, DOI 10.1192/bjp.bp.112.113043; Ullrich S, 2014, SCHIZOPHRENIA BULL, V40, P1174, DOI 10.1093/schbul/sbt126; Van Dorn R, 2012, SOC PSYCH PSYCH EPID, V47, P487, DOI 10.1007/s00127-011-0356-x; Webster C, 2013, VIOLENCE RISK ASSESS; Whitwell JL, 2008, CURR OPIN NEUROL, V21, P410, DOI 10.1097/WCO.0b013e32830719d4; Yang M, 2010, PSYCHOL BULL, V136, P740, DOI 10.1037/a0020473	37	25	25	1	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2015	10	11							e0142493	10.1371/journal.pone.0142493	http://dx.doi.org/10.1371/journal.pone.0142493			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CV7CT	26554711	Green Submitted, Green Published, gold			2023-01-03	WOS:000364430700116
J	Hussey, EK; Ward, N; Christianson, K; Kramer, AF				Hussey, Erika K.; Ward, Nathan; Christianson, Kiel; Kramer, Arthur F.			Language and Memory Improvements following tDCS of Left Lateral Prefrontal Cortex	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; NONINVASIVE BRAIN-STIMULATION; GARDEN-PATH SENTENCES; LATENT-VARIABLE ANALYSIS; WORKING-MEMORY; COGNITIVE CONTROL; MOTOR CORTEX; BROCAS AREA; ELECTRICAL-STIMULATION; INTERFERENCE CONTROL	Recent research demonstrates that performance on executive-control measures can be enhanced through brain stimulation of lateral prefrontal regions. Separate psycholinguistic work emphasizes the importance of left lateral prefrontal cortex executive-control resources during sentence processing, especially when readers must override early, incorrect interpretations when faced with temporary ambiguity. Using transcranial direct current stimulation, we tested whether stimulation of left lateral prefrontal cortex had discriminate effects on language and memory conditions that rely on executive-control (versus cases with minimal executive-control demands, even in the face of task difficulty). Participants were randomly assigned to receive Anodal, Cathodal, or Sham stimulation of left lateral prefrontal cortex while they (1) processed ambiguous and unambiguous sentences in a word-by-word self-paced reading task and (2) performed an n-back memory task that, on some trials, contained interference lure items reputed to require executive-control. Across both tasks, we parametrically manipulated executive-control demands and task difficulty. Our results revealed that the Anodal group outperformed the remaining groups on (1) the sentence processing conditions requiring executive-control, and (2) only the most complex n-back conditions, regardless of executive-control demands. Together, these findings add to the mounting evidence for the selective causal role of left lateral prefrontal cortex for executive-control tasks in the language domain. Moreover, we provide the first evidence suggesting that brain stimulation is a promising method to mitigate processing demands encountered during online sentence processing.	[Hussey, Erika K.; Kramer, Arthur F.] Univ Illinois, Dept Psychol, Champaign, IL 61801 USA; [Christianson, Kiel] Univ Illinois, Dept Educ Psychol, Champaign, IL USA; [Hussey, Erika K.; Ward, Nathan; Christianson, Kiel; Kramer, Arthur F.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Hussey, EK (corresponding author), Univ Illinois, Dept Psychol, Champaign, IL 61801 USA.	ehussey@illinois.edu	Kramer, Arthur/AAB-2937-2019; Ward, Nathan/AAB-5713-2021	Kramer, Arthur/0000-0001-5870-2724	National Institutes of Health [T32-HD055272]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD055272] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by a National Institutes of Health Training Grant T32-HD055272 (PI: Sarah Brown-Schmidt) to EH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altmann GTM, 1999, COGNITION, V73, P247, DOI 10.1016/S0010-0277(99)00059-1; Antal A, 2008, PERCEPTION, V37, P367, DOI 10.1068/p5872; Badre D, 2005, NEURON, V47, P907, DOI 10.1016/j.neuron.2005.07.023; Badre D, 2007, NEUROPSYCHOLOGIA, V45, P2883, DOI 10.1016/j.neuropsychologia.2007.06.015; Baker JM, 2010, STROKE, V41, P1229, DOI 10.1161/STROKEAHA.109.576785; Barr DJ, 2013, J MEM LANG, V68, P255, DOI 10.1016/j.jml.2012.11.001; Bartolotti J, 2012, COGNITIVE SCI, V36, P1129, DOI 10.1111/j.1551-6709.2012.01243.x; Berryhill ME, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00800; Bestmann S, 2015, TRENDS COGN SCI, V19, P13, DOI 10.1016/j.tics.2014.10.003; Bialystok E., 2001, BILINGUALISM DEV LAN, DOI [10.1017/CBO9780511605963, DOI 10.1017/CBO9780511605963]; Bikson M, 2010, CLIN NEUROPHYSIOL, V121, P1976, DOI 10.1016/j.clinph.2010.05.020; Bikson M, 2012, BRAIN STIMUL, V5, P430, DOI 10.1016/j.brs.2011.06.001; Blank I, 2014, J NEUROPHYSIOL, V112, P1105, DOI 10.1152/jn.00884.2013; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brunoni AR, 2014, BRAIN COGNITION, V86, P1, DOI 10.1016/j.bandc.2014.01.008; Capone F, 2014, NEUROBIOL LEARN MEM, V114, P51, DOI 10.1016/j.nlm.2014.04.013; Cappelletti M, 2013, J NEUROSCI, V33, P14899, DOI 10.1523/JNEUROSCI.1692-13.2013; Cattaneo Z, 2011, NEUROSCIENCE, V183, P64, DOI 10.1016/j.neuroscience.2011.03.058; Cerruti C, 2009, J COGNITIVE NEUROSCI, V21, P1980, DOI 10.1162/jocn.2008.21143; Christianson K, 2001, COGNITIVE PSYCHOL, V42, P368, DOI 10.1006/cogp.2001.0752; Christianson K, 2006, DISCOURSE PROCESS, V42, P205, DOI 10.1207/s15326950dp4202_6; Clifton C, 2003, J MEM LANG, V49, P317, DOI 10.1016/S0749-596X(03)00070-6; Coffman BA, 2014, NEUROIMAGE, V85, P895, DOI 10.1016/j.neuroimage.2013.07.083; Cole MW, 2012, J NEUROSCI, V32, P8988, DOI 10.1523/JNEUROSCI.0536-12.2012; D'Esposito M, 1999, NEUROPSYCHOLOGIA, V37, P1303, DOI 10.1016/S0028-3932(99)00021-4; Dahlin E, 2008, SCIENCE, V320, P1510, DOI 10.1126/science.1155466; Datta Abhishek, 2012, Front Psychiatry, V3, P91, DOI 10.3389/fpsyt.2012.00091; de Vries MH, 2010, J COGNITIVE NEUROSCI, V22, P2427, DOI 10.1162/jocn.2009.21385; Ditye T, 2012, EXP BRAIN RES, V219, P363, DOI 10.1007/s00221-012-3098-4; Dockery CA, 2009, J NEUROSCI, V29, P7271, DOI 10.1523/JNEUROSCI.0065-09.2009; Duncan J, 2010, TRENDS COGN SCI, V14, P172, DOI 10.1016/j.tics.2010.01.004; Edwards D, 2013, NEUROIMAGE, V74, P266, DOI 10.1016/j.neuroimage.2013.01.042; Elmasry J, 2015, RESTOR NEUROL NEUROS, V33, P263, DOI 10.3233/RNN-140473; Enders CK, 2007, PSYCHOL METHODS, V12, P121, DOI 10.1037/1082-989X.12.2.121; Farmer T.A., 2012, CAMBRIDGE HDB PSYCHO, P353, DOI 10.1017/CBO9781139029377.018; Fedorenko E, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00335; Fedorenko E, 2014, TRENDS COGN SCI, V18, P120, DOI 10.1016/j.tics.2013.12.006; Fedorenko E, 2013, COGNITIVE SCI, V37, P378, DOI 10.1111/cogs.12021; Fedorenko E, 2012, CURR BIOL, V22, P2059, DOI 10.1016/j.cub.2012.09.011; FERREIRA F, 1986, J MEM LANG, V25, P348, DOI 10.1016/0749-596X(86)90006-9; Ferreira F, 2001, J PSYCHOLINGUIST RES, V30, P3, DOI 10.1023/A:1005290706460; Fertonani A, 2010, BEHAV BRAIN RES, V208, P311, DOI 10.1016/j.bbr.2009.10.030; Fiori V, 2011, J COGNITIVE NEUROSCI, V23, P2309, DOI 10.1162/jocn.2010.21579; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Friedman NP, 2004, J EXP PSYCHOL GEN, V133, P101, DOI 10.1037/0096-3445.133.1.101; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Gladwin TE, 2012, NEUROSCI LETT, V512, P33, DOI 10.1016/j.neulet.2012.01.056; Gray JR, 2003, NAT NEUROSCI, V6, P316, DOI 10.1038/nn1014; Hagoort P, 2014, CURR OPIN NEUROBIOL, V28, P136, DOI 10.1016/j.conb.2014.07.013; Hamilton AC, 2005, COGN AFFECT BEHAV NE, V5, P1; Hamilton RH, 2011, BRAIN LANG, V118, P40, DOI 10.1016/j.bandl.2011.02.005; Harty S, 2014, J NEUROSCI, V34, P3646, DOI 10.1523/JNEUROSCI.5308-13.2014; Herwig U, 2003, BRAIN TOPOGR, V16, P95, DOI 10.1023/B:BRAT.0000006333.93597.9d; Holland R, 2012, APHASIOLOGY, V26, P1169, DOI 10.1080/02687038.2011.616925; Holland R, 2011, CURR BIOL, V21, P1403, DOI 10.1016/j.cub.2011.07.021; Horvath JC, 2015, NEUROPSYCHOLOGIA, V66, P213, DOI 10.1016/j.neuropsychologia.2014.11.021; Hussey EK, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00158; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jacobson L, 2011, J COGNITIVE NEUROSCI, V23, P3380, DOI 10.1162/jocn_a_00020; Jaeger TF, 2008, J MEM LANG, V59, P434, DOI 10.1016/j.jml.2007.11.007; Janacsek K, 2015, BRAIN STIMUL, V8, P277, DOI 10.1016/j.brs.2014.11.008; January D, 2009, J COGNITIVE NEUROSCI, V21, P2434, DOI 10.1162/jocn.2008.21179; Javadi AH, 2012, BRAIN STIMUL, V5, P468, DOI 10.1016/j.brs.2011.08.003; Javadi AH, 2012, BRAIN STIMUL, V5, P231, DOI 10.1016/j.brs.2011.06.007; Jeon SY, 2012, ANN REHABIL MED-ARM, V36, P585, DOI 10.5535/arm.2012.36.5.585; Jones KT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121904; Jonides J, 2006, NEUROSCIENCE, V139, P181, DOI 10.1016/j.neuroscience.2005.06.042; Jung YJ, 2013, BIOMED ENG LETT, V3, P39, DOI 10.1007/s13534-013-0087-x; JUST MA, 1982, J EXP PSYCHOL GEN, V111, P228, DOI 10.1037/0096-3445.111.2.228; Kan IP, 2004, COGN AFFECT BEHAV NE, V4, P43, DOI 10.3758/CABN.4.1.43; Kane MJ, 2007, J EXP PSYCHOL LEARN, V33, P615, DOI 10.1037/0278-7393.33.3.615; Kane MJ, 2000, J EXP PSYCHOL LEARN, V26, P336, DOI 10.1037//0278-7393.26.2.336; Keeser D, 2011, J NEUROSCI, V31, P15284, DOI 10.1523/JNEUROSCI.0542-11.2011; Kim JH, 2014, NEUROSCI LETT, V564, P6, DOI 10.1016/j.neulet.2014.01.054; Kincses TZ, 2004, NEUROPSYCHOLOGIA, V42, P113, DOI 10.1016/S0028-3932(03)00124-6; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kuo HI, 2013, BRAIN STIMUL, V6, P644, DOI 10.1016/j.brs.2012.09.010; Kuperberg GR, 2007, BRAIN RES, V1146, P23, DOI 10.1016/j.brainres.2006.12.063; Lewis RL, 2005, COGNITIVE SCI, V29, P375, DOI 10.1207/s15516709cog0000_25; Linck JA, 2012, BILING-LANG COGN, V15, P651, DOI 10.1017/S136672891100054X; Lopez-Alonso V, 2014, BRAIN STIMUL, V7, P372, DOI 10.1016/j.brs.2014.02.004; Martin DM, 2014, EXP BRAIN RES, V232, P3345, DOI 10.1007/s00221-014-4022-x; Mason RA, 2003, J EXP PSYCHOL LEARN, V29, P1319, DOI 10.1037/0278-7393.29.6.1319; McKinley RA, 2013, BEHAV NEUROSCI, V127, P936, DOI 10.1037/a0034975; Meinzer M, 2014, CORTEX, V50, P137, DOI 10.1016/j.cortex.2013.07.013; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Minhas P, 2011, CLIN NEUROPHYSIOL, V122, P637, DOI 10.1016/j.clinph.2010.09.023; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Mirman D., 2014, MINDING THE BRAIN; Mirman D., 2013, MINDING THE BRAIN; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Monti A, 2008, J NEUROL NEUROSUR PS, V79, P451, DOI 10.1136/jnnp.2007.135277; Monti A, 2013, J NEUROL NEUROSUR PS, V84, P832, DOI 10.1136/jnnp-2012-302825; Nelson JK, 2003, P NATL ACAD SCI USA, V100, P11171, DOI 10.1073/pnas.1334125100; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Norman D. A., 1986, CONSCIOUSNESS SELF R, DOI 10.1007/978-1-4757-0629-1_1; Novick JM, 2014, LANG COGN NEUROSCI, V29, P186, DOI 10.1080/01690965.2012.758297; Novick JM, 2010, LANG LINGUIST COMPAS, V4, P906, DOI 10.1111/j.1749-818x.2010.00244.x; Novick JM, 2009, COGN NEUROPSYCHOL, V26, P527, DOI 10.1080/02643290903519367; Novick JM, 2005, COGN AFFECT BEHAV NE, V5, P263, DOI 10.3758/CABN.5.3.263; Nozari N, 2014, BRAIN STIMUL, V7, P784, DOI 10.1016/j.brs.2014.07.035; Nozari N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084338; Nozari N, 2013, NEUROPSYCHOLOGIA, V51, P2770, DOI 10.1016/j.neuropsychologia.2013.08.019; Oberauer K, 2005, J EXP PSYCHOL GEN, V134, P368, DOI 10.1037/0096-3445.134.3.368; Oelhafen S, 2013, NEUROPSYCHOLOGIA, V51, P2781, DOI 10.1016/j.neuropsychologia.2013.08.012; Ohn SH, 2008, NEUROREPORT, V19, P43, DOI 10.1097/WNR.0b013e3282f2adfd; Oliveira JF, 2013, NEUROSCI LETT, V537, P60, DOI 10.1016/j.neulet.2013.01.023; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pereira JB, 2013, BRAIN STIMUL, V6, P16, DOI 10.1016/j.brs.2012.01.006; Perry LK, 2014, BRAIN LANG, V135, P66, DOI 10.1016/j.bandl.2014.05.005; Persson J, 2013, J COGNITIVE NEUROSCI, V25, P338, DOI 10.1162/jocn_a_00321; Pirulli C, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00226; Pisoni A, 2015, NEUROPSYCHOLOGIA, V66, P267, DOI 10.1016/j.neuropsychologia.2014.11.025; Polania R, 2011, HUM BRAIN MAPP, V32, P1236, DOI 10.1002/hbm.21104; PURPURA DP, 1965, J NEUROPHYSIOL, V28, P166, DOI 10.1152/jn.1965.28.1.166; Richmond LL, 2014, J COGNITIVE NEUROSCI, V26, P2443, DOI 10.1162/jocn_a_00657; Robinson G, 1998, BRAIN, V121, P77, DOI 10.1093/brain/121.1.77; Ruffini G, 2014, NEUROIMAGE, V89, P216, DOI 10.1016/j.neuroimage.2013.12.002; Schlaug G, 2011, NEUROPSYCHOL REV, V21, P288, DOI 10.1007/s11065-011-9181-y; Schmiedek F, 2009, PSYCHOL AGING, V24, P203, DOI 10.1037/a0014685; Sela T, 2012, NEUROPSYCHOLOGIA, V50, P2271, DOI 10.1016/j.neuropsychologia.2012.05.031; Slattery TJ, 2013, J MEM LANG, V69, P104, DOI 10.1016/j.jml.2013.04.001; Sparing R, 2008, NEUROPSYCHOLOGIA, V46, P261, DOI 10.1016/j.neuropsychologia.2007.07.009; Stanislaw H, 1999, BEHAV RES METH INS C, V31, P137, DOI 10.3758/BF03207704; Sturt P, 2007, COGNITION, V105, P477, DOI 10.1016/j.cognition.2006.10.009; Suzuki K, 2012, INT J NEUROSCI, V122, P675, DOI 10.3109/00207454.2012.707715; Szmalec A, 2011, J EXP PSYCHOL HUMAN, V37, P137, DOI 10.1037/a0020365; Thompson-Schill SL, 1999, NEURON, V23, P513, DOI 10.1016/S0896-6273(00)80804-1; Thompson-Schill SL, 1997, P NATL ACAD SCI USA, V94, P14792, DOI 10.1073/pnas.94.26.14792; Thothathiri M, 2012, BRAIN LANG, V120, P259, DOI 10.1016/j.bandl.2011.12.004; Thothathiri M, 2012, J COGNITIVE NEUROSCI, V24, P212, DOI 10.1162/jocn_a_00118; Tremblay S, 2014, BRAIN STIMUL, V7, P773, DOI 10.1016/j.brs.2014.10.003; Truong DQ, 2013, NEUROIMAGE-CLIN, V2, P759, DOI 10.1016/j.nicl.2013.05.011; Tsuchida A, 2009, J COGNITIVE NEUROSCI, V21, P2263, DOI 10.1162/jocn.2008.21172; Turkeltaub PE, 2012, BRAIN STIMUL, V5, P201, DOI 10.1016/j.brs.2011.04.002; Utz KS, 2010, NEUROPSYCHOLOGIA, V48, P2789, DOI 10.1016/j.neuropsychologia.2010.06.002; Van Dyke JA, 2003, J MEM LANG, V49, P285, DOI 10.1016/S0749-596X(03)00081-0; Vosse T, 2000, COGNITION, V75, P105, DOI 10.1016/S0010-0277(00)00063-9; Vuong LC, 2014, FRONT PSYCHOL, DOI [10.3389/conf.fpsyg.2014.64.00044, DOI 10.3389/CONF.FPSYG.2014.64.00044]; Vuong LC, 2011, BRAIN LANG, V116, P22, DOI 10.1016/j.bandl.2010.09.012; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Wirth M, 2011, NEUROPSYCHOLOGIA, V49, P3989, DOI 10.1016/j.neuropsychologia.2011.10.015; Witzel N, 2012, J PSYCHOLINGUIST RES, V41, P105, DOI 10.1007/s10936-011-9179-x; Ye Z, 2008, BRAIN RES, V1203, P103, DOI 10.1016/j.brainres.2008.01.090; Ye Z, 2009, NEUROSCI BIOBEHAV R, V33, P1168, DOI 10.1016/j.neubiorev.2009.03.003; Ye Z, 2009, NEUROIMAGE, V48, P280, DOI 10.1016/j.neuroimage.2009.06.032; Zaehle T, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-2; Zwissler B, 2014, J NEUROSCI, V34, P4022, DOI 10.1523/JNEUROSCI.5407-13.2014	151	32	32	3	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2015	10	11							e0141417	10.1371/journal.pone.0141417	http://dx.doi.org/10.1371/journal.pone.0141417			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV1QH	26528814	Green Submitted, gold, Green Published			2023-01-03	WOS:000364032600027
J	Dewanjee, S; Dua, TK; Khanra, R; Das, S; Barma, S; Joardar, S; Bhattacharjee, N; Zia-Ul-Haq, M; Jaafar, HZE				Dewanjee, Saikat; Dua, Tarun K.; Khanra, Ritu; Das, Shilpa; Barma, Sujata; Joardar, Swarnalata; Bhattacharjee, Niloy; Zia-Ul-Haq, M.; Jaafar, Hawa Z. E.			Water Spinach, Ipomoea aquatic (Convolvulaceae), Ameliorates Lead Toxicity by Inhibiting Oxidative Stress and Apoptosis	PLOS ONE			English	Article							HEAVY-METALS; INVOLVEMENT; IMAGE; ACID; QUANTIFICATION; MECHANISMS; EXPOSURE	Background Ipomoea aquatica (Convolvulaceae), an aquatic edible plant, is traditionally used against heavy metal toxicity in India. The current study intended to explore the protective role of edible (aqueous) extract of I. aquatica (AEIA) against experimentally induced Pb-intoxication. Methods The cytoprotective role of AEIA was measured on mouse hepatocytes by cell viability assay followed by Hoechst staining and flow cytometric assay. The effect on ROS production, lipid peroxidation, protein carbonylation, intracellular redox status were measured after incubating the hepatocytes with Pb-acetate (6.8 mu M) along with AEIA (400 mu g/ml). The effects on the expressions of apoptotic signal proteins were estimated by western blotting. The protective role of AEIA was measured by in vivo assay in mice. Haematological, serum biochemical, tissue redox status, Pb bioaccumulation and histological parameters were evaluated to estimate the protective role of AEIA (100 mg/kg) against Pb-acetate (5 mg/kg) intoxication. Results Pb-acetate treated hepatocytes showed a gradual reduction of cell viability dose-dependently with an IC50 value of 6.8 mu M. Pb-acetate treated hepatocytes exhibited significantly enhanced levels (p < 0.01) of ROS production, lipid peroxidation, protein carbonylation with concomitant depletion (p < 0.01) of antioxidant enzymes and GSH. However, AEIA treatment could significantly restore the aforementioned parameters in murine hepatocytes near to normalcy. Besides, AEIA significantly reversed (p < 0.05-0.01) the alterations of transcription levels of apoptotic proteins viz. Bcl 2, Bad, Cyt C, Apaf-1, cleaved caspases [caspase 3, caspase 8 and caspase 9], Fas and Bid. In in vivo bioassay, Pb-acetate treatment caused significantly high intracellular Pb burden and oxidative pressure in the kidney, liver, heart, brain and testes in mice. In addition, the haematological and serum biochemical factors were changed significantly in Pb-acetate-treated animals. AEIA treatment restored significantly the evaluated-parameters to the near-normal position. Conclusion The extract may offer the protective effect via counteracting with Pb mediated oxidative stress and/or promoting the elimination of Pb by chelating. The presence of substantial quantities of flavonoids, phenolics and saponins would be responsible for the overall protective effect.	[Dewanjee, Saikat; Dua, Tarun K.; Khanra, Ritu; Das, Shilpa; Barma, Sujata; Joardar, Swarnalata; Bhattacharjee, Niloy] Jadavpur Univ, Dept Pharmaceut Technol, Adv Pharmacognosy Res Lab, Kolkata 700032, India; [Zia-Ul-Haq, M.] Univ Karachi, Dept Pharmacognosy, Karachi 75270, Pakistan; [Jaafar, Hawa Z. E.] Univ Putra, Fac Agr, Dept Crop Sci, Selangor 43400, Malaysia	Jadavpur University; University of Karachi; Universiti Putra Malaysia	Dewanjee, S (corresponding author), Jadavpur Univ, Dept Pharmaceut Technol, Adv Pharmacognosy Res Lab, Kolkata 700032, India.	s.dewanjee@yahoo.com; hawazej@gmail.com	Dua, Tarun Kumar/AAM-4891-2020; KHANRA, RITU/AAV-4351-2021; Dewanjee, Saikat/U-9778-2017	Dua, Tarun Kumar/0000-0001-5136-7564; Dewanjee, Saikat/0000-0001-9085-4226	Council for Scientific and Industrial Research [09/096(773)/2013-EMR-I]	Council for Scientific and Industrial Research(Council of Scientific & Industrial Research (CSIR) - India)	This study was supported by the Council for Scientific and Industrial Research-senior research fellowship Ref. No.: 09/096(773)/2013-EMR-I dated 15th March, 2013.	Bouayed J, 2010, OXID MED CELL LONGEV, V3, P228, DOI 10.4161/oxim.3.4.12858; Bressler J, 1999, NEUROCHEM RES, V24, P595, DOI 10.1023/A:1022596115897; Chopra R.N., 1956, GLOSSARY INDIAN MED; DEFIGUEIREDO RJP, 1995, NEUROBIOL AGING, V16, P211, DOI 10.1016/0197-4580(94)00151-0; DESILVA PE, 1981, BRIT J IND MED, V38, P209; Dewanjee S, 2013, FOOD CHEM TOXICOL, V60, P188, DOI 10.1016/j.fct.2013.07.043; Dewanjee S, 2013, FOOD CHEM TOXICOL, V55, P78, DOI 10.1016/j.fct.2012.12.040; Douki T, 1998, CHEM RES TOXICOL, V11, P150, DOI 10.1021/tx970157d; Dua TK, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0598-6; Dua TK, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0430-3; Flora Gagan, 2012, Interdiscip Toxicol, V5, P47, DOI 10.2478/v10102-012-0009-2; Frei B, 2003, J NUTR, V133, p3275S, DOI 10.1093/jn/133.10.3275S; GELMAN BB, 1978, TOXICOL APPL PHARM, V45, P119, DOI 10.1016/0041-008X(78)90033-9; Ghosh J, 2010, FOOD CHEM, V123, P1062, DOI 10.1016/j.foodchem.2010.05.062; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Hong KJ, 2000, CHEMOSPHERE, V41, P345, DOI 10.1016/S0045-6535(99)00489-0; Hsu PC, 2002, TOXICOLOGY, V180, P33, DOI 10.1016/S0300-483X(02)00380-3; HUMPHREYS DJ, 1991, BRIT VET J, V147, P18, DOI 10.1016/0007-1935(91)90063-S; Jackie Tan, 2011, BMC Res Notes, V4, P67, DOI 10.1186/1756-0500-4-67; Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641; Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5; KHALILMANESH F, 1993, AM J HYPERTENS, V6, P723, DOI 10.1093/ajh/6.9.723; Khanra R, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0364-1; Kim JD, 1996, AGING-CLIN EXP RES, V8, P123, DOI 10.1007/BF03339566; LANCRANJAN I, 1975, ARCH ENVIRON HEALTH, V30, P396, DOI 10.1080/00039896.1975.10666733; LEBEL CP, 1990, NEUROCHEM INT, V17, P435, DOI 10.1016/0197-0186(90)90025-O; Mansoor TA, 2013, J ETHNOPHARMACOL, V149, P463, DOI 10.1016/j.jep.2013.06.051; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Pal S, 2011, TOXICOLOGY, V283, P129, DOI 10.1016/j.tox.2011.03.006; PHS (Public Health Service), 1986, PUBL HLTH SERV POL H; Rangan GK, 2007, NEPHROLOGY, V12, P553, DOI 10.1111/j.1440-1797.2007.00855.x; Ruegg MA, 2014, HISTOPATHOLOGY HEMAT; Saeed K, 2015, J PAK MED ASSOC, V65, P43; Sarkar K, 2006, TOXICOL IN VITRO, V20, P634, DOI 10.1016/j.tiv.2005.11.003; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SHARMA RP, 1980, J AM VET MED ASSOC, V177, P149; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; Wu DD, 2015, MED GAS RES, V5, DOI 10.1186/s13618-014-0022-y; ZHANG YY, 1995, J NUTR, V125, P446	40	28	29	1	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2015	10	10							e0139831	10.1371/journal.pone.0139831	http://dx.doi.org/10.1371/journal.pone.0139831			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CU0DF	26473485	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000363185500015
J	Iyengar, R; Altman, RB; Troyanskya, O; FitzGerald, GA				Iyengar, Ravi; Altman, Russ B.; Troyanskya, Olga; FitzGerald, Garret A.			Personalization in practice	SCIENCE			English	Editorial Material									[Iyengar, Ravi] Icahn Sch Med Mt Sinai, Syst Biol Ctr New York, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA; [Altman, Russ B.] Stanford Univ, Sch Med, Dept Bioengn, Stanford, CA 94305 USA; [Troyanskya, Olga] Princeton Univ, Dept Comp Sci, Princeton, NJ 08544 USA; [Troyanskya, Olga] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; [Troyanskya, Olga] Simons Fdn, Simons Ctr Data Anal, New York, NY 10010 USA; [FitzGerald, Garret A.] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA	Icahn School of Medicine at Mount Sinai; Stanford University; Princeton University; Princeton University; University of Pennsylvania; Pennsylvania Medicine	Iyengar, R (corresponding author), Icahn Sch Med Mt Sinai, Syst Biol Ctr New York, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.	ravi.iyengar@mssm.edu; garret@exchange.upenn.edu		Altman, Russ/0000-0003-3859-2905	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL117798] Funding Source: NIH RePORTER; NHLBI NIH HHS [U54 HL117798] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azeloglu EU, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004621; Bhatia SN, 2014, NAT BIOTECHNOL, V32, P760, DOI 10.1038/nbt.2989; Committee on a Framework for Developing a New Taxonomy of Disease, 2011, PREC MED BUILD KNOWL; Crotti L, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-18; Fries S, 2006, GASTROENTEROLOGY, V130, P55, DOI 10.1053/j.gastro.2005.10.002; Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259; Tiscornia G, 2011, NAT MED, V17, P1570, DOI 10.1038/nm.2504	7	16	17	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	2015	350	6258					282	283		10.1126/science.aad5204	http://dx.doi.org/10.1126/science.aad5204			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CT5HD	26472898				2023-01-03	WOS:000362838700024
J	Song, XZ; Zhang, CW; Zhao, MK; Chen, H; Liu, X; Chen, JW; Lonard, DM; Qin, L; Xu, JM; Wang, XS; Li, F; O'Malley, BW; Wang, J				Song, Xianzhou; Zhang, Chengwei; Zhao, Mingkun; Chen, Hui; Liu, Xing; Chen, Jianwei; Lonard, David M.; Qin, Li; Xu, Jianming; Wang, Xiaosong; Li, Feng; O'Malley, Bert W.; Wang, Jin			Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug	PLOS ONE			English	Article							TAMOXIFEN RESISTANCE; PHASE-II; CARDIAC-GLYCOSIDES; PRECLINICAL MODELS; PROMOTE METASTASIS; CELL-MIGRATION; OVARIAN-CANCER; AIB1; GROWTH; EXPRESSION	Triple negative breast cancer (TNBC) has the poorest prognosis of all types of breast cancer and currently lacks efficient targeted therapy. Chemotherapy is the traditional standard-of-care for TNBC, but is frequently accompanied by severe side effects. Despite the fact that high expression of steroid receptor coactivator 3 (SRC-3) is correlated with poor survival in estrogen receptor positive breast cancer patients, its role in TNBC has not been extensively investigated. Here, we show that high expression of SRC-3 correlates with both poor overall survival and post progression survival in TNBC patients, suggesting that SRC-3 can serve as a prognostic marker for TNBC. Furthermore, we demonstrated that bufalin, a SRC-3 small molecule inhibitor, when introduced even at nM concentrations, can significantly reduce TNBC cell viability and motility. However, because bufalin has minimal water solubility, its in vivo application is limited. Therefore, we developed a water soluble prodrug, 3-phospho-bufalin, to facilitate its in vivo administration. In addition, we demonstrated that 3-phospho-bufalin can effectively inhibit tumor growth in an orthotopic TNBC mouse model, suggesting its potential application as a targeted therapy for TNBC treatment.	[Song, Xianzhou; Zhang, Chengwei; Zhao, Mingkun; Chen, Hui; Liu, Xing; Chen, Jianwei; Wang, Jin] Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; [Lonard, David M.; Qin, Li; Xu, Jianming; Li, Feng; O'Malley, Bert W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Wang, Xiaosong] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Wang, Jin] Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA; [Zhao, Mingkun] Baylor Coll Med, Integrat Mol & Biomed Sci Grad Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	berto@bcm.edu; wangj@bcm.edu	Li, Feng/M-5334-2016; Wang, Jin/M-4036-2014; Wang, Jin/AAC-7292-2019	Li, Feng/0000-0002-9680-4614; Wang, Jin/0000-0003-3625-7919; Wang, Jin/0000-0003-3625-7919; Qin, Li/0000-0003-0099-4992	National Institutes of Health [HD076596, DK059820, R01CA112403, 1R01CA181368, 1R01CA183976]; Cancer Prevention and Research Institute of Texas [R1104, RP100348, RP101251, RP120732-P5]; Welch Foundation [Q-1798]; Susan G. Komen Foundation [PG12221410]; Prostate Cancer Foundation; Clayton Foundation; Dunn Foundation; Center for Drug Discovery and the Metabolomics Core Facility at Baylor College of Medicine; Dan L. Duncan Cancer Center; Texas Medical Center Digestive Diseases Center; John S. Dunn Gulf Coast Consortium; Shared Equipment Authority instrumentation at Rice University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD076596, R01HD008188] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA112403] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; Welch Foundation(The Welch Foundation); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Prostate Cancer Foundation; Clayton Foundation; Dunn Foundation; Center for Drug Discovery and the Metabolomics Core Facility at Baylor College of Medicine; Dan L. Duncan Cancer Center; Texas Medical Center Digestive Diseases Center; John S. Dunn Gulf Coast Consortium; Shared Equipment Authority instrumentation at Rice University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by the National Institutes of Health [HD076596 to D.M.L.; DK059820 to B.W.O.; R01CA112403 to J.X.; and 1R01CA181368 and 1R01CA183976 to X-S.W.], the Cancer Prevention and Research Institute of Texas [R1104 to J.W.; RP100348 and RP101251 to B.W.O.; and RP120732-P5 to J.X.], the Welch Foundation [Q-1798 to J.W.], the Susan G. Komen Foundation [PG12221410 to B.W.O.], the Prostate Cancer Foundation [to B.W.O.], the Clayton Foundation and the Dunn Foundation [to B.W.O.], the Center for Drug Discovery and the Metabolomics Core Facility [to F.L.] at Baylor College of Medicine, the Dan L. Duncan Cancer Center, the Texas Medical Center Digestive Diseases Center, the John S. Dunn Gulf Coast Consortium for Chemical Genomics, and the Shared Equipment Authority instrumentation at Rice University. The sponsors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Alkner S, 2010, ANN ONCOL, V21, P238, DOI 10.1093/annonc/mdp293; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bandyopadhyay A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010365; Baselga J, 2005, J CLIN ONCOL, V23, P5323, DOI 10.1200/JCO.2005.08.326; Ben-Eliyahu S, 2002, LANCET ONCOL, V3, P578; Burandt E, 2013, BREAST CANCER RES TR, V137, P745, DOI 10.1007/s10549-013-2406-4; Cai D, 2010, CANCER RES, V70, P6477, DOI 10.1158/0008-5472.CAN-10-0005; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Cenik BK, 2013, MOL CANCER THER, V12, P992, DOI 10.1158/1535-7163.MCT-12-0995; Chang JC, 2009, CANCER INVEST, V27, P699, DOI 10.1080/07357900903152473; Chu V, 2001, BMC Physiol, V1, P6, DOI 10.1186/1472-6793-1-6; Chugh R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004334; Farraj AK, 2011, TOXICOL SCI, V121, P11, DOI 10.1093/toxsci/kfr021; Fu T, 2012, P NATL ACAD SCI USA, V109, P16137, DOI 10.1073/pnas.1205951109; Galanis E, 2013, CLIN CANCER RES, V19, P4816, DOI 10.1158/1078-0432.CCR-13-0708; Grunwald MR, 2013, INT J HEMATOL, V97, P683, DOI 10.1007/s12185-013-1334-8; Helman EE, 2010, CANCER BIOL THER, V10, P166, DOI 10.4161/cbt.10.2.12164; Henke RT, 2004, CLIN CANCER RES, V10, P6134, DOI 10.1158/1078-0432.CCR-04-0561; Kang SP, 2008, CURR OPIN OBSTET GYN, V20, P40, DOI 10.1097/GCO.0b013e3282f40de9; Karmakar S, 2011, ENDOCR-RELAT CANCER, V18, P113, DOI 10.1677/ERC-09-0285; Kayser S, 2014, LEUKEMIA LYMPHOMA, V55, P243, DOI 10.3109/10428194.2013.800198; Korsching E, 2008, J CLIN PATHOL, V61, P553, DOI 10.1136/jcp.2008.055475; Kuang SQ, 2005, CANCER RES, V65, P7993, DOI 10.1158/0008-5472.CAN-05-1179; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Lam ET, 2008, MOL CANCER THER, V7, P3685, DOI 10.1158/1535-7163.MCT-08-0436; Lee JW, 2009, CLIN CANCER RES, V15, P2695, DOI 10.1158/1078-0432.CCR-08-2966; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Levis MJ, 2010, BEST PRACT RES CL HA, V23, P489, DOI 10.1016/j.beha.2010.09.008; Li W, 2014, PATHOL RES PRACT, V210, P1005, DOI 10.1016/j.prp.2014.04.012; Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012; Lonard DM, 2012, NAT REV ENDOCRINOL, V8, P598, DOI 10.1038/nrendo.2012.100; Lonard DM, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.113pe16; Long WW, 2010, MOL CELL, V37, P321, DOI 10.1016/j.molcel.2010.01.004; Malorni L, 2012, BREAST CANCER RES TR, V136, P795, DOI 10.1007/s10549-012-2315-y; Markman JL, 2013, ADV DRUG DELIVER REV, V65, P1866, DOI 10.1016/j.addr.2013.09.019; Mihaly Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mueller KL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3224; Neary MT, 2013, DIS MODEL MECH, V6, P503, DOI 10.1242/dmm.010587; Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8; Norden AD, 2010, J NEURO-ONCOL, V96, P211, DOI 10.1007/s11060-009-9948-7; O'Dwyer PJ, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.35643; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Palmieri C, 2013, BRIT J CANCER, V108, P2039, DOI 10.1038/bjc.2013.199; Park Y, 2011, ONCOLOGY-BASEL, V81, P199, DOI 10.1159/000333455; Penault-Llorca F, 2012, ANN ONCOL, V23, P19, DOI 10.1093/annonc/mds190; Pili R, 2013, CLIN GENITOURIN CANC, V11, P477, DOI 10.1016/j.clgc.2013.05.005; Prassas I, 2008, NAT REV DRUG DISCOV, V7, P926, DOI 10.1038/nrd2682; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Roland CL, 2009, MOL CANCER THER, V8, P1761, DOI 10.1158/1535-7163.MCT-09-0280; Sakakura C, 2000, INT J CANCER, V89, P217; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Su QB, 2008, ONCOLOGY-BASEL, V75, P159, DOI 10.1159/000159267; Sweeny L, 2012, ORAL ONCOL, V48, P1242, DOI 10.1016/j.oraloncology.2012.06.011; Tien JCY, 2012, EXPERT OPINION THERA, P1; Tien JCY, 2013, CANCER RES, V73, P3997, DOI 10.1158/0008-5472.CAN-12-3929; TOMA S, 1991, YAKUGAKU ZASSHI, V111, P676, DOI 10.1248/yakushi1947.111.11_676; Tong ZT, 2013, BRIT J CANCER, V108, P1470, DOI 10.1038/bjc.2013.81; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Wang Y, 2014, CANCER RES, V74, P1506, DOI 10.1158/0008-5472.CAN-13-2939; Wang Y, 2011, MOL ENDOCRINOL, V25, P2041, DOI 10.1210/me.2011-1222; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Yoshida H, 2005, MOL CELL ENDOCRINOL, V245, P77, DOI 10.1016/j.mce.2005.10.008; Zhao WH, 2009, BIOCHEM BIOPH RES CO, V380, P699, DOI 10.1016/j.bbrc.2009.01.155	65	25	27	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2015	10	10							e0140011	10.1371/journal.pone.0140011	http://dx.doi.org/10.1371/journal.pone.0140011			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6HH	26431029	gold, Green Submitted, Green Published			2023-01-03	WOS:000362178700131
J	Xi, JX; Zhao, WZ; Yuan, JE; Kim, J; Si, XH; Xu, XW				Xi, Jinxiang; Zhao, Weizhong; Yuan, Jiayao Eddie; Kim, JongWon; Si, Xiuhua; Xu, Xiaowei			Detecting Lung Diseases from Exhaled Aerosols: Non-Invasive Lung Diagnosis Using Fractal Analysis and SVM Classification	PLOS ONE			English	Article							UPPER TRACHEOBRONCHIAL AIRWAYS; BREATH CONDENSATE; OXIDATIVE STRESS; BRONCHIAL TREE; IMAGE-ANALYSIS; DEPOSITION; CANCER; MODEL; NANOPARTICLE; PARTICLES	Background Each lung structure exhales a unique pattern of aerosols, which can be used to detect and monitor lung diseases non-invasively. The challenges are accurately interpreting the exhaled aerosol fingerprints and quantitatively correlating them to the lung diseases. Objective and Methods In this study, we presented a paradigm of an exhaled aerosol test that addresses the above two challenges and is promising to detect the site and severity of lung diseases. This paradigm consists of two steps: image feature extraction using sub-regional fractal analysis and data classification using a support vector machine (SVM). Numerical experiments were conducted to evaluate the feasibility of the breath test in four asthmatic lung models. A highfidelity image-CFD approach was employed to compute the exhaled aerosol patterns under different disease conditions. Findings By employing the 10-fold cross-validation method, we achieved 100% classification accuracy among four asthmatic models using an ideal 108-sample dataset and 99.1% accuracy using a more realistic 324-sample dataset. The fractal-SVM classifier has been shown to be robust, highly sensitive to structural variations, and inherently suitable for investigating aerosol-disease correlations. Conclusion For the first time, this study quantitatively linked the exhaled aerosol patterns with their underlying diseases and set the stage for the development of a computer-aided diagnostic system for non-invasive detection of obstructive respiratory diseases.	[Xi, Jinxiang; Yuan, Jiayao Eddie] Cent Michigan Univ, Sch Engn & Technol, Mt Pleasant, MI 48859 USA; [Zhao, Weizhong] Xiangtan Univ, Coll Informat Engn, Xiangtan, Hunan, Peoples R China; [Zhao, Weizhong] Natl Ctr Toxicol Res, Div Bioinformat & Biostat, Jefferson, AR 72079 USA; [Kim, JongWon] Univ Georgia, Coll Engn, Athens, GA 30602 USA; [Si, Xiuhua] Calif Baptist Univ, Dept Mech Engn, Riverside, CA USA; [Xu, Xiaowei] Univ Arkansas, Dept Informat Sci, Little Rock, AR 72204 USA	Central Michigan University; Xiangtan University; US Food & Drug Administration (FDA); University System of Georgia; University of Georgia; California Baptist University; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	Xi, JX (corresponding author), Cent Michigan Univ, Sch Engn & Technol, Mt Pleasant, MI 48859 USA.	xi1j@cmich.edu	Xi, Jinxiang/Y-1161-2019		Central Michigan University Early Career Grant [P62242]	Central Michigan University Early Career Grant	Jinxiang Xi was supported by the Central Michigan University Early Career Grant P62242 [https://www.cmich.edu/office_provost/ORSP/Pages/default.aspx]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLEN MD, 1985, AEROSOL SCI TECH, V4, P269, DOI 10.1080/02786828508959055; ANDERSON PJ, 1994, J AEROSOL MED, V7, P77, DOI 10.1089/jam.1994.7.77; Blanchard JD, 1996, J AEROSOL MED, V9, P183, DOI 10.1089/jam.1996.9.183; Boser SR, 2005, AM J RESP CRIT CARE, V172, P817, DOI 10.1164/rccm.200411-1463OC; Canals M, 2000, BIOL RES, V33, P31; Chan HP, 2009, J THORAC ONCOL, V4, P172, DOI 10.1097/JTO.0b013e3181949eb9; Chan HP, 2009, LUNG CANCER, V63, P164, DOI 10.1016/j.lungcan.2008.05.020; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Di Natale C, 2003, BIOSENS BIOELECTRON, V18, P1209, DOI 10.1016/S0956-5663(03)00086-1; Einstein AJ, 1998, J PATHOL, V185, P366; HORSFILED K, 1990, Journal of Applied Physiology, V68, P457; Karperien A, 2013, FRACTAL DIMENSION LA; Kim JW, 2013, INT J NUMER METH BIO, V29, P17, DOI 10.1002/cnm.2490; Kostikas K, 2008, CLIN EXP ALLERGY, V38, P557, DOI 10.1111/j.1365-2222.2008.02940.x; Kostikas K, 2003, CHEST, V124, P1373, DOI 10.1378/chest.124.4.1373; Loukides S, 2011, CURR DRUG TARGETS, V12, P469, DOI 10.2174/138945011794751573; Mauroy B, 2004, NATURE, V427, P633, DOI 10.1038/nature02287; Miekisch W, 2004, CLIN CHIM ACTA, V347, P25, DOI 10.1016/j.cccn.2004.04.023; MORSI SA, 1972, J FLUID MECH, V55, P193, DOI 10.1017/S0022112072001806; Mutlu GM, 2001, AM J RESP CRIT CARE, V164, P731, DOI 10.1164/ajrccm.164.5.2101032; Nicoud F, 1999, FLOW TURBUL COMBUST, V62, P183, DOI 10.1023/A:1009995426001; Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; SERNETZ M, 1992, PHYSICA A, V191, P13, DOI 10.1016/0378-4371(92)90498-F; Si XHA, 2013, RESP PHYSIOL NEUROBI, V186, P22, DOI 10.1016/j.resp.2012.12.005; Tabesh A, 2007, IEEE T MED IMAGING, V26, P1366, DOI 10.1109/TMI.2007.898536; Vapnik, 2013, NATURE STAT LEARNING; WEIBEL ER, 1962, SCIENCE, V137, P577, DOI 10.1126/science.137.3530.577; WILSON TA, 1967, NATURE, V213, P668, DOI 10.1038/213668a0; Longest PW, 2007, AEROSOL SCI TECH, V41, P380, DOI 10.1080/02786820701203223; Xi JX, 2008, ANN BIOMED ENG, V36, P1714, DOI 10.1007/s10439-008-9552-6; Xi JX, 2008, J APPL PHYSIOL, V104, P1761, DOI 10.1152/japplphysiol.01233.2007; Xi JX, 2007, ANN BIOMED ENG, V35, P560, DOI 10.1007/s10439-006-9245-y; Xi JX, 2015, THERANOSTICS, V5, P443, DOI 10.7150/thno.11107; Xi JX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104682; Xi JX, 2014, INHAL TOXICOL, V26, P492, DOI 10.3109/08958378.2014.925992; Xi JX, 2013, J AEROSOL SCI, V64, P24, DOI 10.1016/j.jaerosci.2013.06.003	37	13	13	3	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2015	10	9							e0139511	10.1371/journal.pone.0139511	http://dx.doi.org/10.1371/journal.pone.0139511			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6GF	26422016	Green Submitted, Green Published, gold			2023-01-03	WOS:000362175700125
J	Klein, SD; Torchetti, L; Frei-Erb, M; Wolf, U				Klein, Sabine D.; Torchetti, Loredana; Frei-Erb, Martin; Wolf, Ursula			Usage of Complementary Medicine in Switzerland: Results of the Swiss Health Survey 2012 and Development Since 2007	PLOS ONE			English	Article							ALTERNATIVE MEDICINE; UNITED-STATES; POPULATION; PREGNANCY; CHILDREN; PAIN	Background Complementary medicine (CM) is popular in Switzerland. Several CM methods (traditional Chinese medicine/acupuncture, homeopathy, anthroposophic medicine, neural therapy, and herbal medicine) are currently covered by the mandatory basic health insurance when performed by a certified physician. Treatments by non-medical therapists are partially covered by a supplemental and optional health insurance. In this study, we investigated the frequency of CM use including the evolvement over time, the most popular methods, and the user profile. Methods Data of the Swiss Health Surveys 2007 and 2012 were used. In 2007 and 2012, a population of 14,432 and 18,357, respectively, aged 15 years or older answered the written questionnaire. A set of questions queried about the frequency of use of various CM methods within the last 12 months before the survey. Proportions of usage and 95% confidence intervals were calculated for these methods and CM in general. Users and non-users of CM were compared using logistic regression models. Results The most popular methods in 2012 were homeopathy, naturopathy, osteopathy, herbal medicine, and acupuncture. The average number of treatments within the 12 months preceding the survey ranged from 3 for homeopathy to 6 for acupuncture. 25.0% of the population at the age of 15 and older had used at least one CM method in the previous 12 months. People with a chronic illness or a poor self-perceived health status were more likely to use CM. Similar to other countries, women, people of middle age, and those with higher education were more likely to use CM. 59.9% of the adult population had a supplemental health insurance that partly covered CM treatments. Conclusions Usage of CM in Switzerland remained unchanged between 2007 and 2012. The user profile in Switzerland was similar to other countries, such as Germany, United Kingdom, United States or Australia.	[Klein, Sabine D.; Torchetti, Loredana; Frei-Erb, Martin; Wolf, Ursula] Univ Bern, Inst Complementary Med, Bern, Switzerland	University of Bern	Klein, SD (corresponding author), Univ Bern, Inst Complementary Med, Bern, Switzerland.	sabine.klein@ikom.unibe.ch	Klein, Sabine D./T-2854-2019	Klein, Sabine D./0000-0001-6843-1454; Frei-Erb, Martin/0000-0002-7923-3741				Barnes Patricia M, 2008, Natl Health Stat Report, P1; Birdee GS, 2014, J WOMENS HEALTH, V23, P824, DOI 10.1089/jwh.2013.4568; Bishop JL, 2011, COMPLEMENT THER MED, V19, P303, DOI 10.1016/j.ctim.2011.08.005; Clarke Tainya C, 2015, Natl Health Stat Report, P1; Crivelli L, 2004, INANSPRUCHNAHME 5 TH; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Eizayaga JE, 2012, HOMEOPATHY, V101, P21, DOI 10.1016/j.homp.2011.09.002; Falkenberg T, 2012, FORSCH KOMPLEMENTMED, V19, P6, DOI 10.1159/000343812; Frass M, 2012, OCHSNER J, V12, P45; Huang TP, 2014, COMPLEMENT THER MED, V22, P500, DOI 10.1016/j.ctim.2014.04.002; Klein SD, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13666; Kristoffersen ES, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-36; Lert F, 2014, HOMEOPATHY, V103, P51, DOI 10.1016/j.homp.2013.09.001; Licciardone JC, 2013, MANUAL THER, V18, P533, DOI 10.1016/j.math.2013.05.006; Lin V, 2015, HEALTH EXPECT, V18, P2651, DOI 10.1111/hex.12239; MacPherson H, 2006, COMPLEMENT THER MED, V14, P39; Nedeljkovic M, 2014, MENOPAUSE, V21, P15, DOI [10.1097/GME.0b013e31829374e8, 10.1097/gme.0b013e31829374e8]; Schenker N, 2001, AM STAT, V55, P182, DOI 10.1198/000313001317097960; Simoes-Wust AP, 2014, J ALTERN COMPLEM MED, V20, P40, DOI 10.1089/acm.2012.0762; Sirois FM, 2014, COMPLEMENT THER MED, V22, P701, DOI 10.1016/j.ctim.2014.07.003; Tan MGE, 2013, ANN ACAD MED SINGAP, V42, P133; von Ammon K, 2012, FORSCH KOMPLEMENTMED, V19, P37, DOI 10.1159/000343129; West BT, 2008, J TRAUMA STRESS, V21, P440, DOI 10.1002/jts.20356; Witt CM, 2010, J ALTERN COMPLEM MED, V16, P347, DOI 10.1089/acm.2009.0376	25	52	52	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2015	10	10							e0141985	10.1371/journal.pone.0141985	http://dx.doi.org/10.1371/journal.pone.0141985			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CV0ED	26513370	Green Published, Green Submitted, gold			2023-01-03	WOS:000363920300092
